PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Petrilli, AM; Fernandez-Valle, C				Petrilli, A. M.; Fernandez-Valle, C.			Role of Merlin/NF2 inactivation in tumor biology	ONCOGENE			English	Review							NEUROFIBROMATOSIS TYPE-2 GENE; SUPPRESSOR PROTEIN MERLIN; HISTONE DEACETYLASE INHIBITOR; HUMAN SCHWANNOMA CELLS; MEDIATES CONTACT INHIBITION; HIPPO SIGNALING PATHWAY; CPG ISLAND METHYLATION; ORGAN SIZE CONTROL; NF2 GENE; VESTIBULAR SCHWANNOMAS	Merlin (Moesin-ezrin-radixin-like protein, also known as schwannomin) is a tumor suppressor protein encoded by the neurofibromatosis type 2 gene NF2. Loss of function mutations or deletions in NF2 cause neurofibromatosis type 2 (NF2), a multiple tumor forming disease of the nervous system. NF2 is characterized by the development of bilateral vestibular schwannomas. Patients with NF2 can also develop schwannomas on other cranial and peripheral nerves, as well as meningiomas and ependymomas. The only potential treatment is surgery/radiosurgery, which often results in loss of function of the involved nerve. There is an urgent need for chemotherapies that slow or eliminate tumors and prevent their formation in NF2 patients. Interestingly NF2 mutations and merlin inactivation also occur in spontaneous schwannomas and meningiomas, as well as other types of cancer including mesothelioma, glioma multiforme, breast, colorectal, skin, clear cell renal cell carcinoma, hepatic and prostate cancer. Except for malignant mesotheliomas, the role of NF2 mutation or inactivation has not received much attention in cancer, and NF2 might be relevant for prognosis and future chemotherapeutic approaches. This review discusses the influence of merlin loss of function in NF2-related tumors and common human cancers. We also discuss the NF2 gene status and merlin signaling pathways affected in the different tumor types and the molecular mechanisms that lead to tumorigenesis, progression and pharmacological resistance.	[Petrilli, A. M.; Fernandez-Valle, C.] Univ Cent Florida, Dept Biomed Sci, Coll Med, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Burnett Sch Biomed Sci, Coll Med, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	cfv@ucf.edu			National Institute of Health [5R01DC10189, 5R01NS062825]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010189] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by the National Institute of Health 5R01DC10189 and 5R01NS062825 grants. We thank AB Knott for editorial assistance and Dr C Vivacharawongse for reviewing the manuscript and helpful discussions.	Aboukais R, 2013, ACTA NEUROCHIR, V155, P997, DOI 10.1007/s00701-013-1692-2; Agnihotri S, 2014, J NEUROSURG, V121, P1434, DOI 10.3171/2014.6.JNS131433; Ahmad Z, 2010, OTOL NEUROTOL, V31, P460, DOI 10.1097/MAO.0b013e3181d2777f; Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Allison KH, 2014, ONCOLOGY-NY, V28, P772; Alonso ME, 2004, J NEURO-ONCOL, V67, P159; Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Ammoun S, 2014, ONCOGENE, V33, P336, DOI 10.1038/onc.2012.587; Ammoun S, 2015, MOL ONCOL, V9, P236, DOI 10.1016/j.molonc.2014.08.005; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2012, GLIA, V60, P1721, DOI 10.1002/glia.22391; Ammoun S, 2011, NEURO-ONCOLOGY, V13, P759, DOI 10.1093/neuonc/nor056; Ammoun S, 2010, NEURO-ONCOLOGY, V12, P834, DOI 10.1093/neuonc/noq012; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2; Bai Y, 2007, ONCOGENE, V26, P836, DOI 10.1038/sj.onc.1209849; Barron DA, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-25; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Baylin SB, 1998, ADV CANCER RES, V72, P141; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Bensenor LB, 2010, P NATL ACAD SCI USA, V107, P7311, DOI 10.1073/pnas.0907389107; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Boin A, 2014, NEURO-ONCOLOGY, V16, P1196, DOI 10.1093/neuonc/nou020; Bosco EE, 2010, ONCOGENE, V29, P2540, DOI 10.1038/onc.2010.20; Bourguignon LYW, 2007, J NEUROCHEM, V101, P1002, DOI 10.1111/j.1471-4159.2007.04485.x; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Burns SS, 2013, CANCER RES, V73, P792, DOI 10.1158/0008-5472.CAN-12-1888; Bush ML, 2011, NEURO-ONCOLOGY, V13, P983, DOI 10.1093/neuonc/nor072; Bydon M, 2013, SPINE J, V13, P1379, DOI 10.1016/j.spinee.2013.06.037; Cacev T, 2014, CELL ONCOL, V37, P69, DOI 10.1007/s13402-013-0164-2; Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Cooper J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002314; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Evans DGR, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-16; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Flaiz C, 2008, GLIA, V56, P506, DOI 10.1002/glia.20629; Flaiz C, 2009, BRAIN PATHOL, V19, P27, DOI 10.1111/j.1750-3639.2008.00165.x; Fleury-Feith J, 2003, ONCOGENE, V22, P3799, DOI 10.1038/sj.onc.1206593; Frontzek F, 2014, BIOCHEM CELL BIOL, V92, P530, DOI 10.1139/bcb-2014-0041; Garcia C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097320; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gehlhausen JR, 2015, HUM MOL GENET, V24, P1, DOI 10.1093/hmg/ddu414; Geissler KJ, 2013, P NATL ACAD SCI USA, V110, P20587, DOI 10.1073/pnas.1222078110; Gilbert MR, 2010, CURR NEUROL NEUROSCI, V10, P240, DOI 10.1007/s11910-010-0109-3; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 2014, NEURO-ONCOLOGY, V16, P493, DOI 10.1093/neuonc/not242; Gonzalez-Gomez P, 2003, CLIN CANCER RES, V9, P5601; Goutagny S, 2014, BRAIN PATHOL, V24, P184, DOI 10.1111/bpa.12110; Gronholm M, 1999, J CELL SCI, V112, P895; Guerrero PA, 2015, ONCOGENE, V34, P2621, DOI 10.1038/onc.2014.185; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Hansen JR, 2006, GLIA, V53, P593, DOI 10.1002/glia.20316; Hennigan RF, 2010, MOL CELL BIOL, V30, P54, DOI 10.1128/MCB.00248-09; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Hiemer SE, 2013, BBA-GEN SUBJECTS, V1830, P2323, DOI 10.1016/j.bbagen.2012.07.005; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; Horiguchi A, 2008, PROSTATE, V68, P975, DOI 10.1002/pros.20760; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; Jacob A, 2008, OTOL NEUROTOL, V29, P58, DOI 10.1097/mao.0b013e31816021f7; Jacob A, 2012, LARYNGOSCOPE, V122, P174, DOI 10.1002/lary.22392; James MF, 2012, MOL CANCER RES, V10, P649, DOI 10.1158/1541-7786.MCR-11-0425-T; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Johnson MD, 2002, J NEUROSURG, V97, P668, DOI 10.3171/jns.2002.97.3.0668; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kalamarides M, 2010, J NEURO-ONCOL, V99, P325, DOI 10.1007/s11060-010-0331-5; Kawana Y, 2002, PROSTATE, V53, P60, DOI 10.1002/pros.10131; Khajeh JA, 2014, J MOL BIOL, V426, P2755, DOI 10.1016/j.jmb.2014.05.011; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Kodaka M, 2015, CELL MOL LIFE SCI, V72, P285, DOI 10.1007/s00018-014-1742-9; Koutsimpelas D, 2012, ORL J OTO-RHINO-LARY, V74, P33, DOI 10.1159/000334968; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Larsson J, 2008, CELL STEM CELL, V3, P221, DOI 10.1016/j.stem.2008.06.005; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Laulajainen M, 2011, NEOPLASIA, V13, P643, DOI 10.1593/neo.11356; Lee TX, 2009, EUR J CANCER, V45, P1709, DOI 10.1016/j.ejca.2009.03.013; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Lloyd SKW, 2013, HAND CLINIC, V115, P957, DOI 10.1016/B978-0-444-52902-2.00054-0; Lomas J, 2005, GENE CHROMOSOME CANC, V42, P314, DOI 10.1002/gcc.20141; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Low BC, 2014, FEBS LETT, V588, P2663, DOI 10.1016/j.febslet.2014.04.012; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Malhotra A, 2013, CANCER BIOL THER, V14, P840, DOI 10.4161/cbt.25329; Mawrin C, 2005, CLIN CANCER RES, V11, P4074, DOI 10.1158/1078-0432.CCR-04-2550; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Morales FC, 2010, NEURO-ONCOLOGY, V12, P528, DOI 10.1093/neuonc/nop060; Mori T, 2014, GENES CELLS, V19, P603, DOI 10.1111/gtc.12161; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Mukherjee J, 2009, CANCER RES, V69, P5099, DOI 10.1158/0008-5472.CAN-08-4475; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Muranen T, 2007, HUM MOL GENET, V16, P1742, DOI 10.1093/hmg/ddm122; Murray LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043295; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pass HI, 2004, CURR PROB CANCER, V28, P85; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Petrilli A, 2014, ONCOGENE, V33, P3571, DOI 10.1038/onc.2013.320; Petrilli AM, 2014, AM J TRANSL RES, V6, P471; Petrilli AM, 2013, ONCOTARGET, V4, P2354, DOI 10.18632/oncotarget.1422; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Pineau P, 2003, HEPATOLOGY, V37, P852, DOI 10.1053/jhep.2003.50138; Plotkin SR, 2011, J NEUROSURG-SPINE, V14, P543, DOI 10.3171/2010.11.SPINE10350; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Reinhold WC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101670; Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1; Robinson BS, 2011, CURR BIOL, V21, pR890, DOI 10.1016/j.cub.2011.09.019; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Rustgi AK, 1995, CANCER GENET CYTOGEN, V84, P24, DOI 10.1016/0165-4608(95)00059-3; Sabha N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039412; Sainio M, 1997, J CELL SCI, V110, P2249; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Schroeder MC, 2012, SEMIN CELL DEV BIOL, V23, P803, DOI 10.1016/j.semcdb.2012.06.001; Schulz A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0082-1; Schulz A, 2014, BRAIN, V137, P420, DOI 10.1093/brain/awt327; Schulz A, 2013, NAT NEUROSCI, V16, P426, DOI 10.1038/nn.3348; Scoles DR, 2008, BBA-REV CANCER, V1785, P32, DOI 10.1016/j.bbcan.2007.10.001; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sheikh HA, 2004, AM J SURG PATHOL, V28, P101, DOI 10.1097/00000478-200401000-00012; Sher I, 2012, DEV CELL, V22, P703, DOI 10.1016/j.devcel.2012.03.008; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smole Z, 2014, CANCER RES, V74, P353, DOI 10.1158/0008-5472.CAN-13-1334; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Sperfeld AD, 2002, BRAIN, V125, P996, DOI 10.1093/brain/awf115; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Striedinger K, 2008, NEOPLASIA, V10, P1204, DOI 10.1593/neo.08642; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Thaxton C, 2008, ONCOGENE, V27, P2705, DOI 10.1038/sj.onc.1210923; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; Thurneysen C, 2009, LUNG CANCER, V64, P140, DOI 10.1016/j.lungcan.2008.08.014; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wickremesekera A, 2007, J CLIN NEUROSCI, V14, P1199, DOI 10.1016/j.jocn.2007.05.009; Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; YAEGASHI S, 1995, JPN J CANCER RES, V86, P929, DOI 10.1111/j.1349-7006.1995.tb03003.x; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Ye KQ, 2007, CELL ADHES MIGR, V1, P196, DOI 10.4161/cam.1.4.5192; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yogesha SD, 2011, PROTEIN SCI, V20, P2113, DOI 10.1002/pro.751; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Yoo NJ, 2012, PATHOLOGY, V44, P29, DOI 10.1097/PAT.0b013e32834c3599; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	186	206	212	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					537	548		10.1038/onc.2015.125	http://dx.doi.org/10.1038/onc.2015.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893302	Green Accepted			2022-12-28	WOS:000369548800001
J	Koch, DC; Jang, HS; O'Donnell, EF; Punj, S; Kopparapu, PR; Bisson, WH; Kerkvliet, NI; Kolluri, SK				Koch, D. C.; Jang, H. S.; O'Donnell, E. F.; Punj, S.; Kopparapu, P. R.; Bisson, W. H.; Kerkvliet, N. I.; Kolluri, S. K.			Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-beta 1	ONCOGENE			English	Article							BREAST-CANCER CELLS; AH-RECEPTOR; ESTROGEN-RECEPTOR; DIOXIN-RECEPTOR; CYCLE CONTROL; IN-VIVO; EXPRESSION; PROTEIN; GROWTH; MECHANISM	The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor and a member of the basic helix-loop-helix PER/ARNT/SIM family of chemosensors and developmental regulators. The AhR is widely known as a mediator of dioxin toxicity; however, it also suppresses cancer cell proliferation and recent findings have implicated its role as a tumor suppressor. We conducted a chemical library screen to identify nontoxic AhR ligands with anti-cancer effects and discovered flutamide (Eulexin) as a putative AhR ligand. Flutamide is an androgen receptor (AR) antagonist approved by the United States Food and Drug Administration for the treatment of prostate cancer. We found that flutamide inhibited the growth of several cancer cell lines independent of AR status, and that suppression of AhR expression reversed the anti-proliferative effects of flutamide. We investigated the AhR-dependent mechanism of action of flutamide in human hepatocellular carcinoma cells and identified that transforming growth factor-beta 1 (TGF-beta 1) is induced by flutamide in an AhR-dependent manner. In contrast, the potent AhR agonist 2,3,7,8-Tetrachlorodibenzo-p-dioxin had no effect on TGF-beta 1 expression, indicating the ligand specificity of AhR activation. We also determined that TGF-beta 1 induction is required for the AhR-dependent growth inhibitory effects of flutamide. Therefore, flutamide may be effective in AhR-positive cancers that are sensitive to TGF-beta 1 signaling, such as hepatocellular carcinoma.	[Koch, D. C.; Jang, H. S.; O'Donnell, E. F.; Punj, S.; Kopparapu, P. R.; Kolluri, S. K.] Oregon State Univ, Dept Environm & Mol Toxicol, Canc Res Lab, Corvallis, OR 97331 USA; [Koch, D. C.; Jang, H. S.; O'Donnell, E. F.; Punj, S.; Kopparapu, P. R.; Bisson, W. H.; Kerkvliet, N. I.; Kolluri, S. K.] Oregon State Univ, Dept Environm & Mol Toxicol, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Kolluri, SK (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Canc Res Lab, 1007 ALS Bldg, Corvallis, OR 97331 USA.	siva.kolluri@oregonstate.edu		Jang, Hyo Sang/0000-0003-0460-9924; /0000-0001-9516-9690	American Cancer Society [RSG-13-132-01-CDD]; National Institute of Environmental Health Sciences (NIEHS) [ES016651, ES019000]; US Army Medical Research and Material Command; Cell Imaging and Analysis Facility Cores of the Environmental Health Sciences Center, NIEHS [P30 ES00210]; National Cancer Institute [1F31CA144571-01]; Burroughs Wellcome Fund post-doctoral enrichment program; Department of Defense Breast Cancer Research Program [W81XWH-10-1-0160]; NIEHS [T32ES07060]; NATIONAL CANCER INSTITUTE [F31CA144571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016651, R21ES019000, P30ES000210, T32ES007060] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Cell Imaging and Analysis Facility Cores of the Environmental Health Sciences Center, NIEHS; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Burroughs Wellcome Fund post-doctoral enrichment program; Department of Defense Breast Cancer Research Program(United States Department of Defense); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by American Cancer Society (RSG-13-132-01-CDD), the National Institute of Environmental Health Sciences (NIEHS) grant numbers ES016651 and ES019000, The US Army Medical Research and Material Command and The Cell Imaging and Analysis Facility Cores of the Environmental Health Sciences Center, NIEHS grant number P30 ES00210. DCK was supported by a National Research Service Award (1F31CA144571-01) pre-doctoral fellowship from the National Cancer Institute. DCK is currently supported by the Burroughs Wellcome Fund post-doctoral enrichment program. EFO was supported by a pre-doctoral fellowship from the Department of Defense Breast Cancer Research Program (W81XWH-10-1-0160). DCK and EFO were previously supported by NIEHS training grant (T32ES07060). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank Samuel Bradford for excellent flow cytometry assistance, Sammy Khalil, Cathy Duong and Viktor Dikov for laboratory assistance.	ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20; Bertazzi PA, 1997, EPIDEMIOLOGY, V8, P646, DOI 10.1097/00001648-199710000-00006; Bisson WH, 2009, J MED CHEM, V52, P5635, DOI 10.1021/jm900199u; Bock KW, 2006, BIOCHEM PHARMACOL, V72, P393, DOI 10.1016/j.bcp.2006.01.017; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Carvajal-Gonzalez JM, 2009, J CELL SCI, V122, P1823, DOI 10.1242/jcs.047274; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chang XQ, 2007, MOL CELL BIOL, V27, P6127, DOI 10.1128/MCB.00323-07; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Dohr O, 1997, BIOCHEM BIOPH RES CO, V241, P86, DOI 10.1006/bbrc.1997.7773; EGELAND GM, 1994, AM J EPIDEMIOL, V139, P272, DOI 10.1093/oxfordjournals.aje.a116994; Elizondo G, 2000, MOL PHARMACOL, V57, P1056; Fan YX, 2010, CANCER RES, V70, P212, DOI 10.1158/0008-5472.CAN-09-3090; Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Fritz WA, 2007, CARCINOGENESIS, V28, P497, DOI 10.1093/carcin/bgl179; Funatake CJ, 2008, J IMMUNOTOXICOL, V5, P81, DOI 10.1080/15476910802019037; Gasiewicz TA, 2008, CRIT REV EUKAR GENE, V18, P279, DOI 10.1615/CritRevEukarGeneExpr.v18.i4.10; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gomez-Duran A, 2009, BIOCHEM PHARMACOL, V77, P700, DOI 10.1016/j.bcp.2008.08.032; Hall JM, 2010, MOL ENDOCRINOL, V24, P359, DOI 10.1210/me.2009-0346; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hsu EL, 2007, TOXICOL SCI, V98, P436, DOI 10.1093/toxsci/kfm125; Hu WY, 2007, MOL PHARMACOL, V71, P1475, DOI 10.1124/mol.106.032748; Jin UH, 2012, J PHARMACOL EXP THER, V343, P333, DOI 10.1124/jpet.112.195339; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Lai IK, 2012, TOXICOLOGY, V302, P25, DOI 10.1016/j.tox.2012.07.007; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Mitsuhashi T, 2010, P NATL ACAD SCI USA, V107, P16331, DOI 10.1073/pnas.1002960107; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; Murray IA, 2014, NAT REV CANCER, V14, P801, DOI 10.1038/nrc3846; O'Donnell EF, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.549; O'Donnell EF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040926; O'Donnell EF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013128; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; Perkins Arden, 2014, Biology (Basel), V3, P645, DOI 10.3390/biology3040645; Puga A, 2002, CHEM-BIOL INTERACT, V141, P117, DOI 10.1016/S0009-2797(02)00069-8; Puga A, 2009, BIOCHEM PHARMACOL, V77, P713, DOI 10.1016/j.bcp.2008.08.031; Punj S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088726; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Safe S, 2013, TOXICOL SCI, V135, P1, DOI 10.1093/toxsci/kft128; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Warner M, 2002, AM J EPIDEMIOL, V155, ps102; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Zhang S, 2012, MOL CANCER THER, V11, P108, DOI 10.1158/1535-7163.MCT-11-0548	56	20	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6092	6104		10.1038/onc.2015.55	http://dx.doi.org/10.1038/onc.2015.55			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25867062				2022-12-28	WOS:000366113800006
J	Yang, Y; Gorzelanny, C; Bauer, AT; Halter, N; Komljenovic, D; Bauerle, T; Borsig, L; Roblek, M; Schneider, SW				Yang, Y.; Gorzelanny, C.; Bauer, A. T.; Halter, N.; Komljenovic, D.; Baeuerle, T.; Borsig, L.; Roblek, M.; Schneider, S. W.			Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity	ONCOGENE			English	Article							NF-KAPPA-B; AGGRESSIVE TUMOR PHENOTYPE; ENDOTHELIAL GROWTH-FACTOR; CELL INVASION; NUDE-MICE; RECIPROCAL REGULATION; CLINICAL-SIGNIFICANCE; VASCULAR ENDOTHELIUM; CANCER METASTASIS; CERVICAL-CANCER	Heparanase-1 (HPSE) plays a pivotal role in structural remodeling of the ECM and the glycocalyx, thus conferring protumorigenic, proangiogenic and prometastatic properties to many cancer entities. In addition to its extracellular function, recent studies suggest an intracellular activity of HPSE with a largely unknown significance during tumor progression. Therefore, we investigated the relevance of the dual functions of HPSE to malignant melanoma in vitro, as well as in different mouse melanoma models based on the intradermal or intravenous injection of melanoma cells. Consistent with its extracellular action, an HPSE deficiency led to a reduced shedding of the glycocalyx accompanied by a reduced availability of vascular endothelial growth factor, affecting tumor growth and vascularization. In contrast, we measured an elevated expression of the protumorigenic factors pentraxin-3, tissue factor, TNF-alpha and most prominently, MMP-9, upon HPSE knockdown. In vivo, an HPSE deficiency was related to increased lymph node metastasis. Since the inhibition of its extracellular function with heparin was unable to block the gene regulatory impact of HPSE, we proposed an intracellular mechanism. Immunostaining revealed a counter-staining of HPSE and NF-kappa B in the nucleus, suggesting a close relationship between both proteins. This finding was further supported by the discovery of a direct charge-driven molecular interaction between HPSE and DNA by using atomic force microscopy and a co-precipitation approach. Our findings are novel and point towards a dual function for HPSE in malignant melanoma with a protumorigenic extracellular activity and a tumor-suppressive nuclear action. The identification of molecular strategies to shuttle extracellular HPSE into the nuclei of cancer cells could provide new therapeutic options.	[Yang, Y.; Gorzelanny, C.; Bauer, A. T.; Halter, N.; Schneider, S. W.] Heidelberg Univ, Med Fac Mannheim, Dept Dermatol Expt Dermatol, D-68167 Mannheim, Germany; [Komljenovic, D.] German Canc Res Ctr, Div Med Phys Radiol, Heidelberg, Germany; [Baeuerle, T.] Univ Hosp Erlangen, Inst Radiol, Erlangen, Germany; [Borsig, L.; Roblek, M.] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Borsig, L.; Roblek, M.] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Erlangen Nuremberg; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Schneider, SW (corresponding author), Heidelberg Univ, Med Fac Mannheim, Dept Dermatol Expt Dermatol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	stefan.schneider@medma.uni-heidelberg.de		Borsig, Lubor/0000-0003-2263-9545; Bauerle, Tobias/0000-0002-0206-6199	Deutsche Forschungsgemeinschaft [SFB/Transregio 23]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Katja Oehme for the excellent technical help and advice in dynamic contrast-enhanced magnetic resonance imaging experiments. We acknowledge Prof. Viktor Umansky (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany) for providing a melanoma cell line from ret transgenic mice. This work was supported by the Deutsche Forschungsgemeinschaft within the SFB/Transregio 23 (project A9 to SWS, project Z1 to DK).	Andela VB, 2000, CANCER RES, V60, P6557; AUBERT C, 1980, J NATL CANCER I, V64, P1029; Barash U, 2010, FEBS J, V277, P3890, DOI 10.1111/j.1742-4658.2010.07799.x; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Borczuk AC, 2008, ONCOGENE, V27, P557, DOI 10.1038/sj.onc.1210662; Boyango I, 2014, CANCER RES, V74, P4504, DOI 10.1158/0008-5472.CAN-13-2962; BRIX G, 1991, J COMPUT ASSIST TOMO, V15, P621, DOI 10.1097/00004728-199107000-00018; Cao HJ, 2005, WORLD J GASTROENTERO, V11, P903, DOI 10.3748/wjg.v11.i6.903; Carrer A, 2012, CANCER RES, V72, P6371, DOI 10.1158/0008-5472.CAN-12-0762; Cohen-Kaplan V, 2012, J BIOL CHEM, V287, P6668, DOI 10.1074/jbc.M111.271346; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; Desch A, 2012, AM J PATHOL, V181, P693, DOI 10.1016/j.ajpath.2012.04.012; Doweck I, 2006, NEOPLASIA, V8, P1055, DOI 10.1593/neo.06577; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Goerge T, 2006, CANCER RES, V66, P7766, DOI 10.1158/0008-5472.CAN-05-3897; Gorzelanny C, 2007, BIOMACROMOLECULES, V8, P3035, DOI 10.1021/bm0703214; HART IR, 1979, AM J PATHOL, V97, P587; Hong X, 2012, INT J ONCOL, V40, P494, DOI 10.3892/ijo.2011.1229; Hostettler N, 2007, FASEB J, V21, P3562, DOI 10.1096/fj.07-8450com; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kashani-Sabet M, 2004, J CLIN ONCOL, V22, P617, DOI 10.1200/JCO.2004.06.047; Kelly T, 2003, CANCER RES, V63, P8749; Kerk N, 2010, J INVEST DERMATOL, V130, P2259, DOI 10.1038/jid.2010.136; Liu XY, 2013, INT J BIOL SCI, V9, P564, DOI 10.7150/ijbs.5425; Liu XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038659; Ludwig T, 2002, AM J PHYSIOL-RENAL, V283, pF319, DOI 10.1152/ajprenal.00327.2001; Merz M, 2011, EUR J CANCER, V47, P277, DOI 10.1016/j.ejca.2010.08.019; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Murphy G, 2008, MOL ASPECTS MED, V29, P290, DOI 10.1016/j.mam.2008.05.002; Niwa Y, 2001, CLIN CANCER RES, V7, P285; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200; Purushothaman A, 2011, J BIOL CHEM, V286, P30377, DOI 10.1074/jbc.M111.254789; Roy M, 2005, NEOPLASIA, V7, P253, DOI 10.1593/neo.04493; Roy M, 2009, J CELL BIOCHEM, V106, P200, DOI 10.1002/jcb.22005; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Schnaeker EM, 2004, CANCER RES, V64, P8924, DOI 10.1158/0008-5472.CAN-04-0324; Schubert SY, 2004, LAB INVEST, V84, P535, DOI 10.1038/labinvest.3700084; Shinyo Y, 2003, ANN ONCOL, V14, P1505, DOI 10.1093/annonc/mdg407; Strozyk EA, 2014, EXP DERMATOL, V23, P670, DOI 10.1111/exd.12505; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553; Wu WJ, 2010, ONCOL REP, V23, P255, DOI 10.3892/or_00000631; Zak J, 2000, PFLUG ARCH EUR J PHY, V440, P179, DOI 10.1007/s004240000282; Zcharia E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005181; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zhao F, 2009, CLIN CANCER RES, V15, P4382, DOI 10.1158/1078-0432.CCR-09-0399; Zong F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007346	58	31	33	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5832	5842		10.1038/onc.2015.40	http://dx.doi.org/10.1038/onc.2015.40			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25745999	Green Accepted			2022-12-28	WOS:000365035200006
J	Spring, K; Fournier, P; Lapointe, L; Chabot, C; Roussy, J; Pommey, S; Stagg, J; Royal, I				Spring, K.; Fournier, P.; Lapointe, L.; Chabot, C.; Roussy, J.; Pommey, S.; Stagg, J.; Royal, I.			The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis	ONCOGENE			English	Article							C-SRC; KINASE INHIBITOR; BONE METASTASIS; IN-VITRO; CORTACTIN; GROWTH; ACTIVATION; MIGRATION; RECEPTOR; PHOSPHORYLATION	DEP-1/PTPRJ is a receptor-like protein tyrosine phosphatase mainly known for its antiproliferative and tumor-suppressive functions. Many identified substrates are growth factor receptors, and DEP-1 is deleted and/or mutated in human cancers including that of the breast. However, DEP-1 was also identified as a promoter of Src activation and proinvasive functions in the endothelium, suggesting it could perhaps mediate breast cancer invasiveness that is likewise driven by Src family kinases. We show here that DEP-1 expression was greater in highly invasive breast cancer cells (MDA-MB-231, Hs578T, BT-549) than in the less invasive or untransformed cell lines tested (MCF-7, T47D, SK-BR3 and MCF10A). DEP-1 silencing experiments in invasive cells demonstrated that moderately expressed and catalytically active DEP-1 was required, in collaboration with basal epidermal growth factor receptor activity, for Src activation and the phosphorylation of its substrate Cortactin, and for their colocalization at the cell's leading edge. This correlated with an increased number of cell protrusions, and an enhanced capacity of the cells to migrate and invade. Similarly, moderate overexpression of DEP-1 in the low-invasive cells resulted in the promotion of their invasiveness in an Src-dependent manner. Consistent with these data, the expression of endogenous DEP-1 was elevated in a bone metastatic cell line derived from MDA-MB-231 cells, and promoted increased Src Y418 and Cortactin Y421 phosphorylation, as well as pro-MMP9 secretion and Matrigel invasion. Importantly, the silencing of DEP-1 in MDA-MB-231 cells greatly decreased their ability to metastasize, despite having no effect on tumor growth or angiogenesis. Hence, we found that moderate expression of DEP-1 was associated with the increased relapse and decreased survival of breast cancer patients. These results therefore identify a new and unsuspected role for DEP-1 as a mediator of an invasive cell program implicating Src activation and the promotion of breast cancer progression.	[Spring, K.; Fournier, P.; Lapointe, L.; Chabot, C.; Roussy, J.; Pommey, S.; Stagg, J.; Royal, I.] CHUM, Ctr Rech, Inst Canc Montreal, Montreal, PQ H2X 0A9, Canada; [Stagg, J.] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; [Royal, I.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Royal, I (corresponding author), CHUM, Ctr Rech, 900 Rue St Denis, Montreal, PQ H2X 0A9, Canada.	isabelle.royal@umontreal.ca		Royal, Isabelle/0000-0002-7548-1182; Spring, Kathleen/0000-0001-6747-7725	Cancer Research Society/Quebec Breast Cancer Foundation; FRQS [25988]; CIHR [292353]	Cancer Research Society/Quebec Breast Cancer Foundation; FRQS; CIHR(Canadian Institutes of Health Research (CIHR))	We thank our colleagues for their generous gifts of plasmid DNAs and cell lines. This work was supported by a Cancer Research Society/Quebec Breast Cancer Foundation grant (to IR). KS and CC held partial studentships from Universite de Montreal. PF was supported by FRQS (25988) and CIHR (292353) studentships. KS, PF, CC and JR also held partial studentships from the Montreal Cancer Institute.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Aya-Bonilla C, 2013, GENE CHROMOSOME CANC, V52, P467, DOI 10.1002/gcc.22044; Balavenkatraman KK, 2006, ONCOGENE, V25, P6319, DOI 10.1038/sj.onc.1209647; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Berset TA, 2005, GENE DEV, V19, P1328, DOI 10.1101/gad.333505; Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Chabot C, 2009, MOL CELL BIOL, V29, P241, DOI 10.1128/MCB.01374-08; Chiorean R, 2013, BREAST, V22, P1026, DOI 10.1016/j.breast.2013.08.007; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Eccles SA, 2011, INT J DEV BIOL, V55, P685, DOI 10.1387/ijdb.113396se; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Elias D, 2014, ONCOGENE, P1; Ellinghaus E, 2012, LEUKEMIA, V26, P902, DOI 10.1038/leu.2011.302; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hardy S, 2010, CANCER RES, V70, P8959, DOI 10.1158/0008-5472.CAN-10-2041; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Iuliano R, 2004, ONCOGENE, V23, P8432, DOI 10.1038/sj.onc.1207766; Iuliano R, 2010, ENDOCR-RELAT CANCER, V17, P1001, DOI 10.1677/ERC-10-0143; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Keane MM, 1996, CANCER RES, V56, P4236; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lai FPL, 2009, MOL BIOL CELL, V20, P3209, DOI 10.1091/mbc.E08-12-1180; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lesueur F, 2005, HUM MOL GENET, V14, P2349, DOI 10.1093/hmg/ddi237; Li YS, 2001, CANCER RES, V61, P6906; Ma JG, 2011, BREAST CANCER RES TR, V130, P85, DOI 10.1007/s10549-010-1302-4; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Majumder S, 2014, ARTERIOSCL THROM VAS, V34, P419, DOI 10.1161/ATVBAHA.113.302689; Mezi S, 2012, INT J ONCOL, V41, P2128, DOI 10.3892/ijo.2012.1642; Mita Y, 2010, J CANCER RES CLIN, V136, P249, DOI 10.1007/s00432-009-0656-7; Myoui A, 2003, CANCER RES, V63, P5028; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Petermann A, 2011, BRAIN PATHOL, V21, P405, DOI 10.1111/j.1750-3639.2010.00464.x; Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Sabe H, 2008, CELL ADHES MIGR, V2, P71, DOI 10.4161/cam.2.2.6191; Sallee JL, 2009, J BIOL CHEM, V284, P14997, DOI 10.1074/jbc.M901901200; Senis YA, 2009, BLOOD, V113, P4942, DOI 10.1182/blood-2008-08-174318; Shields BJ, 2013, MOL CELL BIOL, V33, P557, DOI 10.1128/MCB.01016-12; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944; Smart CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040742; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Spring K, 2014, CELL SIGNAL, V26, P1283, DOI 10.1016/j.cellsig.2014.02.008; Spring K, 2012, BLOOD, V120, P2745, DOI 10.1182/blood-2011-12-398040; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Sung BH, 2011, CURR BIOL, V21, P1460, DOI 10.1016/j.cub.2011.06.065; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tonks NK, 2013, FEBS J, V280, P346, DOI 10.1111/febs.12077; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhu JW, 2008, IMMUNITY, V28, P183, DOI 10.1016/j.immuni.2007.11.024	79	23	23	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5536	5547		10.1038/onc.2015.9	http://dx.doi.org/10.1038/onc.2015.9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25772245				2022-12-28	WOS:000364594000003
J	Dong, H; Tian, L; Li, R; Pei, C; Fu, Y; Dong, X; Xia, F; Wang, C; Li, W; Guo, X; Gu, C; Li, B; Liu, A; Ren, H; Wang, C; Xu, H				Dong, H.; Tian, L.; Li, R.; Pei, C.; Fu, Y.; Dong, X.; Xia, F.; Wang, C.; Li, W.; Guo, X.; Gu, C.; Li, B.; Liu, A.; Ren, H.; Wang, C.; Xu, H.			IFNg-induced Irgm1 promotes tumorigenesis of melanoma via dual regulation of apoptosis and Bif-1-dependent autophagy	ONCOGENE			English	Article							INTERFERON-GAMMA; BIF-1/ENDOPHILIN B1; CELL-PROLIFERATION; TUMOR-DEVELOPMENT; FACTOR (IRF)-1; GTPASE IRGM1; T-CELL; GROWTH; EXPRESSION; MYCOBACTERIA	Interferon gamma (IFNg) has been known as the regulator for both tumor immune surveillance and tumorgenesis. However, mechanisms underlying the resistance of tumor cell to IFNg have yet been fully understood. In the current study, we showed that immunity-related GTPase family member 1 (mouse: Irgm1; human: IRGM) is essential for IFNg-mediated regulation of tumor cell growth in melanoma. IRGM/Irgm1 was highly expressed in human and mouse melanoma. IFNg and starvation synergistically induced Irgm1 expression in melanoma B16 cells. In vivo, injection of Irgm1-siRNA-treated cells significantly reduced the number of tumor nodules and prolonged the mice survival. In vitro, knockdown endogenous or IFNg-induced Irgm1 significantly decreases the proliferation and increases apoptosis of B16 cells. In addition, suppressing Irgm1 decreased the IFNg/starvation-induced autophagy, while overexpressing Irgm1 significantly increased autophagy and rescued starvation-challenged cells. Moreover, IFNg and starvation-induced the co-localization of Irgm1 with Bax-interacting factor 1 (Bif-1). Knockdown of Bif-1 decreased Irgm1-mediated tumor cell autophagy. Taken together, these data reveal an Irgm1-dependent mechanism that promotes the tumorigenesis of melanoma via dual regulation of apoptosis and Bif-1-dependent autophagy.	[Dong, H.; Tian, L.; Pei, C.; Fu, Y.; Dong, X.; Xia, F.; Wang, C.; Li, W.; Guo, X.; Gu, C.; Li, B.; Ren, H.; Xu, H.] Harbin Med Univ, Dept Immunol, Heilongjiang Prov Key Lab Infect & Immun, Harbin 150086, Heilongjiang, Peoples R China; [Dong, H.; Wang, C.] Fujian Med Univ, Dept Neurol, Affiliated Sanming Hosp 1, Sanming, Fujian, Peoples R China; [Li, R.] McGill Univ, Neuroinflammat Unit, Montreal Neurol Inst, Montreal, PQ, Canada; [Liu, A.] Harbin Med Univ, Dept Hematol, Affiliated Tumor Hosp, Harbin, Peoples R China	Harbin Medical University; Fujian Medical University; McGill University; Harbin Medical University	Xu, H (corresponding author), Harbin Med Univ, Dept Immunol, Heilongjiang Prov Key Lab Infect & Immun, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China.	cdongwang01@126.com; hongwei56@hotmail.com	Li, Rui/O-7397-2016; Xu, Hongwei/S-3865-2018; Ren, Huan/O-5727-2017	Li, Rui/0000-0002-7210-8358; Ren, Huan/0000-0001-7114-2012; Xu, Hongwei/0000-0001-5763-3894	National Natural Science Foundation Projects [81071949, 31371080]; Heilongjiang Provincial Natural Science Foundation [D201004]; National Natural Science Foundation Project [81371320]	National Natural Science Foundation Projects(National Natural Science Foundation of China (NSFC)); Heilongjiang Provincial Natural Science Foundation(Natural Science Foundation of Heilongjiang Province); National Natural Science Foundation Project(National Natural Science Foundation of China (NSFC))	We thank Dr Zhiheng Xu and Professor Hulun Li for project discussion and technical support. These studies were funded by the National Natural Science Foundation Projects (Nos. 81071949 and 31371080) and Heilongjiang Provincial Natural Science Foundation (D201004) to Dr Hongwei Xu and the National Natural Science Foundation Project (No. 81371320) to Dr Chaodong Wang.	Altman BJ, 2009, AUTOPHAGY, V5, P569, DOI 10.4161/auto.5.4.8254; Bernabei P, 2001, J LEUKOCYTE BIOL, V70, P950; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Feng CG, 2008, NAT IMMUNOL, V9, P1279, DOI 10.1038/ni.1653; Feng CG, 2008, CELL STEM CELL, V2, P83, DOI 10.1016/j.stem.2007.10.007; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; He SY, 2012, AUTOPHAGY, V8, P1621, DOI 10.4161/auto.21561; He YF, 2005, CANCER IMMUNOL IMMUN, V54, P891, DOI 10.1007/s00262-004-0654-1; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; LOLLINI PL, 1993, INT J CANCER, V55, P320, DOI 10.1002/ijc.2910550224; Overwijk W W, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2001s39; Seliger B, 2008, ADV CANCER RES, V101, P249, DOI 10.1016/S0065-230X(08)00407-7; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takahashi Y, 2009, CELL DEATH DIFFER, V16, P947, DOI 10.1038/cdd.2009.19; Takahashi Y, 2008, AUTOPHAGY, V4, P121, DOI 10.4161/auto.5265; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; TANIGUCHI K, 1987, P NATL ACAD SCI USA, V84, P3405, DOI 10.1073/pnas.84.10.3405; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Tiwari S, 2009, NAT IMMUNOL, V10, P907, DOI 10.1038/ni.1759; Wang Y, 2007, CANCER RES, V67, P2535, DOI 10.1158/0008-5472.CAN-06-3530; Xia FC, 2013, SCI REP-UK, V3, DOI 10.1038/srep01867; Xu HW, 2010, FASEB J, V24, P1583, DOI 10.1096/fj.09-137323; Yi Y, 2013, ANN SURG ONCOL, V20, P267, DOI 10.1245/s10434-012-2487-z; Yin XC, 2011, EMBO REP, V12, P727, DOI 10.1038/embor.2011.79; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666	34	18	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5363	5371		10.1038/onc.2014.459	http://dx.doi.org/10.1038/onc.2014.459			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25619828				2022-12-28	WOS:000363479200006
J	Skibinski, A; Kuperwasser, C				Skibinski, A.; Kuperwasser, C.			The origin of breast tumor heterogeneity	ONCOGENE			English	Review							MAMMARY EPITHELIAL-CELLS; BASAL-LIKE SUBTYPE; STEM-CELLS; MOLECULAR PORTRAITS; MESENCHYMAL TRANSITION; STATE TRANSITIONS; GLAND DEVELOPMENT; PROGENITOR CELLS; MOUSE MODELS; LIFE-SPAN	How breast diversity is generated is a fascinating and fundamental question with important clinical implications. It is clear that the diversity of phenotypes displayed by breast cancer cells reflects the array of cell types present in the disease-free breast epithelium, including luminal, basal and stem cells. Therefore, it is hypothesized that the molecular regulators governing normal development of the breast epithelium may double as engines of breast tumor diversity. In the past few years, a deepened understanding of the mammary epithelial hierarchy has prompted the search for the cellular precursors of breast tumors. At the same time, the use of novel experimental strategies including the new technology of massively parallel sequencing has provided insight into the origin and evolution of breast tumors. Here, we review the current understanding of the basis of the intrinsic subtypes and the sources of inter-tumor heterogeneity.	[Skibinski, A.; Kuperwasser, C.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA; [Skibinski, A.; Kuperwasser, C.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Tufts University; Tufts Medical Center	Kuperwasser, C (corresponding author), Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, 800 Washington St,Box 5609, Boston, MA 02111 USA.	Charlotte.Kuperwasser@tufts.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD073035] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA170851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA170851] Funding Source: Medline; NICHD NIH HHS [R01 HD073035] Funding Source: Medline; NIGMS NIH HHS [T32 GM008448] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asselin-Labat ML, 2008, COLD SH Q B, V73, P469, DOI 10.1101/sqb.2008.73.020; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Booth BW, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1538; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chang TH, 2014, BREAST CANCER RES, V16, P1; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; de Ruijter TC, 2011, J CANCER RES CLIN, V137, P183, DOI 10.1007/s00432-010-0957-x; DEOME KB, 1959, CANCER RES, V19, P515; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Hollern DP, 2014, BREAST CANCER RES, V16, P3; HOSHINO K, 1967, NATURE, V213, P193, DOI 10.1038/213193a0; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu BY, 2003, ONCOGENE, V22, P9243, DOI 10.1038/sj.onc.1207217; Liu JC, 2014, EMBO MOL MED, V6, P1542, DOI 10.15252/emmm.201404402; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Macias H, 2012, WIRES DEV BIOL, V1, P533, DOI 10.1002/wdev.35; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; Melchor L, 2014, J PATHOL, V233, P124, DOI 10.1002/path.4345; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Morel E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003000; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prater MD, 2014, NAT CELL BIOL, V16, P942, DOI 10.1038/ncb3025; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Tao LW, 2014, STEM CELL REP, V2, P770, DOI 10.1016/j.stemcr.2014.04.004; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Tsai YC, 1996, CANCER RES, V56, P402; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553	86	91	92	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5309	5316		10.1038/onc.2014.475	http://dx.doi.org/10.1038/onc.2014.475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25703331	Green Accepted			2022-12-28	WOS:000363479200001
J	Hayashi, K; Momoi, Y; Tanuma, N; Kishimoto, A; Ogoh, H; Kato, H; Suzuki, M; Sakamoto, Y; Inoue, Y; Nomura, M; Kiyonari, H; Sakayori, M; Fukamachi, K; Kakugawa, Y; Yamashita, Y; Ito, S; Sato, I; Suzuki, A; Nishio, M; Suganuma, M; Watanabe, T; Shima, H				Hayashi, K.; Momoi, Y.; Tanuma, N.; Kishimoto, A.; Ogoh, H.; Kato, H.; Suzuki, M.; Sakamoto, Y.; Inoue, Y.; Nomura, M.; Kiyonari, H.; Sakayori, M.; Fukamachi, K.; Kakugawa, Y.; Yamashita, Y.; Ito, S.; Sato, I.; Suzuki, A.; Nishio, M.; Suganuma, M.; Watanabe, T.; Shima, H.			Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA	ONCOGENE			English	Article							MOUSE SKIN; TNF-ALPHA; KAPPA-B; CANCER DEVELOPMENT; TUMOR PROMOTION; OKADAIC ACID; CYCLIN D1; MICE; PROGRESSION; ACTIVATION	Somatic mutations in the gene encoding the catalytic subunit of protein phosphatase 6 (Ppp6c) have been identified in malignant melanoma and are thought to function as a driver in B-raf-or N-ras-driven tumorigenesis. To assess the role of Ppp6c in carcinogenesis, we generated skin keratinocyte-specific Ppp6c conditional knockout mice and performed two-stage skin carcinogenesis analysis. Ppp6c deficiency induced papilloma formation with 7,12-dimethylbenz (a) anthracene (DMBA) only, and development of those papillomas was significantly accelerated compared with that seen following DMBA/TPA (12-O-tetradecanoylphorbol 13-acetate) treatment of wild-type mice. NF-kappa B activation either by tumor necrosis factor (TNF)-alpha or interleukin (IL)-1 beta was enhanced in Ppp6c-deficient keratinocytes. Overall, we conclude that Ppp6c deficiency predisposes mice to skin carcinogenesis initiated by DMBA. This is the first report showing that such deficiency promotes tumor formation in mice.	[Hayashi, K.; Momoi, Y.; Tanuma, N.; Kato, H.; Sakamoto, Y.; Inoue, Y.; Nomura, M.; Sakayori, M.; Fukamachi, K.; Kakugawa, Y.; Yamashita, Y.; Shima, H.] Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, Natori, Miyagi 9811293, Japan; [Hayashi, K.; Tanuma, N.; Kato, H.; Shima, H.] Tohoku Univ, Sch Med, Div Canc Mol Biol, Sendai, Miyagi 980, Japan; [Kishimoto, A.; Ogoh, H.; Suzuki, M.; Watanabe, T.] Nara Womens Univ, Dept Biol Sci, Grad Sch Humanities & Sci, Nara 630, Japan; [Kiyonari, H.] RIKEN Ctr Dev Biol, Lab Anim Resources & Genet Engn, Kobe, Hyogo, Japan; [Ito, S.; Sato, I.] Miyagi Canc Ctr, Div Pathol, Natori, Miyagi 9811293, Japan; [Suzuki, A.; Nishio, M.] Kyushu Univ, Med Inst Bioregulat, Div Canc Genet, Fukuoka 812, Japan; [Suganuma, M.] Saitama Canc Ctr, Res Inst Clin Oncol, Saitama, Japan	Miyagi Cancer Center; Tohoku University; Nara Womens University; RIKEN; Miyagi Cancer Center; Kyushu University	Shima, H (corresponding author), Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	shima@med.tohoku.ac.jp	Kiyonari, Hiroshi/N-7936-2015		JSPS KAKENHI [24591928, 25861168, 22590298]; Women's University Intramural Grant for Project Research	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Women's University Intramural Grant for Project Research	We thank Dr Hirota Fujiki for critical advice and Dr Yoshikazu Nishino for statistical analyses. We thank Nozomi Sasaki, Kuniko Komuro and Miyuki Ueki for technical assistance. We thank Dr Elise Lamar for English editing. This work was supported by JSPS KAKENHI grant numbers 24591928 to Yoichiro Kakugawa, 25861168 to Kayoko Fukamachi and 22590298 to Hiroshi Shima and by a Nara Women's University Intramural Grant for Project Research to Toshio Watanabe.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Afshar K, 2010, DEVELOPMENT, V137, P237, DOI 10.1242/dev.042754; Ancrile BB, 2008, MOL INTERV, V8, P22, DOI 10.1124/mi.8.1.6; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bastians H, 1996, J CELL SCI, V109, P2865; Brautigan DL, 2013, FEBS J, V280, P324, DOI 10.1111/j.1742-4658.2012.08609.x; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9; Fimmel S, 2007, ANN NY ACAD SCI, V1119, P176, DOI 10.1196/annals.1404.016; Fujiki H, 2011, ANTI-CANCER AGENT ME, V11, P4, DOI 10.2174/187152011794941163; Goshima G, 2003, EMBO J, V22, P2752, DOI 10.1093/emboj/cdg266; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Kajino T, 2006, J BIOL CHEM, V281, P39891, DOI 10.1074/jbc.M608155200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kolar M, 2012, BIOL CELL, V104, P738, DOI 10.1111/boc.201200018; KOMORI A, 1993, CANCER RES, V53, P3462; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Luke MM, 1996, MOL CELL BIOL, V16, P2744; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Masuda K, 2010, BIOCHEM BIOPH RES CO, V393, P201, DOI 10.1016/j.bbrc.2010.01.097; Mi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004395; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Schioppa T, 2011, P NATL ACAD SCI USA, V108, P10662, DOI 10.1073/pnas.1100994108; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Stefansson B, 2008, BIOCHEMISTRY-US, V47, P1442, DOI 10.1021/bi7022877; Stefansson B, 2006, J BIOL CHEM, V281, P22624, DOI 10.1074/jbc.M601772200; Suganuma M, 1999, CANCER RES, V59, P4516; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Sundberg JP, 1997, MOL CARCINOGEN, V20, P19, DOI 10.1002/(SICI)1098-2744(199709)20:1<19::AID-MC4>3.0.CO;2-D; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Suzuki JS, 2003, CARCINOGENESIS, V24, P1123, DOI 10.1093/carcin/bgg052; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; Valdiglesias V, 2013, MUTAT RES-REV MUTAT, V753, P24, DOI 10.1016/j.mrrev.2013.02.001; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Zhang BX, 1998, CANCER RES, V58, P4044	37	20	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4647	4655		10.1038/onc.2014.398	http://dx.doi.org/10.1038/onc.2014.398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486434				2022-12-28	WOS:000360189300010
J	Zhou, X; Matskova, L; Rathje, LS; Xiao, X; Gish, G; Werner, M; Ignatyev, I; Yu, N; Zhao, W; Tian, F; Hou, B; Zhang, Z; Pawson, T; Chen, F; Ernberg, I				Zhou, X.; Matskova, L.; Rathje, L-Sz; Xiao, X.; Gish, G.; Werner, M.; Ignatyev, I.; Yu, N.; Zhao, W.; Tian, F.; Hou, B.; Zhang, Z.; Pawson, T.; Chen, F.; Ernberg, I.			SYK interaction with ITG beta 4 suppressed by Epstein-Barr virus LMP2A modulates migration and invasion of nasopharyngeal carcinoma cells	ONCOGENE			English	Article							MEMBRANE-PROTEIN 2A; BREAST-CANCER PROGRESSION; BETA(4) INTEGRIN SUBUNIT; TYROSINE KINASE; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; ENCODED LMP2A	Epstein-Barr virus (EBV)-encoded Latent Membrane Protein 2A (LMP2A) is an EBV latency-associated protein regularly expressed in nasopharyngeal carcinoma (NPC). In B cells, LMP2A activity resembles that of a constitutively activated antigen receptor, which recruits the Syk tyrosine kinase to activate a set of downstream signaling pathways. LMP2A also downregulates cellular Syk levels. In the present study, we demonstrate that Syk interacts with the integrin beta 4 subunit (ITG beta 4) of integrin alpha 6 beta 4 in epithelial cells and that concurrent LMP2A expression interferes with this interaction by competitive binding to Syk. We find that both Syk and LMP2A have an effect on ITG beta 4 cell surface expression. However, in LMP2A expressing cells, ITG beta 4 remains concentrated at the cellular protrusions, an expression pattern characteristic of motile cells, including NPC-derived epithelial cells. This effect of LMP2A on ITG beta 4 localization is associated with a greater propensity for migration and invasion in-vitro, and may contribute to the invasive property of LMP2A-expressing NPC.	[Zhou, X.; Matskova, L.; Rathje, L-Sz; Xiao, X.; Werner, M.; Ignatyev, I.; Chen, F.; Ernberg, I.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17177 Stockholm, Sweden; [Zhou, X.; Xiao, X.; Yu, N.; Zhao, W.; Tian, F.; Hou, B.; Zhang, Z.] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Nanning, Peoples R China; [Gish, G.; Pawson, T.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Karolinska Institutet; Guangxi Medical University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ernberg, I (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17177 Stockholm, Sweden.	ingemar.ernberg@ki.se	Gish, Gerald D/C-7228-2017; Zhou, Xiaoying/Y-4217-2019; Pawson, Tony J/E-4578-2013; Matskova, Liudmila/J-3843-2017; Matskova, Liudmila/AAF-4201-2020	Zhou, Xiaoying/0000-0003-3298-5089; Matskova, Liudmila/0000-0002-3174-1560; Matskova, Liudmila/0000-0002-3174-1560; Zhao Rathje, Li-Sophie/0000-0002-8258-8914	Swedish Cancer Society; Swedish Research Council; Karolinska Institutet Research funds; Maths O Sundqvist family foundation; National Key Basic Research Program of China [2012CB526607]; Guangxi Natural Science Foundation [2013GXNSFGA019002]	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Karolinska Institutet Research funds; Maths O Sundqvist family foundation; National Key Basic Research Program of China(National Basic Research Program of China); Guangxi Natural Science Foundation(National Natural Science Foundation of Guangxi Province)	This work was supported by the Swedish Cancer Society, the Swedish Research Council, Karolinska Institutet Research funds and by the Maths O Sundqvist family foundation; National Key Basic Research Program of China (2012CB526607) and Guangxi Natural Science Foundation (2013GXNSFGA019002). We thank Gosta Winberg for valuable comments to the manuscript.	Allen MD, 2005, J VIROL, V79, P1789, DOI 10.1128/JVI.79.3.1789-1802.2005; Bertotti A, 2005, CANCER RES, V65, P10674, DOI 10.1158/0008-5472.CAN-05-2827; Bon G, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1651; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Brennan B, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-23; Buettner M, 2006, VIRCHOWS ARCH, V449, P513, DOI 10.1007/s00428-006-0294-2; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chami M, 2006, BBA-MOL CELL RES, V1763, P1344, DOI 10.1016/j.bbamcr.2006.09.025; Chao C, 1996, CANCER RES, V56, P4811; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dawson CW, 2001, VIROLOGY, V289, P192, DOI 10.1006/viro.2001.1142; Draheim KM, 2010, ONCOGENE, V29, P5032, DOI 10.1038/onc.2010.250; Du ZM, 2012, HEAD NECK-J SCI SPEC, V34, P1456, DOI 10.1002/hed.21953; Dutta U, 2008, CANCER RES, V68, P8779, DOI 10.1158/0008-5472.CAN-08-2125; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Ephstein Y, 2013, J BIOL CHEM, V288, P2191, DOI 10.1074/jbc.M112.404780; FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126; Fotheringham JA, 2012, J VIROL, V86, P10308, DOI 10.1128/JVI.00853-12; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Fung LF, 2000, LIFE SCI, V67, P923, DOI 10.1016/S0024-3205(00)00684-6; Galan JA, 2011, J AM SOC MASS SPECTR, V22, P319, DOI 10.1007/s13361-010-0030-7; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 2007, TRENDS PHARMACOL SCI, V28, P506, DOI 10.1016/j.tips.2007.08.004; Grenklo S, 2008, EUR J CELL BIOL, V87, P905, DOI 10.1016/j.ejcb.2008.06.006; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Heussinger N, 2004, J PATHOL, V203, P696, DOI 10.1002/path.1569; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Kashyap T, 2011, LAB INVEST, V91, P1414, DOI 10.1038/labinvest.2011.104; Kong QL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000940; Koster J, 2001, J INVEST DERMATOL, V117, P1405, DOI 10.1046/j.0022-202x.2001.01567.x; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Li Q, 2013, ONCOGENE, V32, P1772, DOI 10.1038/onc.2012.205; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lo AKF, 2001, CANCER LETT, V163, P117, DOI 10.1016/S0304-3835(00)00683-2; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Lynch DT, 2002, J GEN VIROL, V83, P1025, DOI 10.1099/0022-1317-83-5-1025; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Matskova L, 2001, J VIROL, V75, P10941, DOI 10.1128/JVI.75.22.10941-10949.2001; Matskova LV, 2007, ONCOGENE, V26, P4908, DOI 10.1038/sj.onc.1210298; Merdek KD, 2007, J BIOL CHEM, V282, P30322, DOI 10.1074/jbc.M703156200; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Nakaya T, 2013, VIRUS RES, V174, P108, DOI 10.1016/j.virusres.2013.03.009; Neuhaus B, 2011, CELL MOL LIFE SCI, V68, P3757, DOI 10.1007/s00018-011-0676-8; Nievers MG, 1998, J CELL SCI, V111, P1659; Pegtel DM, 2005, J VIROL, V79, P15430, DOI 10.1128/JVI.79.24.15430-15442.2005; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; Rabinovitz I, 2004, MOL CELL BIOL, V24, P4351, DOI 10.1128/MCB.24.10.4351-4360.2004; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Soung YH, 2011, CURR PROTEIN PEPT SC, V12, P23; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; Tohyama Y, 2009, J BIOCHEM, V145, P267, DOI 10.1093/jb/mvp001; Underwood RA, 2009, J HISTOCHEM CYTOCHEM, V57, P123, DOI 10.1369/jhc.2008.952176; Utskarpen A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010944; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wolfenson H, 2013, DEV CELL, V24, P447, DOI 10.1016/j.devcel.2013.02.012; Yan SR, 1997, J IMMUNOL, V158, P1902; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Yang XQ, 2010, MOL CELL BIOL, V30, P5306, DOI 10.1128/MCB.00326-10; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yoshioka T, 2013, J CLIN INVEST, V123, P682, DOI 10.1172/JCI60720; Zhao JH, 2013, CANCER-AM CANCER SOC, V119, P304, DOI 10.1002/cncr.27724	66	15	16	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4491	4499		10.1038/onc.2014.380	http://dx.doi.org/10.1038/onc.2014.380			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25531330				2022-12-28	WOS:000360189200008
J	Engelmann, D; Meier, C; Alla, V; Putzer, BM				Engelmann, D.; Meier, C.; Alla, V.; Puetzer, B. M.			A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; SPINDLE ASSEMBLY CHECKPOINT; HIGH ANTITUMOR-ACTIVITY; YES-ASSOCIATED PROTEIN; ABL TYROSINE KINASE; P53 FAMILY-MEMBERS; GROWTH-FACTOR-BETA; C-ABL; APOPTOTIC RESPONSE	p73 is the older sibling of p53 and mimics most of its tumor-suppressor functions. Through alternative promoter usage and splicing, the TP73 gene generates more than two dozen isoforms of which N-terminal truncated DNp73 variants have a decisive role in cancer pathogenesis as they outweigh the positive effects of full-length TAp73 and p53 in acting as a barrier to tumor development. Beyond the prevailing view that DNp73 predominantly counteract cell cycle arrest and apoptosis, latest progress indicates that these isoforms acquire novel functions in epithelial-to-mesenchymal transition, metastasis and therapy resistance. New insight into the mechanisms underlying this behavior reinforced the expectation that DNp73 variants contribute to aggressive cellular traits through both loss of wild-type tumor-suppressor activity and gain-of-function, suggesting an equally important role in cancer progression as mutant p53. In this review, we describe the novel properties of DNp73 in the invasion metastasis cascade and outline the comprehensive p73 regulatome with an emphasis on molecular processes putting TAp73 out of action in advanced tumors. These intriguing insights provoke a new understanding of the acquisition of aggressive traits by cancer cells and may help to set novel therapies for a broad range of metastatic tumors.	[Engelmann, D.; Meier, C.; Alla, V.; Puetzer, B. M.] Univ Rostock, Med Ctr, Inst Expt Gene Therapy & Canc Res, D-18057 Rostock, Germany	University of Rostock	Putzer, BM (corresponding author), Univ Rostock, Med Ctr, Inst Expt Gene Therapy & Canc Res, Schillingallee 69, D-18057 Rostock, Germany.	brigitte.puetzer@med.uni-rostock.de			German Cancer Aid; Federal Ministry of Education and Research as part of the project eBio: SysMet; FORUN program of Rostock University Medical Center	German Cancer Aid(Deutsche Krebshilfe); Federal Ministry of Education and Research as part of the project eBio: SysMet; FORUN program of Rostock University Medical Center	This work was supported by funds from the German Cancer Aid, Federal Ministry of Education and Research as part of the project eBio: SysMet and FORUN program of Rostock University Medical Center. We apologize to colleagues whose studies we did not cite owing to space limitations.	Achour M, 2013, BIOCHEM BIOPH RES CO, V430, P208, DOI 10.1016/j.bbrc.2012.11.087; Adamovich Y, 2014, CELL DEATH DIFFER, V21, P1451, DOI 10.1038/cdd.2014.60; Agami R, 1999, NATURE, V399, P809; Alhosin M, 2012, INVEST NEW DRUG, V30, P1813, DOI 10.1007/s10637-011-9734-1; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016/j.bcp.2009.12.015; Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476; Alonso R, 2009, BLOOD, V114, P1563, DOI 10.1182/blood-2009-02-207654; Amelio I, 2014, ONCOGENE, V33, P5039, DOI 10.1038/onc.2013.456; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Azmi AS, 2011, AM J TRANSL RES, V3, P374; Bailey SG, 2011, INT J BIOCHEM CELL B, V43, P482, DOI 10.1016/j.biocel.2010.12.022; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Beitzinger M, 2006, ONCOGENE, V25, P813, DOI 10.1038/sj.onc.1209125; Beitzinger M, 2008, EMBO J, V27, P792, DOI 10.1038/emboj.2008.13; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Blanch A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066436; Blum R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.38; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Broadhead ML, 2009, TRENDS MOL MED, V15, P461, DOI 10.1016/j.molmed.2009.08.003; Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Bunjobpo W, 2014, CELL DEATH DIFFER, V21, P1240, DOI 10.1038/cdd.2014.41; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992; Castillo J, 2009, GASTROENTEROLOGY, V137, P1805, DOI 10.1053/j.gastro.2009.07.065; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Christopherson RI, 2014, NUCLEOS NUCLEOT NUCL, V33, P375, DOI 10.1080/15257770.2013.863334; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Conforti F, 2012, AGING-US, V4, P202, DOI 10.18632/aging.100441; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108; Dar AA, 2008, CANCER RES, V68, P8998, DOI 10.1158/0008-5472.CAN-08-2658; Das R, 2014, APOPTOSIS, V19, P149, DOI 10.1007/s10495-013-0907-6; Daskalos A, 2011, CANCER LETT, V300, P79, DOI 10.1016/j.canlet.2010.09.009; Decrion-Barthod AZ, 2010, ANTICANCER RES, V30, P4049; Di CX, 2013, CELL CYCLE, V12, P1861, DOI 10.4161/cc.24967; Di Vinci A, 2009, INT J ONCOL, V34, P449, DOI 10.3892/ijo_00000169; Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619; Dixit D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.179; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789; Dulloo I, 2010, P NATL ACAD SCI USA, V107, P4902, DOI 10.1073/pnas.0906782107; Emmrich S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-61; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gong JG, 1999, NATURE, V399, P806; Guerrieri F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.302; Hackzell A, 2002, J BIOL CHEM, V277, P39769, DOI 10.1074/jbc.M204483200; Hamilton G, 2014, ONCOTARGET, V5, P6142, DOI 10.18632/oncotarget.2178; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; He Z, 2013, CELL DEATH DIFFER, V20, P1415, DOI 10.1038/cdd.2013.104; Herzog A, 2013, CLIN CANCER RES, V19, P3808, DOI 10.1158/1078-0432.CCR-12-2716; Ho TC, 2007, CARDIOVASC RES, V76, P213, DOI 10.1016/j.cardiores.2007.06.032; Hong B, 2014, CANCER RES, V74, P1153, DOI 10.1158/0008-5472.CAN-13-0955; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Huttinger-Kirchhof N, 2006, CELL DEATH DIFFER, V13, P174, DOI 10.1038/sj.cdd.4401809; Ishimoto O, 2002, CANCER RES, V62, P636; John K, 2011, CELL DEATH DIFFER, V18, P874, DOI 10.1038/cdd.2010.153; Jones EV, 2007, BIOCHEM J, V405, P617, DOI 10.1042/BJ20061778; Katayama H, 2012, CANCER CELL, V21, P196, DOI 10.1016/j.ccr.2011.12.025; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Klanrit P, 2009, ONCOGENE, V28, P3499, DOI 10.1038/onc.2009.191; Koida N, 2008, J BIOL CHEM, V283, P8555, DOI 10.1074/jbc.M710608200; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; Kubo N, 2010, BIOCHEM BIOPH RES CO, V403, P405, DOI 10.1016/j.bbrc.2010.11.043; Kunimoto Y, 2011, ORL-J OTO-RHIN-LARYN, V73, P17, DOI 10.1159/000320997; Lai J, 2014, ONCOTARGET, V5, P6909, DOI 10.18632/oncotarget.2230; Lapalombella R, 2010, BLOOD, V115, P2619, DOI 10.1182/blood-2009-09-242438; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lau LMS, 2009, ONCOGENE, V28, P2024, DOI 10.1038/onc.2009.59; Lee AF, 2004, J NEUROSCI, V24, P9174, DOI 10.1523/JNEUROSCI.1588-04.2004; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lehman JA, 2011, J BIOL CHEM, V286, P36631, DOI 10.1074/jbc.M110.217620; Leung THY, 2013, BRIT J CANCER, V109, P965, DOI 10.1038/bjc.2013.397; Leung THY, 2010, CANCER RES, V70, P6486, DOI 10.1158/0008-5472.CAN-10-0688; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, J BIOL CHEM, V283, P27462, DOI 10.1074/jbc.M803941200; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Lin Y, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-9; Lin YL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000680; Liu KG, 2014, J NANOMATER, V2014, DOI 10.1155/2014/910639; Liu SS, 2004, CLIN CANCER RES, V10, P3309, DOI 10.1158/1078-0432.CCR-03-0119; Liu SS, 2006, CLIN CANCER RES, V12, P3922, DOI 10.1158/1078-0432.CCR-05-2573; Liu T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.203; Liu Y, 2013, TUMOR BIOL, V34, P1641, DOI 10.1007/s13277-013-0697-z; Logotheti S, 2013, CANCER METAST REV, V32, P511, DOI 10.1007/s10555-013-9424-x; Luh LM, 2013, CELL DEATH DIFFER, V20, P1008, DOI 10.1038/cdd.2013.23; Maddika S, 2014, MOL CELL BIOL; Mancini M, 2011, J PHARMACOL EXP THER, V336, P596, DOI 10.1124/jpet.110.172536; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Merlo P, 2005, J BIOL CHEM, V280, P30354, DOI 10.1074/jbc.M500635200; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moll UM, 2004, MOL CANCER RES, V2, P371; Momeny M, 2010, MED ONCOL, V27, P833, DOI 10.1007/s12032-009-9294-9; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nahor I, 2005, GROWTH HORM IGF RES, V15, P388, DOI 10.1016/j.ghir.2005.07.005; Niemantsverdriet M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050815; Oberst A, 2007, P NATL ACAD SCI USA, V104, P11280, DOI 10.1073/pnas.0701773104; Onoda C, 2011, INT J ONCOL, V38, P1403, DOI 10.3892/ijo.2011.951; Paliwal P, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-45; Pan C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02333; Papoutsaki M, 2004, J INVEST DERMATOL, V123, P1162, DOI 10.1111/j.0022-202X.2004.23498.x; Park GB, 2013, J IMMUNOL, V191, P6281, DOI 10.4049/jimmunol.1203442; Patel S, 2008, NUCLEIC ACIDS RES, V36, P5139, DOI 10.1093/nar/gkn490; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Potu H, 2014, ONCOTARGET, V5, P5559, DOI 10.18632/oncotarget.2140; Puppin C, 2011, CELL ONCOL, V34, P131, DOI 10.1007/s13402-011-0009-9; Puri N, 2014, CANCER LETT, V343, P14, DOI 10.1016/j.canlet.2013.09.010; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Qian YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084015; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raab MS, 2009, BLOOD, V113, P1513, DOI 10.1182/blood-2008-05-157040; Racek T, 2005, J BIOL CHEM, V280, P40402, DOI 10.1074/jbc.C500193200; Rastogi S, 2012, CELL DEATH DIFFER, V19, P274, DOI 10.1038/cdd.2011.93; Ray RM, 2011, APOPTOSIS, V16, P35, DOI 10.1007/s10495-010-0538-0; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rokaeus N, 2010, ONCOGENE, V29, P6442, DOI 10.1038/onc.2010.382; Rosenbluth JM, 2008, MOL CELL BIOL, V28, P5951, DOI 10.1128/MCB.00305-08; Rosenbluth JM, 2011, P NATL ACAD SCI USA, V108, P2076, DOI 10.1073/pnas.1011936108; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112; Saha MN, 2013, MOL CANCER THER, V12, P2331, DOI 10.1158/1535-7163.MCT-12-1166; Sampath D, 2009, BLOOD, V113, P3744, DOI 10.1182/blood-2008-09-178707; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Sang MX, 2006, BIOCHEM BIOPH RES CO, V347, P327, DOI 10.1016/j.bbrc.2006.06.079; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sasaki Y, 2003, CANCER RES, V63, P8145; Sayan AE, 2008, ONCOGENE, V27, P4363, DOI 10.1038/onc.2008.64; Sayan BS, 2010, P NATL ACAD SCI USA, V107, P12877, DOI 10.1073/pnas.0911828107; Schipper H, 2014, ONCOTARGET, V5, P5893, DOI 10.18632/oncotarget.1839; Schuster A, 2010, CELL CYCLE, V9, P2629, DOI 10.4161/cc.9.13.12110; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sharif T, 2010, EUR J CANCER, V46, P983, DOI 10.1016/j.ejca.2009.12.029; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Simoes-Wust AP, 2005, J NEURO-ONCOL, V72, P29, DOI 10.1007/s11060-004-3118-8; Soldevilla B, 2013, GENE CHROMOSOME CANC, V52, P989, DOI 10.1002/gcc.22095; Soldevilla B, 2011, CLIN CANCER RES, V17, P6029, DOI 10.1158/1078-0432.CCR-10-2388; Sooriakumaran P., 2009, Cancer Genomics & Proteomics, V6, P93; Stearns ME, 2011, TRANSL ONCOL, V4, P147, DOI 10.1593/tlo.10286; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Stiewe T, 2003, J BIOL CHEM, V278, P14230, DOI 10.1074/jbc.M300357200; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Talos F, 2007, MOL CELL, V27, P647, DOI 10.1016/j.molcel.2007.06.036; Tannapfel A, 2008, CARCINOGENESIS, V29, P211, DOI 10.1093/carcin/bgm236; Tebbi A, 2011, J BIOL CHEM, V286, P7873, DOI 10.1074/jbc.M110.184879; Terrinoni A, 2004, ONCOGENE, V23, P3721, DOI 10.1038/sj.onc.1207342; Testoni B, 2011, ONCOGENE, V30, P2670, DOI 10.1038/onc.2010.635; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tiwary R, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2801; Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Tordella L, 2013, P NATL ACAD SCI USA, V110, P17969, DOI 10.1073/pnas.1309362110; Tuve S, 2004, INT J CANCER, V108, P162, DOI 10.1002/ijc.11552; Tyagi S, 2010, BIOCHEM PHARMACOL, V80, P1326, DOI 10.1016/j.bcp.2010.07.025; Uppada SB, 2014, INT J NANOMED, V9, P43, DOI 10.2147/IJN.S55133; Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290; Vella V, 2009, INT J CANCER, V124, P2539, DOI 10.1002/ijc.24221; Vera J, 2013, CANCER RES, V73, P3511, DOI 10.1158/0008-5472.CAN-12-4095; Vilgelm A, 2008, ONCOGENE, V27, P2170, DOI 10.1038/sj.onc.1210862; Vilgelm AE, 2010, ONCOGENE, V29, P5861, DOI 10.1038/onc.2010.319; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Wei Wan-li, 2011, Chinese Journal of Pathology, V40, P532, DOI 10.3760/cma.j.issn.0529-5807.2011.08.007; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Wetterskog D, 2009, MOL CANCER RES, V7, P2031, DOI 10.1158/1541-7786.MCR-08-0501; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Wojdyla L, 2014, BIOCHEM BIOPH RES CO, V446, P596, DOI 10.1016/j.bbrc.2014.03.013; Wolter JK, 2014, ONCOTARGET, V5, P161, DOI 10.18632/oncotarget.1083; Wong SW, 2011, BREAST CANCER RES TR, V128, P301, DOI 10.1007/s10549-010-1055-0; Yamamura Y, 2008, FEBS LETT, V582, P2663, DOI 10.1016/j.febslet.2008.06.046; Yan WS, 2012, MOL CELL BIOL, V32, P2336, DOI 10.1128/MCB.00215-12; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zaika E, 2011, FASEB J, V25, P4406, DOI 10.1096/fj.11-192815; Zhang J, 2013, J BIOL CHEM, V288, P7727, DOI 10.1074/jbc.M112.429522; Zhang PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042985; Zhang YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066464; Zhang YH, 2012, J BIOL CHEM, V287, P17746, DOI 10.1074/jbc.M112.358143; Zheng TS, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-133; Zheng TS, 2010, J CANCER RES CLIN, V136, P1597, DOI 10.1007/s00432-010-0817-8; Zitterbart K, 2007, ACTA NEUROPATHOL, V114, P641, DOI 10.1007/s00401-007-0298-2	200	38	40	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4287	4299		10.1038/onc.2014.365	http://dx.doi.org/10.1038/onc.2014.365			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381823				2022-12-28	WOS:000359494400001
J	Cheng, Y; Ho, RLKY; Chan, KC; Kan, R; Tung, E; Lung, HL; Yau, WL; Cheung, AKL; Ko, JMY; Zhang, ZF; Luo, DZ; Feng, ZB; Chen, S; Guan, XY; Kwong, D; Stanbridge, EJ; Lung, ML				Cheng, Y.; Ho, R. L. K. Y.; Chan, K. C.; Kan, R.; Tung, E.; Lung, H. L.; Yau, W. L.; Cheung, A. K. L.; Ko, J. M. Y.; Zhang, Z. F.; Luo, D. Z.; Feng, Z. B.; Chen, S.; Guan, X. Y.; Kwong, D.; Stanbridge, E. J.; Lung, M. L.			Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; ENDOTHELIAL-GROWTH-FACTOR; EPIGENETIC INACTIVATION; CHROMOSOME 3P21.3; LUNG-CANCER; THROMBOSPONDIN-1; EXPRESSION; VEGF; P53; HYPERMETHYLATION	Zinc-finger, MYND-type containing 10 (ZMYND10), or more commonly called BLU, expression is frequently downregulated in nasopharyngeal carcinoma (NPC) and many other tumors due to promoter hypermethylation. Functional evidence shows that the BLU gene inhibits tumor growth in animal assays, but the detailed molecular mechanism responsible for this is still not well understood. In current studies, we find that 93.5% of early-stage primary NPC tumors show downregulated BLU expression. Using a PCR array, overexpression of the BLU gene was correlated to the angiogenesis network in NPC cells. Moreover, expression changes of the MMP family, VEGF and TSP1, were often detected in different stages of NPC, suggesting the possibility that BLU may be directly involved in the microenvironment and anti-angiogenic activity in NPC development. Compared with vector-alone control cells, BLU stable transfectants, derived from poorly-differentiated NPC HONE1 cells, suppress VEGF165, VEGF189 and TSP1 expression at both the RNA and protein levels, and significantly reduce the secreted VEGF protein in these cells, reflecting an unknown regulatory mechanism mediated by the BLU gene in NPC. Cells expressing BLU inhibited cellular invasion, migration and tube formation. These in vitro results were further confirmed by in vivo tumor suppression and a matrigel plug angiogenesis assay in nude mice. Tube-forming ability was clearly inhibited, when the BLU gene is expressed in these cells. Up to 70-90% of injected tumor cells expressing increased exogenous BLU underwent cell death in animal assays. Overexpressed BLU only inhibited VEGF165 expression in differentiated squamous NPC HK1 cells, but also showed an anti-angiogenic effect in the animal assay, revealing a complicated mechanism regulating angiogenesis and the microenvironment in different NPC cell lines. Results of these studies indicate that alteration of BLU gene expression influences anti-angiogenesis pathways and is important for the development of NPC.	[Cheng, Y.; Ho, R. L. K. Y.; Chan, K. C.; Kan, R.; Tung, E.; Lung, H. L.; Cheung, A. K. L.; Ko, J. M. Y.; Guan, X. Y.; Kwong, D.; Lung, M. L.] Univ Hong Kong, Ctr Nasopharyngeal Carcinoma Res, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Yau, W. L.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Zhang, Z. F.; Luo, D. Z.; Feng, Z. B.; Chen, S.] Guangxi Med Univ, Dept Pathol, Guangxi, Peoples R China; [Stanbridge, E. J.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of Hong Kong; Chinese University of Hong Kong; Guangxi Medical University; University of California System; University of California Irvine	Cheng, Y (corresponding author), Univ Hong Kong, Dept Clin Oncol, Ctr Nasopharyngeal Carcinoma Res, Li Ka Shing Fac Medicne, L6-02 Lab Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	yuecheng@hotmail.com; mlilung@hku.hk	Chan, Ka Chung/HHR-8759-2022; Ko, Josephine/U-2972-2019; Cheng, Yue/Z-4456-2019; Lung, Maria Li/C-4495-2009; /A-3639-2009	Ko, Josephine/0000-0002-7997-331X; Lung, Maria Li/0000-0003-2559-3626; /0000-0003-1874-9805	General Research Fund [HKU762912M]; Research Grants Council of Hong Kong Special Administrative Region, China	General Research Fund; Research Grants Council of Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council)	We thank Dr Didier Trono for plasmid 12254, pWPI, and Dr Jack Lawler for plasmid 12993, pGEM2 hTSP-1, Addgene, USA. We also thank the Tissue Bank of NPC Area of Excellence Scheme for NPC samples. This work was supported by the General Research Fund (Project number: HKU762912M to Yue Cheng), Research Grants Council of Hong Kong Special Administrative Region, China.	Abe M, 2005, CANCER RES, V65, P828; Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Ancelin M, 2004, LAB INVEST, V84, P502, DOI 10.1038/labinvest.3700053; Ancelin M, 2002, P NATL ACAD SCI USA, V99, P6023, DOI 10.1073/pnas.082110999; Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001; Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8; Chan KC, 2011, INT J CANCER, V129, P1826, DOI 10.1002/ijc.25855; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Cheng Y, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-44; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; do Outeiro-Bernstein MAF, 2002, MATRIX BIOL, V21, P311, DOI 10.1016/S0945-053X(02)00010-0; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Herve MA, 2005, EXP CELL RES, V309, P24, DOI 10.1016/j.yexcr.2005.05.022; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Hui EP, 2002, CLIN CANCER RES, V8, P2595; Ji W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013442; Kaur S, 2010, J BIOL CHEM, V285, P38923, DOI 10.1074/jbc.M110.172304; Koo BH, 2010, AM J PATHOL, V176, P1494, DOI 10.2353/ajpath.2010.090655; Krishna SM, 2006, VIRUS RES, V115, P85, DOI 10.1016/j.virusres.2005.07.010; Lai HC, 2007, GYNECOL ONCOL, V104, P629, DOI 10.1016/j.ygyno.2006.10.003; Law EWL, 2012, ONCOGENE, V31, P728, DOI 10.1038/onc.2011.272; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Lee YJ, 2010, CANCER RES, V70, P948, DOI 10.1158/0008-5472.CAN-09-3094; Lerman MI, 2000, CANCER RES, V60, P6116; Linderholm B, 2000, INT J CANCER, V89, P51, DOI 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.3.CO;2-#; Liu XQ, 2003, INT J CANCER, V106, P60, DOI 10.1002/ijc.11166; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lo PHY, 2006, CANCER LETT, V234, P184, DOI 10.1016/j.canlet.2005.03.036; Lung HL, 2012, TUMOR SUPPRESSOR GEN, P53; Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528; Lung HL, 2012, SEMIN CANCER BIOL, V22, P87, DOI 10.1016/j.semcancer.2011.11.002; Mane DR, 2013, APPL IMMUNOHISTO M M, V21, P431, DOI 10.1097/PAI.0b013e31827c00e1; Marsit CJ, 2005, INT J CANCER, V114, P219, DOI 10.1002/ijc.20714; Miyata Y, 2013, INT J MOL SCI, V14, P12249, DOI 10.3390/ijms140612249; Nucera C, 2010, P NATL ACAD SCI USA, V107, P10649, DOI 10.1073/pnas.1004934107; Park ST, 2013, BIOCHEM BIOPH RES CO, V435, P153, DOI 10.1016/j.bbrc.2013.04.061; Peng XW, 2010, ANTI-CANCER DRUG, V21, P381, DOI 10.1097/CAD.0b013e3283363980; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Trudel D, 2003, CANCER RES, V63, P8511; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; Wilgus TA, 2012, J INVEST DERMATOL, V132, P493, DOI 10.1038/jid.2011.343; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Yang YJ, 2012, J CANCER RES CLIN, V138, P729, DOI 10.1007/s00432-012-1151-0; Yau WL, 2006, INT J CANCER, V119, P2821, DOI 10.1002/ijc.22232; Yoo HJ, 2013, INT J BIOCHEM CELL B, V45, P1236, DOI 10.1016/j.biocel.2013.04.001; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zaslavsky A, 2010, BLOOD, V115, P4605, DOI 10.1182/blood-2009-09-242065; Zhang XN, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-267	56	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4219	4228		10.1038/onc.2014.353	http://dx.doi.org/10.1038/onc.2014.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347745	Green Published, hybrid			2022-12-28	WOS:000359199800008
J	Nguyen, HN; Yang, JM; Rahdar, M; Keniry, M; Swaney, KF; Parsons, R; Park, BH; Sesaki, H; Devreotes, PN; Iijima, M				Nguyen, H-N; Yang, J-M; Rahdar, M.; Keniry, M.; Swaney, K. F.; Parsons, R.; Park, B. H.; Sesaki, H.; Devreotes, P. N.; Iijima, M.			A new class of cancer-associated PTEN mutations defined by membrane translocation defects	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; BINDING; PHOSPHORYLATION; ACTIVATION; MECHANISM; CELLS	Phosphatase and tensin homolog (PTEN), which negatively regulates tumorigenic phosphatidylinositol (3,4,5)-trisphosphate (PIP3) signaling, is a commonly mutated tumor suppressor. The majority of cancer-associated PTEN mutations block its essential PIP3 phosphatase activity. However, there is a group of clinically identified PTEN mutations that maintain enzymatic activity, and it is unknown how these mutations contribute to tumor pathogenesis. Here, we show that these enzymatically competent PTEN mutants fail to translocate to the plasma membrane where PTEN converts PIP3 to PI(4,5) P2. Artificial membrane tethering of the PTEN mutants effectively restores tumor suppressor activity and represses excess PIP3 signaling in cells. Thus, our findings reveal a novel mechanism of tumorigenic PTEN deficiency.	[Nguyen, H-N; Yang, J-M; Rahdar, M.; Swaney, K. F.; Sesaki, H.; Devreotes, P. N.; Iijima, M.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; [Keniry, M.; Parsons, R.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY USA; [Park, B. H.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Medicine	Iijima, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	pnd@jhmi.edu; miijima@jhmi.edu		Yang, Jr-Ming/0000-0002-6296-8987; Parsons, Ramon/0000-0002-6656-3514	NIH [GM084015, GM28007, GM34933, GM089853, NS084154, CA082783, CA155117]; NATIONAL CANCER INSTITUTE [R01CA082783, R01CA155117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, T32GM007445, R01GM089853, R01GM028007, R01GM084015, R01GM034933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS084154] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Todd Waldman (Georgetown University School of Medicine) for lentiviral constructs. The mutation data was obtained from the Sanger Institute Catalogue Of Somatic Mutations In Cancer (COSMIC) web site (http://www.sanger.ac.uk/cosmic).<SUP>27</SUP> This work was supported by NIH grants to MI (GM084015), PND (GM28007 and GM34933), HS (GM089853 and NS084154) and to RP (CA082783 and CA155117).	Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Cai HQ, 2011, METHODS MOL BIOL, V757, P451, DOI 10.1007/978-1-61779-166-6_26; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen CL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002446; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gericke A, 2013, ADV EXP MED BIOL, V991, P85, DOI 10.1007/978-94-007-6331-9_6; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Han SY, 2000, CANCER RES, V60, P3147; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Nguyen HN, 2014, P NATL ACAD SCI USA, V111, pE2684, DOI 10.1073/pnas.1409433111; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Kamimura Y, 2008, CURR BIOL, V18, P1034, DOI 10.1016/j.cub.2008.06.068; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Kim JS, 2011, MOL CELL BIOL, V31, P2756, DOI 10.1128/MCB.01323-10; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Nguyen HN, 2014, ONCOGENE, V33, P5688, DOI 10.1038/onc.2013.507; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Rodriguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tan MH, 2012, CLIN CANCER RES, V18, P400, DOI 10.1158/1078-0432.CCR-11-2283; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang GM, 2013, CANCER RES, V73, P3248, DOI 10.1158/0008-5472.CAN-12-1578; Wang Y, 2013, P NATL ACAD SCI USA, V110, pE4723, DOI 10.1073/pnas.1312540110; Wang Y, 2011, MOL BIOL CELL, V22, P2270, DOI 10.1091/mbc.E10-11-0926; Zhang PB, 2010, P NATL ACAD SCI USA, V107, P11829, DOI 10.1073/pnas.1006153107	34	27	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3737	3743		10.1038/onc.2014.293	http://dx.doi.org/10.1038/onc.2014.293			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25263454	Green Accepted			2022-12-28	WOS:000357679100011
J	Zhao, S; Sedwick, D; Wang, Z				Zhao, S.; Sedwick, D.; Wang, Z.			Genetic alterations of protein tyrosine phosphatases in human cancers	ONCOGENE			English	Review							TUMOR-SUPPRESSOR GENE; CELL-CELL ADHESION; BLOOD-VESSEL DEVELOPMENT; BCR-ABL ONCOGENE; COLON-CANCER; PTP-MU; VE-PTP; BREAST-CANCER; FUNCTIONAL-CHARACTERIZATION; HOMOPHILIC BINDING	Protein tyrosine phosphatases (PTPs) are enzymes that remove phosphate from tyrosine residues in proteins. Recent whole- exome sequencing of human cancer genomes reveals that many PTPs are frequently mutated in a variety of cancers. Among these mutated PTPs, PTP receptor T (PTPRT) appears to be the most frequently mutated PTP in human cancers. Beside PTPN11, which functions as an oncogene in leukemia, genetic and functional studies indicate that most of mutant PTPs are tumor suppressor genes. Identification of the substrates and corresponding kinases of the mutant PTPs may provide novel therapeutic targets for cancers harboring these mutant PTPs.	[Zhao, S.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, Shanghai 200030, Peoples R China; [Zhao, S.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Inst Digest Dis, Shanghai 200030, Peoples R China; [Zhao, S.; Wang, Z.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Zhao, S.; Sedwick, D.; Wang, Z.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Sedwick, D.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Wang, Z (corresponding author), Case Western Reserve Univ, Genet & Genome Sci, 2103 Cornell Rd,WRB 3120, Cleveland, OH 44106 USA.	zxw22@case.edu			NIH [R01CA127590, P50CA150964, P30 CA043703]; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA127590, P50CA150964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Susann Brady-Kalnay for critical reading of the manuscript. This work is supported by NIH grants R01CA127590, P50CA150964 and P30 CA043703.	Abaan OD, 2013, EXP CELL RES, V319, P1, DOI 10.1016/j.yexcr.2012.09.003; Agarwal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062852; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Au AC, 2010, AM J HUM GENET, V87, P436, DOI 10.1016/j.ajhg.2010.08.008; Aya-Bonilla C, 2013, GENE CHROMOSOME CANC, V52, P467, DOI 10.1002/gcc.22044; Baumer S, 2006, BLOOD, V107, P4754, DOI 10.1182/blood-2006-01-0141; Balavenkatraman KK, 2006, ONCOGENE, V25, P6319, DOI 10.1038/sj.onc.1209647; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Becka S, 2010, CELL COMMUN ADHES, V17, P34, DOI 10.3109/15419061.2010.487957; Behjati S, 2014, NAT GENET, V46, P376, DOI 10.1038/ng.2921; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Besco JA, 2006, BRAIN RES, V1116, P50, DOI 10.1016/j.brainres.2006.07.122; Bowen ME, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002050; Brady-Kalnay SM, CELL ADHESION FRONTI, V39, P217; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525; Brognard J, 2011, CURR OPIN GENET DEV, V21, P4, DOI 10.1016/j.gde.2010.10.012; Burden-Gulley SM, 2010, NEOPLASIA, V12, P305, DOI 10.1593/neo.91940; Burgoyne AM, 2009, CANCER RES, V69, P6960, DOI 10.1158/0008-5472.CAN-09-0863; Casagrande S, 2013, J PATHOL, V229, P525, DOI 10.1002/path.4107; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Craig SEL, 2011, CANCER RES, V71, P303, DOI 10.1158/0008-5472.CAN-10-2301; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104; Feng XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100783; Flavell JR, 2008, BLOOD, V111, P292, DOI 10.1182/blood-2006-11-059881; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Freiss G, 2011, ANTI-CANCER AGENT ME, V11, P78, DOI 10.2174/187152011794941262; Funato K, 2011, EXP THER MED, V2, P457, DOI 10.3892/etm.2011.231; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; Giefing M, 2011, GENE CHROMOSOME CANC, V50, P154, DOI 10.1002/gcc.20840; Goel S, 2013, JNCI-J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164; Gunawardana J, 2014, NAT GENET, V46, P329, DOI 10.1038/ng.2900; Hagemann N, 2013, ONCOGENE, V32, P4602, DOI 10.1038/onc.2012.485; Hayashi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2683; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Hoover AC, 2009, ONCOGENE, V28, P3960, DOI 10.1038/onc.2009.251; Huang JM, 2013, ONCOGENE, V32, P2220, DOI 10.1038/onc.2012.231; Huang WQ, 2013, J BIOL CHEM, V288, P12766, DOI 10.1074/jbc.M112.429696; Huang WQ, 2013, LEUKEMIA LYMPHOMA, V54, P619, DOI 10.3109/10428194.2012.720979; Iervolino A, 2006, CANCER RES, V66, P6280, DOI 10.1158/0008-5472.CAN-06-0228; Iuliano R, 2004, ONCOGENE, V23, P8432, DOI 10.1038/sj.onc.1207766; Jiang YY, 2013, ONCOTARGET, V4, P884, DOI 10.18632/oncotarget.1021; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kim YS, 2011, BIOCHEM BIOPH RES CO, V404, P96, DOI 10.1016/j.bbrc.2010.11.071; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Laczmanska I, 2013, J HUM GENET, V58, P11, DOI 10.1038/jhg.2012.119; Lauriol J, 2011, TRENDS CARDIOVAS MED, V21, P97, DOI 10.1016/j.tcm.2012.03.006; Legius E, 2002, J MED GENET, V39, P571, DOI 10.1136/jmg.39.8.571; Lesueur F, 2005, HUM MOL GENET, V14, P2349, DOI 10.1093/hmg/ddi237; Lim SH, 2013, BIOCHEM BIOPH RES CO, V439, P40, DOI 10.1016/j.bbrc.2013.08.033; Liu Dong-Sheng, 2011, SENSORS, V11, P6494, DOI DOI 10.1109/W; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Liu X, 2012, CANCER RES, V72, P5296, DOI 10.1158/0008-5472.CAN-12-1495; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Lucci MA, 2010, CELL ONCOL, V32, P361, DOI 10.3233/CLO-2010-0520; Lui VWY, 2014, P NATL ACAD SCI USA, V111, P1114, DOI 10.1073/pnas.1319551111; Luo L, 2006, CARCINOGENESIS, V27, P1153, DOI 10.1093/carcin/bgi354; Meehan M, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-6; Mellberg S, 2009, FASEB J, V23, P1490, DOI 10.1096/fj.08-123810; Michaloglou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061916; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Nakamura M, 2003, CANCER RES, V63, P737; Nariai Y, 2011, INT J ORAL MAX SURG, V40, P419, DOI 10.1016/j.ijom.2010.10.020; Novellino L, 2008, CELL SIGNAL, V20, P872, DOI 10.1016/j.cellsig.2007.12.024; Omerovic J, 2010, BIOCHEM J, V426, P65, DOI 10.1042/BJ20091413; Ortiz B, 2014, P NATL ACAD SCI USA, V111, P8149, DOI 10.1073/pnas.1401952111; Paduano F, 2013, FEBS J, V280, P401, DOI 10.1111/j.1742-4658.2012.08624.x; Paduano F, 2012, ACS CHEM BIOL, V7, P1666, DOI 10.1021/cb300281t; Park AR, 2012, J CELL SCI, V125, P4518, DOI 10.1242/jcs.105502; Petermann A, 2011, BRAIN PATHOL, V21, P405, DOI 10.1111/j.1750-3639.2010.00464.x; Phillips-Mason PJ, 2014, J CELL BIOCHEM, V115, P1609, DOI 10.1002/jcb.24824; Phillips-Mason PJ, 2011, CELL ADHES MIGR, V5, P298, DOI 10.4161/cam.5.4.16970; Phillips-Mason PJ, 2011, J CELL BIOCHEM, V112, P39, DOI 10.1002/jcb.22710; Phillips-Mason PJ, 2008, J CELL BIOCHEM, V105, P1059, DOI 10.1002/jcb.21907; Purdie KJ, 2007, GENE CHROMOSOME CANC, V46, P661, DOI 10.1002/gcc.20447; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SAP J, 1994, MOL CELL BIOL, V14, P1; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Scrima M, 2012, AM J PATHOL, V180, P1202, DOI 10.1016/j.ajpath.2011.11.038; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272; Spanos WC, 2008, J VIROL, V82, P2493, DOI 10.1128/JVI.02188-07; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Trapasso F, 2006, DNA CELL BIOL, V25, P376, DOI 10.1089/dna.2006.25.376; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Venkatachalam R, 2010, GASTROENTEROLOGY, V139, P2221, DOI 10.1053/j.gastro.2010.08.063; Vermeer PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030447; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang WQ, 2012, GENE DEV, V26, P1959, DOI 10.1101/gad.192955.112; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wieckowski E, 2007, J CELL BIOCHEM, V100, P16, DOI 10.1002/jcb.20922; Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Wyatt L, 2008, CELL CYCLE, V7, P2290, DOI 10.4161/cc.6443; Xiao ZY, 2010, WORLD J GASTROENTERO, V16, P112, DOI 10.3748/wjg.v16.i1.112; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396; Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193; Yip SC, 2010, TRENDS BIOCHEM SCI, V35, P442, DOI 10.1016/j.tibs.2010.03.004; Yu JS, 2008, MOL CANCER RES, V6, P1106, DOI 10.1158/1541-7786.MCR-07-2123; Zhang P, 2013, ONCOGENE, V32, P2087, DOI 10.1038/onc.2012.220; Zhang P, 2011, MOL CANCER RES, V9, P1418, DOI 10.1158/1541-7786.MCR-11-0147; Zhang P, 2009, CELL COMMUN ADHES, V16, P146, DOI 10.3109/15419061003653771; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhao YQ, 2010, P NATL ACAD SCI USA, V107, P2592, DOI 10.1073/pnas.0914884107; Zheng H, 2013, J BIOL CHEM, V288, P25727, DOI 10.1074/jbc.M113.462291; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	125	54	54	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3885	3894		10.1038/onc.2014.326	http://dx.doi.org/10.1038/onc.2014.326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263441	Green Accepted			2022-12-28	WOS:000358544200001
J	Roesch, A				Roesch, A.			Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma	ONCOGENE			English	Review							ACQUIRED-RESISTANCE; BRAF(V600E) INHIBITION; BRAF INHIBITION; RAF INHIBITION; OXIDATIVE-METABOLISM; METASTATIC MELANOMA; IMPROVED SURVIVAL; MEK INHIBITION; CELLS; VEMURAFENIB	Despite the recent success of MAPK signaling-targeted drugs in melanoma, the majority of patients with metastatic melanoma still undergo disease progression after initial tumor shrinkage indicating gradually developing therapy resistance. This review will give an overview on currently suggested concepts of resistance to MAPK pathway inhibitors in melanoma with particular focus on interand intraindividual as well as intratumor heterogeneity. The high plasticity of melanoma cells promotes both the clonal evolution of genetic resistance, for example, because of mutations in the MAPK or PI3K/AKT/PTEN pathways, and the emergence of cell phenotypes that functionally and metabolically overcome MAPK inhibition. Like a 'moving target', melanoma cells are shifting between different metabolic, cell cycle and differentiation states reflecting a highly dynamic potential to adapt to exogenous stressors including drugs. The introduction of MAPK inhibitors into the clinics has tremendously pushed the field of melanoma research not just because of the historic therapeutic success but also by providing a new tool to study human melanoma in its natural microenvironment.	Univ Hosp Essen, Dept Dermatol, D-45122 Essen, Germany	University of Duisburg Essen	Roesch, A (corresponding author), Univ Hosp Essen, Dept Dermatol, Hufelandstr 55, D-45122 Essen, Germany.	alexander.roesch@uk-essen.de						Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Berridge MV, 2010, MITOCHONDRION, V10, P584, DOI 10.1016/j.mito.2010.08.002; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Corazao-Rozas P, 2013, ONCOTARGET, V4, P1986, DOI 10.18632/oncotarget.1420; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Girnun GD, 2012, SEMIN CELL DEV BIOL, V23, P381, DOI 10.1016/j.semcdb.2012.01.007; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hartsough E, 2014, J INVEST DERMATOL, V134, P319, DOI 10.1038/jid.2013.358; Hartsough EJ, 2014, MOL CANCER RES, V12, P795, DOI 10.1158/1541-7786.MCR-13-0581; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Romano E, 2013, CLIN CANCER RES, V19, P5749, DOI 10.1158/1078-0432.CCR-13-0661; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Schadendorf D, 2014, NAT REV CLIN ONCOL, V11, P75, DOI 10.1038/nrclinonc.2013.246; Shao Y, 2012, CELL DEATH DIFFER, V19, P2029, DOI 10.1038/cdd.2012.94; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi H, 2013, CANC DISCOV; Shi HB, 2012, CANCER DISCOV, V2, P414, DOI 10.1158/2159-8290.CD-12-0022; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110	62	77	81	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2951	2957		10.1038/onc.2014.249	http://dx.doi.org/10.1038/onc.2014.249			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25109330				2022-12-28	WOS:000356100500001
J	Gole, B; Baumann, C; Mian, E; Ireno, CI; Wiesmuller, L				Gole, B.; Baumann, C.; Mian, E.; Ireno, C. I.; Wiesmueller, L.			Endonuclease G initiates DNA rearrangements at the MLL breakpoint cluster upon replication stress	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TOPOISOMERASE-II; HISTONE H2B; CELL-DEATH; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL INSTABILITY; OXIDATIVE STRESS; FRAGILE SITES; STEM-CELLS; APOPTOSIS	MLL (myeloid/lymphoid or mixed-lineage leukemia) rearrangements are frequent in therapy-related and childhood acute leukemia, and are associated with poor prognosis. The majority of the rearrangements fall within a 7.3-kb MLL breakpoint cluster region (MLLbcr), particularly in a 0.4-kb hotspot at the intron11-exon12 boundary. The underlying mechanisms are poorly understood, though multiple pathways including early apoptotic signaling, accompanied by high-order DNA fragmentation, have been implicated. We introduced the MLLbcr hotspot in an EGFP-based recombination reporter system and demonstrated enhancement of both spontaneous and genotoxic treatment-induced DNA recombination by the MLLbcr in various human cell types. We identified Endonuclease G (EndoG), an apoptotic nuclease, as an essential factor for MLLbcr-specific DNA recombination after induction of replication stress. We provide evidence for replication stress-induced nuclear accumulation of EndoG, DNA binding by EndoG as well as cleavage of the chromosomal MLLbcr locus in a manner requiring EndoG. We demonstrate additional dependency of MLLbcr breakage on ATM signaling to histone H2B monoubiquitinase RNF20, involved in chromatin relaxation. Altogether our findings provide a novel mechanism underlying MLLbcr destabilization in the cells of origin of leukemogenesis, with replication stress-activated, EndoG-mediated cleavage at the MLLbcr, which may serve resolution of the stalled forks via recombination repair, however, also permits MLL rearrangements.	[Gole, B.; Baumann, C.; Mian, E.; Ireno, C. I.; Wiesmueller, L.] Univ Ulm, Dept Obstet & Gynecol, Gynecol Oncol, D-89075 Ulm, Baden Wuerttemb, Germany	Ulm University	Gole, B (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Gynecol Oncol, Prittwitzstr 43, D-89075 Ulm, Baden Wuerttemb, Germany.	boris.gole@uniklinik-ulm.de; lisa.wiesmueller@uni-ulm.de	Gole, Boris/GWQ-9292-2022	Gole, Boris/0000-0002-2461-6729	German Research Foundation [WI 3099/7-1, WI 3099/7-2]; European/German Space Agency (ESA/DLR); German Ministry of Economy (BMWi) [A0-10-IBER-2, 50WB1225]	German Research Foundation(German Research Foundation (DFG)); European/German Space Agency (ESA/DLR); German Ministry of Economy (BMWi)(Federal Ministry for Economic Affairs and Energy (BMWi))	We thank Daniela Waldraff, Regina Hafele, Rahel Wiehe (all Department of Obstetrics and Gynecology, University of Ulm, Germany) and Dre van der Merwe (Core facility FACS, Medical Faculty, University of Ulm, Germany) for their contributions to this work. This work was supported by the German Research Foundation (WI 3099/7-1, WI 3099/7-2) and by the European/German Space Agency (ESA/DLR) and German Ministry of Economy (BMWi), A0-10-IBER-2 funding 50WB1225.	Abdulwahab A, 2012, CANCER-AM CANCER SOC, V118, P3962, DOI 10.1002/cncr.26735; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Baumann C, 2006, NUCLEIC ACIDS RES, V34, P1036, DOI 10.1093/nar/gkj509; Betti CJ, 2003, CANCER RES, V63, P1377; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Britton S, 2009, CANCER RES, V69, P8120, DOI 10.1158/0008-5472.CAN-08-4400; Buttner S, 2007, MOL CELL, V25, P233, DOI 10.1016/j.molcel.2006.12.021; Carrassa L, 2004, CELL CYCLE, V3, P1177; Chernikova SB, 2012, CANCER RES, V72, P2111, DOI 10.1158/0008-5472.CAN-11-2209; Diener T, 2010, EXP GERONTOL, V45, P638, DOI 10.1016/j.exger.2010.03.002; Ezoe S, 2012, INT J ENV RES PUB HE, V9, P2444, DOI 10.3390/ijerph9072444; Fierz B, 2011, NAT CHEM BIOL, V7, P113, DOI 10.1038/NCHEMBIO.501; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Grabarz A, 2012, AM J CANCER RES, V2, P249; Hars ES, 2006, CANCER RES, V66, P8975, DOI 10.1158/0008-5472.CAN-06-1724; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Lee JS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.181; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Libura J, 2008, EUR J HAEMATOL, V81, P185, DOI 10.1111/j.1600-0609.2008.01103.x; Maddams J, 2011, INT J CANCER, V129, P2885, DOI 10.1002/ijc.26240; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Milyavsky M, 2010, CELL STEM CELL, V7, P186, DOI 10.1016/j.stem.2010.05.016; Mirault ME, 2006, AM J HUM GENET, V79, P779, DOI 10.1086/507791; Mosad E, 2012, ONCOLOGY-BASEL, V83, P128, DOI 10.1159/000338769; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Ousset M, 2010, CELL CYCLE, V9, P2814, DOI 10.4161/cc.9.14.12253; Ozeri-Galai E, 2008, ONCOGENE, V27, P2109, DOI 10.1038/sj.onc.1210849; Ozeri-Galai E, 2011, MOL CELL, V43, P122, DOI 10.1016/j.molcel.2011.05.019; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715; Shivakumar R, 2008, ANN ONCOL, V19, P1634, DOI 10.1093/annonc/mdn182; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200; Stam RW, 2006, BRIT J HAEMATOL, V132, P539, DOI 10.1111/j.1365-2141.2005.05909.x; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Stanulla M, 2001, HUM MOL GENET, V10, P2481, DOI 10.1093/hmg/10.22.2481; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Sun JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013554; Tichy ED, 2013, STEM CELL RES, V10, P428, DOI 10.1016/j.scr.2013.01.010; Varecha M, 2012, MOL CELL BIOCHEM, V363, P301, DOI 10.1007/s11010-011-1182-x; Wu JX, 2009, MOL CELL BIOL, V29, P849, DOI 10.1128/MCB.01302-08; Yang SH, 2006, EXP MOL MED, V38, P435, DOI 10.1038/emm.2006.51; Zan H, 2011, MOL IMMUNOL, V48, P610, DOI 10.1016/j.molimm.2010.10.023; Zhang F, 2009, TRENDS GENET, V25, P298, DOI 10.1016/j.tig.2009.05.005	48	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3391	3401		10.1038/onc.2014.268	http://dx.doi.org/10.1038/onc.2014.268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25132265				2022-12-28	WOS:000356871700005
J	Mahajan, P; Leavey, PJ; Galindo, RL				Mahajan, P.; Leavey, P. J.; Galindo, R. L.			PAX genes in childhood oncogenesis: developmental biology gone awry?	ONCOGENE			English	Review							PAIRED BOX GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; FOLLICULAR THYROID CARCINOMAS; RENAL-CELL CARCINOMA; TRANSCRIPTION FACTOR; SATELLITE CELLS; FUSION GENE; PAX8-PPAR-GAMMA REARRANGEMENT; ALVEOLAR RHABDOMYOSARCOMAS; COOPERATIVE INTERACTIONS	Childhood solid tumors often arise from embryonal-like cells, which are distinct from the epithelial cancers observed in adults, and etiologically can be considered as 'developmental patterning gone awry'. Paired-box (PAX) genes encode a family of evolutionarily conserved transcription factors that are important regulators of cell lineage specification, migration and tissue patterning. PAX loss-of-function mutations are well known to cause potent developmental phenotypes in animal models and underlie genetic disease in humans, whereas dysregulation and/or genetic modification of PAX genes have been shown to function as critical triggers for human tumorigenesis. Consequently, exploring PAX-related pathobiology generates insights into both normal developmental biology and key molecular mechanisms that underlie pediatric cancer, which are the topics of this review.	[Mahajan, P.; Leavey, P. J.; Galindo, R. L.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Galindo, R. L.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Galindo, R. L.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Galindo, RL (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	rene.galindo@utsouthwestern.edu		Leavey, Patrick/0000-0002-0541-2536	Burroughs Wellcome Fund; Alex's Lemonade Stand Foundation; American Cancer Society; UTSW Department of Pathology	Burroughs Wellcome Fund(Burroughs Wellcome Fund); Alex's Lemonade Stand Foundation; American Cancer Society(American Cancer Society); UTSW Department of Pathology	This work was supported by funding to RLG by the Burroughs Wellcome Fund (Career Award for Medical Scientists), Alex's Lemonade Stand Foundation ("A" Award), American Cancer Society (Research Scholars Grant) and UTSW Department of Pathology (Research Grant). We thank Stephen X. Skapek for helpful suggestions regarding this manuscript.	Ali AN, 2012, CANCER-AM CANCER SOC, V118, P2541, DOI 10.1002/cncr.26554; Apuzzo S, 2007, BIOCHEMISTRY-US, V46, P2984, DOI 10.1021/bi062107q; Avirneni-Vadlamudi U, 2012, J CLIN INVEST, V122, P403, DOI 10.1172/JCI59877; Bai SW, 2011, INVEST OPHTH VIS SCI, V52, P4560, DOI 10.1167/iovs.10-5487; Barr FG, 1999, CANCER RES, V59, P5443; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Bishop JA, 2011, HUM PATHOL, V42, P1873, DOI 10.1016/j.humpath.2011.02.004; BOBER E, 1994, DEVELOPMENT, V120, P603; Bousquet M, 2007, BLOOD, V109, P3417, DOI 10.1182/blood-2006-05-025221; Brun T, 2008, J MOL ENDOCRINOL, V40, P37, DOI 10.1677/JME-07-0134; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Carbe C, 2013, J BIOL CHEM, V288, P12130, DOI 10.1074/jbc.M112.436865; Castro P, 2006, J CLIN ENDOCR METAB, V91, P213, DOI 10.1210/jc.2005-1336; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cheung L, 2003, J CLIN ENDOCR METAB, V88, P354, DOI 10.1210/jc.2002-021020; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Coyaud E, 2010, BLOOD, V115, P3089, DOI 10.1182/blood-2009-07-234229; Czerny T, 1999, MOL CELL, V3, P297, DOI 10.1016/S1097-2765(00)80457-8; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; Denk D, 2012, LEUKEMIA RES, V36, pE178, DOI 10.1016/j.leukres.2012.04.015; Desouki MM, 2010, CLIN MED RES, V8, P84, DOI 10.3121/cmr.2010.891; DIETRICH S, 1995, DEV BIOL, V167, P529, DOI 10.1006/dbio.1995.1047; Discenza MT, 2003, ONCOGENE, V22, P8145, DOI 10.1038/sj.onc.1206997; Dohrmann C, 2000, MECH DEVELOP, V92, P47, DOI 10.1016/S0925-4773(99)00324-X; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Eberhard D, 1999, CANCER RES, V59, p1716S; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; Enomoto K, 2013, ENDOCR J, V60, P629, DOI 10.1507/endocrj.EJ12-0372; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Familiades J, 2009, LEUKEMIA, V23, P1989, DOI 10.1038/leu.2009.135; Fernandez C, 2011, PRINCIPLES PRACTICE, P861; Fonsato V, 2006, AM J PATHOL, V168, P706, DOI 10.2353/ajpath.2006.050776; Frazier-Bowers SA, 2002, CONNECT TISSUE RES, V43, P296, DOI 10.1080/03008200290000961; Galindo RL, 2006, P NATL ACAD SCI USA, V103, P13439, DOI 10.1073/pnas.0605926103; Gehring WJ, 1996, GENES CELLS, V1, P11, DOI 10.1046/j.1365-2443.1996.11011.x; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GNARRA JR, 1995, CANCER RES, V55, P4092; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GURNEY JG, 1999, NIH PUB, P111; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hogan AR, 2009, J SURG RES, V156, P167, DOI 10.1016/j.jss.2009.03.098; Hol FA, 1996, J MED GENET, V33, P655, DOI 10.1136/jmg.33.8.655; Holmes Laurens Jr, 2012, ISRN Oncol, V2012, P906197, DOI 10.5402/2012/906197; Holmes ML, 2008, IMMUNOL CELL BIOL, V86, P47, DOI 10.1038/sj.icb.7100134; Huh WW, 2010, CURR ONCOL REP, V12, P402, DOI 10.1007/s11912-010-0130-3; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Hurwitz RL, 2011, PRINCIPLES PRACTICE, P809; Iida S, 1996, BLOOD, V88, P1787; Jo W, 2011, TOHOKU J EXP MED, V223, P113, DOI 10.1620/tjem.223.113; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Jumlongras D, 2004, HUM GENET, V114, P242, DOI 10.1007/s00439-003-1066-6; Jun S, 1996, DEVELOPMENT, V122, P2639; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Kawamata N, 2012, ONCOGENE, V31, P966, DOI 10.1038/onc.2011.291; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190; Lacroix L, 2004, EUR J ENDOCRINOL, V151, P367, DOI 10.1530/eje.0.1510367; Lang D, 2007, BIOCHEM PHARMACOL, V73, P1, DOI 10.1016/j.bcp.2006.06.024; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Li Caiyun G., 2012, Frontiers in Genetics, V3, P6, DOI 10.3389/fgene.2012.00006; Li L, 2011, INVEST OPHTH VIS SCI, V52, P8393, DOI 10.1167/iovs.11-8139; Mailhos C, 1998, DEVELOPMENT, V125, P937; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Naini S, 2008, CANCER RES, V68, P9583, DOI 10.1158/0008-5472.CAN-07-6178; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Nebral K, 2009, LEUKEMIA, V23, P134, DOI 10.1038/leu.2008.306; Nebral K, 2007, BRIT J HAEMATOL, V139, P269, DOI 10.1111/j.1365-2141.2007.06731.x; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Brien P, 2011, CANCER RES, V71, P7345, DOI 10.1158/0008-5472.CAN-11-1874; Ofverholm I, 2013, LEUKEMIA, V27, P1936, DOI 10.1038/leu.2013.92; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Ordonez NG, 2012, ADV ANAT PATHOL, V19, P140, DOI 10.1097/PAP.0b013e318253465d; Oustanina S, 2004, EMBO J, V23, P3430, DOI 10.1038/sj.emboj.7600346; Ozcan A, 2012, ARCH PATHOL LAB MED, V136, P1541, DOI 10.5858/arpa.2012-0072-OA; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Park D, 2006, DEVELOPMENT, V133, P4193, DOI 10.1242/dev.02614; Peters H, 1998, EUR J ORAL SCI, V106, P38, DOI 10.1111/j.1600-0722.1998.tb02151.x; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; PLACHOV D, 1990, DEVELOPMENT, V110, P643; Plengvidhya N, 2007, J CLIN ENDOCR METAB, V92, P2821, DOI 10.1210/jc.2006-1927; POLEEV A, 1992, DEVELOPMENT, V116, P611; Poppe B, 2005, GENE CHROMOSOME CANC, V44, P218, DOI 10.1002/gcc.20214; Powell JG, 2004, ONCOGENE, V23, P3634, DOI 10.1038/sj.onc.1207399; Puglisi F, 2000, ANTICANCER RES, V20, P311; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Ren YX, 2008, CANCER RES, V68, P6587, DOI 10.1158/0008-5472.CAN-08-0859; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; RYAN G, 1995, DEVELOPMENT, V121, P867; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Scouten WT, 2004, THYROID, V14, P1037, DOI 10.1089/thy.2004.14.1037; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Shimajiri Y, 2001, DIABETES, V50, P2864, DOI 10.2337/diabetes.50.12.2864; Silberstein J, 2009, PEDIATR BLOOD CANCER, V52, P237, DOI 10.1002/pbc.21779; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Sosa-Pineda B, 2004, MOL CELLS, V18, P289; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Souabni A, 2007, BLOOD, V109, P281, DOI 10.1182/blood-2006-03-009670; Stockton DW, 2000, NAT GENET, V24, P18, DOI 10.1038/71634; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Strehl S, 2003, LEUKEMIA, V17, P1121, DOI 10.1038/sj.leu.2402923; Su DM, 2001, DEV BIOL, V236, P316, DOI 10.1006/dbio.2001.0342; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; Torres M, 1995, DEVELOPMENT, V121, P4057; von Maltzahn J, 2013, P NATL ACAD SCI USA, V110, P16474, DOI 10.1073/pnas.1307680110; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Walter K, 2010, ONCOGENE, V29, P2927, DOI 10.1038/onc.2010.56; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang JW, 2022, FEBS LETT, DOI 10.1016/j.febslet.2013.04.029; Wang J, 2011, ARCH ORAL BIOL, V56, P1027, DOI 10.1016/j.archoralbio.2011.03.023; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Wilm B, 1998, P NATL ACAD SCI USA, V95, P8692, DOI 10.1073/pnas.95.15.8692; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811; Zhai QJ, 2010, APPL IMMUNOHISTO M M, V18, P323, DOI 10.1097/PAI.0b013e3181d712ef	141	7	8	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2681	2689		10.1038/onc.2014.209	http://dx.doi.org/10.1038/onc.2014.209			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043308				2022-12-28	WOS:000354979500001
J	Fernando, ATP; Andrabi, S; Cizmecioglu, O; Zhu, C; Livingston, DM; Higgins, JMG; Schaffhausen, BS; Roberts, TM				Fernando, A. T. Pores; Andrabi, S.; Cizmecioglu, O.; Zhu, C.; Livingston, D. M.; Higgins, J. M. G.; Schaffhausen, B. S.; Roberts, T. M.			Polyoma small T antigen triggers cell death via mitotic catastrophe	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; MIDDLE-T; KINETOCHORE LOCALIZATION; SPINDLE ORIENTATION; SIMIAN-VIRUS-40; PP2A; ARREST; COHESION; PHOSPHORYLATION; HOLOENZYMES	Polyoma small T antigen (PyST), an early gene product of the polyoma virus, has been shown to cause cell death in a number of mammalian cells in a protein phosphatase 2A (PP2A)-dependent manner. In the current study, using a cell line featuring regulated expression of PyST, we found that PyST arrests cells in mitosis. Live-cell and immunofluorescence studies showed that the majority of the PyST expressing cells were arrested in prometaphase with almost no cells progressing beyond metaphase. These cells exhibited defects in chromosomal congression, sister chromatid cohesion and spindle positioning, thereby resulting in the activation of the spindle assembly checkpoint. Prolonged mitotic arrest then led to cell death via mitotic catastrophe. Cell cycle inhibitors that block cells in G1/S prevented PyST-induced death. PyST-induced cell death that occurs during M is not dependent on p53 status. These data suggested, and our results confirmed, that PP2A inhibition could be used to preferentially kill cancer cells with p53 mutations that proliferate normally in the presence of cell cycle inhibitors.	[Fernando, A. T. Pores; Andrabi, S.; Cizmecioglu, O.; Livingston, D. M.; Roberts, T. M.] Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA; [Fernando, A. T. Pores; Cizmecioglu, O.; Roberts, T. M.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Zhu, C.; Higgins, J. M. G.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Higgins, J. M. G.] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Schaffhausen, B. S.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Newcastle University - UK; Tufts University	Roberts, TM (corresponding author), Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	shaida.andrabi@kashmiruniversity.ac.in; thomas_roberts@dfci.harvard.edu	Cizmecioglu, Onur/AAA-6289-2020; Cizmecioglu, Onur/AAF-5874-2020; Andrabi, Shaida/ABB-8795-2020	Cizmecioglu, Onur/0000-0002-7608-6950; Andrabi, Shaida/0000-0002-4114-4401; Higgins, Jonathan/0000-0001-6622-8268	National Institutes of Health PO1 grant [CA50661]; National Institutes of Health RO1 grant [CA30002, CA34722]; Ramalingaswami fellowship; CREST fellowship; Association for International Cancer Research; NATIONAL CANCER INSTITUTE [R37CA030002, R01CA034722, R37CA034722, P01CA050661, R01CA030002] Funding Source: NIH RePORTER; Worldwide Cancer Research [11-0775] Funding Source: researchfish	National Institutes of Health PO1 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health RO1 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ramalingaswami fellowship; CREST fellowship; Association for International Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Worldwide Cancer Research	This work was supported by an National Institutes of Health PO1 grant CA50661 to TMR, BSS and DML; and an RO1 grant to TMR (CA30002) and BSS (CA34722); and a Ramalingaswami fellowship and a CREST fellowship to SA. JMGH is supported by the Association for International Cancer Research, and is a Scholar of the Leukemia and Lymphoma Society. We thank Drs Jennifer Spangle and Meera Bhanu for their helpful comments on this manuscript.	Andrabi S, 2007, P NATL ACAD SCI USA, V104, P19011, DOI 10.1073/pnas.0706696104; Andrabi S, 2011, J VIROL, V85, P10649, DOI 10.1128/JVI.05034-11; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Blagosklonny MV, 2002, CELL CYCLE, V1, P375, DOI 10.4161/cc.1.6.259; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen HH, 2003, CELL DEATH DIFFER, V10, P516, DOI 10.1038/sj.cdd.4401171; Cheng JW, 2009, SEMIN CANCER BIOL, V19, P218, DOI 10.1016/j.semcancer.2009.03.002; Dai J, 2006, DEV CELL, V11, P741, DOI 10.1016/j.devcel.2006.09.018; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032; Foley EA, 2011, NAT CELL BIOL, V13, P1265, DOI 10.1038/ncb2327; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Gjoerup O, 2001, J VIROL, V75, P9142, DOI 10.1128/JVI.75.19.9142-9155.2001; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hwang JH, 2013, J BIOL CHEM, V288, P32064, DOI 10.1074/jbc.M113.497644; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2012, CURR MOL MED, V12, P268, DOI 10.2174/156652412799218930; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kochupurakkal BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068509; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Li SY, 2009, J VIROL, V83, P8340, DOI 10.1128/JVI.00711-09; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Marusyk A, 2007, MOL CELL BIOL, V27, P5336, DOI 10.1128/MCB.01316-06; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Schaffhausen BS, 2009, VIROLOGY, V384, P304, DOI 10.1016/j.virol.2008.09.042; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Sents W, 2013, FEBS J, V280, P644, DOI 10.1111/j.1742-4658.2012.08579.x; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Swingle Mark, 2007, V365, P23; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Taylor SS, 2001, J CELL SCI, V114, P4385; Toyoshima F, 2007, J CELL PHYSIOL, V213, P407, DOI 10.1002/jcp.21227; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yang CS, 2005, MOL CELL BIOL, V25, P1298, DOI 10.1128/MCB.25.4.1298-1308.2005; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZHENG B, 1991, J BIOL CHEM, V266, P10031; Zhou J, 2003, J BIOL CHEM, V278, P8617, DOI 10.1074/jbc.M211181200; Zhu M, 2013, J CELL BIOL, V200, P773, DOI 10.1083/jcb.201207050; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	52	9	9	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2483	2492		10.1038/onc.2014.192	http://dx.doi.org/10.1038/onc.2014.192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998850	Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000354190400007
J	Shi, Z; Li, Z; Li, ZJ; Cheng, K; Du, Y; Fu, H; Khuri, FR				Shi, Z.; Li, Z.; Li, Z. J.; Cheng, K.; Du, Y.; Fu, H.; Khuri, F. R.			Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3	ONCOGENE			English	Article							CHROMOSOME 18Q; MEDIATED DEGRADATION; DEPENDENT REGULATION; COLORECTAL-CANCER; UBIQUITIN LIGASE; OVARIAN-CANCER; S-PHASE; P21; GENE; PHOSPHORYLATION	The cyclin-dependent kinase (CDK) inhibitor 1A, p21/Cip1, is a vital cell cycle regulator, dysregulation of which has been associated with a large number of human malignancies. One critical mechanism that controls p21 function is through its degradation, which allows the activation of its associated cell cycle-promoting kinases, CDK2 and CDK4. Thus delineating how p21 is stabilized and degraded will enhance our understanding of cell growth control and offer a basis for potential therapeutic interventions. Here we report a novel regulatory mechanism that controls the dynamic status of p21 through its interaction with Cdk5 and Abl enzyme substrate 1 (Cables1). Cables1 has a proposed role as a tumor suppressor. We found that upregulation of Cables1 protein was correlated with increased half-life of p21 protein, which was attributed to Cables1/p21 complex formation and supported by their co-localization in the nucleus. Mechanistically, Cables1 interferes with the proteasome (Prosome, Macropain) subunit alpha type 3 (PSMA3) binding to p21 and protects p21 from PSMA3-mediated proteasomal degradation. Moreover, silencing of p21 partially reverses the ability of Cables1 to induce cell death and inhibit cell proliferation. In further support of a potential pathophysiological role of Cables1, the expression level of Cables1 is tightly associated with p21 in both cancer cell lines and human lung cancer patient tumor samples. Together, these results suggest Cables1 as a novel p21 regulator through maintaining p21 stability and support the model that the tumor-suppressive function of Cables1 occurs at least in part through enhancing the tumor-suppressive activity of p21.	[Shi, Z.] Jinan Univ, Coll Life Sci & Technol, Dept Cell Biol, Guangzhou, Guangdong, Peoples R China; [Shi, Z.] Jinan Univ, Coll Life Sci & Technol, Inst Biomed, Guangzhou, Guangdong, Peoples R China; [Shi, Z.; Li, Z.; Li, Z. J.; Cheng, K.; Du, Y.; Fu, H.] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; [Li, Z. J.] Peking Univ, Hosp 3, Inst Vasc Med, Beijing, Peoples R China; [Cheng, K.] Lishui Inst Agr Sci, Chem Biol Ctr, Lishui, Peoples R China; [Du, Y.; Fu, H.; Khuri, F. R.] Emory Univ, Emory Chem Biol Discovery Ctr, Atlanta, GA 30322 USA; [Fu, H.; Khuri, F. R.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Jinan University; Jinan University; Emory University; Peking University; Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Dept Pharmacol, 5111 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.	hfu@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Cheng, Kejun/0000-0002-1936-9129	National Institutes of Health Grant [P01 CA116676]; Georgia Cancer Coalition; Chinese National Natural Science Foundation [31271444, 81201726]; Foundation for Research Cultivation and Innovation of Jinan University [21612407]; Science and Technology Program of Guangzhou [14200010]; Specialized Research Fund for the Doctoral Program of Higher Education [20124401120007]; NATIONAL CANCER INSTITUTE [P01CA116676] Funding Source: NIH RePORTER	National Institutes of Health Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition; Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Foundation for Research Cultivation and Innovation of Jinan University; Science and Technology Program of Guangzhou; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the past and present members of the Fu/Khuri laboratory for many stimulating discussions. We also thank Dr Zukerberg LR and Dr Rueda BR (Massachusetts General Hospital) for sharing reagents. This work was supported by the National Institutes of Health Grant P01 CA116676 (to FRK and HF), Georgia Cancer Coalition (to HF and FRK), the Chinese National Natural Science Foundation No. 31271444 and No. 81201726 (to ZS), the Foundation for Research Cultivation and Innovation of Jinan University No. 21612407 (to ZS), the Science and Technology Program of Guangzhou No. 14200010 (to ZS) and the Specialized Research Fund for the Doctoral Program of Higher Education No. 20124401120007 (to ZS).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Arnason T, 2013, CANCER BIOL THER, V14, P672, DOI 10.4161/cbt.25089; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Dong Q, 2003, MODERN PATHOL, V16, P863, DOI 10.1097/01.MP.0000084434.88269.0A; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Kirley SD, 2005, CANCER BIOL THER, V4, P654, DOI 10.4161/cbt.4.6.1732; Kirley SD, 2005, CANCER BIOL THER, V4, P861, DOI 10.4161/cbt.4.8.1894; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lopez-Pajares V, 2008, J BIOL CHEM, V283, P13707, DOI 10.1074/jbc.M710030200; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Park DY, 2007, AM J PATHOL, V171, P1509, DOI 10.2353/ajpath.2007.070331; Sakamoto H, 2008, CANCER BIOL THER, V7, P180, DOI 10.4161/cbt.7.2.5253; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Tan DF, 2003, HUM PATHOL, V34, P143, DOI 10.1053/hupa.2003.26; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tsuji K, 2002, J BIOL CHEM, V277, P2951, DOI 10.1074/jbc.M108535200; Wang N, 2010, EMBO REP, V11, P633, DOI 10.1038/embor.2010.82; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Wu CL, 2001, CANCER RES, V61, P7325; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhu HY, 2005, J BIOL CHEM, V280, P29282, DOI 10.1074/jbc.M407352200; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3; Zukerberg LR, 2004, CANCER RES, V64, P202, DOI 10.1158/0008-5472.CAN-03-2833	31	39	39	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2538	2545		10.1038/onc.2014.171	http://dx.doi.org/10.1038/onc.2014.171			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24975575	Green Accepted			2022-12-28	WOS:000354190400012
J	Dodd, KM; Yang, J; Shen, MH; Sampson, JR; Tee, AR				Dodd, K. M.; Yang, J.; Shen, M. H.; Sampson, J. R.; Tee, A. R.			mTORC1 drives HIF-1 alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; MESSENGER-RNA TRANSLATION; ENDOTHELIAL GROWTH-FACTOR; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; SERINE PHOSPHORYLATION; MAXIMAL ACTIVATION; CANCER-THERAPY; TUMOR-GROWTH; RAPAMYCIN	Recent clinical trials using rapalogues in tuberous sclerosis complex show regression in volume of typically vascularised tumours including angiomyolipomas and subependymal giant cell astrocytomas. By blocking mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signalling, rapalogue efficacy is likely to occur, in part, through suppression of hypoxia-inducible factors (HIFs) and vascular endothelial growth factors (VEGFs). We show that rapamycin reduces HIF-1 alpha protein levels, and to a lesser extent VEGF-A levels, in renal cystadenoma cells in a Tsc2+/- mouse model. We established that mTORC1 drives HIF-1 alpha protein accumulation through enhanced transcription of HIF-1 alpha mRNA, a process that is blocked by either inhibition or knockdown of signal transducer and activation of transcription 3 (STAT3). Furthermore, we demonstrated that STAT3 is directly phosphorylated by mTORC1 on Ser727 during hypoxia, promoting HIF-1 alpha mRNA transcription. mTORC1 also regulates HIF-1 alpha synthesis on a translational level via co-operative regulation of both initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase-1 (S6K1), whereas HIF-1 alpha degradation remains unaffected. We therefore proposed that mTORC1 drives HIF-1 alpha synthesis in a multifaceted manner through 4E-BP1/eIF4E, S6K1 and STAT3. Interestingly, we observed a disconnect between HIF-1 alpha protein levels and VEGF-A expression. Although both S6K1 and 4E-BP1 regulate HIF-1 alpha translation, VEGF-A is primarily under the control of 4E-BP1/eIF4E. S6K1 inhibition reduces HIF-1 alpha but not VEGF-A expression, suggesting that mTORC1 mediates VEGF-A expression via both HIF-1 alpha-dependent and -independent mechanisms. Our work has important implications for the treatment of vascularised tumours, where mTORC1 acts as a central mediator of STAT3, HIF-1 alpha, VEGF-A and angiogenesis via multiple signalling mechanisms.	[Dodd, K. M.; Yang, J.; Shen, M. H.; Sampson, J. R.; Tee, A. R.] Cardiff Univ, Inst Canc & Genet, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Tee, AR (corresponding author), Cardiff Univ, Inst Canc & Genet, Canc & Genet Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk		Tee, Andrew/0000-0002-5577-4631	Association for International Cancer Research Career Development Fellowship [06-914/915]; Tuberous Sclerosis Association [2013-F02]; Cancer Research UK development fund; Welsh Government's National Institute of Social Care and Health Research (NISCHR) through the Wales Gene Park; Tuberous Sclerosis Association; Worldwide Cancer Research [06-0914] Funding Source: researchfish	Association for International Cancer Research Career Development Fellowship; Tuberous Sclerosis Association; Cancer Research UK development fund; Welsh Government's National Institute of Social Care and Health Research (NISCHR) through the Wales Gene Park; Tuberous Sclerosis Association; Worldwide Cancer Research	This research was supported by the Association for International Cancer Research Career Development Fellowship (No. 06-914/915) (to AT), a Junior Fellowship from the Tuberous Sclerosis Association [Ref: 2013-F02: Investigating mTORC1 independent functions of TSC2] (to KD) and a Cancer Research UK development fund (to JS and AT). This work is further supported by the Welsh Government's National Institute of Social Care and Health Research (NISCHR) through the Wales Gene Park and by the Tuberous Sclerosis Association.	Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Arbiser JL, 2002, J AM ACAD DERMATOL, V46, P376, DOI 10.1067/mjd.2002.120530; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Choo AY, 2006, CANCER CELL, V9, P77, DOI 10.1016/j.ccr.2006.01.021; Davies DM, 2008, NEW ENGL J MED, V358, P200, DOI 10.1056/NEJMc072500; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dempsey JM, 2010, ENZYMES, V28, P1, DOI 10.1016/S1874-6047(10)28001-0; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Dodd KM, 2012, AM J PHYSIOL-ENDOC M, V302, pE1329, DOI 10.1152/ajpendo.00525.2011; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Dunlop EA, 2011, EUR J HUM GENET, V19, P789, DOI 10.1038/ejhg.2011.38; Dunlop EA, 2009, CELL SIGNAL, V21, P1073, DOI 10.1016/j.cellsig.2009.02.024; El-Hashemite N, 2005, AM J RESP CELL MOL, V33, P227, DOI 10.1165/rcmb.2005-0152RC; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Garcia M, 2009, KU 0063794 IS SPECIF, V421; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guo YA, 2013, MOL CANCER RES, V11, P467, DOI 10.1158/1541-7786.MCR-12-0605; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Kang SA, 2013, SCIENCE, V341, P364, DOI 10.1126/science.1236566; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Marimpietri D, 2007, CLIN CANCER RES, V13, P3977, DOI 10.1158/1078-0432.CCR-06-2757; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024; Pfander D, 2003, J CELL SCI, V116, P1819, DOI 10.1242/jcs.00385; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Preston RS, 2011, ONCOGENE, V30, P1159, DOI 10.1038/onc.2010.497; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rosser Tena, 2006, Semin Pediatr Neurol, V13, P27, DOI 10.1016/j.spen.2006.01.008; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Tandon P, 2011, P NATL ACAD SCI USA, V108, P2361, DOI 10.1073/pnas.1013629108; Tee AR, 2004, FEBS LETT, V564, P58, DOI 10.1016/S0014-5793(04)00313-8; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Woodrum C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-14; Yang J, 2014, ONCOGENE; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	70	171	180	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2239	2250		10.1038/onc.2014.164	http://dx.doi.org/10.1038/onc.2014.164			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931163	Green Accepted			2022-12-28	WOS:000353473000009
J	George, SHL; Milea, A; Sowamber, R; Chehade, R; Tone, A; Shaw, PA				George, S. H. L.; Milea, A.; Sowamber, R.; Chehade, R.; Tone, A.; Shaw, P. A.			Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; INTRAEPITHELIAL CARCINOMA; CANCER; BRCA; SUPPRESSION; EXPRESSION; MUTATIONS; DIAGNOSIS; PATHWAYS; FEATURES	Liver kinase B1 (LKB1) is a tumor suppressor ubiquitously expressed serine/threonine protein kinase involved in energy metabolism and cellular polarity. In microarray experiments that compared normal tubal epithelium with high-grade serous carcinoma (HGSC), we observed a decrease in LKB1 mRNA expression in HGSC. In this study, we demonstrate that loss of cytoplasmic and nuclear LKB1 protein expression is frequently observed in tubal cancer precursor lesions as well as in both sporadic and hereditary HGSCs compared with other ovarian cancer histotypes. Bi-allelic genomic loss of LKB1 in HGSC did not account for the majority of cases with a decrease in protein expression. In vitro, shLKB1-fallopian tube epithelial (FTE) cells underwent premature cellular arrest and in ex vivo FTE culture, LKB1 loss and p53 mutant synergized to disrupt apical to basal polarity and decrease the number of ciliated cells. Overexpression of cyclin E1 allowed for bypass of LKB1-induced cellular arrest, and increased both proliferation and anchorage-independent growth of transformed FTE cells. These data suggest that LKB1 loss early in ovarian serous tumorigenesis has an integral role in tumor promotion by disrupting apical to basal polarity in the presence of mutated p53 in fallopian tube cells.	[George, S. H. L.; Milea, A.; Sowamber, R.; Chehade, R.; Tone, A.; Shaw, P. A.] Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [George, S. H. L.; Milea, A.; Sowamber, R.; Chehade, R.; Shaw, P. A.] Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; [George, S. H. L.; Milea, A.; Sowamber, R.; Tone, A.; Shaw, P. A.] Univ Hlth Network, Dept Lab Med, Toronto, ON, Canada; [Chehade, R.; Tone, A.; Shaw, P. A.] Univ Toronto, Toronto, ON, Canada; [Shaw, P. A.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Shaw, PA (corresponding author), Toronto Gen Hosp, Dept Pathol, Eaton Wing,Room 11-444,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	patricia.shaw@uhn.ca	GEORGE, SOPHIA/AAZ-7443-2020	GEORGE, SOPHIA/0000-0003-1013-1883	CDMRP Ovarian Cancer program [W81WH-0701-0371]; Princess Margaret Cancer Centre Foundation	CDMRP Ovarian Cancer program; Princess Margaret Cancer Centre Foundation(University of Toronto)	We thank the UHN Cancer Biobank Core Laboratory for sample acquisition, the UHN Pathology Research Program for immunohistochemistry, Doug Holmyard at Mount Sinai Hospital for the SEM, as well as the Gynecological Oncologists at the Princess Margaret Cancer Centre. This study was funded by the CDMRP Ovarian Cancer program (W81WH-0701-0371) and the Princess Margaret Cancer Centre Foundation.	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; George SHL, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00005; George SHL, 2012, CLIN CANCER RES, V18, P6199, DOI 10.1158/1078-0432.CCR-12-2155; George SHL, 2011, J PATHOL, V225, P106, DOI 10.1002/path.2927; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kuo KT, 2009, CANCER RES, V69, P4036, DOI 10.1158/0008-5472.CAN-08-3913; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Matulonis UA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024433; May T, 2010, GYNECOL ONCOL, V117, P9, DOI 10.1016/j.ygyno.2010.01.006; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; Milea A, 2014, MODERN PATHOL, V27, P991, DOI 10.1038/modpathol.2013.218; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Ning G, 2013, INT J GYNECOL PATHOL, V32, P345, DOI 10.1097/PGP.0b013e31826feee2; Norquist BM, 2010, CANCER-AM CANCER SOC, V116, P5261, DOI 10.1002/cncr.25439; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Partanen JI, 2009, CELL CYCLE, V8, P716, DOI 10.4161/cc.8.5.7786; Sehdev AS, 2010, MODERN PATHOL, V23, P844, DOI 10.1038/modpathol.2010.60; Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tanwar PS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002906; ten Klooster JP, 2009, DEV CELL, V16, P551, DOI 10.1016/j.devcel.2009.01.016; Tone AA, 2008, CLIN CANCER RES, V14, P4067, DOI 10.1158/1078-0432.CCR-07-4959; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Vang R, 2012, INT J GYNECOL PATHOL, V31, P243, DOI 10.1097/PGP.0b013e31823b8831; Visvanathan K, 2011, AM J SURG PATHOL, V35, P1766, DOI 10.1097/PAS.0b013e31822f58bc; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	39	15	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					59	68		10.1038/onc.2015.62	http://dx.doi.org/10.1038/onc.2015.62			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798842				2022-12-28	WOS:000367812400006
J	Hu, F; Deng, X; Yang, X; Jin, H; Gu, D; Lv, X; Wang, C; Zhang, Y; Huo, X; Shen, Q; Luo, Q; Zhao, F; Ge, T; Zhao, F; Chu, W; Shu, H; Yao, M; Fan, J; Qin, W				Hu, F.; Deng, X.; Yang, X.; Jin, H.; Gu, D.; Lv, X.; Wang, C.; Zhang, Y.; Huo, X.; Shen, Q.; Luo, Q.; Zhao, F.; Ge, T.; Zhao, F.; Chu, W.; Shu, H.; Yao, M.; Fan, J.; Qin, W.			Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1 alpha to promote the metastasis of hepatocellular carcinoma	ONCOGENE			English	Article							INDUCIBLE FACTORS; RAB11; TARGET; PRAS40; AKT; DIFFERENTIATION; PROLIFERATION; MECHANISMS; TRANSPORT; FAMILY	Hypoxic microenvironment is a powerful driving force for the invasion and metastasis of hepatocellular carcinoma (HCC). Hypoxia-inducible factor 1 alpha (HIF-1 alpha), as a crucial regulator of transcriptional responses to hypoxia, induces the expression of multiple target genes involved in different steps of HCC metastatic process. It is critical to find target genes associated with metastasis under hypoxia for shedding new light on molecular mechanism of HCC metastasis. In this study, we uncovered that hypoxia could induce the upregulation of Rab11-family interacting protein 4 (Rab11-FIP4) and activation of Rab11-FIP4 promoter by HIF-1a. The overexpression of Rab11-FIP4 significantly enhanced the mobility and invasiveness of HCC cells in vitro, also contributed to distant lung metastasis in vivo, whereas silencing of Rab11-FIP4 decreased the ability of migration and invasion in HCC cells in vitro and suppressed lung metastasis in vivo. Rab11-FIP4 facilitated HCC metastasis through the phosphorylation of PRAS40, which was regulated by mTOR. Furthermore, the expression level of Rab11-FIP4 was significantly increased in HCC tissues and high expression of Rab11-FIP4 was closely correlated with vascular invasion and poor prognosis in HCC patients. A markedly positive correlation between the expression of Rab11-FIP4 and HIF-1 alpha was observed in HCC tissues and combination of Rab11-FIP4 and HIF-1 alpha was a more valuable predictor of poor prognosis for HCC patients. In conclusion, Rab11-FIP4 is a target gene of HIF-1 alpha and has a pro-metastatic role in HCC, suggesting that Rab11-FIP4 may be a promising candidate target for HCC treatment.	[Hu, F.; Deng, X.; Ge, T.] Fudan Univ, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Hu, F.; Deng, X.; Jin, H.; Gu, D.; Wang, C.; Zhang, Y.; Huo, X.; Shen, Q.; Luo, Q.; Ge, T.; Zhao, F.; Chu, W.; Shu, H.; Yao, M.; Qin, W.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai 200032, Peoples R China; [Yang, X.; Fan, J.] Zhongshan Hosp, Chinese Minist Educ, Liver Canc Inst, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China; [Yang, X.; Fan, J.] Fudan Univ, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Gu, D.] Guangdong Med Coll, Dept Pathophysiol, Dongguan, Peoples R China; [Lv, X.; Zhao, F.] Nantong Univ, Coll Med, Basic Med Res Ctr, Nantong, Peoples R China	Fudan University; Shanghai Jiao Tong University; Fudan University; Fudan University; Guangdong Medical University; Nantong University	Qin, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, 25 Ln 2200 Xie Tu Rd, Shanghai 200032, Peoples R China.	jiafan99@yahoo.com; wxqin@sjtu.edu.cn		Xu, Changlong/0000-0001-7104-9029	National Key Sci-Tech Special Project of China [2012ZX10002011-004]; National Natural Science Foundation of China [81201627, 81371883]; Shanghai Municipal Program of International Cooperation in Science and Technology [12410709800]; Research Fund for the Doctoral Program of Higher Education of China [20120073110091]; Key Basic Research Program of Shanghai Committee of Science and Technology [11JC1412201]; State Key Laboratory of Oncogenes and Related Genes [91-1201, 91-1305]; Doctoral Innovation Fund of Shanghai Jiao Tong University School of Medicine [BXJ201243]; Key Discipline and Specialty Foundation of Shanghai Municipal Commission of Health and Family Planning	National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Program of International Cooperation in Science and Technology; Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Key Basic Research Program of Shanghai Committee of Science and Technology; State Key Laboratory of Oncogenes and Related Genes; Doctoral Innovation Fund of Shanghai Jiao Tong University School of Medicine; Key Discipline and Specialty Foundation of Shanghai Municipal Commission of Health and Family Planning	This work was supported by grants from National Key Sci-Tech Special Project of China (2012ZX10002011-004), National Natural Science Foundation of China (81201627 and 81371883), Shanghai Municipal Program of International Cooperation in Science and Technology (12410709800), Research Fund for the Doctoral Program of Higher Education of China (20120073110091), Key Basic Research Program of Shanghai Committee of Science and Technology (11JC1412201), Grant from the State Key Laboratory of Oncogenes and Related Genes (91-1201, 91-1305), Doctoral Innovation Fund of Shanghai Jiao Tong University School of Medicine (BXJ201243) and Key Discipline and Specialty Foundation of Shanghai Municipal Commission of Health and Family Planning.	Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fielding AB, 2005, EMBO J, V24, P3389, DOI 10.1038/sj.emboj.7600803; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Horgan CP, 2009, BIOCHEM SOC T, V37, P1032, DOI 10.1042/BST0371032; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Krzyzaniak MA, 2009, TRAFFIC, V10, P1439, DOI 10.1111/j.1600-0854.2009.00967.x; Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Meyers JM, 2002, J BIOL CHEM, V277, P49003, DOI 10.1074/jbc.M205728200; Muto A, 2006, DEV BIOL, V292, P90, DOI 10.1016/j.ydbio.2005.12.050; Muto A, 2007, DEV DYNAM, V236, P214, DOI 10.1002/dvdy.21009; Nagase T, 2001, DNA RES, V8, P319, DOI 10.1093/dnares/8.6.319; Nascimento Emmani B. M., 2009, Archives of Physiology and Biochemistry, V115, P163, DOI 10.1080/13813450902988580; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Portolani N, 2006, ANN SURG, V243, P229, DOI 10.1097/01.sla.0000197706.21803.a1; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wallace DME, 2002, BIOCHEM BIOPH RES CO, V299, P770, DOI 10.1016/S0006-291X(02)02720-1; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wiza C, 2012, AM J PHYSIOL-ENDOC M, V302, pE1453, DOI 10.1152/ajpendo.00660.2011; Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012; Wu XZ, 2007, J GASTROEN HEPATOL, V22, P1178, DOI 10.1111/j.1440-1746.2007.04997.x; Xiong XX, 2014, NEUROBIOL DIS, V66, P43, DOI 10.1016/j.nbd.2014.02.006	37	31	34	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					6007	6017		10.1038/onc.2015.49	http://dx.doi.org/10.1038/onc.2015.49			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25745995				2022-12-28	WOS:000366113500007
J	Cheng, X; Yang, Y; Fan, Z; Yu, L; Bai, H; Zhou, B; Wu, X; Xu, H; Fang, M; Shen, A; Chen, Q; Xu, Y				Cheng, X.; Yang, Y.; Fan, Z.; Yu, L.; Bai, H.; Zhou, B.; Wu, X.; Xu, H.; Fang, M.; Shen, A.; Chen, Q.; Xu, Y.			MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription	ONCOGENE			English	Article							PRO-INFLAMMATORY TRANSCRIPTION; BRAHMA-RELATED GENE-1; TGF-BETA; MRTF-A; MESENCHYMAL TRANSITION; LEUKEMIA 1; MATRIX-METALLOPROTEINASE-9; INDUCTION; CHROMATIN; REPRESSION	Malignant tumors are exemplified by excessive proliferation and aggressive migration/invasion contributing to increased mortality of cancer patients. Matrix metalloproteinase 9 (MMP9) expression is positively correlated with lung cancer malignancy. The mechanism underlying an elevated MMP9 expression is not clearly defined. We demonstrate here that the transcriptional modulator megakaryocytic leukemia 1 (MKL1) was activated by hypoxia and transforming growth factor (TGF-beta), two prominent pro-malignancy factors, in cultured lung cancer cells. MKL1 levels were also increased in more invasive types of lung cancer in humans. Depletion of MKL1 in lung cancer cells attenuated migration and invasion both in vitro and in vivo. Overexpression of MKL1 potentiated the induction of MMP9 transcription by hypoxia and TGF-beta, whereas MKL1 silencing diminished MMP9 expression. Of interest, MKL1 knockdown eliminated histone H3K4 methylation surrounding the MMP9 promoter. Further analyses revealed that MKL1 recruited ASH2, a component of the H3K4 methyltransferase complex, to activate MMP9 transcription. Depletion of ASH2 ameliorated cancer cell migration and invasion in an MMP9-dependent manner. Together our data indicate that MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription.	[Cheng, X.; Yang, Y.; Fan, Z.; Yu, L.; Bai, H.; Zhou, B.; Wu, X.; Xu, H.; Fang, M.; Chen, Q.; Xu, Y.] Nanjing Med Univ, Key Lab Cardiovasc Dis, Nanjing 210029, Jiangsu, Peoples R China; [Cheng, X.; Yang, Y.; Fan, Z.; Yu, L.; Bai, H.; Zhou, B.; Wu, X.; Xu, H.; Fang, M.; Chen, Q.; Xu, Y.] Nanjing Med Univ, Dept Pathophysiol, Nanjing 210029, Jiangsu, Peoples R China; [Cheng, X.] Jiangsu Inst Nucl Med, Wuxi, Peoples R China; [Yang, Y.] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China; [Fang, M.] Jiangsu Jiankang Vocat Univ, Dept Nursing, Nanjing, Jiangsu, Peoples R China; [Shen, A.] Nantong Univ, Coll Med, Dept Key Lab Inflammat & Mol Targets, Nantong, Peoples R China	Nanjing Medical University; Nanjing Medical University; China Pharmaceutical University; Nantong University	Xu, Y (corresponding author), Nanjing Med Univ, Key Lab Cardiovasc Dis, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.	mmfangnjmu@yahoo.com; yxu2005@gmail.com	Zhou, Bisheng/M-3143-2016; Zhou, Bisheng/K-2160-2019; Yu, Liming/AAH-6983-2021; wu, xin/GRS-8615-2022	Yu, Liming/0000-0002-6702-7625; Zhou, Bisheng/0000-0003-1551-0612	National Basic Science Project of China [2012CB517503]; National Natural Science Foundation of China [31270805, 31200645, 81402550, 91439106]; Natural Science Foundation of Jiangsu Province [BK2012043, BK20140906, BK21041498]; Education Commission of Jiangsu Province [14KJA31001]; Program for New Century Excellent Talents in University of China [NCET-11-0991]; Ministry of Education [212059, 20123234110008]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Basic Science Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Education Commission of Jiangsu Province; Program for New Century Excellent Talents in University of China(Program for New Century Excellent Talents in University (NCET)); Ministry of Education; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported, in part, by grants from the National Basic Science Project of China (2012CB517503), National Natural Science Foundation of China (31270805, 31200645, 81402550, 91439106), Natural Science Foundation of Jiangsu Province (BK2012043, BK20140906, BK21041498), Education Commission of Jiangsu Province (14KJA31001), the Program for New Century Excellent Talents in University of China (NCET-11-0991), Ministry of Education (212059, 20123234110008) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). YX is a fellow at the Collaborative Innovative Center for Cardiovascular Translational Medicine.	Ballerini P, 2003, LEUKEMIA, V17, P1193, DOI 10.1038/sj.leu.2402914; Basu S, 2007, CELL MICROBIOL, V9, P2804, DOI 10.1111/j.1462-5822.2007.00997.x; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang C, 2013, MOL CELL BIOL, V33, P3795, DOI 10.1128/MCB.00434-13; Chen DW, 2013, CARDIOVASC RES, V100, P363, DOI 10.1093/cvr/cvt214; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052; Cox G, 2000, CLIN CANCER RES, V6, P2349; Fang F, 2013, CIRC RES, V113, P986, DOI 10.1161/CIRCRESAHA.113.301296; Fang F, 2011, CIRC RES, V108, P797, DOI 10.1161/CIRCRESAHA.111.240655; Gilles L, 2009, BLOOD, V114, P4221, DOI 10.1182/blood-2009-03-209932; Gurbuz I, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-22; Hampl V, 2013, EMBO MOL MED, V5, P1367, DOI 10.1002/emmm.201202406; Hanna M, 2009, J BIOL CHEM, V284, P23125, DOI 10.1074/jbc.M109.019059; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Illman SA, 2006, J CELL SCI, V119, P3856, DOI 10.1242/jcs.03157; Jakopovic M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00261; Kaplan A, 2014, NEURON, V81, P333, DOI 10.1016/j.neuron.2013.12.009; Kim JE, 2008, EXP MOL MED, V40, P514, DOI 10.3858/emm.2008.40.5.514; Kim J, 2010, BIOCHEM BIOPH RES CO, V401, P412, DOI 10.1016/j.bbrc.2010.09.068; Kong XC, 2009, J MOL CELL CARDIOL, V46, P292, DOI 10.1016/j.yjmcc.2008.10.023; Larrieu D, 2010, CELL CYCLE, V9, P3984, DOI 10.4161/cc.9.19.13208; Lee SM, 2010, J BIOL CHEM, V285, P22036, DOI 10.1074/jbc.M110.108878; Lin YW, 2013, J PATHOL, V230, P277, DOI 10.1002/path.4179; Lockman K, 2007, CIRC RES, V101, pE115, DOI 10.1161/CIRCRESAHA.107.164178; Lundin A, 2013, CANCER LETT, V338, P89, DOI 10.1016/j.canlet.2012.08.014; Marcus PM, 2000, J NATL CANCER I, V92, P1308, DOI 10.1093/jnci/92.16.1308; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Moutsopoulos NM, 2008, CURR OPIN IMMUNOL, V20, P234, DOI 10.1016/j.coi.2008.04.003; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Osada H, 2005, MOL CARCINOGEN, V44, P233, DOI 10.1002/mc.20135; Pine SR, 2010, P NATL ACAD SCI USA, V107, P2195, DOI 10.1073/pnas.0909390107; Pinto CA, 2003, CLIN CANCER RES, V9, P3098; Rintoul RC, 2001, LANCET ONCOL, V2, P437, DOI 10.1016/S1470-2045(00)00421-6; Risch A, 2008, INT J CANCER, V123, P1, DOI 10.1002/ijc.23605; Robert I, 2009, ONCOGENE, V28, P1626, DOI 10.1038/onc.2009.6; Schaaij-Visser TBM, 2013, BBA-PROTEINS PROTEOM, V1834, P2242, DOI 10.1016/j.bbapap.2013.01.029; Shaposhnikov D, 2013, CELL CYCLE, V12, P1762, DOI 10.4161/cc.24839; Shaposhnikov D, 2012, CELL CYCLE, V11, P141, DOI 10.4161/cc.11.1.18499; Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Sienel W, 2003, INT J CANCER, V103, P647, DOI 10.1002/ijc.10841; Sun LN, 2013, J CELL SCI, V126, P3939, DOI 10.1242/jcs.127381; Sun LN, 2013, JNCI-J NATL CANCER I, V105, P887, DOI 10.1093/jnci/djt118; Takino T, 2003, ONCOGENE, V22, P4617, DOI 10.1038/sj.onc.1206542; Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027; Tian WF, 2015, J HEPATOL, V62, P165, DOI 10.1016/j.jhep.2014.07.029; Tian WF, 2013, HEPATOLOGY, V58, P576, DOI 10.1002/hep.26207; Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190; Ung YC, 2007, JNCI-J NATL CANCER I, V99, P1753, DOI 10.1093/jnci/djm232; Wan M, 2013, J BIOL CHEM, V288, P5039, DOI 10.1074/jbc.M112.424515; Weinl C, 2013, J CLIN INVEST, V123, P2193, DOI 10.1172/JCI64201; Wood SL, 2014, CANCER TREAT REV, V40, P558, DOI 10.1016/j.ctrv.2013.10.001; Xu HH, 2015, J AM SOC NEPHROL, V26, P1648, DOI 10.1681/ASN.2014070678; Yan XL, 2013, HEPATOLOGY, V57, P2274, DOI 10.1002/hep.26257; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Yang YY, 2014, NUCLEIC ACIDS RES, V42, P10460, DOI 10.1093/nar/gku776; Yang YY, 2013, NUCLEIC ACIDS RES, V41, P6005, DOI 10.1093/nar/gkt311; Yoshio T, 2010, CARCINOGENESIS, V31, P1185, DOI 10.1093/carcin/bgq065; Yu LM, 2014, J CELL SCI, V127, P4645, DOI 10.1242/jcs.152314; Yuan ZB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083895; Zhong Q, 2013, DIABETES, V62, P2559, DOI 10.2337/db12-1141; Zhou JL, 2009, ARTERIOSCL THROM VAS, V29, P921, DOI 10.1161/ATVBAHA.109.187229; Zhou X, 2010, CANCER RES, V70, P4214, DOI 10.1158/0008-5472.CAN-09-2942; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	65	47	50	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5570	5581		10.1038/onc.2015.14	http://dx.doi.org/10.1038/onc.2015.14			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25746000				2022-12-28	WOS:000364594000006
J	Kobayashi, S; Kasaishi, Y; Nakada, S; Takagi, T; Era, S; Motegi, A; Chiu, RK; Takeda, S; Hirota, K				Kobayashi, S.; Kasaishi, Y.; Nakada, S.; Takagi, T.; Era, S.; Motegi, A.; Chiu, R. K.; Takeda, S.; Hirota, K.			Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining	ONCOGENE			English	Article							STRAND BREAK REPAIR; UBIQUITIN-CONJUGATING ENZYME; DNA-DAMAGE RESPONSE; TOPOISOMERASE-I; CELLS; UBC13; UBIQUITYLATION; MAINTENANCE; INHIBITORS; PATHWAYS	The E2 ubiquitin conjugating enzyme Ubc13 and the E3 ubiquitin ligases Rad18 and Rnf8 promote homologous recombination (HR)-mediated double-strand break (DSB) repair by enhancing polymerization of the Rad51 recombinase at.-ray-induced DSB sites. To analyze functional interactions between the three enzymes, we created RAD18(-/-), RNF8(-/-), RAD18(-/-) /RNF8(-/-) and UBC13(-/-) clones in chicken DT40 cells. To assess the capability of HR, we measured the cellular sensitivity to camptothecin (topoisomerase I poison) and olaparib (poly(ADP ribose) polymerase inhibitor) because these chemotherapeutic agents induce DSBs during DNA replication, which are repaired exclusively by HR. RAD18(-/-), RNF8(-/-) and RAD18(-/-) /RNF8(-/-) clones showed very similar levels of hypersensitivity, indicating that Rad18 and Rnf8 operate in the same pathway in the promotion of HR. Although these three mutants show less prominent defects in the formation of Rad51 foci than UBC13(-/-) cells, they are more sensitive to camptothecin and olaparib than UBC13(-/-) cells. Thus, Rad18 and Rnf8 promote HR-dependent repair in a manner distinct from Ubc13. Remarkably, deletion of Ku70, a protein essential for nonhomologous end joining (NHEJ) significantly restored tolerance of RAD18(-/-) and RNF8(-/-) cells to camptothecin and olaparib without affecting Rad51 focus formation. Thus, in cellular tolerance to the chemotherapeutic agents, the two enzymes collaboratively promote DSB repair by HR by suppressing the toxic effect of NHEJ on HR rather than enhancing Rad51 focus formation. In contrast, following exposure to gamma-rays, RAD18(-/-), RNF8(-/-), RAD18(-/-) /RNF8(-/-) and UBC13(-/-) cells showed close correlation between cellular survival and Rad51 focus formation at DSB sites. In summary, the current study reveals that Rad18 and Rnf8 facilitate HR by two distinct mechanisms: suppression of the toxic effect of NHEJ on HR during DNA replication and the promotion of Rad51 focus formation at radiotherapy-induced DSB sites.	[Kobayashi, S.; Kasaishi, Y.; Era, S.; Motegi, A.; Takeda, S.; Hirota, K.] Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Kyoto 6068501, Japan; [Nakada, S.] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo, Japan; [Takagi, T.; Hirota, K.] Tokyo Metropolitan Univ, Grad Sch Sci & Engn, Dept Chem, Tokyo 158, Japan; [Chiu, R. K.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands	Kyoto University; Keio University; Tokyo Metropolitan University; University of Groningen	Hirota, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan.	stakeda@rg.med.kyoto-u.ac.jp; khirota@rg.med.kyoto-u.ac.jp	OsakaU/AAY-3661-2020	Nakada, Shinichiro/0000-0001-9297-1565	Ministry of Education, Sports and Culture of Japan; Uehara Memorial Foundation; Naito Foundation; Sumitomo Foundation; Kurata Fundation	Ministry of Education, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Naito Foundation(Naito Memorial Foundation); Sumitomo Foundation; Kurata Fundation	This work was supported in part by the grants-in-aid program of the Ministry of Education, Sports and Culture of Japan (for ST). We thank Drs Tadahiro Shiomi and Naoko Shiomi (National Institute of Radiological Sciences, Japan) for providing us with the HCT116 RAD18<SUP>-/-</SUP> and RAD18<SUP>+/+</SUP> cells and Professor Hitoshi Kurumizaka (Waseda University, Japan) for providing us with the anti-Rad51 antibody. Financial support was provided in part by the Uehara Memorial Foundation, the Naito Foundation, Sumitomo Foundation and Kurata Fundation (for KH).	Adachi N, 2004, J BIOL CHEM, V279, P37343, DOI 10.1074/jbc.M313910200; Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fukushima T, 2007, P NATL ACAD SCI USA, V104, P6371, DOI 10.1073/pnas.0700548104; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Inagaki A, 2009, DNA REPAIR, V8, P190, DOI 10.1016/j.dnarep.2008.10.008; Ji K, 2009, ENVIRON HEALTH PERSP, V117, P1737, DOI 10.1289/ehp.0900842; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Li L, 2010, J EXP MED, V207, P983, DOI 10.1084/jem.20092437; Lu CS, 2012, J BIOL CHEM, V287, P43984, DOI 10.1074/jbc.M112.421545; Lu LY, 2010, DEV CELL, V18, P371, DOI 10.1016/j.devcel.2010.01.010; Luijsterburg MS, 2012, EMBO J, V31, P2511, DOI 10.1038/emboj.2012.104; Maede Y, 2014, MOL CANCER THER, V13, P214, DOI 10.1158/1535-7163.MCT-13-0551; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Oestergaard VH, 2012, DNA REPAIR, V11, P892, DOI 10.1016/j.dnarep.2012.08.005; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Saberi A, 2007, MOL CELL BIOL, V27, P2562, DOI 10.1128/MCB.01243-06; Santos MA, 2010, J EXP MED, V207, P973, DOI 10.1084/jem.20092308; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sun JH, 2009, MECH DEVELOP, V126, P173, DOI 10.1016/j.mod.2008.11.004; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Watanabe K, 2009, NUCLEIC ACIDS RES, V37, P2176, DOI 10.1093/nar/gkp082; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078; Yamamoto M, 2006, NAT IMMUNOL, V7, P962, DOI 10.1038/ni1367; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039; Yoshimura A, 2006, DNA REPAIR, V5, P1307, DOI 10.1016/j.dnarep.2006.05.045; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	35	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4403	4411		10.1038/onc.2014.371	http://dx.doi.org/10.1038/onc.2014.371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417706	Green Submitted			2022-12-28	WOS:000359494400011
J	Stindt, MH; Muller, PAJ; Ludwig, RL; Kehrloesser, S; Dotsch, V; Vousden, KH				Stindt, M. H.; Muller, P. A. J.; Ludwig, R. L.; Kehrloesser, S.; Doetsch, V.; Vousden, K. H.			Functional interplay between MDM2, p63/p73 and mutant p53	ONCOGENE			English	Article							P73 FUNCTION; P63; PROTEIN; DEGRADATION; STABILITY; ISOFORMS; ACTIVATION; MUTATIONS; COMPLEX; DOMAIN	Many cancers express mutant p53 proteins that have lost wild-type tumor suppressor activity and, in many cases, have acquired oncogenic functions that can contribute to tumor progression. These activities of mutant p53 reflect interactions with several other proteins, including the p53 family members p63 and p73. Mutations in p53 that affect protein conformation (such as R175H) show strong binding to p63 and p73, whereas p53 mutants that only mildly affect the conformation (such as R273H) bind less well. A previously described aggregation domain of mutant p53 is not required for p63 or p73 binding; indeed, mutations within this region lead to the acquisition of a mutant p53 phenotype-including a conformational shift, p63/p73 binding and the ability to promote invasion. The activity of wild-type p53 is regulated by an interaction with MDM2 and we have investigated the potential role of MDM2 in the mutant p53/p63/p73 interactions. Both mutant p53 and p73 bind MDM2 well, whereas p63 binds much more weakly. We found that MDM2 can inhibit p63 binding to p53R175H but enhances the weaker p53R273H/p73 interaction. These effects on the interactions are reflected in an ability of MDM2 to relieve the inhibition of p63 by p53R175H, but enhance the inhibition of p73 activity by p53R175H and R273H. We propose a model in which MDM2 competes with p63 for binding to p53R175H to restore p63 activity, but forms a trimeric complex with p73 and p53R273H to more strongly inhibit p73 function.	[Stindt, M. H.; Muller, P. A. J.; Ludwig, R. L.; Vousden, K. H.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Kehrloesser, S.; Doetsch, V.] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany	Beatson Institute; Goethe University Frankfurt	Vousden, KH (corresponding author), Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk	Muller, Patricia AJ/AAH-1888-2019	Muller, Patricia AJ/0000-0002-0926-1499; Kehrloesser, Sebastian/0000-0002-6791-2421; Dotsch, Volker/0000-0001-5720-212X	Cancer Research UK; DFG [DO 545/8-1]; Wellcome Trust/the Royal Society; Cluster of Excellence Frankfurt (Macromolecular Complexes); MRC [MC_UP_1203/3] Funding Source: UKRI; Cancer Research UK [18274] Funding Source: researchfish; Medical Research Council [MC_UP_1203/3] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); DFG(German Research Foundation (DFG)); Wellcome Trust/the Royal Society; Cluster of Excellence Frankfurt (Macromolecular Complexes); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Drs Gerry Melino, Caron de Fromentel and Kevin Ryan for plasmids and are grateful to Cancer Research UK, the DFG (DO 545/8-1), The Wellcome Trust/the Royal Society (Sir Henry Dale Fellowship) and the Cluster of Excellence Frankfurt (Macromolecular Complexes) for funding.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Coutandin D, 2009, CELL DEATH DIFFER, V16, P1582, DOI 10.1038/cdd.2009.139; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Deutsch GB, 2011, CELL, V144, P566, DOI 10.1016/j.cell.2011.01.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ethayathulla AS, 2012, P NATL ACAD SCI USA, V109, P6066, DOI 10.1073/pnas.1115463109; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ishimoto O, 2002, CANCER RES, V62, P636; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Joerger AC, 2007, ADV CANCER RES, V97, P1, DOI 10.1016/S0065-230X(06)97001-8; Joerger AC, 2009, P NATL ACAD SCI USA, V106, P17705, DOI 10.1073/pnas.0905867106; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Luh LM, 2013, CELL DEATH DIFFER, V20, P1008, DOI 10.1038/cdd.2013.23; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Natan E, 2012, J MOL BIOL, V415, P503, DOI 10.1016/j.jmb.2011.11.007; Neilsen PM, 2011, ONCOTARGET, V2, P1203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Santini S, 2014, BBA-GEN SUBJECTS, V1840, P1958, DOI 10.1016/j.bbagen.2014.02.014; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Stindt Maren H, 2011, Cell Cycle, V10, P3176; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Straub WE, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.1; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Wiech M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051426; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zdzalik M, 2010, CELL CYCLE, V9, P4584, DOI 10.4161/cc.9.22.13871; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996	64	77	79	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4300	4310		10.1038/onc.2014.359	http://dx.doi.org/10.1038/onc.2014.359			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417702	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000359494400002
J	Wang, JY; Sun, J; Huang, MY; Wang, YS; Hou, MF; Sun, Y; He, H; Krishna, N; Chiu, SJ; Lin, S; Yang, S; Chang, WC				Wang, J-Y; Sun, J.; Huang, M-Y; Wang, Y-S; Hou, M-F; Sun, Y.; He, H.; Krishna, N.; Chiu, S-J; Lin, S.; Yang, S.; Chang, W-C			STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression	ONCOGENE			English	Article							OPERATED CALCIUM INFLUX; GENE ACTIVATION; CA2+ INFLUX; GROWTH; PROLIFERATION; MIGRATION; CHANNELS; FASCIN; ORAI1; INVOLVEMENT	Tumor metastasis is the major cause of death among cancer patients, with >90% of cancer-related death attributable to the spreading of metastatic cells to secondary organs. Store-operated Ca2+ entry (SOCE) is the predominant Ca2+ entry mechanism in most cancer cells, and stromal interaction molecule 1 (STIM1) is the endoplasmic reticulum (ER) Ca2+ sensor for store-operated channels. Here we reported that the STIM1 was overexpressed in colorectal cancer (CRC) patients. STIM1 overexpression in CRC was significantly associated with tumor size, depth of invasion, lymph node metastasis status and serum levels of carcinoembryonic antigen. Furthermore, ectopic expression of STIM1 promoted CRC cell motility, while depletion of STIM1 with short hairpin RNA inhibited CRC cell migration. Our data further suggested that STIM1 promoted CRC cell migration through increasing the expression of cyclooxygenase-2 (COX-2) and production of prostaglandin E2 (PGE2). Importantly, ectopically expressed COX-2 or exogenous PGE2 were able to rescue migration defect in STIM1 knockdown CRC cells, and inhibition of COX-2 with ibuprofen and indomethacin abrogated STIM1-mediated CRC cell motility. In short, our data provided clinicopathological significance for STIM1 and SOCE in CRC progression, and implicated a role for COX-2 in STIM1-mediated CRC metastasis. Our studies also suggested a new approach to inhibit STIM1-mediated metastasis with COX-2 inhibitors.	[Wang, J-Y; Huang, M-Y; Hou, M-F; Chiu, S-J; Chang, W-C] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan; [Wang, J-Y] Kaohsiung Med Univ Hosp, Div Gastrointestinal & Gen Surg, Kaohsiung, Taiwan; [Wang, J-Y] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Dept Surg, Kaohsiung, Taiwan; [Wang, J-Y] Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung, Taiwan; [Sun, J.; He, H.; Krishna, N.; Lin, S.; Yang, S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr,Dept Tumor Biol, Tampa, FL 33612 USA; [Huang, M-Y; Hou, M-F] Kaohsiung Med Univ Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Huang, M-Y; Hou, M-F] Kaohsiung Med Univ, Fac Med, Dept Radiat Oncol, Kaohsiung, Taiwan; [Wang, Y-S] Kaohsiung Med Univ, Fac Med, Dept Genom Med, Kaohsiung, Taiwan; [Hou, M-F] Kaohsiung Municipal Tatung Hosp, Kaohsiung, Taiwan; [Sun, Y.] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China; [Chiu, S-J; Chang, W-C] Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei, Taiwan; [Chang, W-C] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei 110, Taiwan; [Chang, W-C] Taipei Med Univ, Wanfang Hosp, Dept Pharm, Taipei 110, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Tianjin Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital	Yang, S (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	shengyu.yang@moffitt.org; wcc@tmu.edu.tw	Huang, Ming-Yii/AAS-8132-2021; Lin, Shengchen/T-3529-2018	Lin, Shengchen/0000-0003-1488-8680; Wang, Yu-Shiuan/0000-0001-7204-1256; Chang, Wei-Chiao/0000-0002-8573-5924; Hou, Ming-Feng/0000-0001-6030-9702	Health and welfare surcharge of tobacco products, Taiwan [DOH102-TD-C-111-002]; National Science Council, Taiwan [NSC98-2320-B-037-028, NSC101-2320-B-038-029-MY3]; Center for Biomarkers and Biotech Drugs, Kaohsiung Medical Universit, Aim for the Top Universities Grant [KMU-TP103C00, KMU-TP103C03]; NIH grant [R01CA175741]; NATIONAL CANCER INSTITUTE [R01CA175741] Funding Source: NIH RePORTER	Health and welfare surcharge of tobacco products, Taiwan; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Center for Biomarkers and Biotech Drugs, Kaohsiung Medical Universit, Aim for the Top Universities Grant; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Minjung Kim for assistance with IHC staining and we are grateful to Professor Yun Yen (City of Hope National Medical Center) for reading this paper and providing comments. This study was partly supported by funding from Health and welfare surcharge of tobacco products, Taiwan (Grant no. DOH102-TD-C-111-002), National Science Council, Taiwan (Grant no. NSC98-2320-B-037-028; NSC101-2320-B-038-029-MY3) and Center for Biomarkers and Biotech Drugs, Kaohsiung Medical Universit, Aim for the Top Universities Grant (KMU-TP103C00, KMU-TP103C03) WCC; and an NIH grant R01CA175741 to SY.	Aytes A, 2012, MOL CARCINOGEN, V51, P746, DOI 10.1002/mc.20843; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berry PA, 2011, PROSTATE, V71, P1646, DOI 10.1002/pros.21384; Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039; Chantome A, 2013, CANCER RES, V73, P4852, DOI 10.1158/0008-5472.CAN-12-4572; Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978; Chen YF, 2011, P NATL ACAD SCI USA, V108, P15225, DOI 10.1073/pnas.1103315108; Fedida-Metula S, 2012, CARCINOGENESIS, V33, P740, DOI 10.1093/carcin/bgs021; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Feng ZY, 2009, BIOORGAN MED CHEM, V17, P2147, DOI 10.1016/j.bmc.2008.10.074; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; Hou MF, 2011, BBA-GEN SUBJECTS, V1810, P1278, DOI 10.1016/j.bbagen.2011.07.001; Hsu WL, 2012, CELL CALCIUM, V52, P161, DOI 10.1016/j.ceca.2012.05.007; Hu JJ, 2011, BIOCHEM BIOPH RES CO, V411, P786, DOI 10.1016/j.bbrc.2011.07.025; Huang WC, 2011, CELL CALCIUM, V50, P27, DOI 10.1016/j.ceca.2011.04.004; Jans R, 2013, J INVEST DERMATOL, V133, P793, DOI 10.1038/jid.2012.370; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; McAndrew D, 2011, MOL CANCER THER, V10, P448, DOI 10.1158/1535-7163.MCT-10-0923; McGarrigle D, 2006, J BIOL CHEM, V281, P10583, DOI 10.1074/jbc.M513002200; Munoz E, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.198952; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Ryu S, 2013, CANCER CELL, V23, P63, DOI 10.1016/j.ccr.2012.11.019; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Shin DH, 2011, J PHARMACOL SCI, V115, P144, DOI 10.1254/jphs.10209FP; Sun JW, 2013, J BIOL CHEM, V288, P36971, DOI 10.1074/jbc.M113.506535; Sun JW, 2011, J BIOL CHEM, V286, P38865, DOI 10.1074/jbc.M111.270413; Wang DZ, 2013, ANNU REV MED, V64, P131, DOI 10.1146/annurev-med-112211-154330; Wang JY, 2012, CELL SIGNAL, V24, P162, DOI 10.1016/j.cellsig.2011.08.017; WOLMARK N, 1984, ANN SURG, V199, P375, DOI 10.1097/00000658-198404000-00001; Yang IH, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-41; Yang N, 2013, CANCER LETT, V330, P163, DOI 10.1016/j.canlet.2012.11.040; Yang Shengyu, 2012, Methods Mol Biol, V928, P221, DOI 10.1007/978-1-62703-008-3_17; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200; Yoshida J, 2012, BIOCHEM PHARMACOL, V84, P1592, DOI 10.1016/j.bcp.2012.09.021	38	95	97	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4358	4367		10.1038/onc.2014.366	http://dx.doi.org/10.1038/onc.2014.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381814	Green Accepted			2022-12-28	WOS:000359494400007
J	Erin, N; Podnos, A; Tanriover, G; Duymus, O; Cote, E; Khatri, I; Gorczynski, RM				Erin, N.; Podnos, A.; Tanriover, G.; Duymus, O.; Cote, E.; Khatri, I.; Gorczynski, R. M.			Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response	ONCOGENE			English	Article							SENSORY NEURONS PROMOTES; IMMUNE-RESPONSE; GENE-EXPRESSION; T-CELLS; INTERLEUKIN-10; CARCINOMA; RECEPTOR; MICE; GLYCOPROTEIN; SUPPRESSION	CD200 acts through its receptor (CD200R) to inhibit excessive inflammation. The role of CD200-CD200R1 interaction in tumor immunity is poorly understood. In this study, we examined the role of CD200-CD200R1 interaction in the progression and metastasis of highly aggressive 4THM murine-breast carcinoma using CD200 transgenic (CD200(tg)) and CD200R1 knock-out (CD200R1(-/-)) BALB/c mice. 4THM cells induce extensive visceral metastasis and neutrophil infiltration in affected tissues. CD200 overexpression in the host was associated with decreased primary tumor growth and metastasis, whereas lack of CD200R1 expression by host cells was associated with enhanced visceral metastasis. Absence of CD200R1 expression led to decreased tumor-infiltrating-cytotoxic T cells and increased the release of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6. In contrast, CD200 overexpression led to increased tumor-induced interferon-gamma and IL-10 response and decreased TNF-alpha and IL-6 release. Neutrophil infiltration of tissues was markedly decreased in CD200tg animals and increased in CD200R1(-/-) mice. These findings are contradictory to what has been reported in the EMT6 mouse breast-cancer model. Other distinguishing features of tumor elicited by EMT6 and 4THM cell injections were also examined. Visceral tissues from mice bearing EMT6 tumors showed a lack of neutrophil infiltration and decreased IL-6 release in CD200R1(-/-) mice. EMT6 and 4THM cells also differed in vimentin expression and in vitro migration rate, which was markedly lower in EMT6 tumors. These results support the hypothesis that CD200 expression can alter immune responses, and can inhibit metastatic growth of tumor cells that induce systemic and local inflammatory response. Increasing CD200 activity/signaling might be an important therapeutic strategy for treatment of aggressive breast carcinomas.	[Erin, N.; Duymus, O.] Akdeniz Univ, Sch Med, Dept Med Pharmacol, TR-07070 Antalya, Turkey; [Podnos, A.; Cote, E.; Khatri, I.; Gorczynski, R. M.] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada; [Tanriover, G.] Akdeniz Univ, Sch Med, Dept Histol & Embryol, TR-07070 Antalya, Turkey	Akdeniz University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Akdeniz University	Erin, N (corresponding author), Akdeniz Univ, Sch Med, Dept Med Pharmacol, B Blok Kat 1 Immunol, TR-07070 Antalya, Turkey.	nerin@akdeniz.edu.tr	Gorczynski, Reginald/AAA-1435-2019; Tanriover, Gamze/A-3196-2012; Erin, Nuray/B-8616-2012	Tanriover, Gamze/0000-0002-8002-5544; Erin, Nuray/0000-0002-6116-1970	TUBITAK (the scientific and technological research council of Turkey) [109S449]; Akdeniz University Research Units, Antalya, Turkey [2013.12.0103.001]; Canadian Cancer Society	TUBITAK (the scientific and technological research council of Turkey)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Akdeniz University Research Units, Antalya, Turkey(Akdeniz University); Canadian Cancer Society(Canadian Cancer Society (CCS))	This work was supported by funds from the TUBITAK (the scientific and technological research council of Turkey; project no: 109S449); Akdeniz University Research Units, Antalya, Turkey (project no: 2013.12.0103.001); and the Canadian Cancer Society (grant to RMG). We thank Nilufer Ekinci for her technical help.	Bao LL, 2011, AM J PATHOL, V178, P838, DOI 10.1016/j.ajpath.2010.10.029; Boudakov I, 2007, TRANSPLANTATION, V84, P251, DOI 10.1097/01.tp.0000269795.04592.cc; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Colmont CS, 2013, P NATL ACAD SCI USA, V110, P1434, DOI 10.1073/pnas.1211655110; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Erdman SE, 2003, CANCER RES, V63, P6042; Erin N, 2004, ANTICANCER RES, V24, P1003; Erin N, 2006, BREAST CANCER RES TR, V99, P351, DOI 10.1007/s10549-006-9219-7; Erin N, 2013, BREAST CANCER RES TR, V139, P677, DOI 10.1007/s10549-013-2584-0; Erin N, 2009, INT J CANCER, V124, P1503, DOI 10.1002/ijc.24131; Erin N, 2008, REGUL PEPTIDES, V151, P35, DOI 10.1016/j.regpep.2008.03.012; Geng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054959; Gorczynski R, 2004, J IMMUNOL, V172, P7744, DOI 10.4049/jimmunol.172.12.7744; Gorczynski RM, 2013, BREAST CANCER RES TR, V142, P271, DOI 10.1007/s10549-013-2735-3; Gorczynski RM, 2011, BREAST CANCER RES TR, V130, P49, DOI 10.1007/s10549-010-1259-3; Gorczynski RM, 2010, BREAST CANCER RES TR, V123, P405, DOI 10.1007/s10549-009-0667-8; Gorczynski RM, 2009, J IMMUNOL, V183, P1560, DOI 10.4049/jimmunol.0900200; Gorczynski RM, 2001, CLIN EXP IMMUNOL, V126, P220, DOI 10.1046/j.1365-2249.2001.01689.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hiratsuka S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2856; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kim HJ, 2009, J PROTEOME RES, V8, P1368, DOI 10.1021/pr8007573; Knutson KL, 2006, J IMMUNOL, V177, P1526, DOI 10.4049/jimmunol.177.3.1526; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Kretz-Ronlmel A, 2008, J IMMUNOL, V180, P699, DOI 10.4049/jimmunol.180.2.699; Kundu N, 1996, JNCI-J NATL CANCER I, V88, P536, DOI 10.1093/jnci/88.8.536; Lin GH, 2012, J IMMUNOTHER, V35, P337, DOI 10.1097/CJI.0b013e318255ada3; Lippitz BE, 2013, LANCET ONCOL, V14, pE218, DOI 10.1016/S1470-2045(12)70582-X; Liu Y, 2013, NEURO-ONCOLOGY, V15, P891, DOI 10.1093/neuonc/not031; Maru Y, 2007, CELL ADHES MIGR, V1, DOI 10.4161/cam.1.2.4489; Memarian A, 2013, TUMOR BIOL, V34, P531, DOI 10.1007/s13277-012-0578-x; Montagut C, 2006, ENDOCR-RELAT CANCER, V13, P607, DOI 10.1677/erc.1.01171; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Podnos A, 2012, BREAST CANCER RES TR, V136, P117, DOI 10.1007/s10549-012-2258-3; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Rygiel TP, 2012, ONCOGENE, V31, P2979, DOI 10.1038/onc.2011.477; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Stumpfova M, 2010, CANCER RES, V70, P2962, DOI 10.1158/0008-5472.CAN-09-4380; Talebian F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031442; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; West NR, 2013, BRIT J CANCER, V108, P155, DOI 10.1038/bjc.2012.524; Wong KK, 2012, CANCER RES, V72, P4931, DOI 10.1158/0008-5472.CAN-12-1390; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	54	49	50	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3860	3870		10.1038/onc.2014.317	http://dx.doi.org/10.1038/onc.2014.317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263452				2022-12-28	WOS:000358001600011
J	O'Loghlen, A; Martin, N; Krusche, B; Pemberton, H; Alonso, MM; Chandler, H; Brookes, S; Parrinello, S; Peters, G; Gil, J				O'Loghlen, A.; Martin, N.; Krusche, B.; Pemberton, H.; Alonso, M. M.; Chandler, H.; Brookes, S.; Parrinello, S.; Peters, G.; Gil, J.			The nuclear receptor NR2E1/TLX controls senescence	ONCOGENE			English	Article							CELLULAR SENESCENCE; POLYCOMB ORTHOLOGS; STEM-CELLS; CBX7; TLX; EXPRESSION; TAILLESS; CONTRIBUTES; PROGRESSION; INK4A/ARF	The nuclear receptor NR2E1 (also known as TLX or tailless) controls the self-renewal of neural stem cells (NSCs) and has been implied as an oncogene which initiates brain tumors including glioblastomas. Despite NR2E1 regulating targets like p21(CIP1) or PTEN we still lack a full explanation for its role in NSC self-renewal and tumorigenesis. We know that polycomb repressive complexes also control stem cell self-renewal and tumorigenesis, but so far, no formal connection has been established between NR2E1 and PRCs. In a screen for transcription factors regulating the expression of the polycomb protein CBX7, we identified NR2E1 as one of its more prominent regulators. NR2E1 binds at the CBX7 promoter, inducing its expression. Notably CBX7 represses NR2E1 as part of a regulatory loop. Ectopic NR2E1 expression inhibits cellular senescence, extending cellular lifespan in fibroblasts via CBX7-mediated regulation of p16(INK4a) and direct repression of p21(CIP1). In addition NR2E1 expression also counteracts oncogene-induced senescence. The importance of NR2E1 to restrain senescence is highlighted through the process of knocking down its expression, which causes premature senescence in human fibroblasts and epithelial cells. We also confirmed that NR2E1 regulates CBX7 and restrains senescence in NSCs. Finally, we observed that the expression of NR2E1 directly correlates with that of CBX7 in human glioblastoma multiforme. Overall we identified control of senescence and regulation of polycomb action as two possible mechanisms that can join those so far invoked to explain the role of NR2E1 in control of NSC self-renewal and cancer.	[O'Loghlen, A.; Martin, N.; Brookes, S.; Gil, J.] Univ London Imperial Coll Sci Technol & Med, Epigenet Sect, Cell Proliferat Grp, MRC Clin Sci Ctr, London W12 0NN, England; [O'Loghlen, A.; Pemberton, H.; Chandler, H.; Brookes, S.; Peters, G.] CRUK London Res Inst, Mol Oncol Lab, London, England; [Krusche, B.; Parrinello, S.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Epigenet Sect, Cell Interact & Canc Grp, London W12 0NN, England; [Alonso, M. M.] Univ Hosp Navarra, Dept Med Oncol, Pamplona, Spain	Imperial College London; Cancer Research UK; Imperial College London; Servicio Navarro de Salud - Osasunbidea; University of Navarra	Gil, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Epigenet Sect, Cell Proliferat Grp, MRC Clin Sci Ctr, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	jesus.gil@csc.mrc.ac.uk	Alonso, Marta M/AAI-9457-2020; Gil, Jesus/C-7739-2012; O'Loghlen, Ana/K-9965-2014	Alonso, Marta M/0000-0002-7520-7351; Gil, Jesus/0000-0002-4303-6260; Martin, Nadine/0000-0002-4806-2388; O'Loghlen, Ana/0000-0002-8141-1965	MRC; MRCT; CRUK; AICR; EMBO; Marie Curie fellowships; EMBO Young Investigator Program; Medical Research Council [MC_U120085810, MC_UP_A652_1002] Funding Source: researchfish; MRC [MC_UP_A652_1002, MC_U120085810] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRCT(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); AICR; EMBO(European Molecular Biology Organization (EMBO)); Marie Curie fellowships(European Commission); EMBO Young Investigator Program(European Molecular Biology Organization (EMBO)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to G Dharmalingam and S. Khadayate for help with bioinformatics and to I Farinas and JM Morente for advise and help with NSCs. Core support was received from MRC and grants from MRCT, CRUK and the AICR funded the research in J Gil's laboratory. N Martin was funded by EMBO and Marie Curie fellowships. J Gil is also supported by the EMBO Young Investigator Program.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Forzati F, 2012, CELL CYCLE, V11, P1888, DOI 10.4161/cc.20022; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gui HX, 2011, DEV NEUROSCI-BASEL, V33, P1, DOI 10.1159/000321585; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; Liu HK, 2008, GENE DEV, V22, P2473, DOI 10.1101/gad.479308; Liu HK, 2010, GENE DEV, V24, P683, DOI 10.1101/gad.560310; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Modena P, 2006, J CLIN ONCOL, V24, P5223, DOI 10.1200/JCO.2006.06.3701; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; O'Loghlen A, 2012, CELL STEM CELL, V10, P33, DOI 10.1016/j.stem.2011.12.004; Park HJ, 2010, MOL CELLS, V30, P403, DOI 10.1007/s10059-010-0122-z; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pemberton H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r23; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Qu QH, 2010, NAT CELL BIOL, V12, P31, DOI 10.1038/ncb2001; Scheffler B, 2005, P NATL ACAD SCI USA, V102, P9353, DOI 10.1073/pnas.0503965102; Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041; Sun GQ, 2007, P NATL ACAD SCI USA, V104, P15282, DOI 10.1073/pnas.0704089104; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Yokoyama A, 2008, MOL CELL BIOL, V28, P3995, DOI 10.1128/MCB.02030-07; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhang CL, 2006, GENE DEV, V20, P1308, DOI 10.1101/gad.1413606; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao C, 2009, NAT STRUCT MOL BIOL, V16, P365, DOI 10.1038/nsmb.1576; Zou YH, 2012, MOL CELL BIOL, V32, P4811, DOI 10.1128/MCB.01122-12	47	27	28	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4069	4077		10.1038/onc.2014.335	http://dx.doi.org/10.1038/onc.2014.335			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25328137	Green Accepted, Green Submitted			2022-12-28	WOS:000358780500005
J	Akaike, Y; Kuwano, Y; Nishida, K; Kurokawa, K; Kajita, K; Kano, S; Masuda, K; Rokutan, K				Akaike, Y.; Kuwano, Y.; Nishida, K.; Kurokawa, K.; Kajita, K.; Kano, S.; Masuda, K.; Rokutan, K.			Homeodomain-interacting protein kinase 2 regulates DNA damage response through interacting with heterochromatin protein 1 gamma	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; P53 ACTIVITY; HIPK2; REPAIR; PHOSPHORYLATION; CELLS; HP1; RECRUITMENT	Homeodomain-interacting protein kinase 2 (HIPK2) is a potential tumor suppressor that has a crucial role in the DNA damage response (DDR) by regulating cell-cycle checkpoint activation and apoptosis. However, it is unclear whether HIPK2 exerts distinct roles in DNA damage repair. The aim of this study was to identify novel target molecule(s) of HIPK2, which mediates HIPK2-dependent DNA damage repair. HIPK2-knockdown human colon cancer cells (HCT116) or hipk1/hipk2 double-deficient mouse embryonic fibroblasts could not remove histone H2A.X phosphorylated at Ser139 (gamma H2A.X) after irradiation with a sublethal dose (10 J/m(2)) of ultraviolet (UV)-C, resulting in apoptosis. Knockdown of HIPK2 in p53-null HCT116 cells similarly promoted the UV-C-induced gamma H2A.X accumulation and apoptosis. Proteomic analysis of HIPK2-associated proteins using liquid chromatography-tandem mass spectrometry identified heterochromatin protein 1 gamma (HP1 gamma) as a novel target for HIPK2. Immunoprecipitation experiments with HCT116 cells expressing FLAG-tagged HIPK2 and one of the HA-tagged HP1 family members demonstrated that HIPK2 specifically associated with HP1 gamma, but not with HP1 alpha or HP1 beta, through its chromo-shadow domain. Mutation of the HP1box motif (883-PTVSV-887) within HIPK2 abolished the association. HP1 gamma knockdown also enhanced accumulation of gamma H2A.X and apoptosis after sublethal UV-C irradiation. In vitro kinase assay demonstrated an HP1 gamma-phosphorylating activity of HIPK2. Sublethal UV-C irradiation phosphorylated HP1 gamma. This phosphorylation was absent in endogenous HIPK2-silenced cells with HIPK2 3'UTR siRNA. Overexpression of FLAG-HIPK2, but not the HP1box-mutated or kinase-dead HIPK2 mutant, in the HIPK2-silenced cells increased HP1 gamma binding to trimethylated (Lys9) histone H3 (H3K9me3), rescued the UV-C-induced phosphorylation of HP1 gamma, triggered release of HP1 gamma from histone H3K9me3 and suppressed gamma H2A.X accumulation. Our results suggest that HIPK2-dependent phosphorylation of HP1 gamma may participate in the regulation of dynamic interaction between HP1 gamma and histone H3K9me3 to promote DNA damage repair. This HIPK2/HP1 gamma pathway may uncover a new functional aspect of HIPK2 as a tumor suppressor.	[Akaike, Y.; Kuwano, Y.; Nishida, K.; Kurokawa, K.; Kajita, K.; Kano, S.; Masuda, K.; Rokutan, K.] Univ Tokushima, Grad Sch, Dept Stress Sci, Inst Hlth Biosci, Tokushima 7708503, Japan	Tokushima University	Rokutan, K (corresponding author), Univ Tokushima, Grad Sch, Dept Stress Sci, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	rokutan@tokushima-u.ac.jp	Nishida, Kensei/AAF-2829-2020	Nishida, Kensei/0000-0003-2314-785X	JSPS [24-8354]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by JSPS KAKENHI Grant Number 24-8354 (to YA).	[Anonymous], ONCOGENE; Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Baldeyron C, 2011, J CELL BIOL, V193, P81, DOI 10.1083/jcb.201101030; Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113; Chiolo I, 2011, CELL, V144, P732, DOI 10.1016/j.cell.2011.02.012; Choi DW, 2013, MOL CELL, V51, P374, DOI 10.1016/j.molcel.2013.06.010; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Dinant C, 2009, MOL CELL BIOL, V29, P6335, DOI 10.1128/MCB.01048-09; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Grzenda A, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-21; Hiragami-Hamada K, 2011, MOL CELL BIOL, V31, P1186, DOI 10.1128/MCB.01012-10; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2013, BIOESSAYS, V35, P55, DOI 10.1002/bies.201200060; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; Jakob B, 2011, NUCLEIC ACIDS RES, V39, P6489, DOI 10.1093/nar/gkr230; Kim JA, 2007, J CELL BIOL, V178, P209, DOI 10.1083/jcb.200612031; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Kwon SH, 2008, MOL CELLS, V26, P217; Kwon SH, 2011, BIOESSAYS, V33, P280, DOI 10.1002/bies.201000138; Lee DH, 2011, TRENDS BIOCHEM SCI, V36, P569, DOI 10.1016/j.tibs.2011.08.007; Lee YH, 2013, NUCLEIC ACIDS RES, V41, P5784, DOI 10.1093/nar/gkt231; Leroy G, 2009, MOL CELL PROTEOMICS, V8, P2432, DOI 10.1074/mcp.M900160-MCP200; Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764; Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383; Lomberk G, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-228; Luijsterburg MS, 2009, J CELL BIOL, V185, P577, DOI 10.1083/jcb.200810035; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Mund A, 2012, NUCLEIC ACIDS RES, V40, P11363, DOI 10.1093/nar/gks868; Nardinocchi L, 2007, BIOCHEM BIOPH RES CO, V361, P249, DOI 10.1016/j.bbrc.2007.07.031; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Papamichos-Chronakis M, 2013, NAT REV GENET, V14, P62, DOI 10.1038/nrg3345; Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Rastogi RP, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/592980; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Saul VV, 2013, J MOL CELL BIOL, V5, P27, DOI 10.1093/jmcb/mjs053; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Sombroek D, 2009, CELL DEATH DIFFER, V16, P187, DOI 10.1038/cdd.2008.154; Soria G, 2012, MOL CELL, V46, P722, DOI 10.1016/j.molcel.2012.06.002; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Yamada D, 2009, ONCOGENE, V28, P2535, DOI 10.1038/onc.2009.109; Yamaguchi T, 2001, CANCER RES, V61, P8256; Zarebski M, 2009, CYTOM PART A, V75A, P619, DOI 10.1002/cyto.a.20734; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	51	23	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3463	3473		10.1038/onc.2014.278	http://dx.doi.org/10.1038/onc.2014.278			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25151962				2022-12-28	WOS:000356871700011
J	Russo, RIC; Beguelin, W; Flaque, MCD; Proietti, CJ; Venturutti, L; Galigniana, N; Tkach, M; Guzman, P; Roa, JC; O'Brien, NA; Charreau, EH; Schillaci, R; Elizalde, PV				Cordo Russo, R. I.; Beguelin, W.; Diaz Flaque, M. C.; Proietti, C. J.; Venturutti, L.; Galigniana, N.; Tkach, M.; Guzman, P.; Roa, J. C.; O'Brien, N. A.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.			Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR; PROGESTERONE-RECEPTOR; CYCLIN D1; CELL-PROLIFERATION; SIGNALING PATHWAYS; IN-VIVO; PI3K INHIBITOR; THERAPY; HER2	Membrane overexpression of ErbB-2/HER2 receptor tyrosine kinase (membrane ErbB-2 (MErbB-2)) has a critical role in breast cancer (BC). We and others have also shown the role of nuclear ErbB-2 (NErbB-2) in BC, whose presence we identified as a poor prognostic factor in MErbB-2-positive tumors. Current anti-ErbB-2 therapies, as with the antibody trastuzumab (Ttzm), target only MErbB-2. Here, we found that blockade of NErbB-2 action abrogates growth of BC cells, sensitive and resistant to Ttzm, in a scenario in which ErbB-2, ErbB-3 and Akt are phosphorylated, and ErbB-2/ErbB-3 dimers are formed. Also, inhibition of NErbB-2 presence suppresses growth of a preclinical BC model resistant to Ttzm. We showed that at the cyclin D1 promoter, ErbB-2 assembles a transcriptional complex with Stat3 (signal transducer and activator of transcription 3) and ErbB-3, another member of the ErbB family, which reveals the first nuclear function of ErbB-2/ErbB-3 dimer. We identified NErbB-2 as the major proliferation driver in Ttzm-resistant BC, and demonstrated that Ttzm inability to disrupt the Stat3/ErbB-2/ErbB-3 complex underlies its failure to inhibit growth. Furthermore, our results in the clinic revealed that nuclear interaction between ErbB-2 and Stat3 correlates with poor overall survival in primary breast tumors. Our findings challenge the paradigm of anti-ErbB-2 drug design and highlight NErbB-2 as a novel target to overcome Ttzm resistance.	[Cordo Russo, R. I.; Beguelin, W.; Diaz Flaque, M. C.; Proietti, C. J.; Venturutti, L.; Galigniana, N.; Tkach, M.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.] Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, RA-1428 Buenos Aires, DF, Argentina; [Guzman, P.; Roa, J. C.] Univ La Frontera, Dept Anat Patol BIOREN, Temuco, Chile; [O'Brien, N. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Universidad de La Frontera; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	patriciaelizalde@ibyme.conicet.gov.ar	Russo, Rosalia Cordo/O-9149-2017; Roa, Juan C./K-4749-2014	Russo, Rosalia Cordo/0000-0002-5984-9717; Roa, Juan C./0000-0001-8313-8774; Elizalde, Patricia V./0000-0002-5923-9898; Galigniana, Natalia/0000-0002-0712-719X; Schillaci, Roxana/0000-0002-7776-3378; Diaz Flaque, Maria Celeste/0000-0003-4167-6149	Susan G Komen for the Cure investigator-initiated research Grant [KG090250]; National Agency of Scientific Promotion of Argentina [IDB/PICT 2012-668, PID 2012-066, IDB/PICT 2012-382]; Henry Moore Institute of Argentina [CONICET 1819/03]	Susan G Komen for the Cure investigator-initiated research Grant; National Agency of Scientific Promotion of Argentina(ANPCyT); Henry Moore Institute of Argentina	We thank Mien-Chie Hung (MD Anderson Cancer Center, Houston, TX, USA) for his generous gift of the hErbB-2.NLS, which indeed made this work possible, and AA Molinolo (NIH, Bethesda, MD, USA) for his constant help and support. We also thank J Giudice (Baylor College of Medicine, Houston, TX, USA) for help with quantification of confocal images, and V Chiauzzi for her excellent technical assistance. This work was supported by the Susan G Komen for the Cure KG090250 investigator-initiated research Grant, IDB/PICT 2012-668 and PID 2012-066 from the National Agency of Scientific Promotion of Argentina (all of them awarded to PVE), IDB/PICT 2012-382 from the National Agency of Scientific Promotion of Argentina (awarded to RS) and Oncomed-Reno CONICET 1819/03, from the Henry Moore Institute of Argentina (awarded to PVE and RS).	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Andrique L, 2012, CELL SIGNAL, V24, P1074, DOI 10.1016/j.cellsig.2012.01.002; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Beguelin W, 2010, MOL CELL BIOL, V30, P5456, DOI 10.1128/MCB.00012-10; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brand TM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071518; Breuleux M, 2006, MOL CANCER RES, V4, P27, DOI 10.1158/1541-7786.MCR-05-0016; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Browne BC, 2009, CURR CANCER DRUG TAR, V9, P419, DOI 10.2174/156800909788166484; Chiu CG, 2010, ANN SURG, V251, P1107, DOI 10.1097/SLA.0b013e3181dbb77e; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Henderson IC, 1998, BREAST CANCER RES TR, V52, P261, DOI 10.1023/A:1006141703224; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kataoka Y, 2010, ANN ONCOL, V21, P255, DOI 10.1093/annonc/mdp304; Koninki K, 2010, CANCER LETT, V294, P211, DOI 10.1016/j.canlet.2010.02.002; Koumakpayi IH, 2006, CLIN CANCER RES, V12, P2730, DOI 10.1158/1078-0432.CCR-05-2242; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Landgraf R, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1633; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lenferink AEG, 2001, CANCER RES, V61, P6583; Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Li WL, 1996, ONCOGENE, V12, P2473; Maegawa M, 2007, MOL CANCER RES, V5, P393, DOI 10.1158/1541-7786.MCR-06-0303; Marshall C, 2006, BREAST CANCER RES TR, V96, P163, DOI 10.1007/s10549-005-9073-z; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Ostrander JH, 2007, CANCER RES, V67, P4199, DOI 10.1158/0008-5472.CAN-06-3409; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Rivas MA, 2010, BREAST CANCER RES TR, V122, P111, DOI 10.1007/s10549-009-0546-3; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Salatino M, 2004, ONCOGENE, V23, P5161, DOI 10.1038/sj.onc.1207659; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Schillaci R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-74; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Tanner M, 2004, MOL CANCER THER, V3, P1585; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang YC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3067; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yakes FM, 2002, CANCER RES, V62, P4132; Yao E, 2009, CLIN CANCER RES, V15, P4147, DOI 10.1158/1078-0432.CCR-08-2814	67	39	40	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3413	3428		10.1038/onc.2014.272	http://dx.doi.org/10.1038/onc.2014.272			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174405	Green Published			2022-12-28	WOS:000356871700007
J	Lee, KH; Park, JW; Sung, HS; Choi, YJ; Kim, WH; Lee, HS; Chung, HJ; Shin, HW; Cho, CH; Kim, TY; Li, SH; Youn, HD; Kim, SJ; Chun, YS				Lee, K-H; Park, J-W; Sung, H-S; Choi, Y-J; Kim, W. H.; Lee, H. S.; Chung, H-J; Shin, H-W; Cho, C-H; Kim, T-Y; Li, S-H; Youn, H-D; Kim, S. J.; Chun, Y-S			PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer	ONCOGENE			English	Article							PLANT HOMEODOMAIN; COLON-CANCER; TRANSCRIPTION; ACETYLATION; ACTIVATION; EXPRESSION; BINDING; GENES	Plant homeodomain finger 2 (PHF2) has a role in epigenetic regulation of gene expression by demethylating H3K9-Me2. Several genome-wide studies have demonstrated that the chromosomal region including the PHF2 gene is often deleted in some cancers including colorectal cancer, and this finding encouraged us to investigate the tumor suppressive role of PHF2. As p53 is a critical tumor suppressor in colon cancer, we tested the possibility that PHF2 is an epigenetic regulator of p53. PHF2 was associated with p53, and thereby, promoted p53-driven gene expression in cancer cells under genotoxic stress. PHF2 converted the chromatin that is favorable for transcription by demethylating the repressive H3K9-Me2 mark. In an HCT116 xenograft model, PHF2 was found to be required for the anticancer effects of oxaliplatin and doxorubicin. In PHF2-deficient xenografts, p53 expression was profoundly induced by both drugs, but its downstream product p21 was not, suggesting that p53 cannot be activated in the absence of PHF2. To find clinical evidence about the role of PHF2, we analyzed the expressions of PHF2, p53 and p21 in human colon cancer tissues and adjacent normal tissues from patients. PHF2 was downregulated in cancer tissues and PHF2 correlated with p21 in cancers expressing functional p53. Colon and stomach cancer tissue arrays showed a positive correlation between PHF2 and p21 expressions. Informatics analyses using the Oncomine database also supported our notion that PHF2 is downregulated in colon and stomach cancers. On the basis of these findings, we propose that PHF2 acts as a tumor suppressor in association with p53 in cancer development and ensures p53-mediated cell death in response to chemotherapy.	[Lee, K-H; Park, J-W; Shin, H-W; Youn, H-D; Kim, S. J.; Chun, Y-S] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 110799, South Korea; [Park, J-W; Sung, H-S; Choi, Y-J; Chung, H-J; Cho, C-H; Li, S-H; Youn, H-D; Kim, S. J.; Chun, Y-S] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 110799, South Korea; [Kim, W. H.; Lee, H. S.] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; [Kim, T-Y] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110799, South Korea; [Kim, S. J.; Chun, Y-S] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Chun, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Physiol, 103 Daehak Ro, Seoul 110799, South Korea.	chunys@snu.ac.kr	Lee, Kyoung-Hwa/AAJ-5213-2021	Kim, Sang Jeong/0000-0001-8931-3713	Korean Health Technology RD grant [A121106, A120476]; National Research Foundation grants of Korea [2009-0066985, 20110008634, 2011-0030737]; Seoul National University Hospital Research Fund [0320110180]	Korean Health Technology RD grant; National Research Foundation grants of Korea; Seoul National University Hospital Research Fund	This work was supported by a Korean Health Technology R&D grant (A121106, A120476), National Research Foundation grants of Korea (2009-0066985, 20110008634 and 2011-0030737) and by a grant from the Seoul National University Hospital Research Fund 2011 (0320110180).	Baba A, 2011, NAT CELL BIOL, V13, P668, DOI 10.1038/ncb2228; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Feng WJ, 2010, NAT STRUCT MOL BIOL, V17, P445, DOI 10.1038/nsmb.1778; Fortschegger K, 2011, EPIGENETICS-US, V6, P4, DOI 10.4161/epi.6.1.13297; Ghosh A, 2012, ANN SURG ONCOL, V19, pS528, DOI 10.1245/s10434-011-1991-x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hasenpusch-Theil K, 1999, MAMM GENOME, V10, P294, DOI 10.1007/s003359900989; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jin LH, 2013, BIOCHEM J, V449, P459, DOI 10.1042/BJ20121360; Kleine-Kohlbrecher D, 2010, MOL CELL, V38, P165, DOI 10.1016/j.molcel.2010.03.002; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Munro AJ, 2005, BRIT J CANCER, V92, P434, DOI 10.1038/sj.bjc.6602358; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Ogino S, 2009, CANCER EPIDEM BIOMAR, V18, P2513, DOI 10.1158/1055-9965.EPI-09-0451; Okuno Y, 2013, DIABETES, V62, P1426, DOI 10.2337/db12-0628; Qiu JH, 2010, CELL RES, V20, P908, DOI 10.1038/cr.2010.81; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Sinha S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-84; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020; Wen H, 2010, J BIOL CHEM, V285, P9322, DOI 10.1074/jbc.C109.097667; Wiesner GL, 2003, P NATL ACAD SCI USA, V100, P12961, DOI 10.1073/pnas.2132286100; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	34	44	48	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2897	2909		10.1038/onc.2014.219	http://dx.doi.org/10.1038/onc.2014.219			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25043306				2022-12-28	WOS:000355324300009
J	Zhang, Z; Liang, X; Gao, L; Ma, H; Liu, X; Pan, Y; Yan, W; Shan, H; Wang, Z; Chen, YH; Ma, C				Zhang, Z.; Liang, X.; Gao, L.; Ma, H.; Liu, X.; Pan, Y.; Yan, W.; Shan, H.; Wang, Z.; Chen, Y. H.; Ma, C.			TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells	ONCOGENE			English	Article							DEATH PATHWAYS; RHO-GTPASES; EXPRESSION; SCC-S2; CANCER; LIVER; PROLIFERATION; METASTASIS; MODULATION; IMMUNITY	TIPE1 (tumor necrosis factor-alpha-induced protein 8-like 1 or TNFAIP8L1) is a newly identified member of the TIPE (TNFAIP8) family, which play roles in regulating cell death. However, the biologic functions of TIPE1 in physiologic and pathologic conditions are largely unknown. Here, we report the roles of TIPE1 in hepatocellular carcinoma (HCC). Evaluated by immunohistochemical staining, HCC tissues showed significantly downregulated TIPE1 expression compared with adjacent non-tumor tissues, which positively correlated with tumor pathologic grades and patient survival. Using a homograft tumor model in Balb/c mice, we discovered that TIPE1 significantly diminished the growth and tumor weight of murine liver cancer homografts. Consistently, TIPE1 inhibited both cell growth and colony formation ability of cultured HCC cell lines, which was further identified to be due to TIPE1-inducing apoptosis in a caspase-independent, necrostatin-1 (Nec-1)-insensitive manner. Furthermore, mechanistic investigations revealed that TIPE1 interacted with Rac1, and inhibited the activation of Rac1 and its downstream p65 and c-Jun N-terminal kinase pathway. Moreover, overexpression of constitutively active Rac1 partially rescued the apoptosis induced by TIPE1, and Rac1 knockdown significantly restored the deregulated cell growth induced by TIPE1 small interfering RNA. Our findings revealed that TIPE1 induced apoptosis in HCC cells by negatively regulating Rac1 pathway, and loss of TIPE1 might be a new prognostic indicator for HCC patients.	[Zhang, Z.; Liang, X.; Gao, L.; Ma, H.; Liu, X.; Pan, Y.; Yan, W.; Shan, H.; Ma, C.] Shandong Univ, Sch Med, Key Lab Expt Teratol, Minist Educ, Jinan 250012, Shandong, Peoples R China; [Wang, Z.; Chen, Y. H.] Shandong Univ, Sch Med, Dept Immunol, Jinan 250012, Shandong, Peoples R China; [Wang, Z.; Chen, Y. H.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Shandong University; Shandong University; University of Pennsylvania	Chen, YH (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 713 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	yhc@mail.med.upenn.edu; machunhong@sdu.edu.cn	Wang, Zhaojun/GKS-9141-2022; Chen, Youhai/AAJ-4031-2021; ma, chunhong/C-6043-2008	Wang, Zhaojun/0000-0003-2853-1850; ma, chunhong/0000-0002-8121-4718	National Science Foundation of China [81172353, 81372211]; Cultivating Project, Major Research Plan of National Natural Science Foundation of China [91129704]; Shandong Provincial Nature Science Foundation [JQ200907]; Research Fund for the Doctoral Program of Higher Education of China (RFDP) [20110131110034];  [NCET-10-0524]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Cultivating Project, Major Research Plan of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Nature Science Foundation; Research Fund for the Doctoral Program of Higher Education of China (RFDP)(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); 	This work was supported by grants from the National Science Foundation of China (Nos. 81172353, 81372211), Cultivating Project, Major Research Plan of National Natural Science Foundation of China (91129704), Programme for NCET-10-0524, Research Fund for the Doctoral Program of Higher Education of China (RFDP) (20110131110034) and Shandong Provincial Nature Science Foundation for Distinguished Young Scholars JQ200907.	Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Chaigne-Delalande B, 2008, ONCOGENE, V27, P1876, DOI 10.1038/sj.onc.1210830; Cui J, 2011, MOL IMMUNOL, V48, P1548, DOI 10.1016/j.molimm.2011.04.023; Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200; Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432; Dong QZ, 2010, CANCER SCI, V101, P1562, DOI 10.1111/j.1349-7006.2010.01557.x; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Filmus Jorge, 2004, Mol Diagn, V8, P207, DOI 10.2165/00066982-200408040-00002; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; Gus-Brautbar Y, 2012, MOL CELL, V45, P610, DOI 10.1016/j.molcel.2012.01.006; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Ishak KG, 2000, AM J CLIN PATHOL, V113, P40, DOI 10.1309/42D6-W7PL-FX0A-LBXF; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kumar D, 2004, ONCOGENE, V23, P612, DOI 10.1038/sj.onc.1207123; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Luan F, 2009, GUT, V58, P1528, DOI 10.1136/gut.2008.174029; Ma CH, 2004, WORLD J GASTROENTERO, V10, P2874; Mack NA, 2011, CELL CYCLE, V10, P1571, DOI 10.4161/cc.10.10.15612; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Miao ZF, 2012, TUMOR BIOL, V33, P2099, DOI 10.1007/s13277-012-0469-1; Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x; Ozen C, 2013, NEW BIOTECHNOL, V30, P381, DOI 10.1016/j.nbt.2013.01.007; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sasi N, 2009, MOL CANCER THER, V8, P1421, DOI 10.1158/1535-7163.MCT-08-0895; Shi TY, 2013, CARCINOGENESIS, V34, P770, DOI 10.1093/carcin/bgt001; Shiraha H, 2013, INT J ONCOL, V42, P1133, DOI 10.3892/ijo.2013.1829; Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026; Sun HH, 2012, J IMMUNOL, V189, P2768, DOI 10.4049/jimmunol.1103477; Wang ZJ, 2012, P NATL ACAD SCI USA, V109, P15413, DOI 10.1073/pnas.1204525109; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wilson KD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002609; Woodward MJ, 2010, CELL DEATH DIFFER, V17, P316, DOI 10.1038/cdd.2009.125; Yue XT, 2012, GASTROENTEROLOGY, V142, P1559, DOI 10.1053/j.gastro.2012.02.049; Zhang CB, 2006, MOL THER, V13, P947, DOI 10.1016/j.ymthe.2005.11.020	37	45	51	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2566	2574		10.1038/onc.2014.208	http://dx.doi.org/10.1038/onc.2014.208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043299				2022-12-28	WOS:000354541300003
J	Honda, H; Nagamachi, A; Inaba, T				Honda, H.; Nagamachi, A.; Inaba, T.			-7/7q-syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity	ONCOGENE			English	Review							CHROMOSOME BAND 7Q22; JUVENILE MYELOMONOCYTIC LEUKEMIA; THERAPY-RELATED MYELODYSPLASIA; PROGNOSTIC SCORING SYSTEM; LOW-DOSE DECITABINE; METHYLTRANSFERASE GENE EZH2; COMMONLY DELETED SEGMENT; TUMOR-SUPPRESSOR LOCUS; ONE-STEP GENERATION; SOMATIC MUTATIONS	The recurrence of chromosomal abnormalities in a specific subtype of cancer strongly suggests that dysregulated gene expression in the corresponding region has a critical role in disease pathogenesis. - 7/7q -, defined as the entire loss of chromosome 7 and partial deletion of its long arm, is among the most frequently observed chromosomal aberrations in myeloid-lineage hematopoietic malignancies such as myelodysplastic syndrome and acute myeloid leukemia, particularly in patients treated with cytotoxic agents and/or irradiation. Tremendous efforts have been made to clarify the molecular mechanisms underlying the disease development, and several possible candidate genes have been cloned. However, the study is still underway, and the entire nature of this syndrome is not completely understood. In this review, we focus on the attempts to identify commonly deleted regions in patients with - 7/7q -; isolate the candidate genes responsible for disease development, cooperative genes and the factors affecting disease prognosis; and determine effective and potent therapeutic approaches. We also refer to the possibility that the accumulation of multiple gene haploinsufficiency, rather than the loss of a single tumor suppressor gene, may contribute to the development of diseases with large chromosomal deletions such as - 7/7q -.	[Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Hiroshima, Japan; [Nagamachi, A.; Inaba, T.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Hiroshima, Japan; [Nagamachi, A.; Inaba, T.] Hiroshima Univ, Leukemia Program Project, Res Inst Radiat Biol & Med, Hiroshima, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Honda, H (corresponding author), Res Inst Radiat Biol & Med, Dept Dis Model, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [26293227] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was in part supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Alkelai A, 2012, INT J NEUROPSYCHOPH, V15, P459, DOI 10.1017/S1461145711000903; Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x; Asou H, 2009, BIOCHEM BIOPH RES CO, V383, P245, DOI 10.1016/j.bbrc.2009.04.004; Au WY, 2003, BRIT J HAEMATOL, V120, P1062, DOI 10.1046/j.1365-2141.2003.04194.x; Balgobind BV, 2010, LEUKEMIA, V24, P942, DOI 10.1038/leu.2010.47; BARANGER L, 1990, LEUKEMIA, V4, P345; Barreyro L, 2012, BLOOD, V120, P1290, DOI 10.1182/blood-2012-01-404699; Bejar R, 2012, J CLIN ONCOL, V30, P3376, DOI 10.1200/JCO.2011.40.7379; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bernstein R, 1984, CANCER GENET CYTOGEN, V11, P300; Bisen A, 2013, ADV EXP MED BIOL, V779, P179, DOI 10.1007/978-1-4614-6176-0_8; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Boultwood J, 2013, BLOOD, V121, P869, DOI 10.1182/blood-2012-12-473421; Boultwood J, 2010, BLOOD, V116, P5803, DOI 10.1182/blood-2010-04-273771; Brezinova J, 2007, CANCER GENET CYTOGEN, V173, P10, DOI 10.1016/j.cancergencyto.2006.09.003; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Cadieux C, 2006, CANCER RES, V66, P9492, DOI 10.1158/0008-5472.CAN-05-4230; Cadieux C, 2009, CANCER RES, V69, P7188, DOI 10.1158/0008-5472.CAN-08-4899; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cattaneo F, 2008, J CELL BIOCHEM, V105, P344, DOI 10.1002/jcb.21869; Chen CY, 2007, BRIT J HAEMATOL, V139, P405, DOI 10.1111/j.1365-2141.2007.06811.x; Chen C, 2014, CANCER CELL, V25, P652, DOI 10.1016/j.ccr.2014.03.016; Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765; Chen Z, 2005, CANCER GENET CYTOGEN, V162, P95, DOI 10.1016/j.cancergencyto.2005.03.017; Christiansen DH, 2007, GENE CHROMOSOME CANC, V46, P517, DOI 10.1002/gcc.20426; Christiansen DH, 2004, BLOOD, V104, P1474, DOI 10.1182/blood-2004-02-0754; Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; Cordoba I, 2012, CANCER-AM CANCER SOC, V118, P127, DOI 10.1002/cncr.26279; Cortes J, 2012, BLOOD, V120, P1390, DOI 10.1182/blood-2012-03-378919; Cristobal I, 2010, BLOOD, V115, P615, DOI 10.1182/blood-2009-06-227363; Cuenco GM, 2004, ONCOGENE, V23, P569, DOI 10.1038/sj.onc.1207143; Curtiss NP, 2005, GENOMICS, V85, P600, DOI 10.1016/j.ygeno.2005.01.013; Czarnecka K, 2013, MOL BIOL REP, V40, P6671, DOI 10.1007/s11033-013-2782-1; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Damm F, 2013, LEUKEMIA, V27, P1401, DOI 10.1038/leu.2013.35; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; De Braekeleer E, 2011, FUTURE ONCOL, V7, P77, DOI [10.2217/fon.10.158, 10.2217/FON.10.158]; De Weer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008676; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Dohner K, 1998, BLOOD, V92, P4031, DOI 10.1182/blood.V92.11.4031.423k55_4031_4035; Dolnik A, 2012, BLOOD, V120, pE83, DOI 10.1182/blood-2011-12-401471; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Emerling BM, 2002, ONCOGENE, V21, P4849, DOI 10.1038/sj.onc.1205615; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Estey EH, 2013, LEUKEMIA, V27, P1803, DOI 10.1038/leu.2013.173; EVANS JPM, 1988, BRIT J HAEMATOL, V69, P41, DOI 10.1111/j.1365-2141.1988.tb07600.x; Fenaux P, 2010, BRIT J HAEMATOL, V149, P244, DOI 10.1111/j.1365-2141.2010.08082.x; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Freireich E, 1964, CLIN RES, V12, P284; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142; Germing U, 2005, LEUKEMIA, V19, P2223, DOI 10.1038/sj.leu.2403963; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Glass C, 2014, BLOOD CELL MOL DIS, V53, P67, DOI 10.1016/j.bcmd.2014.01.002; Glockner G, 1998, GENOME RES, V8, P1060; Gohring G, 2010, BLOOD, V116, P3766, DOI 10.1182/blood-2010-04-280313; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489; Griffiths EA, 2013, ADV EXP MED BIOL, V754, P253, DOI 10.1007/978-1-4419-9967-2_13; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Groschel S, 2010, J CLIN ONCOL, V28, P2101, DOI 10.1200/JCO.2009.26.0646; Groves MJ, 2011, CANCER GENET-NY, V204, P39, DOI 10.1016/j.cancergencyto.2010.08.017; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Haase D, 2007, BLOOD, V110, P4385, DOI 10.1182/blood-2007-03-082404; Hackanson B, 2005, ANN HEMATOL, V84, P32, DOI 10.1007/s00277-005-0004-1; Hasegawa D, 2009, PEDIATR BLOOD CANCER, V53, P1011, DOI 10.1002/pbc.22121; Hasle H, 1999, LEUKEMIA, V13, P376, DOI 10.1038/sj.leu.2401342; Hasle H, 2007, BLOOD, V109, P4641, DOI 10.1182/blood-2006-10-051342; HELLSTROMLINDBERG E, 1992, BRIT J HAEMATOL, V81, P503, DOI 10.1111/j.1365-2141.1992.tb02982.x; Herman JG, 1996, CANCER RES, V56, P722; Herrera-Merchan A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1623; Hershkovitz D, 2011, J INVEST DERMATOL, V131, P662, DOI 10.1038/jid.2010.387; Herz HM, 2014, MOL CELL, V53, P859, DOI 10.1016/j.molcel.2014.02.033; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hirayama Y, 2003, BRIT J HAEMATOL, V121, P376, DOI 10.1046/j.1365-2141.2003.04279.x; Hodge JC, 2009, GENE CHROMOSOME CANC, V48, P865, DOI 10.1002/gcc.20692; Hosono N, 2014, LEUKEMIA, V28, P1348, DOI 10.1038/leu.2014.25; Hou HA, 2014, AM J HEMATOL, V89, P181, DOI 10.1002/ajh.23611; Howell VM, 2007, HUM MOL GENET, V16, P2506, DOI 10.1093/hmg/ddm206; Hulea L, 2012, GENE, V497, P18, DOI 10.1016/j.gene.2012.01.039; Hussain FTN, 2012, AM J HEMATOL, V87, P684, DOI 10.1002/ajh.23230; Ichikawa M, 2013, INT J HEMATOL, V97, P726, DOI 10.1007/s12185-013-1347-3; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Itzykson R, 2014, LEUKEMIA, V28, P497, DOI 10.1038/leu.2013.343; Jerez A, 2012, BLOOD, V119, P6109, DOI 10.1182/blood-2011-12-397620; Johnson E, 1997, BLOOD REV, V11, P46, DOI 10.1016/S0268-960X(97)90006-0; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162; Kardos G, 2003, BLOOD, V102, P1997, DOI 10.1182/blood-2002-11-3444; Kawankar N, 2011, HEMATOLOGY, V16, P131, DOI 10.1179/102453311X12940641877966; KERE J, 1987, BLOOD, V70, P1349; Kim M, 2010, LEUKEMIA RES, V34, P718, DOI 10.1016/j.leukres.2009.09.007; Kiuru-Kuhlefelt S, 1997, LEUKEMIA, V11, P2097, DOI 10.1038/sj.leu.2400881; Kjeldsen E, 2013, CELL ONCOL, V36, P395, DOI 10.1007/s13402-013-0145-5; Klco JM, 2013, BLOOD, V121, P1633, DOI 10.1182/blood-2012-09-459313; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kratz CP, 2002, BLOOD, V99, P372, DOI 10.1182/blood.V99.1.372; Kratz CP, 2001, GENOMICS, V77, P171, DOI 10.1006/geno.2001.6636; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Kuhn MWM, 2012, BLOOD, V119, pE67, DOI 10.1182/blood-2011-09-380444; Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008; Largaespada DA, 2001, J EXP MED, V193, pF15, DOI 10.1084/jem.193.4.F15; Larsson N, 2010, CANCER GENET CYTOGEN, V199, P89, DOI 10.1016/j.cancergencyto.2010.02.005; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LeBeau MM, 1996, BLOOD, V88, P1930; LEMIEUX N, 1994, GENOMICS, V24, P191, DOI 10.1006/geno.1994.1603; Lewis S, 1996, BRIT J HAEMATOL, V93, P75, DOI 10.1046/j.1365-2141.1996.4841025.x; Li CF, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-92; Li TT, 2013, J BIOL CHEM, V288, P4135, DOI 10.1074/jbc.M112.345942; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Locatelli F, 2013, BLOOD, V122, P2135, DOI 10.1182/blood-2013-03-491589; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Lubbert M, 2011, J CLIN ONCOL, V29, P1987, DOI 10.1200/JCO.2010.30.9245; Lugthart S, 2010, J CLIN ONCOL, V28, P3890, DOI 10.1200/JCO.2010.29.2771; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Luna-Fineman S, 1999, BLOOD, V93, P459, DOI 10.1182/blood.V93.2.459.402k19_459_466; Madureira ABM, 2011, LEUKEMIA, V25, P449, DOI 10.1038/leu.2010.285; Maestrini E, 2010, MOL PSYCHIATR, V15, P954, DOI 10.1038/mp.2009.34; Makishima H, 2012, BLOOD, V119, P3203, DOI 10.1182/blood-2011-12-399774; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McNerney ME, 2013, BLOOD, V121, P975, DOI 10.1182/blood-2012-04-426965; Meggendorfer M, 2013, LEUKEMIA, V27, P1852, DOI 10.1038/leu.2013.133; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Migas A, 2011, PEDIATR BLOOD CANCER, V57, P583, DOI 10.1002/pbc.22980; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nagamachi A, 2013, CANCER CELL, V24, P305, DOI 10.1016/j.ccr.2013.08.011; Nagasawa M, 2004, LEUKEMIA RES, V28, P315, DOI 10.1016/S0145-2126(03)00263-7; Navarro JT, 2007, AM J HEMATOL, V82, P849, DOI 10.1002/ajh.20859; NEUBAUER A, 1991, BLOOD, V77, P594; Neukirchen J, 2014, LEUKEMIA RES, V38, P57, DOI 10.1016/j.leukres.2013.10.013; Niimi H, 2006, LEUKEMIA, V20, P635, DOI 10.1038/sj.leu.2404136; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Nucifora G, 2006, GENE, V368, P1, DOI 10.1016/j.gene.2005.09.020; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olnes MJ, 2012, LEUKEMIA RES, V36, P982; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Ozaki Y, 2012, MOL CELL, V47, P694, DOI 10.1016/j.molcel.2012.06.033; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; PASSMORE SJ, 1995, BLOOD, V85, P1742, DOI 10.1182/blood.V85.7.1742.bloodjournal8571742; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; Pedersen-Bjergaard J, 2008, LEUKEMIA, V22, P240, DOI 10.1038/sj.leu.2405078; Pellagatti A, 2010, LEUKEMIA, V24, P756, DOI 10.1038/leu.2010.31; Pozdnyakova O, 2008, CANCER-AM CANCER SOC, V113, P3331, DOI 10.1002/cncr.23977; Qian ZJ, 2010, CHEM-BIOL INTERACT, V184, P50, DOI 10.1016/j.cbi.2009.11.025; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; QUESNEL B, 1995, BLOOD, V85, P657, DOI 10.1182/blood.V85.3.657.bloodjournal853657; Raj K, 2007, LEUKEMIA, V21, P1937, DOI 10.1038/sj.leu.2404796; Raj KK, 2005, BLOOD, V106, p710A; RAMBALDI A, 1991, BLOOD, V78, P3248; Ripka S, 2007, CARCINOGENESIS, V28, P1178, DOI 10.1093/carcin/bgl255; Roumier C, 2006, LEUKEMIA, V20, P433, DOI 10.1038/sj.leu.2404097; ROWLEY JD, 1966, BLOOD-J HEMATOL, V27, P782, DOI 10.1182/blood.V27.6.782.782; ROWLEY JD, 1973, LANCET, V2, P1385; Ruault M, 2002, GENE, V284, P73, DOI 10.1016/S0378-1119(02)00392-X; Ruckner FG, 2012, BLOOD, V119, P2114, DOI 10.1182/blood-2011-08-375758; Ruter B, 2007, BLOOD, V110, P1080, DOI 10.1182/blood-2007-03-080630; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; Sansregret L, 2008, GENE, V412, P84, DOI 10.1016/j.gene.2008.01.017; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; SCHERER SW, 1993, GENOMICS, V15, P695, DOI 10.1006/geno.1993.1130; Seetharam M, 2012, LEUKEMIA RES, V36, P98; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Side LE, 2004, GENE CHROMOSOME CANC, V39, P217, DOI 10.1002/gcc.10320; Simon C, 2012, GENE DEV, V26, P651, DOI 10.1101/gad.186411.111; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Sinclair AM, 2001, BLOOD, V98, P3658, DOI 10.1182/blood.V98.13.3658; Singh H, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.16; Slovak ML, 2009, CANCER GENET CYTOGEN, V193, P78, DOI 10.1016/j.cancergencyto.2009.04.013; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Soriano AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576; Spensberger D, 2008, FEBS LETT, V582, P2761, DOI 10.1016/j.febslet.2008.06.056; Steele M, 2005, PEDIATR BLOOD CANCER, V45, P212, DOI 10.1002/pbc.20332; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Takaya A, 2007, MOL BIOL CELL, V18, P1850, DOI 10.1091/mbc.E06-08-0765; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tien HF, 2001, BRIT J HAEMATOL, V112, P148, DOI 10.1046/j.1365-2141.2001.02496.x; Tong WG, 2012, CANCER-AM CANCER SOC, V118, P4462, DOI 10.1002/cncr.27420; Topaz O, 2006, AM J HUM GENET, V79, P759, DOI 10.1086/508069; Tosi S, 1999, GENE CHROMOSOME CANC, V25, P384, DOI 10.1002/(SICI)1098-2264(199908)25:4<384::AID-GCC11>3.0.CO;2-D; Tosi S, 1996, LEUKEMIA, V10, P644; Trobaugh-Lotrario AD, 2005, BONE MARROW TRANSPL, V35, P143, DOI 10.1038/sj.bmt.1704753; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Voso MT, 2010, CHEM-BIOL INTERACT, V184, P46, DOI 10.1016/j.cbi.2009.10.013; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061341; Watanabe-Okochi N, 2008, BLOOD, V111, P4297, DOI 10.1182/blood-2007-01-068346; Webb DKH, 2002, BRIT J HAEMATOL, V117, P33, DOI 10.1046/j.1365-2141.2002.03369.x; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Wolff L, 2013, BLOOD CELL MOL DIS, V50, P227, DOI 10.1016/j.bcmd.2013.01.006; Wong CC, 2014, NAT GENET, V46, P33, DOI 10.1038/ng.2846; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Wong JCY, 2010, BLOOD, V115, P4524, DOI 10.1182/blood-2009-07-232504; Xia JC, 2006, CANCER GENET CYTOGEN, V166, P166, DOI 10.1016/j.cancergencyto.2005.11.005; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yang H, 2013, CELL, V154, P1370, DOI 10.1016/j.cell.2013.08.022; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Yoshimi A, 2011, ONCOTARGET, V2, P575, DOI 10.18632/oncotarget.304; Yoshimi Ayami, 2014, Biol Blood Marrow Transplant, V20, P425, DOI 10.1016/j.bbmt.2013.11.031; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zeng WR, 1999, ONCOGENE, V18, P2015, DOI 10.1038/sj.onc.1202519; Zhou L, 2011, J BIOL CHEM, V286, P25211, DOI 10.1074/jbc.M111.235028; Zinzani PL, 2012, HEMATOL-AM SOC HEMAT, P426, DOI 10.1182/asheducation-2012.1.426; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	231	34	36	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2413	2425		10.1038/onc.2014.196	http://dx.doi.org/10.1038/onc.2014.196			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998854				2022-12-28	WOS:000354190400001
J	Owens, P; Pickup, MW; Novitskiy, SV; Giltnane, JM; Gorska, AE; Hopkins, CR; Hong, CC; Moses, HL				Owens, P.; Pickup, M. W.; Novitskiy, S. V.; Giltnane, J. M.; Gorska, A. E.; Hopkins, C. R.; Hong, C. C.; Moses, H. L.			Inhibition of BMP signaling suppresses metastasis in mammary cancer	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-6; TUMOR-ASSOCIATED MACROPHAGES; TGF-BETA RECEPTOR; BREAST-CANCER; PROSTATE-CANCER; GERMLINE MUTATIONS; JUVENILE POLYPOSIS; EPITHELIAL-CELLS; HAIR-FOLLICLES; EXPRESSION	Bone morphogenetic proteins (BMPs) are secreted cytokines/growth factors that have differing roles in cancer. BMPs are overexpressed in human breast cancers, but loss of BMP signaling in mammary carcinomas can accelerate metastasis. We show that human breast cancers display active BMP signaling, which is rarely downregulated or homozygously deleted. We hypothesized that systemic inhibition of BMP signaling in both the tumor and the surrounding microenvironment could prevent tumor progression and metastasis. To test this hypothesis, we used DMH1, a BMP antagonist, in MMTV. PyVmT expressing mice. Treatment with DMH1 reduced lung metastasis and the tumors were less proliferative and more apoptotic. In the surrounding tumor microenvironment, treatment with DMH1 altered fibroblasts, lymphatic vessels and macrophages to be less tumor promoting. These results indicate that inhibition of BMP signaling may successfully target both the tumor and the surrounding microenvironment to reduce tumor burden and metastasis.	[Owens, P.; Pickup, M. W.; Novitskiy, S. V.; Gorska, A. E.; Moses, H. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Owens, P.; Pickup, M. W.; Novitskiy, S. V.; Gorska, A. E.; Moses, H. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Giltnane, J. M.; Moses, H. L.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Hopkins, C. R.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA; [Hopkins, C. R.] Vanderbilt Univ, Coll Arts & Sci, Dept Chem, Nashville, TN 37235 USA; [Hong, C. C.] Vet Affairs TVHS, Res Med, Nashville, TN USA; [Hong, C. C.] Vanderbilt Univ, Sch Med, Div Cardiovasc Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Owens, P (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 2220 Pierce Ave,Preston Res Bldg 692, Nashville, TN 37232 USA.	philip.owens@vanderbilt.edu			DoD BCRP postdoctoral fellowship [W81XWH-09-1-0421]; NIH/NHLBI [RO1HL104040]; VA Merit Award [101BX000771]; NIH [CA085492, CA102162]; Robert J and Helen C Kleberg Foundation; TJ Martell Foundation;  [CA068485]; NATIONAL CANCER INSTITUTE [R01CA102162, R01CA085492, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL104040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000771] Funding Source: NIH RePORTER	DoD BCRP postdoctoral fellowship; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); VA Merit Award(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert J and Helen C Kleberg Foundation; TJ Martell Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We would like to thank the members of the Moses laboratory for critically reading the manuscript. We thank Dr Connor Lynch for help with tissue acquisition. PO has been supported by DoD BCRP postdoctoral fellowship grant number W81XWH-09-1-0421. CCH is supported by NIH/NHLBI grants RO1HL104040 and VA Merit Award # 101BX000771. This work is supported by NIH grants CA085492, CA102162, the Robert J and Helen C Kleberg Foundation and the TJ Martell Foundation to HLM. Grant number CA068485 provided core laboratory support.	Alarmo EL, 2008, ANN ONCOL, V19, P308, DOI 10.1093/annonc/mdm453; Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549-006-9362-1; Alarmo EL, 2013, MODERN PATHOL, V26, P10, DOI 10.1038/modpathol.2012.128; Alarmo EL, 2010, ENDOCR-RELAT CANCER, V17, pR123, DOI 10.1677/ERC-09-0273; Alarmo EL, 2009, CANCER LETT, V275, P35, DOI 10.1016/j.canlet.2008.09.028; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008-5472.CAN-12-2862; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Calva-Cerqueira D, 2010, HUM MOL GENET, V19, P4654, DOI 10.1093/hmg/ddq396; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen JC, 2013, INT J MOL SCI, V14, P88, DOI 10.3390/ijms14010088; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Cross EE, 2011, ACS CHEM BIOL, V6, P952, DOI 10.1021/cb200205z; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Ehata S, 2013, PATHOL INT, V63, P287, DOI 10.1111/pin.12067; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goto K, 2007, J BIOL CHEM, V282, P20603, DOI 10.1074/jbc.M702100200; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hill CR, 2012, CELL SIGNAL, V24, P1012, DOI 10.1016/j.cellsig.2011.12.022; Hollosi P, 2009, INT J CANCER, V125, P318, DOI 10.1002/ijc.24308; Hong JH, 2009, IMMUNOLOGY, V128, pe442, DOI 10.1111/j.1365-2567.2008.02998.x; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Ketolainen JM, 2010, BREAST CANCER RES TR, V124, P377, DOI 10.1007/s10549-010-0808-0; Kobielak K, 2003, J CELL BIOL, V163, P609, DOI 10.1083/jcb.200309042; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kwan KM, 2004, GENESIS, V39, P10, DOI 10.1002/gene.20021; Kwon SJ, 2009, IMMUNOLOGY, V128, pe758, DOI 10.1111/j.1365-2567.2009.03079.x; Langenfeld E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061256; Laoui D, 2011, INT J DEV BIOL, V55, P861, DOI 10.1387/ijdb.113371dl; Lee GT, 2011, MOL IMMUNOL, V48, P1540, DOI 10.1016/j.molimm.2011.04.019; Lee GT, 2010, J BIOL CHEM, V285, P39401, DOI 10.1074/jbc.M110.103705; Lee JH, 2013, CANCER RES, V73, P3604, DOI 10.1158/0008-5472.CAN-12-4563; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836; Nishimori H, 2012, J BIOL CHEM, V287, P20037, DOI 10.1074/jbc.M112.353094; Novitskiy SV, 2012, J LEUKOCYTE BIOL, V92, P641, DOI 10.1189/jlb.1211639; Novitskiy SV, 2011, CANCER DISCOV, V1, P430, DOI 10.1158/2159-8290.CD-11-0100; Owens P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067533; Owens P, 2012, P NATL ACAD SCI USA, V109, P2814, DOI 10.1073/pnas.1101139108; Owens P, 2010, AM J PATHOL, V176, P122, DOI 10.2353/ajpath.2010.090081; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Pickup MW, 2013, CANCER RES, V73, P5336, DOI 10.1158/0008-5472.CAN-13-0012; Rodriguez-Martinez A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-80; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Su JL, 2007, BRIT J CANCER, V96, P541, DOI 10.1038/sj.bjc.6603487; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Vogt J, 2011, CELL SIGNAL, V23, P1831, DOI 10.1016/j.cellsig.2011.06.019; Wiley DM, 2011, NAT CELL BIOL, V13, P686, DOI 10.1038/ncb2232; Yang S, 2008, CANCER RES, V68, P198, DOI 10.1158/0008-5472.CAN-07-5074; Yuhki M, 2004, DEVELOPMENT, V131, P1825, DOI 10.1242/dev.01079	59	76	78	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2437	2449		10.1038/onc.2014.189	http://dx.doi.org/10.1038/onc.2014.189			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998846	Green Accepted			2022-12-28	WOS:000354190400003
J	Wu, DW; Lee, MC; Hsu, NY; Wu, TC; Wu, JY; Wang, YC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Lee, M-C; Hsu, N-Y; Wu, T-C; Wu, J-Y; Wang, Y-C; Cheng, Y-W; Chen, C-Y; Lee, H.			FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappa B/Slug-mediated PUMA reduction	ONCOGENE			English	Article							P53-MEDIATED APOPTOSIS; TUMOR SUPPRESSION; E6 ONCOPROTEIN; GENE; INACTIVATION; EXPRESSION; SURVIVAL; PATHWAY; GROWTH; TRANSACTIVATION	Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in non-small cell lung cancer (NSCLC) and may confer cisplatin resistance in NSCLC cells. However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. In the present study, inhibition concentration of 50% cell viability induced by cisplatin (IC50) and soft agar growth and invasion capability were increased and decreased in FHIT-knockdown and -overexpressing cells, respectively. Mechanistically, Slug transcription is upregulated by AKT/NF-kappa B activation due to FHIT loss and, in turn, Slug suppresses PUMA expression; this decrease of PUMA by FHIT loss is responsible for cisplatin resistance. In addition, cisplatin resistance due to FHIT loss can be conquered by AKT inhibitor-perifosine in xenograft tumors. Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.	[Wu, D-W; Hsu, N-Y; Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan; [Wu, T-C; Wang, Y-C] Chung Shan Med Univ Hosp, Div Chest Med, Taichung 40201, Taiwan; [Wu, T-C; Wang, Y-C] Chung Shan Med Univ, Sch Med, Taichung 40201, Taiwan; [Wu, J-Y] Buddhist Tzu Chi Gen Hosp, Taichung Branch, Div Thorac Surg, Taichung, Taiwan; [Wu, J-Y] Tzu Chi Univ, Dept Med, Hualien, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Tzu Chi University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Room 5,12F,3 Pk St, Taipei, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (100-2314-B-038-043-MY3) of Taiwan, ROC.	Andriani F, 2006, NEOPLASIA, V8, P9, DOI 10.1593/neo.05517; Andriani F, 2012, J THORAC ONCOL, V7, P631, DOI 10.1097/JTO.0b013e318244aed0; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Cha HS, 2010, EXP MOL MED, V42, P428, DOI 10.3858/emm.2010.42.6.044; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Jayachandran G, 2007, CANCER RES, V67, P10379, DOI 10.1158/0008-5472.CAN-07-0677; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Ji L, 1999, CANCER RES, V59, P3333; Joannes A, 2010, ONCOGENE, V29, P1203, DOI 10.1038/onc.2009.418; Kim CH, 2006, INT J CANCER, V118, P1692, DOI 10.1002/ijc.21573; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; Mimori K, 2006, CANCER RES, V66, P2683, DOI 10.1158/0008-5472.CAN-05-2509; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nishizaki M, 2004, CANCER RES, V64, P5745, DOI 10.1158/0008-5472.CAN-04-0195; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Saegusa M, 2009, AM J PATHOL, V174, P2107, DOI 10.2353/ajpath.2009.081018; Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323; Sozzi G, 1997, CANCER RES, V57, P2121; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Toledo G, 2004, MODERN PATHOL, V17, P440, DOI 10.1038/modpathol.3800081; Tseng JE, 1999, CANCER RES, V59, P4798; Urich D, 2009, FASEB J, V23, P2055, DOI 10.1096/fj.08-114546; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang J, 2006, CANCER LETT, V235, P18, DOI 10.1016/j.canlet.2005.03.058; Weiske J, 2007, P NATL ACAD SCI USA, V104, P20344, DOI 10.1073/pnas.0703664105; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu HH, 2010, CLIN CANCER RES, V16, P5200, DOI 10.1158/1078-0432.CCR-10-0020; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zhang F, 2012, CELL REP, V2, P1272, DOI 10.1016/j.celrep.2012.09.023; Zienolddiny S, 2001, BRIT J CANCER, V84, P226, DOI 10.1054/bjoc.2000.1528	39	32	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2505	2515		10.1038/onc.2014.184	http://dx.doi.org/10.1038/onc.2014.184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998847				2022-12-28	WOS:000354190400009
J	Kumar, S; Torres, MP; Kaur, S; Rachagani, S; Joshi, S; Johansson, SL; Momi, N; Baine, MJ; Gilling, CE; Smith, LM; Wyatt, TA; Jain, M; Joshi, SS; Batra, SK				Kumar, S.; Torres, M. P.; Kaur, S.; Rachagani, S.; Joshi, S.; Johansson, S. L.; Momi, N.; Baine, M. J.; Gilling, C. E.; Smith, L. M.; Wyatt, T. A.; Jain, M.; Joshi, S. S.; Batra, S. K.			Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages	ONCOGENE			English	Article							TRANS-RETINOIC ACID; STELLATE CELL ACTIVATION; SUPPRESSOR-CELLS; CIGARETTE-SMOKE; MONOCYTE DIFFERENTIATION; IMMUNE-RESPONSE; MYELOID CELLS; GROWTH-FACTOR; MICE; ADENOCARCINOMA	Smoking is an established risk factor for pancreatic cancer (PC), but late diagnosis limits the evaluation of its mechanistic role in the progression of PC. We used a well-established genetically engineered mouse model (LSL-K-ras(G12D)) of PC to elucidate the role of smoking during initiation and development of pancreatic intraepithelial neoplasia (PanIN). The 10-week-old floxed mice (K-ras(G12D); Pdx-1cre) and their control unfloxed (LSL-K-ras(G12D)) littermates were exposed to cigarette smoke (total suspended particles: 150 mg/m(3)) for 20 weeks. Smoke exposure significantly accelerated the development of PanIN lesions in the floxed mice, which correlated with tenfold increase in the expression of cytokeratin19. The systemic accumulation of myeloid-derived suppressor cells (MDSCs) decreased significantly in floxed mice compared with unfloxed controls (P<0.01) after the smoke exposure with the concurrent increase in the macrophage (P<0.05) and dendritic cell (DCs) (P<0.01) population. Further, smoking-induced inflammation (IFN-gamma, CXCL2; P<0.05) was accompanied by enhanced activation of pancreatic stellate cells and elevated levels of serum retinoic acid-binding protein 4, indicating increased bioavailability of retinoic acid which contributes to differentiation of MDSCs to tumor-associated macrophages (TAMs) and DCs. TAMs predominantly contribute to the increased expression of heparin-binding epidermal growth factor-like growth factor (EGFR ligand) in pre-neoplastic lesions in smoke-exposed floxed mice that facilitate acinar-to-ductal metaplasia (ADM). Further, smoke exposure also resulted in partial suppression of the immune system early during PC progression. Overall, the present study provides a novel mechanism of smoking-induced increase in ADM in the presence of constitutively active K-ras mutation.	[Kumar, S.; Torres, M. P.; Kaur, S.; Rachagani, S.; Joshi, S.; Momi, N.; Baine, M. J.; Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Torres, M. P.; Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Johansson, S. L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Gilling, C. E.] Univ Nebraska, Dept Biol, Omaha, NE 68182 USA; [Smith, L. M.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Wyatt, T. A.] Univ Nebraska Med Ctr, Div Pulm Crit Care Sleep & Allergy, Omaha, NE 68198 USA; [Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Joshi, S. S.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	Torres, Maria/GVU-3391-2022; Joshi, Sudhanshu/L-2284-2019	Joshi, Sudhanshu/0000-0003-4748-5001	National Institute of Health [R01CA78590, EDRN U01 CA111294, R01 CA133774, R01 CA131944, SPORE P50 CA127297, T32 CA009476, P20 GM103480, R21 CA156037, U54 TMEN CA163120]; NATIONAL CANCER INSTITUTE [P50CA127297, U54CA163120, R21CA156037, T32CA009476, U01CA111294, R01CA133774, R01CA078590, R01CA131944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103480] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Patrick C Swanson, Creighton University, Omaha, for suggestions. We appreciate the UNMC Cell Analysis Facility for analysis and graduate students and technician Erik Moore from Dr Batra's lab for help in sample preparation. This work was supported in part by the grant from National Institute of Health (R01CA78590, EDRN U01 CA111294, R01 CA133774, R01 CA131944, SPORE P50 CA127297, T32 CA009476, P20 GM103480, R21 CA156037 and U54 TMEN CA163120).	Apte MV, 1998, GUT, V43, P128, DOI 10.1136/gut.43.1.128; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Blackford A, 2009, CANCER RES, V69, P3681, DOI 10.1158/0008-5472.CAN-09-0015; Braat H, 2012, CANCER LETT, V318, P1, DOI 10.1016/j.canlet.2011.11.034; Bracci PM, 2012, MOL CARCINOGEN, V51, P53, DOI 10.1002/mc.20778; BREITMAN TR, 1981, BLOOD, V57, P1000; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Colby JK, 2008, NEOPLASIA, V10, P782, DOI 10.1593/neo.08330; Ding QR, 2007, J LEUKOCYTE BIOL, V81, P1568, DOI 10.1189/jlb.1106672; Duell EJ, 2002, JNCI-J NATL CANCER I, V94, P297, DOI 10.1093/jnci/94.4.297; Duell EJ, 2012, MOL CARCINOGEN, V51, P40, DOI 10.1002/mc.20786; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elliott MK, 2006, EXP LUNG RES, V32, P99, DOI 10.1080/01902140600710546; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Habisch Hansjorg, 2010, Cancers (Basel), V2, P1661, DOI 10.3390/cancers2031661; Hengesbach LM, 2004, J NUTR, V134, P2653, DOI 10.1093/jn/134.10.2653; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Hutchison SK, 2008, DIABETES CARE, V31, P1427, DOI 10.2337/dc07-2265; Kroening PR, 2008, J IMMUNOL, V181, P1536, DOI 10.4049/jimmunol.181.2.1536; Kusmartsev S, 2003, CANCER RES, V63, P4441; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Malfertheiner P, 2006, AM J GASTROENTEROL, V101, P160, DOI 10.1111/j.1572-0241.2006.00402.x; Manicassamya S, 2009, SEMIN IMMUNOL, V21, P22, DOI 10.1016/j.smim.2008.07.007; Mathison A, 2010, PANCREATOLOGY, V10, P505, DOI [10.1016/S1424-3903(10)80035-3, 10.1159/000320540]; McCarroll JA, 2006, GUT, V55, P79, DOI 10.1136/gut.2005.064543; McCarroll JA, 2003, PANCREAS, V27, P150, DOI 10.1097/00006676-200308000-00008; Means AL, 2003, GASTROENTEROLOGY, V124, P1020, DOI 10.1053/gast.2003.50150; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Mohty M, 2003, BRIT J HAEMATOL, V122, P829, DOI 10.1046/j.1365-2141.2003.04489.x; Momi N, 2013, ONCOGENE, V32, P1384, DOI 10.1038/onc.2012.163; Moniaux N, 2008, BRIT J CANCER, V98, P1540, DOI 10.1038/sj.bjc.6604329; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Nouri-Shirazi M, 2003, IMMUNOLOGY, V109, P365, DOI 10.1046/j.1365-2567.2003.01655.x; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Ray KC, 2014, ONCOGENE, V33, P823, DOI 10.1038/onc.2013.3; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; Sopori ML, 1998, J NEUROIMMUNOL, V83, P148, DOI 10.1016/S0165-5728(97)00231-2; Toh B, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001162; van Geenen EJM, 2011, AM J GASTROENTEROL, V106, P1161, DOI 10.1038/ajg.2011.43; VANBOCKSTAELE DR, 1993, ANN HEMATOL, V66, P61, DOI 10.1007/BF01695885; Zeidel A, 2002, ACTA ANAESTH SCAND, V46, P959, DOI 10.1034/j.1399-6576.2002.460806.x; Zhang QL, 2012, LECT NOTES CONTR INF, V421, P7; Zhang SB, 1996, INT J IMMUNOPHARMACO, V18, P467, DOI 10.1016/S0192-0561(96)00054-9; Zhao F, 2009, IMMUNOLOGY, V128, P141, DOI 10.1111/j.1365-2567.2009.03105.x	53	39	40	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2052	2060		10.1038/onc.2014.154	http://dx.doi.org/10.1038/onc.2014.154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909166	Green Accepted			2022-12-28	WOS:000353173400005
J	Appolloni, I; Barilari, M; Caviglia, S; Gambini, E; Reisoli, E; Malatesta, P				Appolloni, I.; Barilari, M.; Caviglia, S.; Gambini, E.; Reisoli, E.; Malatesta, P.			A cadherin switch underlies malignancy in high-grade gliomas	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PDGF-INDUCED OLIGODENDROGLIOMA; GROWTH-FACTOR RECEPTOR; CELL-CELL-ADHESION; CONTACT INHIBITION; R-CADHERIN; TUMOR PROGRESSION; NEURAL PROGENITORS; BREAST-CANCER; B-CHAIN	Although the infiltrative behavior of malignant gliomas is one of their most critical aspects, the mechanisms underlying it have not yet been elucidated. To migrate in the brain parenchyma, malignant glioma cells need to bypass the cell-cell contact inhibitory signals. Here we propose that the blinding of cell-cell contact sensing in gliomas is caused by an unusual mechanism of cadherin switch, involving the replacement of N-cadherin with R-cadherin (Rcad) at the cell-cell junctions and the activation of ERK and p27. In our model of malignant glioma, we found that Rcad expression is necessary and sufficient to release cells from contact inhibition of proliferation, and is necessary, although not sufficient, for overriding contact inhibition of migration and for tumorigenicity. Altogether, these observations suggest that Rcad is a potential target for malignant glioma therapies.	[Appolloni, I.; Barilari, M.; Reisoli, E.; Malatesta, P.] IRCCS AOU San Martino IST, UO Trasferimento Genico, I-16132 Genoa, Italy; [Caviglia, S.; Gambini, E.; Malatesta, P.] Univ Genoa, Dept Expt Med DiMES, Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Malatesta, P (corresponding author), IRCCS AOU San Martino IST, UO Trasferimento Genico, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	paolo.malatesta@unige.it	Malatesta, Paolo/J-3570-2012; Appolloni, Irene/AAC-1629-2019	Malatesta, Paolo/0000-0003-3045-3361; Caviglia, Sara/0000-0001-9832-2566	NUSUG grant from AIRC; Ministero della Salute [GR-2008-1135643]; Fondazione S. Paolo (Molecular and cellular basis of glioma); Fondazione CARIGE; FIRC fellowship [9887]	NUSUG grant from AIRC(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Fondazione S. Paolo (Molecular and cellular basis of glioma); Fondazione CARIGE(Fondazione Carige); FIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Dr Magdalena Gotz (Institute of Stem Cell Research-Helmholtz Centre Munich, Germany) for providing access to the time lapse equipment and Dr Masatoshi Takeichi (RIKEN Center for developmental biology, Kobe, Japan) for sharing plasmids. We acknowledge Dr Paola Briata, Dr Filippo Calzolari, Dr Federico Cremisi and Dr Roberto Gherzi for helpful comments on the manuscript. This work was supported by a NUSUG grant from AIRC, by the GR-2008-1135643 grant from Ministero della Salute, by Fondazione S. Paolo (Molecular and cellular basis of glioma) and by Fondazione CARIGE. ER salary was funded by the FIRC fellowship 9887.	Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Appolloni I, 2012, INT J MOL SCI, V13, P14667, DOI 10.3390/ijms131114667; Appolloni I, 2012, INT J CANCER, V131, pE1078, DOI 10.1002/ijc.27606; Appolloni I, 2009, INT J CANCER, V124, P2251, DOI 10.1002/ijc.24206; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Calzolari F, 2008, NEOPLASIA, V10, P1373, DOI 10.1593/neo.08814; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Cooper LAD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012548; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; De Donatis A, 2008, J BIOL CHEM, V283, P19948, DOI 10.1074/jbc.M709428200; Du CP, 2011, CANCER LETT, V309, P54, DOI 10.1016/j.canlet.2011.05.016; Gambini E, 2012, MOL THER, V20, P994, DOI 10.1038/mt.2012.22; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Hsu YM, 2007, CANCER RES, V67, P11064, DOI 10.1158/0008-5472.CAN-07-2443; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; Johnson E, 2004, J BIOL CHEM, V279, P31041, DOI 10.1074/jbc.M400024200; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kucharczak J, 2008, CANCER RES, V68, P6559, DOI 10.1158/0008-5472.CAN-08-0196; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Lei L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020041; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Lien WH, 2006, CURR OPIN CELL BIOL, V18, P499, DOI 10.1016/j.ceb.2006.07.001; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396; Mayor R, 2013, DEVELOPMENT, V140, P2247, DOI 10.1242/dev.091751; Mayor R, 2010, TRENDS CELL BIOL, V20, P319, DOI 10.1016/j.tcb.2010.03.005; McClatchey AI, 2012, CURR OPIN CELL BIOL, V24, P685, DOI 10.1016/j.ceb.2012.06.009; McKinnon RD, 2005, J NEUROSCI, V25, P3499, DOI 10.1523/JNEUROSCI.5049-04.2005; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Motti ML, 2005, CARCINOGENESIS, V26, P1021, DOI 10.1093/carcin/bgi050; Nabi IR, 1999, J CELL SCI, V112, P1803; Puliafito A, 2012, P NATL ACAD SCI USA, V109, P739, DOI 10.1073/pnas.1007809109; Redies C, 2000, PROG NEUROBIOL, V61, P611, DOI 10.1016/S0301-0082(99)00070-2; Sheehan KM, 2008, ONCOGENE, V27, P323, DOI 10.1038/sj.onc.1210647; Siletz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057180; Smith CL, 2010, CELL ADHES MIGR, V4, P561, DOI 10.4161/cam.4.4.12829; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Terrile M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-550; Theisen U, 2012, DEV CELL, V23, P1153, DOI 10.1016/j.devcel.2012.11.005; Theveneau E, 2012, CURR OPIN CELL BIOL, V24, P677, DOI 10.1016/j.ceb.2012.08.002; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Uhrbom L, 1998, CANCER RES, V58, P5275; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Zou L, 2009, CELL MOTIL CYTOSKEL, V66, P1048, DOI 10.1002/cm.20407	59	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1991	2002		10.1038/onc.2014.122	http://dx.doi.org/10.1038/onc.2014.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858041				2022-12-28	WOS:000352725600013
J	Shimozato, O; Waraya, M; Nakashima, K; Souda, H; Takiguchi, N; Yamamoto, H; Takenobu, H; Uehara, H; Ikeda, E; Matsushita, S; Kubo, N; Nakagawara, A; Ozaki, T; Kamijo, T				Shimozato, O.; Waraya, M.; Nakashima, K.; Souda, H.; Takiguchi, N.; Yamamoto, H.; Takenobu, H.; Uehara, H.; Ikeda, E.; Matsushita, S.; Kubo, N.; Nakagawara, A.; Ozaki, T.; Kamijo, T.			Receptor-type protein tyrosine phosphatase. directly dephosphorylates CD133 and regulates downstream AKT activation	ONCOGENE			English	Article							CANCER STEM-CELLS; GROWTH-FACTOR RECEPTOR; R-PTP-KAPPA; BETA-CATENIN; HEMATOPOIETIC STEM; MARKER CD133; PATHWAY; EXPRESSION; PHOSPHORYLATION; DIFFERENTIATION	Although CD133 has been considered to be a molecular marker for cancer stem cells, its functional roles in tumorigenesis remain unclear. We here examined the molecular basis behind CD133-mediated signaling. Knockdown of CD133 resulted in the retardation of xenograft tumor growth of colon cancer-derived HT-29 and LoVo cells accompanied by hypophosphorylation of AKT, which diminished beta-catenin/T-cell factor-mediated CD44 expression. As tyrosine residues of CD133 at positions 828 and 852 were phosphorylated in HT-29 and SW480 cells, we further addressed the significance of this phosphorylation in the tumorigenesis of SW480 cells expressing mutant CD133, with substitution of these tyrosine residues by glutamate (CD133-EE) or phenylalanine (CD133-FF). Forced expression of CD133-EE promoted much more aggressive xenograft tumor growth relative to wild-type CD133-expressing cells accompanied by hyperphosphorylation of AKT; however, CD133-FF expression had negligible effects on AKT phosphorylation and xenograft tumor formation. Intriguingly, the tyrosine phosphorylation status of CD133 was closely linked to the growth of SW480-derived spheroids. Using yeast two-hybrid screening, we finally identified receptor-type protein tyrosine phosphatase. (PTPRK) as a binding partner of CD133. In vitro studies demonstrated that PTPRK associates with the carboxyl-terminal region of CD133 through its intracellular phosphatase domains and also catalyzes dephosphorylation of CD133 at tyrosine-828/tyrosine-852. Silencing of PTPRK elevated the tyrosine phosphorylation of CD133, whereas forced expression of PTPRK reduced its phosphorylation level markedly and abrogated CD133-mediated AKT phosphorylation. Endogenous CD133 expression was also closely associated with higher AKT phosphorylation in primary colon cancer cells, and ectopic expression of CD133 enhanced AKT phosphorylation. Furthermore, lower PTPRK expression significantly correlated with the poor prognosis of colon cancer patients with high expression of CD133. Thus, our present findings strongly indicate that the tyrosine phosphorylation of CD133, which is dephosphorylated by PTPRK, regulates AKT signaling and has a critical role in colon cancer progression.	[Shimozato, O.; Waraya, M.; Nakashima, K.; Takenobu, H.; Uehara, H.; Ikeda, E.; Kamijo, T.] Chiba Canc Ctr Res Inst, Div Biochem & Mol Carcinogenesis, Chiba, Japan; [Souda, H.; Takiguchi, N.; Yamamoto, H.] Chiba Canc Ctr Hosp, Dept Gastrointestinal Surg, Chiba, Japan; [Matsushita, S.; Kubo, N.; Ozaki, T.] Chiba Canc Ctr Res, Lab DNA Damage Signaling, Chiba, Japan; [Nakagawara, A.] Chiba Canc Ctr Res Inst, Div Biochem & Innovat Canc Therapeut, Chiba, Japan; [Kamijo, T.] Saitama Canc Ctr, Res Inst Clin Oncol, Saitama 3620806, Japan	Chiba Cancer Center; Chiba Cancer Center; Chiba Cancer Center; Chiba Cancer Center	Kamijo, T (corresponding author), Saitama Canc Ctr, Res Inst Clin Oncol, 818 Komuro, Saitama 3620806, Japan.	tkamijo@cancer-c.pref.saitama.jp		Takenobu, Hisanori/0000-0001-7355-1565	JSPS [21790397, 23591978, 24390269]; National Cancer Center Research and Development Fund [25-B-3]; Grants-in-Aid for Scientific Research [15K08412, 23591978] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms Kumiko Sakurai for technical assistance, Mr Daniel Mrozek (Medical English Service, Kyoto, Japan) for English editorial assistance and Dr Takafumi Nakamura (Graduate School of Medical Sciences, Tottori University Faculty of Medicine) for pHR lentiviral vectors. This work was supported in part by grants-in-aid from JSPS for Young Scientists (B) and for Scientific Research (C) (Grant numbers: 21790397 and 23591978, respectively), a grant-in-aid for Scientific Research (B) from JSPS (24390269) and a grant-in-aid from the National Cancer Center Research and Development Fund (25-B-3).	Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Artells R, 2010, EUR J CANCER, V46, P642, DOI 10.1016/j.ejca.2009.11.003; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Blaker H, 2008, GENE CHROMOSOME CANC, V47, P159, DOI 10.1002/gcc.20516; Boivin D, 2009, BIOCHEMISTRY-US, V48, P3998, DOI 10.1021/bi900159d; Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002-9440(10)62276-6; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017876, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333]; Chu P, 2009, INT J CANCER, V124, P1312, DOI 10.1002/ijc.24061; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Horst D, 2009, J PATHOL, V219, P427, DOI 10.1002/path.2597; Hu LM, 2000, CLIN CANCER RES, V6, P880; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Kojima M, 2008, CANCER SCI, V99, P1578, DOI 10.1111/j.1349-7006.2008.00849.x; Komatsu S, 2009, ONCOGENE, V28, P3631, DOI 10.1038/onc.2009.216; Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Kubo N, 2013, BIOCHEM BIOPH RES CO, V430, P1034, DOI 10.1016/j.bbrc.2012.11.121; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Nikolova T, 2007, DIFFERENTIATION, V75, P100, DOI 10.1111/j.1432-0436.2006.00119.x; Novellino L, 2008, CELL SIGNAL, V20, P872, DOI 10.1016/j.cellsig.2007.12.024; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Ricci-Vitiani L, 2010, FASEB J, V24, P4291, DOI 10.1096/fj.10-159970; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Xu YR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.212597; Yang Y, 1997, GENE, V186, P77, DOI 10.1016/S0378-1119(96)00684-1; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	61	36	38	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1949	1960		10.1038/onc.2014.141	http://dx.doi.org/10.1038/onc.2014.141			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882578				2022-12-28	WOS:000352725600009
J	de Laurentiis, A; Hiscott, J; Alcalay, M				de Laurentiis, A.; Hiscott, J.; Alcalay, M.			The TEL-AML1 fusion protein of acute lymphoblastic leukemia modulates IRF3 activity during early B-cell differentiation	ONCOGENE			English	Article							INTERFERON REGULATORY FACTOR-3; ORIGINS; EXPRESSION; RECEPTOR; TARGET; GENES	The t(12;21) translocation is the most common genetic rearrangement in childhood acute lymphoblastic leukemia (ALL) and gives rise to the TEL-AML1 fusion gene. Many studies on TEL-AML1 describe specific properties of the fusion protein, but a thorough understanding of its function is lacking. We exploited a pluripotent hematopoietic stem/progenitor cell line, EML1, and generated a cell line (EML-TA) stably expressing the TEL-AML1 fusion protein. EML1 cells differentiate to mature B-cells following treatment with IL7; whereas EML-TA display an impaired differentiation capacity and remain blocked at an early stage of maturation. Global gene expression profiling of EML1 cells at different stages of B-lymphoid differentiation, compared with EML-TA, identified the interferon (IFN)alpha/beta pathway as a primary target of repression by TEL-AML1. In particular, expression and phosphorylation of interferon-regulatory factor 3 (IRF3) was decreased in EML-TA cells; strikingly, stable expression of IRF3 restored the capacity of EML-TA cells to differentiate into mature B-cells. Similarly, IRF3 silencing in EML1 cells by siRNA was sufficient to block B-lymphoid differentiation. The ability of TEL-AML1 to block B-cell differentiation and downregulate the IRF3-IFN alpha/beta pathway was confirmed in mouse and human primary hematopoietic precursor cells (Lin- and CD34+ cells, respectively), and in a patient-derived cell line expressing TEL-AML1 (REH). Furthermore, treatment of TEL-AML1 expressing cells with IFN alpha/beta was sufficient to overcome the maturation block. Our data provide new insight on TEL-AML1 function and may offer a new therapeutic opportunity for B-ALL.	[de Laurentiis, A.; Alcalay, M.] Ist Europeo Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Hiscott, J.] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL USA; [Alcalay, M.] Univ Milan, Dipartimento Sci Salute, Milan, Italy	IRCCS European Institute of Oncology (IEO); Vaccine & Gene Therapy Institute of Florida; University of Milan	de Laurentiis, A (corresponding author), Ist Europeo Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	angela.delaurentiis@ieo.eu	Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272	Associazione Italiana per la Ricerca sul Cancro (AIRC); Fondazione Umberto Veronesi (FUV); Italian Ministry of Health [PO-RF08]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi (FUV)(Fondazione Umberto Veronesi); Italian Ministry of Health(Ministry of Health, Italy)	We are grateful to Giacomo Iros Barozzi and Stefano Casola for their support and advice, the cell culture staff of the IEO-DEO, the microarray and FACS facilities of the IFOM-IEO Campus for excellent technical assistance and to Elisa Barbieri, Alicja M Gruszka, Marco Saia and Rita de Molfetta for many helpful discussions. We are thankful to S Tsai for the EML1 cell line, A Zelent and AM Ford for TEL-AML1 expression vectors. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Fondazione Umberto Veronesi (FUV) and Italian Ministry of Health (PO-RF08) to MA.	Ardekani Ali M., 2011, Avicenna Journal of Medical Biotechnology, V3, P1; Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972; Caraglia M, 2013, PROTEIN PEPTIDE LETT, V20, P412, DOI 10.2174/092986613805290372; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chessells JM, 1998, BRIT J HAEMATOL, V102, P423, DOI 10.1046/j.1365-2141.1998.00776.x; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; de Lendonck LY, 2014, CELL MOL LIFE SCI, V71, P3873, DOI 10.1007/s00018-014-1653-9; Diakos C, 2007, BLOOD, V109, P2607, DOI 10.1182/blood-2006-04-019612; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Fan D, 2015, ONCOGENE, V34, P2083, DOI 10.1038/onc.2014.148; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Fuka G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026348; Gandemer V, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-385; George J, 2009, CLIN CANCER RES, V15, P7186, DOI 10.1158/1078-0432.CCR-09-1425; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Li M, 2013, LEUKEMIA, V27, P1570, DOI 10.1038/leu.2013.15; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Linka Y, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.48; Long LY, 2014, IMMUNITY, V40, P515, DOI 10.1016/j.immuni.2014.01.015; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, EUR J CANCER, V13, P377, DOI 10.1016/0014-2964(77)90085-8; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Tamassia N, 2012, J IMMUNOL, V189, P1500, DOI 10.4049/jimmunol.1102985; Taylor KE, 2013, IMMUNOLOGY, V138, P190, DOI 10.1111/imm.12038; Torrano V, 2011, BLOOD, V118, P4910, DOI 10.1182/blood-2011-05-354266; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; van Delft FW, 2011, BLOOD, V117, P6247, DOI 10.1182/blood-2010-10-314674; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhao JW, 2010, MOL IMMUNOL, V48, P294, DOI 10.1016/j.molimm.2010.07.014	36	9	9	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					6018	6028		10.1038/onc.2015.50	http://dx.doi.org/10.1038/onc.2015.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25893288				2022-12-28	WOS:000366113500008
J	Frances, D; Sharma, N; Pofahl, R; Maneck, M; Behrendt, K; Reuter, K; Krieg, T; Klein, CA; Haase, I; Niemann, C				Frances, D.; Sharma, N.; Pofahl, R.; Maneck, M.; Behrendt, K.; Reuter, K.; Krieg, T.; Klein, C. A.; Haase, I.; Niemann, C.			A role for Rac1 activity in malignant progression of sebaceous skin tumors	ONCOGENE			English	Article							PROSTATE-CANCER; HAIR; DIFFERENTIATION; EXPRESSION; EPIDERMIS; CELLS; MORPHOGENESIS; MUTATIONS; LEF1	The small GTPase Rac1 is crucial for maintaining stem cells (SCs) in mammalian epidermis, and Rac1 activation leads to SC expansion. Loss or inhibition of Rac1 correlates with decreased frequency of skin cancer formation in a chemical carcinogenesis model. Here, we have addressed whether Rac1 activation would enhance carcinogenesis and result in tumor progression. We used K14 Delta NLef1 mice, a model for differentiated sebaceous adenomas (SAs), and activated Rac1 in an epidermis-specific manner (K14L61Rac1). Surprisingly, Rac1 activation did not change the incidence and frequency of sebaceous tumors. However, tumors, which occurred exclusively in K14 Delta NLef1/K14L61Rac1 double-transgenic mice, were poorly differentiated resembling malignant sebaceous tumors and were termed sebaceous carcinoma-like tumors (SCLTs). Compared with SAs, SCLTs showed an aberrant pattern of cell proliferation, invasive growth and less abundant expression of sebocyte differentiation markers, including stearoyl-CoA desaturase-1 and adipophilin. Interestingly, the adnexal SC marker Lrig1 was upregulated in SCLTs, showing that active Rac1 leads to the accumulation of sebocyte precursors in the context of K14 Delta NLef1-induced skin tumors. In a search for targets of Rac1, we found cancer progression-related proteins, Dhcr24/Seladin1 and Nuclear protein 1/P8, to be strongly regulated in SCLTs. At last, Rac1 and Dhcr24/Seladin1 were detected in human sebaceous tumors demonstrating a potential high impact of our findings for human skin disease. This is the first study showing that Rac1 activity can lead to malignant progression of skin tumors.	[Frances, D.; Sharma, N.; Reuter, K.; Niemann, C.] Univ Cologne, CMMC, D-50931 Cologne, Germany; [Pofahl, R.; Behrendt, K.; Krieg, T.; Haase, I.] Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany; [Maneck, M.; Klein, C. A.] Univ Regensburg, Expt Med & Therapy Res, Cologne, Germany; [Niemann, C.] Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany	University of Cologne; University of Cologne; University of Regensburg; University of Cologne	Niemann, C (corresponding author), Univ Cologne, CMMC, Robert Koch Str 21, D-50931 Cologne, Germany.	cnieman1@uni-koeln.de		S, Neha/0000-0002-4287-5994; Klein, Christoph A./0000-0001-7128-1725	Deutsche Krebshilfe;  [SFB 829];  [A3];  [B10]	Deutsche Krebshilfe(Deutsche Krebshilfe); ; ; 	We thank Vera Czichowski, Dagmar Fehrenschild, Peter Schettina, Margot Junker and Michael Tscharntke for expert technical support and are grateful for technical support by Wilhelm Bloch and Cornelia Mauch (SFB 829, Z2). This work was funded by the Deutsche Krebshilfe (to CN and CK) and the SFB 829 (A3 to CN, B10 to IH).	Battista MC, 2010, PROSTATE, V70, P921, DOI 10.1002/pros.21126; Behrendt K, 2012, J CELL SCI, V125, P896, DOI 10.1242/jcs.091868; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Calonje J. E., 2011, MCKEES PATHOLOGY SKI; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Fehrenschild D, 2012, J INVEST DERMATOL, V132, P337, DOI 10.1038/jid.2011.301; Goruppi S, 2010, J BIOL CHEM, V285, P1577, DOI 10.1074/jbc.R109.080887; Gu LH, 2008, AM J PATHOL, V173, P752, DOI 10.2353/ajpath.2008.071089; Hartmann CH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl740; Jaks V, 2010, EXP CELL RES, V316, P1422, DOI 10.1016/j.yexcr.2010.03.014; Jiang WG, 2006, INT J MOL MED, V18, P981; Kakanj P, 2013, CELL REP, V4, P340, DOI 10.1016/j.celrep.2013.06.037; Kamai T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-164; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Niemann C, 2002, DEVELOPMENT, V129, P95; Niemann C, 2007, CANCER RES, V67, P2916, DOI 10.1158/0008-5472.CAN-06-3427; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ree AH, 1999, CANCER RES, V59, P4675; Scheid S, 2005, BIOINFORMATICS, V21, P2921, DOI 10.1093/bioinformatics/bti436; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stachelscheid H, 2008, EMBO J, V27, P2091, DOI 10.1038/emboj.2008.141; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takeda H, 2006, NAT MED, V12, P395, DOI 10.1038/nm1386; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95	26	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5505	5512		10.1038/onc.2014.471	http://dx.doi.org/10.1038/onc.2014.471			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659584				2022-12-28	WOS:000363479700010
J	Gong, J; Weng, D; Eguchi, T; Murshid, A; Sherman, MY; Song, B; Calderwood, SK				Gong, J.; Weng, D.; Eguchi, T.; Murshid, A.; Sherman, M. Y.; Song, B.; Calderwood, S. K.			Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis	ONCOGENE			English	Article							HEAT-SHOCK-PROTEIN; BREAST-CANCER; C-MET; PROGNOSTIC-SIGNIFICANCE; TANESPIMYCIN 17-AAG; MOUSE MODEL; EXPRESSION; HEAT-SHOCK-PROTEIN-70; ACTIVATION; HSP90	Elevated levels of the inducible heat-shock protein 70 (Hsp72) have been implicated in mammary tumorigenesis in histological investigations of human breast cancer. We therefore examined the role of Hsp72 in mice, using animals in which the hsp70 gene was inactivated. We used a spontaneous tumor system with mice expressing the polyomavirus middle T (PyMT) oncogene under control of the mouse mammary tumor virus (MMTV) long-terminal repeat (MMT mice). These mice developed spontaneous, metastatic mammary cancer. We then showed Hsp72 to be upregulated in a fraction of mammary cancer initiating cells (CIC) within the MMT tumor cell population. These cells were characterized by elevated surface levels of stem cell markers CD44 and Sca1 and by rapid metastasis. Inactivation of the hsp70 gene delayed the initiation of mammary tumors. This delay in tumor initiation imposed by loss of hsp70 was correlated with a decreased pool of CIC. Interestingly, hsp70 knockout significantly reduced invasion and metastasis by mammary tumor cells and implicated its product Hsp72 in cell migration and formation of secondary neoplasms. Impaired tumorigenesis and metastasis in hsp70-knockout MMT mice was associated with downregulation of the met gene and reduced activition of the oncogenic c-Met protein. These experiments therefore showed Hsp72 to be involved in the growth and progression of mammary carcinoma and highlighted this protein as a potential target for anticancer drug development.	[Gong, J.; Weng, D.; Song, B.] Boston Univ, Dept Med, Med Ctr, Boston, MA 02118 USA; [Eguchi, T.; Murshid, A.; Calderwood, S. K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Mol & Cellular Radiat Oncol, Boston, MA 02215 USA; [Sherman, M. Y.] Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Gong, J (corresponding author), Boston Univ, Dept Med, Sch Med, 650 Albany St,Room 309, Boston, MA 02118 USA.	jgong@bu.edu; scalderw@bidmc.harvard.edu		Eguchi, Takanori/0000-0002-3297-6126	Department of Radiation Oncology, Beth Israel Deaconess Medical Center; NIH [R01CA119045, RO1CA47407, RO1CA176326]; Harvard JCRT Foundation; NATIONAL CANCER INSTITUTE [R01CA176326, R01CA047407, R01CA119045] Funding Source: NIH RePORTER	Department of Radiation Oncology, Beth Israel Deaconess Medical Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard JCRT Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the support of the Department of Radiation Oncology, Beth Israel Deaconess Medical Center. This work was supported by NIH research grants R01CA119045, RO1CA47407 and RO1CA176326 as well as the Harvard JCRT Foundation. We are grateful to Buzz Hunt for the kind gift of the hsp70 knockout mice.	Barrott JJ, 2013, FEBS J, V280, P1381, DOI 10.1111/febs.12147; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Boroughs LK, 2011, J BIOL CHEM, V286, P37094, DOI 10.1074/jbc.M111.242438; Calderwood SK, 2012, CURR MOL MED, V12, P1102, DOI 10.2174/156652412803306675; Calderwood SK, 2012, J CELL BIOCHEM, V113, P1096, DOI 10.1002/jcb.23461; CARDIFF RD, 1993, CANCER SURV, V16, P97; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Colvin TA, 2014, CANCER RES, V74, P4731, DOI 10.1158/0008-5472.CAN-14-0747; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796; Gallego MI, 2003, ONCOGENE, V22, P8498, DOI 10.1038/sj.onc.1207063; Galluzzi L, 2009, MOL CELL, V36, P176, DOI 10.1016/j.molcel.2009.10.003; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Goloudina AR, 2012, CANCER LETT, V325, P117, DOI 10.1016/j.canlet.2012.06.003; Gomez AV, 2008, MOL CELL, V31, P222, DOI 10.1016/j.molcel.2008.06.015; Grange C, 2008, NEOPLASIA, V10, P1433, DOI 10.1593/neo.08902; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Jiang YF, 2001, CANCER RES, V61, P2365; Kalogeraki A, 2007, J EXP CLIN CANC RES, V26, P367; Kang Y, 2013, KOREAN J PATHOL, V47, P219, DOI 10.4132/KoreanJPathol.2013.47.3.219; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Kishor A, 2013, MOL CELL BIOL, V33, P71, DOI 10.1128/MCB.01275-12; Kluger HM, 2005, CANCER RES, V65, P5578, DOI 10.1158/0008-5472.CAN-05-0108; Kouspou MM, 2011, METHODS MOL BIOL, V787, P303, DOI 10.1007/978-1-61779-295-3_23; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu FF, 1996, INT J HYPERTHER, V12, P197, DOI 10.3109/02656739609022508; Locatelli A, 2012, HORM CANCER-US, V3, P14, DOI 10.1007/s12672-011-0097-z; Meng L, 2011, ONCOGENE, V30, P2836, DOI 10.1038/onc.2011.5; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072; Mukherjee P, 2003, J IMMUNOTHER, V26, P47, DOI 10.1097/00002371-200301000-00006; Nakajima M, 2002, CANCER LETT, V178, P99, DOI 10.1016/S0304-3835(01)00825-4; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Otsuka T, 1998, CANCER RES, V58, P5157; Pocaly M, 2007, LEUKEMIA, V21, P93, DOI 10.1038/sj.leu.2404463; Powers MV, 2010, CELL CYCLE, V9, P1542, DOI 10.4161/cc.9.8.11204; Rerole AL, 2011, METHODS MOL BIOL, V787, P205, DOI 10.1007/978-1-61779-295-3_16; Rodriguez Luis G., 2004, V294, P23; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; SCHLESINGER MJ, 1994, PEDIATR RES, V36, P1; Slattery ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063165; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Sun BC, 2008, CLIN CANCER RES, V14, P7050, DOI 10.1158/1078-0432.CCR-08-0520; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Thanner F, 2003, ANTICANCER RES, V23, P1057; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weng DS, 2013, J IMMUNOL, V191, P755, DOI 10.4049/jimmunol.1203286; Weng DS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3102; Xia JC, 2003, J IMMUNOL, V170, P1980, DOI 10.4049/jimmunol.170.4.1980	67	42	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5460	5471		10.1038/onc.2015.1	http://dx.doi.org/10.1038/onc.2015.1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659585	Green Accepted			2022-12-28	WOS:000363479700006
J	Lozupone, F; Borghi, M; Marzoli, F; Azzarito, T; Matarrese, P; Iessi, E; Venturi, G; Meschini, S; Canitano, A; Bona, R; Cara, A; Fais, S				Lozupone, F.; Borghi, M.; Marzoli, F.; Azzarito, T.; Matarrese, P.; Iessi, E.; Venturi, G.; Meschini, S.; Canitano, A.; Bona, R.; Cara, A.; Fais, S.			TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells	ONCOGENE			English	Article							PROTON PUMP INHIBITORS; VACUOLAR H+-ATPASE; MULTIDRUG-RESISTANCE; INTRACELLULAR PH; MELANOMA-CELLS; ENERGY-METABOLISM; SUBUNIT ISOFORMS; IN-VITRO; INVASION; METASTASIS	An inverted pH gradient across the cell membranes is a typical feature of malignant cancer cells that are characterized by extracellular acidosis and cytosol alkalization. These dysregulations are able to create a unique milieu that favors tumor progression, metastasis and chemo/immune-resistance traits of solid tumors. A key event mediating tumor cell pH alterations is an aberrant activation of ion channels and proton pumps such as (H+)-vacuolar-ATPase (V-ATPase). TM9SF4 is a poorly characterized transmembrane protein that we have recently shown to be related to cannibal behavior of metastatic melanoma cells. Here, we demonstrate that TM9SF4 represents a novel V-ATPase-associated protein involved in V-ATPase activation. We have observed in HCT116 and SW480 colon cancer cell lines that TM9SF4 interacts with the ATP6V1H subunit of the V-ATPase V1 sector. Suppression of TM9SF4 with small interfering RNAs strongly reduces assembly of V-ATPase V0/V1 sectors, thus reversing tumor pH gradient with a decrease of cytosolic pH, alkalization of intracellular vesicles and a reduction of extracellular acidity. Such effects are associated with a significant inhibition of the invasive behavior of colon cancer cells and with an increased sensitivity to the cytotoxic effects of 5-fluorouracil. Our study shows for the first time the important role of TM9SF4 in the aberrant constitutive activation of the V-ATPase, and the development of a malignant phenotype, supporting the potential use of TM9SF4 as a target for future anticancer therapies.	[Lozupone, F.; Marzoli, F.; Azzarito, T.; Matarrese, P.; Iessi, E.; Venturi, G.; Canitano, A.; Bona, R.; Cara, A.; Fais, S.] Ist Super Sanita, Therapeut Res & Med Evaluat Dept, I-00161 Rome, Italy; [Borghi, M.] Ist Super Sanita, Infect Parasit & Immune Mediated Dis Dept, I-00161 Rome, Italy; [Meschini, S.] Ist Super Sanita, Technol & Hlth Dept, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Lozupone, F (corresponding author), Ist Super Sanita, Dept Drug Res & Med Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	francesco.lozupone@iss.it	Lozupone, Francesco/H-2998-2016; Cara, Andrea/M-4865-2015; CANITANO, ANDREA/O-1907-2017; Matarrese, Paola/A-4369-2014; VENTURI, GIULIETTA/O-8123-2015; Cara, Andrea/AAA-4238-2021; BORGHI, MARTINA/M-4355-2015; Iessi, Elisabetta/O-2460-2017; Fais, Stefano/J-8638-2016; Bona, Roberta/O-1730-2017; MESCHINI, STEFANIA/E-9091-2015	Lozupone, Francesco/0000-0002-4959-9400; Cara, Andrea/0000-0003-4967-1895; CANITANO, ANDREA/0000-0002-1494-1237; VENTURI, GIULIETTA/0000-0002-9078-8350; Cara, Andrea/0000-0003-4967-1895; BORGHI, MARTINA/0000-0001-6313-0273; Iessi, Elisabetta/0000-0001-7221-9173; Fais, Stefano/0000-0001-9060-2766; Bona, Roberta/0000-0002-9226-3734; MESCHINI, STEFANIA/0000-0001-9079-1181; matarrese, paola/0000-0001-5477-3752; marzoli, francesca/0000-0002-1353-527X	AIRC Associazione Italiana per la Ricerca sul Cancro; Airc Grant [10602, IG 11505n]	AIRC Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Airc Grant(Fondazione AIRC per la ricerca sul cancro)	We thank Dr Angelo De Milito for helpful discussion, Pasqualina Leone for her contribution in plasmid cloning and Dr Tonino Sofia for his suggestions. This study was supported by AIRC Associazione Italiana per la Ricerca sul Cancro. Airc Grant '10602' and 'IG 11505n'. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Avnet S, 2013, BBA-MOL BASIS DIS, V1832, P1105, DOI 10.1016/j.bbadis.2013.04.003; Capecci J, 2013, J BIOL CHEM, V288, P32731, DOI 10.1074/jbc.M113.503771; Chang H, 2011, BREAST CANCER RES TR, V125, P55, DOI 10.1007/s10549-010-0825-z; Chen M, 2012, J CELL BIOCHEM, V113, P2474, DOI 10.1002/jcb.24122; Chung CH, 2011, LAB INVEST, V91, P732, DOI 10.1038/labinvest.2011.8; Daniel C, 2013, BBA-MOL BASIS DIS, V1832, P606, DOI 10.1016/j.bbadis.2013.01.020; De Milito Angelo, 2005, Future Oncol, V1, P779, DOI 10.2217/14796694.1.6.779; De Milito A, 2012, CURR PHARM DESIGN, V18, P1395, DOI 10.2174/138161212799504911; De Milito A, 2010, INT J CANCER, V127, P207, DOI 10.1002/ijc.25009; Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796; Fais S, 2007, CANCER RES, V67, P10627, DOI 10.1158/0008-5472.CAN-07-1805; Fogarty FM, 2014, ONCOGENE, V33, P4653, DOI 10.1038/onc.2013.403; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Graham RM, 2014, ONCOTARGET, V5, P1162, DOI 10.18632/oncotarget.1699; He PF, 2009, AUTOPHAGY, V5, P52, DOI 10.4161/auto.5.1.7247; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Lozupone F, 2009, EMBO REP, V10, P1348, DOI 10.1038/embor.2009.236; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; MacKinnon RN, 2010, GENE CHROMOSOME CANC, V49, P998, DOI 10.1002/gcc.20806; Marshansky V, 2014, BBA-BIOENERGETICS, V1837, P857, DOI 10.1016/j.bbabio.2014.01.018; Michel V, 2013, INT J CANCER, V132, pE1, DOI 10.1002/ijc.27811; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Niikura K, 2006, DRUG NEWS PERSPECT, V19, P139, DOI 10.1358/dnp.2006.19.3.977442; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Oo HZ, 2014, PATHOBIOLOGY, V81, P138, DOI 10.1159/000357821; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Parks SK, 2011, J CELL PHYSIOL, V226, P299, DOI 10.1002/jcp.22400; Perez-Sayans M, 2010, CANCER LETT, V295, P135, DOI 10.1016/j.canlet.2010.03.019; Perrin J, 2015, J INNATE IMMUN, V7, P37, DOI 10.1159/000365112; Qi J, 2007, J BIOENERG BIOMEMBR, V39, P423, DOI 10.1007/s10863-007-9116-8; Raghunand N, 2000, DRUG RESIST UPDATE, V3, P39, DOI 10.1054/drup.2000.0119; Riemann D, 2005, BIOCHEM BIOPH RES CO, V331, P1408, DOI 10.1016/j.bbrc.2005.04.061; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; de Souza ACS, 2011, CELL PHYSIOL BIOCHEM, V28, P771, DOI 10.1159/000335792; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; SEO JT, 1994, PFLUG ARCH EUR J PHY, V426, P75, DOI 10.1007/BF00374673; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; Spugnini EP, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-221; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sun-Wada GH, 2013, HISTOL HISTOPATHOL, V28, P805, DOI 10.14670/HH-28.805; Supino R, 2009, ANN NY ACAD SCI, V1171, P606, DOI 10.1111/j.1749-6632.2009.04705.x; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wiedmann RM, 2012, CANCER RES, V72, P5976, DOI 10.1158/0008-5472.CAN-12-1772; Xu JY, 2012, CARCINOGENESIS, V33, P2432, DOI 10.1093/carcin/bgs277; You HY, 2009, CANCER LETT, V280, P110, DOI 10.1016/j.canlet.2009.02.023; Zaravinos A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018135; Zhang Y, 2013, CANCER BIOL THER, V14, P81, DOI 10.4161/cbt.22958	52	61	67	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5163	5174		10.1038/onc.2014.437	http://dx.doi.org/10.1038/onc.2014.437			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25659576				2022-12-28	WOS:000362233400006
J	Wade, MA; Sunter, NJ; Fordham, SE; Long, A; Masic, D; Russell, LJ; Harrison, CJ; Rand, V; Elstob, C; Bown, N; Rowe, D; Lowe, C; Cuthbert, G; Bennett, S; Crosier, S; Bacon, CM; Onel, K; Scott, K; Scott, D; Travis, LB; May, FEB; Allan, JM				Wade, M. A.; Sunter, N. J.; Fordham, S. E.; Long, A.; Masic, D.; Russell, L. J.; Harrison, C. J.; Rand, V.; Elstob, C.; Bown, N.; Rowe, D.; Lowe, C.; Cuthbert, G.; Bennett, S.; Crosier, S.; Bacon, C. M.; Onel, K.; Scott, K.; Scott, D.; Travis, L. B.; May, F. E. B.; Allan, J. M.			c-MYC is a radiosensitive locus in human breast cells	ONCOGENE			English	Article							ATOMIC-BOMB SURVIVORS; COMPARATIVE GENOMIC HYBRIDIZATION; INDUCED NEOPLASTIC TRANSFORMATION; IONIZING-RADIATION; ALLELIC IMBALANCE; TUMOR PROGRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; CANCER RISK; AMPLIFICATION	Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is dose-dependent. Although it is well understood which individuals are at risk of radiation-induced breast carcinogenesis, the molecular genetic mechanisms that underlie cell transformation are less clear. To identify genetic alterations potentially responsible for driving radiogenic breast transformation, we exposed the human breast epithelial cell line MCF-10A to fractionated doses of X-rays and examined the copy number and cytogenetic alterations. We identified numerous alterations of c-MYC that included high-level focal amplification associated with increased protein expression. c-MYC amplification was also observed in primary human mammary epithelial cells following exposure to radiation. We also demonstrate that the frequency and magnitude of c-MYC amplification and c-MYC protein expression is significantly higher in breast cancer with antecedent radiation exposure compared with breast cancer without a radiation aetiology. Our data also demonstrate extensive intratumor heterogeneity with respect to c-MYC copy number in radiogenic breast cancer, suggesting continuous evolution at this locus during disease development and progression. Taken together, these data identify c-MYC as a radiosensitive locus, implicating this oncogenic transcription factor in the aetiology of radiogenic breast cancer.	[Wade, M. A.; Sunter, N. J.; Fordham, S. E.; Long, A.; Masic, D.; Russell, L. J.; Harrison, C. J.; Rand, V.; Elstob, C.; Crosier, S.; Bacon, C. M.; May, F. E. B.; Allan, J. M.] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Bown, N.; Rowe, D.; Lowe, C.; Cuthbert, G.; Bennett, S.] Newcastle Univ, Inst Med Genet, Northern Genet Serv, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Onel, K.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Scott, K.] Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; [Scott, D.] Harrogate Dist Hosp, Harrogate & Dist NHS Fdn Trust, Dept Histopathol, Harrogate, Yorks, England; [Travis, L. B.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; [Travis, L. B.] Univ Rochester, Med Ctr, Rubin Ctr Canc Survivorship, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	Newcastle University - UK; Newcastle University - UK; University of Chicago; University of York - UK; University of Rochester; University of Rochester	Allan, JM (corresponding author), Newcastle Univ, Northern Inst Canc Res, Paul OGorman Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	james.allan@newcastle.ac.uk	Wade, Mark/AAA-2685-2019; Russell, Lisa/L-2122-2019	Wade, Mark/0000-0002-4245-097X; Russell, Lisa/0000-0002-3421-3288; Allan, James/0000-0002-7580-5087; Bacon, Chris/0000-0002-8268-2812; Elstob, Claire/0000-0003-4252-493X; Fordham, Sarah/0000-0002-3778-8634; Rand, Vikki/0000-0002-2198-8949	Medical Research Council; Newcastle Healthcare Charity; Leukaemia and Lymphoma Research	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Newcastle Healthcare Charity; Leukaemia and Lymphoma Research	This work was supported by grants from the Medical Research Council (to JMA and FEBM), the Newcastle Healthcare Charity (to JMA and FEBM) and specialist programme funding from Leukaemia and Lymphoma Research (to JMA).	Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; Berg T, 2011, CURR TOP MICROBIOL, V348, P139, DOI 10.1007/82_2010_90; Best T, 2011, NAT MED, V17, P941, DOI 10.1038/nm.2407; Broeks A, 2010, INT J RADIAT ONCOL, V76, P540, DOI 10.1016/j.ijrobp.2009.09.004; Camats N, 2006, MUTAT RES-FUND MOL M, V595, P156, DOI 10.1016/j.mrfmmm.2005.11.002; Carmichael A, 2003, EUR J SURG ONCOL, V29, P475, DOI 10.1016/S0748-7983(03)00010-6; Chiang CS, 1998, MOL DIAGN, V3, P21, DOI 10.1016/S1084-8592(98)80023-4; Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0; Cowell JK, 2005, CANCER GENET CYTOGEN, V163, P23, DOI 10.1016/j.cancergencyto.2005.04.019; Davey RA, 2004, ANTICANCER RES, V24, P465; DAVIS FG, 1989, CANCER RES, V49, P6130; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FELBER M, 1992, RADIAT RES, V131, P297, DOI 10.2307/3578419; Ferber MJ, 2004, CANCER GENET CYTOGEN, V154, P1, DOI 10.1016/j.cancergencyto.2004.01.028; Guo TH, 2011, GENE CHROMOSOME CANC, V50, P25, DOI 10.1002/gcc.20827; HOFFMAN DA, 1989, J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307; HRUBEC Z, 1989, CANCER RES, V49, P229; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kim BY, 2011, ONCOL REP, V26, P1587, DOI 10.3892/or.2011.1432; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Li ZZ, 2012, NEOPLASIA, V14, P1190, DOI 10.1593/neo.121258; Ma HY, 2008, BREAST CANCER RES TR, V109, P77, DOI 10.1007/s10549-007-9625-5; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miura S, 2008, CANCER-AM CANCER SOC, V112, P2143, DOI 10.1002/cncr.23414; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oikawa M, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-168; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; Roy D, 2006, INT J ONCOL, V28, P667; Roy D, 2003, INT J CANCER, V103, P730, DOI 10.1002/ijc.10895; Roy D, 2001, CARCINOGENESIS, V22, P1685, DOI 10.1093/carcin/22.10.1685; SAUTER G, 1995, AM J PATHOL, V146, P1131; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; SOULE HD, 1990, CANCER RES, V50, P6075; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465; Unger K, 2010, ENDOCR-RELAT CANCER, V17, P87, DOI 10.1677/ERC-09-0065; Varma G, 2005, BRIT J CANCER, V93, P699, DOI 10.1038/sj.bjc.6602784; Wang WJ, 2013, CANCER RES, V73, P1219, DOI 10.1158/0008-5472.CAN-12-1408; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691	45	19	19	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4985	4994		10.1038/onc.2014.427	http://dx.doi.org/10.1038/onc.2014.427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531321	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000361693000008
J	Archambault, V; Lepine, G; Kachaner, D				Archambault, V.; Lepine, G.; Kachaner, D.			Understanding the Polo Kinase machine	ONCOGENE			English	Review							SPINDLE ASSEMBLY CHECKPOINT; SMALL-MOLECULE INHIBITORS; CELL-CYCLE CONTROL; BOX DOMAIN; AURORA-A; SUBCELLULAR-LOCALIZATION; CENTRIOLE DUPLICATION; PLK1 PHOSPHORYLATION; STRUCTURAL BASIS; MITOTIC ENTRY	The Polo Kinase is a central regulator of cell division required for several events of mitosis and cytokinesis. In addition to a kinase domain (KD), Polo-like kinases (Plks) comprise a Polo-Box domain (PBD), which mediates protein interactions with targets and regulators of Plks. In all organisms that contain Plks, one Plk family member fulfills several essential functions in the regulation of cell division, and here we refer to this conserved protein as Polo Kinase (Plk1 in humans). The PBD and the KD are capable of both cooperation and mutual inhibition in their functions. Crystal structures of the PBD, the KD and, recently, a PBD-KD complex have helped understanding the inner workings of the Polo Kinase. In parallel, an impressive array of molecular mechanisms has been found to mediate the regulation of the protein. Moreover, the targeting of Polo Kinase in the development of anti-cancer drugs has yielded several molecules with which to chemically modulate Polo Kinase to study its biological functions. Here we review our current understanding of the protein function and regulation of Polo Kinase as a fascinating molecular device in control of cell division.	[Archambault, V.; Lepine, G.; Kachaner, D.] Univ Montreal, Inst Res Immunol & Cancerol, Dept Biochim & Med Mol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Archambault, V (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Pavillon Marcelle Coutu,CP 6128, Montreal, PQ H3C 3J7, Canada.	vincent.archambault.1@umontreal.ca			Canadian Institutes of Health Research; Fonds de recherche du Quebec - Sante (FRQS); Cole Foundation; Canada Foundation for Innovation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de recherche du Quebec - Sante (FRQS)(Fonds de la Recherche en Sante du Quebec); Cole Foundation; Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR)	Research on Polo Kinase in VA's lab is supported by the Canadian Institutes of Health Research. GL holds a studentship from the Fonds de recherche du Quebec - Sante (FRQS). DK holds a postdoctoral fellowship from the Cole Foundation. IRIC is supported in part by the Canada Foundation for Innovation and the FRQS.	Abe S, 2011, GENE DEV, V25, P863, DOI 10.1101/gad.2016411; Andrysik Z, 2010, NUCLEIC ACIDS RES, V38, P2931, DOI 10.1093/nar/gkq011; Archambault V, 2008, GENE DEV, V22, P2707, DOI 10.1101/gad.486808; Archambault V, 2012, CELL CYCLE, V11, P1490, DOI 10.4161/cc.19724; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Beck J, 2013, NAT CELL BIOL, V15, P430, DOI 10.1038/ncb2695; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bonner AM, 2013, P NATL ACAD SCI USA, V110, pE1222, DOI 10.1073/pnas.1301690110; Brennan IM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000409; Bruinsma W, 2014, J CELL SCI, V127, P801, DOI 10.1242/jcs.137216; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Carmena M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001250; Carmena M, 2009, CURR OPIN CELL BIOL, V21, P796, DOI 10.1016/j.ceb.2009.09.008; Chen YC, 2010, J BIOL CHEM, V285, P41244, DOI 10.1074/jbc.M110.155242; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Craig SN, 2014, EXPERT OPIN DRUG DIS, V9, P773, DOI 10.1517/17460441.2014.918100; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; de Carcer G, 2011, MOL CELL BIOL, V31, P1225, DOI 10.1128/MCB.00607-10; Eckl JM, 2014, INT J BIOCH MOL BIOL, V4, P157; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Enserink JM, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-11; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Garcia-Alvarez B, 2007, P NATL ACAD SCI USA, V104, P3107, DOI 10.1073/pnas.0609131104; Gardino AK, 2011, SEMIN CELL DEV BIOL, V22, P688, DOI 10.1016/j.semcdb.2011.09.008; Gilmartin AG, 2009, CANCER RES, V69, P6969, DOI 10.1158/0008-5472.CAN-09-0945; Gjertsen BT, 2015, LEUKEMIA, V29, P11, DOI 10.1038/leu.2014.222; GOLDSTEIN LSB, 1986, J CELL BIOL, V102, P2076, DOI 10.1083/jcb.102.6.2076; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hanisch A, 2006, MOL BIOL CELL, V17, P448, DOI 10.1091/mbc.E05-08-0801; HARTWELL LH, 1973, GENETICS, V74, P267; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kachaner D, 2014, J CELL BIOL, V207, P201, DOI 10.1083/jcb.201408081; Kachaner D, 2012, MOL CELL, V45, P553, DOI 10.1016/j.molcel.2011.12.030; Kang YH, 2006, MOL CELL, V24, P409, DOI 10.1016/j.molcel.2006.10.016; Karpov PA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S1-S14; Kasahara K, 2013, NAT COMMUN, P4; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kong D, 2014, J CELL BIOL, V206, P855, DOI 10.1083/jcb.201407087; Kothe M, 2007, BIOCHEMISTRY-US, V46, P5960, DOI 10.1021/bi602474j; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lera RF, 2012, J BIOL CHEM, V287, P42812, DOI 10.1074/jbc.M112.412544; Liao CZ, 2010, ACS MED CHEM LETT, V1, P110, DOI 10.1021/ml100020e; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Liu F, 2011, NAT CHEM BIOL, V7, P595, DOI 10.1038/nchembio.614; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Martins T, 2009, EMBO J, V28, P234, DOI 10.1038/emboj.2008.283; Matsumura F, 2011, J BIOL CHEM, V286, P10825, DOI 10.1074/jbc.M110.169722; Matthew EM, 2007, CELL CYCLE, V6, P2571, DOI 10.4161/cc.6.20.5079; McInnes C, 2006, NAT CHEM BIOL, V2, P608, DOI 10.1038/nchembio825; McInnes C, 2012, MOL CANCER THER, V11, P1683, DOI 10.1158/1535-7163.MCT-12-0006-T; McKinley KL, 2014, CELL, V158, P397, DOI 10.1016/j.cell.2014.06.016; Miller CT, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000498; Mortensen EM, 2005, CURR BIOL, V15, P2033, DOI 10.1016/j.cub.2005.10.046; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Murugan RN, 2011, MOL CELLS, V32, P209, DOI 10.1007/s10059-011-0126-3; Myer DL, 2005, ONCOGENE, V24, P299, DOI 10.1038/sj.onc.1208278; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Neef R, 2007, NAT CELL BIOL, V9, P436, DOI 10.1038/ncb1557; Oshimori N, 2006, NAT CELL BIOL, V8, P1095, DOI 10.1038/ncb1474; Park JE, 2010, CELL MOL LIFE SCI, V67, P1957, DOI 10.1007/s00018-010-0279-9; Paschal CR, 2012, CHROMOSOMA, V121, P565, DOI 10.1007/s00412-012-0375-8; Petersen J, 2005, NATURE, V435, P507, DOI 10.1038/nature03590; Petronczki M, 2008, DEV CELL, V14, P646, DOI 10.1016/j.devcel.2008.04.014; Petronczki M, 2007, DEV CELL, V12, P713, DOI 10.1016/j.devcel.2007.03.013; Qian WJ, 2013, CHEM BIOL, V20, P1255, DOI 10.1016/j.chembiol.2013.09.005; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Ratsima H, 2011, P NATL ACAD SCI USA, V108, pE914, DOI 10.1073/pnas.1106448108; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016/j.chembiol.2008.03.013; Renner AG, 2009, BLOOD, V114, P659, DOI 10.1182/blood-2008-12-195867; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Santamaria A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004457; Sclafani RA, 2000, J CELL SCI, V113, P2111; Seeburg DP, 2008, NEURON, V58, P571, DOI 10.1016/j.neuron.2008.03.021; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sledz P, 2011, ANGEW CHEM INT EDIT, V50, P4003, DOI 10.1002/anie.201008019; Smith SK, 2008, CELL CYCLE, V7, P698, DOI 10.4161/cc.7.6.5568; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Taniguchi E, 2002, J BIOL CHEM, V277, P48884, DOI 10.1074/jbc.M206307200; van de Weerdt BCM, 2008, BBA-MOL CELL RES, V1783, P1015, DOI 10.1016/j.bbamcr.2008.02.019; van de Weerdt BCM, 2005, MOL CELL BIOL, V25, P2031, DOI 10.1128/MCB.25.5.2031-2044.2005; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Watanabe N, 2009, J BIOL CHEM, V284, P2344, DOI 10.1074/jbc.M805308200; Whitfield ZJ, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001648; Wolfe BA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000110; Wu ZQ, 2008, P NATL ACAD SCI USA, V105, P1919, DOI 10.1073/pnas.0712063105; Xiang Y, 2007, PLOS BIOL, V5, P2831, DOI 10.1371/journal.pbio.0050323; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xu J, 2013, NAT STRUCT MOL BIOL, V20, P1047, DOI 10.1038/nsmb.2623; Yamashiro S, 2008, DEV CELL, V14, P787, DOI 10.1016/j.devcel.2008.02.013; Yin Z, 2013, ACS CHEM BIOL, V8, P303, DOI 10.1021/cb3004379; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zhai B, 2008, J PROTEOME RES, V7, P1675, DOI 10.1021/pr700696a; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zimmerman WC, 2007, P NATL ACAD SCI USA, V104, P1847, DOI 10.1073/pnas.0610856104; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	121	90	95	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4799	4807		10.1038/onc.2014.451	http://dx.doi.org/10.1038/onc.2014.451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25619835				2022-12-28	WOS:000361050000001
J	Keklikoglou, I; Hosaka, K; Bender, C; Bott, A; Koerner, C; Mitra, D; Will, R; Woerner, A; Muenstermann, E; Wilhelm, H; Cao, Y; Wiemann, S				Keklikoglou, I.; Hosaka, K.; Bender, C.; Bott, A.; Koerner, C.; Mitra, D.; Will, R.; Woerner, A.; Muenstermann, E.; Wilhelm, H.; Cao, Y.; Wiemann, S.			MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes	ONCOGENE			English	Article							NF-KAPPA-B; HUMAN-ENDOTHELIAL-CELLS; TUMOR LYMPHANGIOGENESIS; DUCTAL ADENOCARCINOMA; PROMOTES ANGIOGENESIS; TRANSCRIPTION FACTOR; CANCER; GROWTH; SUPPRESSOR; EXPRESSION	Recent advances in cancer biology have emerged important roles for microRNAs (miRNAs) in regulating tumor responses. However, their function in mediating intercellular communication within the tumor microenvironment is thus far poorly explored. Here, we found miR-206 to be abrogated in human pancreatic ductal adenocarcinoma (PDAC) specimens and cell lines. We show that miR-206 directly targets the oncogenes KRAS and annexin a2 (ANXA2), thereby acting as tumor suppressor in PDAC cells by blocking cell cycle progression, cell proliferation, migration and invasion. Importantly, we identified miR-206 as a negative regulator of oncogenic KRAS-induced nuclear factor-kappa B transcriptional activity, resulting in a concomitant reduction of the expression and secretion of pro-angiogenic and pro-inflammatory factors including the cytokine interleukin-8, the chemokines (C-X-C motif) ligand 1 and (C-C motif) ligand 2, and the granulocyte macrophage colony-stimulating factor. We further show that miR-206 abrogates the expression and secretion of the potent pro-lymphangiogenic factor vascular endothelial growth factor C in pancreatic cancer cells through an NF-kappa B-independent mechanism. By using in vitro and in vivo approaches, we reveal that re-expression of miR-206 in PDAC cells is sufficient to inhibit tumor blood and lymphatic vessel formation, thus leading to a significant delay of tumor growth and progression. Taken together, our study sheds light onto the role of miR-206 as a pleiotropic modulator of different hallmarks of cancer, and as such raising the intriguing possibility that miR-206 may be an attractive candidate for miRNA-based anticancer therapies.	[Keklikoglou, I.; Bender, C.; Bott, A.; Koerner, C.; Mitra, D.; Woerner, A.; Muenstermann, E.; Wilhelm, H.; Wiemann, S.] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Germany; [Keklikoglou, I.] Swiss Fed Inst Technol Lausanne EPFL, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, Lausanne, Switzerland; [Hosaka, K.; Cao, Y.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Will, R.] German Canc Res Ctr, Genom & Prote Core Facil, Heidelberg, Germany; [Cao, Y.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Cao, Y.] Glenfield Gen Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester LE3 9QP, Leics, England; [Cao, Y.] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ); University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Linkoping University	Keklikoglou, I (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	ioanna.keklikoglou@epfl.ch; s.wiemann@dkfz-heidelberg.de	Wiemann, Stefan/E-4424-2013	Wiemann, Stefan/0000-0003-4683-3174; Keklikoglou, Ioanna/0000-0003-1219-6912	German Federal Ministry of Education and Research (NGFN grant) [01GS0816]; Deutsche Forschungsgemeinschaft (DIP project) [WI3499/1-1]	German Federal Ministry of Education and Research (NGFN grant); Deutsche Forschungsgemeinschaft (DIP project)	We thank Prof George Mosialos and Dr Joerg Hoheisel for kindly providing us with the 3xKBL and pCMV-p65 vectors, and the BxPC-3, MiaPaca-2, Colo357, Capan-1 and CFPAC-1 cell lines, respectively. We thank Dr Christoph Roesli for providing us with the HPNE and HPDE cell lines and the DKFZ Genomics and Proteomics Core Facility for performing excellent services. This work was supported with funding from the German Federal Ministry of Education and Research (NGFN grant 01GS0816) and the Deutsche Forschungsgemeinschaft (DIP project WI3499/1-1).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Brownstein C, 2004, BLOOD, V103, P317, DOI 10.1182/blood-2003-04-1304; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Campbell PM, 2007, CANCER RES, V67, P2098, DOI 10.1158/0008-5472.CAN-06-3752; Cao RH, 2012, P NATL ACAD SCI USA, V109, P15894, DOI 10.1073/pnas.1208324109; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Donahue TR, 2012, CLIN CANCER RES, V18, P1352, DOI 10.1158/1078-0432.CCR-11-1539; du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hofmann I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044146; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853; Keklikoglou I, 2012, ONCOGENE, V31, P4150, DOI 10.1038/onc.2011.571; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liou GY, 2013, J CELL BIOL, V202, P563, DOI 10.1083/jcb.201301001; Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653; Madureira PA, 2011, BLOOD, V118, P4789, DOI 10.1182/blood-2011-06-334672; Matsuo Y, 2009, INT J CANCER, V125, P1027, DOI 10.1002/ijc.24383; Miyake M, 2013, LAB INVEST, V93, P768, DOI 10.1038/labinvest.2013.71; Munding JB, 2012, INT J CANCER, V131, pE86, DOI 10.1002/ijc.26466; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Sarkar S, 2011, GASTROENTEROLOGY, V140, P583, DOI 10.1053/j.gastro.2010.08.054; Seckinger A, 2012, BLOOD, V120, P1087, DOI 10.1182/blood-2012-03-415588; Sharma M, 2012, EXP MOL PATHOL, V92, P175, DOI 10.1016/j.yexmp.2011.10.003; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stahlhut C, 2012, DEVELOPMENT, V139, P4356, DOI 10.1242/dev.083774; Stamatovic SM, 2006, J IMMUNOL, V177, P2651, DOI 10.4049/jimmunol.177.4.2651; Stupack Dwayne G, 2002, Sci STKE, V2002, ppe7, DOI 10.1126/stke.2002.119.pe7; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040; Wang CY, 2012, J BIOL CHEM, V287, P32512, DOI 10.1074/jbc.M112.351957; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang WX, 1999, CLIN CANCER RES, V5, P119; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031; Zhang G, 2012, J CONTROL SCI ENG, V2012, P7, DOI DOI 10.1371/J0URNAL.P0NE.0044568; Zheng L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019390	47	99	100	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4867	4878		10.1038/onc.2014.408	http://dx.doi.org/10.1038/onc.2014.408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25500542	Green Published, hybrid			2022-12-28	WOS:000361050000007
J	Singleton, DC; Rouhi, P; Zois, CE; Haider, S; Li, JL; Kessler, BM; Cao, Y; Harris, AL				Singleton, D. C.; Rouhi, P.; Zois, C. E.; Haider, S.; Li, J-L; Kessler, B. M.; Cao, Y.; Harris, A. L.			Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis	ONCOGENE			English	Article							BREAST-CANCER; MIGRATING CELLS; CYTOPLASMIC MATURATION; ACTIN DYNAMICS; HIF-1-ALPHA; ACTIVATION; CARCINOMA; HIF-2-ALPHA; PHENOTYPE; NETWORKS	Hypoxia is a common feature of locally advanced breast cancers that is associated with increased metastasis and poorer survival. Stabilisation of hypoxia-inducible factor-1 alpha (HIF1 alpha) in tumours causes transcriptional changes in numerous genes that function at distinct stages of the metastatic cascade. We demonstrate that expression of RIOK3 (RIght Open reading frame kinase 3) was increased during hypoxic exposure in an HIF1 alpha-dependent manner. RIOK3 was localised to distinct cytoplasmic aggregates in normoxic cells and underwent redistribution to the leading edge of the cell in hypoxia with a corresponding change in the organisation of the actin cytoskeleton. Depletion of RIOK3 expression caused MDA-MB-231 to become elongated and this morphological change was due to a loss of protraction at the trailing edge of the cell. This phenotypic change resulted in reduced cell migration in two-dimensional cultures and inhibition of cell invasion through three-dimensional extracellular matrix. Proteomic analysis identified interactions of RIOK3 with actin and several actin-binding factors including tropomyosins (TPM3 and TPM4) and tropomodulin 3. Depletion of RIOK3 in cells resulted in fewer and less organised actin filaments. Analysis of these filaments showed reduced association of TPM3, particularly during hypoxia, suggesting that RIOK3 regulates actin filament specialisation. RIOK3 depletion reduced the dissemination of MDA-MB-231 cells in both a zebrafish model of systemic metastasis and a mouse model of pulmonary metastasis. These findings demonstrate that RIOK3 is necessary for maintaining actin cytoskeletal organisation required for migration and invasion, biological processes that are necessary for hypoxia-driven metastasis.	[Singleton, D. C.; Zois, C. E.; Haider, S.; Li, J-L; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Dept Oncol, Oxford OX3 9DS, England; [Rouhi, P.; Cao, Y.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Kessler, B. M.] Univ Oxford, Nuffield Dept Med, Target Discovery Inst, Oxford OX3 9DS, England; [Cao, Y.] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Cao, Y.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Cao, Y.] Glenfield Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England	University of Oxford; Karolinska Institutet; University of Oxford; Linkoping University; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Dept Oncol, Oxford OX3 9DS, England.	aharris.lab@imm.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Kessler, Benedikt/AAY-8614-2021	Harris, Adrian L/0000-0003-1376-8409; Kessler, Benedikt/0000-0002-8160-2446	European Commission Metoxia [222741]; British Columbia Cancer Agency Branch; Cancer Research UK; Cancer Research UK [11359, 16466] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish	European Commission Metoxia; British Columbia Cancer Agency Branch; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	European Commission Metoxia Grant No. 222741 (D Singleton, P Rouhi, Y Cao, A Harris), Cancer Research UK (A Harris, C Zois, S Haider, J Li), Breast Cancer Research Foundation (A Harris) and Oxford NIHR Biomedical Research Centre (B Kessler). This study makes use of data generated by the Molecular Taxonomy of Breast Cancer International Consortium, which was funded by Cancer Research UK and the British Columbia Cancer Agency Branch.	Agus DB, 2013, SCI REP-UK, V3, DOI 10.1038/srep01449; Alcoser SY, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-124; Baumas K, 2012, RNA BIOL, V9, DOI [10.4161/rna.9.2.18810, 10.4161/rna.18810]; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Cramer LP, 2013, CURR OPIN CELL BIOL, V25, P591, DOI 10.1016/j.ceb.2013.05.001; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fournier MF, 2010, J CELL BIOL, V188, P287, DOI 10.1083/jcb.200906139; Gilkes DM, 2013, CANCER RES, V73, P3285, DOI 10.1158/0008-5472.CAN-12-3963; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koch A, 2010, EUR J CELL BIOL, V89, P184, DOI 10.1016/j.ejcb.2009.11.024; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; LaRonde-LeBlanc N, 2005, J BIOL CHEM, V280, P37297, DOI 10.1074/jbc.R500013200; Mackeen MM, 2010, J PROTEOME RES, V9, P4082, DOI 10.1021/pr100269b; Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rouhi P, 2010, NAT PROTOC, V5, P1911, DOI 10.1038/nprot.2010.150; Rundqvist H, 2010, CURR TOP MICROBIOL, V345, P121, DOI 10.1007/82_2010_77; Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Tojkander S, 2011, CURR BIOL, V21, P539, DOI 10.1016/j.cub.2011.03.007; Vaupel P, 2007, ANTIOXID REDOX SIGN, V9, P1221, DOI 10.1089/ars.2007.1628; Weber KL, 2007, J CELL SCI, V120, P3625, DOI 10.1242/jcs.011445; Weidemann A, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-80; Widmann B, 2012, MOL BIOL CELL, V23, P22, DOI 10.1091/mbc.E11-07-0639; Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1; Zemp I, 2009, J CELL BIOL, V185, P1167, DOI 10.1083/jcb.200904048; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365	41	32	33	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4713	4722		10.1038/onc.2014.396	http://dx.doi.org/10.1038/onc.2014.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25486436	Green Accepted, Green Submitted			2022-12-28	WOS:000360931500005
J	Wang, L; Song, G; Chang, X; Tan, W; Pan, J; Zhu, X; Liu, Z; Qi, M; Yu, J; Han, B				Wang, L.; Song, G.; Chang, X.; Tan, W.; Pan, J.; Zhu, X.; Liu, Z.; Qi, M.; Yu, J.; Han, B.			The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway	ONCOGENE			English	Article							THIOREDOXIN; PROTEIN; EXPRESSION; INHIBITORS; OVEREXPRESSION; TRANSITION; PROGNOSIS; BIOLOGY; DOMAIN; CELLS	Castration-resistant prostate cancer (CRPC) continues to be a major clinical problem and the mechanisms behind it remain unclear. Thioredoxin domain-containing protein 5 (TXNDC5) is involved in protein folding and chaperone activity, and its overexpression has been reported in multiple malignancies. In the current study, we demonstrated that TXNDC5 is up-regulated following long-term androgen-deprivation treatment (ADT) and is highly overexpressed in CRPC tumors compared with hormone-naive prostate cancer (PCa) cases. Functionally, in vitro and in vivo studies demonstrated that TXNDC5 overexpression promotes the growth of both androgen-dependent and castration-resistant PCa xenografts. Mechanistically, TXNDC5 directly interacts with the AR protein to increase its stability and thus enhances its transcriptional activity. TXDNC5-mediated CRPC growth can be fully abolished by AR inhibition, suggesting TXDNC5 up-regulation as an escape pathway for aberrant AR re-activation and CRPC growth in the milieu of low androgen. Indeed, we found that TXNDC5 is increased by ADT-induced hypoxia through HIF-1 alpha in an miR-200b-dependent manner. Overall, we defined an important role of TXNDC5 in CRPC and further investigations are needed to screen TXNDC5 antagonists as a novel therapeutic approaches to treat PCa patients with CRPC.	[Wang, L.; Tan, W.; Liu, Z.; Qi, M.; Han, B.] Shandong Univ, Sch Med, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Wang, L.; Pan, J.] Shandong Acad Med Sci, Key Lab Rare & Uncommon Dis Shandong Prov, Res Ctr Med Biotechnol, Jinan, Peoples R China; [Song, G.] Shandong Acad Med Sci, Inst Basic Med, Jinan, Peoples R China; [Chang, X.] Shandong Univ, Shandong Prov Qianfoshan Hosp, Med Res Ctr, Jinan 250012, Shandong, Peoples R China; [Zhu, X.] Shandong Inst Med & Hlth Informat, Jinan, Peoples R China; [Liu, Z.; Han, B.] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Yu, J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University; Northwestern University; Feinberg School of Medicine	Han, B (corresponding author), Shandong Univ, Sch Med, Dept Pathol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	boh@sdu.edu.cn			National Natural Science Foundation of China [81302239, 81300426]; Foundation for Scientific and Technological Achievements of Jinan [201302046]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Scientific and Technological Achievements of Jinan	We thank Professor Yaoqin Gong and Professor Huiqing Yuan from Shandong University Medical School for their critical reading of the manuscript. AR expression and PSA-Luc vectors were kindly provided by Professor Huiqing Yuan. This work was supported by the National Natural Science Foundation of China (Grant No. 81302239 and No. 81300426) and the Foundation for Scientific and Technological Achievements of Jinan (Grant No. 201302046).	Baumann C, 2012, ACTAS UROL ESP, V36, P1, DOI 10.1016/j.acuro.2011.07.017; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Charlton HK, 2010, BIOCHEM BIOPH RES CO, V392, P234, DOI 10.1016/j.bbrc.2010.01.029; Dvorzhinski D, 2004, PROTEOMICS, V4, P3268, DOI 10.1002/pmic.200400847; Egan A, 2014, CANCER TREAT REV, V40, P426, DOI 10.1016/j.ctrv.2013.09.011; Fujino G, 2006, SEMIN CANCER BIOL, V16, P427, DOI 10.1016/j.semcancer.2006.09.003; Galluzzi L, 2009, MOL CELL, V36, P176, DOI 10.1016/j.molcel.2009.10.003; Gulerez IE, 2012, ACTA CRYSTALLOGR F, V68, P378, DOI 10.1107/S1744309112005866; Han B, 2009, MODERN PATHOL, V22, P1176, DOI 10.1038/modpathol.2009.79; Hsieh CL, 2008, J MOL ENDOCRINOL, V41, P13, DOI 10.1677/JME-07-0158; Hsu FN, 2011, AM J PHYSIOL-ENDOC M, V300, pE902, DOI 10.1152/ajpendo.00610.2010; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Inoue T, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/647987; Leo S, 2011, CHEMOTHERAPY, V57, P115, DOI 10.1159/000323581; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Messaoudi S, 2008, ANTI-CANCER AGENT ME, V8, P761, DOI 10.2174/187152008785914824; Mitani T, 2011, J STEROID BIOCHEM, V123, P58, DOI 10.1016/j.jsbmb.2010.10.009; Ni L, 2010, MOL CELL BIOL, V30, P1243, DOI 10.1128/MCB.01891-08; Pal SK, 2013, EXPERT OPIN PHARMACO, V14, P679, DOI 10.1517/14656566.2013.775251; Ramanathan RK, 2012, INVEST NEW DRUG, V30, P1591, DOI 10.1007/s10637-011-9739-9; Ranasinghe WKB, 2014, CANCER MED-US, V3, P245, DOI 10.1002/cam4.189; Ranasinghe WKB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054251; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sharifi N, 2013, ENDOCRINOLOGY, V154, P4010, DOI 10.1210/en.2013-1466; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Thoenes L, 2010, J PROTEOMICS, V73, P1342, DOI 10.1016/j.jprot.2010.02.019; Tonissen KF, 2009, MOL NUTR FOOD RES, V53, P87, DOI 10.1002/mnfr.200700492; Vincent EE, 2011, ANTICANCER RES, V31, P1577; Wang L, 2014, PROSTATE, V74, P647, DOI 10.1002/pros.22783; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053301; Wang L, 2010, INT J BIOL SCI, V6, P454; Wang YT, 2014, INT J NEUROPSYCHOPH, V17, P469, DOI 10.1017/S1461145713001429; Wang YH, 2007, EXP BIOL MED, V232, P1152, DOI 10.3181/0701-RM-8; Wei Q, 2007, PROSTATE CANCER P D, V10, P167, DOI 10.1038/sj.pcan.4500933; Zhang L, 2010, J CANCER RES CLIN, V136, P1497, DOI 10.1007/s00432-010-0807-x; Zhao LY, 2014, CANCER EPIDEM BIOMAR, V23, P1047, DOI 10.1158/1055-9965.EPI-13-0696; Zhu XJ, 2011, ORAL ONCOL, V47, P609, DOI 10.1016/j.oraloncology.2011.05.006	40	32	34	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4735	4745		10.1038/onc.2014.401	http://dx.doi.org/10.1038/onc.2014.401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25500540				2022-12-28	WOS:000360931500007
J	Mahajan, K; Mahajan, NP				Mahajan, K.; Mahajan, N. P.			ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers	ONCOGENE			English	Review							SURGICAL ADJUVANT BREAST; ANDROGEN RECEPTOR; PROSTATE-CANCER; ACK1; ACTIVATION; AKT; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; MUTATIONS	Deregulated tyrosine kinase signaling alters cellular homeostasis to drive cancer progression. The emergence of a non-receptor tyrosine kinase (non-RTK), ACK1 (also known as activated Cdc42-associated kinase 1 or TNK2) as an oncogenic kinase, has uncovered novel mechanisms by which tyrosine kinase signaling promotes cancer progression. Although early studies focused on ACK1 as a cytosolic effector of activated transmembrane RTKs, wherein it shuttles between the cytosol and the nucleus to rapidly transduce extracellular signals from the RTKs to the intracellular effectors, recent data unfold a new aspect of its functionality as an epigenetic regulator. ACK1 interacts with the estrogen receptor (ER)/histone demethylase KDM3A (JHDM2a) complex, which modifies KDM3A by tyrosine phosphorylation to regulate the transcriptional outcome at HOXA1 locus to promote the growth of tamoxifen-resistant breast cancer. It is also well established that ACK1 regulates the activity of androgen receptor (AR) by tyrosine phosphorylation to fuel the growth of hormone-refractory prostate cancers. Further, recent explosion in genomic sequencing has revealed recurrent ACK1 gene amplification and somatic mutations in a variety of human malignancies, providing a molecular basis for its role in neoplastic transformation. In this review, we will discuss the various facets of ACK1 signaling, including its newly uncovered epigenetic regulator function, which enables cells to bypass the blockade to major survival pathways to promote resistance to standard cancer treatments. Not surprisingly, cancer cells appear to acquire an 'addiction' to ACK1-mediated survival, particularly under stress conditions, such as growth factor deprivation or genotoxic insults or hormone deprivation. With the accelerated development of potent and selective ACK1 inhibitors, targeted treatment for cancers harboring aberrant ACK1 activity may soon become a clinical reality.	[Mahajan, K.; Mahajan, N. P.] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, Tampa, FL 33612 USA; [Mahajan, K.; Mahajan, N. P.] Univ S Florida, Dept Oncol Sci, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Mahajan, K (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.	kiran.mahajan@moffitt.org; nupam.mahajan@moffitt.org	Mahajan, Kiran/ABA-3013-2020	Mahajan, Kiran/0000-0001-7192-396X	Department of Defense [W81XWH-12-1-0248, W81XWH-14-1-0251, W81XWH-14-1-0002, W81XWH-14-1-0003]; National Cancer Institute, NIH [1R01CA135328]; Moffitt Lung Cancer SPORE; NATIONAL CANCER INSTITUTE [R01CA135328] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Moffitt Lung Cancer SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Department of Defense (W81XWH-12-1-0248 and W81XWH-14-1-0251) to KM and by the National Cancer Institute, NIH (1R01CA135328), Department of Defense (W81XWH-14-1-0002 and W81XWH-14-1-0003) and Career Development Award by Moffitt Lung Cancer SPORE to NPM.	Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Buchwald M, 2013, ONCOGENE, V32, P4913, DOI 10.1038/onc.2012.515; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Chan W, 2009, J BIOL CHEM, V284, P8185, DOI 10.1074/jbc.M806877200; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Clarke R, 2001, PHARMACOL REV, V53, P25; DiMauro EF, 2007, BIOORG MED CHEM LETT, V17, P2305, DOI 10.1016/j.bmcl.2007.01.057; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gajiwala KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053994; Galisteo ML, 2006, P NATL ACAD SCI USA, V103, P9796, DOI 10.1073/pnas.0603714103; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hitomi Y, 2013, ANN NEUROL, V74, P496, DOI 10.1002/ana.23934; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jones S, 2014, J CELL SCI, V127, P994, DOI 10.1242/jcs.136895; Kramer OH, 2013, LEUKEMIA, V27, P792, DOI 10.1038/leu.2012.284; La Torre A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.99; La Torre A, 2006, GENE EXPR PATTERNS, V6, P886, DOI 10.1016/j.modgep.2006.02.009; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Lin Q, 2012, BIOCHEM J, V445, P255, DOI 10.1042/BJ20111575; Liu Y, 2010, ONCOGENE, V29, P3208, DOI 10.1038/onc.2010.103; Lupien M, 2009, ENDOCR-RELAT CANCER, V16, P381, DOI 10.1677/ERC-09-0038; Mahajan K, 2014, AACR ED BOOK, V2014, P6; Mahajan K, 2014, J BIOL CHEM, V289, P28179, DOI 10.1074/jbc.M114.584425; Mahajan K, 2013, CANCER LETT, V338, P185, DOI 10.1016/j.canlet.2013.04.004; Mahajan K, 2012, J BIOL CHEM, V287, P22112, DOI 10.1074/jbc.M112.357384; Mahajan K, 2012, J CELL PHYSIOL, V227, P3178, DOI 10.1002/jcp.24065; Mahajan K, 2012, AM J PATHOL, V180, P1386, DOI 10.1016/j.ajpath.2011.12.028; Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163; Mahajan K, 2010, J CELL PHYSIOL, V224, P327, DOI 10.1002/jcp.22162; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Matsumoto J, 2002, JPN J CANCER RES, V93, P1317, DOI 10.1111/j.1349-7006.2002.tb01240.x; Maxson JE, 2013, NEW ENGL J MED, V368, P1781, DOI 10.1056/NEJMoa1214514; Prieto-Echagile V., 2011, J SIGNAL TRANSDUCT, V2011; Prieto-Echague V, 2010, BMC BIOCHEM, V11, DOI 10.1186/1471-2091-11-42; Prieto-Echague V, 2010, J BIOL CHEM, V285, P10605, DOI 10.1074/jbc.M109.060459; Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x; Schlieman MG, 2003, BRIT J CANCER, V89, P2110, DOI 10.1038/sj.bjc.6601396; Schoenherr JA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002725; Shen F, 2007, MOL BIOL CELL, V18, P732, DOI 10.1091/mbc.E06-02-0142; Shinmura K, 2014, J SURG ONCOL, V109, P189, DOI 10.1002/jso.23482; Tan DSW, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-13; Urena JM, 2005, J COMP NEUROL, V490, P119, DOI 10.1002/cne.20656; van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102; Yokoyama N, 2003, J BIOL CHEM, V278, P47713, DOI 10.1074/jbc.M306716200	53	74	76	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4162	4167		10.1038/onc.2014.350	http://dx.doi.org/10.1038/onc.2014.350			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347744	Green Accepted			2022-12-28	WOS:000359199800002
J	Martin, L; Gardner, LB				Martin, L.; Gardner, L. B.			Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; PROMOTES TUMOR-GROWTH; GENE-EXPRESSION; OXIDATIVE STRESS; CELL-SURVIVAL; CANCER-CELLS; IN-VIVO; METABOLISM; AUTOPHAGY	SLC7A11 encodes a subunit of the xCT cystine/glutamate amino-acid transport system and has a critical role in the generation of glutathione and the protection of cells from oxidative stress. Expression of SLC7A11 promotes tumorigenesis and chemotherapy resistance, but while SLC7A11 has been previously noted to be upregulated in hypoxic cells, its regulation has not been fully delineated. We have recently shown that nonsense-mediated RNA decay (NMD) is inhibited by cellular stresses generated by the tumor microenvironment, including hypoxia, and augments tumorigenesis. Here we demonstrate that the inhibition of NMD by various cellular stresses leads to the stabilization and upregulation of SLC7A11 mRNA and protein. The inhibition of NMD and upregulation of SLC7A11 augments intracellular cystine transport and increases intracellular levels of cysteine and glutathione. Accordingly, the inhibition of NMD protects cells against oxidative stress via SLC7A11 upregulation. Together our studies identify a mechanism for the dynamic regulation of SLC7A11, through the stress-inhibited regulation of NMD, and add to the growing evidence that the inhibition of NMD is an adaptive response.	[Martin, L.; Gardner, L. B.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Gardner, L. B.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA; [Gardner, L. B.] NYU, Sch Med, NYU Perlmutter Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University	Gardner, LB (corresponding author), NYU, Sch Med, Div Hematol & Med Oncol, 550 First Ave,Smilow 1204, New York, NY 10016 USA.	Lawrence.gardner@nyumc.org		Gardner, Lawrence/0000-0003-0191-0172	NYU Cancer Institute;  [RO1DK081641]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081641] Funding Source: NIH RePORTER	NYU Cancer Institute; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by RO1DK081641 (to LBG), a generous gift from Mr Arthur Levine and Ms Diane Lederman and the NYU Cancer Institute. LBG was the Saul Farber Associate Professor of Medicine.	Ahlqvist KJ, 2012, CELL METAB, V15, P100, DOI 10.1016/j.cmet.2011.11.012; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Chen RS, 2009, ONCOGENE, V28, P599, DOI 10.1038/onc.2008.414; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Durand S, 2007, J CELL BIOL, V178, P1145, DOI 10.1083/jcb.200611086; Fernandez PC, 1999, BIOL CHEM, V380, P1383, DOI 10.1515/BC.1999.178; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gardner LB, 2008, CELL CYCLE, V7, P1916, DOI 10.4161/cc.7.13.6203; Gardner LB, 2008, MOL CELL BIOL, V28, P3729, DOI 10.1128/MCB.02284-07; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Huang CC, 2010, BIOCHEM J, V429, P215, DOI 10.1042/BJ20100286; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Keeling KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060478; Krokowski D, 2013, J BIOL CHEM, V288, P17202, DOI 10.1074/jbc.M113.466920; Lewerenz J, 2009, J BIOL CHEM, V284, P1106, DOI 10.1074/jbc.M807325200; Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; Martin L, 2010, J BIOL CHEM, V285, P31944, DOI 10.1074/jbc.M110.153148; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Ogunrinu TA, 2010, J BIOL CHEM, V285, P37716, DOI 10.1074/jbc.M110.161190; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Tomi M, 2002, INVEST OPHTH VIS SCI, V43, P774; Wang D, 2011, J BIOL CHEM, V286, P40038, DOI 10.1074/jbc.M111.266361; Wang D, 2011, MOL CELL BIOL, V31, P3670, DOI 10.1128/MCB.05704-11; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wengrod J, 2013, MOL CELL BIOL, V33, P2128, DOI 10.1128/MCB.00174-13; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	42	35	39	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4211	4218		10.1038/onc.2014.352	http://dx.doi.org/10.1038/onc.2014.352			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25399695	Green Accepted			2022-12-28	WOS:000359199800007
J	Merino, D; Best, SA; Asselin-Labat, ML; Vaillant, F; Pal, B; Dickins, RA; Anderson, RL; Strasser, A; Bouillet, P; Lindeman, GJ; Visvader, JE				Merino, D.; Best, S. A.; Asselin-Labat, M-L; Vaillant, F.; Pal, B.; Dickins, R. A.; Anderson, R. L.; Strasser, A.; Bouillet, P.; Lindeman, G. J.; Visvader, J. E.			Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; CANCER CELLS; SURVIVAL SIGNALS; BCL-2 PROTEIN; ANOIKIS; EXPRESSION; RESISTANCE; INDUCTION; DISEASE; PUMA	Evasion of cell death is fundamental to the development of cancer and its metastasis. The role of the BCL-2-mediated (intrinsic) apoptotic program in these processes remains poorly understood. Here we have investigated the relevance of the pro-apoptotic protein BIM to breast cancer progression using the MMTV-Polyoma middle-T (PyMT) transgenic model. BIM deficiency in PyMT females did not affect primary tumor growth, but substantially increased the survival of metastatic cells within the lung. These data reveal a role for BIM in the suppression of breast cancer metastasis. Intriguingly, we observed a striking correlation between the expression of BIM and the epithelial to mesenchymal transition transcription factor SNAI2 at the proliferative edge of the tumors. Overexpression and knockdown studies confirmed that these two genes were coordinately expressed, and chromatin immunoprecipitation analysis further revealed that Bim is a target of SNAI2. Taken together, our findings suggest that SNAI2-driven BIM-induced apoptosis may temper metastasis by governing the survival of disseminating breast tumor cells.	[Merino, D.; Best, S. A.; Asselin-Labat, M-L; Vaillant, F.; Pal, B.; Dickins, R. A.; Strasser, A.; Bouillet, P.; Lindeman, G. J.; Visvader, J. E.] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia; [Merino, D.; Best, S. A.; Asselin-Labat, M-L; Vaillant, F.; Pal, B.; Dickins, R. A.; Strasser, A.; Bouillet, P.; Visvader, J. E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia; [Anderson, R. L.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia; [Lindeman, G. J.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Lindeman, G. J.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne; Peter Maccallum Cancer Center; Royal Melbourne Hospital; University of Melbourne	Lindeman, GJ (corresponding author), Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia.	lindeman@wehi.edu.au; visvader@wehi.edu.au	Strasser, Andreas/C-7581-2013; Dickins, Ross A/K-2852-2012; Bouillet, Philippe/E-1241-2013; Merino, Delphine/L-9159-2017; Pal, Bhupinder/AAF-4011-2020; Anderson, Robin/K-6966-2019; Anderson, Robin/S-1005-2017	Strasser, Andreas/0000-0002-5020-4891; Dickins, Ross A/0000-0003-4112-5304; Bouillet, Philippe/0000-0002-9012-6058; Merino, Delphine/0000-0002-8075-6275; Best, Sarah/0000-0002-4232-9432; Lindeman, Geoffrey/0000-0001-9386-2416; Pal, Bhupinder/0000-0002-3684-4331; Anderson, Robin/0000-0002-6841-7422	National Health and Medical Research Council, Australia (NHMRC) [461221, 1016701]; NHMRC IRIISS; Victorian State Government through Victorian Cancer Agency funding of the Victorian Breast Cancer Research Consortium and Operational Infrastructure Support; Australian Cancer Research Foundation; National Breast Cancer Foundation; NBCF Early Career Fellowship; senior NBCF Fellowship; NHMRC Postgraduate Scholarship [1017256]; NHMRC Australia Fellowship [637307]; National Breast Cancer Foundation [ECF-13-06] Funding Source: researchfish	National Health and Medical Research Council, Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government through Victorian Cancer Agency funding of the Victorian Breast Cancer Research Consortium and Operational Infrastructure Support; Australian Cancer Research Foundation; National Breast Cancer Foundation; NBCF Early Career Fellowship; senior NBCF Fellowship; NHMRC Postgraduate Scholarship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Australia Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	We are grateful to K Rogers, L Whitehead, C Nowell for help with imaging, K Birchall, L Reid and G Siciliano for animal husbandry; B Helbert and C Young for mouse genotyping; K Breslin, M Robati and K Liu for technical assistance. We thank D Metcalf and JM Adams for useful discussion and advice, LA O'Reilly for antibodies and D Huang for knockout MEF cell lines. This work was supported by the National Health and Medical Research Council, Australia (NHMRC, 461221 and 1016701); NHMRC IRIISS; the Victorian State Government through Victorian Cancer Agency funding of the Victorian Breast Cancer Research Consortium and Operational Infrastructure Support; the Australian Cancer Research Foundation; and The National Breast Cancer Foundation. DM was supported by a NBCF Early Career Fellowship, RLA by a senior NBCF Fellowship, and SAB by a NHMRC Postgraduate Scholarship #1017256. JEV and GJL were supported by an NHMRC Australia Fellowship and Research Fellowship (637307), respectively.	Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Bouillet P, 2005, CELL DEATH DIFFER, V12, P831, DOI 10.1038/sj.cdd.4401603; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Buckle T, 2010, LAB ANIM-UK, V44, P40, DOI 10.1258/la.2009.009030; Chambers AF, 2000, BREAST CANCER RES, V2, P400, DOI 10.1186/bcr86; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Clybouw C, 2012, CELL DEATH DIFFER, V19, P1060, DOI 10.1038/cdd.2011.198; Dai DL, 2008, J INVEST DERMATOL, V128, P403, DOI 10.1038/sj.jid.5700989; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gogada R, 2013, J BIOL CHEM, V288, P368, DOI 10.1074/jbc.M112.386102; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Kim S, 2014, CANCER RES, V74, P3695, DOI 10.1158/0008-5472.CAN-13-2591; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Maamer-Azzabi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.328; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; Uehara N, 2008, MOL CANCER RES, V6, P186, DOI 10.1158/1541-7786.MCR-07-0254; Valastyan S, 2011, GENE DEV, V25, P646, DOI 10.1101/gad.2004211; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Voss AK, 2012, METHODS MOL BIOL, V809, P335, DOI 10.1007/978-1-61779-376-9_23; Wong CW, 2001, CANCER RES, V61, P333; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	55	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3926	3934		10.1038/onc.2014.313	http://dx.doi.org/10.1038/onc.2014.313			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263453				2022-12-28	WOS:000358544200005
J	Selmansberger, M; Feuchtinger, A; Zurnadzhy, L; Michna, A; Kaiser, JC; Abend, M; Brenner, A; Bogdanova, T; Walch, A; Unger, K; Zitzelsberger, H; Hess, J				Selmansberger, M.; Feuchtinger, A.; Zurnadzhy, L.; Michna, A.; Kaiser, J. C.; Abend, M.; Brenner, A.; Bogdanova, T.; Walch, A.; Unger, K.; Zitzelsberger, H.; Hess, J.			CLIP2 as radiation biomarker in papillary thyroid carcinoma	ONCOGENE			English	Article							INDUCED GENOMIC INSTABILITY; IONIZING-RADIATION; CHERNOBYL ACCIDENT; CANCER; PROTEIN; REARRANGEMENTS; EXPOSURE; KINESIN; RET/PTC; DYNEIN	A substantial increase in papillary thyroid carcinoma (PTC) among children exposed to the radioiodine fallout has been one of the main consequences of the Chernobyl reactor accident. Recently, the investigation of PTCs from a cohort of young patients exposed to the post-Chernobyl radioiodine fallout at very young age and a matched nonexposed control group revealed a radiation-specific DNA copy number gain on chromosomal band 7q11.23 and the radiation-associated mRNA overexpression of CLIP2. In this study, we investigated the potential role of CLIP2 as a radiation marker to be used for the individual classification of PTCs into CLIP2-positive and - negative cases-a prerequisite for the integration of CLIP2 into epidemiological modelling of the risk of radiation-induced PTC. We were able to validate the radiation-associated CLIP2 overexpression at the protein level by immunohistochemistry (IHC) followed by relative quantification using digital image analysis software (P = 0.0149). Furthermore, we developed a standardized workflow for the determination of CLIP2-positive and - negative cases that combines visual CLIP2 IHC scoring and CLIP2 genomic copy number status. In addition to the discovery cohort (n = 33), two independent validation cohorts of PTCs (n = 115) were investigated. High sensitivity and specificity rates for all three investigated cohorts were obtained, demonstrating robustness of the developed workflow. To analyse the function of CLIP2 in radiation-associated PTC, the CLIP2 gene regulatory network was reconstructed using global mRNA expression data from PTC patient samples. The genes comprising the first neighbourhood of CLIP2 (BAG2, CHST3, KIF3C, NEURL1, PPIL3 and RGS4) suggest the involvement of CLIP2 in the fundamental carcinogenic processes including apoptosis, mitogen-activated protein kinase signalling and genomic instability. In our study, we successfully developed and independently validated a workflow for the typing of PTC clinical samples into CLIP2-positive and CLIP2-negative and provided first insights into the CLIP2 interactome in the context of radiation-associated PTC.	[Selmansberger, M.; Michna, A.; Unger, K.; Zitzelsberger, H.; Hess, J.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Radiat Cytogenet, D-85764 Neuherberg, Germany; [Feuchtinger, A.; Walch, A.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Analyt Pathol, D-85764 Neuherberg, Germany; [Zurnadzhy, L.; Bogdanova, T.] Natl Acad Med Sci Ukraine, Inst Endocrinol & Metab, Kiev, Ukraine; [Kaiser, J. C.] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Radiat Protect, Neuherberg, Germany; [Abend, M.] Bundeswehr Inst Radiobiol, Munich, Germany; [Brenner, A.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Unger, K.; Zitzelsberger, H.; Hess, J.] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Clin Cooperat Grp Personalized Radiotherapy Head, D-85764 Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Hess, J (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Radiat Cytogenet, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	julia.hess@helmholtz-muenchen.de	Unger, Kristian/F-3730-2018; Walch, Axel/B-4554-2012	Unger, Kristian/0000-0002-0374-2320; Walch, Axel/0000-0001-5578-4023; Bogdanova, Tetiana/0000-0001-5119-0236	European Commission, EpiRadBio project, FP7 [269553]; European Commission, DoReMi project [249689]	European Commission, EpiRadBio project, FP7; European Commission, DoReMi project	We thank the International Pathology Panel of the Chernobyl Tissue Bank for confirmation of diagnosis: Professors A Abrosimov, TI Bogdanova, G Fadda, G Hant, V LiVolsi, J Rosai and ED Williams; The Chernobyl Tissue Bank for collection of thyroid tissue samples; Professor G Thomas for establishing the matched Genrisk-T cohort; Dr Peter Jacob for discussion and determination of the proportion of radiation-induced tumours among the exposed cases in the UkrAm cohort; U Buchholz, C Innerlohinger, E Konhauser, CM Pfluger and A Selmaier for technical support; and H Braselmann for mathematical/statistical support. This study was supported by the European Commission, EpiRadBio project, FP7 Grant No. 269553 and in part by the European Commission, DoReMi project, Grant No. 249689.	Abend M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039103; Arndt V, 2005, MOL BIOL CELL, V16, P5891, DOI 10.1091/mbc.E05-07-0660; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brenner AV, 2011, ENVIRON HEALTH PERSP, V119, P933, DOI 10.1289/ehp.1002674; Cardis E, 2011, CLIN ONCOL-UK, V23, P251, DOI 10.1016/j.clon.2011.01.510; Cardis E, 2006, J RADIOL PROT, V26, P127, DOI 10.1088/0952-4746/26/2/001; De S, 2009, CANCER RES, V69, P8035, DOI 10.1158/0008-5472.CAN-09-1224; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Ferrero GB, 2010, EUR J HUM GENET, V18, P33, DOI 10.1038/ejhg.2009.108; Fumoto K, 2006, EMBO J, V25, P5670, DOI 10.1038/sj.emboj.7601459; Galjart N, 2005, NAT REV MOL CELL BIO, V6, P487, DOI 10.1038/nrm1664; Rojo MG, 2009, FOLIA HISTOCHEM CYTO, V47, P349, DOI 10.2478/v10042-008-0114-4; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; Gray KA, 2013, NUCLEIC ACIDS RES, V41, pD545, DOI 10.1093/nar/gks1066; Grewal Thomas, 2011, Genes Cancer, V2, P288, DOI 10.1177/1947601911407330; Hamatani K, 2008, CANCER RES, V68, P7176, DOI 10.1158/0008-5472.CAN-08-0293; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hess J, 2011, P NATL ACAD SCI USA, V108, P9595, DOI 10.1073/pnas.1017137108; Hoogenraad CC, 2003, EMBO J, V22, P6004, DOI 10.1093/emboj/cdg592; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Hoogenraad CC, 2002, NAT GENET, V32, P116, DOI 10.1038/ng954; Hoogenraad SC, 2004, BIOESSAYS, V26, P141, DOI 10.1002/bies.10402; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Iizuka D, 2010, RADIAT RES, V174, P206, DOI 10.1667/RR2006.1; Ishida Y, 2010, CARCINOGENESIS, V31, P1694, DOI 10.1093/carcin/bgq145; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Klugbauer S, 1995, ONCOGENE, V11, P2459; Lansbergen G, 2004, J CELL BIOL, V166, P1003, DOI 10.1083/jcb.200402082; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Leeman-Neill RJ, 2013, CANCER-AM CANCER SOC, V119, P1792, DOI 10.1002/cncr.27893; Little MP, 2008, RADIAT ENVIRON BIOPH, V47, P39, DOI 10.1007/s00411-007-0150-z; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mandelkow E, 2002, TRENDS CELL BIOL, V12, P585, DOI 10.1016/S0962-8924(02)02400-5; Marchler-Bauer A, 2009, NUCLEIC ACIDS RES, V37, pD205, DOI 10.1093/nar/gkn845; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mullenders L, 2009, NAT REV CANCER, V9, P596, DOI 10.1038/nrc2677; Muresan V, 1998, MOL BIOL CELL, V9, P637, DOI 10.1091/mbc.9.3.637; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/modpathol.2008.10; Opgen-Rhein R, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-37; Pernot E, 2012, MUTAT RES-REV MUTAT, V751, P258, DOI 10.1016/j.mrrev.2012.05.003; Ricarte JC, 2013, J CLIN INVEST, V123, P4935, DOI 10.1172/JCI69766; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Strizzi L, 2009, CANCER RES, V69, P7131, DOI 10.1158/0008-5472.CAN-09-1199; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki Tsuyoshi, 2004, Brain Tumor Pathol, V21, P27, DOI 10.1007/BF02482174; Tanenbaum ME, 2006, EMBO J, V25, P45, DOI 10.1038/sj.emboj.7600916; Team RDC, 2013, R LANG ENV STAT COMP; Teider N, 2010, NEURO-ONCOLOGY, V12, P1244, DOI 10.1093/neuonc/noq091; Tronko M, 2012, J RADIOL PROT, V32, pN65, DOI 10.1088/0952-4746/32/1/N65; Tronko MD, 2006, JNCI-J NATL CANCER I, V98, P897, DOI 10.1093/jnci/djj244; Tuttle RM, 2011, CLIN ONCOL-UK, V23, P268, DOI 10.1016/j.clon.2011.01.178; Tuttle RM, 2008, THYROID, V18, P839, DOI 10.1089/thy.2008.0072; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Varga Z, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-615; Wang HQ, 2008, BRIT J PHARMACOL, V155, P655, DOI 10.1038/bjp.2008.302; Wieland G, 2004, MOL CELL BIOL, V24, P6620, DOI 10.1128/mcb.24.15.6620-6630.2004; Williams D, 2002, NAT REV CANCER, V2, P543, DOI 10.1038/nrc845; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Yamashita AS, 2013, TRANSL ONCOL, V6, P197, DOI 10.1593/tlo.12442; Yang XM, 2009, J BIOL CHEM, V284, P28775, DOI 10.1074/jbc.M109.017681	66	35	36	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3917	3925		10.1038/onc.2014.311	http://dx.doi.org/10.1038/onc.2014.311			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284583				2022-12-28	WOS:000358544200004
J	Zhao, D; Pan, C; Sun, J; Gilbert, C; Drews-Elger, K; Azzam, DJ; Picon-Ruiz, M; Kim, M; Ullmer, W; El-Ashry, D; Creighton, CJ; Slingerland, JM				Zhao, D.; Pan, C.; Sun, J.; Gilbert, C.; Drews-Elger, K.; Azzam, D. J.; Picon-Ruiz, M.; Kim, M.; Ullmer, W.; El-Ashry, D.; Creighton, C. J.; Slingerland, J. M.			VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2	ONCOGENE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; BREAST-CANCER; TUMOR-GROWTH; LUNG; SURVIVAL; PATHWAY; ANGIOGENESIS; METASTASIS; EXPRESSION; CAPACITY	Vascular endothelial growth factor-A (VEGF), a potent angiogenic factor, is also implicated in self-renewal in several normal tissue types. VEGF has been shown to drive malignant stem cells but mechanisms thereof and tumor types affected are not fully characterized. Here, we show VEGF promotes breast and lung cancer stem cell (CSC) self-renewal via VEGF receptor-2 (VEGFR-2)/STAT3-mediated upregulation of Myc and Sox2. VEGF increased tumor spheres and aldehyde dehydrogenase activity, both proxies for stem cell function in vitro, in triple-negative breast cancer (TNBC) lines and dissociated primary cancers, and in lung cancer lines. VEGF exposure before injection increased breast cancer-initiating cell abundance in vivo yielding increased orthotopic tumors, and increased metastasis from orthotopic primaries and following tail vein injection without further VEGF treatment. VEGF rapidly stimulated VEGFR-2/JAK2/STAT3 binding and activated STAT3 to bind MYC and SOX2 promoters and induce their expression. VEGFR-2 knockdown or inhibition abrogated VEGF-mediated STAT3 activation, MYC and SOX2 induction and sphere formation. Notably, knockdown of either STAT3, MYC or SOX2 impaired VEGF-upregulation of pSTAT3, MYC and SOX2 expression and sphere formation. Each transcription factor, once upregulated, appears to promote sustained activation of the others, creating a feed-forward loop to drive self-renewal. Thus, in addition to angiogenic effects, VEGF promotes tumor-initiating cell self-renewal through VEGFR-2/STAT3 signaling. Analysis of primary breast and lung cancers (>1300 each) showed high VEGF expression, was prognostic of poor outcome and strongly associated with STAT3 and MYC expression, supporting the link between VEGF and CSC self-renewal. High-VEGF tumors may be most likely to escape anti-angiogenics by upregulating VEGF, driving CSC self-renewal to re-populate post-treatment. Our work highlights the need to better define VEGF-driven cancer subsets and supports further investigation of combined therapeutic blockade of VEGF or VEGFR-2 and JAK2/STAT3.	[Zhao, D.; Pan, C.; Sun, J.; Gilbert, C.; Drews-Elger, K.; Azzam, D. J.; Picon-Ruiz, M.; Kim, M.; Ullmer, W.; El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Zhao, D.; El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Azzam, D. J.; Kim, M.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Creighton, C. J.] Baylor Coll Med, Div Biostat, Duncan Canc Ctr, Houston, TX 77030 USA	University of Miami; University of Miami; University of Miami; University of Miami; Baylor College of Medicine	Slingerland, JM (corresponding author), Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Zhao, Dekuang/H-5671-2015; Azzam, Diana/ABB-8342-2021; Ruiz, Manuel Picón/I-3624-2015	Zhao, Dekuang/0000-0002-7251-2481; Azzam, Diana/0000-0002-2605-8855; Ruiz, Manuel Picón/0000-0002-9427-0946; Drews-Elger, Katherine/0000-0001-9540-0610	Breast Cancer Research Foundation;  [P30 CA125123]; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Breast Cancer Research Foundation (JMS) and P30 CA125123 (CJC). We thank Fengju Chen for technical assistance. We also thank Dr Brekken (UT southwestern Medical Center) for providing VEGFR-2 blocking antibody 2C3.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Annovazzi L, 2011, CANCER GENOM PROTEOM, V8, P139; Assou S, 2007, STEM CELLS, V25, P961, DOI 10.1634/stemcells.2006-0352; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Boere IA, 2010, CANCER SCI, V101, P7, DOI 10.1111/j.1349-7006.2009.01369.x; Brekken RA, 2000, CANCER RES, V60, P5117; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Calvo CF, 2011, GENE DEV, V25, P831, DOI 10.1101/gad.615311; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Cao Y, 2007, J CLIN INVEST, V117, P2362, DOI 10.1172/JCI32239; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Deasy BM, 2009, MOL THER, V17, P1788, DOI 10.1038/mt.2009.136; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Feng XH, 2010, NAT REV MOL CELL BIO, V11, P466, DOI 10.1038/nrm2923; Folkins C, 2009, CANCER RES, V69, P7243, DOI 10.1158/0008-5472.CAN-09-0167; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Guo SC, 2010, BBA-REV CANCER, V1806, P108, DOI 10.1016/j.bbcan.2010.04.004; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Han H, 2001, ANN SURG ONCOL, V8, P72, DOI 10.1245/aso.2001.8.1.72; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Kane NM, 2011, PHARMACOL THERAPEUT, V129, P29, DOI 10.1016/j.pharmthera.2010.10.004; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miller Kathy D, 2003, Clin Breast Cancer, V3, P421, DOI 10.3816/CBC.2003.n.007; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mishra DK, 2014, INT J CANCER, V134, P789, DOI 10.1002/ijc.28428; Montero AJ, 2012, CURR ONCOL REP, V14, P1, DOI 10.1007/s11912-011-0202-z; Montero AJ, 2012, NEW ENGL J MED, V366, P374, DOI 10.1056/NEJMe1113368; Nair R, 2014, ONCOGENE, V33, P3992, DOI 10.1038/onc.2013.368; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nourse MB, 2010, ARTERIOSCL THROM VAS, V30, P80, DOI 10.1161/ATVBAHA.109.194233; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Ryden L, 2005, BREAST CANCER RES TR, V89, P135, DOI 10.1007/s10549-004-1655-7; Sakariassen PO, 2006, P NATL ACAD SCI USA, V103, P16466, DOI 10.1073/pnas.0607668103; Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tang JM, 2011, CARDIOVASC RES, V91, P402, DOI 10.1093/cvr/cvr053; Tanno S, 2004, LUNG CANCER, V46, P11, DOI 10.1016/j.lungcan.2004.03.006; Verseijden F, 2009, TISSUE ENG PT A, V15, P445, DOI 10.1089/ten.tea.2007.0429; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; Yang F, 2011, CANCER RES, V71, P5512, DOI 10.1158/0008-5472.CAN-10-2614; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591	73	165	179	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3107	3119		10.1038/onc.2014.257	http://dx.doi.org/10.1038/onc.2014.257			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25151964				2022-12-28	WOS:000356101100003
J	Zhang, X; Ma, W; Cui, J; Yao, H; Zhou, H; Ge, Y; Xiao, L; Hu, X; Liu, BH; Yang, J; Li, YY; Chen, S; Eaves, CJ; Wu, D; Zhao, Y				Zhang, X.; Ma, W.; Cui, J.; Yao, H.; Zhou, H.; Ge, Y.; Xiao, L.; Hu, X.; Liu, B-H; Yang, J.; Li, Y-Y; Chen, S.; Eaves, C. J.; Wu, D.; Zhao, Y.			Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ACUTE LYMPHOBLASTIC-LEUKEMIA; HELIX TRANSCRIPTION FACTOR; ADULT HEMATOPOIETIC STEM; SAETHRE-CHOTZEN SYNDROME; MYELODYSPLASTIC SYNDROMES; GENE-EXPRESSION; CELLS; PROTEIN; CANCER	TWIST2 has a dual function in tumors. Its implication in the initiation and metastasis of various solid tumors is well established, and its tumor-suppressor role in murine osteosarcoma cells has been reported recently. However, the function of TWIST2 and its underlying mechanisms in human normal and malignant hematopoiesis remain unclear. In the present study, we found that TWIST2 directly regulated p21 in human hematopoietic cells and whose silence promoted cell proliferation and cell cycle progression. Hypermethylation of TWIST2 occurred to 23 out of the 75 adult acute myeloid leukemia (AML) patients and resulted in the impaired expression of both TWIST2 and p21. Conversely, TWIST2 overexpression inhibited the growth of AML cells partially through its direct activation of p21 with intact HLH (helix-loop-helix) domain. The microarray data and gene expression validation showed that TWIST2 was sufficient to activate known tumor-suppressor genes, whereas suppress known oncogenes, which further supported its inhibitory effect against AML cells. Taken together, our data have identified a novel TWIST2-p21 axis that modulates the cell cycle of both normal and leukemic cells and demonstrated that the direct regulation of p21 by TWIST2 has a role in its tumor-suppressor function in AML.	[Zhang, X.; Ma, W.; Cui, J.; Yao, H.; Ge, Y.; Xiao, L.; Zhao, Y.] Soochow Univ, Cyrus Tang Hematol Ctr, Suzhou 215123, Jiangsu, Peoples R China; [Zhang, X.; Ma, W.; Chen, S.; Wu, D.; Zhao, Y.] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou 215123, Jiangsu, Peoples R China; [Cui, J.; Yao, H.; Zhou, H.; Hu, X.; Chen, S.; Wu, D.] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostatis, Suzhou 215123, Jiangsu, Peoples R China; [Liu, B-H; Yang, J.; Li, Y-Y] Shanghai Ctr Bioinformat Technol, Shanghai, Peoples R China; [Eaves, C. J.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	Soochow University - China; Soochow University - China; Soochow University - China; Chinese Academy of Sciences; British Columbia Cancer Agency	Wu, D (corresponding author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostatis, Suzhou 215123, Jiangsu, Peoples R China.	wudepei@medmail.com.cn; zhaoy@suda.edu.cn		, Yun/0000-0002-0065-4675; Eaves, Connie/0000-0002-3452-1926	National Natural Science Foundation of China [31170755]; National Key Scientific Project of China (973 Program) [2011CB933501]; Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [20113201120017]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Province's Key Medical Center [ZX201102]; National Public Health Grand Research Foundation [201202017]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Project of China (973 Program); Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Province's Key Medical Center; National Public Health Grand Research Foundation	This work was funded by National Natural Science Foundation of China (no. 31170755), National Key Scientific Project of China (973 Program no. 2011CB933501), Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP, no. 20113201120017), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Province's Key Medical Center (ZX201102) and National Public Health Grand Research Foundation (No. 201202017).	Ansieau S, 2010, ONCOGENE, V29, P3173, DOI 10.1038/onc.2010.92; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; APLAN PD, 1992, BLOOD, V79, P1327; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Cakouros D, 2012, MOL CELL BIOL, V32, P1433, DOI 10.1128/MCB.06315-11; Capron C, 2006, BLOOD, V107, P4678, DOI 10.1182/blood-2005-08-3145; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cosset E, 2011, BLOOD, V117, P1673, DOI 10.1182/blood-2009-11-254680; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; ElGhouzzi V, 1997, NAT GENET, V15, P42; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Fang X, 2011, ONCOGENE, V30, P4707, DOI 10.1038/onc.2011.181; Franco HL, 2011, NUCLEIC ACIDS RES, V39, P1177, DOI 10.1093/nar/gkq890; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Ishikawa T, 2013, CANCER SCI, V104, P880, DOI 10.1111/cas.12163; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kawagoe H, 2007, CANCER RES, V67, P10677, DOI 10.1158/0008-5472.CAN-07-1118; Kee BL, 2009, NAT REV IMMUNOL, V9, P175, DOI 10.1038/nri2507; Kennah E, 2009, BLOOD, V113, P4646, DOI 10.1182/blood-2008-08-174037; Kim MS, 2013, MOL CELLS, V36, P177, DOI 10.1007/s10059-013-0061-6; Ko J, 2008, P NATL ACAD SCI USA, V105, P12967, DOI 10.1073/pnas.0805073105; Li X, 2013, HAEMATOLOGICA, V98, P414, DOI 10.3324/haematol.2012.071753; Li XA, 2010, BLOOD, V116, P2304, DOI 10.1182/blood-2009-09-242313; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu JH, 2004, LEUKEMIA LYMPHOMA, V45, P2419, DOI 10.1080/10428190400003317; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meng YS, 2005, LEUKEMIA, V19, P1941, DOI 10.1038/sj.leu.2403836; Nagel S, 2007, BLOOD, V109, P3015, DOI 10.1182/blood-2006-08-044347; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Piccinin S, 2012, CANCER CELL, V22, P404, DOI 10.1016/j.ccr.2012.08.003; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Raval A, 2005, J CLIN ONCOL, V23, P3877, DOI 10.1200/JCO.2005.02.196; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sandmann T, 2007, GENE DEV, V21, P436, DOI 10.1101/gad.1509007; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Souroullas GP, 2009, CELL STEM CELL, V4, P180, DOI 10.1016/j.stem.2009.01.001; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thathia SH, 2012, HAEMATOL-HEMATOL J, V97, P371, DOI 10.3324/haematol.2011.049593; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Tukel T, 2010, AM J HUM GENET, V87, P289, DOI 10.1016/j.ajhg.2010.07.009; Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845; Wang M, 2009, LEUKEMIA, V23, P1320, DOI 10.1038/leu.2009.19; Yang DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023965; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yin B, 2009, BLOOD, V113, P1075, DOI 10.1182/blood-2008-03-144436; Zhang WQ, 2014, BIOMATERIALS, V35, P567, DOI 10.1016/j.biomaterials.2013.09.102; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhou HX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086195	57	20	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3000	3010		10.1038/onc.2014.241	http://dx.doi.org/10.1038/onc.2014.241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088197				2022-12-28	WOS:000356100500006
J	Ennen, M; Keime, C; Kobi, D; Mengus, G; Lipsker, D; Thibault-Carpentier, C; Davidson, I				Ennen, M.; Keime, C.; Kobi, D.; Mengus, G.; Lipsker, D.; Thibault-Carpentier, C.; Davidson, I.			Single-cell gene expression signatures reveal melanoma cell heterogeneity	ONCOGENE			English	Article							MITF TRANSCRIPTION FACTORS; MALIGNANT-MELANOMA; INITIATING CELLS; PHENOTYPE; RESISTANCE; IDENTIFICATION; MELANOGENESIS; PATHWAY; SWITCH; STATES	It is well established that tumours are not homogenous, but comprise cells with differing invasive, proliferative and tumourinitiating potential. A major challenge in cancer research is therefore to develop methods to characterize cell heterogeneity. In melanoma, proliferative and invasive cells are characterized by distinct gene expression profiles and accumulating evidence suggests that cells can alternate between these states through a process called phenotype switching. We have used microfluidic technology to isolate single melanoma cells grown in vitro as monolayers or melanospheres or in vivo as xenografted tumours and analyse the expression profiles of 114 genes that discriminate the proliferative and invasive states by quantitative PCR. Single-cell analysis accurately recapitulates the specific gene expression programmes of melanoma cell lines and defines subpopulations with distinct expression profiles. Cell heterogeneity is augmented when cells are grown as spheres and as xenografted tumours. Correlative analysis identifies gene-regulatory networks and changes in gene expression under different growth conditions. In tumours, subpopulations of cells that express specific invasion and drug resistance markers can be identified amongst which is the pluripotency factor POUF51 (OCT4) whose expression correlates with the tumorigenic potential. We therefore show that single-cell analysis can be used to define and quantify tumour heterogeneity based on detection of cells with specific gene expression profiles.	[Ennen, M.; Keime, C.; Kobi, D.; Mengus, G.; Lipsker, D.; Thibault-Carpentier, C.; Davidson, I.] CNRS INSERM UDS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; [Lipsker, D.] Hop Univ Strasbourg, Hop Civil, Fac Med, Strasbourg, France; [Lipsker, D.] Hop Univ Strasbourg, Hop Civil, Serv Dermatol, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), CNRS INSERM UDS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	irwin@igbmc.fr		Thibault-Carpentier, Christelle/0000-0003-1562-1451; Lipsker, Dan/0000-0003-4675-0336; Davidson, Irwin/0000-0001-5533-1171; MENGUS, Gabrielle/0000-0002-2844-1778; KEIME, Celine/0000-0001-7604-3814	Centre National de la Recherche Scientifique; Institut National de Sante et de la Recherche Medicale; Universite de Strasbourg; Association pour la Recherche contre le Cancer; Ligue Nationale contre le Cancer; Institut National du Cancer PAIR-melanoma grant; French state fund through the Agence Nationale de la Recherche [ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02]	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de Sante et de la Recherche Medicale; Universite de Strasbourg; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer PAIR-melanoma grant; French state fund through the Agence Nationale de la Recherche(French National Research Agency (ANR))	We thank D Dembele for help with data analysis, all the staff of the IGBMC common facilities, as well as F Kardouz and the staff of the Strasbourg Hospital Dermatology Clinic, This work was supported by institutional grants from the Centre National de la Recherche Scientifique, the Institut National de Sante et de la Recherche Medicale, the Universite de Strasbourg, the Association pour la Recherche contre le Cancer, the Ligue Nationale contre le Cancer, the Institut National du Cancer PAIR-melanoma grant, the ANR-10-LABX-0030-INRT French state fund through the Agence Nationale de la Recherche under the frame programme Investissements d'Avenir labelled ANR-10-IDEX-0002-02. The IGBMC high throughput sequencing facility is a member of the 'France Genomique' consortium (ANR10-INBS-09-08). ID is an 'equipe labellisee' of the Ligue Nationale contre le Cancer. ME was supported by a fellowship from the Ligue Nationale contre le Cancer.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Castro FV, 2012, CANCER IMMUNOL IMMUN, V61, P1005, DOI 10.1007/s00262-011-1167-3; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Chen KG, 2009, PIGM CELL MELANOMA R, V22, P740, DOI 10.1111/j.1755-148X.2009.00630.x; Chiaverini C, 2008, J BIOL CHEM, V283, P12635, DOI 10.1074/jbc.M800130200; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Haass NK, 2014, PIGM CELL MELANOMA R, DOI [10.1111/pcmr.12274, DOI 10.1111/PCMR.12274)]; Herquel B, 2013, NAT STRUCT MOL BIOL, V20, P339, DOI 10.1038/nsmb.2496; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liu SH, 2008, PIGM CELL MELANOMA R, V21, P545, DOI 10.1111/j.1755-148X.2008.00484.x; McDavid A, 2013, BIOINFORMATICS, V29, P461, DOI 10.1093/bioinformatics/bts714; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Perez-Lorenzo R, 2014, J INVEST DERMATOL, V134, P1359, DOI 10.1038/jid.2013.511; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Somasundaram R, 2012, ADV PHARMACOL, V65, P335, DOI 10.1016/B978-0-12-397927-8.00011-7; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Thies A, 2002, J CLIN ONCOL, V20, P2530, DOI 10.1200/JCO.2002.05.033; Thurber AE, 2011, ONCOGENE, V30, P3036, DOI 10.1038/onc.2011.33; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x	31	60	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3251	3263		10.1038/onc.2014.262	http://dx.doi.org/10.1038/onc.2014.262			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132268				2022-12-28	WOS:000356592300004
J	Watnick, RS; Rodriguez, RK; Wang, S; Blois, AL; Rangarajan, A; Ince, T; Weinberg, RA				Watnick, R. S.; Rodriguez, R. K.; Wang, S.; Blois, A. L.; Rangarajan, A.; Ince, T.; Weinberg, R. A.			Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; LARGE T-ANTIGEN; C-MYC ONCOGENE; PROTEIN-KINASE; TUMOR ANGIOGENESIS; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CANCER CELLS; FACTOR-I	Tumor-associated angiogenesis is postulated to be regulated by the balance between pro- and anti-angiogenic factors. We demonstrate here that the critical step in establishing the angiogenic capability of human tumor cells is the repression of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1). This repression is essential for tumor formation by mammary epithelial cells and kidney cells engineered to express SV40 early region proteins, hTERT, and H-RasV12. In transformed epithelial cells, a signaling pathway leading from Ras to Tsp-1 repression induces the sequential activation of PI3 kinase, Rho and ROCK, leading to activation of Myc through phosphorylation, thereby enabling Myc to repress Tsp-1 transcription. In transformed fibroblasts, however, the repression of Tsp-1 can be achieved by an alternative mechanism involving inactivation of both p53 and pRb. We thus describe novel mechanisms by which the activation of oncogenes in epithelial cells and the inactivation of tumor suppressors in fibroblasts permits angiogenesis and, in turn, tumor formation.	[Watnick, R. S.; Rodriguez, R. K.; Wang, S.; Blois, A. L.] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA; [Watnick, R. S.; Rodriguez, R. K.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Watnick, R. S.; Rangarajan, A.; Ince, T.; Weinberg, R. A.] Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; [Rodriguez, R. K.; Weinberg, R. A.] MIT, Dept Biol, Cambridge, MA USA; [Blois, A. L.] Univ Bergen, Fac Med, Dept Clin Med, Ctr Canc Biomarkers CCBIO, Bergen, Norway	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Bergen	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, Whitehead Inst, Biol, 9 Cambridge Ctr, Cambridge, MA 02139 USA.	Weinberg@wi.mit.edu		Ince, Tan/0000-0003-0315-6425	NIH/NCI [5 R01CA78461]; Merck/MIT; Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA078461] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Merck/MIT(Merck & Company); Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Richard O Hynes, Dr Alan Hall, Dr Michael Detmar, Dr Yoshiyuki Kuchino and Dr James DiCaprio for reagents. We would like to thank Drs Ittai Ben-Porath, Scott Dessain, Lisa Spirio, Sendurai Mani and Sheila Stewart for useful discussions. This work was supported by NIH/NCI grant 5 R01CA78461 and Merck/MIT to RAW. We also thank the Damon Runyon Cancer Research Foundation for post-doctoral support to RSW.	Adhikary S, 2003, MOL CELL BIOL, V23, P7648, DOI 10.1128/MCB.23.21.7648-7657.2003; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; Beachy TM, 2002, J VIROL, V76, P3145, DOI 10.1128/JVI.76.7.3145-3157.2002; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burger P, 2012, BLOOD, V119, P5512, DOI 10.1182/blood-2011-10-386805; Cardone RA, 2005, MOL BIOL CELL, V16, P3117, DOI 10.1091/mbc.e04-10-0945; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; Che XM, 1998, ANN SURG ONCOL, V5, P585, DOI 10.1007/BF02303826; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; DUBIK D, 1987, CANCER RES, V47, P6517; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fleming JB, 2005, MOL CANCER RES, V3, P413, DOI 10.1158/1541-7786.MCR-04-0206; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Guo NH, 1997, CANCER RES, V57, P1735; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He ZQ, 2003, J BIOL CHEM, V278, P26435, DOI 10.1074/jbc.M303859200; Heighway J, 1996, GENOMICS, V35, P207, DOI 10.1006/geno.1996.0340; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JANOCKO LE, 1995, CYTOMETRY, V21, P18, DOI 10.1002/cyto.990210106; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Leung T, 1996, MOL CELL BIOL, V16, P5313; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li YZ, 2013, CELL MOL IMMUNOL, V10, P506, DOI 10.1038/cmi.2013.32; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Martin-Manso G, 2008, CANCER RES, V68, P7090, DOI 10.1158/0008-5472.CAN-08-0643; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mizukami Y, 2006, J BIOL CHEM, V281, P13957, DOI 10.1074/jbc.M511763200; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Nagy A, 2001, ANTICANCER RES, V21, P1321; Naito T, 2004, AM J PHYSIOL-RENAL, V286, pF278, DOI 10.1152/ajprenal.00139.2003; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; OLIVE PL, 1992, INT J RADIAT ONCOL, V22, P397, DOI 10.1016/0360-3016(92)90840-E; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ou Y C, 1998, Zhonghua Yi Xue Za Zhi (Taipei), V61, P441; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PRIVES C, 1979, COLD SPRING HARB SYM, V44, P123, DOI 10.1101/SQB.1980.044.01.014; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, CANCER RES, V60, P490; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ribatti D, 1998, INT J CANCER, V77, P449; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sauzeau V, 2010, ONCOGENE, V29, P3781, DOI 10.1038/onc.2010.134; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; SESHADRI R, 1989, INT J CANCER, V43, P270, DOI 10.1002/ijc.2910430218; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENK TE, 1976, J VIROL, V18, P664, DOI 10.1128/JVI.18.2.664-671.1976; SHENK TE, 1976, P NATL ACAD SCI USA, V73, P1513, DOI 10.1073/pnas.73.5.1513; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; SINGHAL RL, 1994, LIFE SCI, V55, P1487, DOI 10.1016/0024-3205(94)00690-3; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Venkatesha S, 2006, MOL CANCER RES, V4, P821, DOI 10.1158/1541-7786.MCR-06-0110; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLCKAERT G, 1979, J VIROL, V30, P674, DOI 10.1128/JVI.30.3.674-682.1979; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Weng LP, 1999, CANCER RES, V59, P5808; White E, 2003, GENE DEV, V17, P1813, DOI 10.1101/gad.1123103; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wojta J, 1999, LAB INVEST, V79, P427; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	119	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2823	2835		10.1038/onc.2014.228	http://dx.doi.org/10.1038/onc.2014.228			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25109329	Green Accepted			2022-12-28	WOS:000355324300002
J	Lin, L; Huang, H; Liao, W; Ma, H; Liu, J; Wang, L; Huang, N; Liao, Y; Liao, W				Lin, L.; Huang, H.; Liao, W.; Ma, H.; Liu, J.; Wang, L.; Huang, N.; Liao, Y.; Liao, W.			MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect	ONCOGENE			English	Article							CELL-SURVIVAL; TUMOR-GROWTH; GLUCOSE DEPRIVATION; METASTASIS; KINASE; COLON; MET; DEHYDROGENASE; MITOCHONDRIA; PROGRESSION	Cancer cells mainly metabolize by glycolysis (the Warburg effect) and are better adapted to resist metabolic stress. Metastasis-associated in colon cancer-1 (MACC1) is an oncogene promoting gastric cancer (GC) growth and metastasis, and its expression positively correlates with GC progression. However, it is unknown why MACC1 elevates with GC progression and what is its role in cancer metabolism. In this study, we discovered that MACC1 expression was significantly upregulated via adenosine monophosphate-activated protein kinase signaling in response to glucose deprivation-induced metabolic stress. Clinical observation demonstrates that MACC1 expression was higher in advanced stage GC. MACC1 expression was proved to be positively correlated with the maximum standardized uptake value of F-18-deoxyglucose in the patients, and MACC1 enhanced F-18-deoxyglucose uptake in GC cells and the xenografts. The underlying mechanism was that MACC1 promoted the Warburg effect by upregulating the activities and expressions of a series of glycolytic enzymes, including hexokinase, pyruvate dehydrogenase kinase and lactate dehydrogenase, in GC cells. This metabolic shift enhanced cell viability and resistance to apoptosis by facilitating ATP generation, reducing the reactive oxygen species production and stabilizing the mitochondrial membrane potential. In contrast, MACC1-silenced or the Warburg effect-blocked GC cells were more vulnerable to metabolic stress. In conclusion, metabolic stress is one of the mechanisms that elevate MACC1 expression in GC, and MACC1 upregulation compensatively ensures GC growth against metabolic stress by facilitating the Warburg effect.	[Lin, L.; Huang, H.; Liao, W.; Ma, H.; Liu, J.; Wang, L.; Huang, N.; Liao, W.] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Liao, Y.] Southern Med Univ, Nanfang Hosp, Dept Cardiol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Liao, W (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China.	nfyyliaowj@163.com	Liao, Yulin/AAP-6315-2021	Lin, Li/0000-0002-9719-4539; Wangjun, Liao/0000-0002-1364-8442	National Natural Science Foundation of China [31271564]; Guangzhou science and technology plan [134600108]; Team Program of Natural Science Foundation of Guangdong Province [S2011030003134]; Special Foundation for National Clinical Specialties of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou science and technology plan; Team Program of Natural Science Foundation of Guangdong Province; Special Foundation for National Clinical Specialties of China	This work was supported by the National Natural Science Foundation of China (31271564 to WL), Guangzhou science and technology plan (134600108 to WL), the Team Program of Natural Science Foundation of Guangdong Province (S2011030003134 to WL and YL) and the Special Foundation for National Clinical Specialties of China (to Department of Oncology, Nanfang Hospital). We thank Professor Quanshi Wang and Professor Hubing Wu for helping clinical PET data acquisition, Dr Yanjiang Han for assistance with microPET, Professor Zhenhua Ding for assistance with gamma-radiation activity monitor and Jingwen Zhang for language editing. QW, HW and YH are from PET Center, JZ is from Department of Cardiology, Nanfang Hospital and ZD is from Department of Radiation Medicine, School of Public Health and Tropical Medicine, Southern Medical University.	Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Galimi F, 2011, CLIN CANCER RES, V17, P3146, DOI 10.1158/1078-0432.CCR-10-3377; Gao M, 2014, ONCOGENE, V33, P745, DOI 10.1038/onc.2013.2; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huber AL, 2013, MOL CELL, V49, P1049, DOI 10.1016/j.molcel.2013.01.009; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Keller KE, 2012, SCIENCE, V338, P1069, DOI 10.1126/science.1224409; Kokoszynska K, 2009, ACTA BIOCHIM POL, V56, P317; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li GQ, 2014, CANCER CELL, V25, P455, DOI 10.1016/j.ccr.2014.02.007; Meng FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060821; Mimeault M, 2013, MOL ASPECTS MED, DOI DOI 10.1016/J.MAM.2013.2008.2001; Miniotis MF, 2013, CANCER RES, V73, P4039, DOI 10.1158/0008-5472.CAN-12-1969; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pate KT, 2014, EMBO J; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Wang G, 2012, ONCOL LETT, V4, P783, DOI 10.3892/ol.2012.784; Wang L, 2013, INT J CANCER, V133, P1419, DOI 10.1002/ijc.28140; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wu CA, 2013, BBA-MOL CELL RES, V1833, P1147, DOI 10.1016/j.bbamcr.2013.01.025; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Xie C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064235; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211; Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303	32	57	61	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2700	2710		10.1038/onc.2014.204	http://dx.doi.org/10.1038/onc.2014.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043301				2022-12-28	WOS:000354979500003
J	Park, JT; Johnson, N; Liu, S; Levesque, M; Wang, YJ; Ho, H; Huso, D; Maitra, A; Parsons, MJ; Prescott, JD; Leach, SD				Park, J. T.; Johnson, N.; Liu, S.; Levesque, M.; Wang, Y. J.; Ho, H.; Huso, D.; Maitra, A.; Parsons, M. J.; Prescott, J. D.; Leach, S. D.			Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey	ONCOGENE			English	Article							K-RAS CODON-12; ZEBRAFISH; CANCER; INDUCTION; NEOPLASIA; ONCOGENES; ABLATION; TUMORS; MICE	Somatic activation of the KRAS proto-oncogene is evident in almost all pancreatic cancers, and appears to represent an initiating event. These mutations occur primarily at codon 12 and less frequently at codons 13 and 61. Although some studies have suggested that different KRAS mutations may have variable oncogenic properties, to date there has been no comprehensive functional comparison of multiple KRAS mutations in an in vivo vertebrate tumorigenesis system. We generated a Gal4/UAS-based zebrafish model of pancreatic tumorigenesis in which the pancreatic expression of UAS-regulated oncogenes is driven by a ptf1a: Gal4-VP16 driver line. This system allowed us to rapidly compare the ability of 12 different KRAS mutations (G12A, G12C, G12D, G12F, G12R, G12S, G12V, G13C, G13D, Q61L, Q61R and A146T) to drive pancreatic tumorigenesis in vivo. Among fish injected with one of five KRAS mutations reported in other tumor types but not in human pancreatic cancer, 2/79 (2.5%) developed pancreatic tumors, with both tumors arising in fish injected with A146T. In contrast, among fish injected with one of seven KRAS mutations known to occur in human pancreatic cancer, 22/106 (20.8%) developed pancreatic cancer. All eight tumorigenic KRAS mutations were associated with downstream MAPK/ERK pathway activation in preneoplastic pancreatic epithelium, whereas nontumorigenic mutations were not. These results suggest that the spectrum of KRAS mutations observed in human pancreatic cancer reflects selection based on variable tumorigenic capacities, including the ability to activate MAPK/ERK signaling.	[Park, J. T.; Johnson, N.; Liu, S.; Levesque, M.; Parsons, M. J.; Prescott, J. D.; Leach, S. D.] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; [Wang, Y. J.; Parsons, M. J.; Leach, S. D.] Johns Hopkins Med Inst, Grad Program Human Genet, Baltimore, MD 21205 USA; [Ho, H.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Huso, D.] Johns Hopkins Med Inst, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA; [Parsons, M. J.; Leach, S. D.] Johns Hopkins Med Inst, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Leach, SD (corresponding author), Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, 1275 York Ave,Box 20, New York, NY 10065 USA.	leachs@mskcc.org	Wang, Julia/M-4516-2016	Wang, Julia/0000-0003-2641-6904	NCI [P01 CA134292]; Paul K Neumann Professorship in Pancreatic Cancer at Johns Hopkins University; NATIONAL CANCER INSTITUTE [P01CA134292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Paul K Neumann Professorship in Pancreatic Cancer at Johns Hopkins University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Mary Chico, Mara Swaim, Anzer Habibullah and Frazer Matthews for expert administrative and technical support. This work was supported by NCI P01 CA134292. SDL was further supported by the Paul K Neumann Professorship in Pancreatic Cancer at Johns Hopkins University.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Auer TO, 2014, GENOME RES, V24, P142, DOI 10.1101/gr.161638.113; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Charbel C, 2014, J INVEST DERMATOL, V134, P1067, DOI 10.1038/jid.2013.429; Davison JM, 2007, DEV BIOL, V304, P811, DOI 10.1016/j.ydbio.2007.01.033; Er TK, 2014, CANCER LETT, V343, P1, DOI 10.1016/j.canlet.2013.09.012; Fukahori M, 2012, THYROID, V22, P683, DOI 10.1089/thy.2011.0261; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerrero S, 2000, CANCER RES, V60, P6750; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hu G, 2011, DEV DYNAM, V240, P2101, DOI 10.1002/dvdy.22699; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Krasinskas AM, 2013, MODERN PATHOL, V26, P1346, DOI 10.1038/modpathol.2013.71; Kraus MC, 2006, INT J ONCOL, V29, P957; Leach SD, 2009, ZEBRAFISH, V6, P317, DOI 10.1089/zeb.2009.9988; Martin P, 2013, J THORAC ONCOL, V8, P530, DOI 10.1097/JTO.0b013e318283d958; Morelli MP, 2012, J CLIN ONCOL, V30, P3565, DOI 10.1200/JCO.2012.43.6535; Mosimann C, 2013, DEV DYNAM, V242, P949, DOI 10.1002/dvdy.23989; Parikh C, 2006, BLOOD, V108, P2349, DOI 10.1182/blood-2004-08-009498; Park SW, 2008, GASTROENTEROLOGY, V134, P2080, DOI 10.1053/j.gastro.2008.02.084; Pisharath Harshan, 2009, V546, P133, DOI 10.1007/978-1-60327-977-2_9; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Roberts JA, 2014, DEVELOPMENT, V141, P715, DOI 10.1242/dev.100347; Yen J, 2014, CURR OPIN GENET DEV, V24, P38, DOI 10.1016/j.gde.2013.11.003; Yoo J, 2000, ARCH PATHOL LAB MED, V124, P836; Zu Y, 2013, NAT METHODS, V10, P329, DOI 10.1038/NMETH.2374	26	27	27	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2801	2806		10.1038/onc.2014.223	http://dx.doi.org/10.1038/onc.2014.223			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065594	Green Accepted			2022-12-28	WOS:000354979500012
J	Pritchett, TL; Bader, HL; Henderson, J; Hsu, T				Pritchett, T. L.; Bader, H. L.; Henderson, J.; Hsu, T.			Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; MODIFYING GENES; IMAGE-ANALYSIS; URETERAL BUD; CANCER; EXPRESSION; PROTEIN; HYPOXIA; DISEASE; MUTATION	Mutations of the tumor suppressor gene von Hippel-Lindau (VHL) can lead to benign and malignant tumors, including clear-cell renal cell carcinoma (ccRCC). To understand the progression of ccRCC, we generated a novel mouse Vhlh conditional knockout, using Hoxb7-driven Cre that is specific for the collecting ducts and a subset of distal tubules. These mice exhibited wide-spread epithelial disruption and interstitial inflammation as early as 2 months of age with high penetrance. Lesions are cystic, show severe fibrosis and display significant hyperplasia. An abundance of infiltrating macrophages and lymphocytes was detected. Interestingly, the Vhlh mutant lesions could be rescued when Hif-1 alpha, but not Hif-2 alpha, was also knocked out. In addition, administration of a JAK1/2 kinase inhibitor alleviated the Vhlh knockout phenotypes. Taken together, these results suggest that HIF-1 alpha-dependent inflammation and fibrosis may be an early event in the development of ccRCC.	[Pritchett, T. L.; Bader, H. L.; Henderson, J.; Hsu, T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Henderson, J.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Hsu, T.] Natl Cent Univ, Inst Syst Biol & Bioinformat, Jhongli 32001, Taiwan	Boston University; Boston University; National Central University	Hsu, T (corresponding author), Boston Univ, Sch Med, Hematol Oncol Sect, 650 Albany St,EBRC 440, Boston, MA 02118 USA.	tienh@bu.edu		Hsu, Tien/0000-0003-2308-4297; Pritchett, Tracy/0000-0002-3336-9336	National Institutes of Health, USA [R01CA109860, T32HL007501]; NATIONAL CANCER INSTITUTE [R01CA109860] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007501] Funding Source: NIH RePORTER	National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Paraffin embedding and sectioning were performed at the Immunohistochemistry Core of Boston Medical Center. We thank Richard Near (the Boston University School of Medicine) for technical support and Weining Lu (the Boston University School of Medicine) for a gift of the Hoxb7-Cre-EGFP mouse strain. This work was supported by a grant to TH from the National Institutes of Health, USA (#R01CA109860) and a postdoctoral fellowship to HLB from the National Institutes of Health, USA (#T32HL007501).	An JB, 2005, MOL CELL BIOL, V25, P7546, DOI 10.1128/MCB.25.17.7546-7556.2005; Becker LC, 2005, CIRC RES, V96, P812, DOI 10.1161/01.RES.0000165652.82726.d9; Brukamp K, 2007, AM J PHYSIOL-RENAL, V293, pF1397, DOI 10.1152/ajprenal.00133.2007; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Frew IJ, 2008, MOL CELL BIOL, V28, P4536, DOI 10.1128/MCB.02132-07; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Ibragimova I, 2013, EPIGENETICS-US, V8, P486, DOI 10.4161/epi.24552; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Khurana KK, 1998, MODERN PATHOL, V11, P339; Kim Nayoung, 2013, Genomics & Informatics, V11, P239, DOI 10.5808/GI.2013.11.4.239; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kimura K, 2008, AM J PHYSIOL-RENAL, V295, pF1023, DOI 10.1152/ajprenal.90209.2008; Kramann R, 2013, J PATHOL, V231, P273, DOI 10.1002/path.4253; Kraus S, 2002, HUM PATHOL, V33, P60, DOI 10.1053/hupa.2002.29682; Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006; Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035; Larkin J, 2012, NAT REV UROL, V9, P147, DOI 10.1038/nrurol.2011.236; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martelli F, 2005, BLOOD, V106, P4102, DOI 10.1182/blood-2005-03-1060; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Nakagawa Naoki, 2013, Curr Pathobiol Rep, V1, DOI 10.1007/s40139-013-0025-8; Ozcan A, 2009, AM J CLIN PATHOL, V131, P393, DOI 10.1309/AJCPM7DW0XFHDHNY; Perrier S, 2006, FEBS LETT, V580, P6289, DOI 10.1016/j.febslet.2006.10.061; Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ries C, 2014, CELL MOL LIFE SCI, V71, P659, DOI 10.1007/s00018-013-1457-3; Schietke RE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031034; Shay JES, 2012, SEMIN CELL DEV BIOL, V23, P389, DOI 10.1016/j.semcdb.2012.04.004; Shen SS, 2005, MODERN PATHOL, V18, P933, DOI 10.1038/modpathol.3800373; Srinivas S, 1999, DEV GENET, V24, P241; Steenhard BM, 2010, AM J PATHOL, V177, P84, DOI 10.2353/ajpath.2010.090767; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wadleigh Martha, 2010, Clin Adv Hematol Oncol, V8, P557; Wu KL, 2007, AM J PHYSIOL-RENAL, V293, pF1836, DOI 10.1152/ajprenal.00096.2007; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yoshida N, 2002, BRIT J CANCER, V86, P1396, DOI 10.1038/sj.bjc.6600257; Yu J, 2002, DEVELOPMENT, V129, P5301; Zhao HT, 2004, DEV BIOL, V276, P403, DOI 10.1016/j.ydbio.2004.09.002	53	36	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2631	2639		10.1038/onc.2014.197	http://dx.doi.org/10.1038/onc.2014.197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023703				2022-12-28	WOS:000354541300009
J	Condello, S; Morgan, CA; Nagdas, S; Cao, L; Turek, J; Hurley, TD; Matei, D				Condello, S.; Morgan, C. A.; Nagdas, S.; Cao, L.; Turek, J.; Hurley, T. D.; Matei, D.			beta-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids	ONCOGENE			English	Article							STEM-CELL PHENOTYPE; PROTEIN EXPRESSION; WNT/BETA-CATENIN; GENE-EXPRESSION; IN-VITRO; ALDEHYDE DEHYDROGENASE; SIGNALING PATHWAYS; EPITHELIAL-CELLS; RESISTANCE; MONOLAYER	Cancer cells form three-dimensional (3D) multicellular aggregates (or spheroids) under non-adherent culture conditions. In ovarian cancer (OC), spheroids serve as a vehicle for cancer cell dissemination in the peritoneal cavity, protecting cells from environmental stress-induced anoikis. To identify new targetable molecules in OC spheroids, we investigated gene expression profiles and networks upregulated in 3D vs traditional monolayer culture conditions. We identified ALDH1A1, a cancer stem cell marker as being overexpressed in OC spheroids and directly connected to key elements of the beta-catenin pathway. beta-Catenin function and ALDH1A1 expression were increased in OC spheroids vs monolayers and in successive spheroid generations, suggesting that 3D aggregates are enriched in cells with stem cell characteristics. beta-Catenin knockdown decreased ALDH1A1 expression levels and beta-catenin co-immunoprecipitated with the ALDH1A1 promoter, suggesting that ALDH1A1 is a direct beta-catenin target. Both short interfering RNA-mediated beta-catenin knockdown and A37 ((ethyl-2-((4-oxo-3-(3-(pryrrolidin-1-yl) propyl)-3,4-dihydrobenzo [4,5]thioeno [3,2-d] pyrimidin-2-yl) thio) acetate)), a novel ALDH1A1 small-molecule enzymatic inhibitor described here for the first time, disrupted OC spheroid formation and cell viability (P<0.001). beta-Catenin knockdown blocked tumor growth and peritoneal metastasis in an OC xenograft model. These data strongly support the role of beta-catenin-regulated ALDH1A1 in the maintenance of OC spheroids and propose new ALDH1A1 inhibitors targeting this cell population.	[Condello, S.; Cao, L.; Matei, D.] Indiana Univ, Dept Med, Indianapolis, IN USA; [Morgan, C. A.; Hurley, T. D.; Matei, D.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Nagdas, S.] Univ Virginia, Sch Med, Indianapolis, IN USA; [Turek, J.] Purdue Univ, Coll Vet Med, Indianapolis, IN USA; [Hurley, T. D.; Matei, D.] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; [Matei, D.] Indiana Univ Sch Med, VA Roudebush Hosp, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Virginia; Purdue University System; Purdue University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Hurley, TD (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, MS-4019, Indianapolis, IN 46202 USA.	thurley@iu.edu; dmatei@iu.edu	Condello, Salvatore/ABB-6743-2021	Condello, Salvatore/0000-0003-4979-3681; Matei, Daniela/0000-0003-2169-5035; HURLEY, THOMAS/0000-0002-5942-1163	US Department of Veterans Affairs; NIH [R01-AA018123, R01EB016582]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB016582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA018123] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Dr Jeanette McClintick from the Indiana University Center for Medical Genomics, Dr Malgorzata Kamocha from IBCM and Dr Chirayu Goswami from the Bioinformatics Core for technical assistance. This work was made possible by funding from the US Department of Veterans Affairs to DM and from NIH to TDH (R01-AA018123), DM and JT (R01EB016582).	Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Barbone D, 2008, J BIOL CHEM, V283, P13021, DOI 10.1074/jbc.M709698200; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Cai C, 2012, MOL MED REP, V5, P1191, DOI 10.3892/mmr.2012.802; Camper SA, 2011, P NATL ACAD SCI USA, V108, P11303, DOI 10.1073/pnas.1108275108; Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429; Chang TT, 2009, TISSUE ENG PT A, V15, P559, DOI 10.1089/ten.tea.2007.0434; Chau WK, 2013, ONCOGENE, V32, P2767, DOI 10.1038/onc.2012.290; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cody NAL, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-34; Condello S, 2013, FASEB J, V27, P3100, DOI 10.1096/fj.12-222620; David L, 2008, ACTA BIOMATER, V4, P256, DOI 10.1016/j.actbio.2007.08.012; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Frankel A, 1997, CANCER RES, V57, P2388; Gaedtke L, 2007, J PROTEOME RES, V6, P4111, DOI 10.1021/pr0700596; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Jackson Brian, 2011, Human Genomics, V5, P283; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; L'Esperance S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-99; Lawrenson K, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-43; Lee JM, 2013, LAB INVEST, V93, P528, DOI 10.1038/labinvest.2013.41; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Parajuli B, 2011, CHEM-BIOL INTERACT, V191, P153, DOI 10.1016/j.cbi.2011.02.018; Park SH, 2008, MOL ENDOCRINOL, V22, P2085, DOI 10.1210/me.2007-0512; Pierre-Louis O, 2009, STEM CELLS, V27, P2552, DOI 10.1002/stem.186; Poland J, 2002, ELECTROPHORESIS, V23, P1174, DOI 10.1002/1522-2683(200204)23:7/8<1174::AID-ELPS1174>3.0.CO;2-O; Puiffe ML, 2007, NEOPLASIA, V9, P820, DOI 10.1593/neo.07472; Ray A, 2011, INT J ONCOL, V39, P797, DOI 10.3892/ijo.2011.1093; Reuben JM, 2011, EUR J CANCER, V47, P1527, DOI 10.1016/j.ejca.2011.01.011; Serebriiskii I, 2008, MATRIX BIOL, V27, P573, DOI 10.1016/j.matbio.2008.02.008; Shank JJ, 2012, GYNECOL ONCOL, V127, P390, DOI 10.1016/j.ygyno.2012.07.115; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Song XQ, 2003, DEVELOPMENT, V130, P3259, DOI 10.1242/dev.00524; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sumi T, 2008, DEVELOPMENT, V135, P2969, DOI 10.1242/dev.021121; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Weiswald LB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-106; Yasuda K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068187; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	54	117	119	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2297	2308		10.1038/onc.2014.178	http://dx.doi.org/10.1038/onc.2014.178			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954508	Green Accepted, Green Submitted			2022-12-28	WOS:000353824800003
J	Liang, W; Miao, S; Zhang, B; He, S; Shou, C; Manivel, P; Krishna, R; Chen, Y; Shi, YE				Liang, W.; Miao, S.; Zhang, B.; He, S.; Shou, C.; Manivel, P.; Krishna, R.; Chen, Y.; Shi, Y. E.			Synuclein gamma protects Akt and mTOR and renders tumor resistance to Hsp90 disruption	ONCOGENE			English	Article							BREAST-CANCER CELLS; ENDOPLASMIC-RETICULUM STRESS; ESTROGEN-RECEPTOR; INDUCED APOPTOSIS; ALPHA-SYNUCLEIN; TYROSINE KINASE; UP-REGULATION; CHAPERONE; GENE; METASTASIS	Heat shock protein (Hsp)90 regulates many key pathways in oncogenesis, including Akt and mammalian target of rapamycin (mTOR). The strengths of disruption of Hsp90 in cancer therapy include their versatility in inhibiting a wide range of oncogenic pathways. The present study demonstrated that synuclein. (SNCG) protects the functions of Akt and mTOR in the condition when the function of Hsp90 is blocked. Disruption of Hsp90 abolished Akt activity and mTOR signaling. However, expression of SNCG restored Akt activity and mTOR signaling. SNCG bound to Akt and mTOR in the presence and absence of Hsp90. Specifically, the C-terminal (Gln106-Asp127) of SNCG bound to the loop connecting alpha C helix and beta 4 sheet of the kinase domain of Akt. SNCG renders resistance to 17-AAG-induced apoptosis both in vitro and in tumor xenograft. A clinical follow-up study indicates that patients with an SNCG-positive breast cancer have a significantly shorter disease-free survival and overall survival than patients with SNCG-negative tumors. The present study indicates that SNCG protects Hsp90 client proteins of Akt and mTOR, and renders drug resistance to Hsp90 disruption.	[Liang, W.; Miao, S.; Zhang, B.; He, S.; Shi, Y. E.] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China; [Shou, C.] Peking Univ, Beijing Canc Hosp & Inst, Sch Oncol, Beijing 100871, Peoples R China; [Manivel, P.; Krishna, R.] Pondicherry Univ, Sch Life Sci, Ctr Bioinformat, Pondicherry, India; [Chen, Y.] Zhejiang Univ, Sch Med, Womens Hosp, Dept Surg, Hangzhou 310006, Zhejiang, Peoples R China; [Shi, Y. E.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Peking University; Pondicherry University; Zhejiang University; Nanjing Medical University	Shi, YE (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China.	chenyiding@gmail.com; daweieric@gmail.com	Panneerselvam, Manivel/M-5453-2013	Panneerselvam, Manivel/0000-0002-5831-8404	State Key Program of National Natural Science Foundation of China [81230054, 91029739]; National Key Technology R&D Program for the 12th Five-year Plan of China [2013BAI01B06]; State Key Laboratory of Reproductive Medicine; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	State Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technology R&D Program for the 12th Five-year Plan of China(National Key Technology R&D Program); State Key Laboratory of Reproductive Medicine; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This study was supported in part by grants 81230054 and 91029739 from the State Key Program of National Natural Science Foundation of China; a grant from the National Key Technology R&D Program for the 12th Five-year Plan of China (2013BAI01B06); and a grant from the State Key Laboratory of Reproductive Medicine, and a Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Bonvini P, 2002, CANCER RES, V62, P1559; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Caldas-Lopes E, 2009, P NATL ACAD SCI USA, V106, P8368, DOI 10.1073/pnas.0903392106; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Czekierdowski A, 2006, NEUROENDOCRINOL LETT, V27, P381; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Fung KM, 2003, ACTA NEUROPATHOL, V106, P167, DOI 10.1007/s00401-003-0718-x; Gaspar N, 2009, CANCER RES, V69, P1966, DOI 10.1158/0008-5472.CAN-08-3131; Guo J, 2007, INT J CANCER, V121, P1296, DOI 10.1002/ijc.22763; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Hibi T, 2009, CLIN CANCER RES, V15, P2864, DOI 10.1158/1078-0432.CCR-08-2946; Hu H, 2009, CLIN CANCER RES, V15, P5485, DOI 10.1158/1078-0432.CCR-08-2491; Hua H, 2009, J PATHOL, V217, P507, DOI 10.1002/path.2465; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; Iwaki H, 2004, CANCER SCI, V95, P955, DOI 10.1111/j.1349-7006.2004.tb03183.x; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Jiang YF, 2003, CANCER RES, V63, P3899; Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650; Li ZK, 2004, CANCER-AM CANCER SOC, V101, P58, DOI 10.1002/cncr.20321; Liu CY, 2008, CANCER LETT, V269, P148, DOI 10.1016/j.canlet.2008.04.037; Liu CY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-359; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu YE, 2007, ONCOGENE, V26, P2115, DOI 10.1038/sj.onc.1210000; Manivel P, 2011, J MOL MODEL, V17, P251, DOI 10.1007/s00894-010-0718-4; McCollum AK, 2006, CANCER RES, V66, P10967, DOI 10.1158/0008-5472.CAN-06-1629; Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y; Nimmanapalli R, 2001, CANCER RES, V61, P1799; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Okawa Y, 2009, BLOOD, V113, P846, DOI 10.1182/blood-2008-04-151928; Pan ZZ, 2006, INT J ONCOL, V29, P1201; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Shi YE, 2010, AM J PATHOL, V177, P964, DOI 10.2353/ajpath.2010.100061; Singh VK, 2007, CANCER RES, V67, P626, DOI 10.1158/0008-5472.CAN-06-1820; Solit DB, 2003, CANCER RES, V63, P2139; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Taiyab A, 2009, BIOCHEM PHARMACOL, V78, P142, DOI 10.1016/j.bcp.2009.04.001; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhao W, 2006, INT J ONCOL, V28, P1081	48	19	21	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2398	2405		10.1038/onc.2014.126	http://dx.doi.org/10.1038/onc.2014.126			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954510				2022-12-28	WOS:000353824800012
J	Weigel, C; Schmezer, P; Plass, C; Popanda, O				Weigel, C.; Schmezer, P.; Plass, C.; Popanda, O.			Epigenetics in radiation-induced fibrosis	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE INHIBITORS; DNA METHYLATION CHANGES; GROWTH-FACTOR; TGF-BETA; PROMOTER HYPERMETHYLATION; OXIDATIVE STRESS; MYOFIBROBLAST DIFFERENTIATION; FIBROBLAST ACTIVATION; MOLECULAR-MECHANISMS	Radiotherapy is a major cancer treatment option but dose-limiting side effects such as late-onset fibrosis in the irradiated tissue severely impair quality of life in cancer survivors. Efforts to explain radiation-induced fibrosis, for example, by genetic variation remained largely inconclusive. Recently published molecular analyses on radiation response and fibrogenesis showed a prominent role of epigenetic gene regulation. This review summarizes the current knowledge on epigenetic modifications in fibrotic disease and radiation response, and it points out the important role for epigenetic mechanisms such as DNA methylation, microRNAs and histone modifications in the development of this disease. The synopsis illustrates the complexity of radiation-induced fibrosis and reveals the need for investigations to further unravel its molecular mechanisms. Importantly, epigenetic changes are long-term determinants of gene expression and can therefore support those mechanisms that induce and perpetuate fibrogenesis even in the absence of the initial damaging stimulus. Future work must comprise the interconnection of acute radiation response and long-lasting epigenetic effects in order to assess their role in late-onset radiation fibrosis. An improved understanding of the underlying biology is fundamental to better comprehend the origin of this disease and to improve both preventive and therapeutic strategies.	[Weigel, C.; Schmezer, P.; Plass, C.; Popanda, O.] German Canc Res Ctr, Dept Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Popanda, O (corresponding author), German Canc Res Ctr, Dept Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	o.popanda@dkfz.de	Popanda, Odilia/P-6917-2019		Deutsche Krebshilfe [109394]; Helmholtz International Graduation School for Cancer Research	Deutsche Krebshilfe(Deutsche Krebshilfe); Helmholtz International Graduation School for Cancer Research	We apologize to all researchers whose relevant contributions were not cited due to space limitations. This work was supported by a grant from the Deutsche Krebshilfe, project number 109394. CW holds a stipend from the Helmholtz International Graduation School for Cancer Research.	Abderrahmani R, 2009, INT J RADIAT ONCOL, V74, P942, DOI 10.1016/j.ijrobp.2009.01.077; Abrass CK, 2011, AM J PHYSIOL-RENAL, V300, pF531, DOI 10.1152/ajprenal.00237.2010; Alimova I, 2013, NEURO-ONCOLOGY, V15, P149, DOI 10.1093/neuonc/nos285; Almeida C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053628; Amundson SA, 2003, ONCOGENE, V22, P5828, DOI 10.1038/sj.onc.1206681; Andreassen CN, 2009, RADIOTHER ONCOL, V92, P299, DOI 10.1016/j.radonc.2009.06.015; Antwih DA, 2013, EPIGENETICS-US, V8, P839, DOI 10.4161/epi.25498; Ao XP, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-6; Armstrong CA, 2012, EPIGENETICS-US, V7, P892, DOI 10.4161/epi.21094; Arora H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023802; Asuthkar S, 2012, ONCOTARGET, V3, P1439; Balli D, 2013, EMBO J, V32, P231, DOI 10.1038/emboj.2012.336; Bauersachs J, 2010, J CARDIOVASC PHARM, V56, P454, DOI 10.1097/FJC.0b013e3181ee81df; Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135; Bernardo BC, 2012, P NATL ACAD SCI USA, V109, P17615, DOI 10.1073/pnas.1206432109; Bhattacharyya S, 2005, ARTHRITIS RHEUM-US, V52, P1248, DOI 10.1002/art.20996; Bian EB, 2013, TOXICOLOGY, V309, P9, DOI 10.1016/j.tox.2013.04.008; Bian EB, 2012, TOXICOL APPL PHARM, V264, P13, DOI 10.1016/j.taap.2012.06.022; Bielefeld KA, 2013, CELL MOL LIFE SCI, V70, P2059, DOI 10.1007/s00018-012-1152-9; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bowen T, 2013, J PATHOL, V229, P274, DOI 10.1002/path.4119; Chailleux C, 2010, BIOCHEM J, V426, P365, DOI 10.1042/BJ20091329; Chang-Claude J, 2009, BRIT J CANCER, V100, P1680, DOI 10.1038/sj.bjc.6605036; Chaudhry MA, 2012, DNA CELL BIOL, V31, P908, DOI 10.1089/dna.2011.1509; Cheresh P, 2013, BBA-MOL BASIS DIS, V1832, P1028, DOI 10.1016/j.bbadis.2012.11.021; Chernikova SB, 2010, RADIAT RES, V174, P558, DOI 10.1667/RR2184.1; Chung YL, 2004, MOL CANCER THER, V3, P317; Cisneros J, 2012, AM J PHYSIOL-LUNG C, V303, pL295, DOI 10.1152/ajplung.00332.2011; Coppes RP, 2009, SEMIN RADIAT ONCOL, V19, P112, DOI 10.1016/j.semradonc.2008.11.005; Dai Y, 2013, HYPERTENSION, V61, P751, DOI 10.1161/HYPERTENSIONAHA.111.00654; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Daugherity EK, 2012, CELL CYCLE, V11, P1918, DOI 10.4161/cc.20259; De Schutter H, 2009, INT J RADIAT ONCOL, V73, P904, DOI 10.1016/j.ijrobp.2008.10.032; Dees C, 2014, ANN RHEUM DIS, V73, P1232, DOI 10.1136/annrheumdis-2012-203194; Dickey JS, 2011, RADIAT ENVIRON BIOPH, V50, P491, DOI 10.1007/s00411-011-0386-5; Dickey JS, 2009, CARCINOGENESIS, V30, P1686, DOI 10.1093/carcin/bgp192; Dong QH, 2011, J INVEST DERMATOL, V131, P1216, DOI 10.1038/jid.2011.11; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; FitzGerald J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014714; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Fujii H, 2012, J GASTROENTEROL, V47, P215, DOI 10.1007/s00535-012-0527-x; Gaugler MH, 2005, RADIAT RES, V163, P479, DOI 10.1667/RR3302; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; Ghosh AK, 2007, J CELL PHYSIOL, V213, P663, DOI 10.1002/jcp.21162; Goodarzi AA, 2011, NAT STRUCT MOL BIOL, V18, P831, DOI 10.1038/nsmb.2077; Gottlober P, 2001, INT J RADIAT ONCOL, V50, P159, DOI 10.1016/S0360-3016(00)01542-X; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo CY, 2000, CANCER RES, V60, P5667; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Haase MG, 2008, RADIAT RES, V169, P531, DOI 10.1667/RR0946.1; Hamama S, 2012, RADIOTHER ONCOL, V105, P305, DOI 10.1016/j.radonc.2012.08.023; Haydont V, 2008, AM J PHYSIOL-CELL PH, V294, pC1332, DOI 10.1152/ajpcell.90626.2007; He Y, 2012, CELL SIGNAL, V24, P2268, DOI 10.1016/j.cellsig.2012.07.023; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Hofstetter B, 2010, INT J RADIAT ONCOL, V76, P1512, DOI 10.1016/j.ijrobp.2009.10.037; Hromas R, 2012, ONCOGENE, V31, P4245, DOI 10.1038/onc.2011.586; Hu B, 2011, AM J PATHOL, V178, P1500, DOI 10.1016/j.ajpath.2011.01.002; Hu B, 2010, AM J PATHOL, V177, P21, DOI 10.2353/ajpath.2010.090999; Hu SY, 2009, INT J RADIAT ONCOL, V75, P1537, DOI 10.1016/j.ijrobp.2009.07.1697; Huang N, 2012, BIOCHEM BIOPH RES CO, V422, P697, DOI 10.1016/j.bbrc.2012.05.061; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Imaeda M, J RADIAT RES, DOI [10.1093/jrr/rru005, DOI 10.1093/JRR/RRU005)]; Jiang X, 2010, FEBS J, V277, P2015, DOI 10.1111/j.1742-4658.2010.07632.x; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Kalash R, 2014, IN VIVO, V28, P147; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kaup S, 2006, MUTAT RES-FUND MOL M, V597, P87, DOI 10.1016/j.mrfmmm.2005.06.032; Khan S, 2004, ONCOGENE, V23, P6040, DOI 10.1038/sj.onc.1207824; Kim EH, 2010, ONCOGENE, V29, P4725, DOI 10.1038/onc.2010.223; Kim IG, 2014, BIOCHEM BIOPH RES CO, V443, P49, DOI 10.1016/j.bbrc.2013.11.038; Kis E, 2006, INT J RADIAT ONCOL, V66, P1506, DOI 10.1016/j.ijrobp.2006.08.004; Ko YA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r108; Komatsu Y, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-5; Koturbash I, 2006, ONCOGENE, V25, P4267, DOI 10.1038/sj.onc.1209467; Koturbash I, 2007, CARCINOGENESIS, V28, P1831, DOI 10.1093/carcin/bgm053; Koturbash I, 2006, INT J RADIAT ONCOL, V66, P327, DOI 10.1016/j.ijrobp.2006.06.012; Kramer M, 2013, ANN RHEUM DIS, V72, P614, DOI 10.1136/annrheumdis-2012-201615; Krenning G, 2010, J CELL PHYSIOL, V225, P631, DOI 10.1002/jcp.22322; Kruse JJCM, 2009, RADIAT RES, V171, P188, DOI 10.1667/RR1526.1; Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048; Kumar A, 2011, INT J RADIAT BIOL, V87, P1086, DOI 10.3109/09553002.2011.605417; Lahtz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044858; Lakner AM, 2012, HEPATOLOGY, V56, P300, DOI 10.1002/hep.25613; Li CG, 1999, INT J CANCER, V84, P155, DOI 10.1002/(SICI)1097-0215(19990420)84:2<155::AID-IJC11>3.0.CO;2-S; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10; Linard C, 2008, J PHARMACOL EXP THER, V324, P911, DOI 10.1124/jpet.107.129122; Liu DG, 2008, CHINESE MED J-PEKING, V121, P1925, DOI 10.1097/00029330-200810010-00014; Malik IA, 2010, AM J PATHOL, V176, P1801, DOI 10.2353/ajpath.2010.090505; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Mancuso M, 2008, P NATL ACAD SCI USA, V105, P12445, DOI 10.1073/pnas.0804186105; Mann J, 2010, GASTROENTEROLOGY, V138, P705, DOI 10.1053/j.gastro.2009.10.002; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Milliat F, 2006, AM J PATHOL, V169, P1484, DOI 10.2353/ajpath.2006.060116; Moding EJ, 2013, NAT REV DRUG DISCOV, V12, P526, DOI 10.1038/nrd4003; Moriconi F, 2008, RADIAT RES, V169, P162, DOI 10.1667/RR1006.1; Mothersill Carmel, 2012, Frontiers in Genetics, V3, P74, DOI 10.3389/fgene.2012.00074; Nadlonek NA, 2012, J THORAC CARDIOV SUR, V144, P1466, DOI 10.1016/j.jtcvs.2012.08.041; Nawroth I, 2013, ACTA ONCOL, V52, P1730, DOI 10.3109/0284186X.2012.726373; Nguyen AT, 2011, GENE DEV, V25, P263, DOI 10.1101/gad.2018511; Niemantsverdriet M, 2010, RADIOTHER ONCOL, V97, P33, DOI 10.1016/j.radonc.2010.04.002; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Oliva J, 2009, WORLD J GASTROENTERO, V15, P705, DOI 10.3748/wjg.15.705; Ostrau C, 2009, RADIOTHER ONCOL, V92, P492, DOI 10.1016/j.radonc.2009.06.020; Pandit KV, 2011, TRANSL RES, V157, P191, DOI 10.1016/j.trsl.2011.01.012; Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641; Patel V, 2012, CURR OPIN NEPHROL HY, V21, P410, DOI 10.1097/MNH.0b013e328354e559; Penicud K, 2014, ONCOGENE, V33, P525, DOI 10.1038/onc.2012.597; Perugorria MJ, 2012, HEPATOLOGY, V56, P1129, DOI 10.1002/hep.25754; Pogrlbny I, 2005, MOL CANCER RES, V3, P553, DOI 10.1158/1541-7786.MCR-05-0074; Pohlers D, 2009, BBA-MOL BASIS DIS, V1792, P746, DOI 10.1016/j.bbadis.2009.06.004; Polistena A, 2011, J SURG RES, V167, pE137, DOI 10.1016/j.jss.2010.12.031; Popanda O, 2009, MUTAT RES-FUND MOL M, V667, P58, DOI 10.1016/j.mrfmmm.2008.10.014; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Prunotto M, 2012, J PATHOL, V228, P131, DOI 10.1002/path.4049; Purrucker JC, 2010, ONCOL REP, V23, P263, DOI 10.3892/or_00000632; Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC; Qin L, 2010, AM J PATHOL, V177, P1915, DOI 10.2353/ajpath.2010.100011; Rabinovich EI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033770; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Rave-Frank M, 2013, RADIAT ENVIRON BIOPH, V52, P321, DOI 10.1007/s00411-013-0468-7; Rivera AL, 2010, NEURO-ONCOLOGY, V12, P116, DOI 10.1093/neuonc/nop020; Roderburg C, 2011, HEPATOLOGY, V53, P209, DOI 10.1002/hep.23922; Rossetto D, 2010, CLIN CANCER RES, V16, P4543, DOI 10.1158/1078-0432.CCR-10-0513; Rugo RE, 2011, ONCOGENE, V30, P751, DOI 10.1038/onc.2010.480; Ruiz-Ortega M, 2007, CARDIOVASC RES, V74, P196, DOI 10.1016/j.cardiores.2007.02.008; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Sanders YY, 2008, AM J RESP CELL MOL, V39, P610, DOI 10.1165/rcmb.2007-0322OC; Sanders YY, 2012, AM J RESP CRIT CARE, V186, P525, DOI 10.1164/rccm.201201-0077OC; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Sequeira-Lopez MLS, 2010, J AM SOC NEPHROL, V21, P460, DOI 10.1681/ASN.2009090964; Shan B, 2003, J BIOL CHEM, V278, P44009, DOI 10.1074/jbc.M302671200; Sharma GG, 2010, MOL CELL BIOL, V30, P3582, DOI 10.1128/MCB.01476-09; Shintani S, 2010, INT J ORAL MAX SURG, V39, P1115, DOI 10.1016/j.ijom.2010.02.027; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Simon M, 2006, ONCOL REP, V16, P127; Skalicka ZF, 2012, J PHOTOCH PHOTOBIO B, V117, P111, DOI 10.1016/j.jphotobiol.2012.08.009; Sparfel L, 2010, TOXICOL SCI, V114, P247, DOI 10.1093/toxsci/kfq007; Sperk E, 2012, BREAST CANCER RES TR, V135, P253, DOI 10.1007/s10549-012-2168-4; Srivastava SP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/125469; STONE HB, 1984, INT J RADIAT ONCOL, V10, P1053, DOI 10.1016/0360-3016(84)90177-9; Sun CY, 2012, KIDNEY INT, V81, P640, DOI 10.1038/ki.2011.445; Sun GD, 2010, J AM SOC NEPHROL, V21, P2069, DOI 10.1681/ASN.2010060633; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tampe B, 2014, J AM SOC NEPHROL, V25, P905, DOI 10.1681/ASN.2013070723; Tang XY, 2013, MOL PHARMACOL, V83, P283, DOI 10.1124/mol.112.081661; Tao H, 2011, TOXICOLOGY, V290, P327, DOI 10.1016/j.tox.2011.10.011; Thariat J, 2013, NAT REV CLIN ONCOL, V10, P52, DOI 10.1038/nrclinonc.2012.203; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; Veldwijk MR, 2009, STRAHLENTHER ONKOL, V185, P517, DOI 10.1007/s00066-009-1973-0; Volkmann I, 2013, CIRC RES, V113, P997, DOI 10.1161/CIRCRESAHA.113.301702; Wang YQ, 2006, ARTHRITIS RHEUM-US, V54, P2271, DOI 10.1002/art.21948; Weichenhan D, 2013, HUM MOL GENET, V22, pR1, DOI 10.1093/hmg/ddt348; Westbury CB, 2012, CLIN ONCOL-UK, V24, P657, DOI 10.1016/j.clon.2012.04.001; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu CH, 2012, J BIOL CHEM, V287, P25292, DOI 10.1074/jbc.M111.291195; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xiao CY, 2012, J BIOL CHEM, V287, P41903, DOI 10.1074/jbc.M112.415182; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Xu B, 2012, AM J PHYSIOL-LUNG C, V303, pL89, DOI 10.1152/ajplung.00060.2012; Yang JJ, 2013, CELL SIGNAL, V25, P1202, DOI 10.1016/j.cellsig.2013.01.005; Yarnold J, 2010, RADIOTHER ONCOL, V97, P149, DOI 10.1016/j.radonc.2010.09.002; Zager RA, 2009, AM J PHYSIOL-RENAL, V296, pF1032, DOI 10.1152/ajprenal.00061.2009; Zeisberg EM, 2013, J PATHOL, V229, P264, DOI 10.1002/path.4120; Zeybel M, 2012, NAT MED, V18, P1369, DOI 10.1038/nm.2893; Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024680; Zhang Y, 2010, INT J RADIAT BIOL, V86, P964, DOI 10.3109/09553002.2010.496032; Zhao LQ, 2013, CELL SIGNAL, V25, P1625, DOI 10.1016/j.cellsig.2013.04.004; Zhao WL, 2009, CURR MED CHEM, V16, P130, DOI 10.2174/092986709787002790; Zhu FL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074535; Zhu NL, 2012, J BIOL CHEM, V287, P10355, DOI 10.1074/jbc.M111.312751; Zvaifler NJ, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1963	183	57	60	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2145	2155		10.1038/onc.2014.145	http://dx.doi.org/10.1038/onc.2014.145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909163				2022-12-28	WOS:000353473000001
J	Wu, DW; Hsu, NY; Wang, YC; Lee, MC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Hsu, N-Y; Wang, Y-C; Lee, M-C; Cheng, Y-W; Chen, C-Y; Lee, H.			c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT	ONCOGENE			English	Article							NF-KAPPA-B; DNA METHYLTRANSFERASES; ABERRANT METHYLATION; PROTEIN EXPRESSION; ALLELIC DELETION; CHRONIC SMOKERS; DOWN-REGULATION; GENE; CARCINOMA; APOPTOSIS	The dual role of the microRNA-29 (miR-29) family in tumor progression and metastasis in solid tumors has been reported. Evidence for the role of miR-29 in tumor malignancy and its prognostic value in overall survival (OS) and relapse-free survival (RFS) in non-small cell lung cancer (NSCLC) remains conflicting. Mechanistic studies presented herein demonstrated that c-Myc suppressed the expression of miR-29b, promoting soft agar growth and invasion capability in lung cancer cells. Interestingly, the decrease in the expression of miR-29b by c-Myc is responsible for soft agar growth and invasiveness mediated by FHIT loss due to promoter methylation. Among patients, low expression of miR-29b and FHIT was more common in tumors with high c-Myc expression than in tumors with low c-Myc expression. Kaplan-Meier and Cox regression analysis showed that tumors with high c-Myc, low miR-29b and low FHIT expression had shorter OS and RFS periods than their counterparts. In conclusion, the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in NSCLC. Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.	[Wu, D-W; Hsu, N-Y; Cheng, Y-W; Lee, H.] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 115, Taiwan; [Wang, Y-C] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Wang, Y-C] Chung Shan Med Univ Hosp, Dept Chest Med, Taichung 40201, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Thorac Surg, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Taichung Veterans General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Room 5,12th Floor,3,Pk St, Taipei 115, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council(100-2314-B-038-043-MY3) of Taiwan, ROC.	Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; Burke L, 1998, CANCER RES, V58, P2533; Butler D, 2000, J PATHOL, V192, P502, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH718&gt;3.0.CO;2-H; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Kim JS, 2004, CARCINOGENESIS, V25, P2165, DOI 10.1093/carcin/bgh217; Kim JS, 2006, CANCER RES, V66, P4049, DOI 10.1158/0008-5472.CAN-05-3813; Kong GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019518; Kristensen LS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn113; Lee YC, 2004, BRIT J CANCER, V90, P2378, DOI 10.1038/sj.bjc.6601778; Li Y, 2011, J PATHOL, V224, P484, DOI 10.1002/path.2873; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Napoli C, 2002, NEOPLASIA, V4, P185, DOI 10.1038/sj.neo.7900232; Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720; Pavelic K, 2001, MOL MED, V7, P442, DOI 10.1007/BF03401849; Plaisier CL, 2012, GENOME RES, V22, P2302, DOI 10.1101/gr.133991.111; Pylkkanen L, 2002, INT J ONCOL, V20, P285; Robson S, 2006, RECENT PAT ANTI-CANC, V1, P305, DOI 10.2174/157489206778776934; Rothschild SI, 2012, ONCOGENE, V31, P4221, DOI 10.1038/onc.2011.578; Tomizawa Y, 1998, CANCER RES, V58, P5478; Treppendahl MB, 2012, BLOOD, V119, P206, DOI 10.1182/blood-2011-06-362541; Tseng JE, 1999, CANCER RES, V59, P4798; Wang J, 2006, CANCER LETT, V235, P18, DOI 10.1016/j.canlet.2005.03.058; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu MF, 2005, INT J CANCER, V113, P440, DOI 10.1002/ijc.20597; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380; Xu M, 2010, J VIROL, V84, P11461, DOI 10.1128/JVI.00538-10; Yoon SO, 2007, HUM PATHOL, V38, P326, DOI 10.1016/j.humpath.2006.08.012; Yu PN, 2014, INT J CANCER, V134, P542, DOI 10.1002/ijc.28399; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	41	62	68	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2072	2082		10.1038/onc.2014.152	http://dx.doi.org/10.1038/onc.2014.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909176				2022-12-28	WOS:000353173400007
J	Li, JJ; Xie, D				Li, J-J; Xie, D.			RACK1, a versatile hub in cancer	ONCOGENE			English	Review							PROTEIN-KINASE-C; RECEPTOR-INTERACTING PROTEIN; HEPATOCELLULAR-CARCINOMA; TYROSINE-PHOSPHATASE; SCAFFOLD PROTEIN; BINDING-PROTEIN; DOWN-REGULATION; CELL-MIGRATION; BETA-SUBUNIT; INTERFERON RECEPTOR	RACK1 is a highly conserved intracellular adaptor protein with significant homology to G beta and was originally identified as the anchoring protein for activated protein kinase C. In the past 20 years, the number of binding partners and validated cellular functions for RACK1 has increased, which facilitates clarification of its involvement in different biological events. In this review, we will focus on its role in cancer, summarizing its aberrant expression, pro- or anti-oncogenic effects and the underlying mechanisms in various cancers.	[Li, J-J; Xie, D.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Ctr Canc Res, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Xie, D (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Hong Kong New World Joint Lab, Shanghai 200031, Peoples R China.	dxie@sibs.ac.cn		Xie, Dong/0000-0002-1150-8657	National Basic Research Program of China [2010CB912102]; Ministry of Science and Technology Key Program [2012ZX10002009-017]; National Natural Science Foundation of China [81230058, 30930023, 31100551, 31201046, 81021002]; CAS/SAFEA International Partnership Program for Creative Research Teams, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences [SIBS2012004]; Technology Commission of Shanghai Municipality [12XD1405600]; Young Scientist Fund of National Science Foundation of China [31201046]; Sanofi-Aventis-Sibs Scholarship Program	National Basic Research Program of China(National Basic Research Program of China); Ministry of Science and Technology Key Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAS/SAFEA International Partnership Program for Creative Research Teams, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Young Scientist Fund of National Science Foundation of China; Sanofi-Aventis-Sibs Scholarship Program	This work was supported by the National Basic Research Program of China (2010CB912102), Ministry of Science and Technology Key Program (2012ZX10002009-017), the National Natural Science Foundation of China (81230058, 30930023, 31100551, 31201046, 81021002), CAS/SAFEA International Partnership Program for Creative Research Teams, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (SIBS2012004) and Technology Commission of Shanghai Municipality (12XD1405600) to DX. This work was also supported by the Young Scientist Fund of National Science Foundation of China (31201046) and Sanofi-Aventis-Sibs Scholarship Program (2011) to J-JL.	Al-Reefy S, 2010, BREAST CANCER RES TR, V123, P911, DOI 10.1007/s10549-010-1020-y; Baum S, 2004, BIOCHEM J, V380, P823, DOI 10.1042/BJ20031962; Belozerov VE, 2014, MOL CELL BIOL, V34, P474, DOI 10.1128/MCB.00824-13; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Bird RJ, 2010, BIOCHEM J, V432, P207, DOI 10.1042/BJ20101010; Boner W, 2002, VIRUS RES, V90, P113, DOI 10.1016/S0168-1702(02)00145-4; Buensuceso CS, 2005, J BIOL CHEM, V280, P644, DOI 10.1074/jbc.M410229200; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Cao XR, 2010, DISCRETE EVENT DYN S, V20, P1, DOI 10.1007/s10626-010-0088-1; Cao XX, 2011, BREAST CANCER RES TR, V126, P555, DOI 10.1007/s10549-010-0955-3; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Choi DS, 2003, MOL PHARMACOL, V64, P1541, DOI 10.1124/mol.64.6.1541; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Daniels CC, 2008, VIROLOGY, V375, P550, DOI 10.1016/j.virol.2008.01.034; Dave JM, 2013, J BIOL CHEM, V288, P30720, DOI 10.1074/jbc.M113.512467; Deng YZ, 2012, GASTROENTEROLOGY, V142, P812, DOI 10.1053/j.gastro.2011.12.046; Feng C, 2012, J BIOL CHEM, V287, P10714, DOI 10.1074/jbc.M111.299594; Gallina A, 2001, VIROLOGY, V283, P7, DOI 10.1006/viro.2001.0855; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; Guo YY, 2013, HEPATOLOGY, V57, P140, DOI 10.1002/hep.25978; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; He X, 2011, ONCOGENE, V30, P535, DOI 10.1038/onc.2010.427; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hu FQ, 2013, TUMOR BIOL, V34, P3893, DOI 10.1007/s13277-013-0977-7; Ikebuchi Y, 2010, DRUG METAB DISPOS, V38, P2320, DOI 10.1124/dmd.110.034603; Ikebuchi Y, 2009, HEPATOL RES, V39, P1091, DOI 10.1111/j.1872-034X.2009.00544.x; Isacson CK, 2007, AM J PHYSIOL-CELL PH, V292, pC1459, DOI 10.1152/ajpcell.00322.2006; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Kubota T, 2002, J VIROL, V76, P12676, DOI 10.1128/JVI.76.24.12676-12682.2002; Lacombe J, 2013, INT J CANCER, V132, P1105, DOI 10.1002/ijc.27766; Lee HS, 2002, OSTEOARTHR CARTILAGE, V10, P890, DOI 10.1053/joca.2002.0842; Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675; Li J, 2012, J CANCER RES CLIN, V138, P563, DOI 10.1007/s00432-011-1097-7; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lu F, 2012, ONCOL REP, V27, P1646, DOI 10.3892/or.2012.1629; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Mamidipudi V, 2009, ONCOGENE, V28, P4421, DOI 10.1038/onc.2009.293; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Nagashio R, 2010, LUNG CANCER, V69, P54, DOI 10.1016/j.lungcan.2009.09.015; Peng RJ, 2013, ONCOL REP, V30, P2195, DOI 10.3892/or.2013.2723; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Seidl P, 2002, INT J CANCER, V102, P129, DOI 10.1002/ijc.10675; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Serrels B, 2010, CURR BIOL, V20, P1086, DOI 10.1016/j.cub.2010.04.042; Severino A, 2004, J CELL PHYSIOL, V199, P134, DOI 10.1002/jcp.10448; Shi S, 2012, J BIOL CHEM, V287, P7845, DOI 10.1074/jbc.M111.315416; Shor B, 2003, J BIOL CHEM, V278, P49119, DOI 10.1074/jbc.M303968200; Subauste MC, 2009, CANCER BIOL THER, V8, P2297; Sutton P, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-76; Trerotola M, 2012, J CELL PHYSIOL, V227, P3670, DOI 10.1002/jcp.24074; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wang Z, 2009, EUR J CANCER, V45, P490, DOI 10.1016/j.ejca.2008.11.012; Wehner P, 2011, DEVELOPMENT, V138, P1321, DOI 10.1242/dev.056291; Wu J, 2013, BIOMED PHARMACOTHER, V67, P313, DOI 10.1016/j.biopha.2013.01.011; Wu YY, 2010, CELL SIGNAL, V22, P1495, DOI 10.1016/j.cellsig.2010.05.018; Zhang DL, 2013, MOL CELL BIOCHEM, V384, P197, DOI 10.1007/s11010-013-1798-0; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zhong XW, 2013, ANN SURG ONCOL, V20, P1044, DOI 10.1245/s10434-012-2377-4	77	99	104	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1890	1898		10.1038/onc.2014.127	http://dx.doi.org/10.1038/onc.2014.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882575				2022-12-28	WOS:000352725600003
J	Bailly, A; Perrin, A; Malhab, LJB; Pion, E; Larance, M; Nagala, M; Smith, P; O'Donohue, MF; Gleizes, PE; Zomerdijk, J; Lamond, AI; Xirodimas, DP				Bailly, A.; Perrin, A.; Malhab, L. J. Bou; Pion, E.; Larance, M.; Nagala, M.; Smith, P.; O'Donohue, M-F; Gleizes, P-E; Zomerdijk, J.; Lamond, A. I.; Xirodimas, D. P.			The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway	ONCOGENE			English	Article							CANCER-SPECIFIC ACTIVATION; RNA-POLYMERASE I; NEDD8-ACTIVATING ENZYME; PROTEIN NEDDYLATION; DNA-DAMAGE; MDM2; TRANSCRIPTION; REPLICATION; DISRUPTION; ACTINOMYCIN	The ubiquitin-like molecule NEDD8 is essential for viability, growth and development, and is a potential target for therapeutic intervention. We found that the small molecule inhibitor of NEDDylation, MLN4924, alters the morphology and increases the surface size of the nucleolus in human and germline cells of Caenorhabditis elegans in the absence of nucleolar fragmentation. SILAC proteomics and monitoring of rRNA production, processing and ribosome profiling shows that MLN4924 changes the composition of the nucleolar proteome but does not inhibit RNA Pol I transcription. Further analysis demonstrates that MLN4924 activates the p53 tumour suppressor through the RPL11/RPL5-Mdm2 pathway, with characteristics of nucleolar stress. The study identifies the nucleolus as a target of inhibitors of NEDDylation and provides a mechanism for p53 activation upon NEDD8 inhibition. It also indicates that targeting the nucleolar proteome without affecting nucleolar transcription initiates the required signalling events for the control of cell cycle regulators.	[Bailly, A.; Perrin, A.; Malhab, L. J. Bou; Pion, E.; Xirodimas, D. P.] CNRS, Ctr Rech Biochim Macromol, UMR 5237, Montpellier, France; [Larance, M.; Nagala, M.; Zomerdijk, J.; Lamond, A. I.] Univ Dundee, Coll Life Sci, Ctr Gene Regulat & Express, Dundee, Scotland; [Smith, P.] Millennium Pharmaceut Inc, Cambridge, MA USA; [O'Donohue, M-F; Gleizes, P-E] UMR CNRS 5099, Lab Biol Mol Eucaryote, Batiment IBCG, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Dundee; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Xirodimas, DP (corresponding author), CRBM, 1919 Route Mende, F-34293 Montpellier, Langeudoc, France.	dimitris.xirodimas@crbm.cnrs.fr	Gleizes, Pierre-Emmanuel/H-3821-2014; Bailly, Aymeric P/AAA-3141-2021; Gleizes, Pierre-Emmanuel/ABB-9653-2021; Larance, Mark/AAG-8613-2019	Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Bailly, Aymeric P/0000-0002-0842-5631; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Perrin, Aurelien/0000-0001-5895-3064; O'Donohue, Marie-Francoise/0000-0002-1204-8285; Xirodimas, Dimitris/0000-0001-9275-1140; Zomerdijk, Joost/0000-0003-1865-729X; Larance, Mark/0000-0002-8579-2267	ANR (National Agency for Research) postdoctoral fellowship awarded; ATIP/AVENIR; Marie Curie Career Integration (FP7) grants	ANR (National Agency for Research) postdoctoral fellowship awarded(French National Research Agency (ANR)); ATIP/AVENIR; Marie Curie Career Integration (FP7) grants	We are grateful to Dr Yanping Zhang for providing the wild- type and mutant Mdm2 C305F MEFs, the Montpellier RIO Imaging facility and Stefano Fumagalli for critical reading of the manuscript. AB and AP are supported by an ANR (National Agency for Research) postdoctoral fellowship awarded to AB. The project in DPX laboratory was supported by ATIP/AVENIR and Marie Curie Career Integration (FP7) grants.	Abidi N, 2015, ENDOCR-RELAT CANCER, V22, pT55, DOI 10.1530/ERC-14-0315; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Baker NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058266; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blank JL, 2013, CANCER RES, V73, P225, DOI 10.1158/0008-5472.CAN-12-1729; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chadha GS, 2010, MOL CELL, V37, P5, DOI 10.1016/j.molcel.2009.12.028; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; Drygin D, 2014, DRUG DISCOV TODAY, V19, P259, DOI 10.1016/j.drudis.2013.08.012; Duda DM, 2011, CURR OPIN STRUC BIOL, V21, P257, DOI 10.1016/j.sbi.2011.01.003; Duncan K, 2012, FUTURE ONCOL, V8, P1461, DOI [10.2217/FON.12.131, 10.2217/fon.12.131]; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Fuhrman LE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000657; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Greco A, 2009, REV MED VIROL, V19, P201, DOI 10.1002/rmv.614; Hannan RD, 2013, EXPERT OPIN THER TAR, V17, P873, DOI 10.1517/14728222.2013.818658; Harper JW, 2012, MOL CELL PROTEOMICS, V11, P1541, DOI 10.1074/mcp.R112.021154; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; James A, 2014, NUCLEUS-PHILA, V5, P402, DOI 10.4161/nucl.32235; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Larance M, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014407; Lee LW, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601274; Lempiainen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lin JJ, 2010, CANCER RES, V70, P10310, DOI 10.1158/0008-5472.CAN-10-2062; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Lindstrom MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083; Liu G, 2010, ONCOGENE, V29, P2252, DOI 10.1038/onc.2009.494; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Miotto B, 2010, MOL CELL, V37, P57, DOI 10.1016/j.molcel.2009.12.012; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Pestov Dimitri G, 2008, Curr Protoc Cell Biol, VChapter 22, DOI 10.1002/0471143030.cb2211s39; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Teng T, 2013, MOL CELL BIOL, V33, P4660, DOI 10.1128/MCB.01174-13; Vlatkovic N, 2014, CELL MOL LIFE SCI, V71, P771, DOI 10.1007/s00018-013-1361-x; Wang M, 2011, EXPERT OPIN THER TAR, V15, P253, DOI 10.1517/14728222.2011.550877; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; White RJ, 2008, TRENDS GENET, V24, P622, DOI 10.1016/j.tig.2008.10.003; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	67	26	28	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					415	426		10.1038/onc.2015.104	http://dx.doi.org/10.1038/onc.2015.104			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867069	Green Submitted			2022-12-28	WOS:000369056700002
J	Aschacher, T; Wolf, B; Enzmann, F; Kienzl, P; Messner, B; Sampl, S; Svoboda, M; Mechtcheriakova, D; Holzmann, K; Bergmann, M				Aschacher, T.; Wolf, B.; Enzmann, F.; Kienzl, P.; Messner, B.; Sampl, S.; Svoboda, M.; Mechtcheriakova, D.; Holzmann, K.; Bergmann, M.			LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines	ONCOGENE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; EMBRYONIC STEM-CELLS; DNA-DAMAGE-RESPONSE; C-MYC; MAMMALIAN TELOMERES; CATALYTIC SUBUNIT; CANCER-CELLS; CHROMOSOME INSTABILITY; L1 RETROTRANSPOSITION; TERMINAL TRANSFERASE	A hallmark of cancer cells is an activated telomere maintenance mechanism, which allows prolonged survival of the malignant cells. In more than 80% of tumours, telomeres are elongated by the enzyme telomerase, which adds de novo telomere repeats to the ends of chromosomes. Cancer cells are also characterized by expression of active LINE-1 elements (L1s, long interspersed nuclear elements-1). L1 elements are abundant retrotransposons in the eukaryotic genome that are primarily known for facilitating aberrant recombination. Using L1-knockdown (KD), we show for the first time that L1 is critical for telomere maintenance in telomerase-positive tumour cells. The reduced length of telomeres in the L1-KD-treated cells correlated with an increased rate of telomere dysfunction foci, a reduced expression of shelterin proteins and an increased rate of anaphase bridges. The decreased telomere length was associated with a decreased telomerase activity and decreased telomerase mRNA level; the latter was increased upon L1 overexpression. L1-KD also led to a decrease in mRNA and protein expression of cMyc and KLF-4, two main transcription factors of telomerase and altered mRNA levels of other stem-cell-associated proteins such as CD44 and hMyb, as well as a corresponding reduced growth of spheroids. The KD of KLF-4 or cMyc decreased the level of L1-ORF1 mRNA, suggesting a specific reciprocal regulation with L1. Thus, our findings contribute to the understanding of L1 as a pathogenicity factor in cancer cells. As L1 is only expressed in pathophysiological conditions, L1 now appears to be target in the rational treatment of telomerase-positive cancer.	[Aschacher, T.; Messner, B.] Med Univ Vienna, Dept Surg, Cardiac Surg Res Labs, A-1090 Vienna, Austria; [Wolf, B.; Enzmann, F.; Kienzl, P.; Bergmann, M.] Med Univ Vienna, Dept Surg, Surg Res Labs, A-1090 Vienna, Austria; [Sampl, S.; Holzmann, K.] Inst Canc Res, Dept Med 1, Vienna, Austria; [Svoboda, M.; Mechtcheriakova, D.] Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; [Mechtcheriakova, D.; Holzmann, K.; Bergmann, M.] Comprehens Canc Ctr Vienna, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Bergmann, M (corresponding author), Med Univ Vienna, Dept Surg, Surg Res Labs, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	michael.bergmann@meduniwien.ac.at	Enzmann, Florian K/U-6884-2019; Messner, Barbara/GLS-8150-2022; Bergmann, Michael/GZK-7700-2022; Holzmann, Klaus/I-4437-2019	Enzmann, Florian K/0000-0002-7200-4145; Messner, Barbara/0000-0001-8331-6497; Holzmann, Klaus/0000-0003-4077-3377; Bergmann, Michael/0000-0001-8529-1166; Kienzl, Philip/0000-0002-0114-6904; Wolf, Brigitte/0000-0003-2120-5614; Mechtcheriakova, Diana/0000-0002-8737-3592	Medical Scientific Fund of the Mayor of Vienna [10091]	Medical Scientific Fund of the Mayor of Vienna	We want to thank Roger Reddel and Bert Vogelstein for providing cell lines, Silvia Bacchetti for adenovirus expressing hTERT, Satoru Kyo for hTERT promoter constructs. Furthermore, we appreciate the critical discussion with members of the Surgical Research Laboratories of the Medical University of Vienna, as well as with Igor Bondarev, Roger Reddel, Berthold Streubl and Wolfgang Kostler. Further, we appreciate the critical reading of the manuscript by Walter Berger and Christine Brostjan. SS and KH were supported by the Medical Scientific Fund of the Mayor of Vienna #10091.	Ahmad K, 1999, GENETICS, V151, P1041; Aoki Y, 2012, GENOME MED, V4, DOI 10.1186/gm402; Aschacher T, 2012, NEOPLASIA, V14, P44, DOI 10.1593/neo.11426; Atsumi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023432; Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bailey SM, 2006, NUCLEIC ACIDS RES, V34, P2408, DOI 10.1093/nar/gkl303; Beck CR, 2011, ANNU REV GENOM HUM G, V12, P187, DOI 10.1146/annurev-genom-082509-141802; Belancio VP, 2010, NUCLEIC ACIDS RES, V38, P3909, DOI 10.1093/nar/gkq132; Belgnaoui SM, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-13; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Cesare AJ, 2013, MOL CELL, V51, P141, DOI 10.1016/j.molcel.2013.06.006; Chen JM, 2005, HUM GENET, V117, P411, DOI 10.1007/s00439-005-1321-0; Choi KH, 2011, NUCLEIC ACIDS RES, V39, P9206, DOI 10.1093/nar/gkr665; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2010, COLD SH Q B, V75, P167, DOI 10.1101/sqb.2010.75.017; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dikmen ZG, 2005, CANCER RES, V65, P7866, DOI 10.1158/0008-5472.CAN-05-1215; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Fang JL, 2009, TOXICOL SCI, V111, P120, DOI 10.1093/toxsci/kfp136; Farkash EA, 2006, NUCLEIC ACIDS RES, V34, P1196, DOI 10.1093/nar/gkj522; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Fumagalli M, 2012, NAT CELL BIOL, V14, P355, DOI 10.1038/ncb2466; Garcia-Perez JL, 2007, HUM MOL GENET, V16, P1569, DOI 10.1093/hmg/ddm105; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Grandjenette C, 2014, NEOPLASIA, V16, P511, DOI 10.1016/j.neo.2014.05.009; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grusch Michael, 2009, V515, P125, DOI 10.1007/978-1-59745-559-6_8; Guiducci C, 2001, EXP CELL RES, V265, P304, DOI 10.1006/excr.2001.5189; Han JS, 2005, BIOESSAYS, V27, P775, DOI 10.1002/bies.20257; Hao Huang, 2008, J Exp Clin Cancer Res, V27, P27, DOI 10.1186/1756-9966-27-27; Hao LY, 2004, J BIOL CHEM, V279, P45148, DOI 10.1074/jbc.M403924200; Haoudi A, 2004, J BIOMED BIOTECHNOL, P185, DOI 10.1155/S1110724304403131; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hochreiter AE, 2006, CLIN CANCER RES, V12, P3184, DOI 10.1158/1078-0432.CCR-05-2760; Hu XY, 2009, NUCLEOS NUCLEOT NUCL, V28, P1, DOI 10.1080/15257770802581633; Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolosha VO, 2003, J BIOL CHEM, V278, P8112, DOI 10.1074/jbc.M210487200; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lewis KA, 2012, STRUCTURE, V20, P28, DOI 10.1016/j.str.2011.10.017; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Montoya-Durango DE, 2009, MUTAT RES-FUND MOL M, V665, P20, DOI 10.1016/j.mrfmmm.2009.02.011; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morrish TA, 2002, NAT GENET, V31, P159, DOI 10.1038/ng898; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Ohka F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023332; Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Qian YQ, 2014, CELL IMMUNOL, V289, P63, DOI 10.1016/j.cellimm.2014.03.009; Rodic N, 2014, AM J PATHOL, V184, P1280, DOI 10.1016/j.ajpath.2014.01.007; Sampl S, 2012, TRANSL ONCOL, V5, P56, DOI 10.1593/tlo.11202; Schneider-Stock R, 2003, J PATHOL, V199, P517, DOI 10.1002/path.1315; Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562; Sciamanna I, 2013, ONCOTARGET, V4, P2271, DOI 10.18632/oncotarget.1403; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Sinibaldi-Vallebona Paola, 2011, Cancers (Basel), V3, P1141, DOI 10.3390/cancers3011141; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Takakura M, 1999, CANCER RES, V59, P551; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Verdun RE, 2007, NATURE, V447, P924, DOI 10.1038/nature05976; Vitullo P, 2012, MOL REPROD DEV, V79, P118, DOI 10.1002/mrd.22003; Wallace NA, 2008, GENE, V419, P75, DOI 10.1016/j.gene.2008.04.013; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wissing S, 2012, HUM MOL GENET, V21, P208, DOI 10.1093/hmg/ddr455; Wong CW, 2010, STEM CELLS, V28, P1510, DOI 10.1002/stem.477; Xi LH, 2014, NUCLEIC ACIDS RES, V42, P8565, DOI 10.1093/nar/gku560	81	37	39	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					94	104		10.1038/onc.2015.65	http://dx.doi.org/10.1038/onc.2015.65			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798839				2022-12-28	WOS:000367812400009
J	Sarkar, M; Khare, V; Guturi, KKN; Das, N; Ghosh, MK				Sarkar, M.; Khare, V.; Guturi, K. K. N.; Das, N.; Ghosh, M. K.			The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; CANCER CELLS; EXPRESSION; PATHWAY; AKT; OVEREXPRESSION; PROGRESSION; ACTIVATION; KINASE; PLAYS	Increased abundance of proto-oncogene AKT and reduced expression of tumor suppressor Forkhead box O3 (FOXO3a), the downstream target of AKT, is frequent in carcinogenesis. Mechanistic insights of AKT gene regulation are limited. DEAD box RNA helicase p68 is overexpressed in various cancers and acts as a transcriptional co-activator of several transcription factors, including beta-catenin. Here, we report a novel mechanism of p68-mediated transcriptional activation of AKT, and its ensuing effect on FOXO3a, in colon carcinogenesis. Interestingly, we found that the expression of p68 and AKT exhibits strong positive correlation in normal and colon carcinoma patient samples. In addition, p68 increased both AKT messenger RNA (mRNA) and protein, enhanced AKT promoter activity in multiple colon cancer cell lines. Conversely, p68 knockdown led to reduced AKT mRNA and protein, diminished AKT promoter activity. Here, we demonstrated that p68 occupies AKT promoter with beta-catenin as well as nuclear factor-kappa B (NF-kappa B) and cooperates with these in potentiating AKT transcription. Furthermore, p68 and FOXO3a expression followed inverse correlation in the same set of colon carcinoma samples. We observed that p68 significantly reduced FOXO3a protein level in an AKT-dependent manner. Studies in primary tumors and metastatic lung nodules generated in mice colorectal allograft model, using syngeneic cells stably expressing p68, corroborated our in vitro findings. Hence, a new mechanism of oncogenesis is attributed to p68 by upregulation of AKT and consequent nuclear exclusion and degradation of tumor suppressor FOXO3a.	[Sarkar, M.; Khare, V.; Guturi, K. K. N.; Das, N.; Ghosh, M. K.] Indian Inst Chem Biol, CSIR, Canc Biol & Inflammatory Disorder Div, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Sarkar, M (corresponding author), Indian Inst Chem Biol, CSIR, Canc Biol & Inflammatory Disorder Div, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	mrinal.res@gmail.com		Sarkar, Dr Moumita/0000-0002-7437-5353	CSIR, India [EMPOWER-OLP-002, MEDCHEM-BSC0108, CSIR-MAYO: MLP-0017]	CSIR, India(Council of Scientific & Industrial Research (CSIR) - India)	We thank Dr Frances V Fuller-Pace, Dr KM Yamada and Dr B Alman for gifting us the pGS5-p68 construct, pGZ21dx vector and pBI-beta-catenin construct, respectively; Dr Uttara Chatterjee (Park Clinic, Kolkata, India) for providing human normal colon and colon carcinoma samples, associated pathological reports and helping in analysis of the related data; Dr Samit Adhya for kindly providing us the facility for animal lung imaging. This work is supported by grants from CSIR, India (EMPOWER-OLP-002, MEDCHEM-BSC0108 and CSIR-MAYO: MLP-0017).	Bhattacharya S, 2014, FEBS J, V281, P3061, DOI 10.1111/febs.12843; Bhowmik A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059798; Bullock MD, 2013, BRIT J CANCER, V109, P387, DOI 10.1038/bjc.2013.355; Cai BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041742; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Crowell JA, 2007, MOL CANCER THER, V6, P2139, DOI 10.1158/1535-7163.MCT-07-0120; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Du Qiang, 2010, For Immunopathol Dis Therap, V1, P155; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Malinowsky K, 2014, BRIT J CANCER, V110, P2081, DOI 10.1038/bjc.2014.100; Mandal T, 2014, CELL SIGNAL, V26, P1725, DOI 10.1016/j.cellsig.2014.04.003; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Temraz S, 2013, INT J MOL SCI, V14, P17279, DOI 10.3390/ijms140917279; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang R, 2012, NEURO-ONCOLOGY, V14, P1116, DOI 10.1093/neuonc/nos131; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Zhang JX, 2011, NEURO-ONCOLOGY, V13, P600, DOI 10.1093/neuonc/nor034	39	35	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5843	5856		10.1038/onc.2015.42	http://dx.doi.org/10.1038/onc.2015.42			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25745998				2022-12-28	WOS:000365035200007
J	He, Y; Chen, D; Zheng, W				He, Y.; Chen, D.; Zheng, W.			An enhanced functional interrogation/manipulation of intracellular signaling pathways with the peptide 'stapling' technology	ONCOGENE			English	Review							STABILIZED ALPHA-HELICES; BCL-2 FAMILY; BH3 HELIX; PROTEINS; ACTIVATION; DESIGN; P53; INHIBITOR; BINDING; CANCER	Specific protein-protein interactions (PPIs) constitute a key underlying mechanism for the presence of a multitude of intracellular signaling pathways, which are essential for the survival of normal and cancer cells. Specific molecular blockers for a crucial PPI would therefore be invaluable tools for an enhanced functional interrogation of the signaling pathway harboring this particular PPI. On the other hand, if a particular PPI is essential for the survival of cancer cells but is absent in or dispensable for the survival of normal cells, its specific molecular blockers could potentially be developed into effective anticancer therapeutics. Due to the flat and extended PPI interface, it would be conceivably difficult for small molecules to achieve an effective blockade, a problem which could be potentially circumvented with peptides or proteins. However, the well-documented proteolytic instability and cellular impermeability of peptides and proteins in general would make their developing into effective intracellular PPI blockers quite a challenge. With the advent of the peptide 'stapling' technology which was demonstrated to be able to stabilize the a-helical conformation of a peptide via bridging two neighboring amino-acid side chains with a 'molecular staple', a linear parent peptide could be transformed into a stronger PPI blocker with enhanced proteolytic stability and cellular permeability. This review will furnish an account on the peptide 'stapling' technology and its exploitation in efforts to achieve an enhanced functional interrogation or manipulation of intracellular signaling pathways especially those that are cancer relevant.	[He, Y.; Chen, D.; Zheng, W.] Jiangsu Univ, Sch Pharm, Zhenjiang 212013, Peoples R China	Jiangsu University	Zheng, W (corresponding author), Jiangsu Univ, Sch Pharm, 301 Xuefu Rd, Zhenjiang 212013, Peoples R China.	wzheng@ujs.edu.cn			Jiangsu provincial 'innovation and venture talents' award plan	Jiangsu provincial 'innovation and venture talents' award plan	WZ is a Jiangsu provincial specially appointed professor and a recipient of the Jiangsu provincial 'innovation and venture talents' award plan, and the associated financial supports to the completion of this manuscript are appreciated.	Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587; Bernal F, 2014, METHODS MOL BIOL, V1176, P107, DOI 10.1007/978-1-4939-0992-6_9; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bird GH, 2014, ACS CHEM BIOL, V9, P831, DOI 10.1021/cb4003305; Bird GH, 2008, METHOD ENZYMOL, V446, P369, DOI 10.1016/S0076-6879(08)01622-4; Bird Gregory H, 2011, Curr Protoc Chem Biol, V3, P99, DOI 10.1002/9780470559277.ch110042; Blackwell HE, 1998, ANGEW CHEM INT EDIT, V37, P3281, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.0.CO;2-V; BRACKEN C, 1994, J AM CHEM SOC, V116, P6431, DOI 10.1021/ja00093a052; Brown CJ, 2013, ACS CHEM BIOL, V8, P506, DOI 10.1021/cb3005148; Cantel S, 2008, J ORG CHEM, V73, P5663, DOI 10.1021/jo800142s; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Choi YS, 2014, CURR PHARM BIOTECHNO, V15, P192, DOI 10.2174/1389201015666140617093331; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Edwards AL, 2013, CHEM BIOL, V20, P888, DOI 10.1016/j.chembiol.2013.06.007; Flint DG, 2002, CHEM BIOL, V9, P391, DOI 10.1016/S1074-5521(02)00109-6; Frank AO, 2014, J MED CHEM, V57, P2455, DOI 10.1021/jm401730y; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Gavathiotis E, 2010, MOL CELL, V40, P481, DOI 10.1016/j.molcel.2010.10.019; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Goodman M., 1995, BURGERS MED CHEM DRU, VI, P803; Grossmann TN, 2012, P NATL ACAD SCI USA, V109, P17942, DOI 10.1073/pnas.1208396109; Guo ZJ, 2010, CHEM BIOL DRUG DES, V75, P348, DOI 10.1111/j.1747-0285.2010.00951.x; Haney CM, 2011, CHEM COMMUN, V47, P10915, DOI 10.1039/c1cc12010g; Hao YJ, 2013, CANCER CELL, V23, P583, DOI 10.1016/j.ccr.2013.03.021; JACKSON DY, 1991, J AM CHEM SOC, V113, P9391, DOI 10.1021/ja00024a067; Joseph TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043985; Joseph TL, 2010, CELL CYCLE, V9, P4560, DOI 10.4161/cc.9.22.13816; Karle IL, 2001, BIOPOLYMERS, V60, P351, DOI 10.1002/1097-0282(2001)60:5<351::AID-BIP10174>3.0.CO;2-U; Kaul R, 1999, BIOORGAN MED CHEM, V7, P105, DOI 10.1016/S0968-0896(98)00221-1; Kawamoto SA, 2012, J MED CHEM, V55, P1137, DOI 10.1021/jm201125d; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kim YW, 2011, NAT PROTOC, V6, P761, DOI 10.1038/nprot.2011.324; LaBelle JL, 2012, J CLIN INVEST, V122, P2018, DOI 10.1172/JCI46231; Lama D, 2013, SCI REP-UK, V3, DOI 10.1038/srep03451; Lau YH, 2014, ORG BIOMOL CHEM, V12, P4074, DOI 10.1039/c4ob00742e; Lau YH, 2014, CHEM SCI, V5, P1804, DOI 10.1039/c4sc00045e; Leshchiner ES, 2013, P NATL ACAD SCI USA, V110, pE986, DOI 10.1073/pnas.1214313110; Madden MM, 2011, BIOORG MED CHEM LETT, V21, P1472, DOI 10.1016/j.bmcl.2011.01.004; McCrudden MTC, 2013, THER DELIV, V4, P593, DOI [10.4155/tde.13.31, 10.4155/TDE.13.31]; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Moldoveanu T, 2013, NAT STRUCT MOL BIOL, V20, P589, DOI 10.1038/nsmb.2563; Muppidi A, 2014, BIOORG MED CHEM LETT, V24, P1748, DOI 10.1016/j.bmcl.2014.02.038; Muppidi A, 2012, J AM CHEM SOC, V134, P14734, DOI 10.1021/ja306864v; Muppidi A, 2011, CHEM COMMUN, V47, P9396, DOI 10.1039/c1cc13320a; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Phelan JC, 1997, J AM CHEM SOC, V119, P455, DOI 10.1021/ja9611654; Phillips C, 2011, J AM CHEM SOC, V133, P9696, DOI 10.1021/ja202946k; Pitter K, 2008, METHOD ENZYMOL, V446, P387, DOI 10.1016/S0076-6879(08)01623-6; Ramos YFM, 2001, CANCER RES, V61, P1839; Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a; Shim SY, 2013, CHEM BIOL DRUG DES, V82, P635, DOI 10.1111/cbdd.12231; Simerska P, 2011, MED RES REV, V31, P520, DOI 10.1002/med.20191; Sinclair JKL, 2014, J AM CHEM SOC, V136, P11232, DOI 10.1021/ja504076t; Spiegel J, 2014, ANGEW CHEM INT EDIT, V53, P2498, DOI 10.1002/anie.201308568; Stewart ML, 2010, NAT CHEM BIOL, V6, P595, DOI [10.1038/NCHEMBIO.391, 10.1038/nchembio.391]; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Thomas S, 2013, EXPERT OPIN THER TAR, V17, P61, DOI 10.1517/14728222.2013.733001; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; URNES P, 1961, ADV PROTEIN CHEM, V16, P401; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; Verdine GL, 2012, METHOD ENZYMOL, V503, P3, DOI 10.1016/B978-0-12-396962-0.00001-X; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Walensky LD, 2014, J MED CHEM, V57, P6275, DOI 10.1021/jm4011675; Wang YX, 2014, ACS CHEM BIOL, V9, P635, DOI 10.1021/cb400900r; Wei SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081068; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	73	6	6	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5685	5698		10.1038/onc.2015.37	http://dx.doi.org/10.1038/onc.2015.37			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25798838				2022-12-28	WOS:000364594600001
J	Musahl, AS; Huang, X; Rusakiewicz, S; Ntini, E; Marsico, A; Kroemer, G; Kepp, O; Orom, UA				Musahl, A-S; Huang, X.; Rusakiewicz, S.; Ntini, E.; Marsico, A.; Kroemer, G.; Kepp, O.; Orom, U. A.			A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription	ONCOGENE			English	Article							BIDIRECTIONAL PROMOTERS; DIVERGENT TRANSCRIPTION; HUMAN GENOME; GENE-EXPRESSION; MAJOR SOURCE; CHROMATIN; REVEALS; ELEMENTS; CANCER; SITE	A subset of promoters bidirectionally expresses long non-coding RNAs (ncRNAs) of unknown function and protein-coding genes (PCGs) in parallel. Here, we define a set of 1107 highly conserved human bidirectional promoters that mediate the linked expression of long ncRNAs and PCGs. Depletion of the long ncRNA expressed from the RB1 promoter, ncRNA-RB1, reveals regulatory effects different from the RB1-controlled transcriptional program. ncRNA-RB1 positively regulates the expression of calreticulin (CALR) that in response to certain therapeutic interventions can translocate from the endoplasmic reticulum to the cell surface, hence activating anticancer immune responses. Knockdown of ncRNA-RB1 in tumor cells reduced expression of CALR, impaired the translocation of the protein to the cell surface upon treatment with anthracylines and consequently inhibited the cellular uptake by macrophages. In conclusion, co-transcription of ncRNA-RB1 and RB1 provides a positive link between the expression of the two tumor suppressors RB1 and the immune-relevant CALR protein. This regulatory interplay exemplifies disease-relevant co-regulation of two distinct gene products, in which loss of expression of one oncosuppressor protein entails the abolition of additional tumor-inhibitory mechanisms.	[Musahl, A-S; Ntini, E.; Orom, U. A.] Max Planck Inst Mol Genet, Noncoding RNA Res Grp, D-14195 Berlin, Germany; [Huang, X.; Kroemer, G.; Kepp, O.] INSERM, Cordeliers Res Canc, U1138, Team11,Equipe Labellisee Ligue Canc, Paris, France; [Huang, X.; Kroemer, G.; Kepp, O.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Huang, X.; Kroemer, G.; Kepp, O.] Gustave Roussy Comprehens Canc Ctr, Cell Biol & Metabol Platforms, Villejuif, France; [Rusakiewicz, S.] Gustave Roussy, Villejuif, France; [Rusakiewicz, S.] INSERM, U1015, CICBT507, Villejuif, France; [Marsico, A.] Max Planck Inst Mol Genet, Dept Computat Biol, D-14195 Berlin, Germany; [Marsico, A.] Max Planck Inst Mol Genet, RNA Bioinformat Grp, D-14195 Berlin, Germany; [Marsico, A.] Free Univ Berlin, Berlin, Germany; [Kroemer, G.] Univ Paris 06, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Max Planck Society; Max Planck Society; Free University of Berlin; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Orom, UA (corresponding author), Max Planck Inst Mol Genet, Warburg Labs, Ihnestr 63, D-14195 Berlin, Germany.	Oerom@molgen.mpg.de	Marsico, Annalisa/AFU-3262-2022; Kepp, Oliver/GPX-8627-2022; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/N-2763-2017; 黄, 星/AAB-2241-2019	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; 黄, 星/0000-0002-8886-2777; Ntini, Evgenia/0000-0002-4649-6051; Orom, Ulf/0000-0002-0643-0592	Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); German Ministry of education and research through the Alexander von Humboldt Foundation Sofja Kovalevskaja Award	Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); AXA Chair for Longevity Research(AXA Research Fund); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)European Commission); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); German Ministry of education and research through the Alexander von Humboldt Foundation Sofja Kovalevskaja Award	Work in the laboratories of GK and OK are suppported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Work in the laboratory of UAO is supported by the German Ministry of education and research through the Alexander von Humboldt Foundation Sofja Kovalevskaja Award.	Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Almada AE, 2013, NATURE, V499, P360, DOI 10.1038/nature12349; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bhatt DM, 2012, CELL, V150, P279, DOI 10.1016/j.cell.2012.05.043; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chao MP, 2012, NAT REV CANCER, V12, P58, DOI 10.1038/nrc3171; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Flynn RA, 2011, P NATL ACAD SCI USA, V108, P10460, DOI 10.1073/pnas.1106630108; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lenhard B, 2012, NAT REV GENET, V13, P233, DOI 10.1038/nrg3163; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Manning AL, 2011, TRENDS CELL BIOL, V21, P433, DOI 10.1016/j.tcb.2011.05.003; Marquardt S, 2014, CELL, V157, P1712, DOI 10.1016/j.cell.2014.04.036; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; Neil H, 2009, NATURE, V457, P1038, DOI 10.1038/nature07747; Ntini E, 2013, NAT STRUCT MOL BIOL, V20, P923, DOI 10.1038/nsmb.2640; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279; Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022; Polson A, 2014, GENE, V538, P138, DOI 10.1016/j.gene.2013.12.046; Preker P, 2008, SCIENCE, V322, P1851, DOI 10.1126/science.1164096; Rhee HS, 2012, NATURE, V483, P295, DOI 10.1038/nature10799; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Sigova AA, 2013, P NATL ACAD SCI USA, V110, P2876, DOI 10.1073/pnas.1221904110; Sowa Y, 1997, CANCER RES, V57, P3145; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Trimarchi T, 2014, CELL, V158, P593, DOI 10.1016/j.cell.2014.05.049; Uesaka M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-35; Wakano C, 2012, BBA-GENE REGUL MECH, V1819, P688, DOI 10.1016/j.bbagrm.2012.02.006; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wu XB, 2013, CELL, V155, P990, DOI 10.1016/j.cell.2013.10.048; Yang MQ, 2007, PLOS COMPUT BIOL, V3, P733, DOI 10.1371/journal.pcbi.0030072; Zhang L, 2013, MOL CELL BIOCHEM, V382, P237, DOI 10.1007/s11010-013-1739-y; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045	57	36	37	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5046	5054		10.1038/onc.2014.424	http://dx.doi.org/10.1038/onc.2014.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25579178	Green Published			2022-12-28	WOS:000361693300005
J	Riemer, P; Sreekumar, A; Reinke, S; Rad, R; Schafer, R; Sers, C; Blaker, H; Herrmann, BG; Morkel, M				Riemer, P.; Sreekumar, A.; Reinke, S.; Rad, R.; Schaefer, R.; Sers, C.; Blaeker, H.; Herrmann, B. G.; Morkel, M.			Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by beta-catenin activity	ONCOGENE			English	Article							WNT/BETA-CATENIN; ACQUIRED-RESISTANCE; TUMOR PROGRESSION; SERRATED PATHWAY; SENESCENCE; GENE; KINASE; COLON; WNT; ADENOMA	Colon cancer cells frequently carry mutations that activate the beta-catenin and mitogen-activated protein kinase (MAPK) signaling cascades. Yet how oncogenic alterations interact to control cellular hierarchies during tumor initiation and progression is largely unknown. We found that oncogenic BRAF modulates gene expression associated with cell differentiation in colon cancer cells. We therefore engineered a mouse with an inducible oncogenic BRAF transgene, and analyzed BRAF effects on cellular hierarchies in the intestinal epithelium in vivo and in primary organotypic culture. We demonstrate that transgenic expression of oncogenic BRAF in the mouse strongly activated MAPK signal transduction, resulted in the rapid development of generalized serrated dysplasia, but unexpectedly also induced depletion of the intestinal stem cell (ISC) pool. Histological and gene expression analyses indicate that ISCs collectively converted to short-lived progenitor cells after BRAF activation. As Wnt/beta-catenin signals encourage ISC identity, we asked whether beta-catenin activity could counteract oncogenic BRAF. Indeed, we found that intestinal organoids could be partially protected from deleterious oncogenic BRAF effects by Wnt3a or by small-molecule inhibition of GSK3 beta. Similarly, transgenic expression of stabilized beta-catenin in addition to oncogenic BRAF partially prevented loss of stem cells in the mouse intestine. We also used BRAF(V637E) knock-in mice to follow changes in the stem cell pool during serrated tumor progression and found ISC marker expression reduced in serrated hyperplasia forming after BRAF activation, but intensified in progressive dysplastic foci characterized by additional mutations that activate the Wnt/beta-catenin pathway. Our study suggests that oncogenic alterations activating the MAPK and Wnt/beta-catenin pathways must be consecutively and coordinately selected to assure stem cell maintenance during colon cancer initiation and progression. Notably, loss of stem cell identity upon induction of BRAF/MAPK activity may represent a novel fail-safe mechanism protecting intestinal tissue from oncogene activation.	[Riemer, P.; Sreekumar, A.; Schaefer, R.; Sers, C.; Morkel, M.] Charite, Lab Mol Tumor Pathol, Inst Pathol, D-10117 Berlin, Germany; [Riemer, P.; Sreekumar, A.; Reinke, S.; Herrmann, B. G.; Morkel, M.] Max Planck Inst Mol Genet, Dept Dev Genet, D-14195 Berlin, Germany; [Rad, R.] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 2, D-80290 Munich, Germany; [Rad, R.; Schaefer, R.; Sers, C.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Blaeker, H.] Charite, Dept Gen Pathol, Inst Pathol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Morkel, M (corresponding author), Charite, Lab Mol Tumor Pathol, Inst Pathol, CCM, Charitepl 1, D-10117 Berlin, Germany.	markus.morkel@charite.de	Sers, Christine/B-5438-2010; Schäfer, Reinhold/AAB-5110-2021	Riemer, Pamela/0000-0003-3231-7056; Schafer, Reinhold/0000-0001-7952-2124; Reinke, Soren/0000-0003-2412-385X; Sers, christine/0000-0002-6219-1514; Morkel, Markus/0000-0002-2553-9999	NGFNplus grant [PKM-01GS08105]; eBio grant [0316184A]	NGFNplus grant; eBio grant	This work was funded in part by NGFNplus grant PKM-01GS08105 to MM and BGH and eBio grant 0316184A to MM. We gratefully acknowledge Judith Seidemann (Charite Berlin), Gaby Blass and Karol Macura (MPI-MG Berlin) for excellent technical assistance, Sonja Banko (animal facility, MPI-MG) for maintainance of the mice, Jan Dorr (Charite Berlin) for SA-beta-Galactosidase stainings, Tilman Brummer (University of Freiburg) for the gift of Caco2-tet cells and Julian Heuberger (Max-Delbruck-Center for Molecular Medicine, Berlin) for the gift of the ITF antibody.	Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Bettington M, 2013, HISTOPATHOLOGY, V62, P367, DOI 10.1111/his.12055; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; El-Osta H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025806; Farin HF, 2012, GASTROENTEROLOGY, V143, P1518, DOI 10.1053/j.gastro.2012.08.031; Farrall AL, 2012, INT J CANCER, V131, P2242, DOI 10.1002/ijc.27500; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Fritsche-Guenther R, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.27; Gonzalo DH, 2013, J PATHOL, V230, P420, DOI 10.1002/path.4200; Guardavaccaro D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002921; Herr R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-17; Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242; Jurchott K, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001231; Kimura T, 2012, AM J GASTROENTEROL, V107, P460, DOI 10.1038/ajg.2011.457; Laiho P, 2007, ONCOGENE, V26, P312, DOI 10.1038/sj.onc.1209778; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Osaki LH, 2013, INT J MOL SCI, V14, P10143, DOI 10.3390/ijms140510143; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Snover DC, 2011, HUM PATHOL, V42, P1, DOI 10.1016/j.humpath.2010.06.002; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van Es JH, 2012, MOL CELL BIOL, V32, P1918, DOI 10.1128/MCB.06288-11; Vermeulen L, 2013, SCIENCE, V342, P995, DOI 10.1126/science.1243148; Vidigal JA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq199; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wu JM, 2008, AM J CLIN PATHOL, V129, P416, DOI 10.1309/603UQKM7C2KELGJU; Yachida S, 2009, AM J SURG PATHOL, V33, P1823, DOI 10.1097/PAS.0b013e3181b6da19; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968	55	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3164	3175		10.1038/onc.2014.247	http://dx.doi.org/10.1038/onc.2014.247			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109331	Green Published			2022-12-28	WOS:000356101100008
J	Yang, CS; Matsuura, K; Huang, NJ; Robeson, AC; Huang, B; Zhang, L; Kornbluth, S				Yang, C-S; Matsuura, K.; Huang, N-J; Robeson, A. C.; Huang, B.; Zhang, L.; Kornbluth, S.			Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death	ONCOGENE			English	Article							METABOLIC-REGULATION; LIPID-METABOLISM; THERAPEUTIC TARGET; APOPTOSIS; ACTIVATION; MTOR; SUPPRESSOR; HYPOXIA; STRESS; RTP801	Blockade of fatty acid synthase (FASN), a key enzyme involved in de novo lipogenesis, results in robust death of ovarian cancer cells. However, known FASN inhibitors have proven to be poor therapeutic agents due to their ability to induce cachexia. Therefore, we sought to identify additional targets in the pathway linking FASN inhibition and cell death whose modulation might kill ovarian cancer cells without the attendant side effects. Here, we show that the initiator caspase-2 is required for robust death of ovarian cancer cells induced by FASN inhibitors. REDD1 (also known as Rtp801 or DDIT4), a known mTOR inhibitor previously implicated in the response to FASN inhibition, is a novel caspase-2 regulator in this pathway. REDD1 induction is compromised in ovarian cancer cells that do not respond to FASN inhibition. Inhibition of FASN induced an ATF4-dependent transcriptional induction of REDD1; downregulation of REDD1 prevented orlistat-induced activation of caspase-2, as monitored by its cleavage, proteolytic activity and dimerization. Abrogation of REDD1-mediated suppression of mTOR by TSC2 RNAi protected FASN inhibitor-sensitive ovarian cancer cells (OVCA420 cells) from orlistat-induced death. Conversely, suppression of mTOR with the chemical inhibitors PP242 or rapamycin-sensitized DOV13, an ovarian cancer cell line incapable of inducing REDD1, to orlistat-induced cell death through caspase-2. These findings indicate that REDD1 positively controls caspase-2-dependent cell death of ovarian cancer cells by inhibiting mTOR, placing mTOR as a novel upstream regulator of caspase-2 and supporting the possibility of manipulating mTOR to enhance caspase-2 activation in ovarian cancer.	[Yang, C-S; Matsuura, K.; Huang, N-J; Robeson, A. C.; Huang, B.; Zhang, L.; Kornbluth, S.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Kornbluth, S (corresponding author), Duke Univ, Box 90005, Durham, NC 27710 USA.	sally.kornbluth@duke.edu		Matsuura, Kenkyo/0000-0003-4612-6031	 [R01 GM080333]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080333, T32GM007184] Funding Source: NIH RePORTER	; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Susan Murphy and Andrew Berchuck for de-identified human ovarian cancer biopsy samples, and the members of the Kornbluth laboratory for sharing reagents and discussion. This work was supported by R01 GM080333 to SK.	Alo PL, 2000, ONCOL REP, V7, P1383; Andersen JL, 2011, MOL CELL, V43, P834, DOI 10.1016/j.molcel.2011.07.028; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Bandyopadhyay S, 2006, CANCER RES, V66, P5934, DOI 10.1158/0008-5472.CAN-05-3197; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bonzon C, 2006, MOL BIOL CELL, V17, P2150, DOI 10.1091/mbc.E05-12-1107; Bouchier-Hayes L, 2010, J CELL MOL MED, V14, P1212, DOI 10.1111/j.1582-4934.2010.01037.x; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Ho TS, 2007, BIOMED PHARMACOTHER, V61, P578, DOI 10.1016/j.biopha.2007.08.020; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huang NJ, 2012, J CELL BIOL, V197, P361, DOI [10.1083/jcb.201111141, 10.1083/jcb.201108062]; Jin HO, 2011, ONCOGENE, V30, P3792, DOI 10.1038/onc.2011.102; Knowles LM, 2008, J BIOL CHEM, V283, P31378, DOI 10.1074/jbc.M803384200; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Little JL, 2007, CANCER RES, V67, P1262, DOI 10.1158/0008-5472.CAN-06-1794; Malagelada C, 2006, J NEUROSCI, V26, P9996, DOI 10.1523/JNEUROSCI.3292-06.2006; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nutt LK, 2009, DEV CELL, V16, P856, DOI 10.1016/j.devcel.2009.04.005; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Pyragius CE, 2013, INT J MOL SCI, V14, P7742, DOI 10.3390/ijms14047742; Rahman MT, 2012, BRIT J CANCER, V107, P300, DOI 10.1038/bjc.2012.246; Ribe EM, 2012, BIOCHEM J, V444, P591, DOI 10.1042/BJ20111588; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Tania M, 2010, CURR ONCOL, V17, P6; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tomek K, 2011, MOL CANCER RES, V9, P1767, DOI 10.1158/1541-7786.MCR-10-0467; Upreti M, 2008, MOL CANCER THER, V7, P2224, DOI 10.1158/1535-7163.MCT-07-2299; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Yang CS, 2010, EMBO J, V29, P3196, DOI 10.1038/emboj.2010.191; Yoshida T, 2010, NAT MED, V16, P767, DOI 10.1038/nm.2157; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030; Zhou WB, 2007, CANCER RES, V67, P2964, DOI 10.1158/0008-5472.CAN-06-3439	50	34	37	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3264	3272		10.1038/onc.2014.271	http://dx.doi.org/10.1038/onc.2014.271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151963	Green Accepted			2022-12-28	WOS:000356592300005
J	Packham, S; Warsito, D; Lin, Y; Sadi, S; Karlsson, R; Sehat, B; Larsson, O				Packham, S.; Warsito, D.; Lin, Y.; Sadi, S.; Karlsson, R.; Sehat, B.; Larsson, O.			Nuclear translocation of IGF-1R via p150(Glued) and an importin-beta/RanBP2-dependent pathway in cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; IMPORTIN-BETA; DYNACTIN COMPLEX; EARLY ENDOSOME; TUMOR-CELLS; INSULIN; PROTEIN; TRANSPORT; SUMOYLATION	Mounting evidence has shown that the insulin-like growth factor-1 receptor (IGF-1R) has critical roles in cancer cell growth. This has prompted pharmacological companies to develop agents targeting the receptor. Surprisingly, clinical trials using specific IGF-1R antibodies have, however, revealed disappointing results. Further understanding of the role of IGF-1R in cancer cells is therefore necessary for development of efficient therapeutic strategies. Recently, we showed that IGF-1R is sumoylated and translocated into the cell nucleus where it activates gene transcription. Several other studies have confirmed our findings and it has been reported that nuclear IGF-1R (nIGF-1R) has prognostic and predictive impact in cancer. To increase the understanding of IGF-1R in cancer cells, we here present the first study that proposes a pathway by which IGF-1R translocates into the cell nucleus. We could demonstrate that IGF-1R first associates with the dynactin subunit p150(Glued), which transports the receptor to the nuclear pore complex, where it co-localizes with importin-beta followed by association with RanBP2. Sumoylation of IGF-1R seems to be required for interaction with RanBP2, which in turn may serve as the SUMO E3 ligase. In the context of sumoylation, we provided evidence that it may favor nIGF-1R accumulation by increasing the stability of the receptor. Taken together, topographic and functional interactions between dynactin, importin-beta and RanBP2 are involved in nuclear translocation of IGF-1R. Our results provide new understanding of IGF-1R in cancer, which in turn may contribute to development of new therapeutic strategies.	[Packham, S.; Warsito, D.; Lin, Y.; Sehat, B.; Larsson, O.] Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; [Sadi, S.; Karlsson, R.] Stockholm Univ, Dept Mol Biosci, Wenner Gren Inst, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Packham, S (corresponding author), Karolinska Inst, Dept Pathol & Oncol, CCK R8 04, SE-17176 Stockholm, Sweden.	Sylvia.packham@ki.se			Swedish Cancer Foundation; Swedish Research Council; Cancer Society in Stockholm; Swedish Children Cancer Society; Stockholm County Council; Karolinska Institutet	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm; Swedish Children Cancer Society(Swedish Cancer Society); Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet)	This work was supported by the Swedish Cancer Foundation, the Swedish Research Council, the Cancer Society in Stockholm, the Swedish Children Cancer Society, the Stockholm County Council and the Karolinska Institutet.	Aleksic T, 2010, CANCER RES, V70, P6412, DOI 10.1158/0008-5472.CAN-10-0052; Asmane I, 2012, EUR J CANCER, V48, P3027, DOI 10.1016/j.ejca.2012.05.009; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 2013, J CELL PHYSIOL, V228, P675, DOI 10.1002/jcp.24217; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bodzin AS, 2012, J CELL PHYSIOL, V227, P2947, DOI 10.1002/jcp.23041; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Deng H, 2011, BIOCHEM BIOPH RES CO, V404, P667, DOI 10.1016/j.bbrc.2010.12.038; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Flores-Rodriguez N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024479; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Hamada M, 2011, J CELL BIOL, V194, P597, DOI 10.1083/jcb.201102018; Hilgarth Roland S., 2005, V301, P329; Hutten S, 2008, MOL BIOL CELL, V19, P2300, DOI 10.1091/mbc.E07-12-1279; Ibarra C, 2013, CIRC RES, V112, P236, DOI 10.1161/CIRCRESAHA.112.273839; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kazgan N, 2010, MOL BIOL CELL, V21, P3433, DOI 10.1091/mbc.E10-04-0347; Klenk C, 2006, J BIOL CHEM, V281, P8357, DOI 10.1074/jbc.M513703200; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Ozaki Y, 2011, J BIOL CHEM, V286, P5589, DOI 10.1074/jbc.M110.167742; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; Roscioli E, 2012, J CELL BIOL, V196, P435, DOI 10.1083/jcb.201109104; Sarfstein R, 2012, J BIOL CHEM, V287, P2766, DOI 10.1074/jbc.M111.281782; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Shrum CK, 2009, P NATL ACAD SCI USA, V106, P2647, DOI 10.1073/pnas.0806677106; SKOUFIAS DA, 1992, BIOCHEMISTRY-US, V31, P738, DOI 10.1021/bi00118a015; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Strom AC, 2001, GENOME BIOL, V2; van Gaal JC, 2013, EUR J CANCER, V49, P3462, DOI 10.1016/j.ejca.2013.06.022; Warsito D, 2012, EMBO REP, V13, P244, DOI 10.1038/embor.2011.251; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Wu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042483; Yeh TY, 2012, MOL BIOL CELL, V23, P3827, DOI 10.1091/mbc.E12-07-0496; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou Y, 2013, J OPTIMIZ THEORY APP, V156, P1, DOI 10.1007/s10957-013-0271-2	51	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2227	2238		10.1038/onc.2014.165	http://dx.doi.org/10.1038/onc.2014.165			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909165				2022-12-28	WOS:000353473000008
J	Bais, MV; Ozdener, GB; Sonenshein, GE; Trackman, PC				Bais, M. V.; Ozdener, G. B.; Sonenshein, G. E.; Trackman, P. C.			Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways	ONCOGENE			English	Article							ATM PROTEIN-KINASE; TRANSFORMED PHENOTYPE; MRE11 NUCLEASE; EXPRESSION; LUNG; ACTIVATION; RESISTANCE; RADIATION; BINDING; CELLS	Lysyl oxidase (LOX) is a multifunctional protein required for normal collagen and elastin biosynthesis and maturation. In addition, LOX has complex roles in cancer in which the lysyl oxidase propeptide (LOX-PP) domain of secreted pro-LOX has tumor-suppressor activity, while the active enzyme promotes metastasis. In prostate cancer cell lines, recombinant LOX-PP (rLOX-PP) inhibits the growth of PC3 cells in vitro by mechanisms that were not characterized, while in DU145 cells rLOX-PP targeted fibroblast growth factor signaling. Because rLOX-PP can enhance effects of a genotoxic chemotherapeutic on breast cancer cell apoptosis, we reasoned that rLOX-PP could target DNA repair pathways typically elevated in cancer. Here we demonstrate for the first time that rLOX-PP inhibits prostate xenograft growth in vivo and that activating phosphorylations of the key DNA repair molecules ataxia-telangiectasia mutated (ATM) and checkpoint kinase 2 (CHK2) are inhibited by rLOX-PP expression in vivo. In addition, in vitro studies showed that rLOX-PP inhibits radiation-induced activating phosphorylations of ATM and CHK2 and that exogenously added rLOX-PP protein can localize to the nucleus in both DU145 and PC3 cells. rLOX-PP pull-down studies resulted in detection of a protein complex with the nuclear DNA repair regulator MRE11 in both cell lines, and rLOX-PP localized to radiation-induced nuclear DNA repair foci. Finally, rLOX-PP was shown to sensitize both DU145 and PC3 cells to radiation-induced cell death determined in colony-formation assays. These data provide evidence that rLOX-PP has a nuclear mechanism of action in which it directly interacts with DNA repair proteins to sensitize prostate cancer cells to the effects of ionizing radiation.	[Bais, M. V.; Ozdener, G. B.; Trackman, P. C.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; [Sonenshein, G. E.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA	Boston University; Tufts University	Trackman, PC (corresponding author), Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, 700 Albany St,W-201, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Bais, Manish/0000-0003-4198-7377	NIH [DE R01014066, DOD W81XWH-08-1-0349 PC073646, R01 CA143108]; NATIONAL CANCER INSTITUTE [R01CA143108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014066] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the NIH grants DE R01014066, DOD W81XWH-08-1-0349 PC073646 and R01 CA143108.	Agra N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066281; [Anonymous], 2003, METH MOL B; Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239; Bais MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031188; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Berlier JE, 2003, J HISTOCHEM CYTOCHEM, V51, P1699, DOI 10.1177/002215540305101214; Bhatti S, 2011, CELL MOL LIFE SCI, V68, P2977, DOI 10.1007/s00018-011-0683-9; Buis J, 2008, CELL, V135, P85, DOI 10.1016/j.cell.2008.08.015; Buscemi G, 2006, MOL CELL BIOL, V26, P7832, DOI 10.1128/MCB.00534-06; Carlessi L, 2007, MOL CANCER THER, V6, P935, DOI 10.1158/1535-7163.MCT-06-0567; Choudhury A, 2006, SEMIN RADIAT ONCOL, V16, P51, DOI 10.1016/j.semradonc.2005.08.007; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; Delia D, 2003, ONCOGENE, V22, P7866, DOI 10.1038/sj.onc.1207086; Eastman A, 2004, J CELL BIOCHEM, V91, P223, DOI 10.1002/jcb.10699; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hurtado PA, 2008, BIOCHEM BIOPH RES CO, V366, P156, DOI 10.1016/j.bbrc.2007.11.116; Jobson AG, 2007, MOL PHARMACOL, V72, P876, DOI 10.1124/mol.107.035832; Kauffmann A, 2008, ONCOGENE, V27, P565, DOI 10.1038/sj.onc.1210700; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Martinez-Marignac VL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016394; Matos CS, 2012, CURR MED CHEM, V19, P4678; Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867; Min CY, 2010, J CELL BIOCHEM, V111, P1160, DOI 10.1002/jcb.22828; Mok MTS, 2012, RADIOTHER ONCOL, V103, P415, DOI 10.1016/j.radonc.2012.04.009; Munshi A, 2005, METH MOLEC MED, V110, P21; Nakano D, 2012, J AM SOC NEPHROL, V23, P1847, DOI 10.1681/ASN.2012010078; Neel DS, 2013, CLIN CANCER RES, V19, P3, DOI 10.1158/1078-0432.CCR-12-3232; Olson E, 2007, MOL CELL BIOL, V27, P6053, DOI 10.1128/MCB.00532-07; Oxnard GR, 2012, ARCH PATHOL LAB MED, V136, P1205, DOI 10.5858/arpa.2012-0254-RA; Palamakumbura AH, 2009, ONCOGENE, V28, P3390, DOI 10.1038/onc.2009.203; Palamakumbura AH, 2004, J BIOL CHEM, V279, P40593, DOI 10.1074/jbc.M406639200; Palamakumbura AH, 2003, J BIOL CHEM, V278, P30781, DOI 10.1074/jbc.M305238200; Pallis A, 2011, CURR MED CHEM, V18, P1613, DOI 10.2174/092986711795471383; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Podhorecka M, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/920161; Rainey MD, 2008, CANCER RES, V68, P7466, DOI 10.1158/0008-5472.CAN-08-0763; Ritter M, 2008, SEMIN RADIAT ONCOL, V18, P249, DOI 10.1016/j.semradonc.2008.04.007; Sanchez-Morgan N, 2011, MOL CELL BIOL, V31, P3286, DOI 10.1128/MCB.01426-10; Sarasin A, 2008, MUTAT RES-REV MUTAT, V659, P49, DOI 10.1016/j.mrrev.2007.12.002; Sato S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077288; Sato S, 2011, MOL CELL BIOL, V31, P2683, DOI 10.1128/MCB.01148-10; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Spalding AC, 2002, ONCOGENE, V21, P260, DOI 10.1038/sj.onc.1205048; Stolz A, 2011, CLIN CANCER RES, V17, P401, DOI 10.1158/1078-0432.CCR-10-1215; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Vora SR, 2010, BIOCHEMISTRY-US, V49, P2962, DOI 10.1021/bi902218p; Wang LM, 2008, AM J PHYSIOL-HEART C, V295, pH237, DOI 10.1152/ajpheart.01366.2007; Williams RS, 2008, CELL, V135, P97, DOI 10.1016/j.cell.2008.08.017; Wu M, 2007, CANCER RES, V67, P6278, DOI 10.1158/0008-5472.CAN-07-0776; Yu ZB, 2012, CELL RES, V22, P305, DOI 10.1038/cr.2011.128; Zaorsky NG, 2013, CANCER TREAT REV, V39, P728, DOI 10.1016/j.ctrv.2013.01.008; Zhao YS, 2009, J BIOL CHEM, V284, P1385, DOI 10.1074/jbc.M802612200; Zheng Y, 2014, ONCOL REP, V31, P1669, DOI 10.3892/or.2014.3044	64	27	29	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1928	1937		10.1038/onc.2014.147	http://dx.doi.org/10.1038/onc.2014.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882580	Green Accepted			2022-12-28	WOS:000352725600007
J	Elias, D; Vever, H; Laenkholm, AV; Gjerstorff, MF; Yde, CW; Lykkesfeldt, AE; Ditzel, HJ				Elias, D.; Vever, H.; Laenkholm, A-V; Gjerstorff, M. F.; Yde, C. W.; Lykkesfeldt, A. E.; Ditzel, H. J.			Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy	ONCOGENE			English	Article							BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; ANTIESTROGEN RESISTANCE; POSTMENOPAUSAL WOMEN; POOR-PROGNOSIS; C-SRC; GROWTH; LETROZOLE; ER; ACTIVATION	To elucidate the molecular mechanisms of tamoxifen resistance in breast cancer, we performed gene array analyses and identified 366 genes with altered expression in four unique tamoxifen-resistant (TamR) cell lines vs the parental tamoxifen-sensitive MCF-7/S0.5 cell line. Most of these genes were functionally linked to cell proliferation, death and control of gene expression, and include FYN, PRKCA, ITPR1, DPYD, DACH1, LYN, GBP1 and PRLR. Treatment with FYN-specific small interfering RNA or a SRC family kinase inhibitor reduced cell growth of TamR cell lines while exerting no significant effect on MCF-7/S0.5 cells. Moreover, overexpression of FYN in parental tamoxifen-sensitive MCF-7/S0.5 cells resulted in reduced sensitivity to tamoxifen treatment, whereas knockdown of FYN in the FYN-overexpressing MCF-7/S0.5 cells restored sensitivity to tamoxifen, demonstrating growth-and survival-promoting function of FYN in MCF-7 cells. FYN knockdown in TamR cells led to reduced phosphorylation of 14-3-3 and Cdc25A, suggesting that FYN, by activation of important cell cycle-associated proteins, may overcome the anti-proliferative effects of tamoxifen. Evaluation of the subcellular localization of FYN in primary breast tumors from two cohorts of endocrine-treated ER+ breast cancer patients, one with advanced disease (N = 47) and the other with early disease (N = 76), showed that in the former, plasma membrane-associated FYN expression strongly correlated with longer progression-free survival (P < 0.0002). Similarly, in early breast cancer patients, membrane-associated expression of FYN in the primary breast tumor was significantly associated with increased metastasis-free (P < 0.04) and overall (P < 0.004) survival independent of tumor size, grade or lymph node status. Our results indicate that FYN has an important role in tamoxifen resistance, and its subcellular localization in breast tumor cells may be an important novel biomarker of response to endocrine therapy in breast cancer.	[Elias, D.; Vever, H.; Gjerstorff, M. F.; Ditzel, H. J.] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, DK-5000 Odense C, Denmark; [Laenkholm, A-V] Slagelse Hosp, Dept Pathol, Slagelse, Denmark; [Yde, C. W.; Lykkesfeldt, A. E.] Danish Canc Soc Res Ctr, Breast Canc Grp, Cell Death & Metab, Copenhagen, Denmark; [Ditzel, H. J.] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark	University of Southern Denmark; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Elias, D (corresponding author), Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, JB Winsloewsvej 25, DK-5000 Odense C, Denmark.	delias@health.sdu.dk; hditzel@health.sdu.dk		Ditzel, Henrik J./0000-0003-3927-5135; gjerstorff, morten/0000-0002-0845-1952; Laenkholm, Anne-Vibeke/0000-0003-2166-8686	Danish Cancer Society; Danish Cancer Research Foundation; Danish Research Council; Danish Strategic Research Council; A Race Against Breast Cancer; Sino-Danish Breast Cancer Research Centre; NanoCAN Lundbeck Center of Excellence; Region of Southern Denmark Research Foundation; Odense University Hospital Research Council; Danish Center for Translational Breast Cancer research	Danish Cancer Society(Danish Cancer Society); Danish Cancer Research Foundation; Danish Research Council(Det Frie Forskningsrad (DFF)); Danish Strategic Research Council(Danske Strategiske Forskningsrad (DSF)); A Race Against Breast Cancer; Sino-Danish Breast Cancer Research Centre; NanoCAN Lundbeck Center of Excellence; Region of Southern Denmark Research Foundation; Odense University Hospital Research Council; Danish Center for Translational Breast Cancer research	We thank Lisbet Mortensen and Ole Nielsen at the Department of Pathology, Odense University Hospital, for excellent technical assistance and MK Occhipinti-Bender for editorial assistance. This work was supported in part by the Danish Cancer Society, the Danish Cancer Research Foundation, the Danish Research Council, the Danish Strategic Research Council, A Race Against Breast Cancer, Sino-Danish Breast Cancer Research Centre, NanoCAN Lundbeck Center of Excellence, Region of Southern Denmark Research Foundation, Odense University Hospital Research Council and Danish Center for Translational Breast Cancer research.	Ali HR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3061; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bertero T, 2013, CELL DEATH DIFFER, V20, P800, DOI 10.1038/cdd.2013.5; Bilal Erhan, 2010, Genes Cancer, V1, P1063, DOI 10.1177/1947601910395583; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; BRIAND P, 1984, CANCER RES, V44, P1114; Browne BC, 2013, FEBS J, V280, P5237, DOI 10.1111/febs.12441; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; Campbell EJ, 2008, BRIT J CANCER, V99, P1769, DOI 10.1038/sj.bjc.6604768; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Elsberger B, 2012, J CANCER RES CLIN, V138, P327, DOI 10.1007/s00432-011-1096-8; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269; Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946; Frogne T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2230; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Giuliano M, 2011, BREAST, V20, pS42, DOI 10.1016/S0960-9776(11)70293-4; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Henriksen K, 2009, ACTA ONCOL, V48, P522, DOI 10.1080/02841860802676383; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Ito Y, 2002, BREAST CANCER RES TR, V76, P261, DOI 10.1023/A:1020860221099; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Jordan NJ, 2004, BREAST CANCER RES TR, V87, P167, DOI 10.1023/B:BREA.0000041623.21338.47; Leth-Larsen R, 2009, MOL CELL PROTEOMICS, V8, P1436, DOI 10.1074/mcp.M800061-MCP200; Lundholt BK, 2001, BREAST CANCER RES TR, V67, P199, DOI 10.1023/A:1017977406429; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5; Madsen MW, 1997, CANCER RES, V57, P585; Masri S, 2008, CANCER RES, V68, P4910, DOI 10.1158/0008-5472.CAN-08-0303; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454; Morgan L, 2009, CANCER BIOL THER, V8, P1550, DOI 10.4161/cbt.8.16.8954; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Mouridsen H, 2007, J CLIN ONCOL, V25, P5715, DOI 10.1200/JCO.2007.12.1665; Mouridsen Henning T, 2005, MedGenMed, V7, P20; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nehra R, 2010, FASEB J, V24, P2040, DOI 10.1096/fj.09-138305; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Rasmussen BB, 2008, LANCET ONCOL, V9, P23, DOI 10.1016/S1470-2045(07)70386-8; Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Schrecengost RS, 2007, CANCER RES, V67, P6174, DOI 10.1158/0008-5472.CAN-06-3455; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sun M, 2001, CANCER RES, V61, P5985; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; Xu XD, 2003, CLIN CANCER RES, V9, P1764; Yde CW, 2012, BREAST CANCER RES TR, V135, P67, DOI 10.1007/s10549-012-2053-1	54	56	57	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1919	1927		10.1038/onc.2014.138	http://dx.doi.org/10.1038/onc.2014.138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882577				2022-12-28	WOS:000352725600006
J	Satija, YK; Das, S				Satija, Y. K.; Das, S.			Tyr99 phosphorylation determines the regulatory milieu of tumor suppressor p73	ONCOGENE			English	Article							KINASE C-ABL; DNA-DAMAGE; P53 FAMILY; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; DOWN-REGULATION; E3 LIGASE; CANCER; PROTEIN; GENE	p73 is a member of the p53 tumor suppressor family, which mediates genotoxic stress response by triggering cell cycle arrest and apoptosis. Similar to p53, p73 is maintained at very low levels, but it gets rapidly induced upon genotoxic stress. Mounting evidences demonstrate that p73 is primarily regulated posttranslationally. However, the molecular mechanisms which determine its stability and activity discerningly under normal and stress conditions are still not well understood. Here, we employed a proteomics approach to identify differential interactors of p73 under normal and genotoxic stress conditions. We report here that TRIM28, an E3 ligase, interacts with p73 and targets it for proteasomal degradation under normal conditions. Genotoxic stress-induced phosphorylation of p73 at tyrosine 99 residue by c-abl kinase leads to abrogation of this interaction thereby promoting p73 stabilization. Furthermore, the phosphorylated form of p73 specifically interacts with MED15, which serves as a transcriptional coactivator and leads to activation of proarrest, proapoptotic and anti-metastatic genes. RNAi-mediated abrogation of TRIM28 expression facilitates p73-mediated tumor suppression in mouse tumor models, whereas disruption of MED15 expression abrogates p73 tumor suppressor and anti-metastatic functions. These findings provide new insights into the pivotal role of Tyr99 phosphorylation in determining p73 levels and functions.	[Satija, Y. K.; Das, S.] Natl Inst Immunol, Mol Oncol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Das, S (corresponding author), Natl Inst Immunol, Mol Oncol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	sdas@nii.ac.in		Das, Sanjeev/0000-0002-3594-1033	Department of Biotechnology, Government of India [BT/PR7200/BRB/10/1155/2012]; NII Core Fund; Council for Scientific and Industrial Research, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); NII Core Fund; Council for Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India)	We thank the members of the Molecular Oncology Lab for helpful discussions. This work was supported by a grant from the Department of Biotechnology, Government of India (BT/PR7200/BRB/10/1155/2012). We also acknowledge the financial support received from NII Core Fund. YKS was supported by a fellowship from the Council for Scientific and Industrial Research, Government of India.	Agami R, 1999, NATURE, V399, P809; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Beitzinger M, 2008, EMBO J, V27, P792, DOI 10.1038/emboj.2008.13; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Das S, 2006, CANCER BIOL THER, V5, P210, DOI 10.4161/cbt.5.2.2402; Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887; Gong JG, 1999, NATURE, V399, P806; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishikawa H, 2006, FEBS LETT, V580, P4784, DOI 10.1016/j.febslet.2006.07.066; Jiang WG, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-71; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Liang QM, 2011, J IMMUNOL, V187, P4754, DOI 10.4049/jimmunol.1101704; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Ozaki T, 2005, CANCER SCI, V96, P729, DOI 10.1111/j.1349-7006.2005.00116.x; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Sasaki Y, 2012, CANCER BIOL THER, V13, P1512, DOI 10.4161/cbt.22280; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Suzuki F, 2005, ONCOL REP, V14, P1493; Takai N, 2005, MOL CANCER RES, V3, P261, DOI 10.1158/1541-7786.MCR-04-0110; Tanikawa C, 2012, NEOPLASIA, V14, P141, DOI 10.1593/neo.111700; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wezensky SJ, 2010, GENE, V452, P22, DOI 10.1016/j.gene.2009.12.003; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Yokoe T, 2010, ANN SURG ONCOL, V17, P821, DOI 10.1245/s10434-009-0795-8; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhang JM, 2004, ONCOGENE, V23, P2241, DOI 10.1038/sj.onc.1207328; Zhang S, 2011, ONCOGENE, V30, P4941, DOI 10.1038/onc.2011.199; Zhang X, 2007, HEAD NECK-J SCI SPEC, V29, P236, DOI 10.1002/hed.20511; Zhu JH, 1998, CANCER RES, V58, P5061; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	51	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					513	527		10.1038/onc.2015.111	http://dx.doi.org/10.1038/onc.2015.111			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893286				2022-12-28	WOS:000369056700011
J	Sheikh, BN; Phipson, B; El-Saafin, F; Vanyai, HK; Downer, NL; Bird, MJ; Kueh, AJ; May, RE; Smyth, GK; Voss, AK; Thomas, T				Sheikh, B. N.; Phipson, B.; El-Saafin, F.; Vanyai, H. K.; Downer, N. L.; Bird, M. J.; Kueh, A. J.; May, R. E.; Smyth, G. K.; Voss, A. K.; Thomas, T.			MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway	ONCOGENE			English	Article							LEUKEMIA ZINC-FINGER; LEUCINE-ZIPPER KINASE; ACUTE MYELOID-LEUKEMIA; MONOCYTIC LEUKEMIA; GENE-EXPRESSION; TRANSLOCATION T(8/16)(P11,P13); GENOME EXPRESSION; CELL-DEATH; PROTEIN; PROLIFERATION	Cellular senescence is an important mechanism that restricts tumour growth. The Ink4a-Arf locus (also known as Cdkn2a), which encodes p16(INK4A) and p19(ARF), has a central role in inducing and maintaining senescence. Given the importance of cellular senescence in restraining tumour growth, great emphasis is being placed on the identification of novel factors that can modulate senescence. The MYST-family histone acetyltransferase MOZ (MYST3, KAT6A), first identified in recurrent translocations in acute myeloid leukaemia, has been implicated in both the promotion and inhibition of senescence. In this study, we investigate the role of MOZ in cellular senescence and show that MOZ is a potent inhibitor of senescence via the INK4A-ARF pathway. Primary mouse embryonic fibroblasts (MEFs) isolated from Moz-deficient embryos exhibit premature senescence, which was rescued on the Ink4a-Arf(-/-) background. Importantly, senescence resulting from the absence of MOZ was not accompanied by DNA damage, suggesting that MOZ acts independently of the DNA damage response. Consistent with the importance of senescence in cancer, expression profiling revealed that genes overexpressed in aggressive and highly proliferative cancers are expressed at low levels in Mozdeficient MEFs. We show that MOZ is required to maintain normal levels of histone 3 lysine 9 (H3K9) and H3K27 acetylation at the transcriptional start sites of at least four genes, Cdc6, Ezh2, E2f2 and Melk, and normal mRNA levels of these genes. CDC6, EZH2 and E2F2 are known inhibitors of the INK4A-ARF pathway. Using chromatin immunoprecipitation, we show that MOZ occupies the Cdc6, Ezh2 and Melk loci, thereby providing a direct link between MOZ, H3K9 and H3K27 acetylation, and normal transcriptional levels at these loci. This work establishes that MOZ is an upstream inhibitor of the INK4A-ARF pathway, and suggests that inhibiting MOZ may be one way to induce senescence in proliferative tumour cells.	[Sheikh, B. N.; El-Saafin, F.; Vanyai, H. K.; Downer, N. L.; Kueh, A. J.; May, R. E.; Voss, A. K.; Thomas, T.] Walter & Eliza Hall Inst Med Res, Div Dev & Canc, Melbourne, Vic 3052, Australia; [Sheikh, B. N.; El-Saafin, F.; Vanyai, H. K.; Voss, A. K.; Thomas, T.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Phipson, B.; Smyth, G. K.] Walter & Eliza Hall Inst Med Res, Div Bioinformat, Melbourne, Vic 3052, Australia; [Phipson, B.; Bird, M. J.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Bird, M. J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Smyth, G. K.] Univ Melbourne, Dept Math & Stat, Melbourne, Vic, Australia	University of Melbourne; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne	Thomas, T (corresponding author), Walter & Eliza Hall Inst Med Res, Div Dev & Canc, 1G Royal Parade, Melbourne, Vic 3052, Australia.	avoss@wehi.edu.au; tthomas@wehi.edu.au	Smyth, Gordon/B-5276-2008; Voss, Anne K/F-5110-2013; Phipson, Belinda/AAP-2213-2020	Smyth, Gordon/0000-0001-9221-2892; Voss, Anne K/0000-0002-3853-9381; Phipson, Belinda/0000-0002-1711-7454; Bird, Matthew/0000-0003-3185-0780; Sheikh, Bilal/0000-0002-1970-6236; Thomas, Tim/0000-0002-7623-8344	Australian National Health and Medical Research Council; Australian Mitochondrial Disease Foundation; Australian Postgraduate Awards; Australian Federal Government (IRISS); Victorian State Government	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Mitochondrial Disease Foundation; Australian Postgraduate Awards(Australian Government); Australian Federal Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government	We thank Carmen Gatt and Faye Dabrowski for technical support. We thank Andreas Strasser for helpful discussions and Liz Valente for the provision of the anti-p21<SUP>CIP1</SUP> antibody. This work was supported by the Australian National Health and Medical Research Council (senior research fellowships to AKV and TT; scholarship to BNS), the Australian Mitochondrial Disease Foundation (MJB), Australian Postgraduate Awards (to MJB, FE and HKV) and operational infrastructure grants from the Australian Federal Government (IRISS) and the Victorian State Government (OIS).	Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622; Azzam G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074297; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Esteyries S, 2008, LEUKEMIA, V22, P663, DOI 10.1038/sj.leu.2404930; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Haferlach T, 2009, LEUKEMIA, V23, P934, DOI 10.1038/leu.2008.388; Hayama S, 2007, CANCER RES, V67, P4113, DOI 10.1158/0008-5472.CAN-06-4705; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kig C, 2013, J BIOL CHEM, V288, P24200, DOI 10.1074/jbc.M113.471433; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266; Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Muslimovic A, 2008, NAT PROTOC, V3, P1187, DOI 10.1038/nprot.2008.93; Nakano I, 2005, J CELL BIOL, V170, P413, DOI 10.1083/jcb.200412115; Nakano I, 2008, J NEUROSCI RES, V86, P48, DOI 10.1002/jnr.21471; Ohta S, 2001, ONCOL REP, V8, P1063; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; QUELLE DE, 1995, CELL, V83, P993; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Rokudai S, 2009, J BIOL CHEM, V284, P237, DOI 10.1074/jbc.M805101200; Schwickert TA, 2014, NAT IMMUNOL, V15, P283, DOI 10.1038/ni.2828; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shi W, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq871; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; Sun T, 2001, AM J HEMATOL, V66, P207, DOI 10.1002/1096-8652(200103)66:3<207::AID-AJH1046>3.0.CO;2-Q; Tang X, 2007, ONCOGENE, V26, P7302, DOI 10.1038/sj.onc.1210542; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Uchida F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056381; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Voss AK, 1998, DEV DYNAM, V212, P171, DOI 10.1002/(SICI)1097-0177(199806)212:2<171::AID-AJA3>3.0.CO;2-E; Voss AK, 2012, DEV CELL, V23, P652, DOI 10.1016/j.devcel.2012.07.010; Voss AK, 2012, METHODS MOL BIOL, V809, P335, DOI 10.1007/978-1-61779-376-9_23; Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	75	46	49	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5807	5820		10.1038/onc.2015.33	http://dx.doi.org/10.1038/onc.2015.33			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25772242				2022-12-28	WOS:000365035200004
J	Parisi, T; Bronson, RT; Lees, JA				Parisi, T.; Bronson, R. T.; Lees, J. A.			Inactivation of the retinoblastoma gene yields a mouse model of malignant colorectal cancer	ONCOGENE			English	Article							PROSTATE-CANCER; DEFICIENT CELLS; MOLECULAR-BASIS; BETA-CATENIN; RB; PRB; TUMORS; TUMORIGENESIS; EXPRESSION; MICE	The retinoblastoma gene (Rb) is mutated at significant frequency in various human epithelial tumors, including colorectal cancer, and is strongly associated with metastatic disease. However, sole inactivation of Rb in the mouse has so far failed to yield epithelial cancers. Here, we specifically inactivate Rb and/or p53 in the urogenital epithelium and the intestine. We find that the loss of both tumor suppressors is unable to yield tumors in the transitional epithelium lining the bladder, kidneys and ureters. Instead, these mice develop highly metastatic tumors of neuroendocrine, not epithelial, origin within the urogenital tract to give prostate cancer in the males and vaginal tumors in the females. Additionally, we discovered that the sole inactivation of Rb in the intestine was sufficient to induce formation of metastatic colorectal adenocarcinomas. These tumors closely mirror the human disease in regard to the age of onset, histological appearance, invasiveness and metastatic potential. Like most human colorectal carcinomas, our murine Rb-deficient tumors demonstrate genomic instability and they show activation of beta-catenin. Deregulation of the Wnt/beta-catenin pathway is specific to the intestinal tumors, as genomic instability but not activation of beta-catenin was observed in the neuroendocrine tumors. To date, attempts to generate genetically engineered mouse models of colorectal cancer tumors have yielded mostly cancer of the small intestine, which rarely occurs in humans. Our system provides the opportunity to accurately model and study colorectal cancer in the mouse via a single gene mutation.	[Parisi, T.; Lees, J. A.] Koch Inst Integrat Canc Res, Cambridge, MA USA; [Bronson, R. T.] Tufts Cummings Sch Vet Med, Dept Pathol, North Grafton, MA USA; [Lees, J. A.] MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	jalees@mit.edu			NIH/NCI [P30-CA14051, P01-CA42063, RO1-CA121921]; NATIONAL CANCER INSTITUTE [R01CA121921, P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Omer Yilmaz for scientific suggestions and professional evaluation of the pathology slides, Kevin Haigis for unpublished information and reagents, A. Amsterdam and S. Frank for critical reading of the manuscript, and the Koch Institute Swanson Biotechnology Center for technical support, particularly the Histology Core. This work was supported by NIH/NCI grants to the Koch Institute (P30-CA14051), and to JAL (P01-CA42063 and RO1-CA121921), a Ludwig Scholar at MIT.	Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Burgess AW, 2011, EXP CELL RES, V317, P2748, DOI 10.1016/j.yexcr.2011.08.010; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Coschi CH, 2010, GENE DEV, V24, P1351, DOI 10.1101/gad.1917610; Dinney CPN, 2004, CANCER CELL, V6, P111, DOI 10.1016/j.ccr.2004.08.002; GOPE R, 1990, J NATL CANCER I, V82, P310, DOI 10.1093/jnci/82.4.310; Haigis K, 2006, J BIOL CHEM, V281, P638, DOI 10.1074/jbc.M509053200; He F, 2009, CANCER RES, V69, P9413, DOI 10.1158/0008-5472.CAN-09-2158; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Horst D, 2009, CANCER, V115, P2063, DOI 10.1002/cncr.24254; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Humphrey PA, 2012, HISTOPATHOLOGY, V60, P59, DOI 10.1111/j.1365-2559.2011.04039.x; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Johnson RL, 2013, CANCER METAST REV, V32, P39, DOI 10.1007/s10555-012-9404-6; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kucherlapati MH, 2008, P NATL ACAD SCI USA, V105, P15493, DOI 10.1073/pnas.0802933105; Kucherlapati MH, 2006, CANCER RES, V66, P3576, DOI 10.1158/0008-5472.CAN-05-2699; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Manning AL, 2014, MOL CELL, V53, P993, DOI 10.1016/j.molcel.2014.01.032; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Moran A, 2010, WORLD J GASTRO ONCOL, V2, P151, DOI 10.4251/wjgo.v2.i3.151; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nandan MO, 2010, CURR COLORECT CANC R, V6, P51, DOI 10.1007/s11888-010-0046-1; Parisi T, 2009, ONCOGENE, V28, P500, DOI 10.1038/onc.2008.406; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Rosenberg JE, 2009, GENE DEV, V23, P655, DOI 10.1101/gad.1789109; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Yang HS, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-6; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zeineldin M, 2013, CANCER RES, V73, P2389, DOI 10.1158/0008-5472.CAN-12-4607; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	45	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5890	5899		10.1038/onc.2015.30	http://dx.doi.org/10.1038/onc.2015.30			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25745996	Green Submitted, Green Accepted			2022-12-28	WOS:000365434000003
J	Ruiz-Saenz, A; Sandhu, M; Carrasco, Y; Maglathlin, RL; Taunton, J; Moasser, MM				Ruiz-Saenz, A.; Sandhu, M.; Carrasco, Y.; Maglathlin, R. L.; Taunton, J.; Moasser, M. M.			Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum	ONCOGENE			English	Article							FACTOR-RECEPTOR MUTATIONS; BREAST-CANCER; GENE AMPLIFICATION; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODY; TYROSINE KINASE; ERBB3 ANTIBODY; ONCOGENIC UNIT; UP-REGULATION; COLON-CANCER	There is increasing evidence implicating human epidermal growth factor receptor 3 (HER3) in several types of cancer. However, the development of targeted therapies to inactivate HER3 function has been a challenging endeavor. Its kinase domain functions in allostery not catalysis, and the classical ATP-analog class of tyrosine kinase inhibitors fail to inactivate it. Here we describe a novel approach that eliminates HER3 expression. The small-molecule cotransin CT8 binds the Sec61 translocon and prevents the signal peptide of the nascent HER3 protein from initiating its cotranslational translocation, resulting in the degradation of HER3 but not the other HER proteins. CT8 treatment suppresses the induction of HER3 that accompanies lapatinib treatment of HER2-amplified cancers and synergistically enhances the apoptotic effects of lapatinib. The target selectivities of cotransins are highly dependent on their structure and the signal sequence of targeted proteins and can be narrowed through structure-function studies. Targeting Sec61-dependent processing identifies a novel strategy to eliminate HER3 function.	[Ruiz-Saenz, A.; Sandhu, M.; Moasser, M. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA 94143 USA; [Carrasco, Y.; Maglathlin, R. L.; Taunton, J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Taunton, J.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, UCSF Box 1387,2340 Sutter St,Room N-144, San Francisco, CA 94143 USA.	mark.moasser@ucsf.edu	Sandhu, Manbir/AAI-2124-2019; Ruiz-Saenz, Ana/U-3220-2017	Sandhu, Manbir/0000-0003-1182-7268; Ruiz-Saenz, Ana/0000-0001-6033-6153	National Institutes of Health [CA122216, CA112970]; Howard Hughes Medical Institute; Fundacion Ramon Areces Fellowship; NATIONAL CANCER INSTITUTE [U54CA112970, R01CA122216] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Fundacion Ramon Areces Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health CA122216 and CA112970 (to MMM), Howard Hughes Medical Institute (to JT) and a Fundacion Ramon Areces Fellowship (to ARS).	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Amin DN, 2012, BIOCHEM J, V447, P417, DOI 10.1042/BJ20120724; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Beji A, 2012, CLIN CANCER RES, V18, P956, DOI 10.1158/1078-0432.CCR-11-1186; Besemer J, 2005, NATURE, V436, P290, DOI 10.1038/nature03670; Blackburn E, 2012, BREAST CANCER RES TR, V134, P53, DOI 10.1007/s10549-011-1908-1; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Chen Y, 2002, J AM CHEM SOC, V124, P5431, DOI 10.1021/ja020166v; Fattore L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-180; Foreman PK, 2012, MOL CANCER THER, V11, P1411, DOI 10.1158/1535-7163.MCT-12-0068; Frederick L, 2000, CANCER RES, V60, P1383; Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Garrison JL, 2005, NATURE, V436, P285, DOI 10.1038/nature03821; Gerbin CS, 2010, CELL STRESS CHAPERON, V15, P529, DOI 10.1007/s12192-009-0166-1; Gespach C, 2012, CLIN CANCER RES, V18, P917, DOI 10.1158/1078-0432.CCR-11-3143; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GIARETTI W, 1994, METHOD CELL BIOL, V41, P389; Harant H, 2006, J BIOL CHEM, V281, P30492, DOI 10.1074/jbc.M607243200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hulleman JD, 2013, J BIOMOL SCREEN, V18, P647, DOI 10.1177/1087057112469405; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Kugel CH, 2014, CANCER RES, V74, P4122, DOI 10.1158/0008-5472.CAN-14-0464; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lee H, 2001, CANCER RES, V61, P4467; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Licitra L, 2011, ANN ONCOL, V22, P1078, DOI 10.1093/annonc/mdq588; Littlefield P, 2014, CHEM BIOL, V21, P453, DOI 10.1016/j.chembiol.2014.02.011; Lopez-Gines C, 2005, CLIN NEUROPATHOL, V24, P209; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MacKinnon AL, 2007, J AM CHEM SOC, V129, P14560, DOI 10.1021/ja076250y; MacKinnon AL, 2014, ELIFE, V3, DOI 10.7554/eLife.01483; Maifeld SV, 2011, CHEM BIOL, V18, P1082, DOI 10.1016/j.chembiol.2011.06.015; McDonagh CF, 2012, MOL CANCER THER, V11, P582, DOI 10.1158/1535-7163.MCT-11-0820; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Reschke M, 2008, CLIN CANCER RES, V14, P5188, DOI 10.1158/1078-0432.CCR-08-0186; Santin AD, 2005, CANCER-AM CANCER SOC, V104, P1391, DOI 10.1002/cncr.21308; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Tao JJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005125; Vaught DB, 2012, CANCER RES, V72, P2672, DOI 10.1158/0008-5472.CAN-11-3594; Yano T, 2006, ONCOL REP, V15, P65; Yao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078086; Zhang L, 2014, MOL CANCER THER, V13, P1345, DOI 10.1158/1535-7163.MCT-13-1033	52	18	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5288	5294		10.1038/onc.2014.455	http://dx.doi.org/10.1038/onc.2014.455			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619841	Green Accepted, Green Submitted			2022-12-28	WOS:000362575400008
J	Lewis, CA; Brault, C; Peck, B; Bensaad, K; Griffiths, B; Mitter, R; Chakravarty, P; East, P; Dankworth, B; Alibhai, D; Harris, AL; Schulze, A				Lewis, C. A.; Brault, C.; Peck, B.; Bensaad, K.; Griffiths, B.; Mitter, R.; Chakravarty, P.; East, P.; Dankworth, B.; Alibhai, D.; Harris, A. L.; Schulze, A.			SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme	ONCOGENE			English	Article							ELEMENT-BINDING PROTEIN; STEAROYL-COA DESATURASE; UNSATURATED FATTY-ACIDS; SMALL-MOLECULE; TUMOR-CELLS; HYPOXIA; METABOLISM; EXPRESSION; GROWTH; LIPOGENESIS	Oxygen and nutrient limitation are common features of the tumor microenvironment and are associated with cancer progression and induction of metastasis. The inefficient vascularization of tumor tissue also limits the penetration of other serum-derived factors, such as lipids and lipoproteins, which can be rate limiting for cell proliferation and survival. Here we have investigated the effect of hypoxia and serum deprivation on sterol regulatory element-binding protein (SREBP) activity and the expression of lipid metabolism genes in human glioblastoma multiforme (GBM) cancer cells. We found that SREBP transcriptional activity was induced by serum depletion both in normoxic and hypoxic cells and that activation of SREBP was required to maintain the expression of fatty acid and cholesterol metabolism genes under hypoxic conditions. Moreover, expression of stearoyl-CoA desaturase, the enzyme required for the generation of mono-unsaturated fatty acids, and fatty acid-binding protein 7, a regulator of glioma stem cell function, was strongly dependent on SREBP function. Inhibition of SREBP function blocked lipid biosynthesis in hypoxic cancer cells and impaired cell survival under hypoxia and in a three-dimensional spheroid model. Finally, gene expression analysis revealed that SREBP defines a gene signature that is associated with poor survival in glioblastoma.	[Lewis, C. A.; Peck, B.; Griffiths, B.; Schulze, A.] Canc Res UK London Res Inst, Gene Express Anal Lab, London WC2A 3PX, England; [Brault, C.; Dankworth, B.; Schulze, A.] Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Bavaria, Germany; [Bensaad, K.; Harris, A. L.] Univ Oxford, CRUK Growth Factor Grp, Weatherall Inst Mol Med, Oxford, England; [Mitter, R.; Chakravarty, P.; East, P.] Canc Res UK London Res Inst, Bioinformat & Biostat Serv, London WC2A 3PX, England; [Alibhai, D.] Canc Res UK London Res Inst, Light Microscopy Core, London WC2A 3PX, England; [Schulze, A.] Comprehens Canc Ctr Mainfranken Wurzburg, Wurzburg, Germany	Cancer Research UK; University of Wurzburg; University of Oxford; Cancer Research UK; Cancer Research UK	Schulze, A (corresponding author), Theodor Boveri Inst, Dept Biochem & Mol Biol, Bioctr, D-97074 Wurzburg, Bavaria, Germany.	almut.schulze@uni-wuerzburg.de	Schulze, Almut/AAX-8257-2020; Harris, Adrian L/ABA-3343-2020	Schulze, Almut/0000-0002-8199-6422; Harris, Adrian L/0000-0003-1376-8409; Mitter, Richard/0000-0002-1279-3760; Peck, Barrie/0000-0002-6687-8495; chakravarty, probir/0000-0003-1146-8824	Cancer Research UK; Cancer Research UK [18974, 16466, 11359] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish; The Francis Crick Institute [10002] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); The Francis Crick Institute	We thank the LRI Research Services for help with experiments and Charles Mein and Lia Di Faveri (Genome Center Bart's and The London School of Medicine and Dentistry) for microarray analysis. We also thank Barbara Bauer (Department of Biochemistry and Molecular Biology, University of Wurzburg, Wurzburg, Germany) for histological analyses. This work was supported by Cancer Research UK.	Axelson H, 2005, SEMIN CELL DEV BIOL, V16, P554, DOI 10.1016/j.semcdb.2005.03.007; Belanger AJ, 2007, BIOCHEM BIOPH RES CO, V364, P567, DOI 10.1016/j.bbrc.2007.10.062; Bengoechea-Alonso MT, 2007, CURR OPIN CELL BIOL, V19, P215, DOI 10.1016/j.ceb.2007.02.004; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107; Currie E, 2013, CELL METAB; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Espenshade PJ, 2007, ANNU REV GENET, V41, P401, DOI 10.1146/annurev.genet.41.110306.130315; Favaro E, 2011, GENOME MED, V3, DOI 10.1186/gm271; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; GORDON GB, 1977, AM J PATHOL, V88, P663; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hess D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011394; Hilvo M, 2011, CANCER RES, V71, P3236, DOI 10.1158/0008-5472.CAN-10-3894; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Jung SY, 2012, J CELL BIOCHEM, V113, P3730, DOI 10.1002/jcb.24247; Kamisuki S, 2009, CHEM BIOL, V16, P882, DOI 10.1016/j.chembiol.2009.07.007; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Krycer JR, 2012, BIOCHEM J, V446, P191, DOI 10.1042/BJ20120545; Laurenti G, 2011, J CELL BIOCHEM, V112, P3891, DOI 10.1002/jcb.23323; Lee CYS, 2009, EMBO J, V28, P135, DOI 10.1038/emboj.2008.271; Li JG, 2006, PHYSIOL GENOMICS, V25, P450, DOI 10.1152/physiolgenomics.00293.2005; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu RZ, 2012, BIOCHEM BIOPH RES CO, V422, P482, DOI 10.1016/j.bbrc.2012.05.019; Liu RZ, 2010, INT J DEV BIOL, V54, P1229, DOI 10.1387/ijdb.092976rl; Mazzatti D, 2012, ARCH PHYSIOL BIOCHEM, V118, P112, DOI 10.3109/13813455.2012.654611; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mita R, 2010, J BIOL CHEM, V285, P37005, DOI 10.1074/jbc.M110.170076; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Ntambi JM, 2004, LIPIDS, V39, P1061, DOI 10.1007/s11745-004-1331-2; Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Rankin EB, 2009, MOL CELL BIOL, V29, P4527, DOI 10.1128/MCB.00200-09; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; Rysman E, 2010, CANCER RES, V70, P8117, DOI 10.1158/0008-5472.CAN-09-3871; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Schonfeld P, 2008, FREE RADICAL BIO MED, V45, P231, DOI 10.1016/j.freeradbiomed.2008.04.029; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Storch J, 2010, J BIOL CHEM, V285, P32679, DOI 10.1074/jbc.R110.135210; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tang JJ, 2011, CELL METAB, V13, P44, DOI 10.1016/j.cmet.2010.12.004; Therneau TM, 2000, MODELING SURVIVAL DA; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Yoshii Y, 2009, CANCER SCI, V100, P821, DOI 10.1111/j.1349-7006.2009.01099.x; Young RM, 2013, GENE DEV, V27, P1115, DOI 10.1101/gad.198630.112	68	120	124	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5128	5140		10.1038/onc.2014.439	http://dx.doi.org/10.1038/onc.2014.439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619842				2022-12-28	WOS:000362233400003
J	Maric, G; Annis, MG; Dong, Z; Rose, AAN; Ng, S; Perkins, D; MacDonald, PA; Ouellet, V; Russo, C; Siegel, PM				Maric, G.; Annis, M. G.; Dong, Z.; Rose, A. A. N.; Ng, S.; Perkins, D.; MacDonald, P. A.; Ouellet, V.; Russo, C.; Siegel, P. M.			GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin alpha(5)beta(1) for efficient breast cancer metastasis	ONCOGENE			English	Article							GLYCOPROTEIN NONMETASTATIC B; THERAPEUTIC TARGET; DC-HIL; EXPRESSION; OSTEOACTIVIN; PROTEIN; CELLS; ADHESION; ANGIOGENESIS; SIGNATURE	Glycoprotein nmb (GPNMB) promotes breast tumor growth and metastasis and its expression in tumor epithelium correlates with poor prognosis in breast cancer patients. Despite its biological and clinical significance, little is known regarding the molecular mechanisms engaged by GPNMB. Herein, we show that GPNMB engages distinct functional domains and mechanisms to promote primary tumor growth and metastasis. We demonstrate that neuropilin-1 (NRP-1) expression is increased in breast cancer cells that overexpress GPNMB. Interestingly, the GPNMB-driven increase in NRP-1 expression potentiated vascular endothelial growth factor signaling in breast cancer cells and was required for the growth, but not metastasis, of these cells in vivo. Interrogation of RNAseq data sets revealed a positive correlation between GPNMB and NRP-1 levels in human breast tumors. Furthermore, we ascribe pro-growth and pro-metastatic functions of GPNMB to its ability to bind alpha(5)beta(1) integrin and increase downstream signaling in breast cancer cells. We show that GPNMB enhances breast cancer cell adhesion to fibronectin, increases alpha(5)beta(1) expression and associates with this receptor through its RGD motif. GPNMB recruitment into integrin complexes activates Src and Fak signaling pathways in an RGD-dependent manner. Importantly, both the RGD motif and cytoplasmic tail of GPNMB are required to promote primary mammary tumor growth; however, only mutation of the RGD motif impaired the formation of lung metastases. Together, these findings identify novel and distinct molecular mediators of GPNMB-induced breast cancer growth and metastasis.	[Maric, G.; Annis, M. G.; Dong, Z.; Rose, A. A. N.; Ng, S.; Perkins, D.; MacDonald, P. A.; Ouellet, V.; Russo, C.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Maric, G.; Annis, M. G.; Dong, Z.; Rose, A. A. N.; MacDonald, P. A.; Ouellet, V.; Russo, C.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada; [Ng, S.; Perkins, D.; Siegel, P. M.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A3, Canada; [Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada	McGill University; McGill University; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West,Room 513, Montreal, PQ H3A 1A3, Canada.	peter.siegel@mcgill.ca	Rose, April/AAR-8222-2020	Rose, April/0000-0002-9845-4603; Annis, Matthew/0000-0002-8776-004X	Canadian Institutes for Health Research (CIHR); Fonds de recherche en sante du Quebec (FRSQ) research scholar program; CIHR [MOP-119401]	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de recherche en sante du Quebec (FRSQ) research scholar program; CIHR(Canadian Institutes of Health Research (CIHR))	We thank members of the Siegel laboratory for their thoughtful discussions regarding the current work and are also grateful to Dr Josie Ursini-Siegel for her critical reading of the manuscript. We acknowledge the Goodman Cancer Research Centre histology core facility (McGill University) for routine histological services. GM acknowledges studentship support from the Canadian Institutes for Health Research (CIHR). PMS was supported by the Fonds de recherche en sante du Quebec (FRSQ) research scholar program (Junior 2) and is currently a McGill University William Dawson Scholar. This research was supported solely by a grant from the CIHR (MOP-119401).	Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Bachelder RE, 2001, CANCER RES, V61, P5736; Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563; Bendell J, 2013, J CLIN ONCOL, V32, P3619; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chung JS, 2009, J IMMUNOL, V183, P5190, DOI 10.4049/jimmunol.0901319; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Hoashi T, 2010, FASEB J, V24, P1616, DOI 10.1096/fj.09-151019; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; Keir CH, 2012, EXPERT OPIN BIOL TH, V12, P259, DOI 10.1517/14712598.2012.642357; Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656; Le Borgne R, 2001, J CELL SCI, V114, P2831; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Missan DS, 2012, CRIT REV EUKAR GENE, V22, P309, DOI 10.1615/CritRevEukarGeneExpr.v22.i4.50; Moussa FM, 2014, J CELL BIOCHEM, V115, P1243, DOI 10.1002/jcb.24760; Ngan E, 2013, J CELL SCI, V126, P1981, DOI 10.1242/jcs.118315; Northey JJ, 2013, J BIOL CHEM, V288, P5210, DOI 10.1074/jbc.M112.424804; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541-7786.MCR-07-0119; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611; Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030; Sheng MHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035280; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Sondag GR, 2014, J CELL PHYSIOL, V229, P955, DOI 10.1002/jcp.24512; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Theos AC, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12084; Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600-0625.2008.00830.x; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Vaklavas C, 2014, BIODRUGS; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001161; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Xu H, 2014, CLIN CHEM, V60, P122, DOI 10.1373/clinchem.2013.207167; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753	49	47	51	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5494	5504		10.1038/onc.2015.8	http://dx.doi.org/10.1038/onc.2015.8			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25772243				2022-12-28	WOS:000363479700009
J	Dembowy, J; Adissu, HA; Liu, JC; Zacksenhaus, E; Woodgett, JR				Dembowy, J.; Adissu, H. A.; Liu, J. C.; Zacksenhaus, E.; Woodgett, J. R.			Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis	ONCOGENE			English	Article							HEDGEHOG SIGNALING PATHWAY; BREAST-CANCER; BETA-CATENIN; STEM-CELLS; PROGENITOR CELLS; SUBCELLULAR-DISTRIBUTION; METAPLASTIC CARCINOMAS; CUBITUS INTERRUPTUS; TRANSGENIC MICE; SELF-RENEWAL	Many components of the Wnt/beta-catenin signaling pathway have critical functions in mammary gland development and tumor formation, yet the contribution of glycogen synthase kinase-3 (GSK-3 alpha and GSK-3 beta) to mammopoiesis and oncogenesis is unclear. Here, we report that WAP-Cre-mediated deletion of GSK-3 in the mammary epithelium results in activation of Wnt/beta-catenin signaling and induces mammary intraepithelial neoplasia that progresses to squamous transdifferentiation and development of adenosquamous carcinomas at 6 months. To uncover possible beta-catenin-independent activities of GSK-3, we generated mammary-specific knockouts of GSK-3 and beta-catenin. Squamous transdifferentiation of the mammary epithelium was largely attenuated, however, mammary epithelial cells lost the ability to form mammospheres suggesting perturbation of stem cell properties unrelated to loss of beta-catenin alone. At 10 months, adenocarcinomas that developed in glands lacking GSK-3 and beta-catenin displayed elevated levels of gamma-catenin/plakoglobin as well as activation of the Hedgehog and Notch pathways. Collectively, these results establish the two isoforms of GSK-3 as essential integrators of multiple developmental signals that act to maintain normal mammary gland function and suppress tumorigenesis.	[Dembowy, J.; Woodgett, J. R.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Dembowy, J.; Zacksenhaus, E.; Woodgett, J. R.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Adissu, H. A.] Toronto Ctr Phenogen, Ctr Modelling Human Dis, Pathol Core, Toronto, ON, Canada; [Adissu, H. A.; Zacksenhaus, E.] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada; [Liu, J. C.; Zacksenhaus, E.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Woodgett, JR (corresponding author), Mt Sinai Hosp, Room 982,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	woodgett@lunenfeld.ca	Woodgett, Jim/F-1087-2010; adissu, hibret a/R-3282-2018; Zacksenhaus, Eldad/AAD-3584-2020	Woodgett, Jim/0000-0003-3731-5797; adissu, hibret a/0000-0003-3365-7466; 	CBCRA; CIHR [MOP74711]; Terry Fox Foundation; CBCF (Ontario) doctoral fellowship	CBCRA; CIHR(Canadian Institutes of Health Research (CIHR)); Terry Fox Foundation; CBCF (Ontario) doctoral fellowship	We thank Tao Deng, Hartland W Jackson and Purna A Joshi for assistance with mammary gland manipulation and Katrina MacAulay, Brad Doble and Satish Patel for their generation of mice harboring floxed GSK-3 alleles. We wish to thank Tara Paton of The Centre for Applied Genomics (TCAG), The Hospital for Sick Children, Toronto, for assistance with Sanger sequencing and Yanchun Wang of the Centre for Modeling Human Disease Pathology (CMHD) and Cryopreservation Core at the Toronto Centre for Phenogenomics for laser-capture microdissection. This work was supported by grants to JRW from the CBCRA, CIHR (MOP74711) and Terry Fox Foundation team grant to EZ. JD was partially supported by a CBCF (Ontario) doctoral fellowship.	Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Aktary Zackie, 2012, Int J Cell Biol, V2012, P189521, DOI 10.1155/2012/189521; Booth BW, 2007, J CELL PHYSIOL, V212, P729, DOI 10.1002/jcp.21071; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Chen Y, 2011, J BIOL CHEM, V286, P13502, DOI 10.1074/jbc.M110.217604; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Fiaschi M, 2007, J BIOL CHEM, V282, P36090, DOI 10.1074/jbc.M704280200; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Franzen CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042132; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Gauger KJ, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-11; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hui M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3401; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jin YH, 2009, MOL CELLS, V27, P15, DOI 10.1007/s10059-009-0001-7; Kameda C, 2010, BRIT J CANCER, V102, P738, DOI 10.1038/sj.bjc.6605517; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408; Kise Y, 2009, BIOCHEM BIOPH RES CO, V387, P569, DOI 10.1016/j.bbrc.2009.07.087; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Lacroix-Triki M, 2010, MODERN PATHOL, V23, P1438, DOI 10.1038/modpathol.2010.141; Lam L, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.4; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li LJ, 2007, MOL CARCINOGEN, V46, P824, DOI 10.1002/mc.20310; Li N, 2008, STEM CELLS, V26, P1253, DOI 10.1634/stemcells.2007-0691; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Ling H, 2010, ONCOGENE, V29, P4543, DOI 10.1038/onc.2010.186; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; MacAulay K, 2007, CELL METAB, V6, P329, DOI 10.1016/j.cmet.2007.08.013; Mahendram S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065320; Makarem M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001630; Makarem M, 2013, J MAMMARY GLAND BIOL, V18, P209, DOI 10.1007/s10911-013-9284-6; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2003, BREAST CANCER RES, V5, P63, DOI 10.1186/bcr566; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Moraes RC, 2007, DEVELOPMENT, V134, P1231, DOI 10.1242/dev.02797; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Ozaki S, 2005, ONCOL REP, V14, P1437; Parr C, 2004, INT J MOL MED, V14, P779; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Radulescu S, 2013, ONCOGENE, V32, P2048, DOI 10.1038/onc.2012.224; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Renou JP, 2003, ONCOGENE, V22, P4594, DOI 10.1038/sj.onc.1206596; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rieger-Christ KM, 2005, BRIT J CANCER, V92, P2153, DOI 10.1038/sj.bjc.6602651; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Sale S, 2013, NAT CELL BIOL, V15, P451, DOI 10.1038/ncb2725; Sun P, 2010, HISTOCHEM CELL BIOL, V133, P213, DOI 10.1007/s00418-009-0662-5; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wagner KU, 2002, DEVELOPMENT, V129, P1377; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Xu LS, 2010, BREAST CANCER RES TR, V123, P59, DOI 10.1007/s10549-009-0617-5; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Yin TF, 2005, P NATL ACAD SCI USA, V102, P5420, DOI 10.1073/pnas.0501676102; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	78	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3514	3526		10.1038/onc.2014.279	http://dx.doi.org/10.1038/onc.2014.279			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195860	Green Submitted, Green Published, Green Accepted, hybrid			2022-12-28	WOS:000357434900004
J	Schwarzer, A; Holtmann, H; Brugman, M; Meyer, J; Schauerte, C; Zuber, J; Steinemann, D; Schlegelberger, B; Li, Z; Baum, C				Schwarzer, A.; Holtmann, H.; Brugman, M.; Meyer, J.; Schauerte, C.; Zuber, J.; Steinemann, D.; Schlegelberger, B.; Li, Z.; Baum, C.			Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GLUCOCORTICOID RESISTANCE; STEM-CELLS; COMPLEX 2; C-MYC; PTEN; ACTIVATION; PATHWAY; AKT; INHIBITION	High activation of the PI3K-AKT-mTOR pathway is characteristic for T-cell acute lymphoblastic leukemia (T-ALL). The activity of the master regulator of this pathway, PTEN, is often impaired in T-ALL. However, experimental evidence suggests that input from receptor tyrosine kinases (RTKs) is required for sustained mTOR activation, even in the absence of PTEN. We previously reported the expression of Neurotrophin receptor tyrosine kinases (TRKs) and their respective ligands in primary human leukemia samples. In the present study we aimed to dissect the downstream signaling cascades of TRK-induced T-ALL in a murine model and show that T-ALLs induced by deregulated receptor tyrosine kinase signaling acquire activating mutations in Notch1 and lose PTEN during clonal evolution. Some clones additionally lost one allele of the homeodomain transcription factor Cux1. All events independently led to a gradual hyperactivation of both mTORC1 and mTORC2 signaling. We dissected the role of the individual mTOR complexes by shRNA knockdown and found that the separate depletion of mTORC1 or mTORC2 reduced the growth of T-ALL blasts, but was not sufficient to induce apoptosis. In contrast, knockdown of the mTOR downstream effector eIF4E caused a striking cytotoxic effect, demonstrating a critical addiction to cap-dependent mRNA-translation. Although high mTORC2-AKT activation is commonly associated with drug-resistance, we demonstrate that T-ALL displaying a strong mTORC2-AKT activation were specifically susceptible to 4EGI-1, an inhibitor of the eIF4E-eIF4G interaction. To decipher the mechanism of 4EGI-1, we performed a genome-wide analysis of mRNAs that are translationally regulated by 4EGI-1 in T-ALL. 4EGI-1 effectively reduced the ribosomal occupancy of mRNAs that were strongly upregulated in T-ALL blasts compared with normal thymocytes including transcripts important for translation, mitochondria and cell cycle progression, such as cyclins and ribosomal proteins. These data suggest that disrupting the eIF4E-eIF4G interaction constitutes a promising therapy strategy in mTOR-deregulated T-cell leukemia.	[Schwarzer, A.; Brugman, M.; Meyer, J.; Li, Z.; Baum, C.] Hannover Med Sch, Inst Expt Hematol, D-30625 Hannover, Germany; [Holtmann, H.; Schauerte, C.] Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; [Zuber, J.] Res Inst Mol Pathol IMP, Vienna, Austria; [Steinemann, D.; Schlegelberger, B.] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Hannover Medical School	Schwarzer, A (corresponding author), Hannover Med Sch, Inst Expt Hematol, OE6960,Carl Neuberg Str 1, D-30625 Hannover, Germany.	schwarzer.adrian@mh-hannover.de	Brugman, Martijn/F-3389-2011; Schwarzer, Adrian/AAA-2571-2022; Zuber, Johannes/E-7517-2011	Brugman, Martijn/0000-0003-2675-2705; Zuber, Johannes/0000-0001-8810-6835; Schwarzer, Adrian/0000-0001-5684-2280	Hannover Biomedical Research School (HBRS); MD-PhD program 'Molecular Medicine'; Deutsche Krebshilfe [108245, 109800]; Deutsche Jose Carreras Leukamie-Stiftung [DJCLS F10/06]; Deutsche Forschungsgemeinschaft [Li 1608/2-1, SFB738]; DFG-Cluster of Excellence REBIRTH	Hannover Biomedical Research School (HBRS); MD-PhD program 'Molecular Medicine'; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Jose Carreras Leukamie-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG-Cluster of Excellence REBIRTH	AS was supported by the Hannover Biomedical Research School (HBRS) and the MD-PhD program 'Molecular Medicine'. We thank Dr Jan Cools, Center for Human Genetics, KULeuven, Leuven for the MOHITO cell line. We thank Dr Phillip Ivanyi and Professor Anke Franzke, Department of Hematology, MHH for providing human T-ALL cell lines. We thank Rena-Mareike Struss, Institute of Experimental Hematology, Hannover Medical School for help with mouse experiments and Anneke Doerrie, Institute of Biochemistry, for assistance in polysome profiling experiments. We thank Axel Schambach, Institute of Experimental Hematology, for providing pRSF91. IRES. dTomato and pRRL.PPT.SF.IRES.EGFP. WPRE vectors. We thank Thomas Neumann and Maike Stahlhut for performing the microarray experiments. We thank the Cell Sorting Unit of Hannover Medical School for performing sorting experiments and Michael Morgan for proofreading the manuscript. This work was supported by the Deutsche Krebshilfe (grants: 108245 and 109800), the Deutsche Jose Carreras Leukamie-Stiftung (grant: DJCLS F10/06), the Deutsche Forschungsgemeinschaft (grants: Li 1608/2-1 and SFB738) and the DFG-Cluster of Excellence REBIRTH.	Ashworth TD, 2010, BLOOD, V116, P5455, DOI 10.1182/blood-2010-05-286328; Aster JC, 2008, ANNU REV PATHOL-MECH, V3, P587, DOI 10.1146/annurev.pathmechdis.3.121806.154300; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Bonnet M, 2011, BLOOD, V117, P6650, DOI 10.1182/blood-2011-02-336842; Chan SM, 2007, BLOOD, V110, P278, DOI 10.1182/blood-2006-08-039883; Chen LM, 2012, ONCOTARGET, V3, P869, DOI 10.18632/oncotarget.598; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Clappier E, 2011, J EXP MED, V208, P653, DOI 10.1084/jem.20110105; Curry NL, 2013, CANCER DISCOV, V3, P908, DOI 10.1158/2159-8290.CD-12-0507; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dello Sbarba P, 2014, HYPOXIA, V2, P1; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gokbuget N, 2012, BLOOD, V120, P2032, DOI 10.1182/blood-2011-12-399287; Graeber TG, 2001, NAT GENET, V29, P295, DOI 10.1038/ng755; Gutierrez A, 2011, J EXP MED, V208, P1595, DOI 10.1084/jem.20101691; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Kleppe M, 2011, HAEMATOL-HEMATOL J, V96, P779, DOI 10.3324/haematol.2010.035931; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Larsson O, 2011, BIOINFORMATICS, V27, P1440, DOI 10.1093/bioinformatics/btr146; Lee JY, 2010, CELL STEM CELL, V7, P593, DOI 10.1016/j.stem.2010.09.015; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee K, 2012, J EXP MED, V209, P713, DOI 10.1084/jem.20111470; Li ZX, 2009, BLOOD, V113, P2028, DOI 10.1182/blood-2008-05-155200; Lin CJ, 2012, CELL REPORTS, V1, P325, DOI 10.1016/j.celrep.2012.02.010; Meyer J, 2007, LEUKEMIA, V21, P2171, DOI 10.1038/sj.leu.2404882; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Ren MQ, 2009, BLOOD, V114, P1576, DOI 10.1182/blood-2009-03-212704; Renne C, 2008, LEUKEMIA RES, V32, P163, DOI 10.1016/j.leukres.2007.05.019; Rhein M, 2011, ANN HEMATOL, V90, P283, DOI 10.1007/s00277-010-1065-3; Schatz JH, 2011, J EXP MED, V208, P1799, DOI 10.1084/jem.20110846; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Subramaniam PS, 2012, CANCER CELL, V21, P459, DOI 10.1016/j.ccr.2012.02.029; Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Trinquand A, 2013, J CLIN ONCOL, V31, P4333, DOI 10.1200/JCO.2012.48.5292; van Vlierberghe P, 2008, BRIT J HAEMATOL, V143, P153, DOI 10.1111/j.1365-2141.2008.07314.x; Wasag B, 2011, HAEMATOL-HEMATOL J, V96, P922, DOI 10.3324/haematol.2010.036558; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong CC, 2014, NAT GENET, V46, P33, DOI 10.1038/ng.2846	55	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3593	3604		10.1038/onc.2014.290	http://dx.doi.org/10.1038/onc.2014.290			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25241901				2022-12-28	WOS:000357434900011
J	Najib, S; Kowalski-Chauvel, A; Do, C; Roche, S; Cohen-Jonathan-Moyal, E; Seva, C				Najib, S.; Kowalski-Chauvel, A.; Do, C.; Roche, S.; Cohen-Jonathan-Moyal, E.; Seva, C.			Progastrin a new pro-angiogenic factor in colorectal cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; INTESTINAL EPITHELIAL-CELLS; GLYCINE-EXTENDED GASTRIN; TYROSINE PHOSPHORYLATION; VEGF EXPRESSION; MICE; PROLIFERATION; PRECURSOR; CADHERIN; PERMEABILITY	Angiogenesis is essential in tumor progression and metastatic process, and increased angiogenesis has been associated with poor prognosis and relapse of colorectal cancer (CRC). VEGF has become the main target of anti-angiogenic therapy. However, most patients relapse after an initial response or present a resistance to the treatment. Identification of new pro-angiogenic factors may help to improve anti-angiogenic therapy. In this study, we demonstrated that the pro-hormone progastrin (PG), over-expressed in CRC, recognized as a growth factor, is a potent pro-angiogenic factor. In transgenic mice and human colorectal HPs producing high levels of PG, we correlated PG overexpression with an increased vascularization. In vitro, exogenous PG and conditioned media (CM) from CRC cells producing PG increased endothelial cell proliferation and migration. We also showed that treatment with exogenous PG can increase the ability of endothelial cells to form capillary-like structures. Moreover, we demonstrated that PG enhanced endothelial permeability. The finding that PG stimulated the phosphorylation of vascular endothelial (VE)-cadherin, p125-FAK, paxillin and induced actin remodelling was consistent with a role of these components in PG-stimulated endothelial cell migration and permeability. The pro-angiogenic effects observed with CM were significantly inhibited when CRC cells expressed a PG shRNA. In vivo, we found an important decrease in tumor growth and neovascularization when the CRC cells expressing the PG shRNA were xenografted in mice or in the chick chorioallantoic membrane model. We also observed an increase in the coverage of blood vessels by pericytes and a decrease in endothelial permeability when PG expression was blocked. Our results demonstrate that PG is a new pro-angiogenic factor in CRC and an attractive therapeutic target.	[Najib, S.; Kowalski-Chauvel, A.; Do, C.; Cohen-Jonathan-Moyal, E.; Seva, C.] Univ Toulouse 3, CRCT, INSERM, UMR 1037, F-31062 Toulouse, France; [Roche, S.] Univ Montpellier I & II, CRBM, CNRS, UMR5237, Montpellier, France; [Cohen-Jonathan-Moyal, E.] Inst Claudius Regaud, F-31052 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UNICANCER; Institut Claudius Regaud	Seva, C (corresponding author), Inst Claudius Regaud, CRCT, INSERM, UMR 1037, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	cathy.seva@inserm.fr	Kowalski-Chauvel, Aline/O-9212-2014; SEVA, Catherine/O-9166-2014; Moyal, Elizabeth/A-9802-2015	SEVA, Catherine/0000-0002-4265-7372; Moyal, Elizabeth/0000-0002-6593-9276; do, catherine/0000-0002-9796-4345; Najib, Souad/0000-0001-5509-1411; roche, serge/0000-0003-3413-3859	INSERM; ANR	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANR(French National Research Agency (ANR))	We thank Prof Shulkes, Melbourne University (Australia) for the specific antibody against Progastrin. This work was supported by: grants from INSERM and ANR.	Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bertrand C, 2010, INT J CANCER, V126, P2847, DOI 10.1002/ijc.25001; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Clarke JM, 2013, J GASTROINTEST ONCOL, V4, P253, DOI 10.3978/j.issn.2078-6891.2013.036; Clarke PA, 2006, CANCER RES, V66, P3504, DOI 10.1158/0008-5472.CAN-05-0280; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Des Guetz G, 2006, BRIT J CANCER, V94, P1823, DOI 10.1038/sj.bjc.6603176; Dimaline R, 2014, J PHYSIOL-LONDON, V592, P2951, DOI 10.1113/jphysiol.2014.272435; Do C, 2012, CANCER PREV RES, V5, P675, DOI 10.1158/1940-6207.CAPR-11-0408; Duckworth CA, 2013, GASTROENTEROLOGY, V145, P197, DOI 10.1053/j.gastro.2013.03.012; Esser S, 1998, J CELL SCI, V111, P1853; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2003, J CELL SCI, V116, P1187, DOI 10.1242/jcs.00321; Jin GC, 2013, GASTROENTEROLOGY, V145, P820, DOI 10.1053/j.gastro.2013.07.034; Kowalski-Chauvel A, 2012, J BIOL CHEM, V287, P41458, DOI 10.1074/jbc.M112.382465; Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894; NEMETH J, 1993, GUT, V34, P90, DOI 10.1136/gut.34.1.90; Ribatti D, 2006, NAT PROTOC, V1, P85, DOI 10.1038/nprot.2006.13; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; Shojaei F, 2012, CANCER LETT, V320, P130, DOI 10.1016/j.canlet.2012.03.008; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Tokunaga T, 1998, BRIT J CANCER, V77, P998, DOI 10.1038/bjc.1998.164; Umar S, 2008, ONCOGENE, V27, P5599, DOI 10.1038/onc.2008.169; VANSOLINGE WW, 1993, GASTROENTEROLOGY, V104, P1099, DOI 10.1016/0016-5085(93)90279-L; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1097, DOI 10.1152/ajpgi.00216.2003	40	14	15	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3120	3130		10.1038/onc.2014.255	http://dx.doi.org/10.1038/onc.2014.255			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109333				2022-12-28	WOS:000356101100004
J	Bardot, B; Bouarich-Bourimi, R; Leemput, J; Lejour, V; Hamon, A; Plancke, L; Jochemsen, AG; Simeonova, I; Fang, M; Toledo, F				Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Jochemsen, A. G.; Simeonova, I.; Fang, M.; Toledo, F.			Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity	ONCOGENE			English	Article							ACTIVITY IN-VIVO; THERAPEUTIC TARGET; MESSENGER-RNA; HDMX GENE; CANCER; REVEALS; PATHWAY; DOMAIN; CELLS; AMPLIFICATION	Mdm4, a protein related to the ubiquitin-ligase Mdm2, is an essential inhibitor of tumor suppressor protein p53. In both human and mouse cells, the Mdm4 gene encodes two major transcripts: one encodes the full-length oncoprotein (designated below as Mdm4-FL), whereas the other, resulting from a variant splicing that skips exon 6, encodes the shorter isoform Mdm4-S. Importantly, increased Mdm4-S mRNA levels were observed in several human cancers, and correlated with poor survival. However, the role of Mdm4-S in cancer progression remains controversial, because the Mdm4-S protein appeared to be a potent p53 inhibitor when overexpressed, but the splice variant also leads to a decrease in Mdm4-FL expression. To unambiguously determine the physiological impact of the Mdm4-S splice variant, we generated a mouse model with a targeted deletion of the Mdm4 exon 6, thereby creating an obligatory exon skipping. The mutant allele (Mdm4(Delta E6)) prevented the expression of Mdm4-FL, but also led to increased Mdm4-S mRNA levels. Mice homozygous for this allele died during embryonic development, but were rescued by a concomitant p53 deficiency. Furthermore in a hypomorphic p53(Delta P/Delta P) context, the Mdm4(Delta E6) allele led to p53 activation and delayed the growth of oncogene-induced tumors. We next determined the effect of Mdm4(+/Delta E6) heterozygosity in a hypermorphic p53(+/Delta 31) genetic background, recently shown to be extremely sensitive to Mdm4 activity. Mdm4(+/Delta E6) p53(+/Delta 31) pups were born, but suffered from aplastic anemia and died before weaning, again indicating an increased p53 activity. Our results demonstrate that the main effect of a skipping of Mdm4 exon 6 is not the synthesis of the Mdm4-S protein, but rather a decrease in Mdm4-FL expression. These and other data suggest that increased Mdm4-S mRNA levels might correlate with more aggressive cancers without encoding significant amounts of a potential oncoprotein. Hypotheses that may account for this apparent paradox are discussed.	[Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Simeonova, I.; Fang, M.; Toledo, F.] Inst Curie, Ctr Rech, Genet Tumor Suppress Equipe Labellisee Ligue 2014, F-75248 Paris 05, France; [Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Simeonova, I.; Fang, M.; Toledo, F.] Univ Paris 06, Paris, France; [Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Simeonova, I.; Fang, M.; Toledo, F.] CNRS, UMR 3244, Paris, France; [Jochemsen, A. G.] Leiden Univ, Med Ctr, Leiden, Netherlands	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Toledo, F (corresponding author), Inst Curie, Ctr Rech, UMR 3244, Genet Tumor Suppress, F-75248 Paris 05, France.	franck.toledo@curie.fr	Simeonova, Iva/Y-9412-2019; Hamon, Annaïg/AAG-4899-2021	Hamon, Annaïg/0000-0002-1662-1405; Toledo, Franck/0000-0003-3798-4106; Bardot, Boris/0000-0003-4976-9593; Leemput, Julia/0000-0001-8732-0741	Ligue Nationale contre le Cancer; Fondation de France (Comite Tumeurs); Ligue Nationale contre le Cancer (Comite Ile de France); Fondation ARC; Canceropole Ile de France	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Fondation de France (Comite Tumeurs); Ligue Nationale contre le Cancer (Comite Ile de France); Fondation ARC; Canceropole Ile de France(Region Ile-de-France)	We thank members of the Curie technological platforms for their contribution to this study: I Grandjean, C Daviaud and M Verlhac from the Animal facility, C Alberti, E Belloir and N Mebirouk from the transgenesis platform, M Richardson, A Nicolas, R Leclere and M Huerre from the pathology service. Our lab received funding as an Equipe Labellisee by the Ligue Nationale contre le Cancer. The project was initiated by grants from the Fondation de France (Comite Tumeurs), the Ligue Nationale contre le Cancer (Comite Ile de France) and the Fondation ARC. JL was supported by a post-doctoral fellowship from the Canceropole Ile de France.	Bartel F, 2005, INT J CANCER, V117, P469, DOI 10.1002/ijc.21206; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Bezzi M, 2013, GENE DEV, V27, P1903, DOI 10.1101/gad.219899.113; Bista M, 2013, P NATL ACAD SCI USA, V110, P17814, DOI 10.1073/pnas.1317398110; Fang M, 2014, ONCOGENE, V33, P1336, DOI 10.1038/onc.2013.62; Finch RA, 2002, CANCER RES, V62, P3221; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lenos K, 2012, CANCER RES, V72, P4074, DOI 10.1158/0008-5472.CAN-12-0215; Lenos K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/876173; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mancini F, 2009, CURR GENOMICS, V10, P42, DOI 10.2174/138920209787581280; Marine JC, 2011, CURR TOP DEV BIOL, V94, P45, DOI 10.1016/B978-0-12-380916-2.00003-6; Matijasevic Z, 2008, MOL CELL BIOL, V28, P1265, DOI 10.1128/MCB.01108-07; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Prodosmo A, 2008, J MOL MED-JMM, V86, P585, DOI 10.1007/s00109-008-0322-6; Prophet E, 1992, AFIP LAB METHODS HIS; Rallapalli R, 2003, J CELL BIOCHEM, V89, P563, DOI 10.1002/jcb.10535; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; Simeonova I, 2013, CELL REP, V3, P2046, DOI 10.1016/j.celrep.2013.05.028; Simeonova I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002731; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Steinman HA, 2004, ONCOGENE, V23, P303, DOI 10.1038/sj.onc.1206925; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vandenbroucke I I, 2001, Nucleic Acids Res, V29, pE68, DOI 10.1093/nar/29.13.e68; Wang YYV, 2011, GENE DEV, V25, P1426, DOI 10.1101/gad.2024411; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008	38	23	23	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2943	2948		10.1038/onc.2014.230	http://dx.doi.org/10.1038/onc.2014.230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088193				2022-12-28	WOS:000355324300013
J	Yun, EJ; Baek, ST; Xie, D; Tseng, SF; Dobin, T; Hernandez, E; Zhou, J; Zhang, L; Yang, J; Sun, H; Xiao, G; He, D; Kittler, R; Hsieh, JT				Yun, E-J; Baek, S. T.; Xie, D.; Tseng, S-F; Dobin, T.; Hernandez, E.; Zhou, J.; Zhang, L.; Yang, J.; Sun, H.; Xiao, G.; He, D.; Kittler, R.; Hsieh, J-T			DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1	ONCOGENE			English	Article							ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER; C-KIT; TYROSINE KINASE; PROSPECTIVE IDENTIFICATION; MESENCHYMAL TRANSITION; MAMMALIAN TARGET; DOWN-REGULATION; GROWTH-FACTOR	Cancer stem cell (CSC), the primary source of cancer-initiating population, is involved in cancer recurrence and drug-resistant phenotypes. This study demonstrates that the loss of DAB2IP, a novel Ras-GTPase activating protein frequently found in many cancer types, is associated with CSC properties. Mechanistically, DAB2IP is able to suppress stem cell factor receptor (c-kit or CD117) gene expression by interacting with a newly identified silencer in the c-kit gene. Moreover, DAB2IP is able to inhibit c-kit-PI3K-Akt-mTOR signaling pathway that increases c-myc protein to activate ZEB1 gene expression leading to the elevated CSC phenotypes. An inverse correlation between CD117 or ZEB1 and DAB2IP is also found in clinical specimens. Similarly, Elevated expression of ZEB1 and CD117 are found in the prostate basal cell population of DAB2IP knockout mice. Our study reveals that DAB2IP has a critical role in modulating CSC properties via CD117-mediated ZEB1 signaling pathway.	[Yun, E-J; Tseng, S-F; Dobin, T.; Hernandez, E.; Zhou, J.; Zhang, L.; Hsieh, J-T] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Baek, S. T.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Xie, D.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Canc Res Inst, Dept Gen Surg, Wuhan 430074, Hubei, Peoples R China; [Zhou, J.; Zhang, L.; He, D.] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Xian 710049, Peoples R China; [Yang, J.; Sun, H.; Xiao, G.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Kittler, R.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Kittler, R.] Univ Texas SW Med Ctr Dallas, Eugene McDermott Ctr Human Growth, Dallas, TX 75390 USA; [Kittler, R.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dev, Dallas, TX 75390 USA; [Hsieh, J-T] China Med Univ Hosp, Grad Inst Canc Biol, Taichung, Taiwan	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Huazhong University of Science & Technology; Xi'an Jiaotong University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; China Medical University Taiwan; China Medical University Hospital - Taiwan	Hsieh, JT (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Urol, J8-134 Dallas,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jt.hsieh@utsouthwestern.edu	Kittler, Ralf/AAD-4258-2020; Kittler, Ralf/I-4662-2013	Kittler, Ralf/0000-0002-0098-6792; Kittler, Ralf/0000-0002-0098-6792; Baek, Seung Tae/0000-0003-0040-1501	United States Army [W81XWH-11-1-0491]; National Institutes of Health [CA182670]; NATIONAL CANCER INSTITUTE [R01CA182670] Funding Source: NIH RePORTER	United States Army(United States Department of DefenseUnited States Army); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mrs Mary Barnes for editing this manuscript. This work was supported in part by grants from the United States Army (W81XWH-11-1-0491 to J-TH) and National Institutes of Health (CA182670 to J-TH).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Chambeyron S, 2004, CURR OPIN CELL BIOL, V16, P256, DOI 10.1016/j.ceb.2004.03.004; Chen H, 2006, DNA CELL BIOL, V25, P232, DOI 10.1089/dna.2006.25.232; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Hassan HT, 1996, ACTA HAEMATOL-BASEL, V95, P257; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Joensuu H, 2001, ANN MED, V33, P451, DOI 10.3109/07853890109002093; Kim M, 2002, CLIN CANCER RES, V8, P22; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kong ZL, 2010, INT J RADIAT ONCOL, V78, P1210, DOI 10.1016/j.ijrobp.2010.06.019; Kong ZL, 2010, CANCER RES, V70, P2829, DOI 10.1158/0008-5472.CAN-09-2919; Kyprianou N, 2010, P NATL ACAD SCI USA, V107, P2731, DOI 10.1073/pnas.0914721107; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Li JM, 2007, AM J PHYSIOL-ENDOC M, V293, pE475, DOI 10.1152/ajpendo.00172.2007; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Ma FX, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/948683; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Munugalavadla V, 2005, MOL CELL BIOL, V25, P6747, DOI 10.1128/MCB.25.15.6747-6759.2005; NAGLE RB, 1987, CANCER RES, V47, P281; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rangel EB, 2013, STEM CELLS, V31, P1644, DOI 10.1002/stem.1412; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; STROBL H, 1992, BRIT J HAEMATOL, V82, P287, DOI 10.1111/j.1365-2141.1992.tb06420.x; Sundstrom M, 2003, IMMUNOLOGY, V108, P89, DOI 10.1046/j.1365-2567.2003.01559.x; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wright JL, 2010, J UROLOGY, V183, P2213, DOI 10.1016/j.juro.2010.02.017; Wu K, 2013, ONCOGENE, V33, P1954; Wu KJ, 2013, CLIN CANCER RES, V19, P4740, DOI 10.1158/1078-0432.CCR-13-0954; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Xin L, 2007, STEM CELLS, V25, P2760, DOI 10.1634/stemcells.2007-0355; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309; Zhang HF, 2008, J CLIN INVEST, V118, P3904, DOI 10.1172/JCI36168; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	60	42	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2741	2752		10.1038/onc.2014.215	http://dx.doi.org/10.1038/onc.2014.215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043300				2022-12-28	WOS:000354979500007
J	Ubertini, V; Norelli, G; D'Arcangelo, D; Gurtner, A; Cesareo, E; Baldari, S; Gentileschi, MP; Piaggio, G; Nistico, P; Soddu, S; Facchiano, A; Bossi, G				Ubertini, V.; Norelli, G.; D'Arcangelo, D.; Gurtner, A.; Cesareo, E.; Baldari, S.; Gentileschi, M. P.; Piaggio, G.; Nistico, P.; Soddu, S.; Facchiano, A.; Bossi, G.			Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist	ONCOGENE			English	Article							CANCER-RELATED INFLAMMATION; NECROSIS-FACTOR-ALPHA; LI-FRAUMENI-SYNDROME; KAPPA-B ACTIVATION; REGULATORY REGIONS; GENE-EXPRESSION; IL-1 RECEPTOR; TUMOR MALIGNANCY; MESSENGER-RNA; IN-VIVO	The TP53 tumor-suppressor gene is frequently mutated in human cancer. Missense mutations can add novel functions (gain-of-function, GOF) that promote tumor malignancy. Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN). We show that mutp53 but not wild-type (wt) p53 suppresses the sIL-1Ra production in conditioned media of cancer cells. Moreover, mutp53, but not wtp53, binds physically the sIL-1Ra promoter and the protein-protein interaction with the transcriptional corepressor MAFF (v-MAF musculoaponeurotic fibrosarcoma oncogene family, protein F) is required for mutp53-induced sIL-1Ra suppression. Remarkably, when exposed to IL-1 beta (IL-1 beta) inflammatory stimuli, mutp53 sustains a ready-to-be-activated in vitro and in vivo cancer cells' response through the sIL-1Ra repression. Taken together, these results identify sIL-1Ra as a novel mutp53 target gene, whose suppression might be required to generate a chronic pro-inflammatory tumor microenvironment through which mutp53 promotes tumor malignancy.	[Ubertini, V.; Norelli, G.; Gurtner, A.; Baldari, S.; Gentileschi, M. P.; Piaggio, G.; Nistico, P.; Soddu, S.] Regina Elena Inst Canc Res, Expt Oncol Labs, I-00158 Rome, Italy; [D'Arcangelo, D.; Cesareo, E.; Facchiano, A.] IRCCS, Ist Dermopat Immacolata IDI, Rome, Italy; [Bossi, G.] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Bossi, G (corresponding author), Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Via Messi Oro 156, I-00158 Rome, Italy.	bossi@ifo.it	Baldari, Silvia/AAA-5959-2021; D'Arcangelo, Daniela/K-6533-2016; Bossi, Gianluca/ABH-6846-2020; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; gurtner, aymone/AAB-8843-2020; Gurtner, Aymone/J-7217-2018; Bossi, Gianluca/B-9394-2017; Bossi, Gianluca/G-8375-2016; Piaggio, Giulia/AAD-7336-2022; Nisticò, Paola/B-2862-2018; Piaggio, Giulia/J-7214-2018; Maria Pia, Gentileschi/J-2637-2017; Facchiano, Antonio/J-4744-2012; Facchiano, Antonio/K-5984-2016	Baldari, Silvia/0000-0001-7982-9468; D'Arcangelo, Daniela/0000-0002-7862-3289; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; gurtner, aymone/0000-0002-7661-9059; Gurtner, Aymone/0000-0002-7661-9059; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Nisticò, Paola/0000-0003-4409-2261; Piaggio, Giulia/0000-0003-2114-1892; Facchiano, Antonio/0000-0002-4243-2392; Facchiano, Antonio/0000-0002-4243-2392	Associazione Italiana Ricerca sul Cancro (AICR) (IG) [8804, 13234]; Associazione Italiana Ricerca sul Cancro (AICR) (MFAG) [11752]; Associazione Italiana Ricerca sul Cancro (AICR) (RC) [3.5-2013]	Associazione Italiana Ricerca sul Cancro (AICR) (IG)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana Ricerca sul Cancro (AICR) (MFAG)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana Ricerca sul Cancro (AICR) (RC)(Fondazione AIRC per la ricerca sul cancro)	We thank Dr S Bacchetti, Dr FL Graham and Dr G D'Orazi for critical reading of the manuscript; Dr C Gabay for providing pRa-1680-Luc vector; and Dr G Tolstonog for ENCODE in silico analyses on the sIL-1Ra promoter. This work was supported with grants from Associazione Italiana Ricerca sul Cancro (AICR) to GB (IG no. 8804), AG (MFAG no. 11752), PG (IG no. 13234), and AF (RC 3.5-2013). We thank the Proteomic Facility for Complex Potein Muxture (CPM) Analisys at ISS, Rome.	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Addadi Y, 2010, CANCER RES, V70, P9650, DOI 10.1158/0008-5472.CAN-10-1146; Apte RN, 2008, IMMUNOL REV, V222, P222, DOI 10.1111/j.1600-065X.2008.00615.x; Bar J, 2009, ONCOGENE, V28, P933, DOI 10.1038/onc.2008.445; Blank V, 2008, J MOL BIOL, V376, P913, DOI 10.1016/j.jmb.2007.11.074; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Bossi G, 2008, CELL CYCLE, V7, P1870, DOI 10.4161/cc.7.12.6161; CHIRIVI RGS, 1993, CANCER RES, V53, P5051; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; D'Arcangelo D, 2002, CIRC RES, V91, pE4, DOI 10.1161/01.RES.0000036753.50601.E9; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0; Dunn E, 2001, TRENDS IMMUNOL, V22, P533, DOI 10.1016/S1471-4906(01)02034-8; Elaraj DM, 2006, CLIN CANCER RES, V12, P1088, DOI 10.1158/1078-0432.CCR-05-1603; Fischer A, 2005, MOL CELL BIOL, V25, P8960, DOI 10.1128/MCB.25.20.8960-8970.2005; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813; Jenkins JK, 1997, J IMMUNOL, V158, P748; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Kimura T, 1999, BIOCHEM BIOPH RES CO, V264, P86, DOI 10.1006/bbrc.1999.1487; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48; Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Notterman DA, 2001, CANCER RES, V61, P3124; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Puhlmann M, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-37; Quante T, 2012, CELL CYCLE, V11, P3290, DOI 10.4161/cc.21646; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; SMITH MF, 1992, J IMMUNOL, V149, P2000; Streicher KL, 2007, MOL CANCER RES, V5, P847, DOI 10.1158/1541-7786.MCR-06-0427; ULICH TR, 1992, AM J PATHOL, V141, P61; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; WU S, 1994, GYNECOL ONCOL, V53, P59, DOI 10.1006/gyno.1994.1088; Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224	44	51	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2493	2504		10.1038/onc.2014.191	http://dx.doi.org/10.1038/onc.2014.191			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998848				2022-12-28	WOS:000354190400008
J	Tung, PY; Knoepfler, PS				Tung, P-Y; Knoepfler, P. S.			Epigenetic mechanisms of tumorigenicity manifesting in stem cells	ONCOGENE			English	Review							POLYCOMB GROUP PROTEINS; H3 LYSINE 27; DNA METHYLATION; SELF-RENEWAL; BREAST-CANCER; METHYLTRANSFERASE ACTIVITY; DEVELOPMENTAL REGULATORS; HISTONE MODIFICATIONS; SWI/SNF COMPLEX; IDH2 MUTATIONS	One of the biggest roadblocks to using stem cells as the basis for regenerative medicine therapies is the tumorigenicity of stem cells. Unfortunately, the unique abilities of stem cells to self-renew and differentiate into a variety of cell types are also mechanistically linked to their tumorigenic behaviors. Understanding the mechanisms underlying the close relationship between stem cells and cancer cells has therefore become a primary goal in the field. In addition, knowledge gained from investigating the striking parallels between mechanisms orchestrating normal embryogenesis and those that invoke tumorigenesis may well serve as the foundation for developing novel cancer treatments. Emerging discoveries have demonstrated that epigenetic regulatory machinery has important roles in normal stem cell functions, cancer development and cancer stem cell (CSC) identity. These studies provide valuable insights into both the shared and distinct mechanisms by which pluripotency and oncogenicity are established and regulated. In this review, the cancer-related epigenetic mechanisms found in pluripotent stem cells and cancer cells will be discussed, focusing on both the similarities and the differences.	[Tung, P-Y; Knoepfler, P. S.] Univ Calif Davis, Dept Cell Biol & Human Anat, Sch Med, Davis, CA 95616 USA; [Tung, P-Y; Knoepfler, P. S.] Univ Calif Davis, UC Davis Genome Ctr, Davis, CA 95616 USA; [Tung, P-Y; Knoepfler, P. S.] UC Davis Comprehens Canc Ctr, Sacramento, CA USA; [Tung, P-Y; Knoepfler, P. S.] Shriners Hosp Children Northern Calif, Inst Pediat Regenerat Med, Sacramento, CA USA	University of California System; University of California Davis; University of California System; University of California Davis	Knoepfler, PS (corresponding author), Univ Calif Davis, Dept Cell Biol & Human Anat, 4303 Tupper Hall,1 Shields Ave, Davis, CA 95616 USA.	knoepfler@ucdavis.edu		Knoepfler, Paul/0000-0001-5444-334X	NIH [1R01GM100782]; CIRM [RN2-00922-1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100782] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CIRM(California Institute for Regenerative Medicine); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Bonnie Barrilleaux and Benjamin Yuen for providing feedback on this manuscript. This work was supported by an NIH Grant 1R01GM100782 and a CIRM Grant RN2-00922-1 (both to PSK).	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Andrews PW, 2005, BIOCHEM SOC T, V33, P1526, DOI 10.1042/BST0331526; Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003; Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bao B, 2012, CANCER RES, V72, P335, DOI 10.1158/0008-5472.CAN-11-2182; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cao LX, 2011, J CELL BIOCHEM, V112, P2729, DOI 10.1002/jcb.23234; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Costa Y, 2013, NATURE, V495, P370, DOI 10.1038/nature11925; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Crea F, 2012, ANN ONCOL, V23, P1207, DOI 10.1093/annonc/mdr387; Crea F, 2011, EPIGENOMICS-UK, V3, P127, DOI [10.2217/EPI.11.4, 10.2217/epi.11.4]; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dalerba P, 2013, CELL STEM CELL, V13, P5, DOI 10.1016/j.stem.2013.06.012; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Ding XL, 2014, STEM CELLS DEV, V23, P931, DOI 10.1089/scd.2013.0267; Ding XL, 2012, STEM CELLS DEV, V21, P121, DOI 10.1089/scd.2010.0539; Doege CA, 2012, NATURE, V488, P652, DOI 10.1038/nature11333; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Facchino Sabrina, 2011, Cancers (Basel), V3, P1777, DOI 10.3390/cancers3021777; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; Ficz G, 2013, CELL STEM CELL, V13, P351, DOI 10.1016/j.stem.2013.06.004; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fisher CL, 2011, CURR OPIN GENET DEV, V21, P140, DOI 10.1016/j.gde.2011.01.015; Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108; Gao YW, 2013, CELL STEM CELL, V12, P453, DOI 10.1016/j.stem.2013.02.005; Greber B, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-46; Grimaud C, 2006, CHROMOSOME RES, V14, P363, DOI 10.1007/s10577-006-1069-y; Gu TP, 2011, NATURE, V477, P606, DOI 10.1038/nature10443; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Habibi E, 2013, CELL STEM CELL, V13, P360, DOI 10.1016/j.stem.2013.06.002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; HAUPT Y, 1993, ONCOGENE, V8, P3161; Heddleston JM, 2012, CELL DEATH DIFFER, V19, P428, DOI 10.1038/cdd.2011.109; Ho L, 2009, P NATL ACAD SCI USA, V106, P5181, DOI 10.1073/pnas.0812889106; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867; Huang H, 2013, P NATL ACAD SCI USA, V110, P11994, DOI 10.1073/pnas.1310656110; JACOB F, 1978, PROC R SOC SER B-BIO, V201, P249, DOI 10.1098/rspb.1978.0044; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Knoepfler PS, 2008, CELL STEM CELL, V2, P18, DOI 10.1016/j.stem.2007.12.004; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krasteva V, 2012, BLOOD, V120, P4720, DOI 10.1182/blood-2012-04-427047; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Leitch HG, 2013, NAT STRUCT MOL BIOL, V20, P311, DOI 10.1038/nsmb.2510; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li M, 2012, NAT REV MOL CELL BIO, V13, P524, DOI 10.1038/nrm3393; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu L, 2006, ONCOGENE, V25, P4370, DOI 10.1038/sj.onc.1209454; Mack GS, 2006, J NATL CANCER I, V98, P1443, DOI 10.1093/jnci/djj447; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Moon JH, 2011, CELL RES, V21, P1305, DOI 10.1038/cr.2011.107; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohm JE, 2010, CANCER RES, V70, P7662, DOI 10.1158/0008-5472.CAN-10-1361; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Patra SK, 2011, CLIN EPIGENETICS, V2, P27, DOI 10.1007/s13148-010-0016-0; Pawlak M, 2011, GENE DEV, V25, P1035, DOI 10.1101/gad.2039011; Pereira CF, 2010, CELL STEM CELL, V6, P547, DOI 10.1016/j.stem.2010.04.013; Raimondi C, 2010, CURR CANCER DRUG TAR, V10, P496, DOI 10.2174/156800910791517154; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riggs JW, 2013, STEM CELLS DEV, V22, P37, DOI 10.1089/scd.2012.0375; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schuettengruber B, 2011, NAT REV MOL CELL BIO, V12, P799, DOI 10.1038/nrm3230; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sharma A, 2010, WIRES SYST BIOL MED, V2, P654, DOI 10.1002/wsbm.89; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Solter D, 2006, NAT REV GENET, V7, P319, DOI 10.1038/nrg1827; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; Stower H, 2014, NAT REV GENET, V15, DOI [10.1038/nrg3659, 10.1038/nrg3657]; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Thiel AT, 2013, HAEMATOLOGICA, V98, P918, DOI 10.3324/haematol.2012.074195; Tomasson MH, 2009, J CELL BIOCHEM, V106, P745, DOI 10.1002/jcb.22050; Trowbridge JJ, 2012, GENE DEV, V26, P344, DOI 10.1101/gad.184341.111; Tsumura A, 2006, GENES CELLS, V11, P805, DOI 10.1111/j.1365-2443.2006.00984.x; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005; Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950; Xu C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1237; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang P, 2011, STEM CELLS, V29, P791, DOI 10.1002/stem.634; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yoo MH, 2008, MOL CELLS, V26, P514; Yoshikawa R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-461; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Yuen BTK, 2013, CANCER CELL, V24, P567, DOI 10.1016/j.ccr.2013.09.015; Zhang HK, 2010, CELL RES, V20, P1390, DOI 10.1038/cr.2010.156; Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905	163	15	15	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2288	2296		10.1038/onc.2014.172	http://dx.doi.org/10.1038/onc.2014.172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931168	Green Accepted			2022-12-28	WOS:000353824800002
J	Fan, D; Zhou, X; Li, Z; Li, ZQ; Duan, C; Liu, T; Zhang, F; Huang, Y; Zhang, Y; Gao, F; Guo, Y; Gupta, R; Chen, G; Enver, T; Tang, J; Hong, D				Fan, D.; Zhou, X.; Li, Z.; Li, Z-Q; Duan, C.; Liu, T.; Zhang, F.; Huang, Y.; Zhang, Y.; Gao, F.; Guo, Y.; Gupta, R.; Chen, G.; Enver, T.; Tang, J.; Hong, D.			Stem cell programs are retained in human leukemic lymphoblasts	ONCOGENE			English	Article							HUMAN HEMATOPOIETIC STEM; ACUTE MYELOID-LEUKEMIA; SELF-RENEWAL; BONE-MARROW; GENE; TRANSPLANTATION; EXPANSION; CAPACITY; LINEAGE; BMI-1	Leukemic lymphoblasts within different immunophenotypic populations possess stem cell properties. However, whether or not the self-renewal program is retained from stem cells or conferred on progenitors by leukemogenic molecules remains unknown. We have addressed the issue in the context of TEL-AML1-associated acute lymphoblastic leukemia (ALL) by profiling a refined program edited from genes essential for self-renewal of hematopoietic stem cells and B-cell development. Bioinformatic analysis shows that ALL populations are loosely clustered and close to the normal population that contains stem and primitive progenitor cells. This finding indicates that immunophenotypes do not reflect maturation stages in ALL and that the self-renewal program may be retained from stem cells. Results of assessing 'first hit' function of TEL-AML1 in different populations of normal cells demonstrate the molecular model. Therefore, the current study shows a leukemogenic scenario of human ALL in which programs of stem cells are sustained in distinct fractions by leukemogenic mutations.	[Fan, D.; Zhang, F.; Tang, J.; Hong, D.] Shanghai Jiao Tong Univ, Dept Pediat Hematol & Oncol, Shanghai Childrens Med Ctr, Key Lab Pediat Hematol & Oncol,Minist Hlth,Sch Me, Shanghai 200030, Peoples R China; [Zhou, X.; Li, Z-Q; Huang, Y.; Chen, G.; Hong, D.] SJTU SM, Dept Pathophysiol, Minist Educ, Key Lab Cell Differentiat & Apoptosis Natl, Shanghai, Peoples R China; [Li, Z.; Duan, C.; Liu, T.] SJTU SM, Ruijin Hosp, Shanghai, Peoples R China; [Zhang, Y.; Gao, F.] Shanghai Cord Blood Bank, Shanghai, Peoples R China; [Guo, Y.; Gupta, R.; Enver, T.] UCL, UCL Canc Inst, Stem Cell Lab, London, England	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of London; University College London	Tang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Pediat Hematol & Oncol, Shanghai 200030, Peoples R China.	yantfk@gmail.com; dlhong@sjtu.edu.cn	Zhang, Fang/HHN-2153-2022	Gupta, Rajeev/0000-0001-9573-0505; chen, guo qiang/0000-0003-4936-2363; Hong, Dengli/0000-0001-5251-0297; Liu, Tianhui/0000-0002-9301-641X; Guo, Yanping/0000-0001-6217-7133	National Natural Science Foundation of China (NSFC) [90919055, 81120108006]; National Basic Research Program of China [2012CB967000]; Shanghai Pujiang Program [10PJ1406500]; Cancer Research UK [12796] Funding Source: researchfish; Medical Research Council [G1000801g, MC_U137973817, MC_qA137913] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [W1062] Funding Source: researchfish; MRC [MC_qA137913, MC_U137973817] Funding Source: UKRI	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Shanghai Pujiang Program(Shanghai Pujiang Program); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Great Ormond Street Hospital Childrens Charity; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank T Tanaka for providing hybridoma TM-beta 1; and Chenzhi Guo for technical help in flow sorting. This work was supported by grants from the National Natural Science Foundation of China (NSFC, 90919055 and 81120108006), the National Basic Research Program of China (2012CB967000) and the Shanghai Pujiang Program (10PJ1406500).	Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885; Dorrell C, 2000, BLOOD, V95, P102; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Ford AM, 2009, J CLIN INVEST, V119, P826, DOI 10.1172/JCI36428; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926; Gupta R, 2007, SCIENCE, V316, P590, DOI 10.1126/science.1136031; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Hystad ME, 2007, J IMMUNOL, V179, P3662, DOI 10.4049/jimmunol.179.6.3662; Kong Y, 2008, LEUKEMIA, V22, P1207, DOI 10.1038/leu.2008.83; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lin YC, 2010, NAT IMMUNOL, V11, P635, DOI 10.1038/ni.1891; McKenzie JL, 2005, BLOOD, V106, P1259, DOI 10.1182/blood-2005-03-1081; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Piacibello W, 1999, BLOOD, V93, P3736, DOI 10.1182/blood.V93.11.3736.411k01_3736_3749; Pina C, 2007, ONCOGENE, V26, P6750, DOI 10.1038/sj.onc.1210759; Schindler JW, 2009, CELL STEM CELL, V5, P43, DOI 10.1016/j.stem.2009.04.019; Tsuzuki S, 2013, STEM CELLS, V31, P236, DOI 10.1002/stem.1277; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	34	5	7	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2083	2093		10.1038/onc.2014.148	http://dx.doi.org/10.1038/onc.2014.148			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909160				2022-12-28	WOS:000353173400008
J	Jeong, SM; Lee, J; Finley, LWS; Schmidt, PJ; Fleming, MD; Haigis, MC				Jeong, S. M.; Lee, J.; Finley, L. W. S.; Schmidt, P. J.; Fleming, M. D.; Haigis, M. C.			SIRT3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1	ONCOGENE			English	Article							TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; ACTIVATION; HOMEOSTASIS; RESTRICTION; DEACETYLASE; HYPOXIA; ATAXIA	Iron metabolism is essential for many cellular processes, including oxygen transport, respiration and DNA synthesis, and many cancer cells exhibit dysregulation in iron metabolism. Maintenance of cellular iron homeostasis is regulated by iron regulatory proteins (IRPs), which control the expression of iron-related genes by binding iron-responsive elements (IREs) of target mRNAs. Here, we report that mitochondrial SIRT3 regulates cellular iron metabolism by modulating IRP1 activity. SIRT3 loss increases reactive oxygen species production, leading to elevated IRP1 binding to IREs. As a consequence, IRP1 target genes, such as the transferrin receptor (TfR1), a membrane-associated glycoprotein critical for iron uptake and cell proliferation, are controlled by SIRT3. Importantly, SIRT3 deficiency results in a defect in cellular iron homeostasis. SIRT3 null cells contain high levels of iron and lose iron-dependent TfR1 regulation. Moreover, SIRT3 null mice exhibit higher levels of iron and TfR1 expression in the pancreas. We found that the regulation of iron uptake and TfR1 expression contribute to the tumor-suppressive activity of SIRT3. Indeed, SIRT3 expression is negatively correlated with TfR1 expression in human pancreatic cancers. SIRT3 overexpression decreases TfR1 expression by inhibiting IRP1 and represses proliferation in pancreatic cancer cells. Our data uncover a novel role of SIRT3 in cellular iron metabolism through IRP1 regulation and suggest that SIRT3 functions as a tumor suppressor, in part, by modulating cellular iron metabolism.	[Jeong, S. M.; Lee, J.; Finley, L. W. S.; Haigis, M. C.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Schmidt, P. J.; Fleming, M. D.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Schmidt, P. J.; Fleming, M. D.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Haigis, MC (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, SGM 329C,240 Longwood Ave, Boston, MA 02115 USA.	marcia_haigis@hms.harvard.edu		Fleming, Mark/0000-0003-0948-4024; Lee, Jaewon/0000-0002-5677-2398	Takeda Pharmaceuticals; NIH [R01/AG032375]; American Cancer Society New Scholar Award; Glenn Foundation for Medical Research; NATIONAL INSTITUTE ON AGING [R01AG032375] Funding Source: NIH RePORTER	Takeda Pharmaceuticals(Takeda Pharmaceutical Company Ltd); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society New Scholar Award; Glenn Foundation for Medical Research; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Ditte Lee and Annie Lee for technical assistance. We are also grateful to Alec C Kimmelman for providing cell lines and helpful discussions. This work was funded by a grant from Takeda Pharmaceuticals (to MCH). MCH is supported by NIH grant R01/AG032375, the American Cancer Society New Scholar Award and the Glenn Foundation for Medical Research.	Anderson CP, 2012, BBA-MOL CELL RES, V1823, P1468, DOI 10.1016/j.bbamcr.2012.05.010; Anderson SA, 2013, CELL METAB, V17, P282, DOI 10.1016/j.cmet.2013.01.007; Bayeva M, 2012, CELL METAB, V16, P645, DOI 10.1016/j.cmet.2012.10.001; Bell EL, 2011, MOL CELL, V42, P561, DOI 10.1016/j.molcel.2011.05.008; Chen CY, 2013, CELL METAB, V17, P343, DOI 10.1016/j.cmet.2013.01.013; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; KOPPENOL WH, 1993, FREE RADICAL BIO MED, V15, P645, DOI 10.1016/0891-5849(93)90168-T; Lobmayr L, 2005, GENE, V354, P157, DOI 10.1016/j.gene.2005.04.040; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Muckenthaler MU, 2008, ANNU REV NUTR, V28, P197, DOI 10.1146/annurev.nutr.28.061807.155521; Mueller S, 2005, BIOFACTORS, V24, P171, DOI 10.1002/biof.5520240121; Nunez-Millacura C, 2002, J NEUROCHEM, V82, P240, DOI 10.1046/j.1471-4159.2002.00971.x; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Richardson DR, 2009, BBA-GEN SUBJECTS, V1790, P702, DOI 10.1016/j.bbagen.2008.04.003; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Ryschich E, 2004, EUR J CANCER, V40, P1418, DOI 10.1016/j.ejca.2004.01.036; Sanchez M, 2011, BLOOD, V118, pE168, DOI 10.1182/blood-2011-04-343541; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Wagner GR, 2012, HUM MOL GENET, V21, P2688, DOI 10.1093/hmg/dds095; Wang J, 2004, MOL CELL BIOL, V24, P954, DOI 10.1128/MCB.24.3.954-965.2004; Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537	32	47	49	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2115	2124		10.1038/onc.2014.124	http://dx.doi.org/10.1038/onc.2014.124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909164	Green Accepted			2022-12-28	WOS:000353173400011
J	Kreis, NN; Louwen, F; Yuan, J				Kreis, N-N; Louwen, F.; Yuan, J.			Less understood issues: p21(Cip1) in mitosis and its therapeutic potential	ONCOGENE			English	Review							CELL-CYCLE INHIBITORS; DNA-REPLICATION; UBIQUITIN LIGASE; CDK INHIBITOR; CYTOPLASMIC LOCALIZATION; PROTEASOMAL DEGRADATION; DEPENDENT KINASES; NUCLEAR ANTIGEN; BREAST-CANCER; S-PHASE	p21(Cip1) is a multifunctional protein and a key player in regulating different cellular processes. The transcription of p21 is regulated by p53-dependent and -independent pathways. The expression of p21 is increased in response to various cellular stresses to arrest the cell cycle and ensure genomic stability. p21 has been shown to be a tumor suppressor and an oncogene as well. The function of p21 in mitosis has been proposed but not systematically studied. We have recently shown that p21 binds to and inhibits the activity of Cdk1/cyclin B1, and is important for a fine-tuned mitotic progression. Loss of p21 prolongs the duration of mitosis and results in severe mitotic defects like chromosome segregation and cytokinesis failures promoting consequently genomic instability. Moreover, p21 is dramatically stabilized in mitotic tumor cells upon treatment with mitotic agents like paclitaxel or mitotic kinase inhibitors. Increased p21 is mainly localized in the cytoplasm and associates with cell survival indicating a crucial role of p21 in susceptibility to mitotic agents in tumor cells. In this review we will briefly summarize the structure and general physiological functions as well as regulation of p21, discuss in detail its role in mitosis and its potential to serve as a therapeutic target.	[Kreis, N-N; Louwen, F.; Yuan, J.] Goethe Univ Frankfurt, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Kreis, NN (corresponding author), Goethe Univ Frankfurt, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Nina-Naomi.Kreis@kgu.de; yuan@em.uni-frankfurt.de	Kreis, Nina-Naomi/AAF-5407-2019	Kreis, Nina-Naomi/0000-0003-4304-0160; Yuan, Juping/0000-0003-0694-0565	Deutsche Krebshilfe [108553, 109672]; Deutsche Forschungsgemeinschaft [Yu 156/2-1]	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We apologize to the authors whose work could not be cited due to space limitations. We thank our colleagues for the critical reading of this manuscript. The work in the lab has been supported by Deutsche Krebshilfe (#108553 and #109672) and Deutsche Forschungsgemeinschaft (#Yu 156/2-1).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Agell N, 2006, CELL CYCLE, V5, P3, DOI 10.4161/cc.5.1.2270; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chan KS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.148; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cornils H, 2011, MOL CELL BIOL, V31, P1382, DOI 10.1128/MCB.01216-10; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Denicourt C, 2004, GENE DEV, V18, P851, DOI 10.1101/gad.1205304; Densham RM, 2009, MOL CELL BIOL, V29, P6380, DOI 10.1128/MCB.00116-09; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Ferrandiz N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037759; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Follis AV, 2012, ADV EXP MED BIOL, V725, P27, DOI 10.1007/978-1-4614-0659-4_3; Galea CA, 2008, BIOCHEMISTRY-US, V47, P7598, DOI 10.1021/bi8006803; Garcia-Fernandez RA, 2011, LAB INVEST, V91, P1634, DOI 10.1038/labinvest.2011.133; Garrett MA, 2001, CURR SCI INDIA, V81, P515; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gartel AL, 2007, CANCER BIOL THER, V6, P1171; Gillis LD, 2009, CELL CYCLE, V8, P253, DOI 10.4161/cc.8.2.7550; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gordon RR, 2012, DRUG RESIST UPDATE, V15, P123, DOI 10.1016/j.drup.2012.01.002; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Hwang CY, 2007, BIOCHEM BIOPH RES CO, V358, P219, DOI 10.1016/j.bbrc.2007.04.120; Hwang CY, 2009, MOL CELL BIOL, V29, P3379, DOI 10.1128/MCB.01758-08; Inoue H, 2011, CANCER BIOL THER, V12, P827, DOI 10.4161/cbt.12.9.17680; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Jackson RJ, 2003, CANCER RES, V63, P3021; Jarviluoma A, 2006, MOL CELL BIOL, V26, P2430, DOI 10.1128/MCB.26.6.2430-2440.2006; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; JIANG HP, 1995, ONCOGENE, V10, P1855; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474-9726.2012.00870.x; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Khanna AK, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-66; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Koster R, 2010, J CLIN INVEST, V120, P3594, DOI 10.1172/JCI41939; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2009, CELL CYCLE, V8, P460, DOI 10.4161/cc.8.3.7651; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lacy ER, 2004, NAT STRUCT MOL BIOL, V11, P358, DOI 10.1038/nsmb746; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee JY, 2007, MOL CELL BIOL, V27, P3187, DOI 10.1128/MCB.01461-06; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; LI Y, 1994, ONCOGENE, V9, P2261; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Liu RW, 2013, FUTURE MED CHEM, V5, P991, DOI 10.4155/fmc.13.56; Louwen F, 2013, ONCOTARGET, V4, P958, DOI 10.18632/oncotarget.1096; Lu ZM, 2010, CELL CYCLE, V9, P2342, DOI 10.4161/cc.9.12.11988; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mercer SE, 2005, J BIOL CHEM, V280, P25788, DOI 10.1074/jbc.M413594200; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oh YT, 2007, APOPTOSIS, V12, P1339, DOI 10.1007/s10495-007-0066-8; Otieno S, 2011, BIOPHYS J, V100, P2486, DOI 10.1016/j.bpj.2011.04.014; Park SH, 2008, CANCER BIOL THER, V7, P2015, DOI 10.4161/cbt.7.12.7069; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Perez-Tenorio G, 2006, INT J ONCOL, V28, P1031; Ping B, 2006, INT J ONCOL, V29, P1103; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodriguez-Vilarrupla A, 2005, MOL CELL BIOL, V25, P7364, DOI 10.1128/MCB.25.16.7364-7374.2005; Rodriguez-Vilarrupla A, 2002, FEBS LETT, V531, P319, DOI 10.1016/S0014-5793(02)03549-4; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sax JK, 2002, CELL CYCLE, V1, P90, DOI 10.4161/cc.1.1.105; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Solomon H, 2011, J PATHOL, V225, P475, DOI 10.1002/path.2988; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Starostina NG, 2010, DEV CELL, V19, P753, DOI 10.1016/j.devcel.2010.10.013; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Stivala LA, 2012, CURR CANCER DRUG TAR, V12, P85; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Suzuki H, 2013, J CELL SCI, V126, P4358, DOI 10.1242/jcs.125815; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Tian H, 2000, CANCER RES, V60, P679; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Trakala M, 2013, CELL CYCLE, V12, P1030, DOI 10.4161/cc.24004; Ullah Z, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-10; Van Nguyen T, 2007, J EXP MED, V204, P1453, DOI 10.1084/jem.20062453; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vincent AJ, 2012, FEBS LETT, V586, P3429, DOI 10.1016/j.febslet.2012.07.063; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang W, 2005, BIOCHEMISTRY-US, V44, P14553, DOI 10.1021/bi051071j; Wang YF, 2011, NAT CHEM BIOL, V7, P214, DOI 10.1038/NCHEMBIO.536; Wang ZP, 2010, INT J BIOCHEM CELL B, V42, P1030, DOI 10.1016/j.biocel.2010.03.012; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wettersten HI, 2013, CANCER BIOL THER, V14, P278, DOI 10.4161/cbt.23374; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Winters ZE, 2001, EUR J CANCER, V37, P2405, DOI 10.1016/S0959-8049(01)00327-6; Wolf F, 2007, CELL CYCLE, V6, P1408; Wolf F, 2006, EMBO J, V25, P2802, DOI 10.1038/sj.emboj.7601163; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xia X, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-399; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xiong Y, 2010, DEV CELL, V19, P641, DOI 10.1016/j.devcel.2010.10.020; Yamada K, 2011, J BIOL CHEM, V286, P44057, DOI 10.1074/jbc.M111.236711; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yu XG, 2011, CELL CYCLE, V10, P3213, DOI 10.4161/cc.10.19.17051; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhan J, 2007, MOL CELL BIOL, V27, P3530, DOI 10.1128/MCB.00086-06; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	179	73	77	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1758	1767		10.1038/onc.2014.133	http://dx.doi.org/10.1038/onc.2014.133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858045				2022-12-28	WOS:000352158000003
J	Wu, MH; Chen, YA; Chen, HH; Chang, KW; Chang, IS; Wang, LH; Hsu, HL				Wu, M-H; Chen, Y-A; Chen, H-H; Chang, K-W; Chang, I-S; Wang, L-H; Hsu, H-L			MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PTEN; BREAST-CANCER; CHROMOSOME SEGREGATION; TRASTUZUMAB RESISTANCE; CELL-SURVIVAL; AKT PATHWAY; ONCOGENE; 3-KINASE; CYTOKINESIS; INSTABILITY	Multinucleation is associated with malignant neoplasms; however, the molecular mechanism underlying the nuclear abnormality remains unclear. Loss or mutation of PTEN promotes the development of malignant tumors. We now demonstrate that increased expression of the oncogene MCT-1 (multiple copies in T-cell malignancy 1) antagonizes PTEN gene presentation, PTEN protein stability and PTEN functional activity, thereby further promoting phosphoinositide 3 kinase/AKT signaling, survival rate and malignancies of the PTEN-deficient cells. In the PTEN-null cancer cells, MCT-1 interacts with p190B and Src in vivo, supporting that they are in proximity of the signaling complexes. MCT-1 overexpression and PTEN loss synergistically augments the Src/p190B signaling function that leads to inhibition of RhoA activity. Under such a condition, the incidence of mitotic catastrophes including spindle multipolarity and cytokinesis failure is enhanced, driving an Src/p190B/RhoA-dependent neoplastic multinucleation. Targeting MCT-1 by the short hairpin RNA markedly represses the Src/p190B function, improves nuclear structures and suppresses xenograft tumorigenicity of the PTEN-null breast cancer cells. Consistent with the oncogenic effects in vitro, clinical evidence has confirmed that MCT-1 gene stimulation is correlated with p190B gene promotion and PTEN gene suppression in human breast cancer. Accordingly, MCT-1 gene induction is recognized as a potential biomarker of breast tumor development. Abrogating MCT-1 function may be a promising stratagem for management of breast cancer involving Src hyperactivation and/or PTEN dysfunction.	[Wu, M-H; Chen, Y-A; Chen, H-H; Wang, L-H; Hsu, H-L] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan 35053, Miaoli County, Taiwan; [Chang, K-W] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan 35053, Miaoli County, Taiwan; [Chang, I-S] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan; [Chang, I-S] Natl Hlth Res Inst, Div Biostat & Bioinformat, Zhunan 35053, Miaoli County, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan	Hsu, HL (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan.	hsinling88@nhri.org.tw	Chang, I-Shou/D-2084-2010; Wang, Lu-Hai/E-3986-2010; Hsu, Hsin-Ling/E-3672-2010		NSC [99-3112-B-400-002, 100-2320-B-400-013, 101-2320-B-400-014-MY3, NSC102-2319-B-400-001, DOH103-TD-C-111-004]	NSC(Ministry of Science and Technology, Taiwan)	This work was funded by NSC 99-3112-B-400-002 (to HLH), NSC 100-2320-B-400-013 (to HLH), NSC 101-2320-B-400-014-MY3 (to HLH), NSC102-2319-B-400-001 (to ISC) and DOH103-TD-C-111-004 (to LHW). We would like to acknowledge technical support from Cell Sorter Core (Chao-Yang Hsiao), Live Cell Image Core (Kang-Lin Chu) and Optical Biology Core (Shu-Fen Hu) facilities of National Health Research Institutes.	Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Gollin SM, 2005, SEMIN CANCER BIOL, V15, P33, DOI 10.1016/j.semcancer.2004.09.004; Guigon CJ, 2009, ONCOGENE, V28, P509, DOI 10.1038/onc.2008.407; Haskell MD, 2001, J CELL SCI, V114, P1699; Hsu HL, 2007, DNA REPAIR, V6, P1319, DOI 10.1016/j.dnarep.2007.02.028; Hwang Melissa, 2012, Cancers (Basel), V4, P475, DOI 10.3390/cancers4020475; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Kasiappan R, 2009, MOL CANCER RES, V7, P536, DOI 10.1158/1541-7786.MCR-08-0422; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Lan KH, 2005, ANN NY ACAD SCI, V1059, P70, DOI 10.1196/annals.1339.026; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Manchinelly SAS, 2010, J BIOL CHEM, V285, P26923, DOI 10.1074/jbc.M110.103804; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Radke J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056691; Regnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Salmena L, 2007, NAT REV CANCER, V7, P409, DOI 10.1038/nrc2145; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Shih HJ, 2012, ONCOTARGET, V3, P1401; Shih HJ, 2012, CELL CYCLE, V11, P934, DOI 10.4161/cc.11.5.19452; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007; Su L, 2009, EXP CELL RES, V315, P1347, DOI 10.1016/j.yexcr.2009.02.014; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vicente-Duenas C, 2013, EMBO J, V32, P1502, DOI 10.1038/emboj.2013.97; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	50	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5109	5120		10.1038/onc.2014.125	http://dx.doi.org/10.1038/onc.2014.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24858043	hybrid, Green Published			2022-12-28	WOS:000343768400006
J	Lin, C; Liu, SY; Lee, EHY				Lin, Ch; Liu, S. Y.; Lee, E. H. Y.			SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1	ONCOGENE			English	Article							CELL-PROLIFERATION; E3; TUMORIGENESIS; CONJUGATION; EXPRESSION; STABILITY; PATHWAY	SUMOylation is an important post-translational modification, and Akt SUMOylation was found to regulate cell proliferation, tumorigenesis and cell cycle, but the molecular mechanism of Akt SUMOylation is less well known. Here, we show both endogenous and ectopic Akt SUMOylation and Lys276 is the major SUMO acceptor on Akt. Further, Akt SUMOylation is Akt phosphorylation dependent and Akt SUMOylation increases Akt kinase activity without affecting the phosphorylation level of Akt. Moreover, endogenous Akt SUMOylation is enhanced by insulin treatment and this is Akt activity dependent. Heat-shock stimulus also increases Akt SUMOylation and it is also Akt activity dependent. Endogenous Akt SUMOylation is also found in the rat brain and it is enhanced by insulin-like growth factor-1 stimulation. In addition, Akt directly phosphorylates Ubc9 at Thr35 and phosphorylates SUMO1 at Thr76. Ubc9 phosphorylation at Thr35 promotes Ubc9 thioester bond formation and SUMO1 phosphorylation at Thr76 stabilizes the SUMO1 protein. Through these distinct mechanisms, Akt SUMOylation regulates global SUMOylation, including Akt and Ubc9 SUMOylation, and substrate SUMOylation specificity, including STAT1 and CREB SUMOylation, in different manners. Akt SUMOylation also enhances phosphatase and tensin homolog (PTEN) SUMOylation through Akt phosphorylation of Ubc9 and SUMO1, which serves as an endogenous mechanism to stop the positive feedback loop resulted from Akt activation. Further, Akt SUMOylation increases cyclin D1 expression and cell proliferation, and these effects are also mediated through Ubc9 phosphorylation at Thr35 and SUMO1 phosphorylation at Thr76. Here, we have identified a novel mechanism for SUMOylation regulation. Because of the important role Akt plays in tumorigenesis, this mechanism may also be involved in Akt-regulated tumorigenesis.	[Lin, Ch; Liu, S. Y.; Lee, E. H. Y.] Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 115, Taiwan	Academia Sinica - Taiwan	Lee, EHY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	eminy@gate.sinica.edu.tw	Lee, Eminy H.Y./S-7014-2018	Lee, Eminy/0000-0001-6342-0940; Ma, Yun Li/0000-0002-6321-8889	Ministry of Science and Technology in Taiwan [MOST 102-2321-B-001-004]	Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by a Grant from the Ministry of Science and Technology in Taiwan (MOST 102-2321-B-001-004). Thank is given to the Proteomics Core Facility of the Institute of Biomedical Sciences, Academia Sinica, Taiwan.	Chen YC, 2014, J NEUROSCI, V34, P9574, DOI 10.1523/JNEUROSCI.4302-13.2014; Chiou HYC, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-53; de la Cruz-Herrera CF, 2014, ONCOGENE, P1; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Hay RT, 2013, BIOCHEM SOC T, V41, P463, DOI 10.1042/BST20130015; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Klug H, 2013, MOL CELL, V50, P625, DOI 10.1016/j.molcel.2013.03.027; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Liao Y, 2010, AM J TRANSL RES, V2, P19; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Risso G, 2013, CELL CYCLE, V12, P3165, DOI 10.4161/cc.26183; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Su YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034250; Tai DJC, 2011, EMBO J, V30, P205, DOI 10.1038/emboj.2010.290; Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065	26	40	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					595	607		10.1038/onc.2015.115	http://dx.doi.org/10.1038/onc.2015.115			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25867063				2022-12-28	WOS:000369548800007
J	Oneyama, C; Yoshikawa, Y; Ninomiya, Y; Iino, T; Tsukita, S; Okada, M				Oneyama, C.; Yoshikawa, Y.; Ninomiya, Y.; Iino, T.; Tsukita, S.; Okada, M.			Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression	ONCOGENE			English	Article							C-SRC; CORTACTIN PHOSPHORYLATION; CARCINOMA CELLS; FAMILY KINASES; SARCOMA VIRUS; HUMAN CANCER; EXPRESSION; ACTIVATION; EZRIN; TRANSFORMATION	c-Src is upregulated in various human cancers, suggesting its role in malignant progression. However, the molecular circuits of c-Src oncogenic signaling remain elusive. Here we show that Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression. Previously, we showed that transformation of fibroblasts is promoted by the relocation of c-Src to non-raft membranes. In this study, we identified Fer and ezrin as non-raft c-Src targets. c-Src directly activated Fer by initiating its autophosphorylation, which was further amplified by Fer oligomerization. Fer interacted with active c-Src at focal adhesion membranes and activated Fer-phosphorylated ezrin to induce cell transformation. Fer was also crucial for cell transformation induced by v-Src or epidermal growth-factor receptor activation. Furthermore, Fer activation was required for tumorigenesis and invasiveness in some cancer cells in which c-Src is upregulated. We propose that the Src-Fer axis represents a new therapeutic target for treatment of a subset of human cancers.	[Oneyama, C.; Yoshikawa, Y.; Ninomiya, Y.; Iino, T.; Okada, M.] Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan; [Tsukita, S.] Osaka Univ, Grad Sch Frontier Biosci, Lab Biol Sci, Osaka, Japan; [Tsukita, S.] Osaka Univ, Grad Sch Med, Osaka, Japan	Osaka University; Osaka University; Osaka University	Oneyama, C (corresponding author), Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	coneyama@biken.osaka-u.ac.jp			Exciting Leading-Edge Research Project; MEET Project at Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan for Young Scientists; Yasuda Medical Foundation; Grants-in-Aid for Scientific Research [25117716, 26640078] Funding Source: KAKEN	Exciting Leading-Edge Research Project; MEET Project at Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Yasuda Medical Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Akagi for pCX4 vector, N Mochizuki for a series of Fer expression vectors, A Imamoto for SFC - cells, K Saito for technical assistance with the LC-MS/MS analysis and JA Cooper for critical reading and editing of the manuscript. LC-MS/MS analysis was performed in the DNA-chip Development Centre for Infectious Diseases (RIMD, Osaka University). This work was supported by the Exciting Leading-Edge Research Project and the MEET Project at Osaka University; grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Young Scientists (A); and The Yasuda Medical Foundation.	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Elliott BE, 2004, J CELL BIOCHEM, V92, P16, DOI 10.1002/jcb.20033; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Guo CH, 2011, P NATL ACAD SCI USA, V108, P7968, DOI 10.1073/pnas.1105369108; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Heiska L, 2011, ONCOGENE, V30, P4953, DOI 10.1038/onc.2011.207; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Inoue K, 2009, GENE THER, V16, P1383, DOI 10.1038/gt.2009.105; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kawakami M, 2013, INT J CLIN EXP PATHO, V6, P598; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Laszlo GS, 2009, CURR BIOL, V19, P157, DOI 10.1016/j.cub.2008.12.007; Lennartsson J, 2013, J BIOL CHEM, V288, P15736, DOI 10.1074/jbc.M113.476424; Li HY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-366; Lingwood D, 2007, NAT PROTOC, V2, P2159, DOI 10.1038/nprot.2007.294; Mak H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-82; Menges Craig W, 2010, Genes Cancer, V1, P493; Miyata Y, 2013, CANCER SCI, V104, P681, DOI 10.1111/cas.12140; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141; Oneyama C, 2012, ONCOGENE, V31, P1623, DOI 10.1038/onc.2011.367; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Oneyama C, 2008, GENES CELLS, V13, P1, DOI 10.1111/j.1365-2443.2007.01145.x; Oneyama C, 2009, MOL CELL BIOL, V29, P6462, DOI 10.1128/MCB.00941-09; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06; Senis YA, 2003, J THROMB HAEMOST, V1, P1062, DOI 10.1046/j.1538-7836.2003.t01-1-00124.x; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TAKEYA T, 1982, J VIROL, V44, P1; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	47	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					501	512		10.1038/onc.2015.110	http://dx.doi.org/10.1038/onc.2015.110			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867068				2022-12-28	WOS:000369056700010
J	Perdigao-Henriques, R; Petrocca, F; Altschuler, G; Thomas, MP; Le, MTN; Tan, SM; Hide, W; Lieberman, J				Perdigao-Henriques, R.; Petrocca, F.; Altschuler, G.; Thomas, M. P.; Le, M. T. N.; Tan, S. M.; Hide, W.; Lieberman, J.			miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; E-CADHERIN; GENE-EXPRESSION; WIDE IDENTIFICATION; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; CELL; FAMILY; TARGETS; PROTEIN	The miR-200 family promotes the epithelial state by suppressing the Zeb1/Zeb2 epithelial gene transcriptional repressors. To identify other miR-200-regulated genes, we isolated mRNAs bound to transfected biotinylated miR-200c in mouse breast cancer cells. In all, 520 mRNAs were significantly enriched in miR-200c binding at least twofold. Putative miR-200-regulated genes included Zeb2, enriched 3.5-fold in the pull down. However, Zeb2 knockdown does not fully recapitulate miR-200c overexpression, suggesting that regulating other miR-200 targets contributes to miR-200's enhancement of epithelial gene expression. Candidate genes were highly enriched for miR-200c seed pairing in their 3'UTR and coding sequence and for genes that were downregulated by miR-200c overexpression. Epidermal growth factor receptor and downstream MAPK signaling pathways were the most enriched pathways. Genes whose products mediate transforming growth factor (TGF)-beta signaling were also significantly overrepresented, and miR-200 counteracted the suppressive effects of TGF-beta and bone morphogenic protein 2 (BMP-2) on epithelial gene expression. miR-200c regulated the 3'UTRs of 12 of 14 putative miR-200c-binding mRNAs tested. The extent of mRNA binding to miR-200c strongly correlated with gene suppression. Twelve targets of miR-200c (Crtap, Fhod1, Smad2, Map3k1, Tob1, Ywhag/14-3-3 gamma, Ywhab/14-3-3 beta, Smad5, Zfp36, Xbp1, Mapk12, Snail1) were experimentally validated by identifying their 3'UTR miR-200 recognition elements. Smad2 and Smad5 form a complex with Zeb2 and Ywhab/14-3-3 beta and Ywhag/14-3-3 gamma form a complex with Snail1. These complexes that repress transcription assemble on epithelial gene promoters. miR-200 overexpression induced RNA polymerase II localization and reduced Zeb2 and Snail1 binding to epithelial gene promoters. Expression of miR-200-resistant Smad5 modestly, but significantly, reduced epithelial gene induction by miR-200. miR-200 expression and Zeb2 knockdown are known to inhibit cell invasion in in vitro assays. Knockdown of each of three novel miR-200 target genes identified here, Smad5, Ywhag and Crtap, also profoundly suppressed cell invasion. Thus, miR-200 suppresses TGF-beta/BMP signaling, promotes epithelial gene expression and suppresses cell invasion by regulating a network of genes.	[Perdigao-Henriques, R.; Petrocca, F.; Thomas, M. P.; Le, M. T. N.; Tan, S. M.; Lieberman, J.] Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA 02115 USA; [Perdigao-Henriques, R.] Univ Nova Lisboa, ITQB, Anim Cell Technol Unit, P-2780156 Oeiras, Portugal; [Perdigao-Henriques, R.] IBET, Oeiras, Portugal; [Altschuler, G.; Hide, W.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Hide, W.] Univ Sheffield, Dept Neurosci, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England; [Lieberman, J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Universidade Nova de Lisboa; Harvard University; Harvard T.H. Chan School of Public Health; University of Sheffield; Harvard University; Harvard Medical School	Lieberman, J (corresponding author), Childrens Hosp Boston, Program Cellular & Mol Med, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA.	judy.lieberman@childrens.harvard.edu	Hide, Winston Hide/C-7217-2009; Hide, Winston/R-3815-2019; Hide, Winston A/V-2727-2017; Lieberman, Judy/A-2717-2015	Hide, Winston Hide/0000-0002-8621-3271; Hide, Winston/0000-0002-8621-3271; Hide, Winston A/0000-0002-8621-3271; LE, Thi Nguyet Minh/0000-0002-6077-1566	Portuguese Ministry of Science and Technology (FCT) [SFRH/BD/37188/2007]	Portuguese Ministry of Science and Technology (FCT)	R Perdigao-Henriques acknowledges the Portuguese Ministry of Science and Technology (FCT) for Ph.D. fellowship SFRH/BD/37188/2007. We thank Alex Amiet and Devin Leake (Dharmacon) for providing the biotinylated miRNAs, Linfeng Huang (Lieberman laboratory) for assistance with ChIP assays and Francisco Navarro (Lieberman laboratory) for helpful suggestions.	Ahmadi H, 2013, GENOMICS, V101, P94, DOI 10.1016/j.ygeno.2012.11.005; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Bracken CP, 2014, EMBO J, V33, P2040, DOI 10.15252/embj.201488641; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Capobianco V, 2012, J PROTEOME RES, V11, P3358, DOI 10.1021/pr300152z; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen R, 2007, NAT METHODS, V4, P879, DOI 10.1038/nmeth1107-879; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Cloonan N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r126; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Dai YM, 2013, NUCLEIC ACID THER, V23, P29, DOI 10.1089/nat.2012.0385; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Feng B, 2012, CANCER-AM CANCER SOC, V118, P3365, DOI 10.1002/cncr.26560; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175; Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Helwak A, 2013, CELL, V153, P654, DOI 10.1016/j.cell.2013.03.043; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang H, 2012, J BIOL CHEM, V287, P3976, DOI 10.1074/jbc.M111.303156; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Krishnan K, 2013, RNA, V19, P230, DOI 10.1261/rna.034926.112; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Langer EM, 2008, DEV CELL, V14, P424, DOI 10.1016/j.devcel.2008.01.005; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; Li J, 2013, CANCER LETT, V329, P84, DOI 10.1016/j.canlet.2012.10.019; Liu IM, 2009, EMBO J, V28, P88, DOI 10.1038/emboj.2008.266; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Mishra SK, 2004, J BIOL CHEM, V279, P32709, DOI 10.1074/jbc.M402942200; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Obri A, 2014, NATURE, V505, P648, DOI 10.1038/nature12922; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Petrocca F, 2013, CANCER CELL, V24, P182, DOI 10.1016/j.ccr.2013.07.008; Pichler M, 2014, BRIT J CANCER, V110, P1614, DOI 10.1038/bjc.2014.51; Pico AR, 2008, PLOS BIOL, V6, P1403, DOI 10.1371/journal.pbio.0060184; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370; Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin JO, 2012, HISTOCHEM CELL BIOL, V137, P67, DOI 10.1007/s00418-011-0876-1; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tan SM, 2014, CELL REP, V8, P1225, DOI 10.1016/j.celrep.2014.07.023; Tanjore H, 2011, J BIOL CHEM, V286, P30972, DOI 10.1074/jbc.M110.181164; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toiyama Y, 2014, ANN SURG, V259, P735, DOI 10.1097/SLA.0b013e3182a6909d; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Venkov CD, 2007, J CLIN INVEST, V117, P482, DOI 10.1172/JCI29544; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Xia W, 2010, MOL CELL BIOCHEM, V344, P261, DOI 10.1007/s11010-010-0550-2; Yamazaki D, 2005, GENES CELLS, V10, P381, DOI 10.1111/j.1365-2443.2005.00845.x; Yao CX, 2013, RNA BIOL, V10, P465, DOI 10.4161/rna.24370; Ye F, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-17; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3	79	82	85	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					158	172		10.1038/onc.2015.69	http://dx.doi.org/10.1038/onc.2015.69			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25798844	Green Accepted			2022-12-28	WOS:000368193900003
J	Boyle, ST; Ingman, WV; Poltavets, V; Faulkner, JW; Whitfield, RJ; McColl, SR; Kochetkova, M				Boyle, S. T.; Ingman, W. V.; Poltavets, V.; Faulkner, J. W.; Whitfield, R. J.; McColl, S. R.; Kochetkova, M.			The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells	ONCOGENE			English	Article							LYMPH-NODE METASTASIS; BREAST-CANCER CELLS; TUMOR-GROWTH; EXPRESSION; CXCR4; MODEL; DISEASE; ACTIVATION; INCREASES; PREDICTS	The chemokine receptor CCR7 is widely implicated in breast cancer pathobiology. Although recent reports correlated high CCR7 levels with more advanced tumor grade and poor prognosis, limited in vivo data are available regarding its specific function in mammary gland neoplasia and the underlying mechanisms involved. To address these questions we generated a bigenic mouse model of breast cancer combined with CCR7 deletion, which revealed that CCR7 ablation results in a considerable delay in tumor onset as well as significantly reduced tumor burden. Importantly, CCR7 was found to exert its function by regulating mammary cancer stem-like cells in both murine and human tumors. In vivo experiments showed that loss of CCR7 activity either through deletion or pharmacological antagonism significantly decreased functional pools of stem-like cells in mouse primary mammary tumors, providing a mechanistic explanation for the tumor-promoting role of this chemokine receptor. These data characterize the oncogenic properties of CCR7 in mammary epithelial neoplasia and point to a new route for therapeutic intervention to target evasive cancer stem cells.	[Boyle, S. T.; Poltavets, V.; Faulkner, J. W.; McColl, S. R.; Kochetkova, M.] Univ Adelaide, Sch Biol Sci, Dept Mol & Cellular Biol, Adelaide, SA 5005, Australia; [Ingman, W. V.] Univ Adelaide, Robinson Inst, Adelaide, SA 5005, Australia; [Ingman, W. V.] Univ Adelaide, Queen Elizabeth Hosp, Sch Med, Discipline Surg, Adelaide, SA 5005, Australia; [Whitfield, R. J.] Royal Adelaide Hosp, Breast Endocrine & Surg Oncol Unit, Adelaide, SA 5000, Australia; [Whitfield, R. J.] Univ Adelaide, Sch Med, Adelaide, SA 5005, Australia; [McColl, S. R.] Univ Adelaide, Ctr Mol Pathol, Adelaide, SA 5005, Australia	University of Adelaide; Robinson Research Institute; University of Adelaide; University of Adelaide; Royal Adelaide Hospital; University of Adelaide; University of Adelaide	Kochetkova, M (corresponding author), Univ Adelaide, Sch Biol Sci, Dept Mol & Cellular Biol, Adelaide, SA 5005, Australia.	marina.kochetkova@adelaide.edu.au	Kochetkova, Marina/ABE-9538-2021; Boyle, Sarah/B-3048-2019	Kochetkova, Marina/0000-0002-0599-7378; Ingman, Wendy/0000-0003-3116-2902; Poltavets, Valentina/0000-0003-1976-7765; Boyle, Sarah/0000-0001-6143-9285	NHMRC; The Hospital Research Foundation [RF2011/2] Funding Source: researchfish; National Breast Cancer Foundation [ECF-11-06] Funding Source: researchfish	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); The Hospital Research Foundation; National Breast Cancer Foundation	We are grateful to Dr Timothy Proudman and Dr Pallave Dasari from the Queen Elizabeth Hospital for supply of normal human breast tissue and Dr Deepak Dhatrak of the Department of Anatomical Pathology at SA Pathology for procurement of human breast cancer samples. We would also like to sincerely thank Professor Angel Lopez for critical reading of the manuscript, and Dr Michael Samuel and Ms Natasha Pyne for assistance with immunohistochemistry. This work was supported by an NHMRC project grant. WVI is a National Breast Cancer Foundation/The QEH Research Foundation Fellow.	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Biswas S, 2014, BREAST CANCER RES TR, V143, P265, DOI 10.1007/s10549-013-2811-8; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Cabioglu N, 2005, CLIN CANCER RES, V11, P5686, DOI 10.1158/1078-0432.CCR-05-0014; Cassier PA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-213; Chin AR, 2014, MOL CELL ENDOCRINOL, V382, P598, DOI 10.1016/j.mce.2013.03.024; Cunningham HD, 2010, TRANSL ONCOL, V3, P354, DOI 10.1593/tlo.10178; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Giordano A, 2013, ANN ONCOL, V24, P2515, DOI 10.1093/annonc/mdt223; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Iwanaga R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3219; Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190; Lavergne E, 2004, J IMMUNOL, V173, P3755, DOI 10.4049/jimmunol.173.6.3755; Li J, 2011, DIGEST LIVER DIS, V43, P40, DOI 10.1016/j.dld.2010.05.013; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Ma XR, 2009, MOL CANCER THER, V8, P490, DOI 10.1158/1535-7163.MCT-08-0485; Maglione JE, 2001, CANCER RES, V61, P8298; Maxmen A, 2012, NATURE, V485, pS50, DOI 10.1038/485S50a; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pilkington KR, 2004, J BIOL CHEM, V279, P40276, DOI 10.1074/jbc.M405808200; Schwab LP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3087; Sharma S, 2000, J IMMUNOL, V164, P4558, DOI 10.4049/jimmunol.164.9.4558; Smalley MJ, 2012, J MAMMARY GLAND BIOL, V17, P91, DOI 10.1007/s10911-012-9257-1; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Weninger W, 2003, J IMMUNOL, V170, P4638, DOI 10.4049/jimmunol.170.9.4638; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	39	29	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					105	115		10.1038/onc.2015.66	http://dx.doi.org/10.1038/onc.2015.66			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772241	Green Published			2022-12-28	WOS:000367812400010
J	Chen, L; Xu, S; Xu, Y; Lu, W; Liu, L; Yue, D; Teng, J; Chen, J				Chen, L.; Xu, S.; Xu, Y.; Lu, W.; Liu, L.; Yue, D.; Teng, J.; Chen, J.			Cab45S promotes cell proliferation through SERCA2b inhibition and Ca2+ signaling	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; THERAPEUTIC TARGET; ER STRESS; STORE; STIM1; CANCER; CALCINEURIN; APOPTOSIS; FAMILY; TRPC1	Cytosolic Ca2+, closely related to endoplasmic reticulum (ER) Ca2+, plays a critical role in regulating cell proliferation and tumorigenesis. However, the role of ER lumen proteins in regulating cytosolic Ca2+ level remains poorly understood. Here, we find that the Cab45S, localizes in the ER lumen, inhibits sarco/ER Ca2+-ATPase 2b (SERCA2b) activity through its first EF-hand domain directly binding to the intra-lumenal loop 4 of SERCA2b, and reduces ER Ca2+. STIM1 activation, induced by the Cab45S-dependent drop in ER Ca2+, together with the upregulation of the plasma membrane Ca2+ channel TRPC1 ultimately increases extracellular Ca2+ influx. Furthermore, increased cytosolic Ca2+ level elicits Ca2+-NFAT signaling and promotes cell proliferation. Consistently, in cervical carcinoma patients, Cab45S is upregulated. Thus, our data reveal that the ability of Cab45S to inhibit SERCA2b activity is crucial for its role as a modulator of cell proliferation and tumor growth.	[Chen, L.; Xu, S.; Xu, Y.; Lu, W.; Liu, L.; Yue, D.; Teng, J.; Chen, J.] Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Bioengn, Key Lab Cell Proliferat & Differentiat,Minist Edu, Beijing 100871, Peoples R China; [Chen, J.] Peking Univ, Ctr Quantitat Biol, Beijing 100871, Peoples R China	Peking University; Peking University	Teng, J (corresponding author), Peking Univ, Coll Life Sci, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.	junlinteng@pku.edu.cn; chenjg@pku.edu.cn		Chen, Liang/0000-0002-4875-5811	National Natural Science Foundation of China [31471280, 31271424]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Weizhong Zhu (Nantong University) for providing with the Adenovirus containing GFP-tagged NFATc3; Zhili Li (Peking University Medical College), Xiaogai Yang (Peking University Medical College) and Weiguo Zhu (Peking University Medical College) for providing us with Panc1, SW1990, PC3 and SW480 cell lines, respectively. We also extend our thanks to Zhen Cai and Chuanmao Zhang (Peking University) for assistance with instruments and antibodies. This work was supported by the National Natural Science Foundation of China (31471280, 31271424).	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Ambudkar IS, 2007, CELL CALCIUM, V42, P213, DOI 10.1016/j.ceca.2007.01.013; Baggott RR, 2012, CARCINOGENESIS, V33, P2362, DOI 10.1093/carcin/bgs282; BEELER TJ, 1979, J BIOL CHEM, V254, P6229; Bergner A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-25; Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039; Brochet DXP, 2005, P NATL ACAD SCI USA, V102, P3099, DOI 10.1073/pnas.0500059102; Buchholz M, 2007, CELL CYCLE, V6, P16, DOI 10.4161/cc.6.1.3650; Chen L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.193; Chen QQ, 2012, CAN J PHYSIOL PHARM, V90, P1611, DOI 10.1139/y2012-133; Collins SR, 2011, TRENDS CELL BIOL, V21, P202, DOI 10.1016/j.tcb.2011.01.002; Dally S, 2006, BIOCHEM J, V395, P249, DOI 10.1042/BJ20051427; Denmeade SR, 2005, CANCER BIOL THER, V4, P14; Dhitavat J, 2003, J INVEST DERMATOL, V121, P486, DOI 10.1046/j.1523-1747.2003.12410.x; Endo Y, 2004, INT J CANCER, V110, P225, DOI 10.1002/ijc.20118; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Grigoriev I, 2008, CURR BIOL, V18, P177, DOI 10.1016/j.cub.2007.12.050; Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200; Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186; Hovnanian A., 2007, V45, P337; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kang YK, 2005, MOL CELLS, V19, P268; Kurosaki T, 2010, PROG BIOPHYS MOL BIO, V103, P51, DOI 10.1016/j.pbiomolbio.2010.02.004; Lam PPL, 2007, MOL BIOL CELL, V18, P2473, DOI 10.1091/mbc.E06-10-0950; Lechleiter JD, 1998, BIOPHYS CHEM, V72, P123, DOI 10.1016/S0301-4622(98)00128-8; Lee JH, 2013, BIOCHEM BIOPH RES CO, V439, P327, DOI 10.1016/j.bbrc.2013.08.087; Li GL, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-20; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Liao Y, 2007, P NATL ACAD SCI USA, V104, P4682, DOI 10.1073/pnas.0611692104; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Lipskaia L, 2009, PFLUG ARCH EUR J PHY, V457, P673, DOI 10.1007/s00424-007-0428-7; Luik RM, 2008, NATURE, V454, P538, DOI 10.1038/nature07065; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Malli R, 2008, J CELL SCI, V121, P3133, DOI 10.1242/jcs.034496; Marasa BS, 2008, AM J PHYSIOL-CELL PH, V294, pC1277, DOI 10.1152/ajpcell.90635.2007; Marasa BS, 2006, BIOCHEM J, V397, P77, DOI 10.1042/BJ20060124; Mikoshiba K, 2007, BIOCHEM SOC SYMP, V74, P9, DOI 10.1042/BSS2007c02; Pacifico F, 2003, J MOL ENDOCRINOL, V30, P399, DOI 10.1677/jme.0.0300399; Pani B, 2006, MOL BIOL CELL, V17, P4446, DOI 10.1091/mbc.E06-03-0251; Parkash J, 2010, LIFE SCI, V87, P587, DOI 10.1016/j.lfs.2010.09.013; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Roti G, 2013, CANCER CELL, V23, P390, DOI 10.1016/j.ccr.2013.01.015; Savignac M, 2011, BBA-MOL CELL RES, V1813, P1111, DOI 10.1016/j.bbamcr.2010.12.006; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; Stokke MK, 2010, CARDIOVASC RES, V86, P63, DOI 10.1093/cvr/cvp401; Tsuji A, 2006, BIOCHEM J, V396, P51, DOI 10.1042/BJ20051524; Tsukamoto T, 2001, PSYCHOPHARMACOLOGY, V158, P107, DOI 10.1007/s002130100870; Vandecaetsbeek I, 2009, P NATL ACAD SCI USA, V106, P18533, DOI 10.1073/pnas.0906797106; Vangheluwe P, 2005, CELL CALCIUM, V38, P291, DOI 10.1016/j.ceca.2005.06.033; von Blume J, 2012, J CELL BIOL, V199, P1057, DOI 10.1083/jcb.201207180; Wang Qiao, 2012, Front Biosci (Elite Ed), V4, P998, DOI 10.2741/E435; Wang QA, 2010, CELL RES, V20, P713, DOI 10.1038/cr.2010.47; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhu YF, 2008, J GENET GENOMICS, V35, P153, DOI 10.1016/S1673-8527(08)60021-1	59	19	19	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					35	46		10.1038/onc.2015.56	http://dx.doi.org/10.1038/onc.2015.56			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772237				2022-12-28	WOS:000367812400004
J	Sleire, L; Skeie, BS; Netland, IA; Forde, HE; Dodoo, E; Selheim, F; Leiss, L; Heggdal, JI; Pedersen, PH; Wang, J; Enger, PO				Sleire, L.; Skeie, B. S.; Netland, I. A.; Forde, H. E.; Dodoo, E.; Selheim, F.; Leiss, L.; Heggdal, J. I.; Pedersen, P-H; Wang, J.; Enger, P. O.			Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc(-), leading to glutathione depletion	ONCOGENE			English	Article							FACTOR-KAPPA-B; GLUTAMATE TRANSPORTERS; CELLS; GROWTH; GLIOBLASTOMA; INHIBITION; SULPHASALAZINE; RADIOTHERAPY; TEMOZOLOMIDE; ACTIVATION	Glioblastomas (GBMs) are aggressive brain tumors that always recur after radiotherapy. Cystine, mainly provided by the system X-c(-) antiporter, is a requirement for glioma cell synthesis of glutathione (GSH) which has a critical role in scavenging free radicals, for example, after radiotherapy. Thus, we hypothesized that the X-c(-) inhibitor sulfasalazine (SAS) could potentiate the efficacy of radiotherapy against gliomas. Here, we show that the catalytic subunit of system X-c(,)- xCT, was uniformly expressed in a panel of 30 human GBM biopsies. SAS treatment significantly reduced cystine uptake and GSH levels, whereas it significantly increased the levels of reactive oxygen species (ROS) in glioma cells in vitro. Furthermore, SAS and radiation synergistically increased DNA double-strand breaks and increased glioma cell death, whereas adding the antioxidant N-acetyl-L-cysteine (NAC) reversed cell death. Moreover, SAS and gamma knife radiosurgery (GKRS) synergistically prolonged survival in nude rats harboring human GBM xenografts, compared with controls or either treatment alone. In conclusion, SAS effectively blocks cystine uptake in glioma cells in vitro, leading to GSH depletion and increased ROS levels, DNA damage and cell death. Moreover, it potentiates the anti-tumor efficacy of GKRS in rats with human GBM xenografts, providing a survival benefit. Thus, SAS may have a role as a radiosensitizer to enhance the efficacy of current radiotherapies for glioma patients.	[Sleire, L.; Netland, I. A.; Forde, H. E.; Leiss, L.; Wang, J.; Enger, P. O.] Univ Bergen, Oncomatrix Res Lab, Dept Biomed, N-5020 Bergen, Norway; [Skeie, B. S.; Pedersen, P-H] Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway; [Skeie, B. S.; Pedersen, P-H; Enger, P. O.] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; [Dodoo, E.] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Selheim, F.] Univ Bergen, Prote Unit PROBE, Dept Biomed, N-5020 Bergen, Norway; [Leiss, L.] Haukeland Hosp, Neuro Clin, N-5021 Bergen, Norway; [Heggdal, J. I.] Haukeland Hosp, Dept Oncol & Med Phys, N-5021 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Enger, PO (corresponding author), Univ Bergen, Oncomatrix Res Lab, Dept Biomed, Jonas Lies Vei 91, N-5020 Bergen, Norway.	per.enger@biomed.uib.no		Skeie, Bente Sandvei/0000-0001-9876-5826				AKSLEN LA, 1988, ANTICANCER RES, V8, P797; ALLALUNISTURNER MJ, 1991, J NEURO-ONCOL, V11, P157, DOI 10.1007/BF02390175; ARCHIBALD YM, 1994, J NEUROSURG, V80, P247, DOI 10.3171/jns.1994.80.2.0247; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/jns.1990.72.3.0463; Buckingham SC, 2011, NAT MED, V17, P1269, DOI 10.1038/nm.2453; BUMP EA, 1982, SCIENCE, V217, P544, DOI 10.1126/science.7089580; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; DICK AP, 1964, GUT, V5, P437, DOI 10.1136/gut.5.5.437; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hsieh PC, 2005, NEUROSURGERY, V57, P684, DOI 10.1227/01.NEU.0000175550.96901.A3; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; Kim JY, 2001, BBA-BIOMEMBRANES, V1512, P335, DOI 10.1016/S0005-2736(01)00338-8; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; McDonald JT, 2010, CANCER RES, V70, P8886, DOI 10.1158/0008-5472.CAN-10-0171; Narang VS, 2007, CHEMOTHERAPY, V53, P210, DOI 10.1159/000100812; NEUMANN VC, 1984, J ROY SOC MED, V77, P169, DOI 10.1177/014107688407700301; Ogunrinu TA, 2010, J BIOL CHEM, V285, P37716, DOI 10.1074/jbc.M110.161190; Rey M, 1996, NEUROCHIRURGIE, V42, P289; Robe PA, 2004, CLIN CANCER RES, V10, P5595, DOI 10.1158/1078-0432.CCR-03-0392; Robe PA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-372; Robert SM, 2014, CELL MOL LIFE SCI, V71, P1839, DOI 10.1007/s00018-013-1521-z; Rothstein JD, 2001, NAT MED, V7, P994, DOI 10.1038/nm0901-994; Sakariassen PO, 2006, P NATL ACAD SCI USA, V103, P16466, DOI 10.1073/pnas.0607668103; SALCMAN M, 1980, NEUROSURGERY, V7, P435, DOI 10.1227/00006123-198011000-00001; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Skeie BS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/139674; Skeie BS, 2012, WORLD NEUROSURG, V78, P658, DOI 10.1016/j.wneu.2012.03.024; Soffietti R, 2013, J CLIN ONCOL, V31, P65, DOI 10.1200/JCO.2011.41.0639; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Takeuchi S, 2014, NEUROL INDIA, V62, P42, DOI 10.4103/0028-3886.128280; Takeuchi S, 2013, NEUROSURGERY, V72, P33, DOI 10.1227/NEU.0b013e318276b2de; Towner RA, 2013, BBA-MOL BASIS DIS, V1832, P2153, DOI 10.1016/j.bbadis.2013.08.004; Wang J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-465; Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999	40	96	102	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5951	5959		10.1038/onc.2015.60	http://dx.doi.org/10.1038/onc.2015.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25798841				2022-12-28	WOS:000366113500002
J	Ahn, J; Konno, H; Barber, GN				Ahn, J.; Konno, H.; Barber, G. N.			Diverse roles of STING-dependent signaling on the development of cancer	ONCOGENE			English	Article							INNATE; TUMORIGENESIS; INFLAMMATION; ADAPTER; CELLS; TOLL	Stimulator of interferon genes (STING) is a cellular sensor that controls cytosolic DNA-activated innate immune signaling. We have previously demonstrated that STING-deficient mice are resistant to carcinogen-induced skin cancer, similar to myeloid differentiation primary response gene 88 (MyD88) deficient mice, since the production of STING-dependent DNA-damage-induced proinflammatory cytokines, that likely require MyD88 signaling to exert their growth-promoting activity, are prevented. In contrast, MyD88-deficient mice are sensitive to colitis-associated cancer (CAC), since selected cytokines generated following DNA-damage also activate repair pathways, which can help prevent tumor development. Here, we demonstrate that STING signaling facilitates wound repair processes and that analogous to MyD88-deficient mice, STING-deficient mice (SKO) are prone to CAC induced by DNA-damaging agents. SKO mice harboring tumors exhibited low levels of tumor-suppressive interleukin-22 binding protein (IL-22BP) compared to normal mice, a cytokine considered critical for preventing colon-related cancer. Our data indicate that STING constitutes a critical component of the host early response to intestinal damage and is essential for invigorating tissue repair pathways that may help prevent tumorigenesis.	[Barber, G. N.] Univ Miami, Sch Med, Dept Cell Biol, Miami, FL 33136 USA; [Barber, G. N.] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Cell Biol, 511 Papanicolaou Bldg,1550 NW 10th Ave, Miami, FL 33136 USA.	gbarber@med.miami.edu			NATIONAL CANCER INSTITUTE [R01CA194404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079336] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA194404] Funding Source: Medline; NIAID NIH HHS [R01 AI079336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn J, 2014, J IMMUNOL, V193, P4634, DOI 10.4049/jimmunol.1401337; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6166; Ahn J, 2012, P NATL ACAD SCI USA, V109, P19386, DOI 10.1073/pnas.1215006109; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Fukata M, 2009, SEMIN IMMUNOL, V21, P242, DOI 10.1016/j.smim.2009.06.005; Gall A, 2012, IMMUNITY, V36, P120, DOI 10.1016/j.immuni.2011.11.018; Goldszmid RS, 2012, NAT IMMUNOL, V13, P932, DOI 10.1038/ni.2422; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; JACOBY RF, 1991, J CLIN INVEST, V87, P624, DOI 10.1172/JCI115039; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Namjou B, 2011, GENES IMMUN, V12, P270, DOI 10.1038/gene.2010.73; Nowarski R, 2013, CANCER IMMUNOL RES, V1, P77, DOI 10.1158/2326-6066.CIR-13-0081; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Salcedo R, 2013, TRENDS IMMUNOL, V34, P379, DOI 10.1016/j.it.2013.03.008; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zhu QF, 2014, J IMMUNOL, V193, P4779, DOI 10.4049/jimmunol.1402051	26	83	87	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5302	5308		10.1038/onc.2014.457	http://dx.doi.org/10.1038/onc.2014.457			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639870	Green Accepted			2022-12-28	WOS:000362575400010
J	Zhao, X; Parpart, S; Takai, A; Roessler, S; Budhu, A; Yu, Z; Blank, M; Zhang, YE; Jia, HL; Ye, QH; Qin, LX; Tang, ZY; Thorgeirsson, SS; Wang, XW				Zhao, X.; Parpart, S.; Takai, A.; Roessler, S.; Budhu, A.; Yu, Z.; Blank, M.; Zhang, Y. E.; Jia, H-L; Ye, Q-H; Qin, L-X; Tang, Z-Y; Thorgeirsson, S. S.; Wang, X. W.			Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma	ONCOGENE			English	Article							H2B UBIQUITYLATION; SOMATIC MUTATIONS; H3 METHYLATION; CANCER; TUMOR; PREDICTION; GENES; CLASSIFICATION; PROGRESSION; LANDSCAPE	Identification of key drivers and new therapeutic targets is important given the poor prognosis for hepatocellular carcinoma (HCC) patients, particularly those ineligible for surgical resection or liver transplant. However, the approach to identify such driver genes is facing significant challenges due to the genomically heterogenous nature of HCC. Here we tested whether the integrative genomic profiling of a well-defined HCC subset that is classified by an extreme EpCAM(+) AFP(+) gene expression signature and associated with poor prognosis, all attributes of a stem cell-like phenotype, could uncover survival-related driver genes in HCC. Following transcriptomic analysis of the well-defined HCC cases, a Gene Set Enrichment Analysis coupled with genomic copy number alteration assessment revealed that YY1-associated protein 1 (YY1AP1) is a critical oncoprotein specifically activated in EpCAM(+) AFP+ HCC. YY1AP1 silencing eliminates oncogene addiction by altering the chromatin landscape and triggering massive apoptosis in vitro and tumor suppression in vivo. YY1AP1 expression promotes HCC proliferation and is required for the maintenance of stem cell features. We revealed that YY1AP1 cooperates with YY1 to alter the chromatin landscape and activate transcription of stemness regulators. Thus YY1AP1 may serve as a key molecular target for EpCAM(+) AFP(+) HCC subtype. Our results demonstrate the feasibility and power of a new strategy by utilizing well-defined patient samples and integrative genomics to uncover critical pathways linked to HCC subtypes with prognostic impact.	[Zhao, X.; Parpart, S.; Takai, A.; Roessler, S.; Budhu, A.; Yu, Z.; Wang, X. W.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Blank, M.; Zhang, Y. E.] NCI, Lab Cellular & Mol Biol, Ctr Canc Res, Bethesda, MD 20892 USA; [Jia, H-L; Ye, Q-H; Qin, L-X; Tang, Z-Y] Fudan Univ, Liver Canc Inst, Shanghai 200433, Peoples R China; [Thorgeirsson, S. S.] NCI, Lab Expt Carcinogenesis, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fudan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Liver Carcinogenesis Sect, Ctr Canc Res, Bldg 37,Room 3044A,37 Convent Dr, Bethesda, MD 20892 USA.	xw3u@nih.gov	Roessler, Stephanie/J-8432-2019; Zhao, Xuelian/Q-1370-2017; Zhang, Ying E/G-3657-2015; Wang, Xin Wei/B-6162-2009	Roessler, Stephanie/0000-0002-5333-5942; Zhao, Xuelian/0000-0003-2964-3184; Zhang, Ying E/0000-0003-2753-7601; Wang, Xin Wei/0000-0001-9735-606X	Intramural Research Grants of the Center for Cancer Research; US National Cancer Institute [Z01 BC 010313, Z01 BC 010877, Z01 BC 010876]; NATIONAL CANCER INSTITUTE [Z01BC010313, Z01BC010876, Z01BC010877, ZIABC011168] Funding Source: NIH RePORTER	Intramural Research Grants of the Center for Cancer Research; US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Curtis Harris for critical reading of the manuscript, Dr Zheng-Gang Liu for advice on apoptosis study, Dominic Esposito at the Advanced Technology Program of SAIC-Frederick, Inc., for the help in designing the Tet-C2 inducible construct and Liver Tissue Cell Distribution System (LTCDS) at the University of Minnesota (Minneapolis, MN, USA) for generous donation of normal liver specimens. We also thank Karen Yarrick for the bibliographic assistance. This work was supported by the Intramural Research Grants of the Center for Cancer Research and the US National Cancer Institute Z01 BC 010313, Z01 BC 010877 and Z01 BC 010876.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Budhu A, 2013, GASTROENTEROLOGY, V144, P1066, DOI 10.1053/j.gastro.2013.01.054; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Cuddapah S, 2011, MOL CELL BIOL, V31, P700, DOI 10.1128/MCB.00740-10; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kuryshev VY, 2006, GENOMICS, V88, P143, DOI 10.1016/j.ygeno.2006.02.002; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890; Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Rotili Dante, 2011, Genes Cancer, V2, P663, DOI 10.1177/1947601911417976; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Wang CY, 2004, J BIOL CHEM, V279, P17750, DOI 10.1074/jbc.M310532200; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang EB, 1997, CANCER LETT, V117, P93, DOI 10.1016/S0304-3835(97)00206-1; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhang K, 2005, CLIN CANCER RES, V11, P7532, DOI 10.1158/1078-0432.CCR-05-0400; Zhou XD, 2001, CANCER-AM CANCER SOC, V91, P1479, DOI 10.1002/1097-0142(20010415)91:8<1479::AID-CNCR1155>3.0.CO;2-0	44	31	34	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5095	5104		10.1038/onc.2014.438	http://dx.doi.org/10.1038/onc.2014.438			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25597408	Green Accepted			2022-12-28	WOS:000361693300009
J	Deutzmann, A; Ganz, M; Schonenberger, F; Vervoorts, J; Kappes, F; Ferrando-May, E				Deutzmann, A.; Ganz, M.; Schoenenberger, F.; Vervoorts, J.; Kappes, F.; Ferrando-May, E.			The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress	ONCOGENE			English	Article							DAMAGE RESPONSE; PROTEIN DEK; PROTOONCOGENE; PATHWAY; FORKS; POLY(ADP-RIBOSE); CHEMORESISTANCE; APOPTOSIS; RESTART; MITOSIS	DNA replication stress is a major source of DNA strand breaks and genomic instability, and a hallmark of precancerous lesions. In these hyperproliferative tissues, activation of the DNA damage response results in apoptosis or senescence preventing or delaying their development to full malignancy. In cells, in which this antitumor barrier is disabled by mutations ( for example, in p53), viability and further uncontrolled proliferation depend on factors that help to cope with replication-associated DNA damage. Replication problems preferentially arise in chromatin regions harboring complex DNA structures. DEK is a unique chromatin architectural factor which binds to non-B-form DNA structures, such as cruciform DNA or four-way junctions. It regulates DNA topology and chromatin organization, and is essential for the maintenance of heterochromatin integrity. Since its isolation as part of an oncogenic fusion in a subtype of AML, DEK has been consistently associated with tumor progression and chemoresistance. How DEK promotes cancer, however, is poorly understood. Here we show that DEK facilitates cellular proliferation under conditions of DNA replication stress by promoting replication fork progression. DEK also protects from the transmission of DNA damage to the daughter cell generation. We propose that DEK counteracts replication stress and ensures proliferative advantage by resolving problematic DNA and/or chromatin structures at the replication fork.	[Deutzmann, A.; Ganz, M.; Schoenenberger, F.; Ferrando-May, E.] Univ Konstanz, Dept Biol, Bioimaging Ctr, D-78464 Constance, Germany; [Vervoorts, J.; Kappes, F.] Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, Sch Med, Aachen, Germany	University of Konstanz; RWTH Aachen University	Ferrando-May, E (corresponding author), Univ Konstanz, Dept Biol, Bioimaging Ctr, POB 604,Univ Str 10, D-78464 Constance, Germany.	elisa.may@uni-konstanz.de	Ferdinand, Kappes/H-4445-2014	Ferdinand, Kappes/0000-0002-0369-0065; Vervoorts, Jorg/0000-0002-3251-6496; Deutzmann, Anja/0000-0002-3271-1427	German Research Foundation (DFG) [SFB 969, RTG 1331]; DFG [KA 2799/1]; START program of the Faculty of Medicine, RWTH Aachen	German Research Foundation (DFG)(German Research Foundation (DFG)); DFG(German Research Foundation (DFG)); START program of the Faculty of Medicine, RWTH Aachen	We thank G Marra for U2-OS cells, Y Marquardt for NHD fibroblasts, J Schmidt for ImageJ Macro programming, D Hermann, K Weidele and F Teusel for technical assistance; S Burger and the FlowKon facility for support in flow cytometry and M Lopes, C Lukas, A Burkle and B Luscher for fruitful discussions. This work was supported by the German Research Foundation (DFG) through funds of the SFB 969, and of the RTG 1331. Work in the laboratory of FK is supported by a DFG grant (KA 2799/1) and by the START program of the Faculty of Medicine, RWTH Aachen.	Alexiadis V, 2000, GENE DEV, V14, P1308; Bartek J, 2012, NAT STRUCT MOL BIOL, V19, P5, DOI 10.1038/nsmb.2220; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bogliolo M, 2007, EMBO J, V26, P1340, DOI 10.1038/sj.emboj.7601574; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chaudhuri AR, 2012, NAT STRUCT MOL BIOL, V19, P417, DOI 10.1038/nsmb.2258; Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834; de Feraudy S, 2010, P NATL ACAD SCI USA, V107, P6870, DOI 10.1073/pnas.1002175107; Debatisse M, 2012, TRENDS GENET, V28, P22, DOI 10.1016/j.tig.2011.10.003; Fahrer J, 2010, BIOCHEMISTRY-US, V49, P7119, DOI 10.1021/bi1004365; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Kappes F, 2011, GENE DEV, V25, P673, DOI 10.1101/gad.2036411; Kappes F, 2011, HUM PATHOL, V42, P932, DOI 10.1016/j.humpath.2010.10.022; Kavanaugh GM, 2011, NUCLEIC ACIDS RES, V39, P7465, DOI 10.1093/nar/gkr454; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Renaud E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053693; Riveiro-Falkenbach E, 2010, CLIN CANCER RES, V16, P2932, DOI 10.1158/1078-0432.CCR-09-2330; Saha AK, 2013, P NATL ACAD SCI USA, V110, P6847, DOI 10.1073/pnas.1220751110; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Sirbu BM, 2013, J BIOL CHEM, V288, P31458, DOI 10.1074/jbc.M113.511337; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Waldmann T, 2003, NUCLEIC ACIDS RES, V31, P7003, DOI 10.1093/nar/gkg864; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; Wang LC, 2008, DNA REPAIR, V7, P1973, DOI 10.1016/j.dnarep.2008.08.005; Wilhelm T, 2014, P NATL ACAD SCI USA, V111, P763, DOI 10.1073/pnas.1311520111; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330	39	22	22	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4270	4277		10.1038/onc.2014.346	http://dx.doi.org/10.1038/onc.2014.346			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347734	Green Submitted			2022-12-28	WOS:000359199800013
J	Meniel, V; Megges, M; Young, MA; Cole, A; Sansom, OJ; Clarke, AR				Meniel, V.; Megges, M.; Young, M. A.; Cole, A.; Sansom, O. J.; Clarke, A. R.			Apc and p53 interaction in DNA damage and genomic instability in hepatocytes	ONCOGENE			English	Article							POLYPOSIS-COLI PROTEIN; HEPATOCELLULAR-CARCINOMA; CHROMOSOMAL INSTABILITY; MUTATIONS; PREDISPOSES; DEFICIENCY; ANEUPLOIDY; APOPTOSIS; PATHWAYS; GENETICS	Disruption of Apc (adenomatous polyposis coli) within hepatocytes activates Wnt signalling, perturbs differentiation and ultimately leads to neoplasia. Apc negatively regulates Wnt signalling but is also involved in organizing the cytoskeleton and may have a role in chromosome segregation. In vitro studies have implicated Apc in the control of genomic stability. However, the relevance of this data has been questioned in vivo as Apc is lost earlier than the onset of genomic instability. Here we analyse the relationship between immediate loss of Apc and the acquisition of genomic instability in hepatocytes. We used Cre-lox technology to inactivate Apc and in combination with p53 in vivo, to define the consequences of gene loss on cell cycle regulation, proliferation, death and aneuploidy. We show that, although Apc loss leads to increased proliferation, it also leads to increased apoptosis, the accumulation of p53, p21 and markers of double-strand breaks and DNA repair. Flow cytometry revealed an increased 4N DNA content, consistent with a G2 arrest. Levels of anaphase bridges were also elevated, implicating failed chromosome segregation. This was accompanied by an increase in centrosome number, which demonstrates a role for Apc in maintaining euploidy. To address the role of p53 in these processes, we analysed combined loss of Apc and p53, which led to a further increase in proliferation, cell death, DNA damages and repair and a bypass of G2 arrest than was observed with Apc loss. However, we observed only a marginal effect on anaphase bridges and centrosome number, which could be due to increased cell death. Our data therefore establishes, in an in vivo setting, that APC loss leads to a DNA damage signature and genomic instability in the liver and that additional loss of p53 leads to an increase in the DNA damage signal but not to an immediate increase in the genomic instability phenotype.	[Meniel, V.; Young, M. A.; Clarke, A. R.] Cardiff Univ, European Canc Stem Cell Res Inst, Cardiff CF24 4HQ, S Glam, Wales; [Megges, M.] Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany; [Cole, A.; Sansom, O. J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Cardiff University; Max Planck Society; Beatson Institute	Meniel, V (corresponding author), Cardiff Univ, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.	Menielvs@cf.ac.uk		Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X; Young, Maddy/0000-0002-1487-0694	Cancer research UK [RCBMA7613]; Cancer Research UK [12481, 15937] Funding Source: researchfish	Cancer research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank Mark Bishop (genotyping) and Derek Scarborough (histology). This work was financially supported by Cancer research UK RCBMA7613.	Guerrero AA, 2010, P NATL ACAD SCI USA, V107, P4159, DOI 10.1073/pnas.0912143106; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Bree RT, 2004, DNA REPAIR, V3, P989, DOI 10.1016/j.dnarep.2004.03.016; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caldwell CM, 2007, J CELL BIOL, V178, P1109, DOI 10.1083/jcb.200703186; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Feng GJ, 2012, GASTROENTEROLOGY, V143, P1650, DOI 10.1053/j.gastro.2012.08.047; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Godinho SA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0467; Gougelet A, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/816125; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hadjihannas MV, 2006, CELL CYCLE, V5, P2077, DOI 10.4161/cc.5.18.3282; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hanson CA, 2005, GENE, V361, P1, DOI 10.1016/j.gene.2005.07.024; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Hussain SP, 2007, ONCOGENE, V26, P2166, DOI 10.1038/sj.onc.1210279; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jain S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026799; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Nasser M, 2008, J CELL BIOL, V181, P719; Pineau P, 2008, MUTAT RES-GEN TOX EN, V653, P6, DOI 10.1016/j.mrgentox.2008.01.012; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; Reed KR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-162; Reed KR, 2008, P NATL ACAD SCI USA, V105, P18919, DOI 10.1073/pnas.0805778105; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; Torre C, 2011, INT J BIOCHEM CELL B, V43, P271, DOI 10.1016/j.biocel.2009.11.004; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; Vitre BD, 2012, CURR OPIN CELL BIOL, V24, P809, DOI 10.1016/j.ceb.2012.10.006; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002	42	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4118	4129		10.1038/onc.2014.342	http://dx.doi.org/10.1038/onc.2014.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347740	Green Accepted			2022-12-28	WOS:000358780500010
J	Archibald, A; Mihai, C; Macara, IG; McCaffrey, L				Archibald, A.; Mihai, C.; Macara, I. G.; McCaffrey, L.			Oncogenic suppression of apoptosis uncovers a Rac1/JNK proliferation pathway activated by loss of Par3	ONCOGENE			English	Article							MAMMARY-GLAND DEVELOPMENT; POLARITY PROTEIN; BREAST-CANCER; RAC; COOPERATE; OVEREXPRESSION; TUMORIGENESIS; OVERGROWTH; GTPASES; GROWTH	Disruption of epithelial organization and loss of growth control are universal features of carcinomas, yet how these features are linked during cancer progression remains poorly understood. Cell polarity proteins control cellular and tissue organization and are emerging as important mediators of cancer progression. The Par3 polarity protein is a molecular scaffold that functions to recruit and spatially organize signaling factors, and was recently identified as a suppressor of breast cancer invasion and metastasis. Here, we show that loss of Par3 in mammary epithelial cells promotes apoptosis, and that oncogenic Notch overcomes the apoptotic signal to reveal an unexpected pro-proliferative role for loss of Par3 in mammary tumors. In this context, loss of Par3 deregulates Rac1 activity to activate Jun N-terminal Kinase-dependent proliferation and tumor growth. Thus, we demonstrate a mechanism by which loss of Par3 promotes proliferation and tumorigenesis, which supports a tumor-suppressive function for Par3 in the mammary epithelium.	[Archibald, A.; Mihai, C.; McCaffrey, L.] McGill Univ, Dept Oncol, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Macara, I. G.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN USA	McGill University; Vanderbilt University	McCaffrey, L (corresponding author), McGill Univ, Dept Oncol, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.	luke.mccaffrey@mcgill.ca			TFRI [1009]; CIHR [MOP-119482]; NATIONAL CANCER INSTITUTE [R01CA132898] Funding Source: NIH RePORTER	TFRI; CIHR(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Didier Trono (Lausanne, Switzerland) for lentivectors. K8 hybridoma, developed by Philippe Brulet and Rolf Kemler, was obtained from the Universtiy of Iowa Developmental Hybridoma Bank. This work was supported by grants from TFRI (Project #1009) and CIHR (MOP-119482) to LM. LM is a FRQS Research Scholar.	Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Durgan J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174235; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Georgiou M, 2010, J CELL SCI, V123, P1089, DOI 10.1242/jcs.060772; Han JS, 2010, ANTICANCER RES, V30, P3407; Hayase J, 2013, J CELL BIOL, V200, P635, DOI 10.1083/jcb.201208150; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; Kim M, 2007, J CELL SCI, V120, P2309, DOI 10.1242/jcs.007443; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCaffrey LM, 2011, TRENDS CELL BIOL, V21, P727, DOI 10.1016/j.tcb.2011.06.005; McCaffrey LM, 2009, GENE DEV, V23, P1450, DOI 10.1101/gad.1795909; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Simmons MJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3321; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Strumane K, 2009, J CANCER RES CLIN, V135, P69, DOI 10.1007/s00432-008-0437-8; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Warner SJ, 2010, CURR BIOL, V20, P677, DOI 10.1016/j.cub.2010.03.025; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99	37	27	28	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3199	3206		10.1038/onc.2014.242	http://dx.doi.org/10.1038/onc.2014.242			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109337	Green Accepted			2022-12-28	WOS:000356101100011
J	Purayil, HT; Zhang, Y; Dey, A; Gersey, Z; Espana-Serrano, L; Daaka, Y				Purayil, H. T.; Zhang, Y.; Dey, A.; Gersey, Z.; Espana-Serrano, L.; Daaka, Y.			Arrestin2 modulates androgen receptor activation	ONCOGENE			English	Article							NUCLEAR EXPORT SIGNAL; PROSTATE-CANCER; BETA-ARRESTINS; BETA-ARRESTIN1; PROGRESSION; EXPRESSION; IDENTIFICATION; ESTABLISHMENT; LOCALIZATION; ENDOCYTOSIS	Androgen receptor (AR) has a pivotal role in the growth and survival of prostate cancer (PCa). Arrestin2 (Arr2) is a ubiquitous scaffolding/adaptor protein first characterized as a regulator of G protein-coupled receptor signaling. In this study, we report that Arr2 additionally functions as a positive regulator of AR expression and function in PCa cells. Expression level of Arr2 correlates with that of AR, and knockdown of Arr2 inhibits the expression of AR and its effectors prostate-specific antigen, transmembrane protease serine 2, FK506-binding protein 51 and fatty acid synthase. Mechanistically, the knockdown of Arr2 attenuates the binding of AR to androgen response elements and consequently decreases transcription of AR-regulated genes. The inhibition of AR by Arr2 knockdown occurs in both androgen-dependent and castration-resistant PCa (CRPC) cells, although the effect is more prominent in CRPC. Arr2 knockdown inhibits the in vitro CRPC cell proliferation, prostasphere growth and invasion, as well as the in vivo prostate tumor formation, local invasion and distant metastasis. These results illustrate a new role for Arr2 in the expression and activation of AR and its potential relevance as a target for therapeutic intervention and monitoring of disease progression.	[Purayil, H. T.; Zhang, Y.; Dey, A.; Gersey, Z.; Espana-Serrano, L.; Daaka, Y.] Univ Florida, Dept Anat & Cell Biol, Coll Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Daaka, Y (corresponding author), Univ Florida, Dept Anat & Cell Biol, 1333 Ctr Dr,B1-004, Gainesville, FL 32610 USA.	ydaaka@ufl.edu	PURAYIL, HAMSA THAYELE/E-7533-2015	THAYELE PURAYIL, HAMSA/0000-0002-7211-3659				Attard G, 2011, CLIN CANCER RES, V17, P1649, DOI 10.1158/1078-0432.CCR-10-0567; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Boorjian SA, 2009, ENDOCR-RELAT CANCER, V16, P123, DOI 10.1677/ERC-08-0124; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Chen Y, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002595; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Gregory CW, 2001, CANCER RES, V61, P2892; Hara T, 2008, CANCER RES, V68, P1128, DOI 10.1158/0008-5472.CAN-07-1929; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; HOBISCH A, 1995, CANCER RES, V55, P3068; Hoeppner CZ, 2012, J BIOL CHEM, V287, P8932, DOI 10.1074/jbc.M111.294058; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Khaitan D, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-12; Lakshmikanthan V, 2009, P NATL ACAD SCI USA, V106, P9379, DOI 10.1073/pnas.0900258106; Lamont KR, 2010, ADV CANCER RES, V107, P137, DOI 10.1016/S0065-230X(10)07005-3; Lang SH, 2001, BRIT J CANCER, V85, P590, DOI 10.1054/bjoc.2001.1967; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsumoto T, 2013, ANNU REV PHYSIOL, V75, P201, DOI 10.1146/annurev-physiol-030212-183656; Mo W, 2008, MOL CELL, V31, P695, DOI 10.1016/j.molcel.2008.06.017; Rosano L, 2013, ONCOGENE, V32, P5066, DOI 10.1038/onc.2012.527; Saraon P, 2011, CLIN CHEM, V57, P1366, DOI 10.1373/clinchem.2011.165977; Sartor O, 2002, UROLOGY, V60, P138; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shenoy SK, 2012, ONCOGENE, V31, P282, DOI 10.1038/onc.2011.238; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Snoek R, 2009, CLIN CANCER RES, V15, P39, DOI 10.1158/1078-0432.CCR-08-1726; TILLEY WD, 1994, CANCER RES, V54, P4096; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Wang LG, 2012, ASIAN PAC J CANCER P, V13, P5671, DOI 10.7314/APJCP.2012.13.11.5671; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wilbanks AM, 2004, SCIENCE, V306, P2264, DOI 10.1126/science.1104193; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Zou L, 2008, FASEB J, V22, P355, DOI 10.1096/fj.07-9046com	44	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3144	3151		10.1038/onc.2014.252	http://dx.doi.org/10.1038/onc.2014.252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109335				2022-12-28	WOS:000356101100006
J	Choi, MJ; Cho, KH; Lee, S; Bae, YJ; Jeong, KJ; Rha, SY; Choi, EJ; Park, JH; Kim, JM; Lee, JS; Mills, GB; Lee, HY				Choi, M. J.; Cho, K. H.; Lee, S.; Bae, Y. J.; Jeong, K. J.; Rha, S. Y.; Choi, E. J.; Park, J. H.; Kim, J. M.; Lee, J-S; Mills, G. B.; Lee, H. Y.			hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; TELOMERASE ACTIVITY; CHRONIC STRESS; CELLS; SRC; ACTIVATION; PROMOTES; KINASE; TARGET	Stress hormones have been implicated in both tumor initiation and progression. Human telomerase reverse transcriptase (hTERT) is overexpressed in cancer cells and associated with malignant tumor progression and poor outcome. We thus sought to determine whether the stress hormone norepinephrine (NE) could induce hTERT expression and subsequently ovarian cancer progression. Unexpectedly, NE induced hTERT transcript and protein expression, and subsequently ovarian cancer cell invasion. Pharmacologic inhibition of beta 2-adrenergic receptor 2 and protein kinase A, as well as silencing of hypoxia-inducible factor-1 alpha and c-Myc expression, profoundly attenuated NE-induced hTERT expression. Strikingly, stimulation of the cells with NE or ectopic expression of hTERT induced expression of Slug, ovarian cancer cell epithelial-mesenchymal transition (EMT) and invasion. Silencing of hTERT expression abrogated NE-induced ovarian cancer cell invasion, EMT and Slug expression. In addition, silencing of Slug expression significantly inhibited NE-and hTERT-induced ovarian cancer cell EMT and invasion. Moreover, continuous exposure to NE was sufficient to enhance in vivo hTERT expression and metastasis of ovarian cancer cells to the lung. Finally, we provide evidence that hTERT links Src to Slug expression in NE-induced ovarian cancer EMT and metastasis. We thus demonstrate a novel role of hTERT in stress hormone-induced ovarian cancer aggressiveness through inducing Slug, providing novel biomarkers and potential therapeutic targets for ovarian cancer.	[Choi, M. J.; Cho, K. H.; Bae, Y. J.; Lee, H. Y.] Konyang Univ, Dept Pharmacol, Myunggok Med Res Inst, Coll Med, Taejon 302718, South Korea; [Lee, S.; Park, J. H.] Konyang Univ, Dept Biochem, Coll Med, Myunggok Med Res Inst, Taejon 302718, South Korea; [Jeong, K. J.; Lee, J-S; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Rha, S. Y.; Lee, H. Y.] Yonsei Univ, Coll Med, Yonsei Canc Res Inst, Seoul, South Korea; [Choi, E. J.] Konyang Univ, Dept Optometry, Coll Med Sci, Taejon 302718, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Canc Res Inst, Reg Canc Ctr, Taejon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Taejon, South Korea	Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Yonsei University Health System; Konyang University; Chungnam National University; Chungnam National University	Lee, HY (corresponding author), Konyang Univ, Dept Pharmacol, Coll Med, 821 Med Sci Bldg,681 Gasuwon Dong, Taejon 302718, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022	KIM, JIN MAN/0000-0003-0905-9730; Rha, Sun Young/0000-0002-2512-4531; Choi, Moonjung/0000-0002-7218-4924; Choi, Eun Jung/0000-0002-5020-3055	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [121182]; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2011-0015761, 2013R1A1A2A10059565]; NATIONAL CANCER INSTITUTE [P50CA083639] Funding Source: NIH RePORTER	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Bong-Kyeong Oh (KonKuk University, Seoul, South Korea) for a plasmid-containing hTERT, Sun Hee Leem (Dong-A University, Pusan, Korea) for hTERT promoter and Seong-Lan Yu for experimental support. This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (121182) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0015761, 2013R1A1A2A10059565).	Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Chakroborty D, 2009, CANCER RES, V69, P3727, DOI 10.1158/0008-5472.CAN-08-4289; Chao C, 2007, ONCOGENE, V26, P1013, DOI 10.1038/sj.onc.1209862; Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Ghosh JS, 2012, APPL MICROBIOL BIOT, V93, P753, DOI 10.1007/s00253-011-3471-4; Goldstein DS, 2010, CLIN AUTON RES, V20, P331, DOI 10.1007/s10286-010-0065-7; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595; KEMP VH, 1989, RES NURS HEALTH, V12, P331, DOI 10.1002/nur.4770120509; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1999, INT J CANCER, V80, P804; Lambertini E, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-13; Lara HE, 2001, ENDOCRINE, V15, P187, DOI 10.1385/ENDO:15:2:187; Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Low KC, 2013, TRENDS BIOCHEM SCI, V38, P426, DOI 10.1016/j.tibs.2013.07.001; Lutgendorf SK, 2003, CLIN CANCER RES, V9, P4514; McEwen BS, 2002, NEUROBIOL AGING, V23, P921, DOI 10.1016/S0197-4580(02)00027-1; Meng E, 2012, GYNECOL ONCOL, V124, P598, DOI 10.1016/j.ygyno.2011.11.018; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nilsson MB, 2007, J BIOL CHEM, V282, P29919, DOI 10.1074/jbc.M611539200; Palm D, 2006, INT J CANCER, V118, P2744, DOI 10.1002/ijc.21723; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Park SY, 2011, ONCOGENE, V30, P1351, DOI 10.1038/onc.2010.517; Park SY, 2011, INT J CANCER, V128, P2306, DOI 10.1002/ijc.25589; RILEY V, 1975, SCIENCE, V189, P465, DOI 10.1126/science.168638; Sakai D, 2005, DEV GROWTH DIFFER, V47, P471, DOI 10.1111/j.1440-169X.2005.00821.x; Saul AN, 2005, JNCI-J NATL CANCER I, V97, P1760, DOI 10.1093/jnci/dji401; Schmidt C, 1996, Eur J Med Res, V1, P528; Seo JH, 2010, CANCER LETT, V288, P50, DOI 10.1016/j.canlet.2009.06.023; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Wang YP, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-12; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Yu ST, 2009, INT J ONCOL, V35, P329, DOI 10.3892/ijo_00000344; Zhang C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000106	51	48	50	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3402	3412		10.1038/onc.2014.270	http://dx.doi.org/10.1038/onc.2014.270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25151968				2022-12-28	WOS:000356871700006
J	Ferguson, B; Ram, R; Handoko, HY; Mukhopadhyay, P; Muller, HK; Soyer, HP; Morahan, G; Walker, GJ				Ferguson, B.; Ram, R.; Handoko, H. Y.; Mukhopadhyay, P.; Muller, H. K.; Soyer, H. P.; Morahan, G.; Walker, G. J.			Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression	ONCOGENE			English	Article							CUTANEOUS MELANOMA; MELANOCYTIC LESIONS; MALIGNANT-MELANOMA; ATYPICAL NEVI; MUTATIONS; MICE; CLASSIFICATION; IDENTIFICATION; EXPRESSION; PATHWAYS	Susceptibility to most common cancers is likely to involve interaction between multiple low risk genetic variants. Although there has been great progress in identifying such variants, their effect on phenotype and the mechanisms by which they contribute to disease remain largely unknown. We have developed a mouse melanoma model harboring two mutant oncogenes implicated in human melanoma, CDK4(R24C) and NRAS(Q61K). In these mice, tumors arise from benign precursor lesions that are a recognized strong risk factor for this neoplasm in humans. To define molecular events involved in the pathway to melanoma, we have for the first time applied the Collaborative Cross (CC) to cancer research. The CC is a powerful resource designed to expedite discovery of genes for complex traits. We characterized melanoma genesis in more than 50 CC strains and observed tremendous variation in all traits, including nevus and melanoma age of onset and multiplicity, anatomical site predilection, time for conversion of nevi to melanoma and metastases. Intriguingly, neonatal ultraviolet radiation exposure exacerbated nevus and melanoma formation in most, but not all CC strain backgrounds, suggesting that genetic variation within the CC will help explain individual sensitivity to sun exposure, the major environmental skin carcinogen. As genetic variation brings about dramatic phenotypic diversity in a single mouse model, melanoma-related endophenotype comparisons provide us with information about mechanisms of carcinogenesis, such as whether melanoma incidence is dependent upon the density of pre-existing nevus cells. Mouse models have been used to examine the functional role of gene mutations in tumorigenesis. This work represents their next phase of development to study how biological variation greatly influences lesion onset and aggressiveness even in the setting of known somatic driver mutations.	[Ferguson, B.; Handoko, H. Y.; Mukhopadhyay, P.; Walker, G. J.] Queensland Inst Med Res, Herston, Qld 4006, Australia; [Ram, R.; Morahan, G.] Harry Perkins Inst Med Res, Ctr Diabet Res, Perth, WA, Australia; [Muller, H. K.] Univ Tasmania, Sch Med, Hobart, Tas, Australia; [Soyer, H. P.] Univ Queensland, Clin Res Ctr, Herston, Qld, Australia	QIMR Berghofer Medical Research Institute; Harry Perkins Institute of Medical Research; University of Tasmania; University of Queensland	Walker, GJ (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4006, Australia.	Graeme.Walker@qimr.edu.au	Morahan, Grant/T-7501-2019; Soyer, H. Peter/W-3791-2017; Ferguson, Blake/J-4158-2016; Soyer, H. Peter/E-6000-2010; Mukhopadhyay, Pamela/I-6373-2015	Soyer, H. Peter/0000-0002-4770-561X; Soyer, H. Peter/0000-0002-4770-561X; Mukhopadhyay, Pamela/0000-0002-5905-1350; Ferguson, Blake/0000-0002-5643-6976	Melanoma Research Alliance, Washington DC, USA; Scott Kirkbride Melanoma Research Centre, Perth, Western Australia; Diabetes Research Foundation of Western Australia; Australian Research Council Project [DP11010206]; National Health and Medical Research Council of Australia [1037321]; Ride To Cure Cancer, Western Australia	Melanoma Research Alliance, Washington DC, USA; Scott Kirkbride Melanoma Research Centre, Perth, Western Australia; Diabetes Research Foundation of Western Australia; Australian Research Council Project(Australian Research Council); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ride To Cure Cancer, Western Australia	This work was supported by a pilot study grant from the Melanoma Research Alliance, Washington DC, USA and a Discovery Research Priming Grant from the Scott Kirkbride Melanoma Research Centre, Perth, Western Australia. GM is supported by the Diabetes Research Foundation of Western Australia, by Australian Research Council Project DP11010206 and by Program Grant 1037321 from the National Health and Medical Research Council of Australia. RR is supported by RTCC funding from the Ride To Cure Cancer, Western Australia. We thank Geniad Pty Ltd for providing mice from the Collaborative Cross strains.	Abel EL, 2010, JNCI-J NATL CANCER I, V102, P1663, DOI 10.1093/jnci/djq392; Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Aoki H, 2011, PIGM CELL MELANOMA R, V24, P125, DOI 10.1111/j.1755-148X.2010.00801.x; Bradish JR, 2013, FUTURE ONCOL, V9, P245, DOI [10.2217/fon.12.179, 10.2217/FON.12.179]; Campagne C, 2013, PIGM CELL MELANOMA R, V26, P735, DOI 10.1111/pcmr.12115; Chai E, 2013, PIGM CELL MELANOMA R, V27, P317; Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133; Crawford NPS, 2008, CLIN EXP METASTAS, V25, P357, DOI 10.1007/s10585-008-9146-6; de Snoo FA, 2008, EUR J HUM GENET, V16, P1135, DOI 10.1038/ejhg.2008.72; Falchi M, 2009, NAT GENET, V41, P915, DOI 10.1038/ng.410; Faraji F, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002926; Ferguson B, 2010, PIGM CELL MELANOMA R, V23, P771, DOI 10.1111/j.1755-148X.2010.00752.x; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Gandini S, 2005, EUR J CANC, V41, P28; Goldstein AM, 2002, MELANOMA RES, V12, P51, DOI 10.1097/00008390-200202000-00008; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Landsberg J, 2010, PIGM CELL MELANOMA R, V23, P649, DOI 10.1111/j.1755-148X.2010.00744.x; Law MH, 2012, J INVEST DERMATOL, V132, P1763, DOI 10.1038/jid.2012.75; Lee JH, 2011, BRIT J DERMATOL, V164, P776, DOI 10.1111/j.1365-2133.2010.10185.x; LeFur N, 1996, GENOMICS, V37, P245; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; LYNCH HT, 1980, BRIT J CANCER, V42, P58, DOI 10.1038/bjc.1980.203; Molven A, 2005, GENE CHROMOSOME CANC, V44, P10, DOI 10.1002/gcc.20202; Morahan G, 2008, MAMM GENOME, V19, P390, DOI 10.1007/s00335-008-9134-9; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Puig S, 1997, HUM GENET, V101, P359, DOI 10.1007/s004390050642; Quigley D, 2009, NAT REV GENET, V10, P651, DOI 10.1038/nrg2617; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rigel DS, 2008, J AM ACAD DERMATOL, V58, pS129, DOI 10.1016/j.jaad.2007.04.034; Threadgill DW, 2012, G3-GENES GENOM GENET, V2, P153, DOI 10.1534/g3.111.001891; Viros A, 2008, PLOS MED, V5, P941, DOI 10.1371/journal.pmed.0050120; Walker G, 2008, FUTURE ONCOL, V4, P841, DOI 10.2217/14796694.4.6.841; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Welsh CE, 2012, MAMM GENOME, V23, P706, DOI 10.1007/s00335-012-9410-6; Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806; Winter SF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002735; Wurm EMT, 2012, EXP DERMATOL, V21, P676, DOI 10.1111/j.1600-0625.2012.01543.x	38	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2879	2886		10.1038/onc.2014.227	http://dx.doi.org/10.1038/onc.2014.227			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088201				2022-12-28	WOS:000355324300007
J	Gomez-Maldonado, L; Tiana, M; Roche, O; Prado-Cabrero, A; Jensen, L; Fernandez-Barral, A; Guijarro-Munoz, I; Favaro, E; Moreno-Bueno, G; Sanz, L; Aragones, J; Harris, A; Volpert, O; Jimenez, B; del Peso, L				Gomez-Maldonado, L.; Tiana, M.; Roche, O.; Prado-Cabrero, A.; Jensen, L.; Fernandez-Barral, A.; Guijarro-Munoz, I.; Favaro, E.; Moreno-Bueno, G.; Sanz, L.; Aragones, J.; Harris, A.; Volpert, O.; Jimenez, B.; del Peso, L.			EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination	ONCOGENE			English	Article							GENE-EXPRESSION; INDUCIBLE FACTORS; EPH RECEPTORS; MASTER REGULATORS; CELL-ADHESION; HIF-ALPHA; CANCER; IDENTIFICATION; MICRORNA-210; SIGNATURE	The presence of hypoxic regions in solid tumors is an adverse prognostic factor for patient outcome. Here, we show that hypoxia induces the expression of Ephrin-A3 through a novel hypoxia-inducible factor (HIF)-mediated mechanism. In response to hypoxia, the coding EFNA3 mRNA levels remained relatively stable, but HIFs drove the expression of previously unknown long noncoding (lnc) RNAs from EFNA3 locus and these lncRNA caused Ephrin-A3 protein accumulation. Ephrins are cell surface proteins that regulate diverse biological processes by modulating cellular adhesion and repulsion. Mounting evidence implicates deregulated ephrin function in multiple aspects of tumor biology. We demonstrate that sustained expression of both Ephrin-A3 and novel EFNA3 lncRNAs increased the metastatic potential of human breast cancer cells, possibly by increasing the ability of tumor cells to extravasate from the blood vessels into surrounding tissue. In agreement, we found a strong correlation between high EFNA3 expression and shorter metastasis-free survival in breast cancer patients. Taken together, our results suggest that hypoxia could contribute to metastatic spread of breast cancer via HIF-mediated induction of EFNA3 lncRNAs and subsequent Ephrin-A3 protein accumulation.	[Gomez-Maldonado, L.; Tiana, M.; Roche, O.; Prado-Cabrero, A.; Fernandez-Barral, A.; Moreno-Bueno, G.; Jimenez, B.; del Peso, L.] Univ Autonoma Madrid, Dept Bioquim, Madrid, Spain; [Gomez-Maldonado, L.; Tiana, M.; Roche, O.; Prado-Cabrero, A.; Fernandez-Barral, A.; Moreno-Bueno, G.; Jimenez, B.; del Peso, L.] Alberto Sols CSIC UAM, Inst Invest Biomed, Madrid 28029, Spain; [Roche, O.; del Peso, L.] Hosp Univ La Paz, Inst Invest Sanitaria, IdiPaz, Madrid, Spain; [Jensen, L.] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Jensen, L.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Guijarro-Munoz, I.; Sanz, L.] Hosp Univ Puerta Hierro Majadahonda, Mol Immunol Unit, Madrid, Spain; [Favaro, E.; Harris, A.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Oncol Labs, Oxford OX3 9DU, England; [Aragones, J.] Autonomous Univ Madrid, Res Inst Princesa, Hosp Univ Santa Cristina, Res Unit, E-28049 Madrid, Spain; [Volpert, O.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz; Linkoping University; Karolinska Institutet; Hospital Puerta de Hierro-Majadahonda; University of Oxford; Autonomous University of Madrid; Northwestern University; Feinberg School of Medicine	del Peso, L (corresponding author), Alberto Sols Univ Autonoma Madrid, Inst Invest Biomed, Fac Med, Dept Biochem,CSIC UAM, Arturo Duperier 4, Madrid 28029, Spain.	luis.peso@uam.es	Roche, UCLM/F-5697-2019; Harris, Adrian L/ABA-3343-2020; Prado-Cabrero, Alfonso/M-2504-2019; tiana, maria/G-4240-2016; Favaro, Elena/Q-4566-2016; Fernández-Barral, Asunión/O-8133-2015; del Peso, Luis/K-9391-2014; Prado-Cabrero, Alfonso/F-2823-2015; Tiana, María/AAA-1868-2020; Sanz, Laura/F-8542-2010; Moreno-Bueno, Gema/K-9354-2016; Cuenca, Benilde Jimenez/K-9959-2014	Roche, UCLM/0000-0003-1884-8256; Harris, Adrian L/0000-0003-1376-8409; Prado-Cabrero, Alfonso/0000-0001-8268-5362; tiana, maria/0000-0003-0678-1154; Favaro, Elena/0000-0001-5376-5515; Fernández-Barral, Asunión/0000-0002-1278-4645; del Peso, Luis/0000-0003-4014-5688; Prado-Cabrero, Alfonso/0000-0001-8268-5362; Tiana, María/0000-0003-0678-1154; Sanz, Laura/0000-0002-3119-3218; Moreno-Bueno, Gema/0000-0002-5030-6687; Jensen, Lasse/0000-0003-2338-357X; Jimenez Cuenca, Benilde/0000-0002-1806-6636	Ministerio de Ciencia e Innovacion (Spanish Ministry of Science and Innovation, MICINN) [SAF2008-03147, SAF2011_24225, SAF-2010-19256]; Comunidad Autonoma de Madrid [S2010/BMD-2542]; European Union (METOXIA project) [HEALTH-F2-2009-222741]; CSIC [JAE DOC 2010/FSE2007-2013]; Fondo de Investigacion Sanitaria/Instituto de Salud Carlos III [PI08/90856, PS09/00227]; Cancer Research UK [16466, 11359, 18974] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA172669] Funding Source: NIH RePORTER	Ministerio de Ciencia e Innovacion (Spanish Ministry of Science and Innovation, MICINN); Comunidad Autonoma de Madrid(Comunidad de Madrid); European Union (METOXIA project); CSIC; Fondo de Investigacion Sanitaria/Instituto de Salud Carlos III(Instituto de Salud Carlos III); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Amparo Acker-Palmer for expert advice on ephrin detection and Ignacio Palmero DGCR8 reagents. This work was supported by Ministerio de Ciencia e Innovacion (Spanish Ministry of Science and Innovation, MICINN) (grant numbers SAF2008-03147 and SAF2011_24225 to LdeIP and SAF-2010-19256 to BJ); by Comunidad Autonoma de Madrid (grant numbers S2010/BMD-2542 to LdeIP), by the 7th Research Framework Programme of the European Union (grant number METOXIA project ref. HEALTH-F2-2009-222741 to LdeIP); by CSIC (JAE DOC 2010/FSE2007-2013 to OR) and by Fondo de Investigacion Sanitaria/Instituto de Salud Carlos III (grants PI08/90856 and PS09/00227 to LS).	Barderas R, 2013, MOL CELL PROTEOMICS, V12, P1602, DOI 10.1074/mcp.M112.022848; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chen J, 2012, ADV CANCER RES, V114, P1, DOI 10.1016/B978-0-12-386503-8.00001-6; Cheng YM, 2006, BIOINFORMATICS, V22, P2320, DOI 10.1093/bioinformatics/btl394; Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345; Fukaya T, 2012, MOL CELL, V48, P825, DOI 10.1016/j.molcel.2012.09.024; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miro-Murillo M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022589; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733; Nie L, 2012, AM J TRANSL RES, V4, P127; Nievergall E, 2012, CELL MOL LIFE SCI, V69, P1813, DOI 10.1007/s00018-011-0900-6; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Rouhi P, 2010, NAT PROTOC, V5, P1911, DOI 10.1038/nprot.2010.150; Rouhi P, 2010, CELL CYCLE, V9, P913, DOI 10.4161/cc.9.5.10853; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sims D, 2010, BREAST CANCER RES TR, V124, P567, DOI 10.1007/s10549-010-0945-5; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; TEAM RC, 2010, R LANG ENV STAT COMP; Tiana M, 2012, NUCLEIC ACIDS RES, V40, P1916, DOI 10.1093/nar/gkr842; Uniacke J, 2012, NATURE, V486, P126, DOI 10.1038/nature11055; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje; Villar D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045708; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; Yamashita T, 2008, J BIOL CHEM, V283, P18926, DOI 10.1074/jbc.M709133200; Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365	54	75	82	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2609	2620		10.1038/onc.2014.200	http://dx.doi.org/10.1038/onc.2014.200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023702	Green Accepted, Green Submitted			2022-12-28	WOS:000354541300007
J	Kobayashi, T; Masoumi, KC; Massoumi, R				Kobayashi, T.; Masoumi, K. C.; Massoumi, R.			Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells	ONCOGENE			English	Article							NF-KAPPA-B; HIGH-RISK NEUROBLASTOMA; ACID-INDUCED DIFFERENTIATION; HUMAN NEURO-BLASTOMA; TRANS-RETINOIC ACID; 13-CIS-RETINOIC ACID; GENE-EXPRESSION; ENZYME; POLYUBIQUITIN; APOPTOSIS	CYLD is a deubiquitinating (DUB) enzyme that has a pivotal role in modulating nuclear factor kappa B (NF-kappa B) signaling pathways by removing the lysine 63- and linear-linked ubiquitin chain from substrates such as tumor necrosis factor receptor-associated factor 2 (TRAF2) and TRAF6. Loss of CYLD activity is associated with tumorigenicity, and levels of CYLD are lost or downregulated in different types of human tumors. In the present study, we found that high CYLD expression was associated with better overall survival and relapse-free neuroblastoma patient outcome, as well as inversely correlated with the stage of neuroblastoma. Retinoic acid-mediated differentiation of neuroblastoma restored CYLD expression and promoted SUMOylation of CYLD. This posttranslational modification inhibited deubiquitinase activity of CYLD against TRAF2 and TRAF6 and facilitated NF-kappa B signaling. Overexpression of non-SUMOylatable mutant CYLD in neuroblastoma cells reduced retinoic acid-induced NF-kappa B activation and differentiation of cells, but instead promoted cell death.	[Kobayashi, T.; Masoumi, K. C.; Massoumi, R.] Lund Univ, Translat Canc Res, Div Mol Tumor Pathol, Dept Lab Med, S-22363 Lund, Sweden	Lund University	Massoumi, R (corresponding author), Lund Univ, Translat Canc Res, Div Mol Tumor Pathol, Dept Lab Med, Bldg 404,A3,Scheelevagen 8, S-22363 Lund, Sweden.	Ramin.Massoumi@med.lu.se	Massoumi, Ramin/AAG-4786-2019	Masoumi, Katarzyna/0000-0002-9277-6505	Swedish Cancer Foundation; Swedish Medical Research Council; Royal Physiographic Society in Lund; Gunnar Nilsson Foundations; Gyllenstiernska Krapperupps Foundations; BioCARE; European Research Council (ERC), under the European Union [260460]	Swedish Cancer Foundation; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Royal Physiographic Society in Lund; Gunnar Nilsson Foundations; Gyllenstiernska Krapperupps Foundations; BioCARE; European Research Council (ERC), under the European Union(European Research Council (ERC))	The plasmid for mammalian expression of His-SUMO1, His-SUMO2 and MYC-SUMO1 plasmids were a kind gift from Dr Frauke Melchior (ZMBH, Heidelberg, Germany). Flag-TRAF2 and Flag-TRAF6 plasmids were a kind gift from Dr Rene Bernards (The Netherlands Cancer Institute, Amsterdam, The Netherlands). We thank Dr Ingrid Ora for her critical reading of this manuscript. This work was supported by the Swedish Cancer Foundation, the Swedish Medical Research Council, the Royal Physiographic Society in Lund, the Gunnar Nilsson Foundations, the Gyllenstiernska Krapperupps Foundations, the BioCARE and by funding from the European Research Council (ERC), under the European Union's Seventh Framework Programme for Research and Technology Development (grant agreement no. 260460, awarded to RM).	ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; Bauters TGM, 2011, INT J CLIN PHARM-NET, V33, P597, DOI 10.1007/s11096-011-9519-9; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Bryan B, 2004, J BIOL CHEM, V279, P45824, DOI 10.1074/jbc.M406216200; Celay J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062771; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Deyrieux AF, 2007, J CELL SCI, V120, P125, DOI 10.1242/jcs.03317; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; Kiningham KK, 2008, FREE RADICAL BIO MED, V44, P1610, DOI 10.1016/j.freeradbiomed.2008.01.015; KOGNER P, 1993, CANCER RES, V53, P2044; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee Moon H, 2011, MOL CELL, V43, P180; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lovat PE, 1997, JNCI-J NATL CANCER I, V89, P446, DOI 10.1093/jnci/89.6.446; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2011, FUTURE ONCOL, V7, P285, DOI 10.2217/FON.10.187; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; ORTOFT E, 1993, MOL CELL NEUROSCI, V4, P549, DOI 10.1006/mcne.1993.1068; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094; Westermark UK, 2011, SEMIN CANCER BIOL, V21, P256, DOI 10.1016/j.semcancer.2011.08.001; Wilkinson KA, 2010, BRAIN RES REV, V64, P195, DOI 10.1016/j.brainresrev.2010.04.002; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007	43	25	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2251	2260		10.1038/onc.2014.159	http://dx.doi.org/10.1038/onc.2014.159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909169	Green Submitted			2022-12-28	WOS:000353473000010
J	Xi, S; Inchauste, S; Guo, H; Shan, J; Xiao, Z; Xu, H; Miettenen, M; Zhang, MR; Hong, JA; Raiji, MT; Altorki, NK; Casson, AG; Beer, DG; Robles, AI; Bowman, ED; Harris, CC; Steinberg, SM; Schrump, DS				Xi, S.; Inchauste, S.; Guo, H.; Shan, J.; Xiao, Z.; Xu, H.; Miettenen, M.; Zhang, M. R.; Hong, J. A.; Raiji, M. T.; Altorki, N. K.; Casson, A. G.; Beer, D. G.; Robles, A. I.; Bowman, E. D.; Harris, C. C.; Steinberg, S. M.; Schrump, D. S.			Cigarette smoke mediates epigenetic repression of miR-217 during esophageal adenocarcinogenesis	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; LINEAGE PROGRESSION; MICRORNA EXPRESSION; BARRETTS-ESOPHAGUS; CARCINOMA-CELLS; CANCER; PATHOGENESIS; INVASION; OVEREXPRESSION; KALLIKREIN-7	Although microRNAs (miRs) have been implicated in the pathogenesis of various human malignancies, limited information is available regarding mechanisms by which these noncoding RNAs contribute to initiation and progression of tobacco-induced esophageal cancers. In this study, array and quantitative reverse transcriptase-PCR techniques were used to examine miR expression in immortalized esophageal epithelia (IEE) and esophageal adenocarcinoma (EAC) cells cultured in normal media with or without cigarette smoke condensate (CSC). Under relevant exposure conditions, CSC significantly decreased miR-217 expression in these cells. Endogenous levels of miR-217 expression in cultured EAC cells (EACC)/primary EACs were significantly lower than those observed in IEE/paired normal esophageal tissues. RNA crosslink immunoprecipitation, quantitative reverse transcriptase-PCR (qRT-PCR) and immunoblot experiments demonstrated direct interaction of miR-217 with kallikrein 7 (KLK7), encoding a putative oncogene not previously implicated in EAC. Repression of miR-217 correlated with increased levels of KLK7 in primary EACs, particularly those from smokers. Chromatin and methylated DNA immunoprecipitation experiments demonstrated that CSC-mediated repression of miR-217 coincided with DNMT3b-dependent hypermethylation and decreased occupancy of nuclear factor 1 within the miR-217 genomic locus. Deoxyazacytidine induced miR-217 expression and downregulated KLK7 in EACC; deoxyazacytidine also attenuated CSC-mediated miR-217 repression and upregulation of KLK7 in IEE and EACC. Overexpression of miR-217 significantly decreased, whereas overexpression of KLK7 increased proliferation, invasion and tumorigenicity of EACC. Collectively, these data demonstrate that epigenetic repression of miR-217 contributes to the pathogenesis of EAC via upregulation of KLK7 and suggest that restoration of miR-217 expression may be a novel treatment strategy for these malignancies.	[Xi, S.; Inchauste, S.; Zhang, M. R.; Hong, J. A.; Raiji, M. T.; Schrump, D. S.] NCI, Thorac Surg Sect, Thorac & GI Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Guo, H.] Shandong Tumor Hosp & Inst, Gastrointestinal Surg, Jinan, Shandong, Peoples R China; [Shan, J.] NCI, Adv Biomed Comp Ctr, SAIC Frederick, Frederick, MD 21701 USA; [Xiao, Z.] NCI, Canc & Inflammat Lab, Frederick, MD 21701 USA; [Xu, H.] NCI, Lab Canc Prevent, Frederick, MD 21701 USA; [Miettenen, M.] NCI, Pathol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Altorki, N. K.] Weill Cornell Univ, Med Ctr, Dept Thorac Surg, New York, NY USA; [Casson, A. G.] Univ Saskatchewan, Dept Surg, Saskatoon, SK, Canada; [Beer, D. G.] Univ Michigan, Sect Thorac Surg, Ann Arbor, MI 48109 USA; [Robles, A. I.; Bowman, E. D.; Harris, C. C.] NCI, Lab Human Carcinogenesis, Ctr Canc Res, Bethesda, MD 20892 USA; [Steinberg, S. M.] NCI, Biostat & Data Management Sect, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shandong First Medical University & Shandong Academy of Medical Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; University of Saskatchewan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Thorac Surg Sect, Thorac & GI Oncol Branch, Ctr Canc Res, Bldg 10,Room 4-3942,10 Ctr Dr, Bethesda, MD 20892 USA.	David_Schrump@nih.gov		Robles, Ana/0000-0001-5019-4374	NIH intramural funding; Stephen J. Solarz Memorial Fund; NATIONAL CANCER INSTITUTE [ZIABC011492, ZIABC011115, Z01BC005480] Funding Source: NIH RePORTER	NIH intramural funding(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stephen J. Solarz Memorial Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Jan Pappas for assistance with manuscript preparation. This study was supported by NIH intramural funding and the Stephen J. Solarz Memorial Fund.	Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; [Anonymous], 2013, CURR PROB SURG, V50, P192, DOI 10.1067/j.cpsurg.2013.01.004; Carr Jacquelyn S, 2013, J Gastrointest Cancer, V44, P143, DOI 10.1007/s12029-013-9480-z; Cook MB, 2010, JNCI-J NATL CANCER I, V102, P1344, DOI 10.1093/jnci/djq289; David S, 2011, CURR OPIN PHARMACOL, V11, P612, DOI 10.1016/j.coph.2011.09.006; Devetzi M, 2013, THROMB HAEMOSTASIS, V109, P716, DOI 10.1160/TH12-07-0518; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Dong Y, 2010, CANCER RES, V70, P2624, DOI 10.1158/0008-5472.CAN-09-3415; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Ek WE, 2013, JNCI-J NATL CANCER I, V105, P1711, DOI 10.1093/jnci/djt303; Fassan M, 2011, INT J CANCER, V129, P1661, DOI 10.1002/ijc.25823; Frankel A, 2014, GENE CHROMOSOME CANC, V53, P324, DOI 10.1002/gcc.22143; Grabowska MM, 2012, FRONT BIOSCI-LANDMRK, V17, P1948, DOI 10.2741/4031; Gu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081032; Hardikar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052192; Iakovlev V, 2012, CANCER EPIDEM BIOMAR, V21, P1135, DOI 10.1158/1055-9965.EPI-11-1079; Johnson SK, 2007, CANCER, V109, P1811, DOI 10.1002/cncr.22606; Kemp CD, 2012, CLIN CANCER RES, V18, P77, DOI 10.1158/1078-0432.CCR-11-0962; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Leidner RS, 2012, GENE CHROMOSOME CANC, V51, P473, DOI 10.1002/gcc.21934; Li H, 2013, NEOPLASMA, V60, P511, DOI 10.4149/neo_2013_066; Mathe EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467; Mayne GC, 2013, CURR PHARM DESIGN, V19, P1211; Mo LJ, 2010, ANTICANCER RES, V30, P3413; Napier KJ, 2014, WORLD J GASTRO ONCOL, V6, P112, DOI 10.4251/wjgo.v6.i5.112; Nishioka C, 2014, CANCER SCI, V105, P297, DOI 10.1111/cas.12339; Prezas P, 2006, BIOL CHEM, V387, P807, DOI 10.1515/BC.2006.102; Prezas P, 2006, BIOL CHEM, V387, P1607, DOI 10.1515/BC.2006.200; Ramani VC, 2011, BBA-MOL CELL RES, V1813, P1525, DOI 10.1016/j.bbamcr.2011.05.007; Ramani VC, 2008, PANCREAS, V37, P399, DOI 10.1097/MPA.0b013e31817f76f7; Rao M, 2011, CANCER RES, V71, P4192, DOI 10.1158/0008-5472.CAN-10-2442; Shaw JLV, 2007, CLIN CHEM, V53, P1423, DOI 10.1373/clinchem.2007.088104; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Spechler SJ, 2013, JAMA-J AM MED ASSOC, V310, P627, DOI 10.1001/jama.2013.226450; Su J, 2014, MOL CELL BIOCHEM, V392, P289, DOI 10.1007/s11010-014-2039-x; Talieri M, 2009, THROMB HAEMOSTASIS, V101, P741, DOI 10.1160/TH08-07-0471; Tramacere I, 2011, EPIDEMIOLOGY, V22, P344, DOI 10.1097/EDE.0b013e31821092cd; Xi SC, 2013, J CLIN INVEST, V123, P1241, DOI 10.1172/JCI61271; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xu EP, 2013, CARCINOGENESIS, V34, P2750, DOI 10.1093/carcin/bgt286; Zhang Y, 2012, J BIOL CHEM, V287, P21926, DOI 10.1074/jbc.M112.340398; Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160	43	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5548	5559		10.1038/onc.2015.10	http://dx.doi.org/10.1038/onc.2015.10			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25703328	Green Accepted			2022-12-28	WOS:000364594000004
J	Lin, YG; Shen, J; Yoo, E; Liu, R; Yen, HY; Mehta, A; Rajaei, A; Yang, W; Mhawech-Fauceglia, P; DeMayo, FJ; Lydon, J; Gill, P; Lee, AS				Lin, Y. G.; Shen, J.; Yoo, E.; Liu, R.; Yen, H-Y; Mehta, A.; Rajaei, A.; Yang, W.; Mhawech-Fauceglia, P.; DeMayo, F. J.; Lydon, J.; Gill, P.; Lee, A. S.			Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TUMOR-GROWTH; GRP78; CANCER; EXPRESSION; CHAPERONE; CELLS; KNOCKOUT; PROGRESSION; PREDICTOR	Rates of the most common gynecologic cancer, endometrioid adenocarcinoma (EAC), continue to rise, mirroring the global epidemic of obesity, a well-known EAC risk factor. Thus, identifying novel molecular targets to prevent and/or mitigate EAC is imperative. The prevalent Type 1 EAC commonly harbors loss of the tumor suppressor, Pten, leading to AKT activation. The major endoplasmic reticulum (ER) chaperone, GRP78, is a potent pro-survival protein to maintain ER homeostasis, and as a cell surface protein, is known to regulate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. To determine whether targeting GRP78 could suppress EAC development, we created a conditional knockout mouse model using progesterone receptor-Cre-recombinase to achieve Pten and Grp78 (cPten(f/f)Grp78(f/f)) deletion in the endometrial epithelium. Mice with a single Pten (cPten(f/f)) deletion developed well-differentiated EAC by 4 weeks. In contrast, no cPten(f/f)Grp78(f/f) mice developed EAC, even after more than 8 months of observation. Histologic examination of uteri from cPten(f/f)Grp78(f/f) mice also revealed no complex atypical hyperplasia, a well-established EAC precursor. These histologic observations among the cPten(f/f)Grp78(f/f) murine uteri also corresponded to abrogation of AKT activation within the endometrium. We further observed that GRP78 co-localized with activated AKT on the surface of EAC, thus providing an opportunity for therapeutic targeting. Consistent with previous findings that cell surface GRP78 is an upstream regulator of PI3K/AKT signaling, we show here that in vivo short-term systemic treatment with a highly specific monoclonal antibody against GRP78 suppressed AKT activation and increased apoptosis in the cPtenf/f tumors. Collectively, these findings present GRP78-targeting therapy as an efficacious therapeutic option for EAC.	[Lin, Y. G.; Yoo, E.] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol,USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Shen, J.; Lee, A. S.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Liu, R.; Yen, H-Y; Mehta, A.; Rajaei, A.; Yang, W.; Gill, P.] Univ So Calif, Keck Sch Med, Dept Hematol Oncol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Mhawech-Fauceglia, P.] Univ So Calif, Keck Sch Med, Dept Pathol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [DeMayo, F. J.; Lydon, J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; Baylor College of Medicine	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, USC Norris Comprehens Canc Ctr, 1441 Eastlake Ave,NOR 5308, Los Angeles, CA 90089 USA.	yvonne.g.lin@gmail.com; amylee@usc.edu	MEHTA, ARJUN/AAH-2251-2021; DeMayo, Francesco/C-6255-2019; Mehta, Arjun/AFO-2449-2022	DeMayo, Francesco/0000-0002-9480-7336; Lee, Amy/0000-0002-0378-5443; mehta, arjun/0000-0002-8778-7832; Shen, Jieli/0000-0003-1905-9101	USC Department of Obstetrics & Gynecology Seed Grant; Stop Cancer Career Development Award; NIH [R01 CA027607, K08 CA175161, P30 DK048522]; NCI Cancer Center Support Grant [P30 CA014089]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042311] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA014089, R01CA027607, K08CA175161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103311] Funding Source: NIH RePORTER	USC Department of Obstetrics & Gynecology Seed Grant; Stop Cancer Career Development Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the USC Norris Comprehensive Cancer Center Translational Pathology Core for tissue processing and the USC Research Center for Liver Diseases Cell and Tissue Imaging Core. We also thank the members of the Lee lab, particularly Wan-Ting Chen, Genyuan Zhu and Michelle Pong for their input and assistance throughout this project. This work was supported by the USC Department of Obstetrics & Gynecology Seed Grant (YGL), Stop Cancer Career Development Award (YGL), NIH Grant R01 CA027607 (ASL), NIH Grant K08 CA175161 (YGL) and NCI Cancer Center Support Grant (P30 CA014089, ASL/YGL). Microscopy at the Cell and Tissue Imaging Core of the USC Research Center for Liver Diseases was supported by NIH Grant P30 DK048522.	Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Bifulco G, 2012, GYNECOL ONCOL, V125, P220, DOI 10.1016/j.ygyno.2011.11.045; BOKHMAN JV, 1985, GYNECOL ONCOL, V20, P139, DOI 10.1016/0090-8258(85)90135-0; Cali G, 2014, J CELL PHYSIOL, V229, P1417, DOI 10.1002/jcp.24578; Chen WT, 2014, HEPATOLOGY, V59, P947, DOI 10.1002/hep.26711; Conley-LaComb MK, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-85; Cordero-Espinoza L, 2013, J BIOL CHEM, V288, P36020, DOI 10.1074/jbc.M113.510289; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gonzalez-Gronow M, 2009, ANTIOXID REDOX SIGN, V11, P2299, DOI [10.1089/ars.2009.2568, 10.1089/ARS.2009.2568]; Gray MJ, 2013, INT J CANCER, V133, P21, DOI 10.1002/ijc.27994; He LN, 2010, AM J PATHOL, V176, P2302, DOI 10.2353/ajpath.2010.090931; Hill R, 2012, MOL CANCER THER, V11, P2127, DOI 10.1158/1535-7163.MCT-12-0342; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Iglesias David A, 2012, Clin Adv Hematol Oncol, V10, P797; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Lee E, 2011, INT J CANCER, V128, P726, DOI 10.1002/ijc.25370; Leslie KK, 2012, OBSTET GYN CLIN N AM, V39, P255, DOI 10.1016/j.ogc.2012.04.001; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Liu R, 2013, CLIN CANCER RES, V19, P6802, DOI 10.1158/1078-0432.CCR-13-1106; Liu R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-269; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Matsuo K, 2013, GYNECOL ONCOL, V128, P552, DOI 10.1016/j.ygyno.2012.11.024; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sato M, 2010, ADV GENET, V69, P97, DOI 10.1016/S0065-2660(10)69006-2; Schmandt RE, 2011, AM J OBSTET GYNECOL, V205, P518, DOI 10.1016/j.ajog.2011.05.042; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Wey S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039047; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Zhang LH, 2011, BRAIN RES, V1371, P23, DOI 10.1016/j.brainres.2010.11.063; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080071; Zhang Y, 2010, J BIOL CHEM, V285, P15065, DOI 10.1074/jbc.M109.087445; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	44	25	25	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5418	5426		10.1038/onc.2015.4	http://dx.doi.org/10.1038/onc.2015.4			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25684138	Green Accepted			2022-12-28	WOS:000363479700002
J	Wang, N; Ding, H; Liu, C; Li, X; Wei, L; Yu, J; Liu, M; Ying, M; Gao, W; Jiang, H; Wang, Y				Wang, N.; Ding, H.; Liu, C.; Li, X.; Wei, L.; Yu, J.; Liu, M.; Ying, M.; Gao, W.; Jiang, H.; Wang, Y.			A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk	ONCOGENE			English	Article							DNA-DAMAGE CHECKPOINT; OVARIAN-CANCER; HEREDITARY BREAST; CHK2 KINASE; P53; SUSCEPTIBILITY; GENES; FAMILIES; VARIANT; BRCA1	Certain predisposition factors such as BRCA1/2 and CHEK2 mutations cause familial breast cancers that occur early. In China, breast cancers are diagnosed at relatively younger age, and higher percentage of patients are diagnosed before 40 years, than that in Caucasians. However, the prevalence for BRCA1/2 mutations and reported CHEK2 germline mutations is much lower or absent in Chinese population, arguing for the need to study other novel risk alleles among Chinese breast cancer patients. In this study, we searched for CHEK2 mutations in young, high-risk breast cancer patients in China and detected a missense variant Y390C (1169A4G) in 12 of 150 patients (8.0%) and 2 in 250 healthy controls (0.8%, P = 0.0002). Four of the Y390C carriers have family history of breast and/or ovarian cancer. In patients without family history, Y390C carriers tend to develop breast cancer early, before 35 years of age. The codon change at Y390, a highly conserved residue located in CHEK2's kinase domain, appeared to significantly impair CHEK2 activity. Functional analysis suggested that the CHEK2 Y390C mutation is deleterious as judged by the mutant protein's inability to inactivate CDC25A or to activate p53 after DNA damage. Cells expressing the CHEK2 Y390C variant showed impaired p21 and Puma expression after DNA damage, and the deregulated cell cycle checkpoint and apoptotic response may help conserve mutations and therefore contribute to tumorigeneisis. Taken together, our results not only identified a novel CHEK2 allele that is associated with cancer families and confers increased breast cancer risk, but also showed that this allele significantly impairs CHEK2 function during DNA damage response. Our results provide further insight on how the function of such an important cancer gene may be impaired by existing mutations to facilitate tumorigenesis. It also offers a new subject for breast cancer monitoring, prevention and management.	[Wang, N.; Liu, C.; Wei, L.; Ying, M.; Gao, W.; Wang, Y.] Second Mil Med Univ, Dept Oncol, Changhai Hosp, Shanghai, Peoples R China; [Ding, H.; Liu, C.; Li, X.; Yu, J.; Liu, M.; Jiang, H.] Chinese Acad Sci, State Key Lab Cell Biol, Inst Biochem & Cell Biol, Key Lab Syst Biol,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [Wei, L.] PLA, Hosp 401, Dept Oncol, Qingdao, Peoples R China; [Wang, Y.] Shanghai Jiao Tong Univ, Xinhua Canc Ctr, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China	Naval Medical University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Jiang, H (corresponding author), Chinese Acad Sci, State Key Lab Cell Biol, Inst Biochem & Cell Biol, Key Lab Syst Biol,Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	hai@sibcb.ac.cn; yajiewao459@163.com		jiang, hai/0000-0002-2508-5413; Ding, Hongyu/0000-0002-7531-4771	major scientific research project [2013CB910404]; Natural Science Foundation of the People's Republic of China [81372854, 31371418, 81202096, 81102010]; Shanghai Science and Technology Committee [114119a7500, 06DZ19505, 13NM1401504]	major scientific research project; Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	This study was supported by the major scientific research project (2013CB910404), Natural Science Foundation of the People's Republic of China (No. 81372854; 31371418; 81202096; 81102010), and Shanghai Science and Technology Committee (No. 114119a7500, No. 06DZ19505 and No. 13NM1401504). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank Dr Qingpeng Kong of the Kunming Institute of Zoology, Chinese Academy of Sciences for his help in analysis of the 1000 human genome project.	Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Apostolou P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/747318; Baloch AH, 2014, MOL BIOL REP, V41, P1103, DOI 10.1007/s11033-013-2956-x; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baysal BE, 2004, GYNECOL ONCOL, V95, P62, DOI 10.1016/j.ygyno.2004.07.015; Brinkman H, 2006, CLIN GENET, V70, P526, DOI 10.1111/j.1399-0004.2006.00711.x; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Cai Z, 2009, MOL CELL, V35, P818, DOI 10.1016/j.molcel.2009.09.007; Cao AY, 2010, BREAST CANCER RES TR, V120, P271, DOI 10.1007/s10549-009-0598-4; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cybulski C, 2011, J CLIN ONCOL, V29, P3747, DOI 10.1200/JCO.2010.34.0778; de Miranda NFCC, 2013, J EXP MED, V210, P1729, DOI 10.1084/jem.20122842; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Gonzalez-Hormazabal P, 2008, BREAST CANCER RES TR, V110, P543, DOI 10.1007/s10549-007-9743-0; Gutierrez-Enriquez S, 2014, INT J CANCER, V134, P2088, DOI 10.1002/ijc.28540; Jiang H, 2011, NAT CHEM BIOL, V7, P92, DOI 10.1038/NCHEMBIO.503; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kwong A, 2008, WORLD J SURG, V32, P2554, DOI 10.1007/s00268-008-9589-6; Lacroix M, 2005, BREAST CANCER RES TR, V89, P297, DOI 10.1007/s10549-004-2172-4; Liede A, 2002, HUM MUTAT, V20, P413, DOI 10.1002/humu.10154; Liu C, 2012, ASIAN PAC J CANCER P, V13, P1355, DOI 10.7314/APJCP.2012.13.4.1355; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Novak DJ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-239; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Osorio A, 2012, HUM MOL GENET, V21, P2889, DOI 10.1093/hmg/dds115; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shieh SY, 2000, GENE DEV, V14, P289; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Song QK, 2014, ASIAN PAC J CANCER P, V15, P10021, DOI 10.7314/APJCP.2014.15.22.10021; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Stracker TH, 2009, DNA REPAIR, V8, P1047, DOI 10.1016/j.dnarep.2009.04.012; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Wang C, 2008, ADV THER, V25, P496, DOI 10.1007/s12325-008-0057-3; Weischer M, 2008, J CLIN ONCOL, V26, P542, DOI 10.1200/JCO.2007.12.5922; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200	44	21	22	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5198	5205		10.1038/onc.2014.443	http://dx.doi.org/10.1038/onc.2014.443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619829				2022-12-28	WOS:000362233400009
J	Mura, M; Hopkins, TG; Michael, T; Abd-Latip, N; Weir, J; Aboagye, E; Mauri, F; Jameson, C; Sturge, J; Gabra, H; Bushell, M; Willis, AE; Curry, E; Blagden, SP				Mura, M.; Hopkins, T. G.; Michael, T.; Abd-Latip, N.; Weir, J.; Aboagye, E.; Mauri, F.; Jameson, C.; Sturge, J.; Gabra, H.; Bushell, M.; Willis, A. E.; Curry, E.; Blagden, S. P.			LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression	ONCOGENE			English	Article							MESSENGER-RNA STABILITY; GENE-EXPRESSION; EARLY-STAGE; TARGET; TRANSLATION; SPECIMENS; PROTEINS; SURVIVAL; REVEALS; PATHWAY	RNA-binding proteins (RBPs) bind to and post-transcriptionally regulate the stability of mRNAs. La-related protein 1 (LARP1) is a conserved RBP that interacts with poly-A-binding protein and is known to regulate 5'-terminal oligopyrimidine tract (TOP) mRNA translation. Here, we show that LARP1 is complexed to 3000 mRNAs enriched for cancer pathways. A prominent member of the LARP1 interactome is mTOR whose mRNA transcript is stabilized by LARP1. At a functional level, we show that LARP1 promotes cell migration, invasion, anchorage-independent growth and in vivo tumorigenesis. Furthermore, we show that LARP1 expression is elevated in epithelial cancers such as cervical and non-small cell lung cancers, where its expression correlates with disease progression and adverse prognosis, respectively. We therefore conclude that, through the post-transcriptional regulation of genes such as mTOR within cancer pathways, LARP1 contributes to cancer progression.	[Mura, M.; Hopkins, T. G.; Michael, T.; Abd-Latip, N.; Gabra, H.; Curry, E.; Blagden, S. P.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ovarian Canc Act Res Ctr, Div Canc, London W12 0NN, England; [Weir, J.] Charing Cross Hosp, Imperial Coll Healthcare NHS Trust, Dept Cellular Pathol, London, England; [Aboagye, E.; Sturge, J.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Canc Res UK Labs, Div Canc, London W12 0NN, England; [Mauri, F.] Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, Ctr Pathol, London W12 0NN, England; [Jameson, C.] Univ Coll London Hosp, Dept Histopathol, London, England; [Sturge, J.] Univ Hull, Sch Biol Biomed & Environm Sci, Kingston Upon Hull HU6 7RX, N Humberside, England; [Bushell, M.; Willis, A. E.] Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England	Imperial College London; Imperial College London; Cancer Research UK; Imperial College London; Imperial College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Hull; University of Leicester	Blagden, SP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ovarian Canc Act Res Ctr, Div Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	s.blagden@imperial.ac.uk	Latip, Normala Abd/O-1425-2017; Blagden, Sarah Patricia/I-2096-2019	Latip, Normala Abd/0000-0003-4957-5369; Willis, Anne/0000-0002-1470-8531; ABOAGYE, Eric/0000-0003-2276-6771; Curry, Edward/0000-0002-5603-6956; Mauri, Francesco/0000-0003-4818-8500; Sturge, Justin/0000-0002-2657-1106; Gabra, Hani/0000-0002-3322-4399	Wellbeing of Women [RG1319]; Wellcome Trust-GSK Imperial College TMT Fellowship Scheme [PS1903]; Cancer Research UK; Department of Health [C37/A7283]; Ovarian Cancer Action; BBSRC [BB/H024980/1] Funding Source: UKRI; MRC [MC_UP_A600_1024, MC_UP_A600_1023] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/H024980/1] Funding Source: researchfish; Medical Research Council [MC_UP_A600_1023, MC_UP_A600_1024] Funding Source: researchfish; Ovarian Cancer Action [OCA10] Funding Source: researchfish	Wellbeing of Women(Wellbeing of Women (WoW)); Wellcome Trust-GSK Imperial College TMT Fellowship Scheme; Cancer Research UK(Cancer Research UK); Department of Health; Ovarian Cancer Action(Ovarian Cancer Action); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Ovarian Cancer Action(Ovarian Cancer Action)	MM was funded by The Wellbeing of Women (RG1319). TGH was funded by the Wellcome Trust-GSK Imperial College TMT Fellowship Scheme (PS1903). The Division of Cancer at Imperial College London, Imperial College Healthcare NHS Trust is an Experimental Cancer Medicine Centre (ECMC) supported by funds from Cancer Research UK and the Department of Health (C37/A7283) and forms part of Imperial Cancer Research UK Centre (C42671/A12196). SB was supported by Ovarian Cancer Action. We would like to thank Professor Nahum Sonenberg, Dr Bruno Fonseca and Professor Michael Seckl for their contributions and advice in the preparation of this manuscript. We would also like to thank Jenny Steel, Naina Patel and Joel Abrahams for their technical support.	Aoki K, 2013, FEBS LETT, V587, P2173, DOI 10.1016/j.febslet.2013.05.035; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Biewenga P, 2008, GYNECOL ONCOL, V108, P520, DOI 10.1016/j.ygyno.2007.11.024; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Blagden SP, 2009, DEV BIOL, V334, P186, DOI 10.1016/j.ydbio.2009.07.016; Burrows C, 2010, NUCLEIC ACIDS RES, V38, P5542, DOI 10.1093/nar/gkq294; Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031; Chang N, 2010, MOL CELL BIOL, V30, P3875, DOI 10.1128/MCB.00169-10; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Cheng YL, 2012, LAB INVEST, V92, P1013, DOI 10.1038/labinvest.2012.59; Dhillon T, 2010, J THORAC ONCOL, V5, P314, DOI 10.1097/JTO.0b013e3181ce6604; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Graham JR, 2010, MOL CELL BIOL, V30, P5295, DOI 10.1128/MCB.00303-10; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Iwakawa M, 2007, CANCER BIOL THER, V6, P905, DOI 10.4161/cbt.6.6.4098; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Keene JD, 2005, CHROMOSOME RES, V13, P327, DOI 10.1007/s10577-005-0848-1; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Liu D, 2011, CANCER-AM CANCER SOC, V117, P3763, DOI 10.1002/cncr.25959; Lukong KE, 2008, TRENDS GENET, V24, P416, DOI 10.1016/j.tig.2008.05.004; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231; Merret R, 2013, CELL REP, V5, P1279, DOI 10.1016/j.celrep.2013.11.019; Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078-0432.CCR-11-2824; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sommer G, 2011, ONCOGENE, V30, P434, DOI 10.1038/onc.2010.425; Staudacher AH, 2014, EJNMMI RES, V4, DOI 10.1186/2191-219X-4-2; Sugiura R, 2011, J SIGNAL TRANSDUCT, V2011; Tcherkezian J, 2014, GENE DEV, V28, P357, DOI 10.1101/gad.231407.113; Thapar R, 2013, CELL SIGNAL, V25, P1699, DOI 10.1016/j.cellsig.2013.03.026; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; Wang MJ, 2011, TUMOR BIOL, V32, P905, DOI 10.1007/s13277-011-0191-4; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Wu XY, 2012, GENE, V500, P10, DOI 10.1016/j.gene.2012.03.021; Wurth L, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/178525; Xie C, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-272; Xu CL, 2013, MOL CANCER THER, V12, P207, DOI 10.1158/1535-7163.MCT-12-0273; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005	46	75	75	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5025	5036		10.1038/onc.2014.428	http://dx.doi.org/10.1038/onc.2014.428			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531318	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000361693300003
J	Weber, CE; Kothari, AN; Wai, PY; Li, NY; Driver, J; Zapf, MAC; Franzen, CA; Gupta, GN; Osipo, C; Zlobin, A; Syn, WK; Zhang, J; Kuo, PC; Mi, Z				Weber, C. E.; Kothari, A. N.; Wai, P. Y.; Li, N. Y.; Driver, J.; Zapf, M. A. C.; Franzen, C. A.; Gupta, G. N.; Osipo, C.; Zlobin, A.; Syn, W. K.; Zhang, J.; Kuo, P. C.; Mi, Z.			Osteopontin mediates an MZF1-TGF-beta 1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION; STROMAL FIBROBLASTS; PLASMA OSTEOPONTIN; PROMOTES FIBROSIS; TUMOR-GROWTH; TGF-BETA; METASTASIS; ACTIVATION; CARCINOMA; INVASION	Interactions between tumor cells and cancer-associated fibroblasts (CAFs) in the tumor microenvironment significantly influence cancer growth and metastasis. Transforming growth factor-beta (TGF-beta) is known to be a critical mediator of the CAF phenotype, and osteopontin (OPN) expression in tumors is associated with more aggressive phenotypes and poor patient outcomes. The potential link between these two pathways has not been previously addressed. Utilizing in vitro studies using human mesenchymal stem cells (MSCs) and MDA-MB231 (OPN+) and MCF7 (OPN-) human breast cancer cell lines, we demonstrate that OPN induces integrin-dependent MSC expression of TGF-beta 1 to mediate adoption of the CAF phenotype. This OPN-TGF-beta 1 pathway requires the transcription factor, myeloid zinc finger 1 (MZF1). In vivo studies with xenotransplant models in NOD-scid mice showed that OPN expression increases cancer growth and metastasis by mediating MSC-to-CAF transformation in a process that is MZF1 and TGF-beta 1 dependent. We conclude that tumor-derived OPN engenders MSC-to-CAF transformation in the microenvironment to promote tumor growth and metastasis via the OPN-MZF1-TGF-beta 1 pathway.	[Weber, C. E.; Kothari, A. N.; Wai, P. Y.; Li, N. Y.; Driver, J.; Zapf, M. A. C.; Gupta, G. N.; Syn, W. K.; Kuo, P. C.; Mi, Z.] Loyola Univ Chicago, Loyola Univ, Dept Surg, Med Ctr, Maywood, IL USA; [Weber, C. E.; Kothari, A. N.; Wai, P. Y.; Li, N. Y.; Driver, J.; Zapf, M. A. C.; Franzen, C. A.; Gupta, G. N.; Osipo, C.; Zlobin, A.; Zhang, J.; Kuo, P. C.; Mi, Z.] Loyola Univ Chicago, Inst Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL USA; [Franzen, C. A.; Gupta, G. N.] Loyola Univ Chicago, Dept Urol, Cardinal Bernardin Canc Ctr, Med Ctr,Loyola Univ, Maywood, IL USA; [Syn, W. K.] Barts Hlth NHS Trust, Liver Unit, London, England; [Syn, W. K.] Inst Hepatol, Regenerat & Repair, London, England	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Barts Health NHS Trust; University of London; University College London	Kuo, PC (corresponding author), Loyola Univ, Med Ctr, Dept Surg, EMS Bldg,Room 3244,2160 S First Ave, Maywood, IL 60153 USA.	pkuo@lumc.edu	Syn, Wing-Kin/AAB-8406-2020	Li, Neill/0000-0001-9149-4859; Franzen, Carrie/0000-0002-1127-8599; Zapf, Matthew/0000-0001-5544-8900	NIH [GM65113, CA155306, UL1 RR024128]; NATIONAL CANCER INSTITUTE [R21CA155306] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065113, R56GM065113, T32GM008750] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by NIH grants: GM65113, CA155306 and UL1 RR024128. We thank Andy Hall, Research Histology Manager, at the University of Illinois at Chicago Research Resources Center who performed all immunohistochemical staining and mounting. We also thank Dr Dariusz Borys, of the Loyola Department of Pathology, for assistance with the imaging of slides.	Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bhattacharya SD, 2012, ANN SURG, V255, P319, DOI 10.1097/SLA.0b013e31823e3a1c; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Boxall SA, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/975871; Bramwell VHC, 2006, CLIN CANCER RES, V12, P3337, DOI 10.1158/1078-0432.CCR-05-2354; Brauer HA, 2013, CLIN CANCER RES, V19, P571, DOI 10.1158/1078-0432.CCR-12-2123; BROWN LF, 1994, AM J PATHOL, V145, P610; Casey TM, 2008, BREAST CANCER RES TR, V110, P39, DOI 10.1007/s10549-007-9684-7; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Davis C, 2011, MICROSC MICROANAL, V17, P528, DOI 10.1017/S1431927611000043; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Direkze NC, 2004, CANCER RES, V64, P8492, DOI 10.1158/0008-5472.CAN-04-1708; Dumont N, 2013, NEOPLASIA, V15, P249, DOI 10.1593/neo.121950; Elkabets M, 2011, J CLIN INVEST, V121, P784, DOI 10.1172/JCI43757; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Gao MQ, 2010, J CELL SCI, V123, P3507, DOI 10.1242/jcs.072900; Hawinkels LJ, 2012, ONCOGENE, V33, P97, DOI [DOI 10.1038/ONC.2012.536, DOI 10.1038/onc.2012.536]; Helluin O, 2000, J BIOL CHEM, V275, P18337, DOI 10.1074/jbc.M001529200; HROMAS R, 1995, CANCER RES, V55, P3610; Hsieh YH, 2006, BIOCHEM BIOPH RES CO, V339, P217, DOI 10.1016/j.bbrc.2005.11.015; Hsieh YH, 2007, CHINESE J PHYSIOL, V50, P9; Huang WH, 2013, ONCOGENE, V32, P4343, DOI 10.1038/onc.2012.458; Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; KENG PC, 1990, INT J RADIAT ONCOL, V18, P1061, DOI 10.1016/0360-3016(90)90441-L; Kidd S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030563; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kohan M, 2009, AM J RESP CELL MOL, V41, P290, DOI 10.1165/rcmb.2008-0307OC; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943; Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408; Mak GWY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042210; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Matsuzaki H, 2007, J ORAL PATHOL MED, V36, P30; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009; Mi Zhiyong, 2009, BMC Res Notes, V2, P119, DOI 10.1186/1756-0500-2-119; Mi ZY, 2009, MOL THER, V17, P153, DOI 10.1038/mt.2008.235; Mi ZY, 2004, J BIOL CHEM, V279, P46659, DOI 10.1074/jbc.M407952200; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Mishra PJ, 2011, METHODS MOL BIOL, V717, P245, DOI 10.1007/978-1-61779-024-9_14; Miyazaki KI, 2008, INVEST OPHTH VIS SCI, V49, P1367, DOI 10.1167/iovs.07-1007; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Nicholas SB, 2010, KIDNEY INT, V77, P588, DOI 10.1038/ki.2009.518; O'Regan A, 2000, INT J EXP PATHOL, V81, P373, DOI 10.1046/j.1365-2613.2000.00163.x; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Otto WR, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-20; Pang H, 2013, CANCER EPIDEMIOL, V37, P985, DOI 10.1016/j.canep.2013.08.005; Patani N, 2008, ANTICANCER RES, V28, P4105; Qi W, 2008, BIOCHEM J, V416, P453, DOI 10.1042/BJ20080651; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Que-Gewirth NS, 2007, GENE THER, V14, P283, DOI 10.1038/sj.gt.3302900; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008; Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2; Singhal H, 1997, CLIN CANCER RES, V3, P605; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Su G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046685; Syn WK, 2011, HEPATOLOGY, V53, P106, DOI 10.1002/hep.23998; Szalay G, 2009, CIRC RES, V104, P851, DOI 10.1161/CIRCRESAHA.109.193805; Tsai SJ, 2012, BIOCHEM BIOPH RES CO, V425, P462, DOI 10.1016/j.bbrc.2012.07.125; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Udagawa T, 2006, FASEB J, V20, P95, DOI 10.1096/fj.04-3669com; Vetrone SA, 2009, J CLIN INVEST, V119, P1583, DOI 10.1172/JCI37662; Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Wang L, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt96; Wolak T, 2009, KIDNEY INT, V76, P32, DOI 10.1038/ki.2009.90; Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0; Worthington JJ, 2011, TRENDS BIOCHEM SCI, V36, P47, DOI 10.1016/j.tibs.2010.08.002; Xu LN, 2013, GENET MOL RES, V12, P5863, DOI 10.4238/2013.November.22.14; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yu KN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015623	80	123	132	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4821	4833		10.1038/onc.2014.410	http://dx.doi.org/10.1038/onc.2014.410			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25531323	Green Accepted			2022-12-28	WOS:000361050000003
J	Cui, YM; Jiao, HL; Ye, YP; Chen, CM; Wang, JX; Tang, N; Li, TT; Lin, J; Qi, L; Wu, P; Wang, SY; He, MR; Liang, L; Bian, XW; Liao, WT; Ding, YQ				Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; He, M-R; Liang, L.; Bian, X-W; Liao, W-T; Ding, Y-Q			RETRACTED: FOXC2 promotes colorectal cancer metastasis by directly targeting MET (Retracted article. See vol. 41, pg. 2529, 2022)	ONCOGENE			English	Article; Retracted Publication							HEPATOCYTE GROWTH-FACTOR; PRIMARY COLON-CANCER; CELL LUNG-CANCER; C-MET; FACTOR RECEPTOR; REGULATES EXPRESSION; STAGE; GENE; OVEREXPRESSION; PROTOONCOGENE	Metastasis is the major cause of death in colorectal cancer (CRC). Although multiple genes have been identified to be responsible for the development of CRC, the molecular changes that enable CRC cells to undergo early local invasion and to form distant metastatic colonies still remain largely unknown. Herein, we investigated the role of Forkhead box protein C2 (FOXC2) and explored the underlying mechanisms in invasion and metastasis of CRC. We show that both high FOXC2 expression and nuclear localization of FOXC2 are significantly correlated with advanced TNM (T = primary tumor; N = regional lymph nodes; M= distant metastasis) stages. FOXC2 enhanced the invasive abilities of CRC cells in vitro and promoted local invasion and distant metastasis in an orthotopic mouse metastatic model of CRC. Microarray analysis revealed that overexpression of FOXC2 increased the proto-oncogene MET tyrosine kinase expression and activated the hepatocyte growth factor (HGF)-MET signaling pathway. Furthermore, luciferase reporter assays and chromatin immunoprecipitation assays revealed that FOXC2 directly associated with MET promoter to increase the transcriptional activity of MET. Inhibition of MET attenuates the invasive phenotype and metastatic potential of FOXC2-overexpressing CRC cells, indicating that MET is a major mediator of FOXC2-promoted metastasis. In addition, FOXC2 expression was positively correlated with MET expression in CRC tissue samples. Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulating HGF-MET signaling via inducing MET expression, highlighting FOXC2 as a potential therapeutic target for preventing or reducing metastasis in CRC.	[Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; Liang, L.; Liao, W-T; Ding, Y-Q] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; Liang, L.; Liao, W-T; Ding, Y-Q] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; Liang, L.; Liao, W-T; Ding, Y-Q] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Guangdong, Peoples R China; [He, M-R] Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [He, M-R] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [Bian, X-W] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Chongqing, Peoples R China; [Bian, X-W] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Army Medical University; Army Medical University	Liao, WT (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.	liaowt2002@gmail.com; dyqgz@126.com	liang, li/AAB-9126-2022; Bian, Xiu-Wu/D-4736-2017	Bian, Xiu-Wu/0000-0003-4383-0197	National Basic Research Program of China (973 program) [2015CB554002, 2010CB529403]; National Natural Science Foundation of China (NSFC)-Guangdong Joint Fund [U1201226]; National Natural Science Foundation of China [81090422, 30901791, 81172055, 81472313, 81472710, 81071735]; Guangdong Provincial Natural Science Foundation of China [S2012010009643]; Zhu Jiang Science & Technology New Star Foundation in Guangzhou city [2012J2200052, 2012J2200044]; Science and Technology Innovation Foundation of Guangdong Higher Education [CXZD1016]; Key Program of the National Natural Science Foundation of Guangdong, China [2010B031500012]; Guangzhou Science & Technology Plan Project [201300000056]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China (NSFC)-Guangdong Joint Fund(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Zhu Jiang Science & Technology New Star Foundation in Guangzhou city; Science and Technology Innovation Foundation of Guangdong Higher Education; Key Program of the National Natural Science Foundation of Guangdong, China; Guangzhou Science & Technology Plan Project	This work was supported by the National Basic Research Program of China (973 program, nos. 2015CB554002 and 2010CB529403), the National Natural Science Foundation of China (NSFC)-Guangdong Joint Fund (U1201226), the Major Projects of the National Natural Science Foundation of China (no. 81090422), the National Natural Science Foundation of China (nos. 30901791, 81172055, 81472313, 81472710 and 81071735), Guangdong Provincial Natural Science Foundation of China (no. S2012010009643), Zhu Jiang Science & Technology New Star Foundation in Guangzhou city (2012J2200052 and 2012J2200044), the Science and Technology Innovation Foundation of Guangdong Higher Education (CXZD1016), the Key Program of the National Natural Science Foundation of Guangdong, China (2010B031500012), and Guangzhou Science & Technology Plan Project (201300000056).	Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boon EMJ, 2002, CANCER RES, V62, P5126; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Duffy MJ, 2007, EUR J CANCER, V43, P1348, DOI 10.1016/j.ejca.2007.03.021; Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang W, 2012, CLIN LUNG CANCER, V13, P280, DOI 10.1016/j.cllc.2011.11.005; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Kume T, 2012, J ONCOL, V2012, DOI 10.1155/2012/204593; Liang HY, 2004, INT J ONCOL, V24, P1057; Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533; Lin YZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079299; LIU C, 1992, ONCOGENE, V7, P181; Liu XD, 2008, EXPERT OPIN INV DRUG, V17, P997, DOI [10.1517/13543784.17.7.997, 10.1517/13543784.17.7.997 ]; Liu YH, 1998, GENE, V215, P159, DOI 10.1016/S0378-1119(98)00264-9; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mazzone M, 2006, FASEB J, V20, P1611, DOI 10.1096/fj.06-5947rev; Mortazavi F, 2010, MOL CANCER RES, V8, P762, DOI 10.1158/1541-7786.MCR-10-0004; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nishida N, 2011, ANN SURG ONCOL, V18, P535, DOI 10.1245/s10434-010-1274-y; Park SJ, 2011, BONE, V49, P428, DOI 10.1016/j.bone.2011.05.012; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Rasola A, 2007, ONCOGENE, V26, P1078, DOI 10.1038/sj.onc.1209859; Sano H, 2010, BIOCHEM BIOPH RES CO, V392, P201, DOI 10.1016/j.bbrc.2010.01.015; Sattler Martin, 2007, Curr Oncol Rep, V9, P102, DOI 10.1007/s11912-007-0005-4; Shibue T, 2012, CANCER DISCOV, V2, P706, DOI 10.1158/2159-8290.CD-11-0239; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Stein Ulrike, 2007, V176, P61; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; De Oliveira ATT, 2009, ANTICANCER RES, V29, P4807; Tseng William, 2007, J Vis Exp, P484, DOI 10.3791/484; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Van Cutsem E, 2013, LANCET, V381, P1538, DOI 10.1016/S0140-6736(13)60978-2; Xue Y, 2008, P NATL ACAD SCI USA, V105, P10167, DOI 10.1073/pnas.0802486105; Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049; Zhu JL, 2013, HISTOPATHOLOGY, V62, P1038, DOI 10.1111/his.12132	43	65	66	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4379	4390		10.1038/onc.2014.368	http://dx.doi.org/10.1038/onc.2014.368			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381815				2022-12-28	WOS:000359494400009
J	Brun, SN; Markant, SL; Esparza, LA; Garcia, G; Terry, D; Huang, JM; Pavlyukov, MS; Li, XN; Grant, GA; Crawford, JR; Levy, ML; Conway, EM; Smith, LH; Nakano, I; Berezov, A; Greene, MI; Wang, Q; Wechsler-Reya, RJ				Brun, S. N.; Markant, S. L.; Esparza, L. A.; Garcia, G.; Terry, D.; Huang, J-M; Pavlyukov, M. S.; Li, X-N; Grant, G. A.; Crawford, J. R.; Levy, M. L.; Conway, E. M.; Smith, L. H.; Nakano, I.; Berezov, A.; Greene, M. I.; Wang, Q.; Wechsler-Reya, R. J.			Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma	ONCOGENE			English	Article							CELL LUNG-CANCER; PHASE-II; DRUG-RESISTANCE; EXPRESSION; YM155; INHIBITOR; APOPTOSIS; SUPPRESSANT; DELIVERY; PATHWAY	Medulloblastoma (MB) is a highly malignant brain tumor that occurs primarily in children. Although surgery, radiation and high-dose chemotherapy have led to increased survival, many MB patients still die from their disease, and patients who survive suffer severe long-term side effects as a consequence of treatment. Thus, more effective and less toxic therapies for MB are critically important. Development of such therapies depends in part on identification of genes that are necessary for growth and survival of tumor cells. Survivin is an inhibitor of apoptosis protein that regulates cell cycle progression and resistance to apoptosis, is frequently expressed in human MB and when expressed at high levels predicts poor clinical outcome. Therefore, we hypothesized that Survivin may have a critical role in growth and survival of MB cells and that targeting it may enhance MB therapy. Here we show that Survivin is overexpressed in tumors from patched (Ptch) mutant mice, a model of Sonic hedgehog (SHH)-driven MB. Genetic deletion of survivin in Ptch mutant tumor cells significantly inhibits proliferation and causes cell cycle arrest. Treatment with small-molecule antagonists of Survivin impairs proliferation and survival of both murine and human MB cells. Finally, Survivin antagonists impede growth of MB cells in vivo. These studies highlight the importance of Survivin in SHH-driven MB, and suggest that it may represent a novel therapeutic target in patients with this disease.	[Brun, S. N.; Markant, S. L.; Esparza, L. A.; Wechsler-Reya, R. J.] NCI, Sanford Burnham Med Res Inst, Designated Canc Ctr, Initiat & Maintenance Program, La Jolla, CA 92037 USA; [Brun, S. N.; Markant, S. L.; Esparza, L. A.; Wechsler-Reya, R. J.] Sanford Consortium Regenerat Med, La Jolla, CA USA; [Brun, S. N.; Markant, S. L.; Wechsler-Reya, R. J.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Garcia, G.] SBMRI, Histopathol Core, La Jolla, CA USA; [Terry, D.; Smith, L. H.] SBMRI, Conrad Prebys Ctr Chem Genom, Lake Nona, FL USA; [Huang, J-M; Wang, Q.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Womens Canc Program, Los Angeles, CA USA; [Pavlyukov, M. S.; Nakano, I.] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Pavlyukov, M. S.; Nakano, I.] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA; [Li, X-N] Baylor Coll Med, Texas Childrens Canc Ctr, Brain Tumor Program, Houston, TX 77030 USA; [Li, X-N] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Grant, G. A.] Stanford Univ, Lucile Packard Childrens Hosp, Dept Neurosurg, Stanford, CA 94305 USA; [Crawford, J. R.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Crawford, J. R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Crawford, J. R.; Levy, M. L.] Rady Childrens Hosp, San Diego, CA USA; [Levy, M. L.] Univ Calif San Diego, Dept Neurosurg, La Jolla, CA 92093 USA; [Conway, E. M.] Univ British Columbia, Ctr Blood Res, Dept Med, Div Hematol, Vancouver, BC V5Z 1M9, Canada; [Smith, L. H.] Sanford Burnham Med Res Inst, Cardiopathobiol Program, Lake Nona, FL USA; [Berezov, A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Greene, M. I.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sanford Burnham Prebys Medical Discovery Institute; Duke University; Cedars Sinai Medical Center; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Lucile Packard Children's Hospital (LPCH); Stanford University; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; University of British Columbia; Sanford Burnham Prebys Medical Discovery Institute; Cedars Sinai Medical Center; University of Pennsylvania	Wechsler-Reya, RJ (corresponding author), NCI, Sanford Burnham Med Res Inst, Designated Canc Ctr, Initiat & Maintenance Program, 2880 Torrey Pines Scen Dr, La Jolla, CA 92037 USA.	rwreya@sanfordburnham.org	Pavlyukov, Marat S/E-7314-2014; Levy, Michael/AAL-4647-2020; Wang, Qiang/N-7310-2015; Pavlyukov, Marat S/ABB-6791-2021; Nakano, Ichiro/AAR-9562-2020; Crawford, John/ABH-2134-2021	Wang, Qiang/0000-0001-9409-0251; Nakano, Ichiro/0000-0002-0916-3207; Conway, Edward/0000-0003-0081-0305; Smith, Layton/0000-0003-2621-9740	Canadian Institutes for Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada (NSERC); NCI [5P30CA030199, R01 CA122759]; Cedars-Sinai/Sanford-Burnham Grant Program for Cancer Research; Research Leadership Award from the California Institute for Regenerative Medicine [CIRM LA1-01747];  [5R01CA08948]; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA159859, R01CA122759] Funding Source: NIH RePORTER	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cedars-Sinai/Sanford-Burnham Grant Program for Cancer Research; Research Leadership Award from the California Institute for Regenerative Medicine; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the support of the Sanford-Burnham Shared Resources, including Amy Cortez, Jonna Hurtado and Yoav Altman (Flow Cytometry); Robbin Newlin (Histopathology); Danielle McAnally, Michael Vicchiarelli and Arianna Mangravita-Novo (Chemical Genomics); Lili Lacarra, Adriana Charbono and Kenny Venegas (Animal facility); and Anthony Pinkerton and members of the Medicinal Chemistry Resource for generation of S12 and LLP3. We are also grateful to Ana Miletic-Sedy and Robert Rickert for sharing Survivin<SUP>fl/fl</SUP> mice; and to Robert Margolis for helpful discussions. We thank the Flanders Institute for Biotechnology (VIB), Belgium, for allowing us to use the Survivin<SUP>fl/fl</SUP> mice. EMC is supported by grants from the Canadian Institutes for Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC). He holds a Tier 1 Canada Research Chair (CRC) in Endothelial Cell Biology. MIG is supported by Grant 5R01CA08948. This work was supported by NCI award number 5P30CA030199 and R01 CA122759 and by the Cedars-Sinai/Sanford-Burnham Grant Program for Cancer Research. RWR is the recipient of a Research Leadership Award from the California Institute for Regenerative Medicine (CIRM LA1-01747).	Adida C, 2000, BRIT J HAEMATOL, V111, P196, DOI 10.1046/j.1365-2141.2000.02328.x; Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Arora R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003713; Becker JC, 2012, CANCER IMMUNOL IMMUN, V61, P2091, DOI 10.1007/s00262-012-1266-9; Berezov A, 2012, ONCOGENE, V31, P1938, DOI 10.1038/onc.2011.377; Blomstrand M, 2012, NEURO-ONCOLOGY, V14, P882, DOI 10.1093/neuonc/nos120; Brown MT, 1996, CLIN CANCER RES, V2, P963; Carrasco RA, 2011, MOL CANCER THER, V10, P221, DOI 10.1158/1535-7163.MCT-10-0756; Chakravarti A, 2004, ONCOGENE, V23, P7494, DOI 10.1038/sj.onc.1208049; Cheng Qiuying, 2012, Int J Biochem Mol Biol, V3, P179; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Fangusaro JR, 2006, PEDIATR BLOOD CANCER, V47, P4, DOI 10.1002/pbc.20805; Fangusaro JR, 2005, BRIT J CANCER, V92, P359, DOI 10.1038/sj.bjc.6602317; Fossati P, 2009, CANCER TREAT REV, V35, P79, DOI 10.1016/j.ctrv.2008.09.002; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Guvenc H, 2013, CLIN CANCER RES, V19, P631, DOI 10.1158/1078-0432.CCR-12-0647; Haberler C, 2006, EUR J CANCER, V42, P2996, DOI 10.1016/j.ejca.2006.05.038; Hall WA, 2006, EXPERT OPIN DRUG DEL, V3, P371, DOI 10.1517/17425247.3.3.371; Huang LN, 2013, MOL BIOL REP, V40, P917, DOI 10.1007/s11033-012-2132-8; Iwasa T, 2008, CLIN CANCER RES, V14, P6496, DOI 10.1158/1078-0432.CCR-08-0468; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Kunwar S, 2007, J CLIN ONCOL, V25, P837, DOI 10.1200/JCO.2006.08.1117; Lewis KD, 2011, INVEST NEW DRUG, V29, P161, DOI 10.1007/s10637-009-9333-6; Li XN, 2007, NEUROPATH APPL NEURO, V33, P67, DOI 10.1111/j.1365-2990.2006.00782.x; Ling X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045571; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Markant SL, 2013, CANCER RES, V73, P6310, DOI 10.1158/0008-5472.CAN-12-4258; Minematsu T, 2012, BIOPHARM DRUG DISPOS, V33, P160, DOI 10.1002/bdd.1781; Morrison DJ, 2012, LEUKEMIA, V26, P271, DOI 10.1038/leu.2011.199; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Nagaraj S, 2007, J IMMUNOTHER, V30, P169, DOI 10.1097/01.cji.0000211329.83890.ba; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Nakahara T, 2011, ANTI-CANCER DRUG, V22, P454, DOI 10.1097/CAD.0b013e328344ac68; Nakahara T, 2011, CANCER SCI, V102, P614, DOI 10.1111/j.1349-7006.2010.01834.x; Nakamura N, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013243; Northcott PA, 2012, EXPERT REV NEUROTHER, V12, P871, DOI [10.1586/ERN.12.66, 10.1586/ern.12.66]; Okamoto K, 2012, MOL CANCER THER, V11, P204, DOI 10.1158/1535-7163.MCT-11-0638; Olie RA, 2000, CANCER RES, V60, P2805; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; Packer RJ, 2008, ARCH NEUROL-CHICAGO, V65, P1419, DOI 10.1001/archneur.65.11.1419; Pan SF, 2010, ACS MED CHEM LETT, V1, P130, DOI 10.1021/ml1000307; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Rodon J, 2014, CLIN CANCER RES, V20, P1900, DOI 10.1158/1078-0432.CCR-13-1710; Rodel F, 2008, INT J RADIAT ONCOL, V71, P247, DOI 10.1016/j.ijrobp.2008.02.011; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Saito T, 2008, BRIT J CANCER, V98, P345, DOI 10.1038/sj.bjc.6604160; Serwer LP, 2012, ADV DRUG DELIVER REV, V64, P590, DOI 10.1016/j.addr.2012.01.004; Shirai K, 2009, J NEURO-ONCOL, V91, P353, DOI 10.1007/s11060-008-9720-4; Talbot DC, 2010, CLIN CANCER RES, V16, P6150, DOI 10.1158/1078-0432.CCR-10-1932; Tanioka M, 2011, CANCER CHEMOTH PHARM, V68, P505, DOI 10.1007/s00280-010-1506-7; Tao YF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-619; Tolcher AW, 2012, ANN ONCOL, V23, P968, DOI 10.1093/annonc/mdr353; Wheatley SP, 2005, INT REV CYTOL, V247, P35, DOI 10.1016/S0074-7696(05)47002-3; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yamanaka K, 2011, CLIN CANCER RES, V17, P5423, DOI 10.1158/1078-0432.CCR-10-3410; Yamashita SI, 2007, ANTICANCER RES, V27, P2803; Yamauchi T, 2012, BIOCHEM BIOPH RES CO, V425, P711, DOI 10.1016/j.bbrc.2012.07.103; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yue ZJ, 2008, J CELL BIOL, V183, P279, DOI 10.1083/jcb.200806118; Zhao XM, 2012, NEURO-ONCOLOGY, V14, P574, DOI 10.1093/neuonc/nos061; Zhu K, 2007, VACCINE, V25, P7955, DOI 10.1016/j.vaccine.2007.08.050	68	39	41	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3770	3779		10.1038/onc.2014.304	http://dx.doi.org/10.1038/onc.2014.304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25241898	Green Submitted, Green Accepted			2022-12-28	WOS:000358001600003
J	Chen, Z; Wang, Z; Guo, W; Zhang, Z; Zhao, F; Zhao, Y; Jia, D; Ding, J; Wang, H; Yao, M; He, X				Chen, Z.; Wang, Z.; Guo, W.; Zhang, Z.; Zhao, F.; Zhao, Y.; Jia, D.; Ding, J.; Wang, H.; Yao, M.; He, X.			TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma	ONCOGENE			English	Article							NUCLEAR TRANSLOCATION; GENE-TRANSCRIPTION; B-BOX; PKM2; PROMOTES; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION; PROTEIN; GROWTH	Tripartite motif-containing protein 35 (TRIM35) is a member of RBCC family, which has a highly conserved order consisting of a RING domain followed by one or two B-Box domains and then a coiled-coil domain. We previously identified TRIM35 as a novel tumor suppressor in human hepatocellular carcinoma (HCC). However, the molecular mechanism that TRIM35 uses to suppress tumorigenicity is largely unknown. Pyruvate kinase isoform M2 (PKM2) has been demonstrated to have a central role in metabolic reprogramming during cancer progression. Phosphorylation of PKM2 tyrosine residue 105 (Y105) regulates PKM2 to provide a metabolic advantage to tumor cells, thereby promoting tumor growth. In the present work, mass spectrometry analysis demonstrated an interaction between TRIM35 and PKM2. Co-IP experiments confirmed that TRIM35 interacts with PKM2 and that the coiled-coil domain is required for such an interaction. Furthermore, the coiled-coil domain mediates decreases in the Warburg effect and in the cell proliferation of HCC cells. In addition, TRIM35 suppresses the tumorigenicity of HCC cells through the blockade of PKM2 Y105 phosphorylation. Collectively, our data reveal a new function for TRIM35, which is to regulate the Warburg effect and tumorigenicity through interaction with PKM2 in HCC.	[Chen, Z.; Zhao, Y.; Jia, D.; Ding, J.; He, X.] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Chen, Z.; Zhao, Y.; Jia, D.; Ding, J.; He, X.] Inst Biomed Sci, Shanghai 200433, Peoples R China; [Chen, Z.; Zhao, Y.; Jia, D.; Ding, J.; He, X.] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Chen, Z.; Guo, W.; Zhang, Z.; Zhao, F.; Wang, H.; Yao, M.; He, X.] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai 200032, Peoples R China; [Wang, Z.] Fudan Univ, Minist Educ, Liver Canc Inst, Zhongshan Hosp, Shanghai 200433, Peoples R China; [Wang, Z.] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University; Fudan University; Fudan University	He, X (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, 25-Ln 2200,Xie Tu Rd, Shanghai 200032, Peoples R China.	xhhe@shsci.org	He, Xianghuo/I-1497-2014; Chen, Zhiao/AAO-1087-2021; Jia, Deshui/U-9732-2019	He, Xianghuo/0000-0001-8872-668X; Chen, Zhiao/0000-0003-4105-8674; 	National 973 Key Basic Research Program [2013CB910504]; Shanghai Natural Science Fund for Youth Scholars [12ZR1449900]; Shanghai Rising-Star Program [12QA1403100]; Shanghai 'Promising Youth Medical Worker' Project [XYQ2011042]; National Natural Science Foundation of China [81201538, 81125016, 81171942]	National 973 Key Basic Research Program(National Basic Research Program of China); Shanghai Natural Science Fund for Youth Scholars; Shanghai Rising-Star Program; Shanghai 'Promising Youth Medical Worker' Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful for Dr T Didier's gifts of the pWPXL, psPAX2 and pMD2. G lentivirus plasmids. We thank Qunying Lei for discussions throughout this study. We thank Jianhua Zhu for use of the scintillation counter. We thank Feng Wang and Ping Zhang for technical assistance. This work was supported by grants from the National 973 Key Basic Research Program (2013CB910504), Shanghai Natural Science Fund for Youth Scholars (12ZR1449900), Shanghai Rising-Star Program (12QA1403100), Shanghai 'Promising Youth Medical Worker' Project (XYQ2011042), National Natural Science Foundation of China (81201538, 81125016, 81171942).	ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; Baek YM, 2008, PROTEOMICS, V8, P4748, DOI 10.1002/pmic.200800094; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Endersby R, 2008, BLOOD, V111, P1946, DOI 10.1182/blood-2007-04-085746; Figeac N, 2014, DEV BIOL, V386, P135, DOI 10.1016/j.ydbio.2013.11.017; Freeman KW, 2003, CANCER RES, V63, P6237; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; He HC, 2013, MOL BIOL REP, V40, P3799, DOI 10.1007/s11033-012-2458-2; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hoshino A, 2007, J BIOL CHEM, V282, P17706, DOI 10.1074/jbc.M700094200; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia DS, 2011, HEPATOLOGY, V54, P1227, DOI 10.1002/hep.24495; Kimura F, 2003, J BIOL CHEM, V278, P25046, DOI 10.1074/jbc.M303438200; Lalonde JP, 2004, J BIOL CHEM, V279, P8181, DOI 10.1074/jbc.M306751200; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Mcnab FW, 2011, CURR OPIN IMMUNOL, V23, P46, DOI 10.1016/j.coi.2010.10.021; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Welm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119; Yang WW, 2013, CELL CYCLE, V12, P3154, DOI 10.4161/cc.26182; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598	31	53	57	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3946	3956		10.1038/onc.2014.325	http://dx.doi.org/10.1038/onc.2014.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263439				2022-12-28	WOS:000358544200007
J	Komatsu, Y; Christian, SL; Ho, N; Pongnopparat, T; Licursi, M; Hirasawa, K				Komatsu, Y.; Christian, S. L.; Ho, N.; Pongnopparat, T.; Licursi, M.; Hirasawa, K.			Oncogenic Ras inhibits IRF1 to promote viral oncolysis	ONCOGENE			English	Article							INTERFERON-ALPHA RESISTANCE; TRANSCRIPTION FACTOR; MESSENGER-RNA; ANTIVIRAL RESPONSE; SIGNALING PATHWAY; CANCER-THERAPY; CONSTITUTIVE EXPRESSION; INDUCIBLE GENES; MEASLES-VIRUS; IFN-BETA	Oncolytic viruses exploit common molecular changes in cancer cells, which are not present in normal cells, to target and kill cancer cells. Ras transformation and defects in type I interferon (IFN)-mediated antiviral responses are known to be the major mechanisms underlying viral oncolysis. Previously, we demonstrated that oncogenic RAS/Mitogen-activated protein kinase kinase (Ras/MEK) activation suppresses the transcription of many IFN-inducible genes in human cancer cells, suggesting that Ras transformation underlies type I IFN defects in cancer cells. Here, we investigated how Ras/MEK downregulates IFN-induced transcription. By conducting promoter deletion analysis of IFN-inducible genes, namely guanylate-binding protein 2 and IFN gamma inducible protein 47 (Ifi47), we identified the IFN regulatory factor 1 (IRF1) binding site as the promoter region responsible for the regulation of transcription by MEK. MEK inhibition promoted transcription of the IFN-inducible genes in wild type mouse embryonic fibroblasts (MEFs), but not in IRF1(-/-) MEFs, showing that IRF1 is involved in MEK-mediated downregulation of IFN-inducible genes. Furthermore, IRF1 protein expression was lower in RasV12 cells compared with vector control NIH3T3 cells, but was restored to equivalent levels by inhibition of MEK. Similarly, the restoration of IRF1 expression by MEK inhibition was observed in human cancer cells. IRF1 re-expression in human cancer cells caused cells to become resistant to infection by the oncolytic vesicular stomatitis virus strain. Together, this work demonstrates that Ras/MEK activation in cancer cells downregulates transcription of IFN-inducible genes by targeting IRF1 expression, resulting in increased susceptibility to viral oncolysis.	[Komatsu, Y.; Ho, N.; Pongnopparat, T.; Licursi, M.; Hirasawa, K.] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NF A1B 3V6, Canada; [Christian, S. L.] Mem Univ Newfoundland, Fac Med, Dept Biochem, St John, NF A1B 3V6, Canada	Memorial University Newfoundland; Memorial University Newfoundland	Hirasawa, K (corresponding author), Mem Univ Newfoundland, Fac Med, Div Biomed Sci, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.	kensuke@mun.ca		Christian, Sherri/0000-0002-4289-4386	Canadian Institutes for Health Research (CIHR); Regional Development Corporation of Newfoundland and Labrador (RDC); Canadian Breast Cancer Foundation (CBCF); Beatrice Hunter Cancer Research Institute; Cancer Research Training Program as part of The Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Regional Development Corporation of Newfoundland and Labrador (RDC); Canadian Breast Cancer Foundation (CBCF); Beatrice Hunter Cancer Research Institute; Cancer Research Training Program as part of The Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR	This work was supported by grants (to KH) from the Canadian Institutes for Health Research (CIHR), the Regional Development Corporation of Newfoundland and Labrador (RDC) and Canadian Breast Cancer Foundation (CBCF). SLC was supported by a post-doctoral award from CIHR and RDC and a separate trainee award from the Beatrice Hunter Cancer Research Institute with funds provided by the Cancer Research Training Program as part of The Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR. Special thanks to Dr John Bell (Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada) for VSV and VSVM51R, and Nebiur E A for graphic design. We thank Susan Wakeham and Rahul-dev Kalsi for technical support.	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Battcock SA, 2006, J VIROL, V80, P4422, DOI 10.1128/JVI.80.9.4422-4430.2006; Bell J, 2010, MOL THER, V18, P233, DOI 10.1038/mt.2009.314; Bergmann M, 2001, CANCER RES, V61, P8188; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Brien JD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002230; Cascallo M, 2003, CANCER RES, V63, P5544; Christian SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044267; Christian SL, 2009, J VIROL, V83, P6717, DOI 10.1128/JVI.02213-08; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Goetz C, 2010, MOL THER, V18, P1937, DOI 10.1038/mt.2010.145; GOLDSTEIN D, 1986, CANCER RES, V46, P4315; Iankov I, 2014, MOL THER, V22, pS12; Kanazawa N, 2004, J VIROL, V78, P9713, DOI 10.1128/JVI.78.18.9713-9720.2004; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kurokawa C, 2014, MOL THER, V22, pS248; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Lian J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.70; Liu X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058489; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moriyama Y, 2001, CLIN CANCER RES, V7, P1293; Nguyen TLA, 2008, P NATL ACAD SCI USA, V105, P14981, DOI 10.1073/pnas.0803988105; Norman KL, 2005, DRUG DISCOV TODAY, V10, P847, DOI 10.1016/S1359-6446(05)03483-5; Noser JA, 2007, MOL THER, V15, P1531, DOI 10.1038/sj.mt.6300193; Phillips A, 2008, ONCOGENE, V27, P1645, DOI 10.1038/sj.onc.1210785; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950; Puhlmann J, 2010, ONCOGENE, V29, P2205, DOI 10.1038/onc.2009.507; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shang D, 2007, CANCER SCI, V98, P1259, DOI 10.1111/j.1349-7006.2007.00526.x; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	50	24	24	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3985	3993		10.1038/onc.2014.331	http://dx.doi.org/10.1038/onc.2014.331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25347735				2022-12-28	WOS:000358544200011
J	Xu, HG; Zhai, YX; Chen, J; Lu, Y; Wang, JW; Quan, CS; Zhao, RX; Xiao, X; He, Q; Werle, KD; Kim, HG; Lopez, R; Cui, R; Liang, J; Li, YL; Xu, ZX				Xu, H-G; Zhai, Y-X; Chen, J.; Lu, Y.; Wang, J-W; Quan, C-S; Zhao, R-X; Xiao, X.; He, Q.; Werle, K. D.; Kim, H-G; Lopez, R.; Cui, R.; Liang, J.; Li, Y-L; Xu, Z-X			LKB1 reduces ROS-mediated cell damage via activation of p38	ONCOGENE			English	Article							PROTEIN-KINASE; LUNG-CANCER; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; MAP KINASE; OXYGEN; GROWTH; METABOLISM; CDC42; AMPK	Liver kinase B1 (LKB1, also known as serine/threonine kinase 11, STK11) is a tumor suppressor mutated in Peutz-Jeghers syndrome and in a variety of sporadic cancers. Herein, we demonstrate that LKB1 controls the levels of intracellular reactive oxygen species (ROS) and protects the genome from oxidative damage. Cells lacking LKB1 exhibit markedly increased intracellular ROS levels, excessive oxidation of DNA, increased mutation rates and accumulation of DNA damage, which are effectively prevented by ectopic expression of LKB1 and by incubation with antioxidant N-acetylcysteine. The role of LKB1 in suppressing ROS is independent of AMP-activated protein kinase, a canonical substrate of LKB1. Instead, under the elevated ROS, LKB1 binds to and maintains the activity of the cdc42-PAK1 (p21-activated kinase 1) complex, which triggers the activation of p38 and its downstream signaling targets, such as ATF-2, thereby enhancing the activity of superoxide dismutase-2 and catalase, two antioxidant enzymes that protect the cells from ROS accumulation, DNA damage and loss of viability. Our results provide a new paradigm for a non-canonical tumor suppressor function of LKB1 and highlight the importance of targeting ROS signaling as a potential therapeutic strategy for cancer cells lacking LKB1.	[Xu, H-G; Chen, J.; Zhao, R-X; Xiao, X.; He, Q.; Werle, K. D.; Kim, H-G; Lopez, R.; Xu, Z-X] Univ Alabama Birmingham, Dept Med, Ctr Comprehens Canc, Div Hematol & Oncol, Birmingham, AL 35294 USA; [Zhai, Y-X; Wang, J-W; Quan, C-S; Li, Y-L; Xu, Z-X] Jilin Univ, Minist Educ, Norman Bethune Coll Med, Key Lab Pathobiol,Dept Pathol, Changchun 35294, Jilin, Peoples R China; [Lu, Y.] Nanjing Med Univ, Affiliated Hosp 2, Dept Endocrinol, Nanjing, Peoples R China; [Cui, R.] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02215 USA; [Liang, J.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA	University of Alabama System; University of Alabama Birmingham; Jilin University; Nanjing Medical University; Boston University; University of Texas System; UTMD Anderson Cancer Center	Xu, ZX (corresponding author), Jilin Univ, Minist Educ, Norman Bethune Coll Med, Key Lab Pathobiol,Dept Pathol, 126 Xin Min Ave, Changchun 35294, Jilin, Peoples R China.	ylli@jlu.edu.cn; zhixiangxu08@gmail.com			National Cancer Institute [R01CA133053]; National 863 Program [2004AA205020]; National Natural Science Foundation of China [30700872]; NATIONAL CANCER INSTITUTE [R01CA133053] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National 863 Program(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mousseau at University of Saskatchewan for providing p38-WT, CA and DN constructs; Dr Laderoute at SRI International for providing WT and AMPK-null MEFs; Dr Frazier at University of Texas MD Cancer Center for providing the LKB1-null cells; Dr Lizhong Wang from University of Alabama at Birmingham for providing WT and LKB1<SUP>fl/fl</SUP> MEFs. This work was supported by grants from National Cancer Institute R01CA133053 (ZXX) and the National 863 Program #2004AA205020 and the National Natural Science Foundation of China #30700872 (YLL).	Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Archer Herbert, 2002, Methods Mol Biol, V189, P67; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Cao X, 2009, J NEUROCHEM, V111, P101, DOI 10.1111/j.1471-4159.2009.06300.x; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Gutierrez-Uzquiza A, 2012, J BIOL CHEM, V287, P2632, DOI 10.1074/jbc.M111.323709; Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hsieh CC, 2010, AGING-US, V2, P582, DOI 10.18632/aging.100194; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jian WG, 2014, ANTI-CANCER DRUG, V25, P878, DOI 10.1097/CAD.0000000000000114; Jimenez AI, 2003, CANCER RES, V63, P1382; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Li XN, 2009, DIABETES, V58, P2246, DOI 10.2337/db08-1512; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Madesh M, 1998, INDIAN J BIOCHEM BIO, V35, P184; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Montero J, 2013, CELL DEATH DIFFER, V20, P1465, DOI 10.1038/cdd.2013.52; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Pan JX, 2005, CANCER RES, V65, P3671, DOI 10.1158/0008-5472.CAN-04-2744; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sen P, 2005, FEBS LETT, V579, P4402, DOI 10.1016/j.febslet.2005.06.081; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Slaughter MR, 2000, CLIN BIOCHEM, V33, P525, DOI 10.1016/S0009-9120(00)00158-2; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Ui A, 2014, ONCOGENE, V33, P1640, DOI 10.1038/onc.2013.125; Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.358; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xiao XX, 2012, GYNECOL ONCOL, V127, P249, DOI 10.1016/j.ygyno.2012.06.032; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao RX, 2014, CURR DRUG TARGETS, V15, P32, DOI 10.2174/1389450114666140106095811	56	30	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3848	3859		10.1038/onc.2014.315	http://dx.doi.org/10.1038/onc.2014.315			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263448	Green Accepted			2022-12-28	WOS:000358001600010
J	Satoyoshi, R; Aiba, N; Yanagihara, K; Yashiro, M; Tanaka, M				Satoyoshi, R.; Aiba, N.; Yanagihara, K.; Yashiro, M.; Tanaka, M.			Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; SCIRRHOUS CARCINOMA; PODOSOME FORMATION; SURGICAL-TREATMENT; INVADOPODIA; DIALYSIS; MIGRATION; MODELS; LINES	Scirrhous gastric cancer is frequently associated with peritoneal dissemination, and the interaction of cancer cells with peritoneal mesothelial cells (PMCs) is crucial for the establishment of the metastasis in the peritoneum. Although cells derived from PMCs are detected within tumors of peritoneal carcinomatosis, how PMCs are incorporated into tumor architecture is not understood. The present study shows that PMCs create the invasion front of peritoneal carcinomatosis, which depends on activation of Tks5 in PMCs. In peritoneal tumor implants, PMCs represent majority of cells located at the invasive edge of the cancer tissue. Exogenously implanted PMCs and host PMCs aggressively invade into abdominal wall upon the peritoneal inoculation of cancer cells, and PMCs locate ahead of cancer cells in the direction of invasion. Tks5, a substrate of Src kinase, is predominantly expressed in the PMCs of cancer tissue, and promotes the invasion of PMCs and cancer cells. Expression and activation of Tks5 was induced in PMCs following their exposure to gastric cancer cells, and increased Tks5 expression was detected in PMCs located at the invasion front. Reduced Tks5 expression in PMCs blocked PMC invasion, which in turn prevents cancer cell invasion both in vitro and in vivo. The peritoneal dissemination of gastric cancer was significantly increased by mixing cancer cells and PMCs, and was suppressed by knockdown of Tks5 in PMCs. These results suggest that cancer-activated PMCs create invasion front by guiding cancer cells. Signaling leading to Tks5 activation in PMCs may be a suitable therapeutic target for prevention of peritoneal carcinomatosis.	[Satoyoshi, R.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, Akita 0108543, Japan; [Yanagihara, K.] Natl Canc Ctr, Div Translat Res, Exploratory Oncol & Clin Trial Ctr, Chiba, Japan; [Yashiro, M.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 558, Japan	Akita University; National Cancer Center - Japan; Osaka Metropolitan University	Tanaka, M (corresponding author), Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, 1-1-1 Hondo, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp			JSPS KAKENHI [25290042, 26640068]; National Cancer Center Research and Development Fund [23-A-9]; Takeda Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Murata K (Department of Environmental Health Sciences, Akita University School of Medicine) for advice and discussion about statistics. This work was supported by JSPS KAKENHI (Grant Nos 25290042 and 26640068 to MT) Takeda Science Foundation (MT) and the National Cancer Center Research and Development Fund (Grant No. 23-A-9 to MT).	Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Aroeira LS, 2005, AM J KIDNEY DIS, V46, P938, DOI 10.1053/j.ajkd.2005.08.011; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Blouw B, 2008, EUR J CELL BIOL, V87, P555, DOI 10.1016/j.ejcb.2008.02.008; Burger KL, 2014, PROSTATE, V74, P134, DOI 10.1002/pros.22735; Burger KL, 2011, CYTOSKELETON, V68, P694, DOI 10.1002/cm.20545; Courtneidge SA, 2012, BIOCHEM SOC T, V40, P129, DOI 10.1042/BST20110685; Fekete Anna, 2013, J Mol Signal, V8, P8, DOI 10.1186/1750-2187-8-8; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Jayne DG, 2000, BRIT J CANCER, V82, P1233; Kajiyama H, 2007, CELL TISSUE RES, V330, P221, DOI 10.1007/s00441-007-0455-x; Li CMC, 2013, GENE DEV, V27, P1557, DOI 10.1101/gad.222745.113; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Lv ZD, 2013, MOL CELL BIOCHEM, V377, P177, DOI 10.1007/s11010-013-1583-0; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Murphy DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022499; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Mutsaers SE, 2004, INT J BIOCHEM CELL B, V36, P9, DOI 10.1016/S1357-2725(03)00242-5; Nashimoto A, 2013, GASTRIC CANCER, V16, P1, DOI 10.1007/s10120-012-0163-4; Nishimura S, 1998, INT J ONCOL, V12, P847; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; Otsuji E, 2004, AM J SURG, V188, P327, DOI 10.1016/j.amjsurg.2004.06.010; Sako A, 2003, J SURG RES, V115, P113, DOI 10.1016/S0022-4804(03)00307-X; Sandoval P, 2013, J PATHOL, V231, P517, DOI 10.1002/path.4281; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Schauer M, 2011, EUR J MED RES, V16, P29, DOI 10.1186/2047-783X-16-1-29; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Shimamura S, 2013, J BIOL CHEM, V288, P1171, DOI 10.1074/jbc.M112.386722; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; Takemura S, 2004, CANCER SCI, V95, P893, DOI 10.1111/j.1349-7006.2004.tb02199.x; Tsukada T, 2012, INT J ONCOL, V41, P476, DOI 10.3892/ijo.2012.1490; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yashiro M, 2010, CANCER MICROENVIRON, V3, P127, DOI 10.1007/s12307-010-0036-5; Yonemura Y, 2010, EJSO-EUR J SURG ONC, V36, P1131, DOI 10.1016/j.ejso.2010.09.006; Yung S, 2009, PERITON DIALYSIS INT, V29, pS21	41	20	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3176	3187		10.1038/onc.2014.246	http://dx.doi.org/10.1038/onc.2014.246			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25088196				2022-12-28	WOS:000356101100009
J	Suzuki, HI; Katsura, A; Matsuyama, H; Miyazono, K				Suzuki, H. I.; Katsura, A.; Matsuyama, H.; Miyazono, K.			MicroRNA regulons in tumor microenvironment	ONCOGENE			English	Review							CANCER-ASSOCIATED FIBROBLASTS; BREAST-CANCER; SUPPRESSOR-CELLS; GENE-EXPRESSION; MESSENGER-RNAS; METASTASIS; MIRNA; HYPOXIA; MACROPHAGES; DISTINCT	Cancer initiation and progression are defined by the behavior of cancer cells per se and the development of tumor tissues, both of which are modulated by crosstalk between cancer cells and the surrounding microenvironment. Advances in cancer research have highlighted the significance of constant evolution of the tumor microenvironment, leading to tumor formation, metastasis and refractoriness to therapy. MicroRNAs (miRNAs) are small non-coding RNAs that function as major players of posttranscriptional gene regulation in diverse biological processes. They function as both tumor suppressors and promoters in many aspects of the autonomous behavior of cancer cells. Theoretically, dysfunction in the gene regulatory networks of cancer cells is one of the major driving forces for alterations of ostensibly normal surrounding cells. In this context, the core targets of miRNAs, termed miRNA regulons, are currently being expanded to include various modulators of the tumor microenvironment. Recent advances have highlighted two important roles played by miRNAs in the evolution of tumor microenvironments: miRNAs in tumor cells transform the microenvironment via non-cell-autonomous mechanisms, and miRNAs in neighboring cells stabilize cancer hallmark traits. These observations epitomize the distal and proximal functions of miRNAs in tumor microenvironments, respectively. Such regulation by miRNAs affects tumor angiogenesis, immune invasion and tumor-stromal interactions. This review summarizes recent findings on the mechanisms of miRNA-mediated regulation of tumor microenvironments, with a perspective on the design of therapeutic interventions.	[Suzuki, H. I.; Katsura, A.; Matsuyama, H.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Tokyo 1130033, Japan	University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp		Suzuki, Hiroshi/0000-0003-4682-5086	MEXT of Japan [24689018, 23112702, 22112002]; Cell Science Research Foundation; JSPS Postdoctoral Fellowship for Research Abroad; Grants-in-Aid for Scientific Research [22112002] Funding Source: KAKEN	MEXT of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cell Science Research Foundation(Cell Science Research Foundation, Japan); JSPS Postdoctoral Fellowship for Research Abroad(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank members of the Department of Molecular Pathology, the University of Tokyo, Tokyo, Japan. This work was supported by KAKENHI (Grants-in-Aid for Young Scientists (A) (No. 24689018, to HIS) and for Scientific Research on Innovative Areas 'RNA regulation' (No. 23112702, to HIS) and 'Integrative research on cancer microenvironment network' (No. 22112002, to KM)) from the MEXT of Japan, the Cell Science Research Foundation and JSPS Postdoctoral Fellowship for Research Abroad. We apologize to colleagues whose work was not cited because of space limitations.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Aprelikova O, 2013, ONCOGENE, V32, P3246, DOI 10.1038/onc.2012.351; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Aucher A, 2013, J IMMUNOL, V191, P6250, DOI 10.4049/jimmunol.1301728; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Ben-Moshe NB, 2012, NUCLEIC ACIDS RES, V40, P10614, DOI 10.1093/nar/gks841; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Carroll AP, 2013, J MOL CELL BIOL, V5, P73, DOI 10.1093/jmcb/mjt004; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Cirri P, 2011, AM J CANCER RES, V1, P482; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Cubillos-Ruiz JR, 2012, CANCER RES, V72, P1683, DOI 10.1158/0008-5472.CAN-11-3160; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; Dangi-Garimella S, 2011, ONCOGENE, V30, P1002, DOI 10.1038/onc.2010.485; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027; Gould SJ, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20389; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hasebe T, 2010, HUM PATHOL, V41, P262, DOI 10.1016/j.humpath.2009.07.021; HE L, 2004, NAT REV GENET, V5, P522; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Huang JC, 2007, NAT METHODS, V4, P1045, DOI 10.1038/nmeth1130; Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Ishimoto T, 2014, CARCINOGENESIS, V35, P1003, DOI 10.1093/carcin/bgt402; Ivan M, 2014, ADV EXP MED BIOL, V772, P205, DOI 10.1007/978-1-4614-5915-6_10; Jafarifar F, 2011, EMBO J, V30, P1324, DOI 10.1038/emboj.2011.38; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kosaka Nobuyoshi, 2012, Frontiers in Genetics, V2, P97, DOI 10.3389/fgene.2011.00097; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kroh EM, 2010, METHODS, V50, P298, DOI 10.1016/j.ymeth.2010.01.032; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li XL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/762183; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Liu B, 2010, BIOINFORMATICS, V26, P3105, DOI 10.1093/bioinformatics/btq576; Liu Y, 2012, J IMMUNOL, V188, P5500, DOI 10.4049/jimmunol.1103505; Loayza-Puch F, 2010, ONCOGENE, V29, P2638, DOI 10.1038/onc.2010.23; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Matsuyama H, 2011, BLOOD, V118, P6881, DOI 10.1182/blood-2011-05-354654; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Muramatsu F, 2013, ONCOGENE, V32, P414, DOI 10.1038/onc.2012.68; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Nouraee N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073009; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ostrand-Rosenberg S, 2008, CURR OPIN GENET DEV, V18, P11, DOI 10.1016/j.gde.2007.12.007; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Sempere LF, 2011, EXPERT REV MOL DIAGN, V11, P813, DOI [10.1586/ERM.11.69, 10.1586/erm.11.69]; Sempere LF, 2010, CLIN CANCER RES, V16, P4246, DOI 10.1158/1078-0432.CCR-10-1152; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Shen GM, 2013, ACTA PHARMACOL SIN, V34, P336, DOI 10.1038/aps.2012.195; Squadrito ML, 2013, TRENDS IMMUNOL, V34, P350, DOI 10.1016/j.it.2013.02.003; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Sugihara H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081839; Suzuki HI, 2013, LEUKEMIA, V27, P2107, DOI 10.1038/leu.2013.121; Suzuki HI, 2012, ENZYMES, V32, P163, DOI 10.1016/B978-0-12-404741-9.00008-8; Suzuki HI, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1439; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Suzuki HI, 2011, J BIOCHEM, V149, P15, DOI 10.1093/jb/mvq113; Suzuki HI, 2010, J MOL MED, V88, P1085, DOI 10.1007/s00109-010-0650-1; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Turchinovich A., 2013, Frontiers in Genetics, V4, P119, DOI 10.3389/fgene.2013.00119; Ulitsky I, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq570; Vader P, 2014, TRENDS MOL MED, V20, P385, DOI 10.1016/j.molmed.2014.03.002; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Hamburg JP, 2009, ARTHRITIS RHEUM-US, V60, P750, DOI 10.1002/art.24329; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Wei J, 2013, CANCER RES, V73, P3913, DOI 10.1158/0008-5472.CAN-12-4318; Wentz-Hunter KK., 2011, MOL BIOL INT, V2011, P839872, DOI [DOI 10.4061/2011/839872, 10.4061/2011/839872]; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Yu CC, 2013, CANCER RES, V73, P3425, DOI 10.1158/0008-5472.CAN-12-3840; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610; Zhang MM, 2011, J IMMUNOL, V186, P4716, DOI 10.4049/jimmunol.1002989; Zhang Y, 2014, TRENDS CELL BIOL, V24, P153, DOI 10.1016/j.tcb.2013.09.007; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690	115	132	141	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3085	3094		10.1038/onc.2014.254	http://dx.doi.org/10.1038/onc.2014.254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25132266	Green Published, hybrid			2022-12-28	WOS:000356101100001
J	Zhang, J; Qin, X; Sun, Q; Guo, H; Wu, X; Xie, F; Xu, Q; Yan, M; Liu, J; Han, Z; Chen, W				Zhang, J.; Qin, X.; Sun, Q.; Guo, H.; Wu, X.; Xie, F.; Xu, Q.; Yan, M.; Liu, J.; Han, Z.; Chen, W.			Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression	ONCOGENE			English	Article							B-CELL LYMPHOMAS; BREAST-CANCER; DIABETES-MELLITUS; DOWN-REGULATION; PAX4 GENE; INVASION; DISINTEGRIN; CARCINOMA; MIGRATION; MICRORNA	Paired box gene 4 (PAX4) is a transcriptional modulator located on chromosome 7q32, and its expression is dysregulated in a variety of human cancers, suggesting that PAX4 may be important in multiple tumors as a driver gene. Here, we show that PAX4 promoted migration and invasion in human epithelial cancers by decreasing miR-144 and miR-451 (miR-144/451) expression levels. Accordingly, miR-144/451 suppressed the migratory and invasive phenotypes, even in PAX4-expressing cells. Mechanistically, miR-144/451 inhibits cancer metastasis by targeting the A disintegrin and metalloproteinase (ADAM) protein family members ADAMTS5 and ADAM10. Their dysregulation is associated with increased tumor invasiveness and metastasis, then reduced patient prognosis in certain epithelial cancers. This discovery suggests that a PAX4-miR-144/451-ADAMs axis regulates human epithelial cancer metastasis, thus opening up therapeutic possibilities and predicting prognosis for those cancer types.	[Zhang, J.; Qin, X.; Sun, Q.; Wu, X.; Xie, F.; Xu, Q.; Yan, M.; Chen, W.] Shanghai Jiao Tong Univ, Sch Med, Dept Oral & Maxillofacial Head & Neck Oncol, Peoples Hosp 9, Shanghai 200011, Peoples R China; [Zhang, J.; Qin, X.; Sun, Q.; Wu, X.; Xie, F.; Xu, Q.; Yan, M.; Chen, W.] Shanghai Jiao Tong Univ, Sch Med, Fac Oral & Maxillofacial Surg, Peoples Hosp 9, Shanghai 200011, Peoples R China; [Guo, H.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 3, Dept Clin Lab, Shanghai 200011, Peoples R China; [Xu, Q.; Han, Z.; Chen, W.] Shanghai Key Lab Stomatol, Shanghai, Peoples R China; [Xu, Q.; Han, Z.; Chen, W.] Shanghai Res Inst Stomatol, Shanghai, Peoples R China; [Liu, J.] Fudan Univ, Zhongshan Hosp, Dept Integrat Med, Shanghai 200433, Peoples R China; [Han, Z.] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Dis & Hlth Genom, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University	Chen, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Oral & Maxillofacial Head & Neck Oncol, Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.	chenwantao196323@sjtu.edu.cn	建军, 张/R-3679-2019	Han, Ze-Guang/0000-0002-1018-1752	National Natural Science Foundation of China [91229103, 81101515, 81201912, 81272977]; Shanghai Municipal Education Commission [12YZ052, 12ZZ106]; Shanghai Science and Technology Committee [11DZ2291800, 10DZ1951300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	This study was supported by the National Natural Science Foundation of China (grant no. 91229103, 81101515, 81201912 and 81272977), the Program of Shanghai Municipal Education Commission (12YZ052 and 12ZZ106) and Project of the Shanghai Science and Technology Committee (11DZ2291800 and 10DZ1951300). We appreciate Liu Jun and Shanghai Cancer Hospital affiliated to Fudan University for providing the 50 pairs of HNSCC tissues. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Akiyoshi S, 2012, BRIT J CANCER, V107, P1345, DOI 10.1038/bjc.2012.326; Benfey PN, 2003, NATURE, V425, P244, DOI 10.1038/425244a; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Biason-Lauber A, 2005, DIABETOLOGIA, V48, P900, DOI 10.1007/s00125-005-1723-5; Brocker Chad N., 2009, Human Genomics, V4, P43; Cheng C, 2013, J BIOL CHEM, V288, P13748, DOI 10.1074/jbc.M112.381392; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Cross NA, 2005, PROSTATE, V63, P269, DOI 10.1002/pros.20182; Dore LC, 2008, P NATL ACAD SCI USA, V105, P3333, DOI 10.1073/pnas.0712312105; FABBRO D, 1994, CANCER RES, V54, P4744; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Guo HY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-77; Guo HY, 2012, INT J BIOCHEM CELL B, V44, P1465, DOI 10.1016/j.biocel.2012.05.015; Held-Feindt J, 2006, INT J CANCER, V118, P55, DOI 10.1002/ijc.21258; Iwaya T, 2012, CARCINOGENESIS, V33, P2391, DOI 10.1093/carcin/bgs288; Jeon HW, 2010, MOL CANCER THER, V9, P1361, DOI 10.1158/1535-7163.MCT-09-0717; Jerkeman M, 1999, EUR J HAEMATOL, V62, P184; Jones GC, 2006, CURR PHARM BIOTECHNO, V7, P25, DOI 10.2174/138920106775789656; Karan D, 2003, INT J ONCOL, V23, P1365; Kobayashi H, 2013, J BIOL CHEM, V288, P28620, DOI 10.1074/jbc.M113.452169; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; Kumar S, 2012, AM J PATHOL, V181, P1056, DOI 10.1016/j.ajpath.2012.05.022; Li YH, 2006, LEUKEMIA RES, V30, P1547, DOI 10.1016/j.leukres.2006.04.001; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Lu XJ, 2008, CURR CANCER DRUG TAR, V8, P720, DOI 10.2174/156800908786733478; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; McCulloch DR, 2004, CLIN CANCER RES, V10, P314, DOI 10.1158/1078-0432.CCR-0846-3; Miller DJ, 2000, P NATL ACAD SCI USA, V97, P4475, DOI 10.1073/pnas.97.9.4475; Miyaki S, 2009, ARTHRITIS RHEUM-US, V60, P2723, DOI 10.1002/art.24745; Miyamoto T, 2001, BIOCHEM BIOPH RES CO, V282, P34, DOI 10.1006/bbrc.2001.4552; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236; Rasmussen KD, 2010, J EXP MED, V207, P1351, DOI 10.1084/jem.20100458; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Shikata K, 2013, CANCER SCI, V104, P9, DOI 10.1111/cas.12043; Sosa-Pineda B, 2004, MOL CELLS, V18, P289; Sun Q, 2013, INT J BIOCHEM CELL B, V45, P513, DOI 10.1016/j.biocel.2012.12.004; TAMURA T, 1994, CYTOGENET CELL GENET, V66, P132, DOI 10.1159/000133684; Tian Y, 2012, INT J ONCOL, V40, P1105, DOI 10.3892/ijo.2011.1306; Tokuyama Y, 2006, METABOLISM, V55, P213, DOI 10.1016/j.metabol.2005.08.014; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Yan M, 2013, MOL CELL PROTEOMICS, V12, P3271, DOI 10.1074/mcp.M112.025460; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang XW, 2010, J MOL CELL CARDIOL, V49, P841, DOI 10.1016/j.yjmcc.2010.08.007	46	44	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3283	3295		10.1038/onc.2014.259	http://dx.doi.org/10.1038/onc.2014.259			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151965				2022-12-28	WOS:000356592300007
J	Aye, Y; Li, M; Long, MJC; Weiss, RS				Aye, Y.; Li, M.; Long, M. J. C.; Weiss, R. S.			Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies	ONCOGENE			English	Review							CELL LUNG-CANCER; SMALL-SUBUNIT P53R2; DNA-DAMAGE RESPONSE; CHRONIC LYMPHOCYTIC-LEUKEMIA; ONCOGENE-INDUCED SENESCENCE; IN-VITRO; ESCHERICHIA-COLI; MAMMALIAN-CELLS; DEOXYCYTIDINE KINASE; MITOCHONDRIAL-DNA	Accurate DNA replication and repair is essential for proper development, growth and tumor-free survival in all multicellular organisms. A key requirement for the maintenance of genomic integrity is the availability of adequate and balanced pools of deoxyribonucleoside triphosphates (dNTPs), the building blocks of DNA. Notably, dNTP pool alterations lead to genomic instability and have been linked to multiple human diseases, including mitochondrial disorders, susceptibility to viral infection and cancer. In this review, we discuss how a key regulator of dNTP biosynthesis in mammals, the enzyme ribonucleotide reductase (RNR), impacts cancer susceptibility and serves as a target for anti-cancer therapies. Because RNR-regulated dNTP production can influence DNA replication fidelity while also supporting genome-protecting DNA repair, RNR has complex and stage-specific roles in carcinogenesis. Nevertheless, cancer cells are dependent on RNR for de novo dNTP biosynthesis. Therefore, elevated RNR expression is a characteristic of many cancers, and an array of mechanistically distinct RNR inhibitors serve as effective agents for cancer treatment. The dNTP metabolism machinery, including RNR, has been exploited for therapeutic benefit for decades and remains an important target for cancer drug development.	[Aye, Y.] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY USA; [Aye, Y.] Weill Cornell Med Coll, Dept Biochem, New York, NY USA; [Li, M.; Weiss, R. S.] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; [Long, M. J. C.] Brandeis Univ, Grad Program Biochem, Waltham, MA USA	Cornell University; Cornell University; Cornell University; Brandeis University	Aye, Y (corresponding author), 224 Baker Lab Chem & Chem Biol, Ithaca, NY 14853 USA.	ya222@cornell.edu; rsw26@cornell.edu		Long, marcus/0000-0002-0343-9671	ACCEL program; NSF [SBE-0547373]; President's Council of Cornell Women; Milstein sesquicentennial junior faculty fellowship; HHMI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [DP2GM114850] Funding Source: NIH RePORTER	ACCEL program; NSF(National Science Foundation (NSF)); President's Council of Cornell Women; Milstein sesquicentennial junior faculty fellowship; HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Professors Rick Cerione and Jennifer Surtees for helpful discussion and comments on the manuscript. YA acknowledges a faculty development grant from the ACCEL program supported by NSF (SBE-0547373), an Affinito-Stewart grant from the President's Council of Cornell Women and a Milstein sesquicentennial junior faculty fellowship. MJCL acknowledges an HHMI international student predoctoral fellowship.	Ahluwalia D, 2013, P NATL ACAD SCI USA, V110, P18596, DOI 10.1073/pnas.1310849110; Aird KM, 2014, CELL CYCLE, V13, P199, DOI 10.4161/cc.26953; Aird KM, 2013, CELL REP, V3, P1252, DOI 10.1016/j.celrep.2013.03.004; AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; Akita H, 2009, ONCOGENE, V28, P2903, DOI 10.1038/onc.2009.158; Alvarez-Salas LM, 2008, CURR TOP MED CHEM, V8, P1379, DOI 10.2174/156802608786141133; Anderson DD, 2012, J BIOL CHEM, V287, P7051, DOI 10.1074/jbc.M111.333120; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Avolio TM, 2007, ANTI-CANCER DRUG, V18, P377, DOI 10.1097/CAD.0b013e328013c04f; AVRAMIS VI, 1983, BIOCHEM BIOPH RES CO, V113, P35, DOI 10.1016/0006-291X(83)90428-X; Aye Y, 2012, J BIOL CHEM, V287, P35768, DOI 10.1074/jbc.M112.396911; Aye Y, 2012, CHEM BIOL, V19, P799, DOI 10.1016/j.chembiol.2012.05.015; Aye Y, 2011, P NATL ACAD SCI USA, V108, P9815, DOI 10.1073/pnas.1013274108; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; Bepler G, 2004, J CLIN ONCOL, V22, P1878, DOI 10.1200/JCO.2004.12.002; Bepler G, 2008, J THORAC ONCOL, V3, P1112, DOI 10.1097/JTO.0b013e3181874936; Bepler G, 2006, J CLIN ONCOL, V24, P4731, DOI 10.1200/JCO.2006.06.1101; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055; Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040; Burkhalter MD, 2009, DNA REPAIR, V8, P1258, DOI 10.1016/j.dnarep.2009.07.009; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chandra D, 2006, CELL, V125, P1333, DOI 10.1016/j.cell.2006.05.026; Chang LF, 2008, P NATL ACAD SCI USA, V105, P18519, DOI 10.1073/pnas.0803313105; Chaston TB, 2003, CLIN CANCER RES, V9, P402; Chimploy K, 2013, J BIOL CHEM, V288, P13145, DOI 10.1074/jbc.M113.461111; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; CORY JG, 1994, BIOCHEM PHARMACOL, V48, P335, DOI 10.1016/0006-2952(94)90105-8; Cotruvo JA, 2011, ANNU REV BIOCHEM, V80, P733, DOI 10.1146/annurev-biochem-061408-095817; Courbet S, 2008, NATURE, V455, P557, DOI 10.1038/nature07233; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Dong XP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092320; Duxbury MS, 2004, ONCOGENE, V23, P1539, DOI 10.1038/sj.onc.1207272; Duxbury MS, 2004, SURGERY, V136, P261, DOI 10.1016/j.surg.2004.04.029; ELFORD HL, 1970, J BIOL CHEM, V245, P5228; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Faderl S, 2005, BLOOD, V105, P940, DOI 10.1182/blood-2004-05-1933; Fairman JW, 2011, NAT STRUCT MOL BIOL, V18, P316, DOI 10.1038/nsmb.2007; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; FEIG DI, 1994, CANCER RES, V54, pS1890; Ferracin M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-123; Ferrandina G, 2010, CANCER CHEMOTH PHARM, V65, P679, DOI 10.1007/s00280-009-1073-y; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Finch RA, 2000, BIOCHEM PHARMACOL, V59, P983, DOI 10.1016/S0006-2952(99)00419-0; Fisher SB, 2013, CANCER-AM CANCER SOC, V119, P445, DOI 10.1002/cncr.27619; Fu Y, 2013, BIOCHEMISTRY-US, V52, P7050, DOI 10.1021/bi400781z; Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232; Gautam A, 2006, CANCER RES, V66, P6497, DOI 10.1158/0008-5472.CAN-05-4462; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gon S, 2011, P NATL ACAD SCI USA, V108, P19311, DOI 10.1073/pnas.1113664108; Gong WY, 2012, LUNG CANCER, V75, P374, DOI 10.1016/j.lungcan.2011.08.003; Gonzalez H, 1998, HEMATOL CELL THER, V40, P113; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Guittet O, 2008, NITRIC OXIDE-BIOL CH, V19, P84, DOI 10.1016/j.niox.2008.04.011; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; Hofer A, 2012, CRIT REV BIOCHEM MOL, V47, P50, DOI 10.3109/10409238.2011.630372; Hu CM, 2012, CANCER CELL, V22, P36, DOI 10.1016/j.ccr.2012.04.038; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Itoi T, 2007, J GASTROENTEROL, V42, P389, DOI 10.1007/s00535-007-2017-0; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Jordheim LP, 2011, LANCET ONCOL, V12, P693, DOI 10.1016/S1470-2045(10)70244-8; Jordheim LP, 2005, MOL CANCER THER, V4, P1268, DOI 10.1158/1535-7163.MCT-05-0121; Jorgensen CLT, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-541; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; King KM, 2006, MOL PHARMACOL, V69, P346, DOI 10.1124/mol.105.015768; Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; Lee Y, 2003, CANCER RES, V63, P2802; LEVIN VA, 1992, SEMIN ONCOL, V19, P34; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; Lindemalm S, 2004, CANCER LETT, V210, P171, DOI 10.1016/j.canlet.2004.03.007; Lis ET, 2008, DNA REPAIR, V7, P801, DOI 10.1016/j.dnarep.2008.02.007; Liu XY, 2006, CLIN CANCER RES, V12, P6337, DOI 10.1158/1078-0432.CCR-06-0799; Liu XY, 2013, CLIN SCI, V124, P567, DOI 10.1042/CS20120240; Liu XY, 2011, CANCER RES, V71, P3202, DOI 10.1158/0008-5472.CAN-11-0054; Lu AG, 2012, WORLD J GASTROENTERO, V18, P4704, DOI 10.3748/wjg.v18.i34.4704; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; Manegold C, 2000, INVEST NEW DRUG, V18, P29, DOI 10.1023/A:1006327729228; Mannava S, 2012, AGING-US, V4, P917, DOI 10.18632/aging.100512; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Mansson E, 2003, BIOCHEM PHARMACOL, V65, P237, DOI 10.1016/S0006-2952(02)01484-3; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; Matsushita S, 2012, J DERMATOL SCI, V68, P19, DOI 10.1016/j.jdermsci.2012.07.005; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Meyer Y, 2009, ANNU REV GENET, V43, P335, DOI 10.1146/annurev-genet-102108-134201; Minnihan EC, 2013, ACCOUNTS CHEM RES, V46, P2524, DOI 10.1021/ar4000407; Morikawa T, 2010, HISTOPATHOLOGY, V57, P885, DOI 10.1111/j.1365-2559.2010.03725.x; Morikawa T, 2010, HUM PATHOL, V41, P1742, DOI 10.1016/j.humpath.2010.06.001; Moss J, 2010, GENE DEV, V24, P2705, DOI 10.1101/gad.1970810; Nakahira S, 2007, INT J CANCER, V120, P1355, DOI 10.1002/ijc.22390; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Niida H, 2010, GENE DEV, V24, P333, DOI 10.1101/gad.1863810; Nocentini G, 1996, CRIT REV ONCOL HEMAT, V22, P89, DOI 10.1016/1040-8428(95)00187-5; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Nutting CM, 2009, ANN ONCOL, V20, P1275, DOI 10.1093/annonc/mdn775; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018; Ohtaka K, 2008, ONCOL REP, V20, P279, DOI 10.3892/or_00000004; Okumura H, 2006, CLIN CANCER RES, V12, P3740, DOI 10.1158/1078-0432.CCR-05-2416; Okumura H, 2005, BRIT J CANCER, V92, P284, DOI 10.1038/sj.bjc.6602322; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; Pfisterer J, 2005, INT J GYNECOL CANCER, V15, P36, DOI 10.1111/j.1525-1438.2005.15355.x; PLUNKETT W, 1987, CANCER RES, V47, P3005; Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200; Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109; Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105; Popovic-Bijelic A, 2011, J INORG BIOCHEM, V105, P1422, DOI 10.1016/j.jinorgbio.2011.07.003; Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045; Rampazzo C, 2010, MUTAT RES-GEN TOX EN, V703, P2, DOI 10.1016/j.mrgentox.2010.06.002; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1961, J BIOL CHEM, V236, P1150; Reischl D, 2009, NANOMED-NANOTECHNOL, V5, P8, DOI 10.1016/j.nano.2008.06.001; Reubold TF, 2012, CELL SIGNAL, V24, P1420, DOI 10.1016/j.cellsig.2012.03.007; Reynolds C, 2009, J CLIN ONCOL, V27, P5808, DOI 10.1200/JCO.2009.21.9766; Rodriguez J, 2011, EUR J CANCER, V47, P839, DOI 10.1016/j.ejca.2010.11.032; Rofougaran R, 2006, J BIOL CHEM, V281, P27705, DOI 10.1074/jbc.M605573200; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Sabouri N, 2008, NUCLEIC ACIDS RES, V36, P5660, DOI 10.1093/nar/gkn555; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; Sandler A, 1999, Oncologist, V4, P241; Saven A, 1998, BLOOD, V92, P1918, DOI 10.1182/blood.V92.6.1918; Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139; Shao J, 2006, CURR CANCER DRUG TAR, V6, P409, DOI 10.2174/156800906777723949; Sigal DS, 2010, BLOOD, V116, P2884, DOI 10.1182/blood-2010-02-246140; Sigmond J, 2010, ANTI-CANCER DRUG, V21, P591, DOI 10.1097/CAD.0b013e32833a3543; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Spasokoukotskaja T, 1998, ADV EXP MED BIOL, V431, P641; Spasokoukotskaja T, 1999, EUR J CANCER, V35, P1862, DOI 10.1016/S0959-8049(99)00223-3; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Stover PJ, 2012, CANCER CELL, V22, P3, DOI 10.1016/j.ccr.2012.06.010; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang H, 2013, CLIN CANCER RES, V19, P1577, DOI 10.1158/1078-0432.CCR-12-2321; Temperini C, 2006, BIOORG MED CHEM LETT, V16, P4316, DOI 10.1016/j.bmcl.2006.05.068; Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; ULLMAN B, 1980, J BIOL CHEM, V255, P8308; Uramoto H, 2006, ANTICANCER RES, V26, P983; Walker S, 2009, HEALTH TECHNOL ASSES, V13, P35, DOI 10.3310/hta13suppl1/06; Wang J, 2007, P NATL ACAD SCI USA, V104, P14324, DOI 10.1073/pnas.0706803104; Wang LM, 2012, CHINESE MED J-PEKING, V125, P2151, DOI 10.3760/cma.j.issn.0366-6999.2012.12.013; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; Wheeler LJ, 2005, DNA REPAIR, V4, P1450, DOI 10.1016/j.dnarep.2005.09.003; Wonganan P, 2012, CANCER BIOL THER, V13, P908, DOI 10.4161/cbt.20843; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; Xu X, 2008, CANCER RES, V68, P2652, DOI 10.1158/0008-5472.CAN-07-5873; Xue LJ, 2007, CANCER RES, V67, P16, DOI 10.1158/0008-5472.CAN-06-3200; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yanamoto S, 2005, CANCER LETT, V223, P67, DOI 10.1016/j.canlet.2004.10.019; Yanamoto S, 2003, CANCER LETT, V190, P233, DOI 10.1016/S0304-3835(02)00588-8; Yanamoto S, 2009, ORAL ONCOL, V45, P521, DOI 10.1016/j.oraloncology.2008.07.005; Yokomakura N, 2007, ONCOL REP, V18, P561; Zhang KQ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-11; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu LJ, 2009, BIOCHEM PHARMACOL, V78, P1178, DOI 10.1016/j.bcp.2009.06.103	181	227	233	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2011	2021		10.1038/onc.2014.155	http://dx.doi.org/10.1038/onc.2014.155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909171				2022-12-28	WOS:000353173400001
J	Ray, P; Stacer, AC; Fenner, J; Cavnar, SP; Meguiar, K; Brown, M; Luker, KE; Luker, GD				Ray, P.; Stacer, A. C.; Fenner, J.; Cavnar, S. P.; Meguiar, K.; Brown, M.; Luker, K. E.; Luker, G. D.			CXCL12-gamma in primary tumors drives breast cancer metastasis	ONCOGENE			English	Article							LUNG METASTASIS; CXCR4; EXPRESSION; CHEMOKINE; CELLS; ANGIOGENESIS; ISOFORMS; GROWTH; RECRUITMENT; DISRUPTION	Compelling evidence shows that chemokine C-X-C motif chemokine ligand 12 (CXCL12) drives metastasis in multiple malignancies. Similar to other key cytokines in cancer, CXCL12 exists as several isoforms with distinct biophysical properties that may alter signaling and functional outputs. However, effects of CXCL12 isoforms in cancer remain unknown. CXCL12-alpha, -beta and -gamma showed cell-type-specific differences in activating signaling through G protein-dependent pathways in cell-based assays, while CXCL12-gamma had greatest effects on recruitment of the adapter protein beta-arrestin 2. CXCL12-beta and -gamma also stimulated endothelial tube formation to a greater extent than CXCL12-alpha. To investigate the effects of CXCL12 isoforms on tumor growth and metastasis, we used a mouse xenograft model of metastatic human breast cancer combining CXCR4+ breast cancer cells and mammary fibroblasts secreting an isoform of CXCL12. Altough all CXCL12 isoforms produced comparable growth of mammary tumors, CXCL12-gamma significantly increased metastasis to bone marrow and other sites. Breast cancer cells originating from tumors with CXCL12-gamma fibroblasts upregulated RANKL (receptor activator of nuclear factor-kappa B ligand), contributing to bone marrow tropism of metastatic cancer cells. CXCL12-gamma was expressed in metastatic tissues in mice, and we also detected CXCL12-gamma in malignant pleural effusions from patients with breast cancer. In our mouse model, mammary fibroblasts disseminated to sites of breast cancer metastases, providing another mechanism to increase levels of CXCL12 in metastatic environments. These studies identify CXCL12-gamma as a potent pro-metastatic molecule with important implications for cancer biology and effective therapeutic targeting of CXCL12 pathways.	[Ray, P.; Stacer, A. C.; Fenner, J.; Meguiar, K.; Luker, K. E.; Luker, G. D.] Univ Michigan, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA; [Cavnar, S. P.; Luker, G. D.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; [Brown, M.; Luker, G. D.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Breast Oncol Program, Ann Arbor, MI 48109 USA; [Luker, G. D.] Univ Michigan Ctr, Dept Microbiol & Immunol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Radiol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu		luker, gary/0000-0001-6832-2581	United States National Institutes of Health [R01CA136553, R01CA136829, R01CA142750, P50CA093990]; NSF; Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE [R01CA136829, R01CA136553, R01CA142750, P50CA093990] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the United States National Institutes of Health grants R01CA136553, R01CA136829, R01CA142750 and P50CA093990. SPC was supported by an NSF predoctoral fellowship. Research was also supported by Fashion Footwear Association of New York (FFANY)/QVC presents Shoes on Sale.	Altenburg JD, 2007, J VIROL, V81, P8140, DOI 10.1128/JVI.00268-07; Brown Julie M, 2004, Cancer Treat Res, V118, P149; Cavnar SP, 2014, INTEGR BIOL-UK, V6, P564, DOI 10.1039/c4ib00015c; Chu QYD, 2010, J SURG RES, V159, P689, DOI 10.1016/j.jss.2008.09.020; Chueh BH, 2007, ANAL CHEM, V79, P3504, DOI 10.1021/ac062118p; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Diamond P, 2009, J BONE MINER RES, V24, P1150, DOI [10.1359/jbmr.090210, 10.1359/JBMR.090210]; Dona E, 2013, NATURE, V503, P285, DOI 10.1038/nature12635; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Duda DG, 2010, P NATL ACAD SCI USA, V107, P21677, DOI 10.1073/pnas.1016234107; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Gahan JC, 2012, J UROLOGY, V187, P827, DOI 10.1016/j.juro.2011.10.150; Guo P, 2001, CANCER RES, V61, P8569; Ho TK, 2010, J VASC SURG, V51, P689, DOI 10.1016/j.jvs.2009.10.044; Holland J, 2013, CELL REP; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286; Kloen P, 1997, CANCER, V80, P2230; Laguri C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001110; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Luker K, 2012, ONCOGENE, V31, P4570, DOI DOI 10.1038/0NC.2011.633; Luker KE, 2008, ANAL CHEM, V80, P5565, DOI 10.1021/ac8005457; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Luker KE, 2009, NEOPLASIA, V11, P1022, DOI 10.1593/neo.09724; Luker KE, 2009, BIOTECHNIQUES, V47, P625, DOI 10.2144/000113126; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nixon AB, 2013, CLIN CANCER RES, V19, P6957, DOI 10.1158/1078-0432.CCR-13-0926; Odemis V, 2012, GLIA, V60, P372, DOI 10.1002/glia.22271; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Park HR, 2003, J KOREAN MED SCI, V18, P541, DOI 10.3346/jkms.2003.18.4.541; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Rajagopal S, 2010, P NATL ACAD SCI USA, V107, P628, DOI 10.1073/pnas.0912852107; Ray P, INT J BIOCH CELL BIO, V44, P669; Rueda P, 2012, CIRCULATION, V126, P1882, DOI 10.1161/CIRCULATIONAHA.112.113290; Rueda P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002543; Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Shcherbo D, 2010, NAT METHODS, V7, P827, DOI [10.1038/NMETH.1501, 10.1038/nmeth.1501]; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Shu HKG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079768; Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756; Stumm R, 2007, J COMP NEUROL, V502, P382, DOI 10.1002/cne.21336; Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756-3282(99)00210-0; Venkiteswaran G, 2013, CELL, V155, P674, DOI 10.1016/j.cell.2013.09.046; Yu L, 2006, GENE, V374, P174, DOI 10.1016/j.gene.2006.02.001; Zannettino ACW, 2005, CANCER RES, V65, P1700, DOI 10.1158/0008-5472.CAN-04-1687; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zhang SS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-85; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036	55	47	47	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2043	2051		10.1038/onc.2014.157	http://dx.doi.org/10.1038/onc.2014.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909174	Green Accepted			2022-12-28	WOS:000353173400004
J	Li, S; Oh, YT; Yue, P; Khuri, FR; Sun, SY				Li, S.; Oh, Y-T; Yue, P.; Khuri, F. R.; Sun, S-Y			Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; KINASE INHIBITORS; MAMMALIAN TARGET; LIPID-METABOLISM; PHOSPHORYLATION; GROWTH; AKT; ACTIVATION; APOPTOSIS; PATHWAY	Cancer cells feature increased de novo lipogenesis. Sterol regulatory element-binding protein 1 (SREBP1), when presented in its mature form (mSREBP1), enhances lipogenesis by increasing transcription of several of its target genes. Mammalian target of rapamycin (mTOR) complexes, mTORC1 and mTORC2, are master regulators of cellular survival, growth and metabolism. A role for mTORC1 in the regulation of SREBP1 activity has been suggested; however, the connection between mTORC2 and SREBP1 has not been clearly established and hence is the focus of this study. mTOR kinase inhibitors (for example, INK128), which inhibit both mTORC1 and mTORC2, decreased mSREBP1 levels in various cancer cell lines. Knockdown of rictor, but not raptor, also decreased mSREBP1. Consistently, reduced mSREBP1 levels were detected in cells deficient in rictor or Sin1 compared with parent or rictor-deficient cells with re-expression of ectopic rictor. Hence it is mTORC2 inhibition that causes mSREBP1 reduction. As a result, expression of the mSREBP1 target genes acetyl-CoA carboxylase and fatty-acid synthase was suppressed, along with suppressed lipogenesis in cells exposed to INK128. Moreover, mSREBP1 stability was reduced in cells treated with INK128 or rictor knockdown. Inhibition of proteasome, GSK3 or the E3 ubiquitin ligase, FBXW7, prevented mSREBP1 reduction induced by mTORC2 inhibition. Thus mTORC2 inhibition clearly facilitates GSK3-dependent, FBXW7-mediated mSREBP1 degradation, leading to mSREBP1 reduction. Accordingly, we conclude that mTORC2 positively regulates mSREBP1 stability and lipogenesis. Our findings reveal a novel biological function of mTORC2 in the regulation of lipogenesis and warrant further study in this direction.	[Li, S.; Oh, Y-T; Yue, P.; Khuri, F. R.; Sun, S-Y] Emory Univ, Sch Med, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA; [Li, S.; Oh, Y-T; Yue, P.; Khuri, F. R.; Sun, S-Y] Winship Canc Inst, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA; [Li, S.] Beijing Inst Basic Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China	Emory University; Academy of Military Medical Sciences - China	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA.	ssun@emory.edu	Khuri, Fadlo R./AAU-4942-2020; Xia, Bo/P-9380-2016; LI, SHAOHUA/E-2733-2015	Khuri, Fadlo R./0000-0002-8638-7618; 	NIH/NCI [R01 CA118450, R01 CA160522]; Halpern Research Scholar award; NATIONAL CANCER INSTITUTE [R01CA160522, R01CA118450] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Halpern Research Scholar award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs B Vogelstein, MA Magnuson, B Su, DD Sarbassov and R Schweppes for providing us with some cell lines used in this work. We are also grateful to Dr A Hammond in our department for editing the manuscript. This study was supported by the NIH/NCI R01 CA118450 (SYS) and R01 CA160522 (SYS) and Halpern Research Scholar award (to SYS). FRK and SYS are Georgia Research Alliance Distinguished Cancer Scientists. SYS is a Halpern Research Scholar.	Agarwal NK, 2013, ONCOGENE, V32, P2521, DOI 10.1038/onc.2012.287; Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27; Bakan I, 2012, CURR OPIN LIPIDOL, V23, P226, DOI 10.1097/MOL.0b013e328352dd03; Bengoechea-Alonso MT, 2009, J BIOL CHEM, V284, P5885, DOI 10.1074/jbc.M807906200; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Espenshade PJ, 2006, J CELL SCI, V119, P973, DOI 10.1242/jcs02866; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Koo J, 2015, ONCOTARGET; Koo J, 2014, CANCER RES, V74, P2555, DOI 10.1158/0008-5472.CAN-13-2946; Laplante M, 2010, P NATL ACAD SCI USA, V107, P3281, DOI 10.1073/pnas.1000323107; Lewis CA, 2011, BIOCHEM SOC T, V39, P495, DOI 10.1042/BST0390495; Li WH, 2012, CELL CYCLE, V11, P2348, DOI 10.4161/cc.20811; Li XY, 2014, MOL CANCER THER, V13, P855, DOI 10.1158/1535-7163.MCT-13-0797; Liu W, 2011, BREAST CANCER RES TR, V128, P57, DOI 10.1007/s10549-010-1076-8; Ma KL, 2013, CARDIOVASC RES, V100, P450, DOI 10.1093/cvr/cvt203; MEDES G, 1953, CANCER RES, V13, P27; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Porstmann T, 2009, BIOCHEM SOC T, V37, P278, DOI 10.1042/BST0370278; Preuss E, 2013, J BIOL CHEM, V288, P35287, DOI 10.1074/jbc.M113.495986; Punga T, 2006, J BIOL CHEM, V281, P25278, DOI 10.1074/jbc.M604983200; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Sun SY, 2013, CANCER LETT, V340, P1, DOI 10.1016/j.canlet.2013.06.017; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Wang HZ, 2006, REPRODUCTION, V132, P485, DOI 10.1530/rep.1.01213; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Yuan MS, 2012, J BIOL CHEM, V287, P29579, DOI 10.1074/jbc.M112.386854; Zhao LQ, 2013, CANCER RES, V73, P1946, DOI 10.1158/0008-5472.CAN-12-3710	36	39	42	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					642	650		10.1038/onc.2015.123	http://dx.doi.org/10.1038/onc.2015.123			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893295	Green Accepted			2022-12-28	WOS:000369548800011
J	Vassallo, I; Zinn, P; Lai, M; Rajakannu, P; Hamou, MF; Hegi, ME				Vassallo, I.; Zinn, P.; Lai, M.; Rajakannu, P.; Hamou, M-F; Hegi, M. E.			WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1	ONCOGENE			English	Article							TYROSINE KINASE ROR2; GLIOMA-CELL LINES; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; COLON-CANCER; SELF-RENEWAL; BETA-CATENIN; STEM-CELLS; EXPRESSION; PATHWAY	Glioblastoma is the most aggressive primary brain tumor in adults and due to the invasive nature cannot be completely removed. The WNT inhibitory factor 1 (WIF1), a secreted inhibitor of WNTs, is systematically downregulated in glioblastoma and acts as strong tumor suppressor. The aim of this study was the dissection of WIF1-associated tumor-suppressing effects mediated by canonical and non-canonical WNT signaling. We found that WIF1 besides inhibiting the canonical WNT pathway selectively downregulates the WNT/calcium pathway associated with significant reduction of p38-MAPK (p38-mitogen-activated protein kinase) phosphorylation. Knockdown of WNT5A, the only WNT ligand overexpressed in glioblastoma, phenocopied this inhibitory effect. WIF1 expression inhibited cell migration in vitro and in an orthotopic brain tumor model, in accordance with the known regulatory function of the WNT/Ca2+ pathway on migration and invasion. In search of a mediator for this function differential gene expression profiles of WIF1-expressing cells were performed. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a long non-coding RNA and key positive regulator of invasion, emerged as the top downregulated gene. Indeed, knockdown of MALAT1 reduced migration in glioblastoma cells, without effect on proliferation. Hence, loss of WIF1 enhances the migratory potential of glioblastoma through WNT5A that activates the WNT/Ca2+ pathway and MALAT1. These data suggest the involvement of canonical and non-canonical WNT pathways in glioblastoma promoting key features associated with this deadly disease, proliferation on one hand and invasion on the other. Successful targeting will require a dual strategy affecting both canonical and non-canonical WNT pathways.	[Vassallo, I.; Rajakannu, P.; Hamou, M-F; Hegi, M. E.] Lausanne Univ Hosp CHUV, Neurosurg NCH, Lausanne, Switzerland; [Vassallo, I.; Rajakannu, P.; Hamou, M-F; Hegi, M. E.] Lausanne Univ Hosp CHUV, Neurosci Res Ctr CRN, Dept Clin Neurosci, CH-1066 Epalinges, Switzerland; [Zinn, P.] Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA; [Lai, M.] Ecole Polytech Fed Lausanne, Lab Funct & Metab Imaging LIFMET, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Baylor College of Medicine; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Hegi, ME (corresponding author), Lausanne Univ Hosp CHUV, Neurosci Res Ctr CRN, Dept Clin Neurosci, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	Monika.Hegi@chuv.ch	Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495	Swiss National Science Foundation [31003A_138116/1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The presented work was supported by the Swiss National Science Foundation (31003A_138116/1). The results published here are in part based on data generated by The Cancer TCGA Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/.	Andreeff M, 2008, LEUKEMIA, V22, P2041, DOI 10.1038/leu.2008.198; Bady P, 2012, NEURO-ONCOLOGY, V14, P701, DOI 10.1093/neuonc/nos072; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bitler BG, 2011, CANCER RES, V71, P6184, DOI 10.1158/0008-5472.CAN-11-1341; Boerboom D, 2006, CANCER RES, V66, P1964, DOI 10.1158/0008-5472.CAN-05-3493; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cawthorne Christopher, 2007, J Biomol Tech, V18, P120; Cheng RF, 2014, J CELL PHYSIOL, V229, P1908, DOI 10.1002/jcp.24566; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chuderland Dana, 2008, Commun Integr Biol, V1, P4; De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gotze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Habu M, 2014, J BIOCHEM, V156, P29, DOI 10.1093/jb/mvu015; Hutchinson JN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-39; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kamino M, 2011, CANCER SCI, V102, P540, DOI 10.1111/j.1349-7006.2010.01815.x; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370; Lal M, 2008, HUM MOL GENET, V17, P3105, DOI 10.1093/hmg/ddn208; Lambiv WL, 2011, NEURO-ONCOLOGY, V13, P736, DOI 10.1093/neuonc/nor036; Li GB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/780521; Li XY, 2013, MOL PHARMACEUT, V10, P307, DOI 10.1021/mp300445a; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Ma L, 2007, J BIOL CHEM, V282, P28980, DOI 10.1074/jbc.M702840200; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; O'Connell MP, 2009, J INVEST DERMATOL, V129, P1782, DOI 10.1038/jid.2008.433; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Polakis P, 2012, COLD SPRING HARB PER, V4; Pulvirenti T, 2011, CANCER RES, V71, P7280, DOI 10.1158/0008-5472.CAN-11-1531; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sciuscio D, 2011, CLIN CANCER RES, V17, P255, DOI 10.1158/1078-0432.CCR-10-1931; Semenov MV, 2007, CELL, V131, DOI 10.1016/j.cell.2007.12.011; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tano K, 2010, FEBS LETT, V584, P4575, DOI 10.1016/j.febslet.2010.10.008; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Wang Y, 2012, CANC LETT, V331, P139; Wick W, 2008, NEURO-ONCOLOGY, V10, P1019, DOI 10.1215/15228517-2008-058; Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007; Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Yu JM, 2007, CANCER LETT, V257, P172, DOI 10.1016/j.canlet.2007.07.011; Zhang ZN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090318	59	96	98	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					12	21		10.1038/onc.2015.61	http://dx.doi.org/10.1038/onc.2015.61			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772239	Green Submitted, Green Accepted			2022-12-28	WOS:000367812400002
J	Cheung, WKC; Nguyen, DX				Cheung, W. K. C.; Nguyen, D. X.			Lineage factors and differentiation states in lung cancer progression	ONCOGENE			English	Review							TRANSCRIPTION FACTOR-I; EPITHELIAL-MESENCHYMAL TRANSITION; GATA-6 ACTIVATES TRANSCRIPTION; BINDING-PROTEIN-ALPHA; SQUAMOUS-CELL; BETA-CATENIN; DOWN-REGULATION; C/EBP-ALPHA; STEM-CELLS; FUNCTIONAL-CHARACTERIZATION	Lung cancer encompasses a heterogeneous group of malignancies. Here we discuss how the remarkable diversity of major lung cancer subtypes is manifested in their transforming cell of origin, oncogenic dependencies, phenotypic plasticity, metastatic competence and response to therapy. More specifically, we review the increasing evidence that links this biological heterogeneity to the deregulation of cell lineage-specific pathways and the transcription factors that ultimately control them. As determinants of pulmonary epithelial differentiation, these poorly characterized transcriptional networks may underlie the etiology and biological progression of distinct lung cancers, while providing insight into innovative therapeutic strategies.	[Cheung, W. K. C.; Nguyen, D. X.] Yale Univ, Sch Med, Dept Pathol, Pathol & Canc Ctr, New Haven, CT 06520 USA; [Nguyen, D. X.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA	Yale University; Yale University	Nguyen, DX (corresponding author), Yale Univ, Sch Med, Dept Pathol, Pathol & Canc Ctr, POB 208023, New Haven, CT 06520 USA.	don.nguyen@yale.edu			Uniting Against Lung Cancer; National Cancer Institute [1R01CA166376, 1R21CA170537, 1R01CA191489]; NATIONAL CANCER INSTITUTE [R01CA191489, R01CA166376] Funding Source: NIH RePORTER	Uniting Against Lung Cancer; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Nguyen laboratory for their discussions and critical reviews of the manuscript. We apologize for omitting some examples and primary references due to space constraints. Our research is funded by grants from Uniting Against Lung Cancer (to WKCC) and the National Cancer Institute (1R01CA166376, 1R21CA170537 and 1R01CA191489 to DXN).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alam N, 2010, CLIN LUNG CANCER, V11, pE1, DOI 10.3816/CLC.2010.n.046; Allen TD, 2011, CANCER RES, V71, P6010, DOI 10.1158/0008-5472.CAN-11-0595; Allen TD, 2011, CANCER RES, V71, P2212, DOI 10.1158/0008-5472.CAN-10-3590; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Barletta JA, 2009, J CELL MOL MED, V13, P1977, DOI 10.1111/j.1582-4934.2008.00594.x; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basseres DS, 2012, LUNG CANCER, V77, P31, DOI 10.1016/j.lungcan.2012.01.011; Basseres DS, 2006, MOL CELL BIOL, V26, P1109, DOI 10.1128/MCB.26.3.1109-1123.2006; Belaguli NS, 2010, NEOPLASIA, V12, P856, DOI 10.1593/neo.10224; Berghmans T, 2006, ANN ONCOL, V17, P1673, DOI 10.1093/annonc/mdl287; Blanpain C, 2013, NAT CELL BIOL, V15, P126, DOI 10.1038/ncb2657; Bleckmann A, 2013, CLIN EXP METASTAS, V30, P471, DOI 10.1007/s10585-012-9552-7; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Capaccione KM, 2014, ONCOTARGET, V5, P3636, DOI 10.18632/oncotarget.1970; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chang DR, 2013, P NATL ACAD SCI USA, V110, P18042, DOI 10.1073/pnas.1311760110; Chen Y, 2015, J PATHOL, V235, P397, DOI 10.1002/path.4469; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Cohen J Craig, 2004, BMC Dev Biol, V4, P4; Cooke DT, 2010, ANN THORAC SURG, V90, P943, DOI 10.1016/j.athoracsur.2010.05.025; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Costa DB, 2006, LUNG CANCER, V53, P253, DOI 10.1016/j.lungcan.2006.04.011; Curtis SJ, 2010, CELL STEM CELL, V7, P127, DOI 10.1016/j.stem.2010.05.021; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Filosso PL, 2011, LUNG CANCER, V74, P25, DOI 10.1016/j.lungcan.2011.01.030; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Gao YJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5629; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Goss AM, 2009, DEV CELL, V17, P290, DOI 10.1016/j.devcel.2009.06.005; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Halmos B, 2002, CANCER RES, V62, P528; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hanna Jennifer M, 2013, J Carcinog, V12, P6, DOI 10.4103/1477-3163.109033; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; Ischenko I, 2014, CELL DEATH DIFFER, V21, P1218, DOI 10.1038/cdd.2014.38; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Iwakawa R, 2013, GENE CHROMOSOME CANC, V52, P802, DOI 10.1002/gcc.22076; Iwakawa R, 2011, CLIN CANCER RES, V17, P1481, DOI 10.1158/1078-0432.CCR-10-2484; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138; Jimenez FR, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-70; Juan J, 2014, GENE DEV, V28, P561, DOI 10.1101/gad.233627.113; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kamnasaran D, 2007, P NATL ACAD SCI USA, V104, P8053, DOI 10.1073/pnas.0611669104; Katoh H, 2012, NEOPLASIA, V14, P559, DOI 10.1593/neo.12330; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kim IJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2660; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lee JM, 2011, DIFFERENTIATION, V81, P261, DOI 10.1016/j.diff.2011.02.001; Lee KS, 2010, ONCOGENE, V29, P3349, DOI 10.1038/onc.2010.79; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Liang YL, 2014, J THORAC DIS, V6, P694, DOI 10.3978/j.issn.2072-1439.2014.04.09; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053817; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Lu Y, 2010, PLOS ONE, V5; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Mainardi S, 2014, P NATL ACAD SCI USA, V111, P255, DOI 10.1073/pnas.1320383110; Martis PC, 2006, DEVELOPMENT, V133, P1155, DOI 10.1242/dev.02273; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Minoo P, 1995, DEV BIOL, V172, P694, DOI 10.1006/dbio.1995.8080; Minoo P, 2007, MOL CELL BIOL, V27, P2155, DOI 10.1128/MCB.01133-06; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Nakagawa K, 2003, ANN THORAC SURG, V75, P1740, DOI 10.1016/S0003-4975(03)00022-5; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; Ooki A, 2010, ONCOGENE, V29, P3263, DOI 10.1038/onc.2010.76; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Park KS, 2011, CELL CYCLE, V10, P2806, DOI 10.4161/cc.10.16.17012; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Popat S, 2013, LUNG CANCER, V80, P1, DOI 10.1016/j.lungcan.2012.12.019; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Que JW, 2009, DEVELOPMENT, V136, P1899, DOI 10.1242/dev.034629; Quinlan MP, 2008, MOL CELL BIOL, V28, P2659, DOI 10.1128/MCB.01661-07; Rapp UR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006029; Rawlins EL, 2012, AM J RESP CELL MOL, V46, P269, DOI 10.1165/rcmb.2011-0372PS; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Reynolds SD, 2008, STEM CELLS, V26, P1337, DOI 10.1634/stemcells.2008-0053; Rockich BE, 2013, P NATL ACAD SCI USA, V110, pE4456, DOI 10.1073/pnas.1311847110; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Saito RA, 2009, CANCER RES, V69, P2783, DOI 10.1158/0008-5472.CAN-08-3490; Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906; Sato A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057013; Sato A, 2012, AM J RESP CELL MOL, V47, P454, DOI 10.1165/rcmb.2011-0239OC; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Shu WG, 2005, DEV BIOL, V283, P226, DOI 10.1016/j.ydbio.2005.04.014; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sinha S, 2008, GENOME RES, V18, P477, DOI 10.1101/gr.6828808; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Song H, 2012, P NATL ACAD SCI USA, V109, P17531, DOI 10.1073/pnas.1207238109; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Sutherland KD, 2010, MOL ONCOL, V4, P397, DOI 10.1016/j.molonc.2010.05.002; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tang XM, 2011, CLIN CANCER RES, V17, P2434, DOI 10.1158/1078-0432.CCR-10-1412; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Tomita T, 2008, J BIOL CHEM, V283, P25617, DOI 10.1074/jbc.M805140200; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Tremblay AM, 2014, CANCER CELL, V26, P273, DOI 10.1016/j.ccr.2014.05.029; Treutlein B, 2014, NATURE, V509, P371, DOI 10.1038/nature13173; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Uramoto H, 2011, LUNG CANCER, V73, P361, DOI 10.1016/j.lungcan.2011.01.008; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Vaughan AE, 2015, NATURE, V517, P621, DOI 10.1038/nature14112; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Waraya M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-397; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Watanabe H, 2013, CANCER CELL, V23, P707, DOI 10.1016/j.ccr.2013.05.013; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Watanabe S, 2013, LUNG CANCER, V82, P370, DOI 10.1016/j.lungcan.2013.06.003; WATSON WL, 1962, CANCER, V15, P759, DOI 10.1002/1097-0142(196207/08)15:4<759::AID-CNCR2820150410>3.0.CO;2-6; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xiao ZX, 2013, CANCER CELL, V23, P527, DOI 10.1016/j.ccr.2013.03.009; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Xu X, 2014, GENE DEV, V28, P1929, DOI 10.1101/gad.243717.114; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yamaguchi S, 2009, INT J CANCER, V124, P2577, DOI 10.1002/ijc.24217; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Yamashita K, 2008, MOL CANCER RES, V6, P31, DOI 10.1158/1541-7786.MCR-07-0213; Yan M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4661; Yanagawa N, 2007, LUNG CANCER, V58, P131, DOI 10.1016/j.lungcan.2007.05.011; Yang HH, 2002, DEVELOPMENT, V129, P2233; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Yin Z, 2006, AM J PHYSIOL-LUNG C, V291, pL191, DOI 10.1152/ajplung.00385.2005; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zheng Y, 2013, INT J BIOCHEM CELL B, V45, P2369, DOI 10.1016/j.biocel.2013.07.013; Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129; Zhou CH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-18; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	183	30	30	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5771	5780		10.1038/onc.2015.85	http://dx.doi.org/10.1038/onc.2015.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25823023	Green Accepted			2022-12-28	WOS:000365035200001
J	Pazarentzos, E; Bivona, TG				Pazarentzos, E.; Bivona, T. G.			Adaptive stress signaling in targeted cancer therapy resistance	ONCOGENE			English	Review							CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; NEGATIVE BREAST-CANCER; ANTI-EGFR THERAPY; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; MEK INHIBITION; ANDROGEN RECEPTOR; PROSTATE-CANCER; BRAF(V600E) INHIBITION	The identification of specific genetic alterations that drive the initiation and progression of cancer and the development of targeted drugs that act against these driver alterations has revolutionized the treatment of many human cancers. Although substantial progress has been achieved with the use of such targeted cancer therapies, resistance remains a major challenge that limits the overall clinical impact. Hence, despite progress, new strategies are needed to enhance response and eliminate resistance to targeted cancer therapies in order to achieve durable or curative responses in patients. To date, efforts to characterize mechanisms of resistance have primarily focused on molecular events that mediate primary or secondary resistance in patients. Less is known about the initial molecular response and adaptation that may occur in tumor cells early upon exposure to a targeted agent. Although understudied, emerging evidence indicates that the early adaptive changes by which tumor cells respond to the stress of a targeted therapy may be crucial for tumo r cell survival during treatment and the development of resistance. Here we review recent data illuminating the molecular architecture underlying adaptive stress signaling in tumor cells. We highlight how leveraging this knowledge could catalyze novel strategies to minimize or eliminate targeted therapy resistance, thereby unleashing the full potential of targeted therapies to transform many cancers from lethal to chronic or curable conditions.	[Pazarentzos, E.; Bivona, T. G.] Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94158 USA; [Pazarentzos, E.; Bivona, T. G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Bivona, TG (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, Dept Med, 600 16th St Genentech Hall,N212D, San Francisco, CA 94158 USA.	Trever.Bivona@ucsf.edu		Pazarentzos, Evangelos/0000-0002-5453-1646	NIH [NIH R01 CA169338]; Howard Hughes Medical Institute; Doris Duke Charitable Foundation; Searle Scholars Program; California Institute for Quantitative Biosciences; QB3@UCSF; NATIONAL CANCER INSTITUTE [DP2CA174497, R01CA169338, K08CA154787] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Searle Scholars Program; California Institute for Quantitative Biosciences; QB3@UCSF; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Bivona lab for critical review and thoughtful comments on the manuscript. We are grateful to the following funding sources: NIH Director's New Innovator Award, NIH R01 CA169338, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, Searle Scholars Program, California Institute for Quantitative Biosciences, QB3@UCSF (to TGB).	Ahmed KM, 2008, ONCOGENE, V27, P6738, DOI 10.1038/onc.2008.265; Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502; Aparicio A, 2011, CANCER DISCOV, V1, P466, DOI 10.1158/2159-8290.CD-11-0259; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Bailey ST, 2014, MOL CANCER RES, V12, P408, DOI 10.1158/1541-7786.MCR-13-0206-T; Baker NM, 2013, NATURE, V497, P577, DOI 10.1038/nature12248; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Chen XF, 2002, CANCER RES, V62, P1213; Chen YJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3575; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Duru N, 2014, J CANCER RES CLIN, V140, P1, DOI 10.1007/s00432-013-1494-1; Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Flanigan SA, 2013, CLIN CANCER RES, V19, P6219, DOI 10.1158/1078-0432.CCR-13-0145; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015; Godin-Heymann N, 2008, MOL CANCER THER, V7, P874, DOI 10.1158/1535-7163.MCT-07-2387; Goltsov A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00013; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Ishiguro Y, 2013, ONCOTARGET, V4, P550, DOI 10.18632/oncotarget.939; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Kirouac DC, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004008; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; McDonagh CF, 2012, MOL CANCER THER, V11, P582, DOI 10.1158/1535-7163.MCT-11-0820; Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Papa S, 2012, ADV EXP MED BIOL, V942, P3, DOI 10.1007/978-94-007-2869-1_1; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-4; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shi Y, 2005, INT J INF TECH DECIS, V4, P1; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watanabe S, 2013, LUNG CANCER, V82, P370, DOI 10.1016/j.lungcan.2013.06.003; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wetterskog D, 2014, ONCOGENE, V33, P966, DOI 10.1038/onc.2013.41; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	81	37	37	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5599	5606		10.1038/onc.2015.26	http://dx.doi.org/10.1038/onc.2015.26			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25703329	Green Submitted, Green Accepted			2022-12-28	WOS:000364594300001
J	Visciano, C; Liotti, F; Prevete, N; Cali, G; Franco, R; Collina, F; de Paulis, A; Marone, G; Santoro, M; Melillo, RM				Visciano, C.; Liotti, F.; Prevete, N.; Cali, G.; Franco, R.; Collina, F.; de Paulis, A.; Marone, G.; Santoro, M.; Melillo, R. M.			Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; EXPRESSION; CARCINOGENESIS; ANGIOGENESIS; PROGRESSION; MECHANISMS; IMMUNITY; ROLES	There is increasing evidence that mast cells (MCs) and their mediators are involved in the remodeling of the tumor microenvironment and promote tumor growth, angiogenesis and metastasis. We have found that an increased density of MCs in thyroid cancer (TC) correlates with enhanced invasiveness. However, the MC-derived factors responsible for this activity and the mechanisms by which they enhance TC invasiveness remain unidentified. Here, we report that MCs, when activated by TC cells, produce soluble factors that induce epithelial-to-mesenchymal transition (EMT) and stemness features of TC cells. We identified CXCL8/interleukin (IL)-8 as the main mediator contained in activated MC conditioned media (CM) capable of inducing both EMT and stemness of TC cells. Mechanistically, MC CM or exogenous IL-8 stimulated Akt phosphorylation and Slug expression in TC cells. The inhibition of the Akt pathway or depletion of the Slug transcription factor by RNA interference, reverted EMT and stemness responses. TC cells stably transfected with exogenous IL-8 underwent EMT, displayed increased stemness and enhanced tumorigenicity with respect to control cells. The analysis of TC surgical specimens by immunohistochemical analysis demonstrated a positive correlation between MC density (Tryptase(+) cells) and stemness features (OCT4 staining). Taken together, our data identify an MC-dependent IL-8-Akt-Slug pathway that sustains EMT/stemness of TC cells. The blockade of this circuit might be exploited for the therapy of advanced TC.	[Visciano, C.; Liotti, F.; Cali, G.; Santoro, M.; Melillo, R. M.] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, CNR G Salvato, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; [Prevete, N.; de Paulis, A.; Marone, G.] Univ Naples Federico II, Dipartimento Sci Med Traslaz, Ctr Interdipartimentale Ric Sci Immunol Base & Cl, I-80131 Naples, Italy; [Franco, R.; Collina, F.] Ist Nazl Fis Nucl, Struttura Complessa Anat Patol, Fdn G Pascale, I-80125 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale; Istituto Nazionale di Fisica Nucleare (INFN)	Melillo, RM (corresponding author), Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, CNR G Salvato, Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it	Liotti, Federica/AAC-1614-2019; melillo, rosa marina/O-5255-2015; Collina, Francesca/K-6763-2016	Liotti, Federica/0000-0002-0145-988X; Collina, Francesca/0000-0001-9862-3668; MELILLO, Rosa Marina/0000-0002-9233-5275; Franco, Renato/0000-0002-8340-3184; de Paulis, Amato/0000-0003-0347-2540	Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant 'Thyroid cancer and inflammation' [11827]; Italian Health Ministry grant 'Molecular diagnostic and prognostic markers of thyroid neoplasis' [RF-CAM-353005]; Istituto Superiore di Oncologia grant [MIUR PON01_02782/12]; Ministero della Salute; Regione Campania CISI-Lab Project; CREME Project; TIMING Project	Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant 'Thyroid cancer and inflammation'(Fondazione AIRC per la ricerca sul cancro); Italian Health Ministry grant 'Molecular diagnostic and prognostic markers of thyroid neoplasis'; Istituto Superiore di Oncologia grant; Ministero della Salute(Ministry of Health, Italy); Regione Campania CISI-Lab Project(Regione Campania); CREME Project; TIMING Project	We thank A Cerrato (IEOS, CNR, Naples) for helpful discussions and technical suggestions. We thank S Sequino for assistance in animal maintenance. We are grateful to PB Gupta (Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, MA, USA) for shSlug plasmids, to M Kajita (Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Atlanta) for the Slug myc plasmid and to BP Zhou (Department of Molecular and Cellular Oncology, Breast Cancer Basic Research Program, The University of Texas M. D. Anderson Cancer Center, Houston, Texas) for the FLAG Snail wt plasmid. Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant 11827 'Thyroid cancer and inflammation'; Italian Health Ministry grant RF-CAM-353005 'Molecular diagnostic and prognostic markers of thyroid neoplasis'; Istituto Superiore di Oncologia grant (MIUR PON01_02782/12); Ministero della Salute (Ricerca Finalizzata 2009-IZSM RF 2009), Regione Campania CISI-Lab Project, CREME Project and TIMING Project.	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186; Buehler D, 2013, MODERN PATHOL, V26, P54, DOI 10.1038/modpathol.2012.137; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Campbell LM, 2013, PHARMACEUTICALS, V6, P929, DOI 10.3390/ph6080929; Carling T, 2014, ANNU REV MED, V65, P125, DOI 10.1146/annurev-med-061512-105739; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dalton DK, 2012, CANCER IMMUNOL IMMUN, V61, P1511, DOI 10.1007/s00262-012-1246-0; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Fang WY, 2014, CARCINOGENESIS, V35, P1780, DOI 10.1093/carcin/bgu060; French JD, 2012, J CLIN ENDOCR METAB, V97, pE934, DOI 10.1210/jc.2011-3428; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hardy RG, 2007, AM J PATHOL, V171, P1037, DOI 10.2353/ajpath.2007.061211; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kwon MJ, 2013, INT J MOL SCI, V14, P18148, DOI 10.3390/ijms140918148; Lengner CJ, 2008, CELL CYCLE, V7, P725, DOI 10.4161/cc.7.6.5573; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Nehs MA, 2012, ENDOCRINOLOGY, V153, P985, DOI 10.1210/en.2011-1519; Nowak EC, 2012, J EXP MED, V209, P2127, DOI 10.1084/jem.20120408; Palena C, 2012, FUTURE ONCOL, V8, P713, DOI [10.2217/FON.12.59, 10.2217/fon.12.59]; Phay JE, 2013, ENDOCR-RELAT CANCER, V20, pR307, DOI 10.1530/ERC-13-0187; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ryder M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054302; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Salerno P, 2011, J CLIN ENDOCR METAB, V96, pE772, DOI 10.1210/jc.2010-1182; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shaik S, 2012, J EXP MED, V209, P1289, DOI 10.1084/jem.20112446; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Wang YM, 2013, INT J CLIN EXP PATHO, V6, P326; Wasiuk A, 2012, CANCER IMMUNOL IMMUN, V61, P2273, DOI 10.1007/s00262-012-1276-7; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei Q., 2012, THYROID, V22, P905	39	144	148	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5175	5186		10.1038/onc.2014.441	http://dx.doi.org/10.1038/onc.2014.441			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619830				2022-12-28	WOS:000362233400007
J	Park, Y; Kim, W; Lee, JM; Park, J; Cho, JK; Pang, K; Lee, J; Kim, D; Park, SW; Yang, KM; Kim, SJ				Park, Y.; Kim, W.; Lee, J-M; Park, J.; Cho, J. K.; Pang, K.; Lee, J.; Kim, D.; Park, S-W; Yang, K-M; Kim, S-J			Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF-beta 1 tumor suppressor activity by binding to Smad3 to interrupt its complex formation with Smad4	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; TGF-BETA; DAP-KINASE; DOWN-REGULATION; APOPTOSIS; PROTEIN; GENE; PATHWAYS; RECEPTOR	Head and neck squamous cell carcinoma (HNSCC) is an extremely aggressive cancer with a poor prognosis and low patient survival. Because chemotherapy for advanced HNSCC is often ineffective, discovering new therapeutic targets that are important for HNSCC development and progression and elucidating their molecular mechanisms are required. In the present study, we describe the role of DRAK1 (death-associated protein kinase-related apoptosis-inducing kinase 1) as a novel negative regulator of the transforming growth factor-beta (TGF-beta) tumor suppressor signaling pathway for the first time in human HNSCC cells. DRAK1 was significantly overexpressed in primary human HNSCCs and in HNSCC cell lines. Through gain-and loss-of-function experiments, we demonstrated that the DRAK1 expression level regulated TGF-beta 1-induced transcriptional activity and expression of the tumor suppressor gene p21Waf1/Cip1. DRAK1 depletion enhanced TGF-beta 1-induced growth inhibition in vitro and suppressed tumorigenicity in xenograft models in vivo. Mechanistically, DRAK1 was predominantly localized in the cytoplasm and bound to Smad3, thereby interrupting Smad3/Smad4 complex formation, which is the core process for the induction of tumor suppressor genes by TGF-beta 1. Thus, our findings suggest that cytoplasmic DRAK1 increases tumorigenic potential through inhibition of TGF-beta 1-mediated tumor suppressor activity in HNSCC cells and may be a potential therapeutic target for HNSCCs.	[Park, Y.; Kim, W.; Lee, J-M; Park, J.; Cho, J. K.; Pang, K.; Lee, J.; Kim, D.; Yang, K-M; Kim, S-J] CHA Univ, CHA Canc Inst, Seoul 135081, South Korea; [Kim, W.] CHA Univ, Coll Med, Seoul 135081, South Korea; [Lee, J-M; Park, J.] CHA Univ, Coll Pharm, Seoul 135081, South Korea; [Cho, J. K.; Pang, K.; Lee, J.; Kim, S-J] CHA Univ, Dept Biomed Sci, Seoul 135081, South Korea; [Park, S-W] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	Pochon Cha University; Pochon Cha University; Pochon Cha University; Pochon Cha University; Seoul National University (SNU)	Yang, KM (corresponding author), CHA Univ, CHA Canc Inst, Dept Biomed Sci, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	kmyang@cha.ac.kr; kimsj@cha.ac.kr			National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning [NRF-2012M3A9C4048735, NRF-2009-0081756, NRF-2014R1A1A1005186]	National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning	This research was supported by the Bio-Synergy Research Project (NRF-2012M3A9C4048735 to S-JK), Bio & Medical Technology Development Program (NRF-2009-0081756 to S-JK) and Basic Science Research Program (NRF-2014R1A1A1005186 to K-MY), through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning.	Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Itoh S, 2007, CURR OPIN CELL BIOL, V19, P176, DOI 10.1016/j.ceb.2007.02.015; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Koukourakis MI, 2006, J CLIN ONCOL, V24, P727, DOI 10.1200/JCO.2005.02.7474; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Mao P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081803; Mao P, 2011, J BIOL CHEM, V286, P19381, DOI 10.1074/jbc.M111.218040; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Peng CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023452; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Qiu W, 2007, CANCER LETT, V245, P163, DOI 10.1016/j.canlet.2006.01.003; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Watanabe Y, 2010, MOL CELL, V37, P123, DOI 10.1016/j.molcel.2009.10.028; Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187; White RA, 2010, ONCOGENE, V29, P5437, DOI 10.1038/onc.2010.306; Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P409, DOI 10.1001/archotol.132.4.409; Worsham MJ, 2003, ARCH OTOLARYNGOL, V129; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Yang KM, 2013, CANCER RES, V73, P6679, DOI 10.1158/0008-5472.CAN-13-0891; Yang KM, 2012, CELL REP, V2, P1286, DOI 10.1016/j.celrep.2012.09.028; Ye H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-69	33	26	27	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5037	5045		10.1038/onc.2014.423	http://dx.doi.org/10.1038/onc.2014.423			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531329				2022-12-28	WOS:000361693300004
J	Kumar, S; Das, S; Rachagani, S; Kaur, S; Joshi, S; Johansson, SL; Ponnusamy, MP; Jain, M; Batra, SK				Kumar, S.; Das, S.; Rachagani, S.; Kaur, S.; Joshi, S.; Johansson, S. L.; Ponnusamy, M. P.; Jain, M.; Batra, S. K.			NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer	ONCOGENE			English	Article							NUCLEAR RECEPTOR COACTIVATOR; GENE-EXPRESSION; RETINOIC ACID; BREAST-CANCER; POTENTIAL ROLE; GROWTH; ACTIVATION; SRC-3; AIB1; PROGRESSION	Pancreatic cancer (PC) is characterized by aberrant overexpression of mucins that contribute to its pathogenesis. Although the inflammatory cytokines contribute to mucin overexpression, the mucin profile of PC is markedly distinct from that of normal or inflamed pancreas. We postulated that de novo expression of various mucins in PC involves chromatin modifications. Analysis of chromatin modifying enzymes by PCR array identified differential expression of NCOA3 in MUC4-expressing PC cell lines. Immunohistochemistry analysis in tumor tissues from patients and spontaneous mouse models, and microarray analysis following the knockdown of NCOA3 were performed to elucidate its role in mucin regulation and overall impact on PC. Silencing of NCOA3 in PC cell lines resulted in significant downregulation of two most differentially expressed mucins in PC, MUC4 and MUC1 (P<0.01). Immunohistochemistry analysis in PC tissues and metastatic lesions established an association between NCOA3 and mucin (MUC1 and MUC4) expression. Spontaneous mouse model of PC (K-rasG12D; Pdx-1cre) showed early expression of Ncoa3 during preneoplastic lesions. Mechanistically, NCOA3 knockdown abrogated retinoic acid-mediated MUC4 upregulation by restricting MUC4 promoter accessibility as demonstrated by micrococcus nuclease digestion (P<0.05) and chromatin immuno-precipitation analysis. NCOA3 also created pro-inflammatory conditions by upregulating chemokines like CXCL1, 2, 5 and CCL20 (P<0.001). AKT, ubiquitin C, ERK1/2 and NF-kappa B occupied dominant nodes in the networks significantly modulated after NCOA3 silencing. In addition, NCOA3 stabilized mucins post translationally through fucosylation by FUT8, as the knockdown of FUT8 resulted in the downregulation of MUC4 and MUC1 at protein levels.	[Kumar, S.; Das, S.; Rachagani, S.; Kaur, S.; Joshi, S.; Ponnusamy, M. P.; Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Johansson, S. L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	Das, Srustidhar/GVU-1044-2022	Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	NIH [TMEN U54 CA163120, RO1 CA183459, EDRN UO1, CA111294, SPORE P50 CA127297, RO3 CA167342]; NATIONAL CANCER INSTITUTE [U01CA111294, U54CA163120, P50CA127297, R03CA167342, R01CA183459] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Lynette Smith, Dr Joshua Souchek, Ms Kavita Mallya, Dr Neeru Sharma and Dr Parama Dey for help in statistical analysis and technical support. Microarray analysis was performed using BRB-Array Tools developed by Dr. Richard Simon and BRB-Array Development Team. The work was supported, in parts, by grants from the NIH (TMEN U54 CA163120, RO1 CA183459, EDRN UO1, CA111294, SPORE P50 CA127297 and RO3 CA167342).	Al-Otaiby M, 2012, AM J PATHOL, V180, P1474, DOI 10.1016/j.ajpath.2011.12.032; Andrianifahanana M, 2005, ONCOGENE, V24, P6143, DOI 10.1038/sj.onc.1208756; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; Braat H, 2012, CANCER LETT, V318, P1, DOI 10.1016/j.canlet.2011.11.034; Brown K, 2003, J BIOL CHEM, V278, P39402, DOI 10.1074/jbc.M307832200; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chakraborty S, 2010, J CLIN PATHOL, V63, P579, DOI 10.1136/jcp.2010.076125; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dey P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026926; Dharmaraj N, 2010, MOL ENDOCRINOL, V24, P2253, DOI 10.1210/me.2009-0448; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Grzesiak JJ, 2007, PANCREAS, V35, P293, DOI 10.1097/mpa.0b013e31811f4526; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Harigopal M, 2009, BREAST CANCER RES TR, V115, P77, DOI 10.1007/s10549-008-0063-9; Hawker NP, 2007, J INVEST DERMATOL, V127, P874, DOI 10.1038/sj.jid.5700624; Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kawano T, 2008, INT J ONCOL, V33, P153; Koo JS, 2002, EXP LUNG RES, V28, P315, DOI 10.1080/01902140252964393; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Lahusen T, 2007, CANCER RES, V67, P7256, DOI 10.1158/0008-5472.CAN-07-1013; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li J, 2012, MOL CELL BIOCHEM, V364, P29, DOI 10.1007/s11010-011-1201-y; Li X, 2003, J DENT RES, V82, P883, DOI 10.1177/154405910308201107; Li Z, 2012, WORLD J GASTROENTERO, V18, P855, DOI 10.3748/wjg.v18.i8.855; Lin HL, 2011, AM J PHYSIOL-RENAL, V300, pF1017, DOI 10.1152/ajprenal.00426.2010; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; McCarroll JA, 2006, GUT, V55, P79, DOI 10.1136/gut.2005.064543; Mejias-Luque R, 2010, ONCOGENE, V29, P1753, DOI 10.1038/onc.2009.467; Moniaux N, 2008, BRIT J CANCER, V98, P1540, DOI 10.1038/sj.bjc.6604329; Nakles RE, 2011, MOL ENDOCRINOL, V25, P549, DOI 10.1210/me.2010-0114; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Okuyama N, 2006, INT J CANCER, V118, P2803, DOI 10.1002/ijc.21728; Percharde M, 2013, CELL CYCLE, V12, P195, DOI 10.4161/cc.23377; Rachagani S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-68; Reid G, 2009, INT J BIOCHEM CELL B, V41, P155, DOI 10.1016/j.biocel.2008.08.028; Rieder S, 2011, ANTI-CANCER AGENT ME, V11, P427, DOI 10.2174/187152011795677454; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939; Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; York B, 2010, P NATL ACAD SCI USA, V107, P11122, DOI 10.1073/pnas.1005262107; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Zhao C, 2003, CANCER, V98, P18, DOI 10.1002/cncr.11482	57	23	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4879	4889		10.1038/onc.2014.409	http://dx.doi.org/10.1038/onc.2014.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25531332	Green Accepted			2022-12-28	WOS:000361050000008
J	Ryland, KE; Svoboda, LK; Vesely, ED; McIntyre, JC; Zhang, L; Martens, JR; Lawlor, ER				Ryland, K. E.; Svoboda, L. K.; Vesely, E. D.; McIntyre, J. C.; Zhang, L.; Martens, J. R.; Lawlor, E. R.			Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stress	ONCOGENE			English	Article							STEM-CELLS; DIFFERENTIAL EXPRESSION; GROUP PROTEINS; ION CHANNELS; K+ CHANNELS; KV1.5; APOPTOSIS; HYPOXIA; BMI-1; METABOLISM	Relapse after clinical remission remains a leading cause of cancer-associated death. Although the mechanisms of tumor relapse are complex, the ability of cancer cells to survive physiological stress is a prerequisite for recurrence. Ewing sarcoma (ES) and neuroblastoma (NB) are aggressive cancers that frequently relapse after initial remission. In addition, both tumors overexpress the polycomb group (PcG) proteins BMI-1 and EZH2, which contribute to tumorigenicity. We have discovered that ES and NB resist hypoxic stress-induced death and that survival depends on PcG function. Epigenetic repression of developmental programs is the most well-established cancer-associated function of PcG proteins. However, we noted that voltage-gated potassium (Kv) channel genes are also targets of PcG regulation in stem cells. Given the role of potassium in regulating apoptosis, we reasoned that repression of Kv channel genes might have a role in cancer cell survival. Here we describe our novel finding that PcG-dependent repression of the Kv1.5 channel gene KCNA5 contributes to cancer cell survival under conditions of stress. We show that survival of cancer cells in stress is dependent upon suppression of Kv1.5 channel function. The KCNA5 promoter is marked in cancer cells with PcG-dependent chromatin repressive modifications that increase in hypoxia. Genetic and pharmacological inhibition of BMI-1 and EZH2, respectively, restore KCNA5 expression, which sensitizes cells to stress-induced death. In addition, ectopic expression of the Kv1.5 channel induces apoptotic cell death under conditions of hypoxia. These findings identify a novel role for PcG proteins in promoting cancer cell survival via repression of KCNA5.	[Ryland, K. E.; Vesely, E. D.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Ryland, K. E.; Svoboda, L. K.; Lawlor, E. R.] Univ Michigan, Translat Oncol Program, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [McIntyre, J. C.; Zhang, L.; Martens, J. R.] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Lawlor, E. R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; State University System of Florida; University of Florida; University of Michigan System; University of Michigan	Martens, JR (corresponding author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, POB 100267, Gainesville, FL 32610 USA.	martensj@ufl.edu; elawlor@med.umich.edu			CureSearch Children's Oncology Group; Nick Currey Fund; National Institutes of Health [1R01 CA134604, R01HL070973, AACR-SU2C IRG-1309]; Pharmacological Sciences Training Program [T32 GM007767]; UM Cancer Biology Training grant [5T32 CA009676-20]; NATIONAL CANCER INSTITUTE [R01CA134604, T32CA009676] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	CureSearch Children's Oncology Group; Nick Currey Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmacological Sciences Training Program; UM Cancer Biology Training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of the Lawlor and Martens labs for helpful discussion. This research was supported by grants from the CureSearch Children's Oncology Group and Nick Currey Fund, the National Institutes of Health grants 1R01 CA134604 (to ERL), R01HL070973 (to JRM), AACR-SU2C IRG-1309 (to ERL), Pharmacological Sciences Training Program T32 GM007767 (to KER) and UM Cancer Biology Training grant 5T32 CA009676-20 (to LKS).	Archer SL, 2008, AM J PHYSIOL-HEART C, V294, pH570, DOI 10.1152/ajpheart.01324.2007; Arvind S, 2012, BRIT J NEUROSURG, V26, P16, DOI 10.3109/02688697.2011.583365; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bielanska J, 2009, CURR CANCER DRUG TAR, V9, P904, DOI 10.2174/156800909790192400; Bielanska J, 2012, CANCER INVEST, V30, P203, DOI 10.3109/07357907.2012.654872; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Burg ED, 2006, J MEMBRANE BIOL, V209, P3, DOI 10.1007/s00232-005-0838-4; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; Caouette D, 2003, N-S ARCH PHARMACOL, V368, P479, DOI 10.1007/s00210-003-0834-0; Cooper A, 2011, CLIN CANCER RES, V17, P56, DOI 10.1158/1078-0432.CCR-10-1417; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Fedida D, 1995, AM J PHYSIOL-CELL PH, V494, P377; Felipe A, 2012, CURR MED CHEM, V19, P661, DOI 10.2174/092986712798992048; Fiske JL, 2006, CANCER METAST REV, V25, P493, DOI 10.1007/s10555-006-9017-z; Fraser SP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0105; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gutman GA, 2003, PHARMACOL REV, V55, P583, DOI 10.1124/pr.55.4.9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heshe D, 2011, CANCER CHEMOTH PHARM, V67, P647, DOI 10.1007/s00280-010-1361-6; Huang X, 2014, J CELL BIOL, V206, P151, DOI 10.1083/jcb.201404136; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772; Karki P, 2007, CELL DEATH DIFFER, V14, P2068, DOI 10.1038/sj.cdd.4402221; Lang F, 2012, COMPR PHYSIOL, V2, P2037, DOI 10.1002/cphy.c110046; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Lawlor ER, 2002, ONCOGENE, V21, P307, DOI 10.1038/sj.onc.1205053; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McEwen DP, 2007, J BIOL CHEM, V282, P29612, DOI 10.1074/jbc.M704402200; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; MILLER C, 2000, GENOME BIOL, V1, P4; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Pardo LA, 2014, NAT REV CANCER, V14, P39, DOI 10.1038/nrc3635; Platoshyn O, 2006, AM J PHYSIOL-CELL PH, V290, pC907, DOI 10.1152/ajpcell.00028.2005; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Schumacher SM, 2010, HEART RHYTHM, V7, P1309, DOI 10.1016/j.hrthm.2010.02.017; Schumacher SM, 2009, CIRC RES, V104, P1390, DOI 10.1161/CIRCRESAHA.108.192773; Semenza GL, 2013, ONCOGENE, V32, P4057, DOI 10.1038/onc.2012.578; Shieh CC, 2000, PHARMACOL REV, V52, P557; Stapels M, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000502; Stump GL, 2005, J PHARMACOL EXP THER, V315, P1362, DOI 10.1124/jpet.105.092197; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Urrego D, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0094; Vallejo-Gracia A, 2013, J LEUKOCYTE BIOL, V94, P779, DOI 10.1189/jlb.0213094; VanWagoner DR, 1997, CIRC RES, V80, P772; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961; WANG ZG, 1993, CIRC RES, V73, P276, DOI 10.1161/01.RES.73.2.276; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135	59	13	13	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4591	4600		10.1038/onc.2014.384	http://dx.doi.org/10.1038/onc.2014.384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435365	Green Accepted			2022-12-28	WOS:000360189300005
J	Loskutov, YV; Kozyulina, PY; Kozyreva, VK; Ice, RJ; Jones, BC; Roston, TJ; Smolkin, MB; Ivanov, AV; Wysolmerski, RB; Pugacheva, EN				Loskutov, Y. V.; Kozyulina, P. Y.; Kozyreva, V. K.; Ice, R. J.; Jones, B. C.; Roston, T. J.; Smolkin, M. B.; Ivanov, A. V.; Wysolmerski, R. B.; Pugacheva, E. N.			NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTORS; GROWTH-FACTOR; MEMBRANE TRAFFICKING; ARF6 GTPASE; WILD-TYPE; MT1-MMP; ACTIVATION; PROTEIN; NEDD9; MIGRATION	NEDD9 is an established marker of invasive and metastatic cancers. NEDD9 downregulation has been shown to dramatically reduce cell invasion and metastasis in multiple tumors. The mechanisms by which NEDD9 regulates invasion are largely unknown. In the current study, we have found that NEDD9 is required for matrix metalloproteinase 14 (MMP14) enzymatic recovery/recycling through the late endosomes to enable disengagement of tissue inhibitor of matrix metalloproteinase 2 (TIMP2) and tumor invasion. Depletion of NEDD9 decreases targeting of the MMP14/TIMP2 complex to late endosomes and increases trafficking of MMP14 from early/sorting endosomes back to the surface in a small GTPase ADP ribosylation factor-6 (Arf6)-dependent manner. NEDD9 directly binds to Arf6-GTPase-activating protein, ARAP3 and Arf6-effector GGA3, thereby facilitating the Arf6 inactivation required for MMP14/TIMP2 targeting to late endosomes. Re-expression of NEDD9 or a decrease in Arf6 activity is sufficient to restore MMP14 activity and the invasive properties of tumor cells. Importantly, NEDD9 inhibition by Vivo-Morpholinos, an antisense therapy, decreases primary tumor growth and metastasis in xenograft models of breast cancer. Collectively, our findings uncover a novel mechanism to control tumor-cell dissemination through NEDD9/Arf6-dependent regulation of MMP14/TIMP2 trafficking, and validate NEDD9 as a clinically relevant therapeutic target to treat metastatic cancer.	[Loskutov, Y. V.; Kozyreva, V. K.; Ice, R. J.; Ivanov, A. V.; Wysolmerski, R. B.; Pugacheva, E. N.] W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; [Kozyulina, P. Y.; Jones, B. C.; Roston, T. J.; Ivanov, A. V.; Pugacheva, E. N.] W Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Smolkin, M. B.] W Virginia Univ, Sch Med, Dept Pathol, Morgantown, WV 26506 USA; [Wysolmerski, R. B.] W Virginia Univ, Sch Med, Dept Neurobiol & Anat, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University; West Virginia University	Pugacheva, EN (corresponding author), Robert C Byrd Hlth Sci Ctr, MBRCC Rm 2823,1 Med Ctr Dr, Morgantown, WV 26506 USA.	epugacheva@hsc.wvu.edu	Kozyulina, Polina/AAO-2762-2020; Jones, Brandon/AAB-6130-2019	Kozyulina, Polina/0000-0001-8520-3445; Jones, Brandon/0000-0002-3743-2590; Ivanov, Alexey/0000-0002-8617-4604; Loskutov, Juergen/0000-0003-3472-4093; Kozyreva, Varvara/0000-0003-3447-0070	Mary Babb Randolph Cancer Center; NIH [P20 RR016440, P30 RR032138/GM103488, P20 RR016477, P30 GM103488, P30 RR032138, RCP1101809]; NIH-NCI [CA148671]; Susan G Komen For the Cure Foundation [KG100539]; NIH/NCRR [5 P20 RR016440-09]; NATIONAL CANCER INSTITUTE [R21CA208875, R01CA148671] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P30RR032138, P20RR016440, P20RR016477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103488] Funding Source: NIH RePORTER	Mary Babb Randolph Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen For the Cure Foundation(Susan G. Komen Breast Cancer Foundation); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Mrs Yoho and Drs Schaller and Weed for critically reading the manuscript and providing administrative support during manuscript preparation. We also thank the West Virginia University Microscope Imaging Facility, supported by the Mary Babb Randolph Cancer Center and NIH grants P20 RR016440, P30 RR032138/GM103488 and P20 RR016477. The WVU Flow Cytometry Core Facility was supported by NIH grants P30 GM103488, P30 RR032138 and RCP1101809. We also thank Mr Farrugia for his assistance in the analysis of the microarray data. This work was supported by grants from the NIH-NCI (CA148671 to ENP), the Susan G Komen For the Cure Foundation (KG100539 to ENP) and in part by NIH/NCRR (5 P20 RR016440-09).	Ahn J, 2012, J CELL SCI, V125, P1814, DOI 10.1242/jcs.101444; Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Anders N, 2008, CELL MOL LIFE SCI, V65, P3433, DOI 10.1007/s00018-008-8227-7; Anilkumar N, 2005, FASEB J, V19, P1326, DOI 10.1096/fj.04-3651fje; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cai DP, 2003, J IMMUNOL, V170, P969, DOI 10.4049/jimmunol.170.2.969; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1437, DOI 10.1074/mcp.M600050-MCP200; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Giampieri S, 2010, CANCER RES, V70, P3435, DOI 10.1158/0008-5472.CAN-10-0466; Gu JJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002632; Hafner M, 2006, NATURE, V444, P941, DOI 10.1038/nature05415; Hakulinen J, 2008, J CELL BIOCHEM, V105, P1211, DOI 10.1002/jcb.21923; Hattula K, 2006, J CELL SCI, V119, P4866, DOI 10.1242/jcs.03275; Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Ice RJ, 2013, CANCER RES, V73, P3168, DOI 10.1158/0008-5472.CAN-12-4008; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kondo S, 2012, CLIN CANCER RES, V18, P6326, DOI 10.1158/1078-0432.CCR-11-2162; Little JL, 2014, ONCOGENE, V33, P411, DOI 10.1038/onc.2012.607; Lucas JT, 2010, ONCOGENE, V29, P4449, DOI 10.1038/onc.2010.185; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; McLaughlin SL, 2014, MOL CANCER RES, V12, P69, DOI 10.1158/1541-7786.MCR-13-0300; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Oblander SA, 2005, DEV BIOL, V277, P255, DOI 10.1016/j.ydbio.2004.09.033; Pahwa S, 2014, CANCERS, V6, P416, DOI 10.3390/cancers6010416; Paleotti O, 2005, J BIOL CHEM, V280, P21661, DOI 10.1074/jbc.m503099200; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Remacle AG, 2006, ONCOGENE, V25, P5648, DOI 10.1038/sj.onc.1209572; Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x; Sakagami H, 2008, TOHOKU J EXP MED, V214, P191, DOI 10.1620/tjem.214.191; Santy LC, 2005, CURR BIOL, V15, P1749, DOI 10.1016/j.cub.2005.08.052; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; Schweitzer JK, 2011, SEMIN CELL DEV BIOL, V22, P39, DOI 10.1016/j.semcdb.2010.09.002; Shteyn E, 2011, J CELL BIOL, V194, P873, DOI 10.1083/jcb.201106010; Spang A, 2010, FEBS LETT, V584, P2646, DOI 10.1016/j.febslet.2010.04.005; Speranza MC, 2012, ONCOTARGET, V3, P724; Strongin AY, 2010, BBA-MOL CELL RES, V1803, P133, DOI 10.1016/j.bbamcr.2009.04.009; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Vonderheit A, 2005, PLOS BIOL, V3, P1225, DOI 10.1371/journal.pbio.0030233; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Williams KC, 2011, J BIOL CHEM, V286, P43405, DOI 10.1074/jbc.M111.297069; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025; Zhong J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035058; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007	61	23	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3662	3675		10.1038/onc.2014.297	http://dx.doi.org/10.1038/onc.2014.297			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241893	Green Accepted			2022-12-28	WOS:000357679100005
J	Perez, E; Das, G; Bergmann, A; Baehrecke, EH				Perez, E.; Das, G.; Bergmann, A.; Baehrecke, E. H.			Autophagy regulates tissue overgrowth in a context-dependent manner	ONCOGENE			English	Article							CELL-DEATH; GROWTH ARREST; DROSOPHILA; CANCER; RAS; EXPRESSION; TUMORS; NOTCH; PROLIFERATION; TUMORIGENESIS	Autophagy is a catabolic process that has been implicated both as a tumor suppressor and in tumor progression. Here, we investigate this dichotomy in cancer biology by studying the influence of altered autophagy in Drosophila models of tissue overgrowth. We find that the impact of altered autophagy depends on both genotype and cell type. As previously observed in mammals, decreased autophagy suppresses Ras-induced eye epithelial overgrowth. In contrast, autophagy restricts epithelial overgrowth in a Notch-dependent eye model. Even though decreased autophagy did not influence Hippo pathway-triggered overgrowth, activation of autophagy strongly suppresses this eye epithelial overgrowth. Surprisingly, activation of autophagy enhanced Hippo pathway-driven overgrowth in glia cells. These results indicate that autophagy has different influences on tissue growth in distinct contexts, and highlight the importance of understanding the influence of autophagy on growth to augment a rationale therapeutic strategy.	[Perez, E.; Das, G.; Bergmann, A.; Baehrecke, E. H.] Univ Massachusetts, Dept Canc Biol, Sch Med, Worcester, MA 01505 USA	University of Massachusetts System; University of Massachusetts Worcester	Baehrecke, EH (corresponding author), Univ Massachusetts, Dept Canc Biol, Sch Med, 364 Plantat St, Worcester, MA 01505 USA.	Andreas.Bergmann@umassmed.edu; Eric.Baehrecke@umassmed.edu		Bergmann, Andreas/0000-0002-9134-871X	NIH [GM068016, CA159314]; NATIONAL CANCER INSTITUTE [R01CA159314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068016] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T Chang, M Dominguez, M Freeman, G Halder, G Juhasz, M Kango-Singh, TP Neufeld, the Bloomington Stock Center, the VDRC for flies and antibodies, J Lindblad, C Nelson and T Fortier for technical support, and the Bergmann and Baehrecke labs for constructive comments. This work was supported by NIH grants GM068016 to AB and CA159314 to EHB. EHB is an Ellison Medical Foundation Scholar.	Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; BOS JL, 1989, CANCER RES, V49, P4682; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Chang TK, 2013, NAT CELL BIOL, V15, P1067, DOI 10.1038/ncb2804; Chang YY, 2009, MOL BIOL CELL, V20, P2004, DOI 10.1091/mbc.E08-12-1250; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Dutta S, 2008, CURR BIOL, V18, P1466, DOI 10.1016/j.cub.2008.08.052; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/bse0530141, 10.1042/BSE0530141]; Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karim FD, 1998, DEVELOPMENT, V125, P1; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; McPhee CK, 2009, BBA-MOL CELL RES, V1793, P1452, DOI 10.1016/j.bbamcr.2009.02.009; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pircs K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044214; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Reddy BVVG, 2011, DEVELOPMENT, V138, P5201, DOI 10.1242/dev.069385; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rudrapatna VA, 2012, DEV DYNAM, V241, P107, DOI 10.1002/dvdy.22771; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053; Shravage BV, 2013, DEVELOPMENT, V140, P1321, DOI 10.1242/dev.089490; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tipping M, 2014, J CELL PHYSIOL, V229, P27, DOI 10.1002/jcp.24427; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076	41	29	30	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3369	3376		10.1038/onc.2014.285	http://dx.doi.org/10.1038/onc.2014.285			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174403	Bronze, Green Accepted			2022-12-28	WOS:000356871700003
J	Zhu, B; Yan, K; Li, L; Lin, M; Zhang, S; He, Q; Zheng, D; Yang, H; Shao, G				Zhu, B.; Yan, K.; Li, L.; Lin, M.; Zhang, S.; He, Q.; Zheng, D.; Yang, H.; Shao, G.			K63-linked ubiquitination of FANCG is required for its association with the Rap80-BRCA1 complex to modulate homologous recombination repair of DNA interstand crosslinks	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; BINDING PROTEIN; DAMAGE RESPONSE; DEUBIQUITINATING ENZYME; CANCER SUSCEPTIBILITY; TARGETS BRCA1; ANEMIA; PATHWAY; REPLICATION; GENE	DNA interstrand crosslinks (ICLs) are extremely deleterious lesions that are repaired by homologous recombination (HR) through coordination of Fanconi anemia (FA) proteins and breast cancer susceptibility gene 1 (BRCA1) product, but the exact role these proteins have remains unclear. Here we report that FANCG was modified by the addition of lysine63-linked polyubiquitin chains (K63Ub) in response to DNA damage. We show that FANCG K63Ub was dispensable for monoubiquitination of FANCD2, but was required for FANCG to interact with the Rap80-BRCA1 (receptor-associated protein 80-BRCA1) complex for subsequent modulation of HR repair of ICLs induced by mitomycin C. Mutation of three lysine residues within FANCG to arginine (K182, K258 and K347, 3KR) reduced FANCG K63Ub modification, as well as its interaction with the Rap80-BRCA1 complex, and therefore impeded HR repair. In addition, we demonstrated that K63Ub-modified FANCG was deubiquitinated by BRCC36 complex in vitro and in vivo. Inhibition of BRCC36 resulted in increased K63Ub modification of FANCG. Taken together, our results identify a new role of FANCG in HR repair of ICL through K63Ub-mediated interaction with the Rap80-BRCA1 complex.	[Zhu, B.; Yan, K.; Li, L.; Lin, M.; Zhang, S.; Yang, H.; Shao, G.] Peking Univ, Sch Basic Med Sci, Dept fo Cell Biol, Beijing 100191, Peoples R China; [Zhu, B.; Shao, G.] Peking Univ, Inst Syst Biol, Beijing 100191, Peoples R China; [He, Q.] Peking Univ, Ctr Med & Hlth Anal, Beijing 100191, Peoples R China; [Zheng, D.] Shenzhen Univ, Sch Med, Shenzhen, Guangdong, Peoples R China	Peking University; Peking University; Peking University; Shenzhen University	Yang, H (corresponding author), Peking Univ, Sch Basic Med Sci, Dept fo Cell Biol, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	yanghua@bjmu.edu.cn; gzshao@bjmu.edu.cn	Li, Li/B-8842-2019	Li, Li/0000-0002-8630-3699	Beijing Natural Science Foundation [7122099]; Natural Science Foundation of China [81272915]; Research Fund for the Doctoral Program of Higher Education [20110001110013]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry [JWSL44-8]; 985 Program, Ministry of Education of China	Beijing Natural Science Foundation(Beijing Natural Science Foundation); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education(Research Fund for the Doctoral Program of Higher Education of China (RFDP)); Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry(Scientific Research Foundation for the Returned Overseas Chinese Scholars); 985 Program, Ministry of Education of China(Ministry of Education, China)	This work was supported by Beijing Natural Science Foundation (Grant 7122099); Natural Science Foundation of China (Grant 81272915); the Research Fund for the Doctoral Program of Higher Education (20110001110013); the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (JWSL44-8); 985 Program, Ministry of Education of China.	Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Bin W, 2007, P NATL ACAD SCI USA, V104, P20759, DOI 10.1073/pnas.0710061104; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Coleman KA, 2011, J BIOL CHEM, V286, P13669, DOI 10.1074/jbc.M110.213728; Cooper EM, 2010, J BIOL CHEM, V285, P10344, DOI 10.1074/jbc.M109.059667; Cooper EM, 2009, EMBO J, V28, P621, DOI 10.1038/emboj.2009.27; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Deans AJ, 2009, MOL CELL, V36, P943, DOI 10.1016/j.molcel.2009.12.006; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Enoiu M, 2012, NUCLEIC ACIDS RES, V40, P8953, DOI 10.1093/nar/gks670; Feng L, 2012, NAT STRUCT MOL BIOL, V19, P201, DOI 10.1038/nsmb.2211; Feng L, 2010, J BIOL CHEM, V285, P30982, DOI 10.1074/jbc.M110.135392; Feng L, 2009, GENE DEV, V23, P719, DOI 10.1101/gad.1770609; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Greenberg RA, 2006, GENE DEV, V20, P34, DOI 10.1101/gad.1381306; Hofmann K, 2009, DNA REPAIR, V8, P544, DOI 10.1016/j.dnarep.2009.01.003; Hu YD, 2011, GENE DEV, V25, P685, DOI 10.1101/gad.2011011; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621; Kim Y, 2011, NAT GENET, V43, P142, DOI 10.1038/ng.750; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Kratz K, 2010, CELL, V142, P77, DOI 10.1016/j.cell.2010.06.022; Liu ZX, 2007, NAT STRUCT MOL BIOL, V14, P716, DOI 10.1038/nsmb1279; Long DT, 2011, SCIENCE, V333, P84, DOI 10.1126/science.1204258; MacKay C, 2010, CELL, V142, P65, DOI 10.1016/j.cell.2010.06.021; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Moldovan GL, 2009, ANNU REV GENET, V43, P223, DOI 10.1146/annurev-genet-102108-134222; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nakanishi K, 2011, NAT STRUCT MOL BIOL, V18, P500, DOI 10.1038/nsmb.2029; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Raschle M, 2008, CELL, V134, P969, DOI 10.1016/j.cell.2008.08.030; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sato Y, 2009, EMBO J, V28, P2461, DOI 10.1038/emboj.2009.160; Shao G, P NATL ACAD SCI; Shao G, 2009, GENE DEV, V23, P740, DOI 10.1101/gad.1739609; Sims JJ, 2009, MOL CELL, V33, P775, DOI 10.1016/j.molcel.2009.02.011; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Smogorzewska A, 2010, MOL CELL, V39, P36, DOI 10.1016/j.molcel.2010.06.023; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Stoepker C, 2011, NAT GENET, V43, P138, DOI 10.1038/ng.751; Thompson LH, 2009, MUTAT RES-FUND MOL M, V668, P54, DOI 10.1016/j.mrfmmm.2009.02.003; Tischkowitz MD, 2003, J MED GENET, V40, P1, DOI 10.1136/jmg.40.1.1; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang B, 2009, GENE DEV, V23, P729, DOI 10.1101/gad.1770309; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Weake VM, 2008, MOL CELL, V29, P653, DOI 10.1016/j.molcel.2008.02.014; Wilson JB, 2008, ONCOGENE, V27, P3641, DOI 10.1038/sj.onc.1211034; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yan ZJ, 2012, MOL CELL, V47, P61, DOI 10.1016/j.molcel.2012.05.026; Yang YG, 2005, CARCINOGENESIS, V26, P1731, DOI 10.1093/carcin/bgi134; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	72	15	16	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2867	2878		10.1038/onc.2014.229	http://dx.doi.org/10.1038/onc.2014.229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25132264				2022-12-28	WOS:000355324300006
J	Wang, S; Dong, Y; Zhang, Y; Wang, X; Xu, L; Yang, S; Li, X; Dong, H; Xu, L; Su, L; Ng, SSM; Chang, Z; Sung, JJ; Zhang, X; Yu, J				Wang, S.; Dong, Y.; Zhang, Y.; Wang, X.; Xu, L.; Yang, S.; Li, X.; Dong, H.; Xu, L.; Su, L.; Ng, S. S. M.; Chang, Z.; Sung, J. J.; Zhang, X.; Yu, J.			DACT2 is a functional tumor suppressor through inhibiting Wnt/beta-catenin pathway and associated with poor survival in colon cancer	ONCOGENE			English	Article							BETA-CATENIN; COLORECTAL-CANCER; SIGNALING-PATHWAY; WNT; EPIGENETICS; ROLES; TRANSCRIPTION; MECHANISMS; PROTEINS; DAPPER	Dapper homolog (DACT) 2 is one of the Dact gene family members, which are important modulators of Wnt signaling pathway. We aim to clarify its epigenetic inactivation, biological function and clinical implication in colon cancer. DACT2 was silenced in five out of eight colon cancer cell lines, but robustly expressed in normal colon tissues. The loss of DACT2 expression was regulated by promoter hypermethylation. Restoring DACT2 expression in colon cancer cell lines suppressed tumor cell growth by inducing cell apoptosis and inhibiting cell proliferation both in vitro and in vivo. Moreover, DACT2 overexpression effectively reduced lung metastasis of colon cancer cells in nude mice. These effects by DACT2 were attributed to inhibition of Wnt/beta-catenin signaling. Reexpression of DACT2 significantly suppressed the transcriptional activity of both wild-type beta-catenin and degradation-resistant form mutant beta-catenin (S33Y). DACT2 could actively shuttle into and out of nuclei, with its predominant steady-state localization in the cytoplasm dependent on its nuclear export signal. Co-immunoprecipitation results indicated that DACT2 strongly associated beta-catenin as well as lymphoid enhancer-binding factor 1 (LEF1) and directly disrupted the formation of the beta-catenin-LEF1 complex in the nucleus. Whereas in the cytoplasm, DACT2 restored junctional localization of E-cadherin-beta-catenin complexes and prevented beta-catenin nuclear translocation through direct interaction with beta-catenin. DACT2 methylation was detected in 43.3% (29/67) of colon cancer tissues, but none in normal controls. Multivariate analysis revealed that patients with DACT2 methylation had a significant decrease in overall survival (P = 0.006). Kaplan-Meier survival curves showed that DACT2 methylation was significantly associated with shortened survival in stage I-III colon cancer patients. In conclusion, DACT2 acts as a functional tumor suppressor in colon cancer through inhibiting Wnt/beta-catenin signaling. Its methylation at early stages of colon carcinogenesis is an independent prognostic factor.	[Wang, S.; Dong, H.; Xu, L.; Su, L.; Zhang, X.] Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Res Ctr Bioengn & Sensing Technol, Beijing 100083, Peoples R China; [Wang, S.; Dong, Y.; Wang, X.; Xu, L.; Li, X.; Sung, J. J.; Yu, J.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis,Dept Med & Therapeut,State Key La, Shatin, Hong Kong, Peoples R China; [Dong, Y.; Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Zhang, Y.; Yang, S.; Chang, Z.] Tsinghua Univ, Sch Life Sci, Sch Med, State Key Lab Biomembrane & Membrane Biotechnol,N, Beijing 100084, Peoples R China	University of Science & Technology Beijing; Chinese University of Hong Kong; Chinese University of Hong Kong; Tsinghua University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	zhangxueji@ustb.edu.cn; junyu@cuhk.edu.hk	Zhang, Yanquan/D-5615-2017; zhang, xueji/ABE-6497-2020; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Li, Xiao-xing/B-9114-2008; Ng, Simon S. M./M-1219-2018; Chang, Zhijie/AAH-8109-2019	Zhang, Yanquan/0000-0003-3527-9972; zhang, xueji/0000-0002-0035-3821; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Li, Xiao-xing/0000-0001-8791-7505; Ng, Simon S. M./0000-0002-5389-9297; Hou, Jian/0000-0003-1590-4013; Chang, Zhijie/0000-0003-1567-3227	Postdoctoral Special Foundation [2012M510317]; National Natural Science Foundation of China [81301775]; Chinese Central Universities Funds [FRF-TP-12-172A]; 863 Program China [2012AA02A506]; 973 Program China [2013CB531401]; Technology and Innovation Project Fund Shenzhen [JSGG20130412171021059]	Postdoctoral Special Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Central Universities Funds; 863 Program China(National High Technology Research and Development Program of China); 973 Program China(National Basic Research Program of China); Technology and Innovation Project Fund Shenzhen	This project was supported by Postdoctoral Special Foundation (2012M510317), National Natural Science Foundation of China (81301775), the Chinese Central Universities Funds (FRF-TP-12-172A), National Natural Science Foundation of China (81301775), 863 Program China (2012AA02A506), 973 Program China (2013CB531401) and Technology and Innovation Project Fund Shenzhen (JSGG20130412171021059).	Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Brott BK, 2005, DIFFERENTIATION, V73, P323, DOI 10.1111/j.1432-0436.2005.00032.x; Cadigan K.M., 2012, COLD SPRING HARB PER, V4; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009; Choi SW, 2010, ADV NUTR, V1, P8, DOI 10.3945/an.110.1004; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hsieh CJ, 1998, CANCER RES, V58, P3942; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213, DOI 10.1111/j.1349-7006.2002.tb01226.x; Jia Y, 2013, J PATHOL, V230, P194, DOI 10.1002/path.4073; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katsurano M, 2012, ONCOGENE, V31, P342, DOI 10.1038/onc.2011.241; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kivimae S, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-33; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Liu YH, 2010, J AM SOC NEPHROL, V21, P212, DOI 10.1681/ASN.2008121226; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Metcalfe C, 2011, J CELL SCI, V124, P3537, DOI 10.1242/jcs.091991; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2009, ADV EXP MED BIOL, V656, P13, DOI 10.1007/978-1-4419-1145-2_2; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Suriben R, 2009, NAT GENET, V41, P977, DOI 10.1038/ng.435; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wang SY, 2012, MOL MED, V18, P1402, DOI 10.2119/molmed.2012.00243; Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520; Wei W, 2012, MOL CELL BIOL, V32, P3903, DOI 10.1128/MCB.00251-12; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Yu J, 2006, HEPATOLOGY, V43, P826, DOI 10.1002/hep.21108; Yu J, 2010, ONCOGENE, V29, P6464, DOI 10.1038/onc.2010.370; Yuan GH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034004; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200	39	39	43	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2575	2585		10.1038/onc.2014.201	http://dx.doi.org/10.1038/onc.2014.201			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023701	Green Published, hybrid			2022-12-28	WOS:000354541300004
J	Dahmani, R; Just, PA; Delay, A; Canal, F; Finzi, L; Prip-Buus, C; Lambert, M; Sujobert, P; Buchet-Poyau, K; Miller, E; Cavard, C; Marmier, S; Terris, B; Billaud, M; Perret, C				Dahmani, R.; Just, P-A; Delay, A.; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Buchet-Poyau, K.; Miller, E.; Cavard, C.; Marmier, S.; Terris, B.; Billaud, M.; Perret, C.			A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR LKB1; SPLICE VARIANT; CANCER; MUSCLE; INACTIVATION; REVEALS; PATHWAY; LINK	The LKB1 tumor suppressor gene encodes a master kinase that coordinates the regulation of energetic metabolism and cell polarity. We now report the identification of a novel isoform of LKB1 (named Delta N-LKB1) that is generated through alternative transcription and internal initiation of translation of the LKB1 mRNA. The Delta N-LKB1 protein lacks the N-terminal region and a portion of the kinase domain. Although Delta N-LKB1 is catalytically inactive, it potentiates the stimulating effect of LKB1 on the AMP-activated protein kinase (AMPK) metabolic sensor through a direct interaction with the regulatory autoinhibitory domain of AMPK. In contrast, Delta N-LKB1 negatively interferes with the LKB1 polarizing activity. Finally, combining in vitro and in vivo approaches, we showed that Delta N-LKB1 has an intrinsic oncogenic property. Delta N-LKB1 is expressed solely in the lung cancer cell line, NCI-H460. Silencing of Delta N-LKB1 decreased the survival of NCI-H460 cells and inhibited their tumorigenicity when engrafted in nude mice. In conclusion, we have identified a novel LKB1 isoform that enhances the LKB1-controlled AMPK metabolic activity but inhibits LKB1-induced polarizing activity. Both the LKB1 tumor suppressor gene and the oncogene Delta N-LKB1 are expressed from the same locus and this may account for some of the paradoxical effects of LKB1 during tumorigenesis.	[Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] Inst Cochin Genet Mol, INSERM, U1016, F-75014 Paris, France; [Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] CNRS, UMR8104, Paris, France; [Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] Univ Paris 05, Paris, France; [Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] LNCC, Equipe Labellisee, Paris, France; [Delay, A.; Buchet-Poyau, K.; Billaud, M.] UJF, INSERM, Inst Albert Bonniot, CRI,U823, F-38706 La Tronche, France; [Miller, E.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA; [Terris, B.] Hop Cochin, Pathol Unit, F-75674 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Boston University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Billaud, M (corresponding author), UJF, INSERM, Inst Albert Bonniot, CRI,U823, F-38706 La Tronche, France.	Marc.Billaud@ujf-grenoble.fr; christine.perret@inserm.fr	Terris, Benoit/P-1497-2017; PRIP-BUUS, Carina/P-9084-2017; Perret-Mayeux, Christine/L-3297-2017; JUST, Pierre-Alexandre/P-1972-2017; sujobert, pierre/N-8149-2017	Miller, Edward/0000-0002-2156-5962; perret, christine/0000-0003-4710-7051; Prip-Buus, Carina/0000-0002-2153-7857	INSERM; LNCC (France) 'Equipe labelisee Ligue Nationale Contre le Cancer'; INCA grants; LABEX Who amI?; LNCC fellowship	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); LNCC (France) 'Equipe labelisee Ligue Nationale Contre le Cancer'; INCA grants; LABEX Who amI?; LNCC fellowship	We thank Graham Hardie and Simon Hawley (University of Dundee, Dundee, UK) for their helpful comments and valuable scientific input into our work and also for their kindness in providing us with different antibodies and reagents to measure the LKB1-controlled AMPK activity and to test the role of Delta N-LKB1 on different ARKs. We are also grateful to Christelle Forcet, Nicolas Aznar and Maya Ghawitian from Billaud's laboratory for their help with the analysis of LKB1-induced polarizing activity. We are indebted to Benoit Viollet and Marc Foretz for providing us with AMPK plasmids and helpful discussions. We thank Pascal Maire (from Inserm U1016, Paris, France) and all people of the team for helpful discussions, suggestions and critical reading of the manuscript. We are grateful to Helene Blons (HEGP, Paris, France) and Sylvie Grazzeri (Inserm U823, Grenoble, France) for providing the lung cancer cell lines and some lung tumors, respectively. We also thank Veronique Lenoir and Catherine Esnous for technical help in fatty acid oxidation experiments, and animal facility of Institut Cochin for maintenance of mouse colonies. Core fundings came from INSERM, grants from LNCC (France) 'Equipe labelisee Ligue Nationale Contre le Cancer', INCA grants and LABEX Who amI?. RD was funded by an LNCC fellowship.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/nchembio.610, 10.1038/NCHEMBIO.610]; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Friedrichsen M, 2013, MOL CELL ENDOCRINOL, V366, P204, DOI 10.1016/j.mce.2012.06.013; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Ikeda Y, 2009, J BIOL CHEM, V284, P35839, DOI 10.1074/jbc.M109.057273; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kottakis F, 2012, CELL RES, V22, P1617, DOI 10.1038/cr.2012.108; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Neu-Yilik G, 2011, RNA, V17, P843, DOI 10.1261/rna.2401811; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Richter EA, 2009, BIOCHEM J, V418, P261, DOI 10.1042/BJ20082055; Rose AJ, 2009, J PHYSIOL-LONDON, V587, P1547, DOI 10.1113/jphysiol.2008.167528; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zeqiraj E, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000126	33	16	16	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2337	2346		10.1038/onc.2014.182	http://dx.doi.org/10.1038/onc.2014.182			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24998845				2022-12-28	WOS:000353824800007
J	Noy, PJ; Lodhia, P; Khan, K; Zhuang, X; Ward, DG; Verissimo, AR; Bacon, A; Bicknell, R				Noy, P. J.; Lodhia, P.; Khan, K.; Zhuang, X.; Ward, D. G.; Verissimo, A. R.; Bacon, A.; Bicknell, R.			Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth	ONCOGENE			English	Article							LECTIN-LIKE DOMAIN; ENDOTHELIAL MARKERS; IDENTIFICATION; EXPRESSION; ADHESION; CELLS	We previously identified CLEC14A as a tumour endothelial marker. Here we show that CLEC14A is a regulator of sprouting angiogenesis in vitro and in vivo. Using a human umbilical vein endothelial cell spheroid-sprouting assay, we found CLEC14A to be a regulator of sprout initiation. Analysis of endothelial sprouting in aortic ring and in vivo subcutaneous sponge assays from clec14a(+/+) and clec14a(-/-) mice revealed defects in sprouting angiogenesis in CLEC14A-deficient animals. Tumour growth was retarded and vascularity reduced in clec14a(-/)-mice. Pull-down and co-immunoprecipitation experiments confirmed that MMRN2 binds to the extracellular region of CLEC14A. The CLEC14A-MMRN2 interaction was interrogated using mouse monoclonal antibodies. Monoclonal antibodies were screened for their ability to block this interaction. Clone C4, but not C2, blocked CLEC14A-MMRN2 binding. C4 antibody perturbed tube formation and endothelial sprouting in vitro and in vivo, with a similar phenotype to loss of CLEC14A. Significantly, tumour growth was impaired in C4-treated animals and vascular density was also reduced in the C4-treated group. We conclude that CLEC14A-MMRN2 binding has a role in inducing sprouting angiogenesis during tumour growth, which has the potential to be manipulated in future antiangiogenic therapy design.	[Noy, P. J.; Lodhia, P.; Khan, K.; Zhuang, X.; Verissimo, A. R.; Bicknell, R.] Univ Birmingham, Sch Med, Coll Med & Dent Sci, Angiogenesis Lab,Inst Biomed Res,Sch Immun & Infe, Birmingham, W Midlands, England; [Noy, P. J.; Lodhia, P.; Khan, K.; Zhuang, X.; Verissimo, A. R.; Bicknell, R.] Univ Birmingham, Sch Med, Coll Med & Dent Sci, Angiogenesis Lab,Inst Biomed Res,Sch Canc Sci, Birmingham, W Midlands, England; [Ward, D. G.] Univ Birmingham, Sch Canc Sci, Inst Canc Studies, Birmingham, W Midlands, England; [Bacon, A.] Univ Birmingham, Sch Med, Inst Biomed Res, Sch Immun & Infect, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Bicknell, R (corresponding author), Univ Birmingham, Sch Med, Coll Med & Dent Sci, Angiogenesis Lab,Inst Biomed Res,Sch Immun & Infe, Birmingham, W Midlands, England.	r.bicknell@bham.ac.uk	Khan, Kabir/U-8350-2018	Khan, Kabir/0000-0001-8453-3485; Bicknell, Roy/0000-0002-0941-8919; Noy, Peter/0000-0001-6142-8957; Zhuang, Alan Xiaodong/0000-0002-6870-9003	Cancer Research UK (CRUK) [C4719/A6766]; Portuguese Fundacao para a Ciencia e tecnologia; Technology Strategy Board [KTP007696]; MRC; University of Birmingham; Medical Research Council [1304704] Funding Source: researchfish	Cancer Research UK (CRUK)(Cancer Research UK); Portuguese Fundacao para a Ciencia e tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Technology Strategy Board; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Birmingham; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Dr Laurens van der Flier, Somantix and Dr Raj Mehta, Cancer Research Technology, for helpful discussions. PN was funded by Cancer Research UK (CRUK, grant number C4719/A6766 to RB). The Portuguese Fundacao para a Ciencia e tecnologia funded AV. XZ was funded by a knowledge transfer partnership (KTP007696) from the Technology Strategy Board. PL is funded by MRC and the University of Birmingham, and KK is funded by the University of Birmingham. The University of Birmingham Transgenic Mouse Facility is part of the MRC Centre for Immune Regulation.	Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Baker M, 2012, NAT PROTOC, V7, P89, DOI 10.1038/nprot.2011.435; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bignon M, 2011, BLOOD, V118, P3979, DOI 10.1182/blood-2010-10-313296; Chaudhary A, 2012, CANCER CELL, V21, P212, DOI 10.1016/j.ccr.2012.01.004; Colombatti A, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00093; Cullen M, 2009, CANCER RES, V69, P6021, DOI 10.1158/0008-5472.CAN-09-1086; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; Desjobert C, 2009, BIOCHEM J, V417, P121, DOI 10.1042/BJ20080872; Duwel A, 2007, TUMOR BIOL, V28, P1, DOI 10.1159/000097040; Jin H, 2010, BLOOD, V116, P5773, DOI 10.1182/blood-2010-07-296210; Ki MK, 2013, ONCOGENE, V32, P5449, DOI 10.1038/onc.2013.156; Korff T, 2004, EXP CELL RES, V297, P415, DOI 10.1016/j.yexcr.2004.03.043; Lorenzon E, 2012, ONCOGENE, V31, P3136, DOI 10.1038/onc.2011.487; Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004; Mura M, 2012, ONCOGENE, V31, P293, DOI 10.1038/onc.2011.233; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Nanda A, 2004, CURR OPIN ONCOL, V16, P44, DOI 10.1097/00001622-200401000-00009; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pircher A, 2013, LUNG CANCER, V81, P252, DOI 10.1016/j.lungcan.2013.04.014; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; SANZMONCASI MP, 1994, LAB INVEST, V71, P366; Saunders Thomas L, 2003, Methods Mol Biol, V209, P125; Stapor PC., 2011, CARDIOVASC ENG TECHN, V2, P124, DOI [10.1007/S13239-011-0041-Y, DOI 10.1007/S13239-011-0041-Y]; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Welch-Reardon KM, 2014, J CELL SCI, V127, P2017, DOI 10.1242/jcs.143420; Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Zanivan S, 2013, MOL CELL PROTEOMICS, V12, P3599, DOI 10.1074/mcp.M113.031344; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zhuang XD, 2011, BIOCHEM SOC T, V39, P1571, DOI 10.1042/BST20110746; Ziyad Safiyyah, 2011, Genes Cancer, V2, P1085, DOI 10.1177/1947601911432334	33	35	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5821	5831		10.1038/onc.2015.34	http://dx.doi.org/10.1038/onc.2015.34			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25745997	Green Accepted, Green Submitted			2022-12-28	WOS:000365035200005
J	Sun, X; Ou, Z; Xie, M; Kang, R; Fan, Y; Niu, X; Wang, H; Cao, L; Tang, D				Sun, X.; Ou, Z.; Xie, M.; Kang, R.; Fan, Y.; Niu, X.; Wang, H.; Cao, L.; Tang, D.			HSPB1 as a novel regulator of ferroptotic cancer cell death	ONCOGENE			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; HSP27 PHOSPHORYLATION; DRUG-RESISTANCE; IRON; KINASE; HEAT-SHOCK-PROTEIN-27; ACTIVATION; MIGRATION; APOPTOSIS	Ferroptosis is an iron-dependent form of non-apoptotic cell death, but its molecular mechanism remains largely unknown. Here, we demonstrate that heat shock protein beta-1 (HSPB1) is a negative regulator of ferroptotic cancer cell death. Erastin, a specific ferroptosis-inducing compound, stimulates heat shock factor 1 (HSF1)-dependent HSPB1 expression in cancer cells. Knockdown of HSF1 and HSPB1 enhances erastin-induced ferroptosis, whereas heat shock pretreatment and overexpression of HSPB1 inhibits erastin-induced ferroptosis. Protein kinase C-mediated HSPB1 phosphorylation confers protection against ferroptosis by reducing iron-mediated production of lipid reactive oxygen species. Moreover, inhibition of the HSF1-HSPB1 pathway and HSPB1 phosphorylation increases the anticancer activity of erastin in human xenograft mouse tumor models. Our findings reveal an essential role for HSPB1 in iron metabolism with important effects on ferroptosis-mediated cancer therapy.	[Sun, X.; Ou, Z.; Fan, Y.; Niu, X.; Tang, D.] Guangzhou Med Univ, Key Lab Major Obstetr Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Sun, X.; Ou, Z.; Fan, Y.; Niu, X.; Tang, D.] Guangzhou Med Univ, Key Lab Reprod, Guangzhou, Guangdong, Peoples R China; [Sun, X.; Ou, Z.; Fan, Y.; Niu, X.; Tang, D.] Guangzhou Med Univ, Genet Guangdong Higher Educ Inst, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Xie, M.; Cao, L.] Cent S Univ, Dept Pediat, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Kang, R.; Tang, D.] Univ Pittsburgh, Dept Surg, Inst Canc, Pittsburgh, PA USA; [Wang, H.] N Shore Univ Hosp, Dept Emergency Med, Feinstein Inst Med Res, Manhasset, NY USA	Guangzhou Medical University; Guangzhou Medical University; Guangzhou Medical University; Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwell Health; North Shore University Hospital	Sun, X (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr G27A, 5117 Ctr Ave, Pittsburgh, PA 15260 USA.	xiaofangsun@hotmail.com; tangd2@upmc.edu	Kang, Rui/ABD-5291-2021; Tang, Daolin/ABD-5062-2021; Tang, Daolin/B-2905-2010; Wang, Haichao/AAU-2237-2021	Kang, Rui/0000-0003-2725-1574; Tang, Daolin/0000-0002-1903-6180; Wang, Haichao/0000-0002-0211-9000	National Institutes of Health [R01CA160417]; Pancreatic Cancer Action Network-AACR Career Development Award [13-20-25-TANG]; National Natural Science Foundation-Guangdong Joint Fund [U1132005]; Science and Information Technology of Guangzhou Key Project [2011Y1-00038]; National Center of Complementary and Alternative Medicine [R01AT005076]; National Institute of General Medical Sciences [R01GM063075]; NATIONAL CANCER INSTITUTE [R01CA160417] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT005076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063075] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pancreatic Cancer Action Network-AACR Career Development Award; National Natural Science Foundation-Guangdong Joint Fund; Science and Information Technology of Guangzhou Key Project; National Center of Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by the National Institutes of Health (R01CA160417 to DT), a 2013 Pancreatic Cancer Action Network-AACR Career Development Award (Grant Number 13-20-25-TANG), The National Natural Science Foundation-Guangdong Joint Fund (U1132005 to XS) and Science and Information Technology of Guangzhou Key Project (2011Y1-00038 to XS). HW is supported by grants from the National Center of Complementary and Alternative Medicine (R01AT005076) and the National Institute of General Medical Sciences (R01GM063075).	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Arrigo AP, 2005, ANTIOXID REDOX SIGN, V7, P414, DOI 10.1089/ars.2005.7.414; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; Carver JA, 2003, IUBMB LIFE, V55, P661, DOI 10.1080/15216540310001640498; Chen HY, 2006, INT J BIOCHEM CELL B, V38, P1402, DOI 10.1016/j.biocel.2006.02.006; Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Guay J, 1997, J CELL SCI, V110, P357; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001; Huot J, 1996, CANCER RES, V56, P273; JAKOB U, 1993, J BIOL CHEM, V268, P1517; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Lee YJ, 2005, J BIOL CHEM, V280, P18108, DOI 10.1074/jbc.M501131200; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ramanathan R, 2014, J AGR FOOD CHEM, V62, P2112, DOI 10.1021/jf404900y; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Shin KD, 2005, J BIOL CHEM, V280, P41439, DOI 10.1074/jbc.M507209200; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Tait SWG, 2014, J CELL SCI, V127, P2135, DOI 10.1242/jcs.093575; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008; Tang DL, 2005, SHOCK, V23, P434, DOI 10.1097/01.shk.0000159556.95285.df; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Vidyasagar A, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-7; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yang LC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5436; Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zhang QH, 2013, AUTOPHAGY, V9, P451, DOI 10.4161/auto.23691; Zhang X, 2010, HYPERTENSION, V55, P1412, DOI 10.1161/HYPERTENSIONAHA.109.147066	45	274	300	16	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5617	5625		10.1038/onc.2015.32	http://dx.doi.org/10.1038/onc.2015.32			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25728673	Green Accepted			2022-12-28	WOS:000364594300003
J	Kohlhapp, FJ; Mitra, AK; Lengyel, E; Peter, ME				Kohlhapp, F. J.; Mitra, A. K.; Lengyel, E.; Peter, M. E.			MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment	ONCOGENE			English	Review							MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; STROMAL FIBROBLASTS; SUPPRESSOR-CELLS; DOWN-REGULATION; HUMAN BREAST; OVARIAN-CANCER; DUAL ROLE	Cancer cells grow in an environment comprised of multiple components that support tumor growth and contribute to therapy resistance. Major cell types in the tumor microenvironment are fibroblasts, endothelial cells and infiltrating immune cells all of which communicate with cancer cells. One way that these cell types promote cancer progression is by altering the expression of microRNAs (miRNAs), small noncoding RNAs that negatively regulate protein expression, either in the cancer cells or in the associated normal cells. Changes in miRNA expression can be brought about by direct interaction between the stromal cells and cancer cells, by paracrine factors secreted by any of the cell types or even through direct communication between cells through secreted miRNAs. Understanding the role of miRNAs in the complex interactions between the tumor and cells in its microenvironment is necessary if we are to understand tumor progression and devise new treatments.	[Kohlhapp, F. J.; Peter, M. E.] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Mitra, A. K.] Indiana Univ, Indiana Univ Sch Med, Med Sci Program, Bloomington, IN USA; [Lengyel, E.] Univ Chicago, Dept Gynecol & Obstet, Gynecol Oncol Sect, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University Bloomington; University of Chicago	Peter, ME (corresponding author), Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, 303 East Super St,Lurie 6-123, Chicago, IL 60611 USA.	m-peter@northwestern.edu	Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507; Peter, Marcus Ernst/0000-0003-3216-036X	OCRF program [FP049318/PPD/UC];  [T32 CA070085];  [F32 CA180677]; NATIONAL CANCER INSTITUTE [F32CA180677, T32CA070085, P30CA060553] Funding Source: NIH RePORTER	OCRF program; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	FK was supported by grants T32 CA070085 and F32 CA180677. MEP and EL were supported by an OCRF program project development grant FP049318/PPD/UC.	Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Almog N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044001; Aprelikova O, 2013, ONCOGENE, V32, P3246, DOI 10.1038/onc.2012.351; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Aucher A, 2013, J IMMUNOL, V191, P6250, DOI 10.4049/jimmunol.1301728; Barroso-delJesus A, 2008, MOL CELL BIOL, V28, P6609, DOI 10.1128/MCB.00398-08; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Bullock MD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.213; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chang SH, 2013, J BIOL CHEM, V288, P4908, DOI 10.1074/jbc.M112.423871; Chaudhuri AA, 2011, J IMMUNOL, V187, P5062, DOI 10.4049/jimmunol.1102001; Chen L, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-489; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Connolly J. L., 2003, TUMOR STRUCTURE TUMO; Cubillos-Ruiz JR, 2012, CANCER RES, V72, P1683, DOI 10.1158/0008-5472.CAN-11-3160; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Du J, 2012, MED ONCOL, V29, P2814, DOI 10.1007/s12032-012-0175-2; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; El Chartouni C, 2010, IMMUNOBIOLOGY, V215, P821, DOI 10.1016/j.imbio.2010.05.031; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Gatto G, 2008, NUCLEIC ACIDS RES, V36, P6608, DOI 10.1093/nar/gkn666; Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Guduric-Fuchs J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-357; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hu S, MOL ONCOL, P44; Huffaker TB, 2012, CELL REP, V2, P1697, DOI 10.1016/j.celrep.2012.10.025; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Jusufovic E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045577; Kadera BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071978; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Ke G, 2013, ONCOGENE, V32, P3019, DOI 10.1038/onc.2012.323; Kong D, 2012, ONCOGENE, V31, P3949, DOI 10.1038/onc.2011.558; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Kosaka Nobuyoshi, 2013, Frontiers in Genetics, V4, P173, DOI 10.3389/fgene.2013.00173; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Lee JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084256; Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850; Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036; Liu QF, 2011, INT J CANCER, V129, P2662, DOI 10.1002/ijc.25921; Liu Y, 2012, J IMMUNOL, V188, P5500, DOI 10.4049/jimmunol.1103505; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Lwin T, 2010, BLOOD, V116, P5228, DOI 10.1182/blood-2010-03-275925; Mitra AK, 2015, ONCOGENE, V34, P5923, DOI 10.1038/onc.2015.43; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Mongiat M, 2010, NEOPLASIA, V12, P294, DOI 10.1593/neo.91930; Morello M, 2013, CELL CYCLE, V12, P3526, DOI 10.4161/cc.26539; Muramatsu F, 2013, ONCOGENE, V32, P414, DOI 10.1038/onc.2012.68; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Naito Y, 2014, CANCER SCI, V105, P228, DOI 10.1111/cas.12329; Nielsen BS, 2011, CLIN EXP METASTAS, V28, P27, DOI 10.1007/s10585-010-9355-7; Nilsson S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036051; Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658; Nouraee N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073009; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Plummer PN, 2013, CANCER RES, V73, P341, DOI 10.1158/0008-5472.CAN-12-0271; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Rappa G, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-62; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Roybal JD, 2011, MOL CANCER RES, V9, P25, DOI 10.1158/1541-7786.MCR-10-0497; Sasaki K, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-17; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Senst C, 2013, BREAST CANCER RES TR, V137, P69, DOI 10.1007/s10549-012-2321-0; Shih TC, 2012, J HEPATOL, V57, P584, DOI 10.1016/j.jhep.2012.04.031; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smits M, 2012, FASEB J, V26, P2639, DOI 10.1096/fj.11-202820; Sonda N, 2013, IMMUNITY, V38, P1236, DOI 10.1016/j.immuni.2013.06.004; Squadrito ML, 2014, CELL REP, V8, P1432, DOI 10.1016/j.celrep.2014.07.035; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Subramani A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02392; Sugiyama K, 2014, MOL CANCER THER, V13, P2081, DOI 10.1158/1535-7163.MCT-14-0135; Tang B, 2014, J BIOL CHEM, V289, P34595, DOI 10.1074/jbc.M114.614503; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Tuhkanen H, 2006, INT J CANCER, V119, P1345, DOI 10.1002/ijc.21785; Ueda R, 2009, P NATL ACAD SCI USA, V106, P10746, DOI 10.1073/pnas.0811817106; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vecchione A, 2013, P NATL ACAD SCI USA, V110, P9845, DOI 10.1073/pnas.1305472110; Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248; Wang M, 2014, BRIT J CANCER, V110, P1199, DOI 10.1038/bjc.2014.14; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wang RZ, 2013, HEPATOLOGY, V58, P642, DOI 10.1002/hep.26373; Wei J, 2013, CANCER RES, V73, P3913, DOI 10.1158/0008-5472.CAN-12-4318; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Xu QL, 2012, INT J ONCOL, V41, P959, DOI 10.3892/ijo.2012.1541; Yamamichi N, 2009, CLIN CANCER RES, V15, P4009, DOI 10.1158/1078-0432.CCR-08-3257; Yan XL, 2013, HEPATOLOGY, V57, P2274, DOI 10.1002/hep.26257; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yao Q, 2011, INT J CANCER, V128, P1783, DOI 10.1002/ijc.25506; Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323; Zhai HY, 2011, J NEUROSCI, V31, P14346, DOI 10.1523/JNEUROSCI.3299-11.2011; Zhang MM, 2011, J IMMUNOL, V186, P4716, DOI 10.4049/jimmunol.1002989; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690; Zhao LY, 2012, INT J BIOCHEM CELL B, V44, P2051, DOI 10.1016/j.biocel.2012.08.005; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhu K, 2013, CARCINOGENESIS, V34, P2071, DOI 10.1093/carcin/bgt160; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183; Zonari E, 2013, BLOOD, V122, P243, DOI 10.1182/blood-2012-08-449306	116	139	144	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5857	5868		10.1038/onc.2015.89	http://dx.doi.org/10.1038/onc.2015.89			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25867073	Green Accepted, Bronze			2022-12-28	WOS:000365434000001
J	Kern, D; Regl, G; Hofbauer, SW; Altenhofer, P; Achatz, G; Dlugosz, A; Schnidar, H; Greil, R; Hartmann, TN; Aberger, F				Kern, D.; Regl, G.; Hofbauer, S. W.; Altenhofer, P.; Achatz, G.; Dlugosz, A.; Schnidar, H.; Greil, R.; Hartmann, T. N.; Aberger, F.			Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia	ONCOGENE			English	Article							BASAL-CELL CARCINOMAS; PATHWAY INHIBITOR; GLI ACTIVATION; STEM-CELLS; BCR-ABL; CANCER; GROWTH; AKT; MECHANISMS; PROTEIN	The initiation and maintenance of a malignant phenotype requires complex and synergistic interactions of multiple oncogenic signals. The Hedgehog (HH)/GLI pathway has been implicated in a variety of cancer entities and targeted pathway inhibition is of therapeutic relevance. Signal cross-talk with other cancer pathways including PI3K/AKT modulates HH/GLI signal strength and its oncogenicity. In this study, we addressed the role of HH/GLI and its putative interaction with the PI3K/AKT cascade in the initiation and maintenance of chronic lymphocytic leukemia (CLL). Using transgenic mouse models, we show that B-cell-specific constitutive activation of HH/GLI signaling either at the level of the HH effector and drug target Smoothened or at the level of the GLI transcription factors does not suffice to initiate a CLL-like phenotype characterized by the accumulation of CD5(+) B cells in the lymphatic system and peripheral blood. Furthermore, Hh/Gli activation in Pten-deficient B cells with activated Pi3K/Akt signaling failed to enhance the expansion of leukemic CD5(+) B cells, suggesting that genetic or epigenetic alterations leading to aberrant HH/GLI signaling in B cells do not suffice to elicit a CLL-like phenotype in mice. By contrast, we identify a critical role of GLI and PI3K signaling for the survival of human primary CLL cells. We show that combined targeting of GLI and PI3K/AKT/mTOR signaling can have a synergistic therapeutic effect in cells from a subgroup of CLL patients, thereby providing a basis for the evaluation of future combination therapies targeting HH/GLI and PI3K signaling in this common hematopoietic malignancy.	[Kern, D.; Regl, G.; Achatz, G.; Schnidar, H.; Aberger, F.] Paris Lodron Univ Salzburg, Dept Mol Biol, Salzburg, Austria; [Hofbauer, S. W.; Altenhofer, P.; Greil, R.; Hartmann, T. N.] Paracelsus Med Univ, Ctr Oncol, Lab Immunol & Mol Canc Res, Med Dept Haematol Med Oncol Haemostaseol Infect D, Salzburg, Austria; [Hofbauer, S. W.; Altenhofer, P.; Greil, R.; Hartmann, T. N.] Salzburg Canc Res Inst, Salzburg, Austria; [Dlugosz, A.] Univ Michigan, Dermatol & Comprehens Canc Ctr, Ann Arbor, MI 48109 USA; [Schnidar, H.] APEIRON Biol AG, Vienna, Austria	Salzburg University; Paracelsus Private Medical University; University of Michigan System; University of Michigan	Aberger, F (corresponding author), Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria.	Fritz.Aberger@sbg.ac.at	Aberger, Fritz/B-6357-2012; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017; Greil, Richard F/C-7673-2017; Hartmann, Tanja Nicole/C-9345-2017	Aberger, Fritz/0000-0003-2009-6305; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Greil, Richard F/0000-0002-4462-3694; Hartmann, Tanja Nicole/0000-0002-2633-7301	Austrian Science Fund FWF [W1213, SFB-P021]; Austrian Genome Project GEN-AU; priority program Biosciences and Health of the Paris-Lodron University of Salzburg; SCRI-LIMCR GmbH; province of Salzburg; NATIONAL CANCER INSTITUTE [P30CA046592, R01CA087837] Funding Source: NIH RePORTER	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Genome Project GEN-AU; priority program Biosciences and Health of the Paris-Lodron University of Salzburg; SCRI-LIMCR GmbH; province of Salzburg; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Professors Tak Mak and Josef Penninger for providing transgenic mouse strains, and Dr Sandrine Tonon and Professor Christoph Binder for help with B-cell analysis. Work of FA has been supported by the Austrian Science Fund FWF (project W1213), the Austrian Genome Project GEN-AU and the priority program Biosciences and Health of the Paris-Lodron University of Salzburg. Work of RG, TNH, SWH and PA was supported by the Austrian Science Fund FWF (SFB-P021 and W1213 to RG), the SCRI-LIMCR GmbH and the province of Salzburg. We dedicate this study to Gernot Achatz who tragically passed away during the course of this study.	Aberger F, 2014, SEMIN CELL DEV BIOL, V33, P93, DOI 10.1016/j.semcdb.2014.05.003; Aberger F, 2012, VITAM HORM, V88, P25, DOI 10.1016/B978-0-12-394622-5.00002-X; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Beauchamp EM, 2011, J CLIN INVEST, V121, P148, DOI 10.1172/JCI42874; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Brennan D, 2012, VITAM HORM, V88, P55, DOI 10.1016/B978-0-12-394622-5.00003-1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown JR, 2014, BLOOD, V123, P3390, DOI 10.1182/blood-2013-11-535047; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Dao KHT, 2013, CLIN CANCER RES, V19, P1309, DOI 10.1158/1078-0432.CCR-12-3934; de Frias M, 2009, HAEMATOL-HEMATOL J, V94, P1698, DOI 10.3324/haematol.2008.004028; Decker S, 2012, BLOOD, V119, P997, DOI 10.1182/blood-2011-06-359075; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Desch P, 2010, ONCOGENE, V29, P4885, DOI 10.1038/onc.2010.243; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Filbin MG, 2013, NAT MED, V19, P1518, DOI 10.1038/nm.3328; Finetti F, 2011, TRENDS IMMUNOL, V32, P139, DOI 10.1016/j.it.2011.02.001; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Gold MR, 2003, TRENDS IMMUNOL, V24, P104, DOI 10.1016/S1471-4906(03)00022-X; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; Gulino A, 2007, PSYCHONEUROENDOCRINO, V32, pS52, DOI 10.1016/j.psyneuen.2007.03.017; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood-2010-02-271171; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Ingham PW, 2011, NAT REV GENET, V12, P393, DOI 10.1038/nrg2984; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Ju BS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-40; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kasper Maria, 2007, V397, P67; Katagiri S, 2013, CLIN CANCER RES, V19, P1422, DOI 10.1158/1078-0432.CCR-12-1777; Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98; Kim J, 2010, P NATL ACAD SCI USA, V107, P13432, DOI 10.1073/pnas.1006822107; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Mangelberger D, 2012, FRONT BIOSCI-LANDMRK, V17, P90, DOI 10.2741/3917; Mann KK, 2008, MOL CANCER THER, V7, P1680, DOI 10.1158/1535-7163.MCT-07-2164; Merchant A, 2010, BLOOD, V115, P2391, DOI 10.1182/blood-2009-09-241703; Merkel O, 2008, J MOL MED-JMM, V86, P541, DOI 10.1007/s00109-008-0314-6; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Pelczar P, 2013, GASTROENTEROLOGY, V144, P134, DOI 10.1053/j.gastro.2012.09.061; Pleyer L, 2009, NAT REV CLIN ONCOL, V6, P405, DOI 10.1038/nrclinonc.2009.72; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Ruiz I, 2007, TRENDS CELL BIOL, V17, P438, DOI DOI 10.1016/J.TCB.2007.06.007; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Skvara H, 2011, J INVEST DERMATOL, V131, P1735, DOI 10.1038/jid.2011.48; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145-2126(98)00154-4; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Stevenson FK, 2011, BLOOD, V118, P4313, DOI 10.1182/blood-2011-06-338855; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Tsimberidou AM, 2005, CANCER-AM CANCER SOC, V103, P216, DOI 10.1002/cncr.20773; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Wu M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-36; Xue P, 2011, BIOCHEM BIOPH RES CO, V407, P360, DOI 10.1016/j.bbrc.2011.03.024; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Zahreddine HA, 2014, NATURE, V511, P90, DOI 10.1038/nature13283; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	85	43	47	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5341	5351		10.1038/onc.2014.450	http://dx.doi.org/10.1038/onc.2014.450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25639866	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000363479200004
J	Kaur, J; Tikoo, K				Kaur, J.; Tikoo, K.			Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CANCER; EXPRESSION; NANOPARTICLES	Nanomedicine era is not far from its realization, but a major concern of targeted delivery still stands tall in its way. Herein we demonstrate the mechanism underlying the anticancer activity of an RNA aptamer (Apt) conjugated to gefitinib-loaded poly (lactic co-glycolic acid) nanoparticles (GNPs). Apt was selected through Cell-SELEX (systemic evolution of ligands by exponential enrichment) process against gefitinib-resistant H1975 lung cancer cells. The selected aptamer exhibited high specificity toward H1975 cells, both qualitatively as well as quantitatively. Software analysis using the MATCH tool predicted Ets1, a proto-oncoprotein, to be the target of the selected aptamer. Interestingly, the localization of identified aptamer varied in descending order of Ets1 expression, wherein maximum localization was observed in H1975 cells than in MDA-MB231, DU-145, H23, H460, A431, A549 and MCF-7 cells, and minimum in L132 cells. Furthermore, Apt-GNP bio-conjugate showed augmented anticancer activity specifically in Ets1-overexpressing cells. In addition, partial depletion of Ets1 in H1975 cells and overexpression of Ets1 in L132 cells reversed the targeting efficacy of the aptamer. Notably, a single intratumoral injection of the Apt-GNP bio-conjugate abrogated the growth of tumor in H1975 xenograft nude mice. Altogether, we present a pioneering platform, involving aptamers, which can be clinically used as a diagnostic marker for metastasis as well as an effective delivery system to escort the pharmaceutical cargo specifically to Ets1-overexpressing highly progressive tumors.	[Kaur, J.; Tikoo, K.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Lab Epigenet & Dis, Sas Nagar 160062, Punjab, India	National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali)	Tikoo, K (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Lab Epigenet & Dis, Phase 10, Sas Nagar 160062, Punjab, India.	tikoo.k@gmail.com		Tikoo, Kulbhushan/0000-0003-3061-9739				Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Buggy Y, 2004, BRIT J CANCER, V91, P1308, DOI 10.1038/sj.bjc.6602128; Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583; Dassie JP, 2014, MOL THER, V22, P1910, DOI 10.1038/mt.2014.117; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103; Guo KT, 2008, INT J MOL SCI, V9, P668, DOI 10.3390/ijms9040668; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kaur J, 2013, BBA-MOL CELL RES, V1833, P1028, DOI 10.1016/j.bbamcr.2013.01.029; Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kim Y, 2013, CANCER RES, V73, P4923, DOI 10.1158/0008-5472.CAN-12-4556; Li N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020299; Li R, 2000, ONCOGENE, V19, P55; Lupold SE, 2002, CANCER RES, V62, P4029; Meert AP, 2002, EUR RESPIR J, V20, P975, DOI 10.1183/09031936.02.00296502; Mi J, 2010, NAT CHEM BIOL, V6, P22, DOI [10.1038/NCHEMBIO.277, 10.1038/nchembio.277]; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; SACCHI N, 1988, LEUKEMIA, V2, P12; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Valter MM, 1999, CANCER RES, V59, P5608; Van Simaeys D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013770; Xiao ZY, 2012, ACS NANO, V6, P696, DOI 10.1021/nn204165v	30	20	22	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5216	5228		10.1038/onc.2014.447	http://dx.doi.org/10.1038/onc.2014.447			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639877	Green Published			2022-12-28	WOS:000362575400002
J	Kubic, JD; Little, EC; Lui, JW; Iizuka, T; Lang, D				Kubic, J. D.; Little, E. C.; Lui, J. W.; Iizuka, T.; Lang, D.			PAX3 and ETS1 synergistically activate MET expression in melanoma cells	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; DNA-BINDING MOTIF; C-MET; TRANSCRIPTION FACTOR; UP-REGULATION; RECEPTOR EXPRESSION; MELANOCYTIC LESIONS; MALIGNANT-MELANOMA; TERNARY COMPLEXES; TUMOR PROGRESSION	Melanoma is a highly aggressive disease that is difficult to treat owing to rapid tumor growth, apoptotic resistance and high metastatic potential. The MET proto-oncogene (MET) tyrosine kinase receptor promotes many of these cellular processes, but while MET is often overexpressed in melanoma, the mechanism driving this overexpression is unknown. As the MET gene is rarely mutated or amplified in melanoma, MET overexpression may be driven to increased activation through promoter elements. In this report, we find that transcription factors PAX3 and ETS1 directly interact to synergistically activate MET expression. Inhibition of PAX3 and ETS1 expression in melanoma cells leads to a significant reduction of MET receptor levels. The 300-bp 5' proximal MET promoter contains a PAX3 response element and two ETS1 consensus motifs. Although ETS1 can moderately activate both of these sites without cofactors, robust MET promoter activation of the first site is PAX dependent and requires the presence of PAX3, whereas the second site is PAX independent. The induction of MET by ETS1 via this second site is enhanced by hepatocyte growth factor-dependent ETS1 activation, thereby MET indirectly promotes its own expression. We further find that expression of a dominant-negative ETS1 reduces the ability of melanoma cells to grow both in culture and in vivo. Thus, we discover a pathway where ETS1 advances melanoma through the expression of MET via PAX-dependent and -independent mechanisms.	[Kubic, J. D.; Little, E. C.; Lui, J. W.; Iizuka, T.; Lang, D.] Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA	University of Chicago	Lang, D (corresponding author), Univ Chicago, Dept Med, Dermatol Sect, 5841 South Maryland Ave,MC 5067,Room L536, Chicago, IL 60637 USA.	dlang@medicine.bsd.uchicago.edu		Lang, Deborah/0000-0003-1057-0923	University of Chicago Cancer Center Pilot program [P30-CA014599]; American Cancer Society [RSG-CSM-121505]; Friends of Dermatology-University of Chicago; Wendy Will Chase Foundation; National Institutes of Health [R01CA130202, R01AR062547]; NATIONAL CANCER INSTITUTE [P30CA014599, R01CA130202, R01CA184001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR062547] Funding Source: NIH RePORTER	University of Chicago Cancer Center Pilot program(University of Chicago); American Cancer Society(American Cancer Society); Friends of Dermatology-University of Chicago; Wendy Will Chase Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Drs Ravi Salgia, Eric Svensson and Jonathan Epstein for providing material and/or intellectual support for this project. This work was supported by grants and financial support from the University of Chicago Cancer Center Pilot program (P30-CA014599), American Cancer Society (RSG-CSM-121505), Friends of Dermatology-University of Chicago, The Wendy Will Chase Foundation and the National Institutes of Health (R01CA130202 and R01AR062547).	Beuret L, 2007, J BIOL CHEM, V282, P14140, DOI 10.1074/jbc.M611563200; Bonvin E, 2012, MOL CELL BIOL, V32, P4674, DOI 10.1128/MCB.01067-12; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fitzsimmons D, 2009, J MOL BIOL, V392, P452, DOI 10.1016/j.jmb.2009.07.028; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; Gambarotta G, 1996, ONCOGENE, V13, P1911; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; He SJ, 2005, MOL CANCER THER, V4, P996, DOI 10.1158/1535-7163.MCT-04-0252; Holterman CE, 2010, CANCER RES, V70, P730, DOI 10.1158/0008-5472.CAN-09-2090; Horikawa T, 2001, AM J PATHOL, V159, P27, DOI 10.1016/S0002-9440(10)61669-0; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Keehn CA, 2003, MODERN PATHOL, V16, P772, DOI 10.1097/01.MP.0000082395.59356.4F; Kubic JD, 2008, PIGM CELL MELANOMA R, V21, P627, DOI 10.1111/j.1755-148X.2008.00514.x; Lang D, 2003, HUM MOL GENET, V12, P937, DOI 10.1093/hmg/ddg107; Liu F, 2013, J INVEST DERMATOL, V133, P2041, DOI 10.1038/jid.2013.32; Maier H, 2003, NUCLEIC ACIDS RES, V31, P5483, DOI 10.1093/nar/gkg785; Mascarenhas JB, 2010, PIGM CELL MELANOMA R, V23, P225, DOI 10.1111/j.1755-148X.2010.00667.x; Mattia G, 2011, PIGM CELL MELANOMA R, V24, P953, DOI 10.1111/j.1755-148X.2011.00881.x; McGill GG, 2006, J BIOL CHEM, V281, P10365, DOI 10.1074/jbc.M513094200; Medic S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009977; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Pinner S, 2009, CANCER RES, V69, P7679; Plummer RS, 2008, MODERN PATHOL, V21, P525, DOI 10.1038/modpathol.3801019; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J; Sahin A, 2009, INT J ONCOL, V34, P377, DOI 10.3892/ijo_00000161; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; Sato T, 2007, J BIOL CHEM, V282, P27702, DOI 10.1074/jbc.M611862200; Scholl FA, 2001, CANCER RES, V61, P823; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Tomita N, 2003, CIRCULATION, V107, P1411, DOI 10.1161/01.CIR.0000055331.41937.AA; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Wheat W, 1999, MOL CELL BIOL, V19, P2231; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhang XH, 2005, AM J PHYSIOL-RENAL, V288, pF16, DOI 10.1152/ajprenal.00318.2003	49	27	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4964	4974		10.1038/onc.2014.420	http://dx.doi.org/10.1038/onc.2014.420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531327	Green Accepted			2022-12-28	WOS:000361693000006
J	Zhang, Z; Liu, X; Feng, B; Liu, N; Wu, Q; Han, Y; Nie, Y; Wu, K; Shi, Y; Fan, D				Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.			STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer	ONCOGENE			English	Article							STROMAL INTERACTION MOLECULE-1; ACTIVATES CRAC CHANNELS; CA2+ INFLUX; MESENCHYMAL TRANSITION; CALCIUM; GROWTH; MIR-185; STORE; MIGRATION; SENSOR	STIM1 (stromal interaction molecule 1), an endoplasmic reticulum Ca2+ sensor that triggers the store-operated Ca2+ entry activation, has recently been implicated in cancer progression. However, the role of STIM1 in the progression and metastasis of colorectal cancer (CRC) has not been addressed. In this study, we confirmed increased expression of STIM1 in highly invasive CRC cell lines. Enhanced expression of STIM1 promoted CRC cell metastasis in vitro and in vivo, whereas silencing of STIM1 with small interfering RNA resulted in reduced metastasis. Ectopic expression of STIM1 in CRC cells induced epithelial-to-mesenchymal transition (EMT), whereas silencing of STIM1 had the opposite effect. Furthermore, STIM1 expression was markedly higher in CRC tissues than in adjacent noncancerous tissues. STIM1 overexpression correlated with poor differentiation and higher tumor node metastasis stage. CRC patients with positive STIM1 expression had poorer prognoses than those with negative STIM1 expression. Moreover, STIM1 was found to be a direct target of miR-185, a microRNA (miRNA) that has not previously been reported to be involved in EMT, in both CRC tissues and cell lines. Taken together, these findings demonstrate for the first time that STIM1 promotes metastasis and is associated with cancer progression and poor prognosis in patients with CRC. In addition, we show that expression of STIM1 is regulated by a posttranscriptional regulatory mechanism mediated by a new EMT-related miRNA. This novel miR-185-STIM1 axis promotes CRC metastasis and may be a candidate biomarker for prognosis and a target for new therapies.	[Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.] Fourth Mil Med Univ, State Key Lab Canc Biol, 127 Chang Le West Rd, Xian 710032, Shaanxi, Peoples R China; [Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Shi, Y (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, 127 Chang Le West Rd, Xian 710032, Shaanxi, Peoples R China.; Shi, Y (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China.	shiyquan@fmmu.edu.cn; daimingfan@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020		National Basic Research Program of China [2010CB732405, 2010CB529300]; National Natural Science Foundation of China [81030044, 81272343, 81070326, 81172096, 81472300, 81472301, 81201632, 30900675]; National Science and Technology Projects of China [2014ZX09508002]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Projects of China	This work was supported by National Basic Research Program of China (Grant nos: 2010CB732405 and 2010CB529300), National Natural Science Foundation of China (Grant nos: 81030044, 81272343, 81070326, 81172096, 81472300, 81472301, 81201632 and 30900675) and National Science and Technology Projects of China (Grant no.: 2014ZX09508002).	Akcakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Chen YF, 2011, P NATL ACAD SCI USA, V108, P15225, DOI 10.1073/pnas.1103315108; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Duranton B, 2003, AMINO ACIDS, V24, P63, DOI 10.1007/s00726-002-0333-5; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Guo RW, 2009, CARDIOVASC RES, V81, P660, DOI 10.1093/cvr/cvn338; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu JJ, 2011, BIOCHEM BIOPH RES CO, V411, P786, DOI 10.1016/j.bbrc.2011.07.025; Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kraljevic Pavelic S., 2011, MOL CANCER, V10, P22, DOI DOI 10.1186/1476-4598-10-22; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lioudyno MI, 2008, P NATL ACAD SCI USA, V105, P2011, DOI 10.1073/pnas.0706122105; Liu M, 2011, CANCER LETT, V301, P151, DOI 10.1016/j.canlet.2010.11.009; Liu XQ, 2011, CARCINOGENESIS, V32, P1798, DOI 10.1093/carcin/bgr213; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Lu WJ, 2009, AM J PHYSIOL-LUNG C, V297, pL17, DOI 10.1152/ajplung.00063.2009; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Okabe H, 1999, INT J IMPOT RES, V11, P133, DOI 10.1038/sj.ijir.3900394; Parekh AB, 2010, NAT REV DRUG DISCOV, V9, P399, DOI 10.1038/nrd3136; Park CY, 2009, CELL, V136, P876, DOI 10.1016/j.cell.2009.02.014; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; Ritchie MF, 2011, FRONT BIOSCI-LANDMRK, V16, P2402, DOI 10.2741/3862; Roberts-Thomson SJ, 2010, PHARMACOL THERAPEUT, V127, P121, DOI 10.1016/j.pharmthera.2010.04.016; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Stanisz H, 2014, PIGM CELL MELANOMA R, V27, P442, DOI 10.1111/pcmr.12222; Suyama E, 2004, J BIOL CHEM, V279, P38083, DOI 10.1074/jbc.C400313200; Takahashi Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006677; Tan ZQ, 2014, MOL CELL BIOCHEM, V386, P223, DOI 10.1007/s11010-013-1860-y; Tang HL, 2012, CURR CANCER DRUG TAR, V12, P1032, DOI 10.2174/156800912803251180; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Varga-Szabo D, 2008, J EXP MED, V205, P1583, DOI 10.1084/jem.20080302; Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200; Yoon JH, 2013, CLIN CANCER RES, V19, P4599, DOI 10.1158/1078-0432.CCR-12-3675; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zhi QM, 2013, BIOMED PHARMACOTHER, V67, P393, DOI 10.1016/j.biopha.2013.03.022; Zhuang R, 2013, NUCLEIC ACIDS RES, V41, P7905, DOI 10.1093/nar/gkt565	51	84	88	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4808	4820		10.1038/onc.2014.404	http://dx.doi.org/10.1038/onc.2014.404			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25531324	hybrid, Green Published			2022-12-28	WOS:000361050000002
J	Azoulay-Alfaguter, I; Elya, R; Avrahami, L; Katz, A; Eldar-Finkelman, H				Azoulay-Alfaguter, I.; Elya, R.; Avrahami, L.; Katz, A.; Eldar-Finkelman, H.			Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth	ONCOGENE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR TYROSINE KINASES; TUBEROUS-SCLEROSIS; THERAPEUTIC TARGET; SIGNALING PATHWAY; MAMMALIAN TARGET; TUMOR-SUPPRESSOR; AMINO-ACIDS; INHIBITORS; DISEASE	There is controversy over the role of glycogen synthase kinase-3 (GSK-3) in cancer progression. Recent work has implicated GSK-3 in the regulation of mammalian target of rapamycin (mTOR), a known player in malignant transformation. Autophagy, a selfdegradation pathway, is inhibited by mTOR and is tightly associated with cell survival and tumor growth. Here we show that GSK-3 suppresses autophagy via mTOR complex-1 (mTORC1) and lysosomal regulation. We show that overexpression of GSK-3 isoforms (GSK-3 alpha and GSK-3 alpha) activated mTORC1 and suppressed autophagy in MCF-7 human breast cancer cells as indicated by reduced beclin-1 levels and upregulation of sequestosome 1 (p62/SQSTM1). Further, overexpression of GSK-3 increased the number of autophagosomes and inhibited autophagic flux. This activity was directly related to reduced lysosomal acidification triggered by GSK-3 (in which GSK-3 beta has a stronger impact). We found that lysosomal acidification is reduced in MCF-7 cells that also exhibit increased levels of autophagosomes and p62/SQSTM1 and increased activity of mTORC1. Subsequently, treating cells with GSK-3 inhibitors restored lysosomal acidification, enhanced autophagic flux and inhibited mTORC1. Furthermore, GSK-3 inhibitors inhibited cell proliferation. We provide evidence that GSK3-mediated mTORC1 activity and GSK-3-mediated lysosomal acidification occur via distinct pathways, yet both mTORC1 and lysosomes control cell growth. Finally, we show that GSK-3-reduced lysosomal acidification inhibits endocytic clearance as demonstrated by reduced endocytic degradation of the epidermal growth factor receptor. Taken together, our study places GSK-3 as a key regulator coordinating cellular homeostasis. GSK-3 inhibitors may be useful in targeting mTORC1 and lysosomal acidification for cancer therapy.	[Azoulay-Alfaguter, I.; Elya, R.; Avrahami, L.; Katz, A.; Eldar-Finkelman, H.] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Eldar-Finkelman, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.	heldar@post.tau.ac.il		Eldar-Finkelman, Hagit/0000-0002-8460-9686	Israel Science Foundation [341/10]; Finghort Fund for Cancer Research at Tel Aviv University	Israel Science Foundation(Israel Science Foundation); Finghort Fund for Cancer Research at Tel Aviv University	This research was supported by the Israel Science Foundation grant No. 341/10 and the Finghort Fund for Cancer Research at Tel Aviv University. We thank Dr Dan Klionsky and Dr Zvulun Elazar for their constructive comments.	Aguilar-Morante D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013879; Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Avrahami L, 2013, J BIOL CHEM, V288, P1295, DOI 10.1074/jbc.M112.409250; Azoulay-Alfaguter I, 2011, J BIOL CHEM, V286, P13470, DOI 10.1074/jbc.M110.127969; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Birch NW, 2010, CANCER CELL, V17, P529, DOI 10.1016/j.ccr.2010.05.017; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Boya P, 2012, ANTIOXID REDOX SIGN, V17, P766, DOI 10.1089/ars.2011.4405; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158; Cornu M, 2013, CURR OPIN GENET DEV, V23, P53, DOI 10.1016/j.gde.2012.12.005; Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Doherty L, 2006, NEUROLOGY, V67, P156, DOI 10.1212/01.wnl.0000223844.77636.29; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Eldar-Finkelman H, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00032; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Gulen MF, 2012, IMMUNITY, V37, P800, DOI 10.1016/j.immuni.2012.08.019; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Harris RA, 2002, PROTEOMICS, V2, P212, DOI 10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hernandez F, 2013, J ALZHEIMERS DIS, V33, pS141, DOI 10.3233/JAD-2012-129025; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang J, 2009, J CLIN INVEST, V119, P3519, DOI 10.1172/JCI40572; Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Karyo R, 2010, MOL CELL NEUROSCI, V45, P449, DOI 10.1016/j.mcn.2010.08.004; Kim HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060383; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lauring J, 2013, J NATL COMPR CANC NE, V11, P670, DOI 10.6004/jnccn.2013.0086; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032; Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McCubrey James A., 2014, Advances in Biological Regulation, V54, P176, DOI 10.1016/j.jbior.2013.09.013; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Ougolkov Andrei V, 2006, Future Oncol, V2, P91, DOI 10.2217/14796694.2.1.91; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371; Patel S, 2008, CANCER CELL, V14, P351, DOI 10.1016/j.ccr.2008.10.013; Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123; Pluquet O, 2005, MOL CELL BIOL, V25, P9392, DOI 10.1128/MCB.25.21.9392-9405.2005; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Proud CG., 2013, BIOCHEM SOC T, V39, P431; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Rix LLR, 2014, ACS CHEM BIOL, V9, P353, DOI 10.1021/cb400660a; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003; Shin S, 2014, ONCOGENE, V33, P1690, DOI 10.1038/onc.2013.113; Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Suzuki T, 2013, MOL CELL, V50, P407, DOI 10.1016/j.molcel.2013.03.022; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Voss MH, 2011, HEMATOL ONCOL CLIN N, V25, P835, DOI 10.1016/j.hoc.2011.04.008; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Wazir U, 2014, CANCER GENOM PROTEOM, V11, P167; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhou JB, 2013, J CLIN INVEST, V123, P1821, DOI 10.1172/JCI64398; Zhu Q, 2011, PROSTATE, V71, P835, DOI 10.1002/pros.21300; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	89	70	72	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4613	4623		10.1038/onc.2014.390	http://dx.doi.org/10.1038/onc.2014.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25500539				2022-12-28	WOS:000360189300007
J	Tsuchiya, M; Nakajima, Y; Waku, T; Hiyoshi, H; Morishita, T; Furumai, R; Hayashi, Y; Kishimoto, H; Kimura, K; Yanagisawa, J				Tsuchiya, M.; Nakajima, Y.; Waku, T.; Hiyoshi, H.; Morishita, T.; Furumai, R.; Hayashi, Y.; Kishimoto, H.; Kimura, K.; Yanagisawa, J.			CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population	ONCOGENE			English	Article							BREAST-CANCER CELLS; MORPHOLOGICAL EVOLUTION; UBIQUITIN LIGASE; PROTEINS; HSP90; IDENTIFICATION; CAPACITOR; MCF7; GENE; TRANSCRIPTION	Many types of cancer display heterogeneity in various features, including gene expression and malignant potential. This heterogeneity is associated with drug resistance and cancer progression. Recent studies have shown that the expression of a major protein quality control ubiquitin ligase, carboxyl terminus of Hsc70-interacting protein (CHIP), is negatively correlated with breast cancer clinicopathological stages and poor overall survival. Here we show that CHIP acts as a capacitor of heterogeneous Bcl-2 expression levels and prevents an increase in the anticancer drug-resistant population in breast cancer cells. CHIP knockdown in breast cancer cells increased variation in Bcl-2 expression levels, an antiapoptotic protein, among the cells. Our results also showed that CHIP knockdown increased the proportion of anticancer drug-resistant cells. These findings suggest that CHIP buffers variation in gene expression levels, affecting resistance to anticancer drugs. In single-cell clones derived from breast cancer cell lines, CHIP knockdown did not alter the variation in Bcl-2 expression levels and the proportion of anticancer drug-resistant cells. In contrast, when clonal cells were treated with a mutagen, the variation in Bcl-2 expression levels and proportion of anticancer drug-resistant cells were altered by CHIP knockdown. These results suggest that CHIP masks genetic variations to suppress heterogeneous Bcl-2 expression levels and prevents augmentation of the anticancer drug-resistant population of breast cancer cells. Because genetic variation is a major driver of heterogeneity, our results suggest that the degree of heterogeneity in expression levels is decided by a balance between genetic variation and the buffering capacity of CHIP.	[Tsuchiya, M.; Nakajima, Y.; Hiyoshi, H.; Morishita, T.; Hayashi, Y.; Kishimoto, H.; Kimura, K.; Yanagisawa, J.] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058577, Japan; [Nakajima, Y.; Hiyoshi, H.; Furumai, R.; Kishimoto, H.; Yanagisawa, J.] Univ Tsukuba, Life Sci Ctr, Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; [Waku, T.] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan	University of Tsukuba; University of Tsukuba; University of Tokyo	Kimura, K (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tenno Dai, Tsukuba, Ibaraki 3058577, Japan.	kekimura@tara.tsukuba.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We would like to thank Enago (www.enago.jp) for the English language review.	Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; BUTLER WB, 1986, CANCER RES, V46, P6339; Coley HM, 2009, EJC SUPPL, V7, P3, DOI 10.1016/S1359-6349(09)70003-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davis JM, 2003, CLIN CANCER RES, V9, P1161; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; DREWINKO B, 1973, CANCER RES, V33, P3091; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; HEWITT SM, 1995, CANCER RES, V55, P5386; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lambert G, 2011, NAT REV CANCER, V11, P375, DOI 10.1038/nrc3039; Lee JH, 2004, J BIOL CHEM, V279, P42758, DOI 10.1074/jbc.M407357200; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McDiarmid HM, 2001, MUTAT RES-GEN TOX EN, V497, P39, DOI 10.1016/S1383-5718(01)00245-5; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; PAPENDORP JT, 1985, J CELL PHYSIOL, V125, P591, DOI 10.1002/jcp.1041250331; Patani Neill, 2010, J Carcinog, V9, P9, DOI 10.4103/1477-3163.72505; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; RESNICOFF M, 1987, P NATL ACAD SCI USA, V84, P7295, DOI 10.1073/pnas.84.20.7295; Rudin CM, 2003, CANCER RES, V63, P312; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Stevenson HS, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1766; Tabuchi Y, 2009, INT J ONCOL, V34, P313, DOI 10.3892/ijo_00000153; Theodoraki MA, 2012, BBA-MOL CELL RES, V1823, P683, DOI 10.1016/j.bbamcr.2011.08.006; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang JY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-388; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	43	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4656	4663		10.1038/onc.2014.387	http://dx.doi.org/10.1038/onc.2014.387			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435366	Bronze			2022-12-28	WOS:000360189300011
J	Zhu, L; Lu, Z; Zhao, H				Zhu, L.; Lu, Z.; Zhao, H.			Antitumor mechanisms when pRb and p53 are genetically inactivated	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; RETINOBLASTOMA TUMOR-SUPPRESSOR; SYNTHETIC LETHAL INTERACTIONS; SMALL-MOLECULE INHIBITORS; SENESCENCE IN-VIVO; CELL-CYCLE ARREST; DNA-DAMAGE; P53-INDUCIBLE REGULATOR; GLUTAMINE-METABOLISM; TARGET GENES	pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.	[Zhu, L.] Albert Einstein Coll Med, Dept Dev & Mol Biol & Ophthalmol & Visual Sci & M, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; [Zhu, L.] Albert Einstein Coll Med, Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhu, L (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol & Ophthalmol & Visual Sci & M, Albert Einstein Comprehens Canc Ctr, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA.	liang.zhu@einstein.yu.edu		Lu, Zhonglei/0000-0002-8915-4828	NIH [RO1CA127901, RO1CA131421]; DOD PCRP Postdoctoral Fellowship [PC121837]; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE [R01CA131421, R01CA127901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD PCRP Postdoctoral Fellowship; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Work in the authors' laboratory was supported by NIH grants RO1CA127901 and RO1CA131421. HZ is a recipient of DOD PCRP Postdoctoral Fellowship (PC121837), and LZ acknowledges support from the Irma T Hirschl Career Scientist Award.	Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Aksoy O, 2012, GENE DEV, V26, P1546, DOI 10.1101/gad.196238.112; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Clem BF, 2012, CLIN CANCER RES, V18, P6096, DOI 10.1158/1078-0432.CCR-11-3164; Clermont F, 2012, EMBO MOL MED, V4, P688, DOI 10.1002/emmm.201201509; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Conkrite K, 2011, GENE DEV, V25, P1734, DOI 10.1101/gad.17027411; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Emerling BM, 2013, CELL, V155, P844, DOI 10.1016/j.cell.2013.09.057; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Haley VL, 2012, EMBO MOL MED, V4, P705, DOI 10.1002/emmm.201101105; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Korenjak M, 2012, MOL CELL BIOL, V32, P4375, DOI 10.1128/MCB.00536-12; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Lee P, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-1; Li BH, 2010, CANCER CELL, V17, P469, DOI 10.1016/j.ccr.2010.03.019; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; McEvoy J, 2014, ONCOTARGET, V5, P438, DOI 10.18632/oncotarget.1686; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Morandell S, 2013, CELL REP, V5, P868, DOI 10.1016/j.celrep.2013.10.025; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2014, J BIOL CHEM, V289, P122, DOI 10.1074/jbc.M113.502138; Murphy BL, 2013, CANCER RES, V73, P7068, DOI 10.1158/0008-5472.CAN-13-0927; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nickeleit I, 2008, CANCER CELL, V14, P23, DOI 10.1016/j.ccr.2008.05.016; Nicolay BN, 2013, CURR OPIN CELL BIOL, V25, P735, DOI 10.1016/j.ceb.2013.07.012; Nicolay BN, 2013, GENE DEV, V27, P182, DOI 10.1101/gad.206227.112; Nittner D, 2012, NAT CELL BIOL, V14, P958, DOI 10.1038/ncb2556; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Ooi LC, 2013, CANCER SCI, V104, P1461, DOI 10.1111/cas.12246; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CELL CYCLE, V8, P3112, DOI 10.4161/cc.8.19.9626; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Rico-Bautista E, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-153; Sangwan M, 2012, ONCOGENE, V31, P5019, DOI 10.1038/onc.2011.654; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Shats I, 2013, CANCER RES, V73, P6056, DOI 10.1158/0008-5472.CAN-13-0453; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Talluri S, 2010, MOL CELL BIOL, V30, P948, DOI 10.1128/MCB.01168-09; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ungermannova D, 2013, J BIOMOL SCREEN, V18, P910, DOI 10.1177/1087057113485789; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang JK, 2004, CELL CYCLE, V3, P952; Zhang TY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004357; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	146	23	23	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4547	4557		10.1038/onc.2014.399	http://dx.doi.org/10.1038/onc.2014.399			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486431	Green Accepted			2022-12-28	WOS:000360189300001
J	Defamie, V; Sanchez, O; Murthy, A; Khokha, R				Defamie, V.; Sanchez, O.; Murthy, A.; Khokha, R.			TIMP3 controls cell fate to confer hepatocellular carcinoma resistance	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; COMPENSATORY PROLIFERATION; TISSUE INHIBITOR; TUMOR-FORMATION; LIVER; INFLAMMATION; P53; SUPPRESSOR; EXPRESSION; PROMOTER	Inflammation enables human cancers and is a critical promoter of hepatocellular carcinoma (HCC). TIMP3 (Tissue inhibitor of metalloproteinase 3), a natural metalloproteinase inhibitor, controls cytokine and growth factor bioavailability to keep inflammation in check and regulate cell survival in the liver. TIMP3 is also found silenced in human cancers. We therefore tested whether Timp3 affects HCC predisposition. Remarkably, genetic loss of Timp3 protected from carcinogen-induced HCC through the immediate engagement of several tumor suppressor pathways, while tumor necrosis factor (TNF) signaling was dispensable for this protection. All wild-type mice developed HCC by 12 months, whereas HCC incidence was reduced to 33% at 12 months and 57% at 15 months in Timp3 null mice. Upon acute carcinogen treatment the deficient livers exhibited greater cytokine expression, but lower cell death and higher hepatocyte senescence. We found that precocious activation of p53, p38 and Notch preceded senescence and hepatic cell differentiation, and these events were conserved throughout tumorigenesis. Timp3-deficient mouse embryo fibroblasts also responded to carcinogen by favoring senescence over apoptosis. We conclude that Timp3 status determines p53, p38 and Notch coactivation to instruct hepatic cell fate and transformation and uncover mechanisms that are protective even within a proinflammatory microenvironment.	[Defamie, V.; Murthy, A.; Khokha, R.] Univ Toronto, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada; [Sanchez, O.] Univ Ontario, Inst Technol, Oshawa, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Ontario Tech University	Khokha, R (corresponding author), TMDT Res, MARS Med Discovery Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	rkhokha@uhnres.utoronto.ca		Defamie, Virginie/0000-0002-6405-0539; Khokha, Rama/0000-0002-6028-1524	Canadian Institutes of Health Research; Helena H Lam and Fondation pour la Recherche Medicale fellowships	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Helena H Lam and Fondation pour la Recherche Medicale fellowships	We would like to thank Dr Paul Waterhouse and Dr Razqallah Hakem for their constructive criticism of the manuscript. This work was supported by grants from the Canadian Institutes of Health Research to RK. VD was supported by the Helena H Lam and Fondation pour la Recherche Medicale fellowships.	Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Bachman KE, 1999, CANCER RES, V59, P798; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2004, NAT GENET, V36, P934, DOI 10.1038/ng0904-934; Boggs K, 2009, CELL BIOL INT, V33, P318, DOI 10.1016/j.cellbi.2008.12.005; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Catasus L, 2013, HISTOPATHOLOGY, V62, P632, DOI 10.1111/his.12047; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Dill MT, 2013, HEPATOLOGY, V57, P1607, DOI 10.1002/hep.26165; Dolado Ignacio, 2008, V20, P99, DOI 10.1007/4735_2007_0245; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Fiorentino L, 2010, HEPATOLOGY, V51, P103, DOI 10.1002/hep.23250; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Hui LJ, 2007, CELL CYCLE, V6, P2429, DOI 10.4161/cc.6.20.4774; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jeliazkova P, 2013, HEPATOLOGY, V57, P2469, DOI 10.1002/hep.26254; Kang JS, 2007, CANCER RES, V67, P11141, DOI 10.1158/0008-5472.CAN-07-1369; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; Kohler C, 2004, HEPATOLOGY, V39, P1056, DOI 10.1002/hep.20156; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45; Masson D, 2010, EUR J CANCER, V46, P1430, DOI 10.1016/j.ejca.2010.01.009; Menghini R, 2009, GASTROENTEROLOGY, V136, P663, DOI 10.1053/j.gastro.2008.10.079; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Murthy A, 2012, IMMUNITY, V36, P105, DOI 10.1016/j.immuni.2012.01.005; Murthy A, 2010, J CLIN INVEST, V120, P2731, DOI 10.1172/JCI42686; Nakamura M, 2005, LAB INVEST, V85, P165, DOI 10.1038/labinvest.3700223; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Poehlmann A, 2010, PATHOL RES PRACT, V206, P591, DOI 10.1016/j.prp.2010.06.006; Qi RZ, 2003, CANCER RES, V63, P8323; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Smookler DS, 2006, J IMMUNOL, V176, P721, DOI 10.4049/jimmunol.176.2.721; Sun Hong, 2007, V383, P311, DOI 10.1007/978-1-59745-335-6_20; Tchorz JS, 2009, HEPATOLOGY, V50, P871, DOI 10.1002/hep.23048; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; VESSELINOVITCH SD, 1983, CANCER RES, V43, P4253; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wisniewska M, 2008, J MOL BIOL, V381, P1307, DOI 10.1016/j.jmb.2008.06.088; Xu PL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002689; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140	58	19	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4098	4108		10.1038/onc.2014.339	http://dx.doi.org/10.1038/onc.2014.339			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347747				2022-12-28	WOS:000358780500008
J	Jiang, L; Xiao, L; Sugiura, H; Huang, X; Ali, A; Kuro-O, M; Deberardinis, RJ; Boothman, DA				Jiang, L.; Xiao, L.; Sugiura, H.; Huang, X.; Ali, A.; Kuro-o, M.; Deberardinis, R. J.; Boothman, D. A.			Metabolic reprogramming during TGF beta 1-induced epithelial-to-mesenchymal transition	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; ATP CITRATE LYASE; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; CELL-GROWTH; INHIBITION; EXPRESSION; APOPTOSIS; SREBP	Metastatic progression, including extravasation and micrometastatic outgrowth, is the main cause of cancer patient death. Recent studies suggest that cancer cells reprogram their metabolism to support increased proliferation through increased glycolysis and biosynthetic activities, including lipogenesis pathways. However, metabolic changes during metastatic progression, including alterations in regulatory gene expression, remain undefined. We show that transforming growth factor beta 1 (TGF beta 1)-induced epithelial-to-mesenchymal transition (EMT) is accompanied by coordinately reduced enzyme expression required to convert glucose into fatty acids, and concomitant enhanced respiration. Overexpressed Snail1, a transcription factor mediating TGF beta 1-induced EMT, was sufficient to suppress carbohydrate-responsive-element-binding protein (ChREBP, a master lipogenic regulator), and fatty acid synthase (FASN), its effector lipogenic gene. Stable FASN knockdown was sufficient to induce EMT, stimulate migration and extravasation in vitro. FASN silencing enhanced lung metastasis and death in vivo. These data suggest that a metabolic transition that suppresses lipogenesis and favors energy production is an essential component of TGF beta 1-induced EMT and metastasis.	[Jiang, L.; Deberardinis, R. J.] Childrens Med Ctr Res Inst, Dallas, TX 75390 USA; [Xiao, L.; Sugiura, H.; Huang, X.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol & Radiat Oncol, Dallas, TX 75390 USA; [Sugiura, H.; Kuro-o, M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Ali, A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Kuro-o, M.] Jichi Med Univ, Ctr Mol Med, Shimotsuke, Tochigi, Japan	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Jichi Medical University	Deberardinis, RJ (corresponding author), Childrens Med Ctr Res Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ralph.Deberardinis@utsouthwestern.edu; David.Boothman@utsouthwestern.edu	Boothman, David/Q-7776-2019	Sugiura, Hidekazu/0000-0003-2950-4512; Huang, Xiumei/0000-0002-7306-0288	DOE/NASA grant [DE-FG-022179-18-21]; NIH [R01 CA139217, RO1 CA157996]; CPRIT [RP130272]; imaging core of the Simmons Cancer Center Support Grant [5P30 CA142543-03]; NATIONAL CANCER INSTITUTE [R01CA157996, P30CA142543, R01CA139217] Funding Source: NIH RePORTER	DOE/NASA grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; imaging core of the Simmons Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Xiuquan Luo for his aid in the BLI measurements and animal injections. This work was supported by DOE/NASA grant DE-FG-022179-18-21 and by NIH R01 CA139217 to DAB and NIH RO1 CA157996 and CPRIT RP130272 to RJD. We are grateful to the imaging core of the Simmons Cancer Center Support Grant (5P30 CA142543-03).	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; De Schrijver E, 2003, CANCER RES, V63, P3799; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Goetz EM, 2011, ONCOGENE, V30, P3745, DOI 10.1038/onc.2011.92; Hanai J, 2012, J CELL PHYSIOL, V227, P1709, DOI 10.1002/jcp.22895; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang XM, 2012, CANCER RES, V72, P3038, DOI 10.1158/0008-5472.CAN-11-3135; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kim JH, 2007, J KOREAN MED SCI, V22, P898, DOI 10.3346/jkms.2007.22.5.898; Kim WS, 1999, ANTICANCER RES, V19, P301; Klokov D, 2013, ONCOGENE, V32, P479, DOI 10.1038/onc.2012.64; Kurosu H, 2007, J BIOL CHEM, V282, P26687, DOI 10.1074/jbc.M704165200; Liu XP, 2013, NAT CELL BIOL, V15, P829, DOI 10.1038/ncb2765; Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928; Metallo CM, 2013, MOL CELL, V49, P388, DOI 10.1016/j.molcel.2013.01.018; Pallis AG, 2012, CANCER TREAT REV, V38, P861, DOI 10.1016/j.ctrv.2011.12.006; Semenza GL, 2012, TRENDS MOL MED, V18, P534, DOI 10.1016/j.molmed.2012.08.001; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Thompson CB, 2009, NEW ENGL J MED, V360, P813, DOI 10.1056/NEJMe0810213; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Yang L, 2008, CANCER RES, V68, P9107, DOI 10.1158/0008-5472.CAN-08-2556; Yuan HX, 2013, MOL CELL, V49, P379, DOI 10.1016/j.molcel.2013.01.019; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou HJ, 2014, BIOMATERIALS, V35, P1597, DOI 10.1016/j.biomaterials.2013.11.020	32	131	136	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3908	3916		10.1038/onc.2014.321	http://dx.doi.org/10.1038/onc.2014.321			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284588	Green Accepted			2022-12-28	WOS:000358544200003
J	Rajapaksa, G; Nikolos, F; Bado, I; Clarke, R; Gustafsson, JA; Thomas, C				Rajapaksa, G.; Nikolos, F.; Bado, I.; Clarke, R.; Gustafsson, J-A; Thomas, C.			ER beta decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; ESTROGEN-RECEPTOR-BETA; ENDOPLASMIC-RETICULUM STRESS; BOX BINDING PROTEIN-1; GENE-EXPRESSION; KAPPA-B; PROMOTES; XBP-1; BORTEZOMIB; AUTOPHAGY	Unfolded protein response (UPR) is an adaptive reaction that allows cancer cells to survive endoplasmic reticulum (EnR) stress that is often induced in the tumor microenvironment because of inadequate vascularization. Previous studies report an association between activation of the UPR and reduced sensitivity to antiestrogens and chemotherapeutics in estrogen receptor alpha (ER alpha)-positive and triple-negative breast cancers, respectively. ER alpha has been shown to regulate the expression of a key mediator of the EnR stress response, the X-box-binding protein-1 (XBP-1). Although network prediction models have associated ER beta with the EnR stress response, its role as regulator of the UPR has not been experimentally tested. Here, upregulation of wild-type ER beta (ER beta 1) or treatment with ER beta agonists enhanced apoptosis in breast cancer cells in the presence of pharmacological inducers of EnR stress. Targeting the BCL-2 to the EnR of the ER beta 1-expressing cells prevented the apoptosis induced by EnR stress but not by non-EnR stress apoptotic stimuli indicating that ER beta 1 promotes EnR stress-regulated apoptosis. Downregulation of inositol-requiring kinase 1 alpha (IRE1 alpha) and decreased splicing of XBP-1 were associated with the decreased survival of the EnR-stressed ER beta 1-expressing cells. ER beta 1 was found to repress the IRE1 pathway of the UPR by inducing degradation of IRE1 alpha. These results suggest that the ability of ER beta 1 to target the UPR may offer alternative treatment strategies for breast cancer.	[Rajapaksa, G.; Nikolos, F.; Bado, I.; Gustafsson, J-A; Thomas, C.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA; [Clarke, R.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA	University of Houston System; University of Houston; Georgetown University	Thomas, C (corresponding author), Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, 3605 Cullen Blvd, Houston, TX 77204 USA.	chthomas@uh.edu	Bado, Igor/AAY-1214-2021; Clarke, Robert/A-6485-2008; Nikolos, Fotis/AGF-3489-2022	Bado, Igor/0000-0001-8855-4750; Clarke, Robert/0000-0002-9278-0854; Nikolos, Fotis/0000-0002-8622-0017	Swedish Cancer Society; Robert A Welch Foundation [E-0004]; Emerging Technology Fund of Texas [300-9-1958];  [U54-CA149147]; NATIONAL CANCER INSTITUTE [U54CA149147] Funding Source: NIH RePORTER	Swedish Cancer Society(Swedish Cancer Society); Robert A Welch Foundation(The Welch Foundation); Emerging Technology Fund of Texas; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C Koumenis for the Bcl-2 expression vector and Anders Strom for the ER beta 2 expression lentivirus. We also thank Efrocini Cuko for technical assistance with confocal microscopy. This study was supported by grants from the Swedish Cancer Society, the Robert A Welch Foundation (E-0004), the Emerging Technology Fund of Texas under Agreement 300-9-1958 and the U54-CA149147.	BUTLER WB, 1992, CANCER RES, V52, P6164; BUTLER WB, 1986, CANCER RES, V46, P6339; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Cheng L, 2012, J CLIN INVEST, V122, P2857, DOI 10.1172/JCI62676; Clarke R, 2012, CANCER RES, V72, P1321, DOI 10.1158/0008-5472.CAN-11-3213; Clarke Robert, 2011, Horm Mol Biol Clin Investig, V5, P35, DOI 10.1515/HMBCI.2010.073; Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269; Crawford AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008604; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479; Davis AM, 2008, J MOL ENDOCRINOL, V41, P205, DOI 10.1677/JME-08-0029; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; Gao BX, 2008, EMBO REP, V9, P480, DOI 10.1038/embor.2008.37; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Gu ZP, 2002, CANCER RES, V62, P3428; Hartman J, 2009, CANCER RES, V69, P6100, DOI 10.1158/0008-5472.CAN-09-0506; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jones MD, 2010, CLIN CANCER RES, V16, P4978, DOI 10.1158/1078-0432.CCR-09-3293; Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koong AC, 2006, CANCER BIOL THER, V5, P756, DOI 10.4161/cbt.5.7.2973; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee E, 2011, INT J CANCER, V128, P726, DOI 10.1002/ijc.25370; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leung YK, 2006, NEOPLASIA, V8, P242, DOI 10.1593/neo.05853; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Nakajima Y, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001551; Nikolos F, 2014, MOL CANCER RES, V12, P843, DOI 10.1158/1541-7786.MCR-13-0663; Rodriguez DA, 2012, EMBO J, V31, P2322, DOI 10.1038/emboj.2012.84; Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528; Shajahan AN, 2012, J BIOL CHEM, V287, P17682, DOI 10.1074/jbc.M111.304022; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Thomas C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3358; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Thomas CG, 2011, BREAST CANCER RES TR, V127, P417, DOI 10.1007/s10549-010-1011-z; Thomas CG, 2009, J BIOL CHEM, V284, P6282, DOI 10.1074/jbc.M806189200; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yang CH, 2006, ANN ONCOL, V17, P813, DOI 10.1093/annonc/mdj131; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zhang B, 2009, BIOINFORMATICS, V25, P526, DOI 10.1093/bioinformatics/btn660; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec	50	34	35	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4130	4141		10.1038/onc.2014.343	http://dx.doi.org/10.1038/onc.2014.343			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347741				2022-12-28	WOS:000358780500011
J	Ramos, P; Bentires-Alj, M				Ramos, P.; Bentires-Alj, M.			Mechanism-based cancer therapy: resistance to therapy, therapy for resistance	ONCOGENE			English	Review							METASTATIC BREAST-CANCER; PATIENTS RECEIVING IMATINIB; MEDIATED DRUG-RESISTANCE; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TRASTUZUMAB RESISTANCE; ACQUIRED-RESISTANCE; TUMOR MICROENVIRONMENT; PI3K INHIBITORS; MEK INHIBITORS	The introduction of targeted therapy promised personalized and efficacious cancer treatments. However, although some targeted therapies have undoubtedly improved prognosis and outcome for specific cancer patients, the recurrent problem of therapeutic resistance subdues present revolutionary claims in this field. The plasticity of tumor cells leads to the development of drug resistance by distinct mechanisms: (1) mutations in the target, (2) reactivation of the targeted pathway, (3) hyperactivation of alternative pathways and (4) cross-talk with the microenvironment. Moreover, the intra-tumor heterogeneity of most tumors can also limit therapeutic response. Interestingly, the early identification of some mechanisms of resistance led to the use of alternative agents that improved clinical benefit, demonstrating that an understanding of the molecular mechanisms driving resistance to specific therapies is of paramount importance. Here we review the most generalized mechanisms of resistance to targeted therapies, together with some experimental strategies employed to identify such mechanisms. Therapeutic failure is not an option and we need to understand the dynamics of tumor adaptation in order to adequately adjust therapies; in essence 'to fight fire with fire'.	[Ramos, P.; Bentires-Alj, M.] Friedrich Miescher Inst Biomed Res FMI, Mechanisms Canc, Basel, Switzerland; [Ramos, P.] Novartis Inst Biomed Res, Oncol, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Bentires-Alj, M (corresponding author), Friedrich Miescher Inst Biomed Res, Mechanisms Canc, Maulbeerstr 66, CH-4058 Basel, Switzerland.	bentires@fmi.ch	Bentires-Alj, Mohamed/F-4484-2015	Bentires-Alj, Mohamed/0000-0001-6344-1127	Novartis Research Foundation; European Research Council (ERC) [243211-PTP5BDC]; Swiss Cancer League; Swiss national science foundation; Krebsliga Beider Basel; 'Novartis presidential postdoc fellowship'	Novartis Research Foundation; European Research Council (ERC)(European Research Council (ERC)European Commission); Swiss Cancer League; Swiss national science foundation(Swiss National Science Foundation (SNSF)European Commission); Krebsliga Beider Basel; 'Novartis presidential postdoc fellowship'	Research in the laboratory of MB-A is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTP5BDC), the Swiss Cancer League, the Swiss national science foundation and the Krebsliga Beider Basel. PR recevied a 'Novartis presidential postdoc fellowship'.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aftimos PG, 2013, INT J ONCOL, V43, P919, DOI 10.3892/ijo.2013.2008; Alba E, 2014, BRIT J CANCER, V110, P1139, DOI 10.1038/bjc.2013.831; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Andre F, 2010, J CLIN ONCOL, V28, P5110, DOI 10.1200/JCO.2009.27.8549; Barok M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2868; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Beaver JA, 2012, FUTURE ONCOL, V8, P651, DOI [10.2217/fon.12.49, 10.2217/FON.12.49]; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Bousquet G, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3615; Britschgi A, 2013, DRUG RESIST UPDATE, V16, P68, DOI 10.1016/j.drup.2013.10.001; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280-012-2043-3; Burris HA, 2011, J CLIN ONCOL, V29, P398, DOI 10.1200/JCO.2010.29.5865; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-93; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cools J, 2004, CANCER RES, V64, P6385, DOI 10.1158/0008-5472.CAN-04-2148; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Dhillon S, 2013, DRUGS, V73, P475, DOI 10.1007/s40265-013-0034-2; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fang H, 2013, CANCER RES, V73, P4965, DOI 10.1158/0008-5472.CAN-13-0661; Galizia G, 2007, ONCOGENE, V26, P3654, DOI 10.1038/sj.onc.1210381; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Gambacorti-Passerini C, 2011, JNCI-J NATL CANCER I, V103, P553, DOI 10.1093/jnci/djr060; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Gridelli C, 2007, ONCOLOGIST, V12, P840, DOI 10.1634/theoncologist.12-7-840; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233; Ho WJ, 2010, CANCER SCI, V101, P2637, DOI 10.1111/j.1349-7006.2010.01723.x; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hongisto V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077232; Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Janku F, 2014, THER ADV MED ONCOL, V6, P43, DOI 10.1177/1758834013517414; Janku F, 2013, CANCER RES, V73, P276, DOI 10.1158/0008-5472.CAN-12-1726; Jin K, 2012, INT J ONCOL, V41, P583, DOI 10.3892/ijo.2012.1469; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Jordan VC, 2008, EUR J CANCER, V44, P30, DOI 10.1016/j.ejca.2007.11.002; JORDAN VC, 1976, CANCER TREAT REP, V60, P1409; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Junttila TT, 2011, BREAST CANCER RES TR, V128, P347, DOI 10.1007/s10549-010-1090-x; Karvela M, 2012, EXPERT REV ANTICANC, V12, P381, DOI [10.1586/ERA.12.10, 10.1586/era.12.10]; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; Krop IE, 2010, J CLIN ONCOL, V28, P2698, DOI 10.1200/JCO.2009.26.2071; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Legrier ME, 2007, CANCER RES, V67, P11300, DOI 10.1158/0008-5472.CAN-07-0702; Li FF, 2014, INT J CANCER, V134, P1257, DOI 10.1002/ijc.28261; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; McCubrey JA, 2012, ONCOTARGET, V3, P1068, DOI 10.18632/oncotarget.659; McCubrey JA, 2011, J CELL PHYSIOL, V226, P2762, DOI 10.1002/jcp.22647; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood-2004-01-0236; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109; NICHOLSON RI, 1975, EUR J CANCER, V11, P571, DOI 10.1016/0014-2964(75)90129-2; Nielsen DL, 2013, BREAST, V22, P1, DOI 10.1016/j.breast.2012.09.008; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Park CC, 2008, CANCER RES, V68, P4398, DOI 10.1158/0008-5472.CAN-07-6390; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Quintas-Cardama A, 2013, LEUKEMIA RES, V37, P487, DOI 10.1016/j.leukres.2013.01.006; Rad R, 2010, SCIENCE, V330, P1104, DOI 10.1126/science.1193004; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schwartz MA, 2008, CLIN CANCER RES, V14, P6193, DOI 10.1158/1078-0432.CCR-08-1285; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sridhar SS, 2003, LANCET ONCOL, V4, P397, DOI 10.1016/S1470-2045(03)01137-9; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Vecchione L, 2011, EXP CELL RES, V317, P2765, DOI 10.1016/j.yexcr.2011.08.021; Vignot S, 2013, J CLIN ONCOL, V31, P2167, DOI 10.1200/JCO.2012.47.7737; Vignot S, 2012, CRIT REV ONCOL HEMAT, V84, P301, DOI 10.1016/j.critrevonc.2012.05.002; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang LP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-248; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Will M, 2014, CANCER DISCOV, V4, P334, DOI 10.1158/2159-8290.CD-13-0611; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yauch RL, 2012, CURR OPIN GENET DEV, V22, P45, DOI 10.1016/j.gde.2012.01.003; Yu K, 2008, CANCER BIOL THER, V7, P307	128	156	161	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3617	3626		10.1038/onc.2014.314	http://dx.doi.org/10.1038/onc.2014.314			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25263438				2022-12-28	WOS:000357679100001
J	Patsialou, A; Wang, Y; Pignatelli, J; Chen, X; Entenberg, D; Oktay, M; Condeelis, JS				Patsialou, A.; Wang, Y.; Pignatelli, J.; Chen, X.; Entenberg, D.; Oktay, M.; Condeelis, J. S.			Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGF beta in claudin-low breast tumor cells	ONCOGENE			English	Article							STIMULATING FACTOR-I; GENE-EXPRESSION; CIRCULATING LEVELS; MAMMARY-TUMORS; CANCER-CELLS; MOLECULAR PORTRAITS; METASTATIC BEHAVIOR; CSF-1 RECEPTOR; GROWTH; VIVO	Patient data suggest that colony-stimulating factor-1 (CSF1) and its receptor (CSF1R) have critical roles during breast cancer progression. We have previously shown that in human breast tumors expressing both CSF1 and CSF1R, invasion in vivo is dependent both on a paracrine interaction with tumor-associated macrophages and an autocrine regulation of CSF1R in the tumor cells themselves. Although the role of the paracrine interaction between tumor cells and macrophages has been extensively studied, very little is known about the mechanism by which the autocrine CSF1R signaling contributes to tumor progression. We show here that breast cancer patients of the claudin-low subtype have significantly increased expression of CSF1R. Using a panel of breast cancer cell lines, we confirm that CSF1R expression is elevated and regulated by TGF beta specifically in claudin-low cell lines. Abrogation of autocrine CSF1R signaling in MDA-MB-231 xenografts (a claudin-low cell line) leads to increased tumor size by enhanced proliferation, but significantly reduced invasion, dissemination and metastasis. Indeed, we show that proliferation and invasion are oppositely regulated by CSF1R downstream of TGF beta only in claudin-low cell lines. Intravital multiphoton imaging revealed that inhibition of CSF1R in the tumor cells leads to decreased in vivo motility and a more cohesive morphology. We show that, both in vitro and in vivo, CSF1R inhibition results in a reversal of claudin-low marker expression by significant upregulation of luminal keratins and tight-junction proteins such as claudins. Finally, we show that artificial overexpression of claudins in MDA-MB-231 cells is sufficient to tip the cells from an invasive state to a proliferative state. Our results suggest that autocrine CSF1R signaling is essential in maintaining low claudin expression and that it mediates a switch between the proliferative and the invasive state in claudin-low tumor cells downstream of TGF beta.	[Patsialou, A.; Wang, Y.; Pignatelli, J.; Chen, X.; Entenberg, D.; Condeelis, J. S.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA; [Wang, Y.; Entenberg, D.; Condeelis, J. S.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA; [Oktay, M.] Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Patsialou, A (corresponding author), UCL, UCL Canc Inst, Res Dept Canc Biol, 72 Huntley St, London WC1E 6DD, England.	a.patsialou@ucl.ac.uk; john.condeelis@einstein.yu.edu	Entenberg, David/AAT-2722-2020	Entenberg, David/0000-0003-0422-7264	NCI [P30 CA 013330, 5RO1CA164468, RO1CA170507]; NATIONAL CANCER INSTITUTE [P01CA100324, R01CA164468, R01CA170507, P30CA013330] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Paraic Kenny, Richard Stanley, Jeffrey Segall and members of the Condeelis lab for helpful discussions. The AFS98, total and phospho-Y559 CSF1R antibodies were a generous gift from Dr Richard Stanley. For technical help at Albert Einstein College of Medicine, we thank the Histotechnology and Comparative Pathology Facility, the shRNA Core Facility, the FACS Facility (supported by NCI P30 CA 013330) and the Genomics Facility. This work was supported by NCI grants 5RO1CA164468 (AP, YW, XC, DE and JSC) and RO1CA170507 (JP, MO and JSC).	Agarwal R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008002; Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; ARTEAGA CL, 1988, CANCER RES, V48, P3898; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cross M, 2005, PROTEOMICS, V5, P4754, DOI 10.1002/pmic.200500058; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Entenberg D, 2011, NAT PROTOC, V6, P1500, DOI 10.1038/nprot.2011.376; Farina AR, 1998, INT J CANCER, V75, P721; FILDERMAN AE, 1992, CANCER RES, V52, P3661; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; KACINSKI BM, 1990, AM J PATHOL, V137, P135; Kedrin D, 2008, NAT METHODS, V5, P1019, DOI 10.1038/nmeth.1269; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Morandi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027450; Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897; Patsialou Antonia, 2013, Intravital, V2, pe25294; Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008-5472.CAN-05-3523; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Resnick MB, 2005, HUM PATHOL, V36, P886, DOI 10.1016/j.humpath.2005.05.019; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sapi E, 1996, CANCER RES, V56, P5704; Scholl SM, 1996, BREAST CANCER RES TR, V39, P275, DOI 10.1007/BF01806155; SCHOLL SM, 1994, BRIT J CANCER, V69, P342, DOI 10.1038/bjc.1994.62; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Sudo T, 1995, ONCOGENE, V11, P2469; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Wyckoff JB, 2000, CANCER RES, V60, P2504; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	53	32	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2721	2731		10.1038/onc.2014.226	http://dx.doi.org/10.1038/onc.2014.226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25088194	Green Accepted			2022-12-28	WOS:000354979500005
J	Stodden, GR; Lindberg, ME; King, ML; Paquet, M; MacLean, JA; Mann, JL; DeMayo, FJ; Lydon, JP; Hayashi, K				Stodden, G. R.; Lindberg, M. E.; King, M. L.; Paquet, M.; MacLean, J. A.; Mann, J. L.; DeMayo, F. J.; Lydon, J. P.; Hayashi, K.			Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; DIFFERENT HISTOLOGIC TYPES; UTERINE SEROUS CARCINOMA; NF-KAPPA-B; ENDOMETRIAL CARCINOMA; HUMAN BREAST; MICROARRAY ANALYSIS; CANCER DEVELOPMENT; GASTRIC-CARCINOMA; ADHESION	Type II endometrial carcinomas (ECs) are estrogen independent, poorly differentiated tumors that behave in an aggressive manner. As TP53 mutation and CDH1 inactivation occur in 80% of human endometrial type II carcinomas, we hypothesized that mouse uteri lacking both Trp53 and Cdh1 would exhibit a phenotype indicative of neoplastic transformation. Mice with conditional ablation of Cdh1 and Trp53 (Cdh1(d/d)Trp53(d/d)) clearly demonstrate architectural features characteristic of type II ECs, including focal areas of papillary differentiation, protruding cytoplasm into the lumen (hobnailing) and severe nuclear atypia at 6 months of age. Further, Cdh1(d/d)Trp53(d/d) tumors in 12-month-old mice were highly aggressive, and metastasized to nearby and distant organs within the peritoneal cavity, such as abdominal lymph nodes, mesentery and peri-intestinal adipose tissues, demonstrating that tumorigenesis in this model proceeds through the universally recognized morphological intermediates associated with type II endometrial neoplasia. We also observed abundant cell proliferation and complex angiogenesis in the uteri of Cdh1(d/d)Trp53(d/d) mice. Our microarray analysis found that most of the genes differentially regulated in the uteri of Cdh1(d/d)Trp53(d/d) mice were involved in inflammatory responses. CD163 and Arg1, markers for tumor-associated macrophages, were also detected and increased in the uteri of Cdh1(d/d)Trp53(d/d) mice, suggesting that an inflammatory tumor microenvironment with immune cell recruitment is augmenting tumor development in Cdh1(d/d)Trp53(d/d) uteri. Further, inflammatory mediators secreted from CDH1-negative, TP53 mutant endometrial cancer cells induced normal macrophages to express inflammatory-related genes through activation of nuclear factor-kappa B signaling. These results indicate that absence of CDH1 and TP53 in endometrial cells initiates chronic inflammation, promotes tumor microenvironment development following the recruitment of macrophages and promotes aggressive ECs.	[Stodden, G. R.; Lindberg, M. E.; King, M. L.; MacLean, J. A.; Hayashi, K.] So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; [Paquet, M.] Univ Montreal St Hyacinthe, Dept Pathol & Microbiol, Quebec City, PQ, Canada; [Mann, J. L.] So Illinois Univ, Sch Med, Dept Pathol, Springfield, IL USA; [DeMayo, F. J.; Lydon, J. P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Baylor College of Medicine	Hayashi, K (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, 1135 Lincoln Dr, Carbondale, IL 62901 USA.	khayashi@siumed.edu	DeMayo, Francesco/C-6255-2019; Paquet, Marilene/L-3414-2019	DeMayo, Francesco/0000-0002-9480-7336; Paquet, Marilene/0000-0002-3562-4636; Hayashi, Kanako/0000-0002-5028-799X	NIH/NCI [R15CA179214]; ACS-IL [139038]; NIH/NICHD [R15HD065584, U54HD007495]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD065584] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R15CA179214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103311] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS-IL; NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Jenny Zadeh at the University of Illinois at Urbana-Champaign Biotechnology Center for microarray analysis. This work was supported by NIH/NCI R15CA179214 and ACS-IL 139038 (to KH), NIH/NICHD R15HD065584 (to JAM) and NIH/NICHD U54HD007495 (to FJD and JPL).	Acharya S, 2005, LANCET ONCOL, V6, P961, DOI 10.1016/S1470-2045(05)70463-0; Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; AMBROS RA, 1995, HUM PATHOL, V26, P1260, DOI 10.1016/0046-8177(95)90203-1; Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Boussadia O, 2002, MECH DEVELOP, V115, P53, DOI 10.1016/S0925-4773(02)00090-4; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; De Marzo AM, 1999, UROLOGY, V53, P707, DOI 10.1016/S0090-4295(98)00577-9; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Goff BA, 2005, GYNECOL ONCOL, V98, P341, DOI 10.1016/j.ygyno.2005.07.006; GRAFF JR, 1995, CANCER RES, V55, P5195; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hermani Alexander, 2006, Exp Cell Res, V312, P184, DOI 10.1016/j.yexcr.2005.10.013; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Holcomb K, 2002, OBSTET GYNECOL, V100, P1290, DOI 10.1016/S0029-7844(02)02391-8; Horn LC, 2007, ANN DIAGN PATHOL, V11, P297, DOI 10.1016/j.anndiagpath.2007.05.002; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim TH, 2010, ONCOGENE, V29, P3770, DOI 10.1038/onc.2010.126; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Koyuncuoglu M, 2012, GYNECOL ONCOL, V125, P208, DOI 10.1016/j.ygyno.2011.12.433; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lax SF, 2004, VIRCHOWS ARCH, V444, P213, DOI 10.1007/s00428-003-0947-3; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Lin EY, 2004, BRIT J CANCER, V90, P2053, DOI 10.1038/sj.bjc.6601705; Lindberg ME, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.109462; Llobet D, 2009, J CLIN PATHOL, V62, P777, DOI 10.1136/jcp.2008.056101; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Marchetti A, 2005, EUR J GYNAECOL ONCOL, V26, P479; Maxwell GL, 2005, CLIN CANCER RES, V11, P4056, DOI 10.1158/1078-0432.CCR-04-2001; Mazieres J, 2013, LUNG CANCER, V82, P231, DOI 10.1016/j.lungcan.2013.07.016; Medvedev AE, 1999, J BIOL CHEM, V274, P9342, DOI 10.1074/jbc.274.14.9342; MOLL R, 1993, AM J PATHOL, V143, P1731; Moon A, 2008, MOL CANCER RES, V6, P1544, DOI 10.1158/1541-7786.MCR-08-0189; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Raes G, 2005, J IMMUNOL, V174, P6561, DOI 10.4049/jimmunol.174.11.6561; Reardon SN, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.112.098871; Reed JR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2246; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Riethmuller G, 2001, SEMIN CANCER BIOL, V11, P307, DOI 10.1006/scbi.2001.0386; Risinger JI, 2003, CANCER RES, V63, P6; Samarnthai N, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/162363; Santin AD, 2005, BRIT J CANCER, V92, P1561, DOI 10.1038/sj.bjc.6602480; Scotton CJ, 2005, J IMMUNOL, V174, P834, DOI 10.4049/jimmunol.174.2.834; Shaco-Levy R, 2008, ACTA OBSTET GYN SCAN, V87, P868, DOI 10.1080/00016340802253775; SHERMAN ME, 1992, AM J SURG PATHOL, V16, P600, DOI 10.1097/00000478-199206000-00008; Shimada S, 2012, GUT, V61, P344, DOI 10.1136/gutjnl-2011-300050; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Soong R, 1996, BRIT J CANCER, V74, P562, DOI 10.1038/bjc.1996.401; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699; Wu ZY, 2005, WORLD J GASTROENTERO, V11, P3139, DOI 10.3748/wjg.v11.i20.3139; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	86	13	14	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2471	2482		10.1038/onc.2014.193	http://dx.doi.org/10.1038/onc.2014.193			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998851	Green Accepted			2022-12-28	WOS:000354190400006
J	Gaudette, BT; Dwivedi, B; Chitta, KS; Poulain, S; Powell, D; Vertino, P; Leleu, X; Lonial, S; Chanan-Khan, AA; Kowalski, J; Boise, LH				Gaudette, B. T.; Dwivedi, B.; Chitta, K. S.; Poulain, S.; Powell, D.; Vertino, P.; Leleu, X.; Lonial, S.; Chanan-Khan, A. A.; Kowalski, J.; Boise, L. H.			Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia	ONCOGENE			English	Article							CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; MYELOMA; LINE; BIM; BAX; ESTABLISHMENT; ACTIVATION; BCL-X(L); SURVIVAL	Waldenstrom macroglobulinemia (WM) is a proliferative disorder of IgM-secreting, lymphoplasmacytoid cells that inhabit the lymph nodes and bone marrow. The disease carries a high prevalence of activating mutations in MyD88 (91%) and CXCR4 (28%). Because signaling through these pathways leads to Bcl-xL induction, we examined Bcl-2 family expression in WM patients and cell lines. Unlike other B-lymphocyte-derived malignancies, which become dependent on expression of anti-apoptotic proteins to counter expression of pro-apoptotic proteins, WM samples expressed both pro-and anti-apoptotic Bcl-2 proteins at low levels similar to their normal B-cell and plasma cell counterparts. Three WM cell lines expressed pro-apoptotic Bcl-2 family members Bim or Bax and Bak at low levels, which determined their sensitivity to inducers of intrinsic apoptosis. In two cell lines, miR-155 upregulation, which is common in WM, was responsible for the inhibition of FOXO3a and Bim expression. Both antagonizing miR-155 to induce Bim and proteasome inhibition increased the sensitivity to ABT-737 in these lines indicating a lowering of the apoptotic threshold. In this manner, treatments that increase pro-apoptotic protein expression increase the efficacy of agents treated in combination in addition to direct killing.	[Gaudette, B. T.; Lonial, S.; Boise, L. H.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Gaudette, B. T.; Dwivedi, B.; Powell, D.; Vertino, P.; Lonial, S.; Kowalski, J.; Boise, L. H.] Emory Univ, Winship Canc Inst, 1365C Clifton RD NE,Suite C4012, Atlanta, GA 30322 USA; [Gaudette, B. T.; Boise, L. H.] Emory Univ, Grad Program Immunol & Mol Pathogenesis, Atlanta, GA 30322 USA; [Chitta, K. S.] Mayo Clin, Canc Biol, Jacksonville, FL 32224 USA; [Poulain, S.] Hop Valenciennes, Serv Hematol Immunol Cytogenet, Valenciennes, France; [Vertino, P.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Leleu, X.] CHRU Lille, Hop Claude Huriez, Serv Malad Sang, F-59037 Lille, France; [Chanan-Khan, A. A.] Mayo Clin, Hematol & Oncol, Jacksonville, FL 32224 USA; [Boise, L. H.] Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Mayo Clinic; CH de Valenciennes; Emory University; Universite de Lille - ISITE; CHU Lille; Mayo Clinic; Emory University	Boise, LH (corresponding author), Emory Univ, Winship Canc Inst, 1365C Clifton RD NE,Suite C4012, Atlanta, GA 30322 USA.	lboise@emory.edu	Boise, Lawrence/AAD-2314-2019; Poulain, Stéphanie/T-9033-2018	Poulain, Stéphanie/0000-0002-1792-7270; Gaudette, Brian/0000-0001-6627-3085; Boise, Lawrence/0000-0001-9436-8815; Kowalski, Jeanne/0000-0003-3458-3024; Dwivedi, Bhakti/0000-0002-9029-3737	TJ Martell Foundation [R01 CA127910, R01 CA129968]; Leukemia & Lymphoma Society; International Waldenstrom Macroglobulinemia; Comite du Septentrion de la Ligue contre le Cancer; NATIONAL CANCER INSTITUTE [R01CA129968, R01CA127910, P30CA138292] Funding Source: NIH RePORTER	TJ Martell Foundation; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); International Waldenstrom Macroglobulinemia; Comite du Septentrion de la Ligue contre le Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Stephen Ansell and Kelvin Lee for cell lines and reagents. This work was supported by: R01 CA127910 and R01 CA129968 as well as funding from the TJ Martell Foundation (LHB), the Leukemia & Lymphoma Society (AAC), the International Waldenstrom Macroglobulinemia (AAC), and the Comite du Septentrion de la Ligue contre le Cancer (XL). LHB is a GRA Distinguished Cancer Scientist. ABT-737 and ABT-199 were a generous gift of Abbvie, (North Chicago, IL, USA).	Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466; Boise LH, 2010, BLOOD, V115, P4007, DOI 10.1182/blood-2010-02-270231; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chitta KS, 2013, LEUKEMIA LYMPHOMA, V54, P387, DOI 10.3109/10428194.2012.713481; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Gaudette BT, 2014, J BIOL CHEM, V289, P23629, DOI 10.1074/jbc.M114.569376; Gertz MA, 2013, AM J HEMATOL, V88, P703, DOI 10.1002/ajh.23472; Ghobrial IM, 2003, LANCET ONCOL, V4, P679, DOI 10.1016/S1470-2045(03)01246-4; Gutierrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520; HERRINTON LJ, 1993, BLOOD, V82, P3148; Hodge LS, 2011, BLOOD, V117, pE190, DOI 10.1182/blood-2010-12-326868; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; Morales AA, 2011, BLOOD, V118, P1329, DOI 10.1182/blood-2011-01-327197; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Poulain S, 2013, BLOOD, V121, P4504, DOI 10.1182/blood-2012-06-436329; Premkumar DR, 2012, J PHARMACOL EXP THER, V341, P859, DOI 10.1124/jpet.112.191536; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Roccaro AM, 2010, BLOOD, V115, P4051, DOI 10.1182/blood-2009-09-243402; Roccaro AM, 2009, BLOOD, V113, P4391, DOI 10.1182/blood-2008-09-178228; Santos DD, 2007, EXP HEMATOL, V35, P1366, DOI 10.1016/j.exphem.2007.05.022; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Treon SP, 2014, BLOOD, V124, P503, DOI 10.1182/blood-2014-03-566273; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647	31	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					479	490		10.1038/onc.2015.103	http://dx.doi.org/10.1038/onc.2015.103			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893290	Green Accepted			2022-12-28	WOS:000369056700008
J	Fan, YH; Ding, J; Nguyen, S; Liu, XJ; Xu, G; Zhou, HY; Duan, NN; Yang, SM; Zern, MA; Wu, J				Fan, Y-H; Ding, J.; Nguyen, S.; Liu, X-J; Xu, G.; Zhou, H-Y; Duan, N-N; Yang, S-M; Zern, M. A.; Wu, J.			Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; GENE DELIVERY; TARGET GENES; MOUSE MODEL; PATHWAY; METASTASIS; MECHANISMS; COMPONENTS; LDE225	Hepatoma exhibits a series of heterogeneous subpopulations in its cell surface markers, tumorigenicity, invasion and metastatic capability. We previously demonstrated that the CD133(-)/EpCAM(-) hepatoma subpopulation was more metastatic than its counterpart; however, the controlling mechanisms are unexplored. The present study aimed to delineate the significance of aberrant hedgehog (Hh) signaling in the mediation of metastases. Fluorescence-activated cell sorting-enriched CD133(-)/EpCAM(-) (double negative, DN), Huh-7 cells underwent a transwell selection for metastatic cells (transwell-selected, TS). The TS cells displayed much greater metastatic activity as evidenced by an increased invasion rate, extremely upregulated expression of matrix metalloproteinase (MMP)-1/2/9 genes compared with DN and double-positive (DP) subpopulations. In contrast to DP cells, TS cells lost E-cadherin and were all vimentin-positive as shown by immunocytochemistry. There was a transitional increase in Gli-1/2 gene expression levels from DP, DN to TS subpopulations, which was consistent with elevated Gli-1/2 or Twist-1 protein levels in the nuclear fraction. Furthermore, truncated Gli-1 (tGli-1), which transactivates molecules involved in metastasis, was detected in the highly invasive Huh-7 cell subpopulation, but not in less metastatic hepatoma cells or normal hepatocytes. The enhanced metastatic features with increased expression of MMPs as well as the presence of twist and snail genes in TS Huh-7 cells were reversed by LDE225, a potent Smoothened antagonist. In conclusion, the highly metastatic capability of a unique TS subpopulation was highly attributed to significant epithelial-mesenchymal transition, enhanced Hh activity and aberrant occurrence of a tGli-1 variant, which appears to be responsible for the highly invasive behavior.	[Fan, Y-H; Nguyen, S.; Zern, M. A.; Wu, J.] Univ Calif Davis, Med Ctr, Div Gastroenterol & Hepatol, Dept Internal Med, Sacramento, CA 95817 USA; [Fan, Y-H; Yang, S-M] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [Ding, J.; Liu, X-J; Xu, G.; Zhou, H-Y; Duan, N-N; Wu, J.] Fudan Univ, Shanghai Med Coll, Key Lab Mol Virol, Shanghai 200032, Peoples R China; [Ding, J.] Shanghai Jingan Dist Cent Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Zern, M. A.; Wu, J.] Univ Calif Davis, Med Ctr, Inst Regenerat Cures, Sacramento, CA 95817 USA; [Wu, J.] Fudan Univ, Affiliated Zhongshan Hosp, Shanghai Inst Liver Dis, Shanghai 200032, Peoples R China; [Wu, J.] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA	University of California System; University of California Davis; Army Medical University; Fudan University; University of California System; University of California Davis; Fudan University; University of California System; University of California Davis	Wu, J (corresponding author), Fudan Univ, Shanghai Med Coll, Key Lab Mol Virol, 138 Yixue Yuan Rd,POB 228, Shanghai 200032, Peoples R China.	jdwu@ucdavis.edu	Liu, Xuejing/AAB-5617-2022; Wu, Jian/AAU-5221-2020	Wu, Jian/0000-0001-9933-7364; Ding, Jia/0000-0002-7391-8520; Zou, Haoyu/0000-0003-0778-4920	Natural Science Foundation of China [81272436]; California Institute of Regenerative Medicine [TR0-01857]; China Scholarship Council Award [201207610003]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); California Institute of Regenerative Medicine(California Institute for Regenerative Medicine); China Scholarship Council Award(China Scholarship Council)	This study is partially supported by the Natural Science Foundation of China to Dr Jian Wu (#81272436). Dr Mark A Zern was supported by the California Institute of Regenerative Medicine (#TR0-01857). Ya-Han Fan is the recipient of China Scholarship Council Award (201207610003). The authors are grateful to Bridget McLaughlin for her technical support in the FACS enrichment of hepatoma cell subpopulations at the UC Davis Flow Cytometry Shared Resource, and to Mrs Shu-Hui Sun from Fudan University Shanghai Medical College for her technical assistance in flow cytometric analysis. The abstract of this work was presented in the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, USA, 1-5 November 2013, and published in Hepatology (2013;59:1081A).	Adkins Y, 2013, LAB INVEST, V93, P1313, DOI 10.1038/labinvest.2013.123; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Cabarcas SM, 2011, INT J CANCER, V129, P2315, DOI 10.1002/ijc.26312; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Chen XL, 2010, ARCH MED RES, V41, P315, DOI 10.1016/j.arcmed.2010.06.003; Chen XL, 2011, J HEPATOL, V55, P838, DOI 10.1016/j.jhep.2010.12.043; Chen XL, 2011, TRANSPLANTATION, V91, P293, DOI 10.1097/TP.0b013e318204756c; Eichenmuller M, 2009, HEPATOLOGY, V49, P482, DOI 10.1002/hep.22649; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Fendrich V, 2011, ANN SURG, V254, P818, DOI 10.1097/SLA.0b013e318236bc0f; Fouzas I, 2008, TRANSPL P, V40, P3806, DOI 10.1016/j.transproceed.2008.09.050; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lin TL, 2012, ONCOTARGETS THER, V5, P47, DOI 10.2147/OTT.S21957; Lingala S, 2010, EXP MOL PATHOL, V89, P27, DOI 10.1016/j.yexmp.2010.05.005; Liu L, 2003, GENE THER, V10, P180, DOI 10.1038/sj.gt.3301861; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; McNeill B, 2012, MOL CELL NEUROSCI, V49, P333, DOI 10.1016/j.mcn.2011.12.008; NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Philips GM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023943; Price John T, 2002, Expert Opin Ther Targets, V6, P217; Riedlinger D, 2014, J HEPATO-BIL-PAN SCI, V21, P607, DOI 10.1002/jhbp.107; Rodon J, 2014, CLIN CANCER RES, V20, P1900, DOI 10.1158/1078-0432.CCR-13-1710; Ruiz I, 2007, TRENDS CELL BIOL, V17, P438, DOI DOI 10.1016/J.TCB.2007.06.007; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki K, 2014, WORLD J SURG, V38, P1147, DOI 10.1007/s00268-013-2374-1; Shimokawa T, 2008, J BIOL CHEM, V283, P14345, DOI 10.1074/jbc.M800299200; Steg AD, 2012, MOL CANCER THER, V11, P1587, DOI 10.1158/1535-7163.MCT-11-1058; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05; Wege H, 2003, GASTROENTEROLOGY, V124, P432, DOI 10.1053/gast.2003.50064; Wu J, 2004, HEPATOLOGY, V40, P195, DOI 10.1002/hep.20288; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; You N, 2012, ONCOL REP, V28, P2091, DOI 10.3892/or.2012.2035	39	27	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					116	124		10.1038/onc.2015.67	http://dx.doi.org/10.1038/onc.2015.67			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772244	Green Published			2022-12-28	WOS:000367812400011
J	Wimmer, P; Berscheminski, J; Blanchette, P; Groitl, P; Branton, PE; Hay, RT; Dobner, T; Schreiner, S				Wimmer, P.; Berscheminski, J.; Blanchette, P.; Groitl, P.; Branton, P. E.; Hay, R. T.; Dobner, T.; Schreiner, S.			PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR-BODY FORMATION; REGION-1B 55-KDA ONCOPROTEIN; E1B 55-KILODALTON PROTEIN; HUMAN-EMBRYO RETINOBLASTS; SUMO-1 MODIFICATION; E1B-55K ONCOPROTEIN; INFECTED-CELLS; RAR-ALPHA; PREMATURE SENESCENCE	Although modulation of the cellular tumor-suppressor p53 is considered to have the major role in E1A/E1B-55K-mediated tumorigenesis, other promyelocytic leukemia nuclear body (PML-NB)/PML oncogenic domain (POD)-associated factors including SUMO, Mre11, Daxx, as well as the integrity of these nuclear bodies contribute to the transformation process. However, the biochemical consequences and oncogenic alterations of PML-associated E1B-55K by SUMO-dependent PML-IV and PML-V interaction have so far remained elusive. We performed mutational analysis to define a PML interaction motif within the E1B-55K polypeptide. Our results showed that E1B-55K/PML binding is not required for p53, Mre11 and Daxx interaction. We also observed that E1B-55K lacking subnuclear PML localization because of either PML-IV or PML-V-binding deficiency was no longer capable of mediating E1B-55K-dependent SUMOylation of p53, inhibition of p53-mediated transactivation or efficiently transforming primary rodent cells. These results together with the observation that E1B-55K-dependent SUMOylation of p53 is required for efficient cell transformation, provides evidence for the idea that the SUMO ligase activity of the E1B-55K viral oncoprotein is intimately linked to its growth-promoting oncogenic activities.	[Wimmer, P.; Berscheminski, J.; Groitl, P.; Dobner, T.; Schreiner, S.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, D-20251 Hamburg, Germany; [Blanchette, P.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Goodman Canc Ctr, Montreal, PQ, Canada; [Hay, R. T.] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee, Scotland	Heinrich Pette Institute; McGill University; McGill University; McGill University; University of Dundee	Schreiner, S (corresponding author), Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, Martinistr 52, D-20251 Hamburg, Germany.	sabrina.schreiner@tum.de	Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Schreiner, Sabrina/0000-0002-5744-7159	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Peter und Traudl Engelhorn Stiftung; Erich und Gertrud Roggenbuck Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.; Deutsche Forschungsgemeinschaft (DFG); Wilhelm Sander-Stiftung; B Braun Stiftung; Drager Stiftung; Fonds der Chemischen Industrie; Canadian Institutes of Health Research; Canadian Foundation for Innovation (CFI); Ministere du Developpement economique, innovation et exportation Quebec (MDEIE); Cancer Research UK [13067] Funding Source: researchfish	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Peter und Traudl Engelhorn Stiftung; Erich und Gertrud Roggenbuck Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; B Braun Stiftung; Drager Stiftung; Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation (CFI)(Canada Foundation for Innovation); Ministere du Developpement economique, innovation et exportation Quebec (MDEIE); Cancer Research UK(Cancer Research UK)	We thank Roger D Everett for providing reagents, and greatly appreciate the critical comments and very helpful advise from Thomas Sternsdorf. We thank Ellis Jaffray, Gabriele Dobner and Thomas Speiseder for technical support and Hannah Staege for animal work. The Heinrich Pette Institute, Leibniz Institute for Experimental Virology is supported by the Freie und Hansestadt Hamburg and the Bundesministerium fur Gesundheit (BMG). SS was supported by the Peter und Traudl Engelhorn Stiftung and additional grants from the Erich und Gertrud Roggenbuck Stiftung, the Else Kroner-Fresenius-Stiftung and the Deutsche Krebshilfe e. V. TD is supported by the Deutsche Forschungsgemeinschaft (DFG) and the Wilhelm Sander-Stiftung. Part of this work was supported by the B Braun Stiftung, the Drager Stiftung and the Fonds der Chemischen Industrie. PB and PEB were supported by grants from the Canadian Institutes of Health Research. Image collection for the manuscript was performed in the McGill University Life Sciences Complex Imaging Facility. Purchase of equipment in the facility was made possible with funding from the Canadian Foundation for Innovation (CFI) and the Ministere du Developpement economique, innovation et exportation Quebec (MDEIE).	ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Berscheminski J, 2013, J VIROL, V87, P965, DOI 10.1128/JVI.02023-12; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Brand Peter, 2010, PMC Biophys, V3, P3, DOI 10.1186/1757-5036-3-3; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Everett RD, 1999, J CELL SCI, V112, P4581; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Everett RD, 2007, BIOCHIMIE, V89, P819, DOI 10.1016/j.biochi.2007.01.004; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Geng YY, 2012, J BIOL CHEM, V287, P30729, DOI 10.1074/jbc.M112.374769; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; GODDARD AD, 1992, LEUKEMIA, V6, pS117; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Gostissa M, 2003, CURR OPIN CELL BIOL, V15, P351, DOI 10.1016/S0955-0674(03)00038-3; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Graham F.L., 1984, ADENOVIRUSES, P339; GRAHAM FL, 1984, J CELL PHYSIOL, P151; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, BLOOD, V103, P2358, DOI 10.1182/blood-2003-07-2200; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Kindsmuller K, 2009, J VIROL, V83, P9045, DOI 10.1128/JVI.00728-09; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Logan J, 1984, CANCER CELL, V2, P527; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; Melnick A, 1999, LEUKEMIA, V13, P1534, DOI 10.1038/sj.leu.2401513; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Nevels M, 2006, ADENOVIRUS METHODS P, P187; Nevins JR, 1996, VIROLOGY, P301; Nisole S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00125; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Owerbach D, 2005, BIOCHEM BIOPH RES CO, V337, P517, DOI 10.1016/j.bbrc.2005.09.090; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pennella MA, 2010, J VIROL, V84, P12210, DOI 10.1128/JVI.01442-10; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Ricciardi R, 1995, DNA TUMOR VIRUSES ON, P195; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schiedner G, 2000, HUM GENE THER, V11, P2105, DOI 10.1089/104303400750001417; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schreiner S, 2011, J VIROL, V85, P8752, DOI 10.1128/JVI.00440-11; Schreiner S, 2010, J VIROL, V84, P7029, DOI 10.1128/JVI.00074-10; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Stadler M, 1995, ONCOGENE, V11, P2565; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tavalai N, 2008, BBA-MOL CELL RES, V1783, P2207, DOI 10.1016/j.bbamcr.2008.08.004; Torok D, 2009, FRONT BIOSCI-LANDMRK, V14, P1325, DOI 10.2741/3311; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Ullman AJ, 2008, J VIROL, V82, P7325, DOI 10.1128/JVI.00723-08; Ullman AJ, 2007, J VIROL, V81, P4744, DOI 10.1128/JVI.02385-06; Van Damme E, 2011, FRONT BIOSCI-LANDMRK, V16, P2910, DOI 10.2741/3889; Van Damme E, 2010, INT J BIOL SCI, V6, P51, DOI 10.7150/ijbs.6.51; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; Wang ZG, 1998, SCIENCE, V279, P1547; Weidtkamp-Peters S, 2008, J CELL SCI, V121, P2731, DOI 10.1242/jcs.031922; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; WHITTAKER JL, 1984, MOL CELL BIOL, V4, P110, DOI 10.1128/MCB.4.1.110; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Wimmer P, 2013, ONCOGENE, V32, P1626, DOI 10.1038/onc.2012.187; Wimmer P, 2010, ONCOGENE, V29, P5511, DOI 10.1038/onc.2010.284; Wimmer P, 2012, J VIROL, V86, P642, DOI 10.1128/JVI.06227-11; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	139	15	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					69	82		10.1038/onc.2015.63	http://dx.doi.org/10.1038/onc.2015.63			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772236				2022-12-28	WOS:000367812400007
J	Kanu, N; Gronroos, E; Martinez, P; Burrell, RA; Goh, XY; Bartkova, J; Maya-Mendoza, A; Mistrik, M; Rowan, AJ; Patel, H; Rabinowitz, A; East, P; Wilson, G; Santos, CR; McGranahan, N; Gulati, S; Gerlinger, M; Birkbak, NJ; Joshi, T; Alexandrov, LB; Stratton, MR; Powles, T; Matthews, N; Bates, PA; Stewart, A; Szallasi, Z; Larkin, J; Bartek, J; Swanton, C				Kanu, N.; Groenroos, E.; Martinez, P.; Burrell, R. A.; Goh, X. Yi; Bartkova, J.; Maya-Mendoza, A.; Mistrik, M.; Rowan, A. J.; Patel, H.; Rabinowitz, A.; East, P.; Wilson, G.; Santos, C. R.; McGranahan, N.; Gulati, S.; Gerlinger, M.; Birkbak, N. J.; Joshi, T.; Alexandrov, L. B.; Stratton, M. R.; Powles, T.; Matthews, N.; Bates, P. A.; Stewart, A.; Szallasi, Z.; Larkin, J.; Bartek, J.; Swanton, C.			SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; MUTATIONAL PROCESSES; DAMAGE RESPONSE; COPY NUMBER; HISTONE; GENE; METHYLATION; INSTABILITY; FACT; HETEROGENEITY	Defining mechanisms that generate intratumour heterogeneity and branched evolution may inspire novel therapeutic approaches to limit tumour diversity and adaptation. SETD2 (Su(var), Enhancer of zeste, Trithorax-domain containing 2) trimethylates histone-3 lysine-36 (H3K36me3) at sites of active transcription and is mutated in diverse tumour types, including clear cell renal carcinomas (ccRCCs). Distinct SETD2 mutations have been identified in spatially separated regions in ccRCC, indicative of intratumour heterogeneity. In this study, we have addressed the consequences of SETD2 loss-of-function through an integrated bioinformatics and functional genomics approach. We find that bi-allelic SETD2 aberrations are not associated with microsatellite instability in ccRCC. SETD2 depletion in ccRCC cells revealed aberrant and reduced nucleosome compaction and chromatin association of the key replication proteins minichromosome maintenance complex component (MCM7) and DNA polymerase delta hindering replication fork progression, and failure to load lens epithelium-derived growth factor and the Rad51 homologous recombination repair factor at DNA breaks. Consistent with these data, we observe chromosomal breakpoint locations are biased away from H3K36me3 sites in SETD2 wild-type ccRCCs relative to tumours with bi-allelic SETD2 aberrations and that H3K36me3-negative ccRCCs display elevated DNA damage in vivo. These data suggest a role for SETD2 in maintaining genome integrity through nucleosome stabilization, suppression of replication stress and the coordination of DNA repair.	[Kanu, N.; Birkbak, N. J.; Swanton, C.] UCL Canc Inst, London, England; [Groenroos, E.; Martinez, P.; Burrell, R. A.; Goh, X. Yi; Rowan, A. J.; Patel, H.; Rabinowitz, A.; East, P.; Wilson, G.; Santos, C. R.; McGranahan, N.; Gulati, S.; Gerlinger, M.; Birkbak, N. J.; Matthews, N.; Bates, P. A.; Stewart, A.; Swanton, C.] Canc Res UK London Res Inst, London WC2A 3PX, England; [Bartkova, J.; Maya-Mendoza, A.; Bartek, J.] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark; [Mistrik, M.; Bartek, J.] Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, CR-77147 Olomouc, Czech Republic; [Birkbak, N. J.; Joshi, T.; Szallasi, Z.] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, Kongens Lyngby, Denmark; [Alexandrov, L. B.; Stratton, M. R.] Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge, Cambridgeshire, England; [Powles, T.] Univ London, Expt Canc Med Ctr, Barts Canc Inst, London, England; [Szallasi, Z.] Childrens Hosp, Boston, MA 02115 USA; [Larkin, J.] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England	University of London; University College London; Cancer Research UK; Danish Cancer Society; Palacky University Olomouc; Technical University of Denmark; University of Cambridge; Wellcome Trust Sanger Institute; University of London; Queen Mary University London; Harvard University; Boston Children's Hospital; Royal Marsden NHS Foundation Trust	Bartek, J (corresponding author), Danish Canc Soc, Res Ctr, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk; charles.swanton@cancer.org.uk	Gronroos, Eva/P-6951-2015; Bates, Paul A/AAF-8561-2020; McGranahan, Nicholas/ABD-6561-2021; Alexandrov, Ludmil/AAS-1454-2021	Bates, Paul A/0000-0003-0621-0925; McGranahan, Nicholas/0000-0001-9537-4045; Alexandrov, Ludmil/0000-0003-3596-4515; Santos, Claudio/0000-0002-8766-2247; Birkbak, Nicolai/0000-0003-1613-9587; Martinez, Pierre/0000-0001-7069-4413; Swanton, Charles/0000-0002-4299-3018; Patel, Harshil/0000-0003-2707-7940; Gronroos, Eva/0000-0001-8303-5409; Gerlinger, Marco/0000-0003-2719-299X; Mistrik, Martin/0000-0002-2321-0348; Maya-Mendoza, Apolinar/0000-0001-7452-9896; Larkin, James/0000-0001-5569-9523; Szallasi, Zoltan/0000-0001-5395-7509	NHGRI [H3K36me3, H3K27me3]; Cancer Research UK; Breast Cancer Research Foundation; Medical Research Council [G0902275, G0701935/2]; Danish Cancer Society; Lundbeck Foundation [R93-A8990]; Ministry of the interior of the Czech Republic [VG20102014001]; National Program of Sustainability [LO1304]; Danish Council for Independent Research [DFF-1331-00262]; NIHR RMH/ICR Biomedical Research Centre for Cancer; EC [259303, 259892]; UCL Overseas Research Scholarship; European Research Council; Prostate Cancer Foundation; National Institute for Health Research University College London Hospitals Biomedical Research Centre; Rosetrees Trust; Cancer Research UK [18377, 10748, 17786, 19310] Funding Source: researchfish; Medical Research Council [G0701935] Funding Source: researchfish; Rosetrees Trust [M179] Funding Source: researchfish; The Francis Crick Institute [10001, 10002, 10359, 10169, 10303, 10174, 10170, 10172] Funding Source: researchfish; MRC [G0701935, G0902275] Funding Source: UKRI	NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Cancer Research UK(Cancer Research UK); Breast Cancer Research Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden); Ministry of the interior of the Czech Republic; National Program of Sustainability; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); NIHR RMH/ICR Biomedical Research Centre for Cancer; EC(European CommissionEuropean Commission Joint Research Centre); UCL Overseas Research Scholarship; European Research Council(European Research Council (ERC)European Commission); Prostate Cancer Foundation; National Institute for Health Research University College London Hospitals Biomedical Research Centre(General Electric); Rosetrees Trust(Rosetrees Trust); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Rosetrees Trust(Rosetrees Trust); The Francis Crick Institute; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr Simon Boulton and our colleagues for critical discussions of this work. The results published here are in part based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/ (dbGaP accession number: phs000178.v5.p5). We acknowledge the Encyclopedia of DNA Elements (ENCODE) Consortium, funded by the NHGRI, from which we obtained data for H3K36me3 and H3K27me3 analyses. We thank all funding boards for their continued support. The research leading to these results is supported by Cancer Research UK (XYG, RAB, EG, PM, PE, SG, C Santos, AJR, NM, PAB, AS and C Swanton), Breast Cancer Research Foundation (C Swanton and NK), Medical Research Council (ID: G0902275 to MG and C Santos; ID: G0701935/2 to AJR and C Swanton), the Danish Cancer Society (AMM, J Bartkova and J Bartek), the Lundbeck Foundation (R93-A8990 to J Bartek), the Ministry of the interior of the Czech Republic (grant VG20102014001 to MM and J Bartek), the National Program of Sustainability (grant LO1304 to MM and J Bartek), the Danish Council for Independent Research (grant DFF-1331-00262 to J Bartek), NIHR RMH/ICR Biomedical Research Centre for Cancer (JL), the EC Framework 7 (PREDICT 259303 to XYG, EG, PM, MG, TJ and C Swanton; DDResponse 259892 to J Bartek and J Bartkova and RESPONSIFY ID: 259303 to C Swanton), UCL Overseas Research Scholarship (SG). C Swanton is also supported by the European Research Council, Rosetrees Trust and The Prostate Cancer Foundation. This research is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.	Abe T, 2011, J BIOL CHEM, V286, P30504, DOI 10.1074/jbc.M111.264721; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Altavilla G, 2010, ONCOL REP, V24, P927, DOI 10.3892/or_00000938; Anders S, 2012, GENOME RES, V22, P2008, DOI 10.1101/gr.133744.111; Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bengtsson H, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-245; Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045; Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Cahill DP, 1999, TRENDS BIOCHEM SCI, V24, pM57, DOI 10.1016/S0968-0004(99)01466-8; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Carvalho S, 2013, NUCLEIC ACIDS RES, V41, P2881, DOI 10.1093/nar/gks1472; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Daugaard M, 2012, NAT STRUCT MOL BIOL, V19, P803, DOI 10.1038/nsmb.2314; de Almeida SF, 2011, NAT STRUCT MOL BIOL, V18, P977, DOI 10.1038/nsmb.2123; Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120; Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Groth A, 2007, SCIENCE, V318, P1928, DOI 10.1126/science.1148992; Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Larkin J, 2012, NAT REV UROL, V9, P147, DOI 10.1038/nrurol.2011.236; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Li M, 2005, P NATL ACAD SCI USA, V102, P17636, DOI 10.1073/pnas.0506350102; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Martinez P, 2013, J PATHOL, V230, P356, DOI 10.1002/path.4214; Mejlvang J, 2014, J CELL BIOL, V204, P29, DOI 10.1083/jcb.201305017; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Ortiz-Estevez M, 2012, BIOINFORMATICS, V28, P1793, DOI 10.1093/bioinformatics/bts248; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Pradeepa MM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002717; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roylance R, 2011, CANCER EPIDEM BIOMAR, V20, P2183, DOI 10.1158/1055-9965.EPI-11-0343; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113; Statham AL, 2010, BIOINFORMATICS, V26, P1662, DOI 10.1093/bioinformatics/btq247; Suwaki N, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002004; Tan BCM, 2006, EMBO J, V25, P3975, DOI 10.1038/sj.emboj.7601271; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Weaver BA, 2008, CANCER CELL, V14, P431, DOI 10.1016/j.ccr.2008.11.011; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200; Zaret K, 2005, CURR PROT MOL BIOL	58	105	108	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5699	5708		10.1038/onc.2015.24	http://dx.doi.org/10.1038/onc.2015.24			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728682	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000364594600002
J	Lau, E; Sedy, J; Sander, C; Shaw, MA; Feng, Y; Scortegagna, M; Claps, G; Robinson, S; Cheng, P; Srivas, R; Soonthornvacharin, S; Ideker, T; Bosenberg, M; Gonzalez, R; Robinson, W; Chanda, SK; Ware, C; Dummer, R; Hoon, D; Kirkwood, JM; Ronai, ZA				Lau, E.; Sedy, J.; Sander, C.; Shaw, M. A.; Feng, Y.; Scortegagna, M.; Claps, G.; Robinson, S.; Cheng, P.; Srivas, R.; Soonthornvacharin, S.; Ideker, T.; Bosenberg, M.; Gonzalez, R.; Robinson, W.; Chanda, S. K.; Ware, C.; Dummer, R.; Hoon, D.; Kirkwood, J. M.; Ronai, Z. A.			Transcriptional repression of IFN beta 1 by ATF2 confers melanoma resistance to therapy	ONCOGENE			English	Article							METASTATIC MELANOMA; INTERFERON-BETA; RAF INHIBITION; IFN-BETA; KAPPA-B; CELLS; BIOCHEMOTHERAPY; EXPRESSION; INDUCTION; CANCER	The resistance of melanoma to current treatment modalities represents a major obstacle for durable therapeutic response, and thus the elucidation of mechanisms of resistance is urgently needed. The crucial functions of activating transcription factor-2 (ATF2) in the development and therapeutic resistance of melanoma have been previously reported, although the precise underlying mechanisms remain unclear. Here, we report a protein kinase C-epsilon (PKC epsilon)- and ATF2-mediated mechanism that facilitates resistance by transcriptionally repressing the expression of interferon-beta 1 (IFN beta 1) and downstream type-I IFN signaling that is otherwise induced upon exposure to chemotherapy. Treatment of early-stage melanomas expressing low levels of PKC epsilon with chemotherapies relieves ATF2-mediated transcriptional repression of IFN beta 1, resulting in impaired S-phase progression, a senescence-like phenotype and increased cell death. This response is lost in late-stage metastatic melanomas expressing high levels of PKC epsilon. Notably, nuclear ATF2 and low expression of IFN beta 1 in melanoma tumor samples correlates with poor patient responsiveness to biochemotherapy or neoadjuvant IFN-alpha 2a. Conversely, cytosolic ATF2 and induction of IFN beta 1 coincides with therapeutic responsiveness. Collectively, we identify an IFN beta 1-dependent, cell-autonomous mechanism that contributes to the therapeutic resistance of melanoma via the PKC epsilon-ATF2 regulatory axis.	[Lau, E.; Sedy, J.; Feng, Y.; Scortegagna, M.; Claps, G.; Soonthornvacharin, S.; Chanda, S. K.; Ware, C.; Ronai, Z. A.] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA 92037 USA; [Sander, C.; Kirkwood, J. M.] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA; [Shaw, M. A.; Hoon, D.] John Wayne Canc Inst, Santa Monica, CA USA; [Robinson, S.; Gonzalez, R.; Robinson, W.] Univ Colorado, Div Med Oncol, Aurora, CO USA; [Cheng, P.; Dummer, R.] Univ Zurich, Dept Dermatol, Zurich, Switzerland; [Srivas, R.] Stanford Univ, Sch Med, Dept Genet, Palo Alto, CA 94304 USA; [Ideker, T.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Bosenberg, M.] Yale Univ, Sch Med, New Haven, CT USA	Sanford Burnham Prebys Medical Discovery Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; John Wayne Cancer Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Zurich; Stanford University; University of California System; University of California San Diego; Yale University	Lau, E (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.	elau@sbmri.org; ronai@sbmri.org	Hoon, Dave SB/C-7146-2018; Cheng, Phil/AAN-8567-2021; gonzález, rene/W-2081-2019; Claps, Giuseppina/G-6180-2018	Hoon, Dave SB/0000-0003-1915-3683; Cheng, Phil/0000-0003-2940-006X; Robinson, William/0000-0003-1875-9691; RONAI, ZEEV/0000-0002-3859-0400; Ideker, Trey/0000-0002-1708-8454; Srivas, Rohith/0000-0001-9495-9949; Claps, Giuseppina/0000-0002-3064-0063; Sedy, John/0000-0002-6428-1054	NCI [CA128814, CA179170, CA164679, CA177322, CA121973]; Hervey Family Non-endowment Fund at The San Diego Foundation; Melanoma Research Foundation;  [CA172705];  [CA121949]; NATIONAL CANCER INSTITUTE [T32CA121949, K99CA172705, P01CA177322, R01CA164679, P01CA128814, R01CA179170, P50CA121973, R01CA172017, P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048073] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Hervey Family Non-endowment Fund at The San Diego Foundation; Melanoma Research Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Serge Fuchs (UPENN) and members of the Ronai laboratory for crucial scientific discussions and critical reading of this manuscript. Additional thanks to Mitch Levesque and Valerie Amann for their assistance in providing patient samples from the Department of Dermatology, University of Zurich. We are grateful to Jian-Liang Li of the SBMRI Bioinformatics Core, as well as the SBMRI Flow Cytometry and Histology Core, for technical support. Support from NCI P01 (CA128814), R01 (CA179170), Hervey Family Non-endowment Fund at The San Diego Foundation and a Melanoma Research Foundation grant to ZAR are gratefully acknowledged. Support from NCI Grants R01 (CA164679) and P01 (CA177322) to CW and P50 SPORE (CA121973) to JMK is also gratefully acknowledged. EL has been supported by K99 (CA172705) and T32 (CA121949) Grants.	Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Bhoumik A, 2004, P NATL ACAD SCI USA, V101, P4222, DOI 10.1073/pnas.0400195101; Eiro N, 2014, J IMMUNOTHER, V37, P366, DOI 10.1097/CJI.0000000000000045; Gajewski TF, 2012, CANCER IMMUNOL IMMUN, V61, P1343, DOI 10.1007/s00262-012-1305-6; Garbe C, 2011, ONCOLOGIST, V16, P5, DOI 10.1634/theoncologist.2010-0190; Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Ives NJ, 2007, J CLIN ONCOL, V25, P5426, DOI 10.1200/JCO.2007.12.0253; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Koyanagi K, 2005, J CLIN ONCOL, V23, P8057, DOI 10.1200/JCO.2005.02.0958; Koyanagi K, 2010, CLIN CANCER RES, V16, P2402, DOI 10.1158/1078-0432.CCR-10-0037; Lau E, 2012, CELL, V148, P543, DOI 10.1016/j.cell.2012.01.016; Maeda S, 2014, J BIOL CHEM, V289, P23786, DOI 10.1074/jbc.M114.551879; Malmgaard L, 2002, J VIROL, V76, P4520, DOI 10.1128/JVI.76.9.4520-4525.2002; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Pencheva N, 2014, CELL, V156, P986, DOI 10.1016/j.cell.2014.01.038; Rao RD, 2006, CANCER, V106, P375, DOI 10.1002/cncr.21611; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rubin Krista M, 2013, Semin Oncol Nurs, V29, P195, DOI 10.1016/j.soncn.2013.06.005; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Ryu H, 2014, CANCER LETT, V352, P220, DOI 10.1016/j.canlet.2014.06.018; Schuchter LM, 2004, J CLIN ONCOL, V22, P7, DOI 10.1200/JCO.2004.10.907; Snijders AM, 2014, ONCOTARGET, V5, P4011, DOI 10.18632/oncotarget.2148; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Testori A, 2009, ANN ONCOL, V20, P22, DOI 10.1093/annonc/mdp257; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Varsano T, 2013, CLIN CANCER RES, V19, P2710, DOI 10.1158/1078-0432.CCR-12-2689; Wang JM, 2010, J IMMUNOL, V185, P1720, DOI 10.4049/jimmunol.1000114; Yue CY, 2015, INT J CANCER, V136, P117, DOI 10.1002/ijc.29004	35	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5739	5748		10.1038/onc.2015.22	http://dx.doi.org/10.1038/onc.2015.22			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728676	Green Accepted			2022-12-28	WOS:000364594600006
J	Berstad, MB; Cheung, LH; Berg, K; Peng, Q; Fremstedal, ASV; Patzke, S; Rosenblum, MG; Weyergang, A				Berstad, M. B.; Cheung, L. H.; Berg, K.; Peng, Q.; Fremstedal, A. S. V.; Patzke, S.; Rosenblum, M. G.; Weyergang, A.			Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; PHOTODYNAMIC THERAPY; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; ENDOTHELIAL-CELLS; FACTOR-ALPHA; INTERNALIZATION; EXPRESSION; GELONIN	The number of epidermal growth factor receptor (EGFR)-targeting drugs in the development for cancer treatment is continuously increasing. Currently used EGFR-targeted monoclonal antibodies and tyrosine kinase inhibitors have specific limitations related to toxicity and development of resistance, and there is a need for alternative treatment strategies to maximize the clinical potential of EGFR as a molecular target. This study describes the design and production of a novel EGFR-targeted fusion protein, rGel/EGF, composed of the recombinant plant toxin gelonin and EGF. rGel/EGF was custom-made for administration by photochemical internalization (PCI), a clinically tested modality for cytosolic release of macromolecular therapeutics. rGel/EGF lacks efficient mechanisms for endosomal escape and is therefore minimally toxic as monotherapy. However, PCI induces selective and efficient cytosolic release of rGel/EGF in EGFR-expressing target cells by light-directed activation of photosensitizers accumulated selectively in tumor tissue. PCI of rGel/EGF was shown to be highly effective against EGFR-expressing cell lines, including head and neck squamous cell carcinoma (HNSCC) cell lines resistant to cetuximab (Erbitux). Apoptosis, necrosis and autophagy were identified as mechanisms of action following PCI of rGel/EGF in vitro. PCI of rGel/EGF was further shown as a highly tumor-specific and potent modality in vivo, with growth inhibitory effects demonstrated on A-431 squamous cell carcinoma (SCC) xenografts and reduction of tumor perfusion and necrosis induction in SCC-026 HNSCC tumors. Considering the small amount of rGel/EGF injected per animal (0.1 mg/kg), the presented in vivo results are highly promising and warrant optimization and production of rGel/EGF for further preclinical evaluation with PCI.	[Berstad, M. B.; Berg, K.; Fremstedal, A. S. V.; Patzke, S.; Weyergang, A.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, N-0424 Oslo, Norway; [Cheung, L. H.; Rosenblum, M. G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Immunopharmacol & Targeted Therapy Lab, Houston, TX 77030 USA; [Peng, Q.] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0424 Oslo, Norway	University of Oslo; University of Texas System; UTMD Anderson Cancer Center; University of Oslo	Weyergang, A (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, POB 4950, N-0424 Oslo, Norway.	anette.weyergang@rr-research.no	Weyergang, Anette/AAB-9938-2021; Weyergang, Anette/I-2934-2018; Patzke, Sebastian/G-9909-2019	Weyergang, Anette/0000-0003-0147-1763; Weyergang, Anette/0000-0003-0147-1763; Patzke, Sebastian/0000-0001-6821-197X; Berg, Kristian/0000-0002-7816-7543	South-Eastern Norway Regional Health Authority; NCI Grant [CA16672]; Norwegian Radium Hospital Legacies; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	South-Eastern Norway Regional Health Authority; NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Norwegian Radium Hospital Legacies; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kine Mari Bakke at the MRI Core Facility for technical assistance and valuable evaluation of the MRI results, Idun Dale Rein at The Flow Cytometry Core Facility (FCCF) for excellent technical expertise and sample analysis and Khalid A Mohamedali for fruitful discussion. We also thank Karen-Marie Heintz from the Department of Tumorbiology, Norwegian Radium Hospital and the RPPA Core Facility, MD Anderson Cancer Center for assistance in performing DNA fingerprinting assay. The project was supported by the South-Eastern Norway Regional Health Authority. Research was conducted, in part, by the Clayton Foundation for Research and supported by NCI Grant CA16672. Instrumentation for MRI, IVIS and flow cytometry has been financed by the Norwegian Radium Hospital Legacies.	Ahmad N, 2001, ONCOGENE, V20, P2314, DOI 10.1038/sj.onc.1204313; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Amin DN, 2006, CANCER RES, V66, P2173, DOI 10.1158/0008-5472.CAN-05-3387; Ang KK, 2002, CANCER RES, V62, P7350; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Berg K, 1999, CANCER RES, V59, P1180; Berg K, 2011, PHOTOCH PHOTOBIO SCI, V10, P1637, DOI 10.1039/c1pp05128h; Bruell D, 2005, INT J MOL MED, V15, P305; Bull-Hansen B, 2014, J CONTROL RELEASE, V182, P58, DOI 10.1016/j.jconrel.2014.03.014; Cao Y, 2012, MOL CANCER THER, V11, P143, DOI 10.1158/1535-7163.MCT-11-0519; Cao Y, 2009, CANCER RES, V69, P8987, DOI 10.1158/0008-5472.CAN-09-2693; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; GRANDIS JR, 1993, CANCER RES, V53, P3579; Gregoire V, 2010, ANN ONCOL, V21, pv184, DOI 10.1093/annonc/mdq185; Hale ML, 2001, PHARMACOL TOXICOL, V88, P255, DOI 10.1034/j.1600-0773.2001.d01-113.x; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Kim SM, 2010, CANCER LETT, V296, P150, DOI 10.1016/j.canlet.2010.04.006; Lackner MR, 2012, FUTURE ONCOL, V8, P999, DOI [10.2217/fon.12.86, 10.2217/FON.12.86]; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Lippman S M, 1995, Cancer Treat Res, V74, P89; Liu TF, 2005, CLIN CANCER RES, V11, P329; Martin CL, 2008, ORAL ONCOL, V44, P369, DOI 10.1016/j.oraloncology.2007.05.003; Martinez-Torrecuadrada JL, 2008, MOL CANCER THER, V7, P862, DOI 10.1158/1535-7163.MCT-07-0394; Norum OJ, 2009, PHOTOCHEM PHOTOBIOL, V85, P740, DOI 10.1111/j.1751-1097.2008.00477.x; Pastan I, 2007, ANNU REV MED, V58, P221, DOI 10.1146/annurev.med.58.070605.115320; PHILLIPS PC, 1994, CANCER RES, V54, P1008; Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2; Pirie CM, 2011, J BIOL CHEM, V286, P4165, DOI 10.1074/jbc.M110.186973; Rebucci M, 2011, INT J ONCOL, V38, P189, DOI 10.3892/ijo_00000838; Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220; ROSENBLUM MG, 1995, J INTERF CYTOK RES, V15, P547, DOI 10.1089/jir.1995.15.547; Selbo PK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006691; Selbo PK, 2010, J CONTROL RELEASE, V148, P2, DOI 10.1016/j.jconrel.2010.06.008; Selbo PK, 2000, INT J CANCER, V87, P853, DOI 10.1002/1097-0215(20000915)87:6<853::AID-IJC15>3.0.CO;2-0; Selbo PK, 2000, BBA-GEN SUBJECTS, V1475, P307, DOI 10.1016/S0304-4165(00)00082-9; Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4; STIRPE F, 1980, J BIOL CHEM, V255, P6947; Thomas SM, 2004, CLIN CANCER RES, V10, P7079, DOI 10.1158/1078-0432.CCR-04-0587; Veenendaal LM, 2002, P NATL ACAD SCI USA, V99, P7866, DOI [10.1073/pnas.122157899, 10.1073/pnas.162346299]; Vikdal M, 2013, PHOTOCHEM PHOTOBIOL, V89, P1185, DOI 10.1111/php.12126; Wang Q, 2005, EMBO REP, V6, P942, DOI 10.1038/sj.embor.7400491; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Weyergang A, 2008, MOL CANCER THER, V7, P1740, DOI 10.1158/1535-7163.MCT-08-0020; Weyergang A, 2014, J CONTROL RELEASE, V180, P1, DOI 10.1016/j.jconrel.2014.02.003; Weyergang A, 2013, BBA-GEN SUBJECTS, V1830, P2659, DOI 10.1016/j.bbagen.2012.11.010; Weyergang A, 2011, LASER SURG MED, V43, P721, DOI 10.1002/lsm.21084; Weyeyang A, 2007, BIOCHEM PHARMACOL, V74, P226, DOI 10.1016/j.bcp.2007.04.018; Zhou H, 2011, MOL CANCER THER, V10, P1276, DOI 10.1158/1535-7163.MCT-11-0161; Zhou XK, 2012, J CANCER RES CLIN, V138, P1081, DOI 10.1007/s00432-012-1181-7	51	28	28	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5582	5592		10.1038/onc.2015.15	http://dx.doi.org/10.1038/onc.2015.15			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25684137				2022-12-28	WOS:000364594000007
J	Gong, X; Yi, J; Carmon, KS; Crumbley, CA; Xiong, W; Thomas, A; Fan, X; Guo, S; An, Z; Chang, JT; Liu, QJ				Gong, X.; Yi, J.; Carmon, K. S.; Crumbley, C. A.; Xiong, W.; Thomas, A.; Fan, X.; Guo, S.; An, Z.; Chang, J. T.; Liu, Q. J.			Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; PROTEIN-COUPLED RECEPTOR; COLORECTAL-CANCER; WNT/BETA-CATENIN; FUSION TRANSCRIPTS; IDENTIFIES GENES; KNOCKOUT MICE; METASTASIS; KEAP1; LGR4	The four R-spondins (RSPO1-4) and their three related receptors LGR4, 5 and 6 (LGR4-6) have emerged as a major ligand-receptor system with critical roles in development and stem cell survival through modulation of Wnt signaling. Recurrent, gain-of-expression gene fusions of RSPO2 (to EIF3E) and RSPO3 (to PTPRK) occur in a subset of human colorectal cancer. However, the exact roles and mechanisms of the RSPO-LGR system in oncogenesis remain largely unknown. We found that RSPO3 is aberrantly expressed at high levels in approximately half of Keap1-mutated lung adenocarcinomas (ADs). This high RSPO3 expression is driven by a combination of demethylation of its own promoter region and deficiency in Keap1 instead of gene fusion as in colon cancer. Patients with RSPO3-high tumors (similar to 9%, 36/412) displayed much poorer survival than the rest of the cohort (median survival of 28 vs 163 months, log-rank test P<0.0001). Knockdown (KD) of RSPO3, LGR4 or their signaling mediator IQGAP1 in lung cancer cell lines with Keap1 deficiency and high RSPO3-LGR4 expression led to reduction in cell proliferation and migration in vitro, and KD of LGR4 or IQGAP1 resulted in decrease in tumor growth and metastasis in vivo. These findings suggest that aberrant RSPO3-LGR4 signaling potentially acts as a driving mechanism in the aggressiveness of Keap1-deficient lung ADs.	[Gong, X.; Yi, J.; Carmon, K. S.; Crumbley, C. A.; Xiong, W.; Thomas, A.; Fan, X.; An, Z.; Chang, J. T.; Liu, Q. J.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX 77030 USA; [Gong, X.; Yi, J.; Carmon, K. S.; Crumbley, C. A.; Xiong, W.; Thomas, A.; Fan, X.; An, Z.; Liu, Q. J.] Univ Texas Hlth Sci Ctr Houston, Texas Therapeut Inst, Houston, TX 77030 USA; [Guo, S.] Univ Texas Hlth Sci Ctr Houston, Div Oncol, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Ctr Clin & Translat Sci, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Liu, QJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, 1825 Pressler St,Suite 530A, Houston, TX 77030 USA.	Qingyun.liu@uth.tmc.edu	Yi, Jing/S-2586-2016	Yi, Jing/0000-0001-5037-1924; Carmon, Kendra/0000-0002-3244-6096; An, Zhiqiang/0000-0001-9309-2335	Cancer Prevention and Research Institute of Texas (CPRIT) [RP100678]; US National Institute of Health-NIH [R01GM102485]; Texas Emerging Technology Fund; Janice D. Gordon endowment for bowel cancer research; NIH [R00LM009837, TL1TR000371]; CPRIT [R1006]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102485] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas (CPRIT); US National Institute of Health-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas Emerging Technology Fund; Janice D. Gordon endowment for bowel cancer research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank TCGA for generating the genomics data, collecting the clinical information and making them available for analysis. We also thank cBioportal for providing data analysis and visualization tools and downloading capability. We thank Dr B Fang at the University of Texas MD Anderson Cancer for the cell lines A549, H460 and H2009 cells. This work was supported in part by the Cancer Prevention and Research Institute of Texas (CPRIT, RP100678), the US National Institute of Health-NIH (R01GM102485), the Texas Emerging Technology Fund and the Janice D. Gordon endowment for bowel cancer research (to QJL), by NIH (R00LM009837, TL1TR000371) and CPRIT (R1006; to JTC) and by the Texas Emerging Technology Fund (to ZA).	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell SM, 2008, DEVELOPMENT, V135, P1049, DOI 10.1242/dev.013359; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; de Lau WBM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-242; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gattelli A, 2006, J VIROL, V80, P11409, DOI 10.1128/JVI.00234-06; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Gugger M, 2008, DIS MARKERS, V24, P41, DOI 10.1155/2008/857474; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hayashi H, 2010, INT J CANCER, V126, P2563, DOI 10.1002/ijc.24987; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P733, DOI 10.1023/B:CLIN.0000006815.49932.98; Johnson M, 2009, CELL SIGNAL, V21, P1471, DOI 10.1016/j.cellsig.2009.02.023; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kato S, 2006, NEPHRON EXP NEPHROL, V104, pE63, DOI 10.1159/000093999; Ke N, 2011, METHODS MOL BIOL, V740, P33, DOI 10.1007/978-1-61779-108-6_6; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu Y, 2011, HISTOPATHOLOGY, V59, P882, DOI 10.1111/j.1365-2559.2011.04013.x; Lowther W, 2005, J VIROL, V79, P10093, DOI 10.1128/JVI.79.15.10093-10096.2005; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; McDonald T, 1998, BIOCHEM BIOPH RES CO, V247, P266, DOI 10.1006/bbrc.1998.8774; Mendive F, 2006, DEV BIOL, V290, P421, DOI 10.1016/j.ydbio.2005.11.043; Miyoshi T, 2005, PATHOL INT, V55, P419, DOI 10.1111/j.1440-1827.2005.01847.x; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Nam JS, 2007, GENE EXPR PATTERNS, V7, P306, DOI 10.1016/j.modgep.2006.08.006; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Takahashi T, 2010, J SURG ONCOL, V101, P500, DOI 10.1002/jso.21520; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Weng JS, 2008, P NATL ACAD SCI USA, V105, P6081, DOI 10.1073/pnas.0708257105; White CD, 2012, CELL SIGNAL, V24, P826, DOI 10.1016/j.cellsig.2011.12.005; Yamada W, 2009, BIOCHEM BIOPH RES CO, V381, P453, DOI 10.1016/j.bbrc.2009.02.066; Yi J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078144	54	45	48	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4692	4701		10.1038/onc.2014.417	http://dx.doi.org/10.1038/onc.2014.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531322	Green Accepted			2022-12-28	WOS:000360931500003
J	Starenki, D; Hong, SK; Lloyd, RV; Park, JI				Starenki, D.; Hong, S-K; Lloyd, R. V.; Park, J-I			Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells	ONCOGENE			English	Article							INHIBITORY FACTOR/JAK/STAT PATHWAY; BREAST-CANCER; HSP70 FAMILY; MITOCHONDRIA; STRESS; RET; 2-DEOXYGLUCOSE; MUTATIONS; PROTEINS; KINASE	Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the rearranged during transfection (RET) proto-oncogene. For therapy of advanced MTC, the Food and Drug Administration recently approved vandetanib and cabozantinib, the tyrosine kinase inhibitors targeting RET, vascular endothelial growth factor receptor, epidermal growth factor receptor and/or c-MET. Nevertheless, not all patients respond to these drugs, demanding additional therapeutic strategies. We found that mortalin (HSPA9/GRP75), a member of HSP70 family, is upregulated in human MTC tissues and that its depletion robustly induces cell death and growth arrest in MTC cell lines in culture and in mouse xenografts. These effects were accompanied by substantial downregulation of RET, induction of the tumor-suppressor TP53 and altered expression of cell cycle regulatory machinery and apoptosis markers, including E2F-1, p21(CIP1), p27(KIP1) and Bcl-2 family proteins. Our investigation of the molecular mechanisms underlying these effects revealed that mortalin depletion induces transient MEK/ERK (extracellular signal-regulated kinase) activation and altered mitochondrial bioenergetics in MTC cells, as indicated by depolarized mitochondrial membrane, decreased oxygen consumption and extracellular acidification and increased oxidative stress. Intriguingly, mortalin depletion induced growth arrest partly via the MEK/ERK pathway, whereas it induced cell death by causing mitochondrial dysfunction in a Bcl-2-dependent manner. However, TP53 was not necessary for these effects except for p21CIP1 induction. Moreover, mortalin depletion downregulated RET expression independently of MEK/ERK and TP53. These data demonstrate that mortalin is a key regulator of multiple signaling and metabolic pathways pivotal to MTC cell survival and proliferation, proposing mortalin as a novel therapeutic target for MTC.	[Starenki, D.; Hong, S-K; Park, J-I] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; [Lloyd, R. V.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison	Park, JI (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jipark@mcw.edu	Starenki, Dmytro/D-9241-2014	Park, Jong-In/0000-0001-7248-4735	American Cancer Society [RSGM-10-189-01-TBE]; National Cancer Institute [R01CA138441]; NATIONAL CANCER INSTITUTE [R01CA138441] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Sergey Tarima at the Division of Biostatistics, Medical College of Wisconsin (MCW) for statistical analysis; Dr Alexandra F Lerch-Gaggl (Pediatric BioBank and Analytical Tissue Core, MCW) for imaging immunohistochemistry data; and the MCW Cancer Center Bioenergetics shared resource and Advancing Healthier Wisconsin for Seahorse analysis. This work was supported by the American Cancer Society (RSGM-10-189-01-TBE) and the National Cancer Institute (R01CA138441) to J-IP.	Agrawal N, 2013, J CLIN ENDOCR METAB, V98, pE364, DOI 10.1210/jc.2012-2703; Arthan D, 2010, CANCER LETT, V297, P31, DOI 10.1016/j.canlet.2010.04.021; Boichard A, 2012, J CLIN ENDOCR METAB, V97, pE2031, DOI 10.1210/jc.2012-2092; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cheng G, 2012, CANCER RES, V72, P2634, DOI 10.1158/0008-5472.CAN-11-3928; Ciampi R, 2013, THYROID, V1, P1, DOI DOI 10.1089/THY.2013.2301.OB; Degrauwe N., 2012, CLIN MED INSIGHTS ON, V6, P243; Deocaris CC, 2007, ANN NY ACAD SCI, V1119, P165, DOI 10.1196/annals.1404.007; Dundas SR, 2005, J PATHOL, V205, P74, DOI 10.1002/path.1672; Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Iosefson O, 2010, FEBS LETT, V584, P1080, DOI 10.1016/j.febslet.2010.02.019; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kaul SC, 2005, J BIOL CHEM, V280, P39373, DOI 10.1074/jbc.M500022200; Kaul SC, 2007, EXP GERONTOL, V42, P263, DOI 10.1016/j.exger.2006.10.020; Khalil AA, 2011, BBA-REV CANCER, V1816, P89, DOI 10.1016/j.bbcan.2011.05.001; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; Lu WJ, 2011, CELL DEATH DIFFER, V18, P1046, DOI 10.1038/cdd.2010.177; Lu WJ, 2011, INT J CANCER, V129, P1806, DOI 10.1002/ijc.25857; Merrick BA, 1997, CANCER LETT, V119, P185, DOI 10.1016/S0304-3835(97)00270-X; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nagilla M, 2012, ADV THER, V29, P925, DOI 10.1007/s12325-012-0060-6; Park JI, 2005, CYTOKINE, V29, P125, DOI 10.1016/j.cyto.2004.10.005; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Park Jong-In, 2014, Front Biol (Beijing), V9, P95; Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49; Sarosiek KA, 2013, TRENDS CELL BIOL, V23, P612, DOI 10.1016/j.tcb.2013.08.003; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sosonkina N., 2011, Experimental Oncology, V33, P42; Sosonkina N, 2014, CANCERS, V6, P526, DOI 10.3390/cancers6010526; Starenki D, 2013, CANCER LETT, V339, P144, DOI 10.1016/j.canlet.2013.07.006; Starenki D, 2013, J CLIN ENDOCR METAB, V98, P1529, DOI 10.1210/jc.2012-3671; Tuttle RM, 2010, J NATL COMPR CANC NE, V8, P512, DOI 10.6004/jnccn.2010.0040; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2003, BIOCHEM BIOPH RES CO, V302, P735, DOI 10.1016/S0006-291X(03)00226-2; Wadhwa R, 2006, INT J CANCER, V118, P2973, DOI 10.1002/ijc.21773; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040; Wu PK, 2013, MOL CELL BIOL, V33, P4051, DOI 10.1128/MCB.00021-13	40	58	61	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4624	4634		10.1038/onc.2014.392	http://dx.doi.org/10.1038/onc.2014.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435367	Green Accepted			2022-12-28	WOS:000360189300008
J	Jiang, W; Huang, H; Ding, L; Zhu, P; Saiyin, H; Ji, G; Zuo, J; Han, D; Pan, Y; Ding, D; Ma, X; Zhang, Y; Wu, J; Yi, Q; Liu, JO; Huang, H; Dang, Y; Yu, L				Jiang, W.; Huang, H.; Ding, L.; Zhu, P.; Saiyin, H.; Ji, G.; Zuo, J.; Han, D.; Pan, Y.; Ding, D.; Ma, X.; Zhang, Y.; Wu, J.; Yi, Q.; Liu, J. O.; Huang, H.; Dang, Y.; Yu, L.			Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability	ONCOGENE			English	Article							BREAST-CANCER CELLS; GENE-EXPRESSION; MITOTIC CONTROL; NUCLEAR EXPORT; BINDING; PROTEIN; PHOSPHORYLATION; STABILIZATION; OVEREXPRESSION; IDENTIFICATION	Activation of cyclin E1, a key regulator of the G1/S cell-cycle transition, has been implicated in many cancers including hepatocellular carcinoma (HCC). Although much is known about the regulation of cyclin E1 expression and stability, its post-transcriptional regulation mechanism remains incompletely understood. Here, we report that nuclear factor 90 (NF90), a double-stranded RNA (dsRNA) binding protein, regulates cyclin E1 in HCC. We demonstrate that NF90 is upregulated in HCC specimens and that suppression of NF90 decreases HCC cell growth and delays G1/S transition. We identified cyclin E1 as a new target of NF90 and found a significant correlation between NF90 and cyclin E1 expression in HCC. The mRNA and protein levels of cyclin E1 were downregulated upon NF90 knockdown. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA, which was rescued by ectopic expression of NF90. Furthermore, NF90 bound to the 3' untranslated regions (3' UTRs) of cyclin E1 mRNA in vitro and in vivo. Knockdown of NF90 also inhibited tumor growth of HCC cell lines in mouse xenograft model. Moreover, we showed that inhibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine. Taken together, downregulation of NF90 in HCC cell lines can delay cell-cycle progression, inhibit cell proliferation, and reduce tumorigenic capacity in vivo. These results suggest that NF90 has an important role in HCC pathogenesis and that it can serve as a novel therapeutic target for HCC.	[Jiang, W.; Huang, H.; Ding, L.; Zhu, P.; Saiyin, H.; Ji, G.; Zuo, J.; Han, D.; Pan, Y.; Ding, D.; Ma, X.; Zhang, Y.; Wu, J.; Huang, H.; Dang, Y.; Yu, L.] Fudan Univ, State Key Lab Genet Engn,Inst Genet,Sch Life Sci, Key Lab Metab & Mol Med,Minist Educ, Dept Biochem & Mol Biol,Sch Basic Med Sci, Shanghai 200032, Peoples R China; [Ding, L.; Pan, Y.] Mayo Clin, Coll Med, Ctr Canc, Dept Biochem & Mol Biol,Dept Urol, Rochester, NY USA; [Yi, Q.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA; [Liu, J. O.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Fudan University; Mayo Clinic; Cleveland Clinic Foundation; Johns Hopkins University	Dang, Y (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med, 130 Dongan Rd, Shanghai 200032, Peoples R China.	yongjundang@fudan.edu.cn; longyu@fudan.edu.cn	dang, yongjun/M-6531-2016; Han, Dingding/HGD-2042-2022	dang, yongjun/0000-0001-7237-1132; Han, Dingding/0000-0003-0963-6286; Saiyin, Hexige/0000-0003-2993-6817	National Key Sci-Tech Special Project of China [2013ZX10002010]; National Natural Science Foundation of China [31270830]; NATIONAL CANCER INSTITUTE [P30CA015083, P30CA006973] Funding Source: NIH RePORTER	National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Key Sci-Tech Special Project of China (2013ZX10002010), and the National Natural Science Foundation of China (31270830). We thank Dr Tilman Schneider-Poetsch, Sarah Head and Yang Xianmei for generously editing the manuscript.	AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509; Bose SK, 2006, BIOCHEM J, V396, P99, DOI 10.1042/BJ20051548; Cam WR, 2001, DIGEST DIS SCI, V46, P2187, DOI 10.1023/A:1011962915280; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Fung LF, 2000, LIFE SCI, V67, P923, DOI 10.1016/S0024-3205(00)00684-6; Guan DY, 2008, MOL CELL BIOL, V28, P4629, DOI 10.1128/MCB.00120-08; Guo X, 2006, CANCER RES, V66, P7948, DOI 10.1158/0008-5472.CAN-05-4362; Guzi Timothy, 2004, Curr Opin Investig Drugs, V5, P1311; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Larcher JC, 2004, FASEB J, V18, P1761, DOI 10.1096/fj.04-1763fje; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Nanda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003442; Pei Y, 2008, J IMMUNOL, V180, P222, DOI 10.4049/jimmunol.180.1.222; Peng SY, 1998, J HEPATOL, V29, P281, DOI 10.1016/S0168-8278(98)80014-7; Shamanna RA, 2013, ONCOGENE, V32, P5176, DOI 10.1038/onc.2012.533; Shi LF, 2005, J BIOL CHEM, V280, P18981, DOI 10.1074/jbc.M411034200; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Shiohama A, 2007, EXP CELL RES, V313, P4196, DOI 10.1016/j.yexcr.2007.07.020; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; Vumbaca F, 2008, MOL CELL BIOL, V28, P772, DOI 10.1128/MCB.02078-06; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Xu YH, 1999, MOL GENET METAB, V68, P441, DOI 10.1006/mgme.1999.2934; Zhu P, 2010, J IMMUNOL, V185, P5140, DOI 10.4049/jimmunol.1000849	32	40	40	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4460	4470		10.1038/onc.2014.373	http://dx.doi.org/10.1038/onc.2014.373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25399696	Green Accepted			2022-12-28	WOS:000360189200005
J	Quist, T; Jin, H; Zhu, JF; Smith-Fry, K; Capecchi, MR; Jones, KB				Quist, T.; Jin, H.; Zhu, J-F; Smith-Fry, K.; Capecchi, M. R.; Jones, K. B.			The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse	ONCOGENE			English	Article							CANCER STEM-CELLS; TUMOR HETEROGENEITY; EXPRESSION; PROMOTER; MICE; P53; RB; SARCOMA; TUMORIGENESIS; DISRUPTION	Osteosarcomas remain an enigmatic group of malignancies that share in common the presence of transformed cells producing osteoid matrix, even if these cells comprise a minority of the tumor volume. The differentiation state of osteosarcomas has therefore become a topic of interest and challenge to those who study this disease. In order to test how the cell of origin contributes to the final state of differentiation in the transformed cells, we compared the relative tumorigenicity of Cre-LoxP conditional disruption of the cell cycle checkpoint tumor-suppressor genes Trp53 and Rb1 using Prx1-Cre, Collagen-1a1-Cre and Osteocalcin-Cre to transform undifferentiated mesenchyme, preosteoblasts and mature osteoblasts, respectively. The Prx1 and Col1a1 lineages developed tumors with nearly complete penetrance, as anticipated. Osteosarcomas also developed in 44% of Oc-Cre; Rb1(fl/fl); Trp53(fl/fl) mice. We confirmed using 5-ethynyl-2'-deoxyuridine click chemistry that the Oc-Cre lineage includes very few actively cycling cells. By assessing radiographic mineralization and histological osteoid production, the differentiation state of tumors did not correlate with the differentiation state of the lineage of origin. Some of the osteocalcin-lineage-derived osteosarcomas were among the least osteoblastic. Osteocalcin immunohistochemistry in tumors correlated well with the expression of DNA methyl transferases, suggesting that silencing of these epigenetic regulators may influence the final differentiation state of an osteosarcoma. Transformation of differentiated, minimally proliferative osteoblasts is possible but may require such an epigenetic reprogramming that the tumors no longer resemble their differentiated origins.	[Quist, T.; Jin, H.; Zhu, J-F; Smith-Fry, K.; Jones, K. B.] Univ Utah, Dept Orthopaed, Salt Lake City, UT 84112 USA; [Quist, T.; Jin, H.; Zhu, J-F; Smith-Fry, K.; Jones, K. B.] Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Capecchi, M. R.] Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; [Capecchi, M. R.] Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Jones, KB (corresponding author), Univ Utah, Dept Orthopaed, Sarcoma Serv, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA.	kevin.jones@hci.utah.edu			National Cancer Institute (National Institutes of Health, NIH) [K08CA138764]; Damon Runyon Cancer Research Foundation; National Cancer Institute [P30CA042014]; NATIONAL CANCER INSTITUTE [R01CA210165, P30CA042014, K08CA138764] Funding Source: NIH RePORTER	National Cancer Institute (National Institutes of Health, NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Damon Runyon Cancer Research Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Thomas Clemens for the Oc-Cre mouse line, Malcolm Logan for Prx1-Cre and Benoit de Crombrugghe for Col1a1-Cre. This work was directly supported by National Cancer Institute (National Institutes of Health, NIH) K08CA138764. KBJ receives additional career development support from the Damon Runyon Cancer Research Foundation. This work was also partly supported by P30CA042014 from the National Cancer Institute.	Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Angus-Hill ML, 2011, P NATL ACAD SCI USA, V108, P4914, DOI 10.1073/pnas.1102300108; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; Damron TA, 2007, CLIN ORTHOP RELAT R, P40, DOI 10.1097/BLO.0b013e318059b8c9; Desandes E, 2007, CANCER TREAT REV, V33, P609, DOI 10.1016/j.ctrv.2006.12.007; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078-0432.CCR-09-2499; Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Lin PP, 2008, CANCER RES, V68, P8968, DOI 10.1158/0008-5472.CAN-08-0573; Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180; LIU F, 1994, DEV BIOL, V166, P220, DOI 10.1006/dbio.1994.1309; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P5129, DOI 10.1073/pnas.87.13.5129; Ragland BD, 2002, LAB INVEST, V82, P365, DOI 10.1038/labinvest.3780431; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; San Martin IA, 2009, J CELL PHYSIOL, V221, P560, DOI 10.1002/jcp.21894; SHARKEY FE, 1983, ARCH PATHOL LAB MED, V107, P411; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; UNNI KK, 1989, SEMIN ROENTGENOL, V24, P143, DOI 10.1016/0037-198X(89)90010-2; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055; Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106; Weiss A, 2007, CANCER, V109, P1627, DOI 10.1002/cncr.22574; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Yeo HJ, 2007, J BIOL CHEM, V282, P35318, DOI 10.1074/jbc.M702435200	36	33	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4278	4284		10.1038/onc.2014.354	http://dx.doi.org/10.1038/onc.2014.354			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347737	Green Accepted			2022-12-28	WOS:000359199800014
J	Finlay-Schultz, J; Cittelly, DM; Hendricks, P; Patel, P; Kabos, P; Jacobsen, BM; Richer, JK; Sartorius, CA				Finlay-Schultz, J.; Cittelly, D. M.; Hendricks, P.; Patel, P.; Kabos, P.; Jacobsen, B. M.; Richer, J. K.; Sartorius, C. A.			Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a	ONCOGENE			English	Article							MICRORNA EXPRESSION PROFILES; MAMMARY-GLAND DEVELOPMENT; MESENCHYMAL TRANSITION; MIR-200 FAMILY; ESTROGEN; DIFFERENTIATION; IDENTIFICATION; SUPPRESSION; PROGESTINS; PROLACTIN	Progesterone (P4) has emerged as an important hormone-regulating mammary stem cell (MaSC) populations. In breast cancer, P4 and synthetic analogs increase the number of stem-like cells within luminal estrogen receptor (ER)- and progesterone receptor (PR)-positive breast cancers. These cells gain expression of de-differentiated cell markers CD44 and cytokeratin 5 (CK5), lose luminal markers ER and PR, and are more therapy resistant. We previously described that P4 downregulation of microRNA (miR)-29a contributes to the expansion of CD44(high) and CK5(+) cells. Here we investigated P4 downregulation of miR-141, a member of the miR-200 family of tumor suppressors, in facilitating an increase in stem-like breast cancer cells. miR-141 was the sole member of the miR-200 family P4-downregulated at the mature miRNA level in luminal breast cancer cell lines. Stable inhibition of miR-141 alone increased the CD44(high) population, and potentiated P4-mediated increases in both CD44(high) and CK5(+) cells. Loss of miR-141 enhanced both mammosphere formation and tumor initiation. miR-141 directly targeted both PR and signal transducer and activator of transcription 5A (Stat5a), transcription factors important for MaSC expansion. miR-141 depletion increased PR protein levels, even in cell lines where PR expression is estrogen dependent. Stat5a suppression via small interfering RNA or a small-molecule inhibitor reduced the P4-dependent increase in CK5(+) and CD44(high) cells. These data support a mechanism by which P4-triggered loss of miR-141 facilitates breast cancer cell de-differentiation through deregulation of PR and Stat5a, two transcription factors important for controlling mammary cell fate.	[Finlay-Schultz, J.; Cittelly, D. M.; Hendricks, P.; Patel, P.; Jacobsen, B. M.; Richer, J. K.; Sartorius, C. A.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Kabos, P.] Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Finlay-Schultz, J (corresponding author), Univ Colorado, Dept Pathol, MS8104,Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA.	Jessica.Finlay-Schultz@ucdenver.edu; Carol.Sartorius@ucdenver.edu		Finlay-Schultz, Jessica/0000-0002-7855-9870; Cittelly, Diana/0000-0002-8392-0800; Jacobsen, Britta/0000-0001-8234-1690	Department of Defense BCRP grants [W81XWH-11-1-0210, W81XWH-11-1-0101]; NIH [R01 CA140985, K08 CA164048];  [P30CA046934]; NATIONAL CANCER INSTITUTE [R01CA140985, K08CA164048, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	Department of Defense BCRP grants(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the University of Colorado Cancer Center Flow Cytometry and Tissue Culture Cores supported by P30CA046934 and the University of Colorado, Department of Pathology Sequencing Core for their technical assistance and services. This work was supported by Department of Defense BCRP grants W81XWH-11-1-0210 (CAS, JKR) and W81XWH-11-1-0101 (DMC) and NIH R01 CA140985 (CAS). PK was supported by NIH K08 CA164048.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chatterjee S, 2009, NATURE, V461, P546, DOI 10.1038/nature08349; Cittelly DM, 2013, ONCOGENE, V32, P2555, DOI 10.1038/onc.2012.275; CLARK GM, 1983, BREAST CANCER RES TR, V3, pS69, DOI 10.1007/BF01855130; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V357, P50, DOI 10.1016/j.mce.2011.09.022; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V355, P15, DOI 10.1016/j.mce.2011.12.020; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Edwards DP, 2000, J SOC GYNECOL INVEST, V7, pS22, DOI 10.1177/1071557600007001S08; Finnegan EF, 2013, CRIT REV BIOCHEM MOL, V48, P51, DOI 10.3109/10409238.2012.738643; Gantier MP, 2011, NUCLEIC ACIDS RES, V39, P5692, DOI 10.1093/nar/gkr148; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Graham JD, 2009, ENDOCRINOLOGY, V150, P3318, DOI 10.1210/en.2008-1630; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grosshans H, 2010, ADV EXP MED BIOL, V700, P140; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Horwitz KB, 2008, J CLIN ENDOCR METAB, V93, P3295, DOI 10.1210/jc.2008-0938; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Howell SJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2129; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2012, BREAST CANCER RES TR, V135, P415, DOI 10.1007/s10549-012-2164-8; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Li Z, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-731; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Obr AE, 2012, MOL CELL ENDOCRINOL, V357, P4, DOI 10.1016/j.mce.2011.10.030; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pillai MM, 2014, BREAST CANCER RES TR, V146, P85, DOI 10.1007/s10549-014-3004-9; Reid Brian G, 2014, Curr Chem Genom Transl Med, V8, P27, DOI 10.2174/2213988501408010027; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Rouet V, 2010, P NATL ACAD SCI USA, V107, P15199, DOI 10.1073/pnas.0911651107; Santos SJ, 2008, ENDOCRINOLOGY, V149, P329, DOI 10.1210/en.2007-0594; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Schwab R, 2013, EMBO REP, V14, P615, DOI 10.1038/embor.2013.58; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Vafaizadeh V, 2012, FRONT BIOSCI-LANDMRK, V17, P1232, DOI 10.2741/3983; Vafaizadeh V, 2010, STEM CELLS, V28, P928, DOI 10.1002/stem.407; Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095	62	55	59	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3676	3687		10.1038/onc.2014.298	http://dx.doi.org/10.1038/onc.2014.298			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241899	Green Accepted			2022-12-28	WOS:000357679100006
J	Li, MY; Lai, PL; Chou, YT; Chi, AP; Mi, YZ; Khoo, KH; Chang, GD; Wu, CW; Meng, TC; Chen, GC				Li, M-Y; Lai, P-L; Chou, Y-T; Chi, A-P; Mi, Y-Z; Khoo, K-H; Chang, G-D; Wu, C-W; Meng, T-C; Chen, G-C			Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; DROSOPHILA; EPS15; PTPMEG; INTERNALIZATION; ACTIVATION; PATHWAY; TUMORIGENESIS; ORGANIZATION	Epidermal growth factor receptor (EGFR) regulates multiple signaling cascades essential for cell proliferation, growth and differentiation. Using a genetic approach, we found that Drosophila FERM and PDZ domain-containing protein tyrosine phosphatase, dPtpmeg, negatively regulates border cell migration and inhibits the EGFR/Ras/mitogen-activated protein kinase signaling pathway during wing morphogenesis. We further identified EGFR pathway substrate 15 (Eps15) as a target of dPtpmeg and its human homolog PTPN3. Eps15 is a scaffolding adaptor protein known to be involved in EGFR endocytosis and trafficking. Interestingly, PTPN3-mediated tyrosine dephosphorylation of Eps15 promotes EGFR for lipid raft-mediated endocytosis and lysosomal degradation. PTPN3 and the Eps15 tyrosine phosphorylation-deficient mutant suppress non-small-cell lung cancer cell growth and migration in vitro and reduce lung tumor xenograft growth in vivo. Moreover, depletion of PTPN3 impairs the degradation of EGFR and enhances proliferation and tumorigenicity of lung cancer cells. Taken together, these results indicate that PTPN3 may act as a tumor suppressor in lung cancer through its modulation of EGFR signaling.	[Li, M-Y; Lai, P-L; Chi, A-P; Mi, Y-Z; Khoo, K-H; Meng, T-C; Chen, G-C] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Li, M-Y; Khoo, K-H; Chang, G-D; Meng, T-C; Chen, G-C] Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei, Taiwan; [Chou, Y-T; Wu, C-W] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan	Chen, GC (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	gcchen@gate.sinica.edu.tw	Meng, Tzu-Ching/G-5426-2019; Chen, Guang-Chao/P-1262-2019; Khoo, Kay-Hooi/E-1989-2019; Chi, Aiping/AAB-8010-2021	Meng, Tzu-Ching/0000-0001-7693-2021; Chen, Guang-Chao/0000-0002-4980-4718; Khoo, Kay-Hooi/0000-0003-2906-406X; Chou, Yu-Ting/0000-0001-9274-8603	National Science Council of Taiwan [NSC102-2311-B-001-027-MY3]; Academia Sinica	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	We thank Drs J Borst, PP Di Fiore, M McNiven, N Tonks, H Sun, KE Chen, the Bloomington Stock Center and Fly Core Taiwan for reagents. We are grateful to Dr J Settleman for helpful comments on the manuscript, Dr C-C Hung for confocal microscopy assistance and Y-L Huang for peptide synthesis. This work was supported by the National Science Council of Taiwan (NSC102-2311-B-001-027-MY3) and Academia Sinica.	Ali N, 2013, CURR BIOL, V23, P453, DOI 10.1016/j.cub.2013.02.033; Benmerah A, 1999, J CELL SCI, V112, P1303; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Chen DY, 2012, J CELL SCI, V125, P4841, DOI 10.1242/jcs.108597; Chi S, 2008, MOL BIOL CELL, V19, P3564, DOI 10.1091/mbc.E07-10-0997; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Eden ER, 2010, NAT CELL BIOL, V12, P267, DOI 10.1038/ncb2026; Eden ER, 2009, BIOCHEM SOC T, V37, P173, DOI 10.1042/BST0370173; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Gu MX, 1996, P NATL ACAD SCI USA, V93, P12980, DOI 10.1073/pnas.93.23.12980; Hawash IY, 2002, J BIOL CHEM, V277, P5683, DOI 10.1074/jbc.M110002200; Henegouwen PMPVE, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-24; Hironaka K, 2000, J BIOL CHEM, V275, P16167, DOI 10.1074/jbc.M909302199; Hong CF, 2009, J BIOL CHEM, V284, P19613, DOI 10.1074/jbc.M109.005017; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Jung Y, 2012, GENE CHROMOSOME CANC, V51, P590, DOI 10.1002/gcc.21945; Kina S, 2007, EUR J NEUROSCI, V26, P2269, DOI 10.1111/j.1460-9568.2007.05829.x; Ku HY, 2009, MOL CELL BIOL, V29, P3623, DOI 10.1128/MCB.00229-09; Labbe DP, 2012, PROG MOL BIOL TRANSL, V106, P253, DOI 10.1016/B978-0-12-396456-4.00009-2; Lessard L, 2010, BBA-PROTEINS PROTEOM, V1804, P613, DOI 10.1016/j.bbapap.2009.09.018; Martin-Blanco E, 1999, DEVELOPMENT, V126, P5739; Nomura M, 2007, PLOS MED, V4, P715, DOI 10.1371/journal.pmed.0040125; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parachoniak CA, 2009, J BIOL CHEM, V284, P8382, DOI 10.1074/jbc.M807607200; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Pignoni F, 1997, DEVELOPMENT, V124, P271; Roxrud I, 2008, J CELL BIOL, V180, P1205, DOI 10.1083/jcb.200708115; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Whited JL, 2007, DEVELOPMENT, V134, P43, DOI 10.1242/dev.02718; Woodman P, 2009, BIOCHEM SOC T, V37, P146, DOI 10.1042/BST0370146; Wu CW, 2006, ANTICANCER RES, V26, P1643; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yuan TC, 2010, J BIOL CHEM, V285, P14861, DOI 10.1074/jbc.M109.099879; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zhi HY, 2011, ONCOGENE, V30, P1706, DOI 10.1038/onc.2010.543	59	38	40	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3791	3803		10.1038/onc.2014.312	http://dx.doi.org/10.1038/onc.2014.312			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263444				2022-12-28	WOS:000358001600005
J	Teh, JT; Zhu, WL; Ilkayeva, OR; Li, Y; Gooding, J; Casey, PJ; Summers, SA; Newgard, CB; Wang, M				Teh, J. T.; Zhu, W. L.; Ilkayeva, O. R.; Li, Y.; Gooding, J.; Casey, P. J.; Summers, S. A.; Newgard, C. B.; Wang, M.			Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism	ONCOGENE			English	Article							TANDEM MASS-SPECTROMETRY; SMALL-MOLECULE INHIBITOR; K-RAS; CARBOXYL METHYLTRANSFERASE; MAMMALIAN-CELLS; PHOSPHORYLATION; AUTOPHAGY; ENZYMES; GROWTH; AMPK	Isoprenylcysteine carboxylmethyltransferase (Icmt) catalyzes the last of the three-step posttranslational protein prenylation process for the so-called CaaX proteins, which includes many signaling proteins, such as most small GTPases. Despite extensive studies on Icmt and its regulation of cell functions, the mechanisms of much of the impact of Icmt on cellular functions remain unclear. Our recent studies demonstrated that suppression of Icmt results in induction of autophagy, inhibition of cell growth and inhibition of proliferation in various cancer cell types, prompting this investigation of potential metabolic regulation by Icmt. We report here the findings that Icmt inhibition reduces the function of mitochondrial oxidative phosphorylation in multiple cancer cell lines. In-depth oximetry analysis demonstrated that functions of mitochondrial complex I, II and III are subject to Icmt regulation. Consistently, Icmt inhibition decreased cellular ATP and depleted critical tricarboxylic acid cycle metabolites, leading to suppression of cell anabolism and growth, and marked autophagy. Several different approaches demonstrated that the impact of Icmt inhibition on cell proliferation and viability was largely mediated by its effect on mitochondrial respiration. This previously unappreciated function of Icmt, which can be therapeutically exploited, likely has a significant role in the impact of Icmt on tumorigenic processes.	[Teh, J. T.; Zhu, W. L.; Casey, P. J.; Wang, M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Zhu, W. L.; Wang, M.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Ilkayeva, O. R.; Gooding, J.; Newgard, C. B.] Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC USA; [Ilkayeva, O. R.; Gooding, J.; Newgard, C. B.] Duke Univ, Med Ctr, Duke Inst Mol Physiol, Durham, NC USA; [Li, Y.; Summers, S. A.] Duke NUS Grad Med Sch, Program Cardiovasc & Metab Disorders, Singapore 169857, Singapore	National University of Singapore; National University of Singapore; Duke University; Duke University; National University of Singapore	Wang, M (corresponding author), Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg	/AAE-5384-2020; Zhu, Wan Long/GYA-3382-2022	Wang, Mei/0000-0001-6887-6840; zhu, Wanlong/0000-0003-0025-6674; Casey, Patrick/0000-0002-7366-9309	National Medical Research Council (NMRC); Duke-NUS	National Medical Research Council (NMRC)(National Medical Research Council, Singapore); Duke-NUS	These experiments were supported by grant from National Medical Research Council (NMRC) and Duke-NUS institutional funding. Wild-type and Icmt-null MEFs are from Dr M Bergo.	An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CHACE DH, 1993, CLIN CHEM, V39, P66; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Cordell RL, 2008, J CHROMATOGR B, V871, P115, DOI 10.1016/j.jchromb.2008.07.005; Cushman I, 2011, CELL ADHES MIGR, V5, P11, DOI 10.4161/cam.5.1.13196; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GREGOIRE M, 1984, EUR J BIOCHEM, V142, P49, DOI 10.1111/j.1432-1033.1984.tb08249.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KREBS HA, 1955, BIOCHEM J, V61, P435, DOI 10.1042/bj0610435; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Millington DS, 2011, METHODS MOL BIOL, V708, P55, DOI 10.1007/978-1-61737-985-7_3; MILLINGTON DS, 1992, PROG CLIN BIOL RES, V375, P339; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Neuzil J, 2007, MOL ASPECTS MED, V28, P607, DOI 10.1016/j.mam.2007.02.003; Pathania D, 2009, ADV DRUG DELIVER REV, V61, P1250, DOI 10.1016/j.addr.2009.05.010; POTTER VR, 1958, FED PROC, V17, P691; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Wahlstrom AM, 2008, BLOOD, V112, P1357, DOI 10.1182/blood-2007-06-094060; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Wu JY, 2004, J CLIN INVEST, V113, P434, DOI 10.1172/JCI200419574; Zhu WL, 2011, J BIOL CHEM, V286, P35291, DOI 10.1074/jbc.M111.280990	40	19	22	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3296	3304		10.1038/onc.2014.260	http://dx.doi.org/10.1038/onc.2014.260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151967				2022-12-28	WOS:000356592300008
J	Ho, PWM; Goradia, A; Russell, MR; Chalk, AM; Milley, KM; Baker, EK; Danks, JA; Slavin, JL; Walia, M; Crimeen-Irwin, B; Dickins, RA; Martin, TJ; Walkley, CR				Ho, P. W. M.; Goradia, A.; Russell, M. R.; Chalk, A. M.; Milley, K. M.; Baker, E. K.; Danks, J. A.; Slavin, J. L.; Walia, M.; Crimeen-Irwin, B.; Dickins, R. A.; Martin, T. J.; Walkley, C. R.			Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo	ONCOGENE			English	Article							HORMONE-RELATED PROTEIN; SMOOTH-MUSCLE-CELLS; PARATHYROID-HORMONE; BONE-FORMATION; PTH/PTHRP RECEPTOR; ANGIOTENSIN-II; RAT; EXPRESSION; LOCALIZATION; OSTEOBLAST	Osteosarcoma (OS) is the most common cancer of bone. Parathyroid hormone (PTH) regulates calcium homeostasis and bone development, while the paracrine/autocrine PTH-related protein (PTHrP) has central roles in endochondral bone formation and bone remodeling. Using a murine OS model, we found that OS cells express PTHrP and the common PTH/PTHrP receptor (PTHR1). To investigate the role of PTHR1 signaling in OS cell behavior, we used shRNA to reduce PTHR1 expression. This only mildly inhibited proliferation in vitro, but markedly reduced invasion through collagen and reduced expression of RANK ligand (RANKL). Administration of PTH(1-34) did not stimulate OS proliferation in vivo but, strikingly, PTHR1 knockdown resulted in a profound growth inhibition and increased differentiation/mineralization of the tumors. Treatment with neutralizing antibody to PTHrP did not recapitulate the knockdown of PTHR1. Consistent with this lack of activity, PTHrP was predominantly intracellular in OS cells. Knockdown of PTHR1 resulted in increased expression of late osteoblast differentiation genes and upregulation of Wnt antagonists. RANKL production was reduced in knockdown tumors, providing for reduced homotypic signaling through the receptor, RANK. Loss of PTHR1 resulted in the coordinated loss of gene signatures associated with the polycomb repressive complex 2 (PRC2). Using Ezh2 inhibitors, we demonstrate that the increased expression of osteoblast maturation markers is in part mediated by the loss of PRC2 activity. Collectively these results demonstrate that PTHR1 signaling is important in maintaining OS proliferation and undifferentiated state. This is in part mediated by intracellular PTHrP and through regulation of the OS epigenome.	[Ho, P. W. M.; Goradia, A.; Russell, M. R.; Chalk, A. M.; Baker, E. K.; Walia, M.; Crimeen-Irwin, B.; Martin, T. J.; Walkley, C. R.] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Ho, P. W. M.; Goradia, A.; Russell, M. R.; Chalk, A. M.; Baker, E. K.; Walia, M.; Crimeen-Irwin, B.; Martin, T. J.; Walkley, C. R.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; [Milley, K. M.; Danks, J. A.] RMIT Univ, Sch Med Sci, Bundoora, Vic, Australia; [Slavin, J. L.] St Vincents Hosp, Dept Pathol, Fitzroy, Vic 3065, Australia; [Dickins, R. A.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Mol Med, Parkville, Vic 3050, Australia	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; Royal Melbourne Institute of Technology (RMIT); St Vincent's Hospital Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Walkley, CR (corresponding author), St Vincents Inst, Stem Cell Regulat Unit, 9 Princes St, Fitzroy, Vic 3065, Australia.	jmartin@svi.edu.au; cwalkley@svi.edu.au	Milley, Kristi/ADF-2413-2022; Walkley, Carl/AAO-6021-2020; Dickins, Ross A/K-2852-2012; Chalk, Alistair/B-3019-2008	Walkley, Carl/0000-0002-4784-9031; Dickins, Ross A/0000-0003-4112-5304; Chalk, Alistair/0000-0002-9630-6236; Milley, Kristi/0000-0002-3615-4648	National Health and Medical Research Council of Australia (NHMRC); Cancer Council of Victoria; NHMRC Career Development Award; Cure Cancer Australia Foundation Fellowship; Victorian State Government	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); NHMRC Career Development Award(National Health and Medical Research Council (NHMRC) of Australia); Cure Cancer Australia Foundation Fellowship; Victorian State Government	We thank the SVH BioResources Centre; P Kocovski and S Taylor for technical assistance, L Purton and J Heierhorst for comments and discussion. This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC; to CRW and CRW/TJM); Cancer Council of Victoria (to CRW and EKB); NHMRC Career Development Award (CRW); Cure Cancer Australia Foundation Fellowship (EKB); in part by the Victorian State Government Operational Infrastructure Support Program (to St. Vincent's Institute). CRW is the Philip Desbrow Senior Research Fellow of the Leukaemia Foundation. The authors thank Chugai Pharmaceutical Company for providing the alpha-PTHrP neutralizing antibody; The Structural Genomics Consortium for generously providing GSK343 and UNC1999.	Akiyama T, 2010, CLIN EXP METASTAS, V27, P207, DOI 10.1007/s10585-010-9319-y; Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614; Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324; Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872; Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768; Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029; DANKS JA, 1989, J BONE MINER RES, V4, P273; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; Gopalakrishnan R, 2005, CELLS TISSUES ORGANS, V181, P166, DOI 10.1159/000091378; Gorlick R, 2013, PEDIATR BLOOD CANCER, V60, P1009, DOI 10.1002/pbc.24429; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; INGLETON PM, 1977, LAB ANIM SCI, V27, P748; Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470-2045(10)70062-0; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; JIANG BB, 1995, MINER ELECTROL METAB, V21, P157; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018; Kuijjer ML, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-245; Kuijjer ML, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-66; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.3.CO;2-D; Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008-5472.CAN-06-4130; Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209; Maeda S, 1996, ENDOCRINOLOGY, V137, P3154, DOI 10.1210/en.137.8.3154; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARTIN TJ, 1976, NATURE, V260, P436, DOI 10.1038/260436a0; Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; OKANO K, 1994, ENDOCRINOLOGY, V135, P1093, DOI 10.1210/en.135.3.1093; Onuma E, 2004, ANTICANCER RES, V24, P2665; PIROLA CJ, 1993, J BIOL CHEM, V268, P1987; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Takiguchi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054009; Tashjian AH, 2008, J BONE MINER RES, V23, P803, DOI 10.1359/JBMR.080208; Thompson DL, 2002, J BONE MINER RES, V17, P311, DOI 10.1359/jbmr.2002.17.2.311; Vargas MA, 2003, ENDOCRINOLOGY, V144, P4876, DOI 10.1210/en.2003-0253; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Watson PH, 2000, J BONE MINER RES, V15, P1033, DOI 10.1359/jbmr.2000.15.6.1033; Yang R, 2007, INT J CANCER, V121, P943, DOI 10.1002/ijc.22749	46	37	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2922	2933		10.1038/onc.2014.217	http://dx.doi.org/10.1038/onc.2014.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25043296				2022-12-28	WOS:000355324300011
J	Stebbing, J; Zhang, H; Xu, Y; Lit, LC; Green, AR; Grothey, A; Lombardo, Y; Periyasamy, M; Blighe, K; Zhang, W; Shaw, JA; Ellis, IO; Lenz, HJ; Giamas, G				Stebbing, J.; Zhang, H.; Xu, Y.; Lit, L. C.; Green, A. R.; Grothey, A.; Lombardo, Y.; Periyasamy, M.; Blighe, K.; Zhang, W.; Shaw, J. A.; Ellis, I. O.; Lenz, H. J.; Giamas, G.			KSR1 regulates BRCA1 degradation and inhibits breast cancer growth	ONCOGENE			English	Article							KINASE SUPPRESSOR; IN-VIVO; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; RAS-1 PROTECTS; GENE ENCODES; DNA-DAMAGE; C-ELEGANS; ACTIVATION; EXPRESSION	Kinase suppressor of Ras-1 (KSR1) facilitates signal transduction in Ras-dependent cancers, including pancreatic and lung carcinomas but its role in breast cancer has not been well studied. Here, we demonstrate for the first time it functions as a tumor suppressor in breast cancer in contrast to data in other tumors. Breast cancer patients (n>1000) with high KSR1 showed better disease-free and overall survival, results also supported by Oncomine analyses, microarray data (n = 2878) and genomic data from paired tumor and cell-free DNA samples revealing loss of heterozygosity. KSR1 expression is associated with high breast cancer 1, early onset (BRCA1), high BRCA1-associated ring domain 1 (BARD1) and checkpoint kinase 1 (Chk1) levels. Phospho-profiling of major components of the canonical Ras-RAF-mitogen-activated protein kinases pathway showed no significant changes after KSR1 overexpression or silencing. Moreover, KSR1 stably transfected cells formed fewer and smaller size colonies compared to the parental ones, while in vivo mouse model also demonstrated that the growth of xenograft tumors overexpressing KSR1 was inhibited. The tumor suppressive action of KSR1 is BRCA1 dependent shown by 3D-matrigel and soft agar assays. KSR1 stabilizes BRCA1 protein levels by reducing BRCA1 ubiquitination through increasing BARD1 abundance. These data link these proteins in a continuum with clinical relevance and position KSR1 in the major oncoprotein pathways in breast tumorigenesis.	[Stebbing, J.; Zhang, H.; Xu, Y.; Lit, L. C.; Grothey, A.; Lombardo, Y.; Periyasamy, M.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Ctr Translat & Expt Med, Dept Surg & Canc, Div Canc, London W12 0NN, England; [Lit, L. C.; Ellis, I. O.] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur, Malaysia; [Green, A. R.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Dept Cellular Pathol, Nottingham, England; [Blighe, K.; Shaw, J. A.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Zhang, W.; Lenz, H. J.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA	Imperial College London; Universiti Malaya; Nottingham University Hospital NHS Trust; University of Nottingham; University of Leicester; University of Southern California	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Translat & Expt Med, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus,Cane Rd, London W12 0NN, England.	g.giamas@imperial.ac.uk	Periyasamy, Manikandan/AAL-6211-2020; Zhang, Hua/AAV-2344-2020; LIT, LEI CHENG/B-8875-2010; Green, Andrew/AAF-1991-2020; periyasamy, manikandan/AAB-7924-2020; Giamas, Georgios/AAP-3487-2021; Lit, Lei Cheng/AAS-9778-2021	Zhang, Hua/0000-0001-7704-4712; LIT, LEI CHENG/0000-0002-3210-4491; Lit, Lei Cheng/0000-0002-3210-4491; Giamas, Georgios/0000-0002-4417-2707; Shaw, Jacqui/0000-0003-4227-503X; Green, Andrew/0000-0002-0488-5913; Stebbing, Justin/0000-0002-1117-6947; Periyasamy, Manikandan/0000-0001-7626-2531; Blighe, Kevin/0000-0002-6322-6571; Ellis, Ian/0000-0001-5292-8474	Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; National Institute for Health Research; Pink Ribbon Foundation; China Scholarship Council; Action Against Cancer; Breast Cancer Campaign; Cancer Research UK; Cancer Research UK [13462, 14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; National Institute for Health Research(National Institute for Health Research (NIHR)); Pink Ribbon Foundation; China Scholarship Council(China Scholarship Council); Action Against Cancer; Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We would like to thank Chun Fui Lai, Aleksandra Filipovic, Monica Faronato and Dongyun Yang for their technical assistance and Pritesh Trivedi for performing the immunohistochemistry staining. This work was supported by the Imperial Biomedical Research Centre, the Experimental Cancer Medicine Centre, the National Institute for Health Research, the Pink Ribbon Foundation, China Scholarship Council, Action Against Cancer, Breast Cancer Campaign and Cancer Research UK. We thank Richard and Evelina Girling and the 'kinase group' for their support.	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Dalton LW, 2000, MODERN PATHOL, V13, P730, DOI 10.1038/modpathol.3880126; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fusello AM, 2006, J IMMUNOL, V177, P6152, DOI 10.4049/jimmunol.177.9.6152; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Goettel JA, 2011, EXP CELL RES, V317, P452, DOI 10.1016/j.yexcr.2010.11.018; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayami R, 2005, CANCER RES, V65, P6; Hiraike H, 2010, BRIT J CANCER, V102, P1061, DOI 10.1038/sj.bjc.6605577; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kim HS, 2006, CANCER RES, V66, P4561, DOI 10.1158/0008-5472.CAN-05-3629; Kim M, 2005, CANCER RES, V65, P3986, DOI 10.1158/0008-5472.CAN-03-2334; Kolesnick R, 2004, J CLIN INVEST, V114, P1233, DOI 10.1172/JCI200423441; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Lombardo Y, 2012, P NATL ACAD SCI USA, V109, P16558, DOI 10.1073/pnas.1206268109; Lozano J, 2003, CANCER RES, V63, P4232; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; McKay MM, 2011, CURR BIOL, V21, P563, DOI 10.1016/j.cub.2011.02.033; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Salerno M, 2005, MOL CELL BIOL, V25, P1379, DOI 10.1128/MCB.25.4.1379-1388.2005; Shaw JA, 2012, GENOME RES, V22, P220, DOI 10.1101/gr.123497.111; Stebbing J, 2010, CLIN EVID, V2010, P1; Stebbing J, 2012, BREAST CANCER RES TR, V132, P537, DOI 10.1007/s10549-011-1622-z; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Wallace MD, 2012, GENETICS, V192, P385, DOI 10.1534/genetics.112.142802; Witzel F, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00475; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xing HR, 2003, NAT MED, V9, P1266, DOI 10.1038/nm927; Yan F, 2004, J CLIN INVEST, V114, P1272, DOI 10.1172/JCI200421022; Zafrullah M, 2009, BIOCHEM BIOPH RES CO, V390, P434, DOI 10.1016/j.bbrc.2009.09.048; Zhang H, 2013, BRIT J CANCER, V109, P2675, DOI 10.1038/bjc.2013.628; Zhang H, 2010, BREAST CANCER RES TR, V121, P41, DOI 10.1007/s10549-009-0450-x; Zhang H, 2013, BIOCHEM SOC T, V41, P1078, DOI 10.1042/BST20130042; Zhang H, 2012, CELL SIGNAL, V24, P1173, DOI 10.1016/j.cellsig.2012.01.017; Zhang JJ, 2008, CANCER BIOL THER, V7, P1492, DOI 10.4161/cbt.7.9.6472; Zhang Y, 2011, NAT MED, V17, P341, DOI 10.1038/nm.2296	52	11	11	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2103	2114		10.1038/onc.2014.129	http://dx.doi.org/10.1038/onc.2014.129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909178	Green Submitted			2022-12-28	WOS:000353173400010
J	Oh, YT; Deng, J; Yue, P; Owonikoko, TK; Khuri, FR; Sun, SY				Oh, Y-T; Deng, J.; Yue, P.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y			Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing	ONCOGENE			English	Article							RECEPTOR 5 EXPRESSION; AZD6244 ARRY-142886; BRAF; RAF; MEK; COACTIVATION; CARCINOMAS; BENCH	Inhibition of B-Raf/MEK/ERK signaling is an effective therapeutic strategy against certain types of cancers such as melanoma and thyroid cancer. While demonstrated to be effective anticancer agents, B-Raf or MEK inhibitors have also been associated with early tumor progression and development of secondary neoplasms. The ligation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with its receptor, death receptor 5 (DR5), leading to induction of apoptosis, offers a promising anticancer strategy. Importantly, this is also a natural immunosurveillance mechanism against cancer development. We previously demonstrated that activated B-Raf/MEK/ERK signaling positively regulates DR5 expression. Hence, our current work sought to address whether B-Raf/MEK/ERK inhibition and the consequent suppression of DR5 expression impede cancer cell response to DR5 activation-induced apoptosis and activated immune cell-induced killing. We found that both B-Raf (for example, PLX4032) and MEK inhibitors (for example, AZD6244 and PD0325901) effectively inhibited ERK1/2 phosphorylation and reduced DR5 levels in both human thyroid cancer and melanoma cells. Similar to the observed effect of genetic knockdown of the B-Raf gene, pre-treatment of cancer cell lines with either B-Raf or MEK inhibitors attenuated or abolished cellular apoptotic response induced by TRAIL or the DR5 agonistic antibody AMG655 or cell killing by activated T cells. Our findings clearly show that inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs DR5 activation-induced apoptosis and T cell-mediated killing of cancer cells. These findings suggest a potential negative impact of B-Raf or MEK inhibition on TRAIL-or DR5-mediated anticancer therapy and on TRAIL/DR5-mediated immune-clearance of cancer cells.	[Oh, Y-T; Deng, J.; Yue, P.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y] Emory Univ Sch Med & Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3088, Atlanta, GA 30332 USA		Sun, SY (corresponding author), Emory Univ Sch Med & Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3088, Atlanta, GA 30332 USA.	ssun@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618	NIH/NCI SPORE P50 grant [CA128613]; Emory Winship Cancer Institute Robbins Scholar awards; Melanoma Research Fund; Halpern Research Scholar award; Halpern Research Scholar; NATIONAL CANCER INSTITUTE [P30CA138292, P50CA128613] Funding Source: NIH RePORTER	NIH/NCI SPORE P50 grant; Emory Winship Cancer Institute Robbins Scholar awards; Melanoma Research Fund; Halpern Research Scholar award; Halpern Research Scholar; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs P Giannakakou, J Arbiser and R Schweppes for providing cancer cell lines and Amgen Inc. for the generous provision of AMG655. We are also thankful to Dr A Hammond for editing the manuscript. This study was supported by the NIH/NCI SPORE P50 grant CA128613 (to S-Y Sun for Project 2) and Emory Winship Cancer Institute Robbins Scholar awards (to Y-T Oh and to J Deng), Melanoma Research Fund (to J Deng) and Halpern Research Scholar award (to S-Y Sun). FR Khuri, TK Owonikoko and S-Y Sun are Georgia Research Alliance Distinguished Cancer Scientists. S-Y Sun is a Halpern Research Scholar.	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-27; Arnault JP, 2009, J CLIN ONCOL, V27, pE59, DOI 10.1200/JCO.2009.23.4823; Banerji U, 2010, CLIN CANCER RES, V16, P1613, DOI 10.1158/1078-0432.CCR-09-2483; Berger A, 2014, J INVEST DERMATOL, V134, P430, DOI 10.1038/jid.2013.347; Breaker K, 2013, DERMATOL SURG, V39, P981, DOI 10.1111/dsu.12184; Dhandapani L, 2011, CANCER RES, V71, P5245, DOI 10.1158/0008-5472.CAN-10-4180; Dubauskas Z, 2009, CLIN GENITOURIN CANC, V7, P20, DOI 10.3816/CGC.2009.n.003; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Friday BB, 2008, CLIN CANCER RES, V14, P342, DOI 10.1158/1078-0432.CCR-07-4790; Hersey P, 2009, CANCER IMMUNOL IMMUN, V58, P1751, DOI 10.1007/s00262-009-0732-5; Huang TG, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-30; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Llobet D, 2010, EUR J CANCER, V46, P836, DOI 10.1016/j.ejca.2009.12.025; Oh YT, 2012, J BIOL CHEM, V287, P257, DOI 10.1074/jbc.M111.304006; Oh YT, 2010, J BIOL CHEM, V285, P41310, DOI 10.1074/jbc.M110.153775; Rafei M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-121; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Smalley KSM, 2013, NAT REV CLIN ONCOL, V10, P5, DOI 10.1038/nrclinonc.2012.215; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Sun SY, 2007, J BIOL CHEM, V282, P18800, DOI 10.1074/jbc.M611438200; Sun SY, 1997, CANCER RES, V57, P4931; Weeraratna AT, 2012, NEW ENGL J MED, V366, P271, DOI 10.1056/NEJMe1111636; Yang A, 2010, CURR OPIN CELL BIOL, V22, P837, DOI 10.1016/j.ceb.2010.08.001; Zitzmann K, 2011, ENDOCR-RELAT CANCER, V18, P277, DOI 10.1530/ERC-10-0108	27	12	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					459	467		10.1038/onc.2015.97	http://dx.doi.org/10.1038/onc.2015.97			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867065	Green Accepted			2022-12-28	WOS:000369056700006
J	Wang, W; Liao, P; Shen, M; Chen, T; Chen, Y; Li, Y; Lin, X; Ge, X; Wang, P				Wang, W.; Liao, P.; Shen, M.; Chen, T.; Chen, Y.; Li, Y.; Lin, X.; Ge, X.; Wang, P.			SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62	ONCOGENE			English	Article							TERMINAL DOMAIN PHOSPHATASE; PROTEIN-KINASE CK2; GENE-EXPRESSION; BREAST-CANCER; DNA-BINDING; DEGRADATION; CELLS; COMPLEX; ACTIVATION; SUBUNIT	Serine 62 (Ser62) phosphorylation affects the c-Myc protein stability in cancer cells. However, the mechanism for dephosphorylating c-Myc is not well understood. In this study, we identified carboxyl-terminal domain RNA polymerase II polypeptide A small phosphatase 1 (SCP1) as a novel phosphatase specifically dephosphorylating c-Myc Ser62. Ectopically expressed SCP1 strongly dephosphorylated c-Myc Ser62, destabilized c-Myc protein and suppressed c-Myc transcriptional activity. Knockdown of SCP1 increased the c-Myc protein levels in liver cancer cells. SCP1 interacted with c-Myc both in vivo and in vitro. In addition, Ser245 at the C-terminus of SCP1 was essential for its phosphatase activity towards c-Myc. Functionally, SCP1 negatively regulated the cancer cell proliferation. Collectively, our findings indicate that SCP1 is a potential tumor suppressor for liver cancers through dephosphorylating c-Myc Ser62.	[Wang, W.; Liao, P.; Ge, X.; Wang, P.] Tongji Univ, Dept Cent Lab, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China; [Wang, W.; Liao, P.; Shen, M.; Chen, T.; Chen, Y.; Li, Y.; Wang, P.] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China; [Wang, W.; Liao, P.; Shen, M.; Chen, T.; Chen, Y.; Li, Y.; Wang, P.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Lin, X.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; [Wang, P.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tongji University; East China Normal University; East China Normal University; Baylor College of Medicine; Tongji University	Ge, X; Wang, P (corresponding author), Tongji Univ, Dept Cent Lab, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.; Wang, P (corresponding author), E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China.; Wang, P (corresponding author), E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China.	gexx0019@163.com; pwangecnu@163.com	Liao, Peng/Y-1896-2019	Liao, Peng/0000-0002-8409-5574	National Basic Research Program of China (973 program) [2012CB910404, 2010CB529704]; National Natural Science Foundation of China [30971521, 31171338, 31222037]; Shanghai Municipal Education Commission; Shanghai Education Development Foundation [11SG27]; Shanghai Key Laboratory of Regulatory Biology [11DZ2260300]; Shanghai Rising-Star program [09QA1401900, 13QH1401300]; scholar of the Program for New Century Excellent Talents in University [NCET-10-0387]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); Shanghai Education Development Foundation; Shanghai Key Laboratory of Regulatory Biology; Shanghai Rising-Star program; scholar of the Program for New Century Excellent Talents in University	This work was supported by grants from National Basic Research Program of China (973 program 2012CB910404 and 2010CB529704), National Natural Science Foundation of China (30971521, 31171338 and 31222037), 'Shu Guang' project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation (11SG27), Shanghai Key Laboratory of Regulatory Biology (11DZ2260300) and Shanghai Rising-Star program (09QA1401900 and 13QH1401300). PW is a scholar of the Program for New Century Excellent Talents in University (NCET-10-0387).	Amanchy R, 2007, NAT BIOTECHNOL, V25, P285, DOI 10.1038/nbt0307-285; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Conacci-Sorrell M, 2011, CELL CYCLE, V10, P604, DOI 10.4161/cc.10.4.14794; CROUCH DH, 1993, ONCOGENE, V8, P1849; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Farrell A.S., 2014, COLD SPRING HARB PER, V4; Farrell AS, 2013, MOL CELL BIOL, V33, P2930, DOI 10.1128/MCB.01455-12; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kops O, 2002, FEBS LETT, V513, P305, DOI 10.1016/S0014-5793(02)02288-3; Liao P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.536; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Liu Lingfeng, 2012, Genes Cancer, V3, P23, DOI 10.1177/1947601912448067; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Stolk M, 2005, BIOCHEM J, V386, P281, DOI 10.1042/BJ20041571; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wrighton KH, 2006, J BIOL CHEM, V281, P38365, DOI 10.1074/jbc.M607246200; Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200; Xue Y, 2005, NUCLEIC ACIDS RES, V33, pW184, DOI 10.1093/nar/gki393; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Zhang MM, 2010, PROTEIN SCI, V19, P974, DOI 10.1002/pro.375; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P2790, DOI 10.1073/pnas.1100764108; Zhang Y, 2006, MOL CELL, V24, P759, DOI 10.1016/j.molcel.2006.10.027	45	20	20	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					491	500		10.1038/onc.2015.106	http://dx.doi.org/10.1038/onc.2015.106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893300				2022-12-28	WOS:000369056700009
J	Adapala, RK; Thoppil, RJ; Ghosh, K; Cappelli, HC; Dudley, AC; Paruchuri, S; Keshamouni, V; Klagsbrun, M; Meszaros, JG; Chilian, WM; Ingber, DE; Thodeti, CK				Adapala, R. K.; Thoppil, R. J.; Ghosh, K.; Cappelli, H. C.; Dudley, A. C.; Paruchuri, S.; Keshamouni, V.; Klagsbrun, M.; Meszaros, J. G.; Chilian, W. M.; Ingber, D. E.; Thodeti, C. K.			Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy	ONCOGENE			English	Article							RECEPTOR POTENTIAL VANILLOID-4; VESSEL NORMALIZATION; ANTI-ANGIOGENESIS; ENDOTHELIAL-CELLS; BLOOD-VESSELS; INTEGRIN; DELIVERY; RHO; DIFFERENTIATION; CHEMOTHERAPY	Tumor vessels are characterized by abnormal morphology and hyperpermeability that together cause inefficient delivery of chemotherapeutic agents. Although vascular endothelial growth factor has been established as a critical regulator of tumor angiogenesis, the role of mechanical signaling in the regulation of tumor vasculature or tumor endothelial cell (TEC) function is not known. Here we show that the mechanosensitive ion channel transient receptor potential vanilloid 4 (TRPV4) regulates tumor angiogenesis and tumor vessel maturation via modulation of TEC mechanosensitivity. We found that TECs exhibit reduced TRPV4 expression and function, which is correlated with aberrant mechanosensitivity towards extracellular matrix stiffness, increased migration and abnormal angiogenesis by TEC. Further, syngeneic tumor experiments revealed that the absence of TRPV4 induced increased vascular density, vessel diameter and reduced pericyte coverage resulting in enhanced tumor growth in TRPV4 knockout mice. Importantly, overexpression or pharmacological activation of TRPV4 restored aberrant TEC mechanosensitivity, migration and normalized abnormal angiogenesis in vitro by modulating Rho activity. Finally, a small molecule activator of TRPV4, GSK1016790A, in combination with anticancer drug cisplatin, significantly reduced tumor growth in wild-type mice by inducing vessel maturation. Our findings demonstrate TRPV4 channels to be critical regulators of tumor angiogenesis and represent a novel target for antiangiogenic and vascular normalization therapies.	[Adapala, R. K.; Thoppil, R. J.; Cappelli, H. C.; Meszaros, J. G.; Chilian, W. M.; Thodeti, C. K.] Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH 44272 USA; [Adapala, R. K.; Thoppil, R. J.; Cappelli, H. C.; Meszaros, J. G.; Chilian, W. M.; Thodeti, C. K.] Kent State Univ, Sch Biomed Sci, Kent, OH 44242 USA; [Ghosh, K.] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA; [Ghosh, K.; Dudley, A. C.; Klagsbrun, M.; Ingber, D. E.; Thodeti, C. K.] Childrens Hosp, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA; [Ghosh, K.; Dudley, A. C.; Klagsbrun, M.; Ingber, D. E.; Thodeti, C. K.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Dudley, A. C.] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC USA; [Paruchuri, S.] Univ Akron, Dept Chem, Akron, OH 44325 USA; [Keshamouni, V.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Ingber, D. E.] Wyss Inst Biol Inspired Engn, Cambridge, MA USA; [Ingber, D. E.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA	Northeast Ohio Medical University (NEOMED); University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; University of California System; University of California Riverside; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Akron; University of Michigan System; University of Michigan; Harvard University	Thodeti, CK (corresponding author), Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH 44272 USA.	cthodeti@neomed.edu	Adapala, Ravi kumar/AAD-1282-2020; Ingber, Donald E/AAC-5894-2019	Adapala, Ravi kumar/0000-0002-4082-5301; Keshamouni, Venkateshwar/0000-0003-1947-791X	NEOMED; AHA [14GRNT20380935]; NIH [CA55833, CA45548]; NATIONAL CANCER INSTITUTE [P01CA045548, P30CA016086, R01CA055833, R01CA177875] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL106442, R01HL115114, R01HL119705] Funding Source: NIH RePORTER	NEOMED; AHA(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the start-up funds from NEOMED and AHA (14GRNT20380935) (CKT) and NIH grants CA55833 and CA45548 (DI).	Abdollahi A, 2010, DRUG RESIST UPDATE, V13, P16, DOI 10.1016/j.drup.2009.12.001; Adapala RK, 2013, J MOL CELL CARDIOL, V54, P45, DOI 10.1016/j.yjmcc.2012.10.016; Adapala RK, 2011, AM J PHYSIOL-HEART C, V301, pH757, DOI 10.1152/ajpheart.00142.2011; Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Alessandri-Haber N, 2008, J NEUROSCI, V28, P1046, DOI 10.1523/JNEUROSCI.4497-07.2008; Baylie RL, 2011, ACTA PHYSIOL, V203, P99, DOI 10.1111/j.1748-1716.2010.02217.x; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Brackenbury WJ, 2006, J PHYSIOL-LONDON, V573, P343, DOI 10.1113/jphysiol.2006.106906; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Chae SS, 2010, CLIN CANCER RES, V16, P3618, DOI 10.1158/1078-0432.CCR-09-3073; Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/NNANO.2012.45, 10.1038/nnano.2012.45]; Cuevas I, 2009, ADV CANCER RES, V103, P25, DOI 10.1016/S0065-230X(09)03002-4; di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123; Duda DG, 2007, TRENDS MOL MED, V13, P223, DOI 10.1016/j.molmed.2007.04.001; Dudley AC, 2008, CANCER CELL, V14, P201, DOI 10.1016/j.ccr.2008.06.017; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Folkman J, 2003, CANCER BIOL THER, V2, pS127; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Fraser SP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0105; Fukumura D, 2008, APMIS, V116, P695, DOI 10.1111/j.1600-0463.2008.01148.x; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Ghosh K, 2008, P NATL ACAD SCI USA, V105, P11305, DOI 10.1073/pnas.0800835105; Goel S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006486; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Gradilone SA, 2007, P NATL ACAD SCI USA, V104, P19138, DOI 10.1073/pnas.0705964104; Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827; Hu F, 2013, ARCH ORAL BIOL, V58, P192, DOI 10.1016/j.archoralbio.2012.08.013; Ingber D E, 1997, Gravit Space Biol Bull, V10, P49; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; Jain RK, 2008, SCI AM, V298, P56, DOI 10.1038/scientificamerican0108-56; Jain RK, 2012, CELL, V149, P1408, DOI 10.1016/j.cell.2012.05.025; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Liedtke W, 2005, J PHYSIOL-LONDON, V567, P53, DOI 10.1113/jphysiol.2005.088963; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765; Marnmoto A, 2008, CURR OPIN HEMATOL, V15, P228, DOI 10.1097/MOH.0b013e3282fa7445; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; MATTHEWS BD, INTEGR BIOL CAMB, V2, P435; Mendoza SA, 2010, AM J PHYSIOL-HEART C, V298, pH466, DOI 10.1152/ajpheart.00854.2009; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pla AF, 2012, ONCOGENE, V31, P200, DOI 10.1038/onc.2011.231; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Shakibael M, 2003, HISTOL HISTOPATHOL, V18, P343, DOI 10.14670/HH-18.343; Sukharev Sergei, 2004, Sci STKE, V2004, pre4, DOI 10.1126/stke.2192004re4; Thodeti CK, 2009, CIRC RES, V104, P1123, DOI 10.1161/CIRCRESAHA.108.192930; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; Troidl C, 2009, J CELL MOL MED, V13, P2613, DOI 10.1111/j.1582-4934.2008.00579.x; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Van der Veldt AAM, 2012, CANCER CELL, V21, P82, DOI 10.1016/j.ccr.2011.11.023; Wilson PD, 1999, LAB INVEST, V79, P1311; Xu HS, 2006, AM J PHYSIOL-RENAL, V290, pF1103, DOI 10.1152/ajprenal.00245.2005	57	98	105	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					314	322		10.1038/onc.2015.83	http://dx.doi.org/10.1038/onc.2015.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25867067	Green Accepted, Green Submitted			2022-12-28	WOS:000369055300005
J	Lodillinsky, C; Infante, E; Guichard, A; Chaligne, R; Fuhrmann, L; Cyrta, J; Irondelle, M; Lagoutte, E; Vacher, S; Bonsang-Kitzis, H; Glukhova, M; Reyal, F; Bieche, I; Vincent-Salomon, A; Chavrier, P				Lodillinsky, C.; Infante, E.; Guichard, A.; Chaligne, R.; Fuhrmann, L.; Cyrta, J.; Irondelle, M.; Lagoutte, E.; Vacher, S.; Bonsang-Kitzis, H.; Glukhova, M.; Reyal, F.; Bieche, I.; Vincent-Salomon, A.; Chavrier, P.			p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer	ONCOGENE			English	Article							STEM-CELL ACTIVITY; MATRIX-METALLOPROTEINASE; TISSUE LOCALIZATION; TUMOR-CELLS; EXPRESSION; P63; MT1-MMP; IDENTIFICATION; PROGRESSION; METASTASIS	The transition of ductal carcinoma in situ (DCIS) to invasive breast carcinoma requires tumor cells to cross the basement membrane (BM). However, mechanisms underlying BM transmigration are poorly understood. Here, we report that expression of membranetype 1 (MT1)-matrix metalloproteinase (MMP), a key component of the BM invasion program, increases during breast cancer progression at the in situ to invasive breast carcinoma transition. In the intraductal xenograft model, MT1-MMP is required for BM transmigration of MCF10DCIS. com breast adenocarcinoma cells and is overexpressed in cell clusters overlying focal BM disruptions and at the invasive tumor front. Mirrored upregulation of p63 and MT1-MMP is observed at the edge of MCF10DCIS. com xenograft tumors and p63 is required for induction of MT1-MMP-dependent invasive program in response to microenvironmental signals. Immunohistochemistry and analysis of public database reveal that p63 and MT1-MMP are upregulated in human basal-like breast tumors suggesting that p63/MT1-MMP axis contributes to progression of basal-like breast cancers with elevated p63 and MT1-MMP levels.	[Lodillinsky, C.; Infante, E.; Guichard, A.; Fuhrmann, L.; Cyrta, J.; Irondelle, M.; Lagoutte, E.; Chavrier, P.] CNRS, Membrane & Cytoskeleton Dynam Grp, Cell Dynam & Compartmentalizat Unit, Inst Curie,UMR144, 26 Rue Ulm, F-75248 Paris, France; [Chaligne, R.; Vincent-Salomon, A.] Inst Curie, Genet & Dev Biol Unit, Mammalian Dev Epigenet Grp, Paris, France; [Vacher, S.; Bieche, I.] Inst Curie, Dept Genet, Paris, France; [Bonsang-Kitzis, H.; Reyal, F.] Inst Curie, Team RT2Lab, Translat Res Dept, Paris, France; [Glukhova, M.] CNRS, Mol Mech Mammary Gland Dev Grp, Cell Dynam & Compartmentalizat Unit, Inst Curie,UMR144, Paris, France; [Vincent-Salomon, A.] Inst Curie, Pathol Dept, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lodillinsky, C; Chavrier, P (corresponding author), CNRS, Membrane & Cytoskeleton Dynam Grp, Cell Dynam & Compartmentalizat Unit, Inst Curie,UMR144, 26 Rue Ulm, F-75248 Paris, France.	catalina.lodillinsky@curie.fr; philippe.chavrier@curie.fr	CHAVRIER, Philippe/AAG-2645-2020; Bièche, Ivan/O-7399-2017; CHAVRIER, Philippe/B-4707-2010	CHAVRIER, Philippe/0000-0002-7351-733X; Bièche, Ivan/0000-0002-2430-5429; CHAVRIER, Philippe/0000-0002-7351-733X; Guichard, Alan/0000-0001-8623-9570; Infante, Elvira/0000-0002-9883-8391; VACHER, Sophie/0000-0002-0042-6023	Agence Nationale pour la Recherche; Fondation Pierre-Gilles de Gennes pour la Recherche; Region Ile-de-France; Appel a Projet 'Biologie des Systemes' du Plan cancer (INVADE project); Incentive and Cooperative Research Programme 'Breast cancer: cell Invasion and Motility' of Institut Curie; ARC [SL220100601356, SLR20130607099]; Ligue Nationale contre le Cancer (Comite de Paris); Agence Nationale pour la Recherche [ANR-08-BLAN-0111]; Institut National du Cancer [2012-1-PL BIO-02-IC-1]; Institut Curie; Centre National pour la Recherche Scientifique (CNRS)	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Fondation Pierre-Gilles de Gennes pour la Recherche; Region Ile-de-France(Region Ile-de-France); Appel a Projet 'Biologie des Systemes' du Plan cancer (INVADE project); Incentive and Cooperative Research Programme 'Breast cancer: cell Invasion and Motility' of Institut Curie; ARC(Australian Research Council); Ligue Nationale contre le Cancer (Comite de Paris); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National du Cancer(Institut National du Cancer (INCA) France); Institut Curie; Centre National pour la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	We acknowledge the Breast Cancer Study Group and patients of Institut Curie for the breast tumor samples, Dr G Scita for critical reading of the manuscript, the Nikon Imaging Centre @ Institut Curie-CNRS and Cell and Tissue Imaging Facility of Institut Curie for help with image acquisition, V Dangles-Marie and MA Deugnier for help with the intraductal xenograft model, K Lehti, GP Dotto, C Albiges-Rizo and O Destaing for providing reagents, D Gentien for the gift of breast tumor cell line mRNA samples and M Sefta for correlation analysis of MT1-MMP and p63 expression in breast tumor cell lines. CL was supported by grants from Agence Nationale pour la Recherche and Fondation Pierre-Gilles de Gennes pour la Recherche, EI by a grant from Region Ile-de-France, AG by a grant from Appel a Projet 'Biologie des Systemes' 2012 du Plan cancer 2009-2013 (INVADE project) and LF and MI by the Incentive and Cooperative Research Programme 'Breast cancer: cell Invasion and Motility' of Institut Curie. Funding for this work was provided by grants from ARC (SL220100601356 and SLR20130607099), Ligue Nationale contre le Cancer (Comite de Paris), Agence Nationale pour la Recherche (ANR-08-BLAN-0111) and Institut National du Cancer (2012-1-PL BIO-02-IC-1) to PC and by core funding from Institut Curie and Centre National pour la Recherche Scientifique (CNRS).	Allred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127; Awadelkarim KD, 2012, INT J CANCER, V131, P2852, DOI 10.1002/ijc.27600; Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008-5472.CAN-12-2862; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bisson C, 2003, INT J CANCER, V105, P7, DOI 10.1002/ijc.11012; Buckley NE, 2011, CANCER RES, V71, P1933, DOI 10.1158/0008-5472.CAN-10-2717; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Hannemann J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1613; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Martynova E, 2012, ONCOTARGET, V3, P132; Matos I, 2005, VIRCHOWS ARCH, V447, P688, DOI 10.1007/s00428-005-0010-7; McDade SS, 2012, NUCLEIC ACIDS RES, V40, P7190, DOI 10.1093/nar/gks389; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Muggerud AA, 2010, MOL ONCOL, V4, P357, DOI 10.1016/j.molonc.2010.06.007; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Olsen JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062547; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Polyak K, 2005, J MAMMARY GLAND BIOL, V10, P231, DOI 10.1007/s10911-005-9584-6; Prat A, 2013, J CLIN ONCOL, V31, P203, DOI 10.1200/JCO.2012.43.4134; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sakakibara M, 1999, CANCER, V85, P231, DOI 10.1002/(SICI)1097-0142(19990101)85:1<231::AID-CNCR31>3.0.CO;2-3; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shekhar MPV, 2013, ONCOTARGET, V4, P231, DOI 10.18632/oncotarget.818; Szabova L, 2008, ONCOGENE, V27, P3274, DOI 10.1038/sj.onc.1210982; Tetu B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1503; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Ueno H, 1997, CANCER RES, V57, P2055; Vincent-Salomon A, 2007, BRIT J CANCER, V96, P654, DOI 10.1038/sj.bjc.6603584; Vincent-Salomon A, 2008, CLIN CANCER RES, V14, P1956, DOI 10.1158/1078-0432.CCR-07-1465; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yu K, 2004, CANCER RES, V64, P2962, DOI 10.1158/0008-5472.CAN-03-2430; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231	59	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					344	357		10.1038/onc.2015.87	http://dx.doi.org/10.1038/onc.2015.87			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893299				2022-12-28	WOS:000369055300008
J	Choi, JA; Jung, YS; Kim, JY; Kim, HM; Lim, IK				Choi, J-A; Jung, Y. S.; Kim, J. Y.; Kim, H. M.; Lim, I. K.			Inhibition of breast cancer invasion by TIS21(/BTG2/Pc3)-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes	ONCOGENE			English	Article							DIAPHANOUS-RELATED FORMINS; CELL-MIGRATION; INVADOPODIA FORMATION; TRANSCRIPTION FACTOR; TUMOR PROGRESSION; BTG2 EXPRESSION; DOWN-REGULATION; AKT ISOFORMS; PROTEIN; ACTIVATION	The mammalian homolog of Drosophila diaphanous (mDia), actin nucleator, has been known to participate in the process of invasion and metastasis of cancer cells via regulating a number of actin-related biological processes. We have previously reported that tumor suppressor TIS21(/BTG2/Pc3) (TIS21) inhibits invadopodia formation by downregulating reactive oxygen species (ROS) in MDA-MB-231 cells. We herein report that TIS21(/BTG2/Pc3) downregulates diaphanous-related formin (DRF) expression via reducing NADPH oxidase 4 (Nox4)-derived ROS generation by Akt1 activation and subsequently impairs invasion activity of the highly invasive breast cancer cells. Knockdown of Akt1 by RNA interference recovered the TIS21(/BTG2/Pc3)-inhibited F-actin remodeling and ROS generation by recovering Nox4 expression. Furthermore, Sp1-mediated Nox4 transcription was downregulated by TIS21(/BTG2/Pc3)-Akt1 signals, leading to the inhibition of cancer cell invasion via F-actin remodeling by mDia genes. To our best knowledge, this is the first study to show that TIS21(/BTG2/Pc3)-Akt1 inhibited Sp1-Nox4-ROS cascade, subsequently reducing invasion activity via inhibition of mDia family genes.	[Choi, J-A; Lim, I. K.] Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443380, South Korea; [Choi, J-A; Lim, I. K.] Ajou Univ, Grad Sch Med, Dept Biomed Sci, Suwon 443380, South Korea; [Jung, Y. S.; Kim, J. Y.] Ajou Univ, Sch Med, Dept Surg, Suwon 443380, South Korea; [Kim, H. M.] Ajou Univ, Dept Energy Syst Res, Suwon 443380, South Korea	Ajou University; Ajou University; Ajou University; Ajou University	Lim, IK (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, San 5, Suwon 443380, South Korea.	iklim@ajou.ac.kr	Jung, Yongsik/ABH-9311-2020	Jung, Yongsik/0000-0002-2011-1459	Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A121725]; National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea [131280]	Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea; National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea	Authors greatly appreciate Professor Young-Joon Chwae for his kind help in lucigenin-enhanced chemiluminescence assay, excellent advice for statistical analysis by Professor Seung-Soo Sheen, technical help for two-photon fluorescence microscopy by Cheol Ho Heo and careful reading of this manuscript by Professor Woon Ki Paik at Ajou University School of Medicine. This work was supported by a grant of the Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A121725) and a grant from the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (131280).	Arboleda MJ, 2003, CANCER RES, V63, P196; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Bondi CD, 2010, J AM SOC NEPHROL, V21, P93, DOI 10.1681/ASN.2009020146; Boudreau HE, 2012, FREE RADICAL BIO MED, V53, P1489, DOI 10.1016/j.freeradbiomed.2012.06.016; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Carramusa L, 2007, J CELL SCI, V120, P3870, DOI 10.1242/jcs.014365; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Choi JA, 2013, J CANCER RES CLIN, V139, P1657, DOI 10.1007/s00432-013-1484-3; Choi JA, 2010, CARCINOGENESIS, V31, P543, DOI 10.1093/carcin/bgp203; Colvin RA, 2010, NAT IMMUNOL, V11, P495, DOI 10.1038/ni.1878; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Devanand P, 2014, FEBS J, V281, P5581, DOI 10.1111/febs.13099; Diebold I, 2010, MOL BIOL CELL, V21, P2087, DOI 10.1091/mbc.E09-12-1003; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Esteve PO, 2011, NAT STRUCT MOL BIOL, V18, P42, DOI 10.1038/nsmb.1939; Farioli-Vecchioli S, 2007, FASEB J, V21, P2215, DOI 10.1096/fj.06-7548com; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hong JW, 2005, J BIOL CHEM, V280, P21256, DOI 10.1074/jbc.M500318200; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Imran M, 2013, CELL SIGNAL, V25, P2400, DOI 10.1016/j.cellsig.2013.07.015; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Katsuyama M, 2011, FEBS J, V278, P964, DOI 10.1111/j.1742-4658.2011.08018.x; Kawakubo H, 2004, ONCOGENE, V23, P8310, DOI 10.1038/sj.onc.1208008; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kim BC, 2008, STEM CELLS, V26, P2339, DOI 10.1634/stemcells.2008-0327; Kim EY, 2010, FREE RADICAL BIO MED, V49, P1072, DOI 10.1016/j.freeradbiomed.2010.06.023; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Lassegue B, 2012, CIRC RES, V110, P1364, DOI 10.1161/CIRCRESAHA.111.243972; LIM IK, 1995, J CANCER RES CLIN, V121, P279, DOI 10.1007/BF01209594; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lim SK, 2012, CLIN EXP METASTAS, V29, P901, DOI 10.1007/s10585-012-9479-z; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Liu M, 2009, CELL RES, V19, P828, DOI 10.1038/cr.2009.72; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Matheny RW, 2010, CELL DEATH DIFFER, V17, P677, DOI 10.1038/cdd.2009.150; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Park S, 2004, MOL CELL BIOL, V24, P10256, DOI 10.1128/MCB.24.23.10256-10262.2004; Park TJ, 2008, HEPATOLOGY, V47, P1533, DOI 10.1002/hep.22212; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Saji M, 2011, ONCOGENE, V30, P4307, DOI 10.1038/onc.2011.136; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Solomon H, 2012, J CELL SCI, V125, P3144, DOI 10.1242/jcs.099663; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Sundaramoorthy S, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-69; Takahashi F, 2011, ONCOGENE, V30, P3084, DOI 10.1038/onc.2011.24; Turner DP, 2007, CANCER RES, V67, P1618, DOI 10.1158/0008-5472.CAN-06-2913; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Xing H, 2007, ONCOL REP, V17, P117; Yamaguchi H, 2011, J CELL BIOL, V193, P1275, DOI 10.1083/jcb.201009126; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhang L, 2008, FREE RADICAL BIO MED, V45, P679, DOI 10.1016/j.freeradbiomed.2008.05.019	70	33	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					83	93		10.1038/onc.2015.64	http://dx.doi.org/10.1038/onc.2015.64			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798836				2022-12-28	WOS:000367812400008
J	Tian, H; Liu, J; Chen, J; Gatza, ML; Blobe, GC				Tian, H.; Liu, J.; Chen, J.; Gatza, M. L.; Blobe, G. C.			Fibulin-3 is a novel TGF-beta pathway inhibitor in the breast cancer microenvironment	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TUMOR MICROENVIRONMENT; PROMOTER METHYLATION; COLORECTAL-CANCER; DOWN-REGULATION; POOR-PROGNOSIS; STEM-CELLS; PROGRESSION; LUNG; METASTASIS	Transforming growth factor-beta (TGF-beta) is an important regulator of breast cancer progression. However, how the breast cancer microenvironment regulates TGF-beta signaling during breast cancer progression remains largely unknown. Here, we identified fibulin-3 as a secreted protein in the breast cancer microenvironment, which efficiently inhibits TGF-beta signaling in both breast cancer cells and endothelial cells. Mechanistically, fibulin-3 interacts with the type I TGF-beta receptor (T beta RI) to block TGF-beta induced complex formation of T beta RI with the type II TGF-beta receptor (T beta RII) and subsequent downstream TGF-beta signaling. Fibulin-3 expression decreases during breast cancer progression, with low fibulin-3 levels correlating with a poorer prognosis. Functionally, high fibulin-3 levels inhibited TGF-beta-induced epithelial-mesenchymal transition (EMT), migration, invasion and endothelial permeability, while loss of fibulin-3 expression/function promoted these TGF-beta-mediated effects. Further, restoring fibulin-3 expression in breast cancer cells inhibited TGF-beta signaling, breast cancer cell EMT, invasion and metastasis in vivo. These studies provide a novel mechanism for how TGF-beta signaling is regulated by the tumor microenvironment, and provide insight into targeting the TGF-beta signaling pathway in human breast cancer patients.	[Tian, H.; Chen, J.; Blobe, G. C.] Duke Univ, Med Ctr, Div Med Oncol, Dept Med, Durham, NC 27708 USA; [Liu, J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27708 USA; [Liu, J.] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China; [Gatza, M. L.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Blobe, G. C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA	Duke University; Duke University; Chinese Academy of Sciences; Kunming Institute of Botany, CAS; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med Pharmacol & Canc Biol, B354 LSRC,Box 91004, Durham, NC 27708 USA.	gerard.blobe@duke.edu	Wang, Limin/O-3724-2015; Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; Gatza, Michael/0000-0001-6796-7791	Komen for the Cure [KG111383, SAC100002]; NIH/NCI [R01-135006, R01-136786]; NATIONAL CANCER INSTITUTE [R01CA135006, R01CA136786] Funding Source: NIH RePORTER	Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Komen for the Cure Grants KG111383 (HT) and SAC100002 (GCB), NIH/NCI Grants R01-135006 (GCB), and R01-136786 (GCB). We thank Yi-Hong Zhou at University of California Irvine for the fibulin-3 pcDNA3.1 overexpression plasmid.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bierie B, 2009, CELL CYCLE, V8, P3319, DOI 10.4161/cc.8.20.9727; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Chang CF, 2007, FRONT BIOSCI-LANDMRK, V12, P4393, DOI 10.2741/2396; Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023; Cho JA, 2012, INT J ONCOL, V40, P130, DOI 10.3892/ijo.2011.1193; Culig Z, 2011, BBA-MOL CELL RES, V1813, P308, DOI 10.1016/j.bbamcr.2010.12.010; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Drabsch Y, 2011, J MAMMARY GLAND BIOL, V16, P97, DOI 10.1007/s10911-011-9217-1; Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Hanks BA, 2013, J CLIN INVEST, V123, P3925, DOI 10.1172/JCI65745; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Hynes NE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003186; Imamura T, 2012, BREAST CANCER-TOKYO, V19, P118, DOI 10.1007/s12282-011-0321-2; Kim EJ, 2012, INT J ONCOL, V40, P402, DOI 10.3892/ijo.2011.1191; Kim YJ, 2011, CLIN CANCER RES, V17, P4523, DOI 10.1158/1078-0432.CCR-10-2817; Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Laib AM, 2009, NAT PROTOC, V4, P1202, DOI 10.1038/nprot.2009.96; Lee JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084256; Luo RZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070511; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moses H, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003277; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002; O'Brien K, 2013, EUR J CANCER, V49, P1845, DOI 10.1016/j.ejca.2013.01.017; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Tong JD, 2011, NEOPLASMA, V58, P441, DOI 10.4149/neo_2011_05_441; Wang Z, 2012, PATHOL ONCOL RES, V18, P263, DOI 10.1007/s12253-011-9437-0; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zu XY, 2012, CELL TISSUE RES, V347, P73, DOI 10.1007/s00441-011-1225-3	50	36	36	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5635	5647		10.1038/onc.2015.13	http://dx.doi.org/10.1038/onc.2015.13			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25823021	Green Accepted, Green Submitted			2022-12-28	WOS:000364594300005
J	Goka, ET; Lippman, ME				Goka, E. T.; Lippman, M. E.			Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression	ONCOGENE			English	Article							CARCINOMA IN-SITU; SMALL-MOLECULE INHIBITOR; FAMILY SMALL GTPASES; GROWTH-FACTOR-BETA; EPITHELIAL-CELLS; ACTIVE RAC1; OVEREXPRESSION; TUMOR; UBIQUITYLATION; METHYLATION	The transition from ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC) is a crucial step in breast cancer progression. The specific alterations that govern this transition have not been elucidated. HER2/neu is frequently overexpressed in DCIS but is less common in IBC, thereby suggesting additional requirements for transformation. To identify genes capable of cooperating with HER2/neu to fully transform mammary epithelial cells, we used an insertional mutagenesis screen on cells isolated from wild-type neu expressing mice and identified the E3 ligase HACE1 as HER2 cooperative tumor suppressor gene. Loss of HACE1 expression is commonly seen in clinical breast cancer data sets. HACE1 downregulation in normal human mammary epithelial cells (HMECs) results in the accumulation of the activated GTP-bound Rac1 partially transforming these cells. Overexpression of HER2 activates Rac1, which further accumulates upon HACE1 loss resulting in Rac1 hyperactivation. Although the knockdown of HACE1 or overexpression of HER2 alone in HMECs is not sufficient for tumorigenesis, HER2 overexpression combined with HACE1 downregulation fully transforms HMECs resulting in robust tumor formation. The pharmaceutical interference of Rac function abrogates the effects of HACE1 loss both in vitro and in vivo, resulting in marked reduction in tumor burden. Our work supports a critical role for HACE1 in breast cancer progression and identifies patients that may benefit from Rac-targeted therapies.	[Goka, E. T.] Univ Miami, Miller Sch Med, Shelia & David Fuente Grad Program Canc Biol, Miami, FL 33101 USA; [Lippman, M. E.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33101 USA	University of Miami; University of Miami	Lippman, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Biomedical Res Bldg,1501 NW 10th Ave,POB 016960, Miami, FL 33101 USA.	mlippman@med.miami.edu						Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; BARNES DM, 1992, EUR J CANCER, V28A, P644, DOI 10.1016/S0959-8049(05)80117-0; Baxter NN, 2004, JNCI-J NATL CANCER I, V96, P443, DOI 10.1093/jnci/djh069; Castillo-Lluva S, 2012, ONCOGENE; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Ernster V L, 1997, J Natl Cancer Inst Monogr, P151; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hernandez E, 2010, P R HEALTH SCI J, V29, P348; Hibi K, 2008, ANTICANCER RES, V28, P1581; Hyytinen ER, 2002, GENE CHROMOSOME CANC, V34, P306, DOI 10.1002/gcc.10065; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; Kim IY, 2009, CANCER LETT, V275, P227, DOI 10.1016/j.canlet.2008.10.013; Lachance V, 2014, J CELL SCI, V127, P111, DOI 10.1242/jcs.132944; Latta EK, 2002, MODERN PATHOL, V15, P1318, DOI 10.1097/01.MP.0000038462.62634.B1; Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110; Lu T, 2009, P NATL ACAD SCI USA, V106, P16339, DOI 10.1073/pnas.0908560106; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Marcotte R, 2008, J MAMMARY GLAND BIOL, V13, P323, DOI 10.1007/s10911-008-9087-3; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Nethe M, 2010, J CELL SCI, V123, P4011, DOI 10.1242/jcs.078360; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Porter D, 2003, MOL CANCER RES, V1, P362; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sakata M, 2013, HEPATO-GASTROENTEROL, V60, P781, DOI 10.5754/hge10439; Sakata M, 2009, ANTICANCER RES, V29, P2231; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Tang DM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1509; Tina E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-350; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Visvikis O, 2010, BIOL CELL, V102, P377, DOI 10.1042/BC20090151; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621	41	43	44	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5395	5405		10.1038/onc.2014.468	http://dx.doi.org/10.1038/onc.2014.468			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25659579	hybrid, Green Published			2022-12-28	WOS:000363479200009
J	Lindsey, JC; Kawauchi, D; Schwalbe, EC; Solecki, DJ; Selby, MP; McKinnon, PJ; Olson, JM; Hayden, JT; Grundy, RG; Ellison, DW; Williamson, D; Bailey, S; Roussel, MF; Clifford, SC				Lindsey, J. C.; Kawauchi, D.; Schwalbe, E. C.; Solecki, D. J.; Selby, M. P.; McKinnon, P. J.; Olson, J. M.; Hayden, J. T.; Grundy, R. G.; Ellison, D. W.; Williamson, D.; Bailey, S.; Roussel, M. F.; Clifford, S. C.			Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance	ONCOGENE			English	Article							HEDGEHOG PATHWAY; METHYLATION; CANCER; MODEL; PROTOONCOGENE; TUMORIGENESIS; INACTIVATION; ORGANIZATION; CEREBELLUM; INHIBITION	The identification of key tumorigenic events in Sonic Hedgehog (SHH) subgroup medulloblastomas (MBSHH) will be essential for the development of individualized therapies and improved outcomes. However, beyond confirmation of characteristic SHH pathway mutations, recent genome-wide sequencing studies have not revealed commonly mutated genes with widespread relevance as potential therapeutic targets. We therefore examined any role for epigenetic DNA methylation events in MBSHH using a cross-species approach to candidate identification, prioritization and validation. MBSHH-associated DNA methylation events were first identified in 216 subgrouped human medulloblastomas (50 MBSHH, 28 Wnt/Wingless, 44 Group 3 and 94 Group 4) and their conservation then assessed in tumors arising from four independent murine models of Shh medulloblastoma, alongside any role in tumorigenesis using functional assessments in mouse and human models. This strategy identified widespread regional CpG hypomethylation of VAV1, leading to its elevated expression, as a conserved aberrant epigenetic event, which characterizes the majority of MBSHH tumors in both species, and is associated with a poor outcome in MBSHH patients. Moreover, direct modulation of VAV1 in mouse and human models revealed a critical role in tumor maintenance, and its abrogation markedly reduced medulloblastoma growth. Further, Vav1 activity regulated granule neuron precursor germinal zone exit and migration initiation in an ex vivo model of early postnatal cerebellar development. These findings establish VAV1 as a critical epigenetically regulated oncogene with a key role in MBSHH maintenance, and highlight its potential as a validated therapeutic target and prognostic biomarker for the improved therapy of medulloblastoma.	[Lindsey, J. C.; Schwalbe, E. C.; Selby, M. P.; Hayden, J. T.; Williamson, D.; Bailey, S.; Clifford, S. C.] Newcastle Univ, Royal Victoria Infirm, Northern Inst Canc Res, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Kawauchi, D.; Roussel, M. F.] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; [Solecki, D. J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [McKinnon, P. J.] St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; [Olson, J. M.] Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; [Grundy, R. G.] Univ Nottingham, Childrens Brain Tumor Res Ctr, Nottingham NG7 2RD, England; [Ellison, D. W.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	Newcastle University - UK; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Washington; University of Washington Seattle; University of Nottingham; St Jude Children's Research Hospital	Clifford, SC (corresponding author), Newcastle Univ, Royal Victoria Infirm, Northern Inst Canc Res, Sir James Spence Inst Level 5, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	steve.clifford@ncl.ac.uk	Roussel, Martine F/F-1469-2016; Solecki, David/N-8080-2018	Roussel, Martine F/0000-0002-1740-8139; Lindsey, Janet/0000-0002-5043-7513; Clifford, Steve/0000-0003-4893-2184; Schwalbe, Ed/0000-0002-1190-9469	Brain Tumour Charity [16/46, 16/92]; NIH [CA-096832, CA-02165-29]; American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital; Mochida Foundation; Anderson fellowship; LoveOliver; Cancer Research UK [C8464/A13457]; Cancer Research UK [13457] Funding Source: researchfish; The Brain Tumour Charity [16/164, 16/193] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA114567, P30CA021765, P01CA096832, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037956] Funding Source: NIH RePORTER	Brain Tumour Charity; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital(American Lebanese Syrian Associated Charities (ALSAC)); Mochida Foundation; Anderson fellowship; LoveOliver; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); The Brain Tumour Charity; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the Brain Tumour Charity (grants 16/46 (SCC and SB) and 16/92 (SCC, SB, DWE and JCL)), NIH CA-096832, CA-02165-29 (MFR), the American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital (MFR, DK), the Mochida Foundation (DK), the Anderson fellowship (DK), LoveOliver (SCC and DW) and Cancer Research UK (grant C8464/A13457; SCC, SB and DWE). Cell lines D425Med and MEB-Med8A were gifts from Dr D Bigner (Duke University, Durham, USA) and Professor T Pietsch (University of Bonn Medical Centre, Bonn, Germany), respectively. Four normal cerebellar DNAs were gifts from Dr M Fruhwald (University of Munster, Munster, Germany). Vav1CA cDNA was a gift from Dr S Katzav (Hebrew University, Jerusalem, Israel). DAOY and D283Med cell lines were from the ATCC (Manassas, VA, USA). Approval from the Newcastle and North Tyneside Research Ethics Committee (study reference 07/Q0905/71) was obtained for the collection, storage, and biological study of all material described. Medulloblastomas investigated in this study include samples provided by the UK Children's Cancer and Leukaemia Group (CCLG) as part of CCLG-approved biological study BS-2007-04.	Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Anderton JA, 2008, NEURO-ONCOLOGY, V10, P981, DOI 10.1215/15228517-2008-048; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Denkinger DJ, 2000, BBA-GENE STRUCT EXPR, V1491, P253, DOI 10.1016/S0167-4781(00)00008-7; Ellison DW, 2011, J CLIN ONCOL, V29, P1400, DOI 10.1200/JCO.2010.30.2810; Famulski JK, 2010, SCIENCE, V330, P1834, DOI 10.1126/science.1198480; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hovestadt V, 2013, ACTA NEUROPATHOL, V125, P913, DOI 10.1007/s00401-013-1126-5; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; Katzav S, 2007, CANCER LETT, V255, P241, DOI 10.1016/j.canlet.2007.04.015; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Ladd-Acosta C, 2007, AM J HUM GENET, V81, P1304, DOI 10.1086/524110; Langdon JA, 2006, GENE CHROMOSOME CANC, V45, P47, DOI 10.1002/gcc.20262; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lindsey JC, 2014, ACTA NEUROPATHOL, V127, P307, DOI 10.1007/s00401-013-1225-3; Lusher ME, 2002, CANCER RES, V62, P5906; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Oberley MJ, 2012, AM J BLOOD RES, V2, P1; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pizer BL, 2009, BRIT J NEUROSURG, V23, P364, DOI 10.1080/02688690903121807; Quevedo C, 2010, MOL BIOL CELL, V21, P1125, DOI 10.1091/mbc.E09-04-0292; RDevelopmentCoreTeam, 2011, R FDN STAT COMP; Remke M, 2013, ACTA NEUROPATHOL, V126, P917, DOI 10.1007/s00401-013-1198-2; Roussel MF, 2011, CURR TOP DEV BIOL, V94, P235, DOI 10.1016/B978-0-12-380916-2.00008-5; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Schwalbe EC, 2011, CLIN CANCER RES, V17, P1883, DOI 10.1158/1078-0432.CCR-10-2210; Schwalbe EC, 2013, ACTA NEUROPATHOL, V125, P359, DOI 10.1007/s00401-012-1077-2; Sebban S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054321; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Taylor RE, 2003, J CLIN ONCOL, V21, P1581, DOI 10.1200/JCO.2003.05.116; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wells CM, 2005, EXP CELL RES, V310, P303, DOI 10.1016/j.yexcr.2005.07.015; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408; Zindy F, 2007, CANCER RES, V67, P2676, DOI 10.1158/0008-5472.CAN-06-3418	48	9	9	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4746	4757		10.1038/onc.2014.405	http://dx.doi.org/10.1038/onc.2014.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531316	Green Accepted			2022-12-28	WOS:000360931500008
J	Sales, KU; Friis, S; Abusleme, L; Moutsopoulos, NM; Bugge, TH				Sales, K. U.; Friis, S.; Abusleme, L.; Moutsopoulos, N. M.; Bugge, T. H.			Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; TRANSMEMBRANE SERINE-PROTEASE; FACTOR ACTIVATOR INHIBITOR-2; GENE-EXPRESSION; PROSTATE; CANCER; RAS; POTENT; OVEREXPRESSION; PROGNOSIS	Deregulation of matriptase is a consistent feature of human epithelial cancers and correlates with poor disease outcome. We have previously shown that matriptase promotes multi-stage squamous cell carcinogenesis in transgenic mice through dual activation of pro-hepatocyte growth factor-cMet-Akt-mTor proliferation/survival signaling and PAR-2-Gai-NF kappa B inflammatory signaling. Matriptase was congenitally and constitutively deregulated in our prior studies, and therefore it was unclear if aberrant matriptase signaling supports only initiation of tumor formation or if it is also critical for the progression of established tumors. To determine this, we here have generated triple-transgenic mice with constitutive deregulation of matriptase and simultaneous inducible expression of the cognate matriptase inhibitor, hepatocyte growth factor inhibitor (HAI)-2. As expected, constitutive expression of HAI-2 suppressed the formation of matriptase-dependent tumors in 7,12-Dimethylbenz(a)anthracene-treated mouse skin. Interestingly, however, the induction of HAI-2 expression in already established tumors markedly impaired malignant progression and caused regression of individual tumors. Tumor regression correlated with reduced accumulation of tumor-associated inflammatory cells, likely caused by diminished expression of pro-tumorigenic inflammatory cytokines. The data suggest that matriptase-dependent signaling may be a therapeutic target for both squamous cell carcinoma chemoprevention and for the treatment of established tumors.	[Sales, K. U.; Friis, S.; Abusleme, L.; Moutsopoulos, N. M.; Bugge, T. H.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Sales, K. U.] Natl Inst Dent & Craniofacial Res, Clin Res Core, NIH, Bethesda, MD 20892 USA; [Sales, K. U.] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Cell & Mol Biol, BR-14049 Ribeirao Preto, Brazil; [Friis, S.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Cellular & Mol Med, Copenhagen, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universidade de Sao Paulo; University of Copenhagen	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Room 211,30 Convent Dr, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Moutsopoulos, Niki/A-9538-2019; sales, katiuchia u/J-4880-2012	sales, katiuchia/0000-0002-3768-5790; Abusleme, Loreto/0000-0002-7210-1236	NIDCR Intramural Research Program; Sao Paulo Research Foundation [2014/14311-0]; Harboe Foundation; Lundbeck Foundation;  [17.12.1981]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER	NIDCR Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Harboe Foundation; Lundbeck Foundation(Lundbeckfonden); ; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Mary Jo Danton and Dr J Silvio Gutkind for critically reviewing this manuscript. We also thank Andrew Cho and Dr Ashok Kulkarni, NIDCR Gene Targeting Facility, for generation of transgenic mice. Histology was performed by Histoserv, Inc., Germantown, MD, USA. The study was supported by the NIDCR Intramural Research Program (THB), Sao Paulo Research Foundation 2014/14311-0 (KUS), The Harboe Foundation, The Foundation of 17.12.1981 and the Lundbeck Foundation (SF).	Baba T, 2012, J PATHOL, V228, P181, DOI 10.1002/path.3993; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1985, BRIT J CANCER, V51, P1, DOI 10.1038/bjc.1985.1; Bergum C, 2010, PROSTATE, V70, P1422, DOI 10.1002/pros.21177; Bhatt AS, 2007, P NATL ACAD SCI USA, V104, P5771, DOI 10.1073/pnas.0606514104; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Bocheva G, 2009, J INVEST DERMATOL, V129, P1816, DOI 10.1038/jid.2008.449; Cheng HX, 2009, CANCER RES, V69, P1828, DOI 10.1158/0008-5472.CAN-08-3728; Cheng MF, 2014, HISTOPATHOLOGY, V65, P24, DOI 10.1111/his.12361; Chou FP, 2013, AM J PATHOL, V183, P1306, DOI 10.1016/j.ajpath.2013.06.024; Desilets A, 2006, FEBS LETT, V580, P2227, DOI 10.1016/j.febslet.2006.03.030; Enyedy IJ, 2001, J MED CHEM, V44, P1349, DOI 10.1021/jm000395x; Forbs D, 2005, INT J ONCOL, V27, P1061; Galkin AV, 2004, PROSTATE, V61, P228, DOI 10.1002/pros.20094; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray K, 2014, THROMB HAEMOSTASIS, V112, P402, DOI 10.1160/TH13-11-0895; Ha SY, 2014, VIRCHOWS ARCH, V464, P19, DOI 10.1007/s00428-013-1504-3; Hoang CD, 2004, CHEST, V125, P1843, DOI 10.1378/chest.125.5.1843; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jin JS, 2007, HISTOL HISTOPATHOL, V22, P305, DOI 10.14670/HH-22.305; Jin JS, 2006, MODERN PATHOL, V19, P447, DOI 10.1038/modpathol.3800495; Kang JY, 2003, CANCER RES; Kilpatrick LM, 2006, BLOOD, V108, P2616, DOI 10.1182/blood-2006-02-001073; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Long YQ, 2001, BIOORG MED CHEM LETT, V11, P2515, DOI 10.1016/S0960-894X(01)00493-0; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Nakamura K, 2009, ANN ONCOL, V20, P63, DOI 10.1093/annonc/mdn556; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Quimbar P, 2013, J BIOL CHEM, V288, P13885, DOI 10.1074/jbc.M113.460030; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737; Sales KU, 2015, ONCOGENE, V34, P288, DOI 10.1038/onc.2013.563; Santin AD, 2003, CANCER, V98, P1898, DOI 10.1002/cncr.11753; Sun J, 2003, BIOCHEMISTRY-US, V42, P892, DOI 10.1021/bi026878f; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2008, J BIOL CHEM, V283, P29495, DOI 10.1074/jbc.M801970200; Szabo R, 2009, DEVELOPMENT, V136, P2653, DOI 10.1242/dev.038430; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanimoto H, 2005, BRIT J CANCER, V92, P278, DOI 10.1038/sj.bjc.6602320; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Vogel LK, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-176; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228; Ye JJ, 2014, CANCER SCI, V105, P44, DOI 10.1111/cas.12306; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	47	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4664	4672		10.1038/onc.2014.391	http://dx.doi.org/10.1038/onc.2014.391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486433	Green Accepted			2022-12-28	WOS:000360189300012
J	Davies, EM; Kong, AM; Tan, A; Gurung, R; Sriratana, A; Bukczynska, PE; Ooms, LM; McLean, CA; Tiganis, T; Mitchell, CA				Davies, E. M.; Kong, A. M.; Tan, A.; Gurung, R.; Sriratana, A.; Bukczynska, P. E.; Ooms, L. M.; McLean, C. A.; Tiganis, T.; Mitchell, C. A.			Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration	ONCOGENE			English	Article							FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; PLECKSTRIN-HOMOLOGY DOMAINS; GROWTH-FACTOR RECEPTOR; HUMAN GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDES; IDENTIFICATION; LOCALIZATION; ACTIVATION	Glioblastoma is the most common and lethal primary malignant brain tumor in adults. The tumor suppressor gene PTEN is deleted, mutated or hypermethylated in more than 60% of glioblastoma cases resulting in hyperactivation of the phosphoinositide 3-kinase pathway, which leads to sustained PI(3,4,5)P-3 signaling, and thereby hyperactivation of Akt and other effectors. PI(3,4,5) P-3 is also hydrolyzed to PI(3,4)P-2 by inositol polyphosphate 5-phosphatases such as SKIP, but the role this pathway has in glioblastoma is unknown. Microarray expression profiling of SKIP in human glioblastoma has revealed both increased and decreased SKIP gene expression. Here we have screened PTEN-deficient glioblastoma for SKIP protein expression by immunohistochemistry and report that SKIP expression is increased in some cases or decreased relative to normal brain. Using the U-87MG PTEN-deficient cell line we show that SKIP knockdown did not further enhance cell proliferation or survival. However, SKIP overexpression in U-87MG cells suppressed anchorage-independent cell growth and growth factor-induced PI(3,4,5) P3/Akt signaling. Although, SKIP knockdown did not affect cell proliferation or survival, cell migration was significantly retarded, associated with significantly increased PI(4,5)P-2 signals, and decreased phosphorylation of the actin-regulatory protein cofilin, a PI(4,5)P-2-binding protein. Notably, overexpression of SKIP also inhibited migration of U-87MG cells to a similar degree as observed with PTEN reconstitution, however, via distinct mechanisms. PTEN reconstitution promoted sustained lamellipodia generation and focal adhesion formation. In contrast, SKIP overexpression reduced sustained lamellipodia formation, talin incorporation into focal adhesions and recruitment of PI(4,5)P-2-binding proteins to the plasma membrane. Notably, analysis of two independent ONCOMINE microarray data sets revealed a significant correlation between increased SKIP mRNA expression in glioblastoma and improved long-term survival. Therefore, SKIP expression in glioblastoma may affect the local invasion of PTEN-deficient tumors.	[Davies, E. M.; Kong, A. M.; Tan, A.; Gurung, R.; Sriratana, A.; Bukczynska, P. E.; Ooms, L. M.; Tiganis, T.; Mitchell, C. A.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; [McLean, C. A.] Alfred Hosp, Dept Anat Pathol, Prahran, Vic 3181, Australia	Monash University; Florey Institute of Neuroscience & Mental Health	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Bldg 64,SOBS,Wellington Rd, Clayton, Vic 3800, Australia.	christina.mitchell@monash.edu	Tiganis, Tony/AAV-3495-2020; Ooms, Lisa/AGZ-7420-2022	Tiganis, Tony/0000-0002-8065-9942; Ooms, Lisa Michelle/0000-0002-8918-9932; McLean, Catriona/0000-0002-0302-5727; Mitchell, Christina A/0000-0001-9372-3192	National Health & Medical Research Council (NHMRC), Australia [384083]	National Health & Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr Tamas Balla (NIH) for kindly providing the GFP-PH/Btk and GFP-PH/PLC delta constructs and Dr Jelena Becanovic for assistance with ONCOMINE data analysis. This work was supported by the National Health & Medical Research Council (NH&MRC), Australia, grant number 384083. We also thank the Biochemistry Imaging Facility, Department of Biochemistry and Molecular Biology, Monash University and the Monash Micro Imaging Facility for technical advice with image acquisition and analysis. Tony Tiganis is a NHMRC research fellow. The results shown here are in part based upon data generated by The Cancer Genome Atlas Research Network http://cancergenome.nih.gov/.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bertagnolo V, 2007, CARCINOGENESIS, V28, P1638, DOI 10.1093/carcin/bgm078; BIEGEL JA, 1992, CANCER RES, V52, P3391; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Carico C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033684; Chalhoub N, 2009, GENE DEV, V23, P1619, DOI 10.1101/gad.1799609; Davies Elizabeth M, 2012, Subcell Biochem, V58, P281, DOI 10.1007/978-94-007-3012-0_8; Davies MA, 1998, CANCER RES, V58, P5285; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017; Dyson Jennifer M, 2012, Subcell Biochem, V58, P215, DOI 10.1007/978-94-007-3012-0_7; Filippini G, 2008, NEURO-ONCOLOGY, V10, P79, DOI 10.1215/15228517-2007-038; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frame M, 2008, NAT CELL BIOL, V10, P1017, DOI 10.1038/ncb0908-1017; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Golub T, 2005, J CELL BIOL, V169, P151, DOI 10.1083/jcb.200407058; Gorbatyuk VY, 2006, MOL CELL, V24, P511, DOI 10.1016/j.molcel.2006.10.007; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gurung R, 2003, J BIOL CHEM, V278, P11376, DOI 10.1074/jbc.M209991200; Hammond GRV, 2009, BIOCHEM J, V422, P23, DOI 10.1042/BJ20090428; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Huang SH, 2004, MOL CELL BIOL, V24, P9102, DOI 10.1128/MCB.24.20.9102-9123.2004; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Ijuin T, 2003, MOL CELL BIOL, V23, P1209, DOI 10.1128/MCB.23.4.1209-1220.2003; Ijuin T, 2008, MOL CELL BIOL, V28, P5184, DOI 10.1128/MCB.01990-06; Ijuin T, 2012, J BIOL CHEM, V287, P6991, DOI 10.1074/jbc.M111.335539; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kisseleva M, 2005, MOL CELL BIOL, V25, P3956, DOI 10.1128/MCB.25.10.3956-3966.2005; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Koul D, 2008, CANCER BIOL THER, V7, P1321, DOI 10.4161/cbt.7.9.6954; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Mise-Omata S, 2005, BIOCHEM BIOPH RES CO, V328, P1034, DOI 10.1016/j.bbrc.2005.01.066; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nutt CL, 2003, CANCER RES, V63, P1602; Ooms LM, 2006, MOL BIOL CELL, V17, P607, DOI 10.1091/mbc.E05-05-0469; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Rood BR, 2002, CANCER RES, V62, P3794; Sano T, 1999, CANCER RES, V59, P1820; Sasaki J, 2005, J EXP MED, V201, P859, DOI 10.1084/jem.20041891; SAXENA A, 1992, CANCER RES, V52, P6716; Schmid AC, 2004, FEBS LETT, V576, P9, DOI 10.1016/j.febslet.2004.08.052; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Van Troys M, 2008, EUR J CELL BIOL, V87, P649, DOI 10.1016/j.ejcb.2008.04.001; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Yamanaka R, 2006, ONCOGENE, V25, P5994, DOI 10.1038/sj.onc.1209585; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhang Li, 2012, Subcell Biochem, V59, P177, DOI 10.1007/978-94-007-3015-1_6; Zhao HX, 2010, BIOPHYS J, V98, P2327, DOI 10.1016/j.bpj.2010.01.046	84	15	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3711	3727		10.1038/onc.2014.303	http://dx.doi.org/10.1038/onc.2014.303			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241900				2022-12-28	WOS:000357679100009
J	Schoeneberger, H; Belz, K; Schenk, B; Fulda, S				Schoeneberger, H.; Belz, K.; Schenk, B.; Fulda, S.			Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death	ONCOGENE			English	Article							INHIBITOR-MEDIATED SENSITIZATION; KAPPA-B ACTIVATION; APOPTOSIS PROTEINS; BUTHIONINE SULFOXIMINE; MOLECULAR PATHWAYS; LIPID-PEROXIDATION; POTENT INHIBITORS; OXIDATIVE STRESS; REACTIVE OXYGEN; IAP PROTEINS	Evasion of apoptosis in pediatric acute lymphoblastic leukemia (ALL) is linked to aberrant expression of inhibitor of apoptosis (IAP) proteins and dysregulated redox homeostasis, rendering leukemic cells vulnerable to redox-targeting therapies. Here we discover that inhibition of antioxidant defenses via glutathione (GSH) depletion by buthionine sulfoximine (BSO) primes ALL cells for apoptosis induced by the Smac mimetic BV6 that antagonizes IAP proteins. Similarly, BSO cooperates with BV6 to induce cell death in patient-derived primary leukemic samples, underscoring the clinical relevance. In contrast, BSO does not sensitize non-malignant lymphohematopoietic cells from healthy donors toward BV6, pointing to some tumor selectivity. Mechanistically, both agents cooperate to stimulate reactive oxygen species (ROS) production, which is required for BSO/BV6-induced cell death, as ROS inhibitors (that is, N-acetylcysteine, MnTBAP, Trolox) significantly rescue cell death. Further, BSO and BV6 cooperate to trigger lipid peroxidation, which is necessary for cell death, as genetic or pharmacological blockage of lipid peroxidation by GSH peroxidase 4 (GPX4) overexpression or a-tocopherol significantly inhibits BSO/BV6-mediated cell death. Consistently, GPX4 knockdown or GPX4 inhibitor RSL3 enhances lipid peroxidation and cell death by BSO/BV6 cotreatment. The discovery of redox regulation of Smac mimetic-induced cell death has important implications for developing rational Smac mimetic-based combination therapies.	[Schoeneberger, H.; Belz, K.; Schenk, B.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany	Goethe University Frankfurt	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; IUAP VII	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); IUAP VII	We thank D Vucic (Genentech Inc., South San Francisco, CA) for providing BV6, R Brigelius-Flohe for providing the GPX4 vector, T Klingebiel and S Wehner for providing ALL samples, J Leibacher for providing MSCs, PF Angeli and M Conrad for helpful discussions and C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft and IUAP VII (to SF).	Abhari BA, 2013, ONCOGENE, V32, P3263, DOI 10.1038/onc.2012.337; Bailey HH, 1997, J NATL CANCER I, V89, P1789, DOI 10.1093/jnci/89.23.1789; Basit F, 2012, J BIOL CHEM, V287, P38767, DOI 10.1074/jbc.M112.398966; Belz K, 2014, BLOOD, V124, P240, DOI 10.1182/blood-2013-05-500918; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; Caglikulekci M, 2006, J INVEST SURG, V19, P175, DOI 10.1080/08941930600674702; Chen D, 2006, CANCER RES, V66, P11416, DOI 10.1158/0008-5472.CAN-06-0409; CHOU TC, 1980, CARCINOGENESIS, V1, P203, DOI 10.1093/carcin/1.3.203; Curtis J, 2001, HEMAT BLOOD, V40, P257; DAVIES MJ, 1988, BIOCHEM J, V255, P513; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Eckhardt I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.457; Fakler M, 2009, BLOOD, V113, P1710, DOI 10.1182/blood-2007-09-114314; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Franco R, 2008, J BIOL CHEM, V283, P36071, DOI 10.1074/jbc.M807061200; Friesen C, 2004, CELL DEATH DIFFER, V11, pS73, DOI 10.1038/sj.cdd.4401431; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2014, LEUKEMIA, V28, P1414, DOI 10.1038/leu.2014.56; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00003; Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078-0432.CCR-13-0227; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Fulda S, 2009, BRIT J HAEMATOL, V145, P441, DOI 10.1111/j.1365-2141.2009.07603.x; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hundsdoerfer P, 2010, PEDIATR BLOOD CANCER, V55, P260, DOI 10.1002/pbc.22541; Irwin ME, 2013, ANTIOXID REDOX SIGN, V18, P1349, DOI 10.1089/ars.2011.4258; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Kearns PR, 2001, BLOOD, V97, P393, DOI 10.1182/blood.V97.2.393; Koopman Werner J H, 2010, Antioxid Redox Signal, V12, P1431, DOI 10.1089/ars.2009.2743; Latchoumycandane C, 2012, J BIOL CHEM, V287, P17693, DOI 10.1074/jbc.M111.300012; Loder S, 2012, LEUKEMIA, V26, P1020, DOI 10.1038/leu.2011.353; MAUNG ZT, 1994, LEUKEMIA, V8, P1487; Naguib YMA, 1998, ANAL BIOCHEM, V265, P290, DOI 10.1006/abio.1998.2931; Ni Y, 2012, CLIN CANCER RES, V18, P4954, DOI 10.1158/1078-0432.CCR-12-1055; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Repetto M, 2012, LIPID PEROXIDATION, P3, DOI 10.5772/45943; Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Stanulla M, 2009, SEMIN HEMATOL, V46, P52, DOI 10.1053/j.seminhematol.2008.09.007; Tamm I, 2004, CLIN CANCER RES, V10, P3737, DOI 10.1158/1078-0432.CCR-03-0642; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012; Wuchter C, 2004, HAEMATOLOGICA, V89, P363; Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010	59	27	29	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4032	4043		10.1038/onc.2014.338	http://dx.doi.org/10.1038/onc.2014.338			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25381820				2022-12-28	WOS:000358780500002
J	Aranda, F; Bloy, N; Pesquet, J; Petit, B; Chaba, K; Sauvat, A; Kepp, O; Khadra, N; Enot, D; Pfirschke, C; Pittet, M; Zitvogel, L; Kroemer, G; Senovilla, L				Aranda, F.; Bloy, N.; Pesquet, J.; Petit, B.; Chaba, K.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Pfirschke, C.; Pittet, M.; Zitvogel, L.; Kroemer, G.; Senovilla, L.			Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer	ONCOGENE			English	Article							MULTICENTER PHASE-II; CALRETICULIN EXPOSURE; VITAMIN-B6 METABOLISM; DOSE EPIRUBICIN; CHEMOTHERAPY; THERAPY; MECHANISM; DEATH; IMMUNOGENICITY; EFFICACY	cis-Diamminedichloroplatinum(II) (CDDP), which is mostly referred to as cisplatin, is a widely used antineoplastic. The efficacy of cisplatin can be improved by combining it with the vitamin B6 precursor pyridoxine. Here, we evaluated the putative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model of non-small-cell lung cancer (NSCLC). CDDP and pyridoxine exhibited hyperadditive therapeutic effects. However, this synergy was only observed in the context of an intact immune system and disappeared when the otherwise successful drug combination was applied to the same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes). Immunocompetent mice that had been cured from NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechallenge with the same (but not with an unrelated) cancer cell line. In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSCLC cells but also elicited signs of immunogenic cell death including an endoplasmic reticulum stress response and exposure of calreticulin at the surface of the NSCLC cells. NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer immune response upon their injection into immunocompetent mice. Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.	[Aranda, F.; Bloy, N.; Pesquet, J.; Chaba, K.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Kroemer, G.; Senovilla, L.] Ctr Rech Cordeliers, INSERM U1138, Equipe Labellisee Pas Ligue Natl Canc 11, F-75006 Paris, France; [Aranda, F.; Bloy, N.; Pesquet, J.; Chaba, K.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Kroemer, G.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Aranda, F.; Bloy, N.; Pesquet, J.; Sauvat, A.; Kepp, O.; Khadra, N.; Enot, D.; Kroemer, G.; Senovilla, L.] Metab & Cell Biol Platforms, Villejuif, France; [Bloy, N.; Zitvogel, L.] Univ Paris 11, Villejuif, France; [Petit, B.] INSERM, U1030, Villejuif, France; [Pfirschke, C.; Pittet, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol,Pittet Lab, Boston, MA USA; [Zitvogel, L.; Senovilla, L.] INSERM, U1015, Villejuif, France; [Zitvogel, L.] Ctr Invest Clin Biotherapie CICBT 507, Villejuif, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Harvard Medical School; Massachusetts General Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Ctr Rech Cordeliers, INSERM U1138, Equipe Labellisee Pas Ligue Natl Canc 11, 15 Rue Ecole Med, F-75006 Paris, France.	kroemer@orange.fr; laurasenovilla@hotmail.com	Aranda, Fernando/N-2112-2014; Aranda, Fernando/N-9649-2019; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/GPX-8627-2022; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Senovilla, Laura/AAX-5599-2021	Aranda, Fernando/0000-0002-9364-474X; Aranda, Fernando/0000-0002-9364-474X; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Senovilla, Laura/0000-0001-6887-2436; ZITVOGEL, laurence/0000-0003-1596-0998	Deutsche Forschungsgemeinschaft (DFG) [PF809/1-1]; Fondation Tourre; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LabEx Immuno-Oncology; Paris Alliance of Cancer Research Institutes (PACRI)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Fondation Tourre; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)); LabEx Immuno-Oncology; Paris Alliance of Cancer Research Institutes (PACRI)	We are indepted to Dr Gonin (Gustave Roussy) for help in mouse experiments. CP is supported by the Deutsche Forschungsgemeinschaft (DFG) PF809/1-1. LS is supported by the Fondation Tourre, the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) and the SIRIC Cancer Research and Personalized Medicine (CARPEM). GK is supported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).	Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Atmaca A, 2013, BRIT J CANCER, V108, P265, DOI 10.1038/bjc.2012.555; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chao MP, 2012, NAT REV CANCER, V12, P58, DOI 10.1038/nrc3171; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Feldman DR, 2008, JAMA-J AM MED ASSOC, V299, P672, DOI 10.1001/jama.299.6.672; Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Galanski M, 2006, RECENT PAT ANTI-CANC, V1, P285, DOI 10.2174/157489206777442287; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Galluzzi L, 2013, CELL CYCLE, V12, P417, DOI 10.4161/cc.23275; Galluzzi L, 2012, CELL REP, V2, P257, DOI 10.1016/j.celrep.2012.06.017; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Hsu C, 2008, LUNG CANCER, V62, P334, DOI 10.1016/j.lungcan.2008.03.010; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kelland LR, 2004, EUR J CANCER, V40, P827, DOI 10.1016/j.ejca.2003.11.028; KELMAN AD, 1979, CANCER TREAT REP, V63, P1445; Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4; Kim D, 2007, HUM GENE THER, V18, P575, DOI 10.1089/hum.2007.038; Koberle B, 2010, BBA-REV CANCER, V1806, P172, DOI 10.1016/j.bbcan.2010.07.004; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Li QQ, 2013, ANTICANCER RES, V33, P1421; Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; MAYO JG, 1972, CANCER CHEMOTH REP 2, V3, P325; McDonnell AM, 2011, SEMIN IMMUNOPATHOL, V33, P353, DOI 10.1007/s00281-011-0246-z; Menard C, 2008, CANCER IMMUNOL IMMUN, V57, P1579, DOI 10.1007/s00262-008-0505-6; Mordant P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026073; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Otterson GA, 2010, CLIN CANCER RES, V16, P2466, DOI 10.1158/1078-0432.CCR-09-3015; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Phernambucq ECJ, 2006, BRIT J CANCER, V95, P470, DOI 10.1038/sj.bjc.6603289; PRESTAYKO AW, 1979, CANCER TREAT REV, V6, P17, DOI 10.1016/S0305-7372(79)80057-2; Sanderson BJS, 1996, MUTAT RES-FUND MOL M, V355, P59, DOI 10.1016/0027-5107(96)00022-X; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Talmadge JE, 2007, AM J PATHOL, V170, P793, DOI 10.2353/ajpath.2007.060929; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Winter C, 2011, NAT REV ENDOCRINOL, V7, P43, DOI 10.1038/nrendo.2010.196; Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014; Zitvogel L, 2011, NAT REV CLIN ONCOL, V8, P151, DOI 10.1038/nrclinonc.2010.223; Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891	46	53	55	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3053	3062		10.1038/onc.2014.234	http://dx.doi.org/10.1038/onc.2014.234			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25065595				2022-12-28	WOS:000356100500010
J	Karanika, S; Karantanos, T; Li, L; Corn, PG; Thompson, TC				Karanika, S.; Karantanos, T.; Li, L.; Corn, P. G.; Thompson, T. C.			DNA damage response and prostate cancer: defects, regulation and therapeutic implications	ONCOGENE			English	Review							CELL-CYCLE CHECKPOINTS; BRCA MUTATION CARRIERS; DOUBLE-STRAND BREAK; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; SUPPRESSES TUMORIGENESIS; ATAXIA-TELANGIECTASIA; GENETIC INSTABILITY; SYNTHETIC LETHALITY; ANDROGEN RECEPTOR	DNA damage response (DDR) includes the activation of numerous cellular activities that prevent duplication of DNA lesions and maintain genomic integrity, which is critical for the survival of normal and cancer cells. Specific genes involved in the DDR such as BRCA1/2 and P53 are mutated during prostate cancer progression, while various oncogenic signaling such as Akt and c-Myc are activated, enhancing the replication stress and increasing the genomic instability of cancer cells. These events may render prostate cancer cells particularly sensitive to inhibition of specific DDR pathways, such as PARP in homologous recombination DNA repair and Chk1 in cell cycle checkpoint and DNA repair, creating opportunities for synthetic lethality or synergistic cytotoxicity. Recent reports highlight the critical role of androgen receptor (AR) as a regulator of DDR genes, providing a rationale for combining DNA-damaging agents or targeted DDR inhibitors with hormonal manipulation or AR inhibition as treatment for aggressive disease. The aims of this review are to discuss specific DDR defects in prostate cancer that occur during disease progression, to summarize recent advances in understanding the regulation of DDR in prostate cancer, and to present potential therapeutic opportunities through combinational targeting of the intact components of DDR signaling pathways.	[Karanika, S.; Karantanos, T.; Li, L.; Corn, P. G.; Thompson, T. C.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Thompson, TC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, 1515 Holcombe Blvd, Houston, TX 77030 USA.	timthomp@mdanderson.org	Karanika, Styliani/ABH-7576-2020; KARANTANOS, THEODOROS/ABH-7600-2020	Karanika, Styliani/0000-0003-2387-6075; KARANTANOS, THEODOROS/0000-0002-6792-8298	National Institutes of Health through MD Anderson's Cancer Center Support Grant [5 P30 CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA140388] Funding Source: NIH RePORTER	National Institutes of Health through MD Anderson's Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kathryn L Hale, MS, MLIS, for her expert editorial assistance. This research is supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant, 5 P30 CA016672.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Al-Ubaidi FLT, 2013, CLIN CANCER RES, V19, P1547, DOI 10.1158/1078-0432.CCR-12-2795; Albisinni S, 2012, UROLOGY, V80, P162, DOI 10.1016/j.urology.2012.01.068; Angele S, 2004, BRIT J CANCER, V91, P783, DOI 10.1038/sj.bjc.6602007; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; Balistreri CR, 2014, CANCER GENE THER, V21, P2, DOI 10.1038/cgt.2013.77; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beer TM, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.4_suppl.lba1; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cai BW, 2013, CELL REP, V4, P516, DOI 10.1016/j.celrep.2013.06.039; Campaner S, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-6; Chatterjee P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060408; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Debelec-Butuner B, 2014, MOL CARCINOGEN, V53, P85, DOI 10.1002/mc.21948; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Do K, 2013, CELL CYCLE, V12, P3159, DOI 10.4161/cc.26062; Dombernowsky SL, 2008, J CLIN ONCOL, V26, P3057, DOI 10.1200/JCO.2007.14.6613; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Eastham JA, 1995, CLIN CANCER RES, V1, P1111; Elkahwaji JE, 2013, RES REP UROL, V5, P1, DOI 10.2147/RRU.S23386; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gabrielli B, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00009; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guerra L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008924; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Han B, 2009, MODERN PATHOL, V22, P1083, DOI 10.1038/modpathol.2009.69; Heaphy CM, 2013, CANCER DISCOV, V3, P1130, DOI 10.1158/2159-8290.CD-13-0135; Hoglund A, 2011, CLIN CANCER RES, V17, P7067, DOI 10.1158/1078-0432.CCR-11-1198; Ide H, 2012, PROSTATE, V72, P1407, DOI 10.1002/pros.22492; Iglehart JD, 2009, NEW ENGL J MED, V361, P189, DOI 10.1056/NEJMe0903044; Imamoto T, 2008, INT J UROL, V15, P472, DOI 10.1111/j.1442-2042.2008.02074.x; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; KASTAN MB, 1991, CANCER RES, V51, P6304; Khandrika L, 2009, CANCER LETT, V282, P125, DOI 10.1016/j.canlet.2008.12.011; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Landau HJ, 2012, MOL CANCER THER, V11, P1781, DOI 10.1158/1535-7163.MCT-11-0949; Lavin MF, 2007, RADIOTHER ONCOL, V83, P231, DOI 10.1016/j.radonc.2007.04.032; Leongamornlert D, 2012, BRIT J CANCER, V106, P1697, DOI 10.1038/bjc.2012.146; Li LK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005070; Lieber MR, 2010, NAT STRUCT MOL BIOL, V17, P393, DOI 10.1038/nsmb0410-393; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Malins DC, 2003, P NATL ACAD SCI USA, V100, P5401, DOI 10.1073/pnas.0931396100; Malins DC, 2001, CANCER RES, V61, P6025; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Martin Y, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-21; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Pedram A, 2009, MOL BIOL CELL, V20, P3374, DOI 10.1091/mbc.E09-01-0085; Plo I, 2009, ONCOGENE, V28, P2231, DOI 10.1038/onc.2009.85; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sandhu SK, 2013, ANN ONCOL, V24, P1416, DOI 10.1093/annonc/mdt074; Sandhu SK, 2013, LANCET ONCOL, V14, P882, DOI 10.1016/S1470-2045(13)70240-7; Schatzl G, 2001, PROSTATE, V47, P52; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Schlomm T, 2008, MODERN PATHOL, V21, P1371, DOI 10.1038/modpathol.2008.104; Sciarra A, 2007, EUR UROL, V52, P964, DOI 10.1016/j.eururo.2007.06.038; Smith TB, 2010, J CLIN PSYCHOL, V67, P1, DOI DOI 10.1080/14681360903556749; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thacker J, 2005, CANCER LETT, V219, P125, DOI 10.1016/j.canlet.2004.08.018; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; van Asperen CJ, 2005, J MED GENET, V42, P711, DOI 10.1136/jmg.2004.028829; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wang XB, 2012, ONCOL REP, V28, P2247, DOI 10.3892/or.2012.2068; Zhou JY, 2013, AGING-US, V5, P3, DOI 10.18632/aging.100524	106	59	62	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2815	2822		10.1038/onc.2014.238	http://dx.doi.org/10.1038/onc.2014.238			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25132269	Green Accepted			2022-12-28	WOS:000355324300001
J	Josson, S; Gururajan, M; Sung, SY; Hu, P; Shao, C; Zhau, HE; Liu, C; Lichterman, J; Duan, P; Li, Q; Rogatko, A; Posadas, EM; Haga, CL; Chung, LWK				Josson, S.; Gururajan, M.; Sung, S. Y.; Hu, P.; Shao, C.; Zhau, H. E.; Liu, C.; Lichterman, J.; Duan, P.; Li, Q.; Rogatko, A.; Posadas, E. M.; Haga, C. L.; Chung, L. W. K.			Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis	ONCOGENE			English	Article							STEM-CELLS; CANCER PROGRESSION; METASTATIC-DISEASE; CHROMOSOME 12QF1; REACTIVE STROMA; BONE METASTASIS; LARGE ONCOSOMES; MICRORNA; GENE; ACTIVATION	Tumor-stromal interaction is a dynamic process that promotes tumor growth and metastasis via cell-cell interaction and extracellular vesicles. Recent studies demonstrate that stromal fibroblast-derived molecular signatures can be used to predict disease progression and drug resistance. To identify the epigenetic role of stromal noncoding RNAs in tumor-stromal interactions in the tumor microenvironment, we performed microRNA profiling of patient cancer-associated prostate stromal fibroblasts isolated by laser capture dissection microscopy and in bone-associated stromal models. We found specific upregulation of miR-409-3p and miR-409-5p located within the embryonically and developmentally regulated DLK1-DIO3 (delta-like 1 homolog-deiodinase, iodothyronine 3) cluster on human chromosome 14. The findings in cell lines were further validated in human prostate cancer tissues. Strikingly, ectopic expression of miR-409 in normal prostate fibroblasts conferred a cancer-associated stroma-like phenotype and led to the release of miR-409 via extracellular vesicles to promote tumor induction and epithelial-to-mesenchymal transition in vitro and in vivo. miR-409 promoted tumorigenesis through repression of tumor suppressor genes such as Ras suppressor 1 and stromal antigen 2. Thus, stromal fibroblasts derived miR-409-induced tumorigenesis, epithelial-to-mesenchymal transition and stemness of the epithelial cancer cells in vivo. Therefore, miR-409 appears to be an attractive therapeutic target to block the vicious cycle of tumor-stromal interactions that plagues prostate cancer patients.	[Josson, S.; Gururajan, M.; Hu, P.; Shao, C.; Zhau, H. E.; Liu, C.; Lichterman, J.; Duan, P.; Posadas, E. M.; Chung, L. W. K.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA; [Sung, S. Y.] Taipei Med Univ, Phd Program Translat Med, Taipei, Taiwan; [Li, Q.; Rogatko, A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Biostat & Bioinformat, Los Angeles, CA 90048 USA; [Haga, C. L.] Scripps Res Inst, Jupiter, FL USA	Cedars Sinai Medical Center; Taipei Medical University; Cedars Sinai Medical Center; Scripps Research Institute	Josson, S (corresponding author), Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA.	Sajni.Josson@cshs.org; Murali.Gururajan@cshs.org; Leland.Chung@cshs.org	Li, Quanlin/H-2358-2015	Li, Quanlin/0000-0002-3876-0617; Lichterman, Jake/0000-0002-3428-1555	TSRI Stem Cell fellowship;  [P01-CA98912];  [DAMD-17-03-02-0033];  [RO1-CA122602];  [TMU102-AE-B01];  [NSC102-2320-B-039-058];  [MOHW103-TD-B-111-01]; NATIONAL CANCER INSTITUTE [P01CA098912, R01CA122602] Funding Source: NIH RePORTER	TSRI Stem Cell fellowship; ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by a grant from P01-CA98912, DAMD-17-03-02-0033, RO1-CA122602 (LWKC) and TMU102-AE-B01, NSC102-2320-B-039-058, and MOHW103-TD-B-111-01 (S-YS). Dr Haga is funded by the TSRI Stem Cell fellowship. We thank Dr Ladan Fazli for providing the Gleason score tissue array. We also thank Dror Berel for helping with the statistical analysis.	Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; Di Vizio D, 2012, AM J PATHOL, V181, P1573, DOI 10.1016/j.ajpath.2012.07.030; Di Vizio D, 2009, CANCER RES, V69, P5601, DOI 10.1158/0008-5472.CAN-08-3860; Dougherty GW, 2008, EUR J CELL BIOL, V87, P721, DOI 10.1016/j.ejcb.2008.02.011; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Freeman MR, 2013, CLIN CANCER RES, V19, P4905, DOI 10.1158/1078-0432.CCR-13-1694; Gonzalez-Nieves R, 2013, J CELL COMMUN SIGNAL, V7, P279, DOI 10.1007/s12079-013-0207-5; Gross M, 2007, CLIN CANCER RES, V13, P1979, DOI 10.1158/1078-0432.CCR-06-1156; Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761; Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352; Hu PZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028670; Josson S, 2008, PROSTATE, V68, P1599, DOI 10.1002/pros.20827; Josson S, 2011, CANCER RES, V71, P2600, DOI 10.1158/0008-5472.CAN-10-3382; Kim MS, 2012, NEOPLASMA, V59, P524, DOI 10.4149/neo_2012_067; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lempiainen H, 2013, TOXICOL SCI, V131, P375, DOI 10.1093/toxsci/kfs303; Lim L, 2014, HEPATOLOGY, V59, P202, DOI 10.1002/hep.26662; Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995; Luk JM, 2011, J BIOL CHEM, V286, P30706, DOI 10.1074/jbc.M111.229831; Morello M, 2013, CELL CYCLE, V12, P3526, DOI 10.4161/cc.26539; Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405; Nguyen HCN, 2013, PROSTATE, V73, P346, DOI 10.1002/pros.22572; Nomura T, 2006, CLIN CANCER RES, V12, P7294, DOI 10.1158/1078-0432.CCR-06-2060; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008-5472.CAN-08-2492; THALMANN GN, 1994, CANCER RES, V54, P2577; Wang JG, 2010, MAGNETIC FRINGE FIELDS AND INTERFERENCE IN HIGH INTENSITY ACCELERATORS, P1; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690; Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109	35	141	144	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2690	2699		10.1038/onc.2014.212	http://dx.doi.org/10.1038/onc.2014.212			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065597				2022-12-28	WOS:000354979500002
J	Cunnick, JM; Kim, S; Hadsell, J; Collins, S; Cerra, C; Reiser, P; Flynn, DC; Cho, Y				Cunnick, J. M.; Kim, S.; Hadsell, J.; Collins, S.; Cerra, C.; Reiser, P.; Flynn, D. C.; Cho, Y.			Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland	ONCOGENE			English	Article							SRC FAMILY KINASES; C-SRC; PROLACTIN RECEPTOR; AFAP-110; CANCER; PHOSPHORYLATION; EXPRESSION; INTEGRITY; ABILITY; IDENTIFICATION	Actin filament-associated protein 1 (AFAP1) is an adaptor protein of cSrc that binds to filamentous actin and regulates the activity of this tyrosine kinase to affect changes to the organization of the actin cytoskeleton. In breast and prostate cancer cells, AFAP1 has been shown to regulate cellular responses requiring actin cytoskeletal changes such as adhesion, invadopodia formation and invasion. However, a normal physiologic role for AFAP1 has remained elusive. In this study, we generated an AFAP1 knockout mouse model that establishes a novel physiologic role for AFAP1 in lactation. Specifically, these animals displayed a defect in lactation that resulted in an inability to nurse efficiently. Histologically, the mammary glands of the lactating knockout mice were distinguished by the accumulation of large cytoplasmic lipid droplets in the alveolar epithelial cells. There was a reduction in lipid synthesis and the expression of lipogenic genes without a corresponding reduction in the production of beta-casein, a milk protein. Furthermore, these defects were associated with histologic and biochemical signs of precocious involution. This study also demonstrated that AFAP1 responds to prolactin, a lactogenic hormone, by forming a complex with cSrc and becoming tyrosine phosphorylated. Taken together, these observations pointed to a defect in secretory activation. Certain characteristics of this phenotype mirrored the defect in secretory activation in the cSrc knockout mouse, but most importantly, the activity of cSrc in the mammary gland was reduced during early lactation in the AFAP1-null mouse and the localization of active cSrc at the apical surface of luminal epithelial cells during lactation was selectively lost in the absence of AFAP1. These data define, for the first time, the requirement of AFAP1 for the spatial and temporal regulation of cSrc activity in the normal breast, specifically for milk production.	[Cunnick, J. M.; Cho, Y.] Commonwealth Med Coll, Dept Basic Sci, Scranton, PA 18509 USA; [Kim, S.] Commonwealth Med Coll, Grad Sch Med, Scranton, PA 18509 USA; [Hadsell, J.] Fortis Inst Scranton, Scranton, PA USA; [Cerra, C.; Reiser, P.] Pocono Hlth Syst, Dept Pathol, East Stroudsburg, PA USA; [Flynn, D. C.] Univ Delaware, Coll Hlth Sci, Newark, DE USA	Geisinger Commonwealth School of Medicine; Geisinger Commonwealth School of Medicine; University of Delaware	Cho, Y (corresponding author), Commonwealth Med Coll, Dept Basic Sci, 525 Pine St, Scranton, PA 18509 USA.	ycho@tcmedc.org	Cunnick, Jess/F-1715-2018	Collins, Stephen/0000-0003-4515-5412	NIH [R01CA060731-15A1]; NATIONAL CANCER INSTITUTE [R01CA060731] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by NIH Grant R01CA060731-15A1. We thank Victor Malloy for his care of the mice and Wafa Atamna for cell sorting. We also thank Raj Kumar and John Arnott for the careful reading of our manuscript.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Aksamitiene E, 2011, CELL SIGNAL, V23, P1794, DOI 10.1016/j.cellsig.2011.06.014; AMATO PA, 1981, CELL MOTIL CYTOSKEL, V1, P329, DOI 10.1002/cm.970010305; Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653; Baisden JM, 2001, ONCOGENE, V20, P6607, DOI 10.1038/sj.onc.1204802; Baisden JM, 2001, ONCOGENE, V20, P6435, DOI 10.1038/sj.onc.1204784; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Bourguignon LYW, 2011, CYTOSKELETON, V68, P671, DOI 10.1002/cm.20544; Clump DA, 2010, TRANSL ONCOL, V3, P276, DOI 10.1593/tlo.10106; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dimri M, 2007, CANCER RES, V67, P4164, DOI 10.1158/0008-5472.CAN-06-2580; Dorfleutner A, 2008, J CELL SCI, V121, P2394, DOI 10.1242/jcs.026187; Dorfleutner A, 2007, J CELL PHYSIOL, V213, P740, DOI 10.1002/jcp.21143; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRANKE WW, 1981, J CELL BIOL, V89, P485, DOI 10.1083/jcb.89.3.485; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Hughes K, 2012, J PATHOL, V227, P106, DOI 10.1002/path.3961; Kabotyanski EB, 2003, J BIOL CHEM, V278, P17218, DOI 10.1074/jbc.M301578200; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390; Liu Y, 2002, ARTERIOSCL THROM VAS, V22, P76, DOI 10.1161/hq0102.101822; Garcia-Martinez JM, 2010, CELL SIGNAL, V22, P415, DOI 10.1016/j.cellsig.2009.10.013; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; McManaman JL, 2004, ADV EXP MED BIOL, V554, P263; Mirmohammadsadegh A, 2006, J INVEST DERMATOL, V126, P2272, DOI 10.1038/sj.jid.5700385; Naylor MJ, 2005, MOL ENDOCRINOL, V19, P1868, DOI 10.1210/me.2004-0254; Naylor MJ, 2005, J CELL BIOL, V171, P717, DOI 10.1083/jcb.200503144; Ogg SL, 2004, P NATL ACAD SCI USA, V101, P10084, DOI 10.1073/pnas.0402930101; Palmer CA, 2006, J MAMMARY GLAND BIOL, V11, P269, DOI 10.1007/s10911-006-9023-3; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Piazza TM, 2009, MOL ENDOCRINOL, V23, P202, DOI 10.1210/me.2008-0341; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Qian Y, 2002, MOL BIOL CELL, V13, P2311, DOI 10.1091/mbc.E01-12-0148; Reynolds AB, 2014, ONCOGENE, V33, P4537, DOI 10.1038/onc.2013.416; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sandilands E, 2007, J CELL SCI, V120, P2555, DOI 10.1242/jcs.003657; Scott KEN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029761; Shackleford TJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2902; Shimizu A, 2005, BIOL REPROD, V73, P1219, DOI 10.1095/biolreprod.105.041616; Snyder BN, 2011, EUR J CELL BIOL, V90, P376, DOI 10.1016/j.ejcb.2010.11.016; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Vara JAF, 2000, BIOCHEM J, V345, P17, DOI 10.1042/0264-6021:3450017; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Watkin H, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-6; Watson CJ, 2011, INT J DEV BIOL, V55, P757, DOI 10.1387/ijdb.113414cw; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710	53	8	8	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2640	2649		10.1038/onc.2014.205	http://dx.doi.org/10.1038/onc.2014.205			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043309	Green Accepted			2022-12-28	WOS:000354541300010
J	Kastrati, I; Canestrari, E; Frasor, J				Kastrati, I.; Canestrari, E.; Frasor, J.			PHLDA1 expression is controlled by an estrogen receptor-NF kappa B-miR-181 regulatory loop and is essential for formation of ER plus mammospheres	ONCOGENE			English	Article							CANCER STEM-CELLS; NF-KAPPA-B; RESISTANT BREAST-CANCER; IN-VITRO PROPAGATION; PROINFLAMMATORY CYTOKINES; RECEPTOR; METASTASIS; SURVIVAL; ACTIVATION; INHIBITOR	Crosstalk between estrogen receptor (ER) and the inflammatory nuclear factor kappa B (NF kappa B) pathway in ER+ breast cancers may contribute to a more aggressive phenotype. Pleckstrin Homology-Like Domain, Family A, member 1 (PHLDA1), a target gene of ER-NF kappa B crosstalk, has been implicated in cell survival and stem cell properties. 17 beta-estradiol (E2), acting through ER alpha, and pro-inflammatory cytokines, acting through NF kappa B, increase the nascent transcript and PHLDA1 messenger RNA stability, indicating both transcriptional and post-transcriptional control of PHLDA1 expression. We show that PHLDA1 is a direct target of miR-181 and that mature miR-181a and b, as well as their host gene, are synergistically downregulated by E2 and tumor necrosis factor a, also in an ER-and NF kappa B-dependent manner. Thus, ER and NF kappa B work together to upregulate PHLDA1 directly through enhanced transcription and indirectly through repression of miR-181a and b. Previous studies have suggested that PHLDA1 may be a stem cell marker in the human intestine that contributes to tumorigenesis. Our findings that PHLDA1 is upregulated in mammospheres (MS) of ER+ breast cancer cells and that PHLDA1 knockdown impairs both MS formation and the expansion of aldehyde dehydrogenase (ALDH)-positive population, suggest that PHLDA1 may play a similar role in breast cancer cells. Upregulation of PHLDA1 in MS is largely dependent on the NF kappa B pathway, with downregulated miR-181 expression a contributing factor. Over-expression of miR-181 phenocopied PHLDA1 knockdown and significantly impaired MS formation, which was reversed, in part, by protection of the PHLDA1 3' untranslated region (UTR) or overexpression of PHLDA1 lacking the 3' UTR. Furthermore, we find that elevated PHLDA1 expression is associated with a higher risk of distant metastasis in ER+ breast cancer patients. Altogether, these data suggest that high PHLDA1 expression is controlled through an ER-NF kappa B-miR-181 regulatory axis and may contribute to a poor clinical outcome in patients with ER+ breast tumors by enhancing stem-like properties in these tumors.	[Kastrati, I.; Canestrari, E.; Frasor, J.] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Frasor, J (corresponding author), Univ Illinois, Dept Physiol & Biophys, 835 S Wolcott,E202 MSB,MC901, Chicago, IL 60612 USA.	jfrasor@uic.edu	Kastrati, Irida/L-4641-2019	Kastrati, Irida/0000-0002-8086-1411	National Institute of Health [R01 CA130932-05]; University of Illinois at Chicago through the Chancellor's Discovery Fund; Susan G Komen for the Cure [PDF12229484]; NATIONAL CANCER INSTITUTE [R01CA130932] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Illinois at Chicago through the Chancellor's Discovery Fund; Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Shuangping Zhao, Bryant Marure and Tuan-Ahn Tran for technical assistance. We are grateful for the financial support provided by the National Institute of Health (R01 CA130932-05 to JF), the University of Illinois at Chicago through the Chancellor's Discovery Fund (JF), and by a postdoctoral fellowship grant from Susan G Komen for the Cure to IK (PDF12229484).	Baumgarten SC, 2012, MOL ENDOCRINOL, V26, P360, DOI 10.1210/me.2011-1302; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bisso A, 2013, CELL CYCLE, V12, P1679, DOI 10.4161/cc.24757; Bridge G, 2012, BLOOD, V120, P5063, DOI 10.1182/blood-2012-04-423004; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Charafe-Jauffret E, 2008, PATHOBIOLOGY, V75, P75, DOI 10.1159/000123845; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Choi WY, 2007, SCIENCE, V318, P271, DOI 10.1126/science.1147535; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cormier Catherine Y., 2011, Journal of Structural and Functional Genomics, V12, P55, DOI 10.1007/s10969-011-9100-8; Cormier CY, 2010, NUCLEIC ACIDS RES, V38, pD743, DOI 10.1093/nar/gkp999; Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x; deGraffenried LA, 2004, ANN ONCOL, V15, P885, DOI 10.1093/annonc/mdh232; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Frasor J, 2008, ENDOCRINOLOGY, V149, P6272, DOI 10.1210/en.2008-0352; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Johnson EO, 2011, J CELL SCI, V124, P2711, DOI 10.1242/jcs.084970; Jones RL, 2011, J CLIN PATHOL, V64, P130, DOI 10.1136/jcp.2010.082966; Kim K, 2013, HORM CANCER-US, V4, P78, DOI 10.1007/s12672-012-0129-3; Knauss JL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00163; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lobry C, 2014, BLOOD, V123, P2451, DOI 10.1182/blood-2013-08-355818; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Makino K, 2013, J INVEST DERMATOL, V133, P110, DOI 10.1038/jid.2012.252; Meier-Noorden M, 2004, GENE, V338, P197, DOI 10.1016/j.gene.2004.05.006; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Neel JC, 2013, CELL SIGNAL, V25, P1556, DOI 10.1016/j.cellsig.2013.03.013; O'Brien CS, 2009, J MAMMARY GLAND BIOL, V14, P45, DOI 10.1007/s10911-009-9115-y; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pradhan M, 2012, MOL CELL BIOL, V32, P569, DOI 10.1128/MCB.05869-11; Pradhan M, 2010, J BIOL CHEM, V285, P31100, DOI 10.1074/jbc.M110.155309; Riggins RB, 2005, MOL CANCER THER, V4, P33; Sakthianandeswaren A, 2011, CANCER RES, V71, P3709, DOI 10.1158/0008-5472.CAN-10-2342; Seiler CY, 2014, NUCLEIC ACIDS RES, V42, pD1253, DOI 10.1093/nar/gkt1060; Stanculescu Adina, 2010, Hormones & Cancer, V1, P127, DOI 10.1007/s12672-010-0018-6; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Thorner AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013073; Toyoshima Y, 2004, J BIOL CHEM, V279, P25898, DOI 10.1074/jbc.M400661200; Van Laere S, 2010, CANCER-AM CANCER SOC, V116, P2794, DOI 10.1002/cncr.25180; Velasco-Velazquez MA, 2011, AM J PATHOL, V179, P2, DOI 10.1016/j.ajpath.2011.03.005; Yang XP, 2011, NAT METHODS, V8, P659, DOI [10.1038/NMETH.1638, 10.1038/nmeth.1638]; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59; Zhou YM, 2005, INT J BIOCHEM CELL B, V37, P1130, DOI 10.1016/j.biocel.2004.09.006	50	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2309	2316		10.1038/onc.2014.180	http://dx.doi.org/10.1038/onc.2014.180			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954507	Green Accepted			2022-12-28	WOS:000353824800004
J	Li, Y; Luo, H; Liu, T; Zacksenhaus, E; Ben-David, Y				Li, Y.; Luo, H.; Liu, T.; Zacksenhaus, E.; Ben-David, Y.			The ets transcription factor Fli-1 in development, cancer and disease	ONCOGENE			English	Review							GENOME-WIDE ANALYSIS; PROTEIN-KINASE-C; PRIMITIVE NEUROECTODERMAL TUMOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PARIS-TROUSSEAU-SYNDROME; ACUTE MYELOID-LEUKEMIA; STEM-CELL ENHANCER; ENDOTHELIAL-CELLS; EWING SARCOMA; DNA-BINDING	Friend leukemia virus-induced erythroleukemia-1 (Fli-1), an E26 transformation specific (ETS) transcription factor, was isolated a quarter century ago through a retrovirus mutagenesis screen. Fli-1 has since been recognized to play critical roles in normal development and homeostasis. For example, it transcriptionally regulates genes that drive normal hematopoiesis and vasculogenesis. Indeed, Fli-1 is one of 10 key regulators of hematopoietic stem/progenitor cell maintenance and differentiation. Aberrant expression of Fli-1 also underlies a number of virally induced leukemias, including Friend virus-induced erythroleukemia and various types of human cancers, and it is the target of chromosomal translocations in childhood Ewing's sarcoma. Abnormal expression of Fli-1 is important in the etiology of autoimmune diseases such as systemic lupus erythematosus and systemic sclerosis. These studies establish Fli-1 as a strong candidate for drug development. Despite difficulties in targeting transcription factors, recent studies identified small-molecule inhibitors for Fli-1. Here we review past and ongoing research on Fli-1 with emphasis on its mechanistic function in autoimmune disease and malignant transformation. The significance of identifying Fli-1 inhibitors and their clinical applications for treatment of disease and cancer with deregulated Fli-1 expression are discussed.	[Li, Y.] Jilin Univ, Norman Bethune Coll Med, Dept Anat, Changchun 130023, Peoples R China; [Luo, H.; Liu, T.; Ben-David, Y.] Div Biol, Key Lab Chem Nat Prod Guizhou Prov, Guiyang 550002, Peoples R China; [Luo, H.; Liu, T.; Ben-David, Y.] Chinese Acad Sci, Guiyang 550002, Peoples R China; [Zacksenhaus, E.; Ben-David, Y.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Zacksenhaus, E.] Univ Hlth Network, Toronto Gen Res Inst, Div Adv Diagnost, Toronto, ON, Canada	Jilin University; Chinese Academy of Sciences; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Ben-David, Y (corresponding author), Div Biol, Key Lab Chem Nat Prod Guizhou Prov, Guiyang 550002, Peoples R China.	ybd1955@gmail.com	Zacksenhaus, Eldad/AAD-3584-2020		Canadian Institute of Health Research [MOP-110952]; Canadian Breast Cancer Foundation; Science and Technology Department of Guizhou Province [6012, 4001]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Science and Technology Department of Guizhou Province	This work was supported by Canadian Institute of Health Research to YB-D (MOP-110952), Canadian Breast Cancer Foundation to EZ, the Science and Technology Department of Guizhou Province innovation and project grants (6012, 4001) to YB-D.	Anderson MK, 1999, DEVELOPMENT, V126, P3131; Ano S, 2004, J BIOL CHEM, V279, P2993, DOI 10.1074/jbc.M303816200; Asano Y, 2007, J BIOL CHEM, V282, P34672, DOI 10.1074/jbc.M703907200; Asano Y, 2010, J DERMATOL SCI, V59, P153, DOI 10.1016/j.jdermsci.2010.06.008; Asano Y, 2010, AM J PATHOL, V176, P1983, DOI 10.2353/ajpath.2010.090593; Asano Y, 2009, MOL CELL BIOL, V29, P1882, DOI 10.1128/MCB.01320-08; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; Bhatia S, 2007, BLOOD, V109, P46, DOI 10.1182/blood-2006-01-023101; Boro A, 2012, INT J CANCER, V131, P2153, DOI 10.1002/ijc.27472; Bradshaw S, 2008, CLIN IMMUNOL, V129, P19, DOI 10.1016/j.clim.2008.05.010; Brown JG, 2010, AM J SURG PATHOL, V34, P942, DOI 10.1097/PAS.0b013e3181e4f32a; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Bujor AM, 2012, INT J MOL MED, V30, P1473, DOI 10.3892/ijmm.2012.1150; Bujor AM, 2011, ARTHRITIS RHEUM-US, V63, P1729, DOI 10.1002/art.30284; Camoes MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049819; Carmichael CL, 2012, P NATL ACAD SCI USA, V109, P15437, DOI 10.1073/pnas.1213454109; Cuda J, 2013, AM J DERMATOPATH, V35, P316, DOI 10.1097/DAD.0b013e318266b197; Cui JW, 2009, LEUKEMIA, V23, P1311, DOI 10.1038/leu.2009.20; De Val S, 2009, DEV CELL, V16, P180, DOI 10.1016/j.devcel.2009.01.014; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Elkareh J, 2009, AM J PHYSIOL-RENAL, V296, pF1219, DOI 10.1152/ajprenal.90710.2008; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Favier R, 2003, THROMB HAEMOSTASIS, V90, P893, DOI 10.1160/TH03-02-0120; Georgiou P, 1996, INT J ONCOL, V9, P9; Gill R, 2009, ARCH PATHOL LAB MED, V133, P967, DOI 10.1043/1543-2165-133.6.967; Ginsberg M, 2012, CELL, V151, P559, DOI 10.1016/j.cell.2012.09.032; Gosiengfiao Y, 2007, DNA CELL BIOL, V26, P577, DOI 10.1089/dna.2007.0575; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Gottgens B, 2004, MOL CELL BIOL, V24, P1870, DOI 10.1128/MCB.24.5.1870-1883.2004; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; Grohar PJ, 2011, NEOPLASIA, V13, P145, DOI 10.1593/neo.101202; Haller ST, 2012, AM J HYPERTENS, V25, P690, DOI 10.1038/ajh.2012.17; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Heo SH, 2010, J CELL PHYSIOL, V224, P734, DOI 10.1002/jcp.22175; Hewett PW, 2001, INT J BIOCHEM CELL B, V33, P347, DOI 10.1016/S1357-2725(01)00022-X; Johnson AD, 2010, INT J SURG PATHOL, V18, P388, DOI 10.1177/1066896908316903; Juban G, 2009, MOL CELL BIOL, V29, P2852, DOI 10.1128/MCB.01435-08; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; Kornblau SM, 2011, BLOOD, V118, P5604, DOI 10.1182/blood-2011-04-348052; Krishnamurti L, 2001, AM J HEMATOL, V66, P295, DOI 10.1002/ajh.1061; Kruse EA, 2009, P NATL ACAD SCI USA, V106, P13814, DOI 10.1073/pnas.0906556106; Kwiatkowski BA, 2000, BLOOD CELL MOL DIS, V26, P84, DOI 10.1006/bcmd.2000.0282; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Lakhanpal GK, 2010, BLOOD, V116, P428, DOI 10.1182/blood-2009-10-250217; Landry JR, 2005, BLOOD, V106, P2680, DOI 10.1182/blood-2004-12-4755; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Le Bras A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012156; Leavey PJ, 2008, EXPERT REV ANTICANC, V8, P617, DOI 10.1586/14737140.8.4.617; Lee CR, 2003, ANTICANCER RES, V23, P2159; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; Li L, 2014, BLOOD, V123, P501, DOI 10.1182/blood-2013-07-514612; Li YJ, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2011.52; Li Y, 2010, CANCER LETT, V294, P57, DOI 10.1016/j.canlet.2010.01.022; Liu F, 2008, CIRC RES, V103, P1147, DOI 10.1161/CIRCRESAHA.108.179713; Liu F, 2008, CURR BIOL, V18, P1234, DOI 10.1016/j.cub.2008.07.048; Ordonez JL, 2009, CANCER RES, V69, P7140, DOI 10.1158/0008-5472.CAN-08-4041; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Masuya M, 2005, BLOOD, V105, P95, DOI 10.1182/blood-2003-12-4345; Mathenia J, 2010, CLIN EXP IMMUNOL, V162, P362, DOI 10.1111/j.1365-2249.2010.04245.x; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Melet F, 1996, MOL CELL BIOL, V16, P2708; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P694, DOI 10.1136/jcp.2006.039230; Miser JS, 2004, J CLIN ONCOL, V22, P2873, DOI 10.1200/JCO.2004.01.041; Molano I, 2010, CLIN EXP IMMUNOL, V160, P275, DOI 10.1111/j.1365-2249.2009.04080.x; Morris EE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3189; Moussa O, 2010, MOL CELL BIOL, V30, P5194, DOI 10.1128/MCB.01112-09; Nagano A, 2010, INT J CANCER, V126, P2790, DOI 10.1002/ijc.24781; Nikitina ER, 2011, J HYPERTENS, V29, P769, DOI 10.1097/HJH.0b013e32834436a7; Noda S, 2012, BRIT J DERMATOL, V167, P1098, DOI 10.1111/j.1365-2133.2012.11055.x; Nowling TK, 2008, MOL IMMUNOL, V45, P1, DOI 10.1016/j.molimm.2007.05.018; Okada Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024837; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; Paulo P, 2012, GENE CHROMOSOME CANC, V51, P240, DOI 10.1002/gcc.20948; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Pham VN, 2007, DEV BIOL, V303, P772, DOI 10.1016/j.ydbio.2006.10.030; Pimanda JE, 2006, BLOOD, V107, P4737, DOI 10.1182/blood-2005-12-4929; PRASAD DDK, 1992, CANCER RES, V52, P5833; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Remy P, 1996, INT J DEV BIOL, V40, P577; Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009; Sakthianandeswaren A, 2010, INFECT IMMUN, V78, P2734, DOI 10.1128/IAI.00126-10; Sakurai T, 2007, CANCER SCI, V98, P1775, DOI 10.1111/j.1349-7006.2007.00598.x; Schutte J, 2012, WIRES SYST BIOL MED, V4, P285, DOI 10.1002/wsbm.1163; Shaked Y, 2005, BLOOD, V105, P4500, DOI 10.1182/blood-2004-08-3210; Smeets MFMA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062346; Soncin F, 2003, EMBO J, V22, P5700, DOI 10.1093/emboj/cdg549; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 2010, BLOOD, V116, P4795, DOI 10.1182/blood-2010-02-270405; Stockley J, 2013, BLOOD, V122, P4090, DOI 10.1182/blood-2013-06-506873; Suzuki E, 2013, IMMUNOLOGY, V139, P318, DOI 10.1111/imm.12070; Suzuki E, 2012, CLIN IMMUNOL, V145, P201, DOI 10.1016/j.clim.2012.09.006; Svenson JL, 2010, GENES IMMUN, V11, P161, DOI 10.1038/gene.2009.73; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tani C, 2013, CLIN EXP RHEUMATOL, V31, pS172; Torchia EC, 2007, MOL CELL BIOL, V27, P7918, DOI 10.1128/MCB.00099-07; Torlakovic EE, 2008, HISTOL HISTOPATHOL, V23, P1309, DOI 10.14670/HH-23.1309; Truong AHL, 2005, ONCOGENE, V24, P962, DOI 10.1038/sj.onc.1208323; Tyybakinoja A, 2006, GENE CHROMOSOME CANC, V45, P257, DOI 10.1002/gcc.20288; Wang YQ, 2006, ARTHRITIS RHEUM-US, V54, P2271, DOI 10.1002/art.21948; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wenger SL, 2006, AM J MED GENET A, V140A, P704, DOI 10.1002/ajmg.a.31146; Wilson NK, 2010, CELL STEM CELL, V7, P532, DOI 10.1016/j.stem.2010.07.016; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhang XK, 2008, J IMMUNOL, V181, P1644, DOI 10.4049/jimmunol.181.3.1644; Zhang XK, 2004, J IMMUNOL, V173, P6481, DOI 10.4049/jimmunol.173.10.6481; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	119	74	77	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2022	2031		10.1038/onc.2014.162	http://dx.doi.org/10.1038/onc.2014.162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909161	Green Accepted			2022-12-28	WOS:000353173400002
J	Zhu, X; Shen, H; Yin, X; Long, L; Xie, C; Liu, Y; Hui, L; Lin, X; Fang, Y; Cao, Y; Xu, Y; Li, M; Xu, W; Li, Y				Zhu, X.; Shen, H.; Yin, X.; Long, L.; Xie, C.; Liu, Y.; Hui, L.; Lin, X.; Fang, Y.; Cao, Y.; Xu, Y.; Li, M.; Xu, W.; Li, Y.			miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; DOWN-REGULATION; TUMOR-SUPPRESSOR; PROSTATE-CANCER; POOR SURVIVAL; RESISTANCE; CELLS; EXPRESSION; EMT; MODULATION	Epithelial-mesenchymal transition (EMT) has an established role in promoting tumor progression and the acquisition of therapeutic resistance. Here, the EMT phenotype was detected in cisplatin-resistant ovarian cancer tissues and cell lines, and correlated with decreased miR-186 expression, increased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. Introducing miR-186 into EOC cells led to a reduction in twist family bHLH transcription factor 1 (Twist1) expression along with morphological, functional and molecular changes consistent with mesenchymal-to-epithelial transition, G1 cell-cycle arrest and enhanced cell apoptosis, which consequently rendered the cells more sensitive to cisplatin in vitro and in vivo. Furthermore, luciferase reporter and rescue assay results showed that the EMT and drug resistance reversal in response to miR-186 was mediated by Twist1. Collectively, these findings implicate miR-186 as an attractive candidate for overcoming chemoresistance in ovarian cancer therapy.	[Zhu, X.; Yin, X.; Liu, Y.; Lin, X.; Xu, Y.; Xu, W.] Jiangsu Univ, Affiliated Hosp 4, Zhenjiang, Jiangsu, Peoples R China; [Zhu, X.; Shen, H.; Xie, C.; Hui, L.; Cao, Y.] Jiangsu Univ, Zhenjiang, Jiangsu, Peoples R China; [Shen, H.; Fang, Y.] Jiangsu Univ, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China; [Long, L.; Li, M.; Li, Y.] Jiangsu Univ, Affiliated Hosp, Zhenjiang 212001, Jiangsu, Peoples R China	Jiangsu University; Jiangsu University; Jiangsu University; Jiangsu University	Li, Y (corresponding author), Jiangsu Univ, Affiliated Hosp, Zhenjiang 212001, Jiangsu, Peoples R China.; Xu, W (corresponding author), Jiangsu Univ, Affiliated Hosp 4, Cent Lab, 20 Zhengdong Rd, Zhenjiang 212001, Jiangsu, Peoples R China.	zxl0122721@sina.com; xwl630806@126.com		ZHU, XIAOLAN/0000-0002-0499-8045; Zhu, Xiaolan/0000-0001-7034-8617	Natural Science Foundation of China [81402165/81301194]; Natural Science Foundation of Jiangsu Province [BK20131241]; Clinical Special Projects of Science and Technology Department of Jiangsu Province [BL2012059]; Research Projects of Jiangsu Provincial Health Department [H201451]; Maternal and Child Health Research Projects of Jiangsu Province [F201437/F201350/F201215]; Social Development of Zhenjiang [SH2012057/SH2013025]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Clinical Special Projects of Science and Technology Department of Jiangsu Province; Research Projects of Jiangsu Provincial Health Department; Maternal and Child Health Research Projects of Jiangsu Province; Social Development of Zhenjiang	This work was supported by the Natural Science Foundation of China (81402165/81301194), the Natural Science Foundation of Jiangsu Province (BK20131241), the Clinical Special Projects of Science and Technology Department of Jiangsu Province (BL2012059), the Research Projects of Jiangsu Provincial Health Department (H201451), the Maternal and Child Health Research Projects of Jiangsu Province (F201437/F201350/F201215) and the Social Development of Zhenjiang (SH2012057/SH2013025).	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Baribeau S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086987; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Cai JC, 2013, CANCER RES, V73, P756, DOI 10.1158/0008-5472.CAN-12-2651; Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429; Chen DH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004177; Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339; Erdmann K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-82; Farrand L, 2013, J BIOL CHEM, V288, P23740, DOI 10.1074/jbc.M113.487686; Gardi NL, 2014, CLIN CANCER RES, V20, P87, DOI 10.1158/1078-0432.CCR-13-2063; Goeppert B, 2010, HEPATOLOGY, V52, P2023, DOI 10.1002/hep.23939; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hosono S, 2007, BRIT J CANCER, V96, P314, DOI 10.1038/sj.bjc.6603533; Jia LZ, 2012, CANCER LETT, V326, P176, DOI 10.1016/j.canlet.2012.08.004; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Li J, 2007, ONCOGENE, V26, P2860, DOI 10.1038/sj.onc.1210086; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136; Myatt SS, 2010, CANCER RES, V70, P367, DOI 10.1158/0008-5472.CAN-09-1891; Nuti SV, 2014, ONCOTARGET, V5, P7260, DOI 10.18632/oncotarget.2428; Parikh A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3977; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Ries J, 2014, ONCOL REP, V31, P1429, DOI 10.3892/or.2014.2983; Sun CY, 2013, JNCI-J NATL CANCER I, V105, P1750, DOI 10.1093/jnci/djt302; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Zhu XL, 2014, INT J CANCER, V135, P1286, DOI 10.1002/ijc.28774; Zhu XL, 2013, FEBS LETT, V587, P73, DOI 10.1016/j.febslet.2012.11.004	38	116	127	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					323	332		10.1038/onc.2015.84	http://dx.doi.org/10.1038/onc.2015.84			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25867064	Bronze			2022-12-28	WOS:000369055300006
J	Xi, G; Hayes, E; Lewis, R; Ichi, S; Mania-Farnell, B; Shim, K; Takao, T; Allender, E; Mayanil, CS; Tomita, T				Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Mania-Farnell, B.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.; Tomita, T.			CD133 and DNA-PK regulate MDR1 via the PI3K-or Akt-NF-kappa B pathway in multidrug-resistant glioblastoma cells in vitro	ONCOGENE			English	Article							CANCER STEM-CELLS; DEPENDENT PROTEIN-KINASE; ASCITES TUMOR-CELLS; DRUG-RESISTANCE; GENE-EXPRESSION; GLIOMA-CELLS; PI3K/AKT PATHWAY; SIGNALING PATHWAY; MALIGNANT GLIOMA; GLYCOPROTEIN	Chemotherapy is an adjuvant treatment for glioblastomas, however, chemotherapy remains palliative because of the development of multidrug resistance (MDR). Following prolonged chemotherapy, MDR protein 1 (MDR1) and CD133 increase in recurrent glioblastomas. CD133 positive (CD133+) glioma cancer stem-like cells (GCSCs) markedly promote drug resistance and exhibit increased DNA damage repair capability; thus they have a key role in determining tumor chemosensitivity. Although CD133, DNA-dependent protein kinase (DNA-PK), and MDR1 are elevated in CD133+ GCSCs, the relationship among these molecules has not been elucidated. In this study, MDR glioblastoma cell lines were created in response to prolonged doxorubicin chemotherapy. CD133, DNA-PK and MDR1 were markedly elevated in these cells. CD133 and DNA-PK may increase MDR1 via the phosphatidylinositol-3-kinase (PI3K)-Akt signal pathway. PI3K downstream targets Akt and nuclear factor (NF)-kappa B, which interacts with the MDR1 promoter, were also elevated in these cells. Downregulation of CD133 and DNA-PK by small interfering RNA, or inhibition of PI3K or Akt, decreased Akt, NF-kappa B and MDR1 expression. The results indicate that CD133 and DNA-PK regulate MDR1 through the PI3K- or Akt-NF-kappa B signal pathway. Consequently, a novel chemotherapeutic regimen targeting CD133 and DNA-PK in combination with traditional protocols may increase chemotherapeutic efficacy and improve prognosis for individuals who present with glioblastoma.	[Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.; Tomita, T.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst,Div Pediat Neuro, Chicago, IL 60611 USA; [Xi, G.; Tomita, T.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Falk Brain Tumor Ctr, Chicago, IL 60611 USA; [Ichi, S.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dev Biol Program,Stanley Manne Childrens Res Inst, Chicago, IL 60611 USA; [Mania-Farnell, B.] Purdue Univ Calumet, Dept Biol Sci, Hammond, IN USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Purdue University System; Purdue University	Xi, G (corresponding author), Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, 225 East Chicago Ave,POB 28, Chicago, IL 60611 USA.	gxi@luriechildrens.org; ttomita@luriechildrens.org			Rory David Deutsch Foundation; Surgical Neuro-oncology Research Fund of Ann & Robert H Lurie Children's Hospital (A&RLCH) of Chicago; Dr Ralph and Marian C Falk Medical Research Trust	Rory David Deutsch Foundation; Surgical Neuro-oncology Research Fund of Ann & Robert H Lurie Children's Hospital (A&RLCH) of Chicago; Dr Ralph and Marian C Falk Medical Research Trust	We are grateful to Dr Hao Luo for helpful suggestions and Drs Nimrod Miller and Yuping Derek Li for critical reading this article. This project was supported by the Rory David Deutsch Foundation, the Surgical Neuro-oncology Research Fund of Ann & Robert H Lurie Children's Hospital (A&RLCH) of Chicago, and the Dr Ralph and Marian C Falk Medical Research Trust.	Abe T, 1998, J NEURO-ONCOL, V40, P11, DOI 10.1023/A:1005954406809; ABE T, 1994, INT J CANCER, V58, P860; Angelastro JM, 2010, MOL CANCER RES, V8, P1105, DOI 10.1158/1541-7786.MCR-09-0383; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bahr O, 2003, BRAIN PATHOL, V13, P482; Balik V, 2009, CELL MOL NEUROBIOL, V29, P845, DOI 10.1007/s10571-009-9366-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006; Barr MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054193; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Bleau AM, 2009, CELL CYCLE, V8, P2936; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Borst P, 2013, J CLIN INVEST, V123, P4131, DOI 10.1172/JCI70430; Choi BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; de Faria GP, 2008, CANCER INVEST, V26, P883, DOI 10.1080/07357900801975264; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Decleves X, 2002, INT J CANCER, V98, P173, DOI 10.1002/ijc.10135; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FEUN LG, 1994, J NEURO-ONCOL, V20, P165, DOI 10.1007/BF01052726; Freitas DP, 2014, INT J CANCER, V134, P1270, DOI 10.1002/ijc.28478; Frosina G, 2009, MOL CANCER RES, V7, P989, DOI 10.1158/1541-7786.MCR-09-0030; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guo Y, 2011, HISTOPATHOLOGY, V59, P763, DOI 10.1111/j.1365-2559.2011.03993.x; Hambardzumyan D, 2008, STEM CELL REV, V4, P203, DOI 10.1007/s12015-008-9021-5; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hsu FM, 2012, TRANSL CANCER RES, V1, P22, DOI 10.3978/j.issn.2218-676X.2012.04.01; HUET S, 1992, BRIT J CANCER, V65, P538, DOI 10.1038/bjc.1992.111; Hussein D, 2011, NEURO-ONCOLOGY, V13, P70, DOI 10.1093/neuonc/noq144; Jin X, 2013, BIOCHEM BIOPH RES CO, V433, P496, DOI 10.1016/j.bbrc.2013.03.021; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; KEIZER HG, 1989, CANCER RES, V49, P2988; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; Lee PC, 2013, ONCOGENE, V32, P1144, DOI 10.1038/onc.2012.133; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lin X, 2012, NEOPLASMA, V59, P248, DOI 10.4149/neo_2012_032; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu QH, 2009, J NEURO-ONCOL, V94, P1, DOI 10.1007/s11060-009-9919-z; Liu T, 2010, MOL CELL BIOCHEM, V340, P265, DOI 10.1007/s11010-010-0426-5; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Ma L, 2010, ACTA BIOCH BIOPH SIN, V42, P593, DOI 10.1093/abbs/gmq067; Mannervik B, 1981, Methods Enzymol, V77, P231; MARQUARDT D, 1992, CANCER RES, V52, P3157; MATSUMOTO T, 1991, J NEUROSURG, V74, P460, DOI 10.3171/jns.1991.74.3.0460; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; Mould E, 2014, BIOCHEM PHARMACOL, V88, P58, DOI 10.1016/j.bcp.2014.01.001; Nakai E, 2009, CANCER INVEST, V27, P901, DOI 10.3109/07357900801946679; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6; Seo SB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-199; Shimura T, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.12; SKOVSGAARD T, 1978, CANCER RES, V38, P1785; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x; Tamura K, 2013, J NEUROSURG, V119, P1145, DOI 10.3171/2013.7.JNS122417; Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Xi GF, 2014, NANOMED-NANOTECHNOL, V10, P381, DOI 10.1016/j.nano.2013.07.013; Zhong XL, 2007, BIOCHEMISTRY-US, V46, P5766, DOI 10.1021/bi700063b	67	48	50	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					241	250		10.1038/onc.2015.78	http://dx.doi.org/10.1038/onc.2015.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25823028				2022-12-28	WOS:000368193900010
J	Gao, J; He, Q; Subudhi, S; Aparicio, A; Zurita-Saavedra, A; Lee, DH; Jimenez, C; Suarez-Almazor, M; Sharma, P				Gao, J.; He, Q.; Subudhi, S.; Aparicio, A.; Zurita-Saavedra, A.; Lee, D. H.; Jimenez, C.; Suarez-Almazor, M.; Sharma, P.			Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience	ONCOGENE			English	Review							LYMPHOCYTE-ASSOCIATED ANTIGEN-4; DOSE-ESCALATION TRIAL; REGULATORY T-CELLS; STAGE-IV MELANOMA; METASTATIC MELANOMA; CTLA-4 BLOCKADE; AUTOIMMUNE HYPOPHYSITIS; MONOCLONAL-ANTIBODY; ANTI-CTLA-4; THERAPY	Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.	[Gao, J.; He, Q.; Subudhi, S.; Aparicio, A.; Zurita-Saavedra, A.; Lee, D. H.; Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Jimenez, C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia, Houston, TX 77030 USA; [Suarez-Almazor, M.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Houston, TX 77030 USA; [Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol & Immunol, 1155 Pressler St,Unit 1374, Houston, TX 77030 USA.	PadSharma@mdanderson.org		Subudhi, Sumit/0000-0001-5208-7732	American Society of Clinical Oncology Young Investigator Award; NIH K12 grant; NIH R01 grant [1-R01 CA1633793-01]; Cancer Prevention Institute of Texas [RP120108]; Prostate Cancer Foundation Challenge Grant in Immunology; American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant; NATIONAL CANCER INSTITUTE [R01CA163793] Funding Source: NIH RePORTER	American Society of Clinical Oncology Young Investigator Award; NIH K12 grant; NIH R01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Institute of Texas; Prostate Cancer Foundation Challenge Grant in Immunology; American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JG's work is supported by an American Society of Clinical Oncology Young Investigator Award and an NIH K12 grant. PS's work is supported by an NIH R01 grant (1-R01 CA1633793-01), a research grant form Cancer Prevention Institute of Texas (RP120108), a Prostate Cancer Foundation Challenge Grant in Immunology and an American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant. PS also serves as a consultant for Bristol Myers-Squibb, Glaxo-Smith Kline and MedImmune/Astrazeneca. PS is also a founder and consultant for Jounce Therapeutics. The remaining authors declare no conflict of interest.	Alegre ML, 1998, J IMMUNOL, V161, P3347; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Berman David, 2010, Cancer Immun, V10, P11; Bhatia S, 2009, J IMMUNOTHER, V32, P203, DOI 10.1097/CJI.0b013e318193a206; Blansfield JA, 2005, J IMMUNOTHER, V28, P593, DOI 10.1097/01.cji.0000178913.41256.06; Delyon J, 2011, NEW ENGL J MED, V365, P1747, DOI 10.1056/NEJMc1110923; Dillard T, 2010, PITUITARY, V13, P29, DOI 10.1007/s11102-009-0193-z; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fadel F, 2009, NEW ENGL J MED, V361, P211, DOI 10.1056/NEJMc0904283; Fasso M, 2008, P NATL ACAD SCI USA, V105, P3509, DOI 10.1073/pnas.0712269105; Fecher LA, 2013, ONCOLOGIST, V18, P733, DOI 10.1634/theoncologist.2012-0483; Garber K, 2012, NAT BIOTECHNOL, V30, P475, DOI 10.1038/nbt0612-475; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Jaber SH, 2006, ARCH DERMATOL, V142, P166, DOI 10.1001/archderm.142.2.166; Klein O, 2009, CLIN CANCER RES, V15, P2507, DOI 10.1158/1078-0432.CCR-08-2424; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Min L, 2011, EUR J ENDOCRINOL, V164, P303, DOI 10.1530/EJE-10-0833; O'Day SJ, 2010, ANN ONCOL, V21, P1712, DOI 10.1093/annonc/mdq013; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Robinson MR, 2004, J IMMUNOTHER, V27, P478, DOI 10.1097/00002371-200411000-00008; Sanderson K, 2005, J CLIN ONCOL, V23, P741, DOI 10.1200/JCO.2005.01.128; Schadendorf D, 2013, EUR J CANCER, V49, p24LBA; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Sun Jingjing, 2008, Cancer Immun, V8, P9; Tarhini A, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/857519; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; von Euw E, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-35; Voskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053745; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Wilgenhof S, 2011, ANN ONCOL, V22, P991, DOI 10.1093/annonc/mdr028; Wolchok JD, 2013, ANN NY ACAD SCI, V1291, P1, DOI 10.1111/nyas.12180; Wolchok JD, 2010, LANCET ONCOL, V11, P155, DOI 10.1016/S1470-2045(09)70334-1; Ying HY, 2010, J IMMUNOL, V185, P1375, DOI 10.4049/jimmunol.0903369; Yuan JD, 2008, P NATL ACAD SCI USA, V105, P20410, DOI 10.1073/pnas.0810114105	41	40	43	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5411	5417		10.1038/onc.2015.5	http://dx.doi.org/10.1038/onc.2015.5			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659583	Green Accepted			2022-12-28	WOS:000363479700001
J	Labbe, DP; Zadra, G; Ebot, EM; Mucci, LA; Kantoff, PW; Loda, M; Brown, M				Labbe, D. P.; Zadra, G.; Ebot, E. M.; Mucci, L. A.; Kantoff, P. W.; Loda, M.; Brown, M.			Role of diet in prostate cancer: the epigenetic link	ONCOGENE			English	Review							GROWTH-FACTOR-I; TUMOR-SUPPRESSOR GENES; DNA HYPOMETHYLATION; HISTONE ACETYLATION; CELLULAR-METABOLISM; METHYLATION STATUS; ENERGY-BALANCE; LIFE-STYLE; BODY-MASS; FAT DIET	Diet is hypothesized to be a critical environmentally related risk factor for prostate cancer (PCa) development, and specific diets and dietary components can also affect PCa progression; however, the mechanisms underlying these associations remain elusive. As for a maturing organism, PCa's epigenome is plastic and evolves from the pre-neoplastic to the metastatic stage. In particular, epigenetic remodeling relies on substrates or cofactors obtained from the diet. Here we review the evidence that bridges dietary modulation to alterations in the prostate epigenome. We propose that such diet-related effects offer a mechanistic link between the impact of different diets and the course of PCa development and progression.	[Labbe, D. P.; Zadra, G.; Kantoff, P. W.; Loda, M.; Brown, M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Labbe, D. P.; Brown, M.] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA; [Zadra, G.; Loda, M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; [Ebot, E. M.; Mucci, L. A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA; [Mucci, L. A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Brown, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,D730, Boston, MA 02215 USA.	myles_brown@dfci.harvard.edu	Brown, Myles/AAX-5332-2021; Labbé, David P./C-2702-2009; Brown, Myles/B-6906-2008	Brown, Myles/0000-0002-8213-1658; Labbé, David P./0000-0001-8864-8765; Kantoff, Philip/0000-0001-7275-0597	Canadian Institute of Health Research (CIHR) Fellowship; National Cancer Institute [1P01CA163227, P50CA090381]; NATIONAL CANCER INSTITUTE [P01CA163227, P50CA090381] Funding Source: NIH RePORTER	Canadian Institute of Health Research (CIHR) Fellowship(Canadian Institutes of Health Research (CIHR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Edward L Giovannucci, Thomas Westerling, Luz E Tavera-Mendoza and Sonal Jhaveri for the critical review of this manuscript. DPL is a recipient of a Canadian Institute of Health Research (CIHR) Fellowship. LAM was a Young Investigator of the Prostate Cancer Foundation. This work was supported by grants from the National Cancer Institute (1P01CA163227 to MB and P50CA090381 to MB and PWK).	Anzo M, 2008, CANCER RES, V68, P3342, DOI 10.1158/0008-5472.CAN-07-3165; Aronson WJ, 2010, J UROLOGY, V183, P345, DOI 10.1016/j.juro.2009.08.104; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Berquin IM, 2007, J CLIN INVEST, V117, P1866, DOI 10.1172/JCI31494; Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006; Bhusari S, 2011, PROSTATE, V71, P1621, DOI 10.1002/pros.21379; Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555; Bistulfi G, 2011, CANCER PREV RES, V4, P1825, DOI 10.1158/1940-6207.CAPR-11-0140; Blando J, 2011, CANCER PREV RES, V4, P2002, DOI 10.1158/1940-6207.CAPR-11-0182; Boyd LK, 2012, NAT REV UROL, V9, P652, DOI 10.1038/nrurol.2012.185; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Buschemeyer WC, 2007, EUR UROL, V52, P331, DOI 10.1016/j.eururo.2007.04.069; Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004; Canto C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022; Cao Y, 2011, CANCER PREV RES, V4, P486, DOI 10.1158/1940-6207.CAPR-10-0229; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chan JM, 2005, J CLIN ONCOL, V23, P8152, DOI 10.1200/JCO.2005.03.1492; Chen D, 2008, GENE DEV, V22, P1753, DOI 10.1101/gad.1650608; Cooney Craig A, 2002, J Nutr, V132, p2393S, DOI 10.1093/jn/132.8.2393S; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dobosy JR, 2008, PROSTATE, V68, P1187, DOI 10.1002/pros.20782; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Etminan M, 2004, CANCER EPIDEM BIOMAR, V13, P340; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fujiki R, 2011, NATURE, V480, P557, DOI 10.1038/nature10656; Galdieri L, 2012, J BIOL CHEM, V287, P23865, DOI 10.1074/jbc.M112.380519; Gao X, 2005, JNCI-J NATL CANCER I, V97, P1768, DOI 10.1093/jnci/dji402; Giovannucci E, 2007, INT J CANCER, V121, P1571, DOI 10.1002/ijc.22788; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Huffman DM, 2007, CANCER RES, V67, P417, DOI 10.1158/0008-5472.CAN-06-1244; Hurst R, 2012, AM J CLIN NUTR, V96, P111, DOI 10.3945/ajcn.111.033373; Irshad S, 2013, CANCER METAST REV, V32, P109, DOI 10.1007/s10555-012-9409-1; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jackson MD, 2013, GENES NUTR, V8, P199, DOI 10.1007/s12263-012-0321-7; James SJ, 1997, CARCINOGENESIS, V18, P287, DOI 10.1093/carcin/18.2.287; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jeronimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kee K, 2004, J BIOL CHEM, V279, P40076, DOI 10.1074/jbc.M406002200; Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590; Knock E, 2006, CANCER RES, V66, P10349, DOI 10.1158/0008-5472.CAN-06-2477; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Kobayashi N, 2008, CANCER RES, V68, P3066, DOI 10.1158/0008-5472.CAN-07-5616; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kushi LH, 2012, CA-CANCER J CLIN, V62, P30, DOI 10.3322/caac.20140; Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864; Llaverias G, 2010, AM J PATHOL, V177, P3180, DOI 10.2353/ajpath.2010.100568; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3; Majeed N, 2005, ONCOGENE, V24, P4736, DOI 10.1038/sj.onc.1208572; Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290; Malvezzi M, 2014, ANN ONCOL, V25, P1650, DOI 10.1093/annonc/mdu138; McDunn JE, 2013, PROSTATE, V73, P1547, DOI 10.1002/pros.22704; Morrish F, 2010, J BIOL CHEM, V285, P36267, DOI 10.1074/jbc.M110.141606; Moyer VA, 2012, ANN INTERN MED, V157, P120, DOI 10.7326/0003-4819-157-2-201207170-00459; Narita S, 2008, PROSTATE, V68, P321, DOI 10.1002/pros.20681; Nimptsch K, 2011, INT J CANCER, V128, P660, DOI 10.1002/ijc.25381; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ornish D, 2008, P NATL ACAD SCI USA, V105, P8369, DOI 10.1073/pnas.0803080105; Osterhues A, 2013, CRIT REV FOOD SCI, V53, P1180, DOI 10.1080/10408398.2011.575966; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Palmer J, 2008, PROSTATE, V68, P345, DOI 10.1002/pros.20692; Pandey M, 2012, MOL CARCINOGEN, V51, P952, DOI 10.1002/mc.20866; PEGG AE, 1970, BIOCHEM J, V117, P17, DOI 10.1042/bj1170017; Pelton K, 2012, CURR OPIN PHARMACOL, V12, P751, DOI 10.1016/j.coph.2012.07.006; Perry AS, 2007, BRIT J CANCER, V96, P1587, DOI 10.1038/sj.bjc.6603767; Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185; Poirier LA, 2001, CANCER EPIDEM BIOMAR, V10, P649; Pommier AJC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003483; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; Rycyna KJ, 2013, UROLOGY, V82, P1197, DOI 10.1016/j.urology.2013.07.012; Santourlidis S, 1999, PROSTATE, V39, P166; Saraon P, 2014, PROSTATE, V74, P372, DOI 10.1002/pros.22758; Schaid DJ, 2004, HUM MOL GENET, V13, pR103, DOI 10.1093/hmg/ddh072; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Severi G, 2006, CANCER EPIDEM BIOMAR, V15, P1137, DOI 10.1158/1055-9965.EPI-05-0823; Shabbeer S, 2012, CANCER PREV RES, V5, P229, DOI 10.1158/1940-6207.CAPR-11-0357; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Supic G, 2013, NUTR CANCER, V65, P781, DOI 10.1080/01635581.2013.805794; Sutherland BW, 2008, CANCER RES, V68, P3495, DOI 10.1158/0008-5472.CAN-07-6531; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Tio M, 2014, PROSTATE CANCER P D, V17, P213, DOI 10.1038/pcan.2014.16; Trottier G, 2010, NAT REV UROL, V7, P21, DOI 10.1038/nrurol.2009.234; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Valdes-Mora F, 2015, ONCOGENE, V34, P1609, DOI 10.1038/onc.2014.111; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vardi A, 2010, IN VIVO, V24, P393; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Venkateswaran V, 2010, NAT REV UROL, V7, P442, DOI 10.1038/nrurol.2010.102; Wang ZH, 2005, ENDOCRINOLOGY, V146, P5188, DOI 10.1210/en.2005-0607; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2007, FASEB J, V21, P3380, DOI 10.1096/fj.07-8229com; WCRF/AICR, 2007, FOOD NUTR PHYS ACT P, P517; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wilson KM, 2012, ASIAN J ANDROL, V14, P365, DOI 10.1038/aja.2011.142; Wolff GL, 1999, PHYSIOL GENOMICS, V1, P151, DOI 10.1152/physiolgenomics.1999.1.3.151; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Xu W, 2014, ONCOGENE, V33, P2279, DOI 10.1038/onc.2013.163; Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zadra G, 2014, EMBO MOL MED, V6, P519, DOI 10.1002/emmm.201302734; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	131	37	37	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4683	4691		10.1038/onc.2014.422	http://dx.doi.org/10.1038/onc.2014.422			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531313	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000360931500002
J	Siu, MK; Tsai, YC; Chang, YS; Yin, JJ; Suau, F; Chen, WY; Liu, YN				Siu, M. K.; Tsai, Y-C; Chang, Y-S; Yin, J. J.; Suau, F.; Chen, W-Y; Liu, Y-N			Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CANCER; INHIBITION; EXPRESSION; INVASION; RECEPTOR; GENE	Transforming growth factor-beta (TGF beta) is enriched in the bone matrix and serves as a key factor in promoting bone metastasis in cancer. In addition, TGF beta signaling activates mammalian target of rapamycin (mTOR) functions, which is important for the malignant progression. Here, we demonstrate that TGF beta regulates the level of microRNA-96 (miR-96) through Smad-dependent transcription and that miR-96 promotes the bone metastasis in prostate cancer. The enhanced effects in cellular growth and invasiveness suggest that miR-96 functions as an oncomir/and metastamir. Supporting this idea, we identified a downstream target of the TGF beta-miR-96 signaling pathway to be AKT1S1 mRNA, whose translated protein is a negative regulator of mTOR kinase. Our findings provide a novel mechanism accounting for the TGF beta signaling and bone metastasis.	[Siu, M. K.; Tsai, Y-C; Liu, Y-N] Taipei Med Univ, Coll Med Sci & Technol, Program Canc Biol & Drug Discovery, Taipei 11031, Taiwan; [Siu, M. K.; Tsai, Y-C; Liu, Y-N] Acad Sinica, Taipei 115, Taiwan; [Siu, M. K.] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei 11031, Taiwan; [Tsai, Y-C; Chang, Y-S; Liu, Y-N] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 11031, Taiwan; [Yin, J. J.; Suau, F.] NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; [Chen, W-Y] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 11031, Taiwan	Taipei Medical University; Academia Sinica - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Taipei Medical University; Taipei Municipal WanFang Hospital	Liu, YN (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 11031, Taiwan.	yuanchin@tmu.edu.tw; liuy@tmu.edu.tw	Liu, Yen-Nien/AAW-4698-2021		Taipei Medical University-Wan Fang Hospital [102TMU-WFH-05]; Taipei Medical University [TMU102-AE1-B30]; Ministry of Science and Technology [NSC102-2320-B-038-001, NSC103-2311-B-038-001]	Taipei Medical University-Wan Fang Hospital; Taipei Medical University; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was jointly supported by grants from the Taipei Medical University-Wan Fang Hospital (102TMU-WFH-05) to Y-N Liu, Taipei Medical University (TMU102-AE1-B30) to Y-C Tsai, the Ministry of Science and Technology (NSC102-2320-B-038-001) of Taiwan to Y-N Liu, and the Ministry of Science and Technology (NSC103-2311-B-038-001) of Taiwan to Y-C Tsai. We also thank Dr Ji-Hshiung Chen (Tzu Chi University) for reading the manuscript and for his comments and helpful suggestions. We also thank Dr Orla Casey for reviewing our manuscript and discussion.	Ao MF, 2006, CANCER RES, V66, P8007, DOI 10.1158/0008-5472.CAN-05-4451; Bedi A, 2012, MOL CANCER THER, V11, P2429, DOI 10.1158/1535-7163.MCT-12-0101-T; Bertoldo F, 2014, BBA-REV CANCER, V1845, P248, DOI 10.1016/j.bbcan.2014.01.009; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; Butz H, 2012, TRENDS PHARMACOL SCI, V33, P382, DOI 10.1016/j.tips.2012.04.003; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fendler A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080807; Gogna R, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.15; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Haflidadottir BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072400; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299; Lee C, 1999, PROSTATE, V39, P285; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Lin HX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015797; Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Martin P, 2011, AM J PATHOL, V179, P422, DOI 10.1016/j.ajpath.2011.03.035; Mishra S, 2014, ONCOGENE, V33, P4097, DOI 10.1038/onc.2013.374; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Yadav V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047796; Yin JJ, 2010, CANCER RES, V70, P8662, DOI 10.1158/0008-5472.CAN-10-1435; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Yu SN, 2010, CANCER RES, V70, P6015, DOI 10.1158/0008-5472.CAN-09-4531; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	36	67	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4767	4776		10.1038/onc.2014.414	http://dx.doi.org/10.1038/onc.2014.414			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531317				2022-12-28	WOS:000360931500010
J	Mathsyaraja, H; Thies, K; Taffany, DA; Deighan, C; Liu, T; Yu, L; Fernandez, SA; Shapiro, C; Otero, J; Timmers, C; Lustberg, MB; Chalmers, J; Leone, G; Ostrowski, MC				Mathsyaraja, H.; Thies, K.; Taffany, D. A.; Deighan, C.; Liu, T.; Yu, L.; Fernandez, S. A.; Shapiro, C.; Otero, J.; Timmers, C.; Lustberg, M. B.; Chalmers, J.; Leone, G.; Ostrowski, M. C.			CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth	ONCOGENE			English	Article							BREAST-CANCER; IN-VIVO; IMMUNE-RESPONSE; MACROPHAGES; INHIBITION; DIFFERENTIATION; POLARIZATION; ANGIOGENESIS; ACTIVATION; EXPRESSION	Metastasis of solid tumors is associated with poor prognosis and bleak survival rates. Tumor-infiltrating myeloid cells (TIMs) are known to promote metastasis, but the mechanisms underlying their collaboration with tumor cells remain unknown. Here, we report an oncogenic role for microRNA (miR) in driving M2 reprogramming in TIMs, characterized by the acquisition of pro-tumor and pro-angiogenic properties. The expression of miR-21, miR-29a, miR-142-3p and miR-223 increased in myeloid cells during tumor progression in mouse models of breast cancer and melanoma metastasis. Further, we show that these miRs are regulated by the CSF1-ETS2 pathway in macrophages. A loss-of-function approach utilizing selective depletion of the miR-processing enzyme Dicer in mature myeloid cells blocks angiogenesis and metastatic tumor growth. Ectopic expression of miR-21 and miR-29a promotes angiogenesis and tumor cell proliferation through the downregulation of anti-angiogenic genes such as Col4a2, Spry1 and Timp3, whereas knockdown of the miRs impedes these processes. miR-21 and miR-29a are expressed in Csf1r+ myeloid cells associated with human metastatic breast cancer, and levels of these miRs in CD115+ non-classical monocytes correlates with metastatic tumor burden in patients. Taken together, our results suggest that miR-21 and miR-29a are essential for the pro-tumor functions of myeloid cells and the CSF1-ETS2 pathway upstream of the miRs serves as an attractive therapeutic target for the inhibition of M2 remodeling of macrophages during malignancy. In addition, miR-21 and miR-29a in circulating myeloid cells may potentially serve as biomarkers to measure therapeutic efficacy of targeted therapies for CSF1 signaling.	[Mathsyaraja, H.; Thies, K.; Taffany, D. A.; Ostrowski, M. C.] Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Mathsyaraja, H.; Thies, K.; Taffany, D. A.; Liu, T.; Shapiro, C.; Otero, J.; Timmers, C.; Lustberg, M. B.; Chalmers, J.; Leone, G.; Ostrowski, M. C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Deighan, C.; Chalmers, J.] Ohio State Univ, Dept Chem Engn, Columbus, OH 43210 USA; [Yu, L.; Fernandez, S. A.] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Shapiro, C.; Lustberg, M. B.] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Otero, J.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Leone, G.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Leone, G.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ostrowski, MC (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Tumor Microenvironm Program, 598 Biomed Res Tower,460W 12th Ave, Columbus, OH 43210 USA.	michael.ostrowski@osumc.edu	Otero, Jose/AAI-4891-2020; yu, lianbo/B-3472-2010; Otero, Jose Javier/B-8955-2013; Ostrowski, Michael/H-3108-2011	Otero, Jose/0000-0003-0680-4520; Ostrowski, Michael/0000-0003-2948-6297	National Institutes of Health [NIHPO1CA097189, RO1CA053271]; Evelyn Simmers Foundation; NATIONAL CANCER INSTITUTE [P01CA097189, R01CA053271, P30CA016058] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Evelyn Simmers Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yongqi Wu for help with flow cytometry. We also wish to acknowledge the histology core, OSU Comprehensive Cancer Center Microarray, Nucleic Acids, Analytical Cytometry, Microscopy and Biostatistics Core Shared Resources for technical assistance. This work was funded through National Institutes of Health grants (NIHPO1CA097189 and RO1CA053271) and the Evelyn Simmers Foundation to MCO.	Brain O, 2013, IMMUNITY, V39, P521, DOI 10.1016/j.immuni.2013.08.035; BROCKER EB, 1987, CANCER IMMUNOL IMMUN, V25, P81; Chen PW, 2011, CLIN CANCER RES, V17, P7230, DOI 10.1158/1078-0432.CCR-11-1354; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Cho HJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3195; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; FIDLER IJ, 1975, CANCER RES, V35, P218; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gao D, 2009, TRENDS MOL MED, V15, P333, DOI 10.1016/j.molmed.2009.06.006; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Hu R, 2007, MOL CELL BIOL, V27, P4018, DOI 10.1128/MCB.01839-06; Jensen TO, 2009, J CLIN ONCOL, V27, P3330, DOI 10.1200/JCO.2008.19.9919; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Liu G, 2013, ARTERIOSCL THROM VAS, V33, P170, DOI 10.1161/ATVBAHA.112.300068; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Mok S, 2014, CANCER RES, V74, P153, DOI 10.1158/0008-5472.CAN-13-1816; Mossadegh-Keller N, 2013, NATURE, V497, P239, DOI 10.1038/nature12026; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Priceman SJ, 2010, BLOOD, V115, P1461, DOI 10.1182/blood-2009-08-237412; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Rae F, 2007, DEV BIOL, V308, P232, DOI 10.1016/j.ydbio.2007.05.027; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Strauss-Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191; Tagliani E, 2011, J EXP MED, V208, P1901, DOI 10.1084/jem.20110866; Wang T, 2012, PIGM CELL MELANOMA R, V25, P493, DOI 10.1111/j.1755-148X.2012.01005.x; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yan HH, 2010, CANCER RES, V70, P6139, DOI 10.1158/0008-5472.CAN-10-0706; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Zabuawala T, 2010, CANCER RES, V70, P1323, DOI 10.1158/0008-5472.CAN-09-1474; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666; Zonari E, 2013, BLOOD, V122, P243, DOI 10.1182/blood-2012-08-449306	58	48	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3651	3661		10.1038/onc.2014.294	http://dx.doi.org/10.1038/onc.2014.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241894	Green Accepted			2022-12-28	WOS:000357679100004
J	Sangrar, W; Shi, C; Mullins, G; LeBrun, D; Ingalls, B; Greer, PA				Sangrar, W.; Shi, C.; Mullins, G.; LeBrun, D.; Ingalls, B.; Greer, P. A.			Amplified Ras-MAPK signal states correlate with accelerated EGFR internalization, cytostasis and delayed HER2 tumor onset in Fer-deficient model systems	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE FER; HUMAN-BREAST-CANCER; CELL-ADHESION; CORTACTIN PHOSPHORYLATION; MEMBRANE INVAGINATION; MEDIATED ENDOCYTOSIS; RECEPTOR ENDOCYTOSIS; ERBB RECEPTORS; NEU ONCOGENE	The non-receptor tyrosine kinase Fer belongs to a distinct subfamily of F-BAR domain containing kinases implicated in vesicular trafficking and signaling downstream of adhesion and growth factor receptors. Targeted inactivation of the fer gene in a transgenic mouse model of HER2(+), breast cancer was associated with delayed tumor onset and reduced proliferative rates in tumor cells. Fer deficiency was associated with increased rates of epidermal growth factor (EGF)-induced epidermal growth factor receptor (EGFR) internalization and amplified Ras-Raf-Mek-Erk (Ras-MAPK) signaling in primary mammary tumor epithelial cells, as well as increased cytotoxic and anti-proliferative sensitivity to the dual EGFR/HER2 inhibitor Lapatinib (LPN). These observations suggest a model in which accelerated ligand-induced EGFR internalization in Fer-deficient cells hypersensitizes the Ras-MAPK pathway to EGF, resulting in MAPK signal amplification to levels that induce cytostasis, rather than proliferation. Thus, Ras-MAPK cytostatic signaling delays HER2 tumor initiation and increases LPN cytotoxicity in Fer-deficient model systems. Taken together, these data suggest that targeting Fer alone, or in combination with LPN, may be of therapeutic benefit in HER2(+) breast cancer.	[Sangrar, W.; Shi, C.; Mullins, G.; LeBrun, D.; Greer, P. A.] Queens Canc Res Inst, Div Canc Biol & Genet, Kingston, ON, Canada; [Sangrar, W.; Mullins, G.; LeBrun, D.; Greer, P. A.] Queens Univ, Queens Canc Res Inst, Dept Pathol & Mol Med, Kingston, ON, Canada; [Sangrar, W.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Ingalls, B.] Univ Waterloo, Dept Appl Math, Waterloo, ON N2L 3G1, Canada	McMaster University; Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Waterloo	Sangrar, W (corresponding author), Queens Univ, Queens Canc Res Inst, Dept Pathol & Mol Med, Botterell Hall,Room A309, Kingston, ON K7L 3N6, Canada.	ws4@queensu.ca; greerp@queensu.ca			Canadian Breast Cancer Foundation; Canadian Institutes for Health Research; Canadian Cancer Society Research Institute	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	We are grateful to Lee Boudreau, Christine Hall and Yan Gao for technical assistance. This work was funded by operating grants from the Canadian Breast Cancer Foundation, the Canadian Institutes for Health Research, and the Canadian Cancer Society Research Institute to PAG.	Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; de Wit R, 2000, J BIOMOL SCREEN, V5, P133, DOI 10.1177/108705710000500305; Disanza A, 2009, MOL ONCOL, V3, P280, DOI 10.1016/j.molonc.2009.05.008; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Frost A, 2008, CELL, V132, P807, DOI 10.1016/j.cell.2007.12.041; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; IMAI Y, 1982, CANCER RES, V42, P4394; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; Ivanova IA, 2013, ONCOGENE, V32, P5582, DOI 10.1038/onc.2013.277; Iwanishi M, 2000, J BIOL CHEM, V275, P38995, DOI 10.1074/jbc.M006665200; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Kumar N, 2008, MOL PHARMACOL, V73, P1668, DOI 10.1124/mol.107.043794; Laurent CE, 2004, MOL CELL BIOL, V24, P9351, DOI 10.1128/MCB.24.21.9351-9358.2004; Lee CS, 2009, BBA-MOL CELL BIOL L, V1791, P862, DOI 10.1016/j.bbalip.2009.04.007; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Milde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Sangrar W, 2005, CANCER RES, V65, P3518, DOI 10.1158/0008-5472.CAN-04-3468; Sangrar W, 2009, POMBE CDC15 HOMOLOGY, P78; Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06; Schmidt-Glenewinkel H, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-32; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Shimada A, 2007, CELL, V129, P761, DOI 10.1016/j.cell.2007.03.040; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorkin A, 2010, CURR PROTOC CELL BIO, DOI [10. 1002/0471143030. cb1514s46, DOI 10.1002/0471143030.CB1514S46]; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sousa LP, 2012, P NATL ACAD SCI USA, V109, P4419, DOI 10.1073/pnas.1200164109; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang Y, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-78	53	16	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4109	4117		10.1038/onc.2014.340	http://dx.doi.org/10.1038/onc.2014.340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347743				2022-12-28	WOS:000358780500009
J	Truesdell, P; Ahn, J; Chander, H; Meens, J; Watt, K; Yang, X; Craig, AWB				Truesdell, P.; Ahn, J.; Chander, H.; Meens, J.; Watt, K.; Yang, X.; Craig, A. W. B.			CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis	ONCOGENE			English	Article							CDC42-INTERACTING PROTEIN 4; GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-CELL INVASION; ACTIN CYTOSKELETON; MEMBRANE INVAGINATION; TUMOR PROGRESSION; DOWN-REGULATION; KINASE DOMAIN; BAR PROTEINS	Aberrant epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer (NSCLC) is linked to tumor progression, metastasis and poor survival rates. Here we report the role of Cdc42-interacting protein 4 (CIP4) in the regulation of NSCLC cell invasiveness and tumor metastasis. CIP4 was highly expressed in a panel of NSCLC cell lines and normal lung epithelial cell lines. Stable knockdown (KD) of CIP4 in lung adenocarcinoma H1299 cells, expressing wild-type EGFR, led to increased EGFR levels on the cell surface and defects in sustained activation of Erk kinase in H1299 cells treated with EGF. CIP4 localized to leading edge projections in NSCLC cells, and CIP4 KD cells displayed defects in EGF-induced cell motility and invasion through extracellular matrix. This correlated with reduced expression and activity of matrix metalloproteinase-2 (MMP-2) in CIP4 KD cells compared with control. In xenograft assays, CIP4 silencing had no effect on tumor growth but resulted in significant defects in spontaneous metastases to the lungs from these subcutaneous tumors. This correlated with reduced expression of the Erk target gene Zeb1 and the Zeb1 target gene MMP-2 in CIP4 KD tumors compared with control. CIP4 also enhanced rates of metastasis to the liver and lungs in an intrasplenic experimental metastasis model. In human NSCLC tumor sections, CIP4 expression was elevated greater than or equal to twofold in 43% of adenocarcinomas and 32% of squamous carcinomas compared with adjacent normal lung tissues. Analysis of microarray data for NSCLC patients also revealed that high CIP4 transcript levels correlated with reduced overall survival. Together, these results identify CIP4 as a positive regulator of NSCLC metastasis and a potential poor prognostic biomarker in lung adenocarcinoma.	[Truesdell, P.; Ahn, J.; Chander, H.; Meens, J.; Watt, K.; Craig, A. W. B.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada; [Truesdell, P.; Ahn, J.; Chander, H.; Meens, J.; Watt, K.; Craig, A. W. B.] Queens Canc Res Inst, Canc Biol & Genet, Kingston, ON, Canada; [Yang, X.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Craig, AWB (corresponding author), Queens Univ, Dept Biomed & Mol Sci & Canc Biol & Genet, 18 Stuart St, Kingston, ON K7L 3N6, Canada.	andrew.craig@queensu.ca	Craig, Andrew/AAC-6923-2019; Craig, Andrew/G-2312-2017	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393; Watt, Kathleen/0000-0001-6642-9756	Canadian Cancer Society Research Institute; Canadian Institutes for Health Research [MOP119562]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	We thank Stephanie Everingham for technical assistance, Jeff Mewburn for help with time-lapse confocal microscopy and Lee Boudreau (Queen's Laboratory for Molecular Pathology) for help in optimizing IHC staining. Thanks also to Lois Mulligan, Peter Greer and Chris Nicol for sharing reagents and equipment. This research was supported by operating grants from Canadian Cancer Society Research Institute and Canadian Institutes for Health Research to AWBC (MOP119562).	Ahn J, 2013, MOL CANCER RES, V11, P952, DOI 10.1158/1541-7786.MCR-13-0003-T; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Aspenstrom P, 2006, TRENDS BIOCHEM SCI, V31, P670, DOI 10.1016/j.tibs.2006.10.001; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Bae GY, 2013, ONCOTARGET, V4, P2512, DOI 10.18632/oncotarget.1463; Bai SJ, 2012, INT J BIOL SCI, V8, P859, DOI 10.7150/ijbs.3490; Dong QZ, 2013, AM J PATHOL, V182, P954, DOI 10.1016/j.ajpath.2012.11.019; Downward J, 2008, NAT MED, V14, P1315, DOI 10.1038/nm1208-1315; Feng YM, 2010, J BIOL CHEM, V285, P4348, DOI 10.1074/jbc.M109.041038; Frost A, 2008, CELL, V132, P807, DOI 10.1016/j.cell.2007.12.041; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hirsch FR, 2008, J CLIN ONCOL, V26, P3351, DOI 10.1200/JCO.2007.14.0111; Hsu CC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-12; Hu JH, 2011, J CELL SCI, V124, P1739, DOI 10.1242/jcs.078014; Hu JH, 2009, CELL SIGNAL, V21, P1686, DOI 10.1016/j.cellsig.2009.07.007; Huang MS, 2002, CLIN EXP METASTAS, V19, P359, DOI 10.1023/A:1015562532564; Ishikawa D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062104; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Kao SJ, 2012, TOXICOL APPL PHARM, V261, P105, DOI 10.1016/j.taap.2012.03.020; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koduru S, 2010, P NATL ACAD SCI USA, V107, P16252, DOI 10.1073/pnas.1002747107; Koshkina NV, 2013, CURR CANCER DRUG TAR, V13, P48; Leibfried A, 2008, CURR BIOL, V18, P1639, DOI 10.1016/j.cub.2008.09.063; Li ZX, 2012, MOL CARCINOGEN, V51, P522, DOI 10.1002/mc.20815; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malet-Engra G, 2013, CANCER RES, V73, P3412, DOI 10.1158/0008-5472.CAN-12-3564; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; Rosell R, 2010, CLIN TRANSL ONCOL, V12, P75, DOI 10.1007/S12094-010-0473-0; Rusch V, 1997, CLIN CANCER RES, V3, P515; Saengsawang W, 2013, J CELL SCI, V126, P2411, DOI 10.1242/jcs.117473; Saengsawang W, 2012, CURR BIOL, V22, P494, DOI 10.1016/j.cub.2012.01.038; Shimada A, 2007, CELL, V129, P761, DOI 10.1016/j.cell.2007.03.040; Takano K, 2008, EMBO J, V27, P2817, DOI 10.1038/emboj.2008.216; Taylor MJ, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000604; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Tsuji E, 2006, BIOCHEM BIOPH RES CO, V339, P1083, DOI 10.1016/j.bbrc.2005.11.117; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; Yang MM, 2013, INT J CANCER, V132, pE74, DOI 10.1002/ijc.27813; Zhang J, 2013, RENAL FAILURE, V35, P989, DOI 10.3109/0886022X.2013.808957; Zhao M, 2002, FASEB J, V16, P857, DOI 10.1096/fj.01-0811fje; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	44	20	20	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3527	3535		10.1038/onc.2014.280	http://dx.doi.org/10.1038/onc.2014.280			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25174397	Green Accepted, Bronze			2022-12-28	WOS:000357434900005
J	Czarnecka, M; Trinh, E; Lu, C; Kuan-Celarier, A; Galli, S; Hong, SH; Tilan, JU; Talisman, N; Izycka-Swieszewska, E; Tsuei, J; Yang, C; Martin, S; Horton, M; Christian, D; Everhart, L; Maheswaran, I; Kitlinska, J				Czarnecka, M.; Trinh, E.; Lu, C.; Kuan-Celarier, A.; Galli, S.; Hong, S-H; Tilan, J. U.; Talisman, N.; Izycka-Swieszewska, E.; Tsuei, J.; Yang, C.; Martin, S.; Horton, M.; Christian, D.; Everhart, L.; Maheswaran, I.; Kitlinska, J.			Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance	ONCOGENE			English	Article							NEUROTROPHIC FACTOR ACTIVATION; G-PROTEIN; MEDIATED NEUROPROTECTION; TYROSINE KINASES; EWING SARCOMA; IN-VIVO; BRAIN; EXPRESSION; CELLS; TRKB	Neuroblastoma (NB) is a pediatric tumor of neural crest origin with heterogeneous phenotypes. Although low-stage tumors carry a favorable prognosis, >50% of high-risk NB relapses after treatment with a fatal outcome. Thus developing therapies targeting refractory NB remains an unsolved clinical problem. Brain-derived neurotrophic factor (BDNF) and its TrkB receptor are known to protect NB cells from chemotherapy-induced cell death, while neuropeptide Y (NPY), acting via its Y2 receptor (Y2R), is an autocrine proliferative and angiogenic factor crucial for maintaining NB tumor growth. Here we show that in NB cells, BDNF stimulates the synthesis of NPY and induces expression of another one of its receptors, Y5R. In human NB tissues, the expression of NPY and Y5R positively correlated with the expression of BDNF and TrkB. Functionally, BDNF triggered Y5R internalization in NB cells, whereas Y5R antagonist inhibited BDNF-induced p44/42 mitogen-activated protein kinase activation and its pro-survival activity. These observations suggested TrkB-Y5R transactivation that resulted in cross-talk between their signaling pathways. Additionally, NPY and Y5R were upregulated in a BDNF-independent manner in NB cells under pro-apoptotic conditions, such as serum deprivation and chemotherapy, as well as in cell lines and tissues derived from posttreatment NB tumors. Blocking Y5R in chemoresistant NB cells rich in this receptor sensitized them to chemotherapy-induced apoptosis and inhibited their growth in vivo by augmenting cell death. In summary, the NPY/Y5R axis is an inducible survival pathway activated in NB by BDNF or cellular stress. Upon such activation, Y5R augments the pro-survival effect of BDNF via its interactions with TrkB receptor and exerts an additional BDNF-independent anti-apoptotic effect, both of which contribute to NB chemoresistance. Therefore, the NPY/Y5R pathway may become a novel therapeutic target for patients with refractory NB, thus far an incurable form of this disease.	[Czarnecka, M.; Trinh, E.; Kuan-Celarier, A.; Galli, S.; Talisman, N.; Tsuei, J.; Yang, C.; Everhart, L.; Maheswaran, I.; Kitlinska, J.] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA; [Lu, C.] MIT, McGovern Inst, Boston, MA USA; [Hong, S-H] Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Tilan, J. U.] Georgetown Univ, Dept Nursing, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; [Tilan, J. U.; Martin, S.; Horton, M.; Christian, D.] Georgetown Univ, Dept Human Sci, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; [Izycka-Swieszewska, E.] Med Univ Gdansk, Dept Pathol & Neuropathol, Gdansk, Poland	Georgetown University; Massachusetts Institute of Technology (MIT); Georgetown University; Georgetown University; Georgetown University; Fahrenheit Universities; Medical University Gdansk	Kitlinska, J (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, 3900 Reservoir,Basic Sci Bldg,Room 231A, Washington, DC 20057 USA.	jbk4@georgetown.edu	Izycka-Swieszewska, Ewa/AAX-5191-2020	izycka-swieszewska, ewa/0000-0001-7550-1326	National Institutes of Health grants from National Center for Advancing Translational Sciences (NCATS) through the Clinical and Translational Science Awards Program (CTSA) [UL1RR031975, 1R01CA123211, 1R03CA178809, UL1TR000101]; Children's Cancer Foundation (Baltimore, MD, USA); NIH/NCI grant [P30-CA051008]; Georgetown Undergraduate Research Opportunities Program; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA123211, R03CA178809] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000101] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR031975] Funding Source: NIH RePORTER	National Institutes of Health grants from National Center for Advancing Translational Sciences (NCATS) through the Clinical and Translational Science Awards Program (CTSA); Children's Cancer Foundation (Baltimore, MD, USA); NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgetown Undergraduate Research Opportunities Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Human NB samples at diagnosis were provided by the Children's Oncology Group. We thank Dr Garret Brodeur for providing SY5Y/TrkB transfectants. This work was supported by the National Institutes of Health grants: UL1TR000101 (previously UL1RR031975) from the National Center for Advancing Translational Sciences (NCATS), through the Clinical and Translational Science Awards Program (CTSA), 1R01CA123211 and 1R03CA178809 to JK, as well as funding from Children's Cancer Foundation (Baltimore, MD, USA) to JK, and Georgetown Undergraduate Research Opportunities Program to MH and DC. Experiments were performed with use of the Lombardi Comprehensive Cancer Center Shared Resources (Histopathology and Tissue, Biostatistics and Bioinformatics, Microscopy and Imaging, Animal Model and Tissue Culture) partially supported by the NIH/NCI grant P30-CA051008. We thank Dr Aykut Oren, Dr Ruijun Han and Dr Kristi Graves for their critical reading of the manuscript.	Garcia-Sainz JA, 2010, EUR J PHARMACOL, V648, P1, DOI 10.1016/j.ejphar.2010.08.049; Barnea A, 2001, BRAIN RES, V919, P57, DOI 10.1016/S0006-8993(01)02999-7; Borroto-Escuela DO, 2011, IUBMB LIFE, V63, P463, DOI 10.1002/iub.473; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; COHEN PS, 1990, CANCER RES, V50, P6055; Decressac M, 2012, NEUROBIOL AGING, V33, P2125, DOI 10.1016/j.neurobiolaging.2011.06.018; Delcourt N, 2007, TRENDS PHARMACOL SCI, V28, P602, DOI 10.1016/j.tips.2007.09.007; Dotsch J, 1998, REGUL PEPTIDES, V75-6, P185, DOI 10.1016/S0167-0115(98)00067-6; Dudas J, 2011, ORAL ONCOL, V47, P98, DOI 10.1016/j.oraloncology.2010.11.002; Erondu N, 2006, CELL METAB, V4, P275, DOI 10.1016/j.cmet.2006.08.002; Erondu N, 2007, OBESITY, V15, P895, DOI 10.1038/oby.2007.620; Flajolet M, 2008, NAT NEUROSCI, V11, P1402, DOI 10.1038/nn.2216; Gehlert DR, 2007, BIOCHEM PHARMACOL, V74, P1652, DOI 10.1016/j.bcp.2007.08.017; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601; Ho R, 2002, CANCER RES, V62, P6462; Jaboin J, 2003, CANCER LETT, V193, P109, DOI 10.1016/S0304-3835(02)00723-1; Jaboin J, 2002, CANCER RES, V62, P6756; Keshelava N, 1998, CANCER RES, V58, P5396; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Klocker N, 2000, J NEUROSCI, V20, P6962, DOI 10.1523/JNEUROSCI.20-18-06962.2000; KOGNER P, 1994, ACTA PAEDIATR, V83, P423, DOI 10.1111/j.1651-2227.1994.tb18134.x; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Lee FS, 2002, CYTOKINE GROWTH F R, V13, P11, DOI 10.1016/S1359-6101(01)00024-7; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Lu C, 2010, ONCOGENE, V29, P5630, DOI 10.1038/onc.2010.301; Lu CY, 2011, J BIOL CHEM, V286, P27494, DOI 10.1074/jbc.M111.224089; Malva JO, 2012, NEUROPEPTIDES, V46, P299, DOI 10.1016/j.npep.2012.09.001; Maris JM, 2005, CURR OPIN PEDIATR, V17, P7, DOI 10.1097/01.mop.0000150631.60571.89; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Movafagh S, 2006, FASEB J, V20, P1924, DOI 10.1096/fj.05-4770fje; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Nakagawara A, 1997, EUR J CANCER, V33, P2050, DOI 10.1016/S0959-8049(97)00280-3; Pandey SC, 2003, TRENDS PHARMACOL SCI, V24, P456, DOI 10.1016/S0165-6147(03)00226-8; Pedrazzini T, 2003, CELL MOL LIFE SCI, V60, P350, DOI 10.1007/s000180300029; Pellieux C, 2000, P NATL ACAD SCI USA, V97, P1595, DOI 10.1073/pnas.030533197; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Pons J, 2008, CAN J PHYSIOL PHARM, V86, P438, DOI [10.1139/Y08-054, 10.1139/y08-054]; Pyne NJ, 2003, BIOCHEM SOC T, V31, P1220; Rajagopal R, 2004, J NEUROSCI, V24, P6650, DOI 10.1523/JNEUROSCI.0010-04.2004; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; Reibel S, 2000, EUR J NEUROSCI, V12, P595, DOI 10.1046/j.1460-9568.2000.00941.x; Schramm A, 2005, CANCER LETT, V228, P143, DOI 10.1016/j.canlet.2005.02.051; Sheriff' S, 1998, REGUL PEPTIDES, V75-6, P309, DOI 10.1016/S0167-0115(98)00083-4; Sheriff S, 2010, MOL CANCER RES, V8, P604, DOI 10.1158/1541-7786.MCR-09-0301; Skaper SD, 1998, J NEUROCHEM, V70, P1859, DOI 10.1046/j.1471-4159.1998.70051859.x; Takei N, 1996, MOL BRAIN RES, V37, P283; Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651; Tilan JU, 2013, ONCOTARGET, V4, P2487, DOI 10.18632/oncotarget.1604; Tilan JU, 2013, FASEB J, V27, P2244, DOI 10.1096/fj.12-213546; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Wilhelm JC, 2012, J NEUROSCI, V32, P5002, DOI 10.1523/JNEUROSCI.1411-11.2012; Williams AG, 1998, BIOCHEM J, V333, P505, DOI 10.1042/bj3330505; Wirth MJ, 2005, P NATL ACAD SCI USA, V102, P3064, DOI 10.1073/pnas.0404712102; Xapelli S, 2008, EUR J NEUROSCI, V27, P2089, DOI 10.1111/j.1460-9568.2008.06172.x; Yoshimura R, 2009, NEUROSCI LETT, V450, P262, DOI 10.1016/j.neulet.2008.12.010; Zeine R, 2009, MODERN PATHOL, V22, P950, DOI 10.1038/modpathol.2009.52	64	14	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3131	3143		10.1038/onc.2014.253	http://dx.doi.org/10.1038/onc.2014.253			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25132261	Green Accepted			2022-12-28	WOS:000356101100005
J	Mungamuri, S; Wang, S; Manfredi, JJ; Gu, W; Aaronson, SA				Mungamuri, S. K.; Wang, S.; Manfredi, J. J.; Gu, W.; Aaronson, S. A.			Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters	ONCOGENE			English	Article							RNA-POLYMERASE-II; HISTONE H3; STRUCTURAL BASIS; P53; METHYLATION; ACTIVATION; CHROMATIN; TFIIB; SET1; DNA	Chromatin conformation has a major role in all cellular decisions. We showed previously that P53 pro-apoptotic target promoters are enriched with H3K9me3 mark and induction of P53 abrogates this repressive chromatin conformation by downregulating SUV39H1, the writer of this mark present on these promoters. In the present study, we demonstrate that in response to P53 stabilization, its pro-apoptotic target promoters become enriched with the H3K4me3 epigenetic mark as well as its readers, Wdr5, RbBP5 and Ash2L, which were not observed in response to SUV39H1 downregulation alone. Overexpression of Ash2L enhanced P53-dependent apoptosis in response to chemotherapy, associated with increased P53 pro-apoptotic gene promoter occupancy and target gene expression. In contrast, pre-silencing of Ash2L abrogated P53's ability to induce the expression of these transcriptional targets, without affecting P53 or RNAP II recruitment. However, Ash2L pre-silencing, under the same conditions, resulted in reduced RNAP II ser5-CTD phosphorylation on these same pro-apoptotic target promoters, which correlated with reduced promoter occupancy of TFIIB as well as TFIIF (RAP74). Based on these findings, we propose that Ash2L acts in concert with P53 promoter occupancy to activate RNAP II by aiding formation of a stable transcription pre-initiation complex required for its activation.	[Mungamuri, S. K.; Manfredi, J. J.; Aaronson, S. A.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Wang, S.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Gu, W.] Columbia Univ, Dept Pathol & Cell Biol, Coll Phys & Surg, Inst Canc Genet, New York, NY USA	Icahn School of Medicine at Mount Sinai; University of Michigan System; University of Michigan; Columbia University	Aaronson, SA (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu		Mungamuri, Sathish Kumar/0000-0002-0012-5298; Wang, Shaomeng/0000-0002-8782-6950; Manfredi, James/0000-0003-2234-9097	National Cancer Institute [P01CA080058]; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P01CA080058] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank SW Lee (MGH, Harvard) for helpful discussions. This research was supported by grants from the National Cancer Institute (P01CA080058) and Breast Cancer Research Foundation (SAA). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the US National Institutes of Health.	Ardehali MB, 2011, EMBO J, V30, P2817, DOI 10.1038/emboj.2011.194; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bartkowiak B, 2011, TRANSCR-AUSTIN, V2, P115, DOI 10.4161/trns.2.3.15004; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Cabart P, 2011, P NATL ACAD SCI USA, V108, P15786, DOI 10.1073/pnas.1104591108; Deng WS, 2007, CHROMOSOMA, V116, P417, DOI 10.1007/s00412-007-0113-9; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008; Egloff S, 2012, TRENDS GENET, V28, P333, DOI 10.1016/j.tig.2012.03.007; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fu Y, 2009, CURR MED CHEM, V16, P3966, DOI 10.2174/092986709789352277; Gomes NP, 2010, GENE DEV, V24, P111, DOI 10.1101/gad.1893610; Goodman RH, 2000, GENE DEV, V14, P1553; Grewal SIS, 2007, NATURE, V447, P399, DOI 10.1038/nature05914; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Han ZF, 2006, MOL CELL, V22, P137, DOI 10.1016/j.molcel.2006.03.018; Hosoda H, 2011, CYTOTECHNOLOGY, V63, P211, DOI 10.1007/s10616-011-9335-z; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kasper LH, 2010, EMBO J, V29, P3660, DOI 10.1038/emboj.2010.235; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052; Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Patel A, 2009, J BIOL CHEM, V284, P24242, DOI 10.1074/jbc.M109.014498; Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Schmid CD, 2007, CELL, V131, P831, DOI 10.1016/j.cell.2007.11.017; Shandilya J, 2012, P NATL ACAD SCI USA, V109, P18797, DOI 10.1073/pnas.1207483109; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Sims RJ, 2011, SCIENCE, V332, P99, DOI 10.1126/science.1202663; Southall SM, 2009, MOL CELL, V33, P181, DOI 10.1016/j.molcel.2008.12.029; Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Trievel RC, 2009, NAT STRUCT MOL BIOL, V16, P678, DOI 10.1038/nsmb0709-678; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vermeulen M, 2010, EPIGENOMICS-UK, V2, P395, DOI 10.2217/EPI.10.11; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang YM, 2010, CURR BIOL, V20, P548, DOI 10.1016/j.cub.2010.01.052; Zhang DW, 2012, GENET RES INT, V2012, DOI 10.1155/2012/347214; Zheng H, 2014, ONCOGENE, V33, P734, DOI 10.1038/onc.2013.6	61	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2461	2470		10.1038/onc.2014.198	http://dx.doi.org/10.1038/onc.2014.198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	25023704	Green Accepted			2022-12-28	WOS:000354190400005
J	Chou, SD; Murshid, A; Eguchi, T; Gong, J; Calderwood, SK				Chou, S-D; Murshid, A.; Eguchi, T.; Gong, J.; Calderwood, S. K.			HSF1 regulation of beta-catenin in mammary cancer cells through control of HuR/elavL1 expression	ONCOGENE			English	Article							HEAT-SHOCK FACTOR-1; TRANSCRIPTION FACTOR HSF1; RNA STABILITY FACTOR; RICH ELEMENTS; STEM-CELLS; PHOSPHORYLATION; BINDING; HUR; ACTIVATION; PROTEINS	There is now compelling evidence to indicate a place for heat shock factor 1 (HSF1) in mammary carcinogenesis, tumour progression and metastasis. Here we have investigated a role for HSF1 in regulating the expression of the stem cell renewal factor beta-catenin in immortalized human mammary epithelial and carcinoma cells. We found HSF1 to be involved in regulating the translation of beta-catenin, by investigating effects of gain and loss of HSF1 on this protein. Interestingly, although HSF1 is a potent transcription factor, it was not directly involved in regulating levels of beta-catenin mRNA. Instead, our data suggest a complex role in translational regulation. HSF1 was shown to regulate levels of the RNA-binding protein HuR that controlled beta-catenin translation. An extra complexity was added to this scenario when it was shown that the long non-coding RNA molecule lincRNA-p21, known to be involved in beta-catenin mRNA (CTNNB1) translational regulation, was controlled by HSF1 repression. We have shown previously that HSF1 was positively regulated through phosphorylation by mammalian target of rapamycin (mTOR) kinase on a key residue, serine 326, essential for transcriptional activity. In this study, we found that mTOR knockdown not only decreased HSF1-S326 phosphorylation in mammary cells, but also decreased beta-catenin expression through a mechanism requiring HuR. Our data point to a complex role for HSF1 in the regulation of HuR and beta-catenin expression that may be significant in mammary carcinogenesis.	[Chou, S-D; Murshid, A.; Eguchi, T.; Calderwood, S. K.] Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, Boston, MA 02215 USA; [Gong, J.] Boston Univ, Med Ctr, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, 21-27 Burlington Ave,99 Brookline Ave, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu		Eguchi, Takanori/0000-0002-3297-6126	NIH [RO-1CA047407, R01CA119045, RO-1CA094397]; NATIONAL CANCER INSTITUTE [R01CA094397, R01CA176326, R01CA119045, R01CA047407] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Department of Radiation Oncology, Beth Israel Deaconess Medical Center for support and encouragement. We are very grateful for help with construct preparation from Dr Tom Prince. This work was supported by NIH research grants RO-1CA047407, R01CA119045 and RO-1CA094397.	Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Calderwood SK, 2012, CURR MOL MED, V12, P1102, DOI 10.2174/156652412803306675; Calderwood SK, 2012, J CELL BIOCHEM, V113, P1096, DOI 10.1002/jcb.23461; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Jin XJ, 2011, CELL METAB, V14, P91, DOI 10.1016/j.cmet.2011.03.025; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Kim G, 2012, AGING CELL, V11, P617, DOI 10.1111/j.1474-9726.2012.00827.x; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Metcalfe C, 2011, J CELL SCI, V124, P3537, DOI 10.1242/jcs.091991; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Murshid A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013830; Nabors LB, 2001, CANCER RES, V61, P2154; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921; Su J, 2012, INT J ONCOL, V40, P1162, DOI 10.3892/ijo.2011.1322; Veronese A, 2011, P NATL ACAD SCI USA, V108, P4840, DOI 10.1073/pnas.1101734108; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Weng DS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3102; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028950	47	69	70	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2178	2188		10.1038/onc.2014.177	http://dx.doi.org/10.1038/onc.2014.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24954509	Green Accepted, Green Submitted			2022-12-28	WOS:000353473000004
J	Kundu, ST; Byers, LA; Peng, DH; Roybal, JD; Diao, L; Wang, J; Tong, P; Creighton, CJ; Gibbons, DL				Kundu, S. T.; Byers, L. A.; Peng, D. H.; Roybal, J. D.; Diao, L.; Wang, J.; Tong, P.; Creighton, C. J.; Gibbons, D. L.			The miR-200 family and the miR-183 similar to 96 similar to 182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; TRANSCRIPTIONAL REPRESSOR; DOWN-REGULATION; CELL-SURVIVAL; FEEDBACK LOOP; BOX PROTEINS; MICRORNAS; ZEB1; EMT	Metastatic lung cancer is one of the most lethal forms of cancer and molecular pathways driving metastasis are still not clearly elucidated. Metastatic cancer cells undergo an epithelial-mesenchymal transition (EMT) where they lose their epithelial properties and acquire a migratory and invasive phenotype. Here we identify that the expression of microRNAs from the miR-200 family and the miR-183 similar to 96 similar to 182 cluster are significantly co-repressed in non-small cell lung cancer cell lines and primary tumors from multiple TCGA dataset with high EMT scores. Ectopic expression of the miR-183 similar to 96 similar to 182 cluster inhibited cancer cell migration and invasion, whereas its expression was tightly modulated by miR-200. We identified Foxf2 as a common, novel and direct target of both these microRNA families. Foxf2 expression tightly correlates with the transcription factor Zeb1 and is elevated in mesenchymal-like metastatic lung cancer cells. Foxf2 expression induced robust EMT, migration, invasion and metastasis in lung cancer cells, whereas Foxf2 inhibition significantly repressed these phenotypes. We also demonstrated that Foxf2 transcriptionally represses E-cadherin and miR-200, independent of Zeb1, to form a double-negative feedback loop. We, therefore, identified a novel mechanism whereby the miR-200 family and the miR-183 similar to 96 similar to 182 cluster inhibit lung cancer invasion and metastasis by targeting Foxf2.	[Kundu, S. T.; Byers, L. A.; Peng, D. H.; Roybal, J. D.; Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Diao, L.; Wang, J.; Tong, P.; Creighton, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Houston, TX 77030 USA; [Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432,Room FC9-2038, Houston, TX 77030 USA.	dlgibbon@mdanderson.org		Peng, David/0000-0003-0511-1888; Kundu, Samrat/0000-0002-0117-6986	NCI [K08 CA151661, CA125123]; MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer; CDMRP Lung Cancer Research Program [W81XWH-12-10294]; CPRIT Graduate Scholar Training Grant [RP140106]; Lung SPORE [P50 CA070907]; Cancer Center Support Grant [CCSG CA016672]; Mary K. Chapman Foundation; CPRIT [RP120713]; Jeane F. Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE [P30CA125123, K08CA151651, P30CA016672, P50CA070907] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer; CDMRP Lung Cancer Research Program; CPRIT Graduate Scholar Training Grant; Lung SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; Mary K. Chapman Foundation; CPRIT; Jeane F. Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J. Larner (University of Virginia Health System, VA) for the kind gift of the pTRIPZ-GFP vector. We thank Dr G. Goodall (University of Adelaide, Australia) for the kind gift of the miR-200 promoter reporter construct. 16 This work was supported by NCI K08 CA151661 (DLG), an MD Anderson Cancer Center Physician Scientist Award (DLG), Rexanna's Foundation for Fighting Lung Cancer (DLG), a CDMRP Lung Cancer Research Program award W81XWH-12-10294 (DLG and STK). DP was supported by a CPRIT Graduate Scholar Training Grant (RP140106). LD, JW, PT are supported by Lung SPORE (P50 CA070907), Cancer Center Support Grant (CCSG CA016672) and Mary K. Chapman Foundation. CJC was supported by CPRIT grant RP120713 and NCI grant CA125123. DLG and LAB are R. Lee Clark Fellows of the University of Texas MD Anderson Cancer Center, supported by the Jeane F. Shelby Scholarship Fund. We would like to thank members of the Gibbons lab for the assistance and critical reading of the manuscript.	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Browne G, 2010, CELL CYCLE, V9, P886, DOI 10.4161/cc.9.5.10839; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Feng Xiangling, 2014, Cancer Lett, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hirata H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055502; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Huynh C, 2011, ONCOGENE, V30, P1481, DOI 10.1038/onc.2010.523; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Katoh M, 2013, CANCER LETT, V328, P198, DOI 10.1016/j.canlet.2012.09.017; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Knouf EC, 2012, NUCLEIC ACIDS RES, V40, P499, DOI 10.1093/nar/gkr731; Kong PZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061591; Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Lei R, 2014, ONCOGENE, V33, P1287, DOI 10.1038/onc.2013.65; Li GR, 2010, J BIOL CHEM, V285, P5461, DOI 10.1074/jbc.M109.037127; Li XL, 2014, MOL CELL BIOL, V34, P533, DOI 10.1128/MCB.01043-13; Liu XG, 2012, MED ONCOL, V29, P618, DOI 10.1007/s12032-011-9923-y; Lo PK, 2013, EXP MOL PATHOL, V94, P262, DOI 10.1016/j.yexmp.2012.10.014; Lowery AJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-502; Mizuguchi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032449; Nik AM, 2013, GASTROENTEROLOGY, V144, P1001, DOI 10.1053/j.gastro.2013.01.045; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252; Pacurari M, 2013, INT J ONCOL, V43, P548, DOI 10.3892/ijo.2013.1963; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pieraccioli M, 2013, CELL CYCLE, V12, P2309, DOI 10.4161/cc.25405; Roy SS, 2014, ONCOGENE, V33, P3707, DOI 10.1038/onc.2013.332; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wang T, 2003, DEV BIOL, V259, P83, DOI 10.1016/S0012-1606(03)00176-3; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Weeraratne SD, 2012, ACTA NEUROPATHOL, V123, P539, DOI 10.1007/s00401-012-0969-5; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Zhao HE, 2012, INT J MOL MED, V30, P1013, DOI 10.3892/ijmm.2012.1111; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493; Zhu JF, 2012, AM J PATHOL, V180, P2440, DOI 10.1016/j.ajpath.2012.02.023	76	92	97	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					173	186		10.1038/onc.2015.71	http://dx.doi.org/10.1038/onc.2015.71			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25798833	Green Accepted			2022-12-28	WOS:000368193900004
J	Zhu, G; Fan, Z; Ding, M; Zhang, H; Mu, L; Ding, Y; Zhang, Y; Jia, B; Chen, L; Chang, Z; Wu, W				Zhu, G.; Fan, Z.; Ding, M.; Zhang, H.; Mu, L.; Ding, Y.; Zhang, Y.; Jia, B.; Chen, L.; Chang, Z.; Wu, W.			An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis	ONCOGENE			English	Article							EXCHANGE FACTOR TIAM1; RAC ACTIVATOR TIAM1; GROWTH-FACTOR; RHO-GTPASES; 14-3-3 PROTEINS; BREAST-CANCER; MOLECULAR-BASIS; INVASION; KINASES; GEF	Epidermal growth factor receptor (EGFR) signaling regulates cell growth and survival, and its overactivation drives cancer development. One important branch of EGFR signaling is through activation of GTPase Rac1, which further promotes cell proliferation, survival and cancer metastasis. Here, we show that EGFR activates Rac1 via inducing the accumulation of its specific guanine nucleotide exchange factor, T-cell lymphoma invasion and metastasis 1 (Tiam1) in non-small-cell lung cancer and colon cancer cells. Conversely, elevated Tiam1 is required for EGFR-induced tumorigenesis. In human lung adenocarcinoma and colon cancer specimens, Tiam1 expression strongly correlates with EGFR expression. We further reveal that AKT, a key downstream protein kinase of EGFR, phosphorylates Tiam1 at several consensus sites, facilitates the interaction of Tiam1 with scaffold proteins 14-3-3 and leads to an increase of Tiam1 stability. Subsequently, Tiam1 is dephosporylated and destabilized by PP2A. Together, our study identifies a bidirectional (phosphorylation and dephosphorylation) regulatory mechanism controlling Tiam1 stability and provides new insights on how EGFR signaling triggers Rac1 activation and cancer development.	[Zhu, G.; Fan, Z.; Mu, L.; Ding, Y.; Wu, W.] Tsinghua Univ, Sch Life Sci, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China; [Zhu, G.] Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China; [Ding, M.] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; [Zhang, H.; Mu, L.; Chen, L.] Natl Inst Biol Sci, Beijing, Peoples R China; [Zhang, Y.; Chang, Z.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing 100084, Peoples R China; [Jia, B.] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China; [Jia, B.] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China	Tsinghua University; Tsinghua University; Peking University; National Institute of Biological Sciences, Beijing; Tsinghua University; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Wu, W (corresponding author), Tsinghua Univ, Sch Life Sci, Qinghuayuan 1, Beijing 100084, Peoples R China.	wwu@mail.tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019; Zhang, Yanquan/D-5615-2017	Zhang, Yanquan/0000-0003-3527-9972; Chen, Liang/0000-0001-7300-6604	National Natural Science Foundation of China [31221064, 81272235]; Tsinghua-Peking Center for Life Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tsinghua-Peking Center for Life Sciences	We thank Drs Ye-Guang Chen, John G. Collard, Chuanmao Zhang, Joseph R Testa and Yigong Shi for providing plasmids and reagents. We are grateful for Dr Haiteng Deng and Jieyuan Liu for mass spectrometry analysis. This work was supported by grants to WW from the National Natural Science Foundation of China (31221064 and 81272235). GZ is a postdoctoral fellow supported by Tsinghua-Peking Center for Life Sciences.	Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Arai A, 2005, CELL SIGNAL, V17, P497, DOI 10.1016/j.cellsig.2004.09.007; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Caporali S, 2008, MOL PHARMACOL, V74, P173, DOI 10.1124/mol.107.044743; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dise RS, 2008, AM J PHYSIOL-GASTR L, V294, pG276, DOI 10.1152/ajpgi.00340.2007; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Habas R, 2006, METHOD ENZYMOL, V406, P500, DOI 10.1016/S0076-6879(06)06038-1; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hofbauer SW, 2014, BLOOD, V123, P2181, DOI 10.1182/blood-2013-08-523563; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Itoh RE, 2008, J CELL SCI, V121, P2635, DOI 10.1242/jcs.028647; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Karpel-Massler G, 2013, MOL CANCER THER, V12, P1783, DOI 10.1158/1535-7163.MCT-13-0052; Kobayashi H, 2011, J BIOL CHEM, V286, P39259, DOI 10.1074/jbc.M111.255489; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Minard ME, 2006, CLIN EXP METASTAS, V23, P301, DOI 10.1007/s10585-006-9040-z; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; O'Toole TE, 2011, J CELL PHYSIOL, V226, P2965, DOI 10.1002/jcp.22644; Palamidessi A, 2008, CELL, V134, P135, DOI 10.1016/j.cell.2008.05.034; Ramis G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038770; Santos GD, 2011, ANNU REV PATHOL-MECH, V6, P49, DOI 10.1146/annurev-pathol-011110-130206; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Steiner P, 2007, CLIN CANCER RES, V13, P1540, DOI 10.1158/1078-0432.CCR-06-1887; Strumane K, 2009, J CANCER RES CLIN, V135, P69, DOI 10.1007/s00432-008-0437-8; Su XN, 2014, GENE DEV, V28, P622, DOI 10.1101/gad.233239.113; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Viaud J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5080; Vlacich G, 2011, CANCER CELL, V20, P423, DOI 10.1016/j.ccr.2011.10.006; Wang L, 2013, J CELL SCI, V126, P1531, DOI 10.1242/jcs.124255; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Woodcock SA, 2009, J PROTEOME RES, V8, P5629, DOI 10.1021/pr900716e; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Zhu G, 2012, ONCOGENE, V31, P1001, DOI 10.1038/onc.2011.294; Zhu GX, 2014, J BIOL CHEM, V289, P15482, DOI 10.1074/jbc.M114.553388	61	63	64	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5971	5982		10.1038/onc.2015.45	http://dx.doi.org/10.1038/onc.2015.45			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25746002				2022-12-28	WOS:000366113500004
J	Liu, Y; Ye, X; Zhang, JB; Ouyang, H; Shen, Z; Wu, Y; Wang, W; Wu, J; Tao, S; Yang, X; Qiao, K; Zhang, J; Liu, J; Fu, Q; Xie, Y				Liu, Y.; Ye, X.; Zhang, J-B; Ouyang, H.; Shen, Z.; Wu, Y.; Wang, W.; Wu, J.; Tao, S.; Yang, X.; Qiao, K.; Zhang, J.; Liu, J.; Fu, Q.; Xie, Y.			PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing beta-catenin expression and nuclear translocation	ONCOGENE			English	Article							CELL-PROLIFERATION; GENE; LIVER; TRANSCRIPTION; GROWTH; METASTASIS; MODULATION; MUTATIONS; SURVIVAL; PROTEIN	Aberrant activation of the Wnt/beta-catenin pathway is frequent in hepatocellular carcinoma (HCC) and contributes to HCC initiation and progression. This abnormal activation may result from somatic mutations in the genes of the Wnt/beta-catenin pathway and/or dysregulation of the Wnt/beta-catenin pathway. The mechanism for the latter remains poorly understood. Prospero-related homeobox 1 (PROX1) is a downstream target of the Wnt/beta-catenin pathway in human colorectal cancer and elevated PROX1 expression promotes malignant progression. However, the Wnt/beta-catenin pathway does not regulate PROX1 expression in the liver and HCC cells. Here we report that PROX1 promotes HCC cell proliferation in vitro and tumor growth in HCC xenograft mice. PROX1 and beta-catenin levels are positively correlated in tumor tissues as well as in cultured HCC cells. PROX1 can upregulate beta-catenin transcription by stimulating the beta-catenin promoter and enhance the nuclear translocation of beta-catenin in HCC cells, which leads to the activation of the Wnt/beta-catenin pathway. Moreover, we show that increase in PROX1 expression renders HCC cells more resistant to sorafenib treatment, which is the standard therapy for advanced HCC. Overall, we have pinpointed PROX1 as a critical factor activating the Wnt/beta-catenin pathway in HCC, which promotes HCC proliferation and sorafenib resistance.	[Liu, Y.; Ye, X.; Ouyang, H.; Shen, Z.; Wu, Y.; Wang, W.; Wu, J.; Tao, S.; Yang, X.; Qiao, K.; Zhang, J.; Liu, J.; Fu, Q.; Xie, Y.] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Key Lab Med Mol Virol MOE, Shanghai 200032, Peoples R China; [Liu, Y.; Ye, X.; Ouyang, H.; Shen, Z.; Wu, Y.; Wang, W.; Wu, J.; Tao, S.; Yang, X.; Qiao, K.; Zhang, J.; Liu, J.; Fu, Q.; Xie, Y.] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, MOH, Shanghai 200032, Peoples R China; [Liu, Y.] Fudan Univ, Dept Surg, Huashan Hosp, Shanghai 200032, Peoples R China; [Zhang, J-B] Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China; [Zhang, J-B] Fudan Univ, Key Lab Carcinogenesis & Canc Invas MOE, Shanghai 200032, Peoples R China; [Ouyang, H.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Fu, Q.] Binzhou Med Univ, Dept Immunol, Yantai 264003, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Binzhou Medical University	Liu, J (corresponding author), Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Key Lab Med Mol Virol MOE, Yixueyuan Rd 138, Shanghai 200032, Peoples R China.	liujing212@fudan.edu.cn; qiangfu11@fudan.edu.cn; yhxie@fudan.edu.cn			National Key Project for Infectious Diseases [2012ZX10002-006, 2012ZX10004-503, 2012ZX10002012-003]; National Basic Research Program [2012CB519002]; Natural Science Foundation of China [31071143, 31170148, 81472226, 81372654, 81370730]; Shanghai Municipal Health Committee [GWDTR201216]; Nature Science Foundation from Shandong province [ZR2011HQ006]; Municipal Science and Technology Committee [13ZR1407100]	National Key Project for Infectious Diseases; National Basic Research Program(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Health Committee; Nature Science Foundation from Shandong province; Municipal Science and Technology Committee	We thank Prof RH Dashwood of Oregon State University and Prof Long Yu of Fudan University for kindly providing the beta-catenin promoter luciferase reporters. This work is supported by the grants from the National Key Project for Infectious Diseases (2012ZX10002-006, 2012ZX10004-503, 2012ZX10002012-003), National Basic Research Program (2012CB519002), Natural Science Foundation of China (31071143, 31170148, 81472226, 81372654 and 81370730), Shanghai Municipal Health Committee (GWDTR201216), Nature Science Foundation from Shandong province (ZR2011HQ006) and Municipal Science and Technology Committee (13ZR1407100).	Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Burke Z, 2002, MECH DEVELOP, V118, P147, DOI 10.1016/S0925-4773(02)00240-X; Chai H, 2010, INT J CLIN EXP PATHO, V3, P408; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cui J, 2001, J CANCER RES CLIN, V127, P577, DOI 10.1007/s004320100259; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Elsir T, 2012, CANCER METAST REV, V31, P793, DOI 10.1007/s10555-012-9390-8; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Guigon CJ, 2010, ENDOCRINOLOGY, V151, P5528, DOI 10.1210/en.2010-0475; Han L, 2010, BRAIN RES, V1366, P9, DOI 10.1016/j.brainres.2010.09.097; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Iyer R, 2010, EXPERT OPIN PHARMACO, V11, P1943, DOI 10.1517/14656566.2010.496453; Kaltezioti V, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000565; Kamiya A, 2008, HEPATOLOGY, V48, P252, DOI 10.1002/hep.22303; Karalay O, 2011, P NATL ACAD SCI USA, V108, P5807, DOI 10.1073/pnas.1013456108; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lachenmayer A, 2012, CLIN CANCER RES, V18, P4997, DOI 10.1158/1078-0432.CCR-11-2322; Lai TY, 2011, ONCOL REP, V26, P415, DOI 10.3892/or.2011.1323; Lavado A, 2007, DEV DYNAM, V236, P518, DOI 10.1002/dvdy.21024; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Liu GY, 2012, HEPATOLOGY, V55, P1830, DOI 10.1002/hep.25564; Liu YF, 2013, HEPATOLOGY, V58, P692, DOI 10.1002/hep.26398; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ouyang HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062192; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Qin J, 2004, MOL ENDOCRINOL, V18, P2424, DOI 10.1210/me.2004-0009; Riazi AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005698; Risebro CA, 2009, DEVELOPMENT, V136, P495, DOI 10.1242/dev.030007; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Song KH, 2006, J BIOL CHEM, V281, P10081, DOI 10.1074/jbc.M513420200; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhu XD, 2008, J CLIN ONCOL, V26, P2707, DOI 10.1200/JCO.2007.15.6521	34	50	51	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5524	5535		10.1038/onc.2015.7	http://dx.doi.org/10.1038/onc.2015.7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25684142				2022-12-28	WOS:000364594000002
J	Gomes, LR; Vessoni, AT; Menck, CFM				Gomes, L. R.; Vessoni, A. T.; Menck, C. F. M.			Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy	ONCOGENE			English	Article							BREAST-CANCER; CULTURE MODELS; DNA-DAMAGE; CELLS; INHIBITION; P53; EPIRUBICIN; MECHANISMS; APOPTOSIS; SUBTYPES	Preclinical studies of anticancer drugs are typically performed using cancer cell lines maintained in two-dimensional (2D) cultures, ignoring the influences of the extracellular matrix (ECM) and three-dimensional (3D) microenvironment. In this study, we evaluated the microenvironmental control of human breast cancer cells responses to doxorubicin (DOXO) using the 3D laminin-rich ECM (3D lrECM) cell culture model. Under 3D culture conditions, MCF-7 cells displayed drastic morphological alterations, a decrease in proliferation and elevated sensitivity to DOXO. Interestingly, the chemotherapy-mediated activation of autophagy was compromised in the 3D matrix, suggesting an association between the increased cytotoxicity of DOXO and hindered autophagy induction. Indeed, while chloroquine or ATG5 knockdown potentiated DOXO-induced cell death under the 2D culture conditions, the autophagy inducer rapamycin improved the resistance of 3D-cultured cells to this drug. Moreover, in the monolayer-cultured cells, DOXO treatment led to increases in p53 and DRAM-1 expression, which is a p53-dependent activator of autophagy that functions in response to DNA damage. Conversely, p53 and DRAM-1 expression was impaired in 3D-cultured cells. The knockdown of p53 by shRNA blocked DRAM-1 activation, impaired autophagy induction and sensitized only those cells maintained under 2D conditions to DOXO. In addition, 2D-cultured MDA-MB-231 cells (a p53-mutated breast cancer cell line) not only showed increased sensitivity to DOXO compared with MCF-7 cells but also failed to induce DRAM-1 expression or autophagy. Similar to p53 silencing, DRAM-1 knockdown potentiated DOXO cytotoxicity only in 2D-cultured cells. These results suggest that the 3D tissue microenvironment controls tumor cell sensitivity to DOXO treatment by preventing p53-DRAM-autophagy axis activation.	[Gomes, L. R.; Vessoni, A. T.; Menck, C. F. M.] Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil	Universidade de Sao Paulo	Menck, CFM (corresponding author), Inst Ciencias Biomed 2, Ave Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.	cfmmenck@usp.br	Vessoni, Alexandre T/L-5754-2013; Menck, Carlos FM/G-6321-2011; Gomes, Luciana R/M-3056-2014	Vessoni, Alexandre T/0000-0001-9170-5185; Menck, Carlos FM/0000-0003-1941-0694; 	FAPESP (Sao Paulo, Brazil); CAPES; CNPq (Brasilia, Brazil)	FAPESP (Sao Paulo, Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq (Brasilia, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	We thank Professor Maria S. Solengas (Department of Dermatology, University of Michigan Comprehensive Cancer Center) for kindly providing the pEGFP-LC3 construct. We are grateful for the excellent technical assistance provided by the Core Facility for Scientific Research-USP (CEFAP-USP) in conducting the confocal fluorescence microscopy assays. This work was supported by FAPESP (Sao Paulo, Brazil), CAPES and CNPq (Brasilia, Brazil).	Ahn JH, 2011, CANCER LETT, V310, P188, DOI 10.1016/j.canlet.2011.06.034; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Batista LFZ, 2007, CANCER RES, V67, P11886, DOI 10.1158/0008-5472.CAN-07-2964; Beckta JM, 2014, CELL CYCLE, V13, P710, DOI 10.4161/cc.28108; Bertheau P, 2013, BREAST, V22, pS27, DOI 10.1016/j.breast.2013.07.005; Bhana S, 2008, MUTAGENESIS, V23, P43, DOI 10.1093/mutage/gem041; Bissell MJ, 1999, CANCER RES, V59, p1757S; Bramwell VHC, 2002, CLIN CANCER RES, V8, P383; Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Cheng YJ, 2008, INT J CANCER, V123, P1278, DOI 10.1002/ijc.23592; Cortat B, 2013, PHOTOCH PHOTOBIO SCI, V12, P1483, DOI 10.1039/c3pp50023c; Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Debnath J, 2008, AUTOPHAGY, V4, P351, DOI 10.4161/auto.5523; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; do Amaral JB, 2011, TISSUE ENG PART C-ME, V17, P1097, DOI 10.1089/ten.tec.2011.0260; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Ghavami S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016523; Gomes LR, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-26; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058; Li QW, 2010, J PHARMACOL EXP THER, V332, P821, DOI 10.1124/jpet.109.160390; Liang B, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-213; Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002; Manov I, 2011, FEBS J, V278, P3494, DOI 10.1111/j.1742-4658.2011.08271.x; Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015; Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mohan P, 2010, MOL PHARMACEUT, V7, P1959, DOI 10.1021/mp100269f; Moraes MCS, 2012, CANCER LETT, V314, P108, DOI 10.1016/j.canlet.2011.09.019; Novaro V, 2003, J CELL SCI, V116, P2975, DOI 10.1242/jcs.00523; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Pyo JO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3300; Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044; Quinet A, 2014, DNA REPAIR, V14, P27, DOI 10.1016/j.dnarep.2013.12.005; Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004; Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521; Swenson CE, 2003, ANTI-CANCER DRUG, V14, P239, DOI 10.1097/00001813-200303000-00008; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tuloup-Minguez V, 2011, AUTOPHAGY, V7, P27, DOI 10.4161/auto.7.1.13851; Valbuena A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017320; Velez JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018005; Weaver VM, 1999, J MAMMARY GLAND BIOL, V4, P193, DOI 10.1023/A:1018781325716; Woodley-Cook J, 2006, MOL CANCER THER, V5, P3303, DOI 10.1158/1535-7163.MCT-06-0154	56	36	36	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5329	5340		10.1038/onc.2014.461	http://dx.doi.org/10.1038/onc.2014.461			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25619836				2022-12-28	WOS:000363479200003
J	Greenall, SA; Donoghue, JF; Van Sinderen, M; Dubljevic, V; Budiman, S; Devlin, M; Street, I; Adams, TE; Johns, TG				Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Devlin, M.; Street, I.; Adams, T. E.; Johns, T. G.			EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; DOMAIN BINDING-SITE; CELLS; GLIOBLASTOMAS; AMPLIFICATION; ACTIVATION; RESISTANCE; INHIBITORS; MUTATIONS	A truncation mutant of the epidermal growth factor receptor, EGFRvIII, is commonly expressed in glioma, an incurable brain cancer. EGFRvIII is tumorigenic, in part, through its transactivation of other receptor tyrosine kinases (RTKs). Preventing the effects of this transactivation could form part of an effective therapy for glioma; however, the mechanism by which the transactivation occurs is unknown. Focusing on the RTK MET, we show that MET transactivation in U87MG human glioma cells in vitro is proportional to EGFRvIII activity and involves MET heterodimerization associated with a focal adhesion kinase (FAK) scaffold. The transactivation of certain other RTKs was, however, independent of FAK. Simultaneously targeting EGFRvIII (with panitumumab) and the transactivated RTKs themselves (with motesanib) in an intracranial mouse model of glioma resulted in significantly greater survival than with either agent alone, indicating that cotargeting these RTKs has potent antitumor efficacy and providing a strategy for treating EGFRvIII-expressing gliomas, which are usually refractory to treatment.	[Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Johns, T. G.] MIMR PHI Inst Med Res, Ctr Canc Res, Oncogen Signalling Lab, Clayton, Vic 3168, Australia; [Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Johns, T. G.] MIMR PHI Inst Med Res, Ctr Canc Res, Brain Canc Discovery Collaborat, Clayton, Vic 3168, Australia; [Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Johns, T. G.] Monash Univ, Clayton, Vic, Australia; [Greenall, S. A.; Adams, T. E.] CSIRO, Div Mat Sci & Engn, Parkville, Vic, Australia; [Devlin, M.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia; [Street, I.] CRC Canc Therapeut, Bundoora, Vic, Australia; [Street, I.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; [Street, I.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia	Prince Henry's Institute of Medical Research; Prince Henry's Institute of Medical Research; Monash University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Peter Maccallum Cancer Center; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne	Johns, TG (corresponding author), MIMR PHI Inst Med Res, Ctr Canc Res, Oncogen Signalling Lab, 27-31 Wright St, Clayton, Vic 3168, Australia.	terry.johns@monash.edu	Adams, Timothy E/I-6231-2012; Johns, Terrance/C-2441-2008; Street, Ian/GXG-9517-2022	Adams, Timothy E/0000-0003-3436-0066; Johns, Terrance/0000-0002-8874-4543; Dubljevic, Valentina/0000-0002-7944-8937; Greenall, Sameer/0000-0002-1461-7111; Street, Ian/0000-0003-2684-4239; Donoghue, Jacqueline/0000-0003-1370-2469	Commonwealth Scientific and Industrial Research Organisation (CSIRO) OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation postdoctoral fellowship; Victorian Cancer Agency Early Career Seed Grant [ECSG1108]; National Health and Medical Research Council [1028552, 1012020]; Victorian Government's Operational and Infrastructure Support Program; Cure Brain Cancer Foundation; CRC for Cancer Therapeutics, an initiative of the Australian Government	Commonwealth Scientific and Industrial Research Organisation (CSIRO) OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation postdoctoral fellowship; Victorian Cancer Agency Early Career Seed Grant; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational and Infrastructure Support Program; Cure Brain Cancer Foundation; CRC for Cancer Therapeutics, an initiative of the Australian Government	We acknowledge the facilities and scientific and technical assistance of the Histology Facility, Microimaging facility and Monash Animal Services, at MIMR-PHI Institute of Medical Research. We thank Dr D Dadley-Moore for editing the manuscript. SAG is funded by a Commonwealth Scientific and Industrial Research Organisation (CSIRO) OCE Postdoctoral Fellowship. JFD is funded by a Cure Cancer Australia Foundation postdoctoral fellowship and a Victorian Cancer Agency Early Career Seed Grant (ECSG1108). TGJ is funded by National Health and Medical Research Council Project Grants 1028552 and 1012020, the Victorian Government's Operational and Infrastructure Support Program and the Cure Brain Cancer Foundation. This work was supported by the CRC for Cancer Therapeutics, an initiative of the Australian Government. Rilotumumab and motesanib must be obtained through an MTA. Rilotumumab, panitumumab and motesanib were provided by Amgen (rilotumumab and motesanib through an MTA); and dacomitinib was provided by Pfizer.	Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502; Chen TH, 2011, ONCOGENE, V30, P153, DOI 10.1038/onc.2010.398; Del Vecchio CA, 2013, ONCOGENE, V32, P2670, DOI 10.1038/onc.2012.280; Ding LS, 2010, TRANSL RES, V156, P45, DOI 10.1016/j.trsl.2010.05.001; Donoghue JF, 2011, JOVE-J VIS EXP, DOI 10.3791/3157; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Gan HK, 2013, FEBS J, V280, P5350, DOI 10.1111/febs.12393; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Johns TG, 2007, CLIN CANCER RES, V13, P1911, DOI 10.1158/1078-0432.CCR-06-1453; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kong XB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041523, 10.1371/journal.pone.0033381]; Liu MZ, 2010, ARCH BIOCHEM BIOPHYS, V502, P89, DOI 10.1016/j.abb.2010.07.014; Liu TJ, 2007, MOL CANCER THER, V6, P1357, DOI 10.1158/1535-7163.MCT-06-0476; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Polverino A, 2006, CANCER RES, V66, P8715, DOI 10.1158/0008-5472.CAN-05-4665; Riemenschneider MJ, 2005, AM J PATHOL, V167, P1379, DOI 10.1016/S0002-9440(10)61225-4; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Street I, 2012, P 103 ANN M AM ASS C, P72; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wen PY, 2014, NEURO-ONCOLOGY, V16, P567, DOI 10.1093/neuonc/not247; Ymer Susie I, 2011, Cancers (Basel), V3, P2032, DOI 10.3390/cancers3022032	36	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5277	5287		10.1038/onc.2014.448	http://dx.doi.org/10.1038/onc.2014.448			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25659577				2022-12-28	WOS:000362575400007
J	Long, JS; Schoonen, PM; Graczyk, D; O'Prey, J; Ryan, KM				Long, J. S.; Schoonen, P. M.; Graczyk, D.; O'Prey, J.; Ryan, K. M.			p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death	ONCOGENE			English	Article							OUTER-MEMBRANE PERMEABILIZATION; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; P53; ADENOSINE; ACTIVATION; INDUCTION; AUTOPHAGY; PROTEINS	Tumour cells often acquire the ability to escape cell death, a key event leading to the development of cancer. In almost half of all human cancers, the capability to induce cell death is reduced by the mutation and inactivation of p53, a tumour suppressor protein that is a central regulator of apoptosis. As a result, there is a crucial need to identify different cell death pathways that could be targeted in malignancies lacking p53. p73, the closely related p53 family member, can regulate many p53 target genes and therefore some of the same cellular responses as p53. Unlike p53, however, p73 is seldom mutated in cancer, making it an attractive, alternative death effector to target. We report here the ability of p73 to upregulate the expression of the A2B receptor, a recently characterized p53 target that effectively promotes cell death in response to extracellular adenosine-a metabolite that accumulates during various forms of cellular stress. Importantly, we show that p73-dependent stimulation of A2B signalling markedly enhances apoptosis in cancer cells that are devoid of p53. This mode of death is caspase-and puma-dependent, and can be prevented by the overexpression of anti-apoptotic Bcl-XL. Moreover, treatment of p53-null cancer cells with the chemotherapeutic drug adriamycin (doxorubicin) induces A2B in a p73-dependent manner and, in combination with an A2B agonist, substantially enhances apoptotic death. We therefore propose an alternate and distinct p53-independent pathway to stimulate programmed cell death involving p73-mediated engagement of adenosine signalling.	[Long, J. S.; Schoonen, P. M.; Graczyk, D.; O'Prey, J.; Ryan, K. M.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Schoonen, P. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 AV Groningen, Netherlands	Beatson Institute; University of Groningen	Ryan, KM (corresponding author), Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk	Graczyk, Damian/J-6494-2016	Graczyk, Damian/0000-0002-6006-647X; Ryan, Kevin M./0000-0002-1059-9681	Worldwide Cancer Research; Cancer Research UK; Cancer Research UK [15816] Funding Source: researchfish; Worldwide Cancer Research [09-0170, 11-0285] Funding Source: researchfish	Worldwide Cancer Research; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	We thank members of the Tumour Cell Death laboratory for critical reading of the manuscript. Work in the Tumour Cell Death Laboratory is supported by Worldwide Cancer Research and Cancer Research UK.	Agami R, 1999, NATURE, V399, P809; Bell HS, 2007, J CLIN INVEST, V117, P1008, DOI 10.1172/JCI28920; Blay J, 1997, CANCER RES, V57, P2602; Borrmann T, 2009, J MED CHEM, V52, P3994, DOI 10.1021/jm900413e; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Crighton D, 2004, BBA-REV CANCER, V1705, P3, DOI 10.1016/j.bbcan.2004.09.001; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fricker M, 2010, J NEUROCHEM, V114, P772, DOI 10.1111/j.1471-4159.2010.06804.x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gong JG, 1999, NATURE, V399, P806; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Klanrit P, 2008, CELL CYCLE, V7, P205, DOI 10.4161/cc.7.2.5361; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Levrero M, 2000, J CELL SCI, V113, P1661; Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7; Long JS, 2013, MOL CELL, V50, P394, DOI 10.1016/j.molcel.2013.03.016; Lunghi P, 2004, BLOOD, V104, P519, DOI 10.1182/blood-2003-08-2743; Martin AG, 2009, AGING-US, V1, P335, DOI 10.18632/aging.100026; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; O'Prey J, 2009, CELL CYCLE, V8, P2260, DOI 10.4161/cc.8.14.9050; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Oswald C, 2008, CELL CYCLE, V7, P1726, DOI 10.4161/cc.7.12.6148; PELLICCIARI C, 1993, EUR J HISTOCHEM, V37, P381; Raskovalova T, 2005, J IMMUNOL, V175, P4383, DOI 10.4049/jimmunol.175.7.4383; Sauer M, 2008, NUCLEIC ACIDS RES, V36, P1900, DOI 10.1093/nar/gkn044; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stiewe T, 2002, CANCER RES, V62, P3598; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wilkinson S, 2009, GENE DEV, V23, P1283, DOI 10.1101/gad.521709; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	49	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5152	5162		10.1038/onc.2014.436	http://dx.doi.org/10.1038/onc.2014.436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25659586	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000362233400005
J	Takahashi, H; Jin, C; Rajabi, H; Pitroda, S; Alam, M; Ahmad, R; Raina, D; Hasegawa, M; Suzuki, Y; Tagde, A; Bronson, RT; Weichselbaum, R; Kufe, D				Takahashi, H.; Jin, C.; Rajabi, H.; Pitroda, S.; Alam, M.; Ahmad, R.; Raina, D.; Hasegawa, M.; Suzuki, Y.; Tagde, A.; Bronson, R. T.; Weichselbaum, R.; Kufe, D.			MUC1-C activates the TAK1 inflammatory pathway in colon cancer	ONCOGENE			English	Article							BOWEL-DISEASE; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; MOUSE MODEL; ONCOPROTEIN; KINASE; EXPRESSION; MUCIN; INHIBITION; BREAST	The mucin 1 (MUC1) oncoprotein has been linked to the inflammatory response by promoting cytokine-mediated activation of the NF-kappa B pathway. The TGF-beta-activated kinase 1 (TAK1) is an essential effector of proinflammatory NF-kappa B signaling that also regulates cancer cell survival. The present studies demonstrate that the MUC1-C transmembrane subunit induces TAK1 expression in colon cancer cells. MUC1 also induces TAK1 in a MUC1(+/-)/IL-10(-/-) mouse model of colitis and colon tumorigenesis. We show that MUC1C promotes NF-kappa B-mediated activation of TAK1 transcription and, in a positive regulatory loop, MUC1-C contributes to TAK1-induced NF-kappa B signaling. In this way, MUC1-C binds directly to TAK1 and confers the association of TAK1 with TRAF6, which is necessary for TAK1-mediated activation of NF-kappa B. Targeting MUC1-C thus suppresses the TAK1 -> NF-kappa B pathway, downregulates BCL-XL and in turn sensitizes colon cancer cells to MEK inhibition. Analysis of colon cancer databases further indicates that MUC1, TAK1 and TRAF6 are upregulated in tumors associated with decreased survival and that MUC1-C-induced gene expression patterns predict poor outcomes in patients. These results support a model in which MUC1-C-induced TAK1 -> NF-kappa B signaling contributes to intestinal inflammation and colon cancer progression.	[Takahashi, H.; Rajabi, H.; Alam, M.; Ahmad, R.; Hasegawa, M.; Suzuki, Y.; Tagde, A.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA; [Jin, C.; Raina, D.] Genus Oncol, Boston, MA USA; [Pitroda, S.; Weichselbaum, R.] Univ Chicago, Dept Radiat & Cellular Oncol, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA; [Bronson, R. T.] Harvard Univ, Sch Med, Div Immunol, Dept Microbiol & Immunobiol, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Harvard University; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu	Tagde, Ashujit/M-9497-2014	Tagde, Ashujit/0000-0002-0770-097X; Hasegawa, Masanori/0000-0002-4354-6105; Ahmad, Rehan/0000-0003-2612-2818	Department of Defense; National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; CDMRP [CA110495]; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA166480] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CDMRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by Grant CDMRP CA110495 awarded by the Department of Defense and by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Ajibade AA, 2013, TRENDS IMMUNOL, V34, P307, DOI 10.1016/j.it.2013.03.007; Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Baldus SE, 2002, HISTOPATHOLOGY, V40, P440, DOI 10.1046/j.1365-2559.2002.01389.x; Beatty PL, 2007, J IMMUNOL, V179, P735, DOI 10.4049/jimmunol.179.2.735; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Cai PCH, 2014, ONCOTARGET, V5, P7549, DOI 10.18632/oncotarget.2273; Campbell BJ, 2001, GLYCOCONJUGATE J, V18, P851, DOI 10.1023/A:1022240107040; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Duncan Timothy J, 2007, World J Surg Oncol, V5, P31, DOI 10.1186/1477-7819-5-31; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Furr AE, 2010, PEDIATR DEVEL PATHOL, V13, P24, DOI 10.2350/08-06-0479.1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hoebler C, 2006, DIGEST DIS SCI, V51, P381, DOI 10.1007/s10620-006-3142-y; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Lugli A, 2007, J CLIN PATHOL, V60, P534, DOI 10.1136/jcp.2006.039552; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; Niv Y, 2008, WORLD J GASTROENTERO, V14, P2139, DOI 10.3748/wjg.14.2139; Omori E, 2012, P NATL ACAD SCI USA, V109, P3365, DOI 10.1073/pnas.1116188109; Omori E, 2010, CANCER RES, V70, P8417, DOI 10.1158/0008-5472.CAN-10-1227; Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070; Petersson J, 2011, AM J PHYSIOL-GASTR L, V300, pG327, DOI 10.1152/ajpgi.00422.2010; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Ray DM, 2012, BRIT J CANCER, V107, P129, DOI 10.1038/bjc.2012.214; Relic B, 2004, J BIOL CHEM, V279, P22399, DOI 10.1074/jbc.M314118200; Rhodes JM, 1996, LANCET, V347, P40, DOI 10.1016/S0140-6736(96)91563-9; Rowse GJ, 1998, CANCER RES, V58, P315; Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Starczynowski DT, 2011, J CLIN INVEST, V121, P4095, DOI 10.1172/JCI58818; Suzuki H, 2004, CLIN EXP METASTAS, V21, P321, DOI 10.1023/B:CLIN.0000046133.35133.cc; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Yamazaki K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000387	50	70	74	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5187	5197		10.1038/onc.2014.442	http://dx.doi.org/10.1038/onc.2014.442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25659581	Green Accepted, Green Submitted			2022-12-28	WOS:000362233400008
J	Farria, A; Li, W; Dent, SYR				Farria, A.; Li, W.; Dent, S. Y. R.			KATs in cancer: functions and therapies	ONCOGENE			English	Review							HISTONE ACETYLTRANSFERASE ACTIVITY; BET BROMODOMAIN INHIBITION; CREB-BINDING-PROTEIN; DNA-DAMAGE RESPONSE; T-CELL LEUKEMIA; NF-KAPPA-B; ANDROGEN RECEPTOR; C-MYC; TRANSCRIPTION FACTOR; IN-VIVO	Post-translational acetylation of lysines is most extensively studied in histones, but this modification is also found in many other proteins and is implicated in a wide range of biological processes in both the cell nucleus and the cytoplasm. Like phosphorylation, acetylation patterns and levels are often altered in cancer, therefore small molecule inhibition of enzymes that regulate acetylation and deacetylation offers much potential for inhibiting cancer cell growth, as does disruption of interactions between acetylated residues and 'reader' proteins. For more than a decade now, histone deacetylase inhibitors have been investigated for their ability to increase acetylation and promote expression of tumor suppressor genes. However, emerging evidence suggests that acetylation can also promote cancer, in part by enhancing the functions of oncogenic transcription factors. In this review, we focus on how acetylation of both histone and non-histone proteins may drive cancer, and we will discuss the implications of such changes on how patients are assigned to therapeutic agents. Finally, we will explore what the future holds in the design of small-molecule inhibitors for modulation of levels or functions of acetylation states.	[Farria, A.; Li, W.; Dent, S. Y. R.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Ctr Canc Epigenet, Dept Epigenet & Mol Carcinogenesis, Smithville, TX 78657 USA	University of Texas System; UTMD Anderson Cancer Center	Dent, SYR (corresponding author), Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Ctr Canc Epigenet, Dept Epigenet & Mol Carcinogenesis, Sci Pk, Smithville, TX 78657 USA.	sroth@mdanderson.org	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269; Farria, Aimee/0000-0002-3524-8730; Li, Wenqian/0000-0001-6663-9809	NIH [R01067718]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067718] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Evangelia Koutelou for the critical reading of this manuscript and Andria Schibler for advice and contributions to artwork. This work was partially supported by NIH R01067718 to SYRD.	Ahmad A, 2012, MOL CANCER THER, V11, P2193, DOI 10.1158/1535-7163.MCT-12-0232-T; Ahmad Aamir, 2011, Front Biosci (Elite Ed), V3, P1483; Ahmad A, 2010, J CELL BIOCHEM, V109, P1134, DOI 10.1002/jcb.22492; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Arif M, 2009, J MED CHEM, V52, P267, DOI 10.1021/jm800657z; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Bedford DC, 2010, EPIGENETICS-US, V5, P9, DOI 10.4161/epi.5.1.10449; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Bhoumik A, 2008, CELL CYCLE, V7, P2341, DOI 10.4161/cc.6388; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Butler JS, 2012, EPIGENOMICS-UK, V4, P163, DOI [10.2217/EPI.12.3, 10.2217/epi.12.3]; Chen GD, 2012, J INVEST DERMATOL, V132, P2632, DOI 10.1038/jid.2012.193; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Chen L, 2013, J BIOL CHEM, V288, P14510, DOI 10.1074/jbc.M113.458737; Chen R, 2012, J BIOL CHEM, V287, P30800, DOI 10.1074/jbc.M111.244780; Chevillard-Briet M, 2014, HUM MOL GENET, V23, P2120, DOI 10.1093/hmg/ddt604; Chimenti F, 2009, J MED CHEM, V52, P530, DOI 10.1021/jm800885d; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coffey K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045539; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Duong MT, 2013, CANCER RES, V73, P5556, DOI 10.1158/0008-5472.CAN-13-0013; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Endo M, 2014, HUM PATHOL, V45, P276, DOI 10.1016/j.humpath.2013.09.003; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2003, CANCER RES, V63, P304; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Gao CX, 2014, SCI REP-UK, V4, DOI 10.1038/srep05372; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Gao XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055481; Gao YN, 2014, INT J CLIN EXP PATHO, V7, P760; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792; Ghizzoni M, 2012, EUR J MED CHEM, V47, P337, DOI 10.1016/j.ejmech.2011.11.001; Ghizzoni M, 2010, BIOORGAN MED CHEM, V18, P5826, DOI 10.1016/j.bmc.2010.06.089; Gong AY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-492; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grayson AR, 2014, ONCOGENE, V33, P1736, DOI 10.1038/onc.2013.126; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Hao JJ, 2013, CELL REP, V4, P898, DOI 10.1016/j.celrep.2013.07.047; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; Holmlund T, 2013, LEUKEMIA, V27, P578, DOI 10.1038/leu.2012.265; Ianculescu I, 2012, J BIOL CHEM, V287, P4000, DOI 10.1074/jbc.M111.300194; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Jiang ZH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-88; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Kaeser MD, 2008, J BIOL CHEM, V283, P32254, DOI 10.1074/jbc.M806061200; Kalac M, 2011, BLOOD, V118, P5506, DOI 10.1182/blood-2011-02-336891; Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Kim HJ, 2011, AM J TRANSL RES, V3, P166; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kobayashi J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-34; Krebs AR, 2011, MOL CELL, V44, P410, DOI 10.1016/j.molcel.2011.08.037; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Kushal S, 2013, P NATL ACAD SCI USA, V110, P15602, DOI 10.1073/pnas.1312473110; Lange M, 2008, GENE DEV, V22, P2370, DOI 10.1101/gad.471408; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lee SO, 2009, PROSTATE, V69, P126, DOI 10.1002/pros.20865; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Li F, 2013, CANCER PREV RES, V6, P843, DOI 10.1158/1940-6207.CAPR-13-0070; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li YY, 2014, CELL, V159, P558, DOI 10.1016/j.cell.2014.09.049; Liao ZW, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-110; Lin RT, 2013, MOL CELL, V51, P506, DOI 10.1016/j.molcel.2013.07.002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Liu YJ, 2013, NAT MED, V19, P1173, DOI 10.1038/nm.3286; Lleonart ME, 2006, ONCOL REP, V16, P603; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lu HM, 2009, FEBS J, V276, P7291, DOI 10.1111/j.1742-4658.2009.07441.x; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Lv GX, 2014, ONCOL REP, V32, P1021, DOI 10.3892/or.2014.3296; Malatesta M, 2013, CANCER RES, V73, P6323, DOI 10.1158/0008-5472.CAN-12-4660; Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; Miyamoto N, 2008, J BIOL CHEM, V283, P18218, DOI 10.1074/jbc.M802332200; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nagy Z, 2010, CELL MOL LIFE SCI, V67, P611, DOI 10.1007/s00018-009-0199-8; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Nye MD, 2014, J BIOL CHEM, V289, P15495, DOI 10.1074/jbc.M113.545194; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Patel AJ, 2014, CELL REP, V6, P81, DOI 10.1016/j.celrep.2013.12.001; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Pattabiraman DR, 2014, BLOOD, V123, P2682, DOI 10.1182/blood-2012-02-413187; Pattabiraman DR, 2009, MOL CANCER RES, V7, P1477, DOI 10.1158/1541-7786.MCR-09-0070; Prinjha RK, 2012, TRENDS PHARMACOL SCI, V33, P146, DOI 10.1016/j.tips.2011.12.002; Rauh D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3327; Ravindra KC, 2009, J BIOL CHEM, V284, P24453, DOI 10.1074/jbc.M109.023861; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Robles MTS, 2013, J VIROL, V87, P13499, DOI 10.1128/JVI.02658-13; Rotte A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075405; Saadat N, 2012, J ONCOL, V2012, DOI 10.1155/2012/647206; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Santer FR, 2011, MOL CANCER THER, V10, P1644, DOI 10.1158/1535-7163.MCT-11-0182; Santillan DA, 2006, CANCER RES, V66, P10032, DOI 10.1158/0008-5472.CAN-06-2597; Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008; Secci D, 2014, BIOORGAN MED CHEM, V22, P1680, DOI 10.1016/j.bmc.2014.01.022; Sethi G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-66; Shah M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001258; Shah S, 2012, CANCER RES, V72, P1248, DOI 10.1158/0008-5472.CAN-11-0943; Shi DD, 2009, P NATL ACAD SCI USA, V106, P16275, DOI 10.1073/pnas.0904305106; Shiota M, 2010, PROSTATE, V70, P540, DOI 10.1002/pros.21088; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Stimson L, 2005, MOL CANCER THER, V4, P1521, DOI 10.1158/1535-7163.MCT-05-0135; Sun BF, 2011, CELL RES, V21, P1262, DOI 10.1038/cr.2011.105; Sun YL, 2006, FEBS LETT, V580, P4353, DOI 10.1016/j.febslet.2006.06.092; Sun YL, 2010, CELL CYCLE, V9, P930, DOI 10.4161/cc.9.5.10931; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood-2007-10-117994; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Takeuchi A, 2012, MOL MED REP, V5, P173, DOI 10.3892/mmr.2011.593; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Teiten MH, 2011, INT J ONCOL, V38, P603, DOI 10.3892/ijo.2011.905; Thevenet L, 2004, EMBO J, V23, P3336, DOI 10.1038/sj.emboj.7600352; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Tohyama S, 2012, J ORG CHEM, V77, P9044, DOI 10.1021/jo301534b; Trisciuoglio D, 2012, CLIN CANCER RES, V18, P475, DOI 10.1158/1078-0432.CCR-11-0579; Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418; Van Den Broeck A, 2012, CARCINOGENESIS, V33, P320, DOI 10.1093/carcin/bgr292; Wang F, 2013, CELL MOL LIFE SCI, V70, P3989, DOI 10.1007/s00018-012-1254-4; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Xie X, 2014, ONCOGENE, V33, P1037, DOI 10.1038/onc.2013.25; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yan G, 2013, J INVEST DERMATOL, V133, P2444, DOI 10.1038/jid.2013.187; Yang H, 2013, MOL CANCER THER, V12, P610, DOI 10.1158/1535-7163.MCT-12-0930; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Ye X, 2014, ASIAN PAC J CANCER P, V15, P5001, DOI 10.7314/APJCP.2014.15.12.5001; Yin SM, 2012, CLIN CANCER RES, V18, P6623, DOI 10.1158/1078-0432.CCR-12-0861; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yu SY, 2014, J AGR FOOD CHEM, V62, P2085, DOI 10.1021/jf4037722; Yu XD, 2002, J NATL CANCER I, V94, P504; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zeng L, 2010, NATURE, V466, P258, DOI 10.1038/nature09139; Zhang N, 2014, BBA-GENE REGUL MECH, V1839, P395, DOI 10.1016/j.bbagrm.2014.03.017; Zhao HW, 2012, J BIOL CHEM, V287, P925, DOI 10.1074/jbc.M111.279950; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zheng YJ, 2005, J AM CHEM SOC, V127, P17182, DOI 10.1021/ja0558544; Zhong J, 2014, CANCER RES, V74, P1870, DOI 10.1158/0008-5472.CAN-13-2485; Zimmer SN, 2012, EXP HEMATOL, V40, P295, DOI 10.1016/j.exphem.2011.12.004; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	192	78	80	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4901	4913		10.1038/onc.2014.453	http://dx.doi.org/10.1038/onc.2014.453			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25659580	Green Accepted			2022-12-28	WOS:000361693000001
J	Zeng, L; Morinibu, A; Kobayashi, M; Zhu, Y; Wang, X; Goto, Y; Yeom, CJ; Zhao, T; Hirota, K; Shinomiya, K; Itasaka, S; Yoshimura, M; Guo, G; Hammond, EM; Hiraoka, M; Harada, H				Zeng, L.; Morinibu, A.; Kobayashi, M.; Zhu, Y.; Wang, X.; Goto, Y.; Yeom, C. J.; Zhao, T.; Hirota, K.; Shinomiya, K.; Itasaka, S.; Yoshimura, M.; Guo, G.; Hammond, E. M.; Hiraoka, M.; Harada, H.			Aberrant IDH3 alpha expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis	ONCOGENE			English	Article							BREAST-CANCER PATIENTS; TRANSCRIPTIONAL ACTIVITY; RADIATION-THERAPY; GENE-EXPRESSION; HIF-1 ACTIVITY; FACTOR-I; HYPOXIA; CELLS; FACTOR-1; TRANSFORMATION	Cancer cells gain a growth advantage through the so-called Warburg effect by shifting glucose metabolism from oxidative phosphorylation to aerobic glycolysis. Hypoxia-inducible factor 1 (HIF-1) has been suggested to function in metabolic reprogramming; however, the underlying mechanism has not been fully elucidated. We found that the aberrant expression of wild-type isocitrate dehydrogenase 3 alpha (IDH3 alpha), a subunit of the IDH3 heterotetramer, decreased alpha-ketoglutarate levels and increased the stability and transactivation activity of HIF-1 alpha in cancer cells. The silencing of IDH3 alpha significantly delayed tumor growth by suppressing the HIF-1-mediated Warburg effect and angiogenesis. IDH3 alpha expression was associated with the poor postoperative overall survival of lung and breast cancer patients. These results justify the exploitation of IDH3 as a novel target for the diagnosis and treatment of cancers.	[Zeng, L.; Morinibu, A.; Kobayashi, M.; Zhu, Y.; Wang, X.; Goto, Y.; Zhao, T.; Shinomiya, K.; Itasaka, S.; Yoshimura, M.; Hiraoka, M.; Harada, H.] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan; [Zeng, L.; Morinibu, A.; Kobayashi, M.; Zhu, Y.; Wang, X.; Goto, Y.; Yeom, C. J.; Zhao, T.; Shinomiya, K.; Harada, H.] Kyoto Univ, Career Path Promot Unit Young Life Scientists, Grp Radiat & Tumor Biol, Kyoto 6068507, Japan; [Zeng, L.; Wang, X.; Zhao, T.; Guo, G.] Fourth Mil Med Univ, Dept Radiat Med, Xian, Shaanxi, Peoples R China; [Zhu, Y.] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China; [Hirota, K.] Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan; [Hammond, E. M.] Univ Oxford, Oxford Inst Radiat Oncol, Dept Oncol, Oxford, England; [Harada, H.] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi, Saitama, Japan	Kyoto University; Kyoto University; Air Force Military Medical University; Chongqing Medical University; Kyoto University; University of Oxford; Japan Science & Technology Agency (JST)	Harada, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hharada@kuhp.kyoto-u.ac.jp	; Hirota, Kiichi/E-9181-2010	Kobayshi, Minoru/0000-0003-3843-3584; Hammond, Ester/0000-0002-2335-3146; Hirota, Kiichi/0000-0003-1110-0827	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) Japan Society for the Promotion of Science (JSPS), Japan [LS071]; program for Precursory Research for Embryonic Science and Technology (PRESTO) Japan Science and Technology Agency (JST); Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT, Japan [26293276, 26461886, 26670558, 26670555, 25861088, 24791293, 24659563]; Sagawa Foundation; Kobayashi Foundation; Takeda Science Foundation; Mochida Memorial Foundation; International Science and Technology Cooperation Project of China and Japan [2010DFA31900]; Grants-in-Aid for Scientific Research [26670693] Funding Source: KAKEN; Cancer Research UK [19276] Funding Source: researchfish	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) Japan Society for the Promotion of Science (JSPS), Japan; program for Precursory Research for Embryonic Science and Technology (PRESTO) Japan Science and Technology Agency (JST); Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Sagawa Foundation; Kobayashi Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Foundation; International Science and Technology Cooperation Project of China and Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Cancer Research UK(Cancer Research UK)	We thank Dr M Suematsu, Dr YA Minamishima, and Dr N Hayakawa for critical discussion. This study was supported by the Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan to HH (No. LS071), by the program for Precursory Research for Embryonic Science and Technology (PRESTO) from Japan Science and Technology Agency (JST) to HH, by the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to HH, and by Grants-in-Aids for Scientific Research (B) to HH (No. 26293276), for Scientific Research (C) to AM (No. 26461886), for challenging Exploratory Research to HH (No. 26670558) and to MH (No. 26670555), and for Young Scientists (B) to MK (No. 25861088), MY (No. 24791293) and SI (No. 24659563) from MEXT, Japan, by the Sagawa Foundation for the Promotion of Cancer Research to HH, by the Kobayashi Foundation for Cancer Research to HH, by the Takeda Science Foundation to HH, by the Mochida Memorial Foundation for Medical and Pharmaceutical Research to HH, and by the International Science and Technology Cooperation Project of China and Japan to ZL and HH (No. 2010DFA31900).	Adler E, 1939, BIOCHEM J, V33, P1028, DOI 10.1042/bj0331028; Bajad SU, 2006, J CHROMATOGR A, V1125, P76, DOI 10.1016/j.chroma.2006.05.019; Bao Y, 2013, MOL CANCER RES, V11, P973, DOI 10.1158/1541-7786.MCR-12-0669-T; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Harada H, 2007, ONCOGENE, V26, P7508, DOI 10.1038/sj.onc.1210556; Harada H, 2009, BRIT J CANCER, V100, P747, DOI 10.1038/sj.bjc.6604939; Harada H, 2007, BIOCHEM BIOPH RES CO, V360, P791, DOI 10.1016/j.bbrc.2007.06.149; Harada H, 2005, MOL IMAGING, V4, P182; Harada H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1786; Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCarthy N, 2012, NAT REV CANCER, V12, P229, DOI 10.1038/nrc3248; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Shibata T, 1998, INT J RADIAT ONCOL, V42, P913, DOI 10.1016/S0360-3016(98)00298-3; Tomida S, 2009, J CLIN ONCOL, V27, P2793, DOI 10.1200/JCO.2008.19.7053; Wakamatsu T, 2009, EUR J PHARMACOL, V617, P17, DOI 10.1016/j.ejphar.2009.06.060; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Zeng LH, 2008, CANCER SCI, V99, P2327, DOI 10.1111/j.1349-7006.2008.00943.x	30	60	62	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4758	4766		10.1038/onc.2014.411	http://dx.doi.org/10.1038/onc.2014.411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531325				2022-12-28	WOS:000360931500009
J	Wang, P; Chen, SH; Hung, WC; Paul, C; Zhu, F; Guan, PP; Huso, DL; Kontrogianni-Konstantopoulos, A; Konstantopoulos, K				Wang, P.; Chen, S-H; Hung, W-C; Paul, C.; Zhu, F.; Guan, P-P; Huso, D. L.; Kontrogianni-Konstantopoulos, A.; Konstantopoulos, K.			Fluid shear promotes chondrosarcoma cell invasion by activating matrix metalloproteinase 12 via IGF-2 and VEGF signaling pathways	ONCOGENE			English	Article							MACROPHAGE METALLOELASTASE MMP-12; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); INTERSTITIAL CONVECTION; ENDOTHELIAL-CELLS; LOCAL RECURRENCE; EXPRESSION; METASTASIS; CHONDROCYTES; STRESS; FLOW	Interstitial fluid flow in and around the tumor tissue is a physiologically relevant mechanical signal that regulates intracellular signaling pathways throughout the tumor. Yet, the effects of interstitial flow and associated fluid shear stress on the tumor cell function have been largely overlooked. Using in vitro bioengineering models in conjunction with molecular cell biology tools, we found that fluid shear (2 dyn/cm(2)) markedly upregulates matrix metalloproteinase 12 (MMP-12) expression and its activity in human chondrosarcoma cells. MMP-12 expression is induced in human chondrocytes during malignant transformation. However, the signaling pathway regulating MMP-12 expression and its potential role in human chondrosarcoma cell invasion and metastasis have yet to be delineated. We discovered that fluid shear stress induces the synthesis of insulin growth factor-2 (IGF-2) and vascular endothelial growth factor (VEGF) B and D, which in turn transactivate MMP-12 via PI3-K, p38 and JNK signaling pathways. IGF-2-, VEGF-B-or VEGF-D-stimulated chondrosarcoma cells display markedly higher migratory and invasive potentials in vitro, which are blocked by inhibiting MMP-12, PI3-K, p38 or JNK activity. Moreover, recombinant human MMP-12 or MMP-12 overexpression can potentiate chondrosarcoma cell invasion in vitro and the lung colonization in vivo. By reconstructing and delineating the signaling pathway regulating MMP-12 activation, potential therapeutic strategies that interfere with chondrosarcoma cell invasion may be identified.	[Wang, P.; Guan, P-P] Northeastern Univ, Coll Life & Hlth Sci, Shenyang 110819, Peoples R China; [Wang, P.; Chen, S-H; Hung, W-C; Paul, C.; Zhu, F.; Guan, P-P; Konstantopoulos, K.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Chen, S-H; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Hung, W-C; Konstantopoulos, K.] Johns Hopkins Univ, Ctr Canc Nanotechonol Excellence, Baltimore, MD 21218 USA; [Paul, C.; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Huso, D. L.] Johns Hopkins Med Inst, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA; [Huso, D. L.] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Kontrogianni-Konstantopoulos, A.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Kontrogianni-Konstantopoulos, A.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Natl Canc Inst Canc, Baltimore, MD 21201 USA; [Konstantopoulos, K.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA	Northeastern University - China; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Wang, P (corresponding author), Northeastern Univ, Coll Life & Hlth Sci, 3-11 Wenhua Rd, Shenyang 110819, Peoples R China.	wangpu@mail.neu.edu.cn; konstant@jhu.edu			NCI [R01 CA186286, U54 CA143868]; Kleberg Foundation; National Science Foundation [1159823]; Natural Science Foundation of China [31300777]; Fundamental Research Funds of China [N120520001, N120320001, N130120002]; Liaoning Provincial Talent Support Program [LJQ2013029]; NATIONAL CANCER INSTITUTE [P30CA006973, R01CA186286, U54CA143868] Funding Source: NIH RePORTER; Div Of Chem, Bioeng, Env, & Transp Sys [1159823] Funding Source: National Science Foundation	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Kleberg Foundation; National Science Foundation(National Science Foundation (NSF)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds of China; Liaoning Provincial Talent Support Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This work was supported in part or in whole by the NCI (R01 CA186286, U54 CA143868), the Kleberg Foundation, the National Science Foundation (1159823), the Natural Science Foundation of China (31300777), the Fundamental Research Funds of China (N120520001, N120320001 and N130120002) and the Liaoning Provincial Talent Support Program (LJQ2013029).	Abulencia JP, 2003, J BIOL CHEM, V278, P28388, DOI 10.1074/jbc.M301378200; Aigner T, 2002, CANCER, V94, P2273, DOI 10.1002/cncr.10461; Balzer EM, 2012, FASEB J, V26, P4045, DOI 10.1096/fj.12-211441; Berend KR, 1998, J BONE JOINT SURG AM, V80A, P11, DOI 10.2106/00004623-199801000-00004; Chang SF, 2008, P NATL ACAD SCI USA, V105, P3927, DOI 10.1073/pnas.0712353105; Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005; CHARY SR, 1989, P NATL ACAD SCI USA, V86, P5385, DOI 10.1073/pnas.86.14.5385; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Cheng P, 2010, DIGEST DIS SCI, V55, P3138, DOI 10.1007/s10620-010-1127-3; Dafni H, 2002, CANCER RES, V62, P6731; Dallas MR, 2012, FASEB J, V26, P2648, DOI 10.1096/fj.12-203786; dela Paz NG, 2012, J CELL SCI, V125, P831, DOI 10.1242/jcs.084301; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136; Gunningham SP, 2001, J PATHOL, V193, P325, DOI 10.1002/path.814; Hamamura K, 2008, CELL BIOL INT, V32, P1238, DOI 10.1016/j.cellbi.2008.07.007; Healy ZR, 2008, AM J PHYSIOL-CELL PH, V294, pC1146, DOI 10.1152/ajpcell.00542.2007; Healy ZR, 2005, P NATL ACAD SCI USA, V102, P14010, DOI 10.1073/pnas.0506620102; HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706; Hofmann HS, 2005, CLIN CANCER RES, V11, P1086; Houghton AM, 2006, CANCER RES, V66, P6149, DOI 10.1158/0008-5472.CAN-04-0297; Hung WC, 2013, J CELL BIOL, V202, P807, DOI 10.1083/jcb.201302132; Jain RK, 2007, CANCER RES, V67, P2729, DOI 10.1158/0008-5472.CAN-06-4102; Jia HY, 2004, J BIOL CHEM, V279, P36148, DOI 10.1074/jbc.M401538200; Karnezis T, 2012, CANCER CELL, V21, P181, DOI 10.1016/j.ccr.2011.12.026; Kerkela E, 2001, BONE, V29, P487, DOI 10.1016/S8756-3282(01)00595-6; Milkiewicz M, 2001, MICROCIRCULATION, V8, P229, DOI 10.1038/sj.mn.7800074; Orr AW, 2005, J CELL BIOL, V169, P191, DOI 10.1083/jcb.200410073; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Qazi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020348; Rago C, 2007, CANCER RES, V67, P9364, DOI 10.1158/0008-5472.CAN-07-0605; Rutkowski JM, 2007, TRENDS CELL BIOL, V17, P44, DOI 10.1016/j.tcb.2006.11.007; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Sarkar S, 2006, CANCER RES, V66, P11771, DOI 10.1158/0008-5472.CAN-05-0470; Soderstrom M, 2001, APMIS, V109, P305, DOI 10.1034/j.1600-0463.2001.d01-125.x; Stroka KM, 2014, CELL, V157, P611, DOI 10.1016/j.cell.2014.02.052; Tang CH, 2012, BIOMEDICINE-TAIWAN, V2, P92, DOI 10.1016/j.biomed.2012.01.001; Tong ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029211; Wang P, 2012, J BIOL CHEM, V287, P31877, DOI 10.1074/jbc.M112.362731; Yang W, 2001, CANCER, V91, P1277, DOI 10.1002/1097-0142(20010401)91:7<1277::AID-CNCR1129>3.0.CO;2-H; Yang XS, 2007, PATHOL RES PRACT, V203, P499, DOI 10.1016/j.prp.2007.03.008; Yilmaz A, 2003, BIOCHEM BIOPH RES CO, V306, P730, DOI 10.1016/S0006-291X(03)01064-7; Zhu F, 2010, CELL DEATH DIFFER, V17, P1325, DOI 10.1038/cdd.2010.13	44	43	45	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4558	4569		10.1038/onc.2014.397	http://dx.doi.org/10.1038/onc.2014.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435370	Green Accepted			2022-12-28	WOS:000360189300002
J	Kumaraswamy, E; Wendt, KL; Augustine, LA; Stecklein, SR; Sibala, EC; Li, D; Gunewardena, S; Jensen, RA				Kumaraswamy, E.; Wendt, K. L.; Augustine, L. A.; Stecklein, S. R.; Sibala, E. C.; Li, D.; Gunewardena, S.; Jensen, R. A.			BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function	ONCOGENE			English	Article							DUCTAL CARCINOMA; MUTATIONS; PHENOTYPE; MIR-146A; DYSREGULATION; ASSOCIATION; PROGENITORS; MECHANISMS	Breast cancer 1 (BRCA1)-associated breast cancers are mostly basal-like high-grade ductal carcinomas that frequently overexpress epidermal growth factor receptor (EGFR). Aberrant EGFR expression is correlated with disease progression, resistance to radiation and chemotherapy, and poor clinical prognosis. Although BRCA1 is involved in multiple cellular processes, its functional role in EGFR regulation remains enigmatic. Here, we report a previously unrecognized posttranscriptional mechanism by which BRCA1 regulates EGFR expression through the induction of miR-146a. We demonstrate that EGFR expression correlates negatively with BRCA1, whereas miR-146a levels increase with BRCA1. We show that BRCA1 binds to MIR146A promoter and activates transcription, which in turn attenuates EGFR expression. Knockdown of miR-146a in BRCA1-overexpressing cells negated this effect and suppressed its ability to inhibit proliferation and transformation. In archived triple-negative breast cancer samples, we show a strong positive correlation between BRCA1 and miR-146a expression. We also show that low expression of miR-146a strongly predicts positive lymph node status and is associated with distinctively poor overall survival of patients. Together, these observations provide an insight into a novel BRCA1 -> miR-146a -> EGFR paradigm by which BRCA1 carries out an aspect of tumor suppressor function that is potentially amenable to therapeutic intervention.	[Kumaraswamy, E.; Stecklein, S. R.; Jensen, R. A.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Kumaraswamy, E.; Wendt, K. L.; Augustine, L. A.; Sibala, E. C.; Li, D.; Jensen, R. A.] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA; [Gunewardena, S.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Gunewardena, S.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66160 USA; [Jensen, R. A.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66160 USA; [Jensen, R. A.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Jensen, R. A.] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas	Kumaraswamy, E (corresponding author), Univ Kansas, Ctr Canc, 3901 Rainbow Blvd,Mail Stop 1016, Kansas City, KS 66160 USA.	ekumaraswamy@kumc.edu; rjensen@kumc.edu		Stecklein, Shane/0000-0001-8322-5886	University of Kansas Cancer Center;  [P30 CA168524];  [P20 RR016443]; NATIONAL CANCER INSTITUTE [P30CA168524] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016443] Funding Source: NIH RePORTER	University of Kansas Cancer Center; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Vargheese Chennathukuzhi and Lisa Harlan-Williams for critical review of the manuscript. The HA-tagged wild-type and deletion mutant adenoviruses were a kind gift from Jeffrey Parvin (The Ohio State University Medical Center). We thank Dr David Baltimore (Caltech Institute of Technology) for the miR-146a promoter luciferase construct. We thank Dr Ossama Tawfik, Tim Metcalf, Marsha Danley and the Biospecimen Shared Resources for assistance with clinical samples. We also thank Flow-Cytometry Shared Resource (supported by P30 CA168524 and P20 RR016443) of the University of Kansas Medical Center. This work was supported by the University of Kansas Cancer Center.	Arnes JB, 2009, J CLIN PATHOL, V62, P139, DOI 10.1136/jcp.2008.056291; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Booth BW, 2010, EXP CELL RES, V316, P422, DOI 10.1016/j.yexcr.2009.11.006; Buckley NE, 2012, STEM CELL REV REP, V8, P982, DOI 10.1007/s12015-012-9354-y; Burga LN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2850; Chang S, 2012, MOL CELLS, V34, P425, DOI 10.1007/s10059-012-0118-y; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chiba N, 2002, CANCER RES, V62, P4222; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Kawai S, 2012, J CELL BIOL, V197, P201, DOI 10.1083/jcb.201110008; Kumaraswamy E, 2007, MOL CELL BIOL, V27, P6733, DOI 10.1128/MCB.00961-07; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Lian H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031615; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Mei J, 2011, MOL CELL BIOL, V31, P3584, DOI 10.1128/MCB.05821-11; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; SAINSBURY JRC, 1987, LANCET, V1, P1398; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Shuen AY, 2011, J MAMMARY GLAND BIOL, V16, P3, DOI 10.1007/s10911-011-9213-5; Silver DP, 2012, CANCER DISCOV, V2, P679, DOI 10.1158/2159-8290.CD-12-0221; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tanic M, 2012, BREAST CANCER RES TR, V134, P41, DOI 10.1007/s10549-011-1905-4; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Toyama T, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-309; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Uhlmann S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.100; Viale G, 2009, BREAST CANCER RES TR, V116, P317, DOI 10.1007/s10549-008-0206-z; Xu B, 2012, PROSTATE, V72, P1171, DOI 10.1002/pros.22466; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108	50	55	59	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4333	4346		10.1038/onc.2014.363	http://dx.doi.org/10.1038/onc.2014.363			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417703	Green Accepted			2022-12-28	WOS:000359494400005
J	Hu, J; Muller, KA; Furnari, FB; Cavenee, WK; VandenBerg, SR; Gonias, SL				Hu, J.; Muller, K. A.; Furnari, F. B.; Cavenee, W. K.; VandenBerg, S. R.; Gonias, S. L.			Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; UROKINASE PLASMINOGEN-ACTIVATOR; BREAST-CANCER CELLS; SRC-FAMILY KINASES; CONFERS ENHANCED TUMORIGENICITY; TYROSINE KINASE; MUTANT EGFR; PHASE-II; IN-VIVO; C-SRC	In glioblastoma (GBM), the EGF receptor (EGFR) and Src family kinases (SFKs) contribute to an aggressive phenotype. EGFR may be targeted therapeutically; however, resistance to EGFR-targeting drugs such as Erlotinib and Gefitinib develops quickly. In many GBMs, a truncated form of the EGFR (EGFRvIII) is expressed. Although EGFRvIII is constitutively active and promotes cancer progression, its activity is attenuated compared with EGF-ligated wild-type EGFR, suggesting that EGFRvIII may function together with other signaling receptors in cancer cells to induce an aggressive phenotype. In this study, we demonstrate that in EGFRvIII-expressing GBM cells, the urokinase receptor (uPAR) functions as a major activator of SFKs, controlling phosphorylation of downstream targets, such as p130Cas and Tyr-845 in the EGFR in vitro and in vivo. When EGFRvIII expression in GBM cells was neutralized, either genetically or by treating the cells with Gefitinib, paradoxically, the cells demonstrated increased cell migration. The increase in cell migration was explained by a compensatory increase in expression of urokinase-type plasminogen activator, which activates uPAR-dependent cell signaling. GBM cells that were selected for their ability to grow in vivo in the absence of EGFRvIII also demonstrated increased cell migration, due to activation of the uPAR signaling system. The increase in GBM cell migration, induced by genetic or pharmacologic targeting of the EGFR, was blocked by Dasatinib, highlighting the central role of SFKs in uPAR-promoted cell migration. These results suggest that compensatory activation of uPAR-dependent cell signaling, in GBM cells treated with targeted therapeutics, may adversely affect the course of the disease by promoting cell migration, which may be associated with tumor progression.	[Hu, J.; Muller, K. A.; Furnari, F. B.; VandenBerg, S. R.; Gonias, S. L.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Furnari, F. B.; Cavenee, W. K.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Cavenee, W. K.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Gonias, SL (corresponding author), UCSD, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu	Jones, Karra A/GXM-8805-2022	Jones, Karra A/0000-0002-8819-8992; Furnari, Frank/0000-0003-1909-4361	NIH [R01 CA169096, R01 NS080939]; Defeat GBM Research Collaborative; subsidiary of National Brain Tumor Society; NATIONAL CANCER INSTITUTE [P30CA023100, R01CA169096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defeat GBM Research Collaborative; subsidiary of National Brain Tumor Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH R01 CA169096 (to SLG), R01 NS080939 (to FBF) and the Defeat GBM Research Collaborative, a subsidiary of National Brain Tumor Society (to WKC and FBF). WKC is a Fellow of the National Foundation for Cancer Research. We would like to thank Aran Merati and Nancy Du for their technical assistance with some of the experiments.	Ahluwalia MS, 2010, CANCER LETT, V298, P139, DOI 10.1016/j.canlet.2010.08.014; Alfano D, 2005, THROMB HAEMOSTASIS, V93, P205, DOI 10.1160/TH04-09-0592; Alfano D, 2006, J BIOL CHEM, V281, P17758, DOI 10.1074/jbc.M601812200; Alper O, 2005, CURR PHARM DESIGN, V11, P1119, DOI 10.2174/1381612053507576; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Carriero MV, 2011, CURR DRUG TARGETS, V12, P1761; Carriero MV, 1999, CANCER RES, V59, P5307; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Chumbalkar V, 2011, J PROTEOME RES, V10, P1343, DOI 10.1021/pr101075e; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Eastman BM, 2012, CELL SIGNAL, V24, P1847, DOI 10.1016/j.cellsig.2012.05.011; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Franceschi E, 2007, BRIT J CANCER, V96, P1047, DOI 10.1038/sj.bjc.6603669; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hu JJ, 2011, P NATL ACAD SCI USA, V108, P15984, DOI 10.1073/pnas.1113416108; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Huveldt D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056505; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jo M, 2007, ONCOGENE, V26, P2585, DOI 10.1038/sj.onc.1210066; Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960; Jo M, 2009, AM J PATHOL, V175, P190, DOI 10.2353/ajpath.2009.081053; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; Lu-Emerson C, 2011, J NEURO-ONCOL, V104, P287, DOI 10.1007/s11060-010-0489-x; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; Mazar AP, 2011, CURR PHARM DESIGN, V17, P1970; Montuori N, 2013, THROMB HAEMOSTASIS, V109, P309, DOI 10.1160/TH12-08-0546; Mukasa A, 2010, P NATL ACAD SCI USA, V107, P2616, DOI 10.1073/pnas.0914356107; Nagane M, 1996, CANCER RES, V56, P5079; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Parker JJ, 2013, NEURO-ONCOLOGY, V15, P1048, DOI 10.1093/neuonc/not053; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sato K, 2013, INT J MOL SCI, V14, P10761, DOI 10.3390/ijms140610761; SCHLEGEL J, 1994, J NEURO-ONCOL, V22, P201, DOI 10.1007/BF01052920; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shi ZG, 2011, MOL CELL BIOCHEM, V357, P151, DOI 10.1007/s11010-011-0885-3; Smith HW, 2008, J CELL BIOL, V182, P777, DOI 10.1083/jcb.200712050; Stettner AR, 2005, CANCER RES, V65, P5535, DOI 10.1158/0008-5472.CAN-04-3688; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wykosky J, 2010, CELL CYCLE, V9, P1661, DOI 10.4161/cc.9.9.11592; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	67	15	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4078	4088		10.1038/onc.2014.336	http://dx.doi.org/10.1038/onc.2014.336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347738	Green Accepted, Green Submitted			2022-12-28	WOS:000358780500006
J	Lincet, H; Icard, P				Lincet, H.; Icard, P.			How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?	ONCOGENE			English	Review							AUTOCRINE MOTILITY FACTOR; PYRUVATE-KINASE M2; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GAPDH; PHOSPHOGLYCERATE MUTASE 1; NUCLEAR TRANSLOCATION; BREAST-CANCER; HEXOKINASE 2; ALDOLASE-A; TRIOSEPHOSPHATE ISOMERASE; POOR-PROGNOSIS	Cancer cells enhance their glycolysis, producing lactate, even in the presence of oxygen. Glycolysis is a series of ten metabolic reactions catalysed by enzymes whose expression is most often increased in tumour cells. HKII and phosphoglucose isomerase (PGI) have mainly an antiapoptotic effect; PGI and glyceraldehyde-3-phosphate dehydrogenase activate survival pathways (Akt and so on); phosphofructokinase 1 and triose phosphate isomerase participate in cell cycle activation; aldolase promotes epithelial mesenchymal transition; PKM2 enhances various nuclear effects such as transcription, stabilisation and so on. This review outlines the multiple non-glycolytic roles of glycolytic enzymes, which are essential for promoting cancer cells' survival, proliferation, chemoresistance and dissemination.	[Lincet, H.; Icard, P.] Locally Aggress Canc Biol & Therapy Unit BioTICLA, Caen, France; [Lincet, H.] Normandie Univ, Caen, France; [Lincet, H.] Francois Baclesse Ctr Canc, Caen, France; [Icard, P.] Ecole Polytech, Lab Informat, Palaiseau, France	Institut Polytechnique de Paris	Lincet, H (corresponding author), Ctr Francois Baclesse, Locally Aggress Canc Biol & Therapy Unit BioTICLA, EA 4656, Av Gen Harris, F-14032 Caen, France.	h.lincet@baclesse.fr	ICARD, Philippe/K-6510-2015					Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107; Araki K, 2009, J BIOL CHEM, V284, P32305, DOI 10.1074/jbc.M109.008250; ASAKA M, 1994, J CLIN LAB ANAL, V8, P144, DOI 10.1002/jcla.1860080306; Atsumi T, 2002, CANCER RES, V62, P5881; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001; Buscaglia CA, 2006, J BIOL CHEM, V281, P1324, DOI 10.1074/jbc.M506346200; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Canete-Soler R, 2005, J NEUROSCI, V25, P4353, DOI 10.1523/JNEUROSCI.0885-05.2005; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; Chaerkady R, 2008, J PROTEOME RES, V7, P4289, DOI 10.1021/pr800197z; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chen GA, 2002, CLIN CANCER RES, V8, P2298; Chen J, 2014, TUMOR BIOL, V35, P3743, DOI 10.1007/s13277-013-1496-2; Chen JQ, 2012, BBA-REV CANCER, V1826, P370, DOI 10.1016/j.bbcan.2012.06.004; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Chesney J, 2006, CURR OPIN CLIN NUTR, V9, P535, DOI 10.1097/01.mco.0000241661.15514.fb; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Colell A, 2009, CELL DEATH DIFFER, V16, P1573, DOI 10.1038/cdd.2009.137; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; Demaria Marco, 2012, JAKSTAT, V1, P194, DOI 10.4161/jkst.20662; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Demarse NA, 2009, J MOL BIOL, V394, P789, DOI 10.1016/j.jmb.2009.09.062; Desai S, 2013, ONCOTARGET, V5, P1; Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902; Di Michele M, 2010, J PROTEOMICS, V73, P879, DOI 10.1016/j.jprot.2009.11.012; Du S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085804; Evans MJ, 2007, MOL BIOSYST, V3, P495, DOI 10.1039/b705113a; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Funasaka T, 2005, FASEB J, V19, P1422, DOI 10.1096/fj.05-3699com; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Gao ZH, 2000, BIOCHEM BIOPH RES CO, V268, P562, DOI 10.1006/bbrc.2000.2168; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRISOLIA S, 1968, BIOCHEMISTRY-US, V7, P1115, DOI 10.1021/bi00843a032; Gruning NM, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.130232; Gruning NM, 2011, CELL METAB, V14, P415, DOI 10.1016/j.cmet.2011.06.017; Guo CM, 2013, CLIN TRANSL ONCOL, V15, P167, DOI 10.1007/s12094-012-0924-x; Haga A, 2003, INT J CANCER, V107, P707, DOI 10.1002/ijc.11449; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Hamaguchi T, 2008, INT J ONCOL, V33, P725, DOI 10.3892/ijo_00000058; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Hinkle PC, 2005, BBA-BIOENERGETICS, V1706, P1, DOI 10.1016/j.bbabio.2004.09.004; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hoshino A, 2007, J BIOL CHEM, V282, P17706, DOI 10.1074/jbc.M700094200; Huang JS, 2009, BRAIN RES, V1279, P1, DOI 10.1016/j.brainres.2009.05.011; Huang QJ, 2011, J BIOL CHEM, V286, P42211, DOI 10.1074/jbc.M111.296905; Huang W, 2014, ACTA BIOCH BIOPH SIN, V46, P204, DOI 10.1093/abbs/gmt154; Icard P, 2012, BBA-REV CANCER, V1826, P423, DOI 10.1016/j.bbcan.2012.07.001; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Iqbal MA, 2014, FEBS LETT, V588, P2685, DOI 10.1016/j.febslet.2014.04.011; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85; Jenkins CM, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.203661; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Joo HY, 2012, BIOCHEM BIOPH RES CO, V424, P681, DOI 10.1016/j.bbrc.2012.07.006; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Kho DH, 2013, CANCER RES, V73, P1411, DOI 10.1158/0008-5472.CAN-12-2149; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; Krasnov GS, 2013, EXPERT OPIN THER TAR, V17, P681, DOI 10.1517/14728222.2013.775253; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kruger A, 2011, ANTIOXID REDOX SIGN, V15, P311, DOI 10.1089/ars.2010.3797; Krynetski EY, 2003, CANCER RES, V63, P100; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Kwee SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046591; Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; Lee WH, 2010, TOXICOLOGY, V278, P224, DOI 10.1016/j.tox.2010.02.005; Leite TC, 2007, BIOCHEM J, V408, P123, DOI 10.1042/BJ20070687; Lew CR, 2012, J BIOL CHEM, V287, P42554, DOI 10.1074/jbc.M112.405969; Li C, 2006, PROTEOMICS, V6, P547, DOI 10.1002/pmic.200500256; Li J, 2014, CLIN TRANSL ONCOL, V16, P200, DOI 10.1007/s12094-013-1063-8; Li TT, 2014, J BIOL CHEM, V289, P3775, DOI 10.1074/jbc.M113.531640; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Liu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091606; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lu J, 2008, BIOCHEM BIOPH RES CO, V369, P948, DOI 10.1016/j.bbrc.2008.02.122; Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mamczur P, 2013, BBA-MOL CELL RES, V1833, P2812, DOI 10.1016/j.bbamcr.2013.07.013; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Mehla K, 2014, BBA-REV CANCER, V1845, P126, DOI 10.1016/j.bbcan.2014.01.001; MEYERSIEGLER K, 1992, CARCINOGENESIS, V13, P2127, DOI 10.1093/carcin/13.11.2127; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; Min JW, 2013, BIOCHEM BIOPH RES CO, V440, P137, DOI 10.1016/j.bbrc.2013.09.041; MUKAI T, 1986, J BIOL CHEM, V261, P3347; Mukherjee J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057610; NABI IR, 1992, CANCER METAST REV, V11, P5, DOI 10.1007/BF00047599; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Nicholls C, 2012, P NATL ACAD SCI USA, V109, P13308, DOI 10.1073/pnas.1206672109; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Niinaka Y, 1998, CANCER RES, V58, P2667; Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008-5472.CAN-09-3880; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Palmieri D, 2009, MOL CANCER RES, V7, P1438, DOI 10.1158/1541-7786.MCR-09-0234; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Peschiaroli A, 2013, ONCOGENE, V32, P797, DOI 10.1038/onc.2012.100; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Poschmann G, 2009, MOL CELL PROTEOMICS, V8, P1105, DOI 10.1074/mcp.M800422-MCP200; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Ren FL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-81; Rider MH, 2004, BIOCHEM J, V381, P561, DOI 10.1042/BJ20040752; RONAI Z, 1992, BIOCHIM BIOPHYS ACTA, V1130, P20, DOI 10.1016/0167-4781(92)90456-A; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Saez DE, 2000, J CELL BIOCHEM, V78, P62, DOI 10.1002/(SICI)1097-4644(20000701)78:1<62::AID-JCB6>3.3.CO;2-N; Satou W, 2004, BIOCHEM BIOPH RES CO, V315, P845, DOI 10.1016/j.bbrc.2004.01.142; Semenza GL, 2011, COLD SH Q B, V76, P347, DOI 10.1101/sqb.2011.76.010678; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; Sharma NK, 2013, J PROTEOMICS, V79, P277, DOI 10.1016/j.jprot.2012.12.020; Shen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047476; SHINOHARA Y, 1994, CANCER LETT, V82, P27, DOI 10.1016/0304-3835(94)90142-2; Sirover MA, 2012, J CELL BIOCHEM, V113, P2193, DOI 10.1002/jcb.24113; Stetak A, 2007, CANCER RES, V67, P1602, DOI 10.1158/0008-5472.CAN-06-2870; Stryer L, 1981, BIOCHEMISTRY; Takahashi Y, 1998, EUR J BIOCHEM, V254, P497, DOI 10.1046/j.1432-1327.1998.2540497.x; Tarze A, 2007, ONCOGENE, V26, P2606, DOI 10.1038/sj.onc.1210074; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tristan C, 2011, CELL SIGNAL, V23, P317, DOI 10.1016/j.cellsig.2010.08.003; Tsutsumi S, 2003, CANCER RES, V63, P242; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897; Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095; Ventura M, 2010, INT J BIOCHEM CELL B, V42, P1672, DOI 10.1016/j.biocel.2010.06.014; Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111; Wang LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067542; Wang X, 2008, J CANCER RES CLIN, V134, P995, DOI 10.1007/s00432-008-0367-5; Watanabe H, 1996, CANCER RES, V56, P2960; Wierenga RK, 2010, CELL MOL LIFE SCI, V67, P3961, DOI 10.1007/s00018-010-0473-9; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wong N, 2014, CANC LETT IN PRESS; Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816; Yang J, 2010, J THEOR BIOL, V266, P231, DOI 10.1016/j.jtbi.2010.06.009; Yang P, 2014, CELL SIGNAL, V26, P1853, DOI 10.1016/j.cellsig.2014.03.020; Yang WW, 2013, CANCER LETT, V339, P153, DOI 10.1016/j.canlet.2013.06.008; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; You ZM, 2014, ASIAN PAC J CANCER P, V15, P1099, DOI 10.7314/APJCP.2014.15.3.1099; Zhang XL, 2013, PATHOL RES PRACT, V209, P510, DOI 10.1016/j.prp.2013.06.005; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	165	124	127	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3751	3759		10.1038/onc.2014.320	http://dx.doi.org/10.1038/onc.2014.320			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263450				2022-12-28	WOS:000358001600001
J	Haque, I; Banerjee, S; De, A; Maity, G; Sarkar, S; Majumdar, M; Jha, SS; McGragor, D; Banerjee, SK				Haque, I.; Banerjee, S.; De, A.; Maity, G.; Sarkar, S.; Majumdar, M.; Jha, S. S.; McGragor, D.; Banerjee, S. K.			CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; CDK INHIBITOR; INVASIVE PHENOTYPES; ONCOGENIC FUNCTION; TUMOR-CELLS; P27; EXPRESSION; CYCLE; ESTROGEN; DEGRADATION	The matricellular protein CCN5/WISP-2 represents a promising target in triple-negative breast cancer (TNBC) because treatment or induced activation of CCN5 in TNBC cells promotes cell growth arrest at the G0/G1 phase, reduces cell proliferation and delays tumor growth in the xenograft model. Our studies found that the p27(Kip1) tumor suppressor protein is upregulated and relocalized to the nucleus from cytoplasm by CCN5 in these cells and that these two events (upregulation and relocalization of p27(Kip1)) are critical for CCN5-induced growth inhibition of TNBC cells. In the absence of CCN5, p27(Kip1) resides mostly in the cytoplasm, which is associated with the aggressive nature of cancer cells. Mechanistically, CCN5 inhibits Skp2 expression, which seems to stabilize the p27(Kip1) protein in these cells. On the other hand, CCN5 also recruits FOXO3a to mediate the transcriptional regulation of p27(Kip1). The recruitment of FOXO3a is achieved by the induction of its expression and activity through shifting from cytoplasm to the nucleus. Our data indicate that CCN5 blocks PI3K/AKT signaling to dephosphorylate at S318, S253 and Thr32 in FOXO3a for nuclear relocalization and activation of FOXO3a. Moreover, inhibition of alpha 6 beta 1 receptors diminishes CCN5 action on p27(Kip1) in TNBC cells. Collectively, these data suggest that CCN5 effectively inhibits TNBC growth through the accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation, and thus, activation of CCN5 may have the therapeutic potential to kill TNBC.	[Haque, I.; Banerjee, S.; De, A.; Maity, G.; Sarkar, S.; Majumdar, M.; Jha, S. S.; McGragor, D.; Banerjee, S. K.] Vet Adm Med Ctr, Canc Res Unit, Kansas City, MO 64128 USA; [Haque, I.; Banerjee, S.; Maity, G.; Banerjee, S. K.] Univ Kansas, Med Ctr, Dept Med, Div Hematol & Oncol, Kansas City, MO USA; [Sarkar, S.; Banerjee, S. K.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, MO USA; [Sarkar, S.; Banerjee, S. K.] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, MO USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas; University of Kansas	Banerjee, SK (corresponding author), Vet Adm Med Ctr, Canc Res Unit, Res Div 151, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	sbanerjee2@kumc.edu	Banerjee, Sushanta/AAG-6534-2021; Haque, Inamul/I-2482-2019	Banerjee, Sushanta/0000-0002-7698-0717; Haque, Inamul/0000-0002-1307-9446	VA Merit Award; Veterans Affairs [I01BX001989] Funding Source: NIH RePORTER	VA Merit Award(US Department of Veterans Affairs); Veterans Affairs(US Department of Veterans Affairs)	These studies were supported by VA Merit Award grants (SKB and SB).	Alkarain A, 2004, J MAMMARY GLAND BIOL, V9, P67, DOI 10.1023/B:JOMG.0000023589.00994.5e; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Banerjee S, 2005, MOL CANCER RES, V3, P151, DOI 10.1158/1541-7786.MCR-04-0130; Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; Banerjee S, 2008, CANCER RES, V68, P7606, DOI 10.1158/0008-5472.CAN-08-1461; Banerjee S, 2006, MOL CARCINOGEN, V45, P871, DOI 10.1002/mc.20248; Banerjee SK, 2012, J CELL COMMUN SIGNAL, V6, P63, DOI 10.1007/s12079-012-0158-2; Barbareschi M, 2000, INT J CANCER, V89, P236, DOI 10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.3.CO;2-Q; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; De Paola F, 2002, J PATHOL, V196, P26, DOI 10.1002/path.1011; Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316; Dhar G, 2007, CANCER LETT, V254, P63, DOI 10.1016/j.canlet.2007.02.012; Dhar K, 2007, CANCER RES, V67, P1520, DOI 10.1158/0008-5472.CAN-06-3753; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Haque I, 2012, J BIOL CHEM, V287, P38569, DOI 10.1074/jbc.M112.389064; Haque I, 2011, J BIOL CHEM, V286, P43475, DOI 10.1074/jbc.M111.284158; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Mineta H, 1999, CANCER-AM CANCER SOC, V85, P1011, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1011::AID-CNCR1>3.0.CO;2-0; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Nakao T, 2008, CELL CYCLE, V7, P257, DOI 10.4161/cc.7.2.5148; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Oliveira LR, 2010, HISTOL HISTOPATHOL, V25, P371, DOI 10.14670/HH-25.371; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reed W, 1999, VIRCHOWS ARCH, V435, P116, DOI 10.1007/s004280050408; Russo JW, 2010, J CELL COMMUN SIGNAL, V4, P119, DOI 10.1007/s12079-010-0098-7; Sabbah M, 2011, MOL CELL BIOL, V31, P1459, DOI 10.1128/MCB.01316-10; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Simpson PT, 2005, AM J SURG PATHOL, V29, P734, DOI 10.1097/01.pas.0000157295.93914.3b; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Troncone G, 2004, DIAGN CYTOPATHOL, V30, P375, DOI 10.1002/dc.20059; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Wei SO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047298; Zhang SW, 2013, J CELL BIOCHEM, V114, P354, DOI 10.1002/jcb.24371	55	28	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3152	3163		10.1038/onc.2014.250	http://dx.doi.org/10.1038/onc.2014.250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25132260	Bronze			2022-12-28	WOS:000356101100007
J	Krajewska, M; Fehrmann, RSN; Schoonen, PM; Labib, S; de Vries, EGE; Franke, L; van Vugt, MATM				Krajewska, M.; Fehrmann, R. S. N.; Schoonen, P. M.; Labib, S.; de Vries, E. G. E.; Franke, L.; van Vugt, M. A. T. M.			ATR inhibition preferentially targets homologous recombination-deficient tumor cells	ONCOGENE			English	Article							STRAND BREAK REPAIR; CANCER SUSCEPTIBILITY GENE; EMBRYONIC CELLULAR PROLIFERATION; INDUCED REPLICATIVE STRESS; RAD51 RECOMBINASE; MAMMALIAN-CELLS; BRCA2; TRANSFORMATION; MUTATIONS; MOUSE	Homologous recombination (HR) is required for faithful repair of double-strand DNA breaks. Defects in HR repair cause severe genomic instability and challenge cellular viability. Paradoxically, various cancers are HR defective and have apparently acquired characteristics to survive genomic instability. We aimed to identify these characteristics to uncover therapeutic targets for HR-deficient cancers. Cytogenetic analysis of 1143 ovarian cancers showed that the degree of genomic instability was correlated to amplification of replication checkpoint genes ataxia telangiectasia and Rad3-related kinase (ATR) and CHEK1. To test whether genomic instability leads to increased reliance on replication checkpoint signaling, we inactivated Rad51 to model HR-related genomic instability. Rad51 inactivation caused defective HR repair and induced aberrant replication dynamics. Notably, inhibition of Rad51 led to increased ATR/checkpoint kinase-1 (Chk1)-mediated replication stress signaling. Importantly, inhibition of ATR or Chk1 preferentially killed HR-deficient cancer cells. Combined, our data show that defective HR caused by Rad51 inhibition results in differential sensitivity for ATR and Chk1 inhibitors, implicating replication checkpoint kinases as potential drug targets for HR-defective cancers.	[Krajewska, M.; Fehrmann, R. S. N.; Schoonen, P. M.; Labib, S.; de Vries, E. G. E.; van Vugt, M. A. T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 Groningen, Netherlands; [Franke, L.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Genet, NL-9700 Groningen, Netherlands	University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9700 Groningen, Netherlands.	m.vugt@umcg.nl	Krajewska, Malgorzata/AAH-1158-2021; Franke, Lude/P-7036-2016; Fehrmann, Rudolf/E-2551-2011	Franke, Lude/0000-0002-5159-8802; Fehrmann, Rudolf/0000-0002-7516-315X; de Vries, Elisabeth/0000-0002-8949-7425; Krajewska, Malgorzata/0000-0002-2243-5924	NWO [917-3334]; Alpe d'HuZes/Dutch Cancer Society [RUG2013-5960]; Van der Meer-Boerema Foundation	NWO(Netherlands Organization for Scientific Research (NWO)); Alpe d'HuZes/Dutch Cancer Society; Van der Meer-Boerema Foundation	This work was financially supported by an NWO VIDI grant to MATMvV (917-3334), a Bas Mulder grant from the Alpe d'HuZes/Dutch Cancer Society (RUG2013-5960) to RSNF and funding from the Van der Meer-Boerema Foundation to MK. We thank Dr Maria Jasin for generously supplying materials.	Anantha RW, 2007, J BIOL CHEM, V282, P35910, DOI 10.1074/jbc.M704645200; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Fang Y, 2004, EMBO J, V23, P3164, DOI 10.1038/sj.emboj.7600315; Frappart PO, 2009, P NATL ACAD SCI USA, V106, P1880, DOI 10.1073/pnas.0806882106; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Greenblatt MS, 2001, CANCER RES, V61, P4092; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Huang F, 2011, ACS CHEM BIOL, V6, P628, DOI 10.1021/cb100428c; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Oza V, 2012, J MED CHEM, V55, P5130, DOI 10.1021/jm300025r; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; Sonoda E, 2006, DNA REPAIR, V5, P1021, DOI 10.1016/j.dnarep.2006.05.022; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	37	56	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3474	3481		10.1038/onc.2014.276	http://dx.doi.org/10.1038/onc.2014.276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174396				2022-12-28	WOS:000356871700012
J	Fuchs, D; Metzig, M; Bickeboller, M; Brandel, C; Roth, W				Fuchs, D.; Metzig, M.; Bickeboeller, M.; Brandel, C.; Roth, W.			The G beta 5 protein regulates sensitivity to TRAIL-induced cell death in colon carcinoma	ONCOGENE			English	Article							NF-KAPPA-B; X-LINKED INHIBITOR; SMALL-MOLECULE DISRUPTION; GROWTH-FACTOR RECEPTOR; BETA-GAMMA SUBUNITS; NUCLEAR-LOCALIZATION; APOPTOSIS PROTEIN; CANCER-CELLS; COUPLED RECEPTORS; ADENYLYL-CYCLASE	Aberrant signaling via G protein-coupled receptors (GPCRs) is implicated in numerous diseases including colon cancer. The heterotrimeric G proteins transduce signals from GPCRs to various effectors. So far, the G protein subunit G beta 5 has not been studied in the context of cancer. Here we demonstrate that G beta 5 protects colon carcinoma cells from apoptosis induced by the death ligand TRAIL via different routes. The G beta 5 protein (i) causes a decrease in the cell surface expression of the TRAIL-R2 death receptor, (ii) induces the expression of the anti-apoptotic protein XIAP and (iii) activates the NF-kappa B signaling pathway. The intrinsic resistance to TRAIL-triggered apoptosis of colon cancer cells is overcome by antagonization of G beta 5. Based on these results, targeting of G proteins emerges as a novel therapeutic approach in the experimental treatment of colon cancer.	[Fuchs, D.; Metzig, M.; Bickeboeller, M.; Brandel, C.; Roth, W.] German Canc Res Ctr, Mol Tumor Pathol, D-69120 Heidelberg, Germany; [Metzig, M.; Roth, W.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Roth, W (corresponding author), German Canc Res Ctr, Mol Tumor Pathol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de			Else Kroner-Fresenius Foundation [2012_A20]	Else Kroner-Fresenius Foundation	We thank William F Simonds (National Institute of Diabetes and Digestive and Kidney Diseases, USA) for providing pcDNA3-G beta 5-HA and Muxiang Zhou (Emory University School of Medicine, USA) for providing pc-cmv-I kappa B-am. This study was supported by a grant from the Else Kroner-Fresenius Foundation (2012_A20).	Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; Behrens J, 2004, INT J DEV BIOL, V48, P477, DOI 10.1387/ijdb.041815jb; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bhola NE, 2008, FRONT BIOSCI-LANDMRK, V13, P1857, DOI 10.2741/2805; Bonacci TM, 2006, SCIENCE, V312, P443, DOI 10.1126/science.1120378; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Braeuer SJ, 2006, MOL CANCER RES, V4, P715, DOI 10.1158/1541-7786.MCR-05-0231; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Casey LM, 2010, CIRC RES, V107, P532, DOI 10.1161/CIRCRESAHA.110.217075; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Frieze DA, 2006, ANN PHARMACOTHER, V40, P241, DOI 10.1345/aph.1G191; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Gutkind J S, 2000, Sci STKE, V2000, pre1, DOI 10.1126/stke.2000.40.re1; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hepler John R, 2005, Sci STKE, V2005, ppe38, DOI 10.1126/stke.2942005pe38; Hintersteiner M, 2010, ACS CHEM BIOL, V5, P967, DOI 10.1021/cb100094k; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Holubec L, 2012, ANTICANCER RES, V32, P4007; Hull MA, 2004, MOL CANCER THER, V3, P1031; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Karashima T, 2003, CLIN CANCER RES, V9, P2786; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Khan SM, 2013, PHARMACOL REV, V65, P545, DOI 10.1124/pr.111.005603; Kim EH, 2005, ONCOGENE, V24, P838, DOI 10.1038/sj.onc.1208241; Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237; Kojima Y, 2011, J BIOL CHEM, V286, P43383, DOI 10.1074/jbc.M111.309377; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; Lehmann DM, 2008, MOL PHARMACOL, V73, P410, DOI 10.1124/mol.107.041780; Leithner K, 2009, LUNG CANCER, V65, P98, DOI 10.1016/j.lungcan.2008.10.015; Liang JJ, 1998, J NEUROCHEM, V71, P345; Lin-Lee YC, 2006, J BIOL CHEM, V281, P18878, DOI 10.1074/jbc.M513315200; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; McClanahan T, 2006, CANCER BIOL THER, V5, P419, DOI 10.4161/cbt.5.4.2521; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Rojkova AM, 2003, J BIOL CHEM, V278, P12507, DOI 10.1074/jbc.M207302200; Roman DL, 2011, J MED CHEM, V54, P7433, DOI 10.1021/jm101572n; Rosato R, 2004, LEUKEMIA, V18, P1780, DOI 10.1038/sj.leu.2403491; Saif MW, 2010, EXPERT OPIN INV DRUG, V19, P357, DOI 10.1517/13543781003593962; Sakamoto K, 2010, EXPERT OPIN THER TAR, V14, P593, DOI 10.1517/14728221003769903; Schimmer AD, 2009, J CLIN ONCOL, V27, P4741, DOI 10.1200/JCO.2009.21.8172; Shirley S, 2011, RECENT PAT ANTI-CANC, V6, P311, DOI 10.2174/157489211796957757; Slepak VZ, 2009, PROG MOL BIOL TRANSL, V86, P157, DOI 10.1016/S1877-1173(09)86006-7; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; Smrcka AV, 2013, TRENDS PHARMACOL SCI, V34, P290, DOI 10.1016/j.tips.2013.02.006; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Sorokin AV, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1439, DOI 10.1134/S0006297907130032; Straszewski-Chavez SL, 2010, BIOL REPROD, V82, P146, DOI 10.1095/biolreprod.109.078972; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Vogelzang NJ, 2004, CANCER, V100, P65, DOI 10.1002/cncr.11867; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhang JH, 2011, J NEUROCHEM, V119, P544, DOI 10.1111/j.1471-4159.2011.07457.x; Zhang YQ, 2008, MOL CANCER RES, V6, P1861, DOI 10.1158/1541-7786.MCR-08-0313	68	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2753	2763		10.1038/onc.2014.213	http://dx.doi.org/10.1038/onc.2014.213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043307				2022-12-28	WOS:000354979500008
J	Akalay, I; Tan, TZ; Kumar, P; Janji, B; Mami-Chouaib, F; Charpy, C; Vielh, P; Larsen, AK; Thiery, JP; Sabbah, M; Chouaib, S				Akalay, I.; Tan, T. Z.; Kumar, P.; Janji, B.; Mami-Chouaib, F.; Charpy, C.; Vielh, P.; Larsen, A. K.; Thiery, J. P.; Sabbah, M.; Chouaib, S.			Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CTL-MEDIATED LYSIS; INVASIVE PHENOTYPES; IMMUNE SURVEILLANCE; TUMOR; INHIBITION; SUPPRESSES; GENERATION; INDUCTION; ESCAPE	The molecular basis for the resistance of tumor cells to cell-mediated cytotoxicity remains poorly understood and thus poses a major challenge for cancer immunotherapy. The present study was designed to determine whether the WNT1-inducible signaling pathway protein 2 (WISP2, also referred to as CCN5), a key regulator of tumor cell plasticity, interferes with tumor susceptibility to cytotoxic T-lymphocyte (CTL)-mediated lysis. We found that silencing WISP2 signaling in human breast adenocarcinoma MCF7 cells impairs CTL-mediated cell killing by a mechanism involving stem cell marker Kruppel-like factor-4 (KLF-4) induction and microRNA-7 (miR-7) downregulation. Inhibition of transforming growth factor beta (TGF-beta) signaling using the A83-01 inhibitor in MCF7-shWISP2 cells resulted in a significant reversal of the epithelial-to-mesenchymal-transitioned (EMT) phenotype, the expression of KLF-4 and a partial recovery of target susceptibility to CTLs. More importantly, we showed that silencing KLF-4 was accompanied by a reduction in MCF7-shWISP2 resistance to CTLs. Using human breast cancer tissues, we demonstrated the coexpression of KLF-beta with EMT markers and TGF-beta pathway signaling components. More importantly, we found that KLF-4 expression was accompanied by miR-7 inhibition, which is partly responsible for impairing CTL-mediated lysis. Thus, our data indicate that WISP2 has a role in regulating tumor cell susceptibility through EMT by inducing the TGF-beta signaling pathway, KLF-4 expression and miR-7 inhibition. These studies indicate for the first time that WISP2 acts as an activator of CTL-induced killing and suggests that the loss of its function promotes evasion of immunosurveillance and the ensuing progression of the tumor.	[Akalay, I.; Mami-Chouaib, F.; Chouaib, S.] Inst Gustave Roussy, INSERM, U753, F-94805 Villejuif, France; [Tan, T. Z.; Kumar, P.; Thiery, J. P.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Janji, B.] Publ Res Ctr Hlth CRP Sante, Dept Oncol, Lab Expt Hematooncol, Luxembourg, Luxembourg; [Charpy, C.; Vielh, P.] Inst Cancerol Gustave Roussy, Lab Rech Translat Module Histocytopathol, Villejuif, France; [Charpy, C.; Vielh, P.] Inst Cancerol Gustave Roussy, Ctr Ressources Biol, Villejuif, France; [Larsen, A. K.; Sabbah, M.] INSERM, U938, Lab Canc Biol & Therapeut, Ctr Rech St Antoine, Paris, France; [Larsen, A. K.; Sabbah, M.] Univ Paris 06, Paris, France; [Thiery, J. P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Thiery, J. P.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Luxembourg Institute of Health; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; National University of Singapore; National University of Singapore	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U753, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	Salem.CHOUAIB@gustaveroussy.fr	Mami-Chouaib, Fathia/E-5267-2016; Tan, Tuan Zea/I-9227-2019; Sabbah, Michèle/GSN-8858-2022; Thiery, Jean Paul/M-9387-2019; Chouaib, Salem/F-7939-2016; Thiery, Jean Paul/H-1550-2011	Tan, Tuan Zea/0000-0001-6624-1593; Sabbah, Michèle/0000-0001-5368-9022; Thiery, Jean Paul/0000-0003-0478-5020; , Dr. Prashant Kumar/0000-0001-8975-5108; JANJI, Bassam/0000-0002-9763-0943	INSERM; la Ligue Nationale Contre le Cancer; l'Association de Recherche sur le Cancer; A*STAR Institute of Molecular Cell Biology; Cancer Science Institute National University of Singapore; CRP-Sante; Fondation Cancer, Luxembourg	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); l'Association de Recherche sur le Cancer; A*STAR Institute of Molecular Cell Biology(Agency for Science Technology & Research (A*STAR)); Cancer Science Institute National University of Singapore(National University of Singapore); CRP-Sante; Fondation Cancer, Luxembourg	This work was supported by grants from INSERM, la Ligue Nationale Contre le Cancer, l'Association de Recherche sur le Cancer, A*STAR Institute of Molecular Cell Biology, Cancer Science Institute National University of Singapore core grants, CRP-Sante and Fondation Cancer, Luxembourg.	Akalay I, 2013, AUTOPHAGY, V9, P1104, DOI 10.4161/auto.24728; Akalay I, 2013, CANCER RES, V73, P2418, DOI 10.1158/0008-5472.CAN-12-2432; Anichini A, 1999, J EXP MED, V190, P651, DOI 10.1084/jem.190.5.651; Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; Banerjee S, 2008, CANCER RES, V68, P7606, DOI 10.1158/0008-5472.CAN-08-1461; Chouaib S, 2003, J CLIN INVEST, V111, P595, DOI 10.1172/JCI200318044; Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316; Dorothee G, 2003, ONCOGENE, V22, P7192, DOI 10.1038/sj.onc.1206627; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; El Hage F, 2008, P NATL ACAD SCI USA, V105, P10119, DOI 10.1073/pnas.0802753105; El-Karim EA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-89; Fang YX, 2012, HEPATOLOGY, V55, P1852, DOI 10.1002/hep.25576; Frewer KA, 2013, BRIT J SURG, V100, P10; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Giles KM, 2013, BIOCHEM BIOPH RES CO, V430, P706, DOI 10.1016/j.bbrc.2012.11.086; Hamai A, 2010, TISSUE ANTIGENS, V75, P1, DOI 10.1111/j.1399-0039.2009.01401.x; Hasmim M, 2011, J IMMUNOL, V187, P4031, DOI 10.4049/jimmunol.1101011; Holzel M, 2013, NAT REV CANCER, V13, P365, DOI 10.1038/nrc3498; Hu D, 2011, J BIOL CHEM, V286, P6890, DOI 10.1074/jbc.M110.179952; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Magnon C, 2007, J CLIN INVEST, V117, P1844, DOI 10.1172/JCI30269; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017; Reiman JM, 2010, CANCER RES, V70, P3005, DOI 10.1158/0008-5472.CAN-09-4041; Sabbah M, 2011, MOL CELL BIOL, V31, P1459, DOI 10.1128/MCB.01316-10; Shekhani MT, 2013, AM J STEM CELLS, V2, P52; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang L, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt96; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zhang XH, 2012, ARTERIOSCL THROM VAS, V32, P1015, DOI 10.1161/ATVBAHA.111.244962	39	49	49	4	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2261	2271		10.1038/onc.2014.151	http://dx.doi.org/10.1038/onc.2014.151			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931170				2022-12-28	WOS:000353473000011
J	Sausgruber, N; Coissieux, MM; Britschgi, A; Wyckoff, J; Aceto, N; Leroy, C; Stadler, MB; Voshol, H; Bonenfant, D; Bentires-Alj, M				Sausgruber, N.; Coissieux, M-M; Britschgi, A.; Wyckoff, J.; Aceto, N.; Leroy, C.; Stadler, M. B.; Voshol, H.; Bonenfant, D.; Bentires-Alj, M.			Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases	ONCOGENE			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR; IN-VIVO; C-SRC; MIGRATION; PAXILLIN; PHOSPHORYLATION; METASTASIS; TUMORS; DEPHOSPHORYLATION	Tumor cell migration has a fundamental role in early steps of metastasis, the fatal hallmark of cancer. In the present study, we investigated the effects of the tyrosine phosphatase, SRC-homology 2 domain-containing phosphatase 2 (SHP2), on cell migration in metastatic triple-negative breast cancer (TNBC), an aggressive disease associated with a poor prognosis for which a targeted therapy is not yet available. Using mouse models and multiphoton intravital imaging, we have identified a crucial effect of SHP2 on TNBC cell motility in vivo. Further, analysis of TNBC cells revealed that SHP2 also influences cell migration, chemotaxis and invasion in vitro. Unbiased phosphoproteomics and biochemical analysis showed that SHP2 activates several SRC-family kinases and downstream targets, most of which are inducers of migration and invasion. In particular, direct interaction between SHP2 and c-SRC was revealed by a fluorescence resonance energy transfer assay. These results suggest that SHP2 is a crucial factor during early steps of TNBC migration to distant organs.	[Sausgruber, N.; Coissieux, M-M; Britschgi, A.; Wyckoff, J.; Aceto, N.; Leroy, C.; Stadler, M. B.; Bentires-Alj, M.] Friedrich Miescher Inst FMI Biomed Res, Mechanisms Canc, CH-4058 Basel, Switzerland; [Wyckoff, J.] MIT, Koch Inst Integrated Canc Res, Cambridge, MA 02139 USA; [Aceto, N.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA; [Leroy, C.; Voshol, H.; Bonenfant, D.] Novartis Inst Biomed Res, Analyt Sci & Imaging, Basel, Switzerland; [Stadler, M. B.] Swiss Inst Bioinformat, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital; Novartis; Swiss Institute of Bioinformatics	Bentires-Alj, M (corresponding author), Friedrich Miescher Inst FMI Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	bentires@fmi.ch	Mohamed, Bentires-Alj/F-4484-2015; Aceto, Nicola/O-2484-2014	Mohamed, Bentires-Alj/0000-0001-6344-1127; Aceto, Nicola/0000-0001-9579-6918; Coissieux, Marie-May/0000-0001-5017-5253	FP7 Marie-Curie Fellowship; Novartis Research Foundation; European Research Council (ERC starting grant) [243211-PTPsBDC]; Swiss Cancer League; Krebsliga Beider Basel	FP7 Marie-Curie Fellowship; Novartis Research Foundation; European Research Council (ERC starting grant)(European Research Council (ERC)); Swiss Cancer League; Krebsliga Beider Basel	We thank C Kuperwasser for the SUM159 cells and S Gambhir for the pFU-Luc2-eGFP construct, L Bonapace for technical assistance with the intravital microscope, L Gelman for help with the FRET experiments, S Bourke and M Kirschmann for help with image acquisition and analysis, and I Klebba and H Brinkhaus for technical assistance. M-MC is supported by a FP7 Marie-Curie Fellowship and NA is a fellow of the Swiss National Science Foundation and the Human Frontiers Science Program. Research in the laboratory of MB-A is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTPsBDC), the Swiss Cancer League and the Krebsliga Beider Basel.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Bonapace L, 2012, J MAMMARY GLAND BIOL, V17, P125, DOI 10.1007/s10911-012-9250-8; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hartman ZR, 2013, MOL CANCER RES, V11, P651, DOI 10.1158/1541-7786.MCR-12-0578; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Iwasaki T, 2002, INT J CANCER, V97, P330, DOI 10.1002/ijc.1609; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Manes S, 1999, MOL CELL BIOL, V19, P3125; Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; PENG ZY, 1995, ONCOGENE, V11, P1955; Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Sachdev S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-12; Sanders MA, 2005, J BIOL CHEM, V280, P23516, DOI 10.1074/jbc.M413165200; Schober M, 2007, J CELL BIOL, V176, P667, DOI 10.1083/jcb.200608010; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; Wang WG, 2002, CANCER RES, V62, P6278; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zomer A, 2011, CLIN TRANSL ONCOL, V13, P848, DOI 10.1007/s12094-011-0745-3	29	46	46	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2272	2278		10.1038/onc.2014.170	http://dx.doi.org/10.1038/onc.2014.170			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931162				2022-12-28	WOS:000353473000012
J	Robichaud, N; del Rincon, SV; Huor, B; Alain, T; Petruccelli, LA; Hearnden, J; Goncalves, C; Grotegut, S; Spruck, CH; Furic, L; Larsson, O; Muller, WJ; Miller, WH; Sonenberg, N				Robichaud, N.; del Rincon, S. V.; Huor, B.; Alain, T.; Petruccelli, L. A.; Hearnden, J.; Goncalves, C.; Grotegut, S.; Spruck, C. H.; Furic, L.; Larsson, O.; Muller, W. J.; Miller, W. H.; Sonenberg, N.			Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3	ONCOGENE			English	Article							INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; MESSENGER-RNA; STAGE-I; DIFFERENTIAL TRANSLATION; SIGNALING PATHWAY; PROSPECTIVE TRIAL; FACTOR EIF-4E; EXPRESSION	The progression of cancers from primary tumors to invasive and metastatic stages accounts for the overwhelming majority of cancer deaths. Understanding the molecular events which promote metastasis is thus critical in the clinic. Translational control is emerging as an important factor in tumorigenesis. The messenger RNA (mRNA) cap-binding protein eIF4E is an oncoprotein that has an important role in cancer initiation and progression. eIF4E must be phosphorylated to promote tumor development. However, the role of eIF4E phosphorylation in metastasis is not known. Here, we show that mice in which eukaryotic translation initiation factor 4E (eIF4E) cannot be phosphorylated are resistant to lung metastases in a mammary tumor model, and that cells isolated from these mice exhibit impaired invasion. We also demonstrate that transforming growth factor-beta (TGF beta) induces eIF4E phosphorylation to promote the translation of Snail and Mmp-3 mRNAs, and the induction of epithelial-to-mesenchymal transition (EMT). Furthermore, we describe a new model wherein EMT induced by TGF beta requires translational activation via the non-canonical TGF beta signaling branch acting through eIF4E phosphorylation.	[Robichaud, N.; Hearnden, J.; Muller, W. J.; Sonenberg, N.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Robichaud, N.; Hearnden, J.; Muller, W. J.; Sonenberg, N.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [del Rincon, S. V.; Huor, B.; Petruccelli, L. A.; Goncalves, C.; Miller, W. H.] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ H3A 1A3, Canada; [Alain, T.] Univ Ottawa, Childrens Hosp, Eastern Ontario Res Inst, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Grotegut, S.; Spruck, C. H.] Sanford Burnham Med Res Inst, Signal Transduct Program, La Jolla, CA USA; [Furic, L.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Larsson, O.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden	McGill University; McGill University; Lady Davis Institute; McGill University; University of Ottawa; Children's Hospital of Eastern Ontario; Sanford Burnham Prebys Medical Discovery Institute; Monash University; Karolinska Institutet	Miller, WH (corresponding author), McGill Univ, Goodman Canc Res Ctr, Dept Biochem, Canc Pavil,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	wmiller@ldi.jgh.mcgill.ca; nahum.sonenberg@mcgill.ca	Furic, Luc/F-4886-2012	Furic, Luc/0000-0002-1893-9812; Larsson, Ola/0000-0003-1412-1308; Robichaud, Nathaniel/0000-0002-7653-0767	Susan G. Komen Breast Cancer Foundation [IIR12224057]; Canadian Cancer Society [2010-700377]; Cancer Research Society [2012-17280]; PCFA [YI-0310]; Fonds de la Recherche en Sante du Quebec [20874]; Canadian Institutes of Health Research [220151]; Vanier Canada Graduate Scholarship [267839]; Swedish Research Council; Swedish Cancer Society; Wallenberg Academy	Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Canadian Cancer Society(Canadian Cancer Society (CCS)); Cancer Research Society; PCFA; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Wallenberg Academy	This work was by supported by The Susan G. Komen Breast Cancer Foundation (IIR12224057), and the Canadian Cancer Society (2010-700377) to NS. WHM was supported by the Cancer Research Society (2012-17280). LF was supported by PCFA#YI-0310. NS is a Howard Hughes Medical Institute Senior International Scholar. WHM is a Chercheur National of Fonds de la Recherche en Sante du Quebec (FRSQ). NR was supported by scholarships from the Fonds de la Recherche en Sante du Quebec (20874), the Canadian Institutes of Health Research (220151) and the Vanier Canada Graduate Scholarship (267839). OL is supported by the Swedish Research Council, the Swedish Cancer Society and the Wallenberg Academy Fellows Program. We thank I Topisirovic for advice; C Zakaria, A Sylvestre, S Perreault and C Lister for technical assistance, N Siddiqui for critical reading of the manuscript and S Ramon y Cajal (the Vall d'Hebron University Hospital, Barcelona, Spain) for his support and insights into tumor heterogeneity. We thank the Animal Facility and the Histology Facility at the Goodman Cancer Research Centre for mouse work and tissue processing.	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; ALBINI A, 1987, CANCER RES, V47, P3239; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Astanehe A, 2012, ONCOGENE, V31, P4434, DOI 10.1038/onc.2011.617; Bakin AV, 2002, J CELL SCI, V115, P3193; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; BYERS HR, 1991, AM J PATHOL, V139, P423; Byrnes K, 2006, ANN SURG, V243, P684, DOI 10.1097/01.sla.0000216770.23642.d8; C.S.H. Laboratory, 2006, COLD SPRING HARBOR P, V2006; Chen CN, 2004, J SURG ONCOL, V86, P22, DOI 10.1002/jso.20037; Crew JP, 2000, BRIT J CANCER, V82, P161; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Fan SQ, 2009, CANCER BIOL THER, V8, P1463, DOI 10.4161/cbt.8.15.8960; Ferrandiz-Pulido C, 2013, J UROLOGY, V190, P2288, DOI 10.1016/j.juro.2013.06.015; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Guil S, 2006, MOL CELL BIOL, V26, P5744, DOI 10.1128/MCB.00224-06; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Heppner KJ, 1996, AM J PATHOL, V149, P273; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holm N, 2008, ANN SURG ONCOL, V15, P3207, DOI 10.1245/s10434-008-0086-9; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Huang Da Wei, 2009, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1311s27; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Imamura T, 2012, BREAST CANCER-TOKYO, V19, P118, DOI 10.1007/s12282-011-0321-2; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jia Y, 2012, MED RES REV, V32, P786, DOI 10.1002/med.21260; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Larsson O, 2011, BIOINFORMATICS, V27, P1440, DOI 10.1093/bioinformatics/btr146; Larsson O, 2010, P NATL ACAD SCI USA, V107, P21487, DOI 10.1073/pnas.1006821107; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee T, 2012, FUTURE MED CHEM, V4, P19, DOI [10.4155/FMC.11.150, 10.4155/fmc.11.150]; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li BDL, 1998, ANN SURG, V227, P756, DOI 10.1097/00000658-199805000-00016; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Ling C, 2012, CANCER DISCOV, V2, P68, DOI 10.1158/2159-8290.CD-11-0189; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Malina A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012377; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; McClusky DR, 2005, ANN SURG, V242, P584, DOI 10.1097/01.sla.0000184224.55949.90; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nathan CAO, 1999, J CLIN ONCOL, V17, P2909, DOI 10.1200/JCO.1999.17.9.2909; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Ramon y Cajal, CLIN TRANSL IN PRESS; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Salehi Z, 2006, CLIN BIOCHEM, V39, P404, DOI 10.1016/j.clinbiochem.2005.11.007; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Scott PAE, 1998, BRIT J CANCER, V77, P2120, DOI 10.1038/bjc.1998.356; Seki N, 2002, CLIN CANCER RES, V8, P3046; Seki N, 2010, LUNG CANCER, V70, P329, DOI 10.1016/j.lungcan.2010.03.006; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XL, 2012, WORLD J GASTROENTERO, V18, P2540, DOI 10.3748/wjg.v18.i20.2540; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wu MY, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0400-z; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yin B, 2006, LEUKEMIA, V20, P151, DOI 10.1038/sj.leu.2404033; Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zheng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089220	82	172	175	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2032	2042		10.1038/onc.2014.146	http://dx.doi.org/10.1038/onc.2014.146			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909168	Green Accepted			2022-12-28	WOS:000353173400003
J	Havel, LS; Kline, ER; Salgueiro, AM; Marcus, AI				Havel, L. S.; Kline, E. R.; Salgueiro, A. M.; Marcus, A. I.			Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; ACTIN STRESS FIBERS; ENDOTHELIAL-CELLS; MATRIX ADHESION; GROWTH-FACTOR; INTERMEDIATE-FILAMENTS; CARCINOMA METASTASIS; PROSTATE-CANCER; RAC1 ACTIVATION	Vimentin is an intermediate filament protein whose expression correlates with increased metastatic disease, reduced patient survival and poor prognosis across multiple tumor types. Despite these well-characterized correlations, the molecular role of vimentin in cancer cell motility remains undefined. To approach this, we used an unbiased phosphoproteomics screen in lung cancer cell lines to discover cell motility proteins that show significant changes in phosphorylation upon vimentin depletion. We identified the guanine nucleotide exchange factor (GEF), VAV2, as having the greatest loss of phosphorylation owing to vimentin depletion. Since VAV2 serves as a GEF for the small Rho GTPase Rac1, a key player in cell motility and adhesion, we explored the vimentin-VAV2 pathway as a potential novel regulator of lung cancer cell motility. We show that VAV2 localizes to vimentin-positive focal adhesions (FAs) in lung cancer cells and complexes with vimentin and FA kinase (FAK). Vimentin loss impairs both pY142-VAV2 and downstream pY397-FAK activity showing that vimentin is critical for maintaining VAV2 and FAK activity. Importantly, vimentin depletion reduces the activity of the VAV2 target, Rac1, and a constitutively active Rac1 rescues defects in FAK and cell adhesion when vimentin or VAV2 is compromised. Based upon this data, we propose a model whereby vimentin promotes FAK stabilization through VAV2-mediated Rac1 activation. This model may explain why vimentin expressing metastatic lung cancer cells are more motile and invasive.	[Havel, L. S.; Kline, E. R.; Salgueiro, A. M.; Marcus, A. I.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University	Marcus, AI (corresponding author), Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365C Clifton Rd,NE Room C4092, Atlanta, GA 30322 USA.	aimarcu@emory.edu			National Cancer Institute [1R01CA1428580]; Ruth L Kirschstein National Research Service Award [1F32CA168112-01]; Winship and Emory Integrated Cellular Imaging Core; NIH/NCI [P30CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292, R01CA142858, F32CA168112] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Winship and Emory Integrated Cellular Imaging Core; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute (1R01CA1428580) awarded to AIM and through a Ruth L Kirschstein National Research Service Award (1F32CA168112-01) awarded to LSH Research reported in this publication was supported in part by the Winship and Emory Integrated Cellular Imaging Core and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to thank the Custom Cloning Core at Emory University for generating the mutant FAK constructs and Doris Powell in the laboratory of Paula Vertino for her technical assistance with the quantitative RT-PCR experiments. We would also like to thank Anthea Hammond for reviewing this manuscript. In addition, we thank Keith Burridge at the University of North Carolina for generously supplying us with the VAV2 plasmids.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Ahn J, 2013, MOL CANCER RES, V11, P952, DOI 10.1158/1541-7786.MCR-13-0003-T; Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BERSHADSKY AD, 1987, CELL MOTIL CYTOSKEL, V8, P274, DOI 10.1002/cm.970080308; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; Burgstaller G, 2010, MOL BIOL CELL, V21, P3362, DOI 10.1091/mbc.E10-02-0094; Carr HS, 2013, MOL CELL BIOL, V33, P622, DOI 10.1128/MCB.00980-12; Chan KT, 2010, J BIOL CHEM, V285, P11418, DOI 10.1074/jbc.M109.090746; Chang FM, 2007, MOL BIOL CELL, V18, P253, DOI 10.1091/mbc.E06-03-0207; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Charrasse S, 2007, MOL BIOL CELL, V18, P1734, DOI 10.1091/mbc.E06-08-0766; Choma DP, 2007, J INVEST DERMATOL, V127, P31, DOI 10.1038/sj.jid.5700505; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Dauphin M, 2013, LUNG CANCER, V81, P117, DOI 10.1016/j.lungcan.2013.03.011; Deakin NO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037990; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Kallergi G, 2007, CELL PHYSIOL BIOCHEM, V20, P977, DOI 10.1159/000110458; Kreis S, 2005, EXP CELL RES, V305, P110, DOI 10.1016/j.yexcr.2004.12.023; Lai SY, 2008, ORAL ONCOL, V44, P683, DOI 10.1016/j.oraloncology.2007.08.017; Li QF, 2006, J BIOL CHEM, V281, P34716, DOI 10.1074/jbc.M607715200; Lim JA, 2012, FEBS J, V279, P3573, DOI 10.1111/j.1742-4658.2012.08715.x; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu LK, 2010, MODERN PATHOL, V23, P213, DOI 10.1038/modpathol.2009.160; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; MILLER SD, 2007, ONCOGENE, V31, P26; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Patz EF, 2004, J CLIN ONCOL, V22, P2202, DOI 10.1200/JCO.2004.12.046; Pisters KMW, 2005, J CLIN ONCOL, V23, P3270, DOI 10.1200/JCO.2005.11.478; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Singh GK, 2002, JNCI-J NATL CANCER I, V94, P916, DOI 10.1093/jnci/94.12.916; Singh S, 2003, CANCER RES, V63, P2306; Soltermann A, 2008, CLIN CANCER RES, V14, P7430, DOI 10.1158/1078-0432.CCR-08-0935; STOKER M, 1985, J CELL SCI, V77, P209; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Wang JW, 2009, CANCER LETT, V281, P71, DOI 10.1016/j.canlet.2009.02.020; Wei JC, 2008, ANTICANCER RES, V28, P327; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082; Yamauchi J, 2005, P NATL ACAD SCI USA, V102, P14889, DOI 10.1073/pnas.0507125102; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	56	108	112	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1979	1990		10.1038/onc.2014.123	http://dx.doi.org/10.1038/onc.2014.123			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858039	Green Accepted			2022-12-28	WOS:000352725600012
J	Gibaja, V; Shen, F; Harari, J; Korn, J; Ruddy, D; Saenz-Vash, V; Zhai, H; Rejtar, T; Paris, CG; Yu, Z; Lira, M; King, D; Qi, W; Keen, N; Hassan, AQ; Chan, HM				Gibaja, V.; Shen, F.; Harari, J.; Korn, J.; Ruddy, D.; Saenz-Vash, V.; Zhai, H.; Rejtar, T.; Paris, C. G.; Yu, Z.; Lira, M.; King, D.; Qi, W.; Keen, N.; Hassan, A. Q.; Chan, H. M.			Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; SELECTIVE-INHIBITION; LYSINE 27; LYMPHOMA; METHYLTRANSFERASE; METHYLATION; POLYCOMB; CANCER; EPIGENETICS; REGULATORS	The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) is frequently dysregulated in cancers, and gain-of-function (GOF) EZH2 mutations have been identified in non-Hodgkin lymphomas. Small-molecule inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and entered clinical trials. Here, we developed models of acquired resistance to EZH2 inhibitor EI1 with EZH2-mutated lymphoma cells. Resistance was generated by secondary mutations in both wild-type (WT) and GOF Y641N EZH2 alleles. These EZH2 mutants retained the substrate specificity of their predecessor complexes but became refractory to biochemical inhibition by EZH2 inhibitors. Resistant cells were able to maintain a high level of H3K27Me3 in the presence of inhibitors. Interestingly, mutation of EZH2 WT alone generated an intermediate resistance phenotype, which is consistent with a previously proposed model of cooperation between EZH2 WT and Y641N mutants to promote tumorigenesis. In addition, the findings presented here have implications for the clinical translation of EZH2 inhibitors and underscore the need to develop novel EZH2 inhibitors to target potential resistance emerging in clinical settings.	[Gibaja, V.; Shen, F.; Harari, J.; Korn, J.; Ruddy, D.; Saenz-Vash, V.; Zhai, H.; Rejtar, T.; Paris, C. G.; Lira, M.; King, D.; Keen, N.; Hassan, A. Q.; Chan, H. M.] Novartis Inst BioMed Res, 250 Mass Ave, Cambridge, MA 02139 USA; [Yu, Z.; Qi, W.] China Novartis Inst BioMed Res, Shanghai, Peoples R China	Novartis; Novartis	Hassan, AQ; Chan, HM (corresponding author), Novartis Inst BioMed Res, 250 Mass Ave, Cambridge, MA 02139 USA.	quamrul.hassan@novartis.com; homan.chan@novartis.com		Qi, Wei/0000-0003-0813-5316				Antonysamy S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084147; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Ferguson AD, 2011, STRUCTURE, V19, P1262, DOI 10.1016/j.str.2011.06.011; Garapaty-Rao S, 2013, CHEM BIOL, V20, P1329, DOI 10.1016/j.chembiol.2013.09.013; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kipp DR, 2013, BIOCHEMISTRY-US, V52, P6866, DOI 10.1021/bi400805w; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Wehrle J, 2014, RECENT RESULTS CANC, V201, P99, DOI 10.1007/978-3-642-54490-3_5; Wu HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013316; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208	31	96	100	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					558	566		10.1038/onc.2015.114	http://dx.doi.org/10.1038/onc.2015.114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893294	Green Published, hybrid			2022-12-28	WOS:000369548800003
J	Liu, D; Yang, Z; Wang, T; Yang, Z; Chen, H; Hu, Y; Hu, C; Guo, L; Deng, Q; Liu, Y; Yu, M; Shi, M; Du, N; Guo, N				Liu, D.; Yang, Z.; Wang, T.; Yang, Z.; Chen, H.; Hu, Y.; Hu, C.; Guo, L.; Deng, Q.; Liu, Y.; Yu, M.; Shi, M.; Du, N.; Guo, N.			beta 2-AR signaling controls trastuzumab resistance-dependent pathway	ONCOGENE			English	Article							METASTATIC BREAST-CANCER; BETA-BLOCKERS; KINASE ACTIVATION; STAT3 ACTIVATION; SRC ACTIVATION; UP-REGULATION; STRESS; PTEN; THERAPY; MIR-21	Currently, trastuzumab resistance is a major clinical problem in the treatment of Her2-overexpressing breast cancer. The underlying molecular mechanisms are not fully understood. Our previous study demonstrates that beta 2-adrenergic receptor (beta 2-AR) and Her2 comprise a positive feedback loop in human breast cancer cells and that crosstalk between Her2 and beta 2-AR affects the bio-behaviors of breast cancer cells, suggesting that the beta 2-AR activation may be involved in trastuzumab resistance. In this study, we show that the expression of beta 2-AR, which mediates most catecholamine-induced effects, negatively correlates with trastuzumab response in the patients with Her2-overexpressing breast cancer. Catecholamines potently antagonize the anti-proliferative effects of trastuzumab both in vitro and in vivo. Catecholamine stimulation upregulates the expression of miR-21 and MUC-1 by activating Her2 and STAT3, leading to deficiency of phosphatase and tensin homolog and activation of phosphatidylinositol-3-kinase (PI3K) and Akt. Through inhibition of miR-199a/b-3p, catecholamines induce the mammalian target of rapamycin (mTOR) activation. Thus, trastuzumab resistance-dependent PI3K/Akt/mTOR pathway is controlled by catecholamine-induced beta 2-AR activation. The data indicate that beta 2-AR is a reliable molecular marker for prediction of response probability to trastuzumab-based therapy in breast cancer. We also demonstrate that beta-blocker propranolol not only enhances the antitumor activities of trastuzumab but also re-sensitizes the resistant cells to trastuzumab. Our retrospective study shows that concurrent treatment of a-blocker and trastuzumab significantly improved progression-free survival and overall survival in the patients with Her2-overexpressing metastatic breast cancer, implicating the possibility for combination therapy with trastuzumab plus a-blocker in Her2-overexpressing breast cancer.	[Liu, D.; Yang, Z.; Chen, H.; Hu, Y.; Guo, L.; Deng, Q.; Liu, Y.; Yu, M.; Shi, M.; Guo, N.] Inst Basic Med Sci, Dept Pathophysiol, Beijing 100850, Peoples R China; [Wang, T.] Peoples Liberat Army, Hosp 307, Dept Oncol, Beijing, Peoples R China; [Yang, Z.] Beijing Haiyan Pharmaceut Co Ltd, Yangtze River Pharmaceut Grp, Beijing, Peoples R China; [Hu, C.] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Du, N.] Peoples Liberat Army, Gen Hosp, Affiliated Hosp 1, Dept Oncol, Beijing, Peoples R China	Beijing Institute of Microbiology & Epidemiology; Chinese People's Liberation Army General Hospital	Shi, M (corresponding author), Inst Basic Med Sci, Dept Pathophysiol, Taiping Rd 27, Beijing 100850, Peoples R China.	sm200@sohu.com; dunan05@aliyun.com; ningguo@nic.bmi.ac.cn			National Basic Research Program of China (973 program) [2010CB911904]; National Key Technologies R&D Program for New Drugs [2013ZX09102056]; National High-Tech Research and Development Plan (863 program) [2014AA020604]; National Natural Science Foundation of China [31370825, 81402562, 81272232]; Beijing Natural Science Foundation [7122124, 7132163]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Key Technologies R&D Program for New Drugs(National Key Technology R&D Program); National High-Tech Research and Development Plan (863 program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	This work is supported by National Basic Research Program of China (973 program, no. 2010CB911904), National Key Technologies R&D Program for New Drugs (2013ZX09102056), the National High-Tech Research and Development Plan (863 program, no. 2014AA020604), National Natural Science Foundation of China (no. 31370825, 81402562 and 81272232) and Beijing Natural Science Foundation (no. 7122124 and 7132163).	Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Antonova L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2836; Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; Arnould L, 2007, CLIN CANCER RES, V13, P6404, DOI 10.1158/1078-0432.CCR-06-3022; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bhola NE, 2011, CLIN CANCER RES, V17, P4996, DOI 10.1158/1078-0432.CCR-10-3406; Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363; Carbajal L, 2011, MOL ENDOCRINOL, V25, P1055, DOI 10.1210/me.2010-0410; Cardwell CR, 2013, INT J EPIDEMIOL, V42, P1852, DOI 10.1093/ije/dyt196; Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Dominici LS, 2010, CANCER-AM CANCER SOC, V116, P2884, DOI 10.1002/cncr.25152; Esteva FJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1836; Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Ganz PA, 2011, J CLIN ONCOL, V29, P2612, DOI 10.1200/JCO.2011.35.8820; Garcia-Garcia C, 2012, CLIN CANCER RES, V18, P2603, DOI 10.1158/1078-0432.CCR-11-2750; Garcia-Recio S, 2013, CANCER RES, V73, P6424, DOI 10.1158/0008-5472.CAN-12-4573; Gijsen M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000563; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887; Gu L, 2009, CLIN CANCER RES, V15, P7196, DOI 10.1158/1078-0432.CCR-09-0585; Haghikia A, 2011, EUR HEART J, V32, P1287, DOI 10.1093/eurheartj/ehq369; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kuzumaki N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044368; Lamkin DM, 2011, BRAIN BEHAV IMMUN, V25, P555, DOI 10.1016/j.bbi.2010.12.010; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Liang K, 2010, CANCER CELL, V18, P423, DOI 10.1016/j.ccr.2010.10.025; Lutgendorf SK, 2008, J CLIN ONCOL, V26, P4820, DOI 10.1200/JCO.2007.14.1978; Lutgendorf SK, 2010, J CLIN ONCOL, V28, P4094, DOI 10.1200/JCO.2009.26.9357; Lutgendorf SK, 2009, BRAIN BEHAV IMMUN, V23, P176, DOI 10.1016/j.bbi.2008.04.155; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Mukohara T, 2011, CANCER SCI, V102, P1, DOI 10.1111/j.1349-7006.2010.01711.x; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Park BH, 2007, CANCER CELL, V12, P297, DOI 10.1016/j.ccr.2007.10.004; Powe DG, 2011, NAT REV CLIN ONCOL, V8, P511, DOI 10.1038/nrclinonc.2011.123; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Seidman AD, 2008, J CLIN ONCOL, V26, P1642, DOI 10.1200/JCO.2007.11.6699; Shi M, 2013, CANCER METAST REV, V32, P603, DOI 10.1007/s10555-013-9440-x; Shi M, 2013, INT J CARDIOL, V167, P1570, DOI 10.1016/j.ijcard.2012.04.093; Shi M, 2011, BREAST CANCER RES TR, V125, P351, DOI 10.1007/s10549-010-0822-2; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Smith C, 1999, CARDIOVASC DRUG THER, V13, P123, DOI 10.1023/A:1007784109255; Sorensen GV, 2013, J CLIN ONCOL, V31, P2265, DOI 10.1200/JCO.2012.43.9190; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Stern HM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3001539; Waller A, 2012, CURR ONCOL, V19, pE53, DOI 10.3747/co.19.882; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Xiao R P, 2001, Sci STKE, V2001, pre15, DOI 10.1126/stke.2001.104.re15; Yao MY, 2011, LUNG, V189, P453, DOI 10.1007/s00408-011-9327-y; Yuan GG, 2008, CELL SIGNAL, V20, P1284, DOI 10.1016/j.cellsig.2008.02.017; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	63	39	42	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					47	58		10.1038/onc.2015.58	http://dx.doi.org/10.1038/onc.2015.58			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798840				2022-12-28	WOS:000367812400005
J	Zhang, P; Elabd, S; Hammer, S; Solozobova, V; Yan, H; Bartel, F; Inoue, S; Henrich, T; Wittbrodt, J; Loosli, F; Davidson, G; Blattner, C				Zhang, P.; Elabd, S.; Hammer, S.; Solozobova, V.; Yan, H.; Bartel, F.; Inoue, S.; Henrich, T.; Wittbrodt, J.; Loosli, F.; Davidson, G.; Blattner, C.			TRIM25 has a dual function in the p53/Mdm2 circuit	ONCOGENE			English	Article							ESTROGEN-RESPONSIVE GENE; FINGER PROTEIN; BREAST-CANCER; RECEPTOR-ALPHA; P53 PATHWAY; ACETYLATION; EFP; ACTIVATION; 14-3-3-SIGMA; DEGRADATION	P53 is an important tumor suppressor that, upon activation, induces growth arrest and cell death. Control of p53 is thus of prime importance for proliferating cells, but also for cancer therapy, where p53 activity contributes to the eradication of tumors. Mdm2 functionally inhibits p53 and targets the tumor suppressor protein for degradation. In a genetic screen, we identified TRIM25 as a novel regulator of p53 and Mdm2. TRIM25 increased p53 and Mdm2 abundance by inhibiting their ubiquitination and degradation in 26 S proteasomes. TRIM25 co-precipitated with p53 and Mdm2 and interfered with the association of p300 and Mdm2, a critical step for p53 polyubiquitination. Despite the increase in p53 levels, p53 activity was inhibited in the presence of TRIM25. Downregulation of TRIM25 resulted in an increased acetylation of p53 and p53-dependent cell death in HCT116 cells. Upon genotoxic insults, TRIM25 dampened the p53-dependent DNA damage response. The downregulation of TRIM25 furthermore resulted in massive apoptosis during early embryogenesis of medaka, which was rescued by the concomitant downregulation of p53, demonstrating the functional relevance of the regulation of p53 by TRIM25 in an organismal context.	[Zhang, P.; Elabd, S.; Solozobova, V.; Yan, H.; Loosli, F.; Davidson, G.; Blattner, C.] Karlsruhe Inst Technol, Inst Toxicol & Genet, D-76021 Karlsruhe, Baden Wurttembe, Germany; [Zhang, P.; Yan, H.] Heidelberg Univ, Fac Biosci, Heidelberg, Germany; [Hammer, S.; Bartel, F.] Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06108 Halle, Germany; [Inoue, S.] Univ Tokyo, Dept Antiaging Med, Tokyo, Japan; [Henrich, T.] Osaka Univ, Int Coll, Chem Biol Combined Major Program, Osaka, Japan; [Wittbrodt, J.] Heidelberg Univ, Ctr Organismal Studies Dev Biol & Physiol, Heidelberg, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; University of Tokyo; Osaka University; Ruprecht Karls University Heidelberg	Blattner, C (corresponding author), Karlsruhe Inst Technol, Inst Toxicol & Genet, POB 3640, D-76021 Karlsruhe, Baden Wurttembe, Germany.	gary.davidson@kit.edu; christine.blattner@kit.edu	Blattner, Christine/ABI-2152-2020; Wittbrodt, Joachim/D-4735-2014; Loosli, Felix/H-7415-2013; Davidson, Gary/J-6059-2013; Blattner, Christine/H-2105-2013; Davidson, Gary/AAA-7321-2021	Blattner, Christine/0000-0002-7250-5273; Wittbrodt, Joachim/0000-0001-8550-7377; Blattner, Christine/0000-0002-7250-5273; Davidson, Gary/0000-0002-2264-5518; Zhang, Ping/0000-0001-7063-7769	DFG [FOR 1036]; COST Action [BM1307]	DFG(German Research Foundation (DFG)); COST Action(European Cooperation in Science and Technology (COST))	We thank Germana Meroni (CBM S.c.r.l., Trieste) for the TRIM25 plasmid, Yi Su for help with the screening and Christina Bauer, Tanja Kuhn, Beate Heydel and Cathrin Herder for technical assistance. PZ was a CSC fellow. GD acknowledges the funding from the DFG (FOR 1036) for the screening experiments. This work is supported by COST Action BM1307.	Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Bartel F, 2008, CLIN CANCER RES, V14, P89, DOI 10.1158/1078-0432.CCR-07-1192; Boehme KA, 2009, CRIT REV BIOCHEM MOL, V44, P367, DOI 10.3109/10409230903401507; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hurd C, 1999, ONCOGENE, V18, P1067, DOI 10.1038/sj.onc.1202398; Ikeda K, 2000, FEBS LETT, V472, P9, DOI 10.1016/S0014-5793(00)01421-6; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kulikov R, 2010, P NATL ACAD SCI USA, V107, P10038, DOI 10.1073/pnas.0911716107; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Loosli F, 1998, MECH DEVELOP, V74, P159, DOI 10.1016/S0925-4773(98)00055-0; Nakayama H, 2005, PATHOL INT, V55, P707, DOI 10.1111/j.1440-1827.2005.01900.x; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Okumura N, 2002, JPN J CANCER RES, V93, P867, DOI 10.1111/j.1349-7006.2002.tb01331.x; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shimada N, 2004, MOL CELL ENDOCRINOL, V218, P147, DOI 10.1016/j.mce.2003.12.008; Solozobova V, 2010, EXP CELL RES, V316, P2434, DOI 10.1016/j.yexcr.2010.06.006; Souren M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r92; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Watanabe T, 2001, GYNECOL ONCOL, V81, P172, DOI 10.1006/gyno.2001.6132; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	28	54	56	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5729	5738		10.1038/onc.2015.21	http://dx.doi.org/10.1038/onc.2015.21			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728675				2022-12-28	WOS:000364594600005
J	Strohecker, AM; Joshi, S; Possemato, R; Abraham, RT; Sabatini, D; White, E				Strohecker, A. M.; Joshi, S.; Possemato, R.; Abraham, R. T.; Sabatini, D. M.; White, E.			Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening	ONCOGENE			English	Article							ADVANCED SOLID TUMORS; PHASE-I TRIAL; SIRNA SCREEN; TARGETING AUTOPHAGY; PROTEIN-DEGRADATION; SELECTIVE AUTOPHAGY; HUNTINGTONS-DISEASE; BODY FORMATION; CELL-DEATH; CANCER	Deregulation of autophagy has been linked to multiple degenerative diseases and cancer, thus the identification of novel autophagy regulators for potential therapeutic intervention is important. To meet this need, we developed a high content image-based short hairpin RNA screen monitoring levels of the autophagy substrate p62/SQSTM1. We identified 186 genes whose loss caused p62 accumulation indicative of autophagy blockade, and 67 genes whose loss enhanced p62 elimination indicative of autophagy stimulation. One putative autophagy stimulator, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), drives flux through pentose phosphate pathway. Knockdown of PFKFB4 in prostate cancer cells increased p62 and reactive oxygen species (ROS), but surprisingly increased autophagic flux. Addition of the ROS scavenger N-acetyl cysteine prevented p62 accumulation in PFKFB4-depleted cells, suggesting that the upregulation of p62 and autophagy was a response to oxidative stress caused by PFKFB4 elimination. Thus, PFKFB4 suppresses oxidative stress and p62 accumulation, without which autophagy is stimulated likely as a ROS detoxification response.	[Strohecker, A. M.; Joshi, S.; White, E.] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA; [Strohecker, A. M.; Joshi, S.; White, E.] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; [Strohecker, A. M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [Strohecker, A. M.] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Possemato, R.; Sabatini, D. M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Possemato, R.; Sabatini, D. M.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Sabatini, D. M.] MIT, Dept Biol, Cambridge, MA USA; [Possemato, R.] NYU, Dept Pathol, New York, NY 10016 USA; [Abraham, R. T.] Pfizer, Oncol Res Unit, San Diego, CA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); New York University; Pfizer	White, E (corresponding author), Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA.	eileenpwhite@gmail.com	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Possemato, Richard/0000-0002-2401-0030; /0000-0002-1446-7256	NIH [R37 CA53370, RC1 CA147961, R01 CA163591, R01 CA130893]; Rutgers Cancer Institute of New Jersey [P30 CA072720]; Johnson Johnson; New Jersey Commission on Cancer Research [09-2406-CCR-E0, DFHS13PPCO24]; NATIONAL CANCER INSTITUTE [R01CA130893, R01CA163591, R37CA053370, P30CA072720, RC1CA147961] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rutgers Cancer Institute of New Jersey; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); New Jersey Commission on Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Komatsu (conditional Atg7 mice) and Z Yue (Beclin1<SUP>+/-</SUP>) for mice and T Yoshimori for providing the ptf-LC3 plasmid. We also thank the staff of the Genetic Perturbation Platform of the Broad Institute (formerly the RNAi Platform) particularly S Silver and O Alkan for assistance with execution and analysis of screen data, The Genome Core of the Whitehead Institute for assistance with the Arrayscan, A Roberts for fluorescence-activated cell sorting (FACS) analysis, P Chin for technical assistance and members of the White and Sabatini laboratories for helpful discussions. This work was supported by NIH grants R37 CA53370, RC1 CA147961, R01 CA163591, R01 CA130893, the Rutgers Cancer Institute of New Jersey (P30 CA072720), Johnson & Johnson, and a gift to DMS and EW from Pfizer. AMS and SJ were supported by postdoctoral fellowships from the New Jersey Commission on Cancer Research (09-2406-CCR-E0 to AMS, DFHS13PPCO24 to SJ).	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Bernardi P, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011387; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024; Goidts V, 2012, ONCOGENE, V31, P3235, DOI 10.1038/onc.2011.490; Grumati P, 2010, NAT MED, V16, P1313, DOI 10.1038/nm.2247; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; He PF, 2009, AUTOPHAGY, V5, P52, DOI 10.4161/auto.5.1.7247; Hoang B, 2009, MOL CANCER THER, V8, P1974, DOI 10.1158/1535-7163.MCT-08-1177; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jeon YK, 2011, BBA-PROTEINS PROTEOM, V1814, P1340, DOI 10.1016/j.bbapap.2011.05.015; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klarer AC, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-2; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Law BYK, 2010, MOL CANCER THER, V9, P718, DOI 10.1158/1535-7163.MCT-09-0700; Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451; Li L, 2013, J BIOL CHEM, V288, P703, DOI 10.1074/jbc.C112.396903; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McKnight NC, 2012, EMBO J, V31, P1931, DOI 10.1038/emboj.2012.36; Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092; Minchenko OH, 2005, BIOCHIMIE, V87, P1005, DOI 10.1016/j.biochi.2005.04.007; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Qin QY, 2006, J CELL BIOL, V172, P497, DOI 10.1083/jcb.200505079; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Rusten TE, 2012, NAT CELL BIOL, V14, P38, DOI 10.1038/ncb2381; Rusten TE, 2009, J CELL SCI, V122, P2179, DOI 10.1242/jcs.050021; Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sandri M, 2013, J CELL SCI, V126, P5325, DOI 10.1242/jcs.114041; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Shanmugam M, 2009, J BIOL CHEM, V284, P26816, DOI 10.1074/jbc.M109.000646; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Szyniarowski P, 2011, AUTOPHAGY, V7, P892, DOI 10.4161/auto.7.8.15770; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tamai K, 2007, BIOCHEM BIOPH RES CO, V360, P721, DOI 10.1016/j.bbrc.2007.06.105; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Warmoes MO, 2014, BIOCHEM PHARMACOL, V92, P12, DOI 10.1016/j.bcp.2014.07.019; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79; Wooten MW, 2005, J BIOL CHEM, V280, P35625, DOI 10.1074/jbc.C500237200; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang Z, 2014, AUTOPHAGY, V10, P382, DOI 10.4161/auto.27345; Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	97	41	41	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5662	5676		10.1038/onc.2015.23	http://dx.doi.org/10.1038/onc.2015.23			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25772235	Green Submitted, Green Accepted			2022-12-28	WOS:000364594300007
J	Fan, LC; Shiau, CW; Tai, WT; Hung, MH; Chu, PY; Hsieh, FS; Lin, H; Yu, HC; Chen, KF				Fan, L-C; Shiau, C-W; Tai, W-T; Hung, M-H; Chu, P-Y; Hsieh, F-S; Lin, H.; Yu, H-C; Chen, K-F			SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; G-ALPHA-I; TGF-BETA; SIGNAL TRANSDUCER; STAT3 ACTIVATION; CELL-CYCLE; MECHANISMS; SORAFENIB; EXPRESSION	Epithelial-to-mesenchymal transition (EMT) is well known to involve in tumor invasion and metastasis. Src homology region 2 domain-containing phosphatase 1 (SHP-1) functions as a potent tumor suppressor and also acts as a negative regulator of p-STAT3(Tyr705) oncogenic signaling. However, little is known about the molecular mechanism(s) through which SHP-1 regulates EMT during hepatocellular carcinoma (HCC) progression. Here we first reported that endogenous SHP-1 protein levels were significantly downregulated in cells with mesenchymal characteristics and negatively correlated with p-STAT3(Tyr705) and vimentin but positively correlated with E-cadherin. SHP-1 overexpression abolished transforming growth factor-beta 1 (TGF-beta 1)-induced p-STAT3(Tyr705) and EMT, as well inhibited migration and invasion but further rescued by signal transducer and activator of transcription factor 3 (STAT3) overexpression. Depletion of SHP-1 could induce a more increase in TGF-beta 1-induced p-STAT3(Tyr-705) and EMT characteristics, further supporting the mechanism that suppression of TGF-beta 1-induced EMT is dependent on SHP-1-mediated STAT3 inactivation. Constitutively overexpressed SHP-1 tyrosine phosphatase activity by D61A-mutated SHP-1 markedly reduced TGF-beta 1-induced p-STAT3(Tyr705) and EMT features but was not altered by C453S catalytic-dead mutant SHP-1. Consequently, SHP-1 acted as a powerful suppressor in preventing EMT by exerting its tyrosine phosphatase activity that directly downregulated p-STAT3(Tyr705). Most notably, we discovered a novel SHP-1 agonist SC-43 better than sorafenib to exert more potent anti-EMT effects in vitro as well as anti-metastatic growth in vivo. In conclusion, SHP-1 is a potent suppressor of HCC EMT and metastasis, thus highlighting that SC-43-SHP-1 axis may serve as a potential therapeutic target that antagonized p-STAT3(Tyr705) and thereby prevented HCC EMT and metastasis.	[Fan, L-C; Tai, W-T; Hsieh, F-S; Lin, H.; Yu, H-C; Chen, K-F] Natl Taiwan Univ Hosp, Dept Med Res, Taipei 100, Taiwan; [Fan, L-C; Tai, W-T; Hsieh, F-S; Lin, H.; Yu, H-C; Chen, K-F] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei 100, Taiwan; [Shiau, C-W] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan; [Hung, M-H] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan; [Hung, M-H] Natl Yang Ming Univ, Sch Life Sci, Program Mol Med, Taipei 112, Taiwan; [Chu, P-Y] Show Chwan Mem Hosp, Dept Pathol, Changhua, Taiwan; [Chu, P-Y] Fu Jen Catholic Univ, Sch Med, New Taipei City, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Show Chwan Memorial Hospital; Fu Jen Catholic University	Chen, KF (corresponding author), Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan South Rd, Taipei 100, Taiwan.	kfchen1970@ntu.edu.tw		Chu, Pei-Yi/0000-0001-7336-2465; Chen, Kuen-Feng/0000-0002-4686-7019	National Science Council [NSC 102-2325-B-002-031, NHRI-EX102-10246B]; National Health Research Institutes, Taiwan	National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	This work was supported by grants NSC 102-2325-B-002-031 and NHRI-EX102-10246BI from the National Science Council and the National Health Research Institutes, Taiwan. For SHP-1 and E-cadherin, gene expression levels were assessed by using microarray data deposited in the Gene Expression Omnibus (GEO) database under accession no. GSE25097.	BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen KF, 2012, EUR J MED CHEM, V55, P220, DOI 10.1016/j.ejmech.2012.07.023; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Garcia-Marcos M, 2009, P NATL ACAD SCI USA, V106, P3178, DOI 10.1073/pnas.0900294106; Ghosh P, 2010, MOL BIOL CELL, V21, P2338, DOI 10.1091/mbc.E10-01-0028; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Kang JH, 2008, CANCER LETT, V261, P84, DOI 10.1016/j.canlet.2007.11.006; Lee JH, 2014, CANCER LETT, V345, P140, DOI 10.1016/j.canlet.2013.12.008; Liu CY, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3457; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lopez-Ruiz P, 2011, ANTI-CANCER AGENT ME, V11, P89, DOI 10.2174/187152011794941154; Lu HS, 2014, TUMOR BIOL, V35, P9807, DOI 10.1007/s13277-014-2256-7; Luo F, 2013, TOXICOL APPL PHARM, V273, P27, DOI 10.1016/j.taap.2013.08.025; Mittal Y, 2011, J BIOL CHEM, V286, P32404, DOI 10.1074/jbc.M111.275685; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Sainz-Perez A, 2008, J IMMUNOL, V181, P6051, DOI 10.4049/jimmunol.181.9.6051; Simpson D, 2008, DRUGS, V68, P251, DOI 10.2165/00003495-200868020-00007; Tai WT, 2014, HEPATOLOGY, V59, P190, DOI 10.1002/hep.26640; Tai WT, 2011, J HEPATOL, V55, P1041, DOI 10.1016/j.jhep.2011.06.005; Tsui HW, 2002, EUR J BIOCHEM, V269, P3057, DOI 10.1046/j.1432-1033.2002.02986.x; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Witkiewicz A, 2007, HUM PATHOL, V38, P462, DOI 10.1016/j.humpath.2006.09.012; Wu CY, 2003, J CELL BIOCHEM, V90, P1026, DOI 10.1002/jcb.10727; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yang YN, 2006, CANCER RES, V66, P8617, DOI 10.1158/0008-5472.CAN-06-1308; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang Zhuqing, 2013, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V27, P1265	34	37	39	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5252	5263		10.1038/onc.2014.445	http://dx.doi.org/10.1038/onc.2014.445			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619838				2022-12-28	WOS:000362575400005
J	Xu, Q; Liu, LZ; Yin, Y; He, J; Li, Q; Qian, X; You, Y; Lu, Z; Peiper, SC; Shu, Y; Jiang, BH				Xu, Q.; Liu, L-Z; Yin, Y.; He, J.; Li, Q.; Qian, X.; You, Y.; Lu, Z.; Peiper, S. C.; Shu, Y.; Jiang, B-H			Regulatory circuit of PKM2/NF-kappa B/miR-148a/152-modulated tumor angiogenesis and cancer progression	ONCOGENE			English	Article							PYRUVATE-KINASE M2; GENE-TRANSCRIPTION; GLUCOSE-METABOLISM; GROWTH; PROMOTES; CELLS; PKM2; APOPTOSIS; INSULIN; TRANSFORMATION	Upregulation of the embryonic M2 isoform of pyruvate kinase (PKM2) emerges as a critical player in the cancer development and metabolism, yet the underlying mechanism of PKM2 overexpression remains to be elucidated. Here we demonstrate that IGF-1/IGF-IR regulates PKM2 expression by enhancing HIF-1 alpha-p65 complex binding to PKM2 promoter. PKM2 expression is regulated by miR-148a/152 suppression. PKM2 directly interacts with NF-kappa B p65 subunit to promote EGR1 expression for regulating miR-148a/152 feedback circuit in normal cells, but not in cancer cells because of the DNA hypermethylation of miR-148a and miR-152 gene promoters. The silencing of miR-148a/152 contributes to the overexpression of PKM2, NF-kappa B or/and IGF-IR in some cancer cells. We show that disruption of PKM2/NF-kappa B/miR-148a/152 feedback loop can regulate cancer cell growth and angiogenesis, and is also associated with triple-negative breast cancer (TNBC) phenotype, which may have clinical implication for providing novel biomarker(s) of TNBC and potential therapeutic target(s) in the future.	[Xu, Q.; Li, Q.; Qian, X.; Jiang, B-H] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, State Key Lab Reprod Med, Dept Pathol,Canc Ctr, Nanjing, Jiangsu, Peoples R China; [Liu, L-Z; He, J.; Peiper, S. C.; Jiang, B-H] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Shu, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Collaborat Innovat Ctr Canc Personalized Med,Canc, Nanjing, Jiangsu, Peoples R China; [You, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Lu, Z.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; [Lu, Z.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Yin, Y.] Anhui Med Univ, Dept Pathol, Hefei, Peoples R China	Nanjing Medical University; Jefferson University; Nanjing Medical University; Nanjing Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Anhui Medical University	Shu, Y (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.	shuyongqian@csco.org.cn; binghjiang@yahoo.com	Shu, Yongqian/ABD-5698-2021	Jiang, Bing-Hua/0000-0003-4526-2031; Hartl, Carla/0000-0001-9769-7462; He, Jun/0000-0002-5162-6041; Liu, Ling-Zhi/0000-0001-9234-457X	National Natural Science Foundation of China [81320108019, 81270736, 81071642]; Jiangsu Province Clinical Science and Technology Project [BL2012008]; Priority Academic Program Development of Jiangsu Higher Education Institutions [JX10231801]; Jiangsu Province's Key Discipline of Medicine [XK201117]; National Institutes of Health [R01ES020868, R21CA175975]; NATIONAL CANCER INSTITUTE [R21CA175975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020868] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province Clinical Science and Technology Project; Priority Academic Program Development of Jiangsu Higher Education Institutions; Jiangsu Province's Key Discipline of Medicine; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by National Natural Science Foundation of China (81320108019, 81270736, 81071642), by Jiangsu Province Clinical Science and Technology Project (BL2012008), the Priority Academic Program Development of Jiangsu Higher Education Institutions (JX10231801), Jiangsu Province's Key Discipline of Medicine (XK201117), and by National Institutes of Health grants R01ES020868 and R21CA175975.	Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Ferguson EC, 2008, TRENDS BIOCHEM SCI, V33, P359, DOI 10.1016/j.tibs.2008.05.006; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Iqbal MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036764; Jung CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027740; Kefas B, 2010, NEURO-ONCOLOGY, V12, P1102, DOI 10.1093/neuonc/noq080; Kitamura K, 2011, J HEPATOL, V55, P846, DOI 10.1016/j.jhep.2011.01.038; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; Kwon OH, 2012, BIOCHEM BIOPH RES CO, V423, P38, DOI 10.1016/j.bbrc.2012.05.063; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu XG, 2010, J IMMUNOL, V185, P7244, DOI 10.4049/jimmunol.1001573; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Macintyre AN, 2011, MOL CELL, V42, P713, DOI 10.1016/j.molcel.2011.06.003; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950; Schmidt M, 2010, J CANCER RES CLIN, V136, P219, DOI 10.1007/s00432-009-0652-y; Schultz NA, 2012, WORLD J SURG, V36, P2699, DOI 10.1007/s00268-012-1705-y; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Takahashi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046684; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28; Zhang R, 2014, TUMOR BIOL, V35, P837, DOI 10.1007/s13277-013-1115-2	36	69	72	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5482	5493		10.1038/onc.2015.6	http://dx.doi.org/10.1038/onc.2015.6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25703326				2022-12-28	WOS:000363479700008
J	Shalini, S; Puccini, J; Wilson, CH; Finnie, J; Dorstyn, L; Kumar, S				Shalini, S.; Puccini, J.; Wilson, C. H.; Finnie, J.; Dorstyn, L.; Kumar, S.			Caspase-2 protects against oxidative stress in vivo	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-DEATH; ANTIOXIDANT DEFENSE; APOPTOSIS; PARAQUAT; ACTIVATION; PATHWAY; PHOSPHORYLATION; AUTOPHAGY; LIVER	Caspase-2 belongs to the caspase family of cysteine proteases with established roles in apoptosis. Recently, caspase-2 has been implicated in nonapoptotic functions including maintenance of genomic stability and tumor suppression. Our previous studies demonstrated that caspase-2 also regulates cellular redox status and delays the onset of several ageing-related traits. In the current study, we tested stress tolerance ability in caspase-2-deficient (Casp2(-/-)) mice by challenging both young and old mice with a low dose of the potent reactive oxygen species (ROS) generator, PQ that primarily affects lungs. In both groups of mice, PQ induced pulmonary damage. However, the lesions in caspase-2 knockout mice were consistently and reproducibly more severe than those in wild-type (WT) mice. Furthermore, serum interleukin (IL)-1 beta and IL-6 levels were higher in PQ-exposed aged Casp2(-/-) mice indicating increased inflammation. Interestingly, livers from Casp2(-/-)mice displayed karyomegaly, a feature commonly associated with ageing and aneuploidy. Given that Casp2(-/-) mice show impaired antioxidant defense, we tested oxidative damage in these mice. Protein oxidation significantly increased in PQ-injected old Casp2(-/-) mice. Moreover, FoxO1, SOD2 and Nrf2 expression levels were reduced and induction of superoxide dismutase (SOD) and glutathione peroxidase activity was not observed in PQ-treated Casp2(-/-) mice. Strong c-Jun amino-terminal kinase (JNK) activation was observed in Casp2(-/-) mice, indicative of increased stress. Together, our data strongly suggest that caspase-2 deficiency leads to increased cellular stress largely because these mice fail to respond to oxidative stress by upregulating their antioxidant defense mechanism. This makes the mice more vulnerable to exogenous challenges and may partly explain the shorter lifespan of Casp2(-/-) mice.	[Shalini, S.; Puccini, J.; Wilson, C. H.; Dorstyn, L.; Kumar, S.] Univ S Australia, Ctr Canc Biol, Adelaide, SA 5001, Australia; [Finnie, J.] Univ Adelaide, SA Pathol, Adelaide, SA, Australia; [Finnie, J.] Univ Adelaide, Sch Med & Vet Sci, Adelaide, SA, Australia	Centre for Cancer Biology; University of South Australia; SA Pathology; University of Adelaide; University of Adelaide	Kumar, S (corresponding author), Univ S Australia, Ctr Canc Biol, Adelaide, SA 5001, Australia.	sharad.kumar@unisa.edu.au	Kumar, Sharad/AAX-7787-2020; Dorstyn, Loretta/F-3673-2013	Kumar, Sharad/0000-0001-7126-9814; Dorstyn, Loretta/0000-0001-9886-0989; Shah, Sonia Shalini/0000-0002-9106-2324	National Health and Medical Research Council (NHMRC) [1021456, 1002863]; Cancer Council Research Fellowship	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Research Fellowship(Cancer Council Australia)	We thank Jim Manavis for TUNEL, the staff at the SA Pathology animal resource facility for maintaining the mouse strains, and Swati Dawar for help with some of the immunoblots in Figure 4. This work was supported by the National Health and Medical Research Council (NHMRC) project grant (1021456), a Cancer Council Research Fellowship to LD and a NHMRC Senior Principal Research Fellowship (1002863) to SK.	Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; BUS JS, 1976, TOXICOL APPL PHARM, V35, P501, DOI 10.1016/0041-008X(76)90073-9; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorstyn L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.342; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Gentric G, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/282430; Gonzalez-Polo RA, 2009, J NEUROCHEM, V109, P889, DOI 10.1111/j.1471-4159.2009.06020.x; Gorla GR, 2001, J CELL SCI, V114, P2943; HASSAN HM, 1979, J BIOL CHEM, V254, P846; He XQ, 2012, J PHARMACOL EXP THER, V342, P81, DOI 10.1124/jpet.112.194142; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jang S, 2008, P NATL ACAD SCI USA, V105, P7534, DOI 10.1073/pnas.0802865105; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 2009, NAT REV CANCER, V9, P897, DOI 10.1038/nrc2745; Kurz T, 2007, ARCH BIOCHEM BIOPHYS, V462, P220, DOI 10.1016/j.abb.2007.01.013; Li J, 2003, FREE RADICAL BIO MED, V35, P292, DOI 10.1016/S0891-5849(03)00308-3; Li N, 2011, MECH AGEING DEV, V132, P75, DOI 10.1016/j.mad.2010.12.004; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; Meng FY, 2012, AM J PATHOL, V181, P804, DOI 10.1016/j.ajpath.2012.06.010; Mercado N, 2011, BIOCHEM BIOPH RES CO, V406, P292, DOI 10.1016/j.bbrc.2011.02.035; Nakatani T, 1997, EXP CELL RES, V236, P137, DOI 10.1006/excr.1997.3715; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Panaretakis T, 2005, MOL BIOL CELL, V16, P3821, DOI 10.1091/mbc.E04-10-0862; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Res Lopez A., 2012, RESP SYSTEM MEDIASTI, V529; Sanz N, 1997, J HEPATOL, V27, P525, DOI 10.1016/S0168-8278(97)80358-3; Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Smith P, 1975, J Clin Pathol Suppl (R Coll Pathol), V9, P81, DOI 10.1136/jcp.28.Suppl_9.81; Tan M, 2013, TOXICOL LETT, V223, P1, DOI 10.1016/j.toxlet.2013.08.011; Thiruchelvam M, 2000, BRAIN RES, V873, P225, DOI 10.1016/S0006-8993(00)02496-3; Tiwari M, 2014, AUTOPHAGY, V10, P1054, DOI 10.4161/auto.28528; Tiwari M, 2011, J BIOL CHEM, V286, P8493, DOI 10.1074/jbc.M110.163824; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030	48	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4995	5002		10.1038/onc.2014.413	http://dx.doi.org/10.1038/onc.2014.413			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531319				2022-12-28	WOS:000361693000009
J	Gerez, J; Tedesco, L; Bonfiglio, JJ; Fuertes, M; Barontini, M; Silberstein, S; Wu, Y; Renner, U; Paez-Pereda, M; Holsboer, F; Stalla, GK; Arzt, E				Gerez, J.; Tedesco, L.; Bonfiglio, J. J.; Fuertes, M.; Barontini, M.; Silberstein, S.; Wu, Y.; Renner, U.; Paez-Pereda, M.; Holsboer, F.; Stalla, G. K.; Arzt, E.			RSUME inhibits VHL and regulates its tumor suppressor function	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR; SUMO CONJUGATION; GENE-MUTATIONS; PROTEIN; SUMOYLATION; GROWTH; HIF; REQUIRES; BINDING; DEGRADATION	Somatic mutations or loss of von Hippel-Lindau (pVHL) happen in the majority of VHL disease tumors, which present a constitutively active Hypoxia Inducible Factor (HIF), essential for tumor growth. Recently described mechanisms for pVHL modulation shed light on the open question of the HIF/pVHL pathway regulation. The aim of the present study was to determine the molecular mechanism by which RSUME stabilizes HIFs, by studying RSUME effect on pVHL function and to determine the role of RSUME on pVHL-related tumor progression. We determined that RSUME sumoylates and physically interacts with pVHL and negatively regulates the assembly of the complex between pVHL, Elongins and Cullins (ECV), inhibiting HIF-1 and 2 alpha ubiquitination and degradation. We found that RSUME is expressed in human VHL tumors (renal clear-cell carcinoma (RCC), pheochromocytoma and hemangioblastoma) and by overexpressing or silencing RSUME in a pVHL-HIF-oxygen-dependent degradation stability reporter assay, we determined that RSUME is necessary for the loss of function of type 2 pVHL mutants. The functional RSUME/pVHL interaction in VHL-related tumor progression was further confirmed using a xenograft assay in nude mice. RCC clones, in which RSUME was knocked down and express either pVHL wt or type 2 mutation, have an impaired tumor growth, as well as HIF-2 alpha, vascular endothelial growth factor A and tumor vascularization diminution. This work shows a novel mechanism for VHL tumor progression and presents a new mechanism and factor for targeting tumor-related pathologies with pVHL/HIF altered function.	[Gerez, J.; Tedesco, L.; Bonfiglio, J. J.; Fuertes, M.; Silberstein, S.; Arzt, E.] Max Planck Gesell, Partner Inst, CONICET, Inst Invest Biomed Buenos Aires IBioBA, RA-2390 Buenos Aires, DF, Argentina; [Gerez, J.; Bonfiglio, J. J.; Silberstein, S.; Arzt, E.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol & Biol Mol & Celular, Buenos Aires, DF, Argentina; [Barontini, M.] Hosp Ninos Dr Ricardo Gutierrez, Ctr Endocrinol Invest CEDIE, Buenos Aires, DF, Argentina; [Wu, Y.; Renner, U.; Paez-Pereda, M.; Holsboer, F.; Stalla, G. K.] Max Planck Inst Psychiat, Dept Clin Res, D-80804 Munich, Germany	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Max Planck Society; University of Buenos Aires; Hospital de Ninos Doctor Ricardo Gutierrez; University of Buenos Aires; Max Planck Society	Arzt, E (corresponding author), Max Planck Gesell, Partner Inst, CONICET, Inst Invest Biomed Buenos Aires IBioBA, C1425FQD, RA-2390 Buenos Aires, DF, Argentina.	earzt@ibioba-mpsp-conicet.gov.ar	Wu, Yonghe/N-2269-2019; Bonfiglio, Juan José/B-5853-2013	Wu, Yonghe/0000-0001-9667-8198; Bonfiglio, Juan José/0000-0001-7767-0799; Paez-Pereda, Marcelo/0000-0001-6029-0706	Argentinian Instituto Nacional del Cancer (INC); BungeBorn Foundation; Max Planck Society, Germany; University of Buenos Aires; CONICET; Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina; FOCEM-Mercosur [COF 03/11]	Argentinian Instituto Nacional del Cancer (INC); BungeBorn Foundation; Max Planck Society, Germany(Max Planck Society); University of Buenos Aires(University of Buenos Aires); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina(ANPCyT); FOCEM-Mercosur	We thank Sergio Senin, Maria Antunica Noguerol, Jimena Druker and Mariana Haedo for technical help. We also thank the Argentinian Instituto Nacional del Cancer (INC) and Bunge&Born Foundation for financial support to Lucas Tedesco and Juan Jose Bonfiglio, respectively. This work was supported by grants from the Max Planck Society, Germany; the University of Buenos Aires; CONICET; the Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina and FOCEM-Mercosur (COF 03/11).	Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Bergmann TK, 2013, ACTA ONCOL, V52, P871, DOI 10.3109/0284186X.2012.707787; Berra E, 2007, METHOD ENZYMOL, V435, P107, DOI 10.1016/S0076-6879(07)35006-4; Brahimi-Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022; Brooks SA, 2014, EUR UROL, V66, P77, DOI 10.1016/j.eururo.2014.02.035; Cai QL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009720; Carbia-Nagashima A, 2007, CELL, V131, P309, DOI 10.1016/j.cell.2007.07.044; Castro CP, 2003, ENDOCRINOLOGY, V144, P693, DOI 10.1210/en.2002-220891; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Chien W, 2013, BRIT J CANCER, V109, P1795, DOI 10.1038/bjc.2013.531; Cimarosti H, 2008, NEUROPHARMACOLOGY, V54, P280, DOI 10.1016/j.neuropharm.2007.09.010; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Druker J, 2013, MOL CELL BIOL, V33, P2116, DOI 10.1128/MCB.01470-12; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gerez J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057795; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hacker KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003801; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Huang C, 2009, EMBO J, V28, P2748, DOI 10.1038/emboj.2009.210; Huang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076421; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117; Juengel E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-161; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kang X, 2010, ONCOGENE, V29, P5568, DOI 10.1038/onc.2010.297; Keefe SM, 2013, SEMIN ONCOL, V40, P421, DOI 10.1053/j.seminoncol.2013.05.006; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Knauth K, 2009, J BIOL CHEM, V284, P10514, DOI 10.1074/jbc.M809056200; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lolkema MP, 2005, J BIOL CHEM, V280, P22205, DOI 10.1074/jbc.M503220200; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Nunez-O'Mara A, 2013, BIOL CHEM, V394, P459, DOI 10.1515/hsz-2012-0319; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rathmell WK, 2010, CURR OPIN ONCOL, V22, P250, DOI 10.1097/CCO.0b013e328337a5d2; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; Rechsteiner MP, 2011, CANCER RES, V71, P5500, DOI 10.1158/0008-5472.CAN-11-0757; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rojewska E, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-47; Safran M, 2006, P NATL ACAD SCI USA, V103, P105, DOI 10.1073/pnas.0509459103; Schneider BP, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.1000; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Shan B, 2012, ENDOCR-RELAT CANCER, V19, P13, DOI 10.1530/ERC-11-0211; Skuli N, 2012, J CLIN INVEST, V122, P1427, DOI 10.1172/JCI57322; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; van Hagen M, 2010, NUCLEIC ACIDS RES, V38, P1922, DOI 10.1093/nar/gkp1157; Willi-Monnerat S, 2008, MOL CELL NEUROSCI, V37, P845, DOI 10.1016/j.mcn.2008.01.009; Yang W, 2008, J CEREBR BLOOD F MET, V28, P892, DOI 10.1038/sj.jcbfm.9600601; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zimmer M, 2004, MOL CANCER RES, V2, P89	73	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4855	4866		10.1038/onc.2014.407	http://dx.doi.org/10.1038/onc.2014.407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25500545				2022-12-28	WOS:000361050000006
J	Chung, H; Lee, YS; Mayoral, R; Oh, DY; Siu, JT; Webster, NJ; Sears, DD; Olefsky, JM; Ellies, LG				Chung, H.; Lee, Y. S.; Mayoral, R.; Oh, D. Y.; Siu, J. T.; Webster, N. J.; Sears, D. D.; Olefsky, J. M.; Ellies, L. G.			Omega-3 fatty acids reduce obesity-induced tumor progression independent of GPR120 in a mouse model of postmenopausal breast cancer	ONCOGENE			English	Article							POLYUNSATURATED FATTY-ACIDS; INSULIN-RESISTANCE; INFLAMMATION; RISK; RECEPTOR; METABOLISM; PREVENTION; OMEGA-6; FISH	Obesity and inflammation are both risk factors for a variety of cancers, including breast cancer in postmenopausal women. Intake of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) decreases the risk of breast cancer, and also reduces obesity-associated inflammation and insulin resistance, but whether the two effects are related is currently unknown. We tested this hypothesis in a postmenopausal breast cancer model using ovariectomized, immune-competent female mice orthotopically injected with Py230 mammary tumor cells. Obesity, whether triggered genetically or by high-fat diet (HFD) feeding, increased inflammation in the mammary fat pad and promoted mammary tumorigenesis. The presence of tumor cells in the mammary fat pad further enhanced the local inflammatory milieu. Tumor necrosis factor-alpha (TNF-alpha) was the most highly upregulated cytokine in the obese mammary fat pad, and we observed that TNF-alpha dose-dependently stimulated Py230 cell growth in vitro. An omega-3 PUFA-enriched HFD (referred to as fish oil diet, FOD) reduced inflammation in the obese mammary fat pad in the absence of tumor cells and inhibited Py230 tumor growth in vivo. Although some anti-inflammatory effects of omega-3 PUFAs were previously shown to be mediated by the G-protein-coupled receptor 120 (GPR120), the FOD reduced Py230 tumor burden in GPR120-deficient mice to a similar degree as observed in wild-type mice, indicating that the effect of FOD to reduce tumor growth does not require GPR120 in the host mouse. Instead, in vitro studies demonstrated that omega-3 PUFAs act directly on tumor cells to activate c-Jun N-terminal kinase, inhibit proliferation and induce apoptosis. Our results show that obesity promotes mammary tumor progression in this model of postmenopausal breast cancer and that omega-3 PUFAs, independent of GPR120, inhibit mammary tumor progression in obese mice.	[Chung, H.; Lee, Y. S.; Mayoral, R.; Oh, D. Y.; Webster, N. J.; Sears, D. D.; Olefsky, J. M.] Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; [Mayoral, R.] Biomed Network Ctr Study Hepat & Digest Dis CIBER, Madrid, Spain; [Siu, J. T.; Ellies, L. G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Webster, N. J.; Sears, D. D.; Olefsky, J. M.; Ellies, L. G.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Webster, N. J.] San Diego VA Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Ellies, LG (corresponding author), Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	lellies@ucsd.edu	Sears, Dorothy D/AHE-5524-2022; Mayoral Monibas, Rafael/B-3563-2013; Lee, Yun Sok/ABC-9195-2021; Lee, Yun Sok/B-3265-2015; Webster, Nick/AAI-8410-2021	Sears, Dorothy D/0000-0002-9260-3540; Mayoral Monibas, Rafael/0000-0002-6645-7172; Lee, Yun Sok/0000-0001-7967-4734; Lee, Yun Sok/0000-0001-7967-4734; 	National Institutes of Health [U54 CA155435, P30 CA23100, P30 DK063491, K22 CA118182]; Department of Defense [BC102147]; Doris Howell Foundation Scholarship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD012303] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA023100, U54CA155435, K22CA118182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063491, R01DK101395, P01DK074868] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000130] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Doris Howell Foundation Scholarship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Robert Cardiff for reviewing histologic sections of tumors and Hang Ha and Jonathan Hasselmann for assistance with animal maintenance. We thank the UCSD Histology Core lab for technical assistance with processing the tumor samples. The study was funded in part by the National Institutes of Health grants U54 CA155435, P30 CA23100, P30 DK063491 (JMO), K22 CA118182 (LGE), the Department of Defense grant BC102147 (JMO) and a Doris Howell Foundation Scholarship (JTS).	Biswas T, 2014, CANCER LETT, V346, P129, DOI 10.1016/j.canlet.2013.12.018; Calviello G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/743171; Cui LF, 2008, HISTOPATHOLOGY, V53, P381, DOI 10.1111/j.1365-2559.2008.03128.x; de Lorgeril M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-50; Fares H, 2014, CURR ATHEROSCLER REP, V16, DOI 10.1007/s11883-013-0389-6; Golabek T, 2014, UROL INT, V92, P7, DOI 10.1159/000351325; Handgraaf S, 2013, DIABETES, V62, P4098, DOI 10.2337/db13-0282; Healy LA, 2010, CLIN ONCOL-UK, V22, P281, DOI 10.1016/j.clon.2010.02.001; Iyengar NM, 2013, CURR BREAST CANCER R, V5, P247, DOI 10.1007/s12609-013-0112-1; Jing KP, 2013, ANTI-CANCER AGENT ME, V13, P1162, DOI 10.2174/18715206113139990319; Kang KS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010296; Khaw KT, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4518; Kolodecik T, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00415; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Ligibel Jennifer A, 2013, Am Soc Clin Oncol Educ Book, P52, DOI 10.1200/EdBook_AM.2013.33.52; Maccio A, 2011, THESCIENTIFICWORLDJO, V11, P2020, DOI 10.1100/2011/806787; MacLennan MB, 2013, J NUTR BIOCHEM, V24, P388, DOI 10.1016/j.jnutbio.2012.08.002; Manni A, 2014, INT J CANCER, V134, P1549, DOI 10.1002/ijc.28490; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Parada B, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/368178; Patterson RE, 2013, J ACAD NUTR DIET, V113, P288, DOI 10.1016/j.jand.2012.08.015; Ramos-Nino Maria E, 2013, ISRN Oncol, V2013, P697521, DOI 10.1155/2013/697521; Rose DP, 2009, EXPERT REV ANTICANC, V9, P1091, DOI 10.1586/ERA.09.71; Sczaniecka AK, 2012, NUTR CANCER, V64, P1131, DOI 10.1080/01635581.2012.718033; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; SheenChen SM, 1997, BREAST CANCER RES TR, V43, P211, DOI 10.1023/A:1005736712307; Signori C, 2011, CANCER RES, V71, P6091, DOI 10.1158/0008-5472.CAN-11-0977; Simopoulos AP, 2010, EXP BIOL MED, V235, P785, DOI 10.1258/ebm.2010.009298; Simpson ER, 2013, MOL ENDOCRINOL, V27, P715, DOI 10.1210/me.2013-1011; Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381; Sundaram Sneha, 2013, J Carcinog, V12, P19, DOI 10.4103/1477-3163.119606; van Kruijsdijk RCM, 2009, CANCER EPIDEM BIOMAR, V18, P2569, DOI 10.1158/1055-9965.EPI-09-0372; Wong SW, 2009, J BIOL CHEM, V284, P27384, DOI 10.1074/jbc.M109.044065; Wu Q, 2013, ONCOGENE, V32, P5541, DOI 10.1038/onc.2013.264; Xue ML, 2014, J NUTR BIOCHEM, V25, P104, DOI 10.1016/j.jnutbio.2013.09.008; Zheng JS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3706	37	46	48	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3504	3513		10.1038/onc.2014.283	http://dx.doi.org/10.1038/onc.2014.283			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25220417	Green Submitted, Green Accepted			2022-12-28	WOS:000357434900003
J	Lopez-Bertoni, H; Lal, B; Li, A; Caplan, M; Guerrero-Cazares, H; Eberhart, CG; Quinones-Hinojosa, A; Glas, M; Scheffler, B; Laterra, J; Li, Y				Lopez-Bertoni, H.; Lal, B.; Li, A.; Caplan, M.; Guerrero-Cazares, H.; Eberhart, C. G.; Quinones-Hinojosa, A.; Glas, M.; Scheffler, B.; Laterra, J.; Li, Y.			DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; C-MET PATHWAY; DNA METHYLATION; HUMAN GLIOBLASTOMA; MALIGNANT GLIOMA; INITIATING CELLS; GASTRIC-CANCER; TARGETS; DIFFERENTIATION; EXPRESSION	Cancer stem-like cells represent poorly differentiated multipotent tumor-propagating cells that contribute disproportionately to therapeutic resistance and tumor recurrence. Transcriptional mechanisms that control the phenotypic conversion of tumor cells lacking tumor-propagating potential to tumor-propagating stem-like cells remain obscure. Here we show that the reprogramming transcription factors Oct4 and Sox2 induce glioblastoma cells to become stem-like and tumor-propagating via a mechanism involving direct DNA methyl transferase (DNMT) promoter transactivation, resulting in global DNA methylation-and DNMT-dependent downregulation of multiple microRNAs (miRNAs). We show that one such downregulated miRNA, miRNA-148a, inhibits glioblastoma cell stem-like properties and tumor-propagating potential. This study identifies a novel and targetable molecular circuit by which glioma cell stemness and tumor-propagating capacity are regulated.	[Lopez-Bertoni, H.; Lal, B.; Li, A.; Caplan, M.; Laterra, J.; Li, Y.] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Lopez-Bertoni, H.; Lal, B.; Laterra, J.; Li, Y.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Guerrero-Cazares, H.; Quinones-Hinojosa, A.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Eberhart, C. G.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; [Glas, M.; Scheffler, B.] MediClin Robert Janker Klin, Inst Reconstruct Neurobiol, Bonn, Germany; [Glas, M.; Scheffler, B.] Univ Bonn, Med Ctr, Bonn, Germany; [Glas, M.] MediClin Robert Janker Klin, Dept Neurol, Bonn, Germany; [Glas, M.] Univ Bonn, Med Ctr, Bonn, Germany; [Glas, M.] MediClin Robert Janker Klin, Clin Cooperat Unit Neurooncol, Bonn, Germany; [Laterra, J.; Li, Y.] Univ Bonn, Med Ctr, Bonn, Germany	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Bonn; University of Bonn; University of Bonn	Laterra, J (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, 707 N Broadway, Baltimore, MD 21205 USA.	Laterra@kennedykrieger.org; liyu@kennedykrieger.org	Lopez, Hernando/AAY-7655-2020; Scheffler, Björn/AAA-9361-2021	Lopez, Hernando/0000-0001-6618-1092; Li, Angela/0000-0002-2881-5557; Scheffler, Bjorn/0000-0001-8316-6556; Guerrero-Cazares, Hugo/0000-0003-1307-719X	American Brain Tumor Association; James S McDonnell Foundation; United States NIH [RO1NS073611, R01NS070024]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070024, R01NS073611] Funding Source: NIH RePORTER	American Brain Tumor Association; James S McDonnell Foundation; United States NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Daniel Trageser for technical assistance. This work was financially supported by grants from the American Brain Tumor Association (YL), James S McDonnell Foundation (JL), and the United States NIH grants RO1NS073611 (JL) and R01NS070024 (AQ-H).	Artner I, 2007, P NATL ACAD SCI USA, V104, P3853, DOI 10.1073/pnas.0700013104; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642; Foltz G, 2009, ONCOGENE, V28, P2667, DOI 10.1038/onc.2009.122; Fowler A, 2011, EUR J CANCER, V47, P953, DOI 10.1016/j.ejca.2010.11.026; Gailhouste L, 2013, HEPATOLOGY, V58, P1153, DOI 10.1002/hep.26422; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Guo SL, 2011, INT J BIOL SCI, V7, P567, DOI 10.7150/ijbs.7.567; Kim J, 2014, CANCER RES, V74, P1541, DOI 10.1158/0008-5472.CAN-13-1449; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Li MZ, 2012, TRENDS NEUROSCI, V35, P619, DOI 10.1016/j.tins.2012.06.003; Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008-5472.CAN-05-1946; Li YQ, 2012, CANCER RES, V72, P576, DOI 10.1158/0008-5472.CAN-11-3070; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Orr BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041036; Piccirillo SGM, 2009, ONCOGENE, V28, P1807, DOI 10.1038/onc.2009.27; Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2; Rath P, 2013, TRANSL ONCOL, V6, P104, DOI 10.1593/tlo.13127; Reijntjes S, 2010, INT J DEV BIOL, V54, P125, DOI 10.1387/ijdb.082783sr; Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Shi Y, 2008, CELL STEM CELL, V2, P525, DOI 10.1016/j.stem.2008.05.011; Singh RP, 2009, CELL TRANSPLANT, V18, P1197, DOI 10.3727/096368909X12483162197204; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stricker SH, 2013, GENE DEV, V27, P654, DOI 10.1101/gad.212662.112; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398; Wang GY, 2013, P NATL ACAD SCI USA, V110, P2858, DOI 10.1073/pnas.1212769110; Watanabe S, 2010, COLD SH Q B, V75, P35, DOI 10.1101/sqb.2010.75.063; Zhang J. P., 2013, ONCOGENE, V33, P4069; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	51	57	60	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3994	4004		10.1038/onc.2014.334	http://dx.doi.org/10.1038/onc.2014.334			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25328136	Green Accepted			2022-12-28	WOS:000358544200012
J	Pan, J; Deng, Q; Jiang, C; Wang, X; Niu, T; Li, H; Chen, T; Jin, J; Pan, W; Cai, X; Yang, X; Lu, M; Xiao, J; Wang, P				Pan, J.; Deng, Q.; Jiang, C.; Wang, X.; Niu, T.; Li, H.; Chen, T.; Jin, J.; Pan, W.; Cai, X.; Yang, X.; Lu, M.; Xiao, J.; Wang, P.			USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; UBIQUITIN LIGASE; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; PROTEIN; PHOSPHORYLATION; METABOLISM; P53; DEGRADATION; GROWTH	The oncoprotein c-Myc is frequently overexpressed in many cancers and is essential for cancer cell proliferation. Ubiquitin-proteasome-dependent degradation is one of the main ways in which cells control c-Myc abundance at a post-translational level. However, the underlying mechanism by which c-Myc is directly deubiquitinated is not fully understood. In this study, by screening ubiquitin-specific proteases (USPs) that may regulate c-Myc stability, we identified USP37 as a novel deubiquitinating enzyme (DUB) that stabilizes c-Myc via direct binding. The overexpression of USP37 markedly increases c-Myc abundance by blocking its degradation, whereas the depletion of USP37 promotes c-Myc degradation and reduces c-Myc levels. Further studies indicate that USP37 directly interacts with c-Myc and deubiquitinates c-Myc in a DUB activity-dependent manner. Functionally, USP37 regulates cell proliferation and the Warburg effect by regulating c-Myc levels. Clinically, USP37 is significantly upregulated in human lung cancer tissues, where its expression is positively correlated with c-Myc protein expression. Thus, our findings uncover a previously unrecognized role for USP37 in the regulation of c-Myc stability in lung cancer and suggest that USP37 might be a potential therapeutic target for the treatment of lung cancer.	[Pan, J.; Deng, Q.; Jiang, C.; Wang, X.; Niu, T.; Li, H.; Chen, T.; Jin, J.; Pan, W.; Wang, P.] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China; [Pan, J.; Deng, Q.; Jiang, C.; Wang, X.; Niu, T.; Li, H.; Chen, T.; Jin, J.; Pan, W.; Wang, P.] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China; [Cai, X.; Yang, X.; Xiao, J.] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China; [Lu, M.; Wang, P.] Tongji Univ, Sch Life Sci & Technol, Shanghai Peoples Hosp 10, Dept Cent Lab, Shanghai 200092, Peoples R China	East China Normal University; East China Normal University; Naval Medical University; Tongji University	Wang, P (corresponding author), E China Normal Univ, Inst Biomed Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.	jianruxiao83@163.com; pwang@bio.ecnu.edu.cn	Xiao, Jian/GYU-4351-2022		National Basic Research Program of China (973 program) [2010CB529704, 2012CB910404]; National Natural Science Foundation of China [30800587, 30971521, 31171338]; Science and Technology Commission of Shanghai Municipality [11DZ2260300, 09QA1401900, 13QH1401]; Doctoral Fund of Ministry of Education of China [20130076110022]; Program for New Century Excellent Talents in University [NCET-10-0387]; Dawn Program of Shanghai Education Commission [11SG27]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Doctoral Fund of Ministry of Education of China(Ministry of Education, China); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Dawn Program of Shanghai Education Commission	We thank other members of the Wang laboratory for their assistance. This work was supported by grants from the National Basic Research Program of China (973 program 2010CB529704 and 2012CB910404), the National Natural Science Foundation of China (30800587, 30971521 and 31171338), the Science and Technology Commission of Shanghai Municipality (11DZ2260300) and the Doctoral Fund of Ministry of Education of China (20130076110022). PW is a scholar of the Shanghai Rising-Star Program from the Science and Technology Commission of Shanghai Municipality (09QA1401900 and 13QH1401), the Program for New Century Excellent Talents in University (NCET-10-0387) and the Dawn Program of Shanghai Education Commission (11SG27).	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Bianchi F, 2007, J CLIN INVEST, V117, P3436, DOI 10.1172/JCI32007; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Das CM, 2013, ONCOGENE, V32, P1691, DOI 10.1038/onc.2012.182; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Liao P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.536; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Seo HR, 2008, J BIOL CHEM, V283, P15601, DOI 10.1074/jbc.M800987200; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Soga T, 2013, CANCER SCI, V104, P275, DOI 10.1111/cas.12085; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Todi SV, 2011, TRENDS NEUROSCI, V34, P370, DOI 10.1016/j.tins.2011.05.004; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang WC, 2013, ONCOGENE, V32, P5167, DOI 10.1038/onc.2012.537; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874	42	87	93	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3957	3967		10.1038/onc.2014.327	http://dx.doi.org/10.1038/onc.2014.327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284584				2022-12-28	WOS:000358544200008
J	Sarmento, LM; Povoa, V; Nascimento, R; Real, G; Antunes, I; Martins, LR; Moita, C; Alves, PM; Abecasis, M; Moita, LF; Parkhouse, RME; Meijerink, JPP; Barata, JT				Sarmento, L. M.; Povoa, V.; Nascimento, R.; Real, G.; Antunes, I.; Martins, L. R.; Moita, C.; Alves, P. M.; Abecasis, M.; Moita, L. F.; Parkhouse, R. M. E.; Meijerink, J. P. P.; Barata, J. T.			CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress	ONCOGENE			English	Article							DNA-DAMAGE; CROSS-TALK; CHECKPOINT; ATR; KINASE; PROGRESSION; ACTIVATION; INHIBITOR; MUTATIONS; PHOSPHORYLATION	Checkpoint kinase 1 (CHK1) is a key component of the ATR (ataxia telangiectasia-mutated and Rad3-related)-dependent DNA damage response pathway that protect cells from replication stress, a cell intrinsic phenomenon enhanced by oncogenic transformation. Here, we show that CHK1 is overexpressed and hyperactivated in T-cell acute lymphoblastic leukemia (T-ALL). CHEK1 mRNA is highly abundant in patients of the proliferative T-ALL subgroup and leukemia cells exhibit constitutively elevated levels of the replication stress marker phospho-RPA32 and the DNA damage marker gamma H2AX. Importantly, pharmacologic inhibition of CHK1 using PF-004777736 or CHK1 short hairpin RNA-mediated silencing impairs T-ALL cell proliferation and viability. CHK1 inactivation results in the accumulation of cells with incompletely replicated DNA, ensuing DNA damage, ATM/CHK2 activation and subsequent ATM-and caspase-3-dependent apoptosis. In contrast to normal thymocytes, primary T-ALL cells are sensitive to therapeutic doses of PF-004777736, even in the presence of stromal or interleukin-7 survival signals. Moreover, CHK1 inhibition significantly delays in vivo growth of xenotransplanted T-ALL tumors. We conclude that CHK1 is critical for T-ALL proliferation and viability by downmodulating replication stress and preventing ATM/caspase-3-dependent cell death. Pharmacologic inhibition of CHK1 may be a promising therapeutic alternative for T-ALL treatment.	[Sarmento, L. M.; Povoa, V.; Antunes, I.; Martins, L. R.; Moita, C.; Moita, L. F.; Barata, J. T.] Univ Lisbon, Inst Med Mol, Fac Med, P-1649028 Lisbon, Portugal; [Nascimento, R.; Parkhouse, R. M. E.] Inst Gulbenkian Ciencias, Infect & Immun Lab, Oeiras, Portugal; [Real, G.; Alves, P. M.] Inst Biol Expt & Tecnol, iBET, Oeiras, Portugal; [Real, G.; Alves, P. M.] Univ Nova Lisboa, Inst Tecnol Quim & Biol, Oeiras, Portugal; [Abecasis, M.] Hosp Sta Cruz, Cardiol Pediat Med Cirurg, Lisbon, Portugal; [Meijerink, J. P. P.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands	Universidade de Lisboa; Instituto Gulbenkian de Ciencia; Universidade Nova de Lisboa; Erasmus University Rotterdam; Erasmus MC	Barata, JT (corresponding author), Univ Lisbon, Inst Med Mol, Fac Med, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	joao_barata@medicina.ulisboa.pt	Barata, João T./D-9181-2015; Alves, Paula M/C-1070-2008; Moita, Luis F./L-1296-2013; Meijerink, Jules P/D-4393-2017; Moita, Luis/HCI-2793-2022	Barata, João T./0000-0002-4826-8976; Alves, Paula M/0000-0003-1445-3556; Moita, Luis F./0000-0003-0707-315X; Meijerink, Jules P/0000-0002-6860-798X; Moita, Luis/0000-0003-0707-315X; Parkhouse, Michael/0000-0001-5967-3291; Afonso, Rute/0000-0002-4531-6581; Martins, Leila/0000-0002-5887-4734; Real, Goncalo/0000-0003-3157-4341; Ferreira Moita, Catarina/0000-0002-9910-2343	Fundacao para a Ciencia e a Tecnologia (FCT), Portugal [PTDC/SAU-ONC/113202/2009]; FCT	Fundacao para a Ciencia e a Tecnologia (FCT), Portugal(Portuguese Foundation for Science and Technology); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This work was supported by the grant PTDC/SAU-ONC/113202/2009 from Fundacao para a Ciencia e a Tecnologia (FCT), Portugal. LMS, RN, IA, LRM and CM had postdoctoral fellowships, and VP a BI fellowship, all from FCT. We thank Dr J Ferreira for fruitful discussions and reagents. We also thank Dr O Fernandez-Capetillo and Centro Nacional de Investigaciones Oncologicas for providing the ATR inhibitor. We especially thank the generosity of patients and their families, and the collaboration of all the team from the Pediatrics Service of Instituto Portugues de Oncologia de Lisboa.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Bains T, 2012, LEUKEMIA, V26, P2144, DOI 10.1038/leu.2012.74; Barata JT, 2004, BLOOD, V103, P1891, DOI 10.1182/blood-2002-12-3861; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Barde I, 2010, CURR PROTOC NEUROSCI, V53, P4211; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brooks K, 2013, ONCOGENE, V32, P788, DOI 10.1038/onc.2012.72; Brown EJ, 2000, GENE DEV, V14, P397; Carrassa L, 2011, CELL CYCLE, V10, P2121, DOI 10.4161/cc.10.13.16398; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Dai Y, 2005, BLOOD, V105, P1706, DOI 10.1182/blood-2004-07-2767; Dohda T, 2007, EXP CELL RES, V313, P3141, DOI 10.1016/j.yexcr.2007.04.027; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Flex E, 2008, J EXP MED, V205, P751, DOI 10.1084/jem.20072182; Forment JV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023517; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Indraccolo S, 2009, CANCER RES, V69, P1314, DOI 10.1158/0008-5472.CAN-08-2791; Katsuno Y, 2009, P NATL ACAD SCI USA, V106, P3184, DOI 10.1073/pnas.0809350106; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Liu QH, 2000, GENE DEV, V14, P1448; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Lonetti A, 2014, LEUKEMIA, V28, P1196, DOI 10.1038/leu.2013.369; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Real G, 2011, APPL MICROBIOL BIOT, V91, P1581, DOI 10.1007/s00253-011-3392-2; Ribeiro Daniel, 2013, Adv Biol Regul, V53, P211, DOI 10.1016/j.jbior.2012.10.005; Sarmento LM, 2011, EXPERT REV ANTICANC, V11, P1403, DOI [10.1586/ERA.11.73, 10.1586/era.11.73]; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Scupoli MT, 2007, HAEMATOLOGICA, V92, P264, DOI 10.3324/haematol.10356; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Silva A, 2011, CANCER RES, V71, P4780, DOI 10.1158/0008-5472.CAN-10-3606; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Sugimoto K, 2008, ONCOGENE, V27, P3091, DOI 10.1038/sj.onc.1210978; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Toledo LI, 2011, MOL ONCOL, V5, P368, DOI 10.1016/j.molonc.2011.07.002; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xu J, 2013, ONCOGENE, V32, P976, DOI 10.1038/onc.2012.121; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zhang C, 2009, CLIN CANCER RES, V15, P4630, DOI 10.1158/1078-0432.CCR-08-3272; Zhang YW, 2009, MOL CELL, V35, P442, DOI 10.1016/j.molcel.2009.06.030; Zhang YW, 2014, INT J CANCER, V134, P1013, DOI 10.1002/ijc.28226; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	60	44	47	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2978	2990		10.1038/onc.2014.248	http://dx.doi.org/10.1038/onc.2014.248			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25132270	Bronze			2022-12-28	WOS:000356100500004
J	Rosario, CO; Kazazian, K; Zih, FSW; Brashavitskaya, O; Haffani, Y; Xu, RSZ; George, A; Dennis, JW; Swallow, CJ				Rosario, C. O.; Kazazian, K.; Zih, F. S. W.; Brashavitskaya, O.; Haffani, Y.; Xu, R. S. Z.; George, A.; Dennis, J. W.; Swallow, C. J.			A novel role for Plk4 in regulating cell spreading and motility	ONCOGENE			English	Article							POLO-LIKE KINASE; CENTRIOLE DUPLICATION; CENTROSOME DUPLICATION; CYTOKINESIS; EXPRESSION; PROTEIN; REVEALS; FAILURE; CANCER; SAK	Polo family kinase 4 (Plk4) is required for mitotic progression, and is haploinsufficient for tumor suppression and timely hepatocyte polarization in regenerating liver. At the same time, recent evidence suggests that Plk4 expression may have a role in clinical cancer progression, although the mechanisms are not clear. Here we identify a gene expression pattern predictive of reduced motility in Plk4(+/-) murine embryonic fibroblasts (MEFs) and validate this prediction with functional assays of cell spreading, migration and invasion. Increased Plk4 expression enhances cell spreading in Plk4(+/-) MEFs and migration in human embryonic kidney 293T cells, and increases invasion by DLD-1 colon cancer cells. Plk4 depletion impairs invasion of wild-type MEFs and suppresses invasion by MDA-MB231 breast cancer cells. Cytoskeletal reorganization and development of polarity are impaired in Plk4-deficient cells that have been stimulated to migrate. Endogenous Plk4 phosphorylated at the autophosphorylation site S305 localizes to the protrusions of motile cells, coincident with the RhoA GEF Ect2, GTP-bound RhoA and the RhoA effector mDia. Taken together, our findings reveal an unexpected activity of Plk4 that promotes cell migration and may underlie an association between increased Plk4 expression, cancer progression and death from metastasis in solid tumor patients.	[Rosario, C. O.; Kazazian, K.; Zih, F. S. W.; Brashavitskaya, O.; Haffani, Y.; Xu, R. S. Z.; George, A.; Dennis, J. W.; Swallow, C. J.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Rosario, C. O.; Brashavitskaya, O.; Dennis, J. W.; Swallow, C. J.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Kazazian, K.; Zih, F. S. W.; Swallow, C. J.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Kazazian, K.; Zih, F. S. W.; Xu, R. S. Z.; Swallow, C. J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Dennis, J. W.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Swallow, CJ (corresponding author), Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	cswallow@mtsinai.on.ca	Dennis, James/E-7268-2013	Haffani, Yosr Z./0000-0003-2956-3651	CIHR; NCIC; Syd Cooper Program for the Prevention of Cancer Progression	CIHR(Canadian Institutes of Health Research (CIHR)); NCIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Syd Cooper Program for the Prevention of Cancer Progression	This work was supported by grants from CIHR (CJS) and NCIC (JWD), and from the Syd Cooper Program for the Prevention of Cancer Progression (CJS). We acknowledge Karina Pacholczyk, Peter E Wu and Kevin Yau for technical assistance, Judy Pawling for manuscript review, and Jayne Danska and Laurence Pelletier for helpful discussions.	Agarwal R, 2009, CLIN CANCER RES, V15, P3654, DOI 10.1158/1078-0432.CCR-08-3293; Bahtz R, 2012, J CELL SCI, V125, P486, DOI 10.1242/jcs.093930; Basu R, 2007, CURR OPIN CELL BIOL, V19, P88, DOI 10.1016/j.ceb.2006.12.012; Brownlee CW, 2011, J CELL BIOL, V195, P231, DOI 10.1083/jcb.201107086; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Cizmecioglu O, 2010, J CELL BIOL, V191, P731, DOI 10.1083/jcb.201007107; Coelho PA, 2013, DEV CELL, V27, P586, DOI 10.1016/j.devcel.2013.09.029; Cunha-Ferreira I, 2013, CURR BIOL, V23, P2245, DOI 10.1016/j.cub.2013.09.037; Cunha-Ferreira I, 2009, CURR BIOL, V19, P43, DOI 10.1016/j.cub.2008.11.037; Dzhindzhev NS, 2010, NATURE, V467, P714, DOI 10.1038/nature09445; Finetti P, 2008, CANCER RES, V68, P767, DOI 10.1158/0008-5472.CAN-07-5516; Fischer M, 2014, NUCLEIC ACIDS RES, V42, P163, DOI 10.1093/nar/gkt849; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Guderian G, 2010, J CELL SCI, V123, P2163, DOI 10.1242/jcs.068502; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hatch EM, 2010, J CELL BIOL, V191, P721, DOI 10.1083/jcb.201006049; Holland AJ, 2012, GENE DEV, V26, P2684, DOI 10.1101/gad.207027.112; Holland AJ, 2012, MOL BIOL CELL, V23, P1838, DOI 10.1091/mbc.E11-12-1043; Holland AJ, 2010, J CELL BIOL, V188, P191, DOI 10.1083/jcb.200911102; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Johnson EF, 2007, BIOCHEMISTRY-US, V46, P9551, DOI 10.1021/bi7008745; Klebba JE, 2013, CURR BIOL, V23, P2255, DOI 10.1016/j.cub.2013.09.019; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Korzeniewski N, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-61; Laufer R, 2013, J MED CHEM, V56, P6069, DOI 10.1021/jm400380m; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Leung GC, 2007, FEBS LETT, V581, P77, DOI 10.1016/j.febslet.2006.11.080; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Macmillan JC, 2001, ANN SURG ONCOL, V8, P729, DOI 10.1245/aso.2001.8.9.729; Martindill DMJ, 2007, NAT CELL BIOL, V9, P1131, DOI 10.1038/ncb1633; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moss DK, 2007, J CELL SCI, V120, P3064, DOI 10.1242/jcs.010322; Nakamura T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2752; Nguyen TN, 2000, EXP CELL RES, V258, P171, DOI 10.1006/excr.2000.4929; Ohn T, 2010, WIRES RNA, V1, P486, DOI 10.1002/wrna.23; Park AYJ, 2009, J BIOL CHEM, V284, P9418, DOI 10.1074/jbc.M809040200; Petronczki M, 2007, DEV CELL, V12, P713, DOI 10.1016/j.devcel.2007.03.013; Przewloka MR, 2011, CURR BIOL, V21, P399, DOI 10.1016/j.cub.2011.02.005; Puklowski A, 2011, NAT CELL BIOL, V13, P1004, DOI 10.1038/ncb2282; Rogers GC, 2009, J CELL BIOL, V184, P225, DOI 10.1083/jcb.200808049; Rosario CO, 2010, P NATL ACAD SCI USA, V107, P6888, DOI 10.1073/pnas.0910941107; Rosario CO, 2010, EFFECTS POLO LIKE KI; Sillibourne JE, 2010, MOL BIOL CELL, V21, P547, DOI 10.1091/mbc.E09-06-0505; Slevin LK, 2012, STRUCTURE, V20, P1905, DOI 10.1016/j.str.2012.08.025; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Swallow CJ, 2005, ONCOGENE, V24, P306, DOI 10.1038/sj.onc.1208275	51	36	37	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3441	3451		10.1038/onc.2014.275	http://dx.doi.org/10.1038/onc.2014.275			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174401				2022-12-28	WOS:000356871700009
J	Guerrero, PA; Yin, W; Camacho, L; Marchetti, D				Guerrero, P. A.; Yin, W.; Camacho, L.; Marchetti, D.			Oncogenic role of Merlin/NF2 in glioblastoma	ONCOGENE			English	Article							NF2 TUMOR-SUPPRESSOR; CELL-GROWTH; AKT PHOSPHORYLATION; CONTACT INHIBITION; GENE-PRODUCT; PROTEIN; PROLIFERATION; MUTATIONS; BINDING; KINASE	Glioblastoma is the most common and aggressive primary brain tumor in adults, with a poor prognosis because of its resistance to radiotherapy and chemotherapy. Merlin/NF2 (moesin-ezrin-radixin-like protein/neurofibromatosis type 2) is a tumor suppressor found to be mutated in most nervous system tumors; however, it is not mutated in glioblastomas. Merlin associates with several transmembrane receptors and intracellular proteins serving as an anchoring molecule. Additionally, it acts as a key component of cell motility. By selecting sub-populations of U251 glioblastoma cells, we observed that high expression of phosphorylated Merlin at serine 518 (S518-Merlin), NOTCH1 and epidermal growth factor receptor (EGFR) correlated with increased cell proliferation and tumorigenesis. These cells were defective in cell-contact inhibition with changes in Merlin phosphorylation directly affecting NOTCH1 and EGFR expression, as well as downstream targets HES1 (hairy and enhancer of split-1) and CCND1 (cyclin D1). Of note, we identified a function for S518-Merlin, which is distinct from what has been reported when the expression of Merlin is diminished in relation to EGFR and NOTCH1 expression, providing first-time evidence that demonstrates that the phosphorylation of S518-Merlin in glioblastoma promotes oncogenic properties that are not only the result of inactivation of the tumor suppressor role of Merlin but also an independent process implicating a Merlin-driven regulation of NOTCH1 and EGFR.	[Guerrero, P. A.; Yin, W.; Camacho, L.; Marchetti, D.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Marchetti, D.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marchetti, D (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Mail Stop 315,BCM Taub Bldg,Suite T240, Houston, TX 77030 USA.	marchett@bcm.edu	Camacho, Laura/M-2071-2015	Camacho, Laura/0000-0002-5911-1616	Shared Resources CPRIJ grant; NCI Grant [CA016672]; NIH [RO1 CA160335]; NATIONAL CANCER INSTITUTE [R01CA160335, P30CA016672] Funding Source: NIH RePORTER	Shared Resources CPRIJ grant; NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs F Giancotti and D Trono for providing vectors and reagents. We thank Jason Ngo, Andres Espinoza and Flavio Palalon for technical assistance. We also thank BCM Integrated Microscopy Core Facility at BCM supported by Shared Resources CPRIJ grant. The Characterized Cell Line Core at MDACC is supported by NCI Grant CA016672. This work was supported by NIH RO1 CA160335 (to DM).	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Eldridge R, 1981, Adv Neurol, V29, P57; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Gonzales AJ, 2005, EXP CELL RES, V303, P56, DOI 10.1016/j.yexcr.2004.08.040; Gronholm M, 2006, ONCOGENE, V25, P4389, DOI 10.1038/sj.onc.1209475; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; Kang CS, 2006, CANCER GENE THER, V13, P530, DOI 10.1038/sj.cgt.7700932; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Lino MM, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-72; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrow KA, 2011, J BIOL CHEM, V286, P40376, DOI 10.1074/jbc.M111.250035; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Noda N, 2011, GENES CELLS, V16, P704, DOI 10.1111/j.1365-2443.2011.01518.x; Okada M, 2009, CANCER RES, V69, P4043, DOI 10.1158/0008-5472.CAN-08-3931; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; Pecina-Slaus N, 2013, PATHOL ONCOL RES, V19, P365, DOI 10.1007/s12253-013-9644-y; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Takebe N, 2014, PHARMACOL THERAPEUT, V141, P140, DOI 10.1016/j.pharmthera.2013.09.005; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Visser-Grieve S, 2012, ONCOGENE, V31, P1189, DOI 10.1038/onc.2011.318; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598	39	18	19	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2621	2630		10.1038/onc.2014.185	http://dx.doi.org/10.1038/onc.2014.185			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043298	Green Accepted			2022-12-28	WOS:000354541300008
J	Yan, Y; Hein, AL; Greer, PM; Wang, Z; Kolb, RH; Batra, SK; Cowan, KH				Yan, Y.; Hein, A. L.; Greer, P. M.; Wang, Z.; Kolb, R. H.; Batra, S. K.; Cowan, K. H.			A novel function of HER2/Neu in the activation of G2/M checkpoint in response to gamma-irradiation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; DNA-DAMAGE CHECKPOINT; TYROSINE KINASE INHIBITION; CELL-CYCLE CHECKPOINTS; SIGNALING PATHWAY; CANCER-CELLS; PHOSPHORYLATION; RADIATION; EGFR; PROTEIN	In response to gamma-irradiation (IR)-induced DNA damage, activation of cell cycle checkpoints results in cell cycle arrest, allowing time for DNA repair before cell cycle re-entry. Human cells contain G1 and G2 cell cycle checkpoints. While G1 checkpoint is defective in most cancer cells, commonly due to mutations and/or alterations in the key regulators of G1 checkpoint (for example, p53, cyclin D), G2 checkpoint is rarely impaired in cancer cells, which is important for cancer cell survival. G2 checkpoint activation involves activation of ataxia telangiectasia-mutated (ATM)/ATM- and rad3-related (ATR) signalings, which leads to the inhibition of Cdc2 kinase and subsequent G2/M cell cycle arrest. Previous studies from our laboratory show that G2 checkpoint activation following IR exposure of MCF-7 breast cancer cells is dependent on the activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signaling. As HER receptor tyrosine kinases (RTKs), which have important roles in cell proliferation and survival, have been shown to activate ERK1/2 signaling in response to various stimuli, we investigated the role of HER RTKs in IR-induced G2/M checkpoint response in breast cancer cells. Results of the present studies indicate that IR exposure resulted in a striking increase in the phosphorylation of HER1, HER2, HER3 and HER4 in MCF-7 cells, indicative of activation of these proteins. Furthermore, specific inhibition of HER2 using an inhibitor, short hairpin RNA and dominant-negative mutant HER2 abolished IR-induced activation of ATM/ATR signaling, phosphorylation of Cdc2-Y15 and subsequent induction of G2/M arrest. Moreover, the inhibition of HER2 also abrogated IR-induced ERK1/2 phosphorylation. In contrast, inhibition of HER1 using specific inhibitors or decreasing expression of HER3 or HER4 using short hairpin RNAs did not block the induction of G2/M arrest following IR. These results suggest an important role of HER2 in the activation of G2/M checkpoint response following IR.	[Yan, Y.; Hein, A. L.; Greer, P. M.; Wang, Z.; Kolb, R. H.; Cowan, K. H.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Yan, Y (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	yyan@unmc.edu; kcowan@unmc.edu		Hein, Ashley/0000-0002-3309-2218	Nebraska [DHHS-LB506]; NCI [NCI T32 CA009476]; NCI Cancer Center [P30CA036727]; NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER	Nebraska; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Helen Piwnica-Worms for the GST-Cdc25C construct, Dr Ming-Fong Lin for the HER2-mut, wild-type HER2 and control constructs, Victoria Smith and Dr Charles Kuzynski for assistance with FACS analysis and Dr Janina Baranowska-Kortylewicz for assistance with the Mark I 68A Cesium-137 Irradiator. This work was supported by Nebraska DHHS-LB506 Grant 2010-40 to YY, NCI Training Grant (NCI T32 CA009476) to RK and NCI Cancer Center Support Grant (P30CA036727) to KC.	Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Geoerger B, 2008, INT J CANCER, V123, P209, DOI 10.1002/ijc.23488; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hersey P, 2006, INT REV CYTOL, V251, P131, DOI 10.1016/S0074-7696(06)51004-6; Jani JP, 2007, CANCER RES, V67, P9887, DOI 10.1158/0008-5472.CAN-06-3559; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KHARBANDA S, 1994, CANCER RES, V54, P1412; Kiyozuka M, 2013, ANTICANCER RES, V33, P4337; Kolb RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050281; Kuntz K, 2009, CANCER BIOL THER, V8, P1433, DOI 10.4161/cbt.8.15.9081; Leach JK, 2001, CANCER RES, V61, P3894; Lee HC, 2008, MOL CANCER RES, V6, P996, DOI 10.1158/1541-7786.MCR-08-0113; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liang K, 2003, MOL CANCER THER, V2, P1113; Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Navolanic PM, 2003, INT J ONCOL, V22, P237; Nyati MK, 2004, CLIN CANCER RES, V10, P691, DOI 10.1158/1078-0432.CCR-1041-03; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Bo, 2004, Methods Mol Biol, V281, P283; Yamaguchi H, 2014, ONCOGENE, V33, P1073, DOI 10.1038/onc.2013.74; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268; Yan Y, 2010, ONCOGENE, V29, P4317, DOI 10.1038/onc.2010.187; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Yan Y, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3164	51	23	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2215	2226		10.1038/onc.2014.167	http://dx.doi.org/10.1038/onc.2014.167			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909175	Green Accepted			2022-12-28	WOS:000353473000007
J	Senol, O; Schaaij-Visser, TBM; Erkan, EP; Dorfer, C; Lewandrowski, G; Pham, TV; Piersma, SR; Peerdeman, M; Strobel, T; Tannous, B; Saydam, N; Slavc, I; Knosp, E; Jimenez, CR; Saydam, O				Senol, O.; Schaaij-Visser, T. B. M.; Erkan, E. P.; Dorfer, C.; Lewandrowski, G.; Pham, T. V.; Piersma, S. R.; Peerdeman, M.; Stroebel, T.; Tannous, B.; Saydam, N.; Slavc, I.; Knosp, E.; Jimenez, C. R.; Saydam, O.			miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo	ONCOGENE			English	Article							MYOSIN-II; MESENCHYMAL TRANSITION; INVASION	miR-200a has been implicated in the pathogenesis of meningiomas, one of the most common central nervous system tumors in humans. To identify how miR-200a contributes to meningioma pathogenesis at the molecular level, we used a comparative protein profiling approach using Gel-nanoLC-MS/MS and identified approximately 130 dysregulated proteins in miR-200a-overexpressing meningioma cells. Following the bioinformatic analysis to identify potential genes targeted by miR-200a, we focused on the nonmuscle heavy chain IIb (NMHCIIb), and showed that miR-200a directly targeted NMHCIIb. Considering the key roles of NMHCIIb in cell division and cell migration, we aimed to identify whether miR-200a regulated these processes through NMHCIIb. We found that NMHCIIb overexpression partially rescued miR-200a-mediated inhibition of cell migration, as well as cell growth in vitro and in vivo. Moreover, siRNA-mediated silencing of NMHCIIb expression resulted in a similar migration phenotype in these cells and inhibited meningioma tumor growth in mice. Taken together, these results suggest that NMHCIIb might serve as a novel therapeutic target in meningiomas.	[Senol, O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol & Radiol, Boston, MA USA; [Schaaij-Visser, T. B. M.; Pham, T. V.; Piersma, S. R.; Jimenez, C. R.] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, OncoProte Lab, Amsterdam, Netherlands; [Erkan, E. P.; Saydam, N.; Slavc, I.; Saydam, O.] Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria; [Dorfer, C.; Knosp, E.] Med Univ Vienna, Dept Neurosurg, A-1090 Vienna, Austria; [Lewandrowski, G.; Tannous, B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Expt Therapeut & Mol Imaging Lab, Boston, MA USA; [Peerdeman, M.] Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Amsterdam, Netherlands; [Stroebel, T.] Med Univ Vienna, Inst Neurol, A-1090 Vienna, Austria	Harvard University; Harvard Medical School; Massachusetts General Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Medical University of Vienna; Medical University of Vienna; Harvard University; Harvard Medical School; Massachusetts General Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Medical University of Vienna	Saydam, O (corresponding author), Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria.	okay.saydam@meduniwien.ac.at	Erkan, Erdogan Pekcan/GQR-2513-2022; Jimenez, Connie/AAI-3763-2020; Dorfer, Christian/AAP-1990-2020; Erkan, Erdogan Pekcan/ABI-6822-2020; Saydam, Okay/HDM-4999-2022	Erkan, Erdogan Pekcan/0000-0001-9287-4773; Jimenez, Connie R/0000-0002-3103-4508; Dorfer, Christian/0000-0002-1843-7732	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	Support for this work was provided, in part, by Forschungsgesellschaft for Brain Tumors (to OS, NS), EU-FP7-PEOPLE-2011-CIG (to OS) and Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind' (to OS). We thank Dr Marianne F James for providing us with AC030 cells.	Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Badr CE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000571; Beach JR, 2011, P NATL ACAD SCI USA, V108, P17991, DOI 10.1073/pnas.1106499108; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Elson-Schwab I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013176; Figueroa BE, 1999, BRIT J RADIOL, V72, P513, DOI 10.1259/bjr.72.857.10505022; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hu XX, 2009, GYNECOL ONCOL, V114, P457, DOI 10.1016/j.ygyno.2009.05.022; Jacobs K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-255; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2; Pham MH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1117; Pramesh CS, 2003, JPN J CLIN ONCOL, V33, P86, DOI 10.1093/jjco/hyg022; Ragel Brian, 2003, Cancer Control, V10, P148; Ragel BT, 2008, SURG NEUROL, V70, P295, DOI 10.1016/j.surneu.2007.06.031; Ragel BT, 2010, J NEURO-ONCOL, V99, P315, DOI 10.1007/s11060-010-0381-8; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Saydam O, 2010, J PROTEOME RES, V9, P485, DOI 10.1021/pr900834h; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Sureban SM, 2011, CANCER RES, V71, P2328, DOI 10.1158/0008-5472.CAN-10-2738; Takeda K, 2003, CIRC RES, V93, P330, DOI 10.1161/01.RES.0000089256.00309.CB; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wilisch-Neumann A, 2013, CLIN CANCER RES, V19, P5402, DOI 10.1158/1078-0432.CCR-12-0299; Wu QH, 2011, GYNECOL ONCOL, V122, P149, DOI 10.1016/j.ygyno.2011.03.026; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093	29	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1790	1798		10.1038/onc.2014.120	http://dx.doi.org/10.1038/onc.2014.120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858044				2022-12-28	WOS:000352158000006
J	Hwangbo, C; Tae, N; Lee, S; Kim, O; Park, OK; Kim, J; Kwon, SH; Lee, JH				Hwangbo, C.; Tae, N.; Lee, S.; Kim, O.; Park, O. K.; Kim, J.; Kwon, S-H; Lee, J-H			Syntenin regulates TGF-beta 1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I receptor internalization	ONCOGENE			English	Article							HUMAN-MELANOMA CELLS; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; PDZ TANDEM; MDA-9/SYNTENIN; CANCER; DEGRADATION; METASTASIS; PATHWAYS; REQUIREMENTS	Syntenin, a tandem PDZ domain containing scaffold protein, functions as a positive regulator of cancer cell progression in several human cancers. We report here that syntenin positively regulates transforming growth factor (TGF)-beta 1-mediated Smad activation and the epithelial-to-mesenchymal transition (EMT) by preventing caveolin-1-mediated internalization of TGF-beta type I receptor (T beta RI). Knockdown of syntenin suppressed TGF-beta 1-mediated cell migration, transcriptional responses and Smad2/3 activation in various types of cells; however, overexpression of syntenin facilitated TGF-beta 1-mediated responses. In particular, syntenin knockdown abolished both the basal and TGF-beta 1-mediated repression of E-cadherin expression, as well as induction of vimentin expression along with Snail and Slug upregulation; thus, blocking the TGF-beta 1-induced EMT in A549 cells. In contrast, overexpression of syntenin exhibited the opposite effect. Knockdown of syntenin-induced ubiquitination and degradation of T beta RI, but not TGF-beta type II receptor, leading to decreased T beta RI expression at the plasma membrane. Syntenin associated with T beta RI at its C-terminal domain and a syntenin mutant lacking C-terminal domain failed to increase TGF-beta 1-induced responses. Biochemical analyzes revealed that syntenin inhibited the interaction between caveolin-1 and T beta RI and knockdown of syntenin induced a massive internalization of T beta RI and caveolin-1 from lipid rafts, indicating that syntenin may increase TGF-beta signaling by inhibiting caveolin-1-dependent internalization of T beta RI. Moreover, a positive correlation between syntenin expression and phospho-Smad2 levels is observed in human lung tumors. Taken together, these findings demonstrate that syntenin may act as an important positive regulator of TGF-beta signaling by regulating caveolin-1-mediated internalization of T beta RI; thus, providing a novel function for syntenin that is linked to cancer progression.	[Hwangbo, C.; Tae, N.; Lee, S.; Kim, O.; Kim, J.; Lee, J-H] Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Gangwon Do, South Korea; [Park, O. K.; Kwon, S-H] Korea Basic Sci Inst, Chuncheon Ctr, Div Bioimaging, Chunchon, Gangwon Do, South Korea	Kangwon National University; Korea Basic Science Institute (KBSI)	Lee, JH (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Gangwon Do, South Korea.	jhlee36@kangwon.ac.kr			Korean Health Technology RD Project [A111311]; Ministry of Health and Welfare, Republic of Korea; National Research Foundation of Korea (NRF) [2013R1A1A2009026]	Korean Health Technology RD Project; Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	This work was supported by grants from the Korean Health Technology R&D Project (A111311), Ministry of Health and Welfare, Republic of Korea and the National Research Foundation of Korea (NRF, 2013R1A1A2009026).	Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502; Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Boukerche H, 2007, CANCER RES, V67, P1812, DOI 10.1158/0008-5472.CAN-06-3875; Browman DT, 2007, TRENDS CELL BIOL, V17, P394, DOI 10.1016/j.tcb.2007.06.005; Chen YG, 2009, CELL RES, V19, P58, DOI 10.1038/cr.2008.315; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Dasgupta S, 2013, CLIN CANCER RES, V19, P4621, DOI 10.1158/1078-0432.CCR-13-0585; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Grembecka J, 2006, BIOCHEMISTRY-US, V45, P3674, DOI 10.1021/bi052225y; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hwangbo C, 2010, CANCER RES, V70, P1645, DOI 10.1158/0008-5472.CAN-09-2447; Itoh S, 2007, CURR OPIN CELL BIOL, V19, P176, DOI 10.1016/j.ceb.2007.02.015; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lonn P, 2009, CELL RES, V19, P21, DOI 10.1038/cr.2008.308; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shi J, 2009, CANCER RES, V69, P7180, DOI 10.1158/0008-5472.CAN-08-4470; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; van Rheenen J, 2005, EMBO J, V24, P1664, DOI 10.1038/sj.emboj.7600655; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang Y, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3442; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhao B, 2012, CELL RES, V22, P1467, DOI 10.1038/cr.2012.92; Zimmermann P, 2002, MOL CELL, V9, P1215, DOI 10.1016/S1097-2765(02)00549-X	43	58	66	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					389	401		10.1038/onc.2015.100	http://dx.doi.org/10.1038/onc.2015.100			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893292				2022-12-28	WOS:000369055300012
J	Teng, Y; Ren, X; Li, H; Shull, A; Kim, J; Cowell, JK				Teng, Y.; Ren, X.; Li, H.; Shull, A.; Kim, J.; Cowell, J. K.			Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein	ONCOGENE			English	Article							DOMAIN-CONTAINING 3A; ATPASE FAMILY; CANCER-CELLS; LAMELLIPODIA FORMATION; GENE; SUPPRESSION; WAVE3; TRANSLOCATION; LOCALIZATION; INACTIVATION	AAA domain containing 3A (ATAD3A) is an integral mitochondrial membrane protein with unknown function, although we now show that high-level expression is associated with poor survival in breast cancer patients. Using a mass spectrometry approach we have demonstrated that ATAD3A interacts with the WASF3 metastasis-promoting protein. Knockdown of ATAD3A leads to decreased WASF3 protein levels in breast and colon cancer cells. Silencing ATAD3A also results in loss of both cell anchorageindependent growth and invasion and suppression of tumor growth and metastasis in vivo using immuno-compromised mice. HSP70 is responsible for stabilizing WASF3 in the cytoplasm, but inactivation of HSP70 does not lead to the loss of WASF3 stability at the mitochondrial membrane, where presumably it is protected through its interaction with ATAD3A. In response to endoplasmic reticulum (ER) stress, increases in the GRP78 protein level leads to increased WASF3 protein levels. We also show that ATAD3A was present in a WASF3-GRP78 complex, and suppression of GRP78 led to destabilization of WASF3 at the mitochondrial membrane, which was ATAD3A dependent. Furthermore, ATAD3A-mediated suppression of CDH1/E-cadherin occurs through its regulation of GRP78-mediated WASF3 stability. Proteolysis experiments using isolated mitochondria demonstrates the presence of the N-terminal end of WASF3 within the mitochondria, which is the interaction site with the N-terminal end of ATAD3A. It appears, therefore, that stabilization of WASF3 function occurs through its interaction with ATAD3A and GRP78, which may provide a bridge between the ER and mitochondria, allowing communication between the two organelles. These findings also suggest that pharmacologic inhibition of ATAD3A could be an effective therapeutic strategy to treat human cancer.	[Teng, Y.; Ren, X.; Li, H.; Shull, A.; Cowell, J. K.] Georgia Regents Univ, Canc Ctr, 1120 15th St, Augusta, GA 30912 USA; [Teng, Y.; Li, H.] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Kim, J.] Georgia Regents Univ, Dept Biostat & Epidemiol, Augusta, GA USA; [Kim, J.] Sungkyunkwan Univ, Dept Stat, Seoul, South Korea	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Sungkyunkwan University (SKKU)	Teng, Y (corresponding author), Georgia Regents Univ, Canc Ctr, 1120 15th St, Augusta, GA 30912 USA.	yteng@gru.edu	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289	Department of Defense [W81XWH-14-1-0412]; National Institutes of Health [CA120510]; NATIONAL CANCER INSTITUTE [R01CA120510] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grant W81XWH-14-1-0412 from Department of Defense and grant CA120510 from the National Institutes of Health. We would like to thank Yun Mei, James Ross and the staff of Cancer Center Shared Resources at GRU for the technical assistance.	Beene DL, 2007, CURR OPIN CELL BIOL, V19, P192, DOI 10.1016/j.ceb.2007.02.011; Bellot G, 2007, CELL DEATH DIFFER, V14, P785, DOI 10.1038/sj.cdd.4402055; Bisi S, 2013, CURR OPIN CELL BIOL, V25, P565, DOI 10.1016/j.ceb.2013.04.001; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Chen TC, 2011, INT J MOL MED, V28, P689, DOI 10.3892/ijmm.2011.743; Chiang SF, 2012, INT J MOL MED, V29, P365, DOI 10.3892/ijmm.2011.849; Dahl JP, 2003, J NEUROSCI, V23, P3343; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151; Fang HY, 2010, J CELL SCI, V123, P1171, DOI 10.1242/jcs.062034; Gilquin B, 2010, MOL CELL BIOL, V30, P1984, DOI 10.1128/MCB.00007-10; Goller T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054799; Grkovic S, 2013, ONCOGENE, V32, P2412, DOI 10.1038/onc.2012.264; He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158; Hoffmann M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007644; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hubstenberger A, 2008, EXP CELL RES, V314, P2870, DOI 10.1016/j.yexcr.2008.06.017; Iorns E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047995; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li N, 2013, ONCOGENE, V32, P1933, DOI 10.1038/onc.2012.212; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Maitre JL, 2013, CURR BIOL, V23, pR626, DOI 10.1016/j.cub.2013.06.019; Merle N, 2012, MITOCHONDRION, V12, P441, DOI 10.1016/j.mito.2012.05.005; Ogaeri T, 2009, STEM CELLS, V27, P1120, DOI 10.1002/stem.42; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rawe VY, 2004, HUM REPROD, V19, P2594, DOI 10.1093/humrep/deh513; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rotty JD, 2013, NAT REV MOL CELL BIO, V14, P7, DOI 10.1038/nrm3492; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2003, MAMM GENOME, V14, P314, DOI 10.1007/s00335-002-2247-7; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Sotomayor M, 2014, TRENDS CELL BIOL, V24, P524, DOI 10.1016/j.tcb.2014.03.007; Sun FC, 2006, BIOCHEM J, V396, P31, DOI 10.1042/BJ20051916; Teng Y, 2014, ONCOGENE, V33, P203, DOI 10.1038/onc.2012.565; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2013, CARCINOGENESIS, V34, P1994, DOI 10.1093/carcin/bgt167; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Teng Y, 2011, INT J CANCER, V129, P2825, DOI 10.1002/ijc.25964; Yang J, 2010, J THEOR BIOL, V266, P231, DOI 10.1016/j.jtbi.2010.06.009; You WC, 2013, NEURO-ONCOLOGY, V15, P1342, DOI 10.1093/neuonc/not077	44	53	54	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					333	343		10.1038/onc.2015.86	http://dx.doi.org/10.1038/onc.2015.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25823022	Green Accepted			2022-12-28	WOS:000369055300007
J	Park, JM; Wu, T; Cyr, AR; Woodfield, GW; De Andrade, JP; Spanheimer, PM; Li, T; Sugg, SL; Lal, G; Domann, FE; Zhang, W; Weigel, RJ				Park, J. M.; Wu, T.; Cyr, A. R.; Woodfield, G. W.; De Andrade, J. P.; Spanheimer, P. M.; Li, T.; Sugg, S. L.; Lal, G.; Domann, F. E.; Zhang, W.; Weigel, R. J.			The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-2-GAMMA; PATHOLOGICAL COMPLETE RESPONSE; NEGATIVE BREAST-CANCER; FACTOR RECEPTOR; EXPRESSION PATTERNS; CELL-LINES; GENE; TUMORS; AP-2; OVEREXPRESSION	TFAP2C/AP-2 gamma influences development of the mammary gland and regulates patterns of gene expression in luminal and HER2-amplified breast cancer. The roles of TFAP2C in mammary gland tumorigenesis and in pathways critical to cancer progression remain poorly understood. To gain greater insight into oncogenic mechanisms regulated by TFAP2C, we examined mammary tumorigenesis in MMTV-Neu transgenic female mice with or without conditional knockout (KO) of Tcfap2c, the mouse homolog of TFAP2C. Loss of Tcfap2c increased the latency of tumorigenesis and tumors that formed demonstrated reduced proliferative index and increased apoptosis. In addition, tumors formed in Tcfap2c KO animals had a significant reduction in Egfr levels without a change in the expression of the Neu oncogene. The MMneu-flAP2C cell line was established from tumor tissue derived from MMTV-Neu/Tcfap2c(L/L) control animals and parallel cell lines with and without expression of Tcfap2c were created by transduction with adenovirus-empty and adenovirus-Cre, respectively. KO of Tcfap2c in vitro reduced activated phosphorylated-Erk, decreased cell viability, repressed tumor growth and was associated with attenuation of Egfr expression. Chromatin immunoprecipitation and direct sequencing and expression analysis confirmed that Egfr was a Tcfap2c target gene in murine, as well as human, mammary carcinoma cells. Furthermore, decreased viability of mammary cancer cells was directly related to Egfr functional blockade. We conclude that TFAP2C regulates tumorigenesis, cell growth and survival in HER2-amplified breast cancer through transcriptional regulation of EGFR. The findings have important implications for targeting the EGFR pathway in breast cancer.	[Park, J. M.; Wu, T.; Cyr, A. R.; Woodfield, G. W.; De Andrade, J. P.; Spanheimer, P. M.; Sugg, S. L.; Lal, G.; Domann, F. E.; Weigel, R. J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Park, J. M.; Weigel, R. J.] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; [Li, T.] Washington Univ, Genome Inst, St Louis, MO USA; [Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; [Domann, F. E.; Zhang, W.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Weigel, R. J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; Washington University (WUSTL); University of Iowa; University of Iowa; University of Iowa	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr,1516 JCP, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu	Li, Tiandao/F-4039-2012	Li, Tiandao/0000-0003-1650-0555; Lal, Geeta/0000-0001-6471-6479; De Andrade, James/0000-0001-7357-9322; Sugg, Sonia/0000-0001-7530-8526; Weigel, Ronald/0000-0002-9249-0793; Domann, Frederick/0000-0002-0489-2179	National Institutes of Health [R01CA109294, T32CA148062]; NATIONAL CANCER INSTITUTE [R01CA109294, T32CA078586, R01CA115438, T32CA148062, K08CA151658, R00CA158055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Alicia Olivier from University of Iowa Pathology Core Lab for her assistance in IHC. This work was supported by the National Institutes of Health grants R01CA109294 (PI: RJW), T32CA148062 (PI: RJW) and by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund.	Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Auman HJ, 2002, DEVELOPMENT, V129, P2733; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Bogachek MV, 2014, CANCER CELL, V25, P748, DOI 10.1016/j.ccr.2014.04.008; Bos M, 1997, CLIN CANCER RES, V3, P2099; Bosher JM, 1996, ONCOGENE, V13, P1701; Bria E, 2014, CANCER TREAT REV, V40, P847, DOI 10.1016/j.ctrv.2014.05.001; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Cyr AR, 2015, ONCOGENE, V34, P436, DOI 10.1038/onc.2013.569; DeFazio-Eli L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2866; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Huang SX, 2008, NEOPLASIA, V10, P118, DOI 10.1593/neo.07637; Jager R, 2010, DEV DYNAM, V239, P1027, DOI 10.1002/dvdy.22239; Jager R, 2005, BREAST CANCER RES TR, V90, P273, DOI 10.1007/s10549-004-4815-x; Jager R, 2003, MOL CANCER RES, V1, P921; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Nieto Y, 2007, J CLIN ONCOL, V25, P4405, DOI 10.1200/JCO.2006.09.8822; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sale S, 2013, NAT CELL BIOL, V15, P451, DOI 10.1038/ncb2725; Shiu KK, 2014, ONCOGENE, V33, P619, DOI 10.1038/onc.2012.625; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spanheimer PM, 2013, J SURG RES, V184, P519, DOI 10.1016/j.jss.2013.04.042; Turner BC, 1998, CANCER RES, V58, P5466; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wagner KU, 2013, ONCOGENE, V32, P1338, DOI 10.1038/onc.2012.452; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7	42	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6105	6114		10.1038/onc.2015.59	http://dx.doi.org/10.1038/onc.2015.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25772240	Green Accepted			2022-12-28	WOS:000366113800007
J	Kang, JY; Song, SH; Yun, J; Jeon, MS; Kim, HP; Han, SW; Kim, TY				Kang, J. Y.; Song, S. H.; Yun, J.; Jeon, M. S.; Kim, H. P.; Han, S. W.; Kim, T. Y.			Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression	ONCOGENE			English	Article							GENE-EXPRESSION; CTCF; COHESIN; CYCLOOXYGENASE-2; BINDING; CANCER; TRANSCRIPTION; ORGANIZATION; GENOME; PARENT	The CCCTC-binding factor (CTCF)/cohesin complex regulates gene transcription via high-order chromatin organization of the genome. De novo methylation of CpG islands in the promoter region is an epigenetic hallmark of gene silencing in cancer. Although the CTCF/cohesin complex preferentially targets hypomethylated DNA, it remains unclear whether the CTCF/cohesin-mediated high-order chromatin structure is affected by DNA methylation during tumorigenesis. We found that DNA methylation downregulates the expression of prostaglandin-endoperoxide synthase 2 (PTGS2), which is an inducible, rate-limiting enzyme for prostaglandin synthesis, by disrupting CTCF/cohesin-mediated chromatin looping. We show that the CTCF/cohesin complex is enriched near a CpG island associated with PTGS2 and that the PTGS2 locus forms chromatin loops through methylation-sensitive binding of the CTCF/cohesin complex. DNA methylation abolishes the association of the CTCF/cohesin complex with the PTGS2 CpG island. Disruption of chromatin looping by DNA methylation abrogates the enrichment of transcriptional components, such as positive elongation factor b, at the transcriptional start site of the PTGS2 locus. These alterations result in the downregulation of PTGS2. Our results provide evidence that CTCF/cohesin-mediated chromatin looping of the PTGS2 locus is dynamically influenced by the DNA methylation status.	[Kang, J. Y.; Song, S. H.; Yun, J.; Jeon, M. S.; Kim, H. P.; Han, S. W.; Kim, T. Y.] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Kang, J. Y.; Yun, J.; Jeon, M. S.; Kim, T. Y.] Seoul Natl Univ, Coll Med, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul, South Korea; [Han, S. W.; Kim, T. Y.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Kim, TY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	kimty@snu.ac.kr	/Y-5959-2019		National R&D Program for Cancer Control (MOHW) [0720540]; Basic Science Research Program (MOE) [NRF-2011-0021123]; Mid-career Researcher Program (MSIP) [NRF-2013R1A2A2A01009297]; Korea Health Technology R&D Project (MOHW), Republic of Korea [HI14C1277]	National R&D Program for Cancer Control (MOHW); Basic Science Research Program (MOE); Mid-career Researcher Program (MSIP); Korea Health Technology R&D Project (MOHW), Republic of Korea	The authors are grateful to all members of our group for their helpful advice. This research was supported by a grant from the National R&D Program for Cancer Control (MOHW, 0720540), the Basic Science Research Program (MOE, NRF-2011-0021123), the Mid-career Researcher Program (MSIP, NRF-2013R1A2A2A01009297) and the Korea Health Technology R&D Project (MOHW, HI14C1277), Republic of Korea.	Batlle-Lopez A, 2015, ONCOGENE, V34, P246, DOI 10.1038/onc.2013.535; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Chang JF, 2010, P NATL ACAD SCI USA, V107, P21836, DOI 10.1073/pnas.1002130107; Coward WR, 2014, FASEB J, V28, P3183, DOI 10.1096/fj.13-241760; de Maat MFG, 2007, J CLIN ONCOL, V25, P4887, DOI 10.1200/JCO.2006.09.8921; de Wit E, 2013, NATURE, V501, P227, DOI 10.1038/nature12420; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DeMare LE, 2013, GENOME RES, V23, P1224, DOI 10.1101/gr.156570.113; Dorsett D, 2012, CURR BIOL, V22, pR240, DOI 10.1016/j.cub.2012.02.046; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Egloff S, 2012, TRENDS GENET, V28, P333, DOI 10.1016/j.tig.2012.03.007; Gilroy DW, 2001, FASEB J, V15, P288; Gomes NP, 2010, GENE DEV, V24, P1022, DOI 10.1101/gad.1881010; Hadjur S, 2009, NATURE, V460, P410, DOI 10.1038/nature08079; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hou CH, 2010, P NATL ACAD SCI USA, V107, P3651, DOI 10.1073/pnas.0912087107; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Krivega I, 2012, CURR OPIN GENET DEV, V22, P79, DOI 10.1016/j.gde.2011.11.001; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Nagano T, 2013, NATURE, V502, P59, DOI 10.1038/nature12593; Nitzsche A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019470; Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Phillips-Cremins JE, 2013, CELL, V153, P1281, DOI 10.1016/j.cell.2013.04.053; Rhodes JM, 2011, MOL CANCER RES, V9, P1587, DOI 10.1158/1541-7786.MCR-11-0382; Rizzo MT, 2011, CLIN CHIM ACTA, V412, P671, DOI 10.1016/j.cca.2010.12.026; Rodriguez C, 2010, BIOCHEM BIOPH RES CO, V392, P129, DOI 10.1016/j.bbrc.2009.12.159; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Rubio ED, 2008, P NATL ACAD SCI USA, V105, P8309, DOI 10.1073/pnas.0801273105; Schaaf CA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003382; Schoenfelder S, 2010, NAT GENET, V42, P53, DOI 10.1038/ng.496; Seitan VC, 2013, GENOME RES, V23, P2066, DOI 10.1101/gr.161620.113; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Song SH, 2001, CANCER RES, V61, P4628; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Toyota M, 2000, CANCER RES, V60, P4044; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Yan J, 2013, CELL, V154, P801, DOI 10.1016/j.cell.2013.07.034; Yun J, 2012, LAB INVEST, V92, P1033, DOI 10.1038/labinvest.2012.61	45	25	28	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5677	5684		10.1038/onc.2015.17	http://dx.doi.org/10.1038/onc.2015.17			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25703332	Bronze			2022-12-28	WOS:000364594300008
J	Lecointre, C; Desrues, L; Joubert, JE; Perzo, N; Guichet, PO; Le Joncour, V; Brule, C; Chabbert, M; Leduc, R; Prezeau, L; Laquerriere, A; Proust, F; Gandolfo, P; Morin, F; Castel, H				Lecointre, C.; Desrues, L.; Joubert, J. E.; Perzo, N.; Guichet, P-O; Le Joncour, V.; Brule, C.; Chabbert, M.; Leduc, R.; Prezeau, L.; Laquerriere, A.; Proust, F.; Gandolfo, P.; Morin, F.; Castel, H.			Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; CANCER CELL-MIGRATION; EXTRACELLULAR-MATRIX; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; MALIGNANT GLIOMAS; ORPHAN RECEPTOR; IN-VITRO; EXPRESSION; ACTIVATION	Multiform glioblastomas (GBM) are the most frequent and aggressive primary brain tumors in adults. The poor prognosis is due to neo-angiogenesis and cellular invasion, processes that require complex chemotaxic mechanisms involving motility, migration and adhesion. Understanding these different cellular events implies identifying receptors and transduction pathways that lead to and promote either migration or adhesion. Here we establish that glioma express the vasoactive peptide urotensin II (UII) and its receptor UT and that UT-mediated signaling cascades are involved in glioma cell migration and adhesion. Components of the urotensinergic systems, UII and UT, are widely expressed in patient-derived GBM tissue sections, glioma cell lines and fresh biopsy explants. Interestingly, gradient concentrations of UII produced chemoattracting migratory/motility effects in glioma as well as HEK293 cells expressing human UT. These effects mainly involved the G(13)/Rho/rho kinase pathway while partially requiring G(i/o)/PI3K components. In contrast, we observed that homogeneous concentrations of UII drastically blocked cell motility and stimulated cell-matrix adhesions through a UT/G(i/o) signaling cascade, partially involving phosphatidylinositol-3 kinase. Finally, we provide evidence that, in glioma cells, homogeneous concentration of UII allowed translocation of G(alpha 13) to the UT receptor at the plasma membrane and increased actin stress fibers, lamellipodia formation and vinculin-stained focal adhesions. UII also provoked a re-localization of UT precoupled to G(alpha i) in filipodia and initiated integrin-stained focal points. Altogether, these findings suggest that UT behaves as a chemotaxic receptor, relaying a signaling switch between directional migration and cell adhesion under gradient or homogeneous concentrations, thereby redefining sequential mechanisms affecting tumor cells during glioma invasion. Taken together, our results allow us to propose a model in order to improve the design of compounds that demonstrate signaling bias for therapies that target specifically the G(i/o) signaling pathway.	[Lecointre, C.; Desrues, L.; Joubert, J. E.; Perzo, N.; Guichet, P-O; Le Joncour, V.; Proust, F.; Gandolfo, P.; Morin, F.; Castel, H.] Univ Rouen, Lab Neuronal & Neuroendocrine Commun & Differenti, Biomed Res Inst IRIB, Inserm,U982,DC2N,Astrocyte & Vasc Niche,Network T, F-76821 Mont St Aignan, France; [Perzo, N.; Brule, C.; Leduc, R.] Univ Sherbrooke, Fac Med & Sci Sante, Inst Pharmacol, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada; [Brule, C.; Prezeau, L.] Univ Montpellier 1 & 2, Inst Funct Genom, IGF, CNRS,UMR 5203,Inserm,U661, Montpellier, France; [Chabbert, M.] Fac Med 3, UMR CNRS 6214, Inserm 1083, Angers, France; [Laquerriere, A.] CHU Rouen, Serv Anatomocytopathol, INSERM, ERI28, Rouen, France; [Proust, F.] CHU Rouen, Serv Neurosurg, Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; University of Sherbrooke; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen	Castel, H (corresponding author), Univ Rouen, Lab Neuronal & Neuroendocrine Commun & Differenti, Biomed Res Inst IRIB, Inserm,U982,DC2N,Astrocyte & Vasc Niche,Network T, F-76821 Mont St Aignan, France.	helene.castel@univ-rouen.fr	castel, helene/B-8675-2009; Le Joncour, Vadim/X-6274-2019	castel, helene/0000-0002-8972-5555; Le Joncour, Vadim/0000-0001-8153-8563; Guichet, Pierre-Olivier/0000-0003-0115-2199; Morin, Fabrice/0000-0001-6785-1967	CIHR (Canadian Institutes of Health Research); Inserm; Gefluc; TC2N network; LARC Neuroscience; Institute on Innovative and Biomedical Research (IRIB), The University of Rouen; Haute-Normandy or French ministry	CIHR (Canadian Institutes of Health Research)(Canadian Institutes of Health Research (CIHR)); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Gefluc; TC2N network; LARC Neuroscience; Institute on Innovative and Biomedical Research (IRIB), The University of Rouen; Haute-Normandy or French ministry	We thank Mme Marie-Therese Schouft for her expertise in cytometry, the PRIMACEN platform (University of Rouen, France) for imaging equipments and Mr Arnaud Arabo and Mrs Huguette Lemonnier for skillful technical assistance. This work was supported by a CIHR (Canadian Institutes of Health Research) grant to RL and by Inserm, Gefluc, TC2N network, LARC Neuroscience and Institute on Innovative and Biomedical Research (IRIB), The University of Rouen. CL, VL, J-EJ and P-OG were recipients of a fellowship from the Haute-Normandy or French ministry.	Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; BOCCHINI V, 1991, CELL TISSUE RES, V265, P73, DOI 10.1007/BF00318141; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Brule C, 2014, FASEB J, V28, P5148, DOI 10.1096/fj.14-249771; Castel H, 2006, J NEUROCHEM, V99, P582, DOI 10.1111/j.1471-4159.2006.04130.x; Cirillo P, 2008, J THROMB HAEMOST, V6, P726, DOI 10.1111/j.1538-7836.2008.02923.x; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; Cowley E, 2005, BRIT J ANAESTH, V95, P495, DOI 10.1093/bja/aei222; Daher Z, 2008, CELL SIGNAL, V20, P2256, DOI 10.1016/j.cellsig.2008.08.021; Desrues L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036319; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Federico A, 2014, EUR J CLIN INVEST, V44, P285, DOI 10.1111/eci.12231; Filipeanu CM, 2002, J NEUROCHEM, V83, P879, DOI 10.1046/j.1471-4159.2002.01196.x; Franco R, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-48; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477; Gould PS, 2010, HYPERTENSION, V56, P172, DOI 10.1161/HYPERTENSIONAHA.110.152074; Grieco P, 2011, J CELL BIOCHEM, V112, P341, DOI 10.1002/jcb.22933; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Jarjour AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025408; Jarry M, 2010, BIOCHEM J, V428, P113, DOI 10.1042/BJ20090867; Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Kirui JK, 2010, J PHARMACOL EXP THER, V333, P393, DOI 10.1124/jpet.109.164814; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; Lin YZ, 2003, HYPERTENS RES, V26, P839, DOI 10.1291/hypres.26.839; Lu DY, 2010, J CELL BIOCHEM, V110, P141, DOI 10.1002/jcb.22520; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Matsusaka S, 2006, N-S ARCH PHARMACOL, V373, P381, DOI 10.1007/s00210-006-0086-x; Medeiros PJ, 2012, INT J CANCER, V131, P276, DOI 10.1002/ijc.26350; Mitra P, 2001, CELL SIGNAL, V13, P311, DOI 10.1016/S0898-6568(01)00156-5; Monterrubio M, 2009, BIOCHEM BIOPH RES CO, V388, P199, DOI 10.1016/j.bbrc.2009.07.153; Mori M, 1999, BIOCHEM BIOPH RES CO, V265, P123, DOI 10.1006/bbrc.1999.1640; Mugabe BE, 2010, J PHARMACOL EXP THER, V332, P116, DOI 10.1124/jpet.109.157552; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; Nishikawa K, 2011, NEUROCHEM INT, V58, P261, DOI 10.1016/j.neuint.2010.11.013; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; Nothacker HP, 1999, NAT CELL BIOL, V1, P383, DOI 10.1038/14081; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Perzelova A, 1998, NEOPLASMA, V45, P25; Proulx CD, 2008, MOL PHARMACOL, V74, P552, DOI 10.1124/mol.108.045054; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Rossowski WJ, 2002, EUR J PHARMACOL, V438, P159, DOI 10.1016/S0014-2999(02)01341-9; Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034; Segain JP, 2007, J IMMUNOL, V179, P901, DOI 10.4049/jimmunol.179.2.901; Shyu KG, 2012, EUR J CLIN INVEST, V42, P17, DOI 10.1111/j.1365-2362.2011.02549.x; Song W, 2006, N-S ARCH PHARMACOL, V373, P148, DOI 10.1007/s00210-006-0057-2; Stupp R, 2005, ANN ONCOL, V16, P64, DOI 10.1093/annonc/mdi834; Sugo T, 2003, BIOCHEM BIOPH RES CO, V310, P860, DOI 10.1016/j.bbrc.2003.09.102; Takahashi K, 2003, PEPTIDES, V24, P301, DOI 10.1016/S0196-9781(03)00039-1; Takahashi K, 2001, PEPTIDES, V22, P1175, DOI 10.1016/S0196-9781(01)00441-7; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thompson JP, 2003, ANESTH ANALG, V97, P1501, DOI 10.1213/01.ANE.0000086723.97421.BC; Totsune K, 2001, LANCET, V358, P810, DOI 10.1016/S0140-6736(01)06002-0; Tzanidis A, 2003, CIRC RES, V93, P246, DOI 10.1161/01.RES.0000084382.64418.BC; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Watson AMD, 2013, DIABETOLOGIA, V56, P1155, DOI 10.1007/s00125-013-2837-9; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu YQ, 2010, ONCOL REP, V24, P1179, DOI 10.3892/or_00000970; Xie Y, 2013, BIOCHEM PHARMACOL, V85, P1454, DOI 10.1016/j.bcp.2013.03.001; Xu SK, 2009, TOHOKU J EXP MED, V219, P283, DOI 10.1620/tjem.219.283; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yamazaki F, 2005, BIOCHEM BIOPH RES CO, V332, P782, DOI 10.1016/j.bbrc.2005.05.023; Yi KH, 2012, PEPTIDES, V33, P87, DOI 10.1016/j.peptides.2011.11.016; Zagzag D, 2008, AM J PATHOL, V173, P545, DOI 10.2353/ajpath.2008.071197; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482; Zhang YG, 2008, J HYPERTENS, V26, P1119, DOI 10.1097/HJH.0b013e3282fa1412; Zhang YG, 2011, PEPTIDES, V32, P2452, DOI 10.1016/j.peptides.2011.10.018; Zhou CH, 2012, ONCOL LETT, V4, P1259, DOI 10.3892/ol.2012.932; Ziltener P, 2002, J RECEPT SIGNAL TR R, V22, P155, DOI 10.1081/RRS-120014593	76	16	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5080	5094		10.1038/onc.2014.433	http://dx.doi.org/10.1038/onc.2014.433			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25597409				2022-12-28	WOS:000361693300008
J	Shain, KH; Dalton, WS; Tao, J				Shain, K. H.; Dalton, W. S.; Tao, J.			The tumor microenvironment shapes hallmarks of mature B-cell malignancies	ONCOGENE			English	Review							CHRONIC LYMPHOCYTIC-LEUKEMIA; BONE-MARROW MICROENVIRONMENT; MEDIATED DRUG-RESISTANCE; SPLEEN TYROSINE KINASE; MULTIPLE-MYELOMA CELLS; NF-KAPPA-B; FOLLICULAR LYMPHOMA; STROMAL CELLS; THERAPEUTIC TARGET; T-CELLS	B-cell tumorigenesis results from a host of known and unknown genetic anomalies, including non-random translocations of genes that normally function as determinants of cell proliferation or cell survival to regions juxtaposed to active immunoglobulin heavy chain enhancer elements, chromosomal aneuploidy, somatic mutations that further affect oncogenic signaling and loss of heterozygosity of tumor-suppressor genes. However, it is critical to recognize that even in the setting of a genetic disease, the B-cell/plasma cell tumor microenvironment (TME) contributes significantly to malignant transformation and pathogenesis. Over a decade ago, we proposed the concept of cell adhesion-mediated drug resistance to delineate a form of TME-mediated drug resistance that protects hematopoietic tumor cells from the initial effect of diverse therapies. In the interim, it has been increasingly appreciated that TME also contributes to tumor initiation and progression through sustained growth/proliferation, self-renewal capacity, immune evasion, migration and invasion as well as resistance to cell death in a host of B-cell malignancies, including mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstroms macroglobulinemia, chronic lymphocytic leukemia and multiple myeloma. Within this review, we propose that TME and the tumor co-evolve as a consequence of bidirectional signaling networks. As such, TME represents an important target and should be considered integral to tumor progression and drug response.	[Shain, K. H.; Dalton, W. S.] Dept Malignant Hematol, Tampa, FL USA; [Shain, K. H.; Dalton, W. S.] Chem Biol & Mol Med Program, Tampa, FL USA; [Dalton, W. S.] DeBartolo Family Personalized Med Inst, Tampa, FL USA; [Tao, J.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol & Lab Med, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Shain, KH (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, MCC LAB 2071,12902 Magnolia Dr, Tampa, FL 33612 USA.	ken.shain@moffitt.org; jianguo.tao@moffitt.org			Department of Health Bankhead-Coley Team Science Program grant [2BT03]; US Army Medical Research and Materiel Command [W81XWH-08-2-0101]; National Cancer Institute [P30-CA076292]; National Cancer Institutes [R01CA137123]; Lymphoma Research Foundation; Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE [R25CA174664, R01CA137123, P30CA076292] Funding Source: NIH RePORTER	Department of Health Bankhead-Coley Team Science Program grant; US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institutes(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lymphoma Research Foundation; Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Health Bankhead-Coley Team Science Program grant (2BT03), the US Army Medical Research and Materiel Command under Award W81XWH-08-2-0101 for a National Functional Genomics Center, the National Cancer Institute under Award (P30-CA076292), National Cancer Institutes (R01CA137123), Lymphoma Research Foundation, Maher Fund and the Moffitt Cancer Center Foundation.	Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Ai WZ, 2009, INT J CANCER, V124, P239, DOI 10.1002/ijc.23881; Arana E, 2008, J CELL SCI, V121, P2279, DOI 10.1242/jcs.017905; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668; Blotta S, 2012, BLOOD, V120, P5002, DOI 10.1182/blood-2011-07-368142; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Boucher K, 2012, CLIN CANCER RES, V18, P6155, DOI 10.1158/1078-0432.CCR-12-0531; Brown JR, 2014, BLOOD, V123, P3390, DOI 10.1182/blood-2013-11-535047; Buchner M, 2009, CANCER RES, V69, P5424, DOI 10.1158/0008-5472.CAN-08-4252; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burger JA, 2012, CURR OPIN ONCOL, V24, P643, DOI 10.1097/CCO.0b013e3283589950; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Byrd JC, 2014, J CLIN ONCOL, V32, P3039, DOI 10.1200/JCO.2014.55.8262; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Cacciatore M, 2012, ADV HEMATOL, V2012, DOI DOI 10.1155/2012/138079; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dasmahapatra G, 2013, BRIT J HAEMATOL, V161, P43, DOI 10.1111/bjh.12206; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; de Haart SJ, 2013, CLIN CANCER RES, V19, P5591, DOI 10.1158/1078-0432.CCR-12-3676; de Jong D, 2008, J INTERN MED, V264, P528, DOI 10.1111/j.1365-2796.2008.02032.x; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Du WL, 2004, PATHOL INT, V54, P285, DOI 10.1111/j.1440-1827.2004.01622.x; Emmons MF, 2011, MOL CANCER THER, V10, P2257, DOI 10.1158/1535-7163.MCT-11-0149; Fan F, 2012, J ONCOL, V2012, DOI 10.1155/2012/281261; Flinn IW, 2014, BLOOD, V123, P3406, DOI 10.1182/blood-2013-11-538546; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Ghobrial J, 2007, ONCOLOGY-NY, V21, P785; Gilbert LA, 2012, GENE DEV, V26, P1758, DOI 10.1101/gad.197590.112; Glas AM, 2005, BLOOD, V105, P301, DOI 10.1182/blood-2004-06-2298; Gorgun GT, 2013, BLOOD, V121, P2975, DOI 10.1182/blood-2012-08-448548; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Herman SEM, 2012, ASH ANN M, V120, P185; Herreros B, 2008, LEUKEMIA, V22, P49, DOI 10.1038/sj.leu.2404970; Hirsch E, 2014, ONCOGENE, V33, P3083, DOI 10.1038/onc.2013.265; Hodge LS, 2012, BLOOD, V120, P3774, DOI 10.1182/blood-2012-03-419440; Hoellenriegel J, 2012, LEUKEMIA, V26, P1576, DOI 10.1038/leu.2012.24; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Hu YP, 2012, LEUKEMIA LYMPHOMA, V53, P130, DOI 10.3109/10428194.2011.601698; Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood-2009-06-222943; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jones JA, 2014, BLOOD, V123, P1455, DOI 10.1182/blood-2013-09-453092; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Kahl BS, 2014, BLOOD, V123, P3398, DOI 10.1182/blood-2013-11-537555; Kiaii S, 2013, J CLIN ONCOL, V31, P2654, DOI 10.1200/JCO.2012.44.2137; Kimlinger T, 2006, HAEMATOLOGICA, V91, P1033; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Koster A, 2005, CURR OPIN ONCOL, V17, P611, DOI 10.1097/01.cco.0000181404.83084.b5; Kumar S, 2003, LEUKEMIA, V17, P2025, DOI 10.1038/sj.leu.2403084; Kuppers R, 2004, NEW ENGL J MED, V351, P2152, DOI 10.1056/NEJMp048257; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Lin J, 2011, LEUKEMIA, V25, P145, DOI 10.1038/leu.2010.230; Lutzny G, 2013, CANCER CELL, V23, P77, DOI 10.1016/j.ccr.2012.12.003; Lwin T, 2007, LEUKEMIA, V21, P1521, DOI 10.1038/sj.leu.2404723; Lwin T, 2009, LEUKEMIA, V23, P170, DOI 10.1038/leu.2008.266; Lwin T, 2013, J CLIN INVEST, V123, P4612, DOI 10.1172/JCI64210; McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Medina DJ, 2012, HAEMATOL-HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659; Mitsiades CS, 2007, HEMATOL ONCOL CLIN N, V21, P1007, DOI 10.1016/j.hoc.2007.08.007; Moller C, 2003, LEUKEMIA, V17, P203, DOI 10.1038/sj.leu.2402717; Mourcin F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00280; Mraz M, 2011, BRIT J HAEMATOL, V155, P53, DOI 10.1111/j.1365-2141.2011.08794.x; Mueller CG, 2007, J LEUKOCYTE BIOL, V82, P567, DOI 10.1189/jlb.0706481; Neffendorf JE, 2013, NEW ENGL J MED, V369, P1277, DOI 10.1056/NEJMc1309710; Ngo HT, 2008, BLOOD, V112, P150, DOI 10.1182/blood-2007-12-129395; Noonan K, 2011, CANCER MICROENVIRON, V4, P313, DOI 10.1007/s12307-011-0086-3; Nyman JS, 2011, J BONE MINER RES, V26, P1252, DOI 10.1002/jbmr.326; O'Callaghan K, 2012, BLOOD, V119, P1717, DOI 10.1182/blood-2011-04-347518; Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938; Pilarski LM, 2002, CLIN CANCER RES, V8, P3198; Podar K, 2007, CELL CYCLE, V6, P538, DOI 10.4161/cc.6.5.3922; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Quiroga MP, 2009, BLOOD, V114, P1029, DOI 10.1182/blood-2009-03-212837; Rajkumar SV, 2003, LEUKEMIA, V17, P775, DOI 10.1038/sj.leu.2402866; Ramachandran IR, 2013, J IMMUNOL, V190, P3815, DOI 10.4049/jimmunol.1203373; Rappa G, 2008, EXP CELL RES, V314, P2110, DOI 10.1016/j.yexcr.2008.03.008; Richter J, 2012, NAT GENET, V44, P1316, DOI 10.1038/ng.2469; Ruan J, 2013, BLOOD, V121, P5192, DOI 10.1182/blood-2013-03-490763; Sacedon R, 2005, J IMMUNOL, V174, P1456, DOI 10.4049/jimmunol.174.3.1456; Seifert Marc, 2013, Methods Mol Biol, V971, P1, DOI 10.1007/978-1-62703-269-8_1; Shain KH, 2014, ONCOGENE, V33, P4107, DOI 10.1038/onc.2013.379; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Stein R, 2010, BLOOD, V115, P5180, DOI 10.1182/blood-2009-06-228288; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood-2011-12-396853; Tao JC, 2014, CELL CYCLE, V13, P191, DOI 10.4161/cc.27646; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Troeger A, 2012, BLOOD, V119, P4708, DOI 10.1182/blood-2011-12-395939; Vij R, 2012, ASH ANN M, V120, P4039; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Wobus M, 2012, EXP HEMATOL, V40, P867, DOI 10.1016/j.exphem.2012.06.004; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Xu D, 2001, BRIT J CANCER, V84, P621, DOI 10.1054/bjoc.2000.1655; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937; Yu L, 2008, BLOOD, V111, P4617, DOI 10.1182/blood-2007-10-121137; Zhang L, 2012, BLOOD, V120, P3783, DOI 10.1182/blood-2012-04-424630; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	120	73	76	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4673	4682		10.1038/onc.2014.403	http://dx.doi.org/10.1038/onc.2014.403			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25639873	Green Accepted			2022-12-28	WOS:000360931500001
J	Cui, J; Yang, Y; Li, H; Leng, Y; Qian, K; Huang, Q; Zhang, C; Lu, Z; Chen, J; Sun, T; Wu, R; Sun, Y; Song, H; Wei, X; Jing, P; Yang, X; Zhang, C				Cui, J.; Yang, Y.; Li, H.; Leng, Y.; Qian, K.; Huang, Q.; Zhang, C.; Lu, Z.; Chen, J.; Sun, T.; Wu, R.; Sun, Y.; Song, H.; Wei, X.; Jing, P.; Yang, X.; Zhang, C.			MiR-873 regulates ER alpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; CROSS-TALK; PHOSPHORYLATION; MECHANISMS; ANTAGONISM; INHIBITORS; SERINE-118; EXPRESSION; MICRORNAS; SURVIVAL	miRNAs (microRNAs) are frequently and aberrantly expressed in many cancers. MiR-873 has been revealed to be downregulated in colorectal cancer and glioblastoma. However, its function remains unclear. Here we report that miR-873 is downregulated in breast tumor compared with normal tissue. Enforced expression of miR-873 decreases the transcriptional activity of ER (estrogen receptor)-alpha but not ER beta through the modulation of ER alpha phosphorylation in ER-positive breast cancer cells. We also found that miR-873 inhibits breast cancer cell proliferation and tumor growth in nude mice. Reporter gene assays revealed cyclin-dependent kinase 3 (CDK3) as a direct target of miR-873. CDK3 was shown to be overexpressed in breast cancer and phosphorylate ERa at Ser104/116 and Ser118. Furthermore, we found that Mir-873 inhibits ER activity and cell growth via targeting CDK3. Interestingly, miR-873 was observed to be downregulated in tamoxifen-resistant MCF-7/TamR cells, while CDK3 is overexpressed in these cells. More importantly, re-expression of miR-873 reversed tamoxifen resistance in MCF-7/TamR cells. Our data demonstrate that miR-873 is a novel tumor suppressor in ER-positive breast cancer and a potential therapeutic approach for treatment of tamoxifen-resistant breast cancer.	[Cui, J.; Lu, Z.; Wu, R.; Sun, Y.; Song, H.; Zhang, C.] Acad Mil Med Sci, Inst Dis Control & Prevent, Beijing, Peoples R China; [Yang, Y.] Capital Med Univ, Beijing Inst Neurosci, Beijing, Peoples R China; [Li, H.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Leng, Y.; Qian, K.] Jiujiang Univ, Affiliated Hosp, Jiujiang, Peoples R China; [Huang, Q.] Jilin Agr Univ, Dept Anim Sci & Technol, Changchun, Peoples R China; [Zhang, C.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Chen, J.; Sun, T.] Nanchang Univ, Hosp 1, Dept Urol, Nanchang, Peoples R China; [Wei, X.] Peking Univ, Coll Chem & Mol Engn, Dept Appl Chem, Beijing 100871, Peoples R China; [Jing, P.] Purdue Univ, Indiana Univ, Coll Arts & Sci, Dept Chem, Ft Wayne, IN USA; [Yang, X.] Anhui Univ, Inst Hlth Sci, Hefei 230039, Peoples R China	Academy of Military Medical Sciences - China; Capital Medical University; Chinese Academy of Sciences; University of Kentucky; Jiujiang University; Jilin Agricultural University; Cincinnati Children's Hospital Medical Center; Nanchang University; Peking University; Purdue University System; Indiana University Purdue University Fort Wayne; Anhui University	Yang, X (corresponding author), Anhui Univ, Inst Hlth Sci, Hefei 230039, Peoples R China.	Stanleyxingyuan@hotmail.com; zhangcfu@gmail.com		Zhang, Chunni/0000-0002-7329-7162	National Natural Science Foundation of China [81102005, 31271154]; National High Technology Research and Development Program of China [2014AA020516]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China)	We are grateful to Mingjun Bi, Anne-Marie Overstreet and Alex Meredith for their advice, discussion and editor assistance. We thank Dr. Guanxuan Tan and his lab members for reagents and advice. We also thank Bill Evans for editorial support and grammar correction. This study was supported by the National Natural Science Foundation of China (Nos. 81102005, 31271154) and the National High Technology Research and Development Program of China (No. 2014AA020516).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BULLRICH F, 1995, CANCER RES, V55, P1199; Cho YY, 2009, CANCER RES, V69, P272, DOI 10.1158/0008-5472.CAN-08-3125; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Cui JJ, 2012, CANCER RES, V72, P5625, DOI 10.1158/0008-5472.CAN-12-1305; Cui JJ, 2011, CELL MOL LIFE SCI, V68, P1091, DOI 10.1007/s00018-010-0511-7; de Leeuw R, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/232435; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Hoffman JT, 2014, ANN ONCOL         S1, V25, pi27; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Klinge CM, 2012, TRENDS ENDOCRIN MET, V23, P223, DOI 10.1016/j.tem.2012.03.002; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kok M, 2009, JNCI-J NATL CANCER I, V101, P1725, DOI 10.1093/jnci/djp412; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Manavathi B, 2013, ENDOCR REV, V34, P1, DOI 10.1210/er.2011-1057; McCartan D, 2012, CANCER RES, V72, P220, DOI 10.1158/0008-5472.CAN-11-1976; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Nana-Sinkam SP, 2013, CLIN PHARMACOL THER, V93, P98, DOI 10.1038/clpt.2012.192; Nilsson S, 2011, NAT REV DRUG DISCOV, V10, P778, DOI 10.1038/nrd3551; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Sarwar N, 2006, ENDOCR-RELAT CANCER, V13, P851, DOI 10.1677/erc.1.01123; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Skalsky RL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024248; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Sun X, 2014, ONCOGENE, V33, P4967, DOI [10.1038/onc.2013.492, 10.1038/onc.2014.224]; Sutherland RL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2454; Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Tian W, 2013, CLIN TRANSL ONCOL, V15, P335, DOI 10.1007/s12094-012-0929-5; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081; Vendrell JA, 2005, ENDOCR-RELAT CANCER, V12, P75, DOI 10.1677/erc.1.00899; Wang L, 2014, MOL MED REP, V9, P2582, DOI 10.3892/mmr.2014.2095; Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128; Wardell SE, 2013, CLIN CANCER RES, V19, P2420, DOI 10.1158/1078-0432.CCR-12-3771; Wesierska-Gadek J, 2011, J CELL BIOCHEM, V112, P761, DOI 10.1002/jcb.23004; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198; Zhang DX, 2011, J BIOL CHEM, V286, P17746, DOI 10.1074/jbc.M110.206029; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zheng D, 2008, CANCER RES, V68, P7650, DOI 10.1158/0008-5472.CAN-08-1137	55	72	73	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3895	3907		10.1038/onc.2014.430	http://dx.doi.org/10.1038/onc.2014.430			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25531331				2022-12-28	WOS:000358544200002
J	Habel, N; Vilalta, M; Bawa, O; Opolon, P; Blanco, J; Fromigue, O				Habel, N.; Vilalta, M.; Bawa, O.; Opolon, P.; Blanco, J.; Fromigue, O.			Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors	ONCOGENE			English	Article							PRO-ANGIOGENIC ACTIVITIES; IMMEDIATE-EARLY GENE; GROWTH-FACTOR VEGF; ENDOTHELIAL-CELLS; POOR-PROGNOSIS; BREAST-CANCER; UP-REGULATION; CCN1 CYR61; EXPRESSION; INTEGRIN	Osteosarcoma is the most prevalent primary pediatric cancer-related bone disease. These tumors frequently develop resistance to chemotherapy and are highly metastatic, leading to poor outcome. Thus, there is a need for new therapeutic strategies that can prevent cell dissemination. We previously showed that CYR61/CCN1 expression in osteosarcoma cells is correlated to aggressiveness both in vitro and in vivo in mouse models, as well as in patients. In this study, we found that CYR61 is a critical contributor to the vascularization of primary tumor. We demonstrate that silencing CYR61, using lentiviral transduction, leads to a significant reduction in expression level of pro-angiogenic markers such as VEGF, FGF2, PECAM and angiopoietins concomitantly to an increased expression of major anti-angiogenic markers such as thrombospondin-1 and SPARC. Matrix metalloproteinase-2 family member expression, a key pathway in osteosarcoma metastatic capacity was also downregulated when CYR61 was downregulated in osteosarcoma cells. Using a metastatic murine model, we show that CYR61 silencing in osteosarcoma cells results in reduced tumor vasculature and slows tumor growth compared with control. We also find that microvessel density correlates with lung metastasis occurrence and that CYR61 silencing in osteosarcoma cells limits the number of metastases. Taken together, our data indicate that CYR61 silencing can blunt the malignant behavior of osteosarcoma tumor cells by limiting primary tumor growth and dissemination process.	[Habel, N.; Fromigue, O.] Inst Cancerol Gustave Roussy, INSERM, U981, F-94805 Villejuif, France; [Habel, N.; Bawa, O.; Opolon, P.; Fromigue, O.] Gustave Roussy, Villejuif, France; [Habel, N.; Bawa, O.; Opolon, P.; Fromigue, O.] Univ Paris 11, Orsay, France; [Habel, N.] Univ Paris Diderot, Paris, France; [Vilalta, M.; Blanco, J.] CSIC, Inst Adv Chem Catalonia, Cell Therapy Grp, Barcelona, Spain; [Bawa, O.; Opolon, P.] Gustave Roussy, IRCIV, Lab Pathol Expt, Villejuif, France; [Blanco, J.] Networking Biomed Res Ctr Bioengn Biomat & Nanome, Barcelona, Spain	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Quimica Avanzada de Cataluna (IQAC); UNICANCER; Gustave Roussy; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN	Fromigue, O (corresponding author), Inst Cancerol Gustave Roussy, INSERM, U981, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	olivia.fromigue@inserm.fr	Blanco, Jeronimo/H-2764-2015; Fromigue, Olivia/B-8225-2013	Blanco, Jeronimo/0000-0003-3765-0640; Fromigue, Olivia/0000-0002-3050-6155; habel, nadia/0000-0002-4083-8495	Ministere de la Recherche (Paris, France); Inserm (France); Fondation de l'Avenir pour la Recherche Medicale Appliquee (Paris, France); Red Tematica de Investigacion Cooperativa (TERCEL, Spain); MINECO (Spain) [SAF2012-33404]	Ministere de la Recherche (Paris, France)(Ministry of Research, France); Inserm (France)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation de l'Avenir pour la Recherche Medicale Appliquee (Paris, France); Red Tematica de Investigacion Cooperativa (TERCEL, Spain); MINECO (Spain)	NH is a recipient of a PhD award from the Ministere de la Recherche (Paris, France). This work was supported in part by Inserm (France), by Fondation de l'Avenir pour la Recherche Medicale Appliquee (Paris, France), by Red Tematica de Investigacion Cooperativa (TERCEL, Spain) and SAF2012-33404 from MINECO (Spain). We thank the Department of Medical Biology and Pathology of Gustave Roussy Institute (Dr Adam; Villejuif, France) for their contribution.	Athanasopoulos AN, 2007, J BIOL CHEM, V282, P26746, DOI 10.1074/jbc.M705200200; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Babkina IV, 2009, B EXP BIOL MED+, V148, P246, DOI 10.1007/s10517-009-0710-0; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Chen D, 2013, TUMOR BIOL, V34, P1895, DOI 10.1007/s13277-013-0733-z; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Cheng YY, 2004, PEDIATR BLOOD CANCER, V42, P410, DOI 10.1002/pbc.20019; DuBois S, 2007, CANCER-AM CANCER SOC, V109, P813, DOI 10.1002/cncr.22455; Estrada R, 2009, J CELL PHYSIOL, V219, P563, DOI 10.1002/jcp.21701; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Foukas AF, 2002, J BONE JOINT SURG BR, V84B, P706, DOI 10.1302/0301-620X.84B5.12512; Fromigue O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200; Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343; Gomes N, 2005, CLIN EXP METASTAS, V22, P215, DOI 10.1007/s10585-005-7359-5; Grignani G, 2012, ANN ONCOL, V23, P508, DOI 10.1093/annonc/mdr151; Hara H, 2006, ANTICANCER RES, V26, P4307; Huang YP, 2008, ONKOLOGIE, V31, P535, DOI 10.1159/000151685; Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825; Kaya M, 2000, CLIN CANCER RES, V6, P572; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kreuter M, 2004, CLIN CANCER RES, V10, P8531, DOI 10.1158/1078-0432.CCR-04-0969; Lammli J, 2012, INT ORTHOP, V36, P2307, DOI 10.1007/s00264-012-1629-z; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Lee YH, 1999, EUR J CANCER, V35, P1089, DOI 10.1016/S0959-8049(99)00073-8; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Li C, 2013, EUR REV MED PHARMACO, V17, P2804; Maris JM, 2008, PEDIATR BLOOD CANCER, V50, P581, DOI 10.1002/pbc.21232; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Meyuhas R, 2008, MOL CANCER RES, V6, P1397, DOI 10.1158/1541-7786.MCR-07-2086; Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008-5472.CAN-04-2463; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; North S, 2005, CANCER LETT, V218, P1, DOI 10.1016/j.canlet.2004.08.007; Oda Y, 2006, MODERN PATHOL, V19, P738, DOI 10.1038/modpathol.3800587; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Pignochino Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-118; Rastogi S, 2012, INT ORTHOP, V36, P2315, DOI 10.1007/s00264-012-1663-x; Ren T, 2014, CANCER SCI, V105, P186, DOI 10.1111/cas.12334; Roman I, 2007, BIOMATERIALS, V28, P2718, DOI 10.1016/j.biomaterials.2007.02.011; Sabile AA, 2012, J BONE MINER RES, V27, P58, DOI 10.1002/jbmr.535; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Tsou R, 2001, MOL CELL BIOCHEM, V224, P81, DOI 10.1023/A:1011947301849; Vilalta M, 2008, STEM CELLS DEV, V17, P993, DOI 10.1089/scd.2007.0201; Wagner L, 2013, PEDIATR BLOOD CANCER, V60, P1447, DOI 10.1002/pbc.24547; Wang CT, 2013, J ORTHOP RES, V31, P335, DOI 10.1002/jor.22218; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070689; Wen XY, 2014, TUMOR BIOL, V35, P845, DOI 10.1007/s13277-013-1116-1; Wilkinson-Berka JL, 2006, INVEST OPHTH VIS SCI, V47, P1600, DOI 10.1167/iovs.05-1314; Xin ZF, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-105; Yang JL, 2011, CANCER-AM CANCER SOC, V117, P4925, DOI 10.1002/cncr.26116; Zhou QA, 2011, SURG ONCOL, V20, P13, DOI 10.1016/j.suronc.2009.09.002	52	18	21	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3207	3213		10.1038/onc.2014.232	http://dx.doi.org/10.1038/onc.2014.232			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25065593				2022-12-28	WOS:000356101100012
J	Yan, L; Zhou, J; Gao, Y; Ghazal, S; Lu, L; Bellone, S; Yang, Y; Liu, N; Zhao, X; Santin, AD; Taylor, H; Huang, Y				Yan, L.; Zhou, J.; Gao, Y.; Ghazal, S.; Lu, L.; Bellone, S.; Yang, Y.; Liu, N.; Zhao, X.; Santin, A. D.; Taylor, H.; Huang, Y.			Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation	ONCOGENE			English	Article							EPITHELIAL-OVARIAN-CANCER; C-MYC ONCOGENE; NONCODING RNA; SIGNALING PATHWAY; H19; EXPRESSION; GROWTH; LET-7; METASTASIS; BINDING	The imprinted, developmentally regulated H19 long noncoding RNA has been implicated in the pathogenesis of diverse human cancers, but the underlying mechanisms have remained poorly understood. Here, we report that H19 promotes tumor cell migration and invasion by inhibiting let-7, a potent tumor suppressor microRNA that functions to posttranscriptionally suppress the expression of oncogenes that regulate cell growth and motility. We show that H19 depletion impairs, whereas its overexpression enhances the motility and invasiveness of tumor cells. These phenomena occur, at least in part through affecting let-7-mediated regulation of metastasis-promoting genes, including Hmga2, c-Myc and Igf2bp3. This H19/let-7-dependent regulation is recapitulated in vivo where co-expressions of oncogenes and H19 exist in both primary human ovarian and endometrial cancers. Furthermore, we provide evidence that the anti-diabetic drug metformin inhibits tumor cell migration and invasion, partly by downregulating H19 via DNA methylation. Our results reveal a novel mechanism underpinning H19-mediated regulation in metastasis and may explain why in some cases increased let-7 expression unexpectedly correlates with poor prognosis, given the widely accepted role for let-7 as a tumor suppressor. Targeting this newly identified pathway might offer therapeutic opportunities.	[Yan, L.; Zhao, X.] Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China; [Yan, L.; Zhou, J.; Gao, Y.; Ghazal, S.; Bellone, S.; Yang, Y.; Liu, N.; Santin, A. D.; Taylor, H.; Huang, Y.] Yale Univ, Sch Med, Yale Stem Cell Ctr, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06510 USA; [Zhou, J.] Zhejiang Univ, Sch Med, Affiliated Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Gao, Y.] Chinese Peoples Liberat Army Gen Hosp, Dept Gynecol & Obstet, Beijing 100853, Peoples R China; [Lu, L.] Yale Univ, Sch Med, Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT 06510 USA; [Liu, N.] Cent S Univ, Xiangya Hosp, Dept Obstet & Gynecol, Changsha, Hunan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Yale University; Zhejiang University; Chinese People's Liberation Army General Hospital; Yale University; Central South University	Huang, Y (corresponding author), Yale Univ, Sch Med, Yale Stem Cell Ctr, Dept Obstet Gynecol & Reprod Sci, 310 Cedar St LSOG 205C, New Haven, CT 06510 USA.	yingqun.huang@yale.edu	Zhou, Jichun/Q-8646-2019	Zhou, Jichun/0000-0002-0727-4034; Bellone, Stefania/0000-0001-5909-5292	State of Connecticut Stem Cell grant [09SCAYALE14]; Albert McKern Scholar Award [1063338]; National Natural Science Foundation of China [81202057, 81272858]	State of Connecticut Stem Cell grant; Albert McKern Scholar Award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Gil Mor for A2780 and Tara R127 cells. This work was supported by the following grants: the State of Connecticut Stem Cell grant 09SCAYALE14, Albert McKern Scholar Award 1063338, and funds from National Natural Science Foundation of China 81202057 and 81272858.	Akinyeke T, 2013, CARCINOGENESIS, V34, P2823, DOI 10.1093/carcin/bgt307; Bao B, 2012, CANCER PREV RES, V5, P355, DOI 10.1158/1940-6207.CAPR-11-0299; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bednar F, 2012, CANCER PREV RES, V5, P351, DOI 10.1158/1940-6207.CAPR-12-0026; BEHRENS BC, 1987, CANCER RES, V47, P414; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Fu X, 2014, ONCOGENE, V33, P4296, DOI 10.1038/onc.2013.385; Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170; Gao ZH, 2002, J CLIN ENDOCR METAB, V87, P1170, DOI 10.1210/jc.87.3.1170; Gou SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063969; Grayson DR, 2013, NEUROPSYCHOPHARMACOL, V38, P138, DOI 10.1038/npp.2012.125; Green JM, 2009, MOL CANCER THER, V8, P1385; Guo L, 2013, ONCOGENE, V32, P5272, DOI 10.1038/onc.2012.573; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Huang YQ, 2012, WIRES RNA, V3, P483, DOI 10.1002/wrna.1112; Jeng YM, 2008, HEPATOLOGY, V48, P1118, DOI 10.1002/hep.22459; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Liu Q, 2012, MOL BIOL REP, V39, P1239, DOI 10.1007/s11033-011-0854-7; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lu LG, 2011, BREAST CANCER RES TR, V126, P687, DOI 10.1007/s10549-010-1168-5; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Matouk I, 2013, INT J MOL SCI, V14, P4298, DOI 10.3390/ijms14024298; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Qian PX, 2011, CANCER RES, V71, P6463, DOI 10.1158/0008-5472.CAN-11-1322; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Riaz M, 2011, BREAST CANC RES TREA, V133, P12; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Samanta S, 2012, ONCOGENE, V31, P4689, DOI 10.1038/onc.2011.620; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sarfstein R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061537; Srivastava M, 2000, GENE DEV, V14, P1186; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Suvasini R, 2011, J BIOL CHEM, V286, P25882, DOI 10.1074/jbc.M110.178012; Tang ZQ, 2014, INT J CANCER, V134, P306, DOI 10.1002/ijc.28371; Tanos V, 2004, INT J GYNECOL CANCER, V14, P521, DOI 10.1111/j.1048-891x.2004.014314.x; Tanos V, 1999, EUR J OBSTET GYN R B, V85, P7, DOI 10.1016/S0301-2115(98)00275-9; Thornton JE, 2012, TRENDS CELL BIOL, V22, P474, DOI 10.1016/j.tcb.2012.06.001; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187; Toledano H, 2012, NATURE, V485, P605, DOI 10.1038/nature11061; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Wu BC, 2012, ONCOL REP, V28, P903, DOI 10.3892/or.2012.1890; Wurth R, 2013, CELL CYCLE, V12, P145, DOI 10.4161/cc.23050; Yin G, 2013, ONCOGENE, V32, P39, DOI 10.1038/onc.2012.33; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105; Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381; Zhao BT, 2014, CANCER LETT, V342, P43, DOI 10.1016/j.canlet.2013.08.030; Zhao SM, 2013, P NATL ACAD SCI USA, V110, P2916, DOI 10.1073/pnas.1222577110; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	70	153	170	4	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3076	3084		10.1038/onc.2014.236	http://dx.doi.org/10.1038/onc.2014.236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088204				2022-12-28	WOS:000356100500012
J	Martinez, E; Yoshihara, K; Kim, H; Mills, GM; Trevino, V; Verhaak, RGW				Martinez, E.; Yoshihara, K.; Kim, H.; Mills, G. M.; Trevino, V.; Verhaak, R. G. W.			Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects	ONCOGENE			English	Article							PREDICTOR; KNOWLEDGE; RESPONSES; ANTI-PD-1; SUBTYPES; REVEALS; SAFETY; EGFR	Transcriptional profile-based subtypes of cancer are often viewed as identifying different diseases from the same tissue origin. Understanding the mechanisms driving the subtypes may be key in development of novel therapeutics but is challenged by lineage-specific expression signals. Using a t-test statistics approach, we compared gene expression subtypes across 12 tumor types, which identified eight transcriptional superclusters characterized by commonly activated disease pathways and similarities in gene expression. One of the largest superclusters was determined by the upregulation of a proliferation signature, significant enrichment in TP53 mutations, genomic loss of CDKN2A (p16(ARF)), evidence of increased numbers of DNA double strand breaks and high expression of cyclin B1 protein. These correlations suggested that abrogation of the P53-mediated apoptosis response to DNA damage results in activation of cell cycle pathways and represents a common theme in cancer. A second consistent pattern, observed in 9 of 11 solid tumor types, was a subtype related to an activated tumor-associated stroma. The similarity in transcriptional footprints across cancers suggested that tumor subtypes are commonly unified by a limited number of molecular themes.	[Martinez, E.; Yoshihara, K.; Kim, H.; Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Martinez, E.; Trevino, V.] Tecnol Monterrey, Catedra Bioinformat, Monterrey, Nuevo Leon, Mexico; [Yoshihara, K.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Niigata, Japan; [Mills, G. M.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Tecnologico de Monterrey; Niigata University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Verhaak, RGW (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, 1400 Pressler St, Houston, TX 77030 USA.	rverhaak@mdanderson.org	Kim, Hoon/AAL-9283-2020; Verhaak, Roel/ABE-7058-2020; Yoshihara, Kosuke/AAU-9874-2020; Trevino, Victor/C-9219-2009	Kim, Hoon/0000-0003-4244-6126; Yoshihara, Kosuke/0000-0002-2254-3378; Martinez Ledesma, Juan Emmanuel/0000-0003-1191-7917; Trevino, Victor/0000-0002-7472-9844	U.S. National Cancer Institute (NCI; MD Anderson TCGA Genome Data Analysis Center) [CA143883, CA083639]; Odyssey Program; Theodore N, Law Endowment for Scientific Achievement at The University of Texas MD Anderson Cancer Center; MD Anderson Cancer Center [P30 CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, U24CA143883, P50CA083639] Funding Source: NIH RePORTER	U.S. National Cancer Institute (NCI; MD Anderson TCGA Genome Data Analysis Center); Odyssey Program; Theodore N, Law Endowment for Scientific Achievement at The University of Texas MD Anderson Cancer Center; MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The results published here are in whole or part based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at 'http://cancergenome.nih.gov'. This work was supported in part by U.S. National Cancer Institute (NCI; MD Anderson TCGA Genome Data Analysis Center) grant numbers CA143883 and CA083639, and MD Anderson Cancer Center Support Grant P30 CA016672. HK is supported in part by the Odyssey Program and the Theodore N, Law Endowment for Scientific Achievement at The University of Texas MD Anderson Cancer Center.	Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Everitt B. S, 2011, CLUSTER ANAL, DOI DOI 10.1002/9780470977811; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li JN, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.61; Martinsson-Ahlzen HS, 2008, MOL CELL BIOL, V28, P5698, DOI 10.1128/MCB.01833-07; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Team RC, 2013, RA LANG ENV STAT COM, V13, P497; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verhaak RGW, 2009, HAEMATOL-HEMATOL J, V94, P131, DOI 10.3324/haematol.13299; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zheng SY, 2013, GENE DEV, V27, P1462, DOI 10.1101/gad.213686.113; Zheng Y, 2013, NATURE, V499, P166, DOI 10.1038/nature12308	43	33	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2732	2740		10.1038/onc.2014.216	http://dx.doi.org/10.1038/onc.2014.216			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25088195	Green Accepted			2022-12-28	WOS:000354979500006
J	Min, KW; Liggett, JL; Silva, G; Wu, WW; Wang, R; Shen, RF; Eling, TE; Baek, SJ				Min, K-W; Liggett, J. L.; Silva, G.; Wu, W. W.; Wang, R.; Shen, R-F; Eling, T. E.; Baek, S. J.			NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway	ONCOGENE			English	Article							BETA SUPERFAMILY MEMBER; GROWTH-FACTOR-BETA; ACTIVATED GENE NAG-1; CELL-GROWTH; MOUSE MODEL; EXPRESSION; RECEPTOR; LOCALIZATION; APOPTOSIS; PROTEINS	Protein dynamics, modifications and trafficking are all processes that can modulate protein activity. Accumulating evidence strongly suggests that many proteins have distinctive roles dependent on cellular location. Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) is a transforming growth factor-beta (TGF-beta) superfamily protein that has a role in cancer, obesity and inflammation. NAG-1 is synthesized and cleaved into a mature peptide, which is ultimately secreted into the extracellular matrix (ECM). In this study, we have found that full-length NAG-1 is expressed in not only the cytoplasm and ECM, but also in the nucleus. NAG-1 is dynamically moved to the nucleus, exported into cytoplasm and further transported into the ECM. We have also found that nuclear NAG-1 contributes to inhibition of the Smad pathway by interrupting the Smad complex. Overall, our study indicates that NAG-1 is localized in the nucleus and provides new evidence that NAG-1 controls transcriptional regulation in the Smad pathway.	[Min, K-W; Liggett, J. L.; Silva, G.; Baek, S. J.] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, 2407 River Dr, Knoxville, TN 37996 USA; [Wu, W. W.; Wang, R.; Shen, R-F] US FDA, CBER, Facil Biotechnol Resources, Bethesda, MD 20014 USA; [Eling, T. E.] NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Min, K-W] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Medical University of South Carolina	Baek, SJ (corresponding author), Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, 2407 River Dr, Knoxville, TN 37996 USA.	sbaek2@utk.edu	Silva, Gabriel/D-7731-2017	Silva, Gabriel/0000-0002-5660-9769; Min, Kyung-Won/0000-0002-8718-3588	National Institutes of Health [R01CA108975]; Center of Excellence in Livestock Diseases and Human Health, University of Tennessee; CAPES Foundation, Brazil [BEX 3159/14-0]; NIH, NIEHS Intramural Research Program [Z01-ES010016-14]; NATIONAL CANCER INSTITUTE [R01CA108975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center of Excellence in Livestock Diseases and Human Health, University of Tennessee; CAPES Foundation, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NIH, NIEHS Intramural Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Xingya Wang (College of Pharmaceutical Science, Zhejiang Chinese Medical University, China) and Ms Misty Bailey (University of Tennessee) for their critical reading of the manuscript. We also thank Dr John Dunlap (Advanced Microscopy and Imaging Center at The University of Tennessee) for providing technical help on confocal microscopy. This work was supported by the National Institutes of Health (R01CA108975), and the Center of Excellence in Livestock Diseases and Human Health, University of Tennessee, to SJB and a grant (BEX 3159/14-0) from the CAPES Foundation, Brazil (GS). This research was also supported, in part, by the NIH, NIEHS Intramural Research Program (TEE) Z01-ES010016-14.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Baek SJ, 2006, GASTROENTEROLOGY, V131, P1553, DOI 10.1053/j.gastro.2006.09.015; Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001; Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255; Baek SJ, 2004, J BIOL CHEM, V279, P6883, DOI 10.1074/jbc.M305295200; Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bauskin AR, 2005, CANCER RES, V65, P2330, DOI 10.1158/0008-5472.CAN-04-3827; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, GENE, V237, P105, DOI 10.1016/S0378-1119(99)00309-1; Cekanova M, 2009, CANCER PREV RES, V2, P450, DOI 10.1158/1940-6207.CAPR-09-0057; Chan CP, 2010, J CELL SCI, V123, P1438, DOI 10.1242/jcs.067819; Chintharlapalli S, 2005, MOL PHARMACOL, V68, P1782, DOI 10.1124/mol.105.017046; Chrysovergis K, 2014, INT J OBESITY, V38, P1555, DOI 10.1038/ijo.2014.27; Felin JE, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-20; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI 10.2217/FON.09.67; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hutten S, 2007, TRENDS CELL BIOL, V17, P193, DOI 10.1016/j.tcb.2007.02.003; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnen H, 2012, CARDIOVASC PATHOL, V21, P499, DOI 10.1016/j.carpath.2012.02.003; Joshi JP, 2011, BIOCHEM PHARMACOL, V82, P1090, DOI 10.1016/j.bcp.2011.07.082; Kim JM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/641851; Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106; Kuo TF, 2011, FEBS J, V278, P4756, DOI 10.1111/j.1742-4658.2011.08409.x; L/nn P, 2010, MOL CELL, V40, P521; Lee HK, 2010, J CELL BIOCHEM, V111, P755, DOI 10.1002/jcb.22766; Lee SH, 2008, MOL CARCINOGEN, V47, P197, DOI 10.1002/mc.20374; Lee SH, 2008, MOL CANCER THER, V7, P3739, DOI 10.1158/1535-7163.MCT-08-0548; Lee SH, 2006, CARCINOGENESIS, V27, P972, DOI 10.1093/carcin/bgi268; Lee SH, 2005, BIOCHEM BIOPH RES CO, V328, P63, DOI 10.1016/j.bbrc.2004.12.138; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Macia L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034868; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Min KW, 2012, TOXICOL APPL PHARM, V263, P225, DOI 10.1016/j.taap.2012.06.014; Nguyen BA, 2009, BMC BIOINFORMATICS, V10, P202, DOI [10.1186/1471-2105-10-202, DOI 10.1186/1471-2105-10-202]; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Planque Nathalie, 2006, Cell Commun Signal, V4, P7, DOI 10.1186/1478-811X-4-7; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shappell SB, 2003, CANCER RES, V63, P2256; Sharma M, 2012, J BIOL CHEM, V287, P819, DOI 10.1074/jbc.M111.299099; Shim M, 2005, J BIOL CHEM, V280, P18636, DOI 10.1074/jbc.M414613200; Shureiqi I, 2001, CANCER RES, V61, P6307; Sirover MA, 2012, J CELL BIOCHEM, V113, P2193, DOI 10.1002/jcb.24113; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Theodore M, 2008, J BIOL CHEM, V283, P8984, DOI 10.1074/jbc.M709040200; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Turner JG, 2012, BIOCHEM PHARMACOL, V83, P1021, DOI 10.1016/j.bcp.2011.12.016; Waldmann I, 2007, J BIOL CHEM, V282, P27685, DOI 10.1074/jbc.M703301200; Wang XY, 2013, BIOCHEM PHARMACOL, V85, P597, DOI 10.1016/j.bcp.2012.11.025; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Xu J, 2006, CIRC RES, V98, P342, DOI 10.1161/01.RES.0000202804.84885.d0; Yamaguchi K, 2004, J BIOL CHEM, V279, P49617, DOI 10.1074/jbc.M408796200; Yamaguchi K, 2008, MOL CANCER THER, V7, P2779, DOI 10.1158/1535-7163.MCT-08-0173; Yang MH, 2014, LIFE SCI, V100, P75, DOI 10.1016/j.lfs.2014.01.075; Zimmers TA, 2005, SHOCK, V23, P543, DOI 10.1097/01.shk.0000163393.55350.70; Zimmers TA, 2010, J CANCER RES CLIN, V136, P571, DOI 10.1007/s00432-009-0691-4	68	49	50	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					377	388		10.1038/onc.2015.95	http://dx.doi.org/10.1038/onc.2015.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893289	Green Accepted			2022-12-28	WOS:000369055300011
J	Amoroso, F; Capece, M; Rotondo, A; Cangelosi, D; Ferracin, M; Franceschini, A; Raffaghello, L; Pistoia, V; Varesio, L; Adinolfi, E				Amoroso, F.; Capece, M.; Rotondo, A.; Cangelosi, D.; Ferracin, M.; Franceschini, A.; Raffaghello, L.; Pistoia, V.; Varesio, L.; Adinolfi, E.			The P2X7 receptor is a key modulator of the PI3K/GSK3 beta/VEGF signaling network: evidence in experimental neuroblastoma	ONCOGENE			English	Article							INCREASES CELLULAR ATP; P2X(7) RECEPTOR; CANCER-CELLS; EXPRESSION; ACTIVATION; MYCN; DIFFERENTIATION; PROLIFERATION; METASTASIS; INHIBITION	Neuroblastoma (NB) is an aggressive pediatric tumor, responsible for 15% of cancer-related deaths in childhood, lacking an effective treatment in its advanced stages. The P2X7 receptor for extracellular ATP was associated to NB cell proliferation and recently emerged as a promoter of tumor engraftment, growth and vascularization. In an effort to identify new therapeutic options for neuroblastoma, we studied the role of P2X7 receptor in NB biology. We first analyzed the effect of P2X7 activation or down-modulation of the main biochemical ways involved in NB progression: the PI3K/Akt/GSK3 beta/MYCN and the HIF1 alpha/VEGF pathways. In ACN human NB cells, P2X7 stimulation enhanced PI3K/Akt, while decreasing GSK3 beta activity. In the same model, P2X7 silencing or antagonist administration reduced the activity of PI3K/Akt and increased that of GSK3 beta, leading to a decrease in cellular glycogen stores. Similarly, P2X7 downmodulation caused a reduction in HIF1 alpha levels and vascular endothelial growth factor (VEGF) secretion. Systemic administration of two different P2X7 antagonists (AZ10606120 or A740003) in nude/nude mice reduced ACN-derived tumor growth. An even stronger effect of P2X7 blockade was obtained in a syngeneic immune-competent neuroblastoma model: Neuro2A cells injected in AlbinoJ mice. Together with tumor regression, treatment with P2X7 antagonists caused downmodulation of the Akt/HIF1 alpha axis, leading to reduced VEGF content and decreased vessel formation. Interestingly, in both experimental models, P2X7 antagonists strongly reduced the expression of the probably best-accepted oncogene in NB: MYCN. Finally, we associated P2X7 overexpression with poor prognosis in advanced-stage NB patients. Taken together, our data suggest that P2X7 receptor is an upstream regulator of the main signaling pathways involved in NB growth, metabolic activity and angiogenesis, and a promising therapeutic target for neuroblastoma treatment.	[Amoroso, F.; Capece, M.; Rotondo, A.; Ferracin, M.; Franceschini, A.; Adinolfi, E.] Univ Ferrara, Sect Expt Pathol Oncol & Biol, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy; [Cangelosi, D.; Varesio, L.] Ist Giannina Gaslini, Lab Mol Biol, I-16148 Genoa, Italy; [Raffaghello, L.; Pistoia, V.] Ist Giannina Gaslini, Lab Oncol, I-16148 Genoa, Italy	University of Ferrara; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini	Adinolfi, E (corresponding author), Univ Ferrara, Sect Expt Pathol Oncol & Biol, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy.	elena.adinolfi@unife.it	varesio, luigi/J-8261-2016; Cangelosi, Davide/K-2627-2016; Franceschini, Alessia/K-3426-2018; Adinolfi, Elena/F-9169-2010; Ferracin, Manuela/K-2097-2016; Franceschini, Alessia/H-4992-2017	varesio, luigi/0000-0001-5659-2218; Cangelosi, Davide/0000-0002-6010-5619; Franceschini, Alessia/0000-0001-7122-6232; Adinolfi, Elena/0000-0001-8129-9929; Ferracin, Manuela/0000-0002-1595-6887; Franceschini, Alessia/0000-0001-7122-6232; Amoroso, Francesca Saveria/0000-0002-5946-2491; Raffaghello, Lizzia/0000-0003-2357-0607	AIRC [MFAG11630]; Regione Emilia Romagna of Italy (bando Alessandro Liberati)	AIRC(Fondazione AIRC per la ricerca sul cancro); Regione Emilia Romagna of Italy (bando Alessandro Liberati)	This work was supported by AIRC grant MFAG11630 and young researchers' funds of the Regione Emilia Romagna of Italy (bando Alessandro Liberati) to EA.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2015, CURR MED CHEM, V22, P878, DOI 10.2174/0929867321666141012172913; Adinolfi E, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/637863; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Aymeric L, 2010, CANCER RES, V70, P855, DOI 10.1158/0008-5472.CAN-09-3566; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Bartlett R, 2014, PHARMACOL REV, V66, P638, DOI 10.1124/pr.113.008003; Bianchi G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.109; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Cheng KW, 2012, EMBO MOL MED, V4, P125, DOI 10.1002/emmm.201100193; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Chong JH, 2010, BIOCHEM BIOPH RES CO, V391, P498, DOI 10.1016/j.bbrc.2009.11.087; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Dent P, 2014, CANCER BIOL THER, V15, P481, DOI 10.4161/cbt.28465; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; Fardin P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-185; Favaro E, 2012, CELL METAB, V16, P751, DOI 10.1016/j.cmet.2012.10.017; Fransson S, 2013, INT J ONCOL, V42, P609, DOI 10.3892/ijo.2012.1732; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Ghalali A, 2014, CARCINOGENESIS, V35, P1547, DOI 10.1093/carcin/bgu019; Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224; Gomez-Villafuertes R, 2009, FEBS J, V276, P5307, DOI 10.1111/j.1742-4658.2009.07228.x; Gu LQ, 2010, ENDOCRINE, V38, P276, DOI 10.1007/s12020-010-9384-7; Gutierrez-Martin Y, 2011, J BIOL CHEM, V286, P11370, DOI 10.1074/jbc.M110.139410; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heine VM, 2010, CANCER RES, V70, P5220, DOI 10.1158/0008-5472.CAN-10-0554; Hogarty MD, 2012, CANCER CELL, V21, P145, DOI 10.1016/j.ccr.2012.01.018; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; Keystone EC, 2012, ANN RHEUM DIS, P71; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Maurer U, 2014, J CELL SCI, V127, P1369, DOI 10.1242/jcs.138057; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Schumacher D, 2013, CANCER CELL, V24, P130, DOI 10.1016/j.ccr.2013.05.008; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Stock TC, 2012, J RHEUMATOL, V39, P720, DOI 10.3899/jrheum.110874; Sun SH, 2010, MOL NEUROBIOL, V41, P351, DOI 10.1007/s12035-010-8120-x; Takai E, 2012, J CELL SCI, V125, P5051, DOI 10.1242/jcs.104976; Westhoff MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083128; Williams EL, 2013, CLIN CANCER RES, V19, P3545, DOI 10.1158/1078-0432.CCR-12-3226; Witney TH, 2014, CANCER RES, V74, P1319, DOI 10.1158/0008-5472.CAN-13-2768; Wu PY, 2009, CELL SIGNAL, V21, P881, DOI 10.1016/j.cellsig.2009.01.036	51	107	108	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5240	5251		10.1038/onc.2014.444	http://dx.doi.org/10.1038/onc.2014.444			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619831	Green Submitted			2022-12-28	WOS:000362575400004
J	Bhat, AA; Pope, JL; Smith, JJ; Ahmad, R; Chen, X; Washington, MK; Beauchamp, RD; Singh, AB; Dhawan, P				Bhat, A. A.; Pope, J. L.; Smith, J. J.; Ahmad, R.; Chen, X.; Washington, M. K.; Beauchamp, R. D.; Singh, A. B.; Dhawan, P.			Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; E-CADHERIN EXPRESSION; DNA-METHYLATION; DOWN-REGULATION; TIGHT JUNCTION; UP-REGULATION; CANCER; INVASION; RAB25; METASTASIS	In normal colon, claudin-7 is one of the highly expressed claudin proteins and its knockdown in mice results in altered epithelial cell homeostasis and neonatal death. Notably, dysregulation of the epithelial homeostasis potentiates oncogenic transformation and growth. However, the role of claudin-7 in the regulation of colon tumorigenesis remains poorly understood. Using a large colorectal cancer (CRC) patient database and mouse models of colon cancer, we found claudin-7 expression to be significantly downregulated in cancer samples. Most notably, forced claudin-7 expression in poorly differentiated and highly metastatic SW620 colon cancer cells induced epithelial characteristics and inhibited their growth in soft agar and tumor growth in vivo. By contrast, knockdown of claudin-7 in HT-29 or DLD-1 cells induced epithelial-to-mesenchymal transition (EMT), colony formation, xenograft-tumor growth in athymic mice and invasion. Importantly, a claudin-7 signature gene profile generated by overlapping the DEGs (differentially expressed genes in a high-throughput transcriptome analysis using claudin-7-manipulated cells) with human claudin-7 signature genes identified high-risk CRC patients. Furthermore, Rab25, a colon cancer suppressor and regulator of the polarized cell trafficking constituted one of the highly upregulated DEGs in claudin-7 overexpressing cells. Notably, silencing of Rab25 expression counteracted the effects of claudin-7 expression and not only increased proliferation and cell invasion but also increased the expression of p-Src and mitogen-activated protein kinase-extracellular signal-regulated kinase 1/2 that were suppressed upon claudin-7 overexpression. Of interest, CRC cell lines, which exhibited decreased claudin-7 expression, also exhibited promoter DNA hypermethylation, a modification associated with transcriptional silencing. Taken together, our data demonstrate a previously undescribed role of claudin-7 as a colon cancer suppressor and suggest that loss of claudin-7 potentiates EMT to promote colon cancer, in a manner dependent on Rab25.	[Bhat, A. A.; Pope, J. L.; Ahmad, R.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA; [Pope, J. L.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Smith, J. J.; Beauchamp, R. D.; Singh, A. B.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [Chen, X.; Singh, A. B.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Beauchamp, R. D.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Beauchamp, R. D.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Dhawan, P (corresponding author), Vanderbilt Univ, Med Ctr, Div Surg Oncol, Dept Surg,MCN, B-2211,1161 21st Ave South, Nashville, TN 37232 USA.	punita.dhawan@vanderbilt.edu	Bhat, Ajaz/V-3642-2019; Smith, Jesse Joshua/AAN-5440-2020	Bhat, Ajaz/0000-0003-3640-6275; Smith, Jesse Joshua/0000-0003-2538-5456; Beauchamp, Robert Daniel/0000-0002-8446-4114	VA-merit [BX002086, CA124977, DK088902, CA158472, CA069457]; GI Cancer SPORE grant [CA095103]; Vanderbilt DDRC [P30DK058404, VICC P30CA68485]; StarBRITE funds [VR1258]; NATIONAL CANCER INSTITUTE [R01CA124977, R01CA069457, P50CA095103, P30CA068485, R01CA158472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK088902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM062459] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002086] Funding Source: NIH RePORTER	VA-merit; GI Cancer SPORE grant; Vanderbilt DDRC; StarBRITE funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We are thankful to John Neff and Jalal Hamaamen for their technical support. This work was supported by VA-merit BX002086 and CA124977 (to PD), DK088902 (to ABS), CA158472 (to XC and RDB), CA069457 (to RDB), GI Cancer SPORE grant CA095103, Vanderbilt DDRC P30DK058404, VICC P30CA68485 and StarBRITE funds (no. VR1258).	Bates RC, 2005, CANCER BIOL THER, V4, P365; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boireau S, 2007, CARCINOGENESIS, V28, P246, DOI 10.1093/carcin/bgl120; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheng JM, 2006, INT J CANCER, V118, P2957, DOI 10.1002/ijc.21739; Cheng JM, 2010, INT J CANCER, V126, P2799, DOI 10.1002/ijc.24900; de Oliveira SS, 2005, FEBS LETT, V579, P6179, DOI 10.1016/j.febslet.2005.09.091; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Ding L, 2012, GASTROENTEROLOGY, V142, P305, DOI 10.1053/j.gastro.2011.10.025; Esteller M, 2001, CANCER RES, V61, P3225; Evron E, 2001, CANCER RES, V61, P2782; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fujita H, 2006, J HISTOCHEM CYTOCHEM, V54, P933, DOI 10.1369/jhc.6A6944.2006; Goldenring JR, 2011, BRIT J CANCER, V104, P33, DOI 10.1038/sj.bjc.6605983; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343; Lourenco SV, 2010, HISTOPATHOLOGY, V57, P689, DOI 10.1111/j.1365-2559.2010.03685.x; Lu Z, 2011, EXP CELL RES, V317, P1935, DOI 10.1016/j.yexcr.2011.05.019; Melchers LJ, 2013, ORAL ONCOL, V49, P998, DOI 10.1016/j.oraloncology.2013.07.008; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978; Nam KT, 2010, J CLIN INVEST, V120, P840, DOI 10.1172/JCI40728; Park GB, 2014, INVEST OPHTH VIS SCI, V55, P1770, DOI 10.1167/iovs.13-12988; Pope JL, 2014, GUT, V63, P622, DOI 10.1136/gutjnl-2012-304241; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh AB, 2011, GASTROENTEROLOGY, V141, P2140, DOI 10.1053/j.gastro.2011.08.038; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toyota M, 1999, CANCER RES, V59, P5438; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Usami Y, 2006, HUM PATHOL, V37, P569, DOI 10.1016/j.humpath.2005.12.018; Yoshizawa K, 2013, ONCOL REP, V29, P445, DOI 10.3892/or.2012.2161	46	57	60	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4570	4580		10.1038/onc.2014.385	http://dx.doi.org/10.1038/onc.2014.385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25500541	Green Accepted			2022-12-28	WOS:000360189300003
J	Menon, DR; Das, S; Krepler, C; Vultur, A; Rinner, B; Schauer, S; Kashofer, K; Wagner, K; Zhang, G; Rad, EB; Haass, NK; Soyer, HP; Gabrielli, B; Somasundaram, R; Hoefler, G; Herlyn, M; Schaider, H				Menon, D. Ravindran; Das, S.; Krepler, C.; Vultur, A.; Rinner, B.; Schauer, S.; Kashofer, K.; Wagner, K.; Zhang, G.; Rad, E. Bonyadi; Haass, N. K.; Soyer, H. P.; Gabrielli, B.; Somasundaram, R.; Hoefler, G.; Herlyn, M.; Schaider, H.			A stress-induced early innate response causes multidrug tolerance in melanoma	ONCOGENE			English	Article							ALDEHYDE DEHYDROGENASE; CELL-GROWTH; RESISTANCE; INHIBITION; FAMILY; BRAF; PHOSPHORYLATION; EXPRESSION; KINASES; MARKER	Acquired drug resistance constitutes a major challenge for effective cancer therapies with melanoma being no exception. The dynamics leading to permanent resistance are poorly understood but are important to design better treatments. Here we show that drug exposure, hypoxia or nutrient starvation leads to an early innate cell response in melanoma cells resulting in multidrug resistance, termed induced drug-tolerant cells (IDTCs). Transition into the IDTC state seems to be an inherent stress reaction for survival toward unfavorable environmental conditions or drug exposure. The response comprises chromatin remodeling, activation of signaling cascades and markers implicated in cancer stemness with higher angiogenic potential and tumorigenicity. These changes are characterized by a common increase in CD271 expression concomitantly with loss of differentiation markers such as melan-A and tyrosinase, enhanced aldehyde dehydrogenase (ALDH) activity and upregulation of histone demethylases. Accordingly, IDTCs show a loss of H3K4me3, H3K27me3 and gain of H3K9me3 suggesting activation and repression of differential genes. Drug holidays at the IDTC state allow for reversion into parental cells re-sensitizing them to the drug they were primarily exposed to. However, upon continuous drug exposure IDTCs eventually transform into permanent and irreversible drug-resistant cells. Knockdown of CD271 or KDM5B decreases transition into the IDTC state substantially but does not prevent it. Targeting IDTCs would be crucial for sustainable disease management and prevention of acquired drug resistance.	[Menon, D. Ravindran; Rad, E. Bonyadi; Schaider, H.] Med Univ Graz, Dept Dermatol, Canc Biol Unit, Graz, Austria; [Menon, D. Ravindran; Rinner, B.; Wagner, K.; Rad, E. Bonyadi; Schaider, H.] Med Univ Graz, Med Res Ctr, Graz, Austria; [Menon, D. Ravindran; Rad, E. Bonyadi; Soyer, H. P.; Schaider, H.] Univ Queensland, Translat Res Inst, Sch Med, Dermatol Res Ctr, Brisbane, Qld, Australia; [Das, S.; Schauer, S.; Kashofer, K.; Hoefler, G.] Med Univ Graz, Inst Pathol, Graz, Austria; [Krepler, C.; Vultur, A.; Zhang, G.; Somasundaram, R.; Herlyn, M.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Haass, N. K.; Soyer, H. P.; Gabrielli, B.; Schaider, H.] Univ Queensland, Translat Res Inst, Diamantina Inst, Brisbane, Qld, Australia	Medical University of Graz; Medical University of Graz; University of Queensland; Medical University of Graz; The Wistar Institute; University of Queensland	Schaider, H (corresponding author), Univ Queensland, Translat Res Inst, Sch Med, Dermatol Res Ctr, 37 Kent St, Woolloongabba, Qld 4102, Australia.	h.schaider@uq.edu.au	Haass, Nikolas K/M-8507-2015; Soyer, H. Peter/W-3791-2017; Ravindran Menon, Dinoop/F-9247-2014; Gabrielli, Brian G/B-3655-2011; Soyer, H. Peter/E-6000-2010; Menon, Dinoop Ravindran/AAC-3620-2021; Hoefler, Gerald/H-1796-2016	Haass, Nikolas K/0000-0002-3928-5360; Soyer, H. Peter/0000-0002-4770-561X; Ravindran Menon, Dinoop/0000-0002-6335-9227; Gabrielli, Brian G/0000-0003-3933-1651; Soyer, H. Peter/0000-0002-4770-561X; Somasundaram, Rajasekharan/0000-0002-8444-8472; Rinner, Beate/0000-0002-6340-4905; Schaider, Helmut/0000-0003-3195-2517; Vultur, Adina/0000-0003-0068-9496; Hoefler, Gerald/0000-0002-9056-3063	Medical University of Graz; Austrian Science foundation (FWF) [SFB LIPOTOX F30, W1226]; National Health and Medical Research Council) [APP1003637]; Cancer Council New South Wales [RG 09-08]; NATIONAL CANCER INSTITUTE [P01CA025874, P01CA114046, P30CA010815] Funding Source: NIH RePORTER	Medical University of Graz; Austrian Science foundation (FWF)(Austrian Science Fund (FWF)); National Health and Medical Research Council); Cancer Council New South Wales(Cancer Council New South Wales); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Marcus Absenger (ZMF, Medical University of Graz), Xin Xiao and Palmila Liu (The Wistar Institute, PA, USA) and Maria Grygar (Institute of Pathology, Medical University of Graz, Austria) for technical assistance. This work was supported by the PhD program 'Molecular Medicine' of the Medical University of Graz (to DRM and SD) and the Austrian Science foundation (FWF) projects SFB LIPOTOX F30 and W1226 DK "Metabolic and cardiovascular disease'' (to GH). We thank Dr Atsushi Miyawaki, RIKEN, Wako-city, Japan, for providing the FUCCI constructs. The FUCCI work was supported by project grants APP1003637 (National Health and Medical Research Council) and RG 09-08 (Cancer Council New South Wales) to NKH.	Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Chen YT, 1996, P NATL ACAD SCI USA, V93, P5915, DOI 10.1073/pnas.93.12.5915; Cvitic S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079233; Das Thakur M, 2013, CANCER RES, V73, P6106, DOI 10.1158/0008-5472.CAN-13-1633; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Duan ZF, 2004, MOL CANCER THER, V3, P833; Elliott AM, 2009, MOL CANCER RES, V7, P79, DOI 10.1158/1541-7786.MCR-08-0235; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Furuta J, 2014, J INVEST DERMATOL, V134, P1369, DOI 10.1038/jid.2013.490; Glover S, 2004, J CELL PHYSIOL, V199, P77, DOI 10.1002/jcp.10456; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Haass NK, 2014, PIGM CELL MELANOMA R, V27, P764, DOI 10.1111/pcmr.12274; Haughian JM, 2009, INT J CANCER, V125, P2556, DOI 10.1002/ijc.24633; Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702; Khalil A, 2011, CELL CYCLE, V10, P481, DOI 10.4161/cc.10.3.14713; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207; KWON BS, 1993, J INVEST DERMATOL, V100, pS134, DOI 10.1111/1523-1747.ep12465022; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Moreb JS, 2008, CURR STEM CELL RES T, V3, P237, DOI 10.2174/157488808786734006; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Shakhova O, 2013, CANCER LETT, V338, P74, DOI 10.1016/j.canlet.2012.10.009; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Zou L, 2012, J BIOL CHEM, V287, P7190, DOI 10.1074/jbc.M111.304972	34	78	78	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4448	4459		10.1038/onc.2014.372	http://dx.doi.org/10.1038/onc.2014.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25417704	Green Accepted			2022-12-28	WOS:000360189200004
J	Manning, CS; Hooper, S; Sahai, EA				Manning, C. S.; Hooper, S.; Sahai, E. A.			Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells	ONCOGENE			English	Article							CENTROMERE-ASSOCIATED KINESIN; BREAST-CANCER CELLS; STEM-CELLS; PROTEIN EZH2; EXPRESSION; TRANSCRIPTION; METASTASIS; GENE; DIFFERENTIATION; MELANOCYTES	The acquisition of cell motility is an early step in melanoma metastasis. Here we use intravital imaging of signalling reporter cell-lines combined with genome-wide transcriptional analysis to define signalling pathways and genes associated with melanoma metastasis. Intravital imaging revealed heterogeneous cell behaviour in vivo: < 10% of cells were motile and both singly moving cells and streams of cells were observed. Motile melanoma cells had increased Notch- and SRF-dependent transcription. Subsequent genome-wide analysis identified an overlapping set of genes associated with high Notch and SRF activity. We identified EZH2, a histone methyltransferase in the Polycomb repressive complex 2, as a regulator of these genes. Heterogeneity of EZH2 levels is observed in melanoma models, and co-ordinated upregulation of genes positively regulated by EZH2 is associated with melanoma metastasis. EZH2 was also identified as regulating the amelanotic phenotype of motile cells in vivo by suppressing expression of the P-glycoprotein Oca2. Analysis of patient samples confirmed an inverse relationship between EZH2 levels and pigment. EZH2 targeting with siRNA and chemical inhibition reduced invasion in mouse and human melanoma cell lines. The EZH2-regulated genes KIF2C and KIF22 are required for melanoma cell invasion and important for lung colonization. We propose that heterogeneity in EZH2 levels leads to heterogeneous expression of a cohort of genes associated with motile behaviour including KIF2C and KIF22. EZH2-dependent increased expression of these genes promotes melanoma cell motility and early steps in metastasis.	[Manning, C. S.; Hooper, S.; Sahai, E. A.] Canc Res UK London Res Inst, Tumour Cell Biol Lab, London WC2A 3LY, England	Cancer Research UK	Sahai, EA (corresponding author), Canc Res UK London Res Inst, Tumour Cell Biol, 44 Lincolns Inn Fields, London WC2A 3LY, England.	erik.sahai@cancer.org.uk		Manning, Cerys/0000-0001-8656-5878; Sahai, Erik/0000-0002-3932-5086	McGrath Charitable Trust via Cancer Research UK; Cancer Research UK; Cancer Research UK [15154] Funding Source: researchfish	McGrath Charitable Trust via Cancer Research UK; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank members of the Tumour Cell Biology laboratory for their discussion and comments. We thank Richard Treisman's laboratory for reagents. We are indebted to the Experimental Histopathology laboratory, FACS laboratory and Biological Resources Unit at the London Research Institute and Rosamond Nuamah and Charles Mein at Barts and The London Genome Centre. We are extremely grateful for PhD sponsorship of CSM from The McGrath Charitable Trust via Cancer Research UK. This study was supported by Cancer Research UK.	Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Asangani IA, 2012, ONCOTARGET, V3, P1011, DOI 10.18632/oncotarget.622; Bailey CM, 2012, PIGM CELL MELANOMA R, V25, P573, DOI 10.1111/j.1755-148X.2012.01025.x; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Donnelly MP, 2012, HUM GENET, V131, P683, DOI 10.1007/s00439-011-1110-x; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Goswami S, 2004, CANCER RES, V64, P7664, DOI 10.1158/0008-5472.CAN-04-2027; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hou P, 2012, CELL CYCLE, V11, P286, DOI 10.4161/cc.11.2.18707; Ishikawa K, 2008, BRIT J CANCER, V98, P1824, DOI 10.1038/sj.bjc.6604379; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Manning CS, 2013, INTRAVITAL, V2, P33; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McHugh JB, 2007, J CUTAN PATHOL, V34, P597, DOI 10.1111/j.1600-0560.2006.00678.x; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Moriyama M, 2006, J CELL BIOL, V173, P333, DOI 10.1083/jcb.200509084; Nakamura Y, 2007, BRIT J CANCER, V97, P543, DOI 10.1038/sj.bjc.6603905; Nuytten M, 2008, ONCOGENE, V27, P1449, DOI 10.1038/sj.onc.1210774; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546; ROSEMBLAT S, 1994, P NATL ACAD SCI USA, V91, P12071, DOI 10.1073/pnas.91.25.12071; Sahai E, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-14; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Zabierowski SE, 2011, STEM CELLS, V29, P1752, DOI 10.1002/stem.740; Zhao XH, 2007, J CELL SCI, V120, P1801, DOI 10.1242/jcs.001586	42	42	42	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4320	4332		10.1038/onc.2014.362	http://dx.doi.org/10.1038/onc.2014.362			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381824	Green Accepted			2022-12-28	WOS:000359494400004
J	Vincent, EE; Coelho, PP; Blagih, J; Griss, T; Viollet, B; Jones, RG				Vincent, E. E.; Coelho, P. P.; Blagih, J.; Griss, T.; Viollet, B.; Jones, R. G.			Differential effects of AMPK agonists on cell growth and metabolism	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; LKB1-AMPK PATHWAY; CANCER-CELLS; MITOCHONDRIAL DYSFUNCTION; LUNG-CANCER; METFORMIN; LKB1; PHOSPHORYLATION; SURVIVAL; INHIBITION	As a sensor of cellular energy status, the AMP-activated protein kinase (AMPK) is believed to act in opposition to the metabolic phenotypes favored by proliferating tumor cells. Consequently, compounds known to activate AMPK have been proposed as cancer therapeutics. However, the extent to which the anti-neoplastic properties of these agonists are mediated by AMPK is unclear. Here we examined the AMPK dependence of six commonly used AMPK agonists (metformin, phenformin, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), 2-deoxy-D-glucose (2DG), salicylate and A-769662) and their influence on cellular processes often deregulated in tumor cells. We demonstrate that the majority of these agonists display AMPK-independent effects on cell proliferation and metabolism with only the synthetic activator, A-769662, exerting AMPK-dependent effects on these processes. We find that A-769662 promotes an AMPK-dependent increase in mitochondrial spare respiratory capacity. Finally, contrary to the view of AMPK activity being tumor suppressive, we find that A-769662 confers a selective proliferative advantage to tumor cells growing under nutrient deprivation. Our results indicate that many of the antigrowth properties of these agonists cannot be attributed to AMPK activity in cells, and thus any observed effects using these agonists should be confirmed using AMPK-deficient cells. Ultimately, our data urge caution not only regarding the type of AMPK agonist proposed for cancer treatment but also the context in which they are used.	[Vincent, E. E.; Coelho, P. P.; Blagih, J.; Griss, T.; Jones, R. G.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3G 1Y6, Canada; [Vincent, E. E.; Coelho, P. P.; Blagih, J.; Griss, T.; Jones, R. G.] McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; [Viollet, B.] INSERM, Inst Cochin, U1016, Paris, France; [Viollet, B.] CNRS, UMR 8104, Paris, France; [Viollet, B.] Univ Paris 05, Sorbonne Paris Cite, Paris, France	McGill University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Jones, RG (corresponding author), McGill Univ, Dept Physiol, Goodman Canc Res Ctr, 3655 Promenade Sir William Osler,Room 705, Montreal, PQ H3G 1Y6, Canada.	russell.jones@mcgill.ca	Jones, Russell/AAC-2861-2022; Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017; Jones, Russell Graham/ABD-5261-2021	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Jones, Russell Graham/0000-0003-2250-4675; Vincent, Emma/0000-0002-8917-7384	McGill Integrated Cancer Research Training Program (MICRTP); Fonds de researche Sante Quebec; Canadian Institute Health Research (CIHR) [MOP-93799]; Canadian Cancer Society [2010-700586]; Terry Fox Research Foundation [TEF-116128]	McGill Integrated Cancer Research Training Program (MICRTP); Fonds de researche Sante Quebec; Canadian Institute Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Terry Fox Research Foundation	We acknowledge Douglas Elder and Nicole Beauchemin, and members of the Jones Laboratory for critical reading of this manuscript. EEV, PPC and TG were funded by the McGill Integrated Cancer Research Training Program (MICRTP) and JB was funded by Fonds de researche Sante Quebec. This work was supported by grants to RGJ from the Canadian Institute Health Research (CIHR) (MOP-93799), Canadian Cancer Society (2010-700586) and Terry Fox Research Foundation (TEF-116128). This work is dedicated to the memory of Rosalind Goodman.	Appleyard MVCL, 2012, BRIT J CANCER, V106, P1117, DOI 10.1038/bjc.2012.56; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; BRODY TM, 1956, J PHARMACOL EXP THER, V117, P39; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chhipa RR, 2010, CELL SIGNAL, V22, P1554, DOI 10.1016/j.cellsig.2010.05.024; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CRISSMAN HA, 1973, J CELL BIOL, V59, P766, DOI 10.1083/jcb.59.3.766; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Dupuy F, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-18; Dykens JA, 2008, TOXICOL APPL PHARM, V233, P203, DOI 10.1016/j.taap.2008.08.013; El-Masry OS, 2012, ONCOL LETT, V3, P224, DOI 10.3892/ol.2011.458; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Elder DJE, 1996, CANCER RES, V56, P2273; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Faubert B., 2014, CANC LETT; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018; Goransson O, 2007, J BIOL CHEM, V282, P32549, DOI 10.1074/jbc.M706536200; Guigas B, 2006, DIABETES, V55, P865, DOI 10.2337/diabetes.55.04.06.db05-1178; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2013, DIABETES, V62, P2164, DOI 10.2337/db13-0368; Hardie DG, 2011, BIOCHEM SOC T, V39, P1, DOI 10.1042/BST0390001; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kim IY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00175; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001; Nicholls DG, 2009, BIOCHEM SOC T, V37, P1385, DOI 10.1042/BST0371385; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; PACHMAN LM, 1971, J CLIN INVEST, V50, P226, DOI 10.1172/JCI106478; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Rosilio C, 2013, CANCER LETT, V336, P114, DOI 10.1016/j.canlet.2013.04.015; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; Vincent EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066963; VINCENT MF, 1992, BIOCHEM J, V281, P267, DOI 10.1042/bj2810267; Wu N, 2011, NEOPLASMA, V58, P482, DOI 10.4149/neo_2011_06_482; Zadra G, 2014, EMBO MOL MED, V6, P519, DOI 10.1002/emmm.201302734; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zannella VE, 2011, RADIOTHER ONCOL, V99, P293, DOI 10.1016/j.radonc.2011.05.049	63	96	98	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3627	3639		10.1038/onc.2014.301	http://dx.doi.org/10.1038/onc.2014.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241895	Green Accepted			2022-12-28	WOS:000357679100002
J	Marfil, V; Blazquez, M; Serrano, F; Castell, JV; Bort, R				Marfil, V.; Blazquez, M.; Serrano, F.; Castell, J. V.; Bort, R.			Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex	ONCOGENE			English	Article							HEX HOMEOBOX GENE; RICH HOMEODOMAIN PROTEIN; MESSENGER-RNA TRANSPORT; CELL-CYCLE; TUMOR-CELLS; EXPRESSION; PROLIFERATION; TRANSCRIPTION; APOPTOSIS; SIZE	c-Myc transcription factor is a key protein involved in cellular growth, proliferation and metabolism. c-Myc is one of the most frequently activated oncogenes, highlighting the need to identify intracellular molecules that interact directly with c-Myc to suppress its function. Here we show that Hhex is able to interact with the basic region/helix-loop-helix/leucine zipper of c-Myc. Knockdown of Hhex increases proliferation rate in hepatocellular carcinoma cells, whereas Hhex expression cell-autonomously reduces cell proliferation rate in multiple cell lines by increasing G1 phase length through a c-Myc-dependent mechanism. Global transcriptomic analysis shows that Hhex counter-regulates multiple c-Myc targets involved in cell proliferation and metabolism. Concomitantly, Hhex expression leads to reduced cell size, lower levels of cellular RNA, downregulation of metabolism-related genes, decreased sensitivity to methotrexate and severe reduction in the ability to form tumours in nude mouse xenografts, all indicative of decreased c-Myc activity. Our data suggest that Hhex is a novel regulator of c-Myc function that limits c-Myc activity in transformed cells.	[Marfil, V.; Blazquez, M.; Serrano, F.; Castell, J. V.; Bort, R.] CIBERehd, Unidad Hepatol Expt, Inst Invest Sanitaria La Fe, Valencia 46026, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD	Bort, R (corresponding author), CIBERehd, Unidad Hepatol Expt, Inst Invest Sanitaria La Fe, Avda Fernando Abril Martorell 106,Torre A Despach, Valencia 46026, Spain.	bort_ber@gva.es	Bort, Roque/Y-5466-2019; Castell, Jose V/I-9529-2016	Bort, Roque/0000-0002-7285-0536; Castell, Jose V/0000-0003-1179-6430	Ministerio de Ciencia e Innovacion [SAF2010-15376, SAF2011-29718]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	We thank Dr Di Crocce for providing c-Myc truncated plasmids and Dr Ken Zaret for providing total RNA from Hhex-deficient E9.5 mouse embryos. We also thank Dr Laia Tolosa for assistance with Olympus ScanR screening station, Juan Jose Lozano for microarray analysis, Cristina Corchero for assistance in qRT-PCR and Ana Flores and M<SUP>a</SUP> Jesus Segui (Cell Culture and Cell Sorting facility at the SCSIE from Universidad de Valencia) for assistance in flow cytometry and cell sorting. VM and FS were recipients of pre-doctoral fellowships from the Ministerio de Ciencia e Innovacion. This work was supported by the Ministerio de Ciencia e Innovacion (grant number SAF2010-15376 and SAF2011-29718).	Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Bazarov AV, 2001, CANCER RES, V61, P1178; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bort R, 2006, DEV BIOL, V290, P44, DOI 10.1016/j.ydbio.2005.11.006; Bort R, 2004, DEVELOPMENT, V131, P797, DOI 10.1242/dev.00965; Brickman JM, 2000, DEVELOPMENT, V127, P2303; Buschbeck M, 2007, ONCOGENE, V26, P3415, DOI 10.1038/sj.onc.1210128; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053388; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; D'Elia AV, 2002, J CLIN ENDOCR METAB, V87, P1376, DOI 10.1210/jc.87.3.1376; Desjobert C, 2009, BIOCHEM J, V417, P121, DOI 10.1042/BJ20080872; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eekels JJM, 2012, GENE THER, V19, P1058, DOI 10.1038/gt.2011.191; Foley AC, 2005, GENE DEV, V19, P387, DOI 10.1101/gad.1279405; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GERDES J, 1984, J IMMUNOL, V133, P1710; Guiral M, 2001, J BIOL CHEM, V276, P2961, DOI 10.1074/jbc.M004948200; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; Hammoudeh DI, 2009, J AM CHEM SOC, V131, P7390, DOI 10.1021/ja900616b; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jimenez RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009084; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Marfil V, 2010, J BIOL CHEM, V285, P5726, DOI 10.1074/jbc.M109.046649; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Minami T, 2004, J BIOL CHEM, V279, P20626, DOI 10.1074/jbc.M308730200; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Morrish F, 2009, ONCOGENE, V28, P2485, DOI 10.1038/onc.2009.112; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Noy P, 2010, MOL CELL BIOL, V30, P2120, DOI 10.1128/MCB.01511-09; Obinata A, 2002, DEV GROWTH DIFFER, V44, P281; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Paz H, 2010, BLOOD, V116, P1254, DOI 10.1182/blood-2009-11-254383; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; PROUTY SM, 1993, ONCOGENE, V8, P899; Puppin C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-192; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Seol Dongrim, 2011, BMC Res Notes, V4, P162, DOI 10.1186/1756-0500-4-162; Serrano F, 2013, STEM CELLS, V31, P71, DOI 10.1002/stem.1272; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Sims RJ, 2003, BIOTECHNIQUES, V34, P938, DOI 10.2144/03345bm07; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Swingler TE, 2004, J BIOL CHEM, V279, P34938, DOI 10.1074/jbc.M404488200; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xu CR, 2011, SCIENCE, V332, P963, DOI 10.1126/science.1202845; Zanet J, 2005, J CELL SCI, V118, P1693, DOI 10.1242/jcs.02298; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3011	3022		10.1038/onc.2014.240	http://dx.doi.org/10.1038/onc.2014.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25220416				2022-12-28	WOS:000356100500007
J	Cai, Q; Yan, L; Xu, Y				Cai, Q.; Yan, L.; Xu, Y.			Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells	ONCOGENE			English	Article							MOUSE MODEL; CARCINOMA; GROWTH; TUMOR	High-grade serous ovarian cancer is an aggressive form of epithelial ovarian cancer (EOC), and accounts for the majority of deaths due to EOC. The critical cellular processes and underlying molecular mechanisms that define this malignancy remain poorly understood. Using a syngeneic murine model, we investigated the changes that accompanied the progression to increased aggressiveness induced by in vivo passage of mouse EOC cells. We found that enhanced anoikis resistance was a key cellular process associated with greater aggressiveness and tumorigenicity in vivo. Biochemical studies revealed that the enhanced anoikis resistance was associated with the activation of the Src/Akt/Erk signaling pathway. A higher rate of metabolism and autophagy were also associated with increased anoikis resistance. Blocking these pathways with specific inhibitors and/or genetic modifications significantly increased anoikis in vitro and inhibited tumor development in vivo. In addition, we demonstrated that similar signaling pathways were also involved in a human EOC cell line model. Collectively, our data suggest that anoikis resistance represents a critical and a distinguishing feature underlying the aggressiveness of ovarian cancer cells.	[Cai, Q.; Yan, L.; Xu, Y.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Xu, Y (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, 975 W Walnut St IB355A, Indianapolis, IN 46202 USA.	xu2@iupui.edu			National Institutes of Health [RO1 155145]; Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE [R01CA155145] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Caryl Antalis and Christy A Tidwell for their critical reading and editing of this manuscript. This work is supported in part by the National Institutes of Health (RO1 155145 to YX) and the Mary Fendrich-Hulman Charitable Trust Fund to YX.	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; BAUMAL R, 1986, CANCER RES, V46, P3994; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Janat-Amsbury MM, 2006, ANTICANCER RES, V26, P3223; Li H, 2009, MOL CANCER THER, V8, P1692, DOI 10.1158/1535-7163.MCT-08-1106; Miskimins WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085576; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Said NA, 2007, NEOPLASIA, V9, P23, DOI 10.1593/neo.06658; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sher I, 2009, INT J CANCER, V124, P553, DOI 10.1002/ijc.23963; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; YU DH, 1993, CANCER RES, V53, P891	15	65	68	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3315	3324		10.1038/onc.2014.264	http://dx.doi.org/10.1038/onc.2014.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132267	Green Submitted, Green Accepted			2022-12-28	WOS:000356592300010
J	Orticello, M; Fiore, M; Totta, P; Desideri, M; Barisic, M; Passeri, D; Lenzi, J; Rosa, A; Orlandi, A; Maiato, H; Del Bufalo, D; Degrassi, F				Orticello, M.; Fiore, M.; Totta, P.; Desideri, M.; Barisic, M.; Passeri, D.; Lenzi, J.; Rosa, A.; Orlandi, A.; Maiato, H.; Del Bufalo, D.; Degrassi, F.			N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochore-microtubule dynamics	ONCOGENE			English	Article							CANCER-CELLS; CHROMOSOME SEGREGATION; MITOTIC PROGRESSION; GENE DELIVERY; IN-VIVO; CHECKPOINT; PROTEIN; EXPRESSION; INSTABILITY; ATTACHMENT	Mitotic proteins are attractive targets to develop molecular cancer therapeutics due to the intimate interdependence between cell proliferation and mitosis. In this work, we have explored the therapeutic potential of the kinetochore (KT) protein Hec1 (Highly Expressed in Cancer protein 1) as a molecular target to produce massive chromosome missegregation and cell death in cancer cells. Hec1 is a constituent of the Ndc80 complex, which mediates KT-microtubule (MT) attachments at mitosis and is upregulated in various cancer types. We expressed Hec1 fused with enhanced green fluorescent protein (EGFP) at its N-terminus MT-interaction domain in HeLa cells and showed that expression of this modified Hec1, which localized at KTs, blocked cell proliferation and promoted apoptosis in tumour cells. EGFP-Hec1 was extremely potent in tumour cell killing and more efficient than siRNA-induced Hec1 depletion. In striking contrast, normal cells showed no apparent cell proliferation defects or cell death following EGFP-Hec1 expression. Live-cell imaging demonstrated that cancer cell death was associated with massive chromosome missegregation within multipolar spindles after a prolonged mitotic arrest. Moreover, EGFP-Hec1 expression was found to increase KT-MT attachment stability, providing a molecular explanation for the abnormal spindle architecture and the cytotoxic activity of this modified protein. Consistent with cell culture data, EGFP-Hec1 expression was found to strongly inhibit tumour growth in a mouse xenograft model by disrupting mitosis and inducing multipolar spindles. Taken together, these findings demonstrate that stimulation of massive chromosome segregation defects can be used as an anti-cancer strategy through the activation of mitotic catastrophe after a multipolar mitosis. Importantly, this study represents a clear proof of concept that targeting KT proteins required for proper KT-MT attachment dynamics constitutes a powerful approach in cancer therapy.	[Orticello, M.; Fiore, M.; Totta, P.; Degrassi, F.] CNR, Inst Biol Mol Med & Nanobiotechnol, Rome, Italy; [Desideri, M.; Del Bufalo, D.] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy; [Barisic, M.; Maiato, H.] Univ Porto, Inst Biol Mol & Celular, Chromosome Instabil & Dynam Lab, P-4100 Oporto, Portugal; [Passeri, D.; Orlandi, A.] Univ Roma Tor Vergata, Anat Pathol Inst, Rome, Italy; [Lenzi, J.; Rosa, A.] Univ Roma La Sapienza, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy; [Maiato, H.] Univ Porto, Fac Med, Dept Expt Biol, Cell Div Unit, P-4100 Oporto, Portugal	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universidade do Porto; University of Rome Tor Vergata; Sapienza University Rome; Universidade do Porto	Degrassi, F (corresponding author), CNR, Inst Biol Mol Med & Nanobiotechnol, Rome, Italy.	francesca.degrassi@uniroma1.it	desideri, marianna/K-5771-2016; Alessandro, Rosa/A-3860-2012; Totta, Pierangela/I-3251-2018; Del Bufalo, Donatella/K-8673-2016; Del Bufalo, Donatella/AAC-1594-2021; Orlandi, Augusto/AHE-8753-2022; Maiato, Helder/J-9466-2013; Barisic, Marin/K-2301-2013	desideri, marianna/0000-0002-4311-9656; Alessandro, Rosa/0000-0001-9999-7223; Totta, Pierangela/0000-0001-7826-4733; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; orlandi, augusto/0000-0001-7202-5854; Maiato, Helder/0000-0002-6200-9997; Barisic, Marin/0000-0001-7587-3867	Italian Association for Cancer Research [IG 14100]; COMPETE [FCOMP-01-0124-FEDER-015941 (PTDC/SAU-ONC/112917/2009)]; Fundacao para a Ciencia e a Tecnologia of Portugal, Human Frontier Science Program; European Research Council	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); COMPETE; Fundacao para a Ciencia e a Tecnologia of Portugal, Human Frontier Science Program; European Research Council(European Research Council (ERC)European Commission)	Live-cell imaging experiments were performed at the Nikon Reference Centre, CNR Institute of Biology, Molecular Medicine and Nanobiotechnology. We thank Giulia Guarguaglini and Patrizia Lavia for advice and support with live cell analysis. We also thank Giulia Vargiu for her contribution in the initial phases of the work, Enrico Cundari for helpful comments and suggestions, Antonio Pereira for expert advice and software update in the statistical analysis of MT dynamics data and Stephan Geley for mEOS-tubulin vector. This work was partially supported by a grant from the Italian Association for Cancer Research to DDB (IG 14100). Work in HM's laboratory is funded by FCOMP-01-0124-FEDER-015941 (PTDC/SAU-ONC/112917/2009) through COMPETE and Fundacao para a Ciencia e a Tecnologia of Portugal, the Human Frontier Science Program and PRECISE grant from the European Research Council.	Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Bieche I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-23; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Ciferri C, 2008, CELL, V133, P427, DOI 10.1016/j.cell.2008.03.020; Cimini D, 2006, CURR BIOL, V16, P1711, DOI 10.1016/j.cub.2006.07.022; Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2012, CURR OPIN CELL BIOL, V24, P48, DOI 10.1016/j.ceb.2011.11.003; DeLuca JG, 2003, CURR BIOL, V13, P2103, DOI 10.1016/j.cub.2003.10.056; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Ferretti C, 2010, CELL CYCLE, V9, P4174, DOI 10.4161/cc.9.20.13457; Frecha C, 2008, CURR GENE THER, V8, P449, DOI 10.2174/156652308786848003; Galimberti F, 2010, CLIN CANCER RES, V16, P109, DOI 10.1158/1078-0432.CCR-09-2151; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Guimaraes GJ, 2008, CURR BIOL, V18, P1778, DOI 10.1016/j.cub.2008.08.012; Gurzov EN, 2006, GENE THER, V13, P1, DOI 10.1038/sj.gt.3302595; Hayama S, 2006, CANCER RES, V66, P10339, DOI 10.1158/0008-5472.CAN-06-2137; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Janssen A, 2013, ONCOGENE, V32, P4459, DOI 10.1038/onc.2012.576; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Kabeche L, 2013, NATURE, V502, P110, DOI 10.1038/nature12507; Kaneko N, 2009, BIOCHEM BIOPH RES CO, V390, P1235, DOI 10.1016/j.bbrc.2009.10.127; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lacoste A, 2009, CELL STEM CELL, V5, P332, DOI 10.1016/j.stem.2009.07.011; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Li L, 2007, GENE THER, V14, P814, DOI 10.1038/sj.gt.3302933; Logarinho E, 2012, NAT CELL BIOL, V14, P295, DOI 10.1038/ncb2423; Maiato H, 2014, NAT CELL BIOL, V16, P386, DOI 10.1038/ncb2958; Manning AL, 2007, CURR BIOL, V17, P260, DOI 10.1016/j.cub.2006.11.071; Manning AL, 2010, EMBO J, V29, P3531, DOI 10.1038/emboj.2010.230; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Mattiuzzo M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016307; McKinney SA, 2009, NAT METHODS, V6, P131, DOI [10.1038/NMETH.1296, 10.1038/nmeth.1296]; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Miller SA, 2008, CURR BIOL, V18, P1785, DOI 10.1016/j.cub.2008.11.007; Morlando M, 2012, EMBO J, V31, P4502, DOI 10.1038/emboj.2012.319; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; Orlandi A, 2006, MODERN PATHOL, V19, P797, DOI 10.1038/modpathol.3800586; Rosa A, 2011, EMBO J, V30, P237, DOI 10.1038/emboj.2010.319; Schafer J, 2010, BIOMATERIALS, V31, P6892, DOI 10.1016/j.biomaterials.2010.05.043; Senzer N, 2013, MOL THER, V21, P1096, DOI 10.1038/mt.2013.32; Sethi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047086; Singh J, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-7; Stevens D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022969; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wandke C, 2012, J CELL BIOL, V198, P847, DOI 10.1083/jcb.201110060; Wang YQ, 2012, INT J NANOMED, V7, P693, DOI 10.2147/IJN.S27849; Welburn JPI, 2010, MOL CELL, V38, P383, DOI 10.1016/j.molcel.2010.02.034; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721; Zhou Q, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22566	57	8	8	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3325	3335		10.1038/onc.2014.265	http://dx.doi.org/10.1038/onc.2014.265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132262				2022-12-28	WOS:000356592300011
J	Pathiraja, TN; Thakkar, KN; Jiang, S; Stratton, S; Liu, Z; Gagea, M; Shi, X; Shah, PK; Phan, L; Lee, MH; Andersen, J; Stampfer, M; Barton, MC				Pathiraja, T. N.; Thakkar, K. N.; Jiang, S.; Stratton, S.; Liu, Z.; Gagea, M.; Shi, X.; Shah, P. K.; Phan, L.; Lee, M-H; Andersen, J.; Stampfer, M.; Barton, M. C.			TRIM24 links glucose metabolism with transformation of human mammary epithelial cells	ONCOGENE			English	Article							BREAST-CANCER; GENE-EXPRESSION; TUMOR SUPPRESSORS; P53 FUNCTION; PROLIFERATION; GROWTH; WARBURG; LINES; IMMORTALIZATION; INACTIVATION	Tripartite motif 24 protein (TRIM24) is a plant homeodomain/bromodomain histone reader, recently associated with poor overall survival of breast-cancer patients. At a molecular level, TRIM24 is a negative regulator of p53 levels and a co-activator of estrogen receptor. However, the role of TRIM24 in breast tumorigenesis remains largely unknown. We used an isogenic human mammary epithelial cell (HMEC) culture model, derived from reduction mammoplasty tissue, and found that ectopic expression of TRIM24 in immortalized HMECs (TRIM24 iHMECs) greatly increased cellular proliferation and induced malignant transformation. Subcutaneous injection of TRIM24 iHMECs in nude mice led to growth of intermediate to high-grade tumors in 60-70% of mice. Molecular analysis of TRIM24 iHMECs revealed a glycolytic and tricarboxylic acid cycle gene signature, alongside increased glucose uptake and activated aerobic glycolysis. Collectively, these results identify a role for TRIM24 in breast tumorigenesis through reprogramming of glucose metabolism in HMECs, further supporting TRIM24 as a viable therapeutic target in breast cancer.	[Pathiraja, T. N.; Thakkar, K. N.; Jiang, S.; Stratton, S.; Liu, Z.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Ctr Canc Epigenet, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Gagea, M.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Shi, X.; Shah, P. K.; Andersen, J.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [Phan, L.; Lee, M-H] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Stampfer, M.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Barton, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Ctr Canc Epigenet, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Houston 207, Houston, TX 77030 USA.	mbarton@mdanderson.org	Liu, Zhiming/GXG-6785-2022	Shi, Xiaobing/0000-0001-5242-8189; THAKKAR, KAUSHIK/0000-0002-4900-3371; Lee, Mong-Hong/0000-0001-8675-8215; Barton, Michelle/0000-0002-4042-1374	Cancer Prevention and Research Initiative of Texas [RP100602]; Center for Cancer Epigenetics scholarship; MD Anderson Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	Cancer Prevention and Research Initiative of Texas; Center for Cancer Epigenetics scholarship; MD Anderson Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Abhinav Jain and Srikanth Appikonda for helpful discussions. Zeynep Coban and Kadir Akdemir for help with Bioinformatic analyses. Lindsey Minter and Joseph Taube for help with Xenograft experiments. This research is supported by grant RP100602 from the Cancer Prevention and Research Initiative of Texas to MCB, the Center for Cancer Epigenetics scholarship to KNT and in part by the MD Anderson Cancer Center Support Grant CA016672.	Allred DC, 1998, MODERN PATHOL, V11, P155; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chambon M, 2011, AM J PATHOL, V178, P1461, DOI 10.1016/j.ajpath.2010.12.026; Chen JQ, 2012, BBA-REV CANCER, V1826, P370, DOI 10.1016/j.bbcan.2012.06.004; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Diers AR, 2012, BIOCHEM J, V444, P561, DOI 10.1042/BJ20120294; Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lee E, 2013, NEOPLASIA, V15, P112, DOI 10.1593/neo.121638; Lim HY, 2011, MITOCHONDRION, V11, P437, DOI 10.1016/j.mito.2010.12.015; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Milke L, 2013, CARCINOGENESIS, V34, P850, DOI 10.1093/carcin/bgs387; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; PIERCE JH, 1991, ONCOGENE, V6, P1189; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Smolkova K, 2011, INT J BIOCHEM CELL B, V43, P950, DOI 10.1016/j.biocel.2010.05.003; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Stampfer MR, 2013, CELL MOL BIOL BREAST, P323, DOI [10.1007/978-1-62703-634-4_15, DOI 10.1007/978-1-62703-634-4_15]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wen H, 2014, NATURE, V508, P263, DOI 10.1038/nature13045; Werner H, 2012, LANCET ONCOL, V13, pE537, DOI 10.1016/S1470-2045(12)70362-5; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928; Zhu CW, 2011, CLIN DEV IMMUNOL, P1, DOI 10.1155/2011/920146	54	31	33	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2836	2845		10.1038/onc.2014.220	http://dx.doi.org/10.1038/onc.2014.220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25065590	Green Accepted, Green Published			2022-12-28	WOS:000355324300003
J	Chakraborty, AA; Scuoppo, C; Dey, S; Thomas, LR; Lorey, SL; Lowe, SW; Tansey, WP				Chakraborty, A. A.; Scuoppo, C.; Dey, S.; Thomas, L. R.; Lorey, S. L.; Lowe, S. W.; Tansey, W. P.			A common functional consequence of tumor-derived mutations within c-MYC	ONCOGENE			English	Article							BURKITT-LYMPHOMA; MOUSE PLASMACYTOMAS; CODING REGION; ONCOGENE; PROGRESSION; SUPPRESSOR; TARGETS; BIM	The relevance of changes to the coding sequence of the c-MYC oncogene to malignancy is controversial. Overexpression of a pristine form of MYC is observed in many cancers and is sufficient to drive tumorigenesis in most contexts. Yet missense changes to MYC are found in similar to 50% of Burkitt's lymphomas, aggregate within an amino-terminal degron important for proteasomal destruction of MYC, and where examined profoundly enhance the tumorigenic properties of MYC in vitro and in vivo. Much of the controversy surrounding these mutants stems from the limited number of mutations that have been evaluated and their clustering within a single region of the MYC protein; the highly-conserved Myc box I (MbI) element. Here, by analysis of extant genomic data sets, we identify a previously unrecognized hotspot for tumor-associated MYC mutations, located in a conserved central portion of the protein. We show that, despite their distal location in MYC, mutations in this region precisely phenocopy those in MbI in terms of stability, in vitro transformation, growth-promoting properties, in vivo tumorigenesis and ability to escape p53-dependent tumor surveillance mechanisms. The striking parallels between the behavior of tumor-derived mutations in disparate regions of the MYC protein reveals that a common molecular process is disrupted by these mutations, implying an active role for these mutations in tumorigenesis and suggesting that different therapeutic strategies may be needed for treatment of lymphomas expressing wild type versus mutant forms of MYC protein.	[Chakraborty, A. A.; Scuoppo, C.; Lowe, S. W.; Tansey, W. P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Chakraborty, A. A.; Dey, S.; Thomas, L. R.; Lorey, S. L.; Tansey, W. P.] Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; [Lowe, S. W.] Howard Hughes Med Inst, New York, NY USA	Cold Spring Harbor Laboratory; Vanderbilt University; Howard Hughes Medical Institute	Tansey, WP (corresponding author), Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, 465 21st Ave South, Nashville, TN 37232 USA.	william.p.tansey@vanderbilt.edu		Tansey, William/0000-0002-3900-0978	CSHL Cancer Center [CA45508]; Vanderbilt Ingram Cancer Center [CA68485]; US Public Health Service from the NCI [CA-13106]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [P01CA013106, P30CA068485, P30CA045508, P01CA087497] Funding Source: NIH RePORTER	CSHL Cancer Center; Vanderbilt Ingram Cancer Center; US Public Health Service from the NCI; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	For reagents, we thank the CSHL Antibody Shared Resource and the Vanderbilt Antibody and Protein Shared Resource. We thank Simone Salghetti for technical assistance. This work was supported by the CSHL Cancer Center Support Grant CA45508, the Vanderbilt Ingram Cancer Center Support grant CA68485 and by US Public Health Service grant CA-13106 from the NCI (WPT/SWL) and Howard Hughes Medical Institute (SWL). SWL is an investigator in the Howard Hughes Medical Institute.	Axelson H, 1995, EUR J CANCER, V31A, P2099, DOI 10.1016/0959-8049(95)00449-1; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; CLARK HM, 1994, CANCER RES, V54, P3383; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Giulino-Roth L, 2012, BLOOD, V120, P5181, DOI 10.1182/blood-2012-06-437624; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; Tworkowski KA, 2008, P NATL ACAD SCI USA, V105, P6103, DOI 10.1073/pnas.0802095105; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843	23	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2406	2409		10.1038/onc.2014.186	http://dx.doi.org/10.1038/onc.2014.186			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24998853	Green Accepted			2022-12-28	WOS:000353824800013
J	Zhang, C; Casas-Tinto, S; Li, G; Lin, N; Chung, M; Moreno, E; Moberg, KH; Zhou, L				Zhang, C.; Casas-Tinto, S.; Li, G.; Lin, N.; Chung, M.; Moreno, E.; Moberg, K. H.; Zhou, L.			An intergenic regulatory region mediates Drosophila Myc-induced apoptosis and blocks tissue hyperplasia	ONCOGENE			English	Article							C-MYC; CELL-DEATH; ORGAN SIZE; MELANOGASTER; GENES; P53; LYMPHOMAGENESIS; EXPRESSION; ELEMENT; DAMAGE	Induction of cell-autonomous apoptosis following oncogene-induced overproliferation is a major tumor-suppressive mechanism in vertebrates. However, the detailed mechanism mediating this process remains enigmatic. In this study, we demonstrate that dMyc-induced cell-autonomous apoptosis in the fruit fly Drosophila melanogaster relies on an intergenic sequence termed the IRER (irradiation-responsive enhancer region). The IRER mediates the expression of surrounding proapoptotic genes, and we use an in vivo reporter of the IRER chromatin state to gather evidence that epigenetic control of DNA accessibility within the IRER is an important determinant of the strength of this response to excess dMyc. In a previous work, we showed that the IRER also mediates P53-dependent induction of proapoptotic genes following DNA damage, and the chromatin conformation within IRER is regulated by polycomb group-mediated histone modifications. dMyc-induced apoptosis and the P53-mediated DNA damage response thus overlap in a requirement for the IRER. The epigenetic mechanisms controlling IRER accessibility appear to set thresholds for the P53- and dMyc-induced expression of apoptotic genes in vivo and may have a profound impact on cellular sensitivity to oncogene-induced stress.	[Zhang, C.; Li, G.; Lin, N.; Chung, M.; Zhou, L.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Zhang, C.; Li, G.; Lin, N.; Chung, M.; Zhou, L.] Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA; [Zhang, C.; Moberg, K. H.] Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA USA; [Casas-Tinto, S.] Spanish Res Council CSIC, Inst Cajal, Madrid, Spain; [Li, G.; Zhou, L.] Univ Florida, UF Genet Inst, Gainesville, FL 32610 USA; [Moreno, E.] Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Madrid, Spain	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Emory University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); State University System of Florida; University of Florida; Centro Nacional de Investigaciones Oncologicas (CNIO)	Zhou, L (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, 2033 Mowry Rd,Room 261, Gainesville, FL 32610 USA.	leizhou@ufl.edu	Casas-Tinto, Sergio/G-8220-2015; Li, Guangyao/I-8241-2015; Lin, Nianwei/AAD-9805-2019; Moberg, Ken/J-4849-2017	Casas-Tinto, Sergio/0000-0002-9589-9981; Li, Guangyao/0000-0003-0029-3854; Moberg, Ken/0000-0002-9820-5543; moreno, eduardo/0000-0001-5040-452X	NCI NIH HHS [R01 CA095542] Funding Source: Medline; NIGMS NIH HHS [R01 GM106174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM106174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bellosta Paola, 2010, Genes Cancer, V1, P542; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Gallant P, 2009, ADV CANCER RES, V103, P111, DOI 10.1016/S0065-230X(09)03005-X; Gambis A, 2011, DEV BIOL, V351, P128, DOI 10.1016/j.ydbio.2010.12.040; Gilchrist AS, 1999, GENETICS, V153, P1775; Gong WJ, 2003, P NATL ACAD SCI USA, V100, P2556, DOI 10.1073/pnas.0535280100; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; HSU B, 1995, ONCOGENE, V11, P175; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kikuta H, 2007, GENOME RES, V17, P545, DOI 10.1101/gr.6086307; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Lin NW, 2009, APOPTOSIS, V14, P935, DOI 10.1007/s10495-009-0360-8; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; Montero L, 2008, GENESIS, V46, P104, DOI 10.1002/dvg.20373; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Ryder E, 2004, GENETICS, V167, P797, DOI 10.1534/genetics.104.026658; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Steller H, 2008, CELL DEATH DIFFER, V15, P1132, DOI 10.1038/cdd.2008.50; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Sullivan W, 2000, DROSOPHILA PROTOCOLS, V1st; Tan Y, 2011, DEVELOPMENT, V138, P2197, DOI 10.1242/dev.058826; Venken KJT, 2006, SCIENCE, V314, P1747, DOI 10.1126/science.1134426; Verghese S, 2012, CELL DEATH DIFFER, V19, P1664, DOI 10.1038/cdd.2012.48; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Zhang YP, 2008, DEV CELL, V14, P481, DOI 10.1016/j.devcel.2008.01.018; ZHOU L, 1995, CURR BIOL, V5, P784, DOI 10.1016/S0960-9822(95)00155-2	34	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2385	2397		10.1038/onc.2014.160	http://dx.doi.org/10.1038/onc.2014.160			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931167	Green Accepted			2022-12-28	WOS:000353824800011
J	Wang, J; Mikse, O; Liao, RG; Li, Y; Tan, L; Janne, PA; Gray, NS; Wong, KK; Hammerman, PS				Wang, J.; Mikse, O.; Liao, R. G.; Li, Y.; Tan, L.; Janne, P. A.; Gray, N. S.; Wong, K-k; Hammerman, P. S.			Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR-3; SENSITIVE FGFR2; BREAST-CANCER; GENE FUSIONS; LUNG-CANCER; MUTATIONS; IDENTIFICATION; PROGRESSION; NVP-BGJ398	Somatic alterations of fibroblast growth factor receptors (FGFRs) have been described in a wide range of malignancies. A number of anti-FGFR therapies are currently under investigation in clinical trials for subjects with FGFR gene amplifications, mutations and translocations. Here, we develop cell line models of acquired resistance to FGFR inhibition by exposure of cell lines harboring FGFR3 gene amplification and translocation to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib. We show that the acquisition of resistance is rapid, reversible and characterized by an epithelial to mesenchymal transition and a switch from dependency on FGFR3 to ERBB family members. Acquired resistance was associated with demonstrable changes in gene expression including increased production of ERBB2/3 ligands, which were sufficient to drive resistance in the setting of FGFR3 dependency but not dependency on other FGFR family members. These data support the concept that activation of ERBB family members is sufficient to bypass dependency on FGFR3 and suggest that concurrent inhibition of these two pathways may be desirable when targeting FGFR3-dependent cancers.	[Wang, J.; Mikse, O.; Liao, R. G.; Li, Y.; Janne, P. A.; Wong, K-k; Hammerman, P. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Wang, J.] Fudan Univ, Shanghai Med Coll, Dept Integrat Med & Neurobiol, Shanghai 200433, Peoples R China; [Liao, R. G.; Li, Y.; Hammerman, P. S.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Tan, L.; Gray, N. S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Janne, P. A.; Wong, K-k] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Fudan University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Hammerman, PS (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 810A, Boston, MA 02215 USA.	phammerman@partners.org		Tan, Li/0000-0002-1199-9046; Liao, Rachel/0000-0002-7830-1976	NCI [K08 CA163677]; V Foundation the Stephen D; Alice Cutler Fund; NSFC [81202746]; CSC; NATIONAL CANCER INSTITUTE [R01CA140594, R01CA166480, P01CA154303, K08CA163677] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V Foundation the Stephen D; Alice Cutler Fund; NSFC(National Natural Science Foundation of China (NSFC)); CSC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	PSH is supported by NCI K08 CA163677, the V Foundation the Stephen D and Alice Cutler Fund. We thank M Meyerson for assisting with the planning of this study. JW is supported by NSFC 81202746 and CSC.	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Andre F, 2013, CLIN CANCER RES, V19, P3693, DOI 10.1158/1078-0432.CCR-13-0190; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Chell V, 2013, ONCOGENE, V32, P3059, DOI 10.1038/onc.2012.319; Cheng T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057284; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Courjal F, 1997, CANCER RES, V57, P4360; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Herrera-Abreu MT, 2013, CANCER DISCOV, V3, P1058, DOI 10.1158/2159-8290.CD-12-0569; Jenndahl LE, 2005, INT J ONCOL, V27, P439; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kim J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-383; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016; Lemieux S, 2013, ANTI-CANCER AGENT ME, V13, P748, DOI 10.2174/18715206113139990080; Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Majewski IJ, 2013, J PATHOL, V230, P270, DOI 10.1002/path.4209; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Winter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288; Wolf J, 2012, CANC RES, V72; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	46	47	61	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2167	2177		10.1038/onc.2014.161	http://dx.doi.org/10.1038/onc.2014.161			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909170	Green Accepted			2022-12-28	WOS:000353473000003
J	Zhao, T; Du, H; Ding, X; Walls, K; Yan, C				Zhao, T.; Du, H.; Ding, X.; Walls, K.; Yan, C.			Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-/-) mice	ONCOGENE			English	Article							LYSOSOMAL ACID LIPASE; SYSTEMIC INFLAMMATION; EXPRESSION; DISEASE; GROWTH; LUNG; ANGIOGENESIS; CHEMOTHERAPY; CARCINOMA; CORRELATE	Inflammation critically contributes to cancer metastasis, in which myeloid-derived suppressor cells (MDSCs) are an important participant. Although MDSCs are known to suppress immune surveillance, their roles in directly stimulating cancer cell proliferation and metastasis currently remain unclear. Lysosomal acid lipase (LAL) deficiency causes systemic expansion and infiltration of MDSCs in multiple organs and subsequent inflammation. In the LAL-deficient (lal(-/-)) mouse model, melanoma metastasized massively in allogeneic lal(-/-) mice, which was suppressed in allogeneic lal(+/+) mice owing to immune rejection. Here we report for the first time that MDSCs from lal(-/-) mice directly stimulated B16 melanoma cell in vitro proliferation and in vivo growth and metastasis. Cytokines, that is, interleukin-1 beta and tumor necrosis factor-alpha from MDSCs are required for B16 melanoma cell proliferation in vitro. Myeloid-specific expression of human LAL (hLAL) in lal(-/-) mice rescues these malignant phenotypes in vitro and in vivo. The tumor-promoting function of lal(-/-) MDSCs is mediated, at least in part, through overactivation of the mammalian target of rapamycin (mTOR) pathway. Knockdown of mTOR, Raptor or Rictor in lal(-/-) MDSCs suppressed their stimulation on proliferation of cancer cells, including B16 melanoma, Lewis lung carcinoma and transgenic mouse prostate cancer-C2 cancer cells. Our results indicate that LAL has a critical role in regulating MDSCs' ability to directly stimulate cancer cell proliferation and overcome immune rejection of cancer metastasis in allogeneic mice through modulation of the mTOR pathway, which provides a mechanistic basis for targeting MDSCs to reduce the risk of cancer metastasis. Therefore MDSCs possess dual functions to facilitate cancer metastasis: suppress immune surveillance and stimulate cancer cell proliferation and growth.	[Zhao, T.; Du, H.; Ding, X.; Walls, K.; Yan, C.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Du, H.; Yan, C.] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA; [Yan, C.] Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Du, H (corresponding author), Indiana Univ Sch Med, Dept Pathol & Lab Med, 975 W Walnut St,IB424G, Indianapolis, IN 46202 USA.	hongdu@iupui.edu; coyan@iupui.edu	ding, xinchun/P-5490-2017		National Institutes of Health [CA138759, CA152099, HL087001]; NATIONAL CANCER INSTITUTE [R01CA138759, R01CA152099] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087001] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institutes of Health Grants CA138759, CA152099 (to CY) and HL087001 (to HD).	Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Ding XC, 2014, AM J PATHOL, V184, P397, DOI 10.1016/j.ajpath.2013.10.015; Du H, 2001, J LIPID RES, V42, P489; Elleder M, 2000, J HEPATOL, V32, P528, DOI 10.1016/S0168-8278(00)80407-9; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lian XM, 2005, AM J PATHOL, V167, P813, DOI 10.1016/S0002-9440(10)62053-6; Lian XM, 2004, AM J PHYSIOL-LUNG C, V286, pL801, DOI 10.1152/ajplung.00335.2003; Mandruzzato S, 2009, J IMMUNOL, V182, P6562, DOI 10.4049/jimmunol.0803831; Meyer C, 2011, P NATL ACAD SCI USA, V108, P17111, DOI 10.1073/pnas.1108121108; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Qu P, 2011, J IMMUNOL, V187, P3854, DOI 10.4049/jimmunol.1003358; Qu P, 2011, BLOOD, V117, P4476, DOI 10.1182/blood-2010-07-298380; Qu P, 2010, AM J PATHOL, V176, P2394, DOI 10.2353/ajpath.2010.091063; Qu P, 2009, LUNG CANCER, V63, P341, DOI 10.1016/j.lungcan.2008.05.025; Qu P, 2009, J IMMUNOL, V182, P1648, DOI 10.4049/jimmunol.182.3.1648; Rothe G, 1997, ATHEROSCLEROSIS, V130, P215, DOI 10.1016/S0021-9150(97)06065-6; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Wu L, 2012, BLOOD, V119, P115, DOI 10.1182/blood-2011-06-363093; Yan C, 2006, AM J PATHOL, V169, P916, DOI 10.2353/ajpath.2006.051327; Yan C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030701; Zhao T, 2010, AM J PHYSIOL-ENDOC M, V299, pE110, DOI 10.1152/ajpendo.00192.2010	31	42	42	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1938	1948		10.1038/onc.2014.143	http://dx.doi.org/10.1038/onc.2014.143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882582	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000352725600008
J	Itahana, Y; Han, R; Barbier, S; Lei, Z; Rozen, S; Itahana, K				Itahana, Y.; Han, R.; Barbier, S.; Lei, Z.; Rozen, S.; Itahana, K.			The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense	ONCOGENE			English	Article							URATE OXIDASE; IDENTIFICATION; GLUT9; INACTIVATION; REGULATOR; ARREST; FAMILY; CANCER; DAMAGE; RISK	Only humans and higher primates have high uric acid blood levels. Although high uric acid causes gout, it has been linked with human longevity because of its hypothetical antioxidant function. Recent studies reveal that p53 has significant roles in cellular metabolism. One example of this is an antioxidant function that potentially contributes to tumor suppression. Here, we reported a first beneficial link between p53 and uric acid. We identified the uric acid transporter SLC2A9 (also known as GLUT9) as a direct p53 target gene and a key downstream effector in the reduction of reactive oxygen species (ROS) through transporting uric acid as a source of antioxidant. Oxidative stress induced SLC2A9 expression in a p53-dependent manner, and inhibition of SLC2A9 by small interfering RNA (siRNA) or anti-gout drugs such as probenecid significantly increased ROS levels in an uric acid-dependent manner and greatly sensitized cancer cells to chemotherapeutic drugs. Conversely, expression of SLC2A9 reduced ROS and protected against DNA damage and cell death, suggesting its antioxidant function. The increased production of ROS because of p53 loss was rescued by SLC2A9 expression. Furthermore, decreased SLC2A9 expression was observed in several cancer types and was associated with a poorer prognosis. Our findings suggest that the p53-SLC2A9 pathway is a novel antioxidant mechanism that uses uric acid to maintain ROS homeostasis and prevent accumulation of ROS-associated damage that potentially contributes to cancer development.	[Itahana, Y.; Han, R.; Lei, Z.; Rozen, S.; Itahana, K.] Duke NUS Grad Med Sch Singapore, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Barbier, S.] Duke NUS Grad Med Sch Singapore, Ctr Quantitat Med, Off Clin Sci, Singapore 169857, Singapore; [Lei, Z.; Rozen, S.] Duke NUS Grad Med Sch Singapore, Ctr Computat Biol, Singapore 169857, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Itahana, K (corresponding author), Duke NUS Grad Med Sch Singapore, Canc & Stem Cell Biol Program, Room 07-18,Level 7,8 Coll Rd, Singapore 169857, Singapore.	koji.itahana@duke-nus.edu.sg	Rozen, Steven G./J-5939-2013; Itahana, Koji/J-5505-2013	Rozen, Steven G./0000-0002-4288-0056; Itahana, Koji/0000-0002-7241-2894	Singapore Ministry of Education AcRF Tier 2 fund [MOE2013-T2-1-123]; Duke-NUS core grant	Singapore Ministry of Education AcRF Tier 2 fund(Ministry of Education, Singapore); Duke-NUS core grant	We acknowledge funding from the Singapore Ministry of Education AcRF Tier 2 fund (MOE2013-T2-1-123) and the Duke-NUS core grant. We thank Dr Gerald Evan for providing Mdm2<SUP>+/+</SUP>; p53<SUP>ER/-</SUP> and Mdm2<SUP>-/-</SUP>; p53<SUP>ER/-</SUP> MEFs, Dr. Bert Vogelstein for HCT116 (p53<SUP>+/+</SUP>) and HCT116 (p53<SUP>-/-</SUP>) cell lines, Dr Yanping Zhang for p53 and green-fluorescent protein adenoviruses. We also thank Drs David Virshup, Patrick Casey, Kanaga Sabapathy and Paul Yen for critical reading of the manuscript. We thank Lee Guan Hwee Bernard for technical assistance.	AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Anzai N, 2008, J BIOL CHEM, V283, P26834, DOI 10.1074/jbc.C800156200; Augustin R, 2004, J BIOL CHEM, V279, P16229, DOI 10.1074/jbc.M312226200; Augustin R, 2010, IUBMB LIFE, V62, P315, DOI 10.1002/iub.315; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bibert S, 2009, AM J PHYSIOL-RENAL, V297, pF612, DOI 10.1152/ajprenal.00139.2009; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campos-Arroyo D, 2012, CANCER CHEMOTH PHARM, V69, P495, DOI 10.1007/s00280-011-1725-6; Caulfield MJ, 2008, PLOS MED, V5, P1509, DOI 10.1371/journal.pmed.0050197; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Clegg HV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038212; CUTLER RG, 1991, AM J CLIN NUTR, V53, pS373, DOI 10.1093/ajcn/53.1.373S; de Lau LML, 2005, ANN NEUROL, V58, P797, DOI 10.1002/ana.20663; Dehghan A, 2008, LANCET, V372, P1953, DOI 10.1016/S0140-6736(08)61343-4; Doring A, 2008, NAT GENET, V40, P430, DOI 10.1038/ng.107; Gottlieb E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001040; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Itahana Y, 2012, CURR DRUG TARGETS, V13, P1633, DOI 10.2174/138945012803529992; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; KELLOGG EW, 1977, J BIOL CHEM, V252, P6721; Kim TS, 2006, INT J GERIATR PSYCH, V21, P344, DOI 10.1002/gps.1469; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Li S, 2007, PLOS GENET, V3, P2156, DOI 10.1371/journal.pgen.0030194; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Matsuo H, 2008, AM J HUM GENET, V83, P744, DOI 10.1016/j.ajhg.2008.11.001; Oda M, 2002, MOL BIOL EVOL, V19, P640, DOI 10.1093/oxfordjournals.molbev.a004123; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; Pietraforte D, 2006, FREE RADICAL BIO MED, V41, P1753, DOI 10.1016/j.freeradbiomed.2006.08.014; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preitner F, 2009, P NATL ACAD SCI USA, V106, P15501, DOI 10.1073/pnas.0904411106; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; So A, 2010, J CLIN INVEST, V120, P1791, DOI 10.1172/JCI42344; Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; WU XW, 1992, J MOL EVOL, V34, P78, DOI 10.1007/BF00163854; Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3	50	61	67	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1799	1810		10.1038/onc.2014.119	http://dx.doi.org/10.1038/onc.2014.119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858040				2022-12-28	WOS:000352158000007
J	Lee, SH; Luong, R; Johnson, DT; Cunha, GR; Rivina, L; Gonzalgo, ML; Sun, Z				Lee, S. H.; Luong, R.; Johnson, D. T.; Cunha, G. R.; Rivina, L.; Gonzalgo, M. L.; Sun, Z.			Androgen signaling is a confounding factor for beta-catenin-mediated prostate tumorigenesis	ONCOGENE			English	Article							INTRAEPITHELIAL NEOPLASIA; TUMOR-SUPPRESSOR; MURINE PROSTATE; RECEPTOR; CANCER; CELL; APC; RESISTANCE; REGENERATION; ACTIVATION	Emerging evidence has demonstrated the critical roles for both androgen and Wnt pathways in prostate tumorigenesis. A recent integrative genomic analysis of human prostate cancers (PCas) has revealed a unique enrichment of androgen and Wnt signaling in early-onset PCas, implying their clinical significance in the disease. Additionally, interaction between the androgen receptor (AR) and P-catenin has long been detected in PCa cells. However, the consequence of this interaction in prostate tumorigenesis is still unknown. Because mutations in adenomatous polyposis coli, P-catenin and other components of the destruction complex are generally rare in PCas, other mechanisms of aberrant Wnt signaling activation have been speculated. To address these critical questions, we developed Ctnnb1(L(ex3)/1) /R26hAR(L/+):PB-Cre4 mice, in which transgenic AR and stabilized beta-catenin are co-expressed in prostatic epithelial cells. We observed accelerated tumor development, aggressive tumor invasion and a decreased survival rate in Ctnnb1(L(ex3)/+) /R26hAR(L/+):PB-Cre4 compound mice compared with age-matched Ctnnb1(L(ex3)/+):PB-Cre4 littermate controls, which only have stabilized P-catenin expression in the prostate. Castration of the above transgenic mice resulted in significant tumor regression, implying an essential role of androgen signaling in tumor growth and maintenance. Implantation of the prostatic epithelial cells isolated from the transgenic mice regenerated prostate intraepithelial neoplasias and prostatic adenocarcinoma lesions. Microarray analyses of transcriptional profiles showed more robust enrichment of known tumor-and metastasis-promoting genes: Spp1, Egr1, c-Myc, Sp5, and Sp6 genes, in samples isolated from Ctnnb1(L(ex3)/+)/R26hAR(L/1) :PR-Cre4 compound mice than those from Ctnnb1(L(ex3)/+):PB-Cre4 and R26hAR(L/+) :PB-Cre4 littermate controls. Together, these data demonstrate a confounding role of androgen signaling in P-catenin-initiated oncogenic transformation in prostate tumorigenesis.	[Lee, S. H.; Johnson, D. T.; Rivina, L.; Gonzalgo, M. L.; Sun, Z.] Stanford Univ, Sch Med, Dept Urol, S221,Grant Bldg,300 Pasteur Dr, Stanford, CA 94305 USA; [Luong, R.] Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA; [Cunha, G. R.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA	Stanford University; Stanford University; University of California System; University of California San Francisco	Sun, Z (corresponding author), Stanford Univ, Sch Med, Dept Urol, S221,Grant Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	zsun@stanford.edu			NIH [R01-CA070297, R01-CA151623, U01-CA166894, R21-CA190021]; NATIONAL CANCER INSTITUTE [R01CA166894, R01CA151623, U01CA166894, R21CA190021, R01CA070297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK104941] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr William Tu and Dr Chunfang Zhu for their technical assistance. This work was supported by the NIH grants R01-CA070297, R01-CA151623, U01-CA166894 and R21-CA190021.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Bruxvoort KJ, 2007, CANCER RES, V67, P2490, DOI 10.1158/0008-5472.CAN-06-3028; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2013, EUR J HUM GENET, V21, P929, DOI 10.1038/ejhg.2012.281; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; de Ronde JJ, 2013, BREAST CANCER RES TR, V137, P213, DOI 10.1007/s10549-012-2340-x; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henrique R, 2007, CLIN CANCER RES, V13, P6122, DOI 10.1158/1078-0432.CCR-07-1042; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Ibarretxe G, 2012, CELL TISSUE RES, V350, P95, DOI 10.1007/s00441-012-1459-8; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Johnson DT, 2013, J BIOL CHEM, V288, P3727, DOI 10.1074/jbc.M112.417568; Koivisto P, 1997, CANCER RES, V57, P314; Kwak MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053476; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee J, 2007, NUCLEIC ACIDS RES, V35, P4523, DOI 10.1093/nar/gkm476; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; Matusik RJ, 2008, DIFFERENTIATION, V76, P682, DOI 10.1111/j.1432-0436.2008.00276.x; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Pearson HB, 2009, CANCER RES, V69, P94, DOI 10.1158/0008-5472.CAN-08-2895; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang YZ, 2005, PROSTATE, V64, P149, DOI 10.1002/pros.20225; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	53	19	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					702	714		10.1038/onc.2015.117	http://dx.doi.org/10.1038/onc.2015.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25893287	Green Accepted			2022-12-28	WOS:000370331300004
J	Potze, L; Di Franco, S; Grandela, C; Pras-Raves, ML; Picavet, DI; van Veen, HA; van Lenthe, H; Mullauer, FB; van der Wel, NN; Luyf, A; van Kampen, AHC; Kemp, S; Everts, V; Kessler, JH; Vaz, FM; Medema, JP				Potze, L.; Di Franco, S.; Grandela, C.; Pras-Raves, M. L.; Picavet, D. I.; van Veen, H. A.; van Lenthe, H.; Mullauer, F. B.; van der Wel, N. N.; Luyf, A.; van Kampen, A. H. C.; Kemp, S.; Everts, V.; Kessler, J. H.; Vaz, F. M.; Medema, J. P.			Betulinic acid induces a novel cell death pathway that depends on cardiolipin modification	ONCOGENE			English	Article							STEAROYL-COA DESATURASE; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; GENE-EXPRESSION CHANGES; ATP CITRATE LYASE; CANCER-CELLS; FATTY-ACIDS; MASS-SPECTROMETRY; PROSTATE-CANCER; BARTH SYNDROME	Cancer is associated with strong changes in lipid metabolism. For instance, normal cells take up fatty acids (FAs) from the circulation, while tumour cells generate their own and become dependent on de novo FA synthesis, which could provide a vulnerability to target tumour cells. Betulinic acid (BetA) is a natural compound that selectively kills tumour cells through an ill-defined mechanism that is independent of BAX and BAK, but depends on mitochondrial permeability transition-pore opening. Here we unravel this pathway and show that BetA inhibits the activity of steroyl-CoA-desaturase (SCD-1). This enzyme is overexpressed in tumour cells and critically important for cells that utilize de novo FA synthesis as it converts newly synthesized saturated FAs to unsaturated FAs. Intriguingly, we find that inhibition of SCD-1 by BetA or, alternatively, with a specific SCD-1 inhibitor directly and rapidly impacts on the saturation level of cardiolipin (CL), a mitochondrial lipid that has important structural and metabolic functions and at the same time regulates mitochondria-dependent cell death. As a result of the enhanced CL saturation mitochondria of cancer cells, but not normal cells that do not depend on de novo FA synthesis, undergo ultrastructural changes, release cytochrome c and quickly induce cell death. Importantly, addition of unsaturated FAs circumvented the need for SCD-1 activity and thereby prevented BetA-induced CL saturation and subsequent cytotoxicity, supporting the importance of this novel pathway in the cytotoxicity induced by BetA.	[Potze, L.; Di Franco, S.; Grandela, C.; Mullauer, F. B.; Kessler, J. H.; Medema, J. P.] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Lab Expt Oncol & radiobiol LEXOR, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Di Franco, S.] Univ Palermo, Cellular & Mol Pathophysiol Lab, Dept Surg & Oncol Sci, Palermo, Italy; [Pras-Raves, M. L.; Luyf, A.; van Kampen, A. H. C.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Bioinformat Lab, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Picavet, D. I.; van Veen, H. A.; van der Wel, N. N.; Everts, V.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Core Facil Cellular Imaging, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [van Lenthe, H.; Kemp, S.; Vaz, F. M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; University of Palermo; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Medema, JP (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Lab Expt Oncol & radiobiol LEXOR, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.p.medema@amc.uva.nl	Kemp, Stephan/A-3935-2008; Di Franco, Simone/J-4874-2016; Di Franco, Simone/AAD-4391-2019; Van Der Wel, Nicole/AAE-7569-2020; di franco, simone/M-3714-2019	Kemp, Stephan/0000-0003-2023-064X; Di Franco, Simone/0000-0002-6217-2161; di franco, simone/0000-0002-6217-2161; Vaz, Frederic/0000-0002-9048-1041; Medema, Jan Paul/0000-0003-3045-2924	Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands	Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands(Netherlands Government)	We thank Inge Dijkstra, Rob Ofman, Femke Beers-Stet for technical assistance and Louis Vermeulen for his valuable scientific input and helpful discussions. This work was supported by a grant of the Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands (LP).	Acehan D, 2011, BIOPHYS J, V100, P2184, DOI 10.1016/j.bpj.2011.03.031; Alavian KN, 2014, P NATL ACAD SCI USA, V111, P10580, DOI 10.1073/pnas.1401591111; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; BOUGNOUX P, 1992, BREAST CANCER RES TR, V20, P185; Clarke SLN, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-23; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Engelen M, 2008, BBA-MOL CELL BIOL L, V1781, P105, DOI 10.1016/j.bbalip.2007.12.003; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; FRY M, 1981, J BIOL CHEM, V256, P1874; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Gonzalvez F, 2007, APOPTOSIS, V12, P877, DOI 10.1007/s10495-007-0718-8; Gonzalvez F, 2008, J CELL BIOL, V183, P681, DOI 10.1083/jcb.200803129; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Houtkooper RH, 2008, CELL MOL LIFE SCI, V65, P2493, DOI 10.1007/s00018-008-8030-5; Houtkooper RH, 2009, ANAL BIOCHEM, V387, P230, DOI 10.1016/j.ab.2009.01.032; Huttemann M, 2011, MITOCHONDRION, V11, P369, DOI 10.1016/j.mito.2011.01.010; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Jourdain A, 2009, INT J BIOCHEM CELL B, V41, P1884, DOI 10.1016/j.biocel.2009.05.001; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kessler JH, 2007, CANCER LETT, V251, P132, DOI 10.1016/j.canlet.2006.11.003; Kiebish MA, 2008, J LIPID RES, V49, P2545, DOI 10.1194/jlr.M800319-JLR200; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Landes T, 2011, BBA-MOL CELL RES, V1813, P540, DOI 10.1016/j.bbamcr.2011.01.021; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; Li JN, 2000, EXP CELL RES, V261, P159, DOI 10.1006/excr.2000.5054; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Lu JX, 1997, MOL CARCINOGEN, V20, P204, DOI 10.1002/(SICI)1098-2744(199710)20:2<204::AID-MC7>3.0.CO;2-M; Martinou JC, 2006, CELL DEATH DIFFER, V13, P1291, DOI 10.1038/sj.cdd.4401985; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Mullauer FB, 2011, ANTI-CANCER DRUG, V22, P223, DOI 10.1097/CAD.0b013e3283421035; Mullauer FB, 2010, ANTI-CANCER DRUG, V21, P215, DOI 10.1097/CAD.0b013e3283357c62; Mullauer FB, 2009, APOPTOSIS, V14, P191, DOI 10.1007/s10495-008-0290-x; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; OOKHTENS M, 1984, AM J PHYSIOL, V247, pR146, DOI 10.1152/ajpregu.1984.247.1.R146; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006; Patil VA, 2013, ADV EXP MED BIOL, V991, P195, DOI 10.1007/978-94-007-6331-9_11; Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pellegrini L, 2007, CELL DEATH DIFFER, V14, P1275, DOI 10.1038/sj.cdd.4402145; Potze L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.139; Ren MD, 2014, PROG LIPID RES, V55, P1, DOI 10.1016/j.plipres.2014.04.001; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; RUGGIERI S, 1979, J LIPID RES, V20, P772; Rzeski W, 2006, N-S ARCH PHARMACOL, V374, P11, DOI 10.1007/s00210-006-0090-1; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Scaglia N, 2005, J BIOL CHEM, V280, P25339, DOI 10.1074/jbc.M501159200; Scaglia N, 2005, BBA-MOL CELL BIOL L, V1687, P141, DOI 10.1016/j.bbalip.2004.11.015; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Scaglia N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006812; Schug ZT, 2009, BBA-BIOMEMBRANES, V1788, P2022, DOI 10.1016/j.bbamem.2009.05.004; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Thai SF, 2001, CARCINOGENESIS, V22, P1317, DOI 10.1093/carcin/22.8.1317; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; Valianpour F, 2003, MOL GENET METAB, V79, P189, DOI 10.1016/S1096-7192(03)00098-2; WARBURG O, 1956, SCIENCE, V124, P269; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Yahagi N, 2005, EUR J CANCER, V41, P1316, DOI 10.1016/j.ejca.2004.12.037; Zhang TJ, 2013, BBA-MOL CELL BIOL L, V1831, P1542, DOI 10.1016/j.bbalip.2013.03.001; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2	70	46	46	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					427	437		10.1038/onc.2015.102	http://dx.doi.org/10.1038/onc.2015.102			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893306				2022-12-28	WOS:000369056700003
J	Cao, LL; Wei, F; Du, Y; Song, B; Wang, D; Shen, C; Lu, X; Cao, Z; Yang, Q; Gao, Y; Wang, L; Zhao, Y; Wang, H; Yang, Y; Zhu, WG				Cao, L-L; Wei, F.; Du, Y.; Song, B.; Wang, D.; Shen, C.; Lu, X.; Cao, Z.; Yang, Q.; Gao, Y.; Wang, L.; Zhao, Y.; Wang, H.; Yang, Y.; Zhu, W-G			ATM-mediated KDM2A phosphorylation is required for the DNA damage repair	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; MRE11-RAD50-NBS1 COMPLEX; HOMOLOGOUS RECOMBINATION; HISTONE DEMETHYLASE; CELLULAR-RESPONSE; MRE11 COMPLEX; METHYLATION; PROTEIN; CHECKPOINT; PROMOTES	The ataxia-telangiectasia mutated (ATM) protein is a key signaling molecule that modulates the DNA damage response. However, the exact mechanism by which ATM regulates DNA damage repair has not yet been elucidated. Here, we report that ATM regulates the DNA damage response by phosphorylating lysine-specific demethylase 2A (KDM2A), a histone demethylase that acts at sites of H3K36 dimethylation. ATM interacts with KDM2A, and their interaction significantly increases in response to DNA double-stranded, but not single-stranded, breaks. ATM specifically phosphorylates KDM2A at threonine 632 (T632) following DNA damage, as demonstrated by a mutagenesis assay and mass spectrometric analysis. Although KDM2A phosphorylation does not alter its own demethylase activity, T632 phosphorylation of KDM2A largely abrogates its chromatin-binding capacity, and H3K36 dimethylation near DNA damage sites is significantly increased. Consequently, enriched H3K36 dimethylation serves as a platform to recruit the MRE11 complex to DNA damage sites by directly interacting with the BRCT2 domain of NBS1, which results in efficient DNA damage repair and enhanced cell survival. Collectively, our study reveals a novel mechanism for ATM in connecting histone modifications with the DNA damage response.	[Cao, L-L; Wei, F.; Du, Y.; Song, B.; Wang, D.; Shen, C.; Lu, X.; Cao, Z.; Yang, Q.; Wang, L.; Zhao, Y.; Wang, H.; Yang, Y.; Zhu, W-G] Peking Univ, Hlth Sci Ctr,Dept Biochem & Mol Biol,Sch Basic Me, Key Lab Carcinogenesis & Translat Res Minist Educ, State Key Lab Nat & Biomimet Drugs,Beijing Key La, Beijing 100871, Peoples R China; [Gao, Y.] Tsinghua Univ, Sch Biol Sci, Prot Chem Facil, Beijing 100084, Peoples R China; [Zhu, W-G] Peking Univ Tsinghua Univ Joint Ctr Life Sci, Beijing, Peoples R China	Peking University; Tsinghua University; Tsinghua University	Zhu, WG (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Xueyuan Rd 38, Beijing 100191, Peoples R China.	zhuweiguo@bjmu.edu.cn	Du, Yipeng/O-1223-2013	Lu, Xiaopeng/0000-0001-7746-5322; Zhu, Wei-Guo/0000-0001-8385-6581; Wang, Haiying/0000-0001-7729-0649	National Key Basic Research Program of China [2011CB504200, 2013CB911000]; National Natural Science Foundation of China [31070691, 81321003, 91319302]; Minister of Education of China '111 Project'	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Minister of Education of China '111 Project'	We thank Dr David J Chen at University of Texas Southwestern Medical Center for kindly providing YFP-ATM plasmid. We also thank Drs Jun Huang at Zhejiang University and Jiadong Wang at Peking University Health Science Center for kindly providing NBS1 deleted mutants. This work was supported by National Key Basic Research Program of China grant 2011CB504200, 2013CB911000; National Natural Science Foundation of China grants 31070691, 81321003, 91319302; Minister of Education of China '111 Project'.	Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Blackledge NP, 2010, MOL CELL, V38, P179, DOI 10.1016/j.molcel.2010.04.009; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Butler LR, 2012, EMBO J, V31, P3918, DOI 10.1038/emboj.2012.232; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cheng ZJ, 2014, GENE DEV, V28, P1758, DOI 10.1101/gad.246561.114; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Hari FJ, 2010, EMBO REP, V11, P387, DOI 10.1038/embor.2010.30; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Huang YF, 2015, TUMOR BIOL, V36, P271, DOI 10.1007/s13277-014-2630-5; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017; Jha DK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4965; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khoury-Haddad H, 2014, P NATL ACAD SCI USA, V111, pE728, DOI 10.1073/pnas.1317585111; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Liang CY, 2013, MOL BIOL CELL, V24, P3251, DOI 10.1091/mbc.E12-11-0820; Liang CY, 2011, NUCLEIC ACIDS RES, V39, P4151, DOI 10.1093/nar/gkr040; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Lloyd J, 2009, CELL, V139, P100, DOI 10.1016/j.cell.2009.07.043; Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107; Lu T, 2009, P NATL ACAD SCI USA, V106, P16339, DOI 10.1073/pnas.0908560106; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Musselman CA, 2011, NUCLEIC ACIDS RES, V39, P9061, DOI 10.1093/nar/gkr613; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Rass E, 2009, NAT STRUCT MOL BIOL, V16, P819, DOI 10.1038/nsmb.1641; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Tanaka Y, 2010, EMBO J, V29, P1510, DOI 10.1038/emboj.2010.56; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Wagner KW, 2013, J CLIN INVEST, V123, P5231, DOI 10.1172/JCI68642; Wang DL, 2013, P NATL ACAD SCI USA, V110, P5516, DOI 10.1073/pnas.1216596110; Wang HY, 2012, DNA REPAIR, V11, P146, DOI 10.1016/j.dnarep.2011.10.014; Wang QH, 2014, EMBO J, V33, P862, DOI 10.1002/embj.201386064; WOZNIAK AJ, 1983, CANCER RES, V43, P120; Wu LM, 2008, P NATL ACAD SCI USA, V105, P11200, DOI 10.1073/pnas.0802885105; Xie AY, 2009, NAT STRUCT MOL BIOL, V16, P814, DOI 10.1038/nsmb.1640; Xu C, 2008, J MOL BIOL, V381, P361, DOI 10.1016/j.jmb.2008.05.087; Young LC, 2013, J BIOL CHEM, V288, P21376, DOI 10.1074/jbc.M113.491514; Zhou JC, 2012, MOL CELL BIOL, V32, P479, DOI 10.1128/MCB.06332-11; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	65	46	49	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					301	313		10.1038/onc.2015.81	http://dx.doi.org/10.1038/onc.2015.81			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25823024	Bronze			2022-12-28	WOS:000369055300004
J	Malin, D; Strekalova, E; Petrovic, V; Rajanala, H; Sharma, B; Ugolkov, A; Gradishar, WJ; Cryns, VL				Malin, D.; Strekalova, E.; Petrovic, V.; Rajanala, H.; Sharma, B.; Ugolkov, A.; Gradishar, W. J.; Cryns, V. L.			ERK-regulated alpha B-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; BREAST-CANCER; INDUCED APOPTOSIS; ACTIVATION; RESISTANCE; CARCINOMA; MARKER; EXPRESSION; CASPASE-3; MORPHOGENESIS	Evasion of extracellular matrix detachment-induced apoptosis ('anoikis') is a defining characteristic of metastatic tumor cells. The ability of metastatic carcinoma cells to survive matrix detachment and escape anoikis enables them to disseminate as viable circulating tumor cells and seed distant organs. Here we report that alpha B-crystallin, an antiapoptotic molecular chaperone implicated in the pathogenesis of diverse poor-prognosis solid tumors, is induced by matrix detachment and confers anoikis resistance. Specifically, we demonstrate that matrix detachment downregulates extracellular signal-regulated kinase (ERK) activity and increases alpha B-crystallin protein and messenger RNA (mRNA) levels. Moreover, we show that ERK inhibition in adherent cancer cells mimics matrix detachment by increasing alpha B-crystallin protein and mRNA levels, whereas constitutive ERK activation suppresses alpha B-crystallin induction during matrix detachment. These findings indicate that ERK inhibition is both necessary and sufficient for alpha B-crystallin induction by matrix detachment. To examine the functional consequences of alpha B-crystallin induction in anoikis, we stably silenced alpha B-crystallin in two different metastatic carcinoma cell lines. Strikingly, silencing alpha B-crystallin increased matrix detachment-induced caspase activation and apoptosis but did not affect cell viability of adherent cancer cells. In addition, silencing alpha B-crystallin in metastatic carcinoma cells reduced the number of viable circulating tumor cells and inhibited lung metastasis in two orthotopic models, but had little or no effect on primary tumor growth. Taken together, our findings point to alpha B-crystallin as a novel regulator of anoikis resistance that is induced by matrix detachment-mediated suppression of ERK signaling and promotes lung metastasis. Our results also suggest that alpha B-crystallin represents a promising molecular target for antimetastatic therapies.	[Malin, D.; Strekalova, E.; Petrovic, V.; Rajanala, H.; Sharma, B.; Cryns, V. L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Carbone Canc Ctr, Madison, WI 53705 USA; [Ugolkov, A.] Northwestern Univ, Ctr Dev Therapeut, Evanston, IL USA; [Gradishar, W. J.] Northwestern Univ, Dept Med, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA	University of Wisconsin System; University of Wisconsin Madison; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Cryns, VL (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Carbone Canc Ctr, MFCB 4144,1685 Highland Ave, Madison, WI 53705 USA.	vlcryns@medicine.wisc.edu	Ugolkov, Andrey/T-3012-2019	Rajanala, Sai Harisha/0000-0002-7096-3756; SHARMA, BHAWNA/0000-0002-4570-2335	Susan G. Komen; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	Susan G. Komen(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Dr Janet Price for providing the MDA-MB-435-LvBr1 cell line. We also thank Dr Caroline Alexander and members of the Cryns lab for their critical reading of the manuscript. Breast Cancer Research Foundation (VLC and WJG), Susan G. Komen for the Cure Postdoctoral Fellowship Award (DM and VP) and P30CA014520 University of Wisconsin Comprehensive Cancer Center core facility support.	Arrigo AP, 2014, CANCERS, V6, P333, DOI 10.3390/cancers6010333; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Brunquell C, 2012, MOL CANCER RES, V10, P1482, DOI 10.1158/1541-7786.MCR-12-0144; Chelouche-Lev D, 2004, CANCER-AM CANCER SOC, V100, P2543, DOI 10.1002/cncr.20304; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841; Frankel A, 2001, CANCER RES, V61, P4837; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gorges TM, 2013, CANCER IMMUNOL IMMUN, V62, P931, DOI 10.1007/s00262-012-1387-1; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Huang XY, 2013, HEPATOLOGY, V57, P2235, DOI 10.1002/hep.26255; Ivanov O, 2008, BREAST CANCER RES TR, V111, P411, DOI 10.1007/s10549-007-9796-0; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095; Kim HS, 2011, J BREAST CANCER, V14, P14, DOI 10.4048/jbc.2011.14.1.14; Laguinge LM, 2008, CANCER RES, V68, P909, DOI 10.1158/0008-5472.CAN-06-1806; Malin D, 2014, CLIN CANCER RES, V20, DOI 10.1158/1078-0432.CCR-13-1255; Malin D, 2011, CLIN CANCER RES, V17, P5005, DOI 10.1158/1078-0432.CCR-11-0099; Mao Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-101; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Nam DH, 2008, CLIN CANCER RES, V14, P4059, DOI 10.1158/1078-0432.CCR-07-4039; PINDER SE, 1994, J PATHOL, V174, P209, DOI 10.1002/path.1711740310; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sitterding SM, 2008, ANN DIAGN PATHOL, V12, P33, DOI 10.1016/j.anndiagpath.2007.02.004; Stegh AH, 2008, P NATL ACAD SCI USA, V105, P10703, DOI 10.1073/pnas.0712034105; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989	40	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5626	5634		10.1038/onc.2015.12	http://dx.doi.org/10.1038/onc.2015.12			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25684139	Green Accepted			2022-12-28	WOS:000364594300004
J	Jin, R; Yamashita, H; Yu, X; Wang, J; Franco, OE; Wang, Y; Hayward, SW; Matusik, RJ				Jin, R.; Yamashita, H.; Yu, X.; Wang, J.; Franco, O. E.; Wang, Y.; Hayward, S. W.; Matusik, R. J.			Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression	ONCOGENE			English	Article							TRAIL-INDUCED APOPTOSIS; LYMPH-NODE METASTASES; SPLICE VARIANTS; NUCLEAR-LOCALIZATION; ANTITUMOR-ACTIVITY; CHROMOGRANIN-A; SOLID TUMORS; PROGRESSION; ACTIVATION; MECHANISMS	Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are associated with the development of castration-resistant prostate cancer (CRPC), including resistance to the new generation of high-affinity anti-androgens. However, the mechanism by which ARV expression is regulated is not fully understood. In this study, we show that the activation of classical nuclear factor-kappa B (NF-kappa B) signaling increases the expression of ARVs in prostate cancer (PCa) cells and converts androgen-sensitive PCa cells to become androgen-insensitive, whereas downregulation of NF-kappa B signaling inhibits ARV expression and restores responsiveness of CRPC to anti-androgen therapy. In addition, we demonstrated that combination of anti-androgen with NF-kappa B-targeted therapy inhibits efficiently tumor growth of human CRPC xenografts. These results indicate that induction of ARVs by activated NF-kappa B signaling in PCa cells is a critical mechanism by which the PCa progresses to CRPC. This has important implications as it can prolong the survival of CRPC patients by restoring the tumors to once again respond to conventional androgen-deprivation therapy (ADT).	[Jin, R.; Yamashita, H.; Yu, X.; Wang, J.; Franco, O. E.; Wang, Y.; Hayward, S. W.; Matusik, R. J.] Vanderbilt Univ, Med Ctr, Vanderbilt Prostate Canc Ctr, Dept Urol Surg, Nashville, TN 37232 USA	Vanderbilt University	Jin, R (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Prostate Canc Ctr, Dept Urol Surg, A1329,MCN,1161 21st Ave South, Nashville, TN 37232 USA.	renjie.jin@vanderbilt.edu		Matusik, Robert/0000-0003-2057-9892; Yamashita, Hironobu/0000-0003-2587-7100; Hayward, Simon/0000-0002-6059-6550; Yu, Xiuping/0000-0003-2844-7026	Department of Defense (DOD) Prostate Cancer Research Program (PCRP) [W81XWH-10-1-0236]; National Cancer Institute [4R01 CA076142-14]; Frances Preston Laboratories of the TJ Martell Foundation; NATIONAL CANCER INSTITUTE [R01CA076142] Funding Source: NIH RePORTER	Department of Defense (DOD) Prostate Cancer Research Program (PCRP); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Frances Preston Laboratories of the TJ Martell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Martin Leverkus (University of Magdeburg, Germany) for providing us with IKK2-EE and IKK2-KD retroviral vectors, and Tom C Case and Manik Paul for technical assistance. This work was supported to RJ by the Department of Defense (DOD) Prostate Cancer Research Program (PCRP; W81XWH-10-1-0236); to RJM by the National Cancer Institute (4R01 CA076142-14) and the Frances Preston Laboratories of the TJ Martell Foundation.	Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Akfirat C, 2013, J PATHOL, V230, P291, DOI 10.1002/path.4180; Berruti A, 2005, ENDOCR-RELAT CANCER, V12, P109, DOI 10.1677/erc.1.00876; Claessens Frank, 2008, Nucl Recept Signal, V6, pe008, DOI 10.1621/nrs.06008; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; di Sant'Agnese PA, 1998, PROSTATE, P74; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141; Domingo-Domenech J, 2005, BRIT J CANCER, V93, P1285, DOI 10.1038/sj.bjc.6602851; Domingo-Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078-0432.CCR-05-2767; Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995; Gannon PO, 2013, EUR J CANCER, V49, P2441, DOI 10.1016/j.ejca.2013.02.026; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Ismail H, 2004, PROSTATE, V58, P308, DOI 10.1002/pros.10335; Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008-5472.CAN-08-0107; Jin RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060983; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Kraft AS, 2011, CANCER BIOL THER, V12, P119, DOI 10.4161/cbt.12.2.15723; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Lessard L, 2006, CLIN CANCER RES, V12, P5741, DOI 10.1158/1078-0432.CCR-06-0330; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; McCall P, 2012, BRIT J CANCER, V107, P1554, DOI 10.1038/bjc.2012.372; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Morris MJ, 2007, J UROLOGY, V178, P2378, DOI 10.1016/j.juro.2007.08.015; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Setlur SR, 2007, CANCER RES, V67, P10296, DOI 10.1158/0008-5472.CAN-07-2173; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2005, UROLOGY, V66, P386, DOI 10.1016/j.urology.2005.03.040; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727	61	62	64	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3700	3710		10.1038/onc.2014.302	http://dx.doi.org/10.1038/onc.2014.302			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25220414	Green Accepted			2022-12-28	WOS:000357679100008
J	Du, W; Elemento, O				Du, W.; Elemento, O.			Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies	ONCOGENE			English	Review							CELL LUNG-CANCER; BREAST-CANCER; CLONAL EVOLUTION; DNA METHYLATION; IN-VIVO; INTRATUMOR HETEROGENEITY; TUMOR HETEROGENEITY; GENOMIC INSTABILITY; GENE; RESISTANCE	The transformation of normal cells into cancer cells and maintenance of the malignant state and phenotypes are associated with genetic and epigenetic deregulations, altered cellular signaling responses and aberrant interactions with the microenvironment. These alterations are constantly evolving as tumor cells face changing selective pressures induced by the cells themselves, the microenvironment and drug treatments. Tumors are also complex ecosystems where different, sometime heterogeneous, subclonal tumor populations and a variety of nontumor cells coexist in a constantly evolving manner. The interactions between molecules and between cells that arise as a result of these alterations and ecosystems are even more complex. The cancer research community is increasingly embracing this complexity and adopting a combination of systems biology methods and integrated analyses to understand and predictively model the activity of cancer cells. Systems biology approaches are helping to understand the mechanisms of tumor progression and design more effective cancer therapies. These approaches work in tandem with rapid technological advancements that enable data acquisition on a broader scale, with finer accuracy, higher dimensionality and higher throughput than ever. Using such data, computational and mathematical models help identify key deregulated functions and processes, establish predictive biomarkers and optimize therapeutic strategies. Moving forward, implementing patient-specific computational and mathematical models of cancer will significantly improve the specificity and efficacy of targeted therapy, and will accelerate the adoption of personalized and precision cancer medicine.	[Elemento, O.] Weill Cornell Med Coll, Lab Canc Syst Biol, Sandra & Edward Meyer Canc Ctr, Dept Physiol & Biophys,Inst Computat Biomed, New York, NY 10021 USA; Weill Cornell Med Coll, Inst Precis Med, New York, NY 10021 USA	Cornell University; Cornell University	Elemento, O (corresponding author), Weill Cornell Med Coll, Lab Canc Syst Biol, Sandra & Edward Meyer Canc Ctr, Dept Physiol & Biophys,Inst Computat Biomed, 1305 York Ave, New York, NY 10021 USA.	ole2001@med.cornell.edu			NIH; CAREER Grant from National Science Foundation; Starr Cancer Consortium; Hirschl Trust	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CAREER Grant from National Science Foundation; Starr Cancer Consortium; Hirschl Trust	We gratefully acknowledge insightful comments from Dr Yanwen Jiang (Elemento lab) and our anonymous reviewer. We also thank other members in the laboratory and Physiology, Biophysics and Systems Biology program of Weill Cornell Graduate School for helpful discussions. This work was supported by NIH, CAREER Grant from National Science Foundation, Starr Cancer Consortium and Hirschl Trust.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basanta D, 2012, MOL PHARMACEUT, V9, P914, DOI 10.1021/mp200458e; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Burstein HJ, 2005, NEW ENGL J MED, V353, P1652, DOI 10.1056/NEJMp058197; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Casado P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003573; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheng WY, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005974; Choe SC, 2011, SCI REP-UK, V1, DOI 10.1038/srep00031; Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Costello JC, 2014, NAT BIOTECHNOL; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Eikenberry S, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000362; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Eswaran J, 2012, SCI REP-UK, V2, DOI 10.1038/srep00264; Faratian D, 2009, CANCER RES, V69, P6713, DOI 10.1158/0008-5472.CAN-09-0777; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Harris TJR, 2010, NAT REV CLIN ONCOL, V7, P251, DOI 10.1038/nrclinonc.2010.41; Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Horvath A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02256; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Hu J, 2013, NAT BIOTECHNOL, V31, P522, DOI 10.1038/nbt.2530; Jahchan NS, 2013, CANCER DISCOV, V3, P1364, DOI 10.1158/2159-8290.CD-13-0183; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kahlert C, 2014, BRIT J CANCER, V110, P441, DOI 10.1038/bjc.2013.745; Karr JR, 2012, CELL, V150, P389, DOI 10.1016/j.cell.2012.05.044; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Keutgen XM, 2012, CLIN CANCER RES, V18, P2032, DOI 10.1158/1078-0432.CCR-11-2487; Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110; Kirouac DC, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004008; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korolev KS, 2014, NAT REV CANCER, V14, P371, DOI 10.1038/nrc3712; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Leder K, 2014, CELL, V156, P603, DOI 10.1016/j.cell.2013.12.029; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446; Margolin AA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006112; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McFarland CD, 2013, P NATL ACAD SCI USA, V110, P2910, DOI 10.1073/pnas.1213968110; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Niepel M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004379; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Oved K, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.15; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pan H, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.634.634; Park ES, 2011, P NATL ACAD SCI USA, V108, P17456, DOI 10.1073/pnas.1114210108; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Pierobon M, 2015, ONCOGENE, V34, P805, DOI 10.1038/onc.2014.16; Pike BL, 2008, LEUKEMIA, V22, P1035, DOI 10.1038/leu.2008.18; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reth M, 2004, NAT REV IMMUNOL, V4, P269, DOI 10.1038/nri1335; Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sheehan KM, 2008, ONCOGENE, V27, P323, DOI 10.1038/sj.onc.1210647; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Spurrier B, 2008, NAT PROTOC, V3, P1796, DOI 10.1038/nprot.2008.179; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Vakoc BJ, 2009, NAT MED, V15, P1219, DOI 10.1038/nm.1971; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vandin F, 2011, J COMPUT BIOL, V18, P507, DOI 10.1089/cmb.2010.0265; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Venkatasubramanian R, 2010, BRIT J CANCER, V103, P486, DOI 10.1038/sj.bjc.6605773; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wagner JP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003994; Wang K, 2009, NAT BIOTECHNOL, V27, P829, DOI 10.1038/nbt.1563; Wang YG, 2014, NAT MATER, V13, P204, DOI [10.1038/nmat3819, 10.1038/NMAT3819]; Wargo AR, 2007, P NATL ACAD SCI USA, V104, P19914, DOI 10.1073/pnas.0707766104; Wistuba II, 2011, NAT REV CLIN ONCOL, V8, P135, DOI 10.1038/nrclinonc.2011.2; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100; Wu YM, 2013, SCI REP-UK, V3, P1, DOI [10.1038/srep03248, 10.1038/srep02326]; Wu Y, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002355; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67	139	84	84	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3215	3225		10.1038/onc.2014.291	http://dx.doi.org/10.1038/onc.2014.291			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25220419				2022-12-28	WOS:000356592300001
J	Morris, SM; Carter, KT; Baek, JY; Koszarek, A; Yeh, MM; Knoblaugh, SE; Grady, WM				Morris, S. M.; Carter, K. T.; Baek, J. Y.; Koszarek, A.; Yeh, M. M.; Knoblaugh, S. E.; Grady, W. M.			TGF-beta signaling alters the pattern of liver tumorigenesis induced by Pten inactivation	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; EMBRYONIC STEM-CELLS; RECEPTOR C-KIT; CYCLIN D1; CARCINOMA; EXPRESSION; CANCER; DIFFERENTIATION; ROLES; MOUSE	Hepatocarcinogenesis results from the accumulation of genetic and epigenetic changes in liver cells. A common mechanism through which these alterations induce liver cancer is by deregulating signaling pathways. A number of signaling pathways, including the PI3K/PTEN/AKT and transforming growth factor beta (TGF-beta) pathways have been implicated in normal liver development as well as in cancer formation. In this study, we assessed the effect of the TGF-beta signaling pathway on liver tumors induced by phosphatase and tensin homolog (Pten) loss. Inactivation of only the TGF-beta receptor type II, Tgfbr2, in the mouse liver (Tgfbr2(LKO)) had no overt phenotype, while inactivation of Pten alone (Pten(LKO)), resulted in the formation of both hepatocellular carcinomas and cholangiocarcinomas (CC). Interestingly, deletion of both Pten and Tgfbr2 (Pten(LKO); Tgfbr2(LKO)) in the mouse liver resulted in a dramatic shift in tumor type to predominantly CC. Assessment of the PI3K/PTEN/AKT pathway revealed increased phosphorylation of AKT and glycogen synthase kinase 3 beta (GSK-3 beta) in both the Pten(LKO) and Pten(LKO); Tgfbr2(LKO) mice, suggesting that this pathway is constitutively active regardless of the status of the TGF-beta signaling pathway. However, phosphorylation of p70 S6 kinase was observed in the liver of all three phenotypes (Tgfbr2(LKO), Pten(LKO), Pten(LKO); Tgfbr2(LKO)) indicating that the loss of Tgfbr2 and/or Pten leads to an increase in this signaling pathway. Analysis of markers of liver progenitor/stem cells revealed that the loss of TGF-beta signaling resulted in increased expression of c-Kit and CD133. Furthermore, in addition to increased c-Kit and CD133, Scf and EpCam expression were also increased in the double knock-out mice. These results suggest that the alteration in tumor types between the Pten(LKO) mice and Pten(LKO); Tgfbr2(LKO) mice is secondary to the altered regulation of stem-cell features induced by the loss of TGF-beta signaling.	[Morris, S. M.; Carter, K. T.; Koszarek, A.; Grady, W. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Baek, J. Y.] Natl Canc Ctr, Res Inst & Hosp, Ctr Colorectal Canc, Goyang, South Korea; [Yeh, M. M.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; [Knoblaugh, S. E.] Fred Hutchinson Canc Res Ctr, Comparat Med, Seattle, WA 98109 USA; [Grady, W. M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; National Cancer Center - Korea (NCC); University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA.	wgrady@fhcrc.org			Burroughs Wellcome Fund; National Institutes of Health [RO1 DK60669-01, P30 CA015704]; National Institutes of Health Interdisciplinary Training Grant [T32 CA080416]; Experimental Histopathology, Scientific Imaging and Comparative Medicine Cores at the Fred Hutchinson Cancer Research Center; NATIONAL CANCER INSTITUTE [T32CA080416, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060669] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health Interdisciplinary Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Experimental Histopathology, Scientific Imaging and Comparative Medicine Cores at the Fred Hutchinson Cancer Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported in part by funding from Burroughs Wellcome Fund, the National Institutes of Health (RO1 DK60669-01 and P30 CA015704, WMG) and by the National Institutes of Health Interdisciplinary Training Grant (T32 CA080416, SMM). The authors thank Jean Campbell and members of the Grady laboratory for helpful suggestions. We also wish to acknowledge support from the Experimental Histopathology, Scientific Imaging and Comparative Medicine Cores at the Fred Hutchinson Cancer Research Center.	Amin Rupen, 2008, Gastrointest Cancer Res, V2, pS27; Attisano Liliana, 2013, F1000Prime Rep, V5, P17, DOI 10.12703/P5-17; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Cai J, 2007, HEPATOLOGY, V45, P1229, DOI 10.1002/hep.21582; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Clotman F, 2005, GENE DEV, V19, P1849, DOI 10.1101/gad.340305; Deschl U, 2001, INT CLASSIFICATION R, P59; Fabregat I, 2009, WORLD J GASTROENTERO, V15, P513, DOI 10.3748/wjg.15.513; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Galicia VA, 2010, GASTROENTEROLOGY, V139, P2170, DOI 10.1053/j.gastro.2010.09.002; Herrera B, 2012, CURR PHARM DESIGN, V18, P4114, DOI 10.2174/138161212802430503; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hu TH, 2003, CANCER, V97, P1929, DOI 10.1002/cncr.11266; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim H, 2004, J HEPATOL, V40, P298, DOI 10.1016/j.jhep.2003.10.023; Kitisin K, 2007, ONCOGENE, V26, P7103, DOI 10.1038/sj.onc.1210513; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Luo SM, 2005, WORLD J GASTROENTERO, V11, P4272; Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114; Mansuroglu T, 2009, EUR J GASTROEN HEPAT, V21, P1206, DOI 10.1097/MEG.0b013e328317f4ef; Mansuroglu T, 2009, LAB INVEST, V89, P562, DOI 10.1038/labinvest.2009.15; Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29; Morris SM, 2012, HEPATOLOGY, V55, P121, DOI 10.1002/hep.24653; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Peyrou M, 2010, WORLD J GASTROENTERO, V16, P4627, DOI 10.3748/wjg.v16.i37.4627; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Romero-Gallo J, 2005, ONCOGENE, V24, P3028, DOI 10.1038/sj.onc.1208475; Rountree CB, 2009, STEM CELLS, V27, P290, DOI 10.1634/stemcells.2008-0332; Shi YJ, 2012, J CELL SCI, V125, P4687, DOI 10.1242/jcs.093765; Shiraki N, 2008, GENES CELLS, V13, P731, DOI 10.1111/j.1365-2443.2008.01201.x; Singal AK, 2011, J CANCER RES CLIN, V137, P1071, DOI 10.1007/s00432-010-0971-z; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Sugimachi K, 2001, J HEPATOL, V35, P74, DOI 10.1016/S0168-8278(01)00079-4; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; WENNERBERG AE, 1993, AM J PATHOL, V143, P1050; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Wu X, 2012, LIVER TUMORS, P37; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yeh MM, 2010, J GASTROEN HEPATOL, V25, P1485, DOI 10.1111/j.1440-1746.2010.06430.x; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3; Zhou L, 2006, WORLD J GASTROENTERO, V12, P1175, DOI 10.3748/wjg.v12.i8.1175	52	17	18	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3273	3282		10.1038/onc.2014.258	http://dx.doi.org/10.1038/onc.2014.258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132272	Green Accepted			2022-12-28	WOS:000356592300006
J	Kurklu, B; Whitehead, RH; Ong, EK; Minamoto, T; Fox, JG; Mann, JR; Judd, LM; Giraud, AS; Menheniott, TR				Kurklu, B.; Whitehead, R. H.; Ong, E. K.; Minamoto, T.; Fox, J. G.; Mann, J. R.; Judd, L. M.; Giraud, A. S.; Menheniott, T. R.			Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer	ONCOGENE			English	Article							DNA METHYLATION; TUMOR-SUPPRESSOR; T-CELLS; EXPRESSION; GENES; HYPERMETHYLATION; PROTEINS; ENHANCER; COLITIS; ABSENCE	Runt domain transcription factor 3 (RUNX3) is widely regarded as a tumour-suppressor gene inactivated by DNA hypermethylation of its canonical CpG (cytidine-phosphate-guanidine) island (CGI) promoter in gastric cancer (GC). Absence of RUNX3 expression from normal gastric epithelial cells (GECs), the progenitors to GC, coupled with frequent RUNX3 overexpression in GC progression, challenge this longstanding paradigm. However, epigenetic models to better describe RUNX3 deregulation in GC have not emerged. Here, we identify lineage-specific DNA methylation at an alternate, non-CGI promoter (P1) as a new mechanism of RUNX3 epigenetic control. In normal GECs, P1 was hypermethylated and repressed, whereas in immune lineages P1 was hypomethylated and widely expressed. In human GC development, we detected aberrant P1 hypomethylation signatures associated with the early inflammatory, preneoplastic and tumour stages. Aberrant P1 hypomethylation was fully recapitulated in mouse models of gastric inflammation and tumorigenesis. Cell sorting showed that P1 hypomethylation reflects altered cell-type composition of the gastric epithelium/tumour microenvironment caused by immune cell recruitment, not methylation loss. Finally, via long-term culture of gastric tumour epithelium, we revealed that de novo methylation of the RUNX3 canonical CGI promoter is a bystander effect of oncogenic immortalization and not likely causal in GC pathogenesis as previously argued. We propose a new model of RUNX3 epigenetic control in cancer, based on immune-specific, non-CGI promoter hypomethylation. This novel epigenetic signature may have utility in early detection of GC and possibly other epithelial cancers with premalignant immune involvement.	[Kurklu, B.; Ong, E. K.; Mann, J. R.; Judd, L. M.; Giraud, A. S.; Menheniott, T. R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Infect & Immun, Parkville, Vic 3052, Australia; [Kurklu, B.; Whitehead, R. H.; Judd, L. M.; Giraud, A. S.; Menheniott, T. R.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Minamoto, T.] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 920, Japan; [Fox, J. G.] MIT, Div Comparat Med, Dept Biol Engn, Cambridge, MA 02139 USA; [Mann, J. R.] Univ Melbourne, Dept Zool, Melbourne, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Kanazawa University; Massachusetts Institute of Technology (MIT); University of Melbourne	Menheniott, TR (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Infect & Immun, Flemington Rd, Parkville, Vic 3052, Australia.	treve.menheniott@mcri.edu.au	Menheniott, Treve/D-7964-2015	Menheniott, Treve/0000-0003-2349-8238; Judd, Louise/0000-0003-3613-4839	National Health and Medical Research Council (NH&MRC) of Australia [1006542]; Victorian Government's Medical Research Operational Infrastructure Program; Grants-in-Aid for Scientific Research [25670572] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [P01CA028842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	National Health and Medical Research Council (NH&MRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Medical Research Operational Infrastructure Program; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Professor Y Groner and Dr D Levanon (The Weizmann Institute of Science, Rehovot, Israel) for their gift of anti-Runx3 antiserum and critical reviews of the manuscript. We thank Professor I van Driel (University of Melbourne, Australia) for providing H+/K+ ATPase-gmcsf transgenic mice and Professor M Ernst (Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia) for providing gp130<SUP>F/F</SUP> mice. We thank Dr J Dabritz (Murdoch Children's Research Institute) for critically reviewing the manuscript. This work was supported by a project grant (1006542) awarded to TRM by the National Health and Medical Research Council (NH&MRC) of Australia and by the Victorian Government's Medical Research Operational Infrastructure Program.	Biondo M, 2001, J IMMUNOL, V166, P2090, DOI 10.4049/jimmunol.166.3.2090; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; CORREA P, 1975, LANCET, V2, P58; Dedeurwaerder S, 2012, ONCOIMMUNOLOGY, V1, P962, DOI 10.4161/onci.19996; Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fan XY, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-92; Ferlay J, 2013, IARC CANCERBASE; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356; Hoffmann Werner, 2013, Front Biosci (Schol Ed), V5, P720; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hu SL, 2011, MED ONCOL, V28, P447, DOI 10.1007/s12032-010-9467-6; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Jackson CB, 2007, J PATHOL, V213, P140, DOI 10.1002/path.2218; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kalesnikoff J, 2011, METHODS MOL BIOL, V677, P207, DOI 10.1007/978-1-60761-869-0_15; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Lai CB, 2012, J BIOL CHEM, V287, P7324, DOI 10.1074/jbc.M111.306936; Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442; Lee KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030786; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Levanon D, 2014, MOL CELL BIOL, V34, P1158, DOI 10.1128/MCB.01202-13; Levanon D, 2011, EMBO MOL MED, V3, P593, DOI 10.1002/emmm.201100168; Li J, 2004, J CLIN PATHOL, V57, P294, DOI 10.1136/jcp.2003.013011; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Menheniott TR, 2010, GASTROENTEROLOGY, V138, P1823, DOI 10.1053/j.gastro.2010.01.050; Peterson AJ, 2010, GASTROENTEROLOGY, V139, P2005, DOI 10.1053/j.gastro.2010.08.043; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Schier S, 2005, ONCOLOGY-BASEL, V69, P9, DOI 10.1159/000086625; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Schmid CA, 2013, GASTROENTEROLOGY, V144, P22, DOI 10.1053/j.gastro.2012.11.014; Schmidl C, 2009, GENOME RES, V19, P1165, DOI 10.1101/gr.091470.109; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; So K, 2006, PATHOL INT, V56, P571, DOI 10.1111/j.1440-1827.2006.02010.x; Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Sugai M, 2011, J IMMUNOL, V186, P6515, DOI 10.4049/jimmunol.1001671; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Whitehead RH, 2003, CULTURE HUMAN TUMOR, P68; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yeoh KG, 2007, J GASTROEN HEPATOL, V22, P970, DOI 10.1111/j.1440-1746.2007.04956.x	53	17	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2856	2866		10.1038/onc.2014.233	http://dx.doi.org/10.1038/onc.2014.233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088199	Green Published, Green Accepted			2022-12-28	WOS:000355324300005
J	Spaargaren, M; de Rooij, MFM; Kater, AP; Eldering, E				Spaargaren, M.; de Rooij, M. F. M.; Kater, A. P.; Eldering, E.			BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future	ONCOGENE			English	Review							BRUTONS TYROSINE KINASE; B-CELL-RECEPTOR; X-LINKED AGAMMAGLOBULINEMIA; TOLL-LIKE-RECEPTOR; FACTOR-KAPPA-B; BETA-GAMMA-SUBUNITS; MEDIATED ACTIVATION; NUCLEAR-FACTOR; PHASE-II; PHOSPHOLIPASE C-GAMMA-2	The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise. Especially the early clinical success of Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK), has received widespread attention. In this review we will focus on the fundamental and clinical aspects of BTK inhibitors in CLL, with emphasis on Ibrutinib as the best studied of this class of drugs. Furthermore, we summarize recent laboratory as well as clinical findings relating to the first cases of Ibrutinib resistance. Finally, we address combination strategies with Ibrutinib, and attempt to extrapolate its current status to the near future in the clinic.	[Spaargaren, M.; de Rooij, M. F. M.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Spaargaren, M.; Kater, A. P.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Lymphoma & Myeloma Ctr Amsterdam LYMMCARE, NL-1105 AZ Amsterdam, Netherlands; [Kater, A. P.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands; [Eldering, E.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Spaargaren, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	marcel.spaargaren@amc.uva.nl; e.eldering@amc.uva.nl	Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109	Pharmacyclics	Pharmacyclics	MS has received research support from Pharmacyclics. The other authors declare no conflict of interest.	Advani R, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.8012; Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Amrein PC, 2011, CLIN CANCER RES, V17, P2977, DOI 10.1158/1078-0432.CCR-10-2879; Anderson MA, 2013, BLOOD, V122; Antony P, 2004, BIOCHEM SOC T, V32, P113, DOI 10.1042/BST0320113; Apor E, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.4163.4163; Ashworth T, 2007, J IMMUNOL, V178, P2631, DOI 10.4049/jimmunol.178.5.2631; Axelrod M, 2014, LEUKEMIA, V28, P407, DOI 10.1038/leu.2013.249; Bagnara D, 2011, BLOOD, V117, P5463, DOI 10.1182/blood-2010-12-324210; Brown JR, 2014, BLOOD, V123, P3390, DOI 10.1182/blood-2013-11-535047; Brown JR, 2013, BLOOD, V122; Burger JA, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.866.866; Burger JA, 2014, SEMIN CANCER BIOL, V24, P71, DOI 10.1016/j.semcancer.2013.08.011; Burger JA, 2011, HEMATOL-AM SOC HEMAT, P96, DOI 10.1182/asheducation-2011.1.96; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; CAMPANA D, 1990, J IMMUNOL, V145, P1675; Chang BY, 2013, BLOOD, V122, P2412, DOI 10.1182/blood-2013-02-482125; Cheng S, 2014, LEUKEMIA, V28, P649, DOI 10.1038/leu.2013.358; Cheson BD, 2012, J CLIN ONCOL, V30, P2820, DOI 10.1200/JCO.2012.43.3748; Coelho V, 2013, BLOOD, V122, P2664, DOI 10.1182/blood-2013-02-485425; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Cramer P, 2011, NAT REV CLIN ONCOL, V8, P38, DOI 10.1038/nrclinonc.2010.167; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; DAZZI F, 1995, CLIN IMMUNOL IMMUNOP, V75, P26, DOI 10.1006/clin.1995.1048; de Diego RP, 2006, J ALLERGY CLIN IMMUN, V117, P1462, DOI 10.1016/j.jaci.2006.01.037; de Gorter DJJ, 2007, IMMUNITY, V26, P93, DOI 10.1016/j.immuni.2006.11.012; de Gorter DJJ, 2007, J IMMUNOL, V178, P1405, DOI 10.4049/jimmunol.178.3.1405; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; de Weerdt I, 2013, LEUKEMIA RES, V37, P838, DOI 10.1016/j.leukres.2013.03.011; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dubovsky JA, 2013, BLOOD, V122, P2539, DOI 10.1182/blood-2013-06-507947; Duhren-von Minden M, 2012, NATURE, V489, P309, DOI 10.1038/nature11309; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; Faderl S, 2006, CANCER-AM CANCER SOC, V107, P916, DOI 10.1002/cncr.22097; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; Fowler N, 2010, BLOOD, V116, P425; Furman RR, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.4914.4914; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Futatani T, 2001, BRIT J HAEMATOL, V114, P141, DOI 10.1046/j.1365-2141.2001.02905.x; Gagliardi MC, 2003, CLIN EXP IMMUNOL, V133, P115, DOI 10.1046/j.1365-2249.2003.t01-1-02178.x; GENEVIER HC, 1994, EUR J IMMUNOL, V24, P3100, DOI 10.1002/eji.1830241228; Genevier HC, 1997, CLIN EXP IMMUNOL, V110, P386, DOI 10.1046/j.1365-2249.1997.4581478.x; Ghia P, 2007, AUTOIMMUN REV, V7, P127, DOI 10.1016/j.autrev.2007.02.014; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2013, BLOOD, V122, P3723, DOI 10.1182/blood-2013-05-498287; Hantschel O, 2007, P NATL ACAD SCI USA, V104, P13283, DOI 10.1073/pnas.0702654104; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Herman SEM, 2014, LEUKEMIA, V28, P2188, DOI 10.1038/leu.2014.122; Herman SEM, 2013, LEUKEMIA, V27, P2311, DOI 10.1038/leu.2013.131; Herman SEM, 2014, BLOOD, V123, P3286, DOI 10.1182/blood-2014-02-548610; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Hoogeboom R, 2013, J EXP MED, V210, P59, DOI 10.1084/jem.20121801; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Improgo R, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.670.670; Jefferies CA, 2004, IMMUNOL LETT, V92, P15, DOI 10.1016/j.imlet.2003.11.017; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jongstra-Bilen J, 2008, J IMMUNOL, V181, P288, DOI 10.4049/jimmunol.181.1.288; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Karlin L, 2013, ASH ANN M, V122, P676; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kelley TW, 2004, LEUKEMIA RES, V28, P845, DOI 10.1016/j.leukres.2003.12.010; Kil LP, 2013, AM J BLOOD RES, V3, P71; Kil LP, 2012, BLOOD, V119, P3744, DOI 10.1182/blood-2011-12-397919; Kim YJ, 2004, MOL CELL BIOL, V24, P9986, DOI 10.1128/MCB.24.22.9986-9999.2004; Kohrt HE, 2014, BLOOD, V123, P1957, DOI 10.1182/blood-2014-01-547869; Kremer AN, 2014, BIOL BLOOD MARROW TR, V20, P742, DOI 10.1016/j.bbmt.2014.02.005; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Lowry WE, 2002, J BIOL CHEM, V277, P1488, DOI 10.1074/jbc.M110390200; Martensson IL, 2002, SEMIN IMMUNOL, V14, P335, DOI 10.1016/S1044-5323(02)00066-0; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; MENSINK EJBM, 1986, EUR J IMMUNOL, V16, P963, DOI 10.1002/eji.1830160815; Messina M, 2014, BLOOD, V123, P2378, DOI 10.1182/blood-2013-10-534271; Messmer BT, 2004, J EXP MED, V200, P519, DOI 10.1084/jem.20040544; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI200523409; Middendorp S, 2003, J IMMUNOL, V171, P5988, DOI 10.4049/jimmunol.171.11.5988; Monroe JG, 2008, IMMUNITY, V28, P729, DOI 10.1016/j.immuni.2008.05.006; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Connor OA, 2005, J CLIN ONCOL, V23, P676, DOI 10.1200/JCO.2005.02.050; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oda A, 2000, BLOOD, V95, P1663; Ouillette P, 2013, CLIN CANCER RES, V19, P2893, DOI 10.1158/1078-0432.CCR-13-0138; Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Pascutti MF, 2013, BLOOD, V122, P3010, DOI 10.1182/blood-2012-11-467670; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Pospisilova S, 2012, LEUKEMIA, V26, P1458, DOI 10.1038/leu.2012.25; Rajaiya J, 2005, MOL CELL BIOL, V25, P2073, DOI 10.1128/MCB.25.6.2073-2084.2005; Rajaiya J, 2006, MOL CELL BIOL, V26, P4758, DOI 10.1128/MCB.02009-05; Ramadani F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001104; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Ricks JL, 2013, J CLIN ONCOL, V31, DOI 10.1200/jco.2013.31.31_suppl.7; Ridderstad A, 1996, J IMMUNOL, V157, P3357; Rock J, 2007, EUR J IMMUNOL, V37, P3564, DOI 10.1002/eji.200737711; Rossi D, 2014, BLOOD, V123, P2139, DOI 10.1182/blood-2013-11-539726; Rozkova D, 2010, INT J CANCER, V126, P1132, DOI 10.1002/ijc.24832; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; SCHMID C, 1994, HISTOPATHOLOGY, V24, P445, DOI 10.1111/j.1365-2559.1994.tb00553.x; Schulzke JD, 2009, ANN NY ACAD SCI, V1165, P294, DOI 10.1111/j.1749-6632.2009.04062.x; Seymour JF, 2013, BLOOD, V122; Sharma S, 2009, J IMMUNOL, V182, P329, DOI 10.4049/jimmunol.182.1.329; Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Souwer Y, 2009, BRIT J HAEMATOL, V145, P334, DOI 10.1111/j.1365-2141.2009.07625.x; Spaargaren M, 2003, J EXP MED, V198, P1539, DOI 10.1084/jem.20011866; Spaner DE, 2007, LEUKEMIA, V21, P53, DOI 10.1038/sj.leu.2404456; Stevenson FK, 2011, BLOOD, V118, P4313, DOI 10.1182/blood-2011-06-338855; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; van Gent R, 2008, CANCER RES, V68, P10137, DOI 10.1158/0008-5472.CAN-08-2325; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Webb CF, 2000, J IMMUNOL, V165, P6956, DOI 10.4049/jimmunol.165.12.6956; Wierda WG, 2010, J CLIN ONCOL, V28, P1749, DOI 10.1200/JCO.2009.25.3187; Wiestner A, 2012, BLOOD, V120, P4684, DOI 10.1182/blood-2012-05-423194; Wolska A, 2013, LEUKEMIA LYMPHOMA, V54, P1268, DOI 10.3109/10428194.2012.741233; Woyach JA, 2014, BLOOD, V123, P1810, DOI 10.1182/blood-2013-09-527853; Woyach JA, 2014, BLOOD, V123, P1207, DOI 10.1182/blood-2013-07-515361; Yang G, 2013, BLOOD, V122, P1222, DOI 10.1182/blood-2012-12-475111; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Yu L, 2008, BLOOD, V111, P4617, DOI 10.1182/blood-2007-10-121137; Zenz T, 2008, BLOOD, V112, P3322, DOI 10.1182/blood-2008-04-154070; Zenz T, 2009, BLOOD, V114, P2589, DOI 10.1182/blood-2009-05-224071; Zorn CN, 2009, CELL SIGNAL, V21, P79, DOI 10.1016/j.cellsig.2008.09.010	144	23	23	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2426	2436		10.1038/onc.2014.181	http://dx.doi.org/10.1038/onc.2014.181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24954503				2022-12-28	WOS:000354190400002
J	Espinosa, L; Margalef, P; Bigas, A				Espinosa, L.; Margalef, P.; Bigas, A.			Non-conventional functions for NF-kappa B members: the dark side of NF-kappa B	ONCOGENE			English	Review							DEPENDENT GENE-EXPRESSION; SQUAMOUS-CELL CARCINOMAS; CHAIN ASSEMBLY COMPLEX; TUMOR-NECROSIS-FACTOR; NUCLEAR IKK ACTIVITY; KINASE-ALPHA; NF-KAPPA-B2 P100; SIGNALING PATHWAY; UBIQUITIN LIGASE; MICE LACKING	NF-kappa B pathway exerts an essential function in the regulation of the immune response, which has been the nucleus of numerous studies for the past 25 years. Both activation of the pathway and termination of the NF-kappa B response are tightly regulated events, which is essential to prevent exacerbated inflammatory responses. Thus, alterations in NF-kappa B regulatory elements might result in tissue damage and cancer in different systems. In addition, several of the proteins involved in NF-kappa B regulation display additional, and much less studied, functions that connect with specific NF-kappa B-unrelated pathways. Many of these pathways are in turn regulators of particular physiologic and/or pathologic responses. Which are the principal non-conventional functions that have been identified for specific NF-kappa B elements, how they connect with other signaling pathways and what is their potential impact on cancer is the focus of this review.	[Espinosa, L.; Margalef, P.; Bigas, A.] Inst Hosp del Mar Invest Med IMIM, Stem Cells & Canc Res Lab, Barcelona 08003, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Espinosa, L (corresponding author), Inst Hosp del Mar Invest Med IMIM, Stem Cells & Canc Res Lab, Dr Aiguader 88, Barcelona 08003, Spain.	lespinosa@imim.es	Bigas, Anna/A-7457-2014; Espinosa, Lluis/ABA-4564-2020	Espinosa, Lluis/0000-0002-2897-4099; Bigas, Anna/0000-0003-4801-6899	AGAUR [SGR23]; ISCIII [PI13/00448]; RTICC [RD12/0036/0054]	AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); ISCIII(Instituto de Salud Carlos III); RTICC(Instituto de Salud Carlos III)	We thank the members of our laboratory for helpful discussions. This work has been supported by AGAUR (SGR23), ISCIII (PI13/00448) and RTICC (RD12/0036/0054).	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Comb WC, 2011, ONCOGENE, V30, P1727, DOI 10.1038/onc.2010.553; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Descargues P, 2008, P NATL ACAD SCI USA, V105, P2487, DOI 10.1073/pnas.0712044105; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Fernandez-Majada V, 2007, CELL CYCLE, V6, P1748, DOI 10.4161/cc.6.14.4429; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hao L, 2010, ONCOGENE, V29, P201, DOI 10.1038/onc.2009.323; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li L, 2011, J EXP MED, V208, P787, DOI 10.1084/jem.20091346; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Li QS, 2013, NAT MED, V19, P722, DOI 10.1038/nm.3190; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Liu L, 2006, J BIOL CHEM, V281, P1506, DOI 10.1074/jbc.M510402200; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Margalef P, 2012, CELL REP, V2, P840, DOI 10.1016/j.celrep.2012.08.028; Marinari B, 2008, P NATL ACAD SCI USA, V105, P17091, DOI 10.1073/pnas.0809288105; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mulero MC, 2013, CANCER CELL, V24, P1; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; O'Donnell MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041238; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park E, 2007, CANCER RES, V67, P9158, DOI 10.1158/0008-5472.CAN-07-0590; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Prajapati S, 2006, CELL CYCLE, V5, P2371, DOI 10.4161/cc.5.20.3359; Rao P, 2010, NATURE, V466, P1115, DOI 10.1038/nature09283; Rebholz B, 2007, IMMUNITY, V27, P296, DOI 10.1016/j.immuni.2007.05.024; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakamoto K, 2013, ONCOGENE, V32, P1854, DOI 10.1038/onc.2012.192; Schrofelbauer B, 2012, MOL CELL, V47, P111, DOI 10.1016/j.molcel.2012.04.020; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shiha VFS, 2009, P NATL ACAD SCI USA, V106, P9619, DOI 10.1073/pnas.0812367106; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suzuki K, 2008, CELL, V134, P485, DOI 10.1016/j.cell.2008.05.050; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Temmerman ST, 2012, J CLIN INVEST, V122, P315, DOI 10.1172/JCI42534; Teo HL, 2010, NAT CELL BIOL, V12, P758, DOI 10.1038/ncb2080; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsuchiya Y, 2010, MOL CELL, V39, P570, DOI 10.1016/j.molcel.2010.07.030; Tu Z, 2006, J BIOL CHEM, V281, P6699, DOI 10.1074/jbc.M512439200; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wuerzberger-Davis SM, 2011, IMMUNITY, V34, P188, DOI 10.1016/j.immuni.2011.01.014; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012; Zhu F, 2007, MOL CELL, V27, P214, DOI 10.1016/j.molcel.2007.05.042	96	20	20	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2279	2287		10.1038/onc.2014.188	http://dx.doi.org/10.1038/onc.2014.188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24975576				2022-12-28	WOS:000353824800001
J	Mucaj, V; Lee, SS; Skuli, N; Giannoukos, DN; Qiu, B; Eisinger-Mathason, TSK; Nakazawa, MS; Shay, JES; Gopal, PP; Venneti, S; Lal, P; Minn, AJ; Simon, MC; Mathew, LK				Mucaj, V.; Lee, S. S.; Skuli, N.; Giannoukos, D. N.; Qiu, B.; Eisinger-Mathason, T. S. K.; Nakazawa, M. S.; Shay, J. E. S.; Gopal, P. P.; Venneti, S.; Lal, P.; Minn, A. J.; Simon, M. C.; Mathew, L. K.			MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma	ONCOGENE			English	Article							GENE-EXPRESSION; HYPOXIA; MIR-124; PROLIFERATION; PATHWAY; GLIOMA; RADIOTHERAPY; PROGRESSION	Glioblastomas are aggressive adult brain tumors, characterized by inadequately organized vasculature and consequent nutrient and oxygen (O-2)-depleted areas. Adaptation to low nutrients and hypoxia supports glioblastoma cell survival, progression and therapeutic resistance. However, specific mechanisms promoting cellular survival under nutrient and O-2 deprivation remain incompletely understood. Here, we show that miR-124 expression is negatively correlated with a hypoxic gene signature in glioblastoma patient samples, suggesting that low miR-124 levels contribute to pro-survival adaptive pathways in this disease. As miR-124 expression is repressed in various cancer types (including glioblastoma), we quantified miR-124 abundance in normoxic and hypoxic regions in glioblastoma patient tissue, and investigated whether ectopic miR-124 expression compromises cell survival during tumor ischemia. Our results indicate that miR-124 levels are further diminished in hypoxic/ischemic regions within individual glioblastoma patient samples, compared with regions replete in O-2 and nutrients. Importantly, we also show that increased miR-124 expression affects the ability of tumor cells to survive under O-2 and/or nutrient deprivation. Moreover, miR-124 re-expression increases cell death in vivo and enhances the survival of mice bearing intracranial xenograft tumors. miR-124 exerts this phenotype in part by directly regulating TEAD1, MAPK14/p38a and SERP1, factors involved in cell proliferation and survival under stress. Simultaneous suppression of these miR-124 targets results in similar levels of cell death as caused by miR-124 restoration. Importantly, we further demonstrate that SERP1 reintroduction reverses the hypoxic cell death elicited by miR-124, indicating the importance of SERP1 in promoting tumor cell survival. In support of our experimental data, we observed a significant correlation between high SERP1 levels and poor patient outcome in glioblastoma patients. Collectively, among the many pro-tumorigeneic properties of miR-124 repression in glioblastoma, we delineated a novel role in promoting tumor cell survival under stressful microenvironments, thereby supporting tumor progression.	[Mucaj, V.; Lee, S. S.; Skuli, N.; Giannoukos, D. N.; Qiu, B.; Eisinger-Mathason, T. S. K.; Nakazawa, M. S.; Shay, J. E. S.; Minn, A. J.; Simon, M. C.; Mathew, L. K.] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lee, S. S.; Skuli, N.; Giannoukos, D. N.; Simon, M. C.; Mathew, L. K.] Univ Penn, Howard Hughes Med Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Skuli, N.] Inst Claudius Regaud, INSERM U1037, Toulouse, France; [Gopal, P. P.; Venneti, S.; Lal, P.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; University of Pennsylvania; Pennsylvania Medicine	Simon, MC (corresponding author), Univ Penn, Dept Cell & Dev Biol, Sch Med, Abramson Family Canc Res Inst,Howard Hughes Med I, 456 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021	Shay, Jessica/0000-0001-7799-1349; Gopal, Pallavi/0000-0003-4708-8479; Minn, Andy/0000-0003-1418-0906; Qiu, Bo/0000-0003-4199-1659	Howard Hughes Medical Institute; National Institutes of Health [T32 GM-07229, F31CA174211]; NATIONAL CANCER INSTITUTE [F31CA174211, K08CA181475, R01CA172651, F30CA177106, P01CA104838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Hongwei Yu for assistance with histological preparations, Dr Jeremy Rich for providing the patient-derived tumor sphere cells, Dr Stephen Prouty for assistance with Laser-Capture Microdissection and the Simon laboratory for helpful discussions. This work was funded by the Howard Hughes Medical Institute and the National Institutes of Health (T32 GM-07229; F31CA174211). MCS is an investigator of the Howard Hughes Medical Institute.	Amberger-Murphy V, 2009, CURR CANCER DRUG TAR, V9, P381, DOI 10.2174/156800909788166637; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Ben-Hamo R, 2011, GENOME MED, V3, DOI 10.1186/gm293; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cloninger C, 2011, MOL CANCER THER, V10, P2244, DOI 10.1158/1535-7163.MCT-11-0478; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Evans SM, 2010, TRANSL ONCOL, V3, P160, DOI 10.1593/tlo.09265; Gao FB, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-25; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Hori O, 2006, MOL CELL BIOL, V26, P4257, DOI 10.1128/MCB.02055-05; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kang K, 2013, J BIOL CHEM, V288, P25414, DOI 10.1074/jbc.M113.460287; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Krex D, 2007, BRAIN, V130, P2596, DOI 10.1093/brain/awm204; Lawson SK, 2013, MOL CELL BIOL, V33, P127, DOI 10.1128/MCB.00695-12; Li D, 2011, OMICS, V15, P673, DOI 10.1089/omi.2011.0064; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023461; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Malt AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045498; Mathew LK, 2014, P NATL ACAD SCI USA, V111, P291, DOI 10.1073/pnas.1314341111; Nelson PT, 2006, RNA, V12, P187, DOI 10.1261/rna.2258506; Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Sonntag KC, 2012, EXP NEUROL, V235, P427, DOI 10.1016/j.expneurol.2011.11.035; Spence AM, 2008, CLIN CANCER RES, V14, P2623, DOI 10.1158/1078-0432.CCR-07-4995; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wu ZF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047270; Yamaguchi A, 1999, J CELL BIOL, V147, P1195, DOI 10.1083/jcb.147.6.1195; Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	41	45	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2204	2214		10.1038/onc.2014.168	http://dx.doi.org/10.1038/onc.2014.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24954504	Green Accepted			2022-12-28	WOS:000353473000006
J	Robichaux, JP; Hallett, RM; Fuseler, JW; Hassell, JA; Ramsdell, AF				Robichaux, J. P.; Hallett, R. M.; Fuseler, J. W.; Hassell, J. A.; Ramsdell, A. F.			Mammary glands exhibit molecular laterality and undergo left-right asymmetric ductal epithelial growth in MMTV-cNeu mice	ONCOGENE			English	Article							MESSENGER-RNA EXPRESSION; BREAST-CANCER PATIENTS; NEOADJUVANT CHEMOTHERAPY; CANDIDATE BIOMARKERS; KINASE-1 PLK1; RESISTANCE; CELLS; STATHMIN; SURVIVIN; FOXM1	Significant left-right (L-R) differences in tumor incidence and disease outcome occur for cancers of paired organs, including the breasts; however, the basis for this laterality is unknown. Here, we show that despite their morphologic symmetry, left versus right mammary glands in wild-type mice have baseline differences in gene expression that are L-R independently regulated during pubertal development, including genes that regulate luminal progenitor cell renewal, luminal cell differentiation, mammary tumorigenesis, tamoxifen sensitivity and chemotherapeutic resistance. In MMTV-cNeu(Tg/Tg) mice, which model HER2/Neu-amplified breast cancer, baseline L-R differences in mammary gene expression are amplified, sustained or inverted in a gene-specific manner and the mammary ductal epithelium undergoes L-R asymmetric growth and patterning. Comparative genomic analysis of mouse L-R mammary gene expression profiles with gene expression profiles of human breast tumors revealed significant linkage between right-sided gene expression and decreased breast cancer patient survival. Collectively, these findings are the first to demonstrate that mammary glands are lateralized organs, and, moreover, that mammary glands have L-R differential susceptibility to HER2/Neu oncogene-mediated effects on ductal epithelial growth and differentiation. We propose that intrinsic molecular laterality may have a role in L-R asymmetric breast tumor incidence and, furthermore, that interplay between the L-R molecular landscape and oncogene activity may contribute to the differential disease progression and patient outcome that are associated with tumor situs.	[Robichaux, J. P.; Ramsdell, A. F.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA; [Robichaux, J. P.; Ramsdell, A. F.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Hallett, R. M.; Hassell, J. A.] McMaster Univ, Ctr Funct Genom, Dept Biochem Biomed Sci, Hamilton, ON, Canada; [Fuseler, J. W.; Ramsdell, A. F.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29208 USA; [Ramsdell, A. F.] Univ S Carolina, Coll Arts & Sci, Program Womens & Gender Studies, Columbia, SC 29208 USA	Medical University of South Carolina; Medical University of South Carolina; McMaster University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Ramsdell, AF (corresponding author), Univ S Carolina, Sch Med, Dept Cell Biol & Anat, 6439 Garners Ferry Rd,Bldg 1,RM C-36, Columbia, SC 29208 USA.	ramsdell@musc.edu		Ramsdell, Ann F/0000-0003-2469-7079; Robichaux, Jacqulyne/0000-0001-8812-7054	National Institutes of Health [K02HL086737, R21HD068993]; Cancer Center Support Grant [P30CA138313]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD068993] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA138313] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL086737] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Scott Argraves, Dr Jeremey Barth and Mr Victor Fresco of the MUSC Proteogenomics Facility for performing the DNA microarray and Dr Caroline Alexander and Dr Elizabeth Yeh for helpful discussion. This work was supported by National Institutes of Health K02HL086737 (AFR), R21HD068993 (AFR) and conducted in facilities supported, in part, by Cancer Center Support Grant P30CA138313 to the Hollings Cancer Center, MUSC.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Baquero MT, 2012, CANCER-AM CANCER SOC, V118, P4660, DOI 10.1002/cncr.27453; Biro FM, 2013, J ADOLESCENT HEALTH, V52, pS15, DOI 10.1016/j.jadohealth.2012.09.019; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Brill B, 2008, LAB ANIM-UK, V42, P104, DOI 10.1258/la.2007.06003e; Cao XC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056735; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Cheng Y, 2014, MOL CANCER THER, V13, P675, DOI 10.1158/1535-7163.MCT-13-0416; Chintapalli VR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032577; Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943; Colas E, 2011, INT J CANCER, V129, P2435, DOI 10.1002/ijc.25901; Dalgin GS, 2008, J UROLOGY, V180, P1126, DOI 10.1016/j.juro.2008.04.137; de Wit M, 2014, J PROTEOMICS, V99, P26, DOI 10.1016/j.jprot.2014.01.001; DELAHUNT B, 1994, UROLOGY, V43, P300, DOI 10.1016/0090-4295(94)90070-1; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Eccles SA, 2011, INT J DEV BIOL, V55, P685, DOI 10.1387/ijdb.113396se; El Hajj P, 2013, BRIT J CANCER, V108, P1641, DOI 10.1038/bjc.2013.115; Falkenius J, 2013, MELANOMA RES, V23, P452, DOI 10.1097/CMR.0000000000000027; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fatima N, 2013, ASIAN PAC J CANCER P, V14, P43, DOI 10.7314/APJCP.2013.14.1.43; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Fenton SE, 2012, ANNU REV PHARMACOL, V52, P455, DOI 10.1146/annurev-pharmtox-010611-134659; Flanagan JM, 2013, ANN ONCOL, V24, P2813, DOI 10.1093/annonc/mdt370; Fuseler JW, 2014, ANTICANCER RES, V34, P1171; Gakiopoulou H, 2007, BRIT J CANCER, V97, P1124, DOI 10.1038/sj.bjc.6603992; Gasnereau I, 2012, AM J PATHOL, V180, P131, DOI 10.1016/j.ajpath.2011.09.040; Gheibi A, 2012, Adv Biomed Res, V1, P80, DOI 10.4103/2277-9175.102990; Golding JP, 2004, GENE EXPR PATTERNS, V5, P3, DOI 10.1016/j.modgep.2004.08.004; Golding JP, 2004, DEV DYNAM, V231, P795, DOI 10.1002/dvdy.20176; Hallett RM, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-16; Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227; Han ZX, 2013, CANCER BIOTHER RADIO, V28, P398, DOI 10.1089/cbr.2012.1323; HARTVEIT F, 1984, ONCOLOGY, V41, P149, DOI 10.1159/000225812; Hatzis C, JAMA, V305, P1873; Hsu I, 2014, CARCINOGENESIS, V35, P651, DOI 10.1093/carcin/bgt348; Hu KJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3107; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Hwang JE, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-431; Imai K, 2011, BRIT J CANCER, V104, P300, DOI 10.1038/sj.bjc.6606052; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Journe F, 2011, BRIT J CANCER, V105, P1726, DOI 10.1038/bjc.2011.451; Kaneko N, 2013, BIOL PHARM BULL, V36, P1921, DOI 10.1248/bpb.b13-00515; King SI, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3136; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Li A, 2013, ONCOL REP, V29, P535, DOI 10.3892/or.2012.2144; Li WJ, 2013, MOL BIOL REP, V40, P6143, DOI 10.1007/s11033-013-2725-x; Lindsay J, 2008, CTS-CLIN TRANSL SCI, V1, P107, DOI 10.1111/j.1752-8062.2008.00041.x; Liu WJ, 2012, MOL MED REP, V6, P607, DOI 10.3892/mmr.2012.966; Maire V, 2013, CANCER RES, V73, P813, DOI 10.1158/0008-5472.CAN-12-2633; Maynadier M, 2012, MOL CELL ENDOCRINOL, V364, P126, DOI 10.1016/j.mce.2012.08.016; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Meng XL, 2012, GENET TEST MOL BIOMA, V16, P689, DOI 10.1089/gtmb.2011.0298; Miceli C, 2013, CANCER GENE THER, V20, P298, DOI 10.1038/cgt.2013.21; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Mobasheri A, 2014, J MAMMARY GLAND BIOL, V19, P91, DOI 10.1007/s10911-013-9312-6; Mohanan S, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/895343; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Pasini A, 2012, TRANSL ONCOL, V5, P461, DOI 10.1593/tlo.12256; Petrarca CR, 2011, CLIN BREAST CANCER, V11, P129, DOI 10.1016/j.clbc.2011.03.002; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Roychoudhuri R, 2006, CANCER CAUSE CONTROL, V17, P655, DOI 10.1007/s10552-005-0615-9; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Su D, 2009, CANCER-AM CANCER SOC, V115, P2453, DOI 10.1002/cncr.24282; Teh MT, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00146; Valladares-Ayerbes M, 2010, CANCER EPIDEM BIOMAR, V19, P1432, DOI 10.1158/1055-9965.EPI-10-0123; Veltmaat JM, 2006, DEVELOPMENT, V133, P2325, DOI 10.1242/dev.02394; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wang QP, 2013, INT J BIOCHEM CELL B, V45, P2036, DOI 10.1016/j.biocel.2013.06.026; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001; Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439; Wierer M, 2013, CELL REP, V3, P2021, DOI 10.1016/j.celrep.2013.05.024; Wilting J, 2011, CURR MED CHEM, V18, P5519, DOI 10.2174/092986711798347252; Yamashita J, 2012, ACTA DERM-VENEREOL, V92, P593, DOI 10.2340/00015555-1416; Yoruk O, 2009, INT J NEUROSCI, V119, P815, DOI 10.1080/00207450802329639; Zhang EY, 2013, J PROTEOME RES, V12, P2805, DOI 10.1021/pr4001527; Zhang M, TARGET ONCOL; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047; Zhao YC, 2014, MOL MED REP, V9, P614, DOI 10.3892/mmr.2013.1842; Zou J, 2013, CELL CYCLE, V12, P14; Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217	87	13	14	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					2003	2010		10.1038/onc.2014.149	http://dx.doi.org/10.1038/onc.2014.149			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24909172	Green Accepted			2022-12-28	WOS:000352725600014
J	Sharif, GM; Schmidt, MO; Yi, C; Hu, Z; Haddad, BR; Glasgow, E; Riegel, AT; Wellstein, A				Sharif, G. M.; Schmidt, M. O.; Yi, C.; Hu, Z.; Haddad, B. R.; Glasgow, E.; Riegel, A. T.; Wellstein, A.			Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling	ONCOGENE			English	Article							CONTACT INHIBITION; SIZE-CONTROL; TENASCIN-C; STEM-CELLS; METASTASIS; YAP; ANGIOGENESIS; ZEBRAFISH; BIOLOGY; PROGRESSION	Metastasis of cancer cells involves multiple steps, including their dissociation from the primary tumor and invasion through the endothelial cell barrier to enter the circulation and finding their way to distant organ sites where they extravasate and establish metastatic lesions. Deficient contact inhibition is a hallmark of invasive cancer cells, yet surprisingly the vascular invasiveness of commonly studied cancer cell lines is regulated by the density at which cells are propagated in culture. Cells grown at high density were less effective at invading an endothelial monolayer than cells grown at low density. This phenotypic difference was also observed in a zebrafish model of vascular invasion of cancer cells after injection into the yolk sac and extravasation of cancer cells into tissues from the vasculature. The vascular invasive phenotypes were reversible. A kinome-wide RNA interference screen was used to identify drivers of vascular invasion by panning small hairpin RNA (shRNA) library-transduced noninvasive cancer cell populations on endothelial monolayers. The selection of invasive subpopulations showed enrichment of shRNAs targeting the large tumor suppressor 1 (LATS1) kinase that inhibits the activity of the transcriptional coactivator yes-associated protein (YAP) in the Hippo pathway. Depletion of LATS1 from noninvasive cancer cells restored the invasive phenotype. Complementary to this, inhibition or depletion of YAP inhibited invasion in vitro and in vivo. The vascular invasive phenotype was associated with a YAP-dependent upregulation of the cytokines IL6, IL8 and C-X-C motif ligand 1, 2 and 3. Antibody blockade of cytokine receptors inhibited invasion and confirmed that they are rate-limiting drivers that promote cancer cell vascular invasiveness and could provide therapeutic targets.	[Sharif, G. M.; Schmidt, M. O.; Yi, C.; Hu, Z.; Haddad, B. R.; Glasgow, E.; Riegel, A. T.; Wellstein, A.] Georgetown Univ, Lombardi Canc Ctr, 3970 Reservoir Rd, Washington, DC 20057 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Lombardi Canc Ctr, 3970 Reservoir Rd, Washington, DC 20057 USA.	wellstea@georgetown.edu	Schmidt, Marcel/AAV-8054-2021	Schmidt, Marcel/0000-0002-3991-2766; Sharif, Ghada/0000-0001-5344-3575; Glasgow, Eric/0000-0001-7729-3954	NIH/NCI [CA71508, CA113477, CA51008]; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA071508, T32CA009686, R01CA113477, P50CA058185, R01CA108440, R01CA101811, R33CA177466] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Joan Massague kindly provided the MDA-MB-231 derivative cell lines used here. We thank Caroline E Laverriere for excellent assistance with the zebrafish experiments. Work was supported by NIH/NCI grant CA71508 (AW) and CA113477 (ATR) and CA51008 for zebrafish and mouse studies.	Abassi YA, 2009, CHEM BIOL, V16, P712, DOI 10.1016/j.chembiol.2009.05.011; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Al-Otaiby M, 2012, AM J PATHOL, V180, P1474, DOI 10.1016/j.ajpath.2011.12.032; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Erez N, 2011, INT J CANCER, V128, P2536, DOI 10.1002/ijc.26032; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Greten FR, 2014, CELL, V158, P11, DOI 10.1016/j.cell.2014.06.021; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Iorns E, 2012, BREAST CANCER RES TR, V135, P79, DOI 10.1007/s10549-012-2068-7; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Melo SA, 2013, NAT CELL BIOL, V15, P139, DOI 10.1038/ncb2684; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Nance J, 2014, J CELL BIOL, V206, P823, DOI 10.1083/jcb.201407064; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; O'Connell JT, 2011, P NATL ACAD SCI USA, V108, P16002, DOI 10.1073/pnas.1109493108; Oehlers SHB, 2010, DEV COMP IMMUNOL, V34, P352, DOI 10.1016/j.dci.2009.11.007; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rasanen K, 2012, CANCER DISCOV, V2, P775, DOI 10.1158/2159-8290.CD-12-0312; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stoletov K, 2008, ONCOGENE, V27, P4509, DOI 10.1038/onc.2008.95; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tassi E, 2011, AM J PATHOL, V179, P2220, DOI 10.1016/j.ajpath.2011.07.043; van der Aa LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012384; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	57	45	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2015	34	48					5879	5889		10.1038/onc.2015.44	http://dx.doi.org/10.1038/onc.2015.44			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VC0NX	25772246	Green Accepted			2022-12-28	WOS:000426437000001
J	Rohatgi, RA; Janusis, J; Leonard, D; Bellve, KD; Fogarty, KE; Baehrecke, EH; Corvera, S; Shaw, LM				Rohatgi, R. A.; Janusis, J.; Leonard, D.; Bellve, K. D.; Fogarty, K. E.; Baehrecke, E. H.; Corvera, S.; Shaw, L. M.			Beclin 1 regulates growth factor receptor signaling in breast cancer	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE COMPLEXES; EARLY ENDOSOMES; AUTOPHAGY; GENE; TUMORIGENESIS; TRAFFICKING; TRANSFERRIN; METASTASIS; MATURATION; MEMBRANE	Beclin 1 is a haploinsufficient tumor suppressor that is decreased in many human tumors. The function of beclin 1 in cancer has been attributed primarily to its role in the degradative process of macroautophagy. However, beclin 1 is a core component of the vacuolar protein sorting 34 (Vps34)/class III phosphatidylinositoI-3 kinase (PI3KC3) and Vps15/p150 complex that regulates multiple membrane-trafficking events. In the current study, we describe an alternative mechanism of action for beclin 1 in breast cancer involving its control of growth factor receptor signaling. We identify a specific stage of early endosome maturation that is regulated by beclin 1, the transition of APPL1-containing phosphatidyIinositol 3-phosphate-negative (PI3P(-)) endosomes to PI3P(+) endosomes. Beclin 1 regulates PI3P production in response to growth factor stimulation to control the residency time of growth factor receptors in the PI3P(-)/APPL(+)-signaling-competent compartment. As a result, suppression of BECN1 sustains growth factor-stimulated AKT and ERK activation resulting in increased breast carcinoma cell invasion. In human breast tumors, beclin 1 expression is inversely correlated with AKT and ERK phosphorylation. Our data identify a novel role for beclin 1 in regulating growth factor signaling and reveal a mechanism by which loss of beclin 1 expression would enhance breast cancer progression.	[Rohatgi, R. A.; Janusis, J.; Baehrecke, E. H.; Shaw, L. M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Leonard, D.; Corvera, S.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; [Bellve, K. D.; Fogarty, K. E.] Univ Massachusetts, Sch Med, Biomed Imaging Grp, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Shaw, LM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01605 USA.	leslie.shaw@umassmed.edu			National Institute of Health (NIH) [CA142782, CA177167, DK60564, CA159314]; NATIONAL CANCER INSTITUTE [R01CA177167, R01CA159314, R01CA142782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK060564] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institute of Health (NIH) grants CA142782 and CA177167 (LMS), DK60564 (SC) and CA159314 (EHB). We thank Lawrence M Lifshitz and Clive Standley of the UMass Biomedical Imaging Group for their contributions to the programs used to analyze the TESM data. We thank Sha Zhu for assistance with cloning, Usha Acharya for assistance with the PI3P lipid measurements and Chung-Cheng Hsieh for statistical advice.	Arboleda MJ, 2003, CANCER RES, V63, P196; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dong M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0355-0; Dutta Dipannita, 2012, Cell Logist, V2, P203; Er EE, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004015; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; Hayakawa A, 2006, P NATL ACAD SCI USA, V103, P11928, DOI 10.1073/pnas.0508832103; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033; Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Lee MH, 2008, BIOCHEMISTRY-US, V47, P11682, DOI 10.1021/bi801451f; Leonard D, 2008, J CELL SCI, V121, P3445, DOI 10.1242/jcs.031484; Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98; Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Lorincz P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/851349; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Navaroli DM, 2012, P NATL ACAD SCI USA, V109, pE471, DOI 10.1073/pnas.1115495109; Pankratz SL, 2009, J BIOL CHEM, V284, P2031, DOI 10.1074/jbc.M804776200; Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Platta HW, 2011, CURR OPIN CELL BIOL, V23, P393, DOI 10.1016/j.ceb.2011.03.008; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Resnik JL, 1998, CANCER RES, V58, P1159; Ryu JY, 2014, CELL REP, V7, P1227, DOI 10.1016/j.celrep.2014.04.006; Schenck A, 2008, CELL, V133, P486, DOI 10.1016/j.cell.2008.02.044; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Shravage BV, 2013, DEVELOPMENT, V140, P1321, DOI 10.1242/dev.089490; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; Wang JR, 2013, J INEQUAL APPL, P1, DOI 10.1186/1029-242X-2013-308; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zoncu R, 2009, CELL, V136, P1110, DOI 10.1016/j.cell.2009.01.032	47	50	55	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5352	5362		10.1038/onc.2014.454	http://dx.doi.org/10.1038/onc.2014.454			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25639875	Green Accepted			2022-12-28	WOS:000363479200005
J	Bugide, S; David, D; Nair, A; Kannan, N; Samanthapudi, VSK; Prabhakar, J; Manavathi, B				Bugide, S.; David, D.; Nair, A.; Kannan, N.; Samanthapudi, V. S. K.; Prabhakar, J.; Manavathi, B.			Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics	ONCOGENE			English	Article							CALPAIN-MEDIATED PROTEOLYSIS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; KINASE FAK; MICROTUBULE; CANCER; MOTILITY; SRC; INTEGRINS; SURVIVAL	The scaffolding protein, hematopoietic PBX-interacting protein (HPIP/PBXIP1), regulates cell migration necessary for cancer cell dissemination. However, the mechanism that governs this process remains unknown. We show here that HPIP expression is associated with stages of breast cancer where cell dissemination results in poor patient outcome. Our investigation finds a novel association of HPIP with focal adhesion kinase (FAK) regulating FA dynamics. Interestingly, this interaction that led to activation of FAK protein was mediated by the C-terminal domain of HPIP and not the typical integrin-binding motif. Further, short hairpin RNA-mediated knockdown of FAK expression significantly reduced HPIP-induced cell migration indicating participation of FAK pathway. Live-cell time-lapse imaging and biochemical analysis further established the role of HPIP in microtubule-induced FA disassembly. We also found that HPIP-mediated MAPK activation led to phosphorylation and subsequent activation of calpain2, and the activated calpain2 in turn proteolyses FA protein, talin. Interestingly, HPIP is also proteolysed by calpain2 in breast cancer cells. The proteolysis of HPIP and talin by calpain2, and the activation of calapin2 by HPIP-mediated MAPK phosphorylation, is a novel regulatory axis to modulate the cell migration signal. Together, we have determined HPIP as a novel activator of FAK and a new substrate of calpain2. These molecular interactions between HPIP and FAK, and HPIP and calpain2 regulate cell adhesion and migration through modulation of FA dynamics.	[Bugide, S.; Samanthapudi, V. S. K.; Manavathi, B.] Univ Hyderabad, Sch Life Sci, Dept Biochem, Mol & Cellular Oncol Lab, Hyderabad 500046, Telangana, India; [David, D.; Nair, A.] Rajiv Gandhi Ctr Biotechnol, Thiruvananthapuram, Kerala, India; [Kannan, N.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; [Prabhakar, J.] Reg Canc Ctr, Thiruvananthapuram, Kerala, India	University of Hyderabad; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); British Columbia Cancer Agency	Manavathi, B (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Biochem, Mol & Cellular Oncol Lab, Hyderabad 500046, Telangana, India.	manavathibsl@uohyd.ernet.in	Bugide, Suresh/AAD-6053-2022	Manavathi, Bramanandam/0000-0002-1797-398X; Kannan, Nagarajan/0000-0002-8825-2178	Department of Biotechnology (DBT), India [BT/01/IYBA/2009, BT/PR11114/BRB/10/635/2008, BT-BRB-TF-4-2013]; Department of Science and Technology (DST), India [SB/SO/BB/013/2013]	Department of Biotechnology (DBT), India(Department of Biotechnology (DBT) India); Department of Science and Technology (DST), India(Department of Science & Technology (India))	We are grateful to Dr Elaine Fuchs, Rockefeller University, New York, for providing pBABE-FAK, DsRed2-zyxin and pEGFP-paxillin constructs, and Dr Sam Aparicio, British Columbia Cancer Agency, Vancouver, Canada, for providing pGIPz-FAKshRNA clones. This work was supported by Department of Biotechnology (DBT), India Grant Nos: BT/01/IYBA/2009, BT/PR11114/BRB/10/635/2008 and BT-BRB-TF-4-2013, and Department of Science and Technology (DST), Grant Nos: SB/SO/BB/013/2013, India (to BM). SB is Senior Research Fellow, Council for Scientific and Industrial Research, India (CSIR), India. The authors also acknowledge DBT-CREBB, UGC-PURSE, DST-FIST and UOH-SAP-CAS for providing the research facilities at University of Hyderabad.	Abramovich C, 2000, J BIOL CHEM, V275, P26172, DOI 10.1074/jbc.M001323200; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Chan KT, 2010, J BIOL CHEM, V285, P11418, DOI 10.1074/jbc.M109.090746; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Golubovskaya VM, 2010, ANTI-CANCER AGENT ME, V10, P735; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Manavathi B, 2006, P NATL ACAD SCI USA, V103, P15981, DOI 10.1073/pnas.0607445103; Manavathi B, 2012, J BIOL CHEM, V287, P5600, DOI 10.1074/jbc.M111.289843; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nagano M, 2010, J BIOL CHEM, V285, P21013, DOI 10.1074/jbc.M110.106443; OWENS LV, 1995, CANCER RES, V55, P2752; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Ritt M, 2013, J BIOL CHEM, V288, P8875, DOI 10.1074/jbc.M112.421164; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Scolz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051259; Sieg DJ, 1999, J CELL SCI, V112, P2677; Stehbens S, 2012, J CELL BIOL, V198, P481, DOI 10.1083/jcb.201206050; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wang XH, 2008, BBA-MOL CELL RES, V1783, P1220, DOI 10.1016/j.bbamcr.2008.01.026; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Wu XY, 2008, CELL, V135, P137, DOI 10.1016/j.cell.2008.07.045; Xu XJ, 2013, J CLIN INVEST, V123, P630, DOI 10.1172/JCI64265	42	22	26	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4601	4612		10.1038/onc.2014.389	http://dx.doi.org/10.1038/onc.2014.389			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486428				2022-12-28	WOS:000360189300006
J	Radulovich, N; Leung, L; Ibrahimov, E; Navab, R; Sakashita, S; Zhu, CQ; Kaufman, E; Lockwood, WW; Thu, KL; Fedyshyn, Y; Moffat, J; Lam, WL; Tsao, MS				Radulovich, N.; Leung, L.; Ibrahimov, E.; Navab, R.; Sakashita, S.; Zhu, C-Q; Kaufman, E.; Lockwood, W. W.; Thu, K. L.; Fedyshyn, Y.; Moffat, J.; Lam, W. L.; Tsao, M-S			Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							DNA COPY NUMBER; HOMOZYGOUS DELETIONS; EXPRESSION; CANCER; GENE; ASSOCIATION; INSTABILITY; METASTASIS; PHENOTYPE	Using integrative genomics and functional screening, we identified coiled-coil domain containing 68 (CCDC68) as a novel putative tumor suppressor gene (TSG) in pancreatic ductal adenocarcinoma (PDAC). CCDC68 allelic losses were documented in 48% of primary PDAC patient tumors, 50% of PDAC cell lines and 30% of primary patient derived xenografts. We also discovered a single nucleotide polymorphism (SNP) variant (SNP rs1344011) that leads to exon skipping and generation of an unstable protein isoform CCDC68 Delta(69-114) in 31% of PDAC patients. Overexpression of full length CCDC68 (CCDC68(wt)) in PANC-1 and Hs.766T PDAC cell lines lacking CDCC68 expression decreased proliferation and tumorigenicity in scid mice. In contrast, the downregulation of endogenous CCDC68 in MIAPaca-2 cells increased tumor growth rate. These effects were not observed with the deletion-containing isoform, CCDC68 Delta(69-114).	[Radulovich, N.; Leung, L.; Ibrahimov, E.; Navab, R.; Sakashita, S.; Zhu, C-Q; Kaufman, E.; Tsao, M-S] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Dept Lab Med, Toronto, ON, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Dept Pathobiol, Toronto, ON, Canada; [Leung, L.; Tsao, M-S] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Lockwood, W. W.; Thu, K. L.; Lam, W. L.] Univ British Columbia, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1M9, Canada; [Lockwood, W. W.; Thu, K. L.; Lam, W. L.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; [Fedyshyn, Y.; Moffat, J.] Univ Toronto, Banting & Best Dept Med Res, Dept Mol Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of Toronto	Tsao, MS (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, 200 Elizabeth St,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	ming.tsao@uhn.on.ca	Navab, Roya/AGD-7380-2022; Tsao, Ming-Sound/M-3503-2017; Moffat, Jason/AAC-1110-2020; Tsao, Ming Sound/AFQ-7332-2022	Moffat, Jason/0000-0002-5663-8586; Tsao, Ming Sound/0000-0002-9160-5405; Zhu, ChangQi/0000-0002-9992-0258; Thu, Kelsie/0000-0001-9262-7238	Canadian Cancer Society Research Institute [700809]; Canadian Institutes of Health Research [MOP-49585]; Ontario Ministry of Health and Long Term Care; Terry Fox Foundation STIHR Program in Molecular Pathology of Cancer at CIHR [STP 53912]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Terry Fox Foundation STIHR Program in Molecular Pathology of Cancer at CIHR(Canadian Institutes of Health Research (CIHR))	Olga Ludkovksy (FISH), Ni Liu (PCR) and Dennis Wang (support in ICGC analysis). This study was supported by the Canadian Cancer Society Research Institute grant#700809, Canadian Institutes of Health Research grant MOP-49585 and the Ontario Ministry of Health and Long Term Care. N. Radulovich and K. Thu are Vanier Canada Graduate Scholars. Dr S. Sakashita is supported by the Terry Fox Foundation STIHR Program in Molecular Pathology of Cancer at CIHR (STP 53912). Dr Tsao is the M. Qasim Choksi Chair in Lung Cancer Translational Research.	Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Calhoun ES, 2006, CANCER RES, V66, P7920, DOI 10.1158/0008-5472.CAN-06-0721; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Devitt G, 2006, INT J CANCER, V118, P2210, DOI 10.1002/ijc.21626; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Eichmuller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498; Furukawa T, 1996, AM J PATHOL, V148, P1763; Gerhardt A, 2004, CANCER LETT, V208, P197, DOI 10.1016/j.canlet.2003.11.021; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Harada T, 2009, PANCREATOLOGY, V9, P13, DOI 10.1159/000178871; Hassan NZA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092553; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hofstetter G, 2010, ONCOGENE, V29, P1997, DOI 10.1038/onc.2009.482; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Lefter LP, 2002, GENE CHROMOSOME CANC, V34, P234, DOI 10.1002/gcc.10060; Leung L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084366; Lockwood WW, 2006, EUR J HUM GENET, V14, P139, DOI 10.1038/sj.ejhg.5201531; Mak AB, 2010, MOL CELL PROTEOMICS, V9, P811, DOI 10.1074/mcp.M000002-MCP201; Myhre S, 2013, MOL ONCOL, V7, P704, DOI 10.1016/j.molonc.2013.02.018; Navab R, 2009, NEOPLASIA, V11, P1292, DOI 10.1593/neo.09622; Nowak NJ, 2005, CANCER GENET CYTOGEN, V161, P36, DOI 10.1016/j.cancergencyto.2005.01.009; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Radulovich N, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-24; Radulovich N, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-24; Sharrard RM, 2000, BBA-GENE STRUCT EXPR, V1494, P282, DOI 10.1016/S0167-4781(00)00210-4; Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106; Tammaro C, 2012, BIOCHEM SOC T, V40, P768, DOI 10.1042/BST20120140; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	34	21	23	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4238	4247		10.1038/onc.2014.357	http://dx.doi.org/10.1038/onc.2014.357			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25381825	Green Accepted, Bronze			2022-12-28	WOS:000359199800010
J	Shriver, M; Stroka, KM; Vitolo, MI; Martin, S; Huso, DL; Konstantopoulos, K; Kontrogianni-Konstantopoulos, A				Shriver, M.; Stroka, K. M.; Vitolo, M. I.; Martin, S.; Huso, D. L.; Konstantopoulos, K.; Kontrogianni-Konstantopoulos, A.			Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis	ONCOGENE			English	Article							C-HA-RAS; CELL; ADHESION; INVASION; GROWTH; TRANSFORMATION; EXPRESSION; MIGRATION; LOCALIZATION; MECHANISMS	Obscurins, encoded by the single OBSCN gene, are giant cytoskeletal proteins with structural and regulatory roles. The OBSCN gene is highly mutated in different types of cancers. Loss of giant obscurins from breast epithelial cells confers them with a survival and growth advantage, following exposure to DNA-damaging agents. Here we demonstrate that the expression levels and subcellular distribution of giant obscurins are altered in human breast cancer biopsies compared with matched normal samples. Stable clones of non-tumorigenic MCF10A cells lacking giant obscurins fail to form adhesion junctions, undergo epithelial-to-mesenchymal transition and generate >100-mu m mammospheres bearing markers of cancer-initiating cells. Obscurin-knockdown MCF10A cells display markedly increased motility as a sheet in 2-dimensional (2D) substrata and individually in confined spaces and invasion in 3D matrices. In line with these observations, actin filaments redistribute to extending filopodia where they exhibit increased dynamics. MCF10A cells that stably express the K-Ras oncogene and obscurin short hairpin RNA (shRNA), but not scramble control shRNA, exhibit increased primary tumor formation and lung colonization after subcutaneous and tail vein injections, respectively. Collectively, our findings reveal that loss of giant obscurins from breast epithelium results in disruption of the cell-cell contacts and acquisition of a mesenchymal phenotype that leads to enhanced tumorigenesis, migration and invasiveness in vitro and in vivo.	[Shriver, M.; Kontrogianni-Konstantopoulos, A.] Univ Maryland Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Stroka, K. M.; Konstantopoulos, K.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA; [Stroka, K. M.; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD USA; [Stroka, K. M.; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD USA; [Vitolo, M. I.; Martin, S.; Kontrogianni-Konstantopoulos, A.] Univ Maryland Sch Med, Marlene & Stewart Greenebaum Natl Canc Inst Canc, Baltimore, MD 21201 USA; [Huso, D. L.] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Baltimore, MD USA; [Huso, D. L.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Kontrogianni-Konstantopoulos, A (corresponding author), Univ Maryland Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	akons001@umaryland.edu		Vitolo, Michele/0000-0001-8055-9645; Shriver, Marey/0000-0002-1644-6408	Pilot Grant from The Johns Hopkins Physical Sciences-Oncology Center; Johns Hopkins Institute for NanoBioTechnology [U54CA143868]; National Science Foundation [NSF-1159823]; National Cancer Institute [U54-CA143868, R01-CA186286, T32-CA130840, F32-CA177756, R01-CA154624, K01-CA166576]; Kleberg Foundation; NATIONAL CANCER INSTITUTE [R01CA154624, P30CA006973, U54CA143868, P30CA134274, R01CA186286, F32CA177756, K01CA166576, T32CA130840] Funding Source: NIH RePORTER; Div Of Chem, Bioeng, Env, & Transp Sys [1159823] Funding Source: National Science Foundation	Pilot Grant from The Johns Hopkins Physical Sciences-Oncology Center; Johns Hopkins Institute for NanoBioTechnology; National Science Foundation(National Science Foundation (NSF)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Kleberg Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This work was supported by a Pilot Grant from The Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins Institute for NanoBioTechnology (U54CA143868 to AK-K) and by awards from the National Science Foundation (Award NSF-1159823 to KK), the National Cancer Institute (Awards U54-CA143868 to KK; R01-CA186286 to KK; T32-CA130840 to KMS; F32-CA177756 to KMS; R01-CA154624 to SM and K01-CA166576 to MIV) and the Kleberg Foundation (to KK). Portions of this work are included in a United States patent pending, 14/221,755, filed on 21 March 2014.	Ackermann MA, 2009, MOL BIOL CELL, V20, P2963, DOI 10.1091/mbc.E08-12-1251; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Balzer EM, 2012, FASEB J, V26, P4045, DOI 10.1096/fj.12-211441; Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; Borisov AB, 2008, J CELL BIOCHEM, V103, P1621, DOI 10.1002/jcb.21551; Brasch J, 2012, TRENDS CELL BIOL, V22, P299, DOI 10.1016/j.tcb.2012.03.004; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; Dallas MR, 2012, FASEB J, V26, P2648, DOI 10.1096/fj.12-203786; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Ford-Speelman DL, 2009, MOL BIOL CELL, V20, P3905, DOI 10.1091/mbc.E08-10-1029; Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Fukuzawa A, 2005, J MUSCLE RES CELL M, V26, P427, DOI 10.1007/s10974-005-9025-6; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Hu LYR, 2013, FASEB J, V27, P2001, DOI 10.1096/fj.12-221317; Hung WC, 2013, J CELL BIOL, V202, P807, DOI 10.1083/jcb.201302132; Knights Alexander J, 2012, Trends Cancer Res, V8, P61; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; Kontrogianni-Konstantopoulos A, 2005, J MUSCLE RES CELL M, V26, P419, DOI 10.1007/s10974-005-9024-7; Kontrogianni-Konstantopoulos A, 2006, FASEB J, V20, P2102, DOI 10.1096/fj.06-5761com; Kontrogianni-Konstantopoulos A, 2009, PHYSIOL REV, V89, P1217, DOI 10.1152/physrev.00017.2009; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Perry NA, 2013, IUBMB LIFE, V65, P479, DOI 10.1002/iub.1157; Perry NA, 2012, FASEB J, V26, P2764, DOI 10.1096/fj.12-205419; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Price ND, 2007, P NATL ACAD SCI USA, V104, P3414, DOI 10.1073/pnas.0611373104; Rago C, 2007, CANCER RES, V67, P9364, DOI 10.1158/0008-5472.CAN-07-0605; Russell MW, 2002, GENE, V282, P237, DOI 10.1016/S0378-1119(01)00795-8; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tong ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029211; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang B, 1997, ANTICANCER RES, V17, P4387	46	30	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4248	4259		10.1038/onc.2014.358	http://dx.doi.org/10.1038/onc.2014.358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25381817	Green Accepted			2022-12-28	WOS:000359199800011
J	DiMauro, T; Cantor, DJ; Bainor, AJ; David, G				DiMauro, T.; Cantor, D. J.; Bainor, A. J.; David, G.			Transcriptional repression of Sin3B by Bmi-1 prevents cellular senescence and is relieved by oncogene activation	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; POLYCOMB GROUP PROTEINS; MYC TRANSGENIC MICE; INK4A-ARF LOCUS; BMI1-DEFICIENT MICE; SELF-RENEWAL; CYCLE EXIT; CANCER; PROLIFERATION; FIBROBLASTS	The Polycomb group protein Bmi-1 is an essential regulator of cellular senescence and is believed to function largely through the direct repression of the Ink4a/Arf locus. However, concurrent deletion of Ink4a/Arf does not fully rescue the defects detected in Bmi-1(-/-) mice, indicating that additional Bmi-1 targets remain to be identified. The expression of the chromatin-associated Sin3B protein is stimulated by oncogenic stress, and is required for oncogene-induced senescence. Here we demonstrate that oncogenic stress leads to the dissociation of Bmi-1 from the Sin3B locus, resulting in increased Sin3B expression and subsequent entry into cellular senescence. Furthermore, Sin3B is required for the senescent phenotype and elevated levels of reactive oxygen species elicited upon Bmi-1 depletion. Altogether, these results identify Sin3B as a novel direct target of Bmi-1, and establish Bmi-1-driven repression of Sin3B as an essential regulator of cellular senescence.	[David, G.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA; NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA	New York University; New York University	David, G (corresponding author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, MSB417,550 First Ave, New York, NY 10016 USA.	gregory.david@nyumc.org		David, Gregory/0000-0002-1849-3232; Cantor, David/0000-0003-4084-3312; , gregory/0000-0002-3371-4558	American Cancer Society [115014-RSG-08-054-01-GMC]; National Institute of Health [5R01CA148639, 5R21CA155736]; Irma T. Hirschl Charitable Trust; Samuel Waxman Cancer Research Foundation; Feinberg NYU individual grant; NIH [T32CA009161, T32GM066704]; NATIONAL CANCER INSTITUTE [R01CA148639, T32CA009161, R21CA155736, P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM066704] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irma T. Hirschl Charitable Trust; Samuel Waxman Cancer Research Foundation; Feinberg NYU individual grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to all members of the David laboratory for helpful discussions during the preparation of the manuscript. We thank Drs Sally Temple, Gabriella De Vita, Goberdhan Dimri, David Levy and Marty McMahon for the generous gifts of plasmids used in this study and Dr Michael Garabedian for helpful discussions. We wish to acknowledge the Skirball Institute of Biomolecular Medicine for hosting our laboratory following Hurricane Sandy. All animal experiments were done in accordance with the guidelines of the National Institutes of Health (NIH) and were approved by the NYU School of Medicine Institutional Animal Care and Use Committee. This work was funded by the American Cancer Society (115014-RSG-08-054-01-GMC to DG), the National Institute of Health (5R01CA148639 and 5R21CA155736 to DG), the Irma T. Hirschl Charitable Trust (DG), the Samuel Waxman Cancer Research Foundation (DG) and a Feinberg NYU individual grant (DG). DT, CDJ and BAJ were supported by predoctoral NIH training grants T32CA009161 (DT, CDJ) and T32GM066704 (BAJ).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Arranz L, 2012, CELL CYCLE, V11, P65, DOI 10.4161/cc.11.1.18097; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Caldwell ME, 2012, ONCOGENE, V31, P1599, DOI 10.1038/onc.2011.350; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chatoo W, 2009, J NEUROSCI, V29, P529, DOI 10.1523/JNEUROSCI.5303-08.2009; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; David G, 2008, P NATL ACAD SCI USA, V105, P4168, DOI 10.1073/pnas.0710285105; David G, 2012, CANCER BIOL THER, V13, P992, DOI 10.4161/cbt.21116; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Grandinetti KB, 2009, CANCER RES, V69, P6430, DOI 10.1158/0008-5472.CAN-09-0537; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jelinic P, 2011, MOL CELL BIOL, V31, P54, DOI 10.1128/MCB.00840-10; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Liu Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003199; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Rielland M, 2014, J CLIN INVEST, V124, P2125, DOI 10.1172/JCI72619; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; van Oevelen C, 2010, MOL CELL BIOL, V30, P5686, DOI 10.1128/MCB.00975-10; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	46	12	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					4011	4017		10.1038/onc.2014.322	http://dx.doi.org/10.1038/onc.2014.322			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263442	Green Accepted			2022-12-28	WOS:000358544200014
J	Huhn, D; Kousholt, AN; Sorensen, CS; Sartori, AA				Huehn, D.; Kousholt, A. N.; Sorensen, C. S.; Sartori, A. A.			miR-19, a component of the oncogenic miR-17 similar to 92 cluster, targets the DNA-end resection factor CtIP	ONCOGENE			English	Article							DAMAGE RESPONSE; MICRORNAS; IDENTIFICATION; MODULATION; REPAIR; ROLES; SITES	MicroRNA-19 (miR-19) was recently identified as the key oncogenic component of the polycistronic miR-17 +/- 92 cluster, also known as oncomiR-1, which is frequently upregulated or amplified in multiple tumor types. However, the gene targets and the pathways underlying the tumor-promoting activity of miR-19 still remain largely elusive. CtIP/RBBP8 promotes DNA-end resection, a critical step in the repair of DNA double-strand breaks (DSBs) by homologous recombination (HR), and is considered to function as a tumor suppressor. In this study, we show that miR-19 downregulates CtIP expression by binding to two highly conserved sequences located in the 3'-untranslated region of CtIP mRNA. We further demonstrate that CtIP expression is repressed by miR-19 during continuous genotoxic stress in a p53-dependent manner. Finally, we report that miR-19 impairs CtIP-mediated DNA-end resection, which results in reduced HR levels and DNA damage hypersensitivity. By downregulating CtIP, miR-19 overexpression suppresses the faithful repair of DSBs that is crucial for genome maintenance. Our findings thus provide new mechanistic insight into the oncogenic role of the miR-17 similar to 92 cluster.	[Huehn, D.; Sartori, A. A.] Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; [Kousholt, A. N.; Sorensen, C. S.] Univ Copenhagen, BRIC, Copenhagen N, Denmark	University of Zurich; University of Copenhagen	Sartori, AA (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	sartori@imcr.uzh.ch	Sartori, Alessandro/AAK-7840-2021	Sartori, Alessandro/0000-0003-2770-0333; Kousholt, Arne Nedergaard/0000-0002-3972-1740; Sorensen, Claus/0000-0001-6022-9710	Zurich Cancer League; Sophien-Stiftung zur Forderung der klinischen Krebsforschung; Swiss Cancer League; Vontobel-Stiftung	Zurich Cancer League; Sophien-Stiftung zur Forderung der klinischen Krebsforschung; Swiss Cancer League; Vontobel-Stiftung	We are very grateful to M Menigatti, A Mueller and J Stark for providing reagents and cell lines. We wish to thank A Porro and J Jiricny for critical reading of the manuscript. This work was financially supported in part by grants of the Zurich Cancer League and the Sophien-Stiftung zur Forderung der klinischen Krebsforschung (to AAS). DH is supported by the Swiss Cancer League and AAS by the Vontobel-Stiftung.	Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Bunting SF, 2013, NAT REV CANCER, V13, P443, DOI 10.1038/nrc3537; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; Chowdhury D, 2013, NAT REV MOL CELL BIO, V14, P181, DOI 10.1038/nrm3523; Dimitrov SD, 2013, GENE DEV, V27, P2274, DOI 10.1101/gad.225045.113; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Farazi TA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r9; Ferretti Lorenza P., 2013, Frontiers in Genetics, V4, P99, DOI 10.3389/fgene.2013.00099; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jasin M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012740; Jin HY, 2013, EMBO J, V32, P2377, DOI 10.1038/emboj.2013.178; Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685; Kousholt AN, 2012, J CELL BIOL, V197, P869, DOI 10.1083/jcb.201111065; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Martin NT, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003505; Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Olive V, 2013, IMMUNOL REV, V253, P158, DOI 10.1111/imr.12054; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Steger M, 2013, MOL CELL, V50, P333, DOI 10.1016/j.molcel.2013.03.023; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Wan GH, 2013, CELL REP, V3, P2100, DOI 10.1016/j.celrep.2013.05.038; Wang HL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003277; Wang YM, 2013, CELL CYCLE, V12, P32, DOI 10.4161/cc.23051; Wu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.110; You ZS, 2010, TRENDS CELL BIOL, V20, P402, DOI 10.1016/j.tcb.2010.04.002	44	22	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3977	3984		10.1038/onc.2014.329	http://dx.doi.org/10.1038/onc.2014.329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25308476				2022-12-28	WOS:000358544200010
J	Lei, ZJ; Wang, J; Xiao, HL; Guo, Y; Wang, T; Li, Q; Liu, L; Luo, X; Fan, LL; Lin, L; Mao, CY; Wang, SN; Wei, YL; Lan, CH; Jiang, J; Yang, XJ; Liu, PD; Chen, DF; Wang, B				Lei, Z-J; Wang, J.; Xiao, H-L; Guo, Y.; Wang, T.; Li, Q.; Liu, L.; Luo, X.; Fan, L-L; Lin, L.; Mao, C-Y; Wang, S-N; Wei, Y-L; Lan, C-H; Jiang, J.; Yang, X-J; Liu, P-D; Chen, D-F; Wang, B.			Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of beta-catenin signaling	ONCOGENE			English	Article							COUPLED RECEPTOR 5; DRIVE SELF-RENEWAL; THERAPEUTIC TARGET; LSD1; METASTASIS; COLON; DIFFERENTIATION; IDENTIFICATION; CONTRIBUTES; INHIBITION	Cancer initiating cells (CICs) are responsible for the unrestrained cell growth and chemoresistance of malignant tumors. Histone demethylation has been shown to be crucial for self-renewal/differentiation of stem cells, but it remains elusive whether lysine-specific demethylase 1 (LSD1) regulates the stemness properties of CICs. Here we report that the abundant expression of leucinerich repeat-containing G-protein-coupled receptor 5 (Lgr5) is associated with the progression of hepatocellular carcinoma (HCC). Lgr5(+) HCC cells behave similarly to CICs and are highly tumorigenic and resistant to chemotherapeutic agents. Importantly, Lgr5(+) cells express higher levels of LSD1, which in turn regulates Lgr5 expression and promotes the self-renewal and drug resistance of Lgr5(+) CICs. Mechanistically, LSD1 promotes beta-catenin activation by inhibiting the expression of several suppressors of beta-catenin signaling, especially Prickle1 and APC in Lgr5(+) CICs, by directly regulating the levels of mono- and di-methylation of histone H3 lysine-4 at the promoters of these genes. Furthermore, LSD1-associated activation of the beta-catenin signaling is essential for maintaining the activity of Lgr5(+) CICs. Together, our findings unravel the LSD1/Prickle1/APC/beta-catenin signaling axis as a novel molecular circuit regulating the stemness and chemoresistance of hepatic Lgr5(+) CICs and provide potential targets to improve chemotherapeutic efficacies against HCC.	[Lei, Z-J; Wang, J.; Guo, Y.; Wang, T.; Li, Q.; Liu, L.; Luo, X.; Fan, L-L; Wei, Y-L; Lan, C-H; Chen, D-F; Wang, B.] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Gastroenterol, Chongqing 400042, Peoples R China; [Xiao, H-L; Lin, L.; Mao, C-Y] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Pathol, Chongqing 400042, Peoples R China; [Wang, S-N] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Radiol, Chongqing 400042, Peoples R China; [Jiang, J.] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Urol, Chongqing 400042, Peoples R China; [Yang, X-J] Shantou Univ, Coll Med, Ctr Neurosci, Shantou, Peoples R China; [Liu, P-D] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA	Army Medical University; Army Medical University; Army Medical University; Army Medical University; Shantou University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Chen, DF (corresponding author), Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Gastroenterol, Chongqing 400042, Peoples R China.	chendongfeng1981@126.com; wb_tmmu@126.com	Wang, Bin/W-9917-2019; 黄, 梦茜/AAE-9495-2020	Wang, Bin/0000-0001-5574-1760; 	National Natural Science Foundation of China (NSFC) [81472294, 81201949, 81372558]; Natural Science Foundation Project of CQ CSTC [CSTC2012JJA10124]; Science Foundation of Third Military Medical University [2012XJQ22]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of CQ CSTC(Natural Science Foundation Project of CQ CSTC); Science Foundation of Third Military Medical University	We are indebted to Prof Xiang Xu (Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China) for his technical assistance. We are grateful to Miss Chunhua Quan, Ya Li and Qing Li (Department of Gastroenterology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China) for their help in collecting clinical data. This work was supported by the grants from the National Natural Science Foundation of China (NSFC Nos. 81472294, 81201949, and 81372558), the Natural Science Foundation Project of CQ CSTC (No. CSTC2012JJA10124), and the Science Foundation of Third Military Medical University (No. 2012XJQ22).	Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Blaschke K, 2013, NATURE, V500, P222, DOI 10.1038/nature12362; Chan DW, 2006, GASTROENTEROLOGY, V131, P1218, DOI 10.1053/j.gastro.2006.07.020; Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364; Flesken-Nikitin A, 2013, NATURE, V495, P241, DOI 10.1038/nature11979; Fukuma M, 2013, EXP CELL RES, V319, P113, DOI 10.1016/j.yexcr.2012.10.011; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Gil-Sanchis C, 2013, MOL HUM REPROD, V19, P407, DOI 10.1093/molehr/gat014; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; Hirsch D, 2014, CARCINOGENESIS, V35, P849, DOI 10.1093/carcin/bgt377; Hu M, 2007, GASTROENTEROLOGY, V133, P1579, DOI 10.1053/j.gastro.2007.08.036; Huang ZB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070077, 10.1371/journal.pone.0075007]; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017; Qin Y, 2014, CANCER LETT, V347, P225, DOI 10.1016/j.canlet.2014.02.013; Qiu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.125; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Wang B, 2014, CANCER RES, V74, P5746, DOI 10.1158/0008-5472.CAN-13-2563; Wang B, 2013, J GASTROENTEROL, V48, P798, DOI 10.1007/s00535-012-0711-z; Wang B, 2011, STEM CELL REV REP, V7, P458, DOI 10.1007/s12015-010-9175-9; Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wang Z, 2015, ONCOGENE, V34, P1407, DOI 10.1038/onc.2014.75; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Xi HQ, 2014, BRIT J CANCER, V110, P2011, DOI 10.1038/bjc.2014.112; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang W, 2008, CANCER RES, V68, P4287, DOI 10.1158/0008-5472.CAN-07-6691; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yu YY, 2013, BIOCHEM BIOPH RES CO, V437, P192, DOI 10.1016/j.bbrc.2013.05.123; Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018; Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x	50	63	66	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3188	3198		10.1038/onc.2015.129	http://dx.doi.org/10.1038/onc.2015.129			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25893304				2022-12-28	WOS:000356101100010
J	Li, BS; Zuo, QF; Zhao, YL; Xiao, B; Zhuang, Y; Mao, XH; Wu, C; Yang, SM; Zeng, H; Zou, QM; Guo, G				Li, B-S; Zuo, Q-F; Zhao, Y-L; Xiao, B.; Zhuang, Y.; Mao, X-H; Wu, C.; Yang, S-M; Zeng, H.; Zou, Q-M; Guo, G.			MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival	ONCOGENE			English	Article							CELL-PROLIFERATION; TUMOR-SUPPRESSOR; TOB; EXPRESSION; APOPTOSIS; PROTEIN; MIR-25; CONTRIBUTES; NODE	Gastric cancer (GC) is one of the most common tumors and the molecular mechanism underlying its metastasis is still largely unclear. Here, we show that miR-25 was overexpressed in plasma and primary tumor tissues of GC patients with tumor node metastasis stage (III or IV) or lymph node metastasis. MiR-25 inhibition significantly decreased the metastasis, invasion and proliferation of GC cells in vitro, and reduced their capacity to develop distal pulmonary metastases and peritoneal dissemination in vivo. Furthermore, miR-25 repressed transducer of ERBB2, 1 (TOB1) expression by directly binding to TOB1-3'-UTR, and the inverse correlation was observed between the expressions of miR-25 and TOB1 mRNA in primary GC tissues. Moreover, the loss of TOB1 increased the metastasis, invasion and proliferation of GC cells, and the restoration of TOB1 led to suppressed metastasis, invasion and proliferation. The receiver operating characteristics analysis yielded an area under the curve value of 0.7325 in distinguishing the GC patients with death from those with survival. The analysis of optimal cutoff value revealed poor survival in GC patients with high plasma concentrations of miR-25 (40.2333 amol/mu l). Taken together, miR-25 promotes GC progression by directly downregulating TOB1 expression, and may be a noninvasive biomarker for the prognosis of GC patients.	[Li, B-S; Zuo, Q-F; Xiao, B.; Zhuang, Y.; Mao, X-H; Wu, C.; Zeng, H.; Zou, Q-M; Guo, G.] Third Mil Med Univ, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Chongqing 400038, Peoples R China; [Zhao, Y-L] Third Mil Med Univ, Southwest Hosp, Gen Surg, Chongqing 400038, Peoples R China; [Zhao, Y-L] Third Mil Med Univ, Southwest Hosp, Ctr Minimally Invas Gastrointestinal Surg, Chongqing 400038, Peoples R China; [Yang, S-M] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University	Zou, QM (corresponding author), Third Mil Med Univ, Coll Pharm, Dept Microbiol & Biochem Pharm, 30 Gao Tan Yan Rd, Chongqing 400038, Peoples R China.	Qmzou2007@163.com; guogang7001@163.com			National Science Foundation of China (NSFC) [81301729, 81202310]	National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	We thank the staff at National Engineering Research Center of Immunological Products. This work was supported by grants from the National Science Foundation of China (NSFC): grant no. 81301729 (to LBS) and 81202310 (to XB).	AKAGI T, 1976, ACTA MED OKAYAMA, V30, P215; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Esposito F, 2012, J CLIN ENDOCR METAB, V97, pE710, DOI 10.1210/jc.2011-3068; Eulalio A, 2012, NATURE, V492, P376, DOI 10.1038/nature11739; Ezzeddine N, 2007, MOL CELL BIOL, V27, P7791, DOI 10.1128/MCB.01254-07; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Helms MW, 2009, CANCER RES, V69, P5049, DOI 10.1158/0008-5472.CAN-08-4154; Iwanaga K, 2003, CANCER LETT, V202, P71, DOI 10.1016/j.canlet.2003.08.019; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiao Y, 2012, ACTA PHARMACOL SIN, V33, P250, DOI 10.1038/aps.2011.163; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Kim BH, 2013, J SURG ONCOL, V107, P505, DOI 10.1002/jso.23271; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kundu J, 2012, INT J ONCOL, V41, P839, DOI 10.3892/ijo.2012.1517; Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6; Leite KRM, 2013, UROL ONCOL-SEMIN ORI, V31, P796, DOI 10.1016/j.urolonc.2011.07.002; Li BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041629; Li Q, 2013, CANCER LETT, V335, P168, DOI 10.1016/j.canlet.2013.02.029; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Matsuda S, 1996, ONCOGENE, V12, P705; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698; Scapoli L, 2010, INT J IMMUNOPATH PH, V23, P1229, DOI 10.1177/039463201002300427; Swarbrick A, 2010, NAT MED, V16, P1134, DOI 10.1038/nm.2227; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Wahlquist C, 2014, NATURE, V508, P531, DOI 10.1038/nature13073; Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026; Xiong B, 2006, DEV CELL, V11, P225, DOI 10.1016/j.devcel.2006.06.012; Xu XH, 2012, BIOCHEM BIOPH RES CO, V421, P640, DOI 10.1016/j.bbrc.2012.03.048; Yao QY, 2013, CANCER LETT, V335, P219, DOI 10.1016/j.canlet.2013.02.031; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 2003, MECH DEVELOP, V120, P629, DOI 10.1016/S0925-4773(03)00020-0; Yu JC, 2011, MOL CELLS, V32, P47, DOI 10.1007/s10059-011-2316-4; Zhang CX, 2009, CURR OPIN MOL THER, V11, P641; Zhao HY, 2014, MOL CELL BIOCHEM, V385, P207, DOI 10.1007/s11010-013-1829-x; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156; Zheng B, 2012, ONCOGENE, V31, P4509, DOI 10.1038/onc.2011.581	39	100	107	0	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2556	2565		10.1038/onc.2014.214	http://dx.doi.org/10.1038/onc.2014.214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043310				2022-12-28	WOS:000354541300002
J	Kanellis, DC; Bursac, S; Tsichlis, PN; Volarevic, S; Eliopoulos, AG				Kanellis, D. C.; Bursac, S.; Tsichlis, P. N.; Volarevic, S.; Eliopoulos, A. G.			Physical and functional interaction of the TPL2 kinase with nucleophosmin	ONCOGENE			English	Article							NF-KAPPA-B; MAP KINASE; UP-REGULATION; ACTIVATE ERK; P53; PHOSPHORYLATION; SUPPRESSOR; INFLAMMATION; PROGRESSION; INDUCTION	Tumor Progression Locus 2 (TPL2) is widely recognized as a cytoplasmic mitogen-activated protein 3 kinase with a prominent role in the regulation of inflammatory and oncogenic signal transduction. Herein we report that TPL2 may also operate in the nucleus as a physical and functional partner of nucleophosmin (NPM/B23), a major nucleolar phosphoprotein with diverse cellular activities linked to malignancy. We demonstrate that TPL2 mediates the phosphorylation of a fraction of NPM at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state NPM levels. Upon exposure to ultraviolet C, Tpl2 is required for the translocation of de-phosphorylated NPM from the nucleolus to the nucleoplasm. NPM is an endogenous inhibitor of HDM2:p53 interaction and knockdown of TPL2 was found to result in reduced binding of NPM to HDM2, with concomitant defects in p53 accumulation following genotoxic or ribosomal stress. These findings expand our understanding of the function of TPL2 as a negative regulator of carcinogenesis by defining a nuclear role for this kinase in the topological sequestration of NPM, linking p53 signaling to the generation of threonine 199-phosphorylated NPM.	[Kanellis, D. C.; Eliopoulos, A. G.] Univ Crete, Sch Med, Div Basic Sci, Mol & Cellular Biol Lab, Iraklion 71003, Greece; [Kanellis, D. C.; Eliopoulos, A. G.] Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol, Canc Biol Lab, Iraklion, Greece; [Bursac, S.; Volarevic, S.] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia; [Tsichlis, P. N.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA	University of Crete; University of Rijeka; Tufts Medical Center	Eliopoulos, AG (corresponding author), Univ Crete, Sch Med, Div Basic Sci, Mol & Cellular Biol Lab, Iraklion 71003, Greece.	eliopag@imbb.forth.gr	ELIOPOULOS, ARISTIDES/R-9449-2018; Kanellis, Dimitrios/AHB-0318-2022; ELIOPOULOS, ARISTIDES/ABI-6632-2020; Volarevic, Sinisa/O-4349-2018; Bursać, Slađana/Q-7894-2018	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Kanellis, Dimitrios/0000-0001-8690-2010; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Volarevic, Sinisa/0000-0003-4893-389X; Bursać, Slađana/0000-0002-6478-3409	European Commission (EC) research program 'Inflammation AMP; Cancer Research in Europe' (INFLA-CARE) [223151]; EC support program 'Translational Potential' (TransPOT) [285948]; University of Crete Maria Manassaki scholarship; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065298] Funding Source: NIH RePORTER	European Commission (EC) research program 'Inflammation AMP; Cancer Research in Europe' (INFLA-CARE); EC support program 'Translational Potential' (TransPOT); University of Crete Maria Manassaki scholarship; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Moshe Oren and Varda Rotter (Weizmann Institute, Israel), Josef Papamatheakis (FORTH/IMBB, Greece), Angeliki Malliri (Patterson Institute for Cancer Research, UK), Vassilis Gorgoulis (University of Athens Medical School, Greece) and Charalambos Spilianakis (FORTH/IMBB, Greece) for their kind gift of reagents and Marina Ioannou for excellent technical assistance. This work was supported by the European Commission (EC) research program 'Inflammation & Cancer Research in Europe' (INFLA-CARE; EC Contract 223151) to AGE and SV, the EC support program 'Translational Potential' (TransPOT; EC Contract 285948) to AGE and a University of Crete Maria Manassaki scholarship to DK.	Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Brady SN, 2009, ONCOGENE, V28, P3209, DOI 10.1038/onc.2009.178; Bursac S., 2013, BIOCHIM BIOPHYS ACTA, V1842, P817; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Chao A, 2013, J MOL MED, V91, P249, DOI 10.1007/s00109-012-0950-8; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; Choi HS, 2008, FASEB J, V22, P113, DOI 10.1096/fj.07-9078com; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cuomo ME, 2008, NAT CELL BIOL, V10, P723, DOI 10.1038/ncb1735; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; DeCicco-Skinner KL, 2011, ONCOGENE, V30, P389, DOI 10.1038/onc.2010.447; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Erny KM, 1996, ONCOGENE, V13, P2015; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gantke T, 2011, CELL RES, V21, P131, DOI 10.1038/cr.2010.173; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Hatziapostolou M, 2008, CANCER RES, V68, P1851, DOI 10.1158/0008-5472.CAN-07-5793; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Koike A, 2010, CANCER RES, V70, P6746, DOI 10.1158/0008-5472.CAN-10-0382; Koliaraki V, 2012, J CLIN INVEST, V122, P4231, DOI 10.1172/JCI63917; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Lee SB, 2008, P NATL ACAD SCI USA, V105, P16584, DOI 10.1073/pnas.0807668105; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Lin CY, 2010, MOL BIOL CELL, V21, P4409, DOI 10.1091/mbc.E10-03-0239; Lindstrom MS, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/195209; Lopez-Pelaez M, 2012, MOL BIOL CELL, V23, P2982, DOI 10.1091/mbc.E12-02-0135; Louvet E, 2006, MOL BIOL CELL, V17, P2537, DOI 10.1091/mbc.E05-10-0923; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Moore HM, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009241; Negi SS, 2006, J CELL SCI, V119, P3676, DOI 10.1242/jcs.03090; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2008, J BIOCHEM, V143, P441, DOI 10.1093/jb/mvm222; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Rousseau S, 2008, J CELL SCI, V121, P149, DOI 10.1242/jcs.018671; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Serebrennikova OB, 2012, P NATL ACAD SCI USA, V109, pE1082, DOI 10.1073/pnas.1115098109; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vougioukalaki M, 2011, CANCER LETT, V304, P80, DOI 10.1016/j.canlet.2011.02.004; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; Zhang MJ, 2012, FEBS J, V279, P2848, DOI 10.1111/j.1742-4658.2012.08663.x; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	60	7	7	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2516	2526		10.1038/onc.2014.183	http://dx.doi.org/10.1038/onc.2014.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998852				2022-12-28	WOS:000354190400010
J	Tuthill, MH; Montinaro, A; Zinngrebe, J; Prieske, K; Draber, P; Prieske, S; Newsom-Davis, T; von Karstedt, S; Graves, J; Walczak, H				Tuthill, M. H.; Montinaro, A.; Zinngrebe, J.; Prieske, K.; Draber, P.; Prieske, S.; Newsom-Davis, T.; von Karstedt, S.; Graves, J.; Walczak, H.			TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells	ONCOGENE			English	Article							OVARIAN-CANCER; TUMORICIDAL ACTIVITY; PANCREATIC-CANCER; INDUCED APOPTOSIS; LUNG-CANCER; IN-VIVO; CONATUMUMAB; RESISTANCE; COMBINATION; INHIBITION	Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells while sparing normal tissues. Despite promising preclinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic TRAIL resistance within primary human cancers or insufficient agonistic activity of the TRAIL-receptor (TRAIL-R)-targeting drugs. Fc gamma receptors (Fc gamma R)-mediated crosslinking increases the cancer-cell-killing activity of TRAIL-R2-specific antibodies in vivo. We tested this phenomenon using Fc gamma R-expressing immune cells from patients with ovarian cancer. However, even in the presence of high numbers of Fc gamma R-expressing immune cells, as found in ovarian cancer ascites, AMG655-induced apoptosis was not enabled to any significant degree, indicating that this concept may not translate into clinical use. On the basis of these results, we next set out to determine whether AMG655 possibly interferes with apoptosis induction by endogenous TRAIL, which could be expressed by immune cells. To do so, we tested how AMG655 affected apoptosis induction by recombinant TRAIL. This, however, resulted in the surprising discovery of a striking synergy between AMG655 and non-tagged TRAIL (Apo2L/TRAIL) in killing cancer cells. This combination was as effective in killing cancer cells as highly active recombinant isoleucine-zipper-tagged TRAIL (iz-TRAIL). The increased killing efficiency was due to enhanced formation of the TRAIL death-inducing signalling complex, enabled by concomitant binding of Apo2L/TRAIL and AMG655 to TRAIL-R2. The synergy of AMG655 with Apo2L/TRAIL extended to primary ovarian cancer cells and was further enhanced by combination with the proteasome inhibitor bortezomib or a second mitochondrial-derived activator of caspases (SMAC) mimetic. Importantly, primary human hepatocytes were not killed by the AMG655-Apo2L/TRAIL combination, also not when further combined with bortezomib or a SMAC mimetic. We therefore propose that clinical-grade non-tagged recombinant forms of TRAIL, such as dulanermin, could be combined with antibodies such as AMG655 to introduce a highly active TRAIL-R2-agonistic therapy into the cancer clinic.	[Tuthill, M. H.; Montinaro, A.; Zinngrebe, J.; Prieske, K.; Draber, P.; Prieske, S.; Newsom-Davis, T.; von Karstedt, S.; Walczak, H.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Tumour Immunol Unit, London, England; [Tuthill, M. H.] Univ London Imperial Coll Sci Technol & Med, Ctr Clin Sci, MRC, London, England; [Graves, J.] Amgen Inc, Seattle, WA USA	Imperial College London; Imperial College London; Amgen	Walczak, H (corresponding author), UCL, Inst Canc, Room 416,Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England.	h.walczak@ucl.ac.uk	Walczak, Henning/AAV-2214-2020; Draber, Peter/G-3141-2014	Walczak, Henning/0000-0002-6312-4591; Draber, Peter/0000-0001-8658-4614	Medical Research Council [MC_EX_G0802342]; Cancer Research UK [C33499/A10950]; Ovarian Cancer Action; Association for International Cancer Research; Cancer Research UK [10950] Funding Source: researchfish; MRC [MC_EX_G0802342] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Ovarian Cancer Action(Ovarian Cancer Action); Association for International Cancer Research; Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the patients and the staff at Imperial College Healthcare NHS Trust for providing and collecting the ovarian cancer ascites samples for this research. AMG655 was kindly provided by AMGEN Inc. (Thousand Oaks, CA, USA). We thank B Vogelstein and R Youle for providing cell lines. We also thank Dr C Kantari for technical advice and helpful discussions. This work has been funded by the Medical Research Council by providing a Clinical Research Training Fellowship for MHT (MC_EX_G0802342), Cancer Research UK, (C33499/A10950), Ovarian Cancer Action, and the Association for International Cancer Research. The SMAC mimetic compound SM083 (also known as SM 9a) was synthesised and kindly provided by P Seneci and L Manzoni.	Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Gieffers C, 2013, MOL CANCER THER, V12, P2735, DOI 10.1158/1535-7163.MCT-13-0323; Gillissen B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.67; Goncharenko-Khaider N, 2010, ONCOGENE, V29, P5523, DOI 10.1038/onc.2010.288; Haynes NM, 2010, J IMMUNOL, V185, P532, DOI 10.4049/jimmunol.0903624; Herbst RS, 2010, CLIN CANCER RES, V16, P5883, DOI 10.1158/1078-0432.CCR-10-0631; Herbst RS, 2010, J CLIN ONCOL, V28, P2839, DOI 10.1200/JCO.2009.25.1991; Kaplan-Lefko PJ, 2010, CANCER BIOL THER, V9, P618, DOI 10.4161/cbt.9.8.11264; Kindler HL, 2012, ANN ONCOL, V23, P2834, DOI 10.1093/annonc/mds142; Koschny R, 2007, HEPATOLOGY, V45, P649, DOI 10.1002/hep.21555; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lecis D, 2012, BIOORGAN MED CHEM, V20, P6709, DOI 10.1016/j.bmc.2012.09.041; Leinster DA, 2012, J PATHOL, V227, P136, DOI 10.1002/path.4002; Lemke J, 2014, CELL DEATH DIFFER, V21, P491, DOI 10.1038/cdd.2013.179; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Paz-Ares L, 2013, J THORAC ONCOL, V8, P329, DOI 10.1097/JTO.0b013e31827ce554; Petrucci E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035073; Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950; Saulle E, 2007, APOPTOSIS, V12, P635, DOI 10.1007/s10495-006-0025-9; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wilson NS, 2011, CANCER CELL, V19, P101, DOI 10.1016/j.ccr.2010.11.012	27	48	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2138	2144		10.1038/onc.2014.156	http://dx.doi.org/10.1038/onc.2014.156			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909167	Green Accepted			2022-12-28	WOS:000353173400013
J	Miow, QH; Tan, TZ; Ye, J; Lau, JA; Yokomizo, T; Thiery, JP; Mori, S				Miow, Q. H.; Tan, T. Z.; Ye, J.; Lau, J. A.; Yokomizo, T.; Thiery, J-P; Mori, S.			Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer	ONCOGENE			English	Article							NF-KAPPA-B; PLATINUM-BASED CHEMOTHERAPY; GERM-CELL TUMORS; TRANSCRIPTION FACTORS SNAIL; BREAST-CANCER; DRUG-RESISTANCE; MOLECULAR SUBTYPES; CYCLE PROGRESSION; INDUCED APOPTOSIS; OXIDATIVE STRESS	Chemoresistance to platinums, such as cisplatin, is of critical concern in the treatment of ovarian cancer. Recent evidence has linked epithelial-mesenchymal transition (EMT) as a contributing mechanism. The current study explored the connection between cellular responses to cisplatin and EMT in ovarian cancer. Expression microarrays were utilized to estimate the EMT status as a binary phenotype, and the transcriptional responses of 46 ovarian cancer cell lines to cisplatin were measured at dosages equivalent to 50% growth inhibition. Phenotypic responses to cisplatin were quantified with respect to cell number, proliferation rate and apoptosis, and then compared with the epithelial or mesenchymal status. Ovarian cancer cell lines with an epithelial status exhibited higher resistance to cisplatin treatment in the MTS assay than those with a mesenchymal status. Pathway analyses revealed the induction of G1/S- and S-phase genes (P = 0.001) and the activation of multiple NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells) downstream genes (P = 0.0016) by cisplatin selectively in epithelial-like cell lines. BrdU incorporation and Caspase-3/7 release assays confirmed impaired apoptosis in epithelial-like ovarian cancer cells. In clinical samples, we observed resistance to single platinum treatment and the selective activation of the NF-kappa B pathway by platinum in ovarian cancers with an epithelial status. Overall, our results suggest that, in epithelial-like ovarian cancer cells, NF-kappa B activation by cisplatin may lead to defective apoptosis, preferential proliferation arrest and a consequential decreased sensitivity to cisplatin.	[Miow, Q. H.; Tan, T. Z.; Lau, J. A.; Thiery, J-P; Mori, S.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Miow, Q. H.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore, Singapore; [Ye, J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Deans Off, Singapore, Singapore; [Yokomizo, T.; Mori, S.] Japanese Fdn Canc Res, Inst Canc, Div Canc Genom, Tokyo 1358550, Japan; [Thiery, J-P] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Thiery, J-P] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; Japanese Foundation for Cancer Research; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Mori, S (corresponding author), Japanese Fdn Canc Res, Inst Canc, Div Canc Genom, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	seiichi.mori@jfcr.or.jp	Tan, Tuan Zea/I-9227-2019; Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Tan, Tuan Zea/0000-0001-6624-1593; Thiery, Jean Paul/0000-0003-0478-5020; Miow, Qing Hao/0000-0001-8029-8238; Ye, Jieru/0000-0002-5776-9385	Cancer Science Institute of Singapore; Institute of Molecular and Cell Biology at A*STAR, Singapore; Vehicle Racing Commemorative Foundation in Japan; Princess Takamatsu Cancer Research Fund	Cancer Science Institute of Singapore; Institute of Molecular and Cell Biology at A*STAR, Singapore; Vehicle Racing Commemorative Foundation in Japan; Princess Takamatsu Cancer Research Fund	We thank Drs K Yamaguchi, N Matsumura and S Murphy for kindly providing us with a panel of ovarian cancer cell lines. We thank Dr R Jackson for her careful editing of the English language. This work was supported in part through a grant from the Cancer Science Institute of Singapore, the Institute of Molecular and Cell Biology at A*STAR, Singapore, the Vehicle Racing Commemorative Foundation in Japan and the Princess Takamatsu Cancer Research Fund.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bremmer F, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-19; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Du FF, 2013, ONCOL REP, V30, P1113, DOI 10.3892/or.2013.2567; Escarcega RO, 2007, CLIN ONCOL-UK, V19, P154, DOI 10.1016/j.clon.2006.11.013; Gatti L, 2002, CELL DEATH DIFFER, V9, P1352, DOI 10.1038/sj.cdd.4401109; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Gupta N, 2013, GYNECOL ONCOL, V130, P200, DOI 10.1016/j.ygyno.2013.03.019; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Helleman J, 2010, GYNECOL ONCOL, V117, P170, DOI 10.1016/j.ygyno.2010.01.010; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang J, 2012, JNCI-J NATL CANCER I, V104, P670, DOI 10.1093/jnci/djs177; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kondoh E, 2010, INT J CANCER, V126, P2448, DOI 10.1002/ijc.24919; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Leitao MM, 2009, SEMIN ONCOL, V36, P106, DOI 10.1053/j.seminoncol.2008.12.002; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Lin-Chao S., 1994, J Biomed Sci, V1, P131, DOI 10.1007/BF02257987; Liu GH, 2006, INT J GYNECOL CANCER, V16, P1777, DOI 10.1111/j.1525-1438.2006.00652.x; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Marchini S, 2013, EUR J CANCER, V49, P520, DOI 10.1016/j.ejca.2012.06.026; Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120; Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110; MIETTINEN M, 1985, AM J PATHOL, V120, P402; Mizuno H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-137; Mueller S, 2006, INT J ONCOL, V29, P471; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; OSTROW S, 1980, CANCER CLIN TRIALS, V3, P23; Parajuli B, 2013, CANCER EPIDEMIOL, V37, P512, DOI 10.1016/j.canep.2013.02.008; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; Qin LF, 2002, CANCER LETT, V175, P27, DOI 10.1016/S0304-3835(01)00720-0; Rosano L, 2011, CLIN CANCER RES, V17, P2350, DOI 10.1158/1078-0432.CCR-10-2325; Rustin GJS, 2006, J CLIN ONCOL, V24, P45, DOI 10.1200/JCO.2005.01.2757; Samanta AK, 2004, J BIOL CHEM, V279, P7576, DOI 10.1074/jbc.M311659200; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Simons AL, 2007, CANCER RES, V67, P3364, DOI 10.1158/0008-5472.CAN-06-3717; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Solomon LA, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-9; SORENSON CM, 1988, CANCER RES, V48, P4484; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan TZ, 2013, EMBO MOL MED, V5, P1051, DOI 10.1002/emmm.201201823; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Weir NM, 2007, CANCER BIOL THER, V6, P178, DOI 10.4161/cbt.6.2.3577; Wintzell M, 2012, CANCER BIOL THER, V13, P1454, DOI 10.4161/cbt.22007; Xiao GT, 2011, AM J CANCER RES, V1, P192; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yip HT, 2006, ARCH OTOLARYNGOL, V132, P317, DOI 10.1001/archotol.132.3.317; Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409	76	84	87	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1899	1907		10.1038/onc.2014.136	http://dx.doi.org/10.1038/onc.2014.136			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858042				2022-12-28	WOS:000352725600004
J	Vigna, E; Comoglio, PM				Vigna, E.; Comoglio, P. M.			Targeting the oncogenic Met receptor by antibodies and gene therapy	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; MONOVALENT ANTIBODY; ANTITUMOR-ACTIVITY; PHASE-II; AMG 102; GEFITINIB RESISTANCE; ONARTUZUMAB METMAB	The receptor for hepatocyte growth factor (HGF), a tyrosine kinase encoded by the Met oncogene, has a crucial role in cancer growth, invasion and metastasis. It is a validated therapeutic target for 'personalized' treatment of a number of malignancies. Therapeutic tools prompting selective, robust and highly effective Met inhibition potentially represent a major step in the battle against cancer. Antibodies targeting either Met or its ligand HGF, although challenging, demonstrate to be endowed with promising features. Here we briefly review and discuss the state of the art in the field.	Univ Torino, Dept Oncol, Candiolo, TO, Italy; IRCCS, FPO, Candiolo Canc Inst, Candiolo, TO, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia	Vigna, E (corresponding author), Candiolo Canc Inst, Lab Gene Transfer, KM 3-95,Str Provinciale 142, I-10060 Candiolo, TO, Italy.	elisa.vigna@ircc.it; pcomoglio@gmail.com		Comoglio, Paolo/0000-0002-7056-5328; Vigna, Elisa/0000-0001-9787-5732	AIRC (Italy) [11852]; Metheresis Translational Research SA; University of Torino	AIRC (Italy)(Fondazione AIRC per la ricerca sul cancro); Metheresis Translational Research SA; University of Torino	The original work performed by the authors was supported by an IG grant from the AIRC (Italy) no. 11852 and by a research contract between Metheresis Translational Research SA and the University of Torino. The images are unpublished experiments of Dr Letizia Lanzetti. The invaluable secretarial help of Antonella Cignetto is gratefully acknowledged.	Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Ancot F, 2012, TRAFFIC, V13, P1261, DOI 10.1111/j.1600-0854.2012.01384.x; Bardelli C, 2005, BIOCHEM BIOPH RES CO, V334, P1172, DOI 10.1016/j.bbrc.2005.07.020; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Bendell JC, 2013, CLIN COLORECTAL CANC, V12, P218, DOI 10.1016/j.clcc.2013.04.001; Bertotti A, 2013, JNCI-J NATL CANCER I, V105, P1426, DOI 10.1093/jnci/djt253; Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158; Buchanan IM, 2011, J CELL MOL MED, V15, P1999, DOI 10.1111/j.1582-4934.2010.01122.x; Burgess T, 2006, CANCER RES, V66, P1721, DOI 10.1158/0008-5472.CAN-05-3329; Burgess TL, 2010, MOL CANCER THER, V9, P400, DOI 10.1158/1535-7163.MCT-09-0824; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Castoldi R, 2013, ONCOGENE, V32, P5593, DOI 10.1038/onc.2013.245; Catenacci DVT, 2011, CANCER DISCOV, V1, P573, DOI 10.1158/2159-8290.CD-11-0175; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; D'Arcangelo M, 2013, BIOL-TARGETS THER, V7, P61, DOI 10.2147/BTT.S28908; De Bacco F, 2012, CANCER RES, V72, P4537, DOI 10.1158/0008-5472.CAN-11-3490; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Duvvuri M, 2005, FRONT BIOSCI-LANDMRK, V10, P1499, DOI 10.2741/1634; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gillet Jean-Pierre, 2009, V542, P5, DOI 10.1007/978-1-59745-561-9_1; Goetsch L, 2010, CANC RES S1, V70; Goldman JW, 2013, ASCO M, V31, P8093; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Houghton PJ, 2014, PEDIATR BLOOD CANCER, V61, P380, DOI 10.1002/pbc.24756; Jin HK, 2008, CANCER RES, V68, P4360, DOI 10.1158/0008-5472.CAN-07-5960; Jun HT, 2007, CLIN CANCER RES, V13, P6735, DOI 10.1158/1078-0432.CCR-06-2969; Kim K, 2007, BIOCHEM BIOPH RES CO, V354, P115, DOI 10.1016/j.bbrc.2006.12.164; Kim KJ, 2006, CLIN CANCER RES, V12, P1292, DOI 10.1158/1078-0432.CCR-05-1793; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Leiser D, 2014, FEBS LETT, V588, P653, DOI 10.1016/j.febslet.2013.12.025; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; Martin LP, 2014, GYNECOL ONCOL, V132, P526, DOI 10.1016/j.ygyno.2013.12.018; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Merchant M, 2013, P NATL ACAD SCI USA, V110, pE2987, DOI 10.1073/pnas.1302725110; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Mittra ES, 2013, CLIN CANCER RES, V19, P5711, DOI 10.1158/1078-0432.CCR-12-1015; Okamoto W, 2010, MOL CANCER THER, V9, P2785, DOI 10.1158/1535-7163.MCT-10-0481; Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perk LR, 2008, EUR J NUCL MED MOL I, V35, P1857, DOI 10.1007/s00259-008-0774-5; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Rosen PJ, 2010, CLIN CANCER RES, V16, P2677, DOI 10.1158/1078-0432.CCR-09-2862; Ryan CJ, 2013, CLIN CANCER RES, V19, P215, DOI 10.1158/1078-0432.CCR-12-2605; Sadiq AA, 2013, J CLIN ONCOL, V31, P1089, DOI 10.1200/JCO.2012.43.9422; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoffski P, 2011, BJU INT, V108, P679, DOI 10.1111/j.1464-410X.2010.09947.x; Slordahl TS, 2013, EUR J HAEMATOL, V91, P399, DOI 10.1111/ejh.12185; Stella GM, 2011, HUM MUTAT, V32, P44, DOI 10.1002/humu.21374; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Toschi L, 2008, CLIN CANCER RES, V14, P5941, DOI 10.1158/1078-0432.CCR-08-0071; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; van der Horst E, 2009, NEOPLASIA, V11, P355, DOI 10.1593/neo.81536; Vigna E, 2000, J GENE MED, V2, P308; Vigna E, 2008, CANCER RES, V68, P9176, DOI 10.1158/0008-5472.CAN-08-1688; Vigna E, 2014, J MOL MED, V92, P65, DOI 10.1007/s00109-013-1079-0; Vosjan MJWD, 2012, MOL CANCER THER, V11, P1017, DOI 10.1158/1535-7163.MCT-11-0891; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Wen PY, 2011, NEURO-ONCOLOGY, V13, P437, DOI 10.1093/neuonc/noq198; Wu XY, 2013, CANCER LETT, V335, P128, DOI 10.1016/j.canlet.2013.02.002; Xin Y, 2013, J CLIN PHARMACOL, V53, P1103, DOI 10.1002/jcph.148; Zeng W, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-2734; Zhao P, 2010, CANCER LETT, V291, P209, DOI 10.1016/j.canlet.2009.10.014; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	83	27	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1883	1889		10.1038/onc.2014.142	http://dx.doi.org/10.1038/onc.2014.142			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882574	Green Submitted, Bronze			2022-12-28	WOS:000352725600002
J	Zanetti, M; Rodvold, JJ; Mahadevan, NR				Zanetti, M.; Rodvold, J. J.; Mahadevan, N. R.			The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells	ONCOGENE			English	Review							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN-RESPONSE; NF-KAPPA-B; ER QUALITY-CONTROL; TUMOR-CELLS; PROSTATE-CANCER; TRANSCRIPTION FACTOR; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; CALRETICULIN EXPOSURE	The endoplasmic reticulum (ER) stress response/unfolded protein response (UPR) has been thought to influence tumorigenesis mainly through cell-intrinsic, pro-survival effects. In recent years, however, new evidence has emerged showing that the UPR is also the source of cell-extrinsic effects, particularly directed at those immune cells within the tumor microenvironment. Here we will review and discuss this new body of information with focus on the role of cell-extrinsic effects on innate and adaptive immunity, suggesting that the transmission of ER stress from cancer cells to myeloid cells in particular is an expedient used by cancer cells to control the immune microenvironment, which acquires pro-inflammatory as well as immune-suppressive characteristics. These new findings can now be seen in the broader context of similar phenomena described in Caenorhabditis elegans, and an analogy with quorum sensing and 'community effects' in prokaryotes and eukaryotes can be drawn, arguing that a cell-nonautonomous UPR-based regulation of heterologous cells may be phylogenetically conserved. Finally, we will discuss the role of aneuploidy as an inducer of proteotoxic stress and potential initiator of cell-nonautonomous UPR-based regulation. In presenting these new views, we wish to bring attention to the cell-extrinsic regulation of tumor growth, including tumor UPR-based cell-nonautonomous signaling as a mechanism of maintaining tumor heterogeneity and resistance to therapy, and suggest therapeutically targeting such mechanisms within the tumor microenvironment.	[Zanetti, M.; Rodvold, J. J.; Mahadevan, N. R.] Univ Calif San Diego, Immunol Lab, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Zanetti, M.; Rodvold, J. J.; Mahadevan, N. R.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Zanetti, M (corresponding author), Univ Calif San Diego, Immunol Lab, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mzanetti@ucsd.edu			UCSD Academic Senate; Frank H. and Eva B. Buck Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007198] Funding Source: NIH RePORTER	UCSD Academic Senate; Frank H. and Eva B. Buck Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by a grant from the UCSD Academic Senate to MZ. JJR acknowledges the support of the Frank H. and Eva B. Buck Foundation.	Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107; Balmain A, 2003, NAT GENET S, V33, P238; Bartoszewski R, 2011, J BIOL CHEM, V286, P41862, DOI 10.1074/jbc.M111.304956; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Boileve A, 2013, CELL CYCLE, V12, P473, DOI 10.4161/cc.23369; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Chen L, 2009, BIOCHEM PHARMACOL, V78, P70, DOI 10.1016/j.bcp.2009.03.022; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Chen YN, 2013, TRENDS CELL BIOL, V23, P547, DOI 10.1016/j.tcb.2013.06.005; Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Cullen SJ, 2013, AM J CANCER RES, V3, P196; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; de Almeida SF, 2007, J IMMUNOL, V178, P3612, DOI 10.4049/jimmunol.178.6.3612; Delay ML, 2009, ARTHRITIS RHEUM-US, V60, P2633, DOI 10.1002/art.24763; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; DIERICK AM, 1993, HISTOPATHOLOGY, V23, P333, DOI 10.1111/j.1365-2559.1993.tb01216.x; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Drogat B, 2007, CANCER RES, V67, P6700, DOI 10.1158/0008-5472.CAN-06-3235; Duesberg P, 2007, SCI AM, V296, P52, DOI 10.1038/scientificamerican0507-52; Eletto D, 2010, SEMIN CELL DEV BIOL, V21, P479, DOI 10.1016/j.semcdb.2010.03.004; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Goodall JC, 2010, P NATL ACAD SCI USA, V107, P17698, DOI 10.1073/pnas.1011736107; Granados DP, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-10; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; GURDON JB, 1993, CELL, V75, P831, DOI 10.1016/0092-8674(93)90526-V; Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200; Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Iwakoshi NN, 2007, J EXP MED, V204, P2267, DOI 10.1084/jem.20070525; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kim S, 2014, INNATE IMMUN-LONDON, V20, P799, DOI 10.1177/1753425913508593; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Krajcovic M, 2011, NAT CELL BIOL, V13, P324, DOI 10.1038/ncb2174; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Liu B, 2010, NAT COMMUN, V1, P79; Logothetis CJ, 2013, CANCER DISCOV, V3, P849, DOI 10.1158/2159-8290.CD-12-0460; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mahadevan NR, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23901; Mahadevan NR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051845; Mahadevan NR, 2011, J IMMUNOL, V187, P4403, DOI 10.4049/jimmunol.1101531; Mahadevan NR, 2010, J INFLAMM RES, V3, P99, DOI 10.2147/JIR.S11190; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; Meares GP, 2014, MOL CELL BIOL, V34, P3911, DOI 10.1128/MCB.00980-14; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Morales C, 2014, CANCER RES, V74, P446, DOI 10.1158/0008-5472.CAN-13-1677; Mori K, 2009, J BIOCHEM, V146, P743, DOI 10.1093/jb/mvp166; Mumm JB, 2008, ONCOGENE, V27, P5913, DOI 10.1038/onc.2008.275; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Newburger DE, 2013, GENOME RES, V23, P1097, DOI 10.1101/gr.151670.112; Norian LA, 2009, CANCER RES, V69, P3086, DOI 10.1158/0008-5472.CAN-08-2826; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Oh J, 2012, J BIOL CHEM, V287, P11629, DOI 10.1074/jbc.M111.338673; OHYAMA S, 1990, CANCER, V65, P116, DOI 10.1002/1097-0142(19900101)65:1<116::AID-CNCR2820650124>3.0.CO;2-I; Osorio F, 2014, NAT IMMUNOL, V15, P248, DOI 10.1038/ni.2808; OWAINATI AAR, 1987, BRIT J CANCER, V55, P449, DOI 10.1038/bjc.1987.88; Pellicciotta I, 2008, CANCER RES, V68, P8085, DOI 10.1158/0008-5472.CAN-08-1014; Pereira ER, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012521; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Risbridger GP, 2010, NAT REV CANCER, V10, P205, DOI 10.1038/nrc2795; Roberts HR, 2011, CARCINOGENESIS, V32, P1741, DOI 10.1093/carcin/bgr210; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Romero-Ramirez L, 2009, TRANSL ONCOL, V2, P31, DOI 10.1593/tlo.08211; Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Sheltzer JM, 2012, P NATL ACAD SCI USA, V109, P12644, DOI 10.1073/pnas.1209227109; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Siegel JJ, 2012, ANNU REV CELL DEV BI, V28, P189, DOI 10.1146/annurev-cellbio-101011-155807; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Sun JR, 2012, EMBO REP, V13, P855, DOI 10.1038/embor.2012.100; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tam AB, 2014, CELL REP, V9, P850, DOI 10.1016/j.celrep.2014.09.016; Tam AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045078; Tang YC, 2013, CELL, V152, P394, DOI 10.1016/j.cell.2012.11.043; Taylor RC, 2013, CELL, V153, P1435, DOI 10.1016/j.cell.2013.05.042; Thevenot PT, 2014, IMMUNITY, V41, P389, DOI 10.1016/j.immuni.2014.08.015; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Ullrich E, 2008, CELL DEATH DIFFER, V15, P21, DOI 10.1038/sj.cdd.4402266; Uramoto H, 2005, LUNG CANCER, V49, P55, DOI 10.1016/j.lungcan.2004.12.011; Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI [10.4161/onci.27048, 10.4161/onci.27878]; van Galen P, 2014, NATURE, V510, P268, DOI 10.1038/nature13228; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wheeler MC, 2008, J IMMUNOL, V181, P256, DOI 10.4049/jimmunol.181.1.256; Williams KW, 2014, CELL METAB, V20, P471, DOI 10.1016/j.cmet.2014.06.002; Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016; Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018; Yamazaki H, 2009, J IMMUNOL, V183, P1480, DOI 10.4049/jimmunol.0900017; Yang Y, 2005, MOL CELLS, V20, P173; Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005; Yildirim-Assaf S, 2007, J CLIN PATHOL, V60, P649, DOI 10.1136/jcp.2005.035550; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang YL, 2015, J CLIN INVEST, V125, P859, DOI 10.1172/JCI79014	135	30	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					269	278		10.1038/onc.2015.108	http://dx.doi.org/10.1038/onc.2015.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893303				2022-12-28	WOS:000369055300001
J	He, K; Zheng, X; Li, M; Zhang, L; Yu, J				He, K.; Zheng, X.; Li, M.; Zhang, L.; Yu, J.			mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation	ONCOGENE			English	Article							NF-KAPPA-B; TRANSLATION INITIATION; COLORECTAL-CANCER; MAMMALIAN TARGET; MULTIPLE-MYELOMA; KINASE INHIBITOR; PHASE-II; PUMA; PATHWAY; STRESS	The mammalian target of rapamycin (mTOR) is commonly activated in colon cancer. mTOR complex 1 (mTORC1) is a major downstream target of the PI3K/ATK pathway and activates protein synthesis by phosphorylating key regulators of messenger RNA translation and ribosome synthesis. Rapamycin analogs Everolimus and Temsirolimus are non-ATP-competitive mTORC1 inhibitors, and suppress proliferation and tumor angiogenesis and invasion. We now show that apoptosis plays a key role in their anti-tumor activities in colon cancer cells and xenografts through the DR5, FADD and caspase-8 axis, and is strongly enhanced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and 5-fluorouracil. The induction of DR5 by rapalogs is mediated by the ER stress regulator and transcription factor CHOP, but not the tumor suppressor p53, on rapid and sustained inhibition of 4E-BP1 phosphorylation, and attenuated by eIF4E expression. ATP-competitive mTOR/PI3K inhibitors also promote DR5 induction and FADD-dependent apoptosis in colon cancer cells. These results establish activation of ER stress and the death receptor pathway as a novel anticancer mechanism of mTOR inhibitors.	[He, K.; Zheng, X.; Li, M.; Yu, J.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; [He, K.; Zheng, X.; Li, M.; Zhang, L.; Yu, J.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Zhang, L.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Hillman Canc Ctr Res Pavil,Suite 2-26h,5117 Ctr A, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000	NIH [CA129829, CA106348, CA172136]; American Cancer Society [RGS-10-124-01-CCE];  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA172136, R01CA129829, R01CA106348, R01CA121105, P30CA047904] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bert Vogelstein (Howard Hughes Medical Institute, Johns Hopkins University) for p53-KO HCT116, Richard J. Youle (NIH) for BAX/BAK-DKO HCT116 cells, Shi-Yong Sun (Emory University) for FADD-DN construct and Nahum Sonenberg (McGill University) for eIF4E construct. This work is supported by NIH grant CA129829, American Cancer Society grant RGS-10-124-01-CCE (YJ) and NIH grants CA106348, CA172136 (ZL). This project used the UPCI shared facilities including flow cytometry, animal and histopathology and were supported in part by award P30CA047904.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Betz C, 2013, J CELL BIOL, V203, P563, DOI 10.1083/jcb.201306041; Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130; Descamps G, 2012, BRIT J CANCER, V106, P1660, DOI 10.1038/bjc.2012.139; Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; Dudgeon C, 2010, MOL CANCER THER, V9, P2893, DOI 10.1158/1535-7163.MCT-10-0635; Fan SQ, 2010, NEOPLASIA, V12, P346, DOI 10.1593/neo.10144; Fournier MJ, 2013, MOL CELL BIOL, V33, P2285, DOI 10.1128/MCB.01517-12; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; HALL PA, 1994, J CELL SCI, V107, P3569; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasty P, 2014, CANCER PREV RES, V7, P169, DOI 10.1158/1940-6207.CAPR-13-0299; He K, 2013, MOL CANCER THER, V12, P2559, DOI 10.1158/1535-7163.MCT-13-0284; Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353; Kuhn JG, 2007, CLIN CANCER RES, V13, P7401, DOI 10.1158/1078-0432.CCR-07-0781; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.moicel.2007.12.023, 10.1016/j.molcel.2007.12.023]; Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sun J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043158; Sun Q, 2007, MOL CANCER THER, V6, P3180, DOI 10.1158/1535-7163.MCT-07-0265; Sun QH, 2011, CLIN CANCER RES, V17, P2361, DOI 10.1158/1078-0432.CCR-10-2262; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yellen P, 2013, CANCER LETT, V333, P239, DOI 10.1016/j.canlet.2013.01.041; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang L, 2013, CURR COLORECT CANC R, V9, P331, DOI 10.1007/s11888-013-0188-z; Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096; Zheng XN, 2013, MOL CANCER THER, V12, P777, DOI 10.1158/1535-7163.MCT-12-1146	53	61	67	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					148	157		10.1038/onc.2015.79	http://dx.doi.org/10.1038/onc.2015.79			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25867072	Green Accepted			2022-12-28	WOS:000368193900002
J	Kim, SJ; Lee, HW; Baek, JH; Cho, YH; Kang, HG; Jeong, JS; Song, J; Park, HS; Chun, KH				Kim, S-J; Lee, H-W; Baek, J-H; Cho, Y-H; Kang, H. G.; Jeong, J. S.; Song, J.; Park, H-S; Chun, K-H			Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; POSTTRANSLATIONAL REGULATION; GENE; UBIQUITINATION; APOPTOSIS	Mutation in PTEN has not yet been detected, but its function as a tumor suppressor is inactivated in many cancers. In this study we determined that, activated Notch signaling disables PTEN by phosphorylation and thereby contributes to gastric tumorigenesis. Notch inhibition by small interfering RNA or.-secretase inhibitor (GSI) induced mitotic arrest and apoptosis in gastric cancer cells. Notch inhibition induced dephosphorylation in the C-terminal domain of PTEN, which led to PTEN nuclear localization. Overexpression of activated Notch1-induced phosphorylation of PTEN and reversed GSI-induced mitotic arrest. Dephosphorylated nuclear PTEN caused prometaphase arrest by interaction with the cyclin B1-CDK1 complex, resulting in their accumulation in the nucleus and subsequent apoptosis. We found a correlation between high expression levels of Notch1 and low survival rates and, similarly, between reduced nuclear PTEN expression and increasing the TNM classification of malignant tumours stages in malignant tissues from gastric cancer patients. The growth of Notch1-depleted gastric tumors was significantly retarded in xenografted mice, and in addition, PTEN deletion restored growth similar to control tumors. We also demonstrated that combination treatment with GSI and chemotherapeutic agents significantly reduced the orthotopically transplanted gastric tumors in mice without noticeable toxicity. Overall, our findings suggest that inhibition of Notch signaling can be employed as a PTEN activator, making it a potential target for gastric cancer therapy.	[Kim, S-J; Lee, H-W; Baek, J-H; Cho, Y-H; Kang, H. G.; Chun, K-H] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 120752, South Korea; [Kim, S-J; Baek, J-H; Cho, Y-H; Kang, H. G.; Chun, K-H] Severance Med Res Inst, Brain Korea PLUS Project Med Sci 21, Seoul, South Korea; [Lee, H-W; Song, J.] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul 120749, South Korea; [Jeong, J. S.] Dong A Univ, Sch Med, Dept Pathol, Busan, South Korea; [Park, H-S] Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Gwangju, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Dong A University; Chonnam National University	Chun, KH (corresponding author), Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, 50 Yonsei Ro, Seoul 120752, South Korea.	khchun@yuhs.ac		Song, Jaewhan/0000-0001-8152-9210; Chun, Kyung-Hee/0000-0002-9867-7321	National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [NRF-2014R1A2A1A11050600]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2014R1A1A2055009]	National Research Foundation of Korea (NRF) grant - Korea government (MSIP); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	The authors are grateful to the FACS facility staff of the National Cancer Center (NCC) in Korea for their technical support. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. NRF-2014R1A2A1A11050600), and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2014R1A1A2055009).	Ahn YH, 2012, CLIN EXP METASTAS, V29, P359, DOI 10.1007/s10585-012-9458-4; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Bolduc D, 2013, ELIFE, V2, DOI 10.7554/eLife.00691; Boosani CS, 2013, EXPERT OPIN THER PAT, V23, P569, DOI 10.1517/13543776.2013.768985; Byun DS, 2003, INT J CANCER, V104, P318, DOI 10.1002/ijc.10962; Cheong TC, 2010, CANCER SCI, V101, P94, DOI 10.1111/j.1349-7006.2009.01364.x; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8; Efferson CL, 2010, CANCER RES, V70, P2476, DOI 10.1158/0008-5472.CAN-09-3114; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Groth C, 2012, SEMIN CELL DEV BIOL, V23, P465, DOI 10.1016/j.semcdb.2012.01.016; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Kim JH, 2014, CELL DEATH DIFFER, V21, P594, DOI 10.1038/cdd.2013.181; Kim SJ, 2014, CELL DEATH DIFFER, V21, P1769, DOI 10.1038/cdd.2014.88; Kim SJ, 2013, ONCOTARGET, V4, P1461, DOI 10.18632/oncotarget.1219; Kim SJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3098; Kim SJ, 2011, CLIN EXP METASTAS, V28, P743, DOI 10.1007/s10585-011-9406-8; Kim SJ, 2011, J CONTROL RELEASE, V155, P427, DOI 10.1016/j.jconrel.2011.06.026; Kim SJ, 2010, GASTROENTEROLOGY, V138, P1035, DOI 10.1053/j.gastro.2009.09.061; Kim SK, 2011, AUTOMAT CONSTR, V20, P1, DOI 10.1016/j.autcon.2010.07.010; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Kuhnert F, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-20; Lee EW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1981; Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069; Leslie NR, 2011, TRENDS PHARMACOL SCI, V32, P131, DOI 10.1016/j.tips.2010.12.005; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Ohtsu A, 2008, J GASTROENTEROL, V43, P256, DOI 10.1007/s00535-008-2177-6; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sato K, 2002, VIRCHOWS ARCH, V440, P160, DOI 10.1007/s004280100499; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vaisman N Ia, 2012, Izv Akad Nauk Ser Biol, P27; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang X, 2008, ONCOGENE, V27, P5454, DOI 10.1038/onc.2008.242; Wang YG, 2012, EXP MOL MED, V44, P387, DOI 10.3858/emm.2012.44.6.044; Wen YG, 2010, ONCOL REP, V24, P89, DOI 10.3892/or_00000832; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zhang P, 2012, BIOMED PHARMACOTHER, V66, P485, DOI 10.1016/j.biopha.2012.04.004; Zhang Y, 2001, J CELL BIOCHEM, V82, P692, DOI 10.1002/jcb.1191	42	60	66	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					251	260		10.1038/onc.2015.80	http://dx.doi.org/10.1038/onc.2015.80			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25823029				2022-12-28	WOS:000368193900011
J	Gui, Y; Yeganeh, M; Donates, YC; Tobelaim, WS; Chababi, W; Mayhue, M; Yoshimura, A; Ramanathan, S; Saucier, C; Ilangumaran, S				Gui, Y.; Yeganeh, M.; Donates, Y-C; Tobelaim, W-S; Chababi, W.; Mayhue, M.; Yoshimura, A.; Ramanathan, S.; Saucier, C.; Ilangumaran, S.			Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma	ONCOGENE			English	Article							LIVER-REGENERATION; GROWTH-FACTOR; DOWN-REGULATION; TARGETING MET; TPR-MET; C-CBL; CANCER; INHIBITORS; PATHWAY; UBIQUITINATION	Suppressor of cytokine signaling 1 (SOCS1) is considered as a tumor suppressor protein in hepatocellular carcinoma (HCC), but the underlying mechanisms remain unclear. Previously, we have shown that SOCS1-deficient hepatocytes displayed increased responsiveness to hepatocyte growth factor (HGF) due to enhanced signaling via the MET receptor tyrosine kinase. As aberrant MET activation occurs in many tumors including HCC, here we elucidated the mechanisms of SOCS1-mediated regulation. SOCS1 attenuated HGF-induced proliferation of human and mouse HCC cell lines and their growth as tumors in NOD. scid. gamma mice. Tumors formed by SOCS1 expressing HCC cells showed significantly reduced MET expression, indicating that SOCS1 not only attenuates MET signaling but also regulates MET expression. Mechanistically, SOCS1 interacted with MET via the Src homology 2 domain and this interaction was promoted by MET tyrosine kinase activity. The SOCS1-mediated reduction in MET expression does not require the juxtamembrane Y1003 residue implicated in Cbl-mediated downmodulation. Moreover, the proteasome inhibitor MG-132, but not the inhibitors of lysosomal degradation bafilomycin and chloroquine, reversed the SOCS1-mediated reduction in MET expression, indicating that this process is distinct from Cbl-mediated downmodulation. Accordingly, SOCS1 promoted polyubiquitination of MET via K48-dependent but not K63-mediated ubiquitin chain elongation. Furthermore, siRNA-mediated downmodulation of Cbl did not abolish SOCS1-mediated reduction in MET expression in HCC cells. SOCS1-dependent ubiquitination of endogenous MET receptor occurred rapidly following HGF stimulation in HCC cells, leading to proteasomal degradation of phosphorylated MET receptor. These findings indicate that SOCS1 mediates its tumor suppressor functions, at least partly, by binding to MET and interfering with downstream signaling pathways as well as by promoting the turnover of the activated MET receptor. We propose that loss of this control mechanism due to epigenetic repression of SOCS1 could contribute to oncogenic MET signaling in HCC and other cancers, and that MET inhibitors might be useful in treating these patients.	[Gui, Y.; Yeganeh, M.; Donates, Y-C; Mayhue, M.; Ramanathan, S.; Ilangumaran, S.] Univ Sherbrooke, Ctr Rech Clin Etienne Le Bel, Fac Med & Hlth Sci, Immunol Div,Dept Pediat,Ctr Hosp, Sherbrooke, PQ J1H 5N4, Canada; [Tobelaim, W-S; Chababi, W.; Saucier, C.] Univ Sherbrooke, Ctr Rech Clin Etienne Le Bel, Fac Med & Hlth Sci, Dept Anat & Cell Biol,Ctr Hosp, Sherbrooke, PQ J1H 5N4, Canada; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan	University of Sherbrooke; University of Sherbrooke; Keio University	Ilangumaran, S (corresponding author), Univ Sherbrooke, Ctr Rech Clin Etienne Le Bel, Fac Med & Hlth Sci, Immunol Div,Dept Pediat,Ctr Hosp, 3001 North 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	Subburaj.Ilangumaran@Usherbrooke.ca	Yoshimura, Akihiko/K-5515-2013; Saucier, Caroline/Q-9250-2019	Saucier, Caroline/0000-0001-7678-9886; Ilangumaran, Subburaj/0000-0002-7563-576X	Cancer Research Society, Montreal, Canada; Centre de Recherche Clinique du CHUS	Cancer Research Society, Montreal, Canada; Centre de Recherche Clinique du CHUS	We thank Dr Morag Park for generously providing CSF-MET and Tpr-MET expression plasmids. Centre de Recherche Clinique du CHUS is an FRSQ-funded research center. This work was supported by the Cancer Research Society, Montreal, Canada (SI and CS).	Abella JV, 2010, J BIOL CHEM, V285, P24956, DOI 10.1074/jbc.M110.127985; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; De Sepulveda P, 1999, EMBO J, V18, P904; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Goyal L, 2013, CLIN CANCER RES, V19, P2310, DOI 10.1158/1078-0432.CCR-12-2791; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Gui YR, 2011, J HEPATOL, V55, P1300, DOI 10.1016/j.jhep.2011.03.027; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Ilangumaran S, 2004, SEMIN IMMUNOL, V16, P351, DOI 10.1016/j.smim.2004.08.015; Ilangumaran S, 2002, J IMMUNOL, V169, P5010, DOI 10.4049/jimmunol.169.9.5010; Inagaki-Ohara Kyoko, 2013, JAKSTAT, V2, pe24053, DOI 10.4161/jkst.24053; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Johnston JA, 2004, J LEUKOCYTE BIOL, V75, P743, DOI 10.1189/jlb.1003507; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; Kazi JU, 2014, CELL MOL LIFE SCI, V71, P3297, DOI 10.1007/s00018-014-1619-y; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Kobayashi N, 2012, ONCOTARGET, V3, P1455; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Mak HHL, 2007, ONCOGENE, V26, P7213, DOI 10.1038/sj.onc.1210522; Okumura F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00010; Peschard P, 2007, ONCOGENE, V26, P1276, DOI 10.1038/sj.onc.1210201; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Seki E, 2008, J HEPATOL, V48, P237, DOI 10.1016/j.jhep.2007.08.020; Shakya R, 2013, CANCER RES, V73, P885, DOI 10.1158/0008-5472.CAN-12-1880; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Woelk T, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-11; Xu AM, 2010, CANCER RES, V70, P3857, DOI 10.1158/0008-5472.CAN-10-0163; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007; Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	46	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5718	5728		10.1038/onc.2015.20	http://dx.doi.org/10.1038/onc.2015.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728680				2022-12-28	WOS:000364594600004
J	Meng, X; Carlson, NR; Dong, J; Zhang, Y				Meng, X.; Carlson, N. R.; Dong, J.; Zhang, Y.			Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways	ONCOGENE			English	Article							POLYMERASE-I TRANSCRIPTION; RIBOSOME BIOGENESIS; TUMOR SUPPRESSION; ARF; P53; PROTEIN; MICE; APOPTOSIS; CANCER; TARGET	The multifaceted oncogene c-Myc plays important roles in the development and progression of human cancer. Recent in vitro and in vivo studies have shown that the p19Arf-Mdm2-p53 and the ribosomal protein (RP)-Mdm2-p53 pathways are both essential in preventing oncogenic c-Myc-induced tumorigenesis. Disruption of each pathway individually by p19Arf deletion or by Mdm2(C305F) mutation, which disrupts RP-Mdm2 binding, accelerates E mu-myc transgene-induced pre-B/B-cell lymphoma in mice at seemingly similar paces with median survival around 10 and 11 weeks, respectively, compared to 20 weeks for E mu-myc transgenic mice. Because p19Arf can inhibit ribosomal biogenesis through its interaction with nucleophosmin (NPM/B23), RNA helicase DDX5 and RNA polymerase I transcription termination factor (TTF-I), it has been speculated that the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 pathways might be a single p19Arf-RP-Mdm2-p53 pathway, in which p19Arf activates p53 by inhibiting RP biosynthesis; thus, p19Arf deletion or Mdm2(C305F) mutation would result in similar consequences. Here, we generated mice with concurrent p19Arf deletion and Mdm2(C305F) mutation and investigated the compound mice for tumorigenesis in the absence and the presence of oncogenic c-Myc overexpression. In the absence of E mu-myc transgene, the Mdm2(C305)F mutation did not elicit spontaneous tumors in mice, nor did it accelerate spontaneous tumors in mice with p19Arf deletion. In the presence of E mu-myc transgene, however, Mdm2(C305F) mutation significantly accelerated p19Arf deletion-induced lymphomagenesis and promoted rapid metastasis. We found that when p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways are independently disrupted, oncogenic c-Myc-induced p53 stabilization and activation is only partially attenuated. When both pathways are concurrently disrupted, however, c-Myc-induced p53 stabilization and activation are essentially obliterated. Thus, the p19Arf-Mdm2-p53 and the RP-Mdm2-p53 are non-redundant pathways possessing similar capabilities to activate p53 upon c-Myc overexpression.	[Meng, X.; Carlson, N. R.; Zhang, Y.] Univ N Carolina, Dept Radiat Oncol, Sch Med, Chapel Hill, NC 27514 USA; [Meng, X.; Carlson, N. R.; Zhang, Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA; [Meng, X.; Dong, J.] Chinese Peoples Liberat Army Gen Hosp, Hosp & Inst Hepatobiliary Surg, Beijing, Peoples R China; [Meng, X.; Dong, J.; Zhang, Y.] Xuzhou Med Coll, Inst Canc, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Peoples R China; [Carlson, N. R.; Zhang, Y.] Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Chinese People's Liberation Army General Hospital; Xuzhou Medical University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zhang, Y (corresponding author), Univ N Carolina, Dept Radiat Oncol, Box 7512,101 Manning Dr, Chapel Hill, NC 27514 USA.	ypzhang@med.unc.edu		Meng, Xuan/0000-0002-0257-9509	National Institutes of Health [CA127770, CA100302, CA167637]; NSFC; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; National S&T Major Project for Infectious Diseases of China [2012ZX10002-017]; National Institute of General Medical Sciences [5T32 GM007092]; NATIONAL CANCER INSTITUTE [R01CA167637, R01CA155235, R01CA127770, R01CA100302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; National S&T Major Project for Infectious Diseases of China; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Congying Wu, Yizhou He, Yong Liu, Aiwen Jin and Laura Tollini for their helpful advice and technical assistance. We are in debt to Yue Xiong, Guillermina Lozano, Gerard Evan, Charles Sherr and Norman Sharpless for their generosity in sharing mouse strains and reagents. This research was supported by grants from the National Institutes of Health (CA127770, CA100302 and CA167637) to YZ. This research was also supported by grants from the NSFC and Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy to YZ, the National S&T Major Project for Infectious Diseases of China (No. 2012ZX10002-017) to JD. NRC was supported in part by a grant from the National Institute of General Medical Sciences under award 5T32 GM007092.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Aoudjit F, 1998, BLOOD, V91, P623, DOI 10.1182/blood.V91.2.623.623_623_629; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; de Marval PLM, 2011, ONCOTARGET, V2, P234; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; HOAG WG, 1963, ANN NY ACAD SCI, V108, P805, DOI 10.1111/j.1749-6632.1963.tb13421.x; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Liao JM, 2014, ONCOGENE, V33, P4916, DOI 10.1038/onc.2013.430; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meng X, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-80; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shetty S, 2012, HEPATOLOGY, V56, P1521, DOI 10.1002/hep.25790; SIDMAN CL, 1988, CURR TOP MICROBIOL, V141, P94; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Toth P, 2014, J CEREBR BLOOD F MET, V34, P1887, DOI 10.1038/jcbfm.2014.156; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; White P, 2002, J IMMUNOL, V168, P869, DOI 10.4049/jimmunol.168.2.869; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang Q, 2013, P NATL ACAD SCI USA, V110, P978, DOI 10.1073/pnas.1208334110; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	37	20	22	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5709	5717		10.1038/onc.2015.39	http://dx.doi.org/10.1038/onc.2015.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25823025	Green Accepted, Green Submitted			2022-12-28	WOS:000364594600003
J	Chen, X; Pappo, A; Dyer, MA				Chen, X.; Pappo, A.; Dyer, M. A.			Pediatric solid tumor genomics and developmental pliancy	ONCOGENE			English	Review							EMBRYONAL RHABDOMYOSARCOMA; RETINOBLASTOMA; MUTATIONS; ATRX; NEUROBLASTOMA; CELL; SARCOMA; CHILDHOOD; SURVIVAL; THERAPY	Pediatric solid tumors are remarkably diverse in their cellular origins, developmental timing and clinical features. Over the last 5 years, there have been significant advances in our understanding of the genetic lesions that contribute to the initiation and progression of pediatric solid tumors. To date, over 1000 pediatric solid tumors have been analyzed by Next-Generation Sequencing. These genomic data provide the foundation to launch new research efforts to address one of the fundamental questions in cancer biology-why are some cells more susceptible to malignant transformation by particular genetic lesions at discrete developmental stages than others? Because of their developmental, molecular, cellular and genetic diversity, pediatric solid tumors provide an ideal platform to begin to answer this question. In this review, we highlight the diversity of pediatric solid tumors and provide a new framework for studying the cellular and developmental origins of pediatric cancer. We also introduce a new unifying concept called cellular pliancy as a possible explanation for susceptibility to cancer and the developmental origins of pediatric solid tumors.	[Chen, X.] St Jude Childrens Res Hosp, Dept Computat Biol & Bioinformat, Memphis, TN 38105 USA; [Pappo, A.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Dyer, M. A.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [Dyer, M. A.] Howard Hughes Med Inst, Chevy Chase, MD USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute	Dyer, MA (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, MS 323,262 Danny Thomas Pl, Memphis, TN 38105 USA.	michael.dyer@stjude.org	Dyer, Michael/N-8134-2018; Chen, Xiang/N-2524-2018	Chen, Xiang/0000-0002-2499-8261	NATIONAL CANCER INSTITUTE [R01CA168875] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY018599, R01EY023619, R01EY014867] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [R01 CA168875] Funding Source: Medline; NEI NIH HHS [R01 EY018599, R01 EY023619, R01 EY014867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abramson DH, 2002, ARCH OPHTHALMOL-CHIC, V120, P1232; Ajioka I, 2007, CELL, V131, P378, DOI 10.1016/j.cell.2007.09.036; Argentaro A, 2007, P NATL ACAD SCI USA, V104, P11939, DOI 10.1073/pnas.0704057104; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barr FG, 1997, INT J BIOCHEM CELL B, V29, P1449, DOI 10.1016/S1357-2725(97)00095-2; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Cheung NKV, 2012, JAMA-J AM MED ASSOC, V307, P1062, DOI 10.1001/jama.2012.228; Cole KA, 2012, CLIN CANCER RES, V18, P2423, DOI 10.1158/1078-0432.CCR-11-1409; Costa DB, 2006, EUR J HAEMATOL, V76, P53; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Donovan SL, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-14; Downing JR, 2012, NAT GENET, V44, P619, DOI 10.1038/ng.2287; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; Eustermann S, 2011, NAT STRUCT MOL BIOL, V18, P777, DOI 10.1038/nsmb.2070; Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Garrick D, 2006, PLOS GENET, V2, P438, DOI 10.1371/journal.pgen.0020058; Gibbons RJ, 2003, NAT GENET, V34, P446, DOI 10.1038/ng1213; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Howlader N, 2013, SEER CANC STAT REV 1; Johnson DA, 2007, CANCER RES, V67, P2701, DOI 10.1158/0008-5472.CAN-06-3754; Kempf-Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063; Lada AG, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-47; Leavey PJ, 2008, PEDIATR BLOOD CANCER, V51, P334, DOI 10.1002/pbc.21618; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; MacPherson D, 2007, CANCER RES, V67, P7547, DOI 10.1158/0008-5472.CAN-07-0276; McEvoy J, 2014, ONCOTARGET, V5, P438, DOI 10.18632/oncotarget.1686; McEvoy J, 2011, CANCER CELL, V20, P260, DOI 10.1016/j.ccr.2011.07.005; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Pappo AS, 1999, J CLIN ONCOL, V17, P3487, DOI 10.1200/JCO.1999.17.11.3487; Pickett H, 2009, TELOMERES TELOMERASE; Raney RB, 2001, J PEDIAT HEMATOL ONC, V23, P215, DOI 10.1097/00043426-200105000-00008; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Ruza E, 2003, J PEDIAT HEMATOL ONC, V25, P780, DOI 10.1097/00043426-200310000-00007; Scollon S, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0069-3; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Smith MA, 2014, CANCER-AM CANCER SOC, V120, P2497, DOI 10.1002/cncr.28748; Steensma DP, 2004, BLOOD, V103, P2019, DOI 10.1182/blood-2003-09-3360; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Wamstad JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002814; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318	60	41	42	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5207	5215		10.1038/onc.2014.474	http://dx.doi.org/10.1038/onc.2014.474			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639868	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000362575400001
J	Xu, Y; Miriyala, S; Fang, F; Bakthavatchalu, V; Noel, T; Schell, DM; Wang, C; St Clair, WH; St Clair, DK				Xu, Y.; Miriyala, S.; Fang, F.; Bakthavatchalu, V.; Noel, T.; Schell, D. M.; Wang, C.; St Clair, W. H.; St Clair, D. K.			Manganese superoxide dismutase deficiency triggers mitochondrial uncoupling and the Warburg effect	ONCOGENE			English	Article							SKIN CARCINOGENESIS MODEL; LIPID-PEROXIDATION; CANCER METABOLISM; OXIDATIVE STRESS; EPITHELIAL-CELLS; PROTEIN-2; OVEREXPRESSION; EXPRESSION; GLUCOSE; ALPHA	Manganese superoxide dismutase (MnSOD) is a mitochondrially localized primary antioxidant enzyme, known to be essential for the survival of aerobic life and to have important roles in tumorigenesis. Here, we show that MnSOD deficiency in skin tissues of MnSOD-heterozygous knockout (Sod2(+/) (-)) mice leads to increased expresson of uncoupling proteins (UCPs). When MnSOD is deficient, superoxide radical and its resulting reactive oxygen species (ROS) activate ligand binding to peroxisome proliferator-activated receptor alpha (PPAR alpha), suggesting that the activation of PPAR alpha signaling is a major mechanism underlying MnSOD-dependent UCPs expression that consequently triggers the PI3K/Akt/mTOR pathway, leading to increased aerobic glycolysis. Knockdown of UCPs and mTOR suppresses lactate production and increases ATP levels, suggesting that UCPs contribute to increased glycolysis. These results highlight the existence of a free radical-mediated mechanism that activates mitochondria uncoupling to reduce ROS production, which precedes the glycolytic adaptation described as the Warburg Effect.	[Xu, Y.] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Miriyala, S.; Bakthavatchalu, V.; Noel, T.; Schell, D. M.; St Clair, D. K.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Fang, F.; St Clair, W. H.] Univ Kentucky, Dept Radiat Med, Lexington, KY USA; [Wang, C.; St Clair, D. K.] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA	Nanjing Medical University; University of Kentucky; University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Coll Med, Grad Ctr Toxicol, 1095 VA Dr, Lexington, KY 40536 USA.	yxu03558@yahoo.com; dstcl00@uky.edu		Miriyala, Sumitra/0000-0001-7158-9295	National Institutes of Health [CA 049797, CA 143428]; Edward P. Evans Foundation grant; National Nature Science Foundation of China [81372199];  [CA 073599]; NATIONAL CANCER INSTITUTE [R01CA049797, R01CA143428, R29CA049797, R01CA073599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007778] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Edward P. Evans Foundation grant; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants CA 049797 and CA 143428, and an Edward P. Evans Foundation grant to Daret K. St Clair; CA 073599 and CA 143428 to William H. St Clair; and National Nature Science Foundation of China grant 81372199 to Yong Xu. We would like to thank Dr Ronald M. Evans, Howard Hughes Medical Institute, San Diego, California 92186, USA, for providing the PPREx3-TK-luciferase construct for this study.	Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Baffy G, 2010, MITOCHONDRION, V10, P243, DOI 10.1016/j.mito.2009.12.143; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Bouillaud F, 2009, BBA-BIOENERGETICS, V1787, P377, DOI 10.1016/j.bbabio.2009.01.003; Criscuolo F, 2006, BBA-BIOENERGETICS, V1757, P1284, DOI 10.1016/j.bbabio.2006.06.002; Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233; Diano S, 2012, TRENDS MOL MED, V18, P52, DOI 10.1016/j.molmed.2011.08.003; Echtay KS, 2007, FREE RADICAL BIO MED, V43, P1351, DOI 10.1016/j.freeradbiomed.2007.08.011; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Ferreira LMR, 2010, EXP MOL PATHOL, V89, P372, DOI 10.1016/j.yexmp.2010.08.006; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Holley AK, 2014, ANTIOXID REDOX SIGN, V20, P2347, DOI 10.1089/ars.2013.5204; Holley AK, 2013, MITOCHONDRION, V13, P170, DOI 10.1016/j.mito.2012.07.104; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Horimoto M, 2004, CLIN CANCER RES, V10, P6203, DOI 10.1158/1078-0432.CCR-04-0419; Ilizarov AM, 2001, AM J RESP CELL MOL, V24, P436, DOI 10.1165/ajrcmb.24.4.4240; Jansen S, 2009, REPRODUCTION, V138, P493, DOI 10.1530/REP-09-0038; Jarmuszkiewicz W, 2010, BBA-BIOENERGETICS, V1797, P792, DOI 10.1016/j.bbabio.2009.12.005; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Keller JN, 1998, J NEUROSCI, V18, P687; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lin J, 2010, CANCER PREV RES, V3, P505, DOI 10.1158/1940-6207.CAPR-09-0263; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; Miriyala S, 2011, ANTI-CANCER AGENT ME, V11, P181, DOI 10.2174/187152011795255920; Nagano Y, 2012, J PHYSIOL PHARMACOL, V63, P137; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley TD, 2004, ANTIOXID REDOX SIGN, V6, P537, DOI 10.1089/152308604773934297; Okiyama W, 2009, J HEPATOL, V50, P1236, DOI 10.1016/j.jhep.2009.01.025; Patterson AD, 2012, HEPATOLOGY, V56, P281, DOI 10.1002/hep.25645; Pecqueur C, 2008, FASEB J, V22, P9, DOI 10.1096/fj.07-8945com; Porter RK, 2001, BBA-BIOENERGETICS, V1504, P120, DOI 10.1016/S0005-2728(00)00246-2; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Silva JP, 2005, EMBO J, V24, P4061, DOI 10.1038/sj.emboj.7600866; Sluse FE, 2006, BBA-BIOENERGETICS, V1757, P480, DOI 10.1016/j.bbabio.2006.02.004; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Teruel T, 2003, J BIOL CHEM, V278, P263, DOI 10.1074/jbc.M207200200; Valle Adamo, 2010, Cancers (Basel), V2, P567, DOI 10.3390/cancers2020567; Van Remmen H, 2001, AM J PHYSIOL-HEART C, V281, pH1422, DOI 10.1152/ajpheart.2001.281.3.H1422; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Vozza A, 2014, P NATL ACAD SCI USA, V111, P960, DOI 10.1073/pnas.1317400111; Xu Y, 2013, CANCER RES, V73, P4406, DOI 10.1158/0008-5472.CAN-12-4297; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835	50	25	25	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4229	4237		10.1038/onc.2014.355	http://dx.doi.org/10.1038/onc.2014.355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362851	Green Accepted			2022-12-28	WOS:000359199800009
J	Nitta, RT; Gholamin, S; Feroze, AH; Agarwal, M; Cheshier, SH; Mitra, SS; Li, G				Nitta, R. T.; Gholamin, S.; Feroze, A. H.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.			Casein kinase 2 alpha regulates glioblastoma brain tumor-initiating cell growth through the beta-catenin pathway	ONCOGENE			English	Article							CANCER STEM-CELL; PROTEIN-KINASE; SELF-RENEWAL; IN-VIVO; ALPHA-CATENIN; CK2; INHIBITION; EXPRESSION; NOTCH; TUMORIGENICITY	Glioblastoma (GBM) is the most common and fatal primary brain tumor in humans, and it is essential that new and better therapies are developed to treat this disease. Previous research suggests that casein kinase 2 (CK2) may be a promising therapeutic target for GBMs. CK2 has enhanced expression or activity in numerous cancers, including GBM, and it has been demonstrated that inhibitors of CK2 regressed tumor growth in GBM xenograft mouse models. Our studies demonstrate that the CK2 subunit, CK2 alpha, is overexpressed in and has an important role in regulating brain tumor-initiating cells (BTIC) in GBM. Initial studies showed that two GBM cell lines (U87-MG and U138) transduced with CK2 alpha had enhanced proliferation and anchorage-independent growth. Inhibition of CKa using siRNA or small-molecule inhibitors (TBBz, CX-4945) reduced cell growth, decreased tumor size, and increased survival rates in GBM xenograft mouse models. We also verified that inhibition of CK2 alpha decreased the activity of a well-known GBM-initiating cell regulator, beta-catenin. Loss of CK2 alpha decreased two beta-catenin-regulated genes that are involved in GBM-initiating cell growth, OCT4 and NANOG. To determine the importance of CK2 alpha in GBM stem cell maintenance, we reduced CK2 alpha activity in primary GBM samples and tumor spheres derived from GBM patients. We discovered that loss of CK2 alpha activity reduced the sphere-forming capacity of BTIC and decreased numerous GBM stem cell markers, including CD133, CD90, CD49f and A2B5. Our study suggests that CK2 alpha is involved in GBM tumorigenesis by maintaining BTIC through the regulation of beta-catenin.	[Nitta, R. T.; Gholamin, S.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Gholamin, S.; Feroze, A. H.; Cheshier, S. H.; Mitra, S. S.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Li, G (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, 1201 Welch Rd P309, Stanford, CA 94305 USA.	gordonli@stanford.edu		Gholamin, Sharareh/0000-0001-7425-6074; Li, Gordon/0000-0001-8372-0676	K08 Mentored Research Grant [NIH-KNS085333A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS085333] Funding Source: NIH RePORTER	K08 Mentored Research Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Albert Wong for the use of equipment and resources. We also thank Tim Bui for his useful discussions and Cheryl Christensen for her critical review of the paper. This work was supported by the K08 Mentored Research Grant (NIH-KNS085333A) as well as the generous donation from Mr Keith Tsu and Ms Carmelita Ko.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Adesina AM, 2009, HUM PATHOL, V40, P843, DOI 10.1016/j.humpath.2008.10.022; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beier Christoph P, 2011, Front Biosci (Elite Ed), V3, P701, DOI 10.2741/e280; Cheong JW, 2010, ANTICANCER RES, V30, P4625; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; D'Amour KA, 2002, NAT MED, V8, P213, DOI 10.1038/nm0302-213; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Del Vecchio CA, 2012, CANCER RES, V72, P2657, DOI 10.1158/0008-5472.CAN-11-2656; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; He J, 2012, CURR MED CHEM, V19, P6050; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huillard E, 2010, MOL CELL BIOL, V30, P2737, DOI 10.1128/MCB.01566-09; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee Y, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-52; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Louis D, 1997, WHO CLASSIFICATION T, P33; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Moucadel V, 2011, ONCOTARGET, V2, P997; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nager Mireia, 2012, Chemother Res Pract, V2012, P192362, DOI 10.1155/2012/192362; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Nitta RT, 2010, METHOD ENZYMOL, V484, P531, DOI [10.1016/S0076-6879(10)84026-1, 10.1016/B978-0-12-381298-8.00026-5]; Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337; Pagano MA, 2008, BIOCHEM J, V415, P353, DOI 10.1042/BJ20080309; Pierfelice TJ, 2008, COLD SH Q B, V73, P367, DOI 10.1101/sqb.2008.73.013; Ponce DP, 2011, MOL CELL BIOCHEM, V356, P127, DOI 10.1007/s11010-011-0965-4; Ponce DP, 2011, J CELL PHYSIOL, V226, P1953, DOI 10.1002/jcp.22527; Prudent R, 2010, CANCER RES, V70, P9865, DOI 10.1158/0008-5472.CAN-10-0917; Prudent R, 2010, METHOD ENZYMOL, V485, P597, DOI [10.1016/B978-0-12-381296-4.00031-2, 10.1016/S0076-6879(10)85031-1]; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Son YH, 2013, ARCH PHARM RES, V36, P840, DOI 10.1007/s12272-013-0103-9; Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trembley JH, 2010, BIOFACTORS, V36, P187, DOI 10.1002/biof.96; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang SL, 2013, J CELL MOL MED, V17, P854, DOI 10.1111/jcmm.12068; Zhang SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038996; Zheng Y, 2013, CLIN CANCER RES, V19, P6484, DOI 10.1158/1078-0432.CCR-13-0265	47	42	44	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3688	3699		10.1038/onc.2014.299	http://dx.doi.org/10.1038/onc.2014.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241897	Green Accepted			2022-12-28	WOS:000357679100007
J	Shaukat, Z; Liu, D; Choo, A; Hussain, R; O'Keefe, L; Richards, R; Saint, R; Gregory, SL				Shaukat, Z.; Liu, D.; Choo, A.; Hussain, R.; O'Keefe, L.; Richards, R.; Saint, R.; Gregory, S. L.			Chromosomal instability causes sensitivity to metabolic stress	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; OXIDATIVE STRESS; CANCER-CELLS; PAS KINASE; ANEUPLOIDY; DROSOPHILA; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DNA; MITOCHONDRIA; DEHYDROGENASE	Chromosomal INstability (CIN), a hallmark of cancer, refers to cells with an increased rate of gain or loss of whole chromosomes or chromosome parts. CIN is linked to the progression of tumors with poor clinical outcomes such as drug resistance. CIN can give tumors the diversity to resist therapy, but it comes at the cost of significant stress to tumor cells. To tolerate this, cancer cells must modify their energy use to provide adaptation against genetic changes as well as to promote their survival and growth. In this study, we have demonstrated that CIN induction causes sensitivity to metabolic stress. We show that mild metabolic disruption that does not affect normal cells, can lead to high levels of oxidative stress and subsequent cell death in CIN cells because they are already managing elevated stress levels. Altered metabolism is a differential characteristic of cancer cells, so our identification of key regulators that can exploit these changes to cause cell death may provide cancer-specific potential drug targets, especially for advanced cancers that exhibit CIN.	[Shaukat, Z.; Liu, D.; Choo, A.; Hussain, R.; O'Keefe, L.; Richards, R.; Saint, R.; Gregory, S. L.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5006, Australia	University of Adelaide	Gregory, SL (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, N Terrace, Adelaide, SA 5006, Australia.	stephen.gregory@adelaide.edu.au	Choo, Amanda/ABA-9721-2021; Gregory, Stephen L/B-9918-2008; O'Keefe, Louise V/B-9856-2008; Saint, Robert/A-4190-2008; Richards, Robert/ABE-6423-2020	Gregory, Stephen L/0000-0002-0046-5815; Saint, Robert/0000-0002-7989-6043; Choo, Amanda/0000-0002-4510-3615				Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Bauer G, 2012, ANTICANCER RES, V32, P2599; Beumer KJ, 2008, P NATL ACAD SCI USA, V105, P19821, DOI 10.1073/pnas.0810475105; Buffin E, 2007, NAT CELL BIOL, V9, P565, DOI 10.1038/ncb1570; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Coe JP, 2002, FREE RADICAL BIO MED, V32, P187, DOI 10.1016/S0891-5849(01)00792-4; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Fang J, 2007, J DRUG TARGET, V15, P475, DOI 10.1080/10611860701498286; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Hao HX, 2008, IUBMB LIFE, V60, P204, DOI 10.1002/iub.32; Hao HX, 2007, P NATL ACAD SCI USA, V104, P15466, DOI 10.1073/pnas.0705407104; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hockenbery DM, 2010, ENVIRON MOL MUTAGEN, V51, P476, DOI 10.1002/em.20552; Holen K, 2008, INVEST NEW DRUG, V26, P45, DOI 10.1007/s10637-007-9083-2; Iijima K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008498; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; KAPLAN O, 1990, CANCER RES, V50, P544; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kuo WY, 2000, INT J CANCER, V85, P857, DOI 10.1002/(SICI)1097-0215(20000315)85:6<857::AID-IJC20>3.3.CO;2-L; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Liu JK, 1996, FASEB J, V10, P1532, DOI 10.1096/fasebj.10.13.8940299; Manganelli Genesia, 2013, Cardiovascular & Hematological Disorders - Drug Targets, V13, P73; MERTENS F, 1994, PEDIATR HEMAT ONCOL, V11, P361, DOI 10.3109/08880019409140536; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; O'Keefe LV, 2011, HUM MOL GENET, V20, P497, DOI 10.1093/hmg/ddq495; Owusu-Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313; Ozben T, 2007, J PHARM SCI-US, V96, P2181, DOI 10.1002/jps.20874; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Puzio-Kuter Anna M, 2011, Genes Cancer, V2, P385, DOI 10.1177/1947601911409738; Radyuk SN, 2010, FREE RADICAL BIO MED, V49, P1892, DOI 10.1016/j.freeradbiomed.2010.09.014; Ren JG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012520; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Sajesh BV, 2013, GENETICS, V195, P757, DOI 10.1534/genetics.113.156836; Schlafli P, 2009, CELL MOL LIFE SCI, V66, P876, DOI 10.1007/s00018-009-8699-0; Shaukat Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047447; Sheltzer JM, 2012, P NATL ACAD SCI USA, V109, P12644, DOI 10.1073/pnas.1209227109; Sotgia F, 2013, ONCOTARGET, V4, P1309, DOI 10.18632/oncotarget.1182; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Tanaka T, 2006, CELL CYCLE, V5, P1940, DOI 10.4161/cc.5.17.3191; Terhzaz S, 2010, PHYSIOL GENOMICS, V41, P33, DOI 10.1152/physiolgenomics.00147.2009; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Wang JX, 2012, TUMOR BIOL, V33, P95, DOI 10.1007/s13277-011-0251-9; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Wong HW-S, 2013, CELL CYCLE, V13, P1; Wu Defeng, 2005, Toxicol Appl Pharmacol, V207, P70, DOI 10.1016/j.taap.2005.01.057; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang CH, 2014, ANTI-CANCER AGENT ME, V14, P280, DOI 10.2174/18715206113136660337; Zhang JD, 2007, BBA-MOL BASIS DIS, V1772, P1175, DOI 10.1016/j.bbadis.2007.10.001	65	26	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4044	4055		10.1038/onc.2014.344	http://dx.doi.org/10.1038/onc.2014.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347746				2022-12-28	WOS:000358780500003
J	Mi, W; Lin, Q; Childress, C; Sudol, M; Robishaw, J; Berlot, CH; Shabahang, M; Yang, W				Mi, W.; Lin, Q.; Childress, C.; Sudol, M.; Robishaw, J.; Berlot, C. H.; Shabahang, M.; Yang, W.			Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration	ONCOGENE			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN PRENYLATION; YAP; GROWTH; GERANYLGERANYLTRANSFERASE; METASTASIS; MEVALONATE; INHIBITOR; RAS; TUMORIGENESIS	Protein geranylgeranylation (GGylation) is an important biochemical process for many cellular signaling molecules. Previous studies have shown that GGylation is essential for cell survival in many types of cancer. However, the molecular mechanism mediating the cell survival effect remains elusive. In this report, we show that the Hippo pathway mediates GGylation-dependent cell proliferation and migration in breast cancer cells. Blockade of GGylation enhanced phosphorylation of Mst1/2 and Lats1, and inhibited YAP and TAZ activity and the Hippo-YAP/TAZ pathway-dependent transcription. The effect of GGylation blockade on inhibition of breast cancer cell proliferation and migration is dependent on the Hippo-YAP/TAZ signaling, in which YAP appears to regulate cell proliferation and TAZ to regulate cell migration. Furthermore, GGylation-dependent cell proliferation is correlated with the activity of YAP/TAZ in breast cancer cells. Finally, G gamma and RhoA are the GGylated proteins that may transduce GGylation signals to the Hippo-YAP/TAZ pathway. Taken together, our studies have demonstrated that the Hippo-YAP/TAZ pathway is essential for GGylation-dependent cancer cell proliferation and migration.	[Mi, W.; Lin, Q.; Childress, C.; Sudol, M.; Robishaw, J.; Berlot, C. H.; Yang, W.] Weis Ctr Res, Danville, PA USA; [Lin, Q.] Jiangsu Univ, Sch Med Sci & Lab Med, Zhenjiang, Peoples R China; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Shabahang, M.] Weis Ctr Res, Geisinger Clin, Dept Gen Surg, Danville, PA 17822 USA	Jiangsu University; Icahn School of Medicine at Mount Sinai	Yang, W (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	wyang1@geisinger.edu	Yang, Wannian/K-4836-2019		Geisinger Research Large Grant [SRC-081]; NIH [R01GM050369]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050369] Funding Source: NIH RePORTER	Geisinger Research Large Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Pradines of the Departement Innovation Therapeutique et Oncologie Moleculaire, Centre de Physiopathologie, Institut Claudius Regaud for sending us wild-type and the farnesylated RhoA plasmids, Dr Steyger of Oregon Hearing Research Center for the retroviral plasmid pBabe-TRPV4 and Dr Kunliang Guan of University of California at San Diego for HEK293A cell line. This research was supported by Geisinger Research Large Grant (SRC-081, to WY) and NIH R01GM050369 (to CHB).	Ahmed SM, 2010, J BIOL CHEM, V285, P6538, DOI 10.1074/jbc.M109.069948; Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Budman DR, 2007, BREAST CANCER RES TR, V104, P93, DOI 10.1007/s10549-006-9395-5; Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cuello M, 2013, REV MED CHILE, V141, P227, DOI 10.4067/S0034-98872013000200013; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139; Falsetti SC, 2007, MOL CELL BIOL, V27, P8003, DOI 10.1128/MCB.00057-07; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x; Goard CA, 2014, BREAST CANCER RES TR, V143, P301, DOI 10.1007/s10549-013-2800-y; Hill VK, 2011, EPIGENETICS-US, V6, P326, DOI 10.4161/epi.6.3.14404; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kirui JK, 2010, J PHARMACOL EXP THER, V333, P393, DOI 10.1124/jpet.109.164814; Kubatka P, 2011, Klin Onkol, V24, P41; Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055-9965.EPI-07-0726; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; Lehmann DM, 2008, MOL PHARMACOL, V73, P410, DOI 10.1124/mol.107.041780; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Onono F, 2013, J BIOL CHEM, V288, P27444, DOI 10.1074/jbc.M113.482307; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Saini DK, 2007, J BIOL CHEM, V282, P24099, DOI 10.1074/jbc.M701191200; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shen F, 2007, MOL BIOL CELL, V18, P732, DOI 10.1091/mbc.E06-02-0142; Shibata MA, 2004, CARCINOGENESIS, V25, P1887, DOI 10.1093/carcin/bgh201; Sjogren AKM, 2007, J CLIN INVEST, V117, P1294, DOI 10.1172/JCI30868; Smrcka AV, 2008, CELL MOL LIFE SCI, V65, P2191, DOI 10.1007/s00018-008-8006-5; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; Song M, 2012, ANTICANCER RES, V32, P3827; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sudol M, 2012, SEMIN CELL DEV BIOL, V23, P827, DOI 10.1016/j.semcdb.2012.05.002; Sung JZ, 1999, J BIOL CHEM, V274, P6930; Tang XY, 2011, J BIOL CHEM, V286, P13244, DOI 10.1074/jbc.M110.206615; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Xiang SY, 2013, BBA-MOL CELL BIOL L, V1831, P213, DOI 10.1016/j.bbalip.2012.09.004; XU TA, 1995, DEVELOPMENT, V121, P1053; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303	62	56	58	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3095	3106		10.1038/onc.2014.251	http://dx.doi.org/10.1038/onc.2014.251			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109332				2022-12-28	WOS:000356101100002
J	Chen, HH; Yu, HI; Cho, WC; Tarn, WY				Chen, H-H; Yu, H-I; Cho, W-C; Tarn, W-Y			DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway	ONCOGENE			English	Article							RNA HELICASE DDX3; PROTEIN; BETA; TRANSLATION; REQUIREMENT; REVEALS; TARGET; GROWTH; YEAST; RAC1	The DEAD-box RNA helicase DDX3 is a versatile protein involved in multiple steps of gene expression and various cellular signaling pathways. DDX3 mutations have been implicated in the wingless (Wnt) type of medulloblastoma. We show here that small interfering RNA-mediated DDX3 knockdown in various cell lines increased cell-cell adhesion but decreased cell-extracellular matrix adhesion. Moreover, DDX3 depletion suppressed cell motility and impaired directional migration in the wound-healing assay. Accordingly, DDX3-depleted cells exhibited reduced invasive capacities in vitro as well as reduced metastatic potential in mice. We also examined the mechanism underlying DDX3-regulated cell migration. DDX3 knockdown reduced the levels of both Rac1 and beta-catenin proteins, and consequentially downregulated the expression of several beta-catenin target genes. Moreover, we demonstrated that DDX3-regulated Rac1 mRNA translation, possibly through an interaction with its 5'-untranslated region, and affected beta-catenin protein stability in an Rac1-dependent manner. Taken together, our results indicate the DDX3-Rac1-beta-catenin regulatory axis in modulating the expression of Wnt/beta-catenin target genes. Therefore, this report provides a mechanistic context for the role of DDX3 in Wnt-type tumors.	[Chen, H-H; Yu, H-I; Cho, W-C; Tarn, W-Y] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tarn, WY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	wtarn@ibms.sinica.edu.tw	Tarn, Woan-Yuh/N-8464-2018		National Health Research Institutes of Taiwan [NHRI-EX101-10046NI]	National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan)	We thank Dr Yi-Shing Shieh for the TOPflash and FOPflash vectors, and Cho-Ying Chiang for technical assistance. This work was supported by a grant (NHRI-EX101-10046NI to WYT) from the National Health Research Institutes of Taiwan.	Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Chang FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028587; Chen BD, 2011, CELL MOL NEUROBIOL, V31, P251, DOI 10.1007/s10571-010-9615-8; Cheon SS, 2006, FASEB J, V20, P692, DOI 10.1096/fj.05-4759com; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Cruciat CM, 2013, SCIENCE, V339, P1436, DOI 10.1126/science.1231499; Fukumura J, 2003, J BIOCHEM, V134, P71, DOI 10.1093/jb/mvg126; Grallert B, 2000, J CELL SCI, V113, P1447; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Kang DW, 2010, CANCER RES, V70, P4233, DOI 10.1158/0008-5472.CAN-09-3470; Koshio J, 2013, CANCER IMMUNOL IMMUN, V62, P1619, DOI 10.1007/s00262-013-1467-x; Lai MC, 2008, MOL BIOL CELL, V19, P3847, DOI 10.1091/mbc.E07-12-1264; Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Li JS, 2004, AM J PHYSIOL-ENDOC M, V286, pE818, DOI 10.1152/ajpendo.00307.2003; Marsden S, 2006, J MOL BIOL, V361, P327, DOI 10.1016/j.jmb.2006.06.016; Miao XY, 2013, INT J CLIN EXP PATHO, V6, P179; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Schroder M, 2008, EMBO J, V27, P2147, DOI 10.1038/emboj.2008.143; Soto-Rifo R, 2013, NUCLEIC ACIDS RES, V41, P6286, DOI 10.1093/nar/gkt306; Soto-Rifo R, 2012, EMBO J, V31, P3745, DOI 10.1038/emboj.2012.220; Soulat D, 2008, EMBO J, V27, P2135, DOI 10.1038/emboj.2008.126; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Tarn WY, 2009, RNA BIOL, V6, P17, DOI 10.4161/rna.6.1.7440; Vidali L, 2006, MOL BIOL CELL, V17, P2377, DOI 10.1091/mbc.e05-10-0955; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Yang QS, 2005, BIOCHEMISTRY-US, V44, P13591, DOI 10.1021/bi0508946; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; Zavarella S, 2009, J NEUROSURG-PEDIATR, V4, P97, DOI 10.3171/2009.4.PEDS08322; Zhu G, 2012, ONCOGENE, V31, P1001, DOI 10.1038/onc.2011.294	37	85	89	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2790	2800		10.1038/onc.2014.190	http://dx.doi.org/10.1038/onc.2014.190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043297				2022-12-28	WOS:000354979500011
J	Yeom, E; Hong, ST; Choi, KW				Yeom, E.; Hong, S-T; Choi, K-W			Crumbs interacts with Xpd for nuclear division control in Drosophila	ONCOGENE			English	Article							TRANSMEMBRANE PROTEIN CRUMBS; EPITHELIAL-CELLS; DNA METABOLISM; MUTATIONS; POLARITY; MELANOGASTER; COMPLEX; MORPHOGENESIS; ORGANIZATION; EXPRESSION	Crumbs (Crb) family proteins are crucial for cell polarity. Recent studies indicate that they are also involved in growth regulation and cancer. However, it is not well-understood how Crb participates in mitotic processes. Here, we report that Drosophila Crb is critically involved in nuclear division by interacting with Xeroderma pigmentosum D (XPD). A novel gene named galla-1 was identified from a genetic screen for crb modifiers. Galla-1 protein shows homology to MIP18, a subunit of the mitotic spindle-associated MMS19-XPD complex. Loss-of-function galla-1 mutants show abnormal chromosome segregation, defective centrosome positions and branched spindles during nuclear division in early embryos. Embryos with loss-of-function or overexpression of crb show similar mitotic defects and genetic interaction with galla-1. Both Galla-1 and Crb proteins show overlapping localization with spindle microtubules during nuclear division. Galla-1 physically interacts with the intracellular domain of Crb. Interestingly, Galla-1 shows little binding to the Drosophila homolog of XPD, but a related protein Galla-2 binds both Crb and Xpd. Loss-of-function galla-2 mutants show similar mitotic defects as galla-1 and strong genetic interaction with crb. Xpd can form a physical complex with Crb. In imaginal disc, Crb overexpression causes tissue overgrowth as well as DNA damages marked by H2Av phosphorylation. These phenotypes are suppressed by reduction of Xpd. Taken together, this study identifies a novel Crb-Galla-Xpd complex and its function for proper chromosome segregation during nuclear division, implicating a potential link between Crb and Xpd-related genome instability.	[Yeom, E.; Hong, S-T; Choi, K-W] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Choi, K-W] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Choi, KW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Taejon 305701, South Korea.	kchoi100@kaist.ac.kr	Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065; Hong, Sung-Tae/0000-0001-5981-4859	World Class University Program [R31-2008-000-10071-0]; National President Fellowship [35B-2011-1-C00033]; National Research Laboratory grant through the National Research Foundation of Korea - Ministry of Education, Science Technology [NRF-2011-0028326]	World Class University Program; National President Fellowship; National Research Laboratory grant through the National Research Foundation of Korea - Ministry of Education, Science Technology	We are grateful to Kyung-Ok Cho, Sang-Chul Nam and Walton Jones for critical comments on the manuscript. We thank Beat Suter and Tom Kaufmann for xpd mutant and anti-centrosomin antibody, respectively. We also thank Yang Hong for Crb::GFP and crb mutant alleles. We acknowledge the Bloomington Drosophila Stock Center, the National Institute of Genetics stock center and the Developmental Studies Hybridoma Bank for fly stocks and antibodies. This research was supported by grants from the World Class University Program (R31-2008-000-10071-0), the National President Fellowship (35B-2011-1-C00033) and the National Research Laboratory grant (NRF-2011-0028326) through the National Research Foundation of Korea funded by the Ministry of Education, Science & Technology.	Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brust-Mascher I, 2007, INT REV CYTOL, V259, P139, DOI 10.1016/S0074-7696(06)59004-7; Cameroni E, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-24; Capalbo L, 2011, P NATL ACAD SCI USA, V108, P17343, DOI 10.1073/pnas.1103720108; Chen CL, 2010, P NATL ACAD SCI USA, V107, P15810, DOI 10.1073/pnas.1004060107; Chen J, 2003, NATURE, V424, P228, DOI 10.1038/nature01746; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; den Hollander AI, 2001, HUM MOL GENET, V10, P2767, DOI 10.1093/hmg/10.24.2767; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gao GJ, 2009, P NATL ACAD SCI USA, V106, P10728, DOI 10.1073/pnas.0902707106; Gari K, 2012, SCIENCE, V337, P243, DOI 10.1126/science.1219664; Grzeschik NA, 2010, CURR BIOL, V20, P573, DOI 10.1016/j.cub.2010.01.055; Hehnly H, 2014, DEV CELL, V28, P497, DOI 10.1016/j.devcel.2014.01.014; Herranz H, 2006, EMBO REP, V7, P297, DOI 10.1038/sj.embor.7400617; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Huang J, 2009, P NATL ACAD SCI USA, V106, P8284, DOI 10.1073/pnas.0900641106; Ito S, 2010, MOL CELL, V39, P632, DOI 10.1016/j.molcel.2010.07.029; Izaddoost S, 2002, NATURE, V416, P178, DOI 10.1038/nature720; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; KNUST E, 1987, EMBO J, V6, P761, DOI 10.1002/j.1460-2075.1987.tb04818.x; Li KJ, 1996, CELL, V85, P585, DOI 10.1016/S0092-8674(00)81258-1; Li XM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000876; Ling C, 2010, P NATL ACAD SCI USA, V107, P10532, DOI 10.1073/pnas.1004279107; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Medina E, 2002, J CELL BIOL, V158, P941, DOI 10.1083/jcb.200203080; Parsons LM, 2010, FLY, V4, P288, DOI 10.4161/fly.4.4.13116; Pellikka M, 2002, NATURE, V416, P143, DOI 10.1038/nature721; PERRIMON N, 1984, GENETICS, V108, P927; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Stehling O, 2012, SCIENCE, V337, P195, DOI 10.1126/science.1219723; Su TT, 2001, CURR BIOL, V11, P8, DOI 10.1016/S0960-9822(00)00042-7; Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	42	14	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2777	2789		10.1038/onc.2014.202	http://dx.doi.org/10.1038/onc.2014.202			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065591	Bronze			2022-12-28	WOS:000354979500010
J	Ng, KY; Yin, T; Machida, K; Wu, YI; Mayer, BJ				Ng, K. Y.; Yin, T.; Machida, K.; Wu, Y. I.; Mayer, B. J.			Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; FACTOR-INDUCED ACTIVATION; PROTEIN-TYROSINE KINASE; PROLINE-RICH SEQUENCES; V-CRK; ADAPTER PROTEIN; CELL-MIGRATION; NEGATIVE REGULATION; MOLECULAR RESPONSE; DOCKING PROTEIN	The Crk SH2/SH3 adaptor and the Abl nonreceptor tyrosine kinase were first identified as oncoproteins, and both can induce tumorigenesis when overexpressed or mutationally activated. We previously reported the surprising finding that inhibition or knockdown of Abl family kinases enhanced transformation of mouse fibroblasts by CrkI. Abl family inhibitors are currently used or are being tested for treatment of human malignancies, and our finding raised concerns that such inhibitors might actually promote the growth of tumors overexpressing CrkI. Here, we identify the Dok1 adaptor as the key effector for the enhancement of CrkI transformation by Abl inhibition. We show that phosphorylation of tyrosines 295 and 361 of Dok1 by Abl family kinases suppresses CrkI transforming activity, and that upon phosphorylation these tyrosines bind the SH2 domains of the Ras inhibitor p120 RasGAP. Knockdown of RasGAP resulted in a similar enhancement of CrkI transformation, consistent with a critical role for Ras activity. Imaging studies using a FRET sensor of Ras activation revealed alterations in the localization of activated Ras in CrkI-transformed cells. Our results support a model in which Dok1 phosphorylation normally suppresses localized Ras pathway activity in Crk-transformed cells via recruitment and/or activation of RasGAP, and that preventing this negative feedback mechanism by inhibiting Abl family kinases leads to enhanced transformation by Crk.	[Ng, K. Y.; Machida, K.; Mayer, B. J.] Univ Connecticut, Ctr Hlth, Raymond & Beverly Sackler Lab Genet & Mol Med, Dept Genet & Dev Biol, Farmington, CT 06030 USA; [Yin, T.; Wu, Y. I.; Mayer, B. J.] Univ Connecticut, Ctr Hlth, Richard D Berlin Ctr Cell Anal & Modeling, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	bmayer@uchc.edu			National Institutes of Health [CA82258, NS071216]; NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS071216] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Sofya Borinskaya for technical help in soft agar colony counting, Mari Ogiue-Ikeda for the preparation of the SH2 probes and Joshua Jadwin for critically reading this manuscript. In addition, we greatly appreciate Pier Paolo Pandolfi from Harvard Medical School for generously providing the human Dok1 cDNA. This study was supported by grants CA82258 (to BJM) and NS071216 (to YIW) from the National Institutes of Health.	ABELSON HT, 1970, CANCER RES, V30, P2213; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Ashman LK, 2013, EXPERT OPIN INV DRUG, V22, P103, DOI 10.1517/13543784.2013.740010; Bell Emily S, 2012, Genes Cancer, V3, P341, DOI 10.1177/1947601912459951; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Downey C, 2008, CELL MOL LIFE SCI, V65, P1446, DOI 10.1007/s00018-008-8038-x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hodgson L., 2010, CURR PROTOC CELL BIO, DOI [10.1002/0471143030.cb1411s46, DOI 10.1002/0471143030.CB1411S46]; Hughes TP, 2014, BLOOD, V123, P1353, DOI 10.1182/blood-2013-06-510396; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027; Lee S, 2004, ONCOGENE, V23, P2287, DOI 10.1038/sj.onc.1207385; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Machida K, 2007, MOL CELL, V26, P899, DOI 10.1016/j.molcel.2007.05.031; Mashima R, 2010, LAB INVEST, V90, P1357, DOI 10.1038/labinvest.2010.121; Mashima R, 2009, IMMUNOL REV, V232, P273, DOI 10.1111/j.1600-065X.2009.00844.x; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mihrshahi R, 2009, J IMMUNOL, V183, P4879, DOI 10.4049/jimmunol.0901531; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nelms K, 1998, GENOMICS, V53, P243, DOI 10.1006/geno.1998.5514; Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Reichardt P, 2011, CURR CANCER DRUG TAR, V11, P688, DOI 10.2174/156800911796191042; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Saulnier A, 2012, INT J CANCER, V130, P2484, DOI 10.1002/ijc.26299; Scheffzek K, 2001, STRUCTURE, V9, P1043, DOI 10.1016/S0969-2126(01)00674-8; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shinohara H, 2004, GENES CELLS, V9, P601, DOI 10.1111/j.1356-9597.2004.00748.x; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Sriram Ganapathy, 2010, Genes Cancer, V1, P1132, DOI 10.1177/1947601910397188; Takino T, 2003, CANCER RES, V63, P2335; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Wagner MJ, 2013, COLD SPRING HARB PER, V5; Wang BL, 1996, ONCOGENE, V13, P1379; Watanabe T, 2009, CELL RES, V19, P638, DOI 10.1038/cr.2009.40; White D, 2005, BLOOD, V106, P2520, DOI 10.1182/blood-2005-03-1103; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yasuda T, 2004, J EXP MED, V200, P1681, DOI 10.1084/jem.20041247; Yasuda T, 2007, INT IMMUNOL, V19, P487, DOI 10.1093/intimm/dxm015; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zheng J, 2010, ONCOGENE, V29, P6378, DOI 10.1038/onc.2010.369; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	68	4	4	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2650	2659		10.1038/onc.2014.210	http://dx.doi.org/10.1038/onc.2014.210			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043303	Green Accepted			2022-12-28	WOS:000354541300011
J	Walsh, LA; Roy, DM; Reyngold, M; Giri, D; Snyder, A; Turcan, S; Badwe, CR; Lyman, J; Bromberg, J; King, TA; Chan, TA				Walsh, L. A.; Roy, D. M.; Reyngold, M.; Giri, D.; Snyder, A.; Turcan, S.; Badwe, C. R.; Lyman, J.; Bromberg, J.; King, T. A.; Chan, T. A.			RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR SYSTEM; ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; VEGF EXPRESSION; MATRIX METALLOPROTEINASE-2; CONSTITUTIVE ACTIVATION; SUPPRESSOR GENES; INHIBITOR RECK; KAZAL MOTIFS; STAT3	Metastasis is the primary cause of cancer-related death in oncology patients. A comprehensive understanding of the molecular mechanisms that cancer cells usurp to promote metastatic dissemination is critical for the development and implementation of novel diagnostic and treatment strategies. Here we show that the membrane protein RECK (Reversion-inducing cysteine-rich protein with kazal motifs) controls breast cancer metastasis by modulating a novel, non-canonical and convergent signal transducer and activator of transcription factor 3 (STAT3)-dependent angiogenic program. Neoangiogenesis and STAT3 hyperactivation are known to be fundamentally important for metastasis, but the root molecular initiators of these phenotypes are poorly understood. Our study identifies loss of RECK as a critical and previously unknown trigger for these hallmarks of metastasis. Using multiple xenograft mouse models, we comprehensively show that RECK inhibits metastasis, concomitant with a suppression of neoangiogenesis at secondary sites, while leaving primary tumor growth unaffected. Further, with functional genomics and biochemical dissection we demonstrate that RECK controls this angiogenic rheostat through a novel complex with cell surface receptors to regulate STAT3 activation, cytokine signaling, and the induction of both vascular endothelial growth factor and urokinase plasminogen activator. In accordance with these findings, inhibition of STAT3 can rescue this phenotype both in vitro and in vivo. Taken together, our study uncovers, for the first time, that RECK is a novel regulator of multiple well-established and robust mediators of metastasis; thus, RECK is a keystone protein that may be exploited in a clinical setting to target metastatic disease from multiple angles.	[Walsh, L. A.; Roy, D. M.; Snyder, A.; Turcan, S.; Chan, T. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Roy, D. M.] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY USA; [Reyngold, M.; Chan, T. A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Giri, D.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Snyder, A.; Bromberg, J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Badwe, C. R.] Weill Grad Sch Med Sci, New York, NY USA; [Lyman, J.; King, T. A.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave,Box 20, New York, NY 10065 USA.	chant@mskcc.org	Chan, Timothy A/ABD-5850-2021	Turcan, Sevin/0000-0002-0885-5607; Snyder Charen, Alexandra/0000-0002-2606-3523; Walsh, Logan/0000-0001-8771-2577	Department of Defense (DOD) [BC120568]; Frederick Adler Fund; Avon Foundation; Elsa Pardee foundation; MSKCC Metastasis Center; STARR Cancer Consortium; Canadian Institutes of Health Research PDF Award [MFE-127325]; HHMI Research Fellows Program; NIH MSTP grant [T32GM007739]; Ruth L. Kirschstein National Research Award (NRSA) from the National Cancer Institute [T32CA009512]; NIH [5T32CA160001]; NATIONAL CANCER INSTITUTE [P30CA008748, T32CA160001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	Department of Defense (DOD)(United States Department of Defense); Frederick Adler Fund; Avon Foundation; Elsa Pardee foundation; MSKCC Metastasis Center; STARR Cancer Consortium; Canadian Institutes of Health Research PDF Award; HHMI Research Fellows Program; NIH MSTP grant; Ruth L. Kirschstein National Research Award (NRSA) from the National Cancer Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Agnes Viale and Russell Towers for technical assistance. We are indebted to Joan Massague (Memorial Sloan-Kettering Cancer Center) for generously providing cell lines and some constructs. We are grateful to the entire Tumour Procurement Service at MSKCC for facilitating tissue procurement and contributing valuable input. This work was supported by grants from the Department of Defense (DOD) (grant no. BC120568), the Frederick Adler Fund, the Avon Foundation, the Elsa Pardee foundation, the MSKCC Metastasis Center and the STARR Cancer Consortium (all to TAC). LAW was supported by The Canadian Institutes of Health Research PDF Award MFE-127325. DMR was supported by the HHMI Research Fellows Program and NIH MSTP grant T32GM007739. AS was supported by the Ruth L. Kirschstein National Research Award (NRSA) number T32CA009512 from the National Cancer Institute. ST was supported by an NIH T32 grant (5T32CA160001).	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bid HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035513; Bournazou Eirini, 2013, JAKSTAT, V2, pe23828, DOI 10.4161/jkst.23828; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Carbajo-Pescador S, 2013, BRIT J CANCER, V109, P83, DOI 10.1038/bjc.2013.285; Cardoso F, 2012, ANN ONCOL, V23, P11, DOI 10.1093/annonc/mds232; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chandana EPS, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-84; Chang CK, 2008, J CELL MOL MED, V12, P2781, DOI 10.1111/j.1582-4934.2008.00215.x; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; Cho CY, 2007, J CELL PHYSIOL, V213, P65, DOI 10.1002/jcp.21089; Choong PFM, 2003, CLIN ORTHOP RELAT R, pS46, DOI 10.1097/01.blo.0000093845.72468.bd; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Haene N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067029; Cardeal LBD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033585; Dong QA, 2010, INT J EXP PATHOL, V91, P368, DOI 10.1111/j.1365-2613.2010.00724.x; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Gu FM, 2011, WORLD J GASTROENTERO, V17, P3922, DOI 10.3748/wjg.v17.i34.3922; Han L, 2012, CNS NEUROSCI THER, V18, P573, DOI 10.1111/j.1755-5949.2012.00344.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Huang C, 2012, CYTOKINE GROWTH F R, V23, P25, DOI 10.1016/j.cytogfr.2012.01.003; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; Ishikawa S, 2004, CLIN CANCER RES, V10, P6579, DOI 10.1158/1078-0432.CCR-04-0272; Jeon HW, 2010, MOL CANCER THER, V9, P1361, DOI 10.1158/1535-7163.MCT-09-0717; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Kang SH, 2010, NEUROSURGERY, V67, P1386, DOI 10.1227/NEU.0b013e3181f1c0cd; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim JH, 2010, BIOCHEM PHARMACOL, V79, P373, DOI 10.1016/j.bcp.2009.09.008; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Le QT, 2005, J CLIN ONCOL, V23, P8932, DOI 10.1200/JCO.2005.02.0206; Lee MMK, 2012, J IMMUNOL, V189, P5266, DOI 10.4049/jimmunol.1103359; Lin HY, 2013, BRIT J CANCER, V109, P731, DOI 10.1038/bjc.2013.349; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Noda M, 2010, FUTURE ONCOL, V6, P1105, DOI [10.2217/fon.10.80, 10.2217/FON.10.80]; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Onishi A, 2008, EXP CELL RES, V314, P377, DOI 10.1016/j.yexcr.2007.09.018; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Prabhu VV, 2012, ASIAN PAC J CANCER P, V13, P3539, DOI 10.7314/APJCP.2012.13.8.3539; Prendergast A, 2012, DEVELOPMENT, V139, P1141, DOI 10.1242/dev.072439; Rabien A, 2012, PROSTATE, V72, P948, DOI 10.1002/pros.21498; Roomi MW, 2009, ONCOL REP, V21, P1323, DOI 10.3892/or_00000358; Rosenkilde MM, 2004, APMIS, V112, P481, DOI 10.1111/j.1600-0463.2004.apm11207-0808.x; Sasahara RM, 2002, CANCER DETECT PREV, V26, P435, DOI 10.1016/S0361-090X(02)00123-X; Selander KS, 2004, CANCER RES, V64, P6924, DOI 10.1158/0008-5472.CAN-03-2516; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65; Sriuranpong V, 2003, CANCER RES, V63, P2948; Tang LL, 2013, BIOMED PHARMACOTHER, V67, P179, DOI 10.1016/j.biopha.2012.10.003; Thummarati P, 2012, WORLD J GASTROENTERO, V18, P244, DOI 10.3748/wjg.v18.i3.244; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Zarogoulidis Paul, 2013, Immunome Res, V9, P16535, DOI 10.1186/2090-5009-9-1; Zeng L, 2010, CYTOKINE, V49, P294, DOI 10.1016/j.cyto.2009.11.015; Zhang B, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-427; Zhang CS, 2012, INT J BIOL SCI, V8, P451, DOI 10.7150/ijbs.4038; Zhao Y, 2008, BIOCHEM BIOPH RES CO, V369, P1215, DOI 10.1016/j.bbrc.2008.03.038; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	64	28	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2189	2203		10.1038/onc.2014.175	http://dx.doi.org/10.1038/onc.2014.175			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931164	Green Accepted			2022-12-28	WOS:000353473000005
J	Orfanelli, U; Jachetti, E; Chiacchiera, F; Grioni, M; Brambilla, P; Briganti, A; Freschi, M; Martinelli-Boneschi, F; Doglioni, C; Montorsi, F; Bellone, M; Casari, G; Pasini, D; Lavorgna, G				Orfanelli, U.; Jachetti, E.; Chiacchiera, F.; Grioni, M.; Brambilla, P.; Briganti, A.; Freschi, M.; Martinelli-Boneschi, F.; Doglioni, C.; Montorsi, F.; Bellone, M.; Casari, G.; Pasini, D.; Lavorgna, G.			Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer	ONCOGENE			English	Article							CELL-DEATH; EXPRESSION SIGNATURE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; PROGRESSION; CHANNEL; DIFFERENTIATION; ACTIVATION; BIOMARKERS; DISEASE	Overwhelming evidence indicates that cancer is a genetic disease caused by the accumulation of mutations in oncogenes and tumor suppressor genes. It is also increasingly apparent, however, that cancer depends not only on mutations in these coding genes but also on alterations in the large class of non-coding RNAs. Here, we report that one such long non-coding RNA, TRPM2-AS, an antisense transcript of TRPM2, which encodes an oxidative stress-activated ion channel, is overexpressed in prostate cancer (PCa). The high expression of TRPM2-AS and its related gene signature were found to be linked to poor clinical outcome, with the related gene signature working also independently of the patient's Gleason score. Mechanistically, TRPM2-AS knockdown led to PCa cell apoptosis, with a transcriptional profile that indicated an unbearable increase in cellular stress in the dying cells, which was coupled to cell cycle arrest, an increase in intracellular hydrogen peroxide and activation of the sense TRPM2 gene. Moreover, targets of existing drugs and treatments were found to be consistently associated with high TRPM2-AS levels in both targeted cells and patients, ultimately suggesting that the measurement of the expression levels of TRPM2-AS allows not only for the early identification of aggressive PCa tumors, but also identifies a subset of at-risk patients who would benefit from currently available, but mostly differently purposed, therapeutic agents.	[Orfanelli, U.; Briganti, A.; Montorsi, F.; Casari, G.; Lavorgna, G.] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Milan, Italy; [Orfanelli, U.; Casari, G.; Lavorgna, G.] Ctr Translat Genom & Bioinformat, Milan, Italy; [Jachetti, E.; Grioni, M.; Bellone, M.] Ist Sci San Raffaele, Cellular Immunol Unit, I-20132 Milan, Italy; [Chiacchiera, F.; Pasini, D.] European Inst Oncol IEO, Dept Expt Oncol, Milan, Italy; [Brambilla, P.; Martinelli-Boneschi, F.] Ist Sci San Raffaele, Inst Expt Neurol INSPE, Div Neurosci, Lab Genet Neurol Complex Disorders, I-20132 Milan, Italy; [Briganti, A.; Montorsi, F.] Dept Urol, Milan, Italy; [Freschi, M.; Doglioni, C.] Univ Vita Salute San Raffaele, Dept Pathol, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS European Institute of Oncology (IEO); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Lavorgna, G (corresponding author), Ist Sci San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.	matteo.bellone@hsr.it; giovanni.lavorgna@hsr.it	Briganti, Alberto/AAN-1965-2020; Orfanelli, Ugo/AAN-4787-2020; Matteo, Grioni/AAN-5912-2020; Chiacchiera, Fulvio/ABD-6137-2020; Lavorgna, Giovanni/AAN-2575-2020; Jachetti, Elena/C-2145-2017; Montorsi, Francesco/AAN-2473-2020; Bellone, Matteo/B-6922-2013; Casari, Giorgio/J-3070-2018; Chiacchiera, Fulvio/K-6740-2016; Pasini, Diego/J-9674-2012	Matteo, Grioni/0000-0002-9930-042X; Jachetti, Elena/0000-0001-6483-7350; Bellone, Matteo/0000-0002-2586-2569; Casari, Giorgio/0000-0002-0115-8980; Chiacchiera, Fulvio/0000-0003-3830-2090; DOGLIONI, Claudio/0000-0002-4969-5216; Pasini, Diego/0000-0002-9879-6486; Orfanelli, Ugo/0000-0003-3792-9174; martinelli boneschi, filippo/0000-0002-9955-1368	Alleanza Contro il Cancro (AACR); Italian Ministry of Health; Associazione Italiana per la Ricerca sul Cancro (AIRC)	Alleanza Contro il Cancro (AACR); Italian Ministry of Health(Ministry of Health, Italy); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Alleanza Contro il Cancro (AACR) to GL, the Italian Ministry of Health to MB and the Associazione Italiana per la Ricerca sul Cancro (AIRC) to MB.	Agell L, 2012, AM J PATHOL, V181, P1585, DOI 10.1016/j.ajpath.2012.08.005; Bai JZ, 2010, NEUROTOXICOLOGY, V31, P204, DOI 10.1016/j.neuro.2010.01.001; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Brase JC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-507; Chen SJ, 2013, AM J PHYSIOL-CELL PH, V304, pC548, DOI 10.1152/ajpcell.00069.2012; Cheville JC, 2008, J CLIN ONCOL, V26, P3930, DOI 10.1200/JCO.2007.15.6752; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968; Di AK, 2012, NAT IMMUNOL, V13, P29, DOI 10.1038/ni.2171; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Draghici S, 2006, TRENDS GENET, V22, P101, DOI 10.1016/j.tig.2005.12.005; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hessels D, 2009, NAT REV UROL, V6, P255, DOI 10.1038/nrurol.2009.40; Irshad S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006408; Ishii M, 2007, ANTICANCER RES, V27, P3987; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Kaneko S, 2006, J PHARMACOL SCI, V101, P66, DOI 10.1254/jphs.FP0060128; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Lu-Yao GL, 2009, JAMA-J AM MED ASSOC, V302, P1202, DOI 10.1001/jama.2009.1348; Markert EK, 2011, P NATL ACAD SCI USA, V108, P21276, DOI 10.1073/pnas.1117029108; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Miller BA, 2006, J MEMBRANE BIOL, V209, P31, DOI 10.1007/s00232-005-0839-3; Miller EW, 2007, NAT CHEM BIOL, V3, P263, DOI 10.1038/nchembio871; Modarresi F, 2012, NAT BIOTECHNOL, V30, P453, DOI 10.1038/nbt.2158; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Orfanelli U, 2008, CELL RES, V18, P1128, DOI 10.1038/cr.2008.296; Penney KL, 2011, J CLIN ONCOL, V29, P2391, DOI 10.1200/JCO.2010.32.6421; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Prasanth KV, 2007, GENE DEV, V21, P11, DOI 10.1101/gad.1484207; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Ribeiro FR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022317; Sboner A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-8; Schroder FH, 2012, BJU INT, V110, P3, DOI 10.1111/j.1464-410X.2012.011428.x; Simon RM, 2009, J NATL CANCER I, V101, P1446, DOI 10.1093/jnci/djp335; Stark JR, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3601; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tandefelt DG, 2013, EUR UROL, V64, P941, DOI 10.1016/j.eururo.2013.02.039; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; US Department of Health and Human Services FDA, 2007, CTR DRUG EV RES CTR; Verma S, 2012, NEUROSCI LETT, V530, P41, DOI 10.1016/j.neulet.2012.09.044; Wang GH, 2010, AM J TRANSL RES, V2, P65; Xia J, 2013, JNCI-J NATL CANCER I, V105, P546, DOI 10.1093/jnci/djt017; Xing Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000088; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Zeng X, 2010, PROSTATE CANCER P D, V13, P195, DOI 10.1038/pcan.2009.55; Zhang WY, 2006, AM J PHYSIOL-CELL PH, V290, pC1146, DOI 10.1152/ajpcell.00205.2005	55	61	63	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2094	2102		10.1038/onc.2014.144	http://dx.doi.org/10.1038/onc.2014.144			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24931166				2022-12-28	WOS:000353173400009
J	Png, CW; Weerasooriya, M; Guo, J; James, SJ; Poh, HM; Osato, M; Flavell, RA; Dong, C; Yang, H; Zhang, Y				Png, C. W.; Weerasooriya, M.; Guo, J.; James, S. J.; Poh, H. M.; Osato, M.; Flavell, R. A.; Dong, C.; Yang, H.; Zhang, Y.			DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis	ONCOGENE			English	Article							KRUPPEL-LIKE FACTOR-5; IMMUNE-RESPONSES; GENE-EXPRESSION; UP-REGULATION; CANCER; PHOSPHATASE; COLON; MUTATIONS; INNATE; KRAS	Dual specificity phosphatase 10 (DUSP10), also known as MAP kinase phosphatase 5 (MKP5), negatively regulates the activation of MAP kinases. Genetic polymorphisms and aberrant expression of this gene are associated with colorectal cancer (CRC) in humans. However, the role of DUSP10 in intestinal epithelial tumorigenesis is not clear. Here, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Kruppel-like factor 5 (KLF5) expression in IEC. In line with increased IEC proliferation, DUSP10 KO mice developed more colon tumours with increased severity compared with WT mice in response to administration of DSS and azoxymethane (AOM). Furthermore, survival analysis of CRC patients demonstrated that high DUSP10 expression in tumours was associated with significant improvement in survival probability. Overexpression of DUSP10 in Caco-2 and RCM-1 cells inhibited cell proliferation. Our study showed that DUSP10 negatively regulates IEC growth and acts as a suppressor for CRC. Therefore, it could be targeted for the development of therapies for colitis and CRC.	[Png, C. W.; Weerasooriya, M.; James, S. J.; Poh, H. M.; Zhang, Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117597, Singapore; [Png, C. W.; Weerasooriya, M.; James, S. J.; Poh, H. M.; Zhang, Y.] Natl Univ Singapore, Inst Life Sci, Immunol Programme, Singapore 117597, Singapore; [Guo, J.; Osato, M.; Yang, H.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Flavell, R. A.] Yale Univ, Howard Hughes Med Inst, Dept Immunol, New Haven, CT 06511 USA; [Dong, C.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing 100084, Peoples R China	National University of Singapore; National University of Singapore; National University of Singapore; Howard Hughes Medical Institute; Yale University; Tsinghua University	Zhang, Y (corresponding author), Natl Univ Singapore, Dept Microbiol, Ctr Life Sci Inst, Immunol Programme, 28 Med Dr, Singapore 117597, Singapore.	miczy@nus.edu.sg	Osato, Motomi/N-5056-2014; dong, chen/B-3181-2009	Osato, Motomi/0000-0003-3982-9054; dong, chen/0000-0002-0084-9130	Office of Deputy President, National University of Singapore; Ministry of Education [MOE2010-T2-1-079]; National Medical Research Council of Singapore [IRG10nov091, CBRG11nov101]	Office of Deputy President, National University of Singapore(National University of Singapore); Ministry of Education; National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We would like to thank Nicholas Gascoigne for advice and helpful discussion. This study was supported by grants from the Office of Deputy President, National University of Singapore, the Ministry of Education (MOE2010-T2-1-079) and the National Medical Research Council (IRG10nov091 and CBRG11nov101) of Singapore.	Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cao WS, 2008, J EXP MED, V205, P1491, DOI 10.1084/jem.20071728; Chua SW, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl024; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Cornell TT, 2012, AM J PHYSIOL-LUNG C, V303, pL251, DOI 10.1152/ajplung.00063.2012; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Delaunoit T, 2006, CLIN GASTROENTEROL H, V4, P335, DOI 10.1016/j.cgh.2005.12.035; Egan LJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1028, DOI 10.1152/ajpcell.00167.2003; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Foty R, 2011, JOVE-J VIS EXP, DOI 10.3791/2720; Groschl B, 2013, INT J CANCER, V132, P1537, DOI 10.1002/ijc.27834; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670; Hrabe JE, 2014, J SURG ONCOL, V109, P117, DOI 10.1002/jso.23465; Kinnebrew MA, 2012, IMMUNOL REV, V245, P113, DOI 10.1111/j.1600-065X.2011.01081.x; Koch S, 2011, GASTROENTEROLOGY, V141, P259, DOI 10.1053/j.gastro.2011.03.043; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; Matta R, 2012, AM J PHYSIOL-GASTR L, V302, pG1322, DOI 10.1152/ajpgi.00018.2012; McConnell BB, 2011, GASTROENTEROLOGY, V141, P1302, DOI 10.1053/j.gastro.2011.06.086; McConnell BB, 2011, GASTROENTEROLOGY, V140, P540, DOI 10.1053/j.gastro.2010.10.061; McConnell BB, 2009, CANCER RES, V69, P4125, DOI 10.1158/0008-5472.CAN-08-4402; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mori A, 2009, MOL CANCER RES, V7, P1390, DOI 10.1158/1541-7786.MCR-08-0525; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nandan MO, 2005, FEBS LETT, V579, P4757, DOI 10.1016/j.febslet.2005.07.053; Nomura M, 2012, ONCOL REP, V28, P931, DOI 10.3892/or.2012.1862; Oliveira C, 2007, ONCOGENE, V26, P158, DOI 10.1038/sj.onc.1209758; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Popovici V, 2012, J CLIN ONCOL, V30, P1288, DOI 10.1200/JCO.2011.39.5814; Qian F, 2012, AM J PHYSIOL-LUNG C, V302, pL866, DOI 10.1152/ajplung.00277.2011; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shi H, 2013, J CLIN INVEST, V123, P2064, DOI 10.1172/JCI64375; Spain SL, 2012, HUM MOL GENET, V21, P934, DOI 10.1093/hmg/ddr523; Sturm A, 2008, WORLD J GASTROENTERO, V14, P348, DOI 10.3748/wjg.14.348; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Takahashi M, 2004, CANCER SCI, V95, P475, DOI 10.1111/j.1349-7006.2004.tb03235.x; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Turusov VS, 1990, PATHOLOGY TUMOURS LA; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Whiffin N, 2013, HUM MOL GENET, V22, P5075, DOI 10.1093/hmg/ddt357; Yang YZ, 2007, FASEB J, V21, P543, DOI 10.1096/fj.06-6694com; Zhang JH, 2006, GASTROENTEROLOGY, V131, P1179, DOI 10.1053/j.gastro.2006.08.007; Zhang T, 2014, EUR J CANCER PREV, V23, P173, DOI 10.1097/CEJ.0b013e3283647408; Zhang XL, 2005, BIOTECHNOL PROGR, V21, P1289, DOI 10.1021/bp050003l; Zhang YL, 2004, NATURE, V430, P793, DOI 10.1038/nature02764; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794	58	25	26	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					206	217		10.1038/onc.2015.74	http://dx.doi.org/10.1038/onc.2015.74			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25772234				2022-12-28	WOS:000368193900007
J	Yu, J; Wu, WKK; Liang, Q; Zhang, N; He, J; Li, X; Zhang, X; Xu, L; Chan, MTV; Ng, SSM; Sung, JJY				Yu, J.; Wu, W. K. K.; Liang, Q.; Zhang, N.; He, J.; Li, X.; Zhang, X.; Xu, L.; Chan, M. T. V.; Ng, S. S. M.; Sung, J. J. Y.			Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer	ONCOGENE			English	Article							COLON-CANCER; TRANSCRIPTIONAL COACTIVATOR; DEPENDENT ACTIVATION; NUCLEAR RECEPTORS; GENE FUSION; GRIP1; TIF2; DIFFERENTIATION; DISCOVERY; LEUKEMIA	Whole-genome and transcriptome sequencing were used to discover novel gene fusions in a case of colon cancer. A tumor-specific LACTB2-NCOA2 fusion originating from intra-chromosomal rearrangement of chromosome 8 was identified at both DNA and RNA levels. Unlike conventional oncogenic chimeric proteins, the fusion product lacks functional domain from respective genes, indicative of an amorphic rearrangement. This chimeric LACTB2-NCOA2 transcript was detected in 6 out of 99 (6.1%) colorectal cancer (CRC) cases, where NCOA2 was significantly downregulated. Enforced expression of wild-type NCOA2 but not the LACTB2-NCOA2 fusion protein impaired the pro-tumorigenic phenotypes of CRC cells, whereas knockdown of endogenous NCOA2 in normal colonocytes had opposite effects. Mechanistically, NCOA2 inhibited Wnt/beta-catenin signaling through simultaneously upregulating inhibitors and downregulating stimulators of Wnt/beta-catenin pathway. Collectively, our data supports that NCOA2 is a novel negative growth regulatory gene repressing the Wnt/beta-catenin pathway in CRC, where recurrent fusion with LACTB2 contributes to its disruption.	[Yu, J.; Wu, W. K. K.; Liang, Q.; Zhang, N.; He, J.; Li, X.; Zhang, X.; Xu, L.; Sung, J. J. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Digest Dis,Shenzhen Res Inst, Inst Digest Dis,Dept Med & Therapeut,Li Ka Shing, Shatin, Hong Kong, Peoples R China; [Wu, W. K. K.; Chan, M. T. V.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China; [Zhang, N.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Digest Dis,Shenzhen Res Inst, Inst Digest Dis,Dept Med & Therapeut,Li Ka Shing, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	ZHANG, Xiang/N-7918-2015; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015; Liang, Qiaoyi Jessie/G-9612-2019; Li, Xiao-xing/B-9114-2008; wu, william/HII-5817-2022; Wu, William K.K./A-3277-2009; Chan, Matthew/J-2884-2013; Ng, Simon S. M./M-1219-2018	ZHANG, Xiang/0000-0002-3222-5824; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Li, Xiao-xing/0000-0001-8791-7505; Wu, William K.K./0000-0002-5662-5240; Chan, Matthew/0000-0002-3574-7855; Ng, Simon S. M./0000-0002-5389-9297	Shenzhen Municipal Science and Technology RD fund [JCYJ20120619152326450]; Shenzhen Technology and Innovation Project Fund [JSGG20130412171021059]; 863 Program China [2012AA02A506]; 973 Program China [2013CB531401]; Theme-based Research Scheme of the Hong Kong Research Grants Council [T12-403-11]; Shenzhen Virtual University Park Support Scheme	Shenzhen Municipal Science and Technology RD fund; Shenzhen Technology and Innovation Project Fund; 863 Program China(National High Technology Research and Development Program of China); 973 Program China(National Basic Research Program of China); Theme-based Research Scheme of the Hong Kong Research Grants Council; Shenzhen Virtual University Park Support Scheme	Grant Support: The work was supported by Shenzhen Municipal Science and Technology R&D fund (JCYJ20120619152326450), the Shenzhen Technology and Innovation Project Fund (JSGG20130412171021059), 863 Program China (2012AA02A506), 973 Program China (2013CB531401), the Theme-based Research Scheme of the Hong Kong Research Grants Council (T12-403-11) and the Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Akiva P, 2006, GENOME RES, V16, P30, DOI 10.1101/gr.4137606; Annala MJ, 2013, CANCER LETT, V340, P192, DOI 10.1016/j.canlet.2013.01.011; Arbajian E, 2013, GENE CHROMOSOME CANC, V52, P330, DOI 10.1002/gcc.22033; Bass AJ, 2011, NAT GENET, V43, P964, DOI 10.1038/ng.936; Blackledge NP, 2010, MOL CELL, V38, P179, DOI 10.1016/j.molcel.2010.04.009; Bunting SF, 2013, NAT REV CANCER, V13, P443, DOI 10.1038/nrc3537; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; D'Errico I, 2008, CELL MOL LIFE SCI, V65, P1523, DOI 10.1007/s00018-008-7552-1; Dib Amel, 2008, J Natl Cancer Inst Monogr, P25, DOI 10.1093/jncimonographs/lgn011; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Frenkel-Morgenstern M, 2012, GENOME RES, V22, P1231, DOI 10.1101/gr.130062.111; Gingeras TR, 2009, NATURE, V461, P206, DOI 10.1038/nature08452; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Herai RH, 2010, BRIEF BIOINFORM, V11, P198, DOI 10.1093/bib/bbp041; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kefalopoulou Z, 2012, J NEURO-ONCOL, V106, P23, DOI 10.1007/s11060-011-0637-y; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Maher CA, 2012, CELL, V148, P29, DOI 10.1016/j.cell.2012.01.006; Maher CA, 2009, P NATL ACAD SCI USA, V106, P12353, DOI 10.1073/pnas.0904720106; Malkova A, 2013, CURR OPIN GENET DEV, V23, P271, DOI 10.1016/j.gde.2013.05.007; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakayama R, 2012, PATHOL INT, V62, P823, DOI 10.1111/pin.12022; Nothwang HG, 2001, HUM MOL GENET, V10, P797, DOI 10.1093/hmg/10.8.797; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Strehl S, 2008, CLIN CANCER RES, V14, P977, DOI 10.1158/1078-0432.CCR-07-4022; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wong SH, 2013, SEMIN CANCER BIOL, V23, P502, DOI 10.1016/j.semcancer.2013.09.005; Wu J, 2013, CANCER LETT, V329, P155, DOI 10.1016/j.canlet.2012.10.038; Wu WKK, 2013, CRIT REV ONCOL HEMAT, V86, P251, DOI 10.1016/j.critrevonc.2012.11.009; Xi YG, 2006, BIOMARK INSIGHTS, V1, P113; Yoshida H, 2014, ONCOGENE, V33, P5601, DOI 10.1038/onc.2013.491; Yu J, 2014, GUT	42	15	18	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					187	195		10.1038/onc.2015.72	http://dx.doi.org/10.1038/onc.2015.72			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25823027	hybrid, Green Published			2022-12-28	WOS:000368193900005
J	Knezevic, J; Pfefferle, AD; Petrovic, I; Greene, SB; Perou, CM; Rosen, JM				Knezevic, J.; Pfefferle, A. D.; Petrovic, I.; Greene, S. B.; Perou, C. M.; Rosen, J. M.			Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; TUMOR-INITIATING CELLS; DOWN-REGULATION; ANGIOGENESIS; FAMILY; ZEB1; GENE; IDENTIFICATION; PLASTICITY; SUBTYPE	Claudin-low tumors are a highly aggressive breast cancer subtype with no targeted treatments and a clinically documented resistance to chemotherapy. They are significantly enriched in cancer stem cells (CSCs), which makes claudin-low tumor models particularly attractive for studying CSC behavior and developing novel approaches to minimize CSC therapy resistance. One proposed mechanism by which CSCs arise is via an epithelial-mesenchymal transition (EMT), and reversal of this process may provide a potential therapeutic approach for increasing tumor chemosensitivity. Therefore, we investigated the role of known EMT regulators, miR-200 family of microRNAs in controlling the epithelial state, stem-like properties and therapeutic response in an in vivo primary, syngeneic p53(null) claudin-low tumor model that is normally deficient in miR-200 expression. Using an inducible lentiviral approach, we expressed the miR-200c cluster in this model and found that it changed the epithelial state, and consequently, impeded CSC behavior in these mesenchymal tumors. Moreover, these state changes were accompanied by a decrease in proliferation and an increase in the differentiation status. miR-200c expression also forced a significant reorganization of tumor architecture, affecting important cellular processes involved in cell-cell contact, cell adhesion and motility. Accordingly, induced miR200c expression significantly enhanced the chemosensitivity and decreased the metastatic potential of this p53null claudin-low tumor model. Collectively, our data suggest that miR-200c expression in claudin-low tumors offers a potential therapeutic application to disrupt the EMT program on multiple fronts in this mesenchymal tumor subtype, by altering tumor growth, chemosensitivity and metastatic potential in vivo.	[Knezevic, J.; Petrovic, I.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Pfefferle, A. D.; Perou, C. M.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Pfefferle, A. D.; Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Greene, S. B.] Epic Sci Inc, San Diego, CA USA; [Perou, C. M.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA	Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza M638a, Houston, TX 77030 USA.	jrosen@bcm.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	National Cancer Institute [CA148761]; CPRIT [RP130485, RP140102]; Baylor College of Medicine [P30 AI036211, P30 CA125123, S10 RR024574, P30-CA125123]; NATIONAL CANCER INSTITUTE [P30CA016086, P30CA125123, R01CA148761] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT; Baylor College of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	These studies were supported by grants CA148761 (JMR and CP) from the National Cancer Institute and RP130485 (JMR) and RP140102 (JK) from CPRIT. This project was supported by the following core facilities and their funding: Biostatistics and Informatics (P30-CA125123) and Cytometry and Cell Sorting Core at Baylor College of Medicine (P30 AI036211, P30 CA125123 and S10 RR024574). RPPA arrays were performed at the MD Anderson Cancer Center RPPA Core Facility-Functional Proteomics. We thank Drs Kevin Roarty Amy Shore and Michael Toneff for helpful discussions and paper editing, Dr Jason Herschkowitz for help and advice, and Ms Shirley Small for animal husbandry.	Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chuthapisith S, 2010, SURG ONCOL, V19, P27, DOI 10.1016/j.suronc.2009.01.004; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cui JG, 2014, J CELL BIOCHEM, V115, P1033, DOI 10.1002/jcb.24754; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Humphries B, 2014, CARCINOGENESIS, P1; Hurteau GJ, 2009, CELL CYCLE, V8, P2064, DOI 10.4161/cc.8.13.8883; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kopp F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050469; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Pinto CA, 2013, CANCER LETT, V341, P56, DOI 10.1016/j.canlet.2013.06.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Roybal JD, 2011, MOL CANCER RES, V9, P25, DOI 10.1158/1541-7786.MCR-10-0497; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Usary J, 2013, CLIN CANCER RES, V19, P4889, DOI 10.1158/1078-0432.CCR-13-0522; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Welm Bryan E, 2008, Cell Stem Cell, V2, P90, DOI 10.1016/j.stem.2007.10.002; Wu SY, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008362; Yin JH, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-71; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013	51	80	84	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5997	6006		10.1038/onc.2015.48	http://dx.doi.org/10.1038/onc.2015.48			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25746005	Green Accepted, Green Submitted			2022-12-28	WOS:000366113500006
J	Mitra, AK; Chiang, CY; Tiwari, P; Tomar, S; Watters, KM; Peter, ME; Lengyel, E				Mitra, A. K.; Chiang, C. Y.; Tiwari, P.; Tomar, S.; Watters, K. M.; Peter, M. E.; Lengyel, E.			Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis	ONCOGENE			English	Article							UROKINASE PLASMINOGEN-ACTIVATOR; MESOTHELIAL CELLS; DNA METHYLATION; TUMOR INVASION; EXPRESSION; MICRORNA; PROGRESSION; SYSTEM; FIBROBLASTS; INHIBITOR	The cross-talk between ovarian cancer (OvCa) cells and the metastatic microenvironment is an essential determinant of successful colonization. MicroRNAs (miRNAs) have several critical roles during metastasis; however, the role of microenvironmental cues in the regulation of miRNAs in metastasizing cancer cells has not been studied. Using a three-dimensional culture model that mimics the human omentum, one of the principal sites of OvCa metastasis, we identified and characterized the microenvironment-induced downregulation of a tumor suppressor miRNA, miR-193b, in metastasizing OvCa cells. The direct interaction of the OvCa cells with mesothelial cells, which cover the surface of the omentum, caused a DNA methyltransferase 1-mediated decrease in the expression of miR-193b in the cancer cells. The reduction in miR-193b enabled the metastasizing cancer cells to invade and proliferate into human omental pieces ex vivo and into the omentum of a mouse xenograft model of OvCa metastasis. The functional effects of miR-193b were mediated, in large part, by the concomitant increased expression of its target, urokinase-type plasminogen activator, a known tumor-associated protease. These findings link paracrine signals from the microenvironment to the regulation of a key miRNA in cancer cells. Targeting miR-193b, which is essential for metastatic colonization of cancer cells could prove effective in the treatment of OvCa metastasis.	[Mitra, A. K.; Chiang, C. Y.; Tiwari, P.; Watters, K. M.; Lengyel, E.] Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, Chicago, IL 60637 USA; [Mitra, A. K.; Tomar, S.] Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA; [Peter, M. E.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	University of Chicago; Indiana University System; Indiana University Bloomington; Northwestern University; Feinberg School of Medicine	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, MC 2050,5841 South Maryland Ave, Chicago, IL 60637 USA.	anmitra@indiana.edu; elengyel@uchicago.edu	Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507; Tomar, Sunil/0000-0002-9258-399X; Tiwari, Payal/0000-0002-7822-6857; Peter, Marcus Ernst/0000-0003-3216-036X	Marsha Rivkin Pilot Award; National Cancer Institute [R01 CA111882, RO1 CA169604]; Ovarian Cancer Research Fund Program Project Development Grant; NATIONAL CANCER INSTITUTE [R01CA169604, R01CA111882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS075702] Funding Source: NIH RePORTER	Marsha Rivkin Pilot Award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund Program Project Development Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We want to thank Dr AF Haney for collecting omental biopsies, Dr Abir Mukherjee for helpful discussions and G Isenberg for carefully editing the manuscript (all at the University of Chicago, Department of Obstetrics and Gynecology). We are indebted to all the patients, resident and attending physicians in the Department of Obstetrics and Gynecology at the University of Chicago for their participation in tissue collection for these experiments. This research was supported by a Marsha Rivkin Pilot Award (AKM) and by National Cancer Institute R01 CA111882 and RO1 CA169604 grants (EL) and an Ovarian Cancer Research Fund Program Project Development Grant (EL, MEP).	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Gao XN, 2011, LEUKEMIA RES, V35, P1226, DOI 10.1016/j.leukres.2011.06.010; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Konecny G, 2001, CLIN CANCER RES, V7, P1743; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061658; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Lwin T, 2013, J CLIN INVEST, V123, P4612, DOI 10.1172/JCI64210; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mitra AK, 2011, ONCOGENE, V30, P1566, DOI 10.1038/onc.2010.532; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889; NIEDBALA MJ, 1985, EXP CELL RES, V160, P499, DOI 10.1016/0014-4827(85)90197-1; Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Noh Hyangsoon, 2011, Genes Cancer, V2, P140, DOI 10.1177/1947601911408888; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Samudio-Ruiz SL, 2012, EPIGENETICS-US, V7, P216, DOI 10.4161/epi.7.3.19273; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Tang CH, 2008, J CELL SCI, V121, P3747, DOI 10.1242/jcs.029769; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang L, 2009, GYNECOL ONCOL, V114, P265, DOI 10.1016/j.ygyno.2009.04.031; White EA, 2014, ADV DRUG DELIVER REV, V79-80, P184, DOI 10.1016/j.addr.2014.07.003; Xie C, 2013, ONCOGENE, V32, P2282, DOI 10.1038/onc.2012.251; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang W, 2013, ONCOL REP, V29, P637, DOI 10.3892/or.2012.2148; Zhang YL, 2013, MOL CANCER THER, V12, P2628, DOI 10.1158/1535-7163.MCT-13-0204	45	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5923	5932		10.1038/onc.2015.43	http://dx.doi.org/10.1038/onc.2015.43			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25798837	Green Accepted, Green Submitted			2022-12-28	WOS:000365434000007
J	Poirier, JT; Gardner, EE; Connis, N; Moreira, AL; de Stanchina, E; Hann, CL; Rudin, CM				Poirier, J. T.; Gardner, E. E.; Connis, N.; Moreira, A. L.; de Stanchina, E.; Hann, C. L.; Rudin, C. M.			DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2	ONCOGENE			English	Article							GENE; INACTIVATION; LANDSCAPE; CARCINOMA; MODEL; LINES	Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis, rapid development of resistance to chemotherapy and genetic instability. This study profiles DNA methylation in SCLC, patient-derived xenografts (PDX) and cell lines at single-nucleotide resolution. DNA methylation patterns of primary samples are distinct from those of cell lines, whereas PDX maintain a pattern closely consistent with primary samples. Clustering of DNA methylation and gene expression of primary SCLC revealed distinct disease subtypes among histologically indistinguishable primary patient samples with similar genetic alterations. SCLC is notable for dense clustering of high-level methylation in discrete promoter CpG islands, in a pattern clearly distinct from other lung cancers and strongly correlated with high expression of the E2F target and histone methyltransferase gene EZH2. Pharmacologic inhibition of EZH2 in a SCLC PDX markedly inhibited tumor growth.	[Poirier, J. T.; Gardner, E. E.; Rudin, C. M.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Gardner, E. E.] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD USA; [Connis, N.; Hann, C. L.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA; [Moreira, A. L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [de Stanchina, E.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Rudin, CM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 300 E 66th St,Room 1203, New York, NY 10065 USA.	rudinc@mskcc.org	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Gardner, Eric/0000-0002-1552-2675; Poirier, John/0000-0001-9795-5644; Connis, Nick/0000-0001-5725-0674	 [SU2C];  [P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Inna Kodos in the Sloan Kettering Antitumor Assessment Core for her technical expertise. We are grateful to all members of the Rudin and Hann labs for thoughtful discussions. SU2C, P30 CA008748 gave financial support.	Bady P, 2012, ACTA NEUROPATHOL, V124, P547, DOI 10.1007/s00401-012-1016-2; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; CARNEY DN, 1985, CANCER RES, V45, P2913; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Daniel VC, 2009, CANCER RES, V69, P3364, DOI 10.1158/0008-5472.CAN-08-4210; Gardner EE, 2014, CANCER RES, V74, P2846, DOI 10.1158/0008-5472.CAN-13-3460; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hann CL, 2007, TRENDS MOL MED, V13, P150, DOI 10.1016/j.molmed.2007.02.003; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kalari S, 2013, ONCOGENE, V32, P3559, DOI 10.1038/onc.2012.362; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lara PN, 2009, J CLIN ONCOL, V27, P2530, DOI 10.1200/JCO.2008.20.1061; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; MADRIGAL PA, 1982, CANCER CHEMOTH PHARM, V7, P203; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Oze I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007835; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Poirier JT, 2013, JNCI-J NATL CANCER I, V105, P1059, DOI 10.1093/jnci/djt130; Rauch T, 2005, LAB INVEST, V85, P1172, DOI 10.1038/labinvest.3700311; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wee ZN, 2014, CELL REP, V8, P204, DOI 10.1016/j.celrep.2014.05.045; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Wilkerson MD, 2010, CLIN CANCER RES, V16, P4864, DOI 10.1158/1078-0432.CCR-10-0199; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	38	139	141	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5869	5878		10.1038/onc.2015.38	http://dx.doi.org/10.1038/onc.2015.38			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25746006	Green Accepted			2022-12-28	WOS:000365434000002
J	Haney, SL; Hlady, RA; Opavska, J; Klinkebiel, D; Pirruccello, SJ; Dutta, S; Datta, K; Simpson, MA; Wu, L; Opavsky, R				Haney, S. L.; Hlady, R. A.; Opavska, J.; Klinkebiel, D.; Pirruccello, S. J.; Dutta, S.; Datta, K.; Simpson, M. A.; Wu, L.; Opavsky, R.			Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DE-NOVO; DNA METHYLATION; GENE; MUTATIONS; TUMORIGENESIS; EXPRESSION; MICE; TRANSCRIPTION; PATHOGENESIS	DNA methyltransferase 3A (DNMT3A) catalyzes cytosine methylation of mammalian genomic DNA. In addition to myeloid malignancies, mutations in DNMT3A have been recently reported in T-cell lymphoma and leukemia, implying a possible involvement in the pathogenesis of human diseases. However, the role of Dnmt3a in T-cell transformation in vivo is poorly understood. Here we analyzed the functional consequences of Dnmt3a inactivation in a mouse model of MYC-induced T-cell lymphomagenesis (MTCL). Loss of Dnmt3a delayed tumorigenesis by suppressing cellular proliferation during disease progression. Gene expression profiling and pathway analysis identified upregulation of 17 putative tumor suppressor genes, including DNA methyltransferase Dnmt3b, in Dnmt3a-deficient lymphomas as molecular events potentially responsible for the delayed lymphomagenesis in Dnmt3a(Delta/Delta) mice. Interestingly, promoter and gene body methylation of these genes was not substantially changed between control and Dnmt3a-deficient lymphomas, suggesting that Dnmt3a may inhibit their expression in a methylation-independent manner. Re-expression of both wild type and catalytically inactive Dnmt3a in Dnmt3a(Delta/Delta) lymphoma cells in vitro inhibited Dnmt3b expression, indicating that Dnmt3b upregulation may be directly repressed by Dnmt3a. Importantly, genetic inactivation of Dnmt3b accelerated lymphomagenesis in Dnmt3a(Delta/Delta) mice, demonstrating that upregulation of Dnmt3b is a relevant molecular change in Dnmt3a-deficient lymphomas that inhibits disease progression. Collectively, our data demonstrate an unexpected oncogenic role for Dnmt3a in MTCL through methylation-independent repression of Dnmt3b and possibly other tumor suppressor genes.	[Haney, S. L.; Opavsky, R.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA; [Hlady, R. A.; Opavska, J.; Opavsky, R.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Klinkebiel, D.; Dutta, S.; Datta, K.] Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Pirruccello, S. J.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Simpson, M. A.] Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; [Wu, L.] Rutgers New Jersey Med Sch, Ctr Canc, Dept Microbiol & Mol Genet, Newark, NJ USA; [Opavsky, R.] Univ Nebraska Med Ctr, Ctr Lymphoma & Leukemia Res, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Nebraska System; University of Nebraska Medical Center	Opavsky, R (corresponding author), Univ Nebraska Med Ctr, DRCII, Eppley Inst Res Canc & Allied Dis, 985950 Nebraska Med Ctr,Room 4031, Omaha, NE 68198 USA.	ropavsky@unmc.edu			NCI NIH HHS [T32 CA009476] Funding Source: Medline; NIGMS NIH HHS [P30 GM110768, P20 GM103471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103471, P30GM110768] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708; Challen GA, 2012, NAT GENET, V44, P23, DOI 10.1038/ng.1009; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couronne L, 2012, NEW ENGL J MED, V366, P95, DOI 10.1056/NEJMc1111708; Datta J, 2005, CANCER RES, V65, P10891, DOI 10.1158/0008-5472.CAN-05-1455; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fernandez AF, 2012, TRENDS GENET, V28, P474, DOI 10.1016/j.tig.2012.05.006; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883; Hlady RA, 2012, J CLIN INVEST, V122, P163, DOI 10.1172/JCI57292; Iskander K, 2008, CANCER RES, V68, P7915, DOI 10.1158/0008-5472.CAN-08-0766; Kim SJ, 2013, BLOOD, V122, P4086, DOI 10.1182/blood-2013-02-483487; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Li HX, 2014, BLOOD, V123, P1487, DOI 10.1182/blood-2013-05-500264; Lin WQ, 2013, EMBO J, V32, P1425, DOI 10.1038/emboj.2013.88; Liu JG, 2004, J IMMUNOL, V173, P1184, DOI 10.4049/jimmunol.173.2.1184; Neumann M, 2013, BLOOD, V121, P4749, DOI 10.1182/blood-2012-11-465138; Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Opavsky R, 2007, PLOS GENET, V3, P1757, DOI 10.1371/journal.pgen.0030167; Opavsky R, 2007, P NATL ACAD SCI USA, V104, P15400, DOI 10.1073/pnas.0706307104; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Palamarchuk A, 2012, P NATL ACAD SCI USA, V109, P2555, DOI 10.1073/pnas.1200003109; Peters SL, 2014, LEUKEMIA, V28, P1138, DOI 10.1038/leu.2013.364; Peters SL, 2013, MOL CELL BIOL, V33, P4321, DOI 10.1128/MCB.00776-13; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Puto LA, 2008, GENE DEV, V22, P998, DOI 10.1101/gad.1632208; Ramkumar C, 2012, CANCER RES, V72, P2714, DOI 10.1158/0008-5472.CAN-11-3773; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robinson MD, 2007, BIOINFORMATICS, V23, P2881, DOI 10.1093/bioinformatics/btm453; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Russler-Germain DA, 2014, CANCER CELL, V25, P442, DOI 10.1016/j.ccr.2014.02.010; Schaetzlein S, 2013, P NATL ACAD SCI USA, V110, pE2470, DOI 10.1073/pnas.1308512110; Schuster C, 2011, BLOOD, V118, P4635, DOI 10.1182/blood-2010-10-313098; Shang QJ, 2012, MOL MED REP, V5, P1401, DOI 10.3892/mmr.2012.844; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Thorns C, 2007, GENE CHROMOSOME CANC, V46, P37, DOI 10.1002/gcc.20386; Vasanthakumar A, 2013, BLOOD, V121, P2059, DOI 10.1182/blood-2012-04-421065; Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44; Wang Y, 2010, ONCOGENE, V29, P3044, DOI 10.1038/onc.2010.78; Wang YA, 2005, CANCER BIOL THER, V4, P1138, DOI 10.4161/cbt.4.10.2073; Weis B, 2015, ONCOGENE, V34, P1822, DOI 10.1038/onc.2014.114; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485	50	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5436	5446		10.1038/onc.2014.472	http://dx.doi.org/10.1038/onc.2014.472			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25639876	Green Accepted			2022-12-28	WOS:000363479700004
J	Ling, H; Vincent, K; Pichler, M; Fodde, R; Berindan-Neagoe, I; Slack, FJ; Calin, GA				Ling, H.; Vincent, K.; Pichler, M.; Fodde, R.; Berindan-Neagoe, I.; Slack, F. J.; Calin, G. A.			Junk DNA and the long non-coding RNA twist in cancer genetics	ONCOGENE			English	Review							GENOME-WIDE ASSOCIATION; NATURAL ANTISENSE TRANSCRIPTS; CHRONIC LYMPHOCYTIC-LEUKEMIA; X-CHROMOSOME INACTIVATION; PROSTATE-CANCER; COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; CHROMATIN INTERACTIONS; ULTRACONSERVED REGION; RANGE INTERACTION	The central dogma of molecular biology states that the flow of genetic information moves from DNA to RNA to protein. However, in the last decade this dogma has been challenged by new findings on non-coding RNAs (ncRNAs) such as microRNAs (miRNAs). More recently, long non-coding RNAs (lncRNAs) have attracted much attention due to their large number and biological significance. Many lncRNAs have been identified as mapping to regulatory elements including gene promoters and enhancers, ultraconserved regions and intergenic regions of protein-coding genes. Yet, the biological function and molecular mechanisms of lncRNA in human diseases in general and cancer in particular remain largely unknown. Data from the literature suggest that lncRNA, often via interaction with proteins, functions in specific genomic loci or use their own transcription loci for regulatory activity. In this review, we summarize recent findings supporting the importance of DNA loci in lncRNA function and the underlying molecular mechanisms via cis or trans regulation, and discuss their implications in cancer. In addition, we use the 8q24 genomic locus, a region containing interactive SNPs, DNA regulatory elements and lncRNAs, as an example to illustrate how single-nucleotide polymorphism (SNP) located within lncRNAs may be functionally associated with the individual's susceptibility to cancer.	[Ling, H.; Vincent, K.; Pichler, M.; Berindan-Neagoe, I.; Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Fodde, R.] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Berindan-Neagoe, I.] Univ Med & Pharm I Hatieganu, Dept Immunol, Cluj Napoca, Romania; [Berindan-Neagoe, I.] Univ Med & Pharm I Hatieganu, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania; [Berindan-Neagoe, I.] Oncol Inst Ion Chiricuta, Dept Funct Genom, Cluj Napoca, Romania; [Slack, F. J.] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Oncology Institute Prof. Dr. Ion Chiricuta; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calin, GA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1881 East Rd,Unit 1950,APT 1125, Houston, TX 77030 USA.	gcalin@mdanderson.org	Berindan-Neagoe, Ioana/AAH-9854-2019; Calin, George/E-9390-2011; Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324; Calin, George/0000-0001-6704-5615; Slack, Frank/0000-0001-8263-0409; Calin, George/0000-0002-7427-0578	Odyssey Program at The University of Texas MD Anderson Cancer Center; NIH/NCI [1UH2TR00943-01, 1 R01 CA182905-01]; UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI [P50 CA093459]; Aim at Melanoma Foundation; Miriam and Jim Mulva research funds; Brain SPORE [2P50CA127001]; Center for radiation Oncology Research Project; Center for Cancer Epigenetics Pilot project; Knowledge GAP MDACC grant; CLL Moonshot pilot project; UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment; SINF grant in colon cancer; Laura and John Arnold Foundation; RGK Foundation; Estate of C. G. Johnson; Erwin-Schroedinger Scholarship of the Austrian Science Funds [J3389-B23]; NIH [CA131301, CA157749]; Austrian Science Fund (FWF) [J 3389] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P50CA097007, P50CA127001, P50CA093459, P50CA100632, R01CA131301, R01CA182905, R01CA157749] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER	Odyssey Program at The University of Texas MD Anderson Cancer Center; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI; Aim at Melanoma Foundation; Miriam and Jim Mulva research funds; Brain SPORE; Center for radiation Oncology Research Project; Center for Cancer Epigenetics Pilot project; Knowledge GAP MDACC grant; CLL Moonshot pilot project; UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment; SINF grant in colon cancer; Laura and John Arnold Foundation; RGK Foundation; Estate of C. G. Johnson; Erwin-Schroedinger Scholarship of the Austrian Science Funds; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	HL is an Odyssey Fellow, and his work is supported in part by the Odyssey Program at The University of Texas MD Anderson Cancer Center. GAC is The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar. Work in Dr Calin's laboratory is supported in part by the NIH/NCI grants 1UH2TR00943-01 and 1 R01 CA182905-01, the UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI (P50 CA093459), Aim at Melanoma Foundation and the Miriam and Jim Mulva research funds, the Brain SPORE (2P50CA127001), the Center for radiation Oncology Research Project, the Center for Cancer Epigenetics Pilot project, a 2014 Knowledge GAP MDACC grant, a CLL Moonshot pilot project, the UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment, a SINF grant in colon cancer, the Laura and John Arnold Foundation, the RGK Foundation and the Estate of C. G. Johnson, Jr. MP is supported by an Erwin-Schroedinger Scholarship of the Austrian Science Funds (project no. J3389-B23). IBN is a Fulbright Scholar at MD Anderson Cancer Center. FS was supported by NIH grants CA131301 and CA157749. We apologize to all colleagues whose work was not cited because of space restrictions.	Allen TA, 2004, NAT STRUCT MOL BIOL, V11, P816, DOI 10.1038/nsmb813; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bertani S, 2011, MOL CELL, V43, P1040, DOI 10.1016/j.molcel.2011.08.019; Bertucci F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037943; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Braconi C, 2011, P NATL ACAD SCI USA, V108, P786, DOI 10.1073/pnas.1011098108; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chen DY, 2014, CELL IMMUNOL, V289, P91, DOI 10.1016/j.cellimm.2014.03.015; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Chung SY, 2011, CANCER SCI, V102, P245, DOI 10.1111/j.1349-7006.2010.01737.x; COMINGS DE, 1972, ADV HUM GENET, P237; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Di Ruscio A, 2013, NATURE, V503, P371, DOI 10.1038/nature12598; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Ferdin J, 2013, CELL DEATH DIFFER, V20, P1675, DOI 10.1038/cdd.2013.119; Fu XQ, 2006, DNA CELL BIOL, V25, P135, DOI 10.1089/dna.2006.25.135; Gaudet MM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001183; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Ghoussaini M, 2008, JNCI-J NATL CANCER I, V100, P962, DOI 10.1093/jnci/djn190; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Huppi Konrad, 2012, Frontiers in Genetics, V3, P69, DOI 10.3389/fgene.2012.00069; Jeon Y, 2011, CELL, V146, P119, DOI 10.1016/j.cell.2011.06.026; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jia L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000597; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kim HS, 2013, CELL, V152, P387, DOI 10.1016/j.cell.2013.01.027; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kim T, 2014, P NATL ACAD SCI USA, V111, P4173, DOI 10.1073/pnas.1400350111; Koch F, 2011, NAT STRUCT MOL BIOL, V18, P956, DOI 10.1038/nsmb.2085; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kumar V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003201; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016; Lee JT, 2009, GENE DEV, V23, P1831, DOI 10.1101/gad.1811209; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Li LJ, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-104; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035145; Liz J, 2014, MOL CELL, V55, P138, DOI 10.1016/j.molcel.2014.05.005; Maenner S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000276; Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013; Martin L, 2012, NAT METHODS, V9, P1192, DOI [10.1038/NMETH.2225, 10.1038/nmeth.2225]; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802; Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803; Ning SW, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-152; Novikova IV, 2012, NUCLEIC ACIDS RES, V40, P5034, DOI 10.1093/nar/gks071; Ogawa Y, 2008, SCIENCE, V320, P1336, DOI 10.1126/science.1157676; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Paige JS, 2011, SCIENCE, V333, P642, DOI 10.1126/science.1207339; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Pasmant E, 2011, J NATL CANCER I, V103, P1713, DOI 10.1093/jnci/djr416; Pasmant E, 2011, FASEB J, V25, P444, DOI 10.1096/fj.10-172452; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Prensner JR, 2014, CANCER RES, V74, P1651, DOI 10.1158/0008-5472.CAN-13-3159; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Redis RS, 2013, ONCOTARGET, V4, P1748, DOI 10.18632/oncotarget.1292; Ren SC, 2013, EUR J CANCER, V49, P2949, DOI 10.1016/j.ejca.2013.04.026; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rittenhouse H, 2013, CLIN CHEM, V59, P32, DOI 10.1373/clinchem.2012.198739; Sanford JR, 2009, GENOME RES, V19, P381, DOI 10.1101/gr.082503.108; Schmitz KM, 2010, GENE DEV, V24, P2264, DOI 10.1101/gad.590910; Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253; Simon MD, 2013, NATURE, V504, P465, DOI 10.1038/nature12719; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Sun BK, 2006, MOL CELL, V21, P617, DOI 10.1016/j.molcel.2006.01.028; Sur I, 2013, CANCER RES, V73, P4180, DOI 10.1158/0008-5472.CAN-13-0789; Sur IK, 2012, SCIENCE, V338, P1360, DOI 10.1126/science.1228606; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Verhaegh GW, 2008, EUR UROL, V54, P1118, DOI 10.1016/j.eururo.2008.01.060; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang XJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r30; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Wojcik SE, 2010, CARCINOGENESIS, V31, P208, DOI 10.1093/carcin/bgp209; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xue Y, 2013, PROSTATE CANCER P D, V16, P139, DOI 10.1038/pcan.2013.6; Yakovchuk P, 2009, P NATL ACAD SCI USA, V106, P5569, DOI 10.1073/pnas.0810738106; Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002; Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Yildirim E, 2013, CELL, V152, P727, DOI 10.1016/j.cell.2013.01.034; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381; Zhang X, 2010, ENDOCRINOLOGY, V151, P939, DOI 10.1210/en.2009-0657	124	241	249	0	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5003	5011		10.1038/onc.2014.456	http://dx.doi.org/10.1038/onc.2014.456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25619839	Green Accepted, Green Submitted			2022-12-28	WOS:000361693300001
J	Kasinski, AL; Kelnar, K; Stahlhut, C; Orellana, E; Zhao, J; Shimer, E; Dysart, S; Chen, X; Bader, AG; Slack, FJ				Kasinski, A. L.; Kelnar, K.; Stahlhut, C.; Orellana, E.; Zhao, J.; Shimer, E.; Dysart, S.; Chen, X.; Bader, A. G.; Slack, F. J.			A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer	ONCOGENE			English	Article							MOUSE MODELS; MIR-34A; ACTIVATION; EXPRESSION; INITIATION; DELIVERY; TARGET; GROWTH; RAS	Targeted cancer therapies, although often effective, have limited utility owing to preexisting primary or acquired secondary resistance. Consequently, agents are sometimes used in combination to simultaneously affect multiple targets. MicroRNA mimics are excellent therapeutic candidates because of their ability to repress multiple oncogenic pathways at once. Here we treated the aggressive Kras; p53 non-small cell lung cancer mouse model and demonstrated efficacy with a combination of two tumor-suppressive microRNAs (miRNAs). Systemic nanodelivery of miR-34 and let-7 suppressed tumor growth leading to survival advantage. This combinatorial miRNA therapeutic approach engages numerous components of tumor cell-addictive pathways and highlights the ability to deliver multiple miRNAs in a safe and effective manner to target lung tissue.	[Kasinski, A. L.; Stahlhut, C.; Shimer, E.; Chen, X.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Kasinski, A. L.; Orellana, E.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Kelnar, K.; Zhao, J.; Dysart, S.; Bader, A. G.] Mirna Therapeut Inc, Austin, TX 78744 USA; [Slack, F. J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Yale University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Slack, FJ (corresponding author), Harvard Univ, Sch Med, Dept Pathol, BIDMC, 3 Blackfan Circle CLS412, Boston, MA 02115 USA.	abader@mirnarx.com; fslack@bidmc.harvard.edu	Kasinski, Andrea/AAF-3864-2021; Orellana, Esteban/N-8004-2019; Orellana, Esteban/I-3653-2014; Kasinski, Andrea L/E-7951-2014	Kasinski, Andrea/0000-0002-9602-7827; Orellana, Esteban/0000-0003-4369-9416; Orellana, Esteban/0000-0003-4369-9416; Slack, Frank/0000-0001-8263-0409; Stahlhut, Carlos/0000-0002-8472-7156	American Cancer Society [PF-11-244-01]; NIH [CA178091, CA131301]; Cancer Prevention Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE [F32CA153885, R00CA178091, R01CA131301, K99CA178091] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	ALK was supported by an American Cancer Society Fellowship (PF-11-244-01) and an NIH Pathway to Independence Award (CA178091). This work was supported by a grant to FJS from the NIH (CA131301) and by a commercialization grant from the Cancer Prevention Research Institute of Texas (CPRIT) to AGB.	Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Gatsonis CA, 2011, RADIOLOGY, V258, P243, DOI 10.1148/radiol.10091808; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kasinski AL, 2012, CANCER RES, V72, P5576, DOI 10.1158/0008-5472.CAN-12-2001; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lin PY, 2010, BRIT J CANCER, V103, P1144, DOI 10.1038/sj.bjc.6605901; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Xue W, 2011, CANCER DISCOV, V1, P236, DOI 10.1158/2159-8290.CD-11-0073; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zhao J, 2013, MOL THER, V21, P1678, DOI 10.1038/mt.2013.148	34	153	160	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3547	3555		10.1038/onc.2014.282	http://dx.doi.org/10.1038/onc.2014.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25174400	Green Accepted			2022-12-28	WOS:000357434900007
J	Vassilopoulos, A; Tominaga, Y; Kim, HS; Lahusen, T; Li, B; Yu, H; Gius, D; Deng, CX				Vassilopoulos, A.; Tominaga, Y.; Kim, H-Seok; Lahusen, T.; Li, B.; Yu, H.; Gius, D.; Deng, C-X			WEE1 murine deficiency induces hyper-activation of APC/C and results in genomic instability and carcinogenesis	ONCOGENE			English	Article							CELL-CYCLE CHECKPOINTS; DNA-DAMAGING AGENTS; FISSION YEAST; TYROSINE KINASE; CDC25 PROTEIN; MITOTIC INHIBITOR; G(2) CHECKPOINT; GENE DELETION; CANCER; P53	The tyrosine kinase WEE1 controls the timing of entry into mitosis in eukaryotes and its genetic deletion leads to pre-implantation lethality in mice. Here, we show that besides the premature mitotic entry phenotype, Wee1 mutant murine cells fail to complete mitosis properly and exhibit several additional defects that contribute to the deregulation of mitosis, allowing mutant cells to progress through mitosis at the expense of genomic integrity. WEE1 interacts with the anaphase promoting complex, functioning as a negative regulator, and the deletion of Wee1 results in hyper-activation of this complex. Mammary specific knockout mice overcome the DNA damage response pathway triggered by the mis-coordination of the cell cycle in mammary epithelial cells and heterozygote mice spontaneously develop mammary tumors. Thus, WEE1 functions as a haploinsufficient tumor suppressor that coordinates distinct cell division events to allow correct segregation of genetic information into daughter cells and maintain genome integrity.	[Vassilopoulos, A.; Tominaga, Y.; Kim, H-Seok; Lahusen, T.; Deng, C-X] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Vassilopoulos, A.; Gius, D.] Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA; [Kim, H-Seok] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea; [Li, B.; Yu, H.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Northwestern University; Feinberg School of Medicine; Ewha Womans University; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10 Room 9N105, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		NIDDK; NCI [1R01CA152601-01]; DOD [BC093803]; SPORE [P50CA98131]; Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award; CCR, NIH; NATIONAL CANCER INSTITUTE [R01CA152799, P50CA098131, R01CA168292, R01CA152601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056011, ZIADK056009] Funding Source: NIH RePORTER	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); SPORE; Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award; CCR, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful for the critical reading and helpful discussion of members of the Deng laboratory. This work was supported in part by the Intramural Research Program of the NIDDK, NCI and CCR, NIH. DG is supported by 1R01CA152601-01 from the NCI, BC093803 from the DOD, SPORE P50CA98131 and a Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award. Melissa Stauffer, PhD, of Scientific Editing Solutions, provided editorial assistance.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Dine J, 2013, CANCER METAST REV, V32, P25, DOI 10.1007/s10555-012-9403-7; Dixon H, 2002, CELL CYCLE, V1, P362, DOI 10.4161/cc.1.6.257; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; FANTES PA, 1978, EXP CELL RES, V115, P317, DOI 10.1016/0014-4827(78)90286-0; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Harvey SL, 2005, CELL, V122, P407, DOI 10.1016/j.cell.2005.05.029; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iorns E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005120; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Li M, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-2; Lianga N, 2013, J CELL BIOL, V201, P843, DOI 10.1083/jcb.201212038; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Pines J, 2009, MOL CELL, V34, P135, DOI 10.1016/j.molcel.2009.04.006; PosthumaDeBoer J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-156; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Robinson GW, 2011, ANAL BIOCHEM, V412, P92, DOI 10.1016/j.ab.2011.01.020; Saeki T, 2009, INT J BIOL SCI, V5, P722; Schmit TL, 2009, CELL CYCLE, V8, P2697, DOI 10.4161/cc.8.17.9413; Simanski S, 2010, IDENTIFICATION SMALL; Simpson-Lavy KJ, 2010, CELL CYCLE, V9, P3046, DOI [10.4161/cc..9.115.12457, 10.4161/cc.9.115.12457]; Squire CJ, 2005, STRUCTURE, V13, P541, DOI 10.1016/j.str.2004.12.017; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Stumpff J, 2005, CURR BIOL, V15, P1525, DOI 10.1016/j.cub.2005.07.031; THURIAUX P, 1978, MOL GEN GENET, V161, P215, DOI 10.1007/BF00274190; Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552; Tominaga Y, 2006, INT J BIOL SCI, V2, P161; Towler WI, 2013, HUM MUTAT, V34, P439, DOI 10.1002/humu.22251; Trovesi C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002263; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wang YL, 2001, CANCER RES, V61, P8211	59	19	21	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3023	3035		10.1038/onc.2014.239	http://dx.doi.org/10.1038/onc.2014.239			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088202	Green Accepted			2022-12-28	WOS:000356100500008
J	Wei, F; Ojo, D; Lin, X; Wong, N; He, L; Yan, J; Xu, S; Major, P; Tang, D				Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Major, P.; Tang, D.			BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; CELL SELF-RENEWAL; POLYCOMB GROUP PROTEINS; MYC TRANSGENIC MICE; GROUP GENE BMI1; GENOMIC INSTABILITY; MOLECULAR MARKER; PROSTATE-CANCER; HISTONE H2AX	The BMI1 protein contributes to stem cell pluripotency and oncogenesis via multiple functions, including its newly identified role in DNA damage response (DDR). Although evidence clearly demonstrates that BMI1 facilitates the repair of double-stranded breaks via homologous recombination (HR), it remains unclear how BMI1 regulates checkpoint activation during DDR. We report here that BMI1 has a role in G2/M checkpoint activation in response to etoposide (ETOP) treatment. Ectopic expression of BMI1 in MCF7 breast cancer and DU145 prostate cancer cells significantly reduced ETOP-induced G2/M arrest. Conversely, knockdown of BMI1 in both lines enhanced the arrest. Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981). Furthermore, the phosphorylation of ATM targets, including gamma H2AX, threonine 68 (T68) on CHK2 (CHK2 pT68) and serine 15 (S15) on p53 were decreased in overexpression and increased in knockdown BMI1 cells in response to ETOP. In line with the requirement of NBS1 in ATM activation, we were able to show that BMI1 associates with NBS1 and that this interaction altered the binding of NBS1 with ATM. BMI1 consists of a ring finger (RF), helix-turn-helix-turn-helix-turn (HT), proline/serine (PS) domain and two nuclear localization signals (NLS). Although deletion of either RF or HT did not affect the association of BMI1 with NBS1, the individual deletions of PS and one NLS (KRMK) robustly reduced the interaction. Stable expression of these BMI1 mutants decreased ETOP-induced ATM pS1981 and CHK2 pT68, but not ETOP-elicited gamma H2AX in MCF7 cells. Furthermore, ectopic expression of BMI1 in non-transformed breast epithelial MCF10A cells also compromised ETOP-initiated ATM pS1981 and gamma H2AX. Taken together, we provide compelling evidence that BMI1 decreases ETOP-induced G2/M checkpoint activation via reducing NBS1-mediated ATM activation.	[Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Tang, D.] McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; [Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Tang, D.] Father Sean OSullivan Res Inst, Hamilton, ON, Canada; [Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Tang, D.] St Josephs Hosp, Hamilton Ctr Kidney Res, Hamilton, ON L8N 4A6, Canada; [Wei, F.] Inst Women & Childrens Hlth, Genet Lab, Shenzhen, Guangdong, Peoples R China; [He, L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; [Major, P.] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	McMaster University; McGill University; McMaster University; Harvard University; Harvard Medical School; Massachusetts General Hospital; McMaster University	Tang, D (corresponding author), St Josephs Hosp, Father Sean OSullivan Res Inst, T3310,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	CIHR grant [MOP-84381]	CIHR grant(Canadian Institutes of Health Research (CIHR))	This work was supported by a CIHR grant (MOP-84381) to D Tang.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Akala OO, 2008, NATURE, V453, P228, DOI 10.1038/nature06869; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bea S, 2001, CANCER RES, V61, P2409; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chagraoui J, 2006, GENE DEV, V20, P2110, DOI 10.1101/gad.1453406; Chagraoui J, 2011, P NATL ACAD SCI USA, V108, P5284, DOI 10.1073/pnas.1014263108; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Crea F, 2011, INT J CANCER, V128, P1946, DOI 10.1002/ijc.25522; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dong QH, 2011, J INVEST DERMATOL, V131, P1216, DOI 10.1038/jid.2011.11; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gieni RS, 2011, CELL CYCLE, V10, P883, DOI 10.4161/cc.10.6.14907; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200; Liu ZG, 2012, ONCOL REP, V27, P1116, DOI 10.3892/or.2011.1615; Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood-2005-06-2393; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Pan MR, 2011, J BIOL CHEM, V286, P28599, DOI 10.1074/jbc.M111.256297; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; QUELLE DE, 1995, CELL, V83, P993; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; van Galen JC, 2007, J CLIN PATHOL, V60, P167, DOI 10.1136/jcp.2006.038752; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wang EF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017918; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wei FX, 2010, CELL SIGNAL, V22, P1783, DOI 10.1016/j.cellsig.2010.07.007; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	64	21	23	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3063	3075		10.1038/onc.2014.235	http://dx.doi.org/10.1038/onc.2014.235			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088203				2022-12-28	WOS:000356100500011
J	Lopes, MH; Santos, TG; Rodrigues, BR; Queiroz-Hazarbassanov, N; Cunha, IW; Wasilewska-Sampaio, AP; Costa-Silva, B; Marchi, FA; Bleggi-Torres, LF; Sanematsu, PI; Suzuki, SH; Oba-Shinjo, SM; Marie, SKN; Toulmin, E; Hill, AF; Martins, VR				Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Cunha, I. W.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Bleggi-Torres, L. F.; Sanematsu, P. I.; Suzuki, S. H.; Oba-Shinjo, S. M.; Marie, S. K. N.; Toulmin, E.; Hill, A. F.; Martins, V. R.			Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival	ONCOGENE			English	Article							STRESS-INDUCIBLE PROTEIN-1; INDUCED PHOSPHOPROTEIN 1; CANCER-CELL-LINES; SIGNALING PATHWAYS; COLORECTAL-CANCER; PANCREATIC-CANCER; CLINICAL-TRIALS; BREAST-CANCER; BRAIN-TUMOR; PRO-PRION	Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrPC) triggers a large number of trophic effects in the nervous system. We found that both PrPC and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrPC and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrPC binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrPC binding site (HOP230-245) abrogates this effect. PrPC knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrPC-HOP engagement is a promising approach for GBM therapy.	[Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Martins, V. R.] AC Camargo Canc Ctr, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; [Lopes, M. H.] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo, Brazil; [Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Martins, V. R.] CNPq MCT FAPESP, Nat Inst Translat Neurosci, Sao Paulo, Brazil; [Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Martins, V. R.] CNPq MCT FAPESP, Natl Inst Oncogen, Sao Paulo, Brazil; [Cunha, I. W.] AC Camargo Canc Ctr, Dept Pathol, BR-01508010 Sao Paulo, Brazil; [Marchi, F. A.] Univ Sao Paulo, Inst Math & Stat, Interinst Grad Program Bioinformat, Sao Paulo, Brazil; [Bleggi-Torres, L. F.] Univ Fed Parana, Dept Pathol, BR-80060000 Curitiba, Parana, Brazil; [Bleggi-Torres, L. F.] Pele Pequeno Principe Res Inst, Curitiba, Parana, Brazil; [Sanematsu, P. I.; Suzuki, S. H.] AC Camargo Canc Ctr, Dept Neurosurg, BR-01508010 Sao Paulo, Brazil; [Oba-Shinjo, S. M.; Marie, S. K. N.] Univ Sao Paulo, Sch Med, Dept Neurol, BR-05508 Sao Paulo, Brazil; [Toulmin, E.; Hill, A. F.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic, Australia; [Martins, V. R.] Ludwig Inst Canc Res, Sao Paulo, Brazil	A.C.Camargo Cancer Center; Universidade de Sao Paulo; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade Federal do Parana; Hospital Pequeno Principe; A.C.Camargo Cancer Center; Universidade de Sao Paulo; University of Melbourne; Ludwig Institute for Cancer Research	Martins, VR (corresponding author), AC Camargo Canc Ctr, Int Res Ctr, Rua Tagua 440, BR-01508010 Sao Paulo, Brazil.	vmartins@cipe.accamargo.org.br	Santos, Tiago Goss/AAQ-4272-2020; Martins, Vilma/N-5446-2019; Hill, Andrew F/B-4527-2009; Marchi, Fabio Albuquerque/AAC-1380-2021; Martins, Vilma R/E-2547-2012; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F./GZL-4124-2022; Marchi, Fabio A/N-9288-2018; Cunha, Isabela/H-3013-2012; Santos, Tiago/F-2387-2012; Oba-Shinjo, Sueli M./C-4017-2012; Lopes, Marilene/GLV-4734-2022; Queiroz-Hazarbassanov, Nicolle/Q-6901-2019; Costa-Silva, Bruno/AAY-2266-2020; Queiroz-Hazarbassanov, Nicolle/P-4333-2014; dos Santos, Tiago Goss/A-1538-2019; Marie, Suely Kazue Nagahashi/D-1870-2012	Santos, Tiago Goss/0000-0001-6641-7413; Hill, Andrew F/0000-0001-5581-2354; Marchi, Fabio Albuquerque/0000-0001-5815-8423; Martins, Vilma R/0000-0002-2909-8502; Hill, Andrew F./0000-0001-5581-2354; Marchi, Fabio A/0000-0001-5815-8423; Cunha, Isabela/0000-0002-2029-5139; Santos, Tiago/0000-0001-6641-7413; Oba-Shinjo, Sueli M./0000-0002-1650-5973; Lopes, Marilene/0000-0003-2496-0674; Queiroz-Hazarbassanov, Nicolle/0000-0002-5692-0565; Queiroz-Hazarbassanov, Nicolle/0000-0002-5692-0565; dos Santos, Tiago Goss/0000-0001-6641-7413; Marie, Suely Kazue Nagahashi/0000-0003-4419-7928; Costa-Silva, Bruno/0000-0002-5932-6211	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 09/14027-2, 07/08410-2, 04/12133-6]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); FAPESP [2009/51653-9, 2009/51751-0, 2008/55381-0, 2010-13654-0, 2012/19019-0, 2010/20796-6]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 09/14027-2, 07/08410-2 and 04/12133-6) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). Fellowships from FAPESP (to TGS) (2009/51653-9), NGQ (2009/51751-0), BC-S (2008/55381-0), BRR (2010-13654-0, 2012/19019-0), APW-S (2010/20796-6), and from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (to APW-S) are gratefully acknowledged. We are thankful for Maria Del Mar Inda and Severino da Silva Ferreira for technical assistance. Drs Maria Dirlei Begnami, Victor Piana de Andrade and Martin Roffe contributed with helpful discussions. We thank the AC Camargo Biobank for providing the astrocytoma samples used in this study.	Allhenn D, 2012, INT J PHARMACEUT, V436, P299, DOI 10.1016/j.ijpharm.2012.06.025; Alvarenga AW, 2013, J HISTOCHEM CYTOCHEM, V61, P272, DOI 10.1369/0022155413477661; Antonacopoulou AG, 2008, ANTICANCER RES, V28, P1221; Antonacopoulou AG, 2010, MOL CARCINOGEN, V49, P693, DOI 10.1002/mc.20642; Barbieri G, 2011, AUTOPHAGY, V7, P840, DOI 10.4161/auto.7.8.15615; Brown KR, 2009, BIOINFORMATICS, V25, P3327, DOI 10.1093/bioinformatics/btp595; Butowski N, 2012, CURR OPIN NEUROL, V25, P780, DOI 10.1097/WCO.0b013e328359b45e; Caine C, 2012, EXPERT REV ANTICANC, V12, P655, DOI [10.1586/ERA.12.34, 10.1586/era.12.34]; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Coltinho AS, 2007, NEUROBIOL DIS, V26, P282, DOI 10.1016/j.nbd.2007.01.005; Erlich RB, 2007, GLIA, V55, P1690, DOI 10.1002/glia.20579; Eustace BK, 2004, CELL CYCLE, V3, P1098; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gehring K, 2008, LANCET NEUROL, V7, P548, DOI 10.1016/S1474-4422(08)70111-X; Hajj GNM, 2013, CELL MOL LIFE SCI, V70, P3211, DOI 10.1007/s00018-013-1328-y; Horibe T, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-59; Horibe T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-8; Jones TS, 2012, ONCOGENE, V31, P1995, DOI 10.1038/onc.2011.398; Joo KM, 2013, CELL REP, V3, P260, DOI 10.1016/j.celrep.2012.12.013; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kubota H, 2010, CELL STRESS CHAPERON, V15, P1003, DOI 10.1007/s12192-010-0211-0; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Lee CT, 2012, EMBO J, V31, P1518, DOI 10.1038/emboj.2012.37; Li CY, 2010, J BIOL CHEM, V285, P30328, DOI 10.1074/jbc.M110.147413; Li CY, 2009, J CLIN INVEST, V119, P2725, DOI 10.1172/JCI39542; Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x; Lima FRS, 2007, J NEUROCHEM, V103, P2164, DOI 10.1111/j.1471-4159.2007.04904.x; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; Maciejewski A, 2013, BIOMOL NMR ASSIGN, V7, P305, DOI 10.1007/s12104-012-9433-7; Martins VR, 2010, CURR ISSUES MOL BIOL, V12, P63; Meslin F, 2007, ANN ONCOL, V18, P1793, DOI 10.1093/annonc/mdm406; Muller P, 2013, ONCOGENE, V32, P3101, DOI 10.1038/onc.2012.314; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Pan YL, 2006, FASEB J, V20, P1886, DOI 10.1096/fj.06-6138fje; Pimienta G, 2011, MOL PHARMACEUT, V8, P2252, DOI 10.1021/mp200346y; Quant EC, 2010, NEUROIMAG CLIN N AM, V20, P425, DOI 10.1016/j.nic.2010.04.007; Ruckova E, 2012, CELL MOL BIOL LETT, V17, P446, DOI 10.2478/s11658-012-0021-8; Santos TG, 2011, STEM CELLS, V29, P1126, DOI 10.1002/stem.664; Sims JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018848; Sun W, 2007, MOL CELL PROTEOMICS, V6, P1798, DOI 10.1074/mcp.M600449-MCP200; Sy MS, 2011, CANCER BIOMARK, V10, P251, DOI 10.3233/CBM-2012-0256; Tsai CL, 2012, CELL REP, V2, P283, DOI 10.1016/j.celrep.2012.07.002; Walsh N, 2011, CANCER LETT, V306, P180, DOI 10.1016/j.canlet.2011.03.004; Walsh N, 2009, PROTEOME SCI, V7, DOI 10.1186/1477-5956-7-3; Wang TH, 2010, MOL CELL PROTEOMICS, V9, P1873, DOI 10.1074/mcp.M110.000802; Wasilewska-Sampaio AP, 2013, PHYSL BEHAV C, V123C, P55; Weissert R, 1998, J CLIN INVEST, V102, P1265, DOI 10.1172/JCI3022; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Willmer T, 2013, CANCER LETT, V328, P252, DOI 10.1016/j.canlet.2012.09.021; Yu GH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048146; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zhuang DX, 2012, INT J CANCER, V130, P309, DOI 10.1002/ijc.25985	53	36	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3305	3314		10.1038/onc.2014.261	http://dx.doi.org/10.1038/onc.2014.261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151961				2022-12-28	WOS:000356592300009
J	Thomas, A; Perry, T; Berhane, S; Oldreive, C; Zlatanou, A; Williams, LR; Weston, VJ; Stankovic, T; Kearns, P; Pors, K; Grand, RJ; Stewart, GS				Thomas, A.; Perry, T.; Berhane, S.; Oldreive, C.; Zlatanou, A.; Williams, L. R.; Weston, V. J.; Stankovic, T.; Kearns, P.; Pors, K.; Grand, R. J.; Stewart, G. S.			The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; INDUCED REPLICATION STRESS; DEPENDENT PROTEIN-KINASE; RESISTANT OVARIAN-CANCER; DNA TOPOISOMERASE-II; GENE; REPAIR; INACTIVATION; DEFICIENCY; MECHANISMS	Topoisomerase inhibitors are in common use as chemotherapeutic agents although they can display reduced efficacy in chemotherapy-resistant tumours, which have inactivated DNA damage response (DDR) genes, such as ATM and TP53. Here, we characterise the cellular response to the dual-acting agent, Alchemix (ALX), which is a modified anthraquinone that functions as a topoisomerase inhibitor as well as an alkylating agent. We show that ALX induces a robust DDR at nano-molar concentrations and this is mediated primarily through ATR- and DNA-PK- but not ATM-dependent pathways, despite DNA double strand breaks being generated after prolonged exposure to the drug. Interestingly, exposure of epithelial tumour cell lines to ALX in vitro resulted in potent activation of the G2/M checkpoint, which after a prolonged arrest, was bypassed allowing cells to progress into mitosis where they ultimately died by mitotic catastrophe. We also observed effective killing of lymphoid tumour cell lines in vitro following exposure to ALX, although, in contrast, this tended to occur via activation of a p53-independent apoptotic pathway. Lastly, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo by demonstrating its ability to cause a significant reduction in tumour cell growth, irrespective of TP53 status, using a mouse leukaemia xenograft model. Taken together, these data demonstrate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents a novel anti-cancer agent that could be potentially used clinically to treat refractory or relapsed tumours, particularly those harbouring mutations in DDR genes.	[Thomas, A.; Perry, T.; Berhane, S.; Oldreive, C.; Zlatanou, A.; Williams, L. R.; Weston, V. J.; Stankovic, T.; Kearns, P.; Grand, R. J.; Stewart, G. S.] Univ Birmingham, Coll Med & Dent, Sch Canc Sci, IBR West Extens, Birmingham B15 2TT, W Midlands, England; [Pors, K.] Univ Bradford, Sch Life Sci, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England	University of Birmingham; University of Bradford	Stewart, GS (corresponding author), Univ Birmingham, Coll Med & Dent, Sch Canc Sci, IBR West Extens, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	k.pors1@bradford.ac.uk; R.J.A.Grand@bham.ac.uk; G.S.Stewart@bham.ac.uk	Kearns, Pamela/AAD-6011-2021	Stankovic, Tatjana/0000-0002-3780-274X; Stewart, Grant/0000-0002-0960-3241; Berhane, Sarah/0000-0002-1437-0411; Pors, Klaus/0000-0002-0837-5208; Kearns, Pamela/0000-0003-2756-5813	University of Birmingham; MRC [G0900088]; Cancer Research UK [C17183/A13030]; Leukaemia Lymphoma Research [11045]; Lister Institute; Yorkshire Cancer Research; Cancer Research UK [13030] Funding Source: researchfish; Medical Research Council [G0900088] Funding Source: researchfish	University of Birmingham; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Leukaemia Lymphoma Research; Lister Institute; Yorkshire Cancer Research; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are most grateful to Fred Bunz, Alan D'Andrea, Eva Petermann, Panagiotis Kotsantis and Jiri Lukas for the gift of cell lines, and Philip Byrd, Arnold Levine and David Lane for antibodies. We would especially like to thank Cyrus Vaziri for providing cell lines and a recombinant adenovirus expressing Cyclin E, Rebbeca Jones for helping us with PFGE and Malcolm Taylor for helpful discussions. Last, we would also thank the University of Birmingham (AT-PhD studentship), MRC (GSS, RJG-Project grant: G0900088), the Cancer Research UK (GSS-Senior Fellowship: C17183/A13030), the Leukaemia Lymphoma Research (TS, GSS-Programme grant: 11045), the Lister Institute (GSS, AZ-Research Prize) and the Yorkshire Cancer Research (KP) for funding this study.	Abdallah QMA, 2012, BIOCHEM PHARMACOL, V83, P1514, DOI 10.1016/j.bcp.2012.02.017; Al-Ejeh F, 2010, ONCOGENE, V29, P6085, DOI 10.1038/onc.2010.407; Beeharry N, 2013, CELL CYCLE, V12, P1588, DOI 10.4161/cc.24740; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bhojwani D, 2013, LANCET ONCOL, V14, pE205, DOI 10.1016/S1470-2045(12)70580-6; CALDECOTT K, 1990, CANCER RES, V50, P5778; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Forrest RA, 2013, CANCER CHEMOTH PHARM, V71, P809, DOI 10.1007/s00280-012-2049-x; Greaves M, 2013, BRIT J CANCER, V109, P1391, DOI 10.1038/bjc.2013.490; Hof J, 2011, J CLIN ONCOL, V29, P3185, DOI 10.1200/JCO.2011.34.8144; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Larsen AK, 2003, PHARMACOL THERAPEUT, V99, P167, DOI 10.1016/S0163-7258(03)00058-5; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; McNeely S, 2010, CELL CYCLE, V9, P995, DOI 10.4161/cc.9.5.10935; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Orth JD, 2012, MOL BIOL CELL, V23, P567, DOI 10.1091/mbc.E11-09-0781; Pabla N, 2011, J BIOL CHEM, V286, P10411, DOI 10.1074/jbc.M110.210989; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pommier Y, 2013, ACS CHEM BIOL, V8, P82, DOI 10.1021/cb300648v; Pors K, 2005, J MED CHEM, V48, P6690, DOI 10.1021/jm050438f; Pors K, 2004, J MED CHEM, V47, P1856, DOI 10.1021/jm031070u; Pors K, 2003, MOL CANCER THER, V2, P607; Pors K, 2005, CURR TOP MED CHEM, V5, P1133, DOI 10.2174/156802605774370883; Redmond KM, 2008, FRONT BIOSCI-LANDMRK, V13, P5138, DOI 10.2741/3070; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Sy SMH, 2011, J BIOL CHEM, V286, P22355, DOI 10.1074/jbc.M111.232041; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Yajima H, 2006, MOL CELL BIOL, V26, P7520, DOI 10.1128/MCB.00048-06; Yajima H, 2009, J MOL BIOL, V385, P800, DOI 10.1016/j.jmb.2008.11.036	37	2	2	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3336	3348		10.1038/onc.2014.266	http://dx.doi.org/10.1038/onc.2014.266			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132271	Green Accepted			2022-12-28	WOS:000356592300012
J	Wang, WT; Catto, JWF; Meuth, M				Wang, W-T; Catto, J. W. F.; Meuth, M.			Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors	ONCOGENE			English	Article							REPLICATION FORK PROGRESSION; DNA-DAMAGE CHECKPOINT; PHOSPHORYLATION; KINASE; ACTIVATION; APOPTOSIS; RPA; PROMOTES; INACTIVATION; EXPRESSION	While DNA damage response pathways are well characterized in cancer cells, much less is known about their status in normal cells. These pathways protect tumour cells from DNA damage and replication stress and consequently present potential therapeutic targets. Here we characterize the response of human telomerase reverse transcriptase (hTERT)-immortalized normal human urothelial (NHU) and bladder cancer cell lines to agents that disrupt the DNA damage response. Effects of replication and DNA damage response inhibitors on cell cycle progression, checkpoint induction and apoptosis were analysed in hTERT-NHU and bladder cancer cell lines. The primary signalling cascade responding to replication stress in malignant cells (ataxia telangiectasia-mutated (ATM) and Rad3-related-checkpoint kinase 1 (ATR-CHK1)) is not activated in hTERT-NHU cells after treatment with a replication inhibitor and these cells do not depend upon CHK1 for protection from apoptosis during replication stress. Instead, ATM signalling is rapidly activated under these conditions. Intriguingly, an ATM inhibitor suppressed S-phase checkpoint activation after exposure to replication inhibitors and stopped entry of cells into S-phase indicating G1 checkpoint activation. Consistent with this, hTERT-NHU cells treated with the ATM inhibitor showed increased levels of cyclin-dependent kinase inhibitor p19(INK4D), reduced levels of cyclin D1 and CDK4, and reduced phosphorylation of the retinoblastoma protein. In contrast, a bladder cancer cell line cotreated with ATM and replication inhibitors progressed more slowly through S phase and showed a marked increase in apoptosis. Taken together, our findings suggest that ATM and CHK1 signalling cascades have different roles in tumour and normal epithelial cells, confirming these as promising therapeutic targets.	[Wang, W-T; Catto, J. W. F.; Meuth, M.] Univ Sheffield, Sch Med, YCR CRUK Sheffield Canc Res Ctr, Mol Oncol Unit,Dept Oncol, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Meuth, M (corresponding author), Univ Sheffield, Sch Med, YCR CRUK Sheffield Canc Res Ctr, Mol Oncol Unit,Dept Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	m.meuth@sheffield.ac.uk		catto, james/0000-0003-2787-8828	Yorkshire Cancer Research [S305PA]; P. A. Banner Trust	Yorkshire Cancer Research; P. A. Banner Trust	This work was supported in part by a programme grant from Yorkshire Cancer Research (S305PA) and the P. A. Banner Trust. We are grateful to Helen Bryant for her comments on the manuscript.	Anantha RW, 2007, J BIOL CHEM, V282, P35910, DOI 10.1074/jbc.M704645200; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bennett CN, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3230; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Blackwood E, 2013, MOL CANCER THER, V12, P1968, DOI 10.1158/1535-7163.MCT-12-1218; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Carrassa L, 2011, CELL CYCLE, V10, P2121, DOI 10.4161/cc.10.13.16398; Ceruti JM, 2005, ONCOGENE, V24, P4065, DOI 10.1038/sj.onc.1208570; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Courcelle J, 2003, SCIENCE, V299, P1064, DOI 10.1126/science.1081328; Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Liu QH, 2000, GENE DEV, V14, P1448; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Lukas C, 2001, CANCER RES, V61, P4990; Meuth M, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-21; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Rodriguez R, 2008, CELL DEATH DIFFER, V15, P889, DOI 10.1038/cdd.2008.4; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Stracker TH, 2009, DNA REPAIR, V8, P1047, DOI 10.1016/j.dnarep.2009.04.012; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Tavera-Mendoza L, 2006, EMBO REP, V7, P180, DOI 10.1038/sj.embor.7400594; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vassin VM, 2009, J CELL SCI, V122, P4070, DOI 10.1242/jcs.053702; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Walker M, 2009, ONCOGENE, V28, P2314, DOI 10.1038/onc.2009.102; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhang YW, 2009, MOL CELL, V35, P442, DOI 10.1016/j.molcel.2009.06.030; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	54	7	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2887	2896		10.1038/onc.2014.221	http://dx.doi.org/10.1038/onc.2014.221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25043304	Green Submitted			2022-12-28	WOS:000355324300008
J	Vinnedge, LMP; Benight, NM; Wagh, PK; Pease, NA; Nashu, MA; Serrano-Lopez, J; Adams, AK; Cancelas, JA; Waltz, SE; Wells, SI				Vinnedge, L. M. Privette; Benight, N. M.; Wagh, P. K.; Pease, N. A.; Nashu, M. A.; Serrano-Lopez, J.; Adams, A. K.; Cancelas, J. A.; Waltz, S. E.; Wells, S. I.			The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; BETA-CATENIN; MAMMARY-GLAND; STEM-CELL; TYROSINE KINASE; ONCOPROTEIN DEK; TUMOR-FORMATION; BLADDER-CANCER; UP-REGULATION; FEMALE MICE	Disease progression and recurrence are major barriers to survival for breast cancer patients. Understanding the etiology of recurrent or metastatic breast cancer and underlying mechanisms is critical for the development of new treatments and improved survival. Here, we report that two commonly overexpressed breast cancer oncogenes, Ron (Recepteur d'Origine Nantaise) and DEK, cooperate to promote advanced disease through multipronged effects on beta-catenin signaling. The Ron receptor is commonly activated in breast cancers, and Ron overexpression in human disease stimulates beta-catenin nuclear translocation and is an independent predictor of metastatic dissemination. Dek is a chromatin-associated oncogene whose expression has been linked to cancer through multiple mechanisms, including beta-catenin activity. We demonstrate here that Dek is a downstream target of Ron receptor activation in murine and human models. The absence of Dek in the MMTV-Ron mouse model led to a significant delay in tumor development, characterized by decreased cell proliferation, diminished metastasis and fewer cells expressing mammary cancer stem cell markers. Dek complementation of cell lines established from this model was sufficient to promote cellular growth and invasion. Mechanistically, Dek expression stimulated the production and secretion of Wnt ligands to sustain an autocrine/paracrine canonical beta-catenin signaling loop. Finally, we show that Dek overexpression promotes tumorigenic phenotypes in immortalized human mammary epithelial MCF10A cells and, in the context of Ron receptor activation, correlates with disease recurrence and metastasis in patients. Overall, our studies demonstrate that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/beta-catenin signaling.	[Vinnedge, L. M. Privette; Pease, N. A.; Adams, A. K.; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Cincinnati, OH 45229 USA; [Benight, N. M.; Nashu, M. A.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA; [Wagh, P. K.] Cincinnati Childrens Hosp Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45229 USA; [Serrano-Lopez, J.; Cancelas, J. A.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Serrano-Lopez, J.] Univ Hosp Reina Sofia, UCO, IMIBIC, Cordoba, Spain; [Cancelas, J. A.] Univ Cincinnati, Coll Med, Hoxworth Blood Ctr, Cincinnati, OH USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Dept Res, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Wells, SI (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Oncol, MLC 7013,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Lisa.Privette@cchmc.org; Susanne.Wells@cchmc.org	Vinnedge, Lisa Privette/H-5869-2019; Cancelas, Jose/AAR-9324-2020; Serano-Lopez, Juana/O-8874-2017	Vinnedge, Lisa Privette/0000-0003-2087-4920; Serrano Lopez, Juana/0000-0001-8140-9040; Benight, Nancy/0000-0001-7321-3187; Waltz, Susan/0000-0003-3572-4642	NIH [AR-47363]; Ride Cincinnati Foundation for Breast Cancer Research [F32CA139931, T32HL091805, K12HD051953]; Public Health Services [R01CA116316, R01HL875109, T32ES007250, T32CA117846-07, T32CA11784]; Department of Defense [W81XWH-12-1-0194]; Veteran's Administration [BX000803]; Government of the Spanish Junta de Andalucia; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD051953] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [F32CA139931, F32CA189685, T32CA117846, R01CA116316] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000803] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ride Cincinnati Foundation for Breast Cancer Research; Public Health Services(United States Department of Health & Human ServicesUnited States Public Health Service); Department of Defense(United States Department of Defense); Veteran's Administration(US Department of Veterans Affairs); Government of the Spanish Junta de Andalucia; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge James Lessard and Gerard Grosveld for reagents, Kathryn Wikenheiser-Brokamp for technical assistance and the Research Flow Cytometry Core at Cincinnati Children's, supported by NIH AR-47363. LMPV is supported by the Ride Cincinnati Foundation for Breast Cancer Research in honor of Marlene Harris and Public Health Service Grants F32CA139931, T32HL091805 and K12HD051953. Funding also was provided by Public Health Services Grants R01CA116316 (SIW), R01HL875109 (JAC), T32ES007250 (AKA), T32CA117846-07 (PKW) and T32CA11784 (SEW and NMB), Department of Defense Grant W81XWH-12-1-0194 (SIW and SEW) and the Veteran's Administration Grant BX000803 (SEW). JS-W is supported by the Government of the Spanish Junta de Andalucia.	ACS (American Cancer Society), 2011, BREAST CANC FACTS FI; Adams AK, 2015, ONCOGENE, V34, P868, DOI 10.1038/onc.2014.15; Alexiadis V, 2000, GENE DEV, V14, P1308; Benhaj K, 2006, ONCOL REP, V15, P701; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; Danilkovitch-Miagkova A, 2003, CURR CANCER DRUG TAR, V3, P31, DOI 10.2174/1568009033333745; Datta A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-234; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631; Gamble MJ, 2007, NAT STRUCT MOL BIOL, V14, P548, DOI 10.1038/nsmb1248; Gao B, 2012, CURR TOP DEV BIOL, V101, P263, DOI 10.1016/B978-0-12-394592-1.00008-9; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Habib SJ, 2013, SCIENCE, V339, P1445, DOI 10.1126/science.1231077; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; HUGUET EL, 1994, CANCER RES, V54, P2615; Kappes F, 2011, GENE DEV, V25, P673, DOI 10.1101/gad.2036411; Karam M, 2014, NEOPLASIA, V16, P21, DOI 10.1593/neo.131658; Karner C, 2006, SEMIN CELL DEV BIOL, V17, P214, DOI 10.1016/j.semcdb.2006.05.007; Kavanaugh GM, 2011, NUCLEIC ACIDS RES, V39, P7465, DOI 10.1093/nar/gkr454; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Kim DW, 2010, MOL MED REP, V3, P877, DOI 10.3892/mmr.2010.346; Koleva RI, 2012, BLOOD, V119, P4878, DOI 10.1182/blood-2011-10-383083; Kondoh N, 1999, CANCER RES, V59, P4990; Krol M, 2010, J APPL GENET, V51, P37, DOI 10.1007/BF03195709; Kuorelahti A, 2007, ENDOCRINOLOGY, V148, P3694, DOI 10.1210/en.2007-0249; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Leonis Mike A, 2007, Future Oncol, V3, P441, DOI 10.2217/14796694.3.4.441; Liu KR, 2012, BIOSCIENCE REP, V32, P323, DOI 10.1042/BSR20100141; Lossaint G, 2013, MOL CELL, V51, P678, DOI 10.1016/j.molcel.2013.07.023; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Meier-Abt F, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3419; Soares LMM, 2006, SCIENCE, V312, P1961, DOI 10.1126/science.1128659; Miranda-Carboni GA, 2008, GENE DEV, V22, P3121, DOI 10.1101/gad.1692808; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Moll UM, 2004, MOL CANCER RES, V2, P371; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Mor-Vaknin N, 2011, ARTHRITIS RHEUM-US, V63, P556, DOI 10.1002/art.30138; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Rajagopal J, 2008, DEVELOPMENT, V135, P1625, DOI 10.1242/dev.015495; Robinson GW, 2000, GENE DEV, V14, P889; Saha AK, 2013, P NATL ACAD SCI USA, V110, P6847, DOI 10.1073/pnas.1220751110; Sammons M, 2006, J BIOL CHEM, V281, P26802, DOI 10.1074/jbc.M600915200; Sanden C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-440; Sawatsubashi S, 2010, GENE DEV, V24, P159, DOI 10.1101/gad.1857410; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shibata T, 2010, ONCOGENE, V29, P4671, DOI 10.1038/onc.2010.217; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Veltmaat JM, 2004, DEV DYNAM, V229, P349, DOI 10.1002/dvdy.10441; Vinnedge LMP, 2011, ONCOGENE, V30, P2741, DOI 10.1038/onc.2011.2; Vinnedge LMP, 2013, CELL CYCLE, V12, P51, DOI 10.4161/cc.23121; Vinnedge LMP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046985; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wagh PK, 2011, ONCOGENE, V30, P3694, DOI 10.1038/onc.2011.86; Wang JY, 2013, J HISTOCHEM CYTOCHEM, V61, P510, DOI 10.1369/0022155413488120; Wang MH, 2013, J BIOMED RES, V27, P345, DOI 10.7555/JBR.27.20130038; Wend P, 2013, EMBO MOL MED, V5, P264, DOI 10.1002/emmm.201201320; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Yin YJ, 2006, CANCER RES, V66, P5224, DOI 10.1158/0008-5472.CAN-05-4234; Zhao H, 2014, ONCOGENE, V33, P1429, DOI 10.1038/onc.2013.84; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	74	46	47	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2325	2336		10.1038/onc.2014.173	http://dx.doi.org/10.1038/onc.2014.173			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954505	Green Accepted			2022-12-28	WOS:000353824800006
J	Fan, H; Zhang, H; Pascuzzi, PE; Andrisani, O				Fan, H.; Zhang, H.; Pascuzzi, P. E.; Andrisani, O.			Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2	ONCOGENE			English	Article							NF-KAPPA-B; POSITIVE HEPATOCELLULAR-CARCINOMA; LIVER-CANCER PROGRESSION; HEPATOCYTE CELL-LINES; GENE-EXPRESSION; TARGET GENES; TRANSGENIC MICE; MAMMALIAN DNA; ANTIGEN EPCAM; EP-CAM	Chronic hepatitis B virus (HBV) infection is a major risk factor for developing hepatocellular carcinoma (HCC), and HBV X protein (HBx) acts as cofactor in hepatocarcinogenesis. In liver tumors from animals modeling HBx- and HBV-mediated hepatocarcinogenesis, downregulation of chromatin regulating proteins SUZ12 and ZNF198 induces expression of several genes, including epithelial cell adhesion molecule (EpCAM). EpCAM upregulation occurs in HBV-mediated HCCs and hepatic cancer stem cells, by a mechanism not understood. Herein we demonstrate HBx induces EpCAM expression via active DNA demethylation. In hepatocytes, EpCAM is silenced by polycomb repressive complex 2 (PRC2) and ZNF198/LSD1/Co-REST/HDAC1 chromatin-modifying complexes. Cells with stable knockdown of SUZ12, an essential PRC2 subunit, upon HBx expression demethylate a CpG dinucleotide located adjacent to NF-kappa B/RelA half-site. This NF-kappa B/RelA site is in a CpG island downstream from EpCAM transcriptional start site (-155). Chromatin immunoprecipitation (ChIP) assays demonstrate HBx-dependent RelA occupancy of NF-kappa B half-site, whereas RelA knockdown suppresses CpG demethylation and EpCAM expression. Tumor necrosis factor-alpha activates RelA, propagating demethylation to nearby CpG sites, shown by sodium bisulfite sequencing. ReIA-dependent demethylation occurring upon HBx expression requires methyltrasferase EZH2, TET2 a key factor in cytosine demethylation and inactive DNMT3L, shown by knockdown assays and sodium bisulfite sequencing. Co-immunoprecipitations and sequential ChIP assays demonstrate that RelA in the presence of HBx forms a complex with EZH2, TET2 and DNMT3L, although the role of DNMT3L remains to be understood. Interestingly, the human EpCAM gene also has a CpG island downstream from its TSS, and a NF-kappa B-binding site flanked by CpGs. HepG2 cells derived from human HCC exhibit demethylation of these NF-kappa B-flanking CpG sites, and HBV replication propagates demethylation to nearby CpG sites. DLK1, another PRC2 target gene, also upregulated in HBV-mediated HCCs, is demethylated in liver tumors at CpG dinucleotides flanking the NF-kappa B-binding sequence, supporting that this active DNA demethylation mechanism functions during oncogenic transformation.	[Fan, H.; Zhang, H.; Andrisani, O.] Purdue Univ, Dept Basic Med Sci, 205A Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA; [Fan, H.; Zhang, H.; Andrisani, O.] Purdue Univ, Dept Purdue, Ctr Canc Res, W Lafayette, IN 47907 USA; [Pascuzzi, P. E.] Purdue Univ, Purdue Univ Lib, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Andrisani, O (corresponding author), Purdue Univ, Dept Basic Med Sci, 205A Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA.	andrisao@purdue.edu	Pascuzzi, Pete/T-5378-2019	Andrisani, Ourania/0000-0002-6230-0303; Pascuzzi, Pete/0000-0002-9316-4404	NIH [DK044533, P30CA023168]; NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044533, R01DK044533] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant DK044533 to OA. Shared Resources (flow cytometry and DNA sequencing) are supported by NIH grant P30CA023168 to Purdue Cancer Research Center. The authors thank Dr R Hullinger for critical review of the manuscript.	Andrisani OM, 1999, INT J ONCOL, V15, P373; [Anonymous], 2014, R LANG ENV STAT COMP; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; BEASLEY RP, 1981, LANCET, V2, P1129; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cartron Pierre-Francois, 2013, Genes Cancer, V4, P235, DOI 10.1177/1947601913489020; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chaves-Perez A, 2013, ONCOGENE, V32, P641, DOI 10.1038/onc.2012.75; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; de Boer CJ, 1999, J PATHOL, V188, P201, DOI 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8; de la Rica L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r99; Delatte B, 2014, EMBO J, V33, P1198, DOI 10.15252/embj.201488290; Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110; Fujiki K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3262; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gocke CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003255; Hachmeister M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071836; Haring M, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-11; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Ko M, 2013, NATURE, V497, P122, DOI 10.1038/nature12052; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715; Lee HJ, 2014, CELL STEM CELL, V14, P710, DOI 10.1016/j.stem.2014.05.008; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu T, 2013, P NATL ACAD SCI USA, V110, P13510, DOI 10.1073/pnas.1311770110; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Meissner A, 2011, CELL STEM CELL, V9, P388, DOI 10.1016/j.stem.2011.10.014; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Nakamoto Y, 1997, J IMMUNOL, V158, P5692; Neri F, 2013, CELL, V155, P121, DOI 10.1016/j.cell.2013.08.056; Ning BF, 2014, HEPATOLOGY, V60, P1607, DOI 10.1002/hep.27177; Schmelzer E, 2007, J EXP MED, V204, P1973, DOI 10.1084/jem.20061603; Schnell U, 2013, BBA-BIOMEMBRANES, V1828, P1989, DOI 10.1016/j.bbamem.2013.04.018; Studach L, 2010, J BIOL CHEM, V285, P30282, DOI 10.1074/jbc.M109.093963; Studach LL, 2012, HEPATOLOGY, V56, P1240, DOI 10.1002/hep.25781; Studach LL, 2009, HEPATOLOGY, V50, P414, DOI 10.1002/hep.22996; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tanaka M, 2009, MECH DEVELOP, V126, P665, DOI 10.1016/j.mod.2009.06.939; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; van der Gun BTF, 2011, BRIT J CANCER, V105, P312, DOI 10.1038/bjc.2011.231; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang VYF, 2012, CELL REP, V2, P824, DOI 10.1016/j.celrep.2012.08.042; Wang WH, 2011, HEPATOLOGY, V53, P1137, DOI 10.1002/hep.24163; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Zeng SS, 2014, J HEPATOL, V60, P127, DOI 10.1016/j.jhep.2013.08.024; Zhang H, CANC RES IN PRESS; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	63	31	35	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					715	726		10.1038/onc.2015.122	http://dx.doi.org/10.1038/onc.2015.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25893293	Green Accepted			2022-12-28	WOS:000370331300005
J	Haeger, SM; Thompson, JJ; Kalra, S; Cleaver, TG; Merrick, D; Wang, XJ; Malkoski, SP				Haeger, S. M.; Thompson, J. J.; Kalra, S.; Cleaver, T. G.; Merrick, D.; Wang, X-J; Malkoski, S. P.			Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; BASAL-CELLS; STEM-CELLS; REPAIR; ADENOCARCINOMA; MOUSE; EXPRESSION; PTEN; DISRUPTION; ACTIVATION	Non-small-cell lung cancer (NSCLC) is a common malignancy with a poor prognosis. Despite progress targeting oncogenic drivers, there are no therapies targeting tumor-suppressor loss. Smad4 is an established tumor suppressor in pancreatic and colon cancer; however, the consequences of Smad4 loss in lung cancer are largely unknown. We evaluated Smad4 expression in human NSCLC samples and examined Smad4 alterations in large NSCLC data sets and found that reduced Smad4 expression is common in human NSCLC and occurs through a variety of mechanisms, including mutation, homozygous deletion and heterozygous loss. We modeled Smad4 loss in lung cancer by deleting Smad4 in airway epithelial cells and found that Smad4 deletion both initiates and promotes lung tumor development. Interestingly, both Smad4(-/-) mouse tumors and human NSCLC samples with reduced Smad4 expression demonstrated increased DNA damage, whereas Smad4 knockdown in lung cancer cells reduced DNA repair and increased apoptosis after DNA damage. In addition, Smad4-deficient NSCLC cells demonstrated increased sensitivity to both chemotherapeutics that inhibit DNA topoisomerase and drugs that block double-strand DNA break repair by non-homologous end joining. In sum, these studies establish Smad4 as a lung tumor suppressor and suggest that the defective DNA repair phenotype of Smad4-deficient tumors can be exploited by specific therapeutic strategies.	[Haeger, S. M.; Thompson, J. J.; Kalra, S.; Cleaver, T. G.; Malkoski, S. P.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver Anschutz Med Campus,12700 E 19th Ave,RC2,R, Aurora, CO 80045 USA; [Merrick, D.; Wang, X-J; Malkoski, S. P.] Univ Colorado, Dept Pathol, Denver Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Malkoski, SP (corresponding author), Univ Colorado, Div Pulm Sci & Crit Care Med, Denver Anschutz Med Campus,12700 E 19th Ave,RC2,R, Aurora, CO 80045 USA.	Stephen.Malkoski@ucdenver.edu			NIH/NCI [K08 CA131483]; NIH/NIDCR [R01 DE015953]; National Lung Cancer Partnership; Colorado Lung Cancer SPORE [P50 CA058187]; American Cancer Society Institutional Research Grant [ACS IRG 57-001-53];  [P30 CA069533];  [P30 CA046934]; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187, R21CA194662, K08CA131483, P30CA069533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007635] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Lung Cancer Partnership; Colorado Lung Cancer SPORE; American Cancer Society Institutional Research Grant(American Cancer Society); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the NIH/NCI (K08 CA131483 to SPM) and NIH/NIDCR (R01 DE015953 to XJW). SPM was also supported by the National Lung Cancer Partnership and a Career Development Award from the Colorado Lung Cancer SPORE (P50 CA058187) and an American Cancer Society Institutional Research Grant (ACS IRG 57-001-53). The OHSU BioLibrary is supported by P30 CA069533. The Colorado Lung Cancer SPORE Tissue Bank is supported by P30 CA046934 and P50 CA058187. We thank OHSU BioLibrary staff for their assistance with patient samples. We also thank Jerry Haney, Christina Nall, Marina Lewis and Wilbur Franklin at the Colorado Lung SPORE for assistance acquiring patient samples and data.	Achanta G, 2001, CANCER RES, V61, P8723; Adachi N, 2004, J BIOL CHEM, V279, P37343, DOI 10.1074/jbc.M313910200; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Bargonetti J, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/698960; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488; Crul M, 2003, BIOCHEM PHARMACOL, V65, P275, DOI 10.1016/S0006-2952(02)01508-3; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Glick AB, 1997, CANCER RES, V57, P2079; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jalal S, CLIN CANC RES, V17, P6973; Jazag A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni130; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kass EM, 2010, FEBS LETT, V584, P3703, DOI 10.1016/j.febslet.2010.07.057; Ke Z, 2008, NEOPLASMA, V55, P323; Kirshner J, 2006, CANCER RES, V66, P10861, DOI 10.1158/0008-5472.CAN-06-2565; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Malkoski SP, 2014, MOL CARCINOGEN, V53, P841, DOI 10.1002/mc.22030; Malkoski SP, 2012, FEBS LETT, V586, P1984, DOI 10.1016/j.febslet.2012.01.054; Malkoski SP, 2012, CLIN CANCER RES, V18, P2173, DOI 10.1158/1078-0432.CCR-11-2557; Malkoski SP, 2010, INT J BIOL SCI, V6, P68; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Nagatake M, 1996, CANCER RES, V56, P2718; Neal JA, 2011, MUTAT RES-FUND MOL M, V711, P73, DOI 10.1016/j.mrfmmm.2011.02.010; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; Treszezamsky AD, 2007, CANCER RES, V67, P7078, DOI 10.1158/0008-5472.CAN-07-0601; Wachters FM, 2003, INT J RADIAT ONCOL, V57, P553, DOI 10.1016/s0360-3016(03)00503-0; Woods D, 2013, CANCER BIOL THER, V14, P379, DOI 10.4161/cbt.23761; Wunderlich FT, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.10.e47; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Xu X, 2010, ONCOGENE, V29, P674, DOI 10.1038/onc.2009.375; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yu SL, 2013, ONCOL REP, V30, P1293, DOI 10.3892/or.2013.2578	52	34	35	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					577	586		10.1038/onc.2015.112	http://dx.doi.org/10.1038/onc.2015.112			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893305	Green Accepted			2022-12-28	WOS:000369548800005
J	He, C; Lv, X; Hua, G; Lele, SM; Remmenga, S; Dong, J; Davis, JS; Wang, C				He, C.; Lv, X.; Hua, G.; Lele, S. M.; Remmenga, S.; Dong, J.; Davis, J. S.; Wang, C.			YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; SURFACE EPITHELIAL-CELLS; HIPPO PATHWAY; TRANSCRIPTIONAL COACTIVATOR; TUMOR-SUPPRESSOR; GROWTH-FACTOR; PROLIFERATION; DROSOPHILA; EXPRESSION; MIGRATION	Mechanisms underlying ovarian cancer initiation and progression are unclear. Herein, we report that the Yes-associated protein (YAP), a major effector of the Hippo tumor suppressor pathway, interacts with ERBB signaling pathways to regulate the initiation and progression of ovarian cancer. Immunohistochemistry studies indicate that YAP expression is associated with poor clinical outcomes in patients. Overexpression or constitutive activation of YAP leads to transformation and tumorigenesis in human ovarian surface epithelial cells, and promotes growth of cancer cells in vivo and in vitro. YAP induces the expression of epidermal growth factor (EGF) receptors (EGFR, ERBB3) and production of EGF-like ligands (HBEGF, NRG1 and NRG2). HBEGF or NRG1, in turn, activates YAP and stimulates cancer cell growth. Knockdown of ERBB3 or HBEGF eliminates YAP effects on cell growth and transformation, whereas knockdown of YAP abrogates NRG1- and HBEGF-stimulated cell proliferation. Collectively, our study demonstrates the existence of HBEGF & NRGs/ERBBs/YAP/HBEGF & NRGs autocrine loop that controls ovarian cell tumorigenesis and cancer progression.	[He, C.; Lv, X.; Hua, G.; Remmenga, S.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Olson Ctr Womens Hlth, Dept Obstet & Gynecol, Omaha, NE 68198 USA; [He, C.; Hua, G.] Huazhong Agr Univ, Coll Anim Sci & Technol, Wuhan, Hubei Province, Peoples R China; [Lele, S. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Remmenga, S.; Dong, J.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Davis, J. S.] Omaha Vet Affairs Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; Huazhong Agricultural University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Wang, C (corresponding author), Univ Nebraska Med Ctr, Dept Obstet & Gynecol, Fred & Pamela Buffett Canc Ctr, Olson Ctr Womens Hlth,Dept OB GYN, Omaha, NE 68198 USA.	chengwang@unmc.edu	Davis, John S/C-3234-2014; Lv, Xiangmin/I-7106-2019	Lv, Xiangmin/0000-0001-8338-6014; Davis, John/0000-0003-3468-4079	Eunice Kennedy Shriver National Institute of Child Health and Human Development [5R00HD059985, 5P01AG029531]; Olson Center for Women's Health; Fred & Pamela Buffett Cancer Center [LB595]; Omaha Veterans Administration Medical Center [5I01BX000512]; National Institute of Food and Agriculture [2011-67015-20076]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R00HD059985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG029531] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000512] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Olson Center for Women's Health; Fred & Pamela Buffett Cancer Center; Omaha Veterans Administration Medical Center; National Institute of Food and Agriculture(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5R00HD059985, 5P01AG029531); The Olson Center for Women's Health (no number); The Fred & Pamela Buffett Cancer Center (LB595); the Omaha Veterans Administration Medical Center (5I01BX000512) and The National Institute of Food and Agriculture (2011-67015-20076). We wish to thank for Melody A. Montgomery at the University of Nebraska Medical Center Research Editorial Office for her professional assistance in editing this manuscript.	Amsellem-Ouazana D, 2006, J UROLOGY, V175, P1127, DOI 10.1016/S0022-5347(05)00317-4; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fu D, 2014, ENDOCR-RELAT CANCER, V21, P297, DOI 10.1530/ERC-13-0339; Gregoire L, 2001, CLIN CANCER RES, V7, P4280; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kim JM, 2011, HUM PATHOL, V42, P315, DOI 10.1016/j.humpath.2010.08.003; Kojic N, 2010, FASEB J, V24, P1604, DOI 10.1096/fj.09-145367; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lucas EP, 2013, J CELL BIOL, V201, P875, DOI 10.1083/jcb.201210073; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Sasaki R, 2009, CARCINOGENESIS, V30, P423, DOI 10.1093/carcin/bgp007; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Tschumperlin DJ, 2004, CELL CYCLE, V3, P996; Wang C, 2010, ENDOCRINOLOGY, V151, P2319, DOI 10.1210/en.2009-1489; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xia Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091770; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang N, 2012, CELL CYCLE, V11, P2922, DOI 10.4161/cc.21386; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	46	68	71	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6040	6054		10.1038/onc.2015.52	http://dx.doi.org/10.1038/onc.2015.52			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25798835	Green Accepted			2022-12-28	WOS:000366113800002
J	Kim, RK; Suh, Y; Hwang, E; Yoo, KC; Choi, KS; An, S; Hwang, SG; Kim, IG; Kim, MJ; Lee, HJ; Lee, SJ				Kim, R-K; Suh, Y.; Hwang, E.; Yoo, K-C; Choi, K-S; An, S.; Hwang, S-G; Kim, I-G; Kim, M-J; Lee, H-J; Lee, S-J			PKC delta maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback	ONCOGENE			English	Article							PROTEIN-KINASE-C; CANCER STEM-CELLS; GROWTH-FACTOR; GLIOMA; BRAIN; ACTIVATION; SURVIVAL; PATHWAY; IDENTIFICATION; POPULATION	The existence of tumor initiating cells (TICs) has been emerged as a good therapeutic target for treatment of glioblastoma that is the most aggressive brain tumor with poor prognosis. However, the molecular mechanisms that regulate the phenotypes of TICs still remain obscure. In this study, we found that PKC delta, among PKC isoforms, is preferentially activated in TICs and acts as a critical regulator for the maintenance of TICs in glioblastoma. By modulating the expression levels or activity of PKC delta, we demonstrated that PKC delta promotes self-renewal and tumorigenic potentials of TICs. Importantly, we found that the activation of PKC delta persists in TICs through an autocrine loop with positive feedback that was driven by PKC delta/STAT3/IL-23/JAK signaling axis. Moreover, for phenotypes of TICs, we showed that PKC delta activates AKT signaling component by phosphorylation specifically on Ser473. Taken together, we proposed that TICs regulate their own population in glioblastoma through an autocrine loop with positive feedback that is driven by PKC delta-dependent secretion of cytokines.	[Kim, R-K; Suh, Y.; Hwang, E.; Yoo, K-C; Kim, M-J; Lee, S-J] Hanyang Univ, Lab Mol Biochem, Dept Life Sci, Res Inst Nat Sci, Seoul 133791, South Korea; [Choi, K-S] Sungkyunkwan Univ, Mol & Cellular Imaging Ctr, Samsung Biomed Res Inst, Sch Med, Seoul, South Korea; [An, S.] Konkuk Univ, Funct Genoproteome Res Ctr, Seoul, South Korea; [Hwang, S-G] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul, South Korea; [Kim, I-G] Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Taejon, South Korea; [Kim, M-J] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul, South Korea; [Lee, H-J] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul, South Korea	Hanyang University; Sungkyunkwan University (SKKU); Samsung Medical Center; Konkuk University; Korea Institute of Radiological & Medical Sciences; Korea Atomic Energy Research Institute (KAERI); Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences	Lee, SJ (corresponding author), Hanyang Univ, Lab Mol Biochem, Dept Life Sci, Res Inst Nat Sci, 17 Haengdang Dong, Seoul 133791, South Korea.	sj0420@hanyang.ac.kr			National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean government, through its National Nuclear Technology Program [NRF-2012M2B2B1055639, NRF-2013M2A2A7066345]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean government, through its National Nuclear Technology Program	We thank Dr Akio Soeda (Department of Neurological Surgery, University of Virginia, USA) for providing patient-derived glioma cells. This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean government, through its National Nuclear Technology Program (NRF-2012M2B2B1055639 and NRF-2013M2A2A7066345).	Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2010, THESCIENTIFICWORLDJO, V10, P2272, DOI 10.1100/tsw.2010.214; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Brescia P, 2013, STEM CELLS, V31, P857, DOI 10.1002/stem.1317; Carrillo-Garcia C, 2010, MOL CELL NEUROSCI, V44, P318, DOI 10.1016/j.mcn.2010.04.003; Chen ZH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-90; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Duan ZF, 2006, CLIN CANCER RES, V12, P6844, DOI 10.1158/1078-0432.CCR-06-1330; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hernandez-Maqueda JG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058540; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Inagaki A, 2007, BIOCHEM BIOPH RES CO, V361, P586, DOI 10.1016/j.bbrc.2007.07.037; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Kim NH, 2013, BMB REP, V46, P59, DOI 10.5483/BMBRep.2013.46.1.123; Laperriere N, 2002, RADIOTHER ONCOL, V64, P259, DOI 10.1016/S0167-8140(02)00078-6; Lu F, 2005, RADIAT RES, V163, P63, DOI 10.1667/RR3285; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Mandil R, 2001, CANCER RES, V61, P4612; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Salmaggi A, 2006, GLIA, V54, P850, DOI 10.1002/glia.20414; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Suh Y, 2009, MOL CELL NEUROSCI, V42, P308, DOI 10.1016/j.mcn.2009.08.003; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhou YH, 2003, CLIN CANCER RES, V9, P3369	57	6	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5749	5759		10.1038/onc.2015.29	http://dx.doi.org/10.1038/onc.2015.29			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25746003				2022-12-28	WOS:000364594600007
J	Komatsu, N; Fujita, Y; Matsuda, M; Aoki, K				Komatsu, N.; Fujita, Y.; Matsuda, M.; Aoki, K.			mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells	ONCOGENE			English	Article							RAS; ACTIVATION; KINASE; ADDICTION; PATHWAYS; SENSITIVITY; EFFICACY; 3-KINASE; COMPLEX	Cancer cells harboring oncogenic BRaf mutants, but not oncogenic KRas mutants, are sensitive to MEK inhibitors (MEKi). The mechanism underlying the intrinsic resistance to MEKi in KRas-mutant cells is under intensive investigation. Here, we pursued this mechanism by live imaging of extracellular signal-regulated kinases (ERK) and mammalian target of rapamycin complex 1 (mTORC1) activities in oncogenic KRas or BRaf-mutant cancer cells. We established eight cancer cell lines expressing Forster resonance energy transfer (FRET) biosensors for ERK activity and S6K activity, which was used as a surrogate marker for mTORC1 activity. Under increasing concentrations of MEKi, ERK activity correlated linearly with the cell growth rate in BRaf-mutant cancer cells, but not KRas-mutant cancer cells. The administration of PI3K inhibitors resulted in a linear correlation between ERK activity and cell growth rate in KRas-mutant cancer cells. Intriguingly, mTORC1 activity was correlated linearly with the cell growth rate in both BRaf-mutant cancer cells and KRas-mutant cancer cells. These observations suggested that mTORC1 activity had a pivotal role in cell growth and that the mTORC1 activity was maintained primarily by the ERK pathway in BRaf-mutant cancer cells and by both the ERK and PI3K pathways in KRas-mutant cancer cells. FRET imaging revealed that MEKi inhibited mTORC1 activity with slow kinetics, implying transcriptional control of mTORC1 activity by ERK. In agreement with this observation, MEKi induced the expression of negative regulators of mTORC1, including TSC1, TSC2 and Deptor, which occurred more significantly in BRaf-mutant cells than in KRas-mutant cells. These findings suggested that the suppression of mTORC1 activity and induction of negative regulators of mTORC1 in cancer cells treated for at least 1 day could be used as surrogate markers for the MEKi sensitivity of cancer cells.	[Komatsu, N.; Matsuda, M.] Kyoto Univ, Lab Bioimaging & Cell Signaling, Grad Sch Biostudies, Kyoto 6068501, Japan; [Fujita, Y.; Matsuda, M.] Kyoto Univ, Dept Pathol & Biol Dis, Grad Sch Med, Kyoto 6068501, Japan; [Aoki, K.] Kyoto Univ, Imaging Platform Spatio Temporal Informat, Grad Sch Med, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University	Aoki, K (corresponding author), Kyoto Univ, Imaging Platform Spatio Temporal Informat, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	k-aoki@lif.kyoto-u.ac.jp	Aoki, Kazuhiro/I-5483-2019; Aoki, Kazuhiro/B-5777-2013	Aoki, Kazuhiro/0000-0001-7263-1555; Aoki, Kazuhiro/0000-0001-7263-1555; Fujita, Yoshihisa/0000-0002-5086-8188; Matsuda, Michiyuki/0000-0002-5876-9969	Research Program of Innovative Cell Biology by Innovative Technology (the 'Cell Innovation' Program); Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports and Science, Japan;  [23701052]; Grants-in-Aid for Scientific Research [23701052, 26290053] Funding Source: KAKEN	Research Program of Innovative Cell Biology by Innovative Technology (the 'Cell Innovation' Program); Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports and Science, Japan; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to the members of the Matsuda Laboratory for their helpful input. Y Inaoka, K Hirano, A Katsumata, N Nishimoto, N Nonaka and A Kawagishi are also to be thanked for their technical assistance. KA and MM were supported by the Research Program of Innovative Cell Biology by Innovative Technology (the 'Cell Innovation' Program) and Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports and Science, Japan. KA was supported by a Grant-in-Aid for Young Scientists (B) (23701052) and a Grant-in-Aid for Scientific Research (B). NK and YF were supported by a Grant-in-Aid for JSPS Fellows.	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Aoki K, 2013, MOL CELL, V52, P529, DOI 10.1016/j.molcel.2013.09.015; Aoki K, 2009, NAT PROTOC, V4, P1623, DOI 10.1038/nprot.2009.175; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046; Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Friday BB, 2008, CANCER RES, V68, P6145, DOI 10.1158/0008-5472.CAN-08-1430; Fujita Y, 2014, FEBS J, V281, P3177, DOI 10.1111/febs.12852; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Kawakami K, 2004, GENETICS, V166, P895, DOI 10.1534/genetics.166.2.895; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Komatsu N, 2011, MOL BIOL CELL, V22, P4647, DOI 10.1091/mbc.E11-01-0072; LoRusso P, 2012, J CLIN ONCOL, P30; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106; Speranza G, 2012, J CLIN ONCOL, P30; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yusa K, 2009, NAT METHODS, V6, P363, DOI [10.1038/NMETH.1323, 10.1038/nmeth.1323]	40	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5607	5616		10.1038/onc.2015.16	http://dx.doi.org/10.1038/onc.2015.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25703330				2022-12-28	WOS:000364594300002
J	Fulda, S; Kogel, D				Fulda, S.; Koegel, D.			Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy	ONCOGENE			English	Review							SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITOR; PROSTATE-CANCER; REGULATES AUTOPHAGY; BETULINIC ACID; UP-REGULATION; APOPTOSIS; OBATOCLAX; GX15-070; LEUKEMIA	Autophagy is a tightly-regulated catabolic process of cellular self-digestion by which cellular components are targeted to lysosomes for their degradation. Key functions of autophagy are to provide energy and metabolic precursors under conditions of starvation and to alleviate stress by removal of damaged proteins and organelles, which are deleterious for cell survival. Therefore, autophagy appears to serve as a pro-survival stress response in most settings. However, the role of autophagy in modulating cell death is highly dependent on the cellular context and its extent. There is an increasing evidence for cell death by autophagy, in particular in developmental cell death in lower organisms and in autophagic cancer cell death induced by novel cancer drugs. The death-promoting and - executing mechanisms involved in the different paradigms of autophagic cell death (ACD) are very diverse and complex, but a draft scenario of the key molecular targets involved in ACD is beginning to emerge. This review provides an up-to-date and comprehensive report on the molecular mechanisms of drug-induced autophagy-dependent cell death and highlights recent key findings in this exciting field of research.	[Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany; [Koegel, D.] Goethe Univ Hosp, Ctr Neurol & Neurosurg, Expt Neurosurg, Frankfurt, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Goethe University Frankfurt Hospital	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de; koegel@em.uni-frankfurt.de		Kogel, Donat/0000-0003-1209-0210; Fulda, Simone/0000-0002-0459-6417	BMBF	BMBF(Federal Ministry of Education & Research (BMBF))	The expert secretarial assistance of C Hugenberg is greatly appreciated. This work has been partly supported by a grant from the BMBF (to SF).	Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Balakrishnan K, 2008, BLOOD, V112, P1971, DOI 10.1182/blood-2007-12-126946; Basit F, 2013, CELL DEATH DIFFER, V20, P1161, DOI 10.1038/cdd.2013.45; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Brem EA, 2011, BRIT J HAEMATOL, V153, P599, DOI 10.1111/j.1365-2141.2011.08669.x; Calvo-Garrido J, 2010, AUTOPHAGY, V6, P686, DOI 10.4161/auto.6.6.12513; Cao Q, 2008, INT J BIOCHEM CELL B, V40, P272, DOI 10.1016/j.biocel.2007.07.020; Cea M, 2012, BLOOD, V120, P3519, DOI 10.1182/blood-2012-03-416776; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Chen YJ, 2014, ONCOTARGET, V5, P4845, DOI 10.18632/oncotarget.2045; Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331; Friesen C, 2007, CANCER RES, V67, P1950, DOI 10.1158/0008-5472.CAN-06-3569; Fulda S, 2009, DRUG DISCOV TODAY, V14, P885, DOI 10.1016/j.drudis.2009.05.015; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Ginet V, 2014, AUTOPHAGY, V10, P603, DOI 10.4161/auto.27722; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Heidari N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.53; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetschko H, 2008, NEOPLASIA, V10, P873, DOI 10.1593/neo.07842; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030; Kaza N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096733; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017; Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74; Lian JQ, 2010, AUTOPHAGY, V6, P1201, DOI [10.1038/cdd.2010.74, 10.4161/auto.6.8.13549]; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Martin AP, 2009, CANCER BIOL THER, V8, P2084; Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309; McCoy F, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.86; Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333; Munoz-Pinedo C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.246; Nihira K, 2014, CANCER SCI, V105, P568, DOI 10.1111/cas.12396; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Pan JX, 2010, CANCER LETT, V293, P167, DOI 10.1016/j.canlet.2010.01.006; Paoluzzi L, 2008, BLOOD, V111, P5350, DOI 10.1182/blood-2007-12-129833; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Potze L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.139; Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537; Rami A, 2008, AUTOPHAGY, V4, P422, DOI 10.4161/auto.5778; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51; Schwartz-Roberts JL, 2013, MOL CANCER THER, V12, P448, DOI 10.1158/1535-7163.MCT-12-0617; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tang Y, 2012, MOL PHARMACOL, V82, P322, DOI 10.1124/mol.112.078907; Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32; Voss V, 2010, MOL CANCER RES, V8, P1002, DOI 10.1158/1541-7786.MCR-09-0562; Wang WJ, 2014, NAT CHEM BIOL, V10, P133, DOI [10.1038/nchembio.1406, 10.1038/NCHEMBIO.1406]; Wei Y, 2010, CLIN CANCER RES, V16, P3923, DOI 10.1158/1078-0432.CCR-10-0032; Wolter KG, 2006, NEOPLASIA, V8, P163, DOI 10.1593/neo.05691; Yamamoto S, 2008, ANTICANCER RES, V28, P1585; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Yuan Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.191; Zhaorigetu S, 2008, AUTOPHAGY, V4, P1079, DOI 10.4161/auto.7066	76	232	236	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5105	5113		10.1038/onc.2014.458	http://dx.doi.org/10.1038/onc.2014.458			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619832				2022-12-28	WOS:000362233400001
J	Qian, J; Pentz, K; Zhu, Q; Wang, Q; He, J; Srivastava, AK; Wani, AA				Qian, J.; Pentz, K.; Zhu, Q.; Wang, Q.; He, J.; Srivastava, A. K.; Wani, A. A.			USP7 modulates UV-induced PCNA monoubiquitination by regulating DNA polymerase eta stability	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM VARIANT GENE; SENSITIVE SYNDROME; PROTEIN; UVSSA; PROTEOLYSIS; HAUSP; RAD18; P53	DNA polymerase eta (Pol eta) has unique and pivotal functions in several DNA damage-tolerance pathways. Steady-state level of this short-lived protein is tightly controlled by multiple mechanisms including proteolysis. Here, we have identified the deubiquitinating enzyme (DUB), ubiquitin-specific protease 7 (USP7), as a novel regulator of Pol eta stability. USP7 regulates Pol eta stability through both indirect and direct mechanisms. Knockout of USP7 increased the steady-state level of Pol eta and slowed down the turnover of both Pol eta and p53 proteins through destabilizing their E3 ligase murine double minute 2 (Mdm2). Also, USP7 physically binds Pol eta in vitro and in vivo. Overexpression of wild-type USP7 but not its catalytically-defective mutants deubiquitinates Pol eta and increases its cellular steady-state level. Thus, USP7 directly serves as a specific DUB for Pol eta. Furthermore, ectopic expression of USP7 promoted the UV-induced proliferating cell nuclear antigen (PCNA) monoubiquitination in Pol eta-proficient but not in Pol eta-deficient XPV (Xeroderma pigmentosum variant) cells, suggesting that USP7 facilitates UV-induced PCNA monoubiquitination by stabilizing Pol eta. Taken together, our findings reveal a modulatory role of USP7 in PCNA ubiquitination-mediated stress-tolerance pathways by fine-tuning Pol eta turnover.	[Qian, J.; Pentz, K.; Zhu, Q.; Wang, Q.; He, J.; Srivastava, A. K.; Wani, A. A.] Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; [Wani, A. A.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Wani, A. A.] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA; [Wani, A. A.] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Qian, J (corresponding author), Ohio State Univ, Dept Radiol, 1020 Biomed Res Tower,460W 12th Ave, Columbus, OH 43210 USA.	Qian.41@osu.edu; wani.2@osu.edu			National Institutes of Health [ES012991, ES023883]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388, R01ES012991, R21ES023883] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We are thankful to Dr Bert Vogelstein for HCT116, HCT116 p53<SUP>-/-</SUP> and HCT116 USP7<SUP>-/-</SUP> cells; Dr Alan Lehmann for XP30RO and XP30RO-GFP-Pol eta cells; Drs Yanhui Xu and Yang Shi for FLAG-tagged WT and CS USP7 constructs; Dr Carol Prives for Myc-Mdm2 construct. This work was supported by grants from the National Institutes of Health (ES012991 and ES023883) to AAW.	Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Durando M, 2013, NUCLEIC ACIDS RES, V41, P3079, DOI 10.1093/nar/gkt016; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; He JS, 2014, J BIOL CHEM, V289, P27278, DOI 10.1074/jbc.M114.589812; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kim SH, 2008, MOL CELL, V32, P757, DOI 10.1016/j.molcel.2008.11.016; Lehmann AR, 2007, DNA REPAIR, V6, P891, DOI 10.1016/j.dnarep.2007.02.003; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Ma HH, 2012, P NATL ACAD SCI USA, V109, P4828, DOI 10.1073/pnas.1116349109; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Sarasin A, 2012, GENOME MED, V4, DOI 10.1186/gm343; Schwertman P, 2012, NAT GENET, V44, P598, DOI 10.1038/ng.2230; Skoneczna A, 2007, J MOL BIOL, V366, P1074, DOI 10.1016/j.jmb.2006.11.093; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang X, 2012, NAT GENET, V44, P593, DOI 10.1038/ng.2228	21	44	44	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4791	4796		10.1038/onc.2014.394	http://dx.doi.org/10.1038/onc.2014.394			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25435364	Green Accepted			2022-12-28	WOS:000360931500012
J	Wu, H; Zheng, J; Deng, J; Zhang, L; Li, N; Li, W; Li, F; Lu, J; Zhou, Y				Wu, H.; Zheng, J.; Deng, J.; Zhang, L.; Li, N.; Li, W.; Li, F.; Lu, J.; Zhou, Y.			LincRNA-uc002yug.2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SQUAMOUS-CELL CARCINOMA; LONG NONCODING RNA; SUSCEPTIBILITY LOCI; LUNG-CANCER; GENE; CHINESE; PROLIFERATION; TRANSCRIPTION; METASTASIS	Long intergenic noncoding RNAs (lincRNAs) have critical regulatory roles in cancer biology; however, the contributions of lincRNAs to esophageal squamous cell carcinoma (ESCC) have been infrequently explored. The aim of this study was to explore the contribution of lincRNAs, located at ESCC susceptibility loci identified by genome-wide association studies, to the risk and prognosis of ESCC. The associations between lincRNAs and the risk and prognosis of ESCC were analyzed in 358 diagnosed patients from eastern China, and the findings were validated in 326 additional patients from southern China. Functional relevance of lincRNAs was further examined by biochemical assays. We found that lincRNA-uc002yug.2 was commonly overexpressed in ESCC compared with paired peritumoral tissue in eastern and southern Chinese populations. The expression levels of lincRNA-uc002yug.2 in ESCC might be a prognostic factor for survival. Moreover, lincRNA-uc002yug.2 promoted a combination of RUNX1 and alternative splicing (AS) factors in the nucleus to produce more RUNX1 alpha, the short isoform and inhibitor of RUNX1, and reduce CEBP alpha (CCAAT/enhancer-binding protein-alpha) gene expression, thereby promoting ESCC progression. These results indicated that lincRNA-uc002yug.2 might involve in AS of RUNX1/AML1 and serve as a predictor for esophageal cancer and prognosis.	[Wu, H.; Zheng, J.; Deng, J.; Li, N.; Li, W.; Li, F.; Zhou, Y.] Soochow Univ, Coll Med, Dept Genet, Suzhou 215123, Peoples R China; [Zhang, L.] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, Suzhou 215123, Peoples R China; [Lu, J.] Guangzhou Med Univ, State Key Lab Resp Dis, Inst Chem Carcinogenesis, Guangzhou, Guangdong, Peoples R China	Soochow University - China; Soochow University - China; Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Zhou, Y (corresponding author), Soochow Univ, Coll Med, Dept Genet, Renai Rd 199,Bldg 401,Room 1418, Suzhou 215123, Peoples R China.	zhouyifeng@suda.edu.cn		Zhang, Liyuan/0000-0002-7469-1743	National Scientific Foundation of China [81001278, 81171895, 81472630, 81072366]; Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Natural Science Foundation [BK2011297]; Jiangsu Province Science and Technology Support Program [BE2012648]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry [20101561]	National Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Natural Science Foundation; Jiangsu Province Science and Technology Support Program; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry(Scientific Research Foundation for the Returned Overseas Chinese Scholars)	This study was supported by the National Scientific Foundation of China grants 81001278, 81171895, 81472630 and 81072366; a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Natural Science Foundation (No. BK2011297); Jiangsu Province Science and Technology Support Program (No. BE2012648) and the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (No. 20101561).	Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Cui R, 2009, GASTROENTEROLOGY, V137, P1768, DOI 10.1053/j.gastro.2009.07.070; Dinger Marcel E., 2009, Briefings in Functional Genomics & Proteomics, V8, P407, DOI 10.1093/bfgp/elp038; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Girard N, 2013, P NATL ACAD SCI USA, V110, P13522, DOI 10.1073/pnas.1310067110; Guo H, 2012, BLOOD, V119, P4408, DOI 10.1182/blood-2011-12-397091; Han H, 2013, NATURE, V498, P241, DOI 10.1038/nature12270; Hu N, 2005, CANCER RES, V65, P2542, DOI 10.1158/0008-5472.CAN-04-3247; Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jin GF, 2012, AM J HUM GENET, V91, P928, DOI 10.1016/j.ajhg.2012.09.009; Kumar M, 2013, INT J CANCER, V132, P2032, DOI 10.1002/ijc.27880; Kuwano H, 2005, SURG TODAY, V35, P7, DOI 10.1007/s00595-004-2885-3; Liu X, 2009, LEUKEMIA, V23, P739, DOI 10.1038/leu.2008.350; Luco RF, 2011, CURR OPIN GENET DEV, V21, P366, DOI 10.1016/j.gde.2011.03.004; Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Sato A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057013; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; St Kapranov P, 2010, BMC BIOL, V8, P149; Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68; Sun SY, 2010, NAT STRUCT MOL BIOL, V17, P306, DOI 10.1038/nsmb.1750; Szumilo Justyna, 2009, Pol Merkur Lekarski, V26, P82; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tsuzuki S, 2007, PLOS MED, V4, P880, DOI 10.1371/journal.pmed.0040172; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang LD, 2010, NAT GENET, V42, P759, DOI 10.1038/ng.648; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901; Wu C, 2013, NAT GENET, V45, P632, DOI 10.1038/ng.2638; Wu C, 2012, NAT GENET, V44, P1090, DOI 10.1038/ng.2411; Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849; Yamabuki T, 2006, INT J ONCOL, V28, P1375; Yang Howard H., 2008, V141, P23; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021	45	48	50	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4723	4734		10.1038/onc.2014.400	http://dx.doi.org/10.1038/onc.2014.400			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25486427				2022-12-28	WOS:000360931500006
J	Choudhry, H; Albukhari, A; Morotti, M; Haider, S; Moralli, D; Smythies, J; Schodel, J; Green, CM; Camps, C; Buffa, F; Ratcliffe, P; Ragoussis, J; Harris, AL; Mole, DR				Choudhry, H.; Albukhari, A.; Morotti, M.; Haider, S.; Moralli, D.; Smythies, J.; Schoedel, J.; Green, C. M.; Camps, C.; Buffa, F.; Ratcliffe, P.; Ragoussis, J.; Harris, A. L.; Mole, D. R.			Tumor hypoxia induces nuclear paraspeckle formation through HIF-2 alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival	ONCOGENE			English	Article							LONG NONCODING RNA; INDUCIBLE FACTOR-1; GENE-EXPRESSION; BINDING SITES; DNA-BINDING; HIF-1-ALPHA; HIF-1; RELOCATION; PROTEIN; BODIES	Activation of cellular transcriptional responses, mediated by hypoxia-inducible factor (HIF), is common in many types of cancer, and generally confers a poor prognosis. Known to induce many hundreds of protein-coding genes, HIF has also recently been shown to be a key regulator of the non-coding transcriptional response. Here, we show that NEAT1 long non-coding RNA (lncRNA) is a direct transcriptional target of HIF in many breast cancer cell lines and in solid tumors. Unlike previously described lncRNAs, NEAT1 is regulated principally by HIF-2 rather than by HIF-1. NEAT1 is a nuclear lncRNA that is an essential structural component of paraspeckles and the hypoxic induction of NEAT1 induces paraspeckle formation in a manner that is dependent upon both NEAT1 and on HIF-2. Paraspeckles are multifunction nuclear structures that sequester transcriptionally active proteins as well as RNA transcripts that have been subjected to adenosine-to-inosine (A-to-I) editing. We show that the nuclear retention of one such transcript, F11R (also known as junctional adhesion molecule 1, JAM1), in hypoxia is dependent upon the hypoxic increase in NEAT1, thereby conferring a novel mechanism of HIF-dependent gene regulation. Induction of NEAT1 in hypoxia also leads to accelerated cellular proliferation, improved clonogenic survival and reduced apoptosis, all of which are hallmarks of increased tumorigenesis. Furthermore, in patients with breast cancer, high tumor NEAT1 expression correlates with poor survival. Taken together, these results indicate a new role for HIF transcriptional pathways in the regulation of nuclear structure and that this contributes to the pro-tumorigenic hypoxia-phenotype in breast cancer.	[Choudhry, H.; Albukhari, A.] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia; [Choudhry, H.; Moralli, D.; Green, C. M.; Camps, C.; Ragoussis, J.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, Oxon, England; [Albukhari, A.; Morotti, M.; Haider, S.; Harris, A. L.] Univ Oxford, Dept Oncol, Weatherall Inst Mol Med, Oxford OX3 7BN, Oxon, England; [Smythies, J.; Buffa, F.; Ratcliffe, P.; Mole, D. R.] Univ Oxford, Oxford OX3 7BN, Oxon, England; [Schoedel, J.] Univ Erlangen Nurnberg, Dept Nephrol & Hypertens, D-91054 Erlangen, Germany; [Ragoussis, J.] McGill Univ, Montreal, PQ, Canada; [Ragoussis, J.] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Ragoussis, J.] BSRC Alexander Fleming, Athens, Greece	King Abdulaziz University; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; University of Erlangen Nuremberg; McGill University; Alexander Fleming Biomedical Sciences Research Center	Mole, DR (corresponding author), Univ Oxford, Nuffield Dept Med, Henry Wellcome Bldg Mol Biol, Oxford OX3 7BN, Oxon, England.	drmole@well.ox.ac.uk	Buffa, Francesca/D-2574-2013; Ragoussis, Ioannis/AAD-9790-2022; Harris, Adrian L/ABA-3343-2020; Albukhari, Ashwag/M-3690-2016; Morotti, Matteo/AAE-8922-2020	Buffa, Francesca/0000-0003-0409-406X; Harris, Adrian L/0000-0003-1376-8409; Albukhari, Ashwag/0000-0003-3669-1184; Morotti, Matteo/0000-0002-1790-1185; Ratcliffe, Peter/0000-0002-2853-806X; Green, Catherine/0000-0002-7068-7106; Schodel, Johannes/0000-0002-3587-8839; Ragoussis, Ioannis/0000-0002-8515-0934; Mole, David/0000-0002-0984-300X; Choudhry, Hani/0000-0003-0401-6619	Wellcome Trust [088182/Z/09/Z, 078333/Z/05/Z, WT091857MA]; Higher Education Funding Council for England, Cancer Research UK [A16016]; Ludwig Institute for Cancer Research; Interdisciplinary Center of Clinical Research at the University of Erlangen-Nuremberg [TP J31]; Center of Innovation in Personalized Medicine, King Abdulaziz University, Ministry of High Education for Saudi Arabia; Cancer Research UK [11359, 18974, 16016] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Higher Education Funding Council for England, Cancer Research UK; Ludwig Institute for Cancer Research; Interdisciplinary Center of Clinical Research at the University of Erlangen-Nuremberg; Center of Innovation in Personalized Medicine, King Abdulaziz University, Ministry of High Education for Saudi Arabia; Cancer Research UK(Cancer Research UK)	This work was funded by the Wellcome Trust (088182/Z/09/Z, 078333/Z/05/Z and WT091857MA), the Higher Education Funding Council for England, Cancer Research UK (A16016), the Ludwig Institute for Cancer Research, the Interdisciplinary Center of Clinical Research at the University of Erlangen-Nuremberg (TP J31) and Center of Innovation in Personalized Medicine, King Abdulaziz University, Ministry of High Education for Saudi Arabia.	Ben-Zvi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077702; Bond CS, 2009, J CELL BIOL, V186, P637, DOI 10.1083/jcb.200906113; Camps C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-28; Chen LL, 2008, EMBO J, V27, P1694, DOI 10.1038/emboj.2008.94; Chen LL, 2009, MOL CELL, V35, P467, DOI 10.1016/j.molcel.2009.06.027; Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Ferdin J, 2013, CELL DEATH DIFFER, V20, P1675, DOI 10.1038/cdd.2013.119; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HEGGTVEIT HA, 1969, B WORLD HEALTH ORGAN, V41, P865; Hirose T, 2014, MOL BIOL CELL, V25, P169, DOI 10.1091/mbc.E13-09-0558; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Koroleva OA, 2009, PLANT CELL, V21, P1592, DOI 10.1105/tpc.108.060434; Lau KW, 2007, BRIT J CANCER, V96, P1284, DOI 10.1038/sj.bjc.6603675; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Mao YTS, 2011, TRENDS GENET, V27, P295, DOI 10.1016/j.tig.2011.05.006; Matouk IJ, 2010, BBA-MOL CELL RES, V1803, P443, DOI 10.1016/j.bbamcr.2010.01.010; Milani M, 2008, EUR J CANCER, V44, P2766, DOI 10.1016/j.ejca.2008.09.025; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Naganuma T, 2012, EMBO J, V31, P4020, DOI 10.1038/emboj.2012.251; Nakagawa S, 2011, J CELL BIOL, V193, P31, DOI 10.1083/jcb.201011110; Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Risuleo G, 2003, MOL CELL BIOCHEM, V250, P73, DOI 10.1023/A:1024950317684; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Sasaki YTF, 2009, P NATL ACAD SCI USA, V106, P2525, DOI 10.1073/pnas.0807899106; Schodel J, 2012, NAT GENET, V44, P420, DOI 10.1038/ng.2204; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sunwoo H, 2009, GENOME RES, V19, P347, DOI 10.1101/gr.087775.108; Takahashi K, 2014, J CELL SCI, V127, P1585, DOI 10.1242/jcs.141069; Xue M, 2014, TUMOR BIOL, V35, P6901, DOI 10.1007/s13277-014-1925-x; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010	47	172	178	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4482	4490		10.1038/onc.2014.378	http://dx.doi.org/10.1038/onc.2014.378			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25417700	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000360189200007
J	Mavrou, A; Brakspear, K; Hamdollah-Zadeh, M; Damodaran, G; Babaei-Jadidi, R; Oxley, J; Gillatt, DA; Ladomery, MR; Harper, SJ; Bates, DO; Oltean, S				Mavrou, A.; Brakspear, K.; Hamdollah-Zadeh, M.; Damodaran, G.; Babaei-Jadidi, R.; Oxley, J.; Gillatt, D. A.; Ladomery, M. R.; Harper, S. J.; Bates, D. O.; Oltean, S.			Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VITRO EXPRESSION; SPLICE VARIANT; VEGF; ANGIOGENESIS; VEGF(165)B; VIVO; BEVACIZUMAB; PROGRESSION; THERAPIES	Angiogenesis is required for tumour growth and is induced principally by vascular endothelial growth factor A (VEGF-A). VEGF-A pre-mRNA is alternatively spliced at the terminal exon to produce two families of isoforms, pro- and anti-angiogenic, only the former of which is upregulated in prostate cancer (PCa). In renal epithelial cells and colon cancer cells, the choice of VEGF splice isoforms is controlled by the splicing factor SRSF1, phosphorylated by serine-arginine protein kinase 1 (SRPK1). Immunohistochemistry staining of human samples revealed a significant increase in SRPK1 expression both in prostate intraepithelial neoplasia lesions as well as malignant adenocarcinoma compared with benign prostate tissue. We therefore tested the hypothesis that the selective upregulation of pro-angiogenic VEGF in PCa may be under the control of SRPK1 activity. A switch in the expression of VEGF(165) towards the anti-angiogenic splice isoform, VEGF(165)b, was seen in PC-3 cells with SRPK1 knockdown (KD). PC-3 SRPK1-KD cells resulted in tumours that grew more slowly in xenografts, with decreased microvessel density. No effect was seen as a result of SRPK1-KD on growth, proliferation, migration and invasion capabilities of PC-3 cells in vitro. Small-molecule inhibitors of SRPK1 switched splicing towards the anti-angiogenic isoform VEGF(165)b in PC-3 cells and decreased tumour growth when administered intraperitoneally in an orthotopic mouse model of PCa. Our study suggests that modulation of SRPK1 and subsequent inhibition of tumour angiogenesis by regulation of VEGF splicing can alter prostate tumour growth and supports further studies for the use of SRPK1 inhibition as a potential anti-angiogenic therapy in PCa.	[Mavrou, A.; Brakspear, K.; Hamdollah-Zadeh, M.; Damodaran, G.; Harper, S. J.; Bates, D. O.; Oltean, S.] Univ Bristol, Sch Physiol & Pharmacol, Bristol BS1 3NY, Avon, England; [Babaei-Jadidi, R.; Bates, D. O.] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Canc Biol, Nottingham NG2 7QT, England; [Oxley, J.] North Bristol NHS Trust, Dept Cellular Pathol, Bristol, Avon, England; [Gillatt, D. A.] North Bristol NHS Trust, Dept Urol Sci, Bristol, Avon, England; [Ladomery, M. R.] Univ W England, Fac Hlth & Appl Sci, Ctr Res Biosci, Bristol BS16 1QY, Avon, England	University of Bristol; University of Nottingham; North Bristol NHS Trust; North Bristol NHS Trust; University of West England	Bates, DO (corresponding author), Univ Nottingham, Sch Med, Div Canc & Stem Cells, Canc Biol, Nottingham NG2 7QT, England.	david.bates@nottingham.ac.uk; sebastian.oltean@bristol.ac.uk		Bates, David/0000-0003-4850-2360; Oltean, Sebastian/0000-0001-7890-8439; Damodaran, Gopinath/0000-0002-1697-0357	Prostate Cancer Research UK; BBSRC [BB/J007293/1]; Medical Research Council [G10002073]; Cancer Research UK [C11392/A10484]; Richard Bright VEGF Research Trust (North Bristol Cancer Research Projects Fund) [96464]; BBSRC [BB/J007293/2] Funding Source: UKRI; MRC [G1002073, MR/K020366/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/J007293/1] Funding Source: researchfish; Medical Research Council [G1002073, MR/K020366/1] Funding Source: researchfish	Prostate Cancer Research UK; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Richard Bright VEGF Research Trust (North Bristol Cancer Research Projects Fund); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Dr Andrew Armstrong (Duke University) for critical reading of the manuscript and helpful suggestions and the staff from AntiCancer Research Ltd. (San Diego) for training Athina Mavrou in the orthotopic prostate cancer model. This work was supported by Prostate Cancer Research UK, BBSRC (BB/J007293/1), the Medical Research Council (G10002073), Cancer Research UK (C11392/A10484) and Richard Bright VEGF Research Trust (North Bristol Cancer Research Projects Fund no. 96464).	Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Bates DO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068399; Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223; Bates DO, 2002, CANCER RES, V62, P4123; Bok RA, 2001, CANCER RES, V61, P2533; Clarke JM, 2013, CURR TREAT OPTION ON, V14, P109, DOI 10.1007/s11864-012-0222-4; Drake CG, 2014, ONCOGENE, V33, P5053, DOI 10.1038/onc.2013.497; Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090-4295(99)00167-3; Duque José Luis Ferreira, 2006, Clinics, V61, P401, DOI 10.1590/S1807-59322006000500006; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103; Gammons MV, 2013, INVEST OPHTH VIS SCI, V54, P6052, DOI 10.1167/iovs.13-12422; Gatta G, 2013, ANN ONCOL, V24, P1660, DOI 10.1093/annonc/mdt030; Gout S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046539; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505; Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kelly WK, 2012, J CLIN ONCOL, V30, P1534, DOI 10.1200/JCO.2011.39.4767; Lambrechts D, 2013, J CLIN ONCOL, V31, P1219, DOI 10.1200/JCO.2012.46.2762; Malvezzi M, 2013, ANN ONCOL, V24, P792, DOI 10.1093/annonc/mdt010; Mukherji D, 2013, CRIT REV ONCOL HEMAT, V87, P122, DOI 10.1016/j.critrevonc.2013.01.002; Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930; Odunsi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051030; Oltean S, 2012, BIOCHEM SOC T, V40, P831, DOI 10.1042/BST20120051; Quaglia A, 2013, SURG ONCOL, V22, pE31, DOI 10.1016/j.suronc.2013.02.010; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; WEIDNER N, 1993, AM J PATHOL, V143, P401; Whang YE, 2013, UROL ONCOL-SEMIN ORI, V31, P82, DOI 10.1016/j.urolonc.2010.09.018; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Yang M, 2005, PROSTATE, V62, P374, DOI 10.1002/pros.20125; Zhou B, 2013, MOL CELL BIOCHEM, V379, P191, DOI 10.1007/s11010-013-1641-7; Zhou ZH, 2012, MOL CELL, V47, P422, DOI 10.1016/j.molcel.2012.05.014	39	100	104	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4311	4319		10.1038/onc.2014.360	http://dx.doi.org/10.1038/onc.2014.360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381816	Green Accepted			2022-12-28	WOS:000359494400003
J	Tomiatti, V; Istvanffy, R; Pietschmann, E; Kratzat, S; Hoellein, A; Quintanilla-Fend, L; von Bubnoff, N; Peschel, C; Oostendorp, RAJ; Keller, U				Tomiatti, V.; Istvanffy, R.; Pietschmann, E.; Kratzat, S.; Hoellein, A.; Quintanilla-Fend, L.; von Bubnoff, N.; Peschel, C.; Oostendorp, R. A. J.; Keller, U.			Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors	ONCOGENE			English	Article							POOL SIZE; BCR-ABL; SKP2; P27(KIP1); PROTEOLYSIS; MECHANISMS; PROLIFERATION; MAINTENANCE; HOMEOSTASIS; EXPRESSION	Cyclin-dependent kinase subunit 1 (Cks1) is a critical rate-limiting component of the Skp1-Cullin1-Skp2 (SCFSkp2) ubiquitin ligase that controls cell cycle inhibitor abundance. Cyclin-dependent kinase (Cdk) inhibitors (CKIs) regulate hematopoietic stem cell (HSC) self-renewal, regeneration after cytotoxic stress and tumor cell proliferation. We thus studied the role of Cks1 in HSC and in a prototypic stem cell disorder, chronic myeloid leukemia (CML). Cks1 transcript was highly expressed in Lin - Sca-1+Kit+ (LSK) HSC, and the loss resulted in accumulation of the SCFSkp2/Cks1 substrates p21, p27, p57 and p130 particularly in CD150+ LSK cells. This accumulation correlated with decreased proliferation and accumulation of Cks1(-/-)HSC, slower regeneration after stress and prolonged HSC quiescence. At the hematopoietic progenitor (HPC) level, loss of Cks1 sensitized towards apoptosis. In CML, Cks1 expression was increased, and treatment with the Abl kinase inhibitor, imatinib, reduced Cks1 expression. Also, we found that Cks1 is critical for Bcr-Abl-induced cytokine-independent clonogenic activity. In conclusion, our study presents a novel function of Cks1 in maintaining HSC/HPC homeostasis and shows that Cks1 is a possible target in therapies aimed at the SCFSkp2/Cks1 complex that controls CKI abundance and cancer cell proliferation.	[Tomiatti, V.; Istvanffy, R.; Pietschmann, E.; Kratzat, S.; Hoellein, A.; von Bubnoff, N.; Peschel, C.; Oostendorp, R. A. J.; Keller, U.] Tech Univ Munich, Dept Med 3, D-81675 Munich, Germany; [Quintanilla-Fend, L.] Univ Tubingen, Inst Pathol, Tubingen, Germany; [von Bubnoff, N.] Univ Freiburg, Dept Med 1, D-79106 Freiburg, Germany; [Peschel, C.; Keller, U.] German Canc Consortium DKTK, Heidelberg, Germany; [Peschel, C.; Keller, U.] German Canc Res Ctr, Heidelberg, Germany	Technical University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Oostendorp, RAJ (corresponding author), Tech Univ Munich, Dept Med 3, Ismaninger Str 22, D-81675 Munich, Germany.	oostendorp@lrz.tu-muenchen.de; ulrich.keller@lrz.tum.de	von Bubnoff, Nikolas/AAG-1845-2021; von Bubnoff, Nikolas/F-2351-2017; Oostendorp, Robert A. J./K-9841-2018; Keller, Ulrich/L-1763-2016	von Bubnoff, Nikolas/0000-0001-9593-8947; Oostendorp, Robert A. J./0000-0002-4947-0412; Hollein, Alexander/0000-0002-9799-7809; Keller, Ulrich/0000-0002-8485-1958	Deutsche Forschungsgemeinschaft [KE 222/7-1, OO 8/2-3, OO 8/5-1, FOR 2033/1]; Deutsche Jose Carreras Leukamie Stiftung [R11/12, R11/18]; German Cancer Consortium (DKTK)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Jose Carreras Leukamie Stiftung; German Cancer Consortium (DKTK)	We thank Stephanie Schoffmann and Kerstin Behnke for excellent technical support, and the Flow Cytometry Core Facility and the Zentrum Praklinische Forschung (TU Munchen) for expert assistance. This work was supported by the Deutsche Forschungsgemeinschaft (KE 222/7-1, OO 8/2-3, OO 8/5-1 and FOR 2033/1), the Deutsche Jose Carreras Leukamie Stiftung (R11/12 and R11/18) and the German Cancer Consortium (DKTK).	Affer M, 2011, J ONCOL, V2011, DOI 10.1155/2011/798592; Bruennert D, 2009, LEUKEMIA, V23, P983, DOI 10.1038/leu.2008.337; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2004, ONCOGENE, V23, P7256, DOI 10.1038/sj.onc.1207945; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gomez-Casares MT, 2013, ONCOGENE, V32, P2239, DOI 10.1038/onc.2012.246; Hoellein A, 2012, MOL CELL BIOL, V32, P2416, DOI 10.1128/MCB.06771-11; Istvanffy R, 2011, BLOOD, V118, P2712, DOI 10.1182/blood-2010-05-287235; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Le Toriellec E, 2008, BLOOD, V111, P2321, DOI 10.1182/blood-2007-06-095570; LERNER C, 1990, EXP HEMATOL, V18, P114; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Matsumoto A, 2013, BBA-GEN SUBJECTS, V1830, P2335, DOI 10.1016/j.bbagen.2012.07.004; Matsumoto A, 2011, CELL STEM CELL, V9, P262, DOI 10.1016/j.stem.2011.06.014; Miething C, 2006, LEUKEMIA, V20, P650, DOI 10.1038/sj.leu.2404151; Morita Y, 2010, J EXP MED, V207, P1173, DOI 10.1084/jem.20091318; Nagler RM, 2009, CANCER INVEST, V27, P512, DOI 10.1080/07357900802239116; Old JB, 2010, MOL CANCER RES, V8, P353, DOI 10.1158/1541-7786.MCR-09-0232; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 2010, J CLIN INVEST, V120, P2254, DOI 10.1172/JCI41246; Pietras EM, 2011, J CELL BIOL, V195, P709, DOI 10.1083/jcb.201102131; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rodriguez S, 2011, BLOOD, V117, P6509, DOI 10.1182/blood-2010-11-321521; Rossi L, 2012, CELL STEM CELL, V11, P302, DOI 10.1016/j.stem.2012.08.006; Sattler M, 1996, ONCOGENE, V12, P839; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tesio M, 2011, CELL STEM CELL, V9, P187, DOI 10.1016/j.stem.2011.08.005; Viatour P, 2008, CELL STEM CELL, V3, P416, DOI 10.1016/j.stem.2008.07.009; Wang J, 2011, BLOOD, V118, P5429, DOI 10.1182/blood-2010-10-312785; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Westbrook L, 2007, CANCER RES, V67, P11393, DOI 10.1158/0008-5472.CAN-06-4173; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhan FH, 2007, BLOOD, V109, P4995, DOI 10.1182/blood-2006-07-038703; Zhang HJ, 2012, NAT GENET, V44, P861, DOI 10.1038/ng.2350; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zou P, 2011, CELL STEM CELL, V9, P247, DOI 10.1016/j.stem.2011.07.003	45	9	10	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4347	4357		10.1038/onc.2014.364	http://dx.doi.org/10.1038/onc.2014.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417705				2022-12-28	WOS:000359494400006
J	Thrane, S; Pedersen, AM; Thomsen, MBH; Kirkegaard, T; Rasmussen, BB; Duun-Henriksen, AK; Laenkholm, AV; Bak, M; Lykkesfeldt, AE; Yde, CW				Thrane, S.; Pedersen, A. M.; Thomsen, M. B. H.; Kirkegaard, T.; Rasmussen, B. B.; Duun-Henriksen, A. K.; Laenkholm, A. V.; Bak, M.; Lykkesfeldt, A. E.; Yde, C. W.			A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; D ANALOG EB1089; ESTROGEN-RECEPTOR; TAMOXIFEN-RESISTANT; POSTMENOPAUSAL WOMEN; PREDICTIVE MARKERS; SIGNALING PATHWAY; SMALL-MOLECULE; HISTONE H3; PHOSPHORYLATION	Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. In this study, we performed a kinase inhibitor screen on antiestrogen responsive MCF-7 cells and a panel of MCF-7-derived tamoxifen- and fulvestrant-resistant cell lines. Our focus was to identify common and distinct molecular mechanisms involved in tamoxifen- and fulvestrant-resistant cell growth. We identified 18 inhibitors, of which the majority was common for both tamoxifen- and fulvestrant-resistant cell lines. Two compounds, WP1130 and JNJ-7706621, exhibiting prominent preferential growth inhibition of antiestrogen-resistant cell lines, were selected for further studies. WP1130, a deubiquitinase inhibitor, induced caspase-mediated cell death in both tamoxifen- and fulvestrant-resistant cell lines by destabilization of the anti-apoptotic protein Mcl-1. Mcl-1 expression was found upregulated in the antiestrogen-resistant cell lines and depletion of Mcl-1 in resistant cells caused decreased viability. JNJ-7706621, a dual Aurora kinase and cyclin-dependent kinase inhibitor, specifically inhibited growth and caused G2 phase cell cycle arrest of the tamoxifen-resistant cell lines. Knockdown studies showed that Aurora kinase A is essential for growth of the tamoxifen-resistant cells and inhibition of Aurora kinase A resensitized tamoxifen-resistant cells to tamoxifen treatment. Preferential growth inhibition by WP1130 and JNJ-7706621 was also found in T47D-derived tamoxifen-resistant cell lines, pointing at Mcl-1 and Aurora kinase A as potential treatment targets. In addition, tumor samples from 244 estrogen receptor-positive breast cancer patients treated with adjuvant tamoxifen showed that higher expression level of Aurora kinase A was significantly associated with shorter disease-free and overall survival, demonstrating the potential of Aurora kinase A as a biomarker for tamoxifen resistance.	[Thrane, S.; Pedersen, A. M.; Thomsen, M. B. H.; Kirkegaard, T.; Lykkesfeldt, A. E.; Yde, C. W.] Danish Canc Soc Res Ctr, Unit Cell Death & Metab, Breast Canc Grp, DK-2100 Copenhagen O, Denmark; [Rasmussen, B. B.] Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Duun-Henriksen, A. K.] Danish Canc Soc Res Ctr, Stat Bioinformat & Registry, Copenhagen, Denmark; [Laenkholm, A. V.] Slagelse Hosp, Dept Pathol, Slagelse, Denmark; [Bak, M.] Odense Univ Hosp, Dept Clin Pathol, DK-5000 Odense, Denmark	Danish Cancer Society; University of Copenhagen; Herlev & Gentofte Hospital; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Yde, CW (corresponding author), Danish Canc Soc Res Ctr, Unit Cell Death & Metab, Breast Canc Grp, Strandblvd 49, DK-2100 Copenhagen O, Denmark.	cwy@cancer.dk	Bak, Martin/D-1392-2012	Thrane, Susan/0000-0001-6596-3527; Laenkholm, Anne-Vibeke/0000-0003-2166-8686	Race Against Breast Cancer, Astrid Thaysen's grant [ATL12/01]; A.P. Moller Foundation for the Advancement of Medical Science [12-374]; Danish Cancer Research Foundation; Danish Cancer Society; Danske Bank Foundation; Hede Nielsen Family Foundation; Leo Nielsen's grant [LN12/07]; Novo Nordisk Foundation; Sigvald and Edith Rasmussen's grant	Race Against Breast Cancer, Astrid Thaysen's grant; A.P. Moller Foundation for the Advancement of Medical Science; Danish Cancer Research Foundation; Danish Cancer Society(Danish Cancer Society); Danske Bank Foundation; Hede Nielsen Family Foundation; Leo Nielsen's grant; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Sigvald and Edith Rasmussen's grant	We thank Jane Lind Christensen and Birgit Reiter for excellent technical assistance and Klaus Kaae Andersen and Ann-Sophie Sogaard for help with statistical analysis. This study was supported by A Race Against Breast Cancer, Astrid Thaysen's grant (ATL12/01), A.P. Moller Foundation for the Advancement of Medical Science (12-374), Danish Cancer Research Foundation, Danish Cancer Society, Danske Bank Foundation, Hede Nielsen Family Foundation, Leo Nielsen's grant (LN12/07), Novo Nordisk Foundation and Sigvald and Edith Rasmussen's grant.	Ali HR, 2012, BRIT J CANCER, V106, P1798, DOI 10.1038/bjc.2012.167; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Bartholomeusz GA, 2007, BLOOD, V109, P3470, DOI 10.1182/blood-2006-02-005579; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; BRIAND P, 1984, CANCER RES, V44, P1114; Chan SK, 2006, J MAMMARY GLAND BIOL, V11, P3, DOI 10.1007/s10911-006-9008-2; Christensen GL, 2004, BREAST CANCER RES TR, V85, P53, DOI 10.1023/B:BREA.0000021047.37869.95; Cohen NA, 2012, CHEM BIOL, V19, P1175, DOI 10.1016/j.chembiol.2012.07.018; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Drury SC, 2011, ENDOCR-RELAT CANCER, V18, P565, DOI 10.1530/ERC-10-0046; Emanuel S, 2005, CANCER RES, V65, P9038, DOI 10.1158/0008-5472.CAN-05-0882; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946; Frogne T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2230; Frogne T, 2009, BREAST CANCER RES TR, V114, P263, DOI 10.1007/s10549-008-0011-8; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Henriksen KL, 2007, J CLIN PATHOL, V60, P397, DOI 10.1136/jcp.2005.034447; Henriksen K, 2009, ACTA ONCOL, V48, P522, DOI 10.1080/02841860802676383; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kapuria V, 2010, CANCER RES, V70, P9265, DOI 10.1158/0008-5472.CAN-10-1530; Larsen SS, 2001, BRIT J CANCER, V84, P686, DOI 10.1054/bjoc.2000.1646; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; Lundholt BK, 2001, BREAST CANCER RES TR, V67, P199, DOI 10.1023/A:1017977406429; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; Moller S, 2008, ACTA ONCOL, V47, P506, DOI 10.1080/02841860802059259; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nahta R, 2012, BREAST CANCER RES TR, V135, P39, DOI 10.1007/s10549-012-2067-8; Palmieri C, 2014, MOL CELL ENDOCRINOL, V382, P695, DOI 10.1016/j.mce.2013.08.001; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Rasmussen BB, 2008, LANCET ONCOL, V9, P23, DOI 10.1016/S1470-2045(07)70386-8; Robertson JFR, 2003, CANCER, V98, P229, DOI 10.1002/cncr.11468; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Siggelkow W, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-562; Sonne-Hansen K, 2010, BREAST CANCER RES TR, V121, P601, DOI 10.1007/s10549-009-0506-y; Sun HS, 2011, BLOOD, V117, P3151, DOI 10.1182/blood-2010-03-276477; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061; Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yde CW, 2008, ONCOGENE, V27, P4986, DOI 10.1038/onc.2008.146; Yde CW, 2012, BREAST CANCER RES TR, V135, P67, DOI 10.1007/s10549-012-2053-1; Yde CW, 2007, MOL CANCER THER, V6, P1869, DOI 10.1158/1535-7163.MCT-07-0072; Zhang H, 2011, ONCOGENE, V30, P1963, DOI 10.1038/onc.2010.559; Zheng XQ, 2014, ONCOGENE, V33, P4985, DOI 10.1038/onc.2013.444	57	39	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4199	4210		10.1038/onc.2014.351	http://dx.doi.org/10.1038/onc.2014.351			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362855				2022-12-28	WOS:000359199800006
J	Gao, J; Li, N; Dong, Y; Li, S; Xu, L; Li, X; Li, Y; Li, Z; Ng, SS; Sung, JJ; Shen, L; Yu, J				Gao, J.; Li, N.; Dong, Y.; Li, S.; Xu, L.; Li, X.; Li, Y.; Li, Z.; Ng, S. S.; Sung, J. J.; Shen, L.; Yu, J.			miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer	ONCOGENE			English	Article							COLON-CANCER; INHIBITS MIGRATION; P53; EXPRESSION; INVASION; MIR-21; CELLS; SIRT1; COMBINATION; RELAPSE	Although surgery remains the mainstay of curative treatment for colorectal cancer (CRC), many patients still have high chance to experience disease relapse. It is therefore imperative to identify prognostic markers that can help predict the clinical outcomes of CRC. Aberrant microRNA expression holds great potential as diagnostic and prognostic biomarker for CRC. Here we aimed to investigate clinical potential of miR-34a-5p as a prognostic marker for CRC recurrence and its functional significance. First, we validated that miR-34a-5p was downregulated in CRC tumour tissues (P<0.05). The expression level of tissue miR-34a-5p was then evaluated in two independent cohorts of 268 CRC patients. miR-34a-5p expression was positively correlated with disease-free survival in two independent cohorts (cohort I: n = 205, P<0.001; cohort II: n = 63, P = 0.006). Moreover, the expression of miR-34a-5p was an independent prognostic factor for CRC recurrence by multivariate analysis (P<0.001 for cohort I, P = 0.007 for cohort II). Ectopic expression of miR-34a-5p in p53 wild-type colon cancer cell HCT116 significantly inhibited cell growth, migration, invasion and metastasis. miR-34a-5p induced cell apoptosis, cell cycle arrest at G1 phase and p53 transcription activity in HCT116 cells, but not in the HCT116 p53 knockout (p53(-/-))cells. miR-34a-5p significantly suppressed the HCT116 growth in vivo, whereas it showed no effect on the HCT116 p53(-/-) xenograft, indicating that the growth-inhibiting effect by miR-34a-5p was dependent on p53. In addition, the expression level of miR-34a-5p in patients with p53-positive expression was higher than that in patients with p53-negative expression (P<0.01). In conclusion, miR-34a-5p inhibits recurrence of CRC through inhibiting cell growth, migration and invasion, inducing cell apoptosis and cell cycle arrest in a p53-dependent manner.	[Gao, J.; Li, N.; Li, S.; Li, Y.; Shen, L.] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept Gastro, Beijing 100871, Peoples R China; [Gao, J.; Dong, Y.; Xu, L.; Li, X.; Sung, J. J.; Yu, J.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, State Key Lab Digest Dis,Inst Digest Dis,Dept Med, Shatin, Hong Kong, Peoples R China; [Dong, Y.; Ng, S. S.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Li, Z.] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept Pathol, Beijing 100871, Peoples R China	Peking University; Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci,CUHK Shenzhen Res Inst, Inst Digest Dis,Dept Med & Therapeut,State Key La, Shatin, Hong Kong, Peoples R China.	lin100@medmail.com.cn; junyu@cuhk.edu.hk	Li, Xiao-xing/B-9114-2008; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015	Li, Xiao-xing/0000-0001-8791-7505; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153	National Natural Science Foundation of China [81301853, 81072034]; National High Technology Research and Development Program [2012AA 02A 504, 2012AA 02A 506]; Shenzhen Technology and Innovation Project Fund, Shenzhen [JSGG20130412171021059]; China 863 program [2012AA02A506]; Shenzhen Municipal Science and Technology R D fund [JCYJ20120619152326450]; Shenzhen Virtual University Park Support Scheme	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program(National High Technology Research and Development Program of China); Shenzhen Technology and Innovation Project Fund, Shenzhen; China 863 program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology R D fund; Shenzhen Virtual University Park Support Scheme	This work was supported by National Natural Science Foundation of China (No. 81301853, 81072034), National High Technology Research and Development Program (No. 2012AA 02A 504, 2012AA 02A 506), Shenzhen Technology and Innovation Project Fund, Shenzhen (JSGG20130412171021059), China 863 program (2012AA02A506), Shenzhen Municipal Science and Technology R & D fund (JCYJ20120619152326450) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen Q, 2014, CELL MOL BIOL LETT, V19, P52, DOI 10.2478/s11658-013-0115-y; Christensen LL, 2013, INT J CANCER, V133, P67, DOI 10.1002/ijc.28010; Dong Y, 2011, BRIT J CANCER, V104, P893, DOI 10.1038/bjc.2011.57; Dong YJ, 2013, MOL CANCER RES, V11, P1051, DOI 10.1158/1541-7786.MCR-13-0061; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266; Kjaer-Frifeldt S, 2012, BRIT J CANCER, V107, P1169, DOI 10.1038/bjc.2012.365; Leng ZW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056082; Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035; Ma YM, 2013, CURR PHARM DESIGN, V19, P1253; Mandke P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042034; Mirakhorli M, 2013, MOL MED REP, V7, P613, DOI 10.3892/mmr.2012.1226; Mitrea DM, 2012, BIOL CHEM, V393, P259, DOI 10.1515/hsz-2011-0254; Nair VS, 2012, JNCI-J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Tobiume Kei, 2005, J Nippon Med Sch, V72, P192, DOI 10.1272/jnms.72.192; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Wang ZW, 2010, CANCER LETT, V292, P141, DOI 10.1016/j.canlet.2009.11.012; Wu CW, 2014, CLIN CANCER RES, V20, P2994, DOI 10.1158/1078-0432.CCR-13-1750; Wu CW, 2012, GUT, V61, P739, DOI 10.1136/gut.2011.239236; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yang IP, 2012, CARCINOGENESIS, V33, P1522, DOI 10.1093/carcin/bgs166; Yang MM, 2013, EUR J CANCER, V49, P604, DOI 10.1016/j.ejca.2012.09.031; Zhang X, 2011, ANN ONCOL, V22, P2257, DOI 10.1093/annonc/mdq758; Zhu HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052393	37	130	136	1	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4142	4152		10.1038/onc.2014.348	http://dx.doi.org/10.1038/onc.2014.348			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25362853				2022-12-28	WOS:000358780500012
J	Seong, BKA; Lau, J; Adderley, T; Kee, L; Chaukos, D; Pienkowska, M; Malkin, D; Thorner, P; Irwin, MS				Seong, B. K. A.; Lau, J.; Adderley, T.; Kee, L.; Chaukos, D.; Pienkowska, M.; Malkin, D.; Thorner, P.; Irwin, M. S.			SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization	ONCOGENE			English	Article							EPITHELIAL PROTEIN LOST; TUMOR GROWTH; RHO-GTPASES; EXPRESSION; EPLIN; DIFFERENTIATION; CANCER; METASTASIS; PATHOGENESIS; DETERMINANT	Osteosarcoma (OS) is the most common malignant bone tumor and the majority of recurrences are due to metastasis. However, the molecular mechanisms that regulate OS metastatic spread are largely unknown. In this study, we report that special AT-rich-binding protein 2 (SATB2) is highly expressed in OS cells and tumors. Short hairpin RNA-mediated knockdown of SATB2 (sh-SATB2) decreases migration and invasion of OS cells without affecting proliferation or viability. Microarray analysis identified genes that were differentially regulated by SATB2 including the actin-binding protein Epithelial Protein Lost In Neoplasm (EPLIN), which was upregulated in sh-SATB2 cells. Silencing EPLIN rescues the decreased invasion observed in sh-SATB2 cells. Pathway analyses of SATB2-regulated genes revealed enrichment of those involved in cytoskeleton dynamics, and increased stress fiber formation was detected in cells with SATB2 knockdown. Furthermore, sh-SATB2 cells exhibit increased RhoA, decreased Rac1 and increased phosphorylation of focal adhesion kinase (FAK) and paxillin. These findings identify SATB2 as a novel regulator of OS invasion, in part via effects on EPLIN and the cytoskeleton.	[Seong, B. K. A.; Malkin, D.; Irwin, M. S.] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Seong, B. K. A.; Malkin, D.; Irwin, M. S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Seong, B. K. A.; Lau, J.; Adderley, T.; Kee, L.; Chaukos, D.; Irwin, M. S.] Hosp Sick Children, Res Inst, Peter Gilgan Ctr Res & Learning, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Pienkowska, M.; Malkin, D.] Hosp Sick Children, Res Inst, Peter Gilgan Ctr Res & Learning, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; [Malkin, D.; Irwin, M. S.] Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada; [Thorner, P.] Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; [Thorner, P.; Irwin, M. S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Irwin, MS (corresponding author), Hosp Sick Children, Dept Paediat & Cell Biol, 555 Univ Ave,Black Wing,9th Floor, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Malkin, David/AAW-8715-2021		Canadian Cancer Society Research Institute [2010-700580]; Ontario Research Fund; Canada Research Chair in Cancer Biology; Hospital for Sick Children Research Training Centre (Restracomp)	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Ontario Research Fund; Canada Research Chair in Cancer Biology; Hospital for Sick Children Research Training Centre (Restracomp)	This study was supported by funds from the Canadian Cancer Society Research Institute (#2010-700580, MSI), Ontario Research Fund (MSI, DM) and a Canada Research Chair in Cancer Biology (MSI). BKAS and JL received scholarships from Hospital for Sick Children Research Training Centre (Restracomp). We are grateful for assistance with microarray analyses from Daniel Picard and Dr Annie Huang.	Abe K, 2008, P NATL ACAD SCI USA, V105, P13, DOI 10.1073/pnas.0710504105; Abou Zeid Nancy, 2006, Cell Commun Signal, V4, P8, DOI 10.1186/1478-811X-4-8; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028; Britanova O, 2006, AM J HUM GENET, V79, P668, DOI 10.1086/508214; Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248; Chung J, 2010, EMBO REP, V11, P777, DOI 10.1038/embor.2010.125; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Eberhard J, 2012, BRIT J CANCER, V106, P931, DOI 10.1038/bjc.2012.34; Flores RJ, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-50; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Latini FRM, 2008, ENDOCR-RELAT CANCER, V15, P787, DOI 10.1677/ERC-08-0079; Leoyklang P, 2007, HUM MUTAT, V28, P732, DOI 10.1002/humu.20515; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; O'Donoghue LE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-506; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Patani N, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-18; Quizi JL, 2013, ONCOGENE, V32, P4656, DOI 10.1038/onc.2012.488; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sanders AJ, 2010, ANGIOGENESIS, V13, P317, DOI 10.1007/s10456-010-9188-7; Satoh Y, 2013, IMMUNITY, V38, P1105, DOI 10.1016/j.immuni.2013.05.014; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Stehn JR, 2013, CANCER RES, V73, P5169, DOI 10.1158/0008-5472.CAN-12-4501; Tsurumi H, 2014, KIDNEY INT, V86, P548, DOI 10.1038/ki.2014.85; Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057; Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zech T, 2011, J CELL SCI, V124, P3753, DOI 10.1242/jcs.080986; Zhang S, 2011, ONCOGENE, V30, P4941, DOI 10.1038/onc.2011.199; Zhao XY, 2014, CYTOKINE GROWTH F R, V25, P35, DOI 10.1016/j.cytogfr.2013.12.010; Zucchini C, 2014, ONCOGENE, V33, P1912, DOI 10.1038/onc.2013.152	44	38	39	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3582	3592		10.1038/onc.2014.289	http://dx.doi.org/10.1038/onc.2014.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25220418				2022-12-28	WOS:000357434900010
J	King, ML; Lindberg, ME; Stodden, GR; Okuda, H; Ebers, SD; Johnson, A; Montag, A; Lengyel, E; MacLean, JA; Hayashi, K				King, M. L.; Lindberg, M. E.; Stodden, G. R.; Okuda, H.; Ebers, S. D.; Johnson, A.; Montag, A.; Lengyel, E.; MacLean, J. A., II; Hayashi, K.			WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer	ONCOGENE			English	Article							TUMOR-CELL GROWTH; E-CADHERIN; POTENTIAL REGULATION; ADVANCED-STAGE; WNT PATHWAY; EXPRESSION; INHIBITION; CATENIN; TARGET; GENE	We previously characterized the link between WNT7A and the progression of ovarian cancer. Other groups have identified FGF1 as a relevant risk factor in ovarian cancer. Here, we show a linkage between these two signaling pathways that may be exploited to improve treatment and prognosis of patients with ovarian cancer. High expression of WNT7A and FGF1 are correlated in ovarian carcinomas and poor overall patient survival. A chromatin immunoprecipitation assay demonstrated that WNT7A/beta-catenin signaling directly regulates FGF1 expression via TCF binding elements in the FGF1-1C promoter locus. In vitro gene manipulation studies revealed that FGF1 is sufficient to drive the tumor-promoting effects of WNT7A. In vivo xenograft studies confirmed that the stable overexpression of WNT7A or FGF1 induced a significant increase in tumor incidence, whereas FGF1 knockdown in WNT7A overexpressing cells caused a significant reduction in tumor size. Niclosamide most efficiently abrogated WNT7A/beta-catenin signaling in our model, inhibited beta-catenin transcriptional activity and cell viability, and increased cell death. Furthermore, niclosamide decreased cell migration following an increase in E-cadherin subsequent to decreased levels of SLUG. The effects of niclosamide on cell functions were more potent in WNT7A-overexpressing cells. Oral niclosamide inhibited tumor growth and progression in an intraperitoneal xenograft mouse model representative of human ovarian cancer. Collectively, these results indicate that FGF1 is a direct downstream target of WNT7A/beta-catenin signaling and this pathway has potential as a therapeutic target in ovarian cancer. Moreover, niclosamide is a promising inhibitor of this pathway and may have clinical relevance.	[King, M. L.; Lindberg, M. E.; Stodden, G. R.; Ebers, S. D.; MacLean, J. A., II; Hayashi, K.] So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; [Okuda, H.] Kyoto Univ, Grad Sch Med, Lab Malignancy Control Res, Kyoto, Japan; [Johnson, A.; Lengyel, E.] Univ Chicago, Dept Obstet & Gynecol, Med Ctr, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Montag, A.] Univ Chicago, Med Ctr, Dept Pathol, Chicago, IL 60637 USA	Southern Illinois University System; Southern Illinois University; Kyoto University; University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	Hayashi, K (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, 1135 Lincoln Dr, Carbondale, IL 62901 USA.	khayashi@siumed.edu	; Lengyel, Ernst/D-9220-2014	Okuda, Hiroshi/0000-0002-5747-8086; Hayashi, Kanako/0000-0002-5028-799X; Lengyel, Ernst/0000-0001-8624-1507	NIH/NCI [CA179214, ACS-IL 139038]; NIH/NICHD [HD065584]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD065584] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R15CA179214] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Gail Isenberg for editing the manuscript. This work was supported by NIH/NCI CA179214 and ACS-IL 139038 (to KH), and NIH/NICHD HD065584 (to JAM).	Aletti GD, 2007, MAYO CLIN PROC, V82, P751; Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Birrer MJ, 2007, J CLIN ONCOL, V25, P2281, DOI 10.1200/JCO.2006.09.0795; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677; Chen W, 2010, AM J PHYSIOL-GASTR L, V299, pG293, DOI 10.1152/ajpgi.00005.2010; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; Cooke PS, 2013, MOL HUM REPROD, V19, P547, DOI 10.1093/molehr/gat031; Curtin JC, 2010, ONCOTARGET, V1, P563, DOI 10.18632/oncotarget.191; Denkert C, 2009, J PATHOL, V218, P273, DOI 10.1002/path.2547; Dodge ME, 2011, ANNU REV PHARMACOL, V51, P289, DOI 10.1146/annurev-pharmtox-010510-100558; Fonseca BD, 2012, J BIOL CHEM, V287, P17530, DOI 10.1074/jbc.M112.359638; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Goff BA, 2004, JAMA-J AM MED ASSOC, V291, P2705, DOI 10.1001/jama.291.22.2705; Hayashi K, 2007, ENDOCRINOLOGY, V148, P3496, DOI 10.1210/en.2007-0283; Hayashi K, 2009, BIOL REPROD, V80, P989, DOI 10.1095/biolreprod.108.075416; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008-5472.CAN-09-3950; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Lau MT, 2011, ONCOGENE, V30, P2753, DOI 10.1038/onc.2011.6; Li R, 2013, MOL CANCER THER, V12, P2200, DOI 10.1158/1535-7163.MCT-13-0095; Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290; MacLean JA, 2013, J BIOL CHEM, V288, P34809, DOI 10.1074/jbc.M113.486340; Madiai F, 1999, J BIOL CHEM, V274, P11937, DOI 10.1074/jbc.274.17.11937; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Meng QH, 2014, CLIN CHEM, V60, P222, DOI 10.1373/clinchem.2013.211490; Mook RA, 2013, BIOORG MED CHEM LETT, V23, P2187, DOI 10.1016/j.bmcl.2013.01.101; Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008-5472.CAN-10-3978; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Sack U, 2011, JNCI-J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190; Sassoon D, 1999, MOL CELL ENDOCRINOL, V158, P1, DOI 10.1016/S0303-7207(99)00170-7; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Smith GS, 2012, NEUROPSYCHOPHARMACOL, V37, P1, DOI 10.1038/npp.2011.233; Steele IA, 2001, ONCOGENE, V20, P5878, DOI 10.1038/sj.onc.1204755; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Teo R, 2006, DEV BIOL, V289, P91, DOI 10.1016/j.ydbio.2005.10.009; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Wieland A, 2013, CLIN CANCER RES, V19, P4124, DOI 10.1158/1078-0432.CCR-12-2895; Yo YT, 2012, MOL CANCER THER, V11, P1703, DOI 10.1158/1535-7163.MCT-12-0002; Yoshioka S, 2012, MOL CANCER RES, V10, P469, DOI 10.1158/1541-7786.MCR-11-0177; You S, 2014, MOL CANCER THER, V13, P606, DOI 10.1158/1535-7163.MCT-13-0608; Zaid TM, 2013, CLIN CANCER RES, V19, P809, DOI 10.1158/1078-0432.CCR-12-2736	52	63	66	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3452	3462		10.1038/onc.2014.277	http://dx.doi.org/10.1038/onc.2014.277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174399	Green Accepted, hybrid			2022-12-28	WOS:000356871700010
J	Gurgis, FMS; Yeung, YT; Tang, MXM; Heng, B; Buckland, M; Ammit, AJ; Haapasalo, J; Haapasalo, H; Guillemin, GJ; Grewal, T; Munoz, L				Gurgis, F. M. S.; Yeung, Y. T.; Tang, M. X. M.; Heng, B.; Buckland, M.; Ammit, A. J.; Haapasalo, J.; Haapasalo, H.; Guillemin, G. J.; Grewal, T.; Munoz, L.			The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1 beta-driven IL-6 secretion in glioblastoma cells	ONCOGENE			English	Article							PROTEIN-KINASE 2; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; RICH ELEMENTS; HUR; CYTOKINE; EXPRESSION; GLIOMA; INHIBITORS; GROWTH	The microenvironment of glioblastoma (GBM) contains high levels of inflammatory cytokine interleukin 6 (IL-6), which contributes to promote tumour progression and invasion. The common epidermal growth factor receptor variant III (EGFRvIII) mutation in GBM is associated with significantly higher levels of IL-6. Furthermore, elevated IL-1 beta levels in GBM tumours are also believed to activate GBM cells and enhance IL-6 production. However, the crosstalk between these intrinsic and extrinsic factors within the oncogene-microenvironment of GBM causing overproduction of IL-6 is poorly understood. Here, we show that EGFRvIII potentiates IL-1 beta-induced IL-6 secretion from GBM cells. Importantly, exacerbation of IL-6 production is most effectively attenuated in EGFRvIII-expressing GBM cells with inhibitors of p38 mitogen-activated protein kinase (p38 MAPK) and MAPK-activated protein kinase 2 (MK2). Enhanced IL-6 production and increased sensitivity toward pharmacological p38 MAPK and MK2 inhibitors in EGFRvIII-expressing GBM cells is associated with increased MK2-dependent nuclear-cytoplasmic shuttling and accumulation of human antigen R (HuR), an IL-6 mRNA-stabilising protein, in the cytosol. IL-1 beta-stimulated activation of the p38 MAPK-MK2-HuR pathway significantly enhances IL-6 mRNA stability in GBM cells carrying EGFRvIII. Further supporting a role for the p38 MAPK-MK2-HuR pathway in the development of inflammatory environment in GBM, activated MK2 is found in more than 50% of investigated GBM tissues and correlates with lower grade and secondary GBMs. Taken together, p38 MAPK-MK2-HuR signalling may enhance the potential of intrinsic (EGFRvIII) and extrinsic (IL-1 beta) factors to develop an inflammatory GBM environment. Hence, further improvement of brain-permeable and anti-inflammatory inhibitors targeting p38 MAPK, MK2 and HuR may combat progression of lower grade gliomas into aggressive GBMs.	[Gurgis, F. M. S.; Yeung, Y. T.; Tang, M. X. M.; Munoz, L.] Univ Sydney, Sch Med Sci Pharmacol, Sydney, NSW 2006, Australia; [Yeung, Y. T.; Ammit, A. J.; Grewal, T.] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Heng, B.; Guillemin, G. J.] Macquarie Univ, Australian Sch Adv Med, N Ryde, NSW 2109, Australia; [Buckland, M.] Univ Sydney, Sch Med Sci Pathol, Sydney, NSW 2006, Australia; [Haapasalo, J.; Haapasalo, H.] Tampere Univ Hosp, Dept Pathol, Tampere, Finland; [Haapasalo, J.; Haapasalo, H.] Tampere Univ Hosp, Fimlab Labs, Tampere, Finland; [Haapasalo, J.] Tampere Univ Hosp, Neurosurg Unit, Tampere, Finland	University of Sydney; University of Sydney; Macquarie University; University of Sydney; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital	Munoz, L (corresponding author), Univ Sydney, Sch Med Sci Pharmacol, Sydney, NSW 2006, Australia.	lenka.munoz@sydney.edu.au	Guillemin, Gilles J/C-3878-2015; Yeung, Yiu/AAH-6863-2021	Guillemin, Gilles J/0000-0001-8105-4470; Grewal, Thomas/0000-0002-7937-8887; Heng, Ruiwen Benjamin/0000-0002-0247-2920; Ammit, Alaina/0000-0003-0555-2544	National Foundation for Medical Research and Innovation; National Health and Medical Research Council of Australia [510294, 1025637]; University of Sydney [2010-02681]; Australian Research Council [FT120100397]; Tour de Cure; University of Sydney Brown Fellowship	National Foundation for Medical Research and Innovation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney(University of Sydney); Australian Research Council(Australian Research Council); Tour de Cure; University of Sydney Brown Fellowship	This study was supported by grants from National Foundation for Medical Research and Innovation and the University of Sydney Brown Fellowship to LM. TG acknowledges support from the National Health and Medical Research Council of Australia (510294) and the University of Sydney (2010-02681). GJG is supported by the Australian Research Council (FT120100397) and Tour de Cure. AJA is supported by the National Health and Medical Research Council of Australia (1025637). We would like to thank Maggie Lee for technical assistance with immunohistochemistry and Myriam Gorospe for pHuR(S202) antibody.	Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bolognani F, 2012, J NEURO-ONCOL, V106, P531, DOI 10.1007/s11060-011-0707-1; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Brzezinska AA, 2009, IMMUNOLOGY, V127, P386, DOI 10.1111/j.1365-2567.2008.02980.x; Cheng CY, 2010, BRIT J PHARMACOL, V160, P1595, DOI 10.1111/j.1476-5381.2010.00858.x; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Doller A, 2008, CELL SIGNAL, V20, P2165, DOI 10.1016/j.cellsig.2008.05.007; Fernau NS, 2010, J BIOL CHEM, V285, P3896, DOI 10.1074/jbc.M109.081430; Filippova N, 2011, MOL CANCER RES, V9, P648, DOI 10.1158/1541-7786.MCR-10-0325; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Gurgis FMS, 2014, MOL PHARMACOL, V85, P345, DOI 10.1124/mol.113.090365; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jin X, 2011, CANCER RES, V71, P7125, DOI 10.1158/0008-5472.CAN-11-1330; Kim HH, 2008, GENE DEV, V22, P1804, DOI 10.1101/gad.1645808; Li L, 2009, NEURO-ONCOLOGY, V11, P9, DOI 10.1215/15228517-2008-081; Liao WL, 2011, J BIOL CHEM, V286, P35499, DOI 10.1074/jbc.M111.263582; Lin WN, 2011, BRIT J PHARMACOL, V163, P1691, DOI 10.1111/j.1476-5381.2011.01312.x; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Miyata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059095; Mourey RJ, 2010, J PHARMACOL EXP THER, V333, P797, DOI 10.1124/jpet.110.166173; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Munoz L, 2010, EUR J PHARMACOL, V635, P212, DOI 10.1016/j.ejphar.2010.02.037; Munoz L, 2010, ANAL BIOCHEM, V401, P125, DOI 10.1016/j.ab.2010.02.016; Nabors LB, 2001, CANCER RES, V61, P2154; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Ramgolam VS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014450; Schulz I, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-86; Spooren A, 2011, BIOCHEM PHARMACOL, V81, P1004, DOI 10.1016/j.bcp.2011.01.019; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Turner JG, 2012, BIOCHEM PHARMACOL, V83, P1021, DOI 10.1016/j.bcp.2011.12.016; Wang SB, 2008, J LEUKOCYTE BIOL, V83, P982, DOI 10.1189/jlb.0907641; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yeung YT, 2013, BRIT J PHARMACOL, V168, P591, DOI 10.1111/bph.12008; Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289	38	50	53	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2934	2942		10.1038/onc.2014.225	http://dx.doi.org/10.1038/onc.2014.225			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088200	Bronze			2022-12-28	WOS:000355324300012
J	Yang, YM; Lee, WH; Lee, CG; An, J; Kim, ES; Kim, SH; Lee, SK; Lee, CH; Dhanasekaran, DN; Moon, A; Hwang, S; Lee, SJ; Park, JW; Kim, KM; Kim, SG				Yang, Y. M.; Lee, W. H.; Lee, C. G.; An, J.; Kim, E-S; Kim, S. H.; Lee, S-K; Lee, C. H.; Dhanasekaran, D. N.; Moon, A.; Hwang, S.; Lee, S. J.; Park, J-W; Kim, K. M.; Kim, S. G.			G alpha(12) gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma	ONCOGENE			English	Article							HETEROTRIMERIC G-PROTEINS; SPHINGOSINE 1-PHOSPHATE; P53-INDUCIBLE MICRORNAS; TARGETING ZEB1; MIR-200 FAMILY; TUMOR-GROWTH; G12 FAMILY; P53; INVASION; EXPRESSION	Hepatocellular carcinoma (HCC) has a poor prognosis owing to aggressive phenotype. G alpha(12) gep oncogene product couples to G-protein-coupled receptors, whose ligand levels are frequently increased in tumor microenvironments. Here, we report G alpha(12) overexpression in human HCC and the resultant induction of zinc-finger E-box-binding homeobox 1 (ZEB1) as mediated by microRNA deregulation. G alpha(12) expression was higher in HCC than surrounding non-tumorous tissue. Transfection of Huh7 cell with an activated mutant of G alpha(12) (G alpha(12)QL) deregulated microRNA (miRNA or miR)-200b/a/429, -194-2/192 and -194-1/215 clusters in the miRNome. cDNA microarray analyses disclosed the targets affected by G alpha(12) gene knockout. An integrative network of miRNAs and mRNA changes enabled us to predict ZEB1 as a key molecule governed by G alpha(12). Decreases of miR-200a/b, -192 and -215 by G alpha(12) caused ZEB1 induction. The ability of G alpha(12) to decrease p53 levels, as a result of activating protein-1 (AP-1)/c-Jun-mediated mouse double minute 2 homolog induction, contributed to transcriptional deregulation of the miRNAs. G alpha(12)QL induced ZEB1 and other epithelial-mesenchymal transition markers with fibroblastoid phenotype change. Consistently, transfection with miR-200b, -192 or -215 mimic prevented the ability of G alpha(12)QL to increase tumor cell migration/invasion. In xenograft studies, sustained knockdown of G alpha(12) decreased the overall growth rate and average volume of tumors derived from SK-Hep1 cell (mesenchymal-typed). In HCC patients, miR-192, -215 and/or -200a were deregulated with microvascular invasion or growth advantage. In the HCC samples with higher G alpha(12) level, a correlation existed in the comparison of relative changes of G alpha(12) and ZEB1. In conclusion, G alpha(12) overexpressed in HCC causes ZEB1 induction by deregulating p53-responsive miRNAs, which may facilitate epithelial-mesenchymal transition and growth of liver tumor. These findings highlight the significance of G alpha(12) upregulation in liver tumor progression, implicating G alpha(12) as an attractive therapeutic target.	[Yang, Y. M.; Lee, W. H.; Lee, C. G.; Kim, S. G.] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Yang, Y. M.; Lee, W. H.; Lee, C. G.; Kim, S. G.] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; [An, J.; Kim, K. M.] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Liver Ctr,Dept Internal Med, Seoul, South Korea; [Kim, E-S; Moon, A.] Duksung Womens Univ, Coll Pharm, Seoul, South Korea; [Kim, S. H.; Lee, C. H.; Hwang, S.] Hanyang Univ, Coll Med, Seoul 133791, South Korea; [Lee, S-K; Park, J-W] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea; [Dhanasekaran, D. N.] Univ Oklahoma, Hlth Sci Ctr, OU Inst Canc, Dept Cell Biol, Oklahoma City, OK USA; [Lee, S. J.] Gachon Univ, Coll Pharm, Inchon, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center; Duksung Women's University; Hanyang University; National Cancer Center - Korea (NCC); University of Oklahoma System; University of Oklahoma Health Sciences Center; Gachon University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 151742, South Korea.	sgk@snu.ac.kr		Lee, Seung Jin/0000-0003-0625-7774; Yang, Yoon Mee/0000-0003-4281-9906; An, Jihyun/0000-0002-0110-0965	National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [2007-0056817]; World Class University project [R322012000100980]; National Cancer Center [1110050]	National Research Foundation of Korea (NRF) grant - Korea government (MSIP); World Class University project; National Cancer Center	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2007-0056817) and in part by the World Class University project (R322012000100980) and National Cancer Center (No. 1110050). We thank Prof Dr Soon-Sun Hong and Hee-Seung Lee for their indispensable support.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen XL, 2011, J HEPATOL, V55, P838, DOI 10.1016/j.jhep.2010.12.043; Dharel N, 2008, HEPATOLOGY, V47, P1136, DOI 10.1002/hep.22176; Di Como CJ, 1998, ONCOGENE, V16, P2527; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Feng B, 2012, BIOMED PHARMACOTHER, V66, P397, DOI 10.1016/j.biopha.2012.06.002; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Grzelinski M, 2010, CLIN CANCER RES, V16, P1402, DOI 10.1158/1078-0432.CCR-09-1873; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hsieh JL, 2003, CLIN CANCER RES, V9, P338; Kang KW, 2003, J BIOL CHEM, V278, P17368, DOI 10.1074/jbc.M300471200; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Ki SH, 2007, J BIOL CHEM, V282, P1938, DOI 10.1074/jbc.M606080200; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kim MS, 2007, MOL CANCER RES, V5, P473, DOI 10.1158/1541-7786.MCR-06-0395; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Lee JM, 2012, INT J CANCER, V130, P716, DOI 10.1002/ijc.26075; Lee SJ, 2009, ONCOGENE, V28, P1230, DOI 10.1038/onc.2008.488; Lin F, 2009, J CELL BIOL, V184, P909, DOI 10.1083/jcb.200805148; Liu SC, 2009, CANCER RES, V69, P6122, DOI 10.1158/0008-5472.CAN-08-3435; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Mazzocca A, 2011, HEPATOLOGY, V54, P920, DOI 10.1002/hep.24485; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Poon RTP, 2000, ANN SURG, V232, P10, DOI 10.1097/00000658-200007000-00003; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sanchez-Tillo E, 2014, CELL DEATH DIFFER, V21, P247, DOI 10.1038/cdd.2013.123; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Sumie S, 2008, ANN SURG ONCOL, V15, P1375, DOI 10.1245/s10434-008-9846-9; Wang B, 2010, DIABETES, V59, P1794, DOI 10.2337/db09-1736; Wang ZF, 2010, PROTEIN CELL, V1, P1063, DOI 10.1007/s13238-010-0140-9; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yang YM, 2012, HEPATOLOGY, V56, P2209, DOI 10.1002/hep.25912; Yang YM, 2010, CARCINOGENESIS, V31, P1230, DOI 10.1093/carcin/bgq097; Zhou YM, 2012, ANN SURG ONCOL, V19, P1700, DOI 10.1245/s10434-011-1772-6	46	35	35	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2910	2921		10.1038/onc.2014.218	http://dx.doi.org/10.1038/onc.2014.218			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25065598				2022-12-28	WOS:000355324300010
J	Hsu, FF; Yeh, CT; Sun, YJ; Chiang, MT; Lan, WM; Li, FA; Lee, WH; Chau, LY				Hsu, F-F; Yeh, C-T; Sun, Y-J; Chiang, M-T; Lan, W-M; Li, F-A; Lee, W-H; Chau, L-Y			Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; VIRUS CORE PROTEIN; INTRAMEMBRANE PROTEOLYSIS; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; EXPRESSION; OVEREXPRESSION; IDENTIFICATION; TRANSLOCATION; DEGRADATION	Heme oxygenase-1 (HO-1) is a heme-degrading enzyme anchored in the endoplasmic reticulum by a carboxyl-terminal transmembrane segment (TMS). HO-1 is highly expressed in various cancers and its nuclear localization is associated with the progression of some cancers. Nevertheless, the mechanism underlying HO-1 nuclear translocation and its pathological significance remain elusive. Here we show that the signal peptide peptidase (SPP) catalyzes the intramembrane cleavage of HO-1. Coexpression of HO-1 with wild-type SPP, but not a dominant-negative SPP, promoted the nuclear localization of HO-1 in cells. Mass spectrometry analysis of cytosolic HO-1 isolated from HeLa cells overexpressing HO-1 and SPP revealed two adjacent intramembrane cleavage sites located after S-275 and F-276 within the TMS. Mutations of S275F276 to A(275)L(276) significantly hindered SPP-mediated HO-1 cleavage and nuclear localization. Nuclear HO-1 was detected in A549 and DU145 cancer cell lines expressing high levels of endogenous HO-1 and SPP. SPP knockdown or inhibition significantly reduced nuclear HO-1 localization in A549 and DU145 cells. The positive nuclear HO-1 stain was also evident in lung cancer tissues expressing high levels of HO-1 and SPP. Overexpression of a truncated HO-1 (t-HO-1) lacking the TMS in HeLa and H1299 cells promoted cell proliferation and migration/invasion. The effect of t-HO-1 was not affected by a mutation in the catalytic site. However, blockade of t-HO-1 nuclear localization abolished t-HO-1-mediated effect. The tumorigenic effect of t-HO-1 was also demonstrated in the mouse model. These findings disclose that SPP-mediated intramembrane cleavage of HO-1 promotes HO-1 nuclear localization and cancer progression independent of HO-1 enzymatic activity.	[Hsu, F-F; Sun, Y-J; Chiang, M-T; Lan, W-M; Li, F-A; Chau, L-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Yeh, C-T] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Yeh, C-T; Lee, W-H] Taipei Med Univ, Shuang Ho Hosp, Ctr Canc, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sect 2,Acad Rd, Taipei 115, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Li, Fu-An/M-8506-2019	Chau, Lee-Young/0000-0002-6316-2328; Li, Fu-An/0000-0002-0580-7765	National Science Council of Taiwan [NSC-100-2320-B-001-010-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by a grant from the National Science Council of Taiwan (NSC-100-2320-B-001-010-MY3). We thank the National Center for Genome Medicine at Academia Sinica, Taiwan for polymerase chain reaction of short-tandem repeat sequences analysis, and the IBMS proteomics core for LC-MS analysis.	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Bindu S, 2011, J BIOL CHEM, V286, P39387, DOI 10.1074/jbc.M111.279893; Chang HT, 2007, J CELL BIOCHEM, V100, P1266, DOI 10.1002/jcb.21120; Collinson EJ, 2011, J BIOL CHEM, V286, P2205, DOI 10.1074/jbc.M110.187062; Converso DP, 2006, FASEB J, V20, P1236, DOI 10.1096/fj.05-4204fje; Degese MS, 2012, LUNG CANCER, V77, P168, DOI 10.1016/j.lungcan.2012.02.016; El Hage F, 2008, P NATL ACAD SCI USA, V105, P10119, DOI 10.1073/pnas.0802753105; Erez E, 2009, NATURE, V459, P371, DOI 10.1038/nature08146; Fluhrer R, 2009, J BIOL CHEM, V284, P13975, DOI 10.1074/jbc.R800040200; Gandini NA, 2012, EXP MOL PATHOL, V93, P237, DOI 10.1016/j.yexmp.2012.05.001; Giordano A, 2000, FEBS LETT, V487, P171, DOI 10.1016/S0014-5793(00)02217-1; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659; Kocanova S, 2007, APOPTOSIS, V12, P731, DOI 10.1007/s10495-006-0016-x; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Li Volti G, 2004, BIOCHEM BIOPH RES CO, V315, P517, DOI 10.1016/j.bbrc.2004.01.090; Lin PH, 2013, ONCOGENE, V32, P2325, DOI 10.1038/onc.2012.244; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; Mayerhofer M, 2008, BLOOD, V111, P2200, DOI 10.1182/blood-2006-11-055723; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Okamoto K, 2008, J VIROL, V82, P8349, DOI 10.1128/JVI.00306-08; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Sacca P, 2007, BRIT J CANCER, V97, P1683, DOI 10.1038/sj.bjc.6604081; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; Targett-Adams P, 2006, J BIOL CHEM, V281, P29221, DOI 10.1074/jbc.M605373200; Wang XM, 2009, J IMMUNOL, V182, P3809, DOI 10.4049/jimmunol.0712437; Was H, 2006, AM J PATHOL, V169, P2181, DOI 10.2353/ajpath.2006.051365; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x	34	56	57	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2360	2370		10.1038/onc.2014.166	http://dx.doi.org/10.1038/onc.2014.166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931165				2022-12-28	WOS:000353824800009
J	He, Y; Wu, AC; Harrington, BS; Davies, CM; Wallace, SJ; Adams, MN; Palmer, JS; Roche, DK; Hollier, BG; Westbrook, TF; Hamidi, H; Konecny, G; Winterhoff, B; Chetty, NP; Crandon, AJ; Oliveira, NB; Shannon, CM; Tinker, AV; Gilks, CB; Coward, JI; Lumley, JW; Perrin, LC; Armes, JE; Hooper, JD				He, Y.; Wu, A. C.; Harrington, B. S.; Davies, C. M.; Wallace, S. J.; Adams, M. N.; Palmer, J. S.; Roche, D. K.; Hollier, B. G.; Westbrook, T. F.; Hamidi, H.; Konecny, G. E.; Winterhoff, B.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Tinker, A. V.; Gilks, C. B.; Coward, J. I.; Lumley, J. W.; Perrin, L. C.; Armes, J. E.; Hooper, J. D.			Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; SURFACE GLYCOPROTEIN CDCP1; CUB-DOMAIN; ANOIKIS RESISTANCE; SURVIVAL; PROGNOSIS; SRC; IDENTIFICATION; METASTASIS; MECHANISMS	Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Instead dissemination of these tumors is characteristically via direct extension of the primary tumor into nearby organs and the spread of exfoliated tumor cells throughout the peritoneum, initially via the peritoneal fluid, and later via ascites that accumulates as a result of disruption of the lymphatic system. The molecular mechanisms orchestrating these processes are uncertain. In particular, the signaling pathways used by malignant cells to survive the stresses of anchorage-free growth in peritoneal fluid and ascites, and to colonize remote sites, are poorly defined. We demonstrate that the transmembrane glycoprotein CUB-domain-containing protein 1 (CDCP1) has important and inhibitable roles in these processes. In vitro assays indicate that CDCP1 mediates formation and survival of OCC spheroids, as well as cell migration and chemoresistance. Disruption of CDCP1 via silencing and antibody-mediated inhibition markedly reduce the ability of TOV21G OCC cells to form intraperitoneal tumors and induce accumulation of ascites in mice. Mechanistically our data suggest that CDCP1 effects are mediated via a novel mechanism of protein kinase B (Akt) activation. Immunohistochemical analysis also suggested that CDCP1 is functionally important in OCC, with its expression elevated in 90% of 198 OCC tumors and increased CDCP1 expression correlating with poor patient disease-free and overall survival. This analysis also showed that CDCP1 is largely restricted to the surface of malignant cells where it is accessible to therapeutic antibodies. Importantly, antibody-mediated blockade of CDCP1 in vivo significantly increased the anti-tumor efficacy of carboplatin, the chemotherapy most commonly used to treat OCC. In summary, our data indicate that CDCP1 is important in the progression of OCC and that targeting pathways mediated by this protein may be useful for the management of OCC, potentially in combination with chemotherapies and agents targeting the Akt pathway.	[He, Y.; Wu, A. C.; Harrington, B. S.; Davies, C. M.; Adams, M. N.; Palmer, J. S.; Roche, D. K.; Coward, J. I.; Armes, J. E.; Hooper, J. D.] Univ Queensland, Translat Res Inst, Mater Res Inst, Woolloongabba, Qld, Australia; [Davies, C. M.; Wallace, S. J.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Coward, J. I.; Perrin, L. C.; Armes, J. E.] Mater Hlth Serv, South Brisbane, Qld, Australia; [Hollier, B. G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Woolloongabba, Qld, Australia; [Westbrook, T. F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Hamidi, H.; Konecny, G. E.] Univ Calif Los Angeles, Los Angeles, CA USA; [Winterhoff, B.] Mayo Clin, Rochester, MN USA; [Tinker, A. V.] British Columbia Canc Agcy, Div Med Oncol, Vancouver Ctr, Vancouver, BC V5Z 4E6, Canada; [Tinker, A. V.] British Columbia Canc Agcy, Cheryl Brown Ovarian Canc Outcomes Unit, Vancouver, BC V5Z 4E6, Canada; [Gilks, C. B.] Univ British Columbia, Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Lumley, J. W.] Wesley Hosp, Auchenflower, Qld, Australia	Mater Research; University of Queensland; Mater Health Services; Queensland University of Technology (QUT); Baylor College of Medicine; University of California System; University of California Los Angeles; Mayo Clinic; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia; Wesley Hospital	Hooper, JD (corresponding author), Univ Queensland, Translat Res Inst, Canc Biol & Management, Mater Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.	john.hooper@mater.uq.edu.au	Coward, Jermaine/F-2903-2016; Adams, Mark/AAE-1209-2021; Harrington, Brittney/Z-5941-2019; Hooper, John/C-1481-2016; Hamidi, Habib/H-8030-2016; Harrington, Brittney/P-1687-2016; OLIVEIRA, Niara/Y-3471-2018	Coward, Jermaine/0000-0002-2309-9379; Adams, Mark/0000-0003-1906-5018; Harrington, Brittney/0000-0001-7083-069X; Hooper, John/0000-0003-1054-8486; Hamidi, Habib/0000-0003-0196-9852; Harrington, Brittney/0000-0001-7083-069X; Wu, Andy C/0000-0002-0864-4447; Perrin, Lewis/0000-0002-6119-8458; OLIVEIRA, Niara/0000-0001-7103-2200; Davies, Claire/0000-0001-8651-0914; HE, Yaowu/0000-0002-7828-263X; Chetty, Naven/0000-0002-7158-7123	Cancer Council Queensland [614205, 1021827]; Wesley Research Institute grant [2008/06]; MNA; BSH received Australian Post-Graduate Awards; BGH holds a Queensland Government Smart Futures Fund Fellowship; JDH holds Australian Research Council Future Fellowship [FT120100917]	Cancer Council Queensland(Cancer Council Queensland); Wesley Research Institute grant; MNA; BSH received Australian Post-Graduate Awards; BGH holds a Queensland Government Smart Futures Fund Fellowship; JDH holds Australian Research Council Future Fellowship	This work was supported by Cancer Council Queensland grants 614205 and 1021827 and Wesley Research Institute grant 2008/06 to JDH. MNA and BSH received Australian Post-Graduate Awards. BGH holds a Queensland Government Smart Futures Fund Fellowship. JDH holds Australian Research Council Future Fellowship FT120100917.	Adams MN, 2015, ONCOGENE, V34, P1375, DOI 10.1038/onc.2014.88; Al-Barrak J, 2011, GYNECOL ONCOL, V122, P107, DOI 10.1016/j.ygyno.2011.03.011; Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Carduner L, 2014, EXP CELL RES, V320, P329, DOI 10.1016/j.yexcr.2013.11.011; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Hoskins PJ, 2012, J CLIN ONCOL, V30, P1656, DOI 10.1200/JCO.2011.40.1646; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Itamochi H, 2002, JPN J CANCER RES, V93, P723, DOI 10.1111/j.1349-7006.2002.tb01312.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kemp Z, 2013, INT J WOMENS HEALTH, V5, P45, DOI 10.2147/IJWH.S30231; Kollmorgen G, 2013, MOL ONCOL, V7, P1142, DOI 10.1016/j.molonc.2013.08.009; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; McGovern JA, 2013, BRIT J DERMATOL, V168, P496, DOI 10.1111/bjd.12119; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Saga Y, 2008, ONCOL REP, V20, P1299, DOI 10.3892/or_00000144; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Smith JA, 2005, GYNECOL ONCOL, V98, P141, DOI 10.1016/j.ygyno.2005.02.006; Spassov DS, 2013, CANCER RES, V73, P1168, DOI 10.1158/0008-5472.CAN-12-2496; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5; Tan DSP, 2013, BRIT J CANCER, V108, P1553, DOI 10.1038/bjc.2013.126; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tang T, 2010, NAT BIOTECHNOL, V28, P749, DOI 10.1038/nbt.1644; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Yu XH, 2008, CANCER SCI, V99, P543, DOI 10.1111/j.1349-7006.2007.00722.x	39	35	36	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					468	478		10.1038/onc.2015.101	http://dx.doi.org/10.1038/onc.2015.101			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893298	Green Published, hybrid			2022-12-28	WOS:000369056700007
J	Salpeter, SJ; Pozniak, Y; Merquiol, E; Ben-Nun, Y; Geiger, T; Blum, G				Salpeter, S. J.; Pozniak, Y.; Merquiol, E.; Ben-Nun, Y.; Geiger, T.; Blum, G.			A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression	ONCOGENE			English	Article							PROTEASE ACTIVITY; METASTASIS; AUTOPHAGY; PROLIFERATION; POLARIZATION; PROGRESSION; IDENTIFICATION; FRACTIONATION; PLASTICITY; INVASION	Although cysteine cathepsins have been identified as key regulators of cancer growth, their specific role in tumor development remains unclear. Recent studies have shown that high activity levels of tumor cathepsins are primarily a result of increased cathepsin activity in cancer-promoting tumor-associated macrophages (TAMs). To further investigate the role of cysteine cathepsin activity in normal and polarized macrophages, we established in vitro and in vivo models of macrophage differentiation and polarization and used a novel cysteine cathepsin inhibitor, GB111-NH2, to block the activity of cathepsins B, L and S. Here we show that in vitro, cysteine cathepsin inhibition yields both apoptosis and proliferation of macrophages, owing to increased oxidative stress. Proteomic analysis of cathepsin-inhibited macrophages demonstrates inhibition of autophagy, suggesting a likely cause of elevated reactive oxygen species (ROS) levels. In vivo models of mammary cancer further show that cathepsin inhibition yields TAM death owing to increased ROS levels. Strikingly, apoptosis in TAMs yields a seemingly cell non-autonomous death of neighboring cancer cells, and regression of the primary growth. These results show that cysteine cathepsin inhibitors can specifically trigger macrophage cell death and may function as an effective anticancer therapy in tumors with high levels of TAMs.	[Salpeter, S. J.; Merquiol, E.; Ben-Nun, Y.; Blum, G.] Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel; [Pozniak, Y.; Geiger, T.] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Ramat Aviv, Israel	Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine	Blum, G (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel.	galiabl@ekmd.huji.ac.il		Ben-Nun, Yael/0000-0002-5123-649X	Israel Cancer Research Foundation (ICRF); European Research Council (Marie Curie International Reintegration Grant)	Israel Cancer Research Foundation (ICRF); European Research Council (Marie Curie International Reintegration Grant)	We thank Dr Michael Berger (The Hebrew University) for providing reagents and advice regarding the project. We would like to acknowledge Boris Turk (Lubljana, Slovenia) for supplying the recombinant cathepsins. This work was supported by the Israel Cancer Research Foundation (ICRF) (to GB, SJS and TG) and the European Research Council (Marie Curie International Reintegration Grant) (to GB).	Bell-McGuinn KM, 2007, CANCER RES, V67, P7378, DOI 10.1158/0008-5472.CAN-07-0602; Blum G, 2005, NAT CHEM BIOL, V1, P203, DOI 10.1038/nchembio728; Blum G, 2007, NAT CHEM BIOL, V3, P668, DOI 10.1038/nchembio.2007.26; Concha C, 2005, J CELL PHYSIOL, V204, P693, DOI 10.1002/jcp.20338; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Dennemarker J, 2010, BIOL CHEM, V391, P913, DOI 10.1515/BC.2010.097; Dragin N, 2006, FEBS LETT, V580, P3845, DOI 10.1016/j.febslet.2006.06.006; Elie BT, 2010, BIOCHIMIE, V92, P1618, DOI 10.1016/j.biochi.2010.04.023; Galdiero MR, 2013, J CELL PHYSIOL, V228, P1404, DOI 10.1002/jcp.24260; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Goulet B, 2006, BIOL CHEM, V387, P1285, DOI 10.1515/BC.2006.159; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469, DOI 10.1152/ajplung.1998.275.3.L469; Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666; Jacquel A, 2012, BLOOD, V119, P4527, DOI 10.1182/blood-2011-11-392167; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Katunuma Nobuhiko, 2010, J Signal Transduct, V2010, P375345, DOI 10.1155/2010/375345; Larghi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045279; Liao XH, 2012, CELL METAB, V15, P545, DOI 10.1016/j.cmet.2012.01.022; Lin YY, 2013, CANCER SCI, V104, P1217, DOI 10.1111/cas.12202; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Pan LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035315; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Schurigt U, 2008, BIOL CHEM, V389, P1067, DOI 10.1515/BC.2008.115; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; White ES, 2013, J PATHOL, V229, P141, DOI 10.1002/path.4126; Wisniewski JR, 2009, J PROTEOME RES, V8, P5674, DOI 10.1021/pr900748n; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759; Zavasnik-Bergant T, 2007, BIOL CHEM, V388, P1141, DOI 10.1515/BC.2007.144; Zhang Y, 2012, BLOOD, V119, P2895, DOI 10.1182/blood-2011-08-372383	45	42	42	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6066	6078		10.1038/onc.2015.51	http://dx.doi.org/10.1038/onc.2015.51			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25798843				2022-12-28	WOS:000366113800004
J	Klein, SR; Piya, S; Lu, Z; Xia, Y; Alonso, MM; White, EJ; Wei, J; Gomez-Manzano, C; Jiang, H; Fueyo, J				Klein, S. R.; Piya, S.; Lu, Z.; Xia, Y.; Alonso, M. M.; White, E. J.; Wei, J.; Gomez-Manzano, C.; Jiang, H.; Fueyo, J.			C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy	ONCOGENE			English	Article							PATHWAY; PHOSPHORYLATION; VIRUS; ACTIVATION; INHIBITOR; APOPTOSIS; BECLIN-1; STRESS; CELLS; TSC2	Oncolytic adenoviruses, such as Delta-24-RGD (Delta 24RGD), are replication-competent viruses that are genetically engineered to induce selective cancer cell lysis. In cancer cells,Delta 24RGD induces massive autophagy, which is required for efficient cell lysis and adenoviral spread. Understanding the cellular mechanisms underlying the regulation of autophagy in cells treated with oncolytic adenoviruses may provide new avenues to improve the therapeutic effect. In this work, we showed that cancer cells infected with Delta 24RGDundergo autophagy despite the concurrent activation of the AKT/mTOR pathway. Moreover, adenovirus replication induced sustained activation of JNK proteins in vitro. ERK1/2 phosphorylation remained unchanged during adenoviral infection, suggesting specificity of JNK activation. Using genetic ablation and pharmacological inactivation of JNK, we unequivocally demonstrated that cells infected with Delta 24RGD required JNK activation. Thus, genetic co-ablation of JNK1 and JNK2 genes or inhibition of JNK kinase function rendered Delta 24RGD-treated cells resistant to autophagy. Accordingly, JNK activation induced phosphorylation of Bcl-2 and prevented the formation of Bcl-2/Beclin 1 autophagy suppressor complexes. Using an orthotopic model of human glioma xenograft, we showed that treatment with.24RGD induced phosphorylation and nuclear translocation of JNK, as well as phosphorylation of Bcl-2. Collectively, our data identified JNK proteins as an essential mechanistic link between Delta 24RGD infection and autophagy in cancer cells. Activation of JNK without inactivation of the AKT/mTOR pathway constitutes a distinct molecular signature of autophagy regulation that differentiates Delta 24RGD adenovirus from the mechanism used by other oncolytic viruses to induce autophagy and provides a new rationale for the combination of oncolytic viruses and chemotherapy.	[Klein, S. R.; Piya, S.; Lu, Z.; Xia, Y.; White, E. J.; Gomez-Manzano, C.; Jiang, H.; Fueyo, J.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Klein, S. R.; Piya, S.; Gomez-Manzano, C.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX USA; [Alonso, M. M.] Univ Hosp Navarra, Dept Med Oncol, Pamplona, Spain; [Wei, J.; Fueyo, J.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Servicio Navarro de Salud - Osasunbidea; University of Navarra; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, S5-8316,Unit 1002,1515 Holcombe Blvd, Houston, TX 77030 USA.	jfueyo@mdanderson.org	Alonso, Marta M/AAI-9457-2020	Alonso, Marta M/0000-0002-7520-7351; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NHI/NCI [P50CA127001, P30CA016672]; Marnie Rose Foundation; Will Power Foundation; Schissler Foundation; American Legion Auxiliary; NATIONAL CANCER INSTITUTE [P50CA127001, P30CA016672] Funding Source: NIH RePORTER	NHI/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Marnie Rose Foundation; Will Power Foundation; Schissler Foundation; American Legion Auxiliary; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Tamara Locke (Department of Scientific Publications, The University of Texas MD Anderson Cancer Center) for editorial assistance. This work was supported by grants from the NHI/NCI (P50CA127001; Cancer Center Support Grant P30CA016672-High Resolution Electron Microscopy and Research Animal Support Facilities), the Marnie Rose Foundation, the Will Power Foundation, the Schissler Foundation and the American Legion Auxiliary.	Alonso MM, 2008, MOL THER, V16, P487, DOI 10.1038/sj.mt.6300400; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Chen L, 2009, CANCER LETT, V284, P141, DOI 10.1016/j.canlet.2009.04.026; Dong XN, 2013, J INNATE IMMUN, V5, P480, DOI 10.1159/000346388; Eyre TA, 2014, BRIT J HAEMATOL, V166, P336, DOI 10.1111/bjh.12945; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833; Hung CH, 2014, J VIROL, V88, P12133, DOI 10.1128/JVI.02033-14; Ingemarsdotter CK, 2010, ONCOGENE, V29, P6051, DOI 10.1038/onc.2010.335; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161; Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004; Kumar SH, 2009, J VIROL, V83, P8565, DOI 10.1128/JVI.00603-09; Li XD, 2005, VIROLOGY, V333, P180, DOI 10.1016/j.virol.2005.01.002; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Orvedahl A, 2008, AUTOPHAGY, V4, P280, DOI 10.4161/auto.5289; Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001; Piya S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029467; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Shelly S, 2009, IMMUNITY, V30, P588, DOI 10.1016/j.immuni.2009.02.009; Shertz CA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002269; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; Wang W, 2014, MOL CANCER THER, V13, P1480, DOI 10.1158/1535-7163.MCT-13-0629; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Wileman T, 2006, SCIENCE, V312, P875, DOI 10.1126/science.1126766; Xu P, 2011, GENE DEV, V25, P310, DOI 10.1101/gad.1984311	42	36	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5295	5301		10.1038/onc.2014.452	http://dx.doi.org/10.1038/onc.2014.452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619840	Green Accepted			2022-12-28	WOS:000362575400009
J	Fujii, S; Matsumoto, S; Nojima, S; Morii, E; Kikuchi, A				Fujii, S.; Matsumoto, S.; Nojima, S.; Morii, E.; Kikuchi, A.			Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target	ONCOGENE			English	Article							GASTRIC-CANCER; SIGNALING PATHWAYS; EXCHANGE FACTORS; TUMOR-CELLS; WNT; BINDING; ACTIVATION; INVASION; FAMILY; GROWTH	We recently demonstrated that expression of ADP-ribosylation factor (ARF)-like 4c (Arl4c) induced by a combination of Wnt/beta-catenin and epidermal growth factor/Ras signaling in normal epithelial cells grown in three-dimensional culture promotes cellular migration and proliferation, resulting in formation of tube-like structures, suggesting the involvement of Arl4c in epithelial morphogenesis. It is conceivable that there could be a common mechanism between epithelial morphogenesis and carcinogenesis. Therefore the current study was conducted to investigate whether Arl4c might be involved in tumorigenesis. Immunohistochemical analyses of tissue specimens obtained from colorectal and lung cancer patients revealed that Arl4c was not observed in non-tumor regions but was strongly expressed at high frequencies in tumor lesions. Inhibition of Wnt/beta-catenin or Ras/mitogen-activated protein kinase signaling reduced Arl4c mRNA levels in HCT116 colorectal cancer cells and A549 lung cancer cells. Knockdown of Arl4c inhibited Rac activity and also prevented nuclear localization of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) in these cancer cells. Arl4c-depleted cancer cells consistently showed decreased migration, invasion and proliferation capabilities both in vitro and in vivo. Furthermore, direct injection of Arl4c small interfering RNA (siRNA) into HCT116 cell-derived tumors (in vivo treatment with siRNA) inhibited tumor growth in immunodeficient mice. These results suggest that Arl4c is involved in tumorigenesis and might represent a novel therapeutic target for suppressing proliferation and invasion of colorectal and lung cancer cells.	[Fujii, S.; Matsumoto, S.; Kikuchi, A.] Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; [Fujii, S.] Osaka Univ, IPBS, Inst Acad Initiat, Suita, Osaka 5650871, Japan; [Nojima, S.; Morii, E.] Osaka Univ, Dept Pathol, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Kikuchi, A (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp			Ministry of Education, Science and Culture of Japan [25250018, 26861547, 25860211, 23112004]; Uehara Memorial Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation)	We thank Dr Y Shintani and Dr K Shojima for valuable discussions regarding Arl4c expression and their technical assistance. We also thank Dr T Kobayashi, Dr W Yasui and Dr K Matsumoto for donating cells. This work was supported by Grants-in-Aid for Scientific Research to AK (2013-2014) (No. 25250018), SF (2014) (No. 26861547) and SM (2013-2014) (No. 25860211) and for Scientific Research on Innovative Areas to AK (2011-2014) (No. 23112004) from the Ministry of Education, Science and Culture of Japan and by grants from the Uehara Memorial Foundation.	Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Burd CG, 2004, TRENDS CELL BIOL, V14, P687, DOI 10.1016/j.tcb.2004.10.004; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Engel T, 2004, FEBS LETT, V566, P241, DOI 10.1016/j.febslet.2004.04.048; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Gon H, 2013, MOL BIOL CELL, V24, P3764, DOI 10.1091/mbc.E13-07-0357; Hanaki H, 2012, MOL CANCER THER, V11, P298, DOI 10.1158/1535-7163.MCT-11-0682; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hofmann I, 2007, CURR BIOL, V17, P711, DOI 10.1016/j.cub.2007.03.007; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Jacobs S, 1999, FEBS LETT, V456, P384, DOI 10.1016/S0014-5793(99)00759-0; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kagawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083629; Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1; Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Li CC, 2007, MOL BIOL CELL, V18, P4420, DOI 10.1091/mbc.E07-02-0149; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Matsumoto S, 2014, EMBO J, V33, P702, DOI 10.1002/embj.201386942; Matsumoto S, 2010, EMBO J, V29, P1192, DOI 10.1038/emboj.2010.26; McCormick F, 1999, TRENDS BIOCHEM SCI, V24, pM53, DOI 10.1016/S0968-0004(99)01480-2; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Mori M, 2001, MODERN PATHOL, V14, P72, DOI 10.1038/modpathol.3880259; Nieto MA, 2013, SCIENCE, V342; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wei SM, 2009, BIOCHEM BIOPH RES CO, V384, P352, DOI 10.1016/j.bbrc.2009.04.125; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200	46	45	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4834	4844		10.1038/onc.2014.402	http://dx.doi.org/10.1038/onc.2014.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25486429				2022-12-28	WOS:000361050000004
J	Yoshihara, K; Wang, Q; Torres-Garcia, W; Zheng, S; Vegesna, R; Kim, H; Verhaak, RGW				Yoshihara, K.; Wang, Q.; Torres-Garcia, W.; Zheng, S.; Vegesna, R.; Kim, H.; Verhaak, R. G. W.			The landscape and therapeutic relevance of cancer-associated transcript fusions	ONCOGENE			English	Article							GENE FUSIONS; TYROSINE KINASE; BREAST-CANCER; IDENTIFICATION; GENOME; REARRANGEMENTS; ABERRATIONS; INHIBITION; RESOURCE; PATTERNS	Transcript fusions as a result of chromosomal rearrangements have been a focus of attention in cancer as they provide attractive therapeutic targets. To identify novel fusion transcripts with the potential to be exploited therapeutically, we analyzed RNA sequencing, DNA copy number and gene mutation data from 4366 primary tumor samples. To avoid false positives, we implemented stringent quality criteria that included filtering of fusions detected in RNAseq data from 364 normal tissue samples. Our analysis identified 7887 high confidence fusion transcripts across 13 tumor types. Our fusion prediction was validated by evidence of a genomic rearrangement for 78 of 79 fusions in 48 glioma samples where whole-genome sequencing data were available. Cancers with higher levels of genomic instability showed a corresponding increase in fusion transcript frequency, whereas tumor samples harboring fusions contained statistically significantly fewer driver gene mutations, suggesting an important role for tumorigenesis. We identified at least one in-frame protein kinase fusion in 324 of 4366 samples (7.4%). Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenocarcinoma (1.6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for application of kinase inhibitors across tumor types. Inframe fusion transcripts involving histone methyltransferase or histone demethylase genes were detected in 111 samples (2.5%) and may additionally be considered as therapeutic targets. In summary, we described the landscape of transcript fusions detected across a large number of tumor samples and revealed fusion events with clinical relevance that have not been previously recognized. Our results support the concept of basket clinical trials where patients are matched with experimental therapies based on their genomic profile rather than the tissue where the tumor originated.	[Yoshihara, K.; Wang, Q.; Torres-Garcia, W.; Zheng, S.; Vegesna, R.; Kim, H.; Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Yoshihara, K.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Japan; [Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Genome Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Niigata University; University of Texas System; UTMD Anderson Cancer Center	Verhaak, RGW (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Dept Bioinformat & Computat Biol, 1400 Pressler St,Unit 1410, Houston, TX 77030 USA.	rverhaak@mdanderson.org	Verhaak, Roel/ABE-7058-2020; Yoshihara, Kosuke/AAU-9874-2020; Torres-Garcia, Wandaliz/L-6347-2017; Kim, Hoon/AAL-9283-2020	Yoshihara, Kosuke/0000-0002-2254-3378; Kim, Hoon/0000-0003-4244-6126	Mary K Chapman Foundation; Michael & Susan Dell Foundation; US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center) [CA143883, CA083639]; MD Anderson Cancer Center [P30 CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639, U24CA143883] Funding Source: NIH RePORTER	Mary K Chapman Foundation; Michael & Susan Dell Foundation; US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center); MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The results published here are in whole or part based upon data generated by The Cancer Genome Atlas project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at 'http://cancergenome.nih.gov'. This work was supported in part by the Mary K Chapman Foundation, the Michael & Susan Dell Foundation (honoring Lorraine Dell), US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center) grant numbers CA143883 and CA083639, and MD Anderson Cancer Center Support Grant P30 CA016672 (the Bioinformatics Shared Resource).	Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Asmann YW, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr362; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cadot B, 2009, CANCER RES, V69, P6074, DOI 10.1158/0008-5472.CAN-08-2796; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gough SM, 2014, CANCER DISCOV, V4, P564, DOI 10.1158/2159-8290.CD-13-0419; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Honeyman JN, 2014, SCIENCE, V343, P1010, DOI 10.1126/science.1249484; Kalyana-Sundaram S, 2012, NEOPLASIA, V14, P702, DOI 10.1593/neo.12914; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315; Kim P, 2010, NUCLEIC ACIDS RES, V38, pD81, DOI 10.1093/nar/gkp982; Lam ET, 2010, J CLIN ONCOL, V28, P2323, DOI 10.1200/JCO.2009.25.0068; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; NOWELL PC, 1960, SCIENCE, V132, P1497; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; R Development Core Team, 2009, R LANG ENV STAT COMP; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Shah N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-818; Shaw AT, 2013, NAT REV CANCER, V13, P772, DOI 10.1038/nrc3612; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torres-Garcia W, 2014, BIOINFORMATICS, V30, P2224, DOI 10.1093/bioinformatics/btu169; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Wells SA, 2010, J CLIN ONCOL, V28, P767, DOI 10.1200/JCO.2009.23.6604; Wu CX, 2012, J PATHOL, V227, P53, DOI 10.1002/path.3987; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937; Zheng SY, 2013, GENE DEV, V27, P1462, DOI 10.1101/gad.213686.113	53	296	300	1	39	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4845	4854		10.1038/onc.2014.406	http://dx.doi.org/10.1038/onc.2014.406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25500544	Green Accepted			2022-12-28	WOS:000361050000005
J	Agarwal, S; Kazi, JU; Mohlin, S; Pahlman, S; Ronnstrand, L				Agarwal, S.; Kazi, J. U.; Mohlin, S.; Pahlman, S.; Roennstrand, L.			The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V	ONCOGENE			English	Article							HEMATOPOIETIC-CELL LINES; MAST-CELLS; DASATINIB BMS-354825; KINASE INHIBITOR; CATALYTIC DOMAIN; RECEPTOR; MUTATIONS; GROWTH; PHOSPHORYLATION; PROLIFERATION	Oncogenic c-Kit mutations have been shown to display ligand-independent receptor activation and cell proliferation. A substitution of aspartate to valine at amino acid 816 (D816V) is one of the most commonly found oncogenic c-Kit mutations and is found in >90% of cases of mastocytosis and less commonly in germ-cell tumors, core-binding factor acute myeloid leukemia and mucosal melanomas. The mechanisms by which this mutation leads to constitutive activation and transformation are not fully understood. Previous studies have shown that the D816V mutation causes a structural change in the activation loop (A-loop), resulting in weaker binding of the A-loop to the juxtamembrane domain. In this paper, we have investigated the role of Y823, the only tyrosine residue in the A-loop, and its role in oncogenic transformation by c-Kit/D816V by introducing the Y823F mutation. Although dispensable for the kinase activity of c-Kit/D816V, the presence of Y823 was crucial for cell proliferation and survival. Furthermore, mutation of Y823 selectively downregulates the Ras/Erk and Akt pathways as well as the phosphorylation of STAT5 and reduces the transforming capacity of the D816V/c-Kit in vitro. We further show that mice injected with cells expressing c-Kit/ D816V/Y823F display significantly reduced tumor size as well as tumor weight compared with controls. Finally, microarray analysis, comparing Y823F/D816V cells with cells expressing c-Kit/D816V, demonstrate that mutation of Y823 causes upregulation of proapoptotic genes, whereas genes of survival pathways are downregulated. Thus, phosphorylation of Y823 is not necessary for kinase activation, but essential for the transforming ability of the c-Kit/D816V mutant.	[Agarwal, S.; Kazi, J. U.; Mohlin, S.; Pahlman, S.; Roennstrand, L.] Lund Univ, Translat Canc Res, Lund, Sweden; [Agarwal, S.; Kazi, J. U.; Roennstrand, L.] Lund Univ, Lund Stem Cell Ctr, Lund, Sweden; [Mohlin, S.; Pahlman, S.] Lund Univ, CREATE Hlth, Lund, Sweden	Lund University; Lund University; Lund University	Ronnstrand, L (corresponding author), Lund Univ, Translat Canc Res, Scheelevagen 2, Lund, Sweden.	Lars.Ronnstrand@med.lu.se	Kazi, Julhash U./D-9190-2011	Kazi, Julhash U./0000-0002-0719-5336; Ronnstrand, Lars/0000-0003-1275-5809; Mohlin, Sofie/0000-0002-2458-3963	Swedish Research Council; Swedish Cancer Foundation; Gunnar Nilsson Cancer foundation; Stiftelsen Olle Engkvist Byggmastare; Royal Physiographic Society in Lund; Ollie och Elof Ericssons Stiftelse; Stiftelsen Lars Hiertas Minne	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; Gunnar Nilsson Cancer foundation; Stiftelsen Olle Engkvist Byggmastare(Swedish Research Council); Royal Physiographic Society in Lund; Ollie och Elof Ericssons Stiftelse; Stiftelsen Lars Hiertas Minne	This work was supported by grants from the Swedish Research Council, the Swedish Cancer Foundation, Gunnar Nilsson Cancer foundation, the Stiftelsen Olle Engkvist Byggmastare, Royal Physiographic Society in Lund, Ollie och Elof Ericssons Stiftelse and Stiftelsen Lars Hiertas Minne.	Agarwal S, 2013, J BIOL CHEM, V288, P22460, DOI 10.1074/jbc.M113.474072; Aichberger KJ, 2009, BLOOD, V114, P5342, DOI 10.1182/blood-2008-08-175190; An NF, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-12; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Beghini A, 2004, HAEMATOLOGICA, V89, P920; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Blanco-Aparicio C, 2013, BIOCHEM PHARMACOL, V85, P629, DOI 10.1016/j.bcp.2012.09.018; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Bougherara H, 2013, CL LYMPH MYELOM LEUK, V13, P62, DOI 10.1016/j.clml.2012.08.004; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaix A, 2013, ONCOGENE; Chaix A, 2011, J BIOL CHEM, V286, P5956, DOI 10.1074/jbc.M110.182642; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; DiNitto JP, 2010, J BIOCHEM, V147, P601, DOI 10.1093/jb/mvq015; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Foster R, 2004, J MOL GRAPH MODEL, V23, P139, DOI 10.1016/j.jmgm.2004.04.003; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Giridhar PV, 2011, CLIN EXP METASTAS, V28, P887, DOI 10.1007/s10585-011-9420-x; Gleixner KV, 2006, BLOOD, V107, P752, DOI 10.1182/blood-2005-07-3022; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Grundler R, 2009, J EXP MED, V206, P1957, DOI 10.1084/jem.20082074; Hegazy SA, 2010, J BIOL CHEM, V285, P19813, DOI 10.1074/jbc.M110.121988; Heinrich MC, 2002, HUM PATHOL, V33, P484, DOI 10.1053/hupa.2002.124124; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kosmider O, 2007, ONCOGENE, V26, P3904, DOI 10.1038/sj.onc.1210159; Laine E, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002661; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Makki MS, 2013, EXP CELL RES, V319, P612, DOI 10.1016/j.yexcr.2012.12.021; Masson K, 2009, CELL SIGNAL, V21, P1717, DOI 10.1016/j.cellsig.2009.06.002; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Shah NP, 2006, BLOOD, V108, P286, DOI 10.1182/blood-2005-10-3969; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Sun JM, 2009, J BIOL CHEM, V284, P11039, DOI 10.1074/jbc.M808058200; Thieblemont C, 2013, BLOOD, V121, P2165, DOI 10.1182/blood-2013-01-480392; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Wardega P, 2010, CELL SIGNAL, V22, P1363, DOI 10.1016/j.cellsig.2010.05.004; Wu N, 2013, CLIN TRANSL ONCOL, V15, P106, DOI 10.1007/s12094-012-0928-6; Yang QS, 2012, BLOOD, V120, P3491, DOI 10.1182/blood-2012-02-412643; Zhu WT, 2009, CIRC RES, V105, P1240, DOI 10.1161/CIRCRESAHA.109.208785; Zhuang WY, 2013, ONCOL REP, V30, P185, DOI 10.3892/or.2013.2459	53	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4581	4590		10.1038/onc.2014.383	http://dx.doi.org/10.1038/onc.2014.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435369	Green Submitted			2022-12-28	WOS:000360189300004
J	Liang, Y; Gao, H; Lin, SY; Goss, JA; Du, C; Li, K				Liang, Y.; Gao, H.; Lin, S-Y; Goss, J. A.; Du, C.; Li, K.			Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; LI-FRAUMENI-SYNDROME; INDUCED CELL-DEATH; BREAST-CANCER; MITOTIC ENTRY; CENTROSOME AMPLIFICATION; MCPH1 PROTEIN; BRCT DOMAIN; P53; MICROCEPHALIN	MCPH1, also known as BRIT1, has recently been identified as a novel key regulatory gene of the DNA damage response pathway. MCPH1 is located on human chromosome 8p23.1, where human cancers frequently show loss of heterozygosity. As such, MCPH1 is aberrantly expressed in many malignancies, including breast and ovarian cancers, and the function of MCPH1 has been implicated in tumor suppression. However, it remains poorly understood whether MCPH1 deficiency leads to tumorigenesis. Here we generated and studied both Mcph1(-/-) and Mcph1(-/-)p53(-/-) mice; we showed that Mcph1(-/-) mice developed tumors with long latency, and that primary lymphoma developed significantly earlier in Mcph1(-/-)p53(-/-) mice than in Mcph11(+/+)p53(-/-) and Mcph1(+/-)p53(-/-) mice. The Mcph1(-/-)p53(-/-) lymphomas and derived murine embryonic fibroblasts (MEFs) were both more sensitive to irradiation. Mcph1 deficiency resulted in remarkably increased chromosome and chromatid breaks in Mcph1(-/-)p53(-/-) lymphomas and MEFs, as determined by metaphase spread assay and spectral karyotyping analysis. In addition, Mcph1 deficiency significantly enhanced aneuploidy as well as abnormal centrosome multiplication in Mcph1(-/-)p53(-/-) cells. Meanwhile, Mcph1 deficiency impaired double strand break (DSB) repair in Mcph1(-/-)p53(-/-) MEFs as demonstrated by neutral Comet assay. Compared with Mcph1(+/+)p53(-/-) MEFs, homologous recombination and non-homologous end-joining activities were significantly decreased in Mcph1(-/-)p53(-/-) MEFs. Notably, reconstituted MCPH1 rescued the defects of DSB repair and alleviated chromosomal aberrations in Mcph1(-/-)p53(-/-) MEFs. Taken together, our data demonstrate MCPH1 deficiency promotes genomic instability and increases cancer susceptibility. Our study using knockout mouse models provides convincing genetic evidence that MCPH1 is a bona fide tumor suppressor gene. Its deficiency leading to defective DNA repair in tumors can be used to develop novel targeted cancer therapies in the future.	[Liang, Y.; Gao, H.; Goss, J. A.; Li, K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Liang, Y.] Taishan Med Univ, Sch Pharmaceut Sci, Tai An, Shandong, Peoples R China; [Lin, S-Y] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Du, C.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA; [Du, C.] Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH USA	Baylor College of Medicine; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Li, K (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, ABBR, R417,MC BCM390,One Baylor Plaza, Houston, TX 77030 USA.	kli@bcm.edu	Liang, Yulong/A-2171-2013	Liang, Yulong/0000-0001-8219-9575	National Institutes of Health [R01-CA155151, R21-CA161513]; St Luke's Episcopal Hospital McDonald Research Foundation; National Natural Science Foundation of China [81372589]; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA155151, R21CA161513] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Luke's Episcopal Hospital McDonald Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the National Institutes of Health to KL (R01-CA155151 and R21-CA161513), a grant from the St Luke's Episcopal Hospital McDonald Research Foundation to KL and a grant from National Natural Science Foundation of China (to YL, 81372589). We thank BCM Cytometry and Cell Sorting Core (NCRR S10RR024574, NIAID AI036211 and NCI P30CA125123) and Molecular Morphology Core Laboratory (PHS DK56338) for technical assistance. We also thank Drs Zhijie Li, Han Lin, Ana Rodriguez (all from Baylor College of Medicine, Houston, TX, USA) and Guang Peng (UT MD Anderson Cancer Center, Houston, TX, USA) for providing anti-CD4/CD8 antibodies (ZL), assisting in NHEJ analysis (HL), editing of this manuscript (AR) and providing HR-related plasmids (GP).	Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Bachelier R, 2003, ONCOGENE, V22, P528, DOI 10.1038/sj.onc.1206208; Bhattacharya N, 2013, ANN SURG ONCOL, V20, pS424, DOI 10.1245/s10434-012-2715-6; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown JAL, 2010, ONCOGENE, V29, P5537, DOI 10.1038/onc.2010.302; Bruning-Richardson A, 2011, BRIT J CANCER, V104, P1602, DOI 10.1038/bjc.2011.117; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duesberg P, 2004, IUBMB LIFE, V56, P65, DOI 10.1080/15216540410001667902; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Gruber R, 2011, NAT CELL BIOL, V13, P1325, DOI 10.1038/ncb2342; Grundy S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071629; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1998, CANCER RES, V58, P3111; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leung JW, 2011, J BIOL CHEM, V286, P21393, DOI 10.1074/jbc.M110.208793; Liang YL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000826; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lin SY, 2010, YONSEI MED J, V51, P295, DOI 10.3349/ymj.2010.51.3.295; Mailloux AW, 2009, J IMMUNOL, V182, P2753, DOI 10.4049/jimmunol.0801124; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MATSUMOTO K, 1991, IMMUNOLOGY, V72, P20; Mei JJ, 2001, CURR BIOL, V11, P1197, DOI 10.1016/S0960-9822(01)00325-6; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milliken EL, 2008, ONCOGENE, V27, P1759, DOI 10.1038/sj.onc.1210815; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Mohammad DH, 2009, DNA REPAIR, V8, P1009, DOI 10.1016/j.dnarep.2009.04.004; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Rai R, 2008, CELL CYCLE, V7, P2225, DOI 10.4161/cc.7.14.6303; Rai R, 2006, CANCER CELL, V10, P145, DOI 10.1016/j.ccr.2006.07.002; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Richardson J, 2011, BREAST CANCER RES TR, V127, P639, DOI 10.1007/s10549-010-1019-4; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rothenberg EV, 2005, ANNU REV IMMUNOL, V23, P601, DOI 10.1146/annurev.immunol.23.021704.115737; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; Shi L, 2012, GENE, V495, P1, DOI 10.1016/j.gene.2011.12.053; Singh B, 2002, AM J PATHOL, V161, P365, DOI 10.1016/S0002-9440(10)64191-0; Singh N, 2012, J BIOL CHEM, V287, P2854, DOI 10.1074/jbc.M111.307868; Sotiropoulou PA, 2010, NAT CELL BIOL, V12, P572, DOI 10.1038/ncb2059; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tibelius A, 2009, J CELL BIOL, V185, P1149, DOI 10.1083/jcb.200810159; Venkatesh T, 2014, EUR J CELL BIOL, V93, P98, DOI 10.1016/j.ejcb.2014.01.005; Venkatesh T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054643; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wood JL, 2007, J BIOL CHEM, V282, P35416, DOI 10.1074/jbc.M705245200; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu XL, 2009, CANCER RES, V69, P5531, DOI 10.1158/0008-5472.CAN-08-4834; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang B, 2013, CARCINOGENESIS, V34, P2271, DOI 10.1093/carcin/bgt190; Zhang J, 2013, ASIAN PAC J CANCER P, V14, P7295, DOI 10.7314/APJCP.2013.14.12.7295	66	17	17	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4368	4378		10.1038/onc.2014.367	http://dx.doi.org/10.1038/onc.2014.367			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25362854	Green Accepted			2022-12-28	WOS:000359494400008
J	Andruska, N; Zheng, X; Yang, X; Helferich, WG; Shapiro, DJ				Andruska, N.; Zheng, X.; Yang, X.; Helferich, W. G.; Shapiro, D. J.			Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor alpha-positive breast cancer	ONCOGENE			English	Article							REGULATED GENE-EXPRESSION; KINASE PERK; STRESS; TRANSCRIPTION; MICROARRAY; RESISTANCE; GRP78/BIP; INHIBITOR; GROWTH; ATF6	In response to cell stress, cancer cells often activate the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). Little was known about the potential role in cancer of a different mode of UPR activation, anticipatory activation of the UPR prior to accumulation of unfolded protein or cell stress. We show that estrogen, acting via estrogen receptor alpha (ER alpha), induces rapid anticipatory activation of the UPR, resulting in increased production of the antiapoptotic chaperone BiP/GRP78, preparing cancer cells for the increased protein production required for subsequent estrogen-ER alpha-induced cell proliferation. In ER alpha-containing cancer cells, the estrogen, 17 beta-estradiol (E-2) activates the UPR through a phospholipase C gamma (PLC gamma)-mediated opening of EnR IP3R calcium channels, enabling passage of calcium from the lumen of the EnR into the cytosol. siRNA knockdown of ER alpha blocked the estrogen-mediated increase in cytosol calcium and UPR activation. Knockdown or inhibition of PLC gamma, or of IP3R, strongly inhibited the estrogen-mediated increases in cytosol calcium, UPR activation and cell proliferation. E-2-ER alpha activates all three arms of the UPR in breast and ovarian cancer cells in culture and in a mouse xenograft. Knockdown of ATF6 alpha, which regulates UPR chaperones, blocked estrogen induction of BiP and strongly inhibited E-2-ER alpha-stimulated cell proliferation. Mild and transient UPR activation by estrogen promotes an adaptive UPR response that protects cells against subsequent UPR-mediated apoptosis. Analysis of data from ER alpha(+) breast cancers demonstrates elevated expression of a UPR gene signature that is a powerful new prognostic marker tightly correlated with subsequent resistance to tamoxifen therapy, reduced time to recurrence and poor survival. Thus, as an early component of the E-2-ER alpha proliferation program, the mitogen estrogen, drives rapid anticipatory activation of the UPR. Anticipatory activation of the UPR is a new role for estrogens in cancer cell proliferation and resistance to therapy.	[Andruska, N.; Zheng, X.; Shapiro, D. J.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; [Andruska, N.; Helferich, W. G.; Shapiro, D. J.] Univ Illinois, Coll Med, Urbana, IL 61801 USA; [Yang, X.; Helferich, W. G.] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; [Helferich, W. G.; Shapiro, D. J.] Univ Illinois, Ctr Canc, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 419 Roger Adams Lab,600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@illinois.edu	Zheng, Xiaobin/F-8994-2018		NIH [RO1DK 071909]; Westcott predoctoral fellowship; Carter predoctoral fellowship; National Center for Complementary & Integrative Health [P50AT006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071909] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Westcott predoctoral fellowship; Carter predoctoral fellowship; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Mr J Hartman for assistance with xenografts, and Dr S Kaufmann and Dr K Korach for cell lines. This work was supported by NIH RO1DK 071909 (to DS) and Westcott and Carter predoctoral fellowships (to NA). Analyses were performed using BRB-ArrayTools, developed by Dr Richard Simon and BRB-ArrayTools Development Team at the National Cancer Institute.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Andruska N, 2012, J BIOMOL SCREEN, V17, P921, DOI 10.1177/1087057112442960; Ariazi EA, 2011, P NATL ACAD SCI USA, V108, P18879, DOI 10.1073/pnas.1115188108; Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cherian MT, 2012, J BIOL CHEM, V287, P23368, DOI 10.1074/jbc.M112.344671; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Divekar SD, 2011, CANCER RES, V71, P1658, DOI 10.1158/0008-5472.CAN-10-1899; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Dong SY, 2010, MOL CELL BIOCHEM, V341, P195, DOI 10.1007/s11010-010-0450-5; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Graham K, 2010, BRIT J CANCER, V102, P1284, DOI 10.1038/sj.bjc.6605576; Hu CCA, 2009, EMBO J, V28, P1624, DOI 10.1038/emboj.2009.117; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Ju YH, 2002, CANCER RES, V62, P2474; Kretzer NM, 2010, J BIOL CHEM, V285, P41863, DOI 10.1074/jbc.M110.183723; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rutkowski DT, 2007, TRENDS BIOCHEM SCI, V32, P469, DOI 10.1016/j.tibs.2007.09.003; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665; Spiller DG, 2010, NATURE, V465, P736, DOI 10.1038/nature09232; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Teske BF, 2011, MOL BIOL CELL, V22, P4390, DOI 10.1091/mbc.E11-06-0510; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Yue W, 2013, STEROIDS, V78, P161, DOI 10.1016/j.steroids.2012.11.001	42	78	79	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3760	3769		10.1038/onc.2014.292	http://dx.doi.org/10.1038/onc.2014.292			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263449	Green Accepted			2022-12-28	WOS:000358001600002
J	Caruso, JA; Akli, S; Pageon, L; Hunt, KK; Keyomarsi, K				Caruso, J. A.; Akli, S.; Pageon, L.; Hunt, K. K.; Keyomarsi, K.			The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN BREAST-TUMORS; LEUKOCYTE ELASTASE; TRANSGENIC MICE; CATHEPSIN-G; CANCER; PROLIFERATION; EXPRESSION; LUNG; DIFFERENTIATION	The serine protease inhibitor, elafin, is a critical component of the epithelial barrier against neutrophil elastase (NE). Elafin is downregulated in the majority of breast cancer cell lines compared with normal human mammary epithelial cells (HMECs). Here, we evaluated the role of elafin and NE on proliferation and tumorigenesis. Elafin is induced in growth factor-deprived HMECs as they enter a quiescent (G0) state, suggesting that elafin is a counterbalance against the mitogenic effects of NE in G0 HMECs. Stable knockdown of elafin compromises the ability of HMECs to maintain G0 arrest during long-term growth factor deprivation; this effect can be reversed by re-expression of wild-type elafin but not elafin-M25G lacking protease inhibitory function. These results suggest that NE, which is largely contributed by activated neutrophils in the tumor microenvironment, may be negatively regulating the ability of elafin to arrest cells in G0. In fact when purified NE was added to elafin-knocked down HMECs, these cells demonstrated greater sensitivity to the growth-promoting effects of purified NE. Activation of ERK signaling, downstream of toll-like receptor 4, was essential to the mitogenic effect of NE on HMECs. These findings were next translated to patient samples. Immunohistochemical analysis of normal breast tissue revealed robust elafin expression in the mammary epithelium; however, elafin expression was dramatically downregulated in a significant proportion of human breast tumor specimens. The loss of elafin expression during breast cancer progression may promote tumor growth as a consequence of increased NE activity. To address the role of NE in mammary tumorigenesis, we next examined whether deregulated NE activity enhances mammary tumor growth. NE knockout in the C3(1) TAg mouse model of mammary tumorigenesis suppressed proliferation and reduced the kinetics of tumor growth. Overall, the imbalance between NE and its inhibitors, such as elafin, presents an important therapeutic target in breast cancer.	[Caruso, J. A.; Akli, S.; Hunt, K. K.; Keyomarsi, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Caruso, J. A.; Keyomarsi, K.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Pageon, L.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016; Poubelle, Patrice E/G-6537-2013	Keyomarsi, Khandan/0000-0002-5440-0849; 	National Institutes of Health through MD Anderson's Cancer Center Support Grant [CA016672];  [5R01CA087548-10];  [5R01CA15228]; NATIONAL CANCER INSTITUTE [R01CA087548, P30CA016672, R01CA152228] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER	National Institutes of Health through MD Anderson's Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Dr Elizabeth Mittendorf discussions during the course of this study; Dr Vimla Band for HMECs; Dr Eric Campeau and Dr Didier Trono for making plasmids available through the Addgene repository; Wendy Schober and Dr Jared Burks for assistance with flow cytometry and cellular imaging; and Stephanie Deming for editorial assistance with the manuscript. This work was supported by the National Institutes of Health through MD Anderson's Cancer Center Support Grant, CA016672 and grant 5R01CA087548-10 (to KK) 5R01CA15228.	Akli S, 2011, CANCER RES, V71, P3377, DOI 10.1158/0008-5472.CAN-10-4086; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Caruso JA, 2010, CANCER RES, V70, P7125, DOI 10.1158/0008-5472.CAN-10-1547; Cole KA, 2004, AM J PHYSIOL-CELL PH, V286, pC349, DOI 10.1152/ajpcell.00255.2003; Devaney JM, 2003, FEBS LETT, V544, P129, DOI 10.1016/S0014-5793(03)00482-4; DiCamillo SJ, 2002, J BIOL CHEM, V277, P18938, DOI 10.1074/jbc.M200243200; Doucet A, 2007, BIOCHEM J, V405, P455, DOI 10.1042/BJ20070020; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Foekens JA, 2003, CANCER RES, V63, P337; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Huang CD, 2004, LIFE SCI, V74, P2479, DOI 10.1016/j.lfs.2003.07.059; Hunt KK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3374; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; Kerrin A, 2013, THORAX, V68, P315, DOI 10.1136/thoraxjnl-2012-202536; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Korkmaz B, 2010, PHARMACOL REV, V62, P726, DOI 10.1124/pr.110.002733; MAINARDI CL, 1980, J BIOL CHEM, V255, P5435; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Mittendorf EA, 2012, CANCER RES, V72, P3153, DOI 10.1158/0008-5472.CAN-11-4135; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; Motta JP, 2012, SCI TRANSL MED, V4; Ohta K, 2004, AM J PHYSIOL-HEART C, V287, pH286, DOI 10.1152/ajpheart.00479.2002; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Ramachandran R, 2011, J BIOL CHEM, V286, P24638, DOI 10.1074/jbc.M110.201988; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Rogalski C, 2002, J INVEST DERMATOL, V118, P49, DOI 10.1046/j.0022-202x.2001.01650.x; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Simpson AJ, 2001, J IMMUNOL, V167, P1778, DOI 10.4049/jimmunol.167.3.1778; Vandermeeren M, 2001, ARCH DERMATOL RES, V293, P343, DOI 10.1007/s004030100238; Wang ZX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004380; Westin U, 2002, MEDIAT INFLAMM, V11, P7, DOI 10.1080/09629350210304; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; Yamamoto S, 1997, BRIT J CANCER, V76, P1081, DOI 10.1038/bjc.1997.511; Yang HA, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-92; Yang XC, 2010, INT J DERMATOL, V49, P1068, DOI 10.1111/j.1365-4632.2010.04500.x; Yokota T, 2007, CANCER RES, V67, P11272, DOI 10.1158/0008-5472.CAN-07-2322; Yu KS, 2011, BIOCHEM BIOPH RES CO, V408, P160, DOI 10.1016/j.bbrc.2011.04.001; Zaidi SHE, 1999, J CLIN INVEST, V103, P1211, DOI 10.1172/JCI5099; Zaidi SHE, 2002, CIRCULATION, V105, P516, DOI 10.1161/hc0402.102866; ZHANG M, 1995, CANCER RES, V55, P2537; Zwang YR, 2011, MOL CELL, V42, P524, DOI 10.1016/j.molcel.2011.04.017	46	26	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3556	3567		10.1038/onc.2014.284	http://dx.doi.org/10.1038/onc.2014.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195861	Green Accepted			2022-12-28	WOS:000357434900008
J	Chen, Y; Zhang, Z; Yang, K; Du, J; Xu, Y; Liu, S				Chen, Y.; Zhang, Z.; Yang, K.; Du, J.; Xu, Y.; Liu, S.			Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress	ONCOGENE			English	Article							MICRORNA EXPRESSION; FPN1 TRANSCRIPTION; C-MYB; CANCER; GENE; BINDING; RISK; AP4; OVEREXPRESSION; METASTASIS	Although previous studies suggest that myeloid zinc-finger 1 (MZF-1) is a multifaceted transcription factor that may function as either an oncogene or a tumor suppressor, the molecular bases determining its different traits remain elusive. Increasing evidence suggests that disorders in iron metabolism affect tumorigenesis and tumor behaviors, and that excess tumor iron stimulates tumor progression through various mechanisms such as enhancing DNA replication and energy metabolism. Ferroportin (FPN) is the only known iron exporter in mammalian cells, and it determines global iron egress out of cells. FPN reduction leads to decreased iron efflux and increased intracellular iron that consequentially aggravates the oncogenic effects of iron. MZF-1 was recently identified as a transcription factor that regulates FPN expression. Thus far, however, the molecular mechanisms underlying the MZF-1-FPN signaling in cancers are largely unknown. Here, we found a significant reduction of FPN levels in prostate tumors relative to adjacent tissues, and demonstrated a crucial role of FPN in tumor growth through controlling tumor iron concentration. Inhibition of MZF-1 expression led to reduced FPN concentration, coupled with resultant intracellular iron retention, increased iron-related cellular activities and enhanced tumor cell growth. In contrast, increase of MZF-1 expression restrained tumor cell growth by promoting FPN-driven iron egress. Importantly, we demonstrated that AP4 and c-Myb jointly modulated MZF-1 transcription, and that miR-492 was also directly involved in regulating MZF-1 concentration through binding to the 3' untranslated regions of its mRNA. These results correlate with reduced AP4 and c-Myb expression and elevated miR-492 expression found in prostate tumors as compared with adjacent tissues that resulted in diminished MZF-1 and FPN. Moreover, we demonstrated that alterations of AP4, c-Myb and miR-492 levels significantly affected tumor cell growth. Targeting molecules within the MZF-1-FPN signaling thus appears to be a promising approach to restrain prostate cancer.	[Chen, Y.; Zhang, Z.; Yang, K.; Xu, Y.] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China; [Chen, Y.; Liu, S.] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing, Peoples R China; [Du, J.] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China	Tianjin Medical University; Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Tsinghua University	Xu, Y (corresponding author), Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China.	xuyong8816@sina.com; sjliu@rcees.ac.cn		Du, Jin/0000-0002-8224-250X	national '973' program [2014CB932000]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB14000000]; National Natural Science Foundation of China [21377159, 81172451-H1620]; Tianjin Research Program of Application Foundation and Advanced Technology [12JCYBJC31400]	national '973' program(National Basic Research Program of China); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Research Program of Application Foundation and Advanced Technology	This work was supported by a grant under the national '973' program (Grant Number: 2014CB932000), the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB14000000) and grants from the National Natural Science Foundation of China (Grant Numbers: 21377159 and 81172451-H1620) and Tianjin Research Program of Application Foundation and Advanced Technology (Grant Number: 12JCYBJC31400). We thank all the laboratory members for their great assistance with experiments and reagents.	Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Brzoska K, 2006, ACTA BIOCHIM POL, V53, P685; Buschemeyer WC, 2007, EUR UROL, V52, P331, DOI 10.1016/j.eururo.2007.04.069; Choi JY, 2008, CARCINOGENESIS, V29, P964, DOI 10.1093/carcin/bgn056; Clapp Richard W., 2008, Reviews on Environmental Health, V23, P1; Cross AJ, 2011, CANCER PREV RES, V4, P1465, DOI 10.1158/1940-6207.CAPR-11-0103; Deng Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/868131; Donnianni RA, 2013, P NATL ACAD SCI USA, V110, P13475, DOI 10.1073/pnas.1309800110; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003; Egawa T, 2011, P NATL ACAD SCI USA, V108, P14873, DOI 10.1073/pnas.1112293108; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Gaedcke J, 2012, CLIN CANCER RES, V18, P4919, DOI 10.1158/1078-0432.CCR-12-0016; Greig KT, 2010, BLOOD, V115, P2796, DOI 10.1182/blood-2009-08-239210; Heath JL, 2013, NUTRIENTS, V5, P2836, DOI 10.3390/nu5082836; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hromas R, 1996, LEUKEMIA, V10, P1049; Hsieh YH, 2006, BIOCHEM BIOPH RES CO, V339, P217, DOI 10.1016/j.bbrc.2005.11.015; Huang X, 2008, LANCET ONCOL, V9, P803, DOI 10.1016/S1470-2045(08)70200-6; Hugo H, 2006, GENE CHROMOSOME CANC, V45, P1143, DOI 10.1002/gcc.20378; Jackstadt R, 2013, J EXP MED, V210, P1331, DOI 10.1084/jem.20120812; Jung P, 2009, CELL CYCLE, V8, P982, DOI 10.4161/cc.8.7.7949; Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105; KNEKT P, 1994, INT J CANCER, V56, P379, DOI 10.1002/ijc.2910560315; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lutwyche JK, 2006, BIOCHEM BIOPH RES CO, V344, P1300, DOI 10.1016/j.bbrc.2006.04.045; Marro S, 2010, HAEMATOL-HEMATOL J, V95, P1261, DOI 10.3324/haematol.2009.020123; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Ornstein DL, 2007, NUTR CANCER, V58, P115, DOI 10.1080/01635580701308265; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Richardson DR, 2009, BBA-GEN SUBJECTS, V1790, P702, DOI 10.1016/j.bbagen.2008.04.003; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Schultz NA, 2012, MODERN PATHOL, V25, P1609, DOI 10.1038/modpathol.2012.122; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; Taylor M, 2011, GASTROENTEROLOGY, V140, P2044, DOI 10.1053/j.gastro.2011.03.007; Thorner AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013073; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Troadec MB, 2010, BLOOD, V116, P4657, DOI 10.1182/blood-2010-04-278614; Tsai SJ, 2012, BIOCHEM BIOPH RES CO, V425, P462, DOI 10.1016/j.bbrc.2012.07.125; von Frowein J, 2011, HEPATOLOGY, V53, P833, DOI 10.1002/hep.24125; Ward DM, 2012, BBA-MOL CELL RES, V1823, P1426, DOI 10.1016/j.bbamcr.2012.03.004; Wu YL, 2012, NUCLEIC ACIDS RES, V40, P4247, DOI 10.1093/nar/gks039; Yuan YN, 2011, J NUTRIGENET NUTRIGE, V4, P121, DOI 10.1159/000327902; Zhang SP, 2014, CELL SIGNAL, V26, P2539, DOI 10.1016/j.cellsig.2014.07.029	53	44	48	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3839	3847		10.1038/onc.2014.310	http://dx.doi.org/10.1038/onc.2014.310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25284586				2022-12-28	WOS:000358001600009
J	Cui, H; Seubert, B; Stahl, E; Dietz, H; Reuning, U; Moreno-Leon, L; Ilie, M; Hofman, P; Nagase, H; Mari, B; Kruger, A				Cui, H.; Seubert, B.; Stahl, E.; Dietz, H.; Reuning, U.; Moreno-Leon, L.; Ilie, M.; Hofman, P.; Nagase, H.; Mari, B.; Krueger, A.			Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes	ONCOGENE			English	Article							BREAST EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; LIVER METASTASIS; GENE-EXPRESSION; TUMOR-CELLS; HYPOXIA; MICRORNA-210; TIMP-1; CARCINOMA; PROTEINS	Tissue inhibitor of metalloproteinases-1 (TIMP-1) recently emerged as a pro-metastatic factor highly associated with poor prognosis in a number of cancers. This correlation seemed paradox as TIMP-1 is best described as an inhibitor of pro-tumourigenic matrix metalloproteinases. Only recently, TIMP-1 has been revealed as a signalling molecule that can regulate cancer progression independent of its inhibitory properties. In the present study, we demonstrate that an increase of both exogenous and endogenous TIMP-1 led to the upregulation of miR-210 in a CD63/PI3K/AKT/HIF-1-dependent pathway in lung adenocarcinoma cells. TIMP-1 induced P110/P85 PI3K-signalling and AKT phosphorylation. It also led to increase of HIF-1 alpha protein levels positively correlating with HIF-1-regulated mRNA expression and upregulation of the microRNA miR-210. Downstream targets of miR-210, namely FGFRL1, E2F3, VMP-1, RAD52 and SDHD, were decreased in the presence of TIMP-1. Upon the overexpression of TIMP-1 in tumour cells, miR-210 was accumulated in exosomes in vitro and in vivo. These exosomes promoted tube formation activity in human umbilical vein endothelial cell (HUVECs), which was reflected in increased angiogenesis in A549L-derived tumour xenografts. Activation and elevation of PI3K, AKT, HIF-1A and miR-210 in tumours additionally confirmed our in vitro data. This new pro-tumourigenic signalling function of TIMP-1 may explain why elevated TIMP-1 levels in lung cancer patients are highly correlated with poor prognosis.	[Cui, H.; Seubert, B.; Krueger, A.] Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, Ismaninger Str 22, D-80290 Munich, Germany; [Stahl, E.; Dietz, H.] Tech Univ Munich, Walter Schottky Inst, Dept Phys, D-80290 Munich, Germany; [Reuning, U.] Tech Univ Munich, Klinikum Rechts Isar, Klin Forsch Grp Frauenklin, D-80290 Munich, Germany; [Moreno-Leon, L.; Ilie, M.; Hofman, P.; Mari, B.] Univ Nice Sophia Antipolis, F-06189 Nice, France; [Moreno-Leon, L.; Mari, B.] UNSA, CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, Sophia Antipolis, France; [Ilie, M.; Hofman, P.] Ctr Hosp Univ Nice, Lab Clin & Expt Pathol, Nice, France; [Ilie, M.; Hofman, P.] Ctr Hosp Univ Nice, Hosp Integrated Biobank, Nice, France; [Nagase, H.] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Muscolosketal, London, England	Technical University of Munich; Technical University of Munich; University of Munich; Technical University of Munich; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; University of Oxford	Kruger, A (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, Ismaninger Str 22, D-80290 Munich, Germany.	achim.krueger@lrz.tu-muenchen.de	Mari, Bernard/Q-5832-2019; Hofman, Paul/P-7654-2018; Moreno Leon, Laura/AGP-7137-2022	Mari, Bernard/0000-0002-0422-9182; Hofman, Paul/0000-0003-0431-9353; Moreno Leon, Laura/0000-0002-5560-1765; Ilie, Marius/0000-0002-2014-1236; Cui, Haissi/0000-0003-3358-8958	Deutsche Forschungsgesellschaft [KR2047/1-2, KR2047/3-1]	Deutsche Forschungsgesellschaft(German Research Foundation (DFG))	We thank Katja Honert for expert technical assistance in cell culture experiments and Susanne Schaten for immunohistochemical advice. We are grateful to Carolin Wander for cloning pRRL.PPT.SF.CD63-mCherry and Dominik Alterauge for cloning pRRL.PPT.SF.N-TIMP-1 and pRRL.PPT.SF.TIMP-1_T2G. We thank Georg Sedlmeier for help with experiments regarding the TIMP-1 variants. Financial support came from the Deutsche Forschungsgesellschaft KR2047/1-2 and KR2047/3-1 to AK.	Alaiti MA, 2012, J CELL MOL MED, V16, P2413, DOI 10.1111/j.1582-4934.2012.01557.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600-0854.2011.01225.x; Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003; Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chan YC, 2012, MICROCIRCULATION, V19, P215, DOI 10.1111/j.1549-8719.2011.00154.x; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Cruz-Munoz W, 2008, CRIT REV CL LAB SCI, V45, P291, DOI 10.1080/10408360801973244 ; Cui H, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00134; De Lorenzo MS, 2003, IN VIVO, V17, P45; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Giannakakis A, 2008, CANCER BIOL THER, V7, P255, DOI 10.4161/cbt.7.2.5297; Gouyer V, 2005, CANCER-AM CANCER SOC, V103, P1676, DOI 10.1002/cncr.20965; Grosso S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.71; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauser S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018989; Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Ilie MI, 2013, VIRCHOWS ARCH, V463, P437, DOI 10.1007/s00428-013-1453-x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281; Jung YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038773; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kelly TJ, 2011, MOL CELL BIOL, V31, P2696, DOI 10.1128/MCB.01242-10; Kim HW, 2009, J BIOL CHEM, V284, P33161, DOI 10.1074/jbc.M109.020925; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; Kruger A, 2010, BBA-MOL CELL RES, V1803, P95, DOI 10.1016/j.bbamcr.2009.09.016; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lasser C, 2012, JOVE-J VIS EXP, DOI 10.3791/3037; Li GY, 1999, CANCER RES, V59, P6267; Liu H, 2008, ANGIOGENESIS, V11, P223, DOI 10.1007/s10456-008-9102-8; Liu XW, 2005, CANCER RES, V65, P898; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Lu Y, 2011, MOL CELLS, V31, P225, DOI 10.1007/s10059-011-0023-9; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Murphy G, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-233; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nagase H, 2002, ARTHRITIS RES THER, V4, pS51, DOI 10.1186/ar573; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Pesta M, 2011, ANTICANCER RES, V31, P4031; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006; Rauvala M, 2005, GYNECOL ONCOL, V99, P656, DOI 10.1016/j.ygyno.2005.07.009; Ries C, 2014, CELL MOL LIFE SCI, V71, P659, DOI 10.1007/s00018-013-1457-3; Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068451; Schambach A, 2006, GENE THER, V13, P1524, DOI 10.1038/sj.gt.3302807; Schelter F, 2011, CLIN EXP METASTAS, V28, P91, DOI 10.1007/s10585-010-9360-x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shimoda M, 2013, PROTEOMICS, V13, P1624, DOI 10.1002/pmic.201200458; Stetler-Stevenson WG, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127re6; Taube ME, 2006, ONCOGENE, V25, P3041, DOI 10.1038/sj.onc.1209336; Tsuchiya S, 2011, J BIOL CHEM, V286, P420, DOI 10.1074/jbc.M110.170852; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang CS, 2006, ANN CLIN LAB SCI, V36, P23; Wang HP, 2014, NAT IMMUNOL, V15, P393, DOI 10.1038/ni.2846; Wilczynski J, 2011, ARCH IMMUNOL THER EX, V59, P301, DOI 10.1007/s00005-011-0132-3; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Ying Q, 2011, HEPATOLOGY, V54, P2064, DOI 10.1002/hep.24614; Ylisirnio S, 2001, CLIN CANCER RES, V7, P1633; Ylisirnio S, 2000, ANTICANCER RES, V20, P1311; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Zhang Z, 2009, CELL CYCLE, V8, P2756, DOI 10.4161/cc.8.17.9387	76	129	136	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3640	3650		10.1038/onc.2014.300	http://dx.doi.org/10.1038/onc.2014.300			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25263437				2022-12-28	WOS:000357679100003
J	Redmond, AM; Byrne, C; Bane, FT; Brown, GD; Tibbitts, P; O'Brien, K; Hill, ADK; Carroll, JS; Young, LS				Redmond, A. M.; Byrne, C.; Bane, F. T.; Brown, G. D.; Tibbitts, P.; O'Brien, K.; Hill, A. D. K.; Carroll, J. S.; Young, L. S.			Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells	ONCOGENE			English	Article							RECEPTOR COACTIVATOR SRC-1; ESTROGEN-RECEPTOR; DNA-BINDING; TAMOXIFEN RESISTANCE; HORMONE-RECEPTORS; FOXA1 EXPRESSION; IN-VITRO; PROTEINS; TRANSCRIPTION; PROGRESSION	Breast cancer resistance to endocrine therapies such as tamoxifen and aromatase inhibitors is a significant clinical problem. Steroid receptor coactivator-1 (SRC-1), a coregulatory protein of the oestrogen receptor (ER), has previously been shown to have a significant role in the progression of breast cancer. The chromatin protein high mobility group box 2 (HMGB2) was identified as an SRC-1 interacting protein in the endocrine-resistant setting. We investigated the expression of HMGB2 in a cohort of 1068 breast cancer patients and found an association with increased disease-free survival time in patients treated with endocrine therapy. However, it was also verified that HMGB2 expression could be switched on in endocrine-resistant tumours from breast cancer patients. To explore the function of this poorly characterized protein, we performed HMGB2 ChIPseq and found distinct binding patterns between the two contexts. In the resistant setting, the HMGB2, SRC-1 and ER complex are enriched at promoter regions of target genes, with bioinformatic analysis indicating a switch in binding partners between the sensitive and resistant phenotypes. Integration of binding and gene expression data reveals a concise set of target genes of this complex including the RNA helicase DDX18. Modulation of DDX18 directly affects growth of tamoxifen-resistant cells, suggesting that it may be a critical downstream effector of the HMGB2:ER complex. This study defines HMGB2 interactions with the ER complex at specific target genes in the tamoxifen-resistant setting.	[Redmond, A. M.; Byrne, C.; Bane, F. T.; Tibbitts, P.; O'Brien, K.; Hill, A. D. K.; Young, L. S.] Royal Coll Surgeons Ireland, Endocrine Oncol Res Grp, Dept Surg, Dublin 2, Ireland; [Redmond, A. M.; Brown, G. D.; Carroll, J. S.] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge CB2 0RE, England	Royal College of Surgeons - Ireland; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Carroll, JS (corresponding author), Univ Cambridge, Li Ka Shing Ctr, Cambridge Inst, Canc Res UK, Robinson Way, Cambridge CB2 0RE, England.	jason.carroll@cruk.cam.ac.uk; lyoung@rcsi.ie	Byrne, Christopher/D-2824-2016	Carroll, Jason/0000-0003-3643-0080; Young, Leonie/0000-0002-4904-0367	Irish Research Council for Science Engineering and Technology; Marie Curie Actions under FP7; Breast Cancer Ireland; Health Research Board; University of Cambridge; Cancer Research UK; Hutchison Whampoa Limited; European Molecular Biology Organisation; Cancer Research UK [20411] Funding Source: researchfish	Irish Research Council for Science Engineering and Technology(Irish Research Council for Science, Engineering and TechnologyCGIAR); Marie Curie Actions under FP7; Breast Cancer Ireland; Health Research Board; University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); Hutchison Whampoa Limited; European Molecular Biology Organisation; Cancer Research UK(Cancer Research UK)	We would like to acknowledge the support of Irish Research Council for Science Engineering and Technology co-funded by Marie Curie Actions under FP7, Breast Cancer Ireland, Health Research Board, The University of Cambridge, Cancer Research UK, Hutchison Whampoa Limited and European Molecular Biology Organisation. We thank the members of the genomics core facility and Stuart MacArthur, former member of the bioinformatics core facility at Cancer Research UK.	Al-Azawi D, 2008, ONCOGENE, V27, P3021, DOI 10.1038/sj.onc.1210964; Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Cairns JM, 2008, BIOINFORMATICS, V24, P2921, DOI 10.1093/bioinformatics/btn557; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; de Leeuw R, 2013, ONCOGENE, V32, P3543, DOI 10.1038/onc.2012.361; Dillon MF, 2008, ENDOCR-RELAT CANCER, V15, P745, DOI 10.1677/ERC-08-0009; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hisamatsu Y, 2012, ANN SURG ONCOL, V19, P1145, DOI 10.1245/s10434-011-2094-4; Jolma A, 2013, CELL, V152, P327, DOI 10.1016/j.cell.2012.12.009; Kharchenko PV, 2008, NAT BIOTECHNOL, V26, P1351, DOI 10.1038/nbt.1508; Laurent B, 2010, BLOOD, V115, P687, DOI 10.1182/blood-2009-06-230094; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li Q, ANN APPL STAT, V5, P1752; Limer JL, 2006, INT J CANCER, V119, P515, DOI 10.1002/ijc.21863; Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073; McCartan D, 2012, CANCER RES, V72, P220, DOI 10.1158/0008-5472.CAN-11-1976; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Melvin VS, 2004, J BIOL CHEM, V279, P14763, DOI 10.1074/jbc.M313335200; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; ONATE SA, 1995, SCIENCE, V270, P1354; Payne EM, 2011, BLOOD, V118, P903, DOI 10.1182/blood-2010-11-318022; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Redmond AM, 2009, CLIN CANCER RES, V15, P2098, DOI 10.1158/1078-0432.CCR-08-1649; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Shiota M, 2008, CANCER SCI, V99, P1950, DOI 10.1111/j.1349-7006.2008.00912.x; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Wang W, 2013, ONCOL LETT, V5, P884, DOI 10.3892/ol.2012.1091; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang ZH, 2011, NUCLEIC ACIDS RES, V39, pW391, DOI 10.1093/nar/gkr387	44	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3871	3880		10.1038/onc.2014.323	http://dx.doi.org/10.1038/onc.2014.323			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25284587				2022-12-28	WOS:000358001600012
J	Yang-Hartwich, Y; Soteras, MG; Lin, ZP; Holmberg, J; Sumi, N; Craveiro, V; Liang, M; Romanoff, E; Bingham, J; Garofalo, F; Alvero, A; Mor, G				Yang-Hartwich, Y.; Soteras, M. G.; Lin, Z. P.; Holmberg, J.; Sumi, N.; Craveiro, V.; Liang, M.; Romanoff, E.; Bingham, J.; Garofalo, F.; Alvero, A.; Mor, G.			p53 protein aggregation promotes platinum resistance in ovarian cancer	ONCOGENE			English	Article							MUTANT P53; WILD-TYPE; AMYLOID FORMATION; STABILIZES P53; BREAST-CANCER; MDM2; MECHANISMS; DISEASES; BINDING; CELLS	High-grade serous ovarian carcinoma (HGSOC), the most lethal gynecological cancer, often leads to chemoresistant diseases. The p53 protein is a key transcriptional factor regulating cellular homeostasis. A majority of HGSOCs have inactive p53 because of genetic mutations. However, genetic mutation is not the only cause of p53 inactivation. The aggregation of p53 protein has been discovered in different types of cancers and may be responsible for impairing the normal transcriptional activation and pro-apoptotic functions of p53. We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance. When these cancer stem cells differentiated into their chemosensitive progeny, they lost tumor-initiating capacity and p53 aggregates. In addition to the association of p53 aggregation and chemoresistance in HGSOC cells, we further demonstrated that the overexpression of a p53-positive regulator, p14ARF, inhibited MDM2-mediated p53 degradation and led to the imbalance of p53 turnover that promoted the formation of p53 aggregates. With in vitro and in vivo models, we demonstrated that the inhibition of p14ARF could suppress p53 aggregation and sensitize cancer cells to platinum treatment. Moreover, by two-dimensional gel electrophoresis and mass spectrometry we discovered that the aggregated p53 may function uniquely by interacting with proteins that are critical for cancer cell survival and tumor progression. Our findings help us understand the poor chemoresponse of a subset of HGSOC patients and suggest p53 aggregation as a new marker for chemoresistance. Our findings also suggest that inhibiting p53 aggregation can reactivate p53 pro-apoptotic function. Therefore, p53 aggregation is a potential therapeutic target for reversing chemoresistance. This is paramount for improving ovarian cancer patients' responses to chemotherapy, and thus increasing their survival rate.	[Yang-Hartwich, Y.; Soteras, M. G.; Holmberg, J.; Sumi, N.; Craveiro, V.; Liang, M.; Romanoff, E.; Bingham, J.; Garofalo, F.; Alvero, A.; Mor, G.] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA; [Lin, Z. P.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University; Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Reprod Sci, 333 Cedar St,LSOG 305A, New Haven, CT 06520 USA.	gil.mor@yale.edu		Holmberg, Jennie/0000-0002-1106-4718; Alvero, Ayesha/0000-0002-6593-3595	NIH [RO1CA118678, RO1CA127913]; Sands Family Foundation; Discovery to Cure Program; NATIONAL CANCER INSTITUTE [R01CA127913, R01CA118678] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sands Family Foundation; Discovery to Cure Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH Grants RO1CA118678 and RO1CA127913, Sands Family Foundation and Discovery to Cure Program. We thank Drs Alice Soragni and David Eisenberg of UCLA for their suggestion that aggregated p53 could act as a potential therapeutic target.	Aguzzi A, 2010, NAT REV DRUG DISCOV, V9, P237, DOI 10.1038/nrd3050; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Albor A, 1998, CANCER RES, V58, P2091; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Biancalana M, 2010, BBA-PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Craveiro V, 2013, CANCER MED-US, V2, P751, DOI 10.1002/cam4.115; Dieguez-Acuna F, 2010, INT J BIOCHEM CELL B, V42, P1651, DOI 10.1016/j.biocel.2009.12.001; Erica Golemis PDA, 2002, PROT PROT INT MOL CL; Forget KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069242; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Higashimoto Y, 2006, BIOCHEMISTRY-US, V45, P1608, DOI 10.1021/bi051192j; Houben R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022096; Ishimaru D, 2004, BIOPHYS J, V87, P2691, DOI 10.1529/biophysj.104.044685; Ishimaru D, 2003, BIOCHEMISTRY-US, V42, P9022, DOI 10.1021/bi034218k; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Kayed R, 2006, METHOD ENZYMOL, V413, P326, DOI 10.1016/S0076-6879(06)13017-7; Klump B, 2003, CLIN CANCER RES, V9, P1773; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; Lasagna-Reeves CA, 2013, BIOCHEM BIOPH RES CO, V430, P963, DOI 10.1016/j.bbrc.2012.11.130; Levy CB, 2011, INT J BIOCHEM CELL B, V43, P60, DOI 10.1016/j.biocel.2010.10.017; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Olzscha H, 2011, CELL, V144, P67, DOI 10.1016/j.cell.2010.11.050; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Rigacci S, 2008, BIOPHYS J, V94, P3635, DOI 10.1529/biophysj.107.122283; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Shih IM, 2009, FUTURE ONCOL, V5, P1641, DOI [10.2217/fon.09.126, 10.2217/FON.09.126]; Silva JL, 2014, TRENDS BIOCHEM SCI, V39, P260, DOI 10.1016/j.tibs.2014.04.001; Silva JL, 2013, BIOSCIENCE REP, V33, P593, DOI 10.1042/BSR20130065; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Szybka M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-278; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; TOMINAGA O, 1993, ONCOGENE, V8, P2653; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wilcken R, 2012, P NATL ACAD SCI USA, V109, P13584, DOI 10.1073/pnas.1211550109; Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575; Wong KK, 2013, GYNECOL ONCOL, V130, P565, DOI 10.1016/j.ygyno.2013.06.016; Wu Terence L., 2006, V328, P71; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057	56	94	98	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3605	3616		10.1038/onc.2014.296	http://dx.doi.org/10.1038/onc.2014.296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25263447				2022-12-28	WOS:000357434900012
J	Fernandez, S; Risolino, M; Mandia, N; Talotta, F; Soini, Y; Incoronato, M; Condorelli, G; Banfi, S; Verde, P				Fernandez, S.; Risolino, M.; Mandia, N.; Talotta, F.; Soini, Y.; Incoronato, M.; Condorelli, G.; Banfi, S.; Verde, P.			miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer	ONCOGENE			English	Article							MESSENGER-RNA; EXPRESSION; MICRORNA; MIR-222; MIRNA; OVEREXPRESSION; DEGRADATION; PROGRESSION; FAMILY; SKP2	MicroRNAs (miRNAs) control cell cycle progression by targeting the transcripts encoding for cyclins, CDKs and CDK inhibitors, such as p27(KIP1) (p27).p27 expression is controlled by multiple transcriptional and posttranscriptional mechanisms, including translational inhibition by miR-221/222 and posttranslational regulation by the SCFSKP2 complex. The oncosuppressor activity of miR-340 has been recently characterized in breast, colorectal and osteosarcoma tumor cells. However, the mechanisms underlying miR-340-induced cell growth arrest have not been elucidated. Here, we describe miR-340 as a novel tumor suppressor in non-small cell lung cancer (NSCLC). Starting from the observation that the growth-inhibitory and proapoptotic effects of miR-340 correlate with the accumulation of p27 in lung adenocarcinoma and glioblastoma cells, we have analyzed the functional relationship between miR-340 and p27 expression. miR-340 targets three key negative regulators of p27. The miR-340-mediated inhibition of both Pumilio family RNA-binding proteins (PUM1 and PUM2), required for the miR-221/222 interaction with the p27 3'-UTR, antagonizes the miRNA-dependent downregulation of p27. At the same time, miR-340 induces the stabilization of p27 by targeting SKP2, the key posttranslational regulator of p27. Therefore, miR-340 controls p27 at both translational and posttranslational levels. Accordingly, the inhibition of either PUM1 or SKP2 partially recapitulates the miR-340 effect on cell proliferation and apoptosis. In addition to the effect on tumor cell proliferation, miR-340 also inhibits intercellular adhesion and motility in lung cancer cells. These changes correlate with the miR-340-mediated inhibition of previously validated (MET and ROCK1) and potentially novel (RHOA and CDH1) miR-340 target transcripts. Finally, we show that in a small cohort of NSCLC patients (n = 23), representative of all four stages of lung cancer, miR-340 expression inversely correlates with clinical staging, thus suggesting that miR-340 downregulation contributes to the disease progression.	[Fernandez, S.; Risolino, M.; Mandia, N.; Talotta, F.; Verde, P.] CNR, Inst Genet & Biophys, I-80123 Naples, Italy; [Soini, Y.] Univ Eastern Finland, Canc Ctr Eastern Finland, Sch Med, Inst Clin Med Pathol & Forens Med, Kuopio, Finland; [Incoronato, M.] IRCCS SDN, Naples, Italy; [Condorelli, G.] Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, Naples, Italy; [Banfi, S.] Telethon Inst Genet & Med TIGEM, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Eastern Finland; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); University of Naples Federico II; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)	Verde, P (corresponding author), CNR, Inst Genet & Biophys, Via P Castellino 111, I-80123 Naples, Italy.	pasquale.verde@igb.cnr.it	Condorelli, Gerolama/AAC-3472-2022; Banfi, Sandro/K-3963-2018; Incoronato, Mariarosaria/AAA-7541-2021; Incoronato, Mariarosaria/K-8727-2016	Condorelli, Gerolama/0000-0003-0177-8829; Banfi, Sandro/0000-0002-6541-8833; Incoronato, Mariarosaria/0000-0001-7019-0581; Incoronato, Mariarosaria/0000-0001-7019-0581	AIRC (Associazione Italiana per la Ricerca sul Cancro) [10489]; AICR (Association for International Cancer Research, UK) [08-182]; MERIT Grant (MIUR) [RBNE08YFN3]; AIRC [14046]; Fondazione Berlucchi; Fondazione Telethon Funding Source: Custom	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AICR (Association for International Cancer Research, UK); MERIT Grant (MIUR); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Berlucchi; Fondazione Telethon(Fondazione Telethon)	We thank Reuven Agami, Judy Lieberman and Vladimir Spiegelman for expression vectors. We also thank the IGB FACS and Microscopy facilities. This work was supported by the AIRC (Associazione Italiana per la Ricerca sul Cancro) Grant-10489, AICR (Association for International Cancer Research, UK) Grant-08-182 and MERIT Grant-RBNE08YFN3 (MIUR) to Pasquale Verde. Gerolama Condorelli was supported by grants from AIRC (Grant-14046) and Fondazione Berlucchi.	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Cai HQ, 2014, INT J MOL SCI, V15, P560, DOI 10.3390/ijms15010560; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Das S, 2013, ONCOGENE, V32, P2927, DOI 10.1038/onc.2012.311; Dong H, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-163; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Galgano A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003164; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Gennarino VA, 2012, GENOME RES, V22, P1163, DOI 10.1101/gr.130435.111; Goswami S, 2010, J BIOL CHEM, V285, P20532, DOI 10.1074/jbc.M110.109298; Hashimoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062589; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Huang YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019718; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; le Sage C, 2007, CELL CYCLE, V6, P2742, DOI 10.4161/cc.6.22.4900; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lin PY, 2010, BRIT J CANCER, V103, P1144, DOI 10.1038/sj.bjc.6605901; Medina R, 2008, CANCER RES, V68, P2773, DOI 10.1158/0008-5472.CAN-07-6754; Miles WO, 2012, GENE DEV, V26, P356, DOI 10.1101/gad.182568.111; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nassirpour R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062170; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Sun Y, 2012, ONCOL REP, V28, P1346, DOI 10.3892/or.2012.1958; Takanami I, 2005, ONCOL REP, V13, P727; Talotta F, 2010, ONCOGENE, V29, P4732, DOI 10.1038/onc.2010.211; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Zhang C, 2010, INT J ONCOL, V37, P1; Zhou X, 2013, BIOCHEM BIOPH RES CO, V437, P653, DOI 10.1016/j.bbrc.2013.07.033	41	141	148	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3240	3250		10.1038/onc.2014.267	http://dx.doi.org/10.1038/onc.2014.267			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151966	Green Accepted			2022-12-28	WOS:000356592300003
J	Saqcena, M; Mukhopadhyay, S; Hosny, C; Alhamed, A; Chatterjee, A; Foster, DA				Saqcena, M.; Mukhopadhyay, S.; Hosny, C.; Alhamed, A.; Chatterjee, A.; Foster, D. A.			Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs	ONCOGENE			English	Article							PANCREATIC-CANCER; TRANSFORMED-CELLS; METABOLISM; GROWTH; MYC; P53; GLYCOLYSIS; ACTIVATION; HALLMARK; BIOLOGY	Cancer cells undergo a metabolic transformation that allows for increased anabolic demands, wherein glycolytic and tricarboxylic acid (TCA) cycle intermediates are shunted away for the synthesis of biological molecules required for cell growth and division. One of the key shunts is the exit of citrate from the mitochondria and the TCA cycle for the generation of cytosolic acetyl-coenzyme A that can be used for fatty acid and cholesterol biosynthesis. With the loss of mitochondrial citrate, cancer cells rely on the 'conditionally essential' amino acid glutamine (Q) as an anaplerotic carbon source for TCA cycle intermediates. Although Q deprivation causes G1 cell cycle arrest in non-transformed cells, its impact on the cancer cell cycle is not well characterized. We report here a correlation between bypass of the Q-dependent G1 checkpoint and cancer cells harboring K-Ras mutations. Instead of arresting in G1 in response to Q-deprivation, K-Ras-driven cancer cells arrest in either S-or G2/M-phase. Inhibition of K-Ras effector pathways was able to revert cells to G1 arrest upon Q deprivation. Blocking anaplerotic utilization of Q mimicked Q deprivation-causing S-and G2/M-phase arrest in K-Ras mutant cancer cells. Significantly, Q deprivation or suppression of anaplerotic Q utilization created synthetic lethality to the cell cycle phase-specific cytotoxic drugs, capecitabine and paclitaxel. These data suggest that disabling of the G1 Q checkpoint could represent a novel vulnerability of cancer cells harboring K-Ras and possibly other mutations that disable the Q-dependent checkpoint.	[Saqcena, M.; Mukhopadhyay, S.; Hosny, C.; Alhamed, A.; Chatterjee, A.; Foster, D. A.] CUNY, Hunter Coll, Dept Biol Sci, New York, NY 10065 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY, Hunter Coll, Dept Biol Sci, 695 Pk Ave,Room 927, New York, NY 10065 USA.	foster@genectr.hunter.cuny.edu	Mukhopadhyay, Suman/N-3556-2017; Saqcena, Mahesh/U-5973-2017; damiani, chiara/R-4256-2016	Mukhopadhyay, Suman/0000-0002-4658-1942; Saqcena, Mahesh/0000-0002-2210-3444; 	National Institute of Health [R01-CA046677]; National Center for Research Resources of the National Institute of Health [RP-03037]; Research Centers in Minority Institutions; NATIONAL CANCER INSTITUTE [R01CA179542, R01CA046677] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007599] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources of the National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Research Centers in Minority Institutions(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This study was supported by the National Institute of Health grant R01-CA046677 and a pilot project award from the Research Centers in Minority Institutions award RP-03037 from the National Center for Research Resources of the National Institute of Health.	Baker NM, 2013, NATURE, V497, P577, DOI 10.1038/nature12248; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOS JL, 1989, CANCER RES, V49, P4682; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DOTTO GP, 1985, NATURE, V318, P472; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Salloum D, 2014, MOL CANCER THER, V13, P733, DOI 10.1158/1535-7163.MCT-13-0762; Saqcena M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074157; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Thornburg JM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2154; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005; Wang XS, 2011, CANCER DISCOV, V1, P35, DOI 10.1158/2159-8274.CD-10-0022; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099	41	34	36	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2672	2680		10.1038/onc.2014.207	http://dx.doi.org/10.1038/onc.2014.207			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023699	Green Accepted			2022-12-28	WOS:000354541300013
J	El Ghamrasni, S; Cardoso, R; Halaby, MJ; Zeegers, D; Harding, S; Kumareswaran, R; Yavorska, T; Chami, N; Jurisicova, A; Sanchez, O; Hande, MP; Bristow, R; Hakem, R; Hakem, A				El Ghamrasni, S.; Cardoso, R.; Halaby, M. J.; Zeegers, D.; Harding, S.; Kumareswaran, R.; Yavorska, T.; Chami, N.; Jurisicova, A.; Sanchez, O.; Hande, M. P.; Bristow, R.; Hakem, R.; Hakem, A.			Cooperation of Blm and Mus81 in development, fertility, genomic integrity and cancer suppression	ONCOGENE			English	Article							DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; DOWN-REGULATION; RECQ HELICASES; S-PHASE; ENDONUCLEASE; REPLICATION; REPAIR; PROMOTE; MEIOSIS	BLM is a DNA helicase important for the restart of stalled replication forks and for homologous recombination (HR) repair. Mutations of BLM lead to Bloom Syndrome, a rare autosomal recessive disorder characterized by elevated levels of sister chromatid exchanges (SCEs), dwarfism, immunodeficiency, infertility and increased cancer predisposition. BLM physically interacts with MUS81, an endonuclease involved in the restart of stalled replication forks and HR repair. Herein we report that loss of Mus81 in Blm hypomorph mutant mice leads to infertility, and growth and developmental defects that are not observed in single mutants. Double mutant cells and mice were hypersensitive to Mitomycin C and gamma-irradiation (IR) compared with controls and their repair of DNA double-strand breaks (DSBs) mediated by HR pathway was significantly defective, whereas their non-homologous-end-joining repair was elevated compared with controls. We also demonstrate the importance of the loss of the nuclease activity of Mus81 in the defects observed in Mus81(-/-) and double mutant cells. Exacerbated IR-induced chromosomal aberration was observed in double mutant mice and despite their reduced SCE levels, these mutants showed increased tumorigenesis risks. Our data highlight the importance of Mus81 and Blm in DNA DSB repair pathways, fertility, development and cancer.	[El Ghamrasni, S.; Cardoso, R.; Halaby, M. J.; Harding, S.; Kumareswaran, R.; Bristow, R.; Hakem, R.; Hakem, A.] Univ Toronto, Univ Hlth Network, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; [El Ghamrasni, S.; Chami, N.] Univ SMBA, Fac Sci DHEM, Lab Biotechnol, Fes, Morocco; [Zeegers, D.; Hande, M. P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117548, Singapore; [Zeegers, D.; Hande, M. P.] Natl Univ Singapore, Tembusu Coll, Singapore 117548, Singapore; [Yavorska, T.; Jurisicova, A.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Obstet & Gynecol & Physiol, Toronto, ON M5G 2M9, Canada; [Sanchez, O.] Univ Ontario, Inst Technol, Dept Pathol, Oshawa, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Sidi Mohamed Ben Abdellah University of Fez; National University of Singapore; National University of Singapore; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Ontario Tech University	Hakem, R (corresponding author), Univ Toronto, Univ Hlth Network, Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave,10th Floor Room 622, Toronto, ON M5G 2M9, Canada.	rhakem@uhnres.utoronto.ca; ahakem@uhnres.utoronto.ca	Jurisicova, Andrea/E-4580-2013; Harding, Shane M/N-2377-2017; El Ghamrasni, Samah/AAA-1350-2022; Hande, M. Prakash/B-1645-2008	Harding, Shane M/0000-0002-5524-3566; El Ghamrasni, Samah/0000-0003-4346-1360; Hande, M. Prakash/0000-0002-4511-6256; Hakem, Razqallah/0000-0001-5948-7931; Bristow, Robert/0000-0002-8553-9544	Canadian Institute of Health Research	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	We thank G Brown, P McPherson, R Hill and A Koch for reviewing the manuscript and for their valuable comments and suggestions. This study was supported by the Canadian Institute of Health Research (R Hakem).	Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Bohgaki Toshiyuki, 2010, Genome Integr, V1, P15, DOI 10.1186/2041-9414-1-15; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Chester N, 2006, MOL CELL BIOL, V26, P6713, DOI 10.1128/MCB.00296-06; Chu WK, 2010, ONCOGENE, V29, P4705, DOI 10.1038/onc.2010.214; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; Ciccia A, 2008, ANNU REV BIOCHEM, V77, P259, DOI 10.1146/annurev.biochem.77.070306.102408; de los Santos T, 2003, GENETICS, V164, P81; de los Santos T, 2001, GENETICS, V159, P1511; De Muyt A, 2012, MOL CELL, V46, P43, DOI 10.1016/j.molcel.2012.02.020; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Dendouga N, 2005, MOL CELL BIOL, V25, P7569, DOI 10.1128/MCB.25.17.7569-7579.2005; El Ghamrasni S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001385; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; Higgins JD, 2008, PLANT J, V54, P152, DOI 10.1111/j.1365-313X.2008.03403.x; Hiyama T, 2006, NUCLEIC ACIDS RES, V34, P880, DOI 10.1093/nar/gkj495; Hoadley KA, 2012, P NATL ACAD SCI USA, V109, P4437, DOI 10.1073/pnas.1117279109; Holloway JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000186; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Klein HL, 2012, CELL, V149, P257, DOI 10.1016/j.cell.2012.03.020; LaRocque JR, 2010, MOL CELL BIOL, V30, P1887, DOI 10.1128/MCB.01553-09; Loizidou MA, BREAST CANC RES TREA, V121, P147; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Matulova P, 2009, J BIOL CHEM, V284, P7733, DOI 10.1074/jbc.M806192200; Mazina OM, 2008, P NATL ACAD SCI USA, V105, P18249, DOI 10.1073/pnas.0807016105; McPherson JP, 2004, SCIENCE, V304, P1822, DOI 10.1126/science.1094557; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Mullen JR, 2001, GENETICS, V157, P103; Munoz-Galvan S, 2012, MOL CELL BIOL, V32, P1592, DOI 10.1128/MCB.00111-12; Naim V, 2013, NAT CELL BIOL, V15, P1008, DOI 10.1038/ncb2793; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811; Oh SD, 2008, MOL CELL, V31, P324, DOI 10.1016/j.molcel.2008.07.006; Ouyang KJ, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000252; Pamidi A, 2007, CANCER RES, V67, P8527, DOI 10.1158/0008-5472.CAN-07-1161; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Shimura T, 2008, J MOL BIOL, V375, P1152, DOI 10.1016/j.jmb.2007.11.006; Singh DK, 2009, BIOGERONTOLOGY, V10, P235, DOI 10.1007/s10522-008-9205-z; Smith GR, 2003, GENETICS, V165, P2289; So S, 2004, J BIOL CHEM, V279, P55433, DOI 10.1074/jbc.M409827200; Szakal B, 2013, EMBO J, V32, P1155, DOI 10.1038/emboj.2013.67; Taylor ER, 2008, P NATL ACAD SCI USA, V105, P3757, DOI 10.1073/pnas.0710291105; Theunissen JWF, 2006, METHOD ENZYMOL, V409, P251, DOI 10.1016/S0076-6879(05)09015-4; Tripathi V, 2008, CARCINOGENESIS, V29, P52, DOI 10.1093/carcin/bgm238; Trowbridge K, 2007, GENETICS, V176, P1993, DOI 10.1534/genetics.106.070060; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wu F, 2008, CANCER-AM CANCER SOC, V112, P2002, DOI 10.1002/cncr.23396; Wu F, 2011, CANCER SCI, V102, P472, DOI 10.1111/j.1349-7006.2010.01790.x; Wu F, 2010, ANTICANCER RES, V30, P5011; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; Zakharyevich K, 2012, CELL, V149, P334, DOI 10.1016/j.cell.2012.03.023; Zhang R, 2005, CANCER RES, V65, P2526, DOI 10.1158/0008-5472.CAN-04-2421	56	12	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1780	1789		10.1038/onc.2014.121	http://dx.doi.org/10.1038/onc.2014.121			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858046				2022-12-28	WOS:000352158000005
J	Pugh, TJ; Yu, W; Yang, J; Field, AL; Ambrogio, L; Carter, SL; Cibulskis, K; Giannikopoulos, P; Kiezun, A; Kim, J; McKenna, A; Nickerson, E; Getz, G; Hoffher, S; Messinger, YH; Dehner, LP; Roberts, CWM; Rodriguez-Galindo, C; Williams, GM; Rossi, CT; Meyerson, M; Hill, DA				Pugh, T. J.; Yu, W.; Yang, J.; Field, A. L.; Ambrogio, L.; Carter, S. L.; Cibulskis, K.; Giannikopoulos, P.; Kiezun, A.; Kim, J.; McKenna, A.; Nickerson, E.; Getz, G.; Hoffher, S.; Messinger, Y. H.; Dehner, L. P.; Roberts, C. W. M.; Rodriguez-Galindo, C.; Williams, G. M.; Rossi, C. T.; Meyerson, M.; Hill, D. A.			Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences	ONCOGENE			English	Article							COPY-NUMBER ALTERATION; EMBRYONAL RHABDOMYOSARCOMA; MUTATIONS; CANCER; TUMORS	Pleuropulmonary blastoma is a rare childhood malignancy of lung mesenchymal cells that can remain dormant as epithelial cysts or progress to high-grade sarcoma. Predisposing germline loss-of-function DICER1 variants have been described. We sought to uncover additional contributors through whole exome sequencing of 15 tumor/normal pairs, followed by targeted resequencing, miRNA analysis and immunohistochemical analysis of additional tumors. In addition to frequent biallelic loss of TP53 and mutations of NRAS or BRAF in some cases, each case had compound disruption of DICER1: a germline (12 cases) or somatic (3 cases) loss-of-function variant plus a somatic missense mutation in the RNase IIIb domain. 5p-Derived microRNA (miRNA) transcripts retained abnormal precursor miRNA loop sequences normally removed by DICER1. This work both defines a genetic interaction landscape with DICER1 mutation and provides evidence for alteration in miRNA transcripts as a consequence of DICER1 disruption in cancer.	[Pugh, T. J.; Ambrogio, L.; Carter, S. L.; Cibulskis, K.; Giannikopoulos, P.; Kiezun, A.; Kim, J.; McKenna, A.; Nickerson, E.; Getz, G.; Meyerson, M.] Broad Inst MIT & Harvard, Cambridge, MA USA; [Pugh, T. J.; Roberts, C. W. M.; Rodriguez-Galindo, C.; Meyerson, M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA; [Pugh, T. J.; Roberts, C. W. M.; Rodriguez-Galindo, C.; Meyerson, M.] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Yu, W.; Yang, J.; Field, A. L.; Hoffher, S.; Rossi, C. T.; Hill, D. A.] George Washington Univ, Dept Integrat Syst Biol, Washington, DC USA; [Yu, W.; Yang, J.; Field, A. L.; Hoffher, S.; Hill, D. A.] Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; [Yu, W.; Yang, J.; Field, A. L.; Hoffher, S.; Hill, D. A.] Childrens Natl Med Ctr, Dept Pathol, Washington, DC 20010 USA; [Messinger, Y. H.; Williams, G. M.] Childrens Hosp, Minneapolis, MN USA; [Messinger, Y. H.; Williams, G. M.] Clin Minnesota, Minneapolis, MN USA; [Dehner, L. P.] Washington Univ, Med Ctr, Dept Pathol & Immunol, St Louis, MO USA; [Roberts, C. W. M.; Rodriguez-Galindo, C.] Boston Childrens Hosp, Boston, MA USA; [Roberts, C. W. M.; Rodriguez-Galindo, C.] Dana Farber Childrens Canc Ctr, Boston, MA USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; George Washington University; Children's National Health System; Children's National Health System; Children's Hospitals & Clinics of Minnesota; Washington University (WUSTL); Harvard University; Boston Children's Hospital	Meyerson, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Mailstop Dana 1540, Boston, MA 02215 USA.	matthew_meyerson@dfci.harvard.edu; dashill@childrensnational.org	Rodriguez-Galindo, Carlos/N-8071-2018; Cibulskis, Kristian/AAC-7380-2019; Pugh, Trevor/Y-2535-2019; Roberts, Charles/N-2541-2018	Pugh, Trevor/0000-0002-8073-5888; Roberts, Charles/0000-0003-1135-1896; Meyerson, Matthew/0000-0002-9133-8108; Cibulskis, Kristian/0000-0003-1343-1582; Kiezun, Adam/0000-0002-6634-1073	Carlos Slim Health Institute in Mexico; Canadian Institutes of Health Research Fellowship; National Cancer Institute [R01CA143167]; National Heart, Lung and Blood Institute [R01HL109265, R01HL111190]; NATIONAL CANCER INSTITUTE [R01CA143167] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL111190, R01HL109265] Funding Source: NIH RePORTER	Carlos Slim Health Institute in Mexico; Canadian Institutes of Health Research Fellowship(Canadian Institutes of Health Research (CIHR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Sequence data used for this analysis are available from dbGaP under accession phs000543. The work was conducted as part of the Slim Initiative for Genomic Medicine, a project funded by the Carlos Slim Health Institute in Mexico. We would like to acknowledge the technical expertise and data generation efforts of The Broad Institute Genomics Platform and Cancer Genome Analysis group. TJP was supported by a Canadian Institutes of Health Research Fellowship. DAH is supported by National Cancer Institute (R01CA143167), and National Heart, Lung and Blood Institute (R01HL109265 and R01HL111190). We thank the members of the Ogawa Laboratory for shared insights during reporting of genomic findings of PPB.<SUP>34</SUP>	Anglesio MS, 2013, J PATHOL, V229, P400, DOI 10.1002/path.4135; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cifuentes D, 2010, SCIENCE, V328, P1694, DOI 10.1126/science.1190809; Dehner LP, 2012, MODERN PATHOL, V25, P602, DOI 10.1038/modpathol.2011.185; Doros L, 2012, PEDIATR BLOOD CANCER, V59, P558, DOI 10.1002/pbc.24020; Doros LA, 2014, MODERN PATHOL, V27, P1267, DOI 10.1038/modpathol.2013.242; Eisenhardt AE, 2011, INT J CANCER, V129, P2297, DOI 10.1002/ijc.25893; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Foulkes WD, 2011, HUM MUTAT, V32, P1381, DOI 10.1002/humu.21600; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Frio TR, 2011, JAMA-J AM MED ASSOC, V305, P68, DOI 10.1001/jama.2010.1910; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Getz G, 2007, SCIENCE, V317, DOI 10.1126/science.1138764; Gurtan AM, 2012, RNA, V18, P1116, DOI 10.1261/rna.032680.112; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Hill DA, 2008, AM J SURG PATHOL, V32, P282, DOI 10.1097/PAS.0b013e3181484165; Hou P, 2007, CELL CYCLE, V6, P377, DOI 10.4161/cc.6.3.3818; Lawrence MS, 2013, NATURE; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Schultz KAP, 2011, GYNECOL ONCOL, V122, P246, DOI 10.1016/j.ygyno.2011.03.024; Seki M, 2014, CANCER RES, V74, P2742, DOI 10.1158/0008-5472.CAN-13-2470; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Slade I, 2011, J MED GENET, V48, P273, DOI 10.1136/jmg.2010.083790; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wei W, 2012, CELL, V149, P101, DOI 10.1016/j.cell.2012.03.002	34	92	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5295	5302		10.1038/onc.2014.150	http://dx.doi.org/10.1038/onc.2014.150			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24909177	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000345120400007
J	Shi, D; Dai, C; Qin, J; Gu, W				Shi, D.; Dai, C.; Qin, J.; Gu, W.			Negative regulation of the p300-p53 interplay by DDX24	ONCOGENE			English	Article							BOX RNA HELICASES; IN-VITRO; KAPPA-B; TRANSCRIPTIONAL REGULATION; P53 RESPONSE; ACETYLATION; CANCER; MUTATIONS; CELLS; ACTIVATION	Numerous studies indicate that p300 acts as a key transcriptional cofactor in vivo, at least, in part, by modulating activities of p53 by acetylation. Nevertheless, the regulation of the p53-p300 interplay is not completely understood. Here, we have identified the DEAD (Asp-Glu-Ala-Asp) box RNA helicase 24 (DDX24) as a novel regulator of the p300-p53 axis. We found that DDX24 interacts with p300, and this interaction leads to suppression of p300-mediated acetylation of p53. Notably, RNA interference-mediated knockdown of endogenous DDX24 significantly increases the acetylation levels of endogenous p53 in human cancer cells and subsequently promotes p53-mediated activation of its transcriptional targets such as p21 and p53 upregulated modulator of apoptosis (PUMA). In contrast, DDX24 expression inhibits the p300-p53 interaction and suppresses p300-mediated acetylation of p53. Moreover, DDX24 is overexpressed in human cancer cells and reduction of DDX24 protein levels by RNA interference induces cell cycle arrest and senescence in a p53-dependent manner. These results reveal DDX24 as an important regulator of p300 and suggest that the modulation of the p53-p300 interplay by DDX24 is critical in controlling p53 activities in human cancer cells.	[Shi, D.; Dai, C.; Gu, W.] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, Inst Canc Genet,Herbert Irving Comprehens Canc Ct, New York, NY USA; [Qin, J.] Baylor Coll Med, Dept Biochem, One Baylor Plaza, Houston, TX 77030 USA; [Qin, J.] Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA	Columbia University; Baylor College of Medicine; Baylor College of Medicine	Gu, W (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, ICRC BLDG 609A,1130 St Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu			National Cancer Institute of the National Institutes of Health [5RO1 CA172023, 5RO1 CA166294, 5RO1CA085533, 2P01CA080058]; NIH cancer biology training grant [T32-CA09503]; NATIONAL CANCER INSTITUTE [P01CA080058, R01CA169246, R01CA085533, R01CA166294, R01CA172023] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH cancer biology training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute of the National Institutes of Health under Award 5RO1 CA172023, 5RO1 CA166294, 5RO1CA085533 and 2P01CA080058 to WG. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D Shi is also supported by NIH cancer biology training grant T32-CA09503. We especially thank Dr Ruping Sun for his help with the analysis of TCGA database.	Abdelhaleem M, 2004, BBA-REV CANCER, V1704, P37, DOI 10.1016/j.bbcan.2004.05.001; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Charvet C, 2011, MOL CELL, V42, P584, DOI 10.1016/j.molcel.2011.03.033; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Cruciat CM, 2013, SCIENCE, V339, P1436, DOI 10.1126/science.1231499; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Delvecchio M, 2013, NAT STRUCT MOL BIOL, V20, P1040, DOI 10.1038/nsmb.2642; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fukawa T, 2012, CANCER RES, V72, P5867, DOI 10.1158/0008-5472.CAN-12-1645; Fuller-Pace FV, 2008, BIOCHEM SOC T, V36, P609, DOI 10.1042/BST0360609; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; Fuller-Pace FV, 2013, RNA BIOL, V10, P121, DOI 10.4161/rna.23312; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gustafson EA, 2010, BIOCHEM BIOPH RES CO, V395, P1, DOI 10.1016/j.bbrc.2010.02.172; Iyer NG, 2007, ONCOGENE, V26, P21, DOI 10.1038/sj.onc.1209771; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Johnson RF, 2012, TRENDS BIOCHEM SCI, V37, P317, DOI 10.1016/j.tibs.2012.04.002; Jung SY, 2005, MOL ENDOCRINOL, V19, P2451, DOI 10.1210/me.2004-0476; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Ma Z, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003721; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Payne EM, 2011, BLOOD, V118, P903, DOI 10.1182/blood-2010-11-318022; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199; Shi DD, 2009, P NATL ACAD SCI USA, V106, P16275, DOI 10.1073/pnas.0904305106; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Szerlong HJ, 2010, J BIOL CHEM, V285, P31954, DOI 10.1074/jbc.M110.148718; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomasova D, 2012, NEOPLASIA, V14, P1097, DOI 10.1593/neo.121534; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Yamauchi T, 2014, MOL CELL BIOL, V34, P3321, DOI 10.1128/MCB.00320-14; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhao Hong, 2013, Methods Mol Biol, V965, P83, DOI 10.1007/978-1-62703-239-1_5; Zhao Y, 2000, GENOMICS, V67, P351, DOI 10.1006/geno.2000.6255; Zhu YH, 2012, PROG MOL BIOL TRANSL, V106, P307, DOI 10.1016/B978-0-12-396456-4.00001-8	47	22	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					528	536		10.1038/onc.2015.77	http://dx.doi.org/10.1038/onc.2015.77			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867071	Green Accepted			2022-12-28	WOS:000369056700012
J	Fleisig, HB; Hukezalie, KR; Thompson, CAH; Au-Yeung, TTT; Ludlow, AT; Zhao, CR; Wong, JMY				Fleisig, H. B.; Hukezalie, K. R.; Thompson, C. A. H.; Au-Yeung, T. T. T.; Ludlow, A. T.; Zhao, C. R.; Wong, J. M. Y.			Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability	ONCOGENE			English	Article							CATALYTIC SUBUNIT; HTERT; LENGTH; MAINTENANCE; BIOGENESIS; VARIANT; APOPTOSIS; CHROMATIN; TARGET; CANCER	Reactivation of telomerase reverse transcriptase (TERT) expression is found in more than 85% of human cancers. The remaining cancers rely on the alternative lengthening of telomeres (ALT), a recombination-based mechanism for telomere-length maintenance. Prevalence of TERT reactivation over the ALT mechanism was linked to secondary TERT function unrelated to telomere length maintenance. To characterize this non-canonical function, we created a panel of ALT cells with recombinant expression of TERT and TERT variants: TERT-positive ALT cells showed higher tolerance to genotoxic insults compared with their TERT-negative counterparts. We identified telomere synthesis-defective TERT variants that bestowed similar genotoxic stress tolerance, indicating that telomere synthesis activity is dispensable for this survival phenotype. TERT expression improved the kinetics of double-strand chromosome break repair and reduced DNA damage-related nuclear division abnormalities, a phenotype associated with ALT tumors. Despite this reduction in cytological abnormalities, surviving TERT-positive ALT cells were found to have gross chromosomal instabilities. We sorted TERT-positive cells with cytogenetic changes and followed their growth. We found that the chromosome-number changes persisted, and TERT-positive ALT cells surviving genotoxic events propagated through subsequent generations with new chromosome numbers. Our data confirm that telomerase expression protects against doublestrand DNA (dsDNA)-damaging events, and show that this protective function is uncoupled from its role in telomere synthesis. TERT expression promotes oncogene-transformed cell growth by reducing the inhibitory effects of cell-intrinsic (telomere attrition) and cell-extrinsic (chemical-or metabolism-induced genotoxic stress) challenges. These data provide the impetus to develop new therapeutic interventions for telomerase-positive cancers through simultaneous targeting of multiple telomerase activities.	[Fleisig, H. B.; Hukezalie, K. R.; Thompson, C. A. H.; Au-Yeung, T. T. T.; Zhao, C. R.; Wong, J. M. Y.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada; [Ludlow, A. T.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA	University of British Columbia; University of Texas System; University of Texas Southwestern Medical Center Dallas	Wong, JMY (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	judy.wong@ubc.ca	Wong, Judy/AAG-1868-2021	Wong, Judy/0000-0001-5572-4143	Canadian Cancer Society Research Institute [019250]; Research Reinvestment Funds from the Faculty of Pharmaceutical Sciences at UBC; Michael Smith Foundation for Health Research Career Development program	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Research Reinvestment Funds from the Faculty of Pharmaceutical Sciences at UBC; Michael Smith Foundation for Health Research Career Development program	We thank members of Judy Wong's laboratory for providing helpful insights. Kathleen Collins and Bill Hahn kindly provided reagents. Shirley Yeung, Irene Iu and Arthur Chan assisted with method development. Nigel O'Neil assisted with optimization of the chromosomal healing assay. Andy Johnson from the UBC Flow-Cytometry Facility provided expertise with FACS procedures. We thank them for their assistance. Financial support for this work was provided by the Canadian Cancer Society Research Institute (operating grant #019250), and Research Reinvestment Funds from the Faculty of Pharmaceutical Sciences at UBC. JMYW is supported by the Michael Smith Foundation for Health Research Career Development program.	Armbruster BN, 2003, MOL CELL BIOL, V23, P3237, DOI 10.1128/MCB.23.9.3237-3246.2003; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryant Helen E, 2012, Methods Mol Biol, V920, P315, DOI 10.1007/978-1-61779-998-3_22; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Egan ED, 2012, RNA, V18, P1747, DOI 10.1261/rna.034629.112; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77; Fleisig HB, 2012, ONCOGENE, V31, P954, DOI 10.1038/onc.2011.292; Fleisig HB, 2007, EXP GERONTOL, V42, P102, DOI 10.1016/j.exger.2006.05.011; Fu D, 2007, MOL CELL, V28, P773, DOI 10.1016/j.molcel.2007.09.023; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Hukezalie KR, 2013, FEBS J, V280, P3194, DOI 10.1111/febs.12272; Lincz LF, 2008, NEOPLASIA, V10, P1131, DOI 10.1593/neo.08644; Listerman I, 2013, CANCER RES, V73, P2817, DOI 10.1158/0008-5472.CAN-12-3082; Lovejoy CA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002772; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Okamoto N, 2011, P NATL ACAD SCI USA, V108, P20388, DOI 10.1073/pnas.1015171108; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Poon SSS, 2001, METHOD CELL BIOL, V64, P69; Robin JD, 2014, GENE DEV, V28, P2464, DOI 10.1101/gad.251041.114; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Tamakawa RA, 2010, CANCER RES, V70, P8684, DOI 10.1158/0008-5472.CAN-10-2227; Ulaner GA, 1998, CANCER RES, V58, P4168; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3; Wright WE, 1996, DEV GENET, V18, P173; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113	30	23	23	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					218	227		10.1038/onc.2015.75	http://dx.doi.org/10.1038/onc.2015.75			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25893297				2022-12-28	WOS:000368193900008
J	Rodriguez-Perales, S; Torres-Ruiz, R; Suela, J; Acquadro, F; Martin, MC; Yebra, E; Ramirez, JC; Alvarez, S; Cigudosa, JC				Rodriguez-Perales, S.; Torres-Ruiz, R.; Suela, J.; Acquadro, F.; Martin, M. C.; Yebra, E.; Ramirez, J. C.; Alvarez, S.; Cigudosa, J. C.			Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; INCREASED FLT3 EXPRESSION; POINT MUTATIONS; MYELODYSPLASTIC SYNDROME; STEM-CELLS; TRANSCRIPTIONAL ACTIVATION; AML1/PEBP2-ALPHA-B GENE; ACQUIRED TRISOMY-21	We have identified a new t(1;21)(p32;q22) chromosomal translocation in a MDS/AML patient that results in expression of an aberrant C-terminally truncated RUNX1 protein lacking several regulatory domains. As similar truncated RUNX1 proteins are generated by genetic aberrations including chromosomal translocations and point mutations, we used the t(1;21)(p32;q22) chromosomal translocation as a model to explore whether C-terminally truncated RUNX1 proteins trigger effects similar to those induced by well-characterized leukemogenic RUNX1 fusion genes. In vitro analysis of transduced human hematopoietic/progenitor stem cells showed that truncated RUNX1 proteins increase proliferation and self-renewal and disrupt the differentiation program by interfering with RUNX1b. These effects are similar to but milder than those induced by the RUNX1/ETO fusion protein. GSEA analysis confirmed similar altered gene expression patterns in the truncated RUNX1 and RUNX1/ETO models, with both models showing alterations in genes involved in self-renewal and leukemogenesis, including homeobox genes, primitive erythroid genes and leukemogenic transcription factors. We propose that C-terminally truncated RUNX1 proteins can contribute to leukemogenesis in a similar way to RUNX1 fusion genes but through a milder phenotype.	[Rodriguez-Perales, S.; Suela, J.; Acquadro, F.; Martin, M. C.; Alvarez, S.; Cigudosa, J. C.] Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Mol Cytogenet Grp, Madrid 28029, Spain; [Torres-Ruiz, R.; Ramirez, J. C.] Fdn Ctr Nacl Invest Cardiovasc CNIC, Viral Vector Tech Unit, Madrid, Spain; [Yebra, E.] Hosp Severo Ochoa, Hematol Serv, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Severo Ochoa University Hospital	Rodriguez-Perales, S (corresponding author), Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Mol Cytogenet Grp, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	srodriguezp@cnio.es; jccigudosa@cnio.es	Cigudosa, Juan C/E-4105-2016; Ruiz, Raul Torres/J-1649-2018; Rodriguez-Perales, Sandra/T-7667-2017; SUELA, JAVIER/K-3968-2016	Ruiz, Raul Torres/0000-0001-9606-0398; Rodriguez-Perales, Sandra/0000-0001-7221-3636; 	INTRASALUD project [PI 12-00425]	INTRASALUD project	This work was supported by an INTRASALUD project PI 12-00425 to JCC. We thank all the coworkers in our laboratory for their excellent technical assistance.	Afonja O, 2000, LEUKEMIA RES, V24, P849, DOI 10.1016/S0145-2126(00)00059-X; Agerstam H, 2007, GENE CHROMOSOME CANC, V46, P635, DOI 10.1002/gcc.20442; Alvarez S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012197; Aoki T, 2008, INT J HEMATOL, V88, P571, DOI 10.1007/s12185-008-0198-9; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Chen CY, 2007, BRIT J HAEMATOL, V139, P405, DOI 10.1111/j.1365-2141.2007.06811.x; Cherry AM, 2001, CANCER GENET CYTOGEN, V129, P155, DOI 10.1016/S0165-4608(01)00439-3; Chinen Y, 2008, ONCOGENE, V27, P2249, DOI 10.1038/sj.onc.1210857; Christiansen DH, 2004, BLOOD, V104, P1474, DOI 10.1182/blood-2004-02-0754; De Braekeleer E, 2011, FUTURE ONCOL, V7, P77, DOI [10.2217/fon.10.158, 10.2217/FON.10.158]; Dicker F, 2007, BLOOD, V110, P1308, DOI 10.1182/blood-2007-02-072595; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Frank R, 1995, ONCOGENE, V11, P2667; Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; HAGEMEIJER A, 1984, Cancer Genetics and Cytogenetics, V11, P284; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hromas R, 2001, BLOOD, V97, P2168, DOI 10.1182/blood.V97.7.2168; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Lawrence HJ, 2005, BLOOD, V106, P3988, DOI 10.1182/blood-2005-05-2003; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Li Z, 2007, J BIOL CHEM, V282, P3428, DOI 10.1074/jbc.C600277200; Liu X, 2009, LEUKEMIA, V23, P739, DOI 10.1038/leu.2008.350; Maiques-Diaz A, 2012, LEUKEMIA, V26, P1329, DOI 10.1038/leu.2011.376; Maki K, 2012, INT J HEMATOL, V96, P268, DOI 10.1007/s12185-012-1112-z; Matsuura S, 2012, BLOOD, V120, P4028, DOI 10.1182/blood-2012-01-404533; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2004, GENE CHROMOSOME CANC, V39, P110, DOI 10.1002/gcc.10302; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Miyoshi OSMHIYSO, 1995, NUCLEIC ACIDS RES, V23, P1; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Nguyen TDT, 2006, GENE CHROMOSOME CANC, V45, P918, DOI 10.1002/gcc.20355; Niebuhr BB, 2008, BLOOD CELL MOL DIS, V40, P8; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Osato M, 2001, INT J HEMATOL, V74, P245, DOI 10.1007/BF02982056; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Proudfoot NJ, 2011, GENE DEV, V25, P1770, DOI 10.1101/gad.17268411; Ramsey H, 2003, LEUKEMIA, V17, P1665, DOI 10.1038/sj.leu.2403048; Rhoades KL, 2000, BLOOD, V96, P2108; Roumier C, 2003, BLOOD, V101, P1277, DOI 10.1182/blood-2002-05-1474; Schnittger S, 2011, BLOOD, V117, P2348, DOI 10.1182/blood-2009-11-255976; Silva FPG, 2007, HAEMATOLOGICA, V92, P1123, DOI 10.3324/haematol.11296; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stevens-Kroef MJPL, 2006, LEUKEMIA, V20, P1187, DOI 10.1038/sj.leu.2404210; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Torres R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4964; Torres R, 2014, GENE THER, V21, P343, DOI 10.1038/gt.2014.1; Tsuzuki S, 2007, PLOS MED, V4, P880, DOI 10.1371/journal.pmed.0040172; Uchida H, 1997, J IMMUNOL, V158, P2251; Wei H, 2008, FEBS LETT, V582, P2167, DOI 10.1016/j.febslet.2008.05.030; Yamagata T, 2005, INT J HEMATOL, V82, P1, DOI 10.1532/IJH97.05075; Yeh JRJ, 2008, DEVELOPMENT, V135, P401, DOI 10.1242/dev.008904; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	63	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					125	134		10.1038/onc.2015.70	http://dx.doi.org/10.1038/onc.2015.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798834				2022-12-28	WOS:000367812400012
J	Cui, YH; Suh, Y; Lee, HJ; Yoo, KC; Uddin, N; Jeong, YJ; Lee, JS; Hwang, SG; Nam, SY; Kim, MJ; Lee, SJ				Cui, Y-H; Suh, Y.; Lee, H-J; Yoo, K-C; Uddin, N.; Jeong, Y-J; Lee, J-S; Hwang, S-G; Nam, S-Y; Kim, M-J; Lee, S-J			Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; FACTOR G-CSF; SIGNALING PATHWAY; GM-CSF; FEEDBACK LOOP; BETA-CATENIN; METASTASIS; ACTIVATION; CARCINOMA	Despite ionizing radiation (IR) is being widely used as a standard treatment for lung cancer, many evidences suggest that IR paradoxically promotes cancer malignancy. However, its molecular mechanisms underlying radiation-induced cancer progression remain obscure. Here, we report that exposure to fractionated radiation (2 Gy per day for 3 days) induces the secretion of granulocyte-colony-stimulating factor (G-CSF) that has been commonly used in cancer therapies to ameliorate neutropenia. Intriguingly, radiation-induced G-CSF promoted the migratory and invasive properties by triggering the epithelial-mesenchymal cell transition (EMT) in non-small-cell lung cancer cells (NSCLCs). By irradiation, G-CSF was upregulated transcriptionally by beta-catenin/TCF4 complex that binds to the promoter region of G-CSF as a transcription factor. Importantly, irradiation increased the stability of beta-catenin through the activation of PI3K/AKT (phosphatidylinositol 3-kinase/AKT), thereby upregulating the expression of G-CSF. Radiation-induced G-CSF is recognized by G-CSFR and transduced its intracellular signaling JAK/STAT3 (Janus kinase/ signal transducers and activators of transcription), thereby triggering EMT program in NSCLCs. Taken together, our findings suggest that the application of G-CSF in cancer therapies to ameliorate neutropenia should be reconsidered owing to its effect on cancer progression, and G-CSF could be a novel therapeutic target to mitigate the harmful effect of radiotherapy for the treatment of NSCLC.	[Cui, Y-H; Suh, Y.; Yoo, K-C; Uddin, N.; Lee, S-J] Hanyang Univ, Lab Mol Biochem, Dept Life Sci, Res Inst Nat Sci, Seoul 133791, South Korea; [Lee, H-J; Jeong, Y-J] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea; [Lee, J-S] Sungkyunkwan Univ, Dept Biol Sci, Coll Sci, Suwon, South Korea; [Hwang, S-G] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul 139706, South Korea; [Nam, S-Y] Korea Hydro & Nucl Power Co Ltd, Radiat Hlth Inst, Seoul, South Korea; [Kim, M-J] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul 139706, South Korea	Hanyang University; Korea Institute of Radiological & Medical Sciences; Sungkyunkwan University (SKKU); Korea Institute of Radiological & Medical Sciences; Korea Hydro & Nuclear Power; Korea Institute of Radiological & Medical Sciences	Kim, MJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul 139706, South Korea.	kimmj74@kirams.re.kr; sj0420@hanyang.ac.kr	Lee, Jae-Seong/H-6013-2015; Cui, Yanhong/ABB-1148-2021	Lee, Jae-Seong/0000-0003-0944-5172; Cui, Yanhong/0000-0002-4169-6521; Ud Din, Nizam/0000-0002-9845-3109	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program [2012M2A2A7035878]; Ministry of Trade, Industry and Energy [20131610101840]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program; Ministry of Trade, Industry and Energy	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program (2012M2A2A7035878), and the Ministry of Trade, Industry and Energy (Grant No: 20131610101840).	Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006; Bernier J, 2004, NAT REV CANCER, V4, P737, DOI 10.1038/nrc1451; BURGESS AW, 1980, BLOOD, V56, P947; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; DALE DC, 1995, J INFECT DIS, V172, P1061, DOI 10.1093/infdis/172.4.1061; DEMETRI GD, 1991, BLOOD, V78, P2791; Diederich K, 2009, J NEUROSCI, V29, P11572, DOI 10.1523/JNEUROSCI.0453-09.2009; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Jiang YG, 2007, INT J UROL, V14, P1034, DOI 10.1111/j.1442-2042.2007.01866.x; Kawamoto A, 2012, ONCOL REP, V27, P51, DOI 10.3892/or.2011.1485; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Liu W, 2014, LAB INVEST, V94, P362, DOI 10.1038/labinvest.2013.153; Looyenga BD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030820; Marino VJ, 2008, J CELL BIOCHEM, V103, P1512, DOI 10.1002/jcb.21542; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; Mroczko B, 2004, CLIN CHEM LAB MED, V42, P1347, DOI 10.1515/CCLM.2004.253; Mroczko B, 2000, POL ARCH MED WEWN, V103, P163; Multhoff G, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00058; Novak U, 1996, GROWTH FACTORS, V13, P251, DOI 10.3109/08977199609003226; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Ross GM, 1999, ENDOCR-RELAT CANCER, V6, P41, DOI 10.1677/erc.0.0060041; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Teramachi M, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P1327; Uemura Y, 2004, INT J CANCER, V109, P826, DOI 10.1002/ijc.20023; Uemura Y, 2007, ONCOL REP, V17, P955; Uemura Y, 2006, INT J MOL MED, V18, P365; Wang WC, 2011, J CELL BIOCHEM, V112, P1544, DOI 10.1002/jcb.23067; Wang ZW, 2010, CURR DRUG TARGETS, V11, P745, DOI 10.2174/138945010791170860; Watanabe M, 1998, JPN J CLIN ONCOL, V28, P559, DOI 10.1093/jjco/28.9.559; Wendt Michael K, 2014, JAKSTAT, V3, pe28975, DOI 10.4161/jkst.28975; Yan S, 2013, INT J ONCOL, V42, P1801, DOI 10.3892/ijo.2013.1852; YOUNG MRI, 1994, INT J CANCER, V56, P446, DOI 10.1002/ijc.2910560327; Zhang JN, 2013, NEURAL DEV, V8, DOI 10.1186/1749-8104-8-7	42	44	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5372	5382		10.1038/onc.2014.466	http://dx.doi.org/10.1038/onc.2014.466			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25639867				2022-12-28	WOS:000363479200007
J	Warnier, M; Roudbaraki, M; Derouiche, S; Delcourt, P; Bokhobza, A; Prevarskaya, N; Mariot, P				Warnier, M.; Roudbaraki, M.; Derouiche, S.; Delcourt, P.; Bokhobza, A.; Prevarskaya, N.; Mariot, P.			CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; GATED CALCIUM-CHANNELS; TUMOR-SUPPRESSOR; ION CHANNELS; GENE; ALPHA(2)DELTA; SUBUNITS; METHYLATION; PROGRESSION; TRAFFICKING	In the present study, we have assessed whether a putative calcium channel alpha 2 delta 2 auxiliary subunit (CACNA2D2 gene) could be involved in prostate cancer (PCA) progression. We therefore carried out experiments to determine whether this protein is expressed in PCA LNCaP cells and in PCA tissues, and whether its expression may be altered during cancer development. In addition, we evaluated the influence on cell proliferation of overexpressing or downregulating this subunit. In vitro experiments show that alpha 2 delta 2 subunit overexpression is associated with increased cell proliferation, alterations of calcium homeostasis and the recruitment of a nuclear factor of activated T-cells pathway. Furthermore, we carried out in vivo experiments on immuno-deficient nude mice in order to evaluate the tumorigenic potency of the alpha 2 delta 2 subunit. We show that alpha 2 delta 2-overexpressing PCA LNCaP cells are more tumorigenic than control LNCaP cells when injected into nude mice. In addition, gabapentin, a ligand of alpha 2 delta 2, reduces tumor development in LNCaP xenografts. Finally, we show that the action of alpha 2 delta 2 on tumor development occurs not only through a stimulation of proliferation, but also through a stimulation of angiogenesis, via an increased secretion of vascular endothelial growth factor in cells overexpressing alpha 2 delta 2.	[Warnier, M.; Roudbaraki, M.; Derouiche, S.; Delcourt, P.; Bokhobza, A.; Prevarskaya, N.; Mariot, P.] INSERM, Lab Phys Cellulaire, U1003, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Mariot, P (corresponding author), Univ Lille 1, Lab Physiol Cellulaire, INSERM, U1003, Batiment SN3, F-59655 Villeneuve Dascq, France.	Pascal.Mariot@univ-lille1.fr		Mariot, Pascal/0000-0001-7226-9162; Prevarskaya, natacha/0000-0003-0316-197X; bokhobza, Alexandre/0000-0001-7953-4328; Morad, Roudbaraki/0000-0001-5751-3323	INSERM; University of Lille1; Region Nord-Pas de Calais	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Lille1; Region Nord-Pas de Calais(Region Hauts-de-FranceEuropean Commission)	We thank the members of the imaging platform BICEL, E Richard and C Slommiany for their helpful contribution. This work was supported by INSERM, the University of Lille1 and the Region Nord-Pas de Calais. This work was supported by INSERM, the University of Lille1 and the Region Nord-Pas de Calais.	Bennett ES, 2004, PFLUG ARCH EUR J PHY, V447, P908, DOI 10.1007/s00424-003-1205-x; Bidaud I, 2006, BBA-MOL CELL RES, V1763, P1169, DOI 10.1016/j.bbamcr.2006.08.049; Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8; Canti C, 2005, P NATL ACAD SCI USA, V102, P11230, DOI 10.1073/pnas.0504183102; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies A, 2007, TRENDS PHARMACOL SCI, V28, P220, DOI 10.1016/j.tips.2007.03.005; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; Dolphin AC, 2012, NAT REV NEUROSCI, V13, P542, DOI 10.1038/nrn3311; Dooley DJ, 2007, TRENDS PHARMACOL SCI, V28, P75, DOI 10.1016/j.tips.2006.12.006; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Fiske JL, 2006, CANCER METAST REV, V25, P493, DOI 10.1007/s10555-006-9017-z; Gackiere F, 2006, CELL CALCIUM, V39, P357, DOI 10.1016/j.ceca.2005.12.003; Gackiere F, 2008, J BIOL CHEM, V283, P10162, DOI 10.1074/jbc.M707159200; Gackiere F, 2013, BIOL OPEN, V2, P941, DOI 10.1242/bio.20135215; Garcia K, 2008, J PHYSIOL-LONDON, V586, P727, DOI 10.1113/jphysiol.2007.147959; Ghosh S, 2008, INT J CANCER, V123, P2594, DOI 10.1002/ijc.23834; Halatsch ME, 2009, J NEUROSURG, V111, P211, DOI 10.3171/2008.9.JNS08551; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Katsogiannou M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007068; Kondratska K., 2014, ONCOGENE, V1843, P2263; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Lee JM, 2011, AM J PHYSIOL-CELL PH, V301, pC969, DOI 10.1152/ajpcell.00136.2011; Li Z, 2011, EUR J PHARMACOL, V667, P80, DOI 10.1016/j.ejphar.2011.05.054; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; LIU CM, 1978, J BIOL CHEM, V253, P5892; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006; Oh C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02623; Pelosi G, 2010, ANTICANCER RES, V30, P4269; Prando ED, 2011, EPIGENETICS-US, V6, P1413, DOI 10.4161/epi.6.12.18271; Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com; Starborg M, 1996, J CELL SCI, V109, P143; Toyota M, 1999, CANCER RES, V59, P4535; Wanajo A, 2008, GASTROENTEROLOGY, V135, P580, DOI 10.1053/j.gastro.2008.05.041; Wang XT, 2000, AM J PATHOL, V157, P1549, DOI 10.1016/S0002-9440(10)64792-X; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Zhao W, 2013, CANCER CELL, V23, P541, DOI 10.1016/j.ccr.2013.02.025; ZOUR E, 1992, PHARMACEUT RES, V9, P595, DOI 10.1023/A:1015833622943	41	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5383	5394		10.1038/onc.2014.467	http://dx.doi.org/10.1038/onc.2014.467			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25619833				2022-12-28	WOS:000363479200008
J	Stolzenburg, S; Beltran, AS; Swift-Scanlan, T; Rivenbark, AG; Rashwan, R; Blancafort, P				Stolzenburg, S.; Beltran, A. S.; Swift-Scanlan, T.; Rivenbark, A. G.; Rashwan, R.; Blancafort, P.			Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX2; STEM-CELLS; EXPRESSION; GENES; DIFFERENTIATION; REPRESSION; EFFECTORS; PROTEINS; MEMORY; TUMORS	With the recent comprehensive mapping of cancer genomes, there is now a need for functional approaches to edit the aberrant epigenetic state of key cancer drivers to reprogram the epi-pathology of the disease. In this study we utilized a programmable DNA-binding methyltransferase to induce targeted incorporation of DNA methylation (DNAme) in the SOX2 oncogene in breast cancer through a six zinc finger (ZF) protein linked to DNA methyltransferase 3A (ZF-DNMT3A). We demonstrated long-lasting oncogenic repression, which was maintained even after suppression of ZF-DNMT3A expression in tumor cells. The de novo DNAme was faithfully propagated and maintained through cell generations even after the suppression of the expression of the chimeric methyltransferase in the tumor cells. Xenograft studies in NUDE mice demonstrated stable SOX2 repression and long-term breast tumor growth inhibition, which lasted for >100 days post implantation of the tumor cells in mice. This was accompanied with a faithful maintenance of DNAme in the breast cancer implants. In contrast, downregulation of SOX2 by ZF domains engineered with the Krueppel-associated box repressor domain resulted in a transient and reversible suppression of oncogenic gene expression. Our results indicated that targeted de novo DNAme of the SOX2 oncogenic promoter was sufficient to induce long-lasting epigenetic silencing, which was not only maintained during cell division but also significantly delayed the tumorigenic phenotype of cancer cells in vivo, even in the absence of treatment. Here, we outline a genome-based targeting approach to long-lasting tumor growth inhibition with potential applicability to many other oncogenic drivers that are currently refractory to drug design.	[Stolzenburg, S.; Rashwan, R.; Blancafort, P.] Harry Perkins Inst Med Res, Canc Epigenet Grp, Nedlands, WA, Australia; [Stolzenburg, S.; Rashwan, R.; Blancafort, P.] Univ Western Australia, Sch Anat Physiol & Human Biol, Nedlands, WA 6009, Australia; [Stolzenburg, S.; Beltran, A. S.; Blancafort, P.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC USA; [Swift-Scanlan, T.] Univ N Carolina, Sch Nursing, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Rivenbark, A. G.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA	Harry Perkins Institute of Medical Research; University of Western Australia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Blancafort, P (corresponding author), Harry Perkins Inst Med Res, Canc Epigenet Grp, Nedlands, WA, Australia.	pilar.blancafort@uwa.edu.au		Rashwan, Rabab/0000-0001-9557-0062; Blancafort, Pilar/0000-0002-3881-7396	Australian Research Council (ARC) Future Fellowship [FT130101767]; Cancer Council of Western Australia Research Fellowship; National Health and Medical Research Council [APP1069308]; National Institutes of Health [R01CA170370, R01DA036906]; National Breast Cancer Foundation [NC-14-024]; Barbara Senich Genomics Innovation Award; Barbara Senich Genomics Innovation Endowment Fund; Susan G Komen Foundation [KG090180]; NATIONAL CANCER INSTITUTE [R01CA170370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA036906] Funding Source: NIH RePORTER	Australian Research Council (ARC) Future Fellowship(Australian Research Council); Cancer Council of Western Australia Research Fellowship(Cancer Council Western Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Breast Cancer Foundation; Barbara Senich Genomics Innovation Award; Barbara Senich Genomics Innovation Endowment Fund; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This research was supported by an Australian Research Council (ARC) Future Fellowship FT130101767, the Cancer Council of Western Australia Research Fellowship, National Health and Medical Research Council grant APP1069308, National Institutes of Health grants R01CA170370, R01DA036906, the National Breast Cancer Foundation NC-14-024 (PB) and the Barbara Senich Genomics Innovation Award, the Barbara Senich Genomics Innovation Endowment Fund and the Susan G Komen Foundation KG090180 (TSS).	Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Blancafort P, 2013, MOL PHARMACOL, V83, P563, DOI 10.1124/mol.112.080697; Boch J, 2009, SCIENCE, V326, P1509, DOI 10.1126/science.1178811; Bogdanove AJ, 2011, SCIENCE, V333, P1843, DOI 10.1126/science.1204094; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x; Chaikind B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096931; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Groote ML, 2012, NUCLEIC ACIDS RES, V40, P10596, DOI 10.1093/nar/gks863; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Hathaway NA, 2012, CELL, V149, P1447, DOI 10.1016/j.cell.2012.03.052; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Konermann S, 2013, NATURE; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lange UC, 2010, BIOESSAYS, V32, P659, DOI 10.1002/bies.201000030; Lara H, 2012, J BIOL CHEM, V287, P29873, DOI 10.1074/jbc.M112.360768; Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035; Nunna S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087703; Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507; Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105; Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008; Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696; Siddique A, 2013, J MOL BIOL, V425, P479, DOI 10.1016/j.jmb.2012.11.038; Sikorska M, 2008, J NEUROSCI RES, V86, P1680, DOI 10.1002/jnr.21635; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360; Stolzenburg S, 2010, METHODS MOL BIOL, V649, P117, DOI 10.1007/978-1-60761-753-2_7; Sussman RT, 2013, J BIOL CHEM, V288, P24234, DOI 10.1074/jbc.M113.469783; Wiedenheft B, 2012, NATURE, V482, P331, DOI 10.1038/nature10886; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94	39	57	58	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5427	5435		10.1038/onc.2014.470	http://dx.doi.org/10.1038/onc.2014.470			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25684141	Green Published, hybrid			2022-12-28	WOS:000363479700003
J	Kim, HJ; Kim, SH; Yu, EJ; Seo, WY; Kim, JH				Kim, H. J.; Kim, S-H; Yu, E. J.; Seo, W-Y; Kim, J. H.			A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR PEA3; DNA-BINDING; MATRIX METALLOPROTEINASE-1; ACTIVATOR PEA3; ACETYLATION; EXPRESSION; SUMOYLATION; DOMAIN; CELLS; SIRT1	Deleted in Breast Cancer 1 (DBC1), a negative regulator of deacetylase SIRT1, has been shown to act as an estrogen receptor a (ER) coactivator that has a key role in ER transcription complex assembly and estrogen-dependent breast cancer cell proliferation. However, little is known about its physiological role and mechanism of action in ER-negative breast cancer cells. Here we report that DBC1 functions as a coactivator for the oncogenic ETS transcription factor PEA3 to promote ER-negative breast cancer progression. DBC1 is required for the expression of PEA3 target genes and for recruitment of PEA3 and RNA polymerase II to PEA3 target promoters. We also demonstrated that acetylation of PEA3 stimulates its DNA binding and association with DBC1 by disrupting the intramolecular interaction of PEA3. The molecular mechanism underlying DBC1 function in PEA3-mediated transcription involves inhibition of SIRT1 interaction with PEA3 and of SIRT1-mediated deacetylation of PEA3. Moreover, DBC1 depletion inhibited the tumorigenic properties of ER-negative breast cancer cells in vitro and in vivo. Importantly, increased DBC1 expression correlated with shorter relapse-free survival of ER-negative breast cancer patients. Our results firmly established DBC1 as a critical coactivator of PEA3 and as a key player in PEA3-mediated breast cancer progression.	[Kim, H. J.; Kim, S-H; Yu, E. J.; Seo, W-Y; Kim, J. H.] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea; [Kim, H. J.; Yu, E. J.; Seo, W-Y; Kim, J. H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Biomed Sci,Samsung Biomed Res Inst, Seoul, South Korea; [Kim, S-H] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, JH (corresponding author), Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Samsung Canc Ctr, 50 Irwon Dong, Seoul 135710, South Korea.	jeongkim@skku.edu			Samsung Biomedical Research Institute (SBRI) [SMX1132501]; National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2013R1A1A2059697]	Samsung Biomedical Research Institute (SBRI); National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning	We thank Jason W Chin (MRC Laboratory for Molecular Biology, Cambridge, UK) for providing vectors and Yoon-La Choi (Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea) for providing the tissue microarray slides of primary invasive breast carcinoma specimens. This work was supported by Samsung Biomedical Research Institute (SBRI) grant (SMX1132501) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2013R1A1A2059697) to JHK.	Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Barcellos-Hoff MH, 2013, CLIN CANCER RES, V19, P541, DOI 10.1158/1078-0432.CCR-12-2241; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bohn OL, 2010, INT J CLIN EXP PATHO, V3, P139; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Chini CCS, 2010, J BIOL CHEM, V285, P40830, DOI 10.1074/jbc.M110.153270; Choi YL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-507; Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109; Eck SM, 2009, MOL CANCER RES, V7, P1033, DOI 10.1158/1541-7786.MCR-09-0015; Fu JJ, 2009, J BIOL CHEM, V284, P6832, DOI 10.1074/jbc.M808988200; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gu SM, 2011, ACTA BIOCH BIOPH SIN, V43, P771, DOI 10.1093/abbs/gmr070; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guo BQ, 2011, NUCLEIC ACIDS RES, V39, P6403, DOI 10.1093/nar/gkr267; Guo BQ, 2009, MOL CELL BIOL, V29, P3204, DOI 10.1128/MCB.01128-08; Hiraike H, 2011, EXP THER MED, V2, P1105, DOI 10.3892/etm.2011.333; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kim SH, 2012, HISTOL HISTOPATHOL, V27, P49, DOI 10.14670/HH-27.49; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Myers E, 2006, BRIT J CANCER, V95, P1404, DOI 10.1038/sj.bjc.6603427; Neumann H, 2009, MOL CELL, V36, P153, DOI 10.1016/j.molcel.2009.07.027; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; OHagan RC, 1996, ONCOGENE, V13, P1323; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Seo WY, 2013, NUCLEIC ACIDS RES, V41, P8526, DOI 10.1093/nar/gkt644; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sun YB, 2002, J BIOL CHEM, V277, P1544, DOI 10.1074/jbc.M100567200; Wollenick K, 2012, NUCLEIC ACIDS RES, V40, P1928, DOI 10.1093/nar/gkr978; Yu EJ, 2013, ONCOGENE, V32, P4160, DOI 10.1038/onc.2012.420; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515	37	11	11	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4500	4508		10.1038/onc.2014.381	http://dx.doi.org/10.1038/onc.2014.381			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25417701				2022-12-28	WOS:000360189200009
J	Zhang, X; Pageon, L; Post, SM				Zhang, X.; Pageon, L.; Post, S. M.			Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; SINGLE NUCLEOTIDE POLYMORPHISM; ACCELERATES TUMOR-FORMATION; MDM2 GENE; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL REGULATION; P53; PROMOTER; CELL; EXPRESSION	A single-nucleotide polymorphism (SNP) in the promoter of the Mdm2 gene (Mdm2(SNP309-G)) results in an increased Mdm2 expression, partial attenuation of the p53 pathway and accelerated tumor development. Clinical case-control studies indicate the Mdm2(SNP309-G) allele associates with a significant increase in colorectal cancer (CRC) risk that is heightened in women, but the biological significance of this polymorphism has never been directly evaluated. To examine whether the Mdm2(SNP309-G) allele contributes to colorectal cancer, we generated cohorts of mice harboring either the G (minor allelic variant) or T (major allelic variant) allele and treated them with azoxymethane (AOM), a carcinogen that induces sporadic colorectal cancer. Mdm2(SNP309-G/G) mice displayed a significant reduction in survival following AOM treatment with more colonic lesions in a wider distribution throughout the lower and upper colon and an attenuated apoptotic response following exposure. AOM did not significantly induce stabilization of wild-type p53 or activate p53 downstream targets following AOM treatment, regardless of the genotype. Instead, Mdm2(SNP309-G/G) colons had significant changes in the expression of genes that regulate Mdm2 transcription (ERa and Sp1) as well as downstream targets of Mdm2. Together these results suggest the Mdm2(SNP309-G) allele significantly impacts CRC through mechanisms outside the p53 pathway.	[Zhang, X.; Post, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Pageon, L.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Post, SM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	spost@mdanderson.org			Cancer Center [CA016672]; Center for Genetics and Genomics; MDACC; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Cancer Center; Center for Genetics and Genomics; MDACC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Maurisa Flynn-Croce and Brittany N Kleb for reviewing and editing the manuscript. These studies were supported by Cancer Center support grant CA016672 and funding from the Center for Genetics and Genomics and MDACC start-up funds to (SMP).	Abdel-Fattah G, 2000, J GASTROINTEST SURG, V4, P109, DOI 10.1016/S1091-255X(00)80041-4; Armstrong CM, 2013, ENDOCR-RELAT CANCER, V20, P515, DOI 10.1530/ERC-12-0308; Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Bissahoyo A, 2005, TOXICOL SCI, V88, P340, DOI 10.1093/toxsci/kfi313; Bond GL, 2006, J MED GENET, V43, P950, DOI 10.1136/jmg.2006.043539; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brekman A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2804; Brendel A, 2013, RESTOR NEUROL NEUROS, V31, P199, DOI 10.3233/RNN-120272; Chaar I, 2012, EUR J GASTROEN HEPAT, V24, P320, DOI 10.1097/MEG.0b013e32834bdf84; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Ferreira KS, 2012, APOPTOSIS, V17, P503, DOI 10.1007/s10495-011-0691-0; Ferriere F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069081; Firoz EF, 2009, CLIN CANCER RES, V15, P2573, DOI 10.1158/1078-0432.CCR-08-2678; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Heijmans J, 2014, GUT, V63, P310, DOI 10.1136/gutjnl-2012-304216; Hu WW, 2007, CANCER RES, V67, P2757, DOI 10.1158/0008-5472.CAN-06-2656; Hu Y, 2005, INT J CANCER, V115, P561, DOI 10.1002/ijc.20876; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Itoh Y, 2007, J IMMUNOL, V178, P3059, DOI 10.4049/jimmunol.178.5.3059; James AW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007120; Jin J, 2014, J RADIAT RES, V55, P443, DOI 10.1093/jrr/rrt132; Kim K, 2011, J MOL ENDOCRINOL, V46, P67, DOI 10.1677/JME-10-0110; Knappskog S, 2012, EUR J CANCER, V48, P1988, DOI 10.1016/j.ejca.2011.10.024; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lind H, 2006, INT J CANCER, V119, P718, DOI 10.1002/ijc.21872; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nambiar PR, 2002, CANCER RES, V62, P3667; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Post SM, 2010, ONCOGENE, V29, P1260, DOI 10.1038/onc.2009.423; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Qin X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076031; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Spandidos A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-633; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Tien JCY, 2012, EXPERT OPIN THER TAR, V16, P1085, DOI 10.1517/14728222.2012.718330; U.S. Department of Health and Human Services, 1999, US CANC STAT 1999 20; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WZ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04851	48	6	6	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4412	4420		10.1038/onc.2014.377	http://dx.doi.org/10.1038/onc.2014.377			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25435368				2022-12-28	WOS:000359494400012
J	Chen, T; Sun, Y; Ji, P; Kopetz, S; Zhang, W				Chen, T.; Sun, Y.; Ji, P.; Kopetz, S.; Zhang, W.			Topoisomerase II alpha in chromosome instability and personalized cancer therapy	ONCOGENE			English	Review							SPINDLE ASSEMBLY CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; IN-SITU HYBRIDIZATION; BREAST-CANCER; CELL-CYCLE; MITOTIC CHECKPOINT; DNA TOPOISOMERASES; GENE-EXPRESSION; DOWN-REGULATION; CHROMATID COHESION	Genome instability is a hallmark of cancer cells. Chromosome instability (CIN), which is often mutually exclusive from hypermutation genotypes, represents a distinct subtype of genome instability. Hypermutations in cancer cells are due to defects in DNA repair genes, but the cause of CIN is still elusive. However, because of the extensive chromosomal abnormalities associated with CIN, its cause is likely a defect in a network of genes that regulate mitotic checkpoints and chromosomal organization and segregation. Emerging evidence has shown that the chromosomal decatenation checkpoint, which is critical for chromatin untangling and packing during genetic material duplication, is defective in cancer cells with CIN. The decatenation checkpoint is known to be regulated by a family of enzymes called topoisomerases. Among them, the gene encoding topoisomerase II alpha (TOP2A) is commonly altered at both gene copy number and gene expression level in cancer cells. Thus, abnormal alterations of TOP2A, its interacting proteins, and its modifications may have a critical role in CIN in human cancers. Clinically, a large arsenal of topoisomerase inhibitors has been used to suppress DNA replication in cancer. However, they often lead to the secondary development of leukemia because of their effect on the chromosomal decatenation checkpoint. Therefore, topoisomerase drugs must be used judiciously and administered on an individual basis. In this review, we highlight the biological function of TOP2A in chromosome segregation and the mechanisms that regulate this enzyme's expression and activity. We also review the roles of TOP2A and related proteins in human cancers, and raise a perspective for how to target TOP2A in personalized cancer therapy.	[Chen, T.; Ji, P.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Chen, T.] Fudan Univ, Zhongshan Hosp, Dept Endoscopy Ctr, Shanghai 200433, Peoples R China; [Sun, Y.] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China; [Kopetz, S.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Fudan University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Kopetz, Scott/AAC-1387-2019	Kopetz, Scott/0000-0001-9647-3416	MD Anderson's National Cancer Institute core grant [CA16672]; National Foundation for Cancer Research; China Education Council; A Lavoy Moore Endowment Fund; Tianjin Municipal Science and Technology Commission [14JCYBJC27500]; NSFC [81472263]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	MD Anderson's National Cancer Institute core grant; National Foundation for Cancer Research; China Education Council; A Lavoy Moore Endowment Fund; Tianjin Municipal Science and Technology Commission; NSFC(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Ann Sutton in the Department of Scientific Publications for editing this manuscript. This work was partially supported by MD Anderson's National Cancer Institute core grant (CA16672), a Sister Institute Network Fund and a grant from the National Foundation for Cancer Research. Dr Tao Chen was supported by a Fellowship from the China Education Council. Dr Y Sun was supported by The A Lavoy Moore Endowment Fund, a grant from the Tianjin Municipal Science and Technology Commission (14JCYBJC27500), and a grant from NSFC (81472263).	Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Akimitsu N, 2003, GENES CELLS, V8, P393, DOI 10.1046/j.1365-2443.2003.00643.x; ANDOH T, 1993, BIOTECHNOL APPL BIOC, V18, P165; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Azuma Y, 2009, METHODS MOL BIOL, V582, P221, DOI 10.1007/978-1-60761-340-4_17; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Belluti S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.287; Bhargava R, 2005, AM J CLIN PATHOL, V123, P889, DOI 10.1309/PCFK8YTQPYWD534F; Bordeleau L, 2010, BREAST CANCER RES TR, V119, P13, DOI 10.1007/s10549-009-0566-z; Bower JJ, 2010, ONCOGENE, V29, P4787, DOI 10.1038/onc.2010.232; Buffin E, 2005, CURR BIOL, V15, P856, DOI 10.1016/j.cub.2005.03.052; Carpenter AJ, 2004, MOL BIOL CELL, V15, P5700, DOI 10.1091/mbc.E04-08-0732; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang CJ, 2003, J CELL SCI, V116, P4715, DOI 10.1242/jcs.00797; Chen J, 2012, GYNECOL ONCOL, V126, P109, DOI 10.1016/j.ygyno.2012.03.051; Chen J, 2012, CHIN J CANCER, V31, P215, DOI 10.5732/cjc.011.10364; CHEN M, 1995, ONCOL RES, V7, P103; CHEN M, 1993, CANCER RES, V53, P5946; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chikamori K, 2003, J BIOL CHEM, V278, P12696, DOI 10.1074/jbc.M300837200; CLARKE DJ, 1993, J CELL SCI, V105, P563; Coelho PA, 2008, PLOS BIOL, V6, P1758, DOI 10.1371/journal.pbio.0060207; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; CUMMINGS J, 1995, MUTAT RES-GENET TOX, V344, P55, DOI 10.1016/0165-1218(95)90038-1; Dal Molin M, 2012, HUM PATHOL, V43, P585, DOI 10.1016/j.humpath.2011.06.009; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Dawlaty MM, 2008, CELL, V133, P103, DOI 10.1016/j.cell.2008.01.045; de Voer RM, 2013, GASTROENTEROLOGY, V145, P544, DOI 10.1053/j.gastro.2013.06.001; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Depowski PL, 2000, MODERN PATHOL, V13, P542, DOI 10.1038/modpathol.3880094; Diaz-Martinez LA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000053; Dorairaj JJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-421; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Faggad A, 2009, MODERN PATHOL, V22, P579, DOI 10.1038/modpathol.2009.14; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Ferguson LR, 1998, ENVIRON MOL MUTAGEN, V27, P255; Ganapathi RN, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00089; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Gilmore PM, 2003, BIOCHEM SOC T, V31, P257, DOI 10.1042/bst0310257; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gunduz E, 2006, MED HYPOTHESES, V67, P1313, DOI 10.1016/j.mehy.2006.05.032; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hande KR, 2008, UPDATE CANC THERAPEU, V3, P13, DOI DOI 10.1016/J.UCT.2008.02.001; Hasinoff BB, 2001, MOL PHARMACOL, V59, P453, DOI 10.1124/mol.59.3.453; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Huang B, 2014, J CELL BIOCHEM, V115, P1077, DOI 10.1002/jcb.24703; Iida M, 2008, BIOCHEM J, V411, P27, DOI 10.1042/BJ20071394; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ISHIDA R, 1991, CANCER RES, V51, P4909; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Jeganathan KB, 2006, CELL CYCLE, V5, P366, DOI 10.4161/cc.5.4.2483; Ji P, 2010, ONCOGENE, V29, P3501, DOI 10.1038/onc.2010.114; Johnson M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp480; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kallio M, 1997, ENVIRON MOL MUTAGEN, V29, P16, DOI 10.1002/(SICI)1098-2280(1997)29:1<16::AID-EM3>3.0.CO;2-B; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Koivunen J, 2006, CANCER LETT, V235, P1, DOI 10.1016/j.canlet.2005.03.033; Kolb RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050281; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lan J, 2014, TUMOR BIOL, V35, P179, DOI 10.1007/s13277-013-1022-6; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li H, 2008, J BIOL CHEM, V283, P6209, DOI 10.1074/jbc.M709007200; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Li Y, 2012, CHIN J CANCER, V31, P364, DOI 10.5732/cjc.012.10086; Lin WC, 2013, BBA-MOL CELL RES, V1833, P3206, DOI 10.1016/j.bbamcr.2013.08.020; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Liu DG, 2002, CANCER, V94, P2239, DOI 10.1002/cncr.10450; Liu H, 2013, CURR BIOL, V23, P1927, DOI 10.1016/j.cub.2013.07.078; Liu Y, 2010, EUR J CANCER, V46, P3007, DOI 10.1016/j.ejca.2010.07.016; London N, 2014, GENE DEV, V28, P140, DOI 10.1101/gad.233700.113; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Lynch HT, 2005, CANCER GENET CYTOGEN, V158, P119, DOI 10.1016/j.cancergencyto.2004.01.032; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Meng H, 2012, PATHOL INT, V62, P391, DOI 10.1111/j.1440-1827.2012.02808.x; Michor F, 2005, SEMIN CANCER BIOL, V15, P43, DOI 10.1016/j.semcancer.2004.09.007; Mo YY, 1997, CANCER RES, V57, P5004; Mueller RE, 2004, GENE CHROMOSOME CANC, V39, P288, DOI 10.1002/gcc.20008; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Obado SO, 2011, NUCLEIC ACIDS RES, V39, P1023, DOI 10.1093/nar/gkq839; Parker BC, 2013, CHIN J CANCER, V32, P594, DOI 10.5732/cjc.013.10178; Patel AN, 2011, BREAST CANCER RES TR, V126, P601, DOI 10.1007/s10549-010-0960-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Privette LM, 2008, NEOPLASIA, V10, P643, DOI 10.1593/neo.08176; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Qi XM, 2011, J BIOL CHEM, V286, P35883, DOI 10.1074/jbc.M111.229260; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; Reisman DN, 2003, CANCER RES, V63, P560; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; RITKE MK, 1995, MOL PHARMACOL, V48, P798; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Schmidt BH, 2012, NAT STRUCT MOL BIOL, V19, P1147, DOI 10.1038/nsmb.2388; Schmidt BH, 2010, NATURE, V465, P641, DOI 10.1038/nature08974; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shinagawa H, 2008, ANTIOXID REDOX SIGN, V10, P939, DOI 10.1089/ars.2007.1851; Stros M, 2009, NUCLEIC ACIDS RES, V37, P2070, DOI 10.1093/nar/gkp067; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; SUMNER AT, 1995, EXP CELL RES, V217, P440, DOI 10.1006/excr.1995.1107; Sumner AT, 1998, CHROMOSOMA, V107, P486, DOI 10.1007/s004120050333; Takahashi Y, 2006, GENETICS, V172, P783, DOI 10.1534/genetics.105.047167; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tipton AR, 2013, J BIOL CHEM, V288, P35149, DOI 10.1074/jbc.M113.522375; Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Villman K, 2002, MODERN PATHOL, V15, P486, DOI 10.1038/modpathol.3880552; Wang H, 1997, BIOCHEM BIOPH RES CO, V237, P217, DOI 10.1006/bbrc.1997.7115; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang LHC, 2008, CHROMOSOMA, V117, P123, DOI 10.1007/s00412-007-0131-7; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang XS, 2013, CHIN J CANCER, V32, P155, DOI 10.5732/cjc.012.10114; Washiro M, 2008, J CANCER RES CLIN, V134, P793, DOI 10.1007/s00432-007-0348-0; Watanabe T, 2012, J CLIN ONCOL, V30, P2256, DOI 10.1200/JCO.2011.38.6490; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Wendorff TJ, 2012, J MOL BIOL, V424, P109, DOI 10.1016/j.jmb.2012.07.014; Williams AO, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-36; Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624; Wirth KG, 2006, J CELL BIOL, V172, P847, DOI 10.1083/jcb.200506119; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yanagida M, 2005, PHILOS T R SOC B, V360, P609, DOI 10.1098/rstb.2004.1615; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Yang GL, 2012, J SURG ONCOL, V106, P57, DOI 10.1002/jso.23040; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yuan CF, 2012, MOL CELL BIOCHEM, V359, P333, DOI 10.1007/s11010-011-1027-7	161	108	115	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4019	4031		10.1038/onc.2014.332	http://dx.doi.org/10.1038/onc.2014.332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25328138	Green Accepted			2022-12-28	WOS:000358780500001
J	Mounir, Z; Lin, F; Lin, VG; Korn, JM; Yu, Y; Valdez, R; Aina, OH; Buchwalter, G; Jaffe, AB; Korpal, M; Zhu, P; Brown, M; Cardiff, RD; Rocnik, JL; Yang, Y; Pagliarini, R				Mounir, Z.; Lin, F.; Lin, V. G.; Korn, J. M.; Yu, Y.; Valdez, R.; Aina, O. H.; Buchwalter, G.; Jaffe, A. B.; Korpal, M.; Zhu, P.; Brown, M.; Cardiff, R. D.; Rocnik, J. L.; Yang, Y.; Pagliarini, R.			TMPRSS2: ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation	ONCOGENE			English	Article							ANDROGEN RECEPTOR; MOLECULAR CHARACTERIZATION; GENOME BROWSER; GENE FUSIONS; IN-VIVO; PROGRESSION; EXPRESSION; TRANSDIFFERENTIATION; ADENOCARCINOMA; HYBRIDIZATION	The biological outcome of TMPRSS2: ERG chromosomal translocations in prostate cancer (PC) remains poorly understood. To address this, we compared the transcriptional effects of TMPRSS2: ERG expression in a transgenic mouse model with those of ERG knockdown in a TMPRSS2: ERG-positive PC cell line. This reveals that ERG represses the expression of a previously unreported set of androgen receptor (AR)-independent neuronal genes that are indicative of neuroendocrine (NE) cell differentiation-in addition to previously reported AR-regulated luminal genes. Cell sorting and proliferation assays performed after sustained ERG knockdown indicate that ERG drives proliferation and blocks the differentiation of prostate cells to both NE and luminal cell types. Inhibition of ERG expression in TMPRSS2: ERG-positive PC cells through blockade of AR signaling is tracked with increased NE gene expression. We also provide evidence that these NE cells are resistant to pharmacological AR inhibition and can revert to the phenotype of parental cells upon restoration of AR/ERG signaling. Our findings highlight an ERG-regulated mechanism capable of repopulating the parent tumor through the transient generation of an anti-androgen therapy-resistant cell population, suggesting that ERG may have a direct role in preventing resistance to anti-androgen therapy.	[Mounir, Z.; Lin, F.; Lin, V. G.; Korn, J. M.; Yu, Y.; Valdez, R.; Jaffe, A. B.; Korpal, M.; Zhu, P.; Rocnik, J. L.; Yang, Y.; Pagliarini, R.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA; [Aina, O. H.; Cardiff, R. D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Buchwalter, G.; Brown, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Buchwalter, G.; Brown, M.] Harvard Univ, Sch Med, Boston, MA USA; [Buchwalter, G.; Brown, M.] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA	Novartis; University of California System; University of California Davis; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Pagliarini, R (corresponding author), Novartis Inst BioMed Res, 250 Massachusetts Ave, Cambridge, MA 02139 USA.	raymond.pagliarini@novartis.com	Brown, Myles/AAX-5332-2021; Brown, Myles/B-6906-2008	Brown, Myles/0000-0002-8213-1658; Jaffe, Aron/0000-0002-6220-0476	Novartis Institutes for Biomedical Research; Novartis	Novartis Institutes for Biomedical Research; Novartis(Novartis)	ZM is the recipient of presidential postdoctoral fellowship from the Novartis Institutes for Biomedical Research. ZM, FL, VGL, JMK, YY, RV, ABJ, YY and RP are all employees of Novartis Institutes for Biomedical Research. MK and PZ are employees of H3 Biomedicine. MB is a consultant to Novartis and the recipient of sponsored research support from Novartis. JLR is an employee of Sanofi. The other authors declare no conflict of interest.	Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Aumuller G, 1999, UROLOGY, V53, P1041, DOI 10.1016/S0090-4295(98)00631-1; Baena E, 2013, GENE DEV, V27, P683, DOI 10.1101/gad.211011.112; Balbas MD, 2013, ELIFE, V2, DOI 10.7554/eLife.00499; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; BOSTWICK DG, 1994, AM J SURG PATHOL, V18, P1240, DOI 10.1097/00000478-199412000-00007; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Carmichael CL, 2012, P NATL ACAD SCI USA, V109, P15437, DOI 10.1073/pnas.1213454109; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Casey OM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041668; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Cher ML, 1996, CANCER RES, V56, P3091; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Jongsma J, 2000, PROSTATE, V42, P34, DOI 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li Z, 2013, ASIAN J ANDROL, V15, P328, DOI 10.1038/aja.2013.7; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Mani RS, 2011, CANCER RES, V71, P5387, DOI 10.1158/0008-5472.CAN-11-0876; Matei DV, 2012, CLIN GENITOURIN CANC, V10, P164, DOI 10.1016/j.clgc.2011.12.004; Mertz KD, 2007, NEOPLASIA, V9, P200, DOI 10.1593/neo.07103; Meyer LR, 2013, NUCLEIC ACIDS RES, V41, pD64, DOI 10.1093/nar/gks1048; Palapattu GS, 2009, PROSTATE, V69, P787, DOI 10.1002/pros.20928; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Schelling LA, 2013, HUM PATHOL, V44, P2227, DOI 10.1016/j.humpath.2013.05.005; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Signoretti S, 2005, P NATL ACAD SCI USA, V102, P11355, DOI 10.1073/pnas.0500165102; Simon RA, 2009, HUM PATHOL, V40, P252, DOI 10.1016/j.humpath.2008.07.014; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Sun HF, 2013, BIOINFORMATICS, V29, P1352, DOI 10.1093/bioinformatics/btt135; Svensson C, 2014, NUCLEIC ACIDS RES, V42, P999, DOI 10.1093/nar/gkt921; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Yang JC, 2009, CANCER RES, V69, P151, DOI 10.1158/0008-5472.CAN-08-0442; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043	46	42	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3815	3825		10.1038/onc.2014.308	http://dx.doi.org/10.1038/onc.2014.308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263440				2022-12-28	WOS:000358001600007
J	Su, R; Lin, HS; Zhang, XH; Yin, XL; Ning, HM; Liu, B; Zhai, PF; Gong, JN; Shen, C; Song, L; Chen, J; Wang, F; Zhao, HL; Ma, YN; Yu, J; Zhang, JW				Su, R.; Lin, H-S; Zhang, X-H; Yin, X-L; Ning, H-M; Liu, B.; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W			MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets	ONCOGENE			English	Article							PROTEIN-KINASE-C; RETINOIC ACID; CELL-DIFFERENTIATION; MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; PKC-DELTA; CARDIAC FIBROBLASTS; DOWN-REGULATION; BREAST-CANCER	MicroRNAs have been shown to play an important role in normal hematopoisis and leukemogenesis. Here, we report function and mechanisms of miR-181 family in myeloid differentiation and acute myeloid leukemia (AML). The aberrant overexpression of all the miR-181 family members (miR-181a/b/c/d) was detected in French-American-British M1, M2 and M3 subtypes of adult AML patients. By conducting gain-and loss-of-function experiments, we demonstrated that miR-181a inhibits granulocytic and macrophage-like differentiation of HL-60 cells and CD34+ hematopoietic stem/progenitor cells (HSPCs) by directly targeting and downregulating the expression of PRKCD (which then affected the PRKCD-P38-C/EBPa pathway), CTDSPL (which then affected the phosphorylation of retinoblastoma protein) and CAMKK1. The three genes were also demonstrated to be the targets of miR-181b, miR-181c and miR-181d, respectively. Significantly decreases in the expression levels of the target proteins were detected in AML patients. Inhibition of the expression of miR-181 family members owing to Lenti-miRZip-181a infection in bone marrow blasts of AML patients increased target protein expression levels and partially reversed myeloid differentiation blockage. In the mice implanted with AML CD34+ HSPCs, expression inhibition of the miR-181 family by Lenti-miRZip-181a injection improved myeloid differentiation, inhibited engraftment and infiltration of the leukemic CD34+ cells into the bone marrow and spleen, and released leukemic symptoms. In conclusion, our findings revealed new mechanism of miR-181 family in normal hematopoiesis and AML development, and suggested that expression inhibition of the miR-181 family could provide a new strategy for AML therapy.	[Su, R.; Lin, H-S; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W] Chinese Acad Med Sci, Key State Lab Med Mol Biol, Dept Biochem & Mol Biol, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Su, R.; Lin, H-S; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, X-H; Yin, X-L] 303 Hosp, Dept Hematol, Nanning, Guangxi, Peoples R China; [Ning, H-M] Acad Mil Med Sci, Inst Mil Hemopoiet Stem Cell, Dept Stem Cell Transplantat Ctr, Hosp, Beijing, Peoples R China; [Ning, H-M] Acad Mil Med Sci, Affiliated Hosp, Lvy Translat Med Ctr 307, Lab Oncol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Academy of Military Medical Sciences - China; Academy of Military Medical Sciences - China	Zhang, JW (corresponding author), Chinese Acad Med Sci, Key State Lab Med Mol Biol, Dept Biochem & Mol Biol, Inst Basic Med Sci, Beijing 100730, Peoples R China.	junwu_zhang@pumc.edu.cn	Su, Rui/Y-8157-2018	Shen, Chao/0000-0002-9406-7075; Su, Rui/0000-0002-4807-6229	National Natural Science Foundation of China [31171311, 30970616, 81070435]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Natural Science Foundation of China grants 31171311 and 30970616 (to J-WZ) and 81070435 (to H-MN).	BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bisso A, 2013, CELL CYCLE, V12, P1679, DOI 10.4161/cc.24757; Careccia S, 2009, ONCOGENE, V28, P4034, DOI 10.1038/onc.2009.255; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chen C, 2012, BRIT J PHARMACOL, V166, P676, DOI 10.1111/j.1476-5381.2011.01785.x; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Cuesta R, 2009, MOL CELL BIOL, V29, P2841, DOI 10.1128/MCB.01971-08; Debernardi S, 2007, LEUKEMIA, V21, P912, DOI 10.1038/sj.leu.2404605; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; EGELAND T, 1991, BLOOD, V78, P3192; Feng W, 2010, BRIT J PHARMACOL, V159, P1598, DOI 10.1111/j.1476-5381.2009.00558.x; Fragoso R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002855; Gan XQ, 2012, NAT CELL BIOL, V14, P686, DOI 10.1038/ncb2507; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749; Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104; Guest CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001606; Hampson P, 2005, BLOOD, V106, P1362, DOI 10.1182/blood-2004-10-4117; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Ke G, 2013, ONCOGENE, V32, P3019, DOI 10.1038/onc.2012.323; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Lawson ND, 1999, EXP HEMATOL, V27, P1682, DOI 10.1016/S0301-472X(99)00108-3; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Li ZJ, 2012, BLOOD, V119, P2314, DOI 10.1182/blood-2011-10-386235; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Marcucci G, 2008, NEW ENGL J MED, V358, P1919, DOI 10.1056/NEJMoa074256; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; Nitti M, 2010, CELL SIGNAL, V22, P828, DOI 10.1016/j.cellsig.2010.01.007; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Pons A, 2009, LEUKEMIA LYMPHOMA, V50, P1854, DOI 10.3109/10428190903147645; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Schwind S, 2010, J CLIN ONCOL, V28, P5257, DOI 10.1200/JCO.2010.29.2953; Senchenko VN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-75; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Studzinski GP, 2005, J STEROID BIOCHEM, V97, P47, DOI 10.1016/j.jsbmb.2005.06.010; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Verploegen S, 2005, BLOOD, V106, P1076, DOI 10.1182/blood-2004-09-3755; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wang XS, 2012, BLOOD, V119, P4992, DOI 10.1182/blood-2011-10-385716; Wang XN, 2009, CELL CYCLE, V8, P736, DOI 10.4161/cc.8.5.7870; Yendamuri S, 2009, LEUKEMIA, V23, P1257, DOI 10.1038/leu.2008.382; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zheng YS, 2012, ONCOGENE, V31, P80, DOI 10.1038/onc.2011.208	50	118	120	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3226	3239		10.1038/onc.2014.274	http://dx.doi.org/10.1038/onc.2014.274			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25174404				2022-12-28	WOS:000356592300002
J	Sun, Y; Kaneko, S; Li, XK; Li, X				Sun, Y.; Kaneko, S.; Li, X. K.; Li, X.			The PI3K/Akt signal hyperactivates Eya1 via the SUMOylation pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER CELL-LINES; EYES ABSENT PROTEINS; BREAST-CANCER; CONJUGATING ENZYME; TRANSCRIPTIONAL REPRESSION; TUMOR-CELLS; GENE; PHOSPHATASE; EXPRESSION	Eyes absent 1 (Eya1) is a conserved critical regulator of organ-specific stem cells. Ectopic Eya1 activities, however, promote transformation of mammary epithelial cells. Signals that instigate Eya1 oncogenic activities remain to be determined. Here, we show that Akt1 kinase physically interacts with Eya1 and phosphorylates a conserved consensus site of the Akt kinase. PI3K/Akt signaling enhances Eya1 transcription activity, which largely attributes to the phosphorylation-induced reduction of Eya1 SUMOylation. Indeed, SUMOylation inhibits Eya1 transcription activity; and pharmacologic and genetic activation of PI3K/Akt robustly reduces Eya1 SUMOylation. Wild-type but not Akt phosphorylation site mutant Eya1 variant rescues the cell migratory phenotype of EYA1-silenced breast cancer cells, highlighting the importance of Eya1 phosphorylation. Furthermore, knockdown EYA1 sensitizes breast cancer cells to the PI3K/Akt1 inhibitor and irradiation treatments. Thus, the PI3K/Akt signal pathway activates Eya1. These findings further suggest that regulation of SUMOylation by PI3K/Akt signaling is likely an important aspect of tumorigenesis.	[Sun, Y.; Kaneko, S.; Li, X.] Boston Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA; [Sun, Y.; Kaneko, S.; Li, X.] Harvard Univ, Sch Med, Dept Surg, Boston, MA USA; [Sun, Y.; Kaneko, S.; Li, X.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; [Li, X. K.] Wenzhou Med Coll, Sch Pharmaceut Sci, Wenzhou, Peoples R China	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Wenzhou Medical University	Li, XK (corresponding author), Boston Childrens Hosp, Urol Dis Res Ctr, 300 Longwood Ave, Boston, MA 02115 USA.	sean.li@childrens.harvard.edu		Sun, Ye/0000-0002-7674-9056	NIH/NIDCR [1R01DE019823]; NIH/NIDDK [R01DK916451, P50DK65298]; AHA [13GRNT16950006]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065298, R01DK091645] Funding Source: NIH RePORTER	NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHA(American Heart Association); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank S Morley for suggestions and critical reading of the manuscript. We thank I Teng, CS Guo, XJ Shi, ZF Chai and K Pelton for technical supports. We are grateful to R Adam, G Gill, J Brugge, C Kuperwasser for providing reagents, cell lines and helpful discussion. This work was supported by grant from NIH/NIDCR (1R01DE019823, XL), NIH/NIDDK (R01DK916451 and P50DK65298, XL) and AHA (13GRNT16950006, XL).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Alkuraya FS, 2006, SCIENCE, V313, P1751, DOI 10.1126/science.1128406; Bawa-Khalfe T, 2012, P NATL ACAD SCI USA, V109, P17466, DOI 10.1073/pnas.1209378109; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Dunnebier T, 2010, BREAST CANCER RES TR, V121, P185, DOI 10.1007/s10549-009-0530-y; Dunnebier T, 2009, INT J CANCER, V125, P596, DOI 10.1002/ijc.24286; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Guo CS, 2011, J CLIN INVEST, V121, P1585, DOI 10.1172/JCI44630; Jian OY, 2009, MOL CELL, V34, P145, DOI 10.1016/j.molcel.2009.03.013; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Machon O, 2000, MECH DEVELOP, V97, P3, DOI 10.1016/S0925-4773(00)00402-0; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Moschos SJ, 2010, HUM PATHOL, V41, P1286, DOI 10.1016/j.humpath.2010.02.007; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Pandey RN, 2010, ONCOGENE, V29, P3715, DOI 10.1038/onc.2010.122; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sajithlal G, 2005, DEV BIOL, V284, P323, DOI 10.1016/j.ydbio.2005.05.029; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Synowiec E, 2010, MUTAT RES-FUND MOL M, V694, P31, DOI 10.1016/j.mrfmmm.2010.09.002; Tadjuidje E, 2013, CELL MOL LIFE SCI, V70, P1897, DOI 10.1007/s00018-012-1144-9; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Torbett NE, 2008, BIOCHEM J, V415, P97, DOI 10.1042/BJ20080639; Wu KM, 2013, CANCER RES, V73, P4488, DOI 10.1158/0008-5472.CAN-12-4078; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang XJ, 2006, MOL CELL, V23, P779, DOI 10.1016/j.molcel.2006.08.009; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	49	13	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2527	2537		10.1038/onc.2014.179	http://dx.doi.org/10.1038/onc.2014.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24954506	Green Accepted, Green Submitted			2022-12-28	WOS:000354190400011
J	Koo, BS; Lee, SH; Kim, JM; Huang, S; Kim, SH; Rho, YS; Bae, WJ; Kang, HJ; Kim, YS; Moon, JH; Lim, YC				Koo, B. S.; Lee, S. H.; Kim, J. M.; Huang, S.; Kim, S. H.; Rho, Y. S.; Bae, W. J.; Kang, H. J.; Kim, Y. S.; Moon, J. H.; Lim, Y. C.			Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER CELLS; RESISTANCE; IDENTIFICATION; PLURIPOTENCY; EXPRESSION; DISEASE; PROTEIN	Cancer stem cells (CSCs) have been suggested as responsible for the initiation and progression of cancers. Octamer-binding transcription factor 4 (Oct4) is an important regulator of embryonic stem cell fate. Here, we investigated whether Oct4 regulates stemness of head and neck squamous carcinoma (HNSC) CSCs. Our study showed that ectopic expression of Oct4 promotes tumor growth through cyclin E activation, increases chemoresistance through ABCC6 expression and enhances tumor invasion through slug expression. Also, Oct4 dedifferentiates differentiated HNSC cells to CSC-like cells. Furthermore, Oct4(high) HNSC CSCs have more stem cell-like traits compared with Oct4(low) cells, such as self-renewal, stem cell markers' expression, chemoresistance, invasion capacity and xenograft tumorigeneity in vitro and in vivo. In addition, knockdown of Oct4 led to markedly lower HNSC CSC stemness. Finally, there was a significant correlation between Oct4 expression and survival of 119 HNSC patients. Collectively, these data suggest that Oct4 may be a critical regulator of HNSC CSCs and its targeting may be potentially valuable in the treatment of HNSC CSCs.	[Koo, B. S.; Kim, S. H.] Canc Res Inst, Dept Otolaryngol Head & Neck Surg, Taejon, South Korea; [Lee, S. H.] Sungkyunkwan Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Kangbuk Samsung Hosp, Seoul, South Korea; [Kim, J. M.; Huang, S.] Chungnam Natl Univ, Coll Med, Res Inst Med Sci & Pathol, Taejon, South Korea; [Rho, Y. S.] Ewha Womans Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; [Bae, W. J.] Hallym Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Seoul, South Korea; [Kang, H. J.; Kim, Y. S.; Moon, J. H.; Lim, Y. C.] Konkuk Univ, Dept Otorhinolaryngol Head & Neck Surg, Res Inst Med Sci, Sch Med, Seoul 143729, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Chungnam National University; Ewha Womans University; Hallym University; Konkuk University; Konkuk University Medical Center	Lim, YC (corresponding author), Konkuk Univ, Dept Otorhinolaryngol Head & Neck Surg, Res Inst Med Sci, Sch Med, 120-1 Neungdong Ro Hwayang Dong, Seoul 143729, South Korea.	yclim69@hanmail.net		KIM, JIN MAN/0000-0003-0905-9730; Koo, Bon Seok/0000-0002-5928-0006	Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A111700]; National Research Foundation of Korea (NRF) grant - Korea government (MEST) [2012R1A2A2A01046214, 2013R1A2A2A01015281]	Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; National Research Foundation of Korea (NRF) grant - Korea government (MEST)	This work was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (Grant number A111700 to YCL) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (Grant number 2012R1A2A2A01046214 to YCL and 2013R1A2A2A01015281 to BSK).	Chang CC, 2008, CANCER RES, V68, P6281, DOI 10.1158/0008-5472.CAN-08-0094; Chen KG, 2012, CLIN CANCER RES, V18, P1863, DOI 10.1158/1078-0432.CCR-11-1590; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Ge N, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-94; Gerrard L, 2005, STEM CELLS, V23, P124, DOI 10.1634/stemcells.2004-0102; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jung JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028068; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lengner CJ, 2008, CELL CYCLE, V7, P725, DOI 10.4161/cc.7.6.5573; Lim YC, 2011, ORAL ONCOL, V47, P83, DOI 10.1016/j.oraloncology.2010.11.011; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tsai LL, 2011, J ORAL PATHOL MED, V40, P621, DOI 10.1111/j.1600-0714.2011.01015.x; Wang XQ, 2010, HEPATOLOGY, V52, P528, DOI 10.1002/hep.23692; Wiegand S, 2005, CANCER-AM CANCER SOC, V104, P94, DOI 10.1002/cncr.21131; Xie LQ, 2010, ANN SURG ONCOL, V17, P1927, DOI 10.1245/s10434-010-0922-6; Yamano Y, 2010, INT J CANCER, V126, P437, DOI 10.1002/ijc.24704; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu FG, 2013, LARYNGOSCOPE, V123, P1903, DOI 10.1002/lary.24003	27	81	85	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2317	2324		10.1038/onc.2014.174	http://dx.doi.org/10.1038/onc.2014.174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954502	Bronze			2022-12-28	WOS:000353824800005
J	Delbridge, ARD; Grabow, S; Bouillet, P; Adams, JM; Strasser, A				Delbridge, A. R. D.; Grabow, S.; Bouillet, P.; Adams, J. M.; Strasser, A.			Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis	ONCOGENE			English	Article							B-CELL LYMPHOMAS; DRIVEN LYMPHOMAGENESIS; HOMOZYGOUS DELETIONS; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; DEFICIENT MICE; C-MYC; PUMA; BCL-X(L); DEATH	Genomic analyses revealed that many cancers have acquired abnormalities in their expression of pro-or anti-apoptotic members of the BCL-2 protein family. It is, however, unknown whether changes in pro-or anti-apoptotic BCL-2 family members have similar impact on tumorigenesis or whether changes in one subgroup have disproportionate impact. We compared the consequences of concomitant loss of anti-apoptotic Bclx and pro-apoptotic Bim on MYC-induced lymphomagenesis. Whereas only loss of both Bclx alleles markedly forestalled tumorigenesis, loss of a single Bim allele overcame this blockade. Conversely, loss of even a single Bim allele sufficed to substantially accelerate lymphomagenesis, and only loss of both but not loss of a single allele of Bclx could attenuate this acceleration. The evidence that modest (two-fold) monoallelic changes in the expression of at least some BH3-only proteins can profoundly impact tumorigenesis suggests that such aberrations, imposed by epigenetic or genetic changes, may expedite tumorigenesis more effectively than elevated expression of pro-survival BCL-2 family members. These findings further our understanding of the mechanisms of lymphomagenesis and possibly also cancer therapy.	[Delbridge, A. R. D.; Grabow, S.; Bouillet, P.; Adams, J. M.; Strasser, A.] Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, Melbourne, Vic 3050, Australia; [Delbridge, A. R. D.; Grabow, S.; Bouillet, P.; Adams, J. M.; Strasser, A.] Univ Melbourne, Dept Mol Biol, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Strasser, A (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Parkville, Vic 3050, Australia.	strasser@wehi.edu.au	Adams, Jerry M/E-1199-2013; Strasser, Andreas/C-7581-2013; Bouillet, Philippe/E-1241-2013	Strasser, Andreas/0000-0002-5020-4891; Bouillet, Philippe/0000-0002-9012-6058; Adams, Jerry/0000-0002-4360-8628	National Health and Medical Research Council of Australia [461221/1016701, 1020363, 1046010]; Leukemia and Lymphoma Society [7413, 7001-13]; Cancer Council Victoria (CCV) [1052309]; Cancer Council of Victoria; Lady Tata Postdoctoral Fellowship; Melbourne International Research Scholarship (University of Melbourne); Melbourne International Fee Remission Scholarship (University of Melbourne); Australian Postgraduate Award; Cancer Therapeutics CRC Top-up Scholarship; Australian Government (IRISS); Victorian State Government (OIS)	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Cancer Council Victoria (CCV)(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Lady Tata Postdoctoral Fellowship; Melbourne International Research Scholarship (University of Melbourne); Melbourne International Fee Remission Scholarship (University of Melbourne); Australian Postgraduate Award(Australian Government); Cancer Therapeutics CRC Top-up Scholarship(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Australian Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government (OIS)	We thank PN Kelly (NIH) for previously published work that laid the foundation for the present study, G Siciliano and his team for animal husbandry, the FACS facility and the histology facility at The Walter and Eliza Hall Institute. Work in the authors' laboratory was supported by the National Health and Medical Research Council of Australia (program grant 461221/1016701, Fellowship 1020363, NHMRC Project 1046010), the Leukemia and Lymphoma Society (SCOR grant #7413; 7001-13), the Cancer Council Victoria (CCV grant 1052309), and fellowships from the Cancer Council of Victoria (SG), Lady Tata Postdoctoral Fellowship (SG), Melbourne International Research Scholarship (University of Melbourne, SG), Melbourne International Fee Remission Scholarship (University of Melbourne, SG), Australian Postgraduate Award (ARDD) and Cancer Therapeutics CRC Top-up Scholarship (SG and ARDD). This work was made possible by operational infrastructure grants through the Australian Government (IRISS) and the Victorian State Government (OIS).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Akhtar RS, 2008, J HISTOCHEM CYTOCHEM, V56, P921, DOI 10.1369/jhc.2008.951749; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Delbridge ARD, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008789; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Happo L, 2010, BLOOD, V116, P5256, DOI 10.1182/blood-2010-04-280818; KAPLAN HENRY S., 1964, NAT CANCER INST MONOGR, V14, P207; Kelly PN, 2013, CELL DEATH DIFFER, V20, P57, DOI 10.1038/cdd.2012.92; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kelly PN, 2011, BLOOD, V118, P6380, DOI 10.1182/blood-2011-07-367672; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Swanson PJ, 2004, J IMMUNOL, V172, P6684, DOI 10.4049/jimmunol.172.11.6684; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211	27	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1872	1876		10.1038/onc.2014.132	http://dx.doi.org/10.1038/onc.2014.132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858047				2022-12-28	WOS:000352158000014
J	Ge, C; Zhao, G; Li, Y; Li, H; Zhao, X; Pannone, G; Bufo, P; Santoro, A; Sanguedolce, F; Tortorella, S; Mattoni, M; Papagerakis, S; Keller, ET; Franceschi, RT				Ge, C.; Zhao, G.; Li, Y.; Li, H.; Zhao, X.; Pannone, G.; Bufo, P.; Santoro, A.; Sanguedolce, F.; Tortorella, S.; Mattoni, M.; Papagerakis, S.; Keller, E. T.; Franceschi, R. T.			Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; MOUSE MODEL; IN-VIVO; GENE; ACTIVATION; ANDROGEN; PROTEIN; EXPRESSION	The osteogenic transcription factor, Runx2, is abnormally expressed in prostate cancer (PCa) and associated with metastatic disease. During bone development, Runx2 is activated by signals known to be hyperactive in PCa including the RAS/MAP kinase pathway, which phosphorylates Runx2 on multiple serine residues including S301 and S319 (equivalent to S294 and S312 in human Runx2). This study examines the role of these phosphorylation sites in PCa. Runx2 was preferentially expressed in more invasive PCa cell lines (PC34C4-2B4LNCaP). Furthermore, analysis using a P-S319-Runx2-specific antibody revealed that the ratio of P-S319-Runx2/total Runx2 as well as P-ERK/total ERK was highest in PC3 followed by C4-2B and LNCaP cells. These results were confirmed by immunofluorescence confocal microscopy, which showed a higher percentage of PC3 cells staining positive for P-S319-Runx2 relative to C4-2B and LNCaP cells. Phosphorylated Runx2 had an exclusively nuclear localization. When expressed in prostate cell lines, wild-type Runx2 increased metastasis-associated gene expression, in vitro migratory and invasive activity as well as in vivo growth of tumor cell xenografts. In contrast, S301A/S319A phosphorylation site mutations greatly attenuated these Runx2 responses. Analysis of tissue microarrays from 129 patients revealed strong nuclear staining with the P-S319-Runx2 antibody in primary PCas and metastases. P-S319-Runx2 staining was positively correlated with Gleason score and occurrence of lymph node metastases while little or no Runx2 phosphorylation was seen in normal prostate, benign prostate hyperplasia or prostatitis indicating that Runx2 S319 phosphorylation is closely associated with PCa induction and progression towards an aggressive phenotype. These studies establish the importance of Runx2 phosphorylation in prostate tumor growth and highlight its value as a potential diagnostic marker and therapeutic target.	[Ge, C.; Zhao, G.; Li, Y.; Li, H.; Zhao, X.; Papagerakis, S.; Franceschi, R. T.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 USA; [Pannone, G.; Bufo, P.; Santoro, A.; Sanguedolce, F.; Tortorella, S.; Mattoni, M.] Univ Foggia, Dept Clin & Expt Med, Sect Anat Pathol, Foggia, Italy; [Bufo, P.] RCCS Ctr Riferimento Oncol Basilicata Rionero Vul, Potenza, Italy; [Papagerakis, S.] Univ Michigan, Sch Med, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; [Keller, E. T.] Univ Michigan, Sch Med, Lab Anim Med, Ann Arbor, MI 48109 USA; [Franceschi, R. T.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Foggia; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Franceschi, RT (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 USA.	rennyf@umich.edu	santoro, angela/AAC-2025-2019; FRANCESCHI, RENNY/K-3533-2019; Santoro, Angela/AAC-5833-2022; Keller, Evan T/M-1446-2016	santoro, angela/0000-0002-6964-5152; Keller, Evan T/0000-0002-7592-7535; Sanguedolce, Francesca/0000-0001-7459-3521	Department of Defense [W81XWH-11-1-0317]; National Institutes of Health [P01 CA093900]; I.R.C.C.S Centro di Riferimento Oncologico Della Basilicata Rionero in Vulture; NATIONAL CANCER INSTITUTE [R01CA108975, P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723, K12DE023574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); I.R.C.C.S Centro di Riferimento Oncologico Della Basilicata Rionero in Vulture; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by award number W81XWH-11-1-0317 from the Department of Defense (to RTF), and P01 CA093900 from the National Institutes of Health (EK) and I.R.C.C.S Centro di Riferimento Oncologico Della Basilicata Rionero in Vulture (PB). The pOPN-Luc plasmid was a generous gift from Dr. Martha Somerman (NIDCR).	AKECH J, 2009, ONCOGENE, V2009, P1; Aytes A, 2013, P NATL ACAD SCI USA, V110, pE3506, DOI 10.1073/pnas.1303558110; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007; Browne G, 2012, BRIT J CANCER, V107, P1714, DOI 10.1038/bjc.2012.455; Chang YM, 2007, NEOPLASIA, V9, P90, DOI 10.1593/neo.06694; Cho NY, 2006, INT J CANCER, V119, P1858, DOI 10.1002/ijc.22071; Chua CW, 2009, CLIN CANCER RES, V15, P4322, DOI 10.1158/1078-0432.CCR-08-3157; Fatherazi S, 2009, J DENT RES, V88, P39, DOI 10.1177/0022034508328072; Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046; Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561; Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980; Gioeli D, 1999, CANCER RES, V59, P279; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285; Gupta A, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-66; Han B, 2009, MODERN PATHOL, V22, P1083, DOI 10.1038/modpathol.2009.69; Havens A, 2008, NEOPLASIA, V10, P371, DOI 10.1593/neo.08154; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jeong JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003949; Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058; Kim HR, 2008, J CELL BIOCHEM, V105, P1048, DOI 10.1002/jcb.21906; Kwon TG, 2011, J CELL BIOCHEM, V112, P3582, DOI 10.1002/jcb.23289; Li Y, 2012, J BONE MINER RES, V27, P1263, DOI 10.1002/jbmr.1574; Li Y, 2010, J BONE MINER RES, V25, P154, DOI 10.1359/jbmr.090705; Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pande S, 2013, J CELL PHYSIOL, V228, P1784, DOI 10.1002/jcp.24339; Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Stewart M, 2007, CANCER RES, V67, P5126, DOI 10.1158/0008-5472.CAN-07-0433; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; THALMANN GN, 1994, CANCER RES, V54, P2577; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; van der Deen M, 2010, J CELL BIOCHEM, V109, P828, DOI 10.1002/jcb.22463; Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WARE JL, 1982, J UROLOGY, V128, P1064, DOI 10.1016/S0022-5347(17)53345-5; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Yoshimi M, 2012, EUR J IMMUNOL, V42, P1044, DOI 10.1002/eji.201040746; Yun SJ, 2012, PROSTATE CANCER P D, V15, P369, DOI 10.1038/pcan.2012.31; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zhang HJ, 2011, CANCER RES, V71, P3257, DOI 10.1158/0008-5472.CAN-10-2603; Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	54	44	44	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					366	376		10.1038/onc.2015.91	http://dx.doi.org/10.1038/onc.2015.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25867060	Green Accepted			2022-12-28	WOS:000369055300010
J	Giotopoulos, G; Chan, WI; Horton, SJ; Ruau, D; Gallipoli, P; Fowler, A; Crawley, C; Papaemmanuil, E; Campbell, PJ; Gottgens, B; Van Deursen, JM; Cole, PA; Huntly, BJP				Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Fowler, A.; Crawley, C.; Papaemmanuil, E.; Campbell, P. J.; Goettgens, B.; Van Deursen, J. M.; Cole, P. A.; Huntly, B. J. P.			The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia	ONCOGENE			English	Article							CREB-BINDING-PROTEIN; MUTATIONS; GENE; RECRUITMENT; MECHANISMS; INTERACTS; CHROMATIN; REQUIRES	Growing evidence links abnormal epigenetic control to the development of hematological malignancies. Accordingly, inhibition of epigenetic regulators is emerging as a promising therapeutic strategy. The acetylation status of lysine residues in histone tails is one of a number of epigenetic post-translational modifications that alter DNA-templated processes, such as transcription, to facilitate malignant transformation. Although histone deacetylases are already being clinically targeted, the role of histone lysine acetyltransferases (KAT) in malignancy is less well characterized. We chose to study this question in the context of acute myeloid leukemia (AML), where, using in vitro and in vivo genetic ablation and knockdown experiments in murine models, we demonstrate a role for the epigenetic regulators CBP and p300 in the induction and maintenance of AML. Furthermore, using selective small molecule inhibitors of their lysine acetyltransferase activity, we validate CBP/p300 as therapeutic targets in vitro across a wide range of human AML subtypes. We proceed to show that growth retardation occurs through the induction of transcriptional changes that induce apoptosis and cell-cycle arrest in leukemia cells and finally demonstrate the efficacy of the KAT inhibitors in decreasing clonogenic growth of primary AML patient samples. Taken together, these data suggest that CBP/p300 are promising therapeutic targets across multiple subtypes in AML.	[Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Fowler, A.; Crawley, C.; Campbell, P. J.; Goettgens, B.; Huntly, B. J. P.] Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England; [Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Fowler, A.; Crawley, C.; Campbell, P. J.; Goettgens, B.; Huntly, B. J. P.] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Giotopoulos, G.; Chan, W-I; Horton, S. J.; Ruau, D.; Gallipoli, P.; Goettgens, B.; Huntly, B. J. P.] Wellcome Trust Res Labs, Med Res Council, Cambridge Stem Cell Inst, Cambridge, England; [Chan, W-I] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China; [Papaemmanuil, E.; Campbell, P. J.] Wellcome Trust Sanger Inst, Hinxton, England; [Van Deursen, J. M.] Mayo Clin, Dept Pediat & Adolescent Med, Coll Med, Rochester, MN USA; [Cole, P. A.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Cambridge; Wellcome Trust Sanger Institute; Macau University of Science & Technology; Wellcome Trust Sanger Institute; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine	Huntly, BJP (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.	bjph2@cam.ac.uk	Gallipoli, Paolo/AAA-7094-2019; huntly, brian/E-6725-2014	Gallipoli, Paolo/0000-0001-7254-2253; Gottgens, Berthold/0000-0001-6302-5705; huntly, brian/0000-0003-0312-161X; Giotopoulos, George/0000-0003-1390-6592	Cancer Research UK; Leukemia Lymphoma Research; Kay Kendal Leukemia Fund; Leukemia lymphoma Society of America; Wellcome Trust; Medical Research Council; NIHR Cambridge Biomedical Research Centre grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM062437, R01GM062437] Funding Source: NIH RePORTER; BBSRC [BB/I00050X/1] Funding Source: UKRI; MRC [MR/M010392/1] Funding Source: UKRI; Academy of Medical Sciences (AMS) [AMS-SGCL10-Gallipoli] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish; Cancer Research UK [12765] Funding Source: researchfish; Medical Research Council [MR/M010392/1, MC_PC_12009] Funding Source: researchfish; Worldwide Cancer Research [14-1069] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Leukemia Lymphoma Research; Kay Kendal Leukemia Fund; Leukemia lymphoma Society of America(Leukemia and Lymphoma Society); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Cambridge Biomedical Research Centre grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Worldwide Cancer Research	Funding in the Huntly laboratory comes from Cancer Research UK, Leukemia Lymphoma Research, the Kay Kendal Leukemia Fund, the Leukemia lymphoma Society of America, the Wellcome Trust, The Medical Research Council and an NIHR Cambridge Biomedical Research Centre grant. Patient samples were processed in the Cambridge Blood and Stem Cell Biobank.	Allard S, 2004, BBA-GENE STRUCT EXPR, V1677, P158, DOI 10.1016/j.bbaexp.2003.10.016; Baljeyic M, 2011, HEMATOL ONCOL CLIN N, V25, P1215, DOI 10.1016/j.hoc.2011.10.002; Bayly R, 2004, J BIOL CHEM, V279, P55362, DOI 10.1074/jbc.M408654200; Bedford DC, 2010, EPIGENETICS-US, V5, P9, DOI 10.4161/epi.5.1.10449; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Cao G., 2014, EVID-BASED COMPL ALT, V2014, P1, DOI DOI 10.1109/WCSP.2013.6677085; Chan WI, 2011, MOL CELL BIOL, V31, P5046, DOI 10.1128/MCB.05830-11; Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Grunwald MR, 2013, INT J HEMATOL, V97, P683, DOI 10.1007/s12185-013-1334-8; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kimbrel EA, 2009, BLOOD, V114, P4804, DOI 10.1182/blood-2009-04-217794; Kung AL, 2000, GENE DEV, V14, P272; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Oki Y, 2010, CANCER TREAT RES, V145, P19, DOI 10.1007/978-0-387-69259-3_2; Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Roelfsema Jeroen H., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000415; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Walter RB, 2012, BLOOD, V119, P6198, DOI 10.1182/blood-2011-11-325050; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662	36	42	45	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					279	289		10.1038/onc.2015.92	http://dx.doi.org/10.1038/onc.2015.92			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893291	Green Accepted			2022-12-28	WOS:000369055300002
J	Morton, JJ; Bird, G; Keysar, SB; Astling, DP; Lyons, TR; Anderson, RT; Glogowska, MJ; Estes, P; Eagles, JR; Le, PN; Gan, G; McGettigan, B; Fernandez, P; Padilla-Just, N; Varella-Garcia, M; Song, JI; Bowles, DW; Schedin, P; Tan, AC; Roop, DR; Wang, XJ; Refaeli, Y; Jimeno, A				Morton, J. J.; Bird, G.; Keysar, S. B.; Astling, D. P.; Lyons, T. R.; Anderson, R. T.; Glogowska, M. J.; Estes, P.; Eagles, J. R.; Le, P. N.; Gan, G.; McGettigan, B.; Fernandez, P.; Padilla-Just, N.; Varella-Garcia, M.; Song, J. I.; Bowles, D. W.; Schedin, P.; Tan, A-C; Roop, D. R.; Wang, X-J; Refaeli, Y.; Jimeno, A.			XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; LARGE GENE LISTS; PANCREATIC-CANCER; STEM-CELLS; NUDE-MICE; RNA-SEQ; TUMOR; RECEPTOR; THERAPY; LYMPHANGIOGENESIS	The limitations of cancer cell lines have led to the development of direct patient-derived xenograft models. However, the interplay between the implanted human cancer cells and recruited mouse stromal and immune cells alters the tumor microenvironment and limits the value of these models. To overcome these constraints, we have developed a technique to expand human hematopoietic stem and progenitor cells (HSPCs) and use them to reconstitute the radiation-depleted bone marrow of a NOD/SCID/IL2rg(-/-) (NSG) mouse on which a patient's tumor is then transplanted (XactMice). The human HSPCs produce immune cells that home into the tumor and help replicate its natural microenvironment. Despite previous passage on nude mice, the expression of epithelial, stromal and immune genes in XactMice tumors aligns more closely to that of the patient tumor than to those grown in nonhumanized mice-an effect partially facilitated by human cytokines expressed by both the HSPC progeny and the tumor cells. The human immune and stromal cells produced in the XactMice can help recapitulate the microenvironment of an implanted xenograft, reverse the initial genetic drift seen after passage on non-humanized mice and provide a more accurate tumor model to guide patient treatment.	[Morton, J. J.; Keysar, S. B.; Astling, D. P.; Lyons, T. R.; Anderson, R. T.; Glogowska, M. J.; Eagles, J. R.; Le, P. N.; McGettigan, B.; Padilla-Just, N.; Varella-Garcia, M.; Bowles, D. W.; Schedin, P.; Tan, A-C; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Dept Med, Aurora, CO USA; [Bird, G.; Estes, P.; Roop, D. R.; Refaeli, Y.] Univ Colorado, Sch Med, Dept Dermatol, 12800 E 19th Ave,MS-8320, Aurora, CO 80045 USA; [Astling, D. P.; Tan, A-C] Univ Colorado, Sch Med, Dept Biostat & Informat, Aurora, CO USA; [Gan, G.] Univ Colorado, Sch Med, Dept Radiat Oncol, Aurora, CO USA; [Fernandez, P.; Wang, X-J] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA; [Song, J. I.; Jimeno, A.] Univ Colorado, Sch Med, Dept Otolaryngol, Aurora, CO USA; [Roop, D. R.; Wang, X-J; Refaeli, Y.; Jimeno, A.] Univ Colorado, Sch Med, Charles C Gates Ctr Regenerat Med & Stem Cell Bio, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Refaeli, Y (corresponding author), Univ Colorado, Sch Med, Dept Dermatol, 12800 E 19th Ave,MS-8320, Aurora, CO 80045 USA.; Jimeno, A (corresponding author), Univ Colorado, Sch Med, Dept Med Oncol & Otolaryngol, 12801 E 17th Ave,MS-8117, Aurora, CO 80045 USA.	Yosef.Refaeli@ucdenver.edu; Antonio.Jimeno@ucdenver.edu	McGettigan, Brett/AAT-2828-2021; Schedin, Pepper/C-2532-2009; Tan, Aik Choon/A-3135-2011	Tan, Aik Choon/0000-0003-2955-8369; Astling, David/0000-0001-8179-0304	Department of Defense Award [W81XWN-10-1-0798]; Charles C Gates Center for Regenerative Medicine and Stem Cell Biology; National Institutes of Health Cancer Center [P30 CA046934]; NIH [R21 DE019712, R01 CA149456, R01 CA117802-06, P30 AR057212-02, P01 AI022295-24, T32 CA174648]; Janet Mordecai Foundation; Peter and Rhonda Grant Foundation; Translational Research Award from the Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [R01CA117802, R01CA149456, P30CA046934, R21CA156114, T32CA174648] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE024371, R01DE015953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE019712] Funding Source: NIH RePORTER	Department of Defense Award(United States Department of Defense); Charles C Gates Center for Regenerative Medicine and Stem Cell Biology; National Institutes of Health Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Janet Mordecai Foundation; Peter and Rhonda Grant Foundation; Translational Research Award from the Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank the patients and normal subjects for their time and generous tissue and blood donations. This work was primarily supported by Department of Defense Award W81XWN-10-1-0798 (principal investigator AJ; co-investigator YR), the Charles C Gates Center for Regenerative Medicine and Stem Cell Biology, and National Institutes of Health Cancer Center Support Grant P30 CA046934 (AJ, YR). Additionally supported by NIH R21 DE019712 (AJ), NIH R01 CA149456 (AJ), the Janet Mordecai Foundation (AJ), the Peter and Rhonda Grant Foundation (AJ), NIH R01 CA117802-06 (YR), NIH P30 AR057212-02 (YR), NIH P01 AI022295-24 (YR), NIH T32 CA174648 (principal investigator XJW; co-investigator PNL) and a Translational Research Award from the Leukemia and Lymphoma Society (YR).	Abate-Daga D, 2014, HUM GENE THER, V25, P1003, DOI 10.1089/hum.2013.209; Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; Bankert RB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024420; Bird GA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105525; Christiansen Ailsa, 2011, Genes Cancer, V2, P1146, DOI 10.1177/1947601911423028; Dadras SS, 2003, AM J PATHOL, V162, P1951, DOI 10.1016/S0002-9440(10)64328-3; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; ENGELHOLM SA, 1985, EUR J CANCER CLIN ON, V21, P815, DOI 10.1016/0277-5379(85)90221-4; Fullar A, 2012, EXP CELL RES, V318, P1517, DOI 10.1016/j.yexcr.2012.03.023; Garrido-Laguna I, 2011, CLIN CANCER RES, V17, P5793, DOI 10.1158/1078-0432.CCR-11-0341; Geary SM, 2008, EXP CELL RES, V314, P2165, DOI 10.1016/j.yexcr.2008.04.011; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; Hausser HJ, 2005, BIOCHEM BIOPH RES CO, V333, P216, DOI 10.1016/j.bbrc.2005.05.097; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Iorns E, 2012, BREAST CANCER RES TR, V131, P321, DOI 10.1007/s10549-011-1784-8; Jackson DG, 2003, TRENDS CARDIOVAS MED, V13, P1, DOI 10.1016/S1050-1738(02)00189-5; Keysar SB, 2013, MOL ONCOL, V7, P776, DOI 10.1016/j.molonc.2013.03.004; Keysar SB, 2013, CANCER RES, V73, P3381, DOI 10.1158/0008-5472.CAN-12-4047; Kidd S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030563; Kimple RJ, 2013, CLIN CANCER RES, V19, P855, DOI 10.1158/1078-0432.CCR-12-2746; Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388; Lee HJ, 2009, ARTHRITIS RHEUM-US, V60, P2325, DOI 10.1002/art.24786; Leskov I, 2013, ONCOGENE, V32, P1066, DOI 10.1038/onc.2012.117; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; McBride WH, 2004, RADIAT RES, V162, P1, DOI 10.1667/RR3196; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; Pallasch CP, 2014, CELL, V156, P590, DOI 10.1016/j.cell.2013.12.041; Redon Richard, 2009, V529, P267, DOI 10.1007/978-1-59745-538-1_17; Rong ZL, 2014, CELL STEM CELL, V14, P121, DOI 10.1016/j.stem.2013.11.014; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Ruitberg CM, 2001, NUCLEIC ACIDS RES, V29, P320, DOI 10.1093/nar/29.1.320; Suggitt M, 2005, CLIN CANCER RES, V11, P971; Tawada M, 2012, J GASTROENTEROL, V47, P1057, DOI 10.1007/s00535-012-0638-4; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Wege AK, 2011, INT J CANCER, V129, P2194, DOI 10.1002/ijc.26159; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; WENNERBERG J, 1983, ACTA OTO-LARYNGOL, V95, P183, DOI 10.3109/00016488309130933; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Zhou QJ, 2014, CANCER LETT, V344, P13, DOI 10.1016/j.canlet.2013.10.015	45	84	90	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					290	300		10.1038/onc.2015.94	http://dx.doi.org/10.1038/onc.2015.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893296	Green Accepted			2022-12-28	WOS:000369055300003
J	Zunino, B; Rubio-Patino, C; Villa, E; Meynet, O; Proics, E; Cornille, A; Pommier, S; Mondragon, L; Chiche, J; Bereder, JM; Carles, M; Ricci, JE				Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Bereder, J-M; Carles, M.; Ricci, J-E			Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90	ONCOGENE			English	Article							PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; DENDRITIC CELL; CANCER; TUMOR; HEAT-SHOCK-PROTEIN-90; IMMUNOSURVEILLANCE; INHIBITION; APOPTOSIS	The occurrence of peritoneal carcinomatosis is a major cause of treatment failure in colorectal cancer and is considered incurable. However, new therapeutic approaches have been proposed, including cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Although HIPEC has been effective in selected patients, it is not known how HIPEC prolongs a patient's lifespan. Here, we have demonstrated that HIPEC-treated tumor cells induce the activation of tumor-specific T cells and lead to vaccination against tumor cells in mice. We have established that this effect results from the HIPEC-mediated exposure of heat shock protein (HSP) 90 at the plasma membrane. Inhibition or blocking of HSP90, but not HSP70, prevented the HIPECmediated antitumoral vaccination. Our work raises the possibility that the HIPEC procedure not only kills tumor cells but also induces an efficient anticancer immune response, therefore opening new opportunities for cancer treatment.	[Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Carles, M.; Ricci, J-E] Ctr Mediterraneen Med Mol C3M, INSERM, U1065, Equipe Controle Metab Morts Cellulaires, F-06204 Nice 03, France; [Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Carles, M.; Ricci, J-E] Univ Nice Sophia Antipolis, Fac Med, F-06189 Nice, France; [Zunino, B.; Pommier, S.; Carles, M.; Ricci, J-E] CHU Nice, Dept Anesthesie Reanimat, F-06202 Nice, France; [Bereder, J-M] CHU Nice, Serv Chirurg Gen & Cancerol Digest, F-06202 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice	Ricci, JE (corresponding author), Ctr Mediterraneen Med Mol C3M, INSERM, U1065, Equipe Controle Metab Morts Cellulaires, 151 Route St Antoine de Ginestiere,BP 23194, F-06204 Nice 03, France.	ricci@unice.fr	Martinez, Laura Mondragon/P-1670-2018; Martinez, Laura Mondragon/X-1577-2019; Ricci, Jean Ehrland/I-7117-2016; Chiche, Johanna/P-6382-2016; Carles, Michel/CAH-0065-2022; RICCI, Jean Ehrland/AAS-4379-2020	Martinez, Laura Mondragon/0000-0002-3257-045X; Martinez, Laura Mondragon/0000-0002-3257-045X; Ricci, Jean Ehrland/0000-0003-1585-8117; Chiche, Johanna/0000-0001-5276-1125; RICCI, Jean Ehrland/0000-0003-1585-8117; CARLES, MICHEL/0000-0001-5485-1511; Rubio-Patino, Camila/0000-0002-0489-2419	Fondation ARC (Association pour la Recherche sur le Cancer); Agence Nationale de la Recherche (LABEX SIGNALIFE) [ANR-11-LABX-0028-01]; Fondation ARC; la Ville de Nice; Fondation pour la Recherche Medicale (FRM); la Fondation de France	Fondation ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche (LABEX SIGNALIFE)(French National Research Agency (ANR)); Fondation ARC; la Ville de Nice; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); la Fondation de France(Fondation de France)	We gratefully acknowledge the Centre Mediterraneen de Medecine Moleculaire animal room and imaging facilities. We thank Jozef Bossowski, Drs Raucoules and Benchimol, Benjamin Lefebvre and all of the operating room and surgical digestive service nurses for their help. This work was supported by the Fondation ARC (Association pour la Recherche sur le Cancer), the Agence Nationale de la Recherche (LABEX SIGNALIFE ANR-11-LABX-0028-01). CRP is supported by the Fondation ARC, LM is supported by la Ville de Nice and by Fondation pour la Recherche Medicale (FRM) and JC is supported by la Fondation de France.	Bae J, 2007, J IMMUNOL, V178, P7730, DOI 10.4049/jimmunol.178.12.7730; Beneteau M, 2012, P NATL ACAD SCI USA, V109, P20071, DOI 10.1073/pnas.1206360109; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Elias D, 2009, J CLIN ONCOL, V27, P681, DOI 10.1200/JCO.2008.19.7160; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; John K, 2002, BIOPHYS J, V83, P3315, DOI 10.1016/S0006-3495(02)75332-0; Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691; Kim YS, 2009, CURR TOP MED CHEM, V9, P1479, DOI 10.2174/156802609789895728; Klaver YLB, 2010, BRIT J SURG, V97, P1874, DOI 10.1002/bjs.7249; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Lanneau D, 2008, J CELL MOL MED, V12, P743, DOI 10.1111/j.1582-4934.2008.00273.x; Massey AJ, 2010, CANCER CHEMOTH PHARM, V66, P535, DOI 10.1007/s00280-009-1194-3; Murshid A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00063; Pelz JOW, 2013, ANN SURG ONCOL, V20, P1105, DOI 10.1245/s10434-012-2784-6; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Spiliotis JD, 2010, HEPATO-GASTROENTEROL, V57, P1173; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Sugarbaker PH, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/623417; Tsutsumi S, 2008, ONCOGENE, V27, P2478, DOI 10.1038/sj.onc.1210897; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Wilke CM, 2010, INT J CANCER, V127, P748, DOI 10.1002/ijc.25464; Yang XJ, 2009, ANN SURG ONCOL, V16, P345, DOI 10.1245/s10434-008-0226-2; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	26	34	45	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					261	268		10.1038/onc.2015.82	http://dx.doi.org/10.1038/onc.2015.82			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25867070				2022-12-28	WOS:000368193900012
J	Leroy, C; Shen, Q; Strande, V; Meyer, R; McLaughlin, ME; Lezan, E; Bentires-Alj, M; Voshol, H; Bonenfant, D; Gaither, LA				Leroy, C.; Shen, Q.; Strande, V.; Meyer, R.; McLaughlin, M. E.; Lezan, E.; Bentires-Alj, M.; Voshol, H.; Bonenfant, D.; Gaither, L. Alex			CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases	ONCOGENE			English	Article							TYROSINE PHOSPHORYLATION; PKC-DELTA; METASTASIS; CDCP1; EPITHELIA; MIGRATION; INVASION; REVEALS; FYN	The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CDCP1) is overexpressed in several cancer types and is a predictor of poor prognosis for patients on standard of care therapies. Phosphorylation of CDCP1 tyrosine sites is induced upon loss of cell adhesion and is thought to be linked to metastatic potential of tumor cells. Using a tyrosine-phosphoproteomics screening approach, we characterized the phosphorylation state of CDCP1 across a panel of breast cancer cell lines. We focused on two phospho-tyrosine pTyr peptides of CDCP1, containing Tyr707 and Tyr806, which were identified in all six lines, with the human epidermal growth factor 2-positive HCC1954 cells showing a particularly high phosphorylation level. Pharmacological modulation of tyrosine phosphorylation indicated that, the Src family kinases (SFKs) were found to phosphorylate CDCP1 at Tyr707 and Tyr806 and play a critical role in CDCP1 activity. We demonstrated that CDCP1 overexpression in HEK293 cells increases global phosphotyrosine content, promotes anchorage-independent cell growth and activates several SFK members. Conversely, CDCP1 downregulation in multiple solid cancer cell lines decreased both cell growth and SFK activation. Analysis of primary human tumor samples demonstrated a correlation between CDCP1 expression, SFK and protein kinase C (PKC) activity. Taken together, our results suggest that CDCP1 overexpression could be an interesting therapeutic target in multiple solid cancers and a good biomarker to stratify patients who could benefit from an anti-SFK-targeted therapy. Our data also show that multiple tyrosine phosphorylation sites of CDCP1 are important for the functional regulation of SFKs in several tumor types.	[Leroy, C.; Strande, V.; Lezan, E.; Voshol, H.; Bonenfant, D.] Novartis Inst BioMed Res, Basel, Switzerland; [Shen, Q.; Meyer, R.; McLaughlin, M. E.; Gaither, L. Alex] Novartis Inst BioMed Res Inc, Cambridge, MA 02139 USA; [Bentires-Alj, M.] Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Novartis; Novartis; Friedrich Miescher Institute for Biomedical Research	Gaither, LA (corresponding author), Novartis Inst BioMed Res Inc, 500 Technol Sq, Cambridge, MA 02139 USA.	alex.gaither@novartis.com	Bentires-Alj, Mohamed/F-4484-2015	Bentires-Alj, Mohamed/0000-0001-6344-1127				Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Verma R, 2003, J BIOL CHEM, V278, P20716, DOI 10.1074/jbc.M301689200; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198	20	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5593	5598		10.1038/onc.2015.19	http://dx.doi.org/10.1038/onc.2015.19			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25728678	hybrid, Green Published			2022-12-28	WOS:000364594000008
J	Wang, Z; Xu, D; Ding, HF; Kim, J; Zhang, J; Hai, T; Yan, C				Wang, Z.; Xu, D.; Ding, H-F; Kim, J.; Zhang, J.; Hai, T.; Yan, C.			Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR-3; GENE-EXPRESSION; ADAPTIVE-RESPONSE; TUMOR-SUPPRESSOR; METASTASIS; KINASE; TRANSACTIVATION; ADENOCARCINOMA; REPRESSION	Activating transcription factor 3 (ATF3) responds to diverse cellular stresses, and regulates oncogenic activities (for example, proliferation, survival and migration) through direct transcriptional regulation or protein-protein interactions. Although aberrant ATF3 expression is frequently found in human cancers, the role of ATF3 in tumorigenesis is poorly understood. Here, we demonstrate that ATF3 suppresses the development of prostate cancer induced by knockout of the tumor suppressor Pten in mouse prostates. Whereas the oncogenic stress elicited by Pten loss induced ATF3 expression in prostate epithelium, we found that ATF3 deficiency increased cell proliferation and promoted cell survival, leading to early onset of mouse prostatic intraepithelial neoplasia and the progression of prostate lesions to invasive adenocarcinoma. Importantly, the loss of ATF3 promoted activation of the oncogenic AKT signaling evidenced by high levels of phosphorylated AKT and S6 proteins in ATF3-null prostate lesions. In line with these in vivo results, knockdown of ATF3 expression in human prostate cancer cells by single guided RNA-mediated targeting activated AKT and increased matrix metalloproteinase-9 expression. Our results thus link ATF3 to the AKT signaling, and suggest that ATF3 is a tumor suppressor for the major subset of prostate cancers harboring dysfunctional Pten.	[Wang, Z.; Ding, H-F; Yan, C.] Georgia Regents Univ, GRU Canc Ctr, Augusta, GA 30912 USA; [Wang, Z.; Xu, D.; Yan, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Ding, H-F] Georgia Regents Unviers, Dept Pathol, Augusta, GA 30912 USA; [Kim, J.] Georgia Regents Unviers, Dept Biostat & Epidemiol, Augusta, GA 30912 USA; [Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH USA; [Hai, T.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Yan, C.] Georgia Regents Unviers, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Albany Medical College; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Case Western Reserve University; University System of Ohio; Ohio State University; University System of Georgia; Augusta University	Yan, C (corresponding author), Georgia Regents Univ, GRU Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA.	cyan@gru.edu	Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Yan, Chunhong/0000-0002-3974-7991; Ding, Han-Fei/0000-0001-5702-3439	NIH [R01CA139107, R01CA164006]; Department of Defense [W81XWH-07-1-0095]; NATIONAL CANCER INSTITUTE [R01CA164006, R01CA154625, R01CA139107] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants R01CA139107, R01CA164006 and a Department of Defense award W81XWH-07-1-0095 to CY. We thank Dr George Church for providing sgRNA targeting reagents and Dr Honglin Li for providing NF-kappa B reagents.	Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Blando J, 2009, AM J PATHOL, V174, P1869, DOI 10.2353/ajpath.2009.080055; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen HH, 2004, MOL PHARMACOL, V65, P1130, DOI 10.1124/mol.65.5.1130; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gilchrist M, 2010, BLOOD, V115, P4734, DOI 10.1182/blood-2009-03-213512; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Huang CY, 2015, MOL NEUROBIOL, V51, P543, DOI 10.1007/s12035-014-8710-0; Huang XW, 2008, J BIOL CHEM, V283, P29795, DOI 10.1074/jbc.M802515200; Ishiguro T, 1996, CANCER RES, V56, P875; Jan YH, 2012, CANCER RES, V72, P5119, DOI 10.1158/0008-5472.CAN-12-1842; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Liu W, 2011, J BIOL CHEM, V286, P18949, DOI 10.1074/jbc.M111.232637; Liu YQ, 2013, CANCER LETT, V337, P66, DOI 10.1016/j.canlet.2013.05.022; Liu YP, 2013, CANCER RES, V73, P6194, DOI 10.1158/0008-5472.CAN-13-0518; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stearns ME, 2004, MOL CANCER RES, V2, P403; Svensson RU, 2011, AM J PATHOL, V179, P502, DOI 10.1016/j.ajpath.2011.03.014; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Varambally S, 2012, CANCER CELL, V8, P393; Wang HB, 2012, MOL CELL BIOL, V32, P3190, DOI 10.1128/MCB.00159-12; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wei SS, 2014, J BIOL CHEM, V289, P8947, DOI 10.1074/jbc.M113.503755; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948; Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311-06; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879; Zhang QY, 2012, CANCER RES, V72, P2589, DOI 10.1158/0008-5472.CAN-11-3795	51	49	50	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4975	4984		10.1038/onc.2014.426	http://dx.doi.org/10.1038/onc.2014.426			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531328	Green Accepted			2022-12-28	WOS:000361693000007
J	Yang, HW; Kim, TM; Song, SS; Menon, L; Jiang, X; Huang, W; Black, PM; Park, PJ; Carroll, RS; Johnson, MD				Yang, H. W.; Kim, T-M; Song, S. S.; Menon, L.; Jiang, X.; Huang, W.; Black, P. M.; Park, P. J.; Carroll, R. S.; Johnson, M. D.			A small subunit processome protein promotes cancer by altering translation	ONCOGENE			English	Article							INTERNAL RIBOSOME ENTRY; MESSENGER-RNA; CHILDHOOD MEDULLOBLASTOMA; C-MYC; NEUROBLASTOMA; REVEALS; PROGRESSION; INHIBITION; BIOGENESIS; DEFECTS	Dysregulation of ribosome biogenesis or translation can promote cancer, but the underlying mechanisms remain unclear. UTP18 is a component of the small subunit processome, a nucleolar multi-protein complex whose only known function is to cleave pre-ribosomal RNA to yield the 18S ribosomal RNA component of 40S ribosomal subunits. Here, we show that UTP18 also alters translation to promote stress resistance and growth, and that UTP18 is frequently gained and overexpressed in cancer. We observed that UTP18 localizes to the cytoplasm in a subset of cells, and that serum withdrawal increases cytoplasmic UTP18 localization. Cytoplasmic UTP18 associates with the translation complex and Hsp90 to upregulate the translation of IRES-containing transcripts such as HIF1a, Myc and VEGF, thereby inducing stress resistance. Hsp90 inhibition decreases cytoplasmic UTP18 and UTP18-induced increases in translation. Importantly, elevated UTP18 expression correlates with increased aggressiveness and decreased survival in numerous cancers. Enforced UTP18 overexpression promotes transformation and tumorigenesis, whereas UTP18 knockdown inhibits these processes. This stress adaptation mechanism is thus co-opted for growth by cancers, and its inhibition may represent a promising new therapeutic target.	[Yang, H. W.; Song, S. S.; Menon, L.; Jiang, X.; Huang, W.; Black, P. M.; Carroll, R. S.; Johnson, M. D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; [Kim, T-M; Park, P. J.] Harvard Univ, Ctr Biomed Informat, Sch Med, Boston, MA 02115 USA; [Johnson, M. D.] Dana Farber Brigham & Womens Canc Ctr, Program Neurooncol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Johnson, MD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.	mjohnson27@partners.org			Brain Science Foundation; Santos Family Foundation; National Institute of Neurological Disorders and Stroke [R01 NS062219]; NIH [DP2 OD002319]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062219] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002319] Funding Source: NIH RePORTER	Brain Science Foundation; Santos Family Foundation; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a Brain Science Foundation Research Award, the Santos Family Foundation, a Hagerty Fund Research Award, R01 NS062219 from the National Institute of Neurological Disorders and Stroke and an NIH Director's New Innovator Award (DP2 OD002319) to MDJ.	Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147; Bernstein KA, 2004, EUKARYOT CELL, V3, P1619, DOI 10.1128/EC.3.6.1619-1626.2004; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; Calabrese C, 2003, J BIOL CHEM, V278, P24951, DOI 10.1074/jbc.M211600200; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Del Prete MJ, 2007, RNA, V13, P414, DOI 10.1261/rna.79407; Fichelson P, 2009, NAT CELL BIOL, V11, P685, DOI 10.1038/ncb1874; Goda N, 2012, INT J HEMATOL, V95, P457, DOI 10.1007/s12185-012-1069-y; Goutagny S, 2010, CLIN CANCER RES, V16, P4155, DOI 10.1158/1078-0432.CCR-10-0891; Holzel M, 2010, J BIOL CHEM, V285, P6364, DOI 10.1074/jbc.M109.054734; Jackson SE, 2013, TOP CURR CHEM, V328, P155, DOI 10.1007/128_2012_356; Kang J, 2006, ANTICANCER RES, V26, P1903; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Kim TM, 2013, GENOME RES, V23, P217, DOI 10.1101/gr.140301.112; Kim TM, 2011, CANCER RES, V71, P3387, DOI 10.1158/0008-5472.CAN-10-4117; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Pan E, 2005, CLIN CANCER RES, V11, P4733; Pisa V, 2009, GENE, V432, P67, DOI 10.1016/j.gene.2008.11.025; Reardon DA, 1997, CANCER RES, V57, P4042; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Schleiermacher G, 2007, BRIT J CANCER, V97, P238, DOI 10.1038/sj.bjc.6603820; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Spriggs KA, 2008, BIOL CELL, V100, P27, DOI 10.1042/BC20070098; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Suzuki Y, 2009, J BIOL CHEM, V284, P35597, DOI 10.1074/jbc.M109.036285; Ujino S, 2012, VIRUS RES, V163, P390, DOI 10.1016/j.virusres.2011.10.003; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Willimott S, 2010, BIOCHEM SOC T, V38, P1571, DOI 10.1042/BST0381571	35	8	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4471	4481		10.1038/onc.2014.376	http://dx.doi.org/10.1038/onc.2014.376			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25435373				2022-12-28	WOS:000360189200006
J	Neri, F; Dettori, D; Incarnato, D; Krepelova, A; Rapelli, S; Maldotti, M; Parlato, C; Paliogiannis, P; Oliviero, S				Neri, F.; Dettori, D.; Incarnato, D.; Krepelova, A.; Rapelli, S.; Maldotti, M.; Parlato, C.; Paliogiannis, P.; Oliviero, S.			TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; LARGE GENE LISTS; DNA METHYLATION; EPIGENETIC INACTIVATION; BREAST-CANCER; MAMMALIAN DEVELOPMENT; COLORECTAL-CANCER; POTENTIAL ROLES; 5-HYDROXYMETHYLCYTOSINE; MUTATIONS	Ten eleven translocation (TET) enzymes catalyse the oxidative reactions of 5-methylcytosine (5mC) to promote the demethylation process. The reaction intermediate 5-hydroxymethylcytosine (5hmC) has been shown to be abundant in embryonic stem cells and tissues but strongly depleted in human cancers. Genetic mutations of TET2 gene were associated with leukaemia, whereas TET1 downregulation has been shown to promote malignancy in breast cancer. Here we report that TET1 is downregulated in colon tumours from the initial stage. TET1 silencing in primary epithelial colon cells increase their cellular proliferation while its re-expression in colon cancer cells inhibits their proliferation and the growth of tumour xenografts even at later stages. We found that TET1 binds to the promoter of the DKK gene inhibitors of the WNT signalling to maintain them hypomethylated. Downregulation of TET1 during colon cancer initiation leads to repression, by DNA methylation, the promoters of the inhibitors of the WNT pathway resulting in a constitutive activation of the WNT pathway. Thus the DNA hydroxymethylation mediated by TET1 controlling the WNT signalling is a key player of tumour growth. These results provide new insights for understanding how tumours escape cellular controls.	[Neri, F.; Dettori, D.; Incarnato, D.; Krepelova, A.; Rapelli, S.; Maldotti, M.; Parlato, C.; Oliviero, S.] Human Genet Fdn HuGeF, Epigenet, Turin, Italy; [Incarnato, D.; Krepelova, A.; Rapelli, S.] Univ Siena, Dipartimento Biotecnol Chim & Farm, I-53100 Siena, Italy; [Paliogiannis, P.] Univ Sassari, Dipartimento Sci Chirurg Microchirurg & Med, I-07100 Sassari, Italy; [Oliviero, S.] Univ Turin, Dipartimento Sci Vita & Biol Sistemi, Turin, Italy	University of Siena; University of Sassari; University of Turin	Oliviero, S (corresponding author), Human Genet Fdn, Epigenet, Via Nizza52, I-10126 Turin, Italy.	salvatore.oliviero@hugef-torino.org	Neri, Francesco/A-3321-2014; Paliogiannis, Panagiotis/M-6870-2016; oliviero, salvatore/R-6657-2019	Neri, Francesco/0000-0003-3903-1974; Paliogiannis, Panagiotis/0000-0001-5485-6056; oliviero, salvatore/0000-0002-3405-765X; Krepelova, Anna/0000-0002-2775-1336; PARLATO, CATERINA/0000-0001-5304-3117; Maldotti, Mara/0000-0002-3299-9053	Associazione Italiana Ricerca sul Cancro (AIRC) [IG 2011/11982]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Associazione Italiana Ricerca sul Cancro (AIRC) IG 2011/11982. We thank Carola Ponzetto and Riccardo Taulli for the critical reading of the manuscript.	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Bacher U, 2010, ANN HEMATOL, V89, P643, DOI 10.1007/s00277-010-0920-6; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Evellin S, 2013, MOL CELL BIOL, V33, P1198, DOI 10.1128/MCB.01054-12; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Haffner MC, 2011, ONCOTARGET, V2, P627; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Incarnato D, 2013, NUCLEIC ACIDS RES, V41, P8421, DOI 10.1093/nar/gkt629; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ivanov M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r83; Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116; Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kallin EM, 2012, MOL CELL, V48, P266, DOI 10.1016/j.molcel.2012.08.007; Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kosmider O, 2009, BLOOD, V114, P3285, DOI 10.1182/blood-2009-04-215814; Krepelova A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088933; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946; Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620; Neri F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r91; Neri F, 2013, CELL, V155, P121, DOI 10.1016/j.cell.2013.08.056; Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pfeifer GP, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-10; Prensner JR, 2011, NAT MED, V17, P291, DOI 10.1038/nm0311-291; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rhee JK, 2013, NUCLEIC ACIDS RES, V41, P8464, DOI 10.1093/nar/gkt643; Saint-Martin C, 2009, BLOOD, V114, P1628, DOI 10.1182/blood-2009-01-197525; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47; Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008-5472.CAN-10-3418; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67	49	130	140	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4168	4176		10.1038/onc.2014.356	http://dx.doi.org/10.1038/onc.2014.356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362856	Green Submitted			2022-12-28	WOS:000359199800003
J	Cetinbas, N; Daugaard, M; Mullen, AR; Hajee, S; Rotblat, B; Lopez, A; Li, A; DeBerardinis, RJ; Sorensen, PH				Cetinbas, N.; Daugaard, M.; Mullen, A. R.; Hajee, S.; Rotblat, B.; Lopez, A.; Li, A.; DeBerardinis, R. J.; Sorensen, P. H.			Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction	ONCOGENE			English	Article							LIGASE HACE1; CANCER; METABOLISM; GROWTH; GENERATION; METHYLATION; EXPRESSION; BIOLOGY; PROTEIN; RAC1	Cellular transformation is associated with altered glutamine (Gln) metabolism. Tumor cells utilize Gln in the tricarboxylic acid (TCA) cycle to maintain sufficient pools of biosynthetic precursors to support rapid growth and proliferation. However, Gln metabolism also generates NADPH, and Gln-derived glutamate is used for synthesis of glutathione (GSH). As both NADPH and GSH are antioxidants, Gln may also contribute to redox balance in transformed cells. The Hace1 E3 ligase is a tumor suppressor inactivated in diverse human cancers. Hace1 targets the Rac1 GTPase for degradation at Rac1-dependent NADPH oxidase complexes, blocking superoxide generation by the latter. Consequently, loss of Hace1 increases reactive oxygen species (ROS) levels in vitro and in vivo. Given the link between Hace1 loss and increased ROS, we investigated whether genetic inactivation of Hace1 alters Gln metabolism. We demonstrate that mouse embryonic fibroblasts (MEFs) derived from Hace1(-/-) mice are highly sensitive to Gln withdrawal, leading to enhanced cell death compared with wild-type (wt) MEFs, and Gln depletion or chemical inhibition of Gln uptake blocks soft agar colony formation by Hace1(-/-) MEFs. Hace1(-/-) MEFs exhibit increased Gln uptake and ammonia secretion, and metabolic labeling using C-13-Gln revealed that Hace1 loss increases incorporation of Gln carbons into the TCA cycle intermediates. Gln starvation markedly increases ROS levels in Hace1(-/-) but not in wt MEFs, and treatment with the antioxidant N-acetyl cysteine or the TCA cycle intermediate oxaloacetate efficiently rescues Gln starvation-induced ROS elevation and cell death in Hace1(-/-) MEFs. Finally, Gln starvation increases superoxide levels in Hace1(-/-) MEFs, and NADPH oxidase inhibitors block the induction of superoxide and cell death by Gln starvation. Together, these results suggest that increased ROS production due to Hace1 loss leads to Gln addiction as a mechanism to cope with increased ROS-induced oxidative stress.	[Cetinbas, N.; Daugaard, M.; Hajee, S.; Rotblat, B.; Lopez, A.; Li, A.; Sorensen, P. H.] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Cetinbas, N.; Daugaard, M.; Rotblat, B.; Sorensen, P. H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Mullen, A. R.; DeBerardinis, R. J.] Texas So Univ, Med Ctr, Dept Pediat, Dallas, TX USA; [Mullen, A. R.; DeBerardinis, R. J.] Texas So Univ, Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX USA	British Columbia Cancer Agency; University of British Columbia; Texas Southern University; Texas Southern University	Sorensen, PH (corresponding author), BC Canc Res Ctr, Dept Mol Oncol, 675 W10th Ave,Room 4112, Vancouver, BC V5Z 1L3, Canada.	psor@mail.ubc.ca	Rotblat, Barak/H-5970-2019; damiani, chiara/R-4256-2016; Daugaard, Mads/Y-6483-2018	Rotblat, Barak/0000-0003-2985-7115; Daugaard, Mads/0000-0001-8383-055X	Canadian Institute of Health Research [MOP-123416]; British Columbia Cancer Foundation [R01 CA157996]; Damon-Runyon Cancer Research Foundation; Canadian Institutes of Health Research; Frederick Banting; Charles Best Canada; NATIONAL CANCER INSTITUTE [R01CA157996] Funding Source: NIH RePORTER	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); British Columbia Cancer Foundation; Damon-Runyon Cancer Research Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Frederick Banting; Charles Best Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by funds from the Canadian Institute of Health Research (MOP-123416) and British Columbia Cancer Foundation through generous donations from Team Finn and Ride to Conquer Cancer (to PHS), and from the National Institutes of Health (R01 CA157996) and Damon-Runyon Cancer Research Foundation (to RJD). NC was funded by the Canadian Institutes of Health Research, Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award.	Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Cheng G, 2006, J BIOL CHEM, V281, P17718, DOI 10.1074/jbc.M512751200; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Daugaard M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3180; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Diskin SJ, 2012, NAT GENET, V44, P1126, DOI 10.1038/ng.2387; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gianni D, 2010, ACS CHEM BIOL, V5, P981, DOI 10.1021/cb100219n; Hibi K, 2008, ANTICANCER RES, V28, P1581; Huang YL, 2010, BLOOD, V115, P1226, DOI 10.1182/blood-2009-05-221275; Klimberg VS, 1996, AM J SURG, V172, P418; Li XN, 2004, CLIN CANCER RES, V10, P1150, DOI 10.1158/1078-0432.CCR-0747-3; MOLDAVE K, 1957, J BIOL CHEM, V229, P463; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Nicolay BN, 2013, GENE DEV, V27, P182, DOI 10.1101/gad.206227.112; Rajagopalan KN, 2011, J NUCL MED, V52, P1005, DOI 10.2967/jnumed.110.084244; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Rotblat B, 2014, P NATL ACAD SCI USA, V111, P3032, DOI 10.1073/pnas.1314421111; Sakata M, 2009, ANTICANCER RES, V29, P2231; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Slade I, 2010, J MED GENET, V47, P342, DOI 10.1136/jmg.2009.072983; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Thelander EF, 2008, LEUKEMIA LYMPHOMA, V49, P477, DOI 10.1080/10428190701817282; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621	39	21	25	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					4005	4010		10.1038/onc.2014.316	http://dx.doi.org/10.1038/onc.2014.316			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284589	Green Accepted			2022-12-28	WOS:000358544200013
J	Itkonen, HM; Engedal, N; Babaie, E; Luhr, M; Guldvik, IJ; Minner, S; Hohloch, J; Tsourlakis, MC; Schlomm, T; Mills, IG				Itkonen, H. M.; Engedal, N.; Babaie, E.; Luhr, M.; Guldvik, I. J.; Minner, S.; Hohloch, J.; Tsourlakis, M. C.; Schlomm, T.; Mills, I. G.			UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation	ONCOGENE			English	Article							ANDROGEN-DEPRIVATION THERAPY; HEXOSAMINE BIOSYNTHETIC-PATHWAY; GLUCOSE-METABOLISM; INSULIN-RESISTANCE; CELL-LINES; EXPRESSION; TRANSFERASE; TUNICAMYCIN; AUTOPHAGY; DIFFERENTIATION	Prostate cancer is the second most common cause of cancer-associated deaths in men, and signaling via a transcription factor called androgen receptor (AR) is an important driver of the disease. Consequently, AR target genes are prominent candidates to be specific for prostate cancer and also important for the survival of the cancer cells. Here we assess the levels of all hexosamine biosynthetic pathway (HBP) enzymes in 15 separate clinical gene expression data sets and identify the last enzyme in the pathway, UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1), to be highly overexpressed in prostate cancer. We analyzed 3261 prostate cancers on a tissue microarray and found that UAP1 staining correlates negatively with Gleason score (P = 0.0039) and positively with high AR expression (P<0.0001). Cells with high UAP1 expression have 10-fold increased levels of the HBP end-product, UDP-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is essential for N-linked glycosylation occurring in the endoplasmic reticulum (ER) and high UAP1 expression associates with resistance against inhibitors of N-linked glycosylation (tunicamycin and 2-deoxyglucose) but not with a general ER stress-inducing agent, the calcium ionophore A23187. Knockdown of UAP1 expression re-sensitized cells towards inhibitors of N-linked glycosylation, as measured by proliferation and activation of ER stress markers. Taken together, we have identified an enzyme, UAP1, which is highly overexpressed in prostate cancer and protects cancer cells from ER stress conferring a growth advantage.	[Itkonen, H. M.; Engedal, N.; Luhr, M.; Guldvik, I. J.; Mills, I. G.] Univ Oslo, Ctr Mol Med Norway, Prostate Canc Res Grp, N-0318 Oslo, Norway; [Itkonen, H. M.; Engedal, N.; Luhr, M.; Guldvik, I. J.; Mills, I. G.] Oslo Univ Hosp, Oslo, Norway; [Babaie, E.] Univ Oslo, Biotechnol Ctr Oslo, N-0318 Oslo, Norway; [Minner, S.; Hohloch, J.; Tsourlakis, M. C.] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Hamburg, Germany; [Schlomm, T.] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Sect Translat Prostate Canc Res, Hamburg, Germany; [Schlomm, T.] Univ Med Ctr Hamburg Eppendorf, Prostate Canc Ctr, Martini Clin, Hamburg, Germany; [Mills, I. G.] Oslo Univ Hosp, Dept Canc Prevent, Oslo, Norway; [Mills, I. G.] Oslo Univ Hosp, Dept Urol, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Oslo; University of Oslo	Mills, IG (corresponding author), Univ Oslo, NCMM, Gaustadalleen 21,POB 1137, N-0318 Oslo, Norway.	harri.itkonen@ncmm.uio.no; ian.mills@ncmm.uio.no	Mills, Ian/AAK-9292-2020; Engedal, Nikolai/AAJ-8951-2020	Mills, Ian/0000-0001-5347-5083; Engedal, Nikolai/0000-0003-3718-3464; Schlomm, Thorsten/0000-0001-9557-4653; Itkonen, Harri/0000-0002-5194-7064	Early Stage Researcher fellowship as part of the EU FP7 Marie Curie Integrated Training Network; PRO-NEST (Prostate Research Organizations Network Early Stage Training) Norwegian Cancer Society; Finnish Cultural Foundation; Norwegian Research Council; Helse; University of Oslo through the Centre for Molecular Medicine (Norway), Nordic EMBL (European Molecular Biology Laboratory); Norwegian Cancer Society; EU	Early Stage Researcher fellowship as part of the EU FP7 Marie Curie Integrated Training Network; PRO-NEST (Prostate Research Organizations Network Early Stage Training) Norwegian Cancer Society; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Norwegian Research Council(Research Council of NorwayEuropean Commission); Helse; University of Oslo through the Centre for Molecular Medicine (Norway), Nordic EMBL (European Molecular Biology Laboratory); Norwegian Cancer Society(Norwegian Cancer Society); EU(European Commission)	HMI is funded by an Early Stage Researcher fellowship as part of the EU FP7 Marie Curie Integrated Training Network, PRO-NEST (Prostate Research Organizations Network Early Stage Training) Norwegian Cancer Society and Finnish Cultural Foundation. IGM is supported by funding from the Norwegian Research Council, Helse and the University of Oslo through the Centre for Molecular Medicine (Norway), which is a part of the Nordic EMBL (European Molecular Biology Laboratory) partnership. IGM is also supported by the Norwegian Cancer Society and by EU FP7 funding. IGM holds a visiting scientist position with Cancer Research UK through the Cambridge Research Institute and a Senior Visiting Research Fellowship with Cambridge University through the Department of Oncology. We thank Professor Olli Kallioniemi's group (Institute for Molecular Medicine Finland, Helsinki, Finland) for technical support.	Bassik MC, 2011, P NATL ACAD SCI USA, V108, P11731, DOI 10.1073/pnas.1109035108; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; BERTHON P, 1995, INT J ONCOL, V6, P333; Bosch RR, 2004, ENDOCRINE, V23, P17, DOI 10.1385/ENDO:23:1:17; Braga-Basaria M, 2006, J CLIN ONCOL, V24, P3979, DOI 10.1200/JCO.2006.05.9741; Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Chen R, 2013, J CELL BIOCHEM, V114, P816, DOI 10.1002/jcb.24420; Dennis JW, 2009, TRAFFIC, V10, P1569, DOI 10.1111/j.1600-0854.2009.00981.x; Derweesh IH, 2007, BJU INT, V100, P1060, DOI 10.1111/j.1464-410X.2007.07184.x; Diekman AB, 1998, MOL REPROD DEV, V50, P284; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Dricu A, 1997, CANCER RES, V57, P543; Grassian AR, 2011, COLD SH Q B, V76, P313, DOI 10.1101/sqb.2011.76.010967; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Gunter Jennifer H, 2013, Int J Cell Biol, V2013, P834684, DOI 10.1155/2013/834684; Hagisawa S, 2005, GLYCOBIOLOGY, V15, P1016, DOI 10.1093/glycob/cwi086; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Humphrey PA, 2007, J CLIN PATHOL, V60, P35, DOI 10.1136/jcp.2005.036442; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Itkonen HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065016; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; KELLER RK, 1979, BIOCHEMISTRY-US, V18, P3946, DOI 10.1021/bi00585a016; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; Krzeslak A, 2012, CLIN EXP MED, V12, P61, DOI 10.1007/s10238-011-0138-5; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Lau KS, 2007, CELL, V129, P123, DOI 10.1016/j.cell.2007.01.049; Luo J, 2002, CANCER RES, V62, P2220; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Monauni T, 2000, DIABETES, V49, P926, DOI 10.2337/diabetes.49.6.926; Moon JS, 2011, BIOCHEM J, V433, P225, DOI 10.1042/BJ20101104; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Nakajima K, 2010, GLYCOBIOLOGY, V20, P865, DOI 10.1093/glycob/cwq044; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sartor O, 2013, NAT REV CLIN ONCOL, V10, P6, DOI 10.1038/nrclinonc.2012.202; Schwarz F, 2011, CURR OPIN STRUC BIOL, V21, P576, DOI 10.1016/j.sbi.2011.08.005; Slawson C, 2010, TRENDS BIOCHEM SCI, V35, P547, DOI 10.1016/j.tibs.2010.04.005; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Wang ZV, 2014, CELL, V156, P1179, DOI 10.1016/j.cell.2014.01.014; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Xi HB, 2011, CANCER CHEMOTH PHARM, V67, P899, DOI 10.1007/s00280-010-1391-0; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058	49	63	63	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3744	3750		10.1038/onc.2014.307	http://dx.doi.org/10.1038/onc.2014.307			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241896				2022-12-28	WOS:000357679100012
J	Liu, G; Yu, FX; Kim, YC; Meng, Z; Naipauer, J; Looney, DJ; Liu, X; Gutkind, JS; Mesri, EA; Guan, KL				Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Naipauer, J.; Looney, D. J.; Liu, X.; Gutkind, J. S.; Mesri, E. A.; Guan, K-L			Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; ORGAN SIZE CONTROL; PRIMARY EFFUSION LYMPHOMA; YES-ASSOCIATED PROTEIN; SCF-BETA-TRCP; GENE-EXPRESSION; CELL-PROLIFERATION; YAP PATHWAY; TEAD/TEF FAMILY; GROWTH-CONTROL	Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic virus and the culprit behind the human disease Kaposi sarcoma (KS), an AIDS-defining malignancy. KSHV encodes a viral G-protein-coupled receptor (vGPCR) critical for the initiation and progression of KS. In this study, we identified that YAP/TAZ, two homologous oncoproteins inhibited by the Hippo tumor suppressor pathway, are activated in KSHV-infected cells in vitro, KS-like mouse tumors and clinical human KS specimens. The KSHV-encoded vGPCR acts through Gq/11 and G12/13 to inhibit the Hippo pathway kinases Lats1/2, promoting the activation of YAP/TAZ. Furthermore, depletion of YAP/TAZ blocks vGPCR-induced cell proliferation and tumorigenesis in a xenograft mouse model. The vGPCR-transformed cells are sensitive to pharmacologic inhibition of YAP. Our study establishes a pivotal role of the Hippo pathway in mediating the oncogenic activity of KSHV and development of KS, and also suggests a potential of using YAP inhibitors for KS intervention.	[Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Guan, K-L] Shandong Univ, Sch Life Sci, Jinan 250100, Peoples R China; [Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Guan, K-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Guan, K-L] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Naipauer, J.; Mesri, E. A.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Naipauer, J.; Mesri, E. A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Viral Oncol Program,Miami Ctr AIDS Res, Miami, FL 33136 USA; [Looney, D. J.] Univ Calif San Diego, VA San Diego Healthcare Syst, Dept Med, La Jolla, CA 92093 USA; [Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	Shandong University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Miami; University of Miami; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Guan, KL (corresponding author), Univ Calif San Diego, Dept Pharmacol, RM4010,2880 Torrey Pines Scenic Dr, La Jolla, CA 92093 USA.	kuguan@ucsd.edu	Liu, Guangbo/O-7636-2016; Guan, Kun-Liang/ADK-7088-2022; Gutkind, J. Silvio/J-1201-2016; Liu, Xiangguo/G-1091-2010	Liu, Guangbo/0000-0001-5623-8227; Gutkind, J. Silvio/0000-0002-5150-4482; Liu, Xiangguo/0000-0002-1879-3817; Yu, Fa-Xing/0000-0003-4834-9335; Kim, Young Chul/0000-0002-6782-2186; Naipauer, Julian/0000-0001-6842-6815	NIH/NCI [P30 CA23100]; NIAID [P30 AI36214, R01CA132809, R01GM51586]; Chinese Scholarship Council; NIH [CA136387]; Miami CFAR Grant [P30AI073961]; NATIONAL CANCER INSTITUTE [R01CA136387, P30CA023100, R01CA132809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI073961, P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Chinese Scholarship Council(China Scholarship Council); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Miami CFAR Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank AIDS and Cancer Specimen Resource at the University of California, San Francisco (particularly Ronald Honrada, Andrew Ma and Michael McGrath) for providing the tissue microarrays and carrying out the HHV-8 staining. We also thank Jenna Jewell, Steve Plouffe and Fabian Flores for critical reading of this manuscript, and Drs Dirk Dittmer, Carsten Gram Hansen and Toshiro Moroishi for insightful discussions. EAM and JN would like to thank Santas Rosario and Darlah Lopez Rodriguez for their help with the infection systems. This study was supported by grants from NIH/NCI P30 CA23100, NIAID P30 AI36214, R01CA132809, R01GM51586 (to KLG) and the Chinese Scholarship Council (to GL). EAM and JN were supported by NIH Grants CA136387 and Miami CFAR Grant P30AI073961.	Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cavallin LE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004154; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Edelman DC, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-78; Feng H, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000157; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hermans P, 2000, HIV Med, V1, P137, DOI 10.1046/j.1468-1293.2000.00027.x; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543; Kaplan LD, 2013, HEMATOL-AM SOC HEMAT, P103, DOI 10.1182/asheducation-2013.1.103; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Leung HJ, 2012, ANTIMICROB AGENTS CH, V56, P5794, DOI 10.1128/AAC.01126-12; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma Q, 2013, ANTIOXID REDOX SIGN, V18, P80, DOI 10.1089/ars.2012.4584; Marinissen MJ, 2006, J BIOL CHEM, V281, P11332, DOI 10.1074/jbc.M512199200; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Martin D, 2011, CANCER CELL, V19, P805, DOI 10.1016/j.ccr.2011.05.005; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2013, ANNU REV PHARMACOL, V53, P331, DOI 10.1146/annurev-pharmtox-010510-100608; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; St JM, 1999, NAT GENET, V21, P182; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strassburger K, 2012, DEV BIOL, V367, P187, DOI 10.1016/j.ydbio.2012.05.008; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vieira J, 2004, VIROLOGY, V325, P225, DOI 10.1016/j.virol.2004.03.049; von Gise A, 2012, P NATL ACAD SCI USA, V109, P2394, DOI 10.1073/pnas.1116136109; Wen KW, 2010, CANCER LETT, V289, P140, DOI 10.1016/j.canlet.2009.07.004; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2013, GENE DEV, V27, P1223, DOI 10.1101/gad.219402.113; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	67	51	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3536	3546		10.1038/onc.2014.281	http://dx.doi.org/10.1038/onc.2014.281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195862	Green Submitted, Green Accepted			2022-12-28	WOS:000357434900006
J	Sarkar, TR; Battula, VL; Werden, SJ; Vijay, GV; Ramirez-Pena, EQ; Taube, JH; Chang, JT; Miura, N; Porter, W; Sphyris, N; Andreeff, M; Mani, SA				Sarkar, T. R.; Battula, V. L.; Werden, S. J.; Vijay, G. V.; Ramirez-Pena, E. Q.; Taube, J. H.; Chang, J. T.; Miura, N.; Porter, W.; Sphyris, N.; Andreeff, M.; Mani, S. A.			GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; STEM-CELLS; TUMOR PROGRESSION; FACTOR RECEPTOR; MET; EXPRESSION; MORPHOGENESIS; GENE; PLASTICITY; PATHWAYS	The epithelial-mesenchymal transition (EMT) bestows cancer cells with increased stem cell properties and metastatic potential. To date, multiple extracellular stimuli and transcription factors have been shown to regulate EMT. Many of them are not druggable and therefore it is necessary to identify targets, which can be inhibited using small molecules to prevent metastasis. Recently, we identified the ganglioside GD2 as a novel breast cancer stem cell marker. Moreover, we found that GD3 synthase (GD3S)-an enzyme involved in GD2 biosynthesis-is critical for GD2 production and could serve as a potential druggable target for inhibiting tumor initiation and metastasis. Indeed, there is a small molecule known as triptolide that has been shown to inhibit GD3S function. Accordingly, in this manuscript, we demonstrate that the inhibition of GD3S using small hairpin RNA or triptolide compromises the initiation and maintenance of EMT instigated by various signaling pathways, including Snail, Twist and transforming growth factor-beta 1 as well as the mesenchymal characteristics of claudin-low breast cancer cell lines (SUM159 and MDA-MB-231). Moreover, GD3S is necessary for wound healing, migration, invasion and stem cell properties in vitro. Most importantly, inhibition of GD3S in vivo prevents metastasis in experimental as well as in spontaneous syngeneic wild-type mouse models. We also demonstrate that the transcription factor FOXC2, a central downstream effector of several EMT pathways, directly regulates GD3S expression by binding to its promoter. In clinical specimens, the expression of GD3S correlates with poor prognosis in triple-negative human breast tumors. Moreover, GD3S expression correlates with activation of the c-Met signaling pathway leading to increased stem cell properties and metastatic competence. Collectively, these findings suggest that the GD3S-c-Met axis could serve as an effective target for the treatment of metastatic breast cancers.	[Sarkar, T. R.; Werden, S. J.; Vijay, G. V.; Ramirez-Pena, E. Q.; Taube, J. H.; Sphyris, N.; Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Battula, V. L.; Andreeff, M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Miura, N.] Hamamatsu Univ, Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4312102, Japan; [Porter, W.] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX 77030 USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cells & Dev Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Hamamatsu University School of Medicine; Texas A&M University System; Texas A&M University College Station; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Andreeff, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	mandreef@mdanderson.org; smani@mdanderson.org	SPHYRIS, NATHALIE/GQY-6349-2022; Mani, Sendurai A./A-7244-2009	Mani, Sendurai A./0000-0002-5918-4276; Sphyris, Nathalie/0000-0003-1860-1958; Raja, Geraldine Vidhya/0000-0002-4644-3080; Taube, Joseph/0000-0002-3636-5189; Ramirez-Pena, Esmeralda/0000-0002-5200-7488	MD Anderson Research Trust Fellow Award; George and Barbara Bush Endowment for Innovative Cancer Research; Cancer Center Support Grant from the National Cancer Institute [CA16672]; Breast Cancer Research Foundation; Rolanette and Berdon Lawrence Research award from Bone Disease Program of Texas; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	MD Anderson Research Trust Fellow Award; George and Barbara Bush Endowment for Innovative Cancer Research; Cancer Center Support Grant from the National Cancer Institute; Breast Cancer Research Foundation; Rolanette and Berdon Lawrence Research award from Bone Disease Program of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the entire Mani Lab for invaluable suggestions and discussions, and Thiru Arumugam for his valuable help in animal imaging. This work was supported by an MD Anderson Research Trust Fellow Award, funded by the George and Barbara Bush Endowment for Innovative Cancer Research (SAM). Flow cytometry, confocal microscopy and animal imaging were in part funded by the Cancer Center Support Grant from the National Cancer Institute (CA16672). We also acknowledge support from the Breast Cancer Research Foundation (MA) and the Rolanette and Berdon Lawrence Research award from Bone Disease Program of Texas (VLB).	Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Battula VL, 2012, J CLIN INVEST, V122, P2066, DOI 10.1172/JCI59735; Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cazet A, 2010, MOL CANCER RES, V8, P1526, DOI 10.1158/1541-7786.MCR-10-0302; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DIRENZO MF, 1995, CANCER RES, V55, P1129; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hao L, 2000, ACTA PHARMACOL SIN, V21, P782; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hay ED, 1995, ACTA ANAT, V154, P8; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; Kiviharju TM, 2002, CLIN CANCER RES, V8, P2666; Kwon HY, 2010, EXP MOL MED, V42, P849, DOI 10.3858/emm.2010.42.12.088; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Tuck AB, 1996, AM J PATHOL, V148, P225; van Leenders GJLH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026753; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Xue CS, 2003, CANCER RES, V63, P3386; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	43	74	79	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2958	2967		10.1038/onc.2014.245	http://dx.doi.org/10.1038/onc.2014.245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25109336	Green Accepted			2022-12-28	WOS:000356100500002
J	Gelb, T; Pshenichkin, S; Rodriguez, OC; Hathaway, HA; Grajkowska, E; DiRaddo, JO; Wroblewska, B; Yasuda, RP; Albanese, C; Wolfe, BB; Wroblewski, JT				Gelb, T.; Pshenichkin, S.; Rodriguez, O. C.; Hathaway, H. A.; Grajkowska, E.; DiRaddo, J. O.; Wroblewska, B.; Yasuda, R. P.; Albanese, C.; Wolfe, B. B.; Wroblewski, J. T.			Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas	ONCOGENE			English	Article							HUMAN MELANOCYTES; EXPRESSION; GRM1; GLUTAMATE-RECEPTOR-1; BLOCKADE; NETRIN-1; EXCITOTOXICITY; PROLIFERATION; SUPPRESSION; INHIBITION	Metabotropic glutamate 1 (mGlu) receptor has been proposed as a target for the treatment of metastatic melanoma. Studies have demonstrated that inhibiting the release of glutamate (the natural ligand of mGlu1 receptors), results in a decrease of melanoma tumor growth in mGlu1 receptor-expressing melanomas. Here we demonstrate that mGlu1 receptors, which have been previously characterized as oncogenes, also behave like dependence receptors by creating a dependence on glutamate for sustained cell viability. In the mGlu1 receptor-expressing melanoma cell lines SK-MEL-2 (SK2) and SK-MEL-5 (SK5), we show that glutamate is both necessary and sufficient to maintain cell viability, regardless of underlying genetic mutations. Addition of glutamate increased DNA synthesis, whereas removal of glutamate not only suppressed DNA synthesis but also promoted cell death in SK2 and SK5 melanoma cells. Using genetic and pharmacological inhibitors, we established that this effect of glutamate is mediated by the activation of mGlu1 receptors. The stimulatory potential of mGlu1 receptors was further confirmed in vivo in a melanoma cell xenograft model. In this model, subcutaneous injection of SK5 cells with short hairpin RNA-targeted downregulation of mGlu1 receptors resulted in a decrease in the rate of tumor growth relative to control. We also demonstrate for the first time that a selective mGlu1 receptor antagonist JNJ16259685 ((3,4-Dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-methanone) slows SK2 and SK5 melanoma tumor growth in vivo. Taken together, these data suggest that pharmacological inhibition of mGlu1 receptors may be a novel approach for the treatment of metastatic melanoma.	[Gelb, T.; Pshenichkin, S.; Hathaway, H. A.; Grajkowska, E.; DiRaddo, J. O.; Wroblewska, B.; Yasuda, R. P.; Wolfe, B. B.; Wroblewski, J. T.] Georgetown Univ, Med Ctr, Dept Physiol & Pharmacol, Washington, DC 20057 USA; [Rodriguez, O. C.; Albanese, C.] Georgetown Univ, Dept Lombardi Comprehens Canc Ctr, Washington, DC USA	Georgetown University; Georgetown University	Wroblewski, JT (corresponding author), Georgetown Univ, Med Ctr, Dept Physiol & Pharmacol, 3900 Reservoir Rd,NW, Washington, DC 20057 USA.	wroblewj@georgetown.edu		Hathaway, Hannah/0000-0003-0906-1726	NIH/NCI grant [P30-CA051008]; Pharmaceutical Research and Manufacturers of America Foundation Pre Doctoral Fellowship in Pharmacology/Toxicology; National Institutes of Health grant [NS37436, CA129003]; NATIONAL CANCER INSTITUTE [R01CA129003, P30CA051008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037436] Funding Source: NIH RePORTER	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmaceutical Research and Manufacturers of America Foundation Pre Doctoral Fellowship in Pharmacology/Toxicology; National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the Flow Cytometry and Cell Sorting Shared Resource (partially supported by the NIH/NCI grant P30-CA051008), particularly Karen Creswell, and the Histopathology and Tissue Shared Resource (partially supported by the NIH/NCI grant P30-CA051008) at The Georgetown-Lombardi Comprehensive Cancer Center (Georgetown University, Washington, DC, USA) for their expertise. Also, we thank Dr Suzie Chen from Rutgers University for her guidance and generosity and Maria Salinas (Georgetown) for her technical expertise. This work was partially supported by the Pharmaceutical Research and Manufacturers of America Foundation Pre Doctoral Fellowship in Pharmacology/Toxicology to TG, The National Institutes of Health grant NS37436 to JTW and CA129003 to CA.	American Cancer Society, 2013, CANC FACTS FIG 2013; Banda M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081126; Blaabjerg M, 2003, EXP NEUROL, V183, P573, DOI 10.1016/S0014-4886(03)00204-8; Brocke KS, 2010, CANCER BIOL THER, V9; Chang HJ, 2005, CLIN CANCER RES, V11, P3288, DOI 10.1158/1078-0432.CCR-04-1912; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; de Groot J, 2011, GLIA, V59, P1181, DOI 10.1002/glia.21113; Delloye-Bourgeois C, 2009, J EXP MED, V206, P833, DOI 10.1084/jem.20082299; Delloye-Bourgeois C, 2009, JNCI-J NATL CANCER I, V101, P237, DOI 10.1093/jnci/djn491; Deng WB, 2006, J NEUROCHEM, V98, P213, DOI 10.1111/j.1471-4159.2006.03861.x; DiRaddo JO, 2013, GENE, V519, P367, DOI 10.1016/j.gene.2013.02.009; Emery AC, 2010, J BIOL CHEM, V285, P26041, DOI 10.1074/jbc.M110.139899; Fitamant J, 2008, P NATL ACAD SCI USA, V105, P4850, DOI 10.1073/pnas.0709810105; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Frati C, 2000, J CELL PHYSIOL, V183, P364, DOI 10.1002/(SICI)1097-4652(200006)183:3<364::AID-JCP9>3.3.CO;2-O; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Hartsough EJ, 2014, MOL CANCER RES, V12, P795, DOI 10.1158/1541-7786.MCR-13-0581; Hoogduijn MJ, 2006, PIGM CELL RES, V19, P58, DOI 10.1111/j.1600-0749.2005.00284.x; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Khan AJ, 2011, CLIN CANCER RES, V17, P1807, DOI 10.1158/1078-0432.CCR-10-1276; Koochekpour S, 2012, CLIN CANCER RES, V18, P5888, DOI 10.1158/1078-0432.CCR-12-1308; Lavreysen H, 2004, NEUROPHARMACOLOGY, V47, P961, DOI 10.1016/j.neuropharm.2004.08.007; Le MN, 2010, J INVEST DERMATOL, V130, P2240, DOI 10.1038/jid.2010.126; Lee HJ, 2012, BBA-GENE REGUL MECH, V1819, P1123, DOI 10.1016/j.bbagrm.2012.06.005; Lee HJ, 2011, CLIN CANCER RES, V17, P7080, DOI 10.1158/1078-0432.CCR-11-0098; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Maira F, 2012, CURR DRUG DELIV, V9, P17, DOI 10.2174/156720112798376032; Martino JJ, 2013, ONCOGENE, V32, P4366, DOI 10.1038/onc.2012.471; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Ohtani Y, 2008, ONCOGENE, V27, P7162, DOI 10.1038/onc.2008.329; Ortiz P, 2007, EUR J HUM GENET, V15, P1176, DOI 10.1038/sj.ejhg.5201887; Park SY, 2007, ONCOL REP, V17, P81; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Prickett TD, 2012, CLIN CANCER RES, V18, P4240, DOI 10.1158/1078-0432.CCR-11-1217; Pshenichkin S, 2008, NEUROPHARMACOLOGY, V55, P500, DOI 10.1016/j.neuropharm.2008.06.039; Ringer L, 2011, CANCER BIOL THER, V12, P818, DOI 10.4161/cbt.12.9.17682; Rzeski W, 2002, BIOCHEM PHARMACOL, V64, P1195, DOI 10.1016/S0006-2952(02)01218-2; Seidlitz EP, 2009, CLIN EXP METASTAS, V26, P781, DOI 10.1007/s10585-009-9277-4; Shin SS, 2008, NEUROPHARMACOLOGY, V55, P396, DOI 10.1016/j.neuropharm.2008.04.021; Shin SS, 2008, PIGM CELL MELANOMA R, V21, P368, DOI 10.1111/j.1755-148X.2008.00452.x; Speyer CL, 2012, BREAST CANCER RES TR, V132, P565, DOI 10.1007/s10549-011-1624-x; Steckler T, 2005, BEHAV BRAIN RES, V164, P52, DOI 10.1016/j.bbr.2005.05.010; Steckler T, 2005, PSYCHOPHARMACOLOGY, V179, P198, DOI 10.1007/s00213-004-2056-7; Teh Jessica, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P211; Wangari-Talbot J, 2012, MOL CANCER RES, V10, P1440, DOI 10.1158/1541-7786.MCR-12-0158; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Wen Y, 2014, CANCER RES, V74, P2499, DOI 10.1158/0008-5472.CAN-13-1531; Willard SS, 2013, INT J BIOL SCI, V9, P948, DOI 10.7150/ijbs.6426; Yajima I, 2012, DERMAT RES PRACT, V2012, DOI 10.1155/2012/354191; Ye ZC, 1999, CANCER RES, V59, P4383	52	17	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2711	2720		10.1038/onc.2014.231	http://dx.doi.org/10.1038/onc.2014.231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065592	Green Accepted			2022-12-28	WOS:000354979500004
J	Kagawa, S; Natsuizaka, M; Whelan, KA; Facompre, N; Naganuma, S; Ohashi, S; Kinugasa, H; Egloff, AM; Basu, D; Gimotty, PA; Klein-Szanto, AJ; Bass, AJ; Wong, KK; Diehl, JA; Rustgi, AK; Nakagawa, H				Kagawa, S.; Natsuizaka, M.; Whelan, K. A.; Facompre, N.; Naganuma, S.; Ohashi, S.; Kinugasa, H.; Egloff, A. M.; Basu, D.; Gimotty, P. A.; Klein-Szanto, A. J.; Bass, A. J.; Wong, K-K; Diehl, J. A.; Rustgi, A. K.; Nakagawa, H.			Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities	ONCOGENE			English	Article							HUMAN ESOPHAGEAL KERATINOCYTES; TO-MESENCHYMAL TRANSITION; ZEB TRANSCRIPTION FACTORS; EPITHELIAL-CELLS; TGF-BETA; PREMATURE SENESCENCE; SQUAMOUS CANCER; NOTCH; CARCINOMA; P53	Notch activity regulates tumor biology in a context-dependent and complex manner. Notch may act as an oncogene or a tumor-suppressor gene even within the same tumor type. Recently, Notch signaling has been implicated in cellular senescence. Yet, it remains unclear as to how cellular senescence checkpoint functions may interact with Notch-mediated oncogenic and tumor-suppressor activities. Herein, we used genetically engineered human esophageal keratinocytes and esophageal squamous cell carcinoma cells to delineate the functional consequences of Notch activation and inhibition along with pharmacological intervention and RNA interference experiments. When expressed in a tetracycline-inducible manner, the ectopically expressed activated form of Notch1 (ICN1) displayed oncogene-like characteristics inducing cellular senescence corroborated by the induction of G0/G1 cell-cycle arrest, Rb dephosphorylation, flat and enlarged cell morphology and senescence-associated beta-galactosidase activity. Notch-induced senescence involves canonical CSL/RBPJ-dependent transcriptional activity and the p16(INK4A)-Rb pathway. Loss of p16(INK4A) or the presence of human papilloma virus (HPV) E6/E7 oncogene products not only prevented ICN1 from inducing senescence but permitted ICN1 to facilitate anchorage-independent colony formation and xenograft tumor growth with increased cell proliferation and reduced squamous-cell differentiation. Moreover, Notch1 appears to mediate replicative senescence as well as transforming growth factor-beta-induced cellular senescence in non-transformed cells and that HPV E6/E7 targets Notch1 for inactivation to prevent senescence, revealing a tumor-suppressor attribute of endogenous Notch1. In aggregate, cellular senescence checkpoint functions may influence dichotomous Notch activities in the neoplastic context.	[Kagawa, S.; Natsuizaka, M.; Whelan, K. A.; Naganuma, S.; Ohashi, S.; Kinugasa, H.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA; [Kagawa, S.; Natsuizaka, M.; Whelan, K. A.; Naganuma, S.; Ohashi, S.; Kinugasa, H.; Gimotty, P. A.; Diehl, J. A.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Natsuizaka, M.] Hokkaido Univ, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan; [Facompre, N.; Basu, D.] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA; [Facompre, N.; Basu, D.] Univ Penn, Dept Head & Neck Surg, Philadelphia, PA 19104 USA; [Facompre, N.; Basu, D.] Philadelphia VA Med Ctr, Philadelphia, PA USA; [Naganuma, S.] Kochi Univ, Sch Med, Dept Pathol, Kochi 780, Japan; [Ohashi, S.] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Kyoto, Japan; [Kinugasa, H.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama 7008530, Japan; [Egloff, A. M.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Gimotty, P. A.] Univ Penn, Div Biostat, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; [Bass, A. J.; Wong, K-K] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Bass, A. J.; Wong, K-K] Dana Farber Canc Inst, Div Cellular & Mol Oncol, Boston, MA 02115 USA; [Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Hokkaido University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Kochi University; Kyoto University; Okayama University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania; University of Pennsylvania	Nakagawa, H (corresponding author), Univ Penn, Div Gastroenterol, Dept Med, 956 BRB,421 Curie Blvd, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu	Gimotty, Phyllis/GWZ-4136-2022; Ohashi, Shinya/AAD-8920-2022	Gimotty, Phyllis/0000-0002-3850-9799; Natsuizaka, Mitsuteru/0000-0002-1819-1955	NIH [P01CA098101, U01CA143056, R01DK077005, K26 RR032714]; Pennsylvania CURE Program Grant [F32-CA174176, F32-DE024685, K08DE022842]; Trio/ACS Career Award; VA CPPF Grant [K07CA137140]; University of Pennsylvania University Research Foundation Award; University of Pennsylvania; Abramson Cancer Center Pilot Project Grant; American Cancer Society [RP-10-033-01-CCE]; NATIONAL CANCER INSTITUTE [P30CA016520, K07CA137140, F31CA174176, P01CA098101, U01CA143056, F32CA174146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR032714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE022842, F32DE024685, R21DE024396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077005, P30DK050306] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K26OD011179] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania CURE Program Grant; Trio/ACS Career Award; VA CPPF Grant; University of Pennsylvania University Research Foundation Award; University of Pennsylvania; Abramson Cancer Center Pilot Project Grant; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr Hiroshi Shirasawa (Chiba University, Chiba, Japan) for the gift of EN60 cells. We are grateful to the Molecular Pathology & Imaging, Molecular Biology/Gene Expression and Cell Culture Core Facilities of the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306) and of the NIH P01CA098101. This study was supported in part by NIH Grants P01CA098101 (to SK, MN, KAW, DB, HK, SN, SO, PAG, AJK-S, AB, K-KW, JAD, HN and AKR), U01CA143056 (to AKR), R01DK077005 (to HN), K26 RR032714 (to HN), Pennsylvania CURE Program Grant (to HN), F32-CA174176 (to KAW), F32-DE024685 to (NF), K08DE022842, Trio/ACS Career Award and VA CPPF Grant (to DB), K07CA137140 (to AME), University of Pennsylvania University Research Foundation Award (to HN), University of Pennsylvania, Abramson Cancer Center Pilot Project Grant (to HN), and the American Cancer Society RP-10-033-01-CCE (to AKR).	Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cui H, 2013, CANCER RES, V73, P3451, DOI 10.1158/0008-5472.CAN-12-3902; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dotto GP, 2009, NAT REV CANCER, V9, P587, DOI 10.1038/nrc2675; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Harada H, 2003, MOL CANCER RES, V1, P729; Hijioka H, 2010, INT J ONCOL, V36, P817, DOI 10.3892/ijo_00000558; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kim SH, 2006, CANCER RES, V66, P10415, DOI 10.1158/0008-5472.CAN-06-2104; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kurz DJ, 2000, J CELL SCI, V113, P3613; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Li T, 2007, J NEUROSCI, V27, P10849, DOI 10.1523/JNEUROSCI.2152-07.2007; Lin S, 2012, MOL BIOL CELL, V23, P1569, DOI 10.1091/mbc.E11-10-0849; Ling H, 2013, CANCER RES, V73, P5963, DOI 10.1158/0008-5472.CAN-13-0409; LIU QY, 1995, ONCOGENE, V10, P619; Liu ZJ, 2012, ATHEROSCLEROSIS, V225, P296, DOI 10.1016/j.atherosclerosis.2012.04.010; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Maruo S, 2011, P NATL ACAD SCI USA, V108, P1919, DOI 10.1073/pnas.1019599108; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; Mroz EA, 2008, CANCER RES, V68, P6049, DOI 10.1158/0008-5472.CAN-08-1279; Nakagawa H, 2003, GASTROINTESTINAL CAN, P241; Natsugoe S, 2002, CLIN CANCER RES, V8, P1838; Natsuizaka M, 2012, FASEB J, V26, P2620, DOI 10.1096/fj.11-198598; Natsuizaka M, 2010, CARCINOGENESIS, V31, P1344, DOI 10.1093/carcin/bgq108; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Ohashi S, 2010, GASTROENTEROLOGY, V139, P2113, DOI 10.1053/j.gastro.2010.08.040; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Okawa T, 2007, GENE DEV, V21, P2788, DOI 10.1101/gad.1544507; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; Oyama K, 2007, ONCOGENE, V26, P2353, DOI 10.1038/sj.onc.1210025; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Pascal T, 2005, FEBS LETT, V579, P3651, DOI 10.1016/j.febslet.2005.05.056; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Sashiyama H, 2001, INT J ONCOL, V19, P97; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Takaoka M, 2004, ONCOGENE, V23, P6760, DOI 10.1038/sj.onc.1207923; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; Venkatesh D, 2011, ARTERIOSCL THROM VAS, V31, P876, DOI 10.1161/ATVBAHA.110.221945; Wang NJ, 2011, P NATL ACAD SCI USA, V108, P17761, DOI 10.1073/pnas.1114669108; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang YW, 2007, P NATL ACAD SCI USA, V104, P10613, DOI 10.1073/pnas.0703903104	67	49	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2347	2359		10.1038/onc.2014.169	http://dx.doi.org/10.1038/onc.2014.169			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931169	Green Accepted, Green Submitted			2022-12-28	WOS:000353824800008
J	Seviourig, EG; Sehgal, V; Lu, Y; Luo, Z; Moss, T; Zhang, F; Hill, SM; Liu, W; Maiti, SN; Cooper, L; Azencot, R; Lopez-Berestein, G; Rodriguez-Aguayo, C; Roopaimoole, R; Pecot, CV; Sood, AK; Mukherjee, S; Gray, JW; Mills, G; Ram, P				Seviourig, E. G.; Sehgal, V.; Lu, Y.; Luo, Z.; Moss, T.; Zhang, F.; Hill, S. M.; Liu, W.; Maiti, S. N.; Cooper, L.; Azencot, R.; Lopez-Berestein, G.; Rodriguez-Aguayo, C.; Roopaimoole, R.; Pecot, C. V.; Sood, A. K.; Mukherjee, S.; Gray, J. W.; Mills, G. B.; Ram, P. T.			Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; C-MYC; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; MICRO RNAS; MIR-124; EXPRESSION; GENE; ACTIVATION; P27(KIP1)	The myc oncogene is overexpressed in almost half of all breast and ovarian cancers, but attempts at therapeutic interventions against myc have proven to be challenging. Myc regulates multiple biological processes, including the cell cycle, and as such is associated with cell proliferation and tumor progression. We identified a protein signature of high myc, low p27 and high phospho-Rb significantly correlated with poor patient survival in breast and ovarian cancers. Screening of a miRNA library by functional proteomics in multiple cell lines and integration of data from patient tumors revealed a panel of five microRNAs (miRNAs) (miR-124, miR-365, miR-34b*, miR-18a and miR-506) as potential tumor suppressors capable of reversing the p27/myc/phospho-Rb protein signature. Mechanistic studies revealed an RNA-activation function of miR-124 resulting in direct induction of p27 protein levels by binding to and inducing transcription on the p27 promoter region leading to a subsequent G1 arrest. Additionally, in vivo studies utilizing a xenograft model demonstrated that nanoparticle-mediated delivery of miR-124 could reduce tumor growth and sensitize cells to etoposide, suggesting a clinical application of miRNAs as therapeutics to target the functional effect of myc on tumor growth.	[Seviourig, E. G.; Sehgal, V.; Lu, Y.; Luo, Z.; Moss, T.; Zhang, F.; Mills, G. B.; Ram, P. T.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Hill, S. M.] Cambridge Inst Publ Hlth, MRC Biostat Unit, Cambridge, England; [Liu, W.] UTMDACC, Dept Bioinformat & Computat Biol, Houston, TX USA; [Maiti, S. N.] UTMDACC, Dept Pediat, Houston, TX USA; [Azencot, R.] Univ Houston, Dept Math, Houston, TX 77204 USA; [Lopez-Berestein, G.; Rodriguez-Aguayo, C.; Roopaimoole, R.] UTMDACC, Dept Expt Therapeut, Houston, TX USA; [Lopez-Berestein, G.] UTMDACC, Ctr RNA Interference & Noncoding RNA, Houston, TX USA; [Pecot, C. V.] UTMDACC, Div Canc Med, Houston, TX USA; [Sood, A. K.] UTMDACC, Dept Gynecol Oncol, Houston, TX USA; [Gray, J. W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR USA	University of Texas System; UTMD Anderson Cancer Center; MRC Biostatistics Unit; University of Cambridge; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Houston System; University of Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University	Ram, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pram@mdandcrson.org	Sood, Anoop Kumar/A-7344-2013; rupaimoole, rajesha/K-3272-2016	Sood, Anoop Kumar/0000-0001-5702-4108; rupaimoole, rajesha/0000-0002-4795-7921; Ram, Prahlad/0000-0003-4739-3166; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Seviour, Elena/0000-0003-2885-4246	NIH/NCI ICBP grant [U54-CA112970]; Blanton Davis Foundation; Odessy Fellowship (MDACC); CCBTP training grant from the CPRIT; NATIONAL CANCER INSTITUTE [P50CA083639, U54CA112970, P30CA016672] Funding Source: NIH RePORTER	NIH/NCI ICBP grant; Blanton Davis Foundation; Odessy Fellowship (MDACC); CCBTP training grant from the CPRIT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	All the data reported are presented and available in the Supplementary Materials. The work presented here was funded by an NIH/NCI ICBP grant U54-CA112970 to JWG (Project 1 Co-PI SM, Project 2 PI-JWG, Project 4 Co-PI's PTR and GBM) and the Blanton Davis Foundation. TM is partly funded by the Odessy Fellowship (MDACC) and ZL and VS are funded by the CCBTP training grant from the CPRIT.	Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Cao XW, 2007, GENE DEV, V21, P531, DOI 10.1101/gad.1519207; Chandramohan V, 2008, J CELL BIOCHEM, V104, P2091, DOI 10.1002/jcb.21765; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; DeGregori J, 2004, J CELL SCI, V117, P3411, DOI 10.1242/jcs.01189; Evan G, 2012, SCIENCE, V335, P293, DOI 10.1126/science.1217819; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; Hoyt DG, 1996, CANCER RES, V56, P4146; Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038; Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kang SS, 2014, PROSTATE, V74, P1095, DOI 10.1002/pros.22822; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lang QB, 2012, BIOCHEM BIOPH RES CO, V426, P247, DOI 10.1016/j.bbrc.2012.08.075; Li CX, 2006, CELL CYCLE, V5, P2103, DOI 10.4161/cc.5.18.3192; Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103; Li YF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00058; Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Lu YX, 2013, BIOCHEM BIOPH RES CO, V441, P873, DOI 10.1016/j.bbrc.2013.10.157; Luo ZH, 2013, CARCINOGENESIS, V34, P415, DOI 10.1093/carcin/bgs329; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Szymaski M, 2003, INT REV CYTOL, V231, P197, DOI 10.1016/S0074-7696(03)31005-8; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Wei J, 2013, CANCER RES, V73, P3913, DOI 10.1158/0008-5472.CAN-12-4318; Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627; Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030; Xu XL, 2014, ANN THORAC SURG, V97, P1037, DOI 10.1016/j.athoracsur.2013.10.042; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhang H, 2002, CANCER, V95, P896, DOI 10.1002/cncr.10751; Zhang JH, 2013, INT J BUS SOC RES, V3, P124; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145	51	31	33	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					691	701		10.1038/onc.2014.469	http://dx.doi.org/10.1038/onc.2014.469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25639871	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000370331300003
J	Chua, JS; Liew, HP; Guo, L; Lane, DP				Chua, J. S.; Liew, H. P.; Guo, L.; Lane, D. P.			Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish	ONCOGENE			English	Article							ZINC-FINGER NUCLEASES; LI-FRAUMENI-SYNDROME; ACTIVITY IN-VIVO; EMBRYONIC LETHALITY; MDM4-NULL MICE; CELL-DEATH; PROTEIN; RESCUE; UBIQUITINATION; ONCOPROTEIN	In mice, the deletion of either Mdm2 or Mdm4 results in a p53-dependent embryonic lethality. We used zinc-finger nucleases to construct mutations in the mdm2 and mdm4 genes of zebrafish. Although the loss of mdm2 results in a p53-dependent early embryonic lethality, mdm4 mutant fish are viable and grow to adulthood. We also found that an in-frame five-amino acid deletion in mdm2 creates a novel hypomorphic allele. The lethal phenotype observed in the mdm2 mutant fish could be partially rescued by injecting mRNA encoding functional Mdm2, and this required the E3 ligase activity of the protein. Complete rescue was obtained by crossing the mdm2 mutant fish onto a p53M214K mutant background. Although p53 mutant fish on a wild-type mdm2 background were shown to accumulate high levels of p53 protein specifically in tumor tissues, we detected extensive staining of p53 in many normal tissues of the mdm2-p53M214K double-mutant fish. Our results are suggestive of the hypothesis that p53 protein accumulates during tumor formation as a result of tumor-specific inactivation of the Mdm2 pathway.	[Chua, J. S.; Liew, H. P.; Lane, D. P.] ASTAR, Inst Biomed Sci, Lab p53, Singapore 138648, Singapore; [Guo, L.] Aegis Biotech, Singapore, Singapore	Agency for Science Technology & Research (A*STAR)	Lane, DP (corresponding author), ASTAR, Inst Biomed Sci, Lab p53, 06-04-05 Immunos, Singapore 138648, Singapore.	dplane@p53lab.a-star.edu.sg		Lane, David/0000-0003-0551-3545	Biomedical Research Council of Singapore	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by the Biomedical Research Council of Singapore. We thank Dr Verma Chandra, Bioinformatics Institute, Singapore, for the homology modeling of Mdm4 and p53; Dr Venkatesh Byrappa, Institute of Molecular and Cell Biology, Singapore, for scouring the databases for zebrafish Mdm4 homologs; Dr Julin Wong for growing the hybridomas for the p53-5.1 and p53-9.1 antibodies; and our students who helped with genotyping of the zebrafish. The zebrafish p53M214K mutant line was provided by Professor A. Thomas Look (Dana Farber Cancer Institute, Boston, MA, USA). Adult zebrafish were processed and paraffin embedded at the Advanced Molecular Pathology Laboratory, IMCB, A*STAR, Singapore. All the adult zebrafish were maintained by the Zebrafish Facility at the Institute of Molecular and Cell Biology.	Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Doumont G, 2005, EMBO J, V24, P3093, DOI 10.1038/sj.emboj.7600769; Doyon Y, 2008, NAT BIOTECHNOL, V26, P702, DOI 10.1038/nbt1409; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Guo L, 2013, ONCOGENE, V32, P4009, DOI 10.1038/onc.2012.409; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Lane David P, 2012, Genes Cancer, V3, P320, DOI 10.1177/1947601912458285; Lane DP, 2010, CELL CYCLE, V9, P540, DOI 10.4161/cc.9.3.10516; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Lee KC, 2008, ONCOGENE, V27, P629, DOI 10.1038/sj.onc.1210695; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; LUNA RMD, 1995, NATURE, V378, P203; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Meng XD, 2008, NAT BIOTECHNOL, V26, P695, DOI 10.1038/nbt1398; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Peller S, 1998, SEMIN CANCER BIOL, V8, P379, DOI 10.1006/scbi.1998.0100; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zhang Y, 2014, J PATHOL, V233, P380, DOI 10.1002/path.4368	42	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5933	5941		10.1038/onc.2015.57	http://dx.doi.org/10.1038/onc.2015.57			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25746004	Green Published, hybrid			2022-12-28	WOS:000365434000008
J	Chen, HY; Hu, JY; Chen, TH; Lin, YC; Liu, X; Lin, MY; Lang, YD; Yen, Y; Chen, RH				Chen, H. Y.; Hu, J. Y.; Chen, T. H.; Lin, Y. C.; Liu, X.; Lin, M. Y.; Lang, Y. D.; Yen, Y.; Chen, R. H.			KLHL39 suppresses colon cancer metastasis by blocking KLHL20-mediated PML and DAPK ubiquitination	ONCOGENE			English	Article							KELCH FAMILY PROTEIN; TUMOR-SUPPRESSOR; COLORECTAL CANCERS; LIGASES; KINASE; KEAP1; NRF2; CELLS; DEGRADATION; INTERACTS	Cullin 3 (Cul3)-family ubiquitin ligases use the BTB-domain-containing proteins for the recruitment of substrates, but the regulation of this family of ubiquitin ligases has not been completely understood. KLHL20 is a BTB-family protein and targets tumor suppressor promyelocytic leukemia protein (PML) and death-associated protein kinase (DAPK) to its kelch-repeat domain for ubiquitination and degradation. Here, we show that another BTB-kelch protein KLHL39 is recruited to the substrate-binding domain of KLHL20 but is not a substrate of Cul3-KLHL20 complex. Interestingly, KLHL39 does not bind Cul3 because of the absence of certain conserved residues in the BTB domain. Instead, KLHL39 blocks KLHL20-mediated ubiquitination of PML and DAPK by disrupting the binding of these substrates to KLHL20 as well as the binding of KLHL20 to Cul3. Through the two mechanisms, KLHL39 increases the stability of PML and DAPK. In human colon cancers, downregulations of KLHL39, PML and DAPK are associated with metastatic progression. Furthermore, preclinical data indicate that KLHL39 promotes colon cancer migration, invasion and survival in vitro and metastasis in vivo through a PML- and DAPK-dependent mechanism. Our study identifies KLHL39 as a negative regulator of Cul3-KLHL20 ubiquitin ligase and reveals a role of KLHL39-mediated PML and DAPK stabilization in colon cancer metastasis.	[Chen, H. Y.; Liu, X.; Yen, Y.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Chen, H. Y.; Hu, J. Y.; Chen, T. H.; Lin, Y. C.; Lin, M. Y.; Chen, R. H.] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Hu, J. Y.; Chen, T. H.; Chen, R. H.] Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan; [Lang, Y. D.] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Chen, R. H.] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei, Taiwan	Taipei Medical University; Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan; National Taiwan University	Chen, RH (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	rhchen@gate.sinica.edu.tw	Yen, Yun/H-9591-2016; Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832	Academia Sinica Investigator Award; Taipei Medical University	Academia Sinica Investigator Award(Academia Sinica - Taiwan); Taipei Medical University	We thank National RNAi Core Facility for RNAi. This work was supported by Academia Sinica Investigator Award (RHC) and Aim for the Top University Project from Taipei Medical University (HYC).	Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bialik S, 2004, SEMIN CANCER BIOL, V14, P283, DOI 10.1016/j.semcancer.2004.04.008; Camp ND, 2012, J BIOL CHEM, V287, P6539, DOI 10.1074/jbc.M111.316471; Canning P, 2013, J BIOL CHEM, V288, P7803, DOI 10.1074/jbc.M112.437996; Chen HY, 2014, APOPTOSIS, V19, P364, DOI 10.1007/s10495-013-0923-6; Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667; Ebert MPA, 2005, NEOPLASIA, V7, P771, DOI 10.1593/neo.05235; Errington WJ, 2012, STRUCTURE, V20, P1141, DOI 10.1016/j.str.2012.04.009; Genschik P, 2013, EMBO J, V32, P2307, DOI 10.1038/emboj.2013.173; Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hast BE, 2013, CANCER RES, V73, P2199, DOI 10.1158/0008-5472.CAN-12-4400; Ji AX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060445; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Lee YR, 2010, EMBO J, V29, P1748, DOI 10.1038/emboj.2010.62; Liu XY, 2013, CLIN SCI, V124, P567, DOI 10.1042/CS20120240; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ohta Y, 2010, INT J ONCOL, V36, P427, DOI 10.3892/ijo_00000516; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Rabellino A, 2012, CANCER RES, V72, P2275, DOI 10.1158/0008-5472.CAN-11-3159; Reineke EL, 2010, J BIOL CHEM, V285, P9485, DOI 10.1074/jbc.M109.063362; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Sasagawa K, 2002, J BIOL CHEM, V277, P44140, DOI 10.1074/jbc.M202596200; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schneider-Stock R, 2006, J PATHOL, V209, P95, DOI 10.1002/path.1951; Tsai PL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003460; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Wang WJ, 2007, MOL CELL, V27, P701, DOI 10.1016/j.molcel.2007.06.037; Wolff T, 1998, J VIROL, V72, P7170, DOI 10.1128/JVI.72.9.7170-7180.1998; Wolyniec K, 2012, BLOOD, V120, P822, DOI 10.1182/blood-2011-10-387647; Wu HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4214; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441; Yen CC, 2011, J SURG ONCOL, V103, P761, DOI 10.1002/jso.21855; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	40	19	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5141	5151		10.1038/onc.2014.435	http://dx.doi.org/10.1038/onc.2014.435			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619834				2022-12-28	WOS:000362233400004
J	Kim, JY; Lim, SC; Kim, G; Yun, HJ; Ahn, SG; Choi, HS				Kim, J. Y.; Lim, S-C; Kim, G.; Yun, H. J.; Ahn, S-G; Choi, H. S.			Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity	ONCOGENE			English	Article							NF-KAPPA-B; ACTIVATED SIGNAL TRANSDUCER; RECEPTOR ACCESSORY PROTEIN; IL-1 RECEPTOR; MAST-CELLS; NUCLEAR FACTOR; AP-1 ACTIVITY; CANCER CELLS; STAT3; GROWTH	Cytokines of the interleukin-1 (IL-1) family, such as IL-1 alpha/beta and IL-18, have pleiotropic activities in innate and adaptive immune responses in host defense and diseases. Insight into their biological functions helped develop novel therapeutic approaches to treat human inflammatory diseases. IL-33 is an important member of the IL-1 family of cytokines and is a ligand of the ST2 receptor, a member of the IL-1 receptor family. However, the role of the IL-33/ST2 axis in tumor growth and metastasis of breast cancer remains unclear. Here, we demonstrate that IL-33 is a critical tumor promoter during epithelial cell proliferation and tumorigenesis in the breast. IL-33 dose-and time-dependently increased Cancer Osaka Thyroid (COT) phosphorylation via ST2-COT interaction in normal epithelial and breast cancer cells. The IL-33/ST2/COT cascade induced the activation of the MEK-ERK (MEK-extracellular signal-regulated kinase), JNK-cJun (cJun N-terminal kinase-cJun) and STAT3 (signal transducer and activator of transcription 3) signaling pathways, followed by increased AP-1 and stat3 transcriptional activity. When small interfering RNAs of ST2 and COT were introduced into cells, IL-33-induced AP-1 and stat3 activity were significantly decreased, unlike that in the control cells. The inhibition of COT activity resulted in decreased IL-33-induced epithelial cell transformation, and knockdown of IL-33, ST2 and COT in breast cancer cells attenuated tumorigenicity of breast cancer cells. Consistent with these observations, ST2 levels were positively correlated with COT expression in human breast cancer. These findings provide a novel perspective on the role of the IL-33/ST2/COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment. Therapeutic approaches that target this pathway may, therefore, effectively inhibit carcinogenesis in the breast.	[Kim, J. Y.; Kim, G.; Yun, H. J.; Choi, H. S.] Chosun Univ, Coll Pharm, Gwangju 501759, Jeollanamdo, South Korea; [Lim, S-C] Chosun Univ, Sch Med, Dept Pathol, Gwangju 501759, Jeollanamdo, South Korea; [Ahn, S-G] Chosun Univ, Sch Dent, Dept Pathol, Gwangju 501759, Jeollanamdo, South Korea	Chosun University; Chosun University; Chosun University	Choi, HS (corresponding author), Chosun Univ, Coll Pharm, Gwangju 501759, Jeollanamdo, South Korea.	chs@chosun.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST) [NRF-2013R1A1A2004714]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST)	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST) (NRF-2013R1A1A2004714).	Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Berclaz G, 2001, INT J ONCOL, V19, P1155; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Choi HS, 2008, FASEB J, V22, P113, DOI 10.1096/fj.07-9078com; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Funakoshi-Tago M, 2008, CELL SIGNAL, V20, P1679, DOI 10.1016/j.cellsig.2008.05.013; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GELIN J, 1991, CANCER RES, V51, P415; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; Hu WT, 2014, MOL HUM REPROD, V20, P358, DOI 10.1093/molehr/gat094; Itoh M, 2006, ONCOGENE, V25, P1195, DOI 10.1038/sj.onc.1209149; Jovanovic I, 2011, EUR J IMMUNOL, V41, P1902, DOI 10.1002/eji.201141417; Jovanovic IP, 2014, INT J CANCER, V134, P1669, DOI 10.1002/ijc.28481; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khanal P, 2011, MOL CARCINOGEN, V50, P961, DOI 10.1002/mc.20761; Kim G, 2013, CARCINOGENESIS, V34, P341, DOI 10.1093/carcin/bgs342; Kim K, 2014, CARCINOGENESIS, V35, P1352, DOI 10.1093/carcin/bgu044; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Onda H, 1999, J CEREBR BLOOD F MET, V19, P1279, DOI 10.1097/00004647-199911000-00013; Palmer G, 2008, CYTOKINE, V42, P358, DOI 10.1016/j.cyto.2008.03.008; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sugimoto K, 2004, J CLIN INVEST, V114, P857, DOI 10.1172/JCI200420014; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827	48	63	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4928	4938		10.1038/onc.2014.418	http://dx.doi.org/10.1038/onc.2014.418			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531326				2022-12-28	WOS:000361693000003
J	Goyama, S; Huang, G; Kurokawa, M; Mulloy, JC				Goyama, S.; Huang, G.; Kurokawa, M.; Mulloy, J. C.			Posttranslational modifications of RUNX1 as potential anticancer targets	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FAMILIAL PLATELET DISORDER; HEMATOPOIETIC STEM-CELLS; E3 UBIQUITIN LIGASE; POINT MUTATIONS; MYELODYSPLASTIC SYNDROME; TUMOR-SUPPRESSOR; AML1/RUNX1 GENE; DOWN-REGULATION	The transcription factor RUNX1 is a master regulator of hematopoiesis. Disruption of RUNX1 activity has been implicated in the development of hematopoietic neoplasms. Recent studies also highlight the importance of RUNX1 in solid tumors both as a tumor promoter and a suppressor. Given its central role in cancer development, RUNX1 is an excellent candidate for targeted therapy. A potential strategy to target RUNX1 is through modulation of its posttranslational modifications (PTMs). Numerous studies have shown that RUNX1 activity is regulated by PTMs, including phosphorylation, acetylation, methylation and ubiquitination. These PTMs regulate RUNX1 activity either positively or negatively by altering RUNX1-mediated transcription, promoting protein degradation and affecting protein interactions. In this review, we first summarize the available data on the context-and dosagedependent roles of RUNX1 in various types of neoplasms. We then provide a comprehensive overview of RUNX1 PTMs from biochemical and biologic perspectives. Finally, we discuss how aberrant PTMs of RUNX1 might contribute to tumorigenesis and also strategies to develop anticancer therapies targeting RUNX1 PTMs.	[Goyama, S.; Huang, G.; Mulloy, J. C.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Tokyo	Mulloy, JC (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.	susumu.goyama@cchmc.org; james.mulloy@cchmc.org			Grants-in-Aid for Scientific Research [15H01481] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Ben-Ami O, 2013, CELL REP, V4, P1131, DOI 10.1016/j.celrep.2013.08.020; Biggs JR, 2006, MOL CELL BIOL, V26, P7420, DOI 10.1128/MCB.00597-06; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Bresciani E, 2014, BLOOD, V124, P70, DOI 10.1182/blood-2013-10-531988; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Della Gatta G, 2012, NAT MED, V18, P436, DOI 10.1038/nm.2610; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Giambra V, 2012, NAT MED, V18, P1693, DOI 10.1038/nm.2960; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gorczynski MJ, 2007, CHEM BIOL, V14, P1186, DOI 10.1016/j.chembiol.2007.09.006; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Goyama S, 2013, J CLIN INVEST, V123, P3876, DOI 10.1172/JCI68557; Goyama S, 2011, INT J HEMATOL, V94, P126, DOI 10.1007/s12185-011-0858-z; Greif PA, 2012, HAEMATOL-HEMATOL J, V97, P1909, DOI 10.3324/haematol.2012.064667; Grossmann V, 2013, GENE CHROMOSOME CANC, V52, P410, DOI 10.1002/gcc.22039; Grossmann V, 2011, HAEMATOL-HEMATOL J, V96, P1874, DOI 10.3324/haematol.2011.043919; Gu JA, 2010, CANCER PREV RES, V3, P1176, DOI 10.1158/1940-6207.CAPR-09-0265; Guo H, 2011, J BIOL CHEM, V286, P208, DOI 10.1074/jbc.M110.149013; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Herglotz J, 2013, ONCOGENE, V32, P2565, DOI 10.1038/onc.2012.274; Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang G, 2011, BLOOD, V118, P6544, DOI 10.1182/blood-2010-11-317909; Huang H, 2012, GENE DEV, V26, P1587, DOI 10.1101/gad.192054.112; Huang SP, 2011, BJU INT, V107, P486, DOI 10.1111/j.1464-410X.2010.09512.x; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Itzykson R, 2013, J CLIN ONCOL, V31, P2428, DOI 10.1200/JCO.2012.47.3314; Jacob B, 2010, BLOOD, V115, P1610, DOI 10.1182/blood-2009-07-232249; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kamikubo Y, 2010, CANCER CELL, V17, P455, DOI 10.1016/j.ccr.2010.03.022; Kawazu M, 2005, J IMMUNOL, V174, P3526, DOI 10.4049/jimmunol.174.6.3526; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Komeno Y, 2014, BLOOD, V123, P3760, DOI 10.1182/blood-2013-08-521252; Kurokawa M, 2006, INT J HEMATOL, V84, P136, DOI 10.1532/IJH97.06070; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Link KA, 2010, J CELL PHYSIOL, V222, P50, DOI 10.1002/jcp.21950; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Ma SK, 2001, LEUKEMIA, V15, P1442, DOI 10.1038/sj.leu.2402202; Mendler JH, 2012, J CLIN ONCOL, V30, P3109, DOI 10.1200/JCO.2011.40.6652; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Migas A, 2011, PEDIATR BLOOD CANCER, V57, P583, DOI 10.1002/pbc.22980; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Neel BG, 2012, GENE DEV, V26, P1520, DOI 10.1101/gad.198051.112; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Nishimoto N, 2011, BLOOD, V118, P2541, DOI 10.1182/blood-2010-10-315440; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Owen CJ, 2008, BLOOD, V112, P4639, DOI 10.1182/blood-2008-05-156745; Peter A, 2009, EUR J HAEMATOL, V83, P420, DOI 10.1111/j.1600-0609.2009.01315.x; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Rocquain J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-401; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Scheitz CJF, 2013, J CELL BIOCHEM, V114, P985, DOI 10.1002/jcb.24453; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; Schwaab J, 2013, BLOOD, V122, P2460, DOI 10.1182/blood-2013-04-496448; Shang Y, 2009, BIOCHEM BIOPH RES CO, V386, P242, DOI 10.1016/j.bbrc.2009.06.043; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Slattery ML, 2011, CARCINOGENESIS, V32, P318, DOI 10.1093/carcin/bgq245; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tachibana M, 2008, BIOCHEM BIOPH RES CO, V368, P536, DOI 10.1016/j.bbrc.2008.01.124; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Vu LP, 2013, CELL REP, V5, P1625, DOI 10.1016/j.celrep.2013.11.025; Wang CQ, 2014, CELL REP, V8, P767, DOI 10.1016/j.celrep.2014.06.046; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang L, 2009, BLOOD CELL MOL DIS, V43, P30, DOI 10.1016/j.bcmd.2009.03.005; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wotton S, 2002, CANCER RES, V62, P7181; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yoshimi M, 2012, EUR J IMMUNOL, V42, P1044, DOI 10.1002/eji.201040746; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhang LS, 2008, BLOOD, V111, P1193, DOI 10.1182/blood-2007-08-109702; Zhang YH, 2004, J BIOL CHEM, V279, P53116, DOI 10.1074/jbc.M405502200; Zhao XH, 2014, BLOOD, V123, P1729, DOI 10.1182/blood-2013-03-489575; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608	102	40	41	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3483	3492		10.1038/onc.2014.305	http://dx.doi.org/10.1038/onc.2014.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25263451				2022-12-28	WOS:000357434900001
J	Althoff, K; Beckers, A; Bell, E; Nortmeyer, M; Thor, T; Sprussel, A; Lindner, S; De Preter, K; Florin, A; Heukamp, LC; Klein-Hitpass, L; Astrahantseff, K; Kumps, C; Speleman, F; Eggert, A; Westermann, F; Schramm, A; Schulte, JH				Althoff, K.; Beckers, A.; Bell, E.; Nortmeyer, M.; Thor, T.; Spruessel, A.; Lindner, S.; De Preter, K.; Florin, A.; Heukamp, L. C.; Klein-Hitpass, L.; Astrahantseff, K.; Kumps, C.; Speleman, F.; Eggert, A.; Westermann, F.; Schramm, A.; Schulte, J. H.			A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies	ONCOGENE			English	Article							RISK STRATIFICATION; MIRNA EXPRESSION; GENE-EXPRESSION; P-TEFB; DIFFERENTIATION; PROGRESSION; PHENOTYPE; BIOLOGY; GAINS	Neuroblastoma, a childhood cancer that originates from neural crest-derived cells, is the most common deadly solid tumor of infancy. Amplification of the MYCN oncogene, which occurs in approximately 20-25% of human neuroblastomas, is the most prominent genetic marker of high-stage disease. The availability of valid preclinical in vivo models is a prerequisite to develop novel targeted therapies. We here report on the generation of transgenic mice with Cre-conditional induction of MYCN in dopamine a-hydroxylase-expressing cells, termed LSL-MYCN; Dbh-iCre. These mice develop neuroblastic tumors with an incidence of 475%, regardless of strain background. Molecular profiling of tumors revealed upregulation of the MYCN-dependent miR-17-92 cluster as well as expression of neuroblastoma marker genes, including tyrosine hydroxylase and the neural cell adhesion molecule 1. Gene set enrichment analyses demonstrated significant correlation with MYC-associated expression patterns. Array comparative genome hybridization showed that chromosomal aberrations in LSL-MYCN; Dbh-iCre tumors were syntenic to those observed in human neuroblastomas. Treatment of a cell line established from a tumor derived from a LSL-MYCN; Dbh-iCre mouse with JQ1 or MLN8237 reduced cell viability and demonstrated oncogene addiction to MYCN. Here we report establishment of the first Cre-conditional human MYCN-driven mouse model for neuroblastoma that closely recapitulates the human disease with respect to tumor localization, histology, marker expression and genomic make up. This mouse model is a valuable tool for further functional studies and to assess the effect of targeted therapies.	[Althoff, K.; Thor, T.; Spruessel, A.; Lindner, S.; Schramm, A.; Schulte, J. H.] Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, D-45122 Essen, Germany; [Althoff, K.; Thor, T.; Spruessel, A.; Lindner, S.; Schulte, J. H.] German Canc Consortium DKTK, Hufelandstr, Germany; [Beckers, A.; De Preter, K.; Kumps, C.; Speleman, F.; Schulte, J. H.] Ghent Univ Hosp, Ctr Med Genet Ghent, Ghent, Belgium; [Bell, E.; Nortmeyer, M.; Thor, T.; Spruessel, A.; Lindner, S.; Westermann, F.; Schulte, J. H.] German Canc Res Ctr, Heidelberg, Germany; [Thor, T.; Spruessel, A.; Lindner, S.; Schulte, J. H.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Translat Neurooncol, Essen, Germany; [Florin, A.; Heukamp, L. C.] Univ Hosp Cologne, Inst Pathol, Cologne, Germany; [Heukamp, L. C.] Blackfield AG, New Oncol, Cologne, Germany; [Klein-Hitpass, L.] Univ Duisburg Essen, Fac Med, Inst Cell Biol Canc Res, Essen, Germany; [Astrahantseff, K.; Eggert, A.] Charite, Dept Pediat Oncol Hematol & BMT, D-13353 Berlin, Germany	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Ghent University; Ghent University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Cologne; University of Duisburg Essen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schulte, JH (corresponding author), Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, Hufeland St 55, D-45122 Essen, Germany.	Johannes.schulte@uni-due.de	Schulte, Johannes H./V-2474-2018; speleman, frank/AAR-5184-2020; Westermann, Frank/F-7509-2013; Schramm, Alexander/G-5688-2010; Eggert, Angelika/AAE-6907-2022; De Preter, Katleen/I-7135-2013; Heukamp, Lukas/G-9967-2012	speleman, frank/0000-0002-6628-8559; Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; De Preter, Katleen/0000-0002-7726-5096; Heukamp, Lukas/0000-0002-3388-3482; Schulte, Johannes Hubertus/0000-0003-0671-1201	National Genome Research Network of the German Ministry for Education and Research (NGFNplus) [PKN-01GS0894-6]; European Union [259348-2]; German research council [SFB 832]; German Cancer Aid [111301]; Agency for Innovation by Science and Technology (IWT); Fund for Scientific Research Flanders (FWO)	National Genome Research Network of the German Ministry for Education and Research (NGFNplus); European Union(European Commission); German research council(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); Agency for Innovation by Science and Technology (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Fund for Scientific Research Flanders (FWO)(FWO)	We thank S Dreesmann, A Odersky, S Schafers and N Solomentsew for excellent technical assistance and A Henssen for helpful discussions. This work was supported by the National Genome Research Network of the German Ministry for Education and Research (NGFNplus grant #PKN-01GS0894-6 to JHS, AE and AS), the 7th framework European Union project, ASSET (contract #259348-2 to AE, FS and JHS), the German research council (SFB 832, A5 and Z1 to LCH), by the German Cancer Aid (Grant No 111301 to JHS), by the Agency for Innovation by Science and Technology (IWT PhD grant to AB and CK) and the Fund for Scientific Research Flanders (FWO post-doc grant to KDP).	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Casola S, 2010, METHODS MOL BIOL, V667, P145, DOI 10.1007/978-1-60761-811-9_10; Cimmino F, 2009, ONCOGENE, V28, P2015, DOI 10.1038/onc.2009.70; De Preter K, 2011, CLIN CANCER RES, V17, P7684, DOI 10.1158/1078-0432.CCR-11-0610; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Gargano B, 2007, CELL CYCLE, V6, P2031, DOI 10.4161/cc.6.16.4554; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hackett CS, 2003, CANCER RES, V63, P5266; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Heukamp LC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003967; Hong F, 2011, R PACKAGE VERSION; Jiang MR, 2011, CURR TOP DEV BIOL, V94, P77, DOI 10.1016/B978-0-12-380916-2.00004-8; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Menten B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-124; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Ora I, 2011, SEMIN CANCER BIOL, V21, P217, DOI 10.1016/j.semcancer.2011.07.002; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rasmuson A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051297; Schleiermacher G, 2010, J CLIN ONCOL, V28, P3122, DOI 10.1200/JCO.2009.26.7955; Schramm A, 2007, CLIN CANCER RES, V13, P1459, DOI 10.1158/1078-0432.CCR-06-2032; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Simon T, 2011, PEDIATR BLOOD CANCER, V56, P578, DOI 10.1002/pbc.22693; Stallings RL, 2003, CANCER GENET CYTOGEN, V140, P133, DOI 10.1016/S0165-4608(02)00681-7; Stanke M, 2006, DEVELOPMENT, V133, P141, DOI 10.1242/dev.02189; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tchorz JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030011; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Vandesompele J, 2001, MED PEDIATR ONCOL, V36, P5, DOI 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E; Weiss WA, 2000, CANCER RES, V60, P2483; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Whiteford CC, 2007, CANCER RES, V67, P32, DOI 10.1158/0008-5472.CAN-06-0610; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07	44	69	69	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3357	3368		10.1038/onc.2014.269	http://dx.doi.org/10.1038/onc.2014.269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174395	Green Published, hybrid			2022-12-28	WOS:000356871700002
J	Li, M; Yu, X				Li, M.; Yu, X.			The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy	ONCOGENE			English	Review							DOUBLE-STRAND BREAKS; NUCLEOTIDE EXCISION-REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; HISTONE ADP-RIBOSYLATION; HOMOLOGY-DIRECTED REPAIR; ATM PROTEIN-KINASE; DOMAIN BARD1 GENE; RING DOMAIN; POLYNUCLEOTIDE KINASE; BRCT DOMAIN	DNA damage is a deleterious threat, but occurs daily in all types of cells. In response to DNA damage, poly(ADP-ribosyl)ation, a unique post-translational modification, is immediately catalyzed by poly(ADP-ribose) polymerases (PARPs) at DNA lesions, which facilitates DNA damage repair. Recent studies suggest that poly(ADP-ribosyl) ation is one of the first steps of cellular DNA damage response and governs early DNA damage response pathways. Suppression of DNA damage-induced poly(ADP-ribosyl) ation by PARP inhibitors impairs early DNA damage response events. Moreover, PARP inhibitors are emerging as anti-cancer drugs in phase III clinical trials for BRCA-deficient tumors. In this review, we discuss recent findings on poly(ADP-ribosyl) ation in DNA damage response as well as the molecular mechanism by which PARP inhibitors selectively kill tumor cells with BRCA mutations.	[Li, M.] Peking Univ, Hosp 3, Reprod Med Ctr, Dept Obstet & Gynecol, Beijing 100871, Peoples R China; [Li, M.; Yu, X.] Univ Michigan, Sch Med, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA	Peking University; University of Michigan System; University of Michigan	Yu, X (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 109 Zina Pitcher Pl,BSRB 1520, Ann Arbor, MI 48109 USA.	xiayu@umich.edu			National Institute of Health [CA132755, CA130899]; Department of Defense; Ovarian Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA132755, R01CA130899, R01CA187209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108647] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Ovarian Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Chao Liu to proofread the manuscript. This work was supported by the National Institute of Health (CA132755 and CA130899 to XY). XY is a recipient of the Era of Hope Scholar Award from the Department of Defense. ML is a recipient of the Ovarian Cancer Research Foundation Award.	Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321; Ahel I, 2008, NATURE, V451, P81, DOI 10.1038/nature06420; Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164; Ali AAE, 2012, NAT STRUCT MOL BIOL, V19, P685, DOI 10.1038/nsmb.2335; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ALVAREZGONZALEZ R, 1994, MOL CELL BIOCHEM, V138, P33, DOI 10.1007/BF00928440; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Baer R, 2013, CANCER CELL, V23, P565, DOI 10.1016/j.ccr.2013.04.013; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brem R, 2005, NUCLEIC ACIDS RES, V33, P2512, DOI 10.1093/nar/gki543; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Caldecott KW, 2008, NAT REV GENET, V9, P619, DOI 10.1038/nrg2380; Caldecott KW, 2003, BIOCHEM SOC T, V31, P247, DOI 10.1042/bst0310247; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Chapman JD, 2013, J PROTEOME RES, V12, P1868, DOI 10.1021/pr301219h; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Daniels CM, 2014, J PROTEOME RES, V13, P3510, DOI 10.1021/pr401032q; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; De Lorenzo SB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00228; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Deriano L, 2013, ANNU REV GENET, V47, P433, DOI 10.1146/annurev-genet-110711-155540; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Enders A, 2006, J IMMUNOL, V176, P5060, DOI 10.4049/jimmunol.176.8.5060; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng XX, 2013, INT REV CEL MOL BIO, V304, P227, DOI 10.1016/B978-0-12-407696-9.00005-1; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Flynn RL, 2010, CRIT REV BIOCHEM MOL, V45, P266, DOI 10.3109/10409238.2010.488216; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gagne JP, 2003, BIOCHEM J, V371, P331, DOI 10.1042/BJ20021675; Gasser A, 2005, J CHROMATOGR B, V821, P181, DOI 10.1016/j.jchromb.2005.05.002; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Gottschalk AJ, 2009, P NATL ACAD SCI USA, V106, P13770, DOI 10.1073/pnas.0906920106; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Haenni SS, 2008, INT J BIOCHEM CELL B, V40, P2274, DOI 10.1016/j.biocel.2008.03.008; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Han J, 2004, BRIT J CANCER, V91, P1604, DOI 10.1038/sj.bjc.6602174; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Hegde ML, 2008, CELL RES, V18, P27, DOI 10.1038/cr.2008.8; HILZ H, 1981, H-S Z PHYSIOL CHEM, V362, P1415; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Ishitobi M, 2003, CANCER LETT, V200, P1, DOI 10.1016/S0304-3835(03)00387-2; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; JACOBSON EL, 1983, J BIOL CHEM, V258, P103; Jankevicius G, 2013, NAT STRUCT MOL BIOL, V20, P508, DOI 10.1038/nsmb.2523; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; Jungmichel S, 2013, MOL CELL, V52, P272, DOI 10.1016/j.molcel.2013.08.026; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Le Page F, 2003, J BIOL CHEM, V278, P18471, DOI 10.1074/jbc.M212905200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee MS, 2010, CANCER RES, V70, P4880, DOI 10.1158/0008-5472.CAN-09-4563; Leung AKL, 2014, J CELL BIOL, V205, P613, DOI 10.1083/jcb.201402114; Li GY, 2010, P NATL ACAD SCI USA, V107, P9129, DOI 10.1073/pnas.1000556107; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Li ML, 2012, TRENDS BIOCHEM SCI, V37, P418, DOI 10.1016/j.tibs.2012.06.007; Li M, 2013, GENE DEV, V27, P1752, DOI 10.1101/gad.226357.113; Li M, 2013, CANCER CELL, V23, P693, DOI 10.1016/j.ccr.2013.03.025; Li SC, 2011, J BIOL CHEM, V286, P36368, DOI 10.1074/jbc.M111.287797; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Mahajan A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.151re12; Malanga M, 2008, J BIOL CHEM, V283, P19991, DOI 10.1074/jbc.M709495200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Martinez-Zamudio R, 2012, MOL CELL BIOL, V32, P2490, DOI 10.1128/MCB.06667-11; Messner S, 2011, TRENDS CELL BIOL, V21, P534, DOI 10.1016/j.tcb.2011.06.001; Messner S, 2010, NUCLEIC ACIDS RES, V38, P6350, DOI 10.1093/nar/gkq463; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; Michels J, 2014, ONCOGENE, V33, P3894, DOI 10.1038/onc.2013.352; Min W, 2009, FRONT BIOSCI-LANDMRK, V14, P1619, DOI 10.2741/3329; MIWA M, 1981, J BIOL CHEM, V256, P2916; Mohammad DH, 2009, DNA REPAIR, V8, P1009, DOI 10.1016/j.dnarep.2009.04.004; Mortusewicz O, 2011, NUCLEIC ACIDS RES, V39, P5045, DOI 10.1093/nar/gkr099; MOSS J, 1992, J BIOL CHEM, V267, P10481; Nelson HH, 2002, CANCER RES, V62, P152; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Petrucelli N, 2010, GENET MED, V12, P245, DOI 10.1097/GIM.0b013e3181d38f2f; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188; Polyak K, 2011, NAT MED, V17, P283, DOI 10.1038/nm0311-283; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; Richard DJ, 2011, NUCLEIC ACIDS RES, V39, P3643, DOI 10.1093/nar/gkq1340; Robu M, 2013, P NATL ACAD SCI USA, V110, P1658, DOI 10.1073/pnas.1209507110; Rosenthal F, 2013, NAT STRUCT MOL BIOL, V20, P502, DOI 10.1038/nsmb.2521; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SAKURA H, 1977, NUCLEIC ACIDS RES, V4, P2903, DOI 10.1093/nar/4.8.2903; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharifi R, 2013, EMBO J, V32, P1225, DOI 10.1038/emboj.2013.51; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Slade D, 2011, NATURE, V477, P616, DOI 10.1038/nature10404; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Tartier L, 2003, MUTAGENESIS, V18, P411, DOI 10.1093/mutage/geg015; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang ZZ, 2012, GENE DEV, V26, P235, DOI 10.1101/gad.182618.111; WEILL JD, 1963, BIOCHEM BIOPH RES CO, V10, P122, DOI 10.1016/0006-291X(63)90036-6; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Williams RS, 2009, CELL, V139, P87, DOI 10.1016/j.cell.2009.07.033; Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang F, 2014, P NATL ACAD SCI USA, V111, P7278, DOI 10.1073/pnas.1318367111; Zhang F, 2013, J CELL SCI, V126, P4850, DOI 10.1242/jcs.132514; Zhang YJ, 2013, NAT METHODS, V10, P981, DOI 10.1038/nmeth.2603; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	142	68	69	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3349	3356		10.1038/onc.2014.295	http://dx.doi.org/10.1038/onc.2014.295			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25220415	Green Accepted			2022-12-28	WOS:000356871700001
J	Voce, DJ; Schmitt, AM; Uppal, A; McNerney, ME; Bernal, GM; Cahill, KE; Wahlstrom, JS; Nassiri, A; Yu, X; Crawley, CD; White, KP; Onel, K; Weichselbaum, RR; Yamini, B				Voce, D. J.; Schmitt, A. M.; Uppal, A.; McNerney, M. E.; Bernal, G. M.; Cahill, K. E.; Wahlstrom, J. S.; Nassiri, A.; Yu, X.; Crawley, C. D.; White, K. P.; Onel, K.; Weichselbaum, R. R.; Yamini, B.			Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor	ONCOGENE			English	Article							NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; MYELOID-LEUKEMIA; CELL LYMPHOMA; P50 SUBUNIT; EXPRESSION; GENE; TEMOZOLOMIDE; MICROARRAY; MICE	NF-kappa B proteins play a central and subunit-specific role in the response to DNA damage. Previous work identified p50/NF-kappa B1 as being necessary for cytotoxicity in response to DNA alkylation damage. Given the importance of damage-induced cell death for the maintenance of genomic stability, we examined whether Nfkb1 acts as a tumor suppressor in the setting of alkylation damage. Hprt mutation analysis demonstrates that Nfkb1(-/-) cells accumulate more alkylator-induced, but not ionizing radiation (IR)-induced, mutations than similarly treated wild-type cells. Subsequent in vivo tumor induction studies reveal that following alkylator treatment, but not IR, Nfkb1(-/-) mice develop more lymphomas than similarly treated Nfkb1(+/+) animals. Heterozygous mice develop lymphomas at an intermediate rate and retain functional p50 in their tumors, indicating that Nfkb1 acts in a haploinsufficient manner. Analysis of human cancers, including therapy-related myeloid neoplasms, demonstrates that NFKB1 mRNA expression is downregulated compared with control samples in multiple hematological malignancies. These data indicate that Nfkb1 is a haploinsufficient, pathway-specific tumor suppressor that prevents the development of hematologic malignancy in the setting of alkylation damage.	[Voce, D. J.; Schmitt, A. M.; Bernal, G. M.; Cahill, K. E.; Wahlstrom, J. S.; Nassiri, A.; Yu, X.; Crawley, C. D.; Yamini, B.] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA; [Uppal, A.] Univ Chicago, Dept Surg, Sect Gen Surg, Chicago, IL 60637 USA; [McNerney, M. E.] Univ Chicago, Dept Pathol, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [White, K. P.] Univ Chicago, Dept Human Genet, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [Onel, K.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Weichselbaum, R. R.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; [Weichselbaum, R. R.] Univ Chicago, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Yamini, B (corresponding author), Univ Chicago, Neurosurg Sect, MC3026,5841S Maryland Ave, Chicago, IL 60637 USA.	byamini@surgery.bsd.uchicago.edu		McNerney, Megan/0000-0002-8260-3598	NIH [1R01CA136937]; Ludwig Center for Metastasis Research; Leukemia & Lymphoma Society; Chicago Cancer Genomes Project; NATIONAL CANCER INSTITUTE [R01CA136937, K08CA181254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Center for Metastasis Research; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Chicago Cancer Genomes Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to RF de Pooter and B Kee for helpful contributions. This work was supported by NIH grant 1R01CA136937 (to BY), The Ludwig Center for Metastasis Research; Leukemia & Lymphoma Society Fellow award (M.E.M) and the Chicago Cancer Genomes Project.	Allan JM, 2005, NAT REV CANCER, V5, P943, DOI 10.1038/nrc1749; Andersson A, 2007, LEUKEMIA, V21, P1198, DOI 10.1038/sj.leu.2404688; Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184; Chang PY, 2006, CANCER RES, V66, P6008, DOI 10.1158/0008-5472.CAN-06-0194; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Glauert HP, 2006, TOXICOL SCI, V90, P331, DOI 10.1093/toxsci/kfj116; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; JOSHI VV, 1970, J NATL CANCER I, V45, P335; Karban AS, 2004, HUM MOL GENET, V13, P35, DOI 10.1093/hmg/ddh008; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Li ZP, 2005, J IMMUNOL, V174, P205, DOI 10.4049/jimmunol.174.1.205; Margison GP, 2002, MUTAGENESIS, V17, P483, DOI 10.1093/mutage/17.6.483; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; McNerney ME, 2013, BLOOD, V121, P975, DOI 10.1182/blood-2012-04-426965; Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0; Neyns B, 2008, J CLIN ONCOL, V26, P4518, DOI 10.1200/JCO.2008.18.8177; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Piccaluga PP, 2007, J CLIN INVEST, V117, P823, DOI 10.1172/JCI26833; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schmitt AM, 2011, MOL CELL, V44, P785, DOI 10.1016/j.molcel.2011.09.026; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Smith SM, 2003, BLOOD, V102, P43, DOI 10.1182/blood-2002-11-3343; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wood ME, 2012, J CLIN ONCOL, V30, P3734, DOI 10.1200/JCO.2012.41.8681; Yamini B, 2007, CANCER RES, V67, P6889, DOI 10.1158/0008-5472.CAN-06-4496	38	17	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2807	2813		10.1038/onc.2014.211	http://dx.doi.org/10.1038/onc.2014.211			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043302	Green Accepted			2022-12-28	WOS:000354979500013
J	del Rincon, SV; Widschwendter, M; Sun, D; Ekholm-Reed, S; Tat, J; Teixeira, LK; Ellederova, Z; Grolieres, E; Reed, SI; Spruck, C				del Rincon, S. V.; Widschwendter, M.; Sun, D.; Ekholm-Reed, S.; Tat, J.; Teixeira, L. K.; Ellederova, Z.; Grolieres, E.; Reed, S. I.; Spruck, C.			Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE; CELL-CYCLE; UBIQUITIN LIGASE; GENE-EXPRESSION; INDEPENDENT FUNCTION; BLADDER-CANCER; PROGRESSION; P27(KIP1); SKP2; PHOSPHORYLATION	Cdc kinase subunit (Cks) proteins Cks1 and Cks2 are adaptor-like proteins that bind many cyclin-dependent kinases. A wealth of clinical data has shown that Cks proteins are overexpressed in many types of human cancers and this often correlates with increased tumor aggressiveness. Previously, we showed that Cks overexpression abrogates the intra-S-phase checkpoint, a major barrier to oncogene-mediated transformation. Interestingly, the intra-S-phase checkpoint is crucial for the cellular response to replication stress, a major pathway of apoptosis induction by many chemotherapeutic agents. Here, we demonstrate cancer cells that overexpress Cks1 or Cks2 override the intra-S-phase checkpoint in the presence of replication stress-inducing chemotherapies such as 5-Fluorouracil (5-FU) and methotrexate (MTX) leading to enhanced sensitivity in vitro and in vivo. Furthermore, enforced expression of Cks1 in an MTX-resistant breast cancer cell line was found to restore drug sensitivity. Our results suggest that Cks proteins are important determinants of apoptosis induction of replication stress-inducing chemotherapies such as 5-FU.	[del Rincon, S. V.; Sun, D.; Ellederova, Z.; Grolieres, E.; Spruck, C.] Sanford Burnham Med Res Inst, Ctr Canc, Tumor Initiat & Maintenance Program, La Jolla, CA 92037 USA; [Widschwendter, M.] UCL, Dept Gynaecol Oncol, London, England; [Ekholm-Reed, S.; Tat, J.; Teixeira, L. K.; Reed, S. I.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; University of London; University College London; Scripps Research Institute	Spruck, C (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, Tumor Initiat & Maintenance Program, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.	cspruck@sanfordburnham.org	Teixeira, Leonardo Karam/S-8773-2016	Teixeira, Leonardo Karam/0000-0001-6117-423X; Widschwendter, Martin/0000-0002-7778-8380	American Cancer Society [RSG-06-020-01]; National Institutes of Health [7R01HD049539-05]; Department of Defense Breast Cancer Research Program [W81XWH-06-1-0344]; National Cancer Institute [CA074224]; UCLH/UCL Comprehensive Biomedical Research Centre grant; Department of Health NIHR Biomedical Research Centres funding scheme; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD049539] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA078343, P30CA030199, R01CA074224] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UCLH/UCL Comprehensive Biomedical Research Centre grant; Department of Health NIHR Biomedical Research Centres funding scheme(National Institute for Health Research (NIHR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank C Torres and Y Altman (Sanford-Burnham Medical Research Institute) for technical assistance with flow cytometry analyses. This work was supported by grants from the American Cancer Society (RSG-06-020-01) and National Institutes of Health (7R01HD049539-05) to CS, Department of Defense Breast Cancer Research Program (W81XWH-06-1-0344) to SVdR, and National Cancer Institute (CA074224) to SIR. Additional support came from a UCLH/UCL Comprehensive Biomedical Research Centre grant and was undertaken at UCLH/UCL, which received a portion of its funding from the Department of Health NIHR Biomedical Research Centres funding scheme.	Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bhatt KV, 2007, ONCOGENE, V26, P1056, DOI 10.1038/sj.onc.1209861; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Chaves S, 2010, MOL CELL BIOL, V30, P5284, DOI 10.1128/MCB.00952-10; Chen R, 2011, J INT MED RES, V39, P533, DOI 10.1177/147323001103900222; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Kawakami K, 2007, J UROLOGY, V178, P301, DOI 10.1016/j.juro.2007.03.002; Kawakami K, 2006, ONCOL REP, V16, P521; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kunz C, 2009, PLOS BIOL, V7, P967, DOI 10.1371/journal.pbio.1000091; Lee SW, 2013, HEPATO-GASTROENTEROL, V60, P932, DOI 10.5754/hge121214; Li MH, 2004, INT J ONCOL, V24, P305; Liberal V, 2012, P NATL ACAD SCI USA, V109, P2754, DOI 10.1073/pnas.1102434108; Lin HM, 2007, ONCOL REP, V17, P1541; Liu Z, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-51; Martin-Ezquerra G, 2011, HISTOL HISTOPATHOL, V26, P71, DOI 10.14670/HH-26.71; Martinsson-Ahlzen HS, 2008, MOL CELL BIOL, V28, P5698, DOI 10.1128/MCB.01833-07; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Menghi F, 2011, ONCOLOGIST, V16, P1440, DOI 10.1634/theoncologist.2010-0249; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Perez-Magan E, 2012, J NEUROPATH EXP NEUR, V71, P882, DOI 10.1097/NEN.0b013e31826bf704; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; Shapira M, 2005, CANCER-AM CANCER SOC, V103, P1336, DOI 10.1002/cncr.20917; Shen DY, 2013, LIVER INT, V33, P137, DOI 10.1111/liv.12014; Slotky M, 2005, BREAST CANCER RES, V7, pR737, DOI 10.1186/bcr1278; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2003, SCIENCE, V300, P647, DOI 10.1126/science.1084149; Tanaka F, 2011, INT J ONCOL, V39, P361, DOI 10.3892/ijo.2011.1056; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang JJ, 2013, DIS ESOPHAGUS, V26, P729, DOI 10.1111/dote.12013; Wang XC, 2009, BIOCHEM BIOPH RES CO, V379, P1107, DOI 10.1016/j.bbrc.2009.01.028; Wang XZ, 2009, STUD FUZZ SOFT COMP, V245, P1; Wiese AH, 2007, CANCER DETECT PREV, V31, P282, DOI 10.1016/j.cdp.2007.07.003; Yamamoto S, 2010, HISTOPATHOLOGY, V56, P740, DOI 10.1111/j.1365-2559.2010.03551.x; Yu VPCC, 2005, MOL CELL, V17, P145, DOI 10.1016/j.molcel.2004.11.020	43	10	10	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1961	1967		10.1038/onc.2014.137	http://dx.doi.org/10.1038/onc.2014.137			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858038	Green Accepted			2022-12-28	WOS:000352725600010
J	Olsson, M; Forsberg, J; Zhivotovsky, B				Olsson, M.; Forsberg, J.; Zhivotovsky, B.			Caspase-2: the reinvented enzyme	ONCOGENE			English	Review							DNA-DAMAGE; OXIDATIVE STRESS; CELL-DEATH; CHROMOSOMAL INSTABILITY; METABOLIC-REGULATION; ER STRESS; APOPTOSIS; ACTIVATION; P53; PHOSPHORYLATION	On the basis of evidences that caspase-2 gene targeting in several generated mouse models accelerates tumor formation, this enzyme was recently implicated in tumor suppression. The observed function, however, compels other molecular perturbations harboring tumorigenic properties. Therefore, the question remains as to whether or not caspase-2 can be considered a true tumor suppressor? The traditional view of caspase-2 being vital for the apoptotic response to induced cell stress in some systems is in line with these findings. Yet, caspase-2 has also been associated with other processes which equally might interfere with tumorigenic potential, including the oxidative stress response, aging and genome surveillance. By different mechanisms, this enzyme has been proposed to function as a checkpoint regulator in the cell cycle. Together, these data indicate that caspase-2 is a highly versatile factor, a view that is contrasted by the alternative explanation where the enzyme harbors a mechanism affecting a discrete process, which in turn is functionally connected to other cell systems. In any case, it is clear that the general view of caspase-2 as a protein mainly involved in apoptotic cell death is shattered. Hence, we wish to discuss the perspectives of recent achievements in caspase-2-related research.	[Olsson, M.; Forsberg, J.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Zhivotovsky, B.] Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow, Russia	Karolinska Institutet; Lomonosov Moscow State University	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Nobels Vag 13, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Olsson, Magnus/E-3140-2012; Zhivotovsky, Boris/A-4346-2014	Olsson, Magnus/0000-0002-6370-8423; Zhivotovsky, Boris/0000-0002-2238-3482	Swedish Cancer Society; Stockholm Cancer Society; Swedish Childhood Cancer Foundation; Swedish Research Council; Russian Science Foundation	Swedish Cancer Society(Swedish Cancer Society); Stockholm Cancer Society; Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Russian Science Foundation(Russian Science Foundation (RSF))	This work was supported by grants from the Swedish and the Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation, the Swedish Research Council and Russian Science Foundation.	Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Ando K, 2012, MOL CELL, V47, P681, DOI 10.1016/j.molcel.2012.06.024; Baptiste-Okoh N, 2008, CELL CYCLE, V7, P1133, DOI 10.4161/cc.7.9.5805; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boros LG, 2002, DRUG DISCOV TODAY, V7, P364, DOI 10.1016/S1359-6446(02)02179-7; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Chen CC, 2013, J BIOL CHEM, V288, P11689, DOI 10.1074/jbc.M112.401844; Cosentino C, 2011, EMBO J, V30, P546, DOI 10.1038/emboj.2010.330; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Farber-Katz SE, 2014, CELL, V156, P413, DOI 10.1016/j.cell.2013.12.023; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Imre G, 2012, EMBO J, V31, P2615, DOI 10.1038/emboj.2012.93; Jean YY, 2013, BIOCHEM J, V455, P15, DOI 10.1042/BJ20130556; Johnson ES, 2013, J BIOL CHEM, V288, P14463, DOI 10.1074/jbc.M112.437210; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lopez-Cruzan M, 2013, BIOGERONTOLOGY, V14, P121, DOI 10.1007/s10522-013-9415-x; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Manzl C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.470; Manzl C, 2012, CELL DEATH DIFFER, V19, P1722, DOI 10.1038/cdd.2012.54; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; McCoy F, 2013, J BIOL CHEM, V288, P8838, DOI 10.1074/jbc.M112.437186; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Sandow JJ, 2014, CELL DEATH DIFFER, V21, P475, DOI 10.1038/cdd.2013.168; Santini S, 2014, ONCOGENE, V33, P1113, DOI 10.1038/onc.2013.52; Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Sohn D, 2011, CELL DEATH DIFFER, V18, P1664, DOI 10.1038/cdd.2011.34; Song T, 2013, J CANCER RES CLIN, V139, P1189, DOI 10.1007/s00432-013-1392-6; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Taghiyev Agshin F, 2011, Genes Cancer, V2, P745, DOI 10.1177/1947601911426007; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Upton JP, 2012, SCIENCE, V338, P818, DOI 10.1126/science.1226191; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Wu ZH, 2005, CELL, V123, P980, DOI 10.1016/j.cell.2005.11.025; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	55	20	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1877	1882		10.1038/onc.2014.139	http://dx.doi.org/10.1038/onc.2014.139			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882576				2022-12-28	WOS:000352725600001
J	Maeng, YS; Aguilar, B; Choi, SI; Kim, EK				Maeng, Y-S; Aguilar, B.; Choi, S-I; Kim, E. K.			Inhibition of TGFBIp expression reduces lymphangiogenesis and tumor metastasis	ONCOGENE			English	Article							CELL-ADHESION; VEGF-C; VASCULAR-PERMEABILITY; MOLECULAR-MECHANISMS; ENDOTHELIAL-CELLS; BREAST-CANCER; BETA-IG-H3; BETA; PROTEIN; GROWTH	Transforming growth factor-beta-induced protein (TGFBIp) is an extracellular matrix protein that has a role in a wide range of pathological conditions. However, the role of TGFBIp signaling in lymphangiogenesis is poorly understood. The purpose of this study was therefore to analyze the effects of TGFBIp on lymphangiogenesis and determine whether TGFBIp-related lymphangiogenesis is important for the metastasis of tumor cells. TGFBIp increased adhesion, migration, and morphologic differentiation of human lymphatic endothelial cells (LECs), consistent with an increase in lymphatic vessel sprouting in a three-dimensional lymphatic ring assay. TGFBIp also induced phosphorylation of intracellular signaling molecules SRC, FAK, AKT, JNK and ERK. TGFBIp-induced lymphatic vessel sprouting was inhibited by addition of anti-integrin beta 3 antibody and pharmacologic inhibitors of FAK, AKT, JNK or ERK. TGFBIp increased both CCL21 expression in LECs, a chemokine that actively recruits tumor cells expressing the cognate chemokine receptors to lymphatic vessels and LEC permeability by inducing the dissociation of VE-cadherin junctions between LECs via the activation of SRC signaling. In vivo, inhibition of TGFBIp expression in SW620 cancer cells dramatically reduced tumor lymphangiogenesis and metastasis. Collectively, our findings demonstrate that TGFBIp is a lymphangiogenic factor contributing to tumor dissemination and represents a potential target to inhibit metastasis.	[Maeng, Y-S; Choi, S-I; Kim, E. K.] Yonsei Univ, Coll Med, Dept Ophthalmol, Corneal Dystrophy Res Inst, Seoul 120752, South Korea; [Aguilar, B.] Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; [Kim, E. K.] Yonsei Univ, Coll Med, Brain Korea Plus Project Med Sci 21, Severance Biomed Sci Inst, Seoul, South Korea	Yonsei University; Yonsei University Health System; University of California System; University of California San Diego; Yonsei University; Yonsei University Health System	Kim, EK (corresponding author), Yonsei Univ, Coll Med, Dept Ophthalmol, 250 Seongsanno, Seoul 120752, South Korea.	eungkkim@yuhs.ac		Kim, Eung Kweon/0000-0002-1453-8042; Maeng, Yong-Sun/0000-0003-1694-8405; choi, seung-il/0000-0001-7168-8795	National Research Foundation of Korea (NRF) grant - Korea government (MEST) [2011-0028699]	National Research Foundation of Korea (NRF) grant - Korea government (MEST)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0028699).	Aguilar B, 2012, CANCER RES, V72, P5833, DOI 10.1158/0008-5472.CAN-12-1229; Albrecht I, 2011, INT J DEV BIOL, V55, P483, DOI 10.1387/ijdb.103226ia; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Becker J, 2006, CANCER RES, V66, P5314, DOI 10.1158/0008-5472.CAN-05-3049; Boensch C, 1999, J BIOL CHEM, V274, P10582, DOI 10.1074/jbc.274.15.10582; Bruyere F, 2008, NAT METHODS, V5, P431, DOI [10.1038/nmeth.1205, 10.1038/NMETH.1205]; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Christiansen Ailsa, 2011, Genes Cancer, V2, P1146, DOI 10.1177/1947601911423028; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; Hewitt RE, 2000, J PATHOL, V192, P446; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2003, ONCOGENE, V22, P2045, DOI 10.1038/sj.onc.1206269; Kim YH, 2012, J BIOL CHEM, V287, P38957, DOI 10.1074/jbc.M112.357863; Lee AS, 2011, CANCER RES, V71, P4506, DOI 10.1158/0008-5472.CAN-10-3787; Maeng YS, 2009, BLOOD, V113, P233, DOI 10.1182/blood-2008-06-162891; Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298; Miyagaki T, 2011, J INVEST DERMATOL, V131, P1927, DOI 10.1038/jid.2011.135; Mohammed RAA, 2007, BRIT J CANCER, V96, P1092, DOI 10.1038/sj.bjc.6603678; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; Park SW, 2004, EXP MOL MED, V36, P211, DOI 10.1038/emm.2004.29; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Schoppmann SF, 2006, SURGERY, V139, P839, DOI 10.1016/j.surg.2005.12.008; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; Sleeman JP, 2009, INT J CANCER, V125, P2747, DOI 10.1002/ijc.24702; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Stacker SA, 2002, FASEB J, V16, P922, DOI 10.1096/fj.01-0945rev; Thapa N, 2007, INT J BIOCHEM CELL B, V39, P2183, DOI 10.1016/j.biocel.2007.06.004; Wartiovaara U, 1998, THROMB HAEMOSTASIS, V80, P171, DOI 10.1055/s-0037-1615158; Ween MP, 2012, INT J MOL SCI, V13, P10461, DOI 10.3390/ijms130810461; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Zhang Y, 2009, CANCER RES, V69, P37, DOI 10.1158/0008-5472.CAN-08-1648	35	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					196	205		10.1038/onc.2015.73	http://dx.doi.org/10.1038/onc.2015.73			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25772247				2022-12-28	WOS:000368193900006
J	Wang, J; Tang, X; Weng, W; Qiao, Y; Lin, J; Liu, W; Liu, R; Ma, L; Yu, W; Yu, Y; Pan, Q; Sun, F				Wang, J.; Tang, X.; Weng, W.; Qiao, Y.; Lin, J.; Liu, W.; Liu, R.; Ma, L.; Yu, W.; Yu, Y.; Pan, Q.; Sun, F.			The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; LONG NONCODING RNA; LIVER-CANCER CELLS; TRANSLATION INITIATION; MUTUAL INTERACTION; YAP; GROWTH; TRANSCRIPTION; ACTIVATION; INHIBITION	Yes-associated protein (YAP) is overexpressed and has an oncogenic role in hepatocellular carcinoma (HCC). However, whether membrane protein can serve not only as a tumor marker that reflects YAP function but also as a therapeutic target that stimulates tumorigenesis in HCC remains unknown. Here we report that the membrane protein melanoma cell adhesion molecule (MCAM) was under positive regulation by YAP and was highly elevated in HCC cells. Within the MCAM promoter, we found the presence of a cAMP Response Element (CRE; -32 to -25 nt), which is conserved among species and is essential for YAP-and CREB-dependent regulation. Moreover, the interaction between CREB and YAP at the CRE site was dependent on PTPIY-WW domain interactions. However, MCAM expression was low and could not be regulated by YAP in breast and colon cancer cells because of the low levels of the acetyltransferase p300. In HCC cells, high levels of p300 facilitated the binding of YAP to the MCAM promoter, which in turn enhanced histone acetylation and polymerase II recruitment through the dissociation of the deacetylase Sirt1. These results suggest that MCAM is an HCC-specific target of YAP. In clinical serum samples, we found that the serum levels of MCAM were highly elevated in patients with HCC compared with healthy controls and with patients with cirrhosis, hepatitis, colon cancer and breast cancer. MCAM levels were shown to be a slightly better indicator than serum alpha-fetoprotein for predicting HCC. We further demonstrated that MCAM is essential for the survival and transformation of HCC. Mechanistically, MCAM induced translation initiation and the transcriptional activities of c-Jun/c-Fos. In addition, AKT activation had an essential role in the MCAM-promoted binding of eukaryotic initiation factor 4E to c-Jun/c-Fos mRNA. In conclusion, we demonstrated that MCAM may be a potential tumor marker and therapeutic target for the diagnosis and treatment of HCC.	[Wang, J.; Tang, X.; Weng, W.; Liu, W.; Ma, L.; Yu, W.; Sun, F.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China; [Qiao, Y.] Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, Shanghai, Peoples R China; [Lin, J.] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Clin Lab Med, Shanghai, Peoples R China; [Liu, R.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Sci & Res, Shanghai 200072, Peoples R China; [Yu, Y.] Shanghai TCM Univ, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China; [Pan, Q.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cent Lab, Shanghai 200072, Peoples R China	Tongji University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University; Tongji University	Sun, F (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Clin Lab Med, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.	panqiuhui@263.net; sunfenyong@126.com		Wang, Jiayi/0000-0003-1688-2864	China National 973 Project [2012CB966904, 20110402]; National Natural Science Foundation of China [81301689, 81201884]; Yangfan Project of the Shanghai Committee of Science and Technology [14YF1412300]; Outstanding Youth Training Program of Tongji University [1501219080]; Shanghai Tenth People's Hospital Climbing Training Program [04.01.13024]	China National 973 Project(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yangfan Project of the Shanghai Committee of Science and Technology; Outstanding Youth Training Program of Tongji University; Shanghai Tenth People's Hospital Climbing Training Program	This work was supported by the China National 973 Project (2012CB966904 and 20110402), the National Natural Science Foundation of China (81301689 and 81201884), the Yangfan Project of the Shanghai Committee of Science and Technology (14YF1412300), the Outstanding Youth Training Program of Tongji University (1501219080) and the Shanghai Tenth People's Hospital Climbing Training Program (04.01.13024).	Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bardin N, 1998, FEBS LETT, V421, P12, DOI 10.1016/S0014-5793(97)01455-5; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; He L, 2006, J BIOL CHEM, V281, P11126, DOI 10.1074/jbc.M510724200; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; LEHMANN JM, 1987, CANCER RES, V47, P841; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Li LL, 2013, FEBS LETT, V587, P3921, DOI 10.1016/j.febslet.2013.10.042; Ma LF, 2014, J BIOL CHEM, V289, P6921, DOI 10.1074/jbc.M113.524819; Mills L, 2002, CANCER RES, V62, P5106; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Quan TH, 2010, J INVEST DERMATOL, V130, P1697, DOI 10.1038/jid.2010.29; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Sudol Marius, 2010, Genes Cancer, V1, P1115, DOI 10.1177/1947601911401911; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Wang JY, 2014, CELL SIGNAL, V26, P1048, DOI 10.1016/j.cellsig.2014.01.022; Wang JY, 2013, HEPATOLOGY, V58, P1011, DOI 10.1002/hep.26420; Wang JY, 2013, MOL CELL, V51, P211, DOI 10.1016/j.molcel.2013.05.013; Wang JY, 2011, NUCLEIC ACIDS RES, V39, P6440, DOI 10.1093/nar/gkr302; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; Xiao WF, 2013, BIOCHEM BIOPH RES CO, V439, P167, DOI 10.1016/j.bbrc.2013.08.071; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Xue HP, 2011, INT J BIOCHEM CELL B, V43, P348, DOI 10.1016/j.biocel.2010.11.002; Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200; Yu WJ, 2014, CELL SIGNAL, V26, P2961, DOI 10.1016/j.cellsig.2014.09.011; Zhang H, 2012, CELL SIGNAL, V24, P224, DOI 10.1016/j.cellsig.2011.09.004; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	39	34	37	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5781	5795		10.1038/onc.2015.36	http://dx.doi.org/10.1038/onc.2015.36			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25728681				2022-12-28	WOS:000365035200002
J	Xu, TP; Liu, XX; Xia, R; Yin, L; Kong, R; Chen, WM; Huang, MD; Shu, YQ				Xu, T-P; Liu, X-X; Xia, R.; Yin, L.; Kong, R.; Chen, W-M; Huang, M-D; Shu, Y-Q			SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SP1; KRUPPEL-LIKE FACTOR-2; POOR-PROGNOSIS; DECREASED EXPRESSION; REPRESSION; INHIBITORS; HALLMARKS; SURVIVAL; NCRNAS; DECAY	The long noncoding RNA TINCR shows aberrant expression in human squamous carcinomas. However, its expression and function in gastric cancer remain unclear. We report that TINCR is strongly upregulated in human gastric carcinoma (GC), where it was found to contribute to oncogenesis and cancer progression. We also revealed that TINCR overexpression is induced by nuclear transcription factor SP1. Silencing TINCR expression inhibited cell proliferation, colony formation, tumorigenicity and apoptosis promotion, whereas TINCR overexpression promoted cell growth, as documented in the SGC7901 and BGC823 cell lines. Mechanistic analyses indicated that TINCR could bind to STAU1 (staufen1) protein, and influence KLF2 mRNA stability and expression, then KLF2 regulated cyclin-dependent kinase genes CDKN1A/P21 and CDKN2B/P15 transcription and expression, thereby affecting the proliferation and apoptosis of GC cells. Together, our findings suggest that TINCR contributes to the oncogenic potential of GC and may constitute a potential therapeutic target in this disease.	[Xu, T-P; Xia, R.; Yin, L.; Chen, W-M; Shu, Y-Q] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China; [Liu, X-X] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Dept Gastrointestinal Surg, Sch Clin Med, Yangzhou 225009, Jiangsu, Peoples R China; [Kong, R.] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Clin Med Examinat Ctr, Sch Clin Med, Yangzhou 225009, Jiangsu, Peoples R China; [Huang, M-D] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Med Oncol, Huaian, Peoples R China	Nanjing Medical University; Yangzhou University; Yangzhou University; Nanjing Medical University	Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	yongqian_shu@163.com	Shu, Yongqian/ABD-5698-2021		National Natural Science Foundation of China [81172140, 81272532]; Jiangsu Province Clinical Science and Technology projects (Clinical Research Center) [BL2012008]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine) [JX10231801]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province Clinical Science and Technology projects (Clinical Research Center); Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine)	We thank Dr Taniguchi (First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan) for the kind gift of KLF2-FLAG expression vector, Dr Wei-liang Xiong (Department of Biochemistry and The Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University) for the help of RNA pull down assay, and Professor Wei De and Dr Ming Sun (Department of Biochemistry and Molecular Biology, Nanjing Medical University) for the help of assay design. This study was supported by the National Natural Science Foundation of China (81172140, 81272532), Jiangsu Province Clinical Science and Technology projects (Clinical Research Center, BL2012008) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine, JX10231801).	Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Cesana M, 2011, CELL, V147, P947, DOI 10.1016/j.cell.2011.10.031; Cho H, 2012, MOL CELL, V46, P495, DOI 10.1016/j.molcel.2012.03.009; Duhagon MA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-324; Fu XQ, 2006, DNA CELL BIOL, V25, P135, DOI 10.1089/dna.2006.25.135; Gong CG, 2011, CELL CYCLE, V10, P1882, DOI 10.4161/cc.10.12.15589; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kim YK, 2005, CELL, V120, P195, DOI 10.1016/j.cell.2004.11.050; Kim YK, 2007, EMBO J, V26, P2670, DOI 10.1038/sj.emboj.7601712; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105; Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088; Okugawa Y, 2014, CARCINOGENESIS; Pibouin L, 2002, CANCER GENET CYTOGEN, V133, P55, DOI 10.1016/S0165-4608(01)00634-3; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Ravasi T, 2006, GENOME RES, V16, P11, DOI 10.1101/gr.4200206; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-319; Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277-013-1142-z; Sun M, 2012, MOL CANCER THER, V11, P842, DOI 10.1158/1535-7163.MCT-11-1015; Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wan DF, 2004, P NATL ACAD SCI USA, V101, P17565, DOI 10.1073/pnas.0408124101; Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zhang SZ, 2005, MOL CANCER THER, V4, P1577, DOI 10.1158/1535-7163.MCT-05-0106; Zhuang M, 2014, BIOCHEM BIOPH RES CO, V448, P315, DOI 10.1016/j.bbrc.2013.12.126	38	201	209	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5648	5661		10.1038/onc.2015.18	http://dx.doi.org/10.1038/onc.2015.18			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25728677				2022-12-28	WOS:000364594300006
J	Zhang, M; Xu, E; Zhang, J; Chen, X				Zhang, M.; Xu, E.; Zhang, J.; Chen, X.			PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38	ONCOGENE			English	Article							CHK2 KINASE; WIP1; RNPC1; BREAST; EXPRESSION; FAMILY; ACTIVATION; MUTATIONS; HUR	PPM1D phosphatase, also called wild-type p53-induced phosphatase 1, promotes tumor development by inactivating the p53 tumor suppressor pathway. RBM38 RNA-binding protein, also called RNPC1 and a target of p53, inhibits p53 messenger RNA (mRNA) translation, which can be reversed by GSK3 protein kinase via phosphorylation of RBM38 at serine 195. Here we showed that ectopic expression of RBM38 increases, whereas knockdown of RBM38 inhibits, PPM1D mRNA translation. Consistent with this, we found that RBM38 directly binds to PPM1D 3'-untranslated region (3'-UTR) and promotes expression of a heterologous reporter gene that carries PPM1D 3'-UTR in a dose-dependent manner. Interestingly, we showed that PPM1D directly interacts with and dephosphorylates RBM38 at serine 195. Furthermore, we showed that PPM1D modulates p53 mRNA translation and p53-dependent growth suppression through dephosphorylation of RBM38. These findings provide evidence that the crosstalk between PPM1D and RBM38, both of which are targets and modulators of p53, has a critical role in p53 expression and activity.	[Zhang, M.; Xu, E.; Zhang, J.; Chen, X.] Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Dept Surg & Radiol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, 2128A Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NIH [CA076069, CA081237, CA121137]; NATIONAL CANCER INSTITUTE [R01CA121137, R01CA076069, R29CA076069, R01CA081237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by NIH grants CA076069, CA081237 and CA121137.	Bonifacino J S, 2001, Curr Protoc Protein Sci, VChapter 3, DOI 10.1002/0471140864.ps0307s17; Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229; Cho SJ, 2012, J BIOL CHEM, V287, P14535, DOI 10.1074/jbc.M111.326827; Feldstein O, 2012, MOL CANCER RES, V10, P1169, DOI 10.1158/1541-7786.MCR-12-0331; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/nchembio.1427, 10.1038/NCHEMBIO.1427]; Heinicke LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078031; Kleiblova P, 2013, J CELL BIOL, V201, P511, DOI 10.1083/jcb.201210031; Leveille N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1519; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Parssinen J, 2008, CANCER GENET CYTOGEN, V182, P33, DOI 10.1016/j.cancergencyto.2007.12.013; Peritz T, 2006, NAT PROTOC, V1, P577, DOI 10.1038/nprot.2006.82; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Wang W, 2014, BRAZ J MED BIOL RES, V47, P1044, DOI 10.1590/1414-431X20143645; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Xu E, 2013, ONCOGENE, V32, P2169, DOI 10.1038/onc.2012.238; Yan WS, 2012, MOL CELL BIOL, V32, P2336, DOI 10.1128/MCB.00215-12; Yin T, 2013, J BIOL CHEM, V288, P23680, DOI 10.1074/jbc.M113.480186; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Zhang J, 2007, MOL CELL BIOL, V27, P3868, DOI 10.1128/MCB.02112-06; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang J, 2010, P NATL ACAD SCI USA, V107, P9614, DOI 10.1073/pnas.0912594107; Zhang M, 2013, GENE DEV, V27, P2246, DOI 10.1101/gad.221739.113; ZHANG W, 1994, CANCER RES, V54, P4448	37	17	18	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5900	5911		10.1038/onc.2015.31	http://dx.doi.org/10.1038/onc.2015.31			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25823026	Green Accepted, Green Submitted			2022-12-28	WOS:000365434000004
J	Zhang, H; Hu, L; Qiu, W; Deng, T; Zhang, Y; Bergholz, J; Xiao, ZX				Zhang, H.; Hu, L.; Qiu, W.; Deng, T.; Zhang, Y.; Bergholz, J.; Xiao, Z-X			MDMX exerts its oncogenic activity via suppression of retinoblastoma protein	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; MOLECULAR-BASIS; P53 ACTIVITY; DOMAIN; INACTIVATION; CANCER; PHOSPHORYLATION; UBIQUITINATION; MECHANISMS; CELLS	Inactivation of the retinoblastoma protein (RB) has a major role in the development of human malignancies. We have previously shown that MDM2, an ubiquitin E3 ligase and major negative regulator of p53, binds to and promotes proteasome-mediated degradation of RB. MDMX, a homolog of MDM2, also binds to and inhibits p53 transactivation activity, yet it does not possess intrinsic ubiquitin ligase activity. Here, we show that MDMX binds to and promotes RB degradation in an MDM2-dependent manner. Specifically, the MDMX C-terminal ring domain binds to the RB C-pocket and enhances MDM2-RB interaction. Silencing MDMX induces RB accumulation, cell cycle arrest and senescence-like phenotypes, which are reverted by simultaneous RB knockdown. Furthermore, MDMX ablation leads to significant retardation of xenograft tumor growth, concomitant with RB accumulation. These results demonstrate that MDMX exerts oncogenic activity via suppression of RB, and suggest that both MDM2 and MDMX could be chemotherapeutic targets.	[Zhang, H.; Hu, L.; Deng, T.; Zhang, Y.; Bergholz, J.; Xiao, Z-X] Sichuan Univ, Ctr Growth Metab & Aging, Key Lab Bioresource & Ecoenvironm, Minist Educ,Coll Life Sci, Chengdu 610014, Peoples R China; [Zhang, H.; Hu, L.; Deng, T.; Zhang, Y.; Bergholz, J.; Xiao, Z-X] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610014, Peoples R China; [Qiu, W.; Xiao, Z-X] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Sichuan University; Sichuan University; Boston University	Xiao, ZX (corresponding author), Sichuan Univ, Ctr Growth Metab & Aging, Key Lab Bioresource & Ecoenvironm, Minist Educ,Coll Life Sci, Chengdu 610014, Peoples R China.	jimzx@scu.edu.cn	zhang, haibo/K-5146-2019		National Key Basic Research Program (973 Program) of China [2012CB910700]; National Natural Science Foundation of China (NSFC) [81330054, 31171362]; NSFC [31350110216]	National Key Basic Research Program (973 Program) of China(National Basic Research Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NSFC(National Natural Science Foundation of China (NSFC))	We thank Dr Scott Lowe (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for kindly providing short hairpin RNA plasmids against human RB. This work was supported by the National Key Basic Research Program (973 Program) of China (2012CB910700) and National Natural Science Foundation of China (NSFC) grant (81330054 and 31171362) to Z-XX, and NSFC grant (31350110216) to JB.	Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CORDONCARDO C, 1994, CANCER RES, V54, P794; Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Kato MV, 1996, CANCER LETT, V106, P75, DOI 10.1016/0304-3835(96)04305-4; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Okamoto K, 2009, FEBS LETT, V583, P2710, DOI 10.1016/j.febslet.2009.07.021; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Suda T, 2011, ONCOL REP, V26, P49, DOI 10.3892/or.2011.1270; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Uchida C, 2006, FEBS LETT, V580, P1753, DOI 10.1016/j.febslet.2006.02.029; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2009, MOL CANCER RES, V7, P1, DOI 10.1158/1541-7786.MCR-08-0423; WATANABE T, 1994, BLOOD, V84, P3158; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wunderlich M, 2004, CELL CYCLE, V3, P472; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	47	16	17	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5560	5569		10.1038/onc.2015.11	http://dx.doi.org/10.1038/onc.2015.11			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25703327				2022-12-28	WOS:000364594000005
J	Bikkavilli, RK; Avasarala, S; Van Scoyk, M; Arcaroli, J; Brzezinski, C; Zhang, W; Edwards, M; Rathinam, MKK; Zhou, T; Tauler, J; Borowicz, S; Lussier, Y; Parr, BA; Cool, CD; Winn, RA				Bikkavilli, R. K.; Avasarala, S.; Van Scoyk, M.; Arcaroli, J.; Brzezinski, C.; Zhang, W.; Edwards, M. G.; Rathinam, M. K. K.; Zhou, T.; Tauler, J.; Borowicz, S.; Lussier, Y. A.; Parr, B. A.; Cool, C. D.; Winn, R. A.			Wnt7a is a novel inducer of beta-catenin-independent tumor-suppressive cellular senescence in lung cancer	ONCOGENE			English	Article							ATYPICAL ADENOMATOUS HYPERPLASIA; ONCOGENIC RAS; CELLS; SKP2; ACTIVATION; INACTIVATION; ACCUMULATION; PROGRESSION; REGULATOR; LIGASE	Cellular senescence is an initial barrier for carcinogenesis. However, the signaling mechanisms that trigger cellular senescence are incompletely understood, particularly in vivo. Here we identify Wnt7a as a novel upstream inducer of cellular senescence. In two different mouse strains (C57Bl/6J and FVB/NJ), we show that the loss of Wnt7a is a major contributing factor for increased lung tumorigenesis owing to reduced cellular senescence, and not reduced apoptosis, or autophagy. Wnt7a-null mice under de novo conditions and in both the strains display E-cadherin-to-N-cadherin switch, reduced expression of cellular senescence markers and reduced expression of senescence-associated secretory phenotype, indicating a genetic predisposition of these mice to increased carcinogen-induced lung tumorigenesis. Interestingly, Wnt7a induced an alternate senescence pathway, which was independent of beta-catenin, and distinct from that of classical oncogene-induced senescence mediated by the well-known p16(INK4a) and p19(ARF) pathways. Mechanistically, Wnt7a induced cellular senescence via inactivation of S-phase kinase-associated protein 2, an important alternate regulator of cellular senescence. Additionally, we identified Iloprost, a prostacyclin analog, which initiates downstream signaling cascades similar to that of Wnt7a, as a novel inducer of cellular senescence, presenting potential future clinical translational strategies. Thus pro-senescence therapies using either Wnt7a or its mimic, Iloprost, might represent a new class of therapeutic treatments for lung cancer.	[Bikkavilli, R. K.; Avasarala, S.; Van Scoyk, M.; Brzezinski, C.; Rathinam, M. K. K.; Zhou, T.; Tauler, J.; Winn, R. A.] Univ Illinois, Dept Pulm Crit Care Sleep & Allergy, Chicago, IL USA; [Arcaroli, J.] Univ Colorado, Sch Med, Div Med Oncol, Aurora, CO USA; [Zhang, W.] Univ Illinois, Coll Med, Dept Pediat, Chicago, IL USA; [Edwards, M. G.] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Edwards, M. G.] Univ Illinois, Coll Med, Dept Hematol & Oncol, Chicago, IL USA; [Lussier, Y. A.] Univ Arizona, Ctr Canc, Tucson, AZ USA; [Parr, B. A.] Albany State Univ, Ctr Funct Gen, Rensselaer, NY USA; [Cool, C. D.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA; [Winn, R. A.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arizona; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Winn, RA (corresponding author), Univ Illinois, Dept Pulm Crit Care Sleep & Allergy, Coll Med Res Bldg, Chicago, IL USA.	rwinn@uic.edu	Lussier, Yves/N-4891-2017	Lussier, Yves/0000-0001-9854-1005	US Department of Veterans Affairs; NIH [R01CA138528]; NATIONAL CANCER INSTITUTE [P50CA058187, P30CA046934, R01CA138528] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are immensely grateful to Dr Judith Campisi (Buck Institute for Research on Aging) for her critical reading of this manuscript. We thank Dr Bifeng Gao, Katrina Diener and Dr Ken Jones of the Genomics and Microarray core, University of Colorado Denver, for their expert help in RNA sequencing. We also thank Dr Meredith Tennis, Dr Lora Wilson, Marybeth Sechler and Nicole Kelley for their helpful suggestions on this manuscript. This study was supported by a Merit Award from the US Department of Veterans Affairs and NIH grants R01CA138528 to RW.	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Baek KH, 2013, J CLIN INVEST, V123, P4375, DOI 10.1172/JCI67465; Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854; Bitler BG, 2011, CANCER RES, V71, P6184, DOI 10.1158/0008-5472.CAN-11-1341; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chan CH, 2014, CELL CYCLE, V13, P679, DOI 10.4161/cc.27853; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Ji Lin, 2005, Future Oncol, V1, P79, DOI 10.1517/14796694.1.1.79; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070; Keith RL, 2011, CANCER PREV RES, V4, P793, DOI 10.1158/1940-6207.CAPR-11-0057; Keith RL, 2010, LUNG CANCER, V70, P37, DOI 10.1016/j.lungcan.2010.01.004; Kondratov AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047012; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Malbon CC, 2004, FRONT BIOSCI-LANDMRK, V9, P1048, DOI 10.2741/1308; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Mikels A, 2009, J BIOL CHEM, V284, P30167, DOI 10.1074/jbc.M109.041715; Mori M, 2001, MODERN PATHOL, V14, P72, DOI 10.1038/modpathol.3880259; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nomori H, 2001, JPN J CLIN ONCOL, V31, P514, DOI 10.1093/jjco/hye103; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Parr BA, 1998, DEV BIOL, V202, P228, DOI 10.1006/dbio.1998.9007; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Rodier Francis, 2013, Methods Mol Biol, V965, P165, DOI 10.1007/978-1-62703-239-1_10; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Romanov VS, 2010, CELL CYCLE, V9, P3945, DOI 10.4161/cc.9.19.13160; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; te Poele RH, 2002, CANCER RES, V62, P1876; Tennis M, 2010, NEOPLASIA, V12, P244, DOI 10.1593/neo.91690; Tennis MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032921; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Vikis Haris G, 2013, Front Biosci (Elite Ed), V5, P939; Wang GC, 2012, CHIN J CANCER, V31, P169, DOI 10.5732/cjc.011.10319; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Widelitz R, 2005, GROWTH FACTORS, V23, P111, DOI 10.1080/08977190500125746; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; Winn RA, 2006, J BIOL CHEM, V281, P26943, DOI 10.1074/jbc.M604145200	55	31	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5317	5328		10.1038/onc.2015.2	http://dx.doi.org/10.1038/onc.2015.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25728679	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000363479200002
J	Rivero, S; Ceballos-Chavez, M; Bhattacharya, SS; Reyes, JC				Rivero, S.; Ceballos-Chavez, M.; Bhattacharya, S. S.; Reyes, J. C.			HMG20A is required for SNAI1-mediated epithelial to mesenchymal transition	ONCOGENE			English	Article							E-CADHERIN REPRESSION; CELL-MIGRATION; EXPRESSION; COMPLEX; LSD1; SNAIL; TRANSCRIPTION; MELANOMA; COREST; GENES	HMG20A is a high mobility group (HMG) domain containing protein homologous to HMG20B, a core subunit of the Lys-specific demethylase 1/REST co-repressor 1 (LSD1-CoREST) histone demethylase complex. Here, we show that HMG20A can replace HMG20B and, therefore, they are mutually exclusive subunits of the complex. Both proteins interact through a coiled-coil domain with BHC80, another subunit of the LSD1-CoREST complex. To investigate the functional differences between the two proteins, we performed transcriptomic analysis of HMG20A-and HMG20B-depleted cells. Analysis of the misregulated genes in HMG20A-knockdown cells evidenced a high proportion of genes related to the epithelial-to-mesenchymal transition (EMT) process. EMT occurs during embryonic development or during the course of malignant cancer progression and consists in the dynamic and reversible transitions between epithelial and mesenchymal phenotypes. We show that HMG20A together with LSD1 are required for SNAI1-dependent repression of epithelial genes and for (transforming growth factor beta) TGF-beta-triggered EMT. Importantly, HMG20A-depleted cells displayed reduced binding of LSD1 to epithelial gene promoters and increased methylation of lysine 4 of histone H3, suggesting a role of HMG20A in recruiting or in stabilizing the complex at the chromatin. SNAI1 and the TGF-beta-related transcription factor SMAD4 were found to be associated with the LSD1-CoREST complex containing HMG20A. Furthermore, we show that HMG20A-depleted cells displayed reduced motility and invasion activity. Finally, we show that expression of HMG20A correlates positively with mesenchymal markers and negatively with epithelial markers in human tumor samples. Taken together, our data demonstrate that HMG20A is essential for the mesenchymal phenotype.	[Rivero, S.; Ceballos-Chavez, M.; Reyes, J. C.] CSIC, Dept Mol Biol, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Seville 41092, Spain; [Bhattacharya, S. S.] Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Cell Therapy & Regenerat Med Dept, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER)	Reyes, JC (corresponding author), CSIC, Dept Mol Biol, CABIMER, Ave Americo Vespucio, Seville 41092, Spain.	jose.reyes@cabimer.es	Reyes, Jose C/K-3699-2014	Reyes, Jose C/0000-0002-8042-5142; Rivero, Sabrina/0000-0001-6359-1432	Spanish Ministry of Economy and Competitiveness [BFU-2011-23442]; Juan de la Cierva; Junta de Andalucia [P09-CTS-04967]	Spanish Ministry of Economy and Competitiveness(Spanish Government); Juan de la Cierva(Instituto de Salud Carlos III); Junta de Andalucia(Junta de Andalucia)	We thank L Sumoy, T Baba, A Garcia de Herreros and J Lu for reagents and plasmids. We thank Dr M Garcia-Dominguez and Dr JA Pintor-Toro for critical reading of the manuscript. We thank E Andujar and M Perez from the CABIMER Genomic Unit for microarray expression analysis. The results published here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This work was funded by the Spanish Ministry of Economy and Competitiveness [BFU-2011-23442 to JCR] and a Juan de la Cierva grant to SR and by Junta de Andalucia (P09-CTS-04967 to SSB).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Ceballos-Chavez M, 2012, P NATL ACAD SCI US; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gordon GJ, 2005, AM J PATHOL, V166, P1827, DOI 10.1016/S0002-9440(10)62492-3; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iwase S, 2004, BIOCHEM BIOPH RES CO, V322, P601, DOI 10.1016/j.bbrc.2004.07.163; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; McKay BS, 1997, EXP EYE RES, V65, P661, DOI 10.1006/exer.1997.0374; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subtil-Rodriguez A, 2010, EMBO REP, V11, P751, DOI 10.1038/embor.2010.131; Sumoy L, 2000, CYTOGENET CELL GENET, V88, P62, DOI 10.1159/000015486; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005; Wynder C, 2005, NAT CELL BIOL, V7, P1113, DOI 10.1038/ncb1312; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454	59	31	32	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5264	5276		10.1038/onc.2014.446	http://dx.doi.org/10.1038/onc.2014.446			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639869				2022-12-28	WOS:000362575400006
J	Gong, C; Fujino, K; Monteiro, LJ; Gomes, AR; Drost, R; Davidson-Smith, H; Takeda, S; Khoo, US; Jonkers, J; Sproul, D; Lam, EWF				Gong, C.; Fujino, K.; Monteiro, L. J.; Gomes, A. R.; Drost, R.; Davidson-Smith, H.; Takeda, S.; Khoo, U. S.; Jonkers, J.; Sproul, D.; Lam, E. W-F			FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE EZH2; POLYCOMB TARGET GENES; DNA METHYLATION; CELL FATE; PROGNOSTIC-SIGNIFICANCE; ALPHA EXPRESSION; DIFFERENTIATION; INHIBITION; GATA-3; PROLIFERATION	FOXA1 expression correlates with the breast cancer luminal subtype and patient survival. RNA and protein analysis of a panel of breast cancer cell lines revealed that BRCA1 deficiency is associated with the downregulation of FOXA1 expression. Knockdown of BRCA1 resulted in the downregulation of FOXA1 expression and enhancement of FOXA1 promoter methylation in MCF-7 breast cancer cells, whereas the reconstitution of BRCA1 in Brca1-deficent mouse mammary epithelial cells (MMECs) promoted Foxa1 expression and methylation. These data suggest that BRCA1 suppresses FOXA1 hypermethylation and silencing. Consistently, the treatment of MMECs with the DNA methylation inhibitor 5-aza-2'-deoxycitydine induced Foxa1 mRNA expression. Furthermore, treatment with GSK126, an inhibitor of EZH2 methyltransferase activity, induced FOXA1 expression in BRCA1-deficient but not in BRCA1-reconstituted MMECs. Likewise, the depletion of EZH2 by small interfering RNA enhanced FOXA1 mRNA expression. Chromatin immunoprecipitation (ChIP) analysis demonstrated that BRCA1, EZH2, DNA methyltransferases (DNMT) 1/3a/3b and H3K27me3 are recruited to the endogenous FOXA1 promoter, further supporting the hypothesis that these proteins interact to modulate FOXA1 methylation and repression. Further co-immunoprecipitation and ChIP analysis showed that both BRCA1 and DNMT3b form complexes with EZH2 but not with each other, consistent with the notion that BRCA1 binds to EZH2 and negatively regulates its methyltransferase activity. We also found that EZH2 promotes and BRCA1 impairs the deposit of the gene silencing histone mark H3K27me3 on the FOXA1 promoter. These associations were validated in a familial breast cancer patient cohort. Integrated analysis of the global gene methylation and expression profiles of a set of 33 familial breast tumours revealed that FOXA1 promoter methylation is inversely correlated with the transcriptional expression of FOXA1 and that BRCA1 mutation breast cancer is significantly associated with FOXA1 methylation and downregulation of FOXA1 expression, providing physiological evidence to our findings that FOXA1 expression is regulated by methylation and chromatin silencing and that BRCA1 maintains FOXA1 expression through suppressing FOXA1 gene methylation in breast cancer.	[Gong, C.; Fujino, K.; Monteiro, L. J.; Gomes, A. R.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England; [Gong, C.; Khoo, U. S.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Fujino, K.; Takeda, S.] Juntendo Univ, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo, Japan; [Drost, R.; Jonkers, J.] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [Drost, R.; Jonkers, J.] Netherlands Canc Inst, Canc Genom Ctr Netherlands, Amsterdam, Netherlands; [Davidson-Smith, H.; Sproul, D.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland	Imperial College London; University of Hong Kong; Juntendo University; Netherlands Cancer Institute; Netherlands Cancer Institute; University of Edinburgh	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, ICTEM, Hammersmith Hosp Campus,Room 134,1st Floor, London W12 0NN, England.	eric.lam@imperial.ac.uk	Jonkers, Jos/AAG-3246-2019; Lam, Eric W-F/AAW-8566-2020; Khoo, Ui Soon/K-2041-2019; Khoo, Ui Soon/C-4293-2009; Monteiro, Lara J/AAU-8518-2020; Khoo, Ui Soon/C-1345-2014	Jonkers, Jos/0000-0002-9264-9792; Lam, Eric W-F/0000-0003-1274-3576; Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Takeda, Satoru/0000-0001-9547-1435	Breast Cancer Campaign; Cancer Research UK; Joint Imperial College London and University of Hong Kong; Research and Conference Grants from the University of Hong Kong (CRCG) [201007176118]; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Breast Cancer Campaign [2012NovPhD016, 2012MayPR070] Funding Source: researchfish	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Joint Imperial College London and University of Hong Kong; Research and Conference Grants from the University of Hong Kong (CRCG); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Breast Cancer Campaign	This work is funded by grants from the Breast Cancer Campaign and Cancer Research UK. CG is a recipient of the Joint Imperial College London and University of Hong Kong studentship. We also thank Kevin Brennan and James M Flanagan (Department of Surgery and Cancer, Imperial College London) for their help with pyrosequencing. USK is supported by Research and Conference Grants from the University of Hong Kong (CRCG)(201007176118).	Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Bae WK, 2014, MOL CELL ENDOCRINOL, V382, P593, DOI 10.1016/j.mce.2013.05.002; Bernardo GM, 2013, ONCOGENE, V32, P554, DOI 10.1038/onc.2012.62; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Buckley NE, 2013, NUCLEIC ACIDS RES, V41, P8601, DOI 10.1093/nar/gkt626; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ehrlich M, 2013, EPIGENOMICS-UK, V5, P553, DOI 10.2217/epi.13.43; Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008; Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933; Habashy HO, 2008, EUR J CANCER, V44, P1541, DOI 10.1016/j.ejca.2008.04.020; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Hsu NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056256; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li JL, 2013, NAT NEUROSCI, V16, P1745, DOI 10.1038/nn.3564; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Liu ZW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040943; Martins-Taylor K, 2012, EPIGENETICS-US, V7, P71, DOI 10.4161/epi.7.1.18750; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Mehta RJ, 2012, BREAST CANCER RES TR, V131, P881, DOI 10.1007/s10549-011-1482-6; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Myatt SS, 2014, ONCOGENE, V33, P4316, DOI 10.1038/onc.2013.546; Nakshatri H, 2007, EXPERT OPIN THER TAR, V11, P507, DOI 10.1517/14728222.11.4.507; Nakshatri H, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001008; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Reddington JP, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r25; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876; Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49; Wu L, 2013, BREAST CANCER RES TR, V142, P619, DOI 10.1007/s10549-013-2774-9	47	29	33	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5012	5024		10.1038/onc.2014.421	http://dx.doi.org/10.1038/onc.2014.421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531315	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-28	WOS:000361693300002
J	Lemieux, E; Cagnol, S; Beaudry, K; Carrier, J; Rivard, N				Lemieux, E.; Cagnol, S.; Beaudry, K.; Carrier, J.; Rivard, N.			Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASES; BETA-CATENIN; TUMOR PROGRESSION; REGULATED KINASE; K-RAS; WNT; TUMORIGENESIS; APC; MUTATIONS	Aberrant regulation of the Wnt/beta-catenin signaling pathway is one of the major causes of colorectal cancer (CRC). Loss-of-function mutations in APC are commonly found in CRC, leading to inappropriate activation of canonical Wnt signaling. Conversely, gain-of-function mutations in KRAS and BRAF genes are detected in up to 60% of CRCs. Whereas KRAS/mitogen-activated protein kinase (MAPK) and canonical Wnt/beta-catenin pathways are critical for intestinal tumorigenesis, mechanisms integrating these two important signaling pathways during CRC development are unknown. Results herein demonstrate that transformation of normal intestinal epithelial cells (IECs) by oncogenic forms of KRAS, BRAF or MEK1 was associated with a marked increase in beta-catenin/TCF4 and c-MYC promoter transcriptional activities and mRNA levels of c-Myc, Axin2 and Lef1. Notably, expression of a dominant-negative mutant of T-Cell Factor 4 (.NTCF4) severely attenuated IEC transformation induced by oncogenic MEK1 and markedly reduced their tumorigenic and metastatic potential in immunocompromised mice. Interestingly, the Frizzled co-receptor LRP6 was phosphorylated in a MEK-dependent manner in transformed IECs and in human CRC cell lines. Expression of LRP6 mutant in which serine/threonine residues in each particular ProlineProlineProlineSerine/ThreonineProline motif were mutated to alanines (LRP6-5A) significantly reduced beta-catenin/TCF4 transcriptional activity. Accordingly, MEK inhibition in human CRC cells significantly diminished beta-catenin/TCF4 transcriptional activity and c-MYC mRNA and protein levels without affecting beta-catenin expression or stability. Lastly, LRP6 phosphorylation was also increased in human colorectal tumors, including adenomas, in comparison with healthy adjacent normal tissues. Our data indicate that oncogenic activation of KRAS/BRAF/MEK signaling stimulates the canonical Wnt/beta-catenin pathway, which in turn promotes intestinal tumor growth and invasion. Moreover, LRP6 phosphorylation by ERK1/2 may provide a unique point of convergence between KRAS/MAPK and Wnt/beta-catenin signalings during oncogenesis.	[Lemieux, E.; Cagnol, S.; Beaudry, K.; Rivard, N.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Anat & Cell Biol, Sherbrooke, PQ J1E 4K8, Canada; [Carrier, J.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Med, Gastroenterol Serv, Sherbrooke, PQ J1E 4K8, Canada	University of Sherbrooke; University of Sherbrooke	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Anat & Cell Biol, Canc Res Pavil,3201 Jean Mignault, Sherbrooke, PQ J1E 4K8, Canada.	Nathalie.Rivard@USherbrooke.ca			Canadian Institutes of Health Research [MT-14405]; Canadian Research Chair	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Research Chair(Canada Research Chairs)	We thank Guillaume Arguin and Gerald Bernatchez for technical assistance. The biobank of colorectal cancer specimens was supported by a Team grant on digestive epithelium from the Canadian Institutes of Health Research. This research was supported by a grant from the Canadian Institutes of Health Research Grant to Nathalie Rivard (MT-14405). Etienne Lemieux is a student scholar from the Fonds de la Recherche en Sante du Quebec (FRSQ). Nathalie Rivard and Julie C Carrier are members of the FRSQ-Funded Centre de Recherche du CHUS. Nathalie Rivard is a recipient of a Canadian Research Chair in colorectal cancer and inflammatory cell signalling. This research was supported by a grant from the Canadian Institutes of Health Research to NR (MT-14405).	Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Ashton GH, 2010, DEV CELL, V19, P259, DOI 10.1016/j.devcel.2010.07.015; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Bergeron S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-271; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Boucher MJ, 2004, AM J PHYSIOL-GASTR L, V286, pG736, DOI 10.1152/ajpgi.00453.2003; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Cagnol S, 2013, ONCOGENE, V32, P564, DOI 10.1038/onc.2012.88; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Dasari A, 2010, CLIN CANCER RES, V16, P3811, DOI 10.1158/1078-0432.CCR-09-2283; Daugherty RL, 2007, PHYSIOLOGY, V22, P303, DOI 10.1152/physiol.00020.2007; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Dienstmann R, 2011, ANTI-CANCER AGENT ME, V11, P285, DOI 10.2174/187152011795347469; Eggstein S, 1999, GUT, V44, P834, DOI 10.1136/gut.44.6.834; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Ettenberg SA, 2010, P NATL ACAD SCI USA, V107, P15473, DOI 10.1073/pnas.1007428107; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fodde R, 2010, J PATHOL, V221, P239, DOI 10.1002/path.2718; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Horst D, 2012, CANCER RES, V72, P1547, DOI 10.1158/0008-5472.CAN-11-3222; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Komatsu K, 2005, GASTROENTEROLOGY, V129, P577, DOI 10.1053/j.gastro.2005.06.003; Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826; Langlois MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015742; Lee SH, 2004, APMIS, V112, P233, DOI 10.1111/j.1600-0463.2004.apm11204-0502.x; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Lemieux E, 2009, INT J CANCER, V125, P1575, DOI 10.1002/ijc.24485; Li WQ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-2; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Luo FJ, 2009, INT J EXP PATHOL, V90, P558, DOI 10.1111/j.1365-2613.2009.00667.x; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Naishiro Y, 2001, CANCER RES, V61, P2751; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Obrador-Hevia A, 2010, J PATHOL, V221, P57, DOI 10.1002/path.2685; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Pretlow TP, 2005, BBA-REV CANCER, V1756, P83, DOI 10.1016/j.bbcan.2005.06.002; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Saucier C, 2010, CANCER METAST BIOL T, V14, P205, DOI 10.1007/978-90-481-8833-8_8; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Simoneau M, 2011, CELL SIGNAL, V23, P269, DOI 10.1016/j.cellsig.2010.09.011; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Smakman N, 2005, BBA-REV CANCER, V1756, P103, DOI 10.1016/j.bbcan.2005.07.001; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Voisin L, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-337; Wang CH, 2013, DEV BIOL, V378, P122, DOI 10.1016/j.ydbio.2013.03.020; Wolf J, 2008, FEBS LETT, V582, P255, DOI 10.1016/j.febslet.2007.12.013; Worthley Daniel L, 2010, Clin Biochem Rev, V31, P31; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08; Yuen ST, 2002, CANCER RES, V62, P6451; Zeller E, 2013, ARCH TOXICOL, V87, P611, DOI 10.1007/s00204-013-1035-3	86	106	106	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4914	4927		10.1038/onc.2014.416	http://dx.doi.org/10.1038/onc.2014.416			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25500543	Green Published, hybrid			2022-12-28	WOS:000361693000002
J	Dhillon, AS; Tulchinsky, E				Dhillon, A. S.; Tulchinsky, E.			FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMA; NEGATIVE FEEDBACK LOOP; BREAST-CANCER; TGF-BETA; STEM-CELLS; MIR-200 FAMILY; PROTEASOMAL DEGRADATION; E-CADHERIN; TRANSCRIPTIONAL ACTIVATION	Tumour heterogeneity is a major factor undermining the success of therapies targeting metastatic cancer. Two major theories are thought to explain the phenomenon of heterogeneity in cancer-clonal evolution and cell plasticity. In this review, we examine a growing body of work implicating the transcription factor FOS-related antigen 1 (FRA-1) as a central node in tumour cell plasticity networks, and discuss mechanisms regulating its activity in cancer cells. We also discuss evidence from the FRA-1 perspective supporting the notion that clonal selection and cell plasticity represent two sides of the same coin. We propose that FRA-1overexpressing clones featuring high plasticity undergo positive selection during consecutive stages of multistep tumour progression. This model underscores a potential mechanism through which tumour cells retaining elevated levels of plasticity acquire a selective advantage over other clonal populations within a tumour.	[Dhillon, A. S.] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia; [Tulchinsky, E.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE2 7LX, Leics, England	Peter Maccallum Cancer Center; University of Leicester	Dhillon, AS (corresponding author), Peter MacCallum Canc Ctr, Growth & Differentiat Program Res Div, St Andrews Pl, Melbourne, Vic 3002, Australia.	Amardeep.Dhillon@petermac.org; et32@le.ac.uk	Tulchinsky, Eugene/ABD-7070-2021	Dhillon, Amardeep/0000-0002-6065-663X	National Health and Medical Research Council of Australia; Cancer Research UK (CRUK); Association for International Cancer Research (AICR)	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Research UK (CRUK)(Cancer Research UK); Association for International Cancer Research (AICR)	We apologize to the colleagues whose relevant work we were unable to cite owing to space limitations. This work was supported by project grants from the National Health and Medical Research Council of Australia (to ASD), and Cancer Research UK (CRUK) and Association for International Cancer Research (AICR) (to ET).	Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Basbous J, 2008, BIOCHIMIE, V90, P296, DOI 10.1016/j.biochi.2007.07.016; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Belguise K, 2012, ONCOGENE, V31, P4889, DOI 10.1038/onc.2011.659; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cha YH, 2012, CELL CYCLE, V11, P1273, DOI 10.4161/cc.19618; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Gilan O, 2015, ONCOGENE, V34, P1340, DOI 10.1038/onc.2014.460; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gu XX, 2013, P NATL ACAD SCI USA, V110, P14960, DOI 10.1073/pnas.1309110110; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Kahlert C, 2011, CLIN CANCER RES, V17, P7654, DOI 10.1158/1078-0432.CCR-10-2816; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li X, 2014, ONCOGENE, V33, P4077, DOI 10.1038/onc.2013.370; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marusyk A, 2014, NATURE; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Nishimura G, 2006, DEV CELL, V11, P93, DOI 10.1016/j.devcel.2006.05.011; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pakay JL, 2012, ONCOGENE, V31, P1817, DOI 10.1038/onc.2011.375; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Signore M, 2013, CANCER LETT, V332, P374, DOI 10.1016/j.canlet.2011.01.013; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Usui A, 2012, CANCER-AM CANCER SOC, V118, P3387, DOI 10.1002/cncr.26652; Van Grunsven LA, 2006, DEV DYNAM, V235, P1491, DOI 10.1002/dvdy.20727; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang GN, 2011, CANCER LETT, V313, P137, DOI 10.1016/j.canlet.2011.05.030; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	127	45	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4421	4428		10.1038/onc.2014.374	http://dx.doi.org/10.1038/onc.2014.374			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25381818	Green Accepted			2022-12-28	WOS:000360189200001
J	Martin-Villar, E; Borda-d'Agua, B; Carrasco-Ramirez, P; Renart, J; Parsons, M; Quintanilla, M; Jones, GE				Martin-Villar, E.; Borda-d'Agua, B.; Carrasco-Ramirez, P.; Renart, J.; Parsons, M.; Quintanilla, M.; Jones, G. E.			Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; IN-VIVO; EXTRACELLULAR-MATRIX; REGULATES COFILIN; TUMOR-METASTASIS; PA2.26 ANTIGEN; ORAL-CANCER; TGF-BETA; INVASION; PODOSOMES	Invadopodia are actin-rich cell membrane projections used by invasive cells to penetrate the basement membrane. Control of invadopodia stability is critical for efficient degradation of the extracellular matrix (ECM); however, the underlying molecular mechanisms remain poorly understood. Here, we uncover a new role for podoplanin, a transmembrane glycoprotein closely associated with malignant progression of squamous cell carcinomas (SCCs), in the regulation of invadopodia-mediated matrix degradation. Podoplanin downregulation in SCC cells impairs invadopodia stability, thereby reducing the efficiency of ECM degradation. We report podoplanin as a novel component of invadopodia-associated adhesion rings, where it clusters prior to matrix degradation. Early podoplanin recruitment to invadopodia is dependent on lipid rafts, whereas ezrin/moesin proteins mediate podoplanin ring assembly. Finally, we demonstrate that podoplanin regulates invadopodia maturation by acting upstream of the ROCK-LIMK-Cofilin pathway through the control of RhoC GTPase activity. Thus, podoplanin has a key role in the regulation of invadopodia function in SCC cells, controlling the initial steps of cancer cell invasion.	[Martin-Villar, E.; Carrasco-Ramirez, P.; Renart, J.; Quintanilla, M.] Inst Invest Biomed Alberto Sols CSIC UAM, Madrid 28029, Spain; [Martin-Villar, E.; Borda-d'Agua, B.; Parsons, M.; Jones, G. E.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of London; King's College London	Martin-Villar, E (corresponding author), Inst Invest Biomed Alberto Sols CSIC UAM, Arturo Duperier 4, Madrid 28029, Spain.	emvillar@iib.uam.es; gareth.jones@kcl.ac.uk	Jones, Gareth E/H-2282-2012; Quintanilla, Miguel/K-9293-2017; Martin-Villar, Ester/F-1982-2016; Renart, Jaime/B-7661-2009; Parsons, Maddy/B-2203-2013	Jones, Gareth E/0000-0001-5879-3048; Martin-Villar, Ester/0000-0003-2910-2345; Renart, Jaime/0000-0001-6620-3706; Quintanilla, Miguel/0000-0002-2124-7657; Parsons, Maddy/0000-0002-2021-8379	Cancer Research UK [C7125/A9926, A13651]; Medical Research Council [G0401026]; Spanish Ministry of Economy and Competitiveness [SAF 2010-19152/SAF2013-46183R]; Community of Madrid [S2010/BMD-2359]; Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); MRC [G1100041, G0401026] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Spanish Ministry of Economy and Competitiveness(Spanish Government); Community of Madrid(Comunidad de Madrid); Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Professor Anne Ridley for critical advice and help with ERM, and Rho GTPase siRNAs; Dr Yolanda Calle for her support and helpful suggestions; Drs Asier Jayo and Patricia Costa for help with LIMK studies, technical advice and critical discussions on this work and Dr David Sarrio for critical reading of the manuscript. This work has been funded by grants from Cancer Research UK (C7125/A9926; A13651) to GEJ and EM-V, the Medical Research Council (G0401026) to GEJ and from the Spanish Ministry of Economy and Competitiveness (SAF 2010-19152/SAF2013-46183R) and Community of Madrid (S2010/BMD-2359, SkinModel-CM) to MQ. EM-V is currently a recipient of a Postdoctoral Research Contract from Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC).	Antelmi E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075113; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Astarita JL, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00283; Beaty BT, 2014, J CELL BIOL, V205, P737, DOI 10.1083/jcb.201312046; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Beaty BT, 2014, EUR J CELL BIOL, DOI [10.1016/ j. ejcb. 2014. 07. 003, DOI 10.1016/J.EJCB.2014.07.003)]; Branch KM, 2012, BIOL OPEN, V1, P711, DOI 10.1242/bio.20121867; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Caldieri G, 2009, J CELL MOL MED, V13, P1728, DOI 10.1111/j.1582-4934.2008.00568.x; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Fernandez-Munoz B, 2011, INT J BIOCHEM CELL B, V43, P886, DOI 10.1016/j.biocel.2011.02.010; Gandarillas A, 1997, MOL CARCINOGEN, V20, P10, DOI 10.1002/(SICI)1098-2744(199709)20:1<10::AID-MC3>3.0.CO;2-M; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Hagedorn EJ, 2014, J CELL BIOL, V204, P1209, DOI 10.1083/jcb.201312098; Hagedorn EJ, 2013, J CELL BIOL, V201, P903, DOI 10.1083/jcb.201301091; Honma M, 2012, J DERMATOL SCI, V65, P134, DOI 10.1016/j.jdermsci.2011.11.011; Hoshino D, 2013, J CELL SCI, V126, P2979, DOI 10.1242/jcs.079475; Hwang YS, 2012, CARCINOGENESIS, V33, P2135, DOI 10.1093/carcin/bgs258; Inoue H, 2012, TUMOR BIOL, V33, P183, DOI 10.1007/s13277-011-0261-7; Kawaguchi H, 2008, J CLIN ONCOL, V26, P354, DOI 10.1200/JCO.2007.13.4072; Kelley LC, 2014, J CELL BIOL, V204, P291, DOI 10.1083/jcb.201311112; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Linder S, 2009, J CELL SCI, V122, P3009, DOI 10.1242/jcs.032631; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; Mahtab EAF, 2008, DEV DYNAM, V237, P847, DOI 10.1002/dvdy.21463; Martin-Villar E, 2005, INT J CANCER, V113, P899, DOI 10.1002/ijc.20656; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Martin-Villar E, 2010, MOL BIOL CELL, V21, P4387, DOI 10.1091/mbc.E10-06-0489; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Oser M, 2009, J CELL BIOCHEM, V108, P1252, DOI 10.1002/jcb.22372; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Parekh A, 2009, CELL ADHES MIGR, V3, P288, DOI 10.4161/cam.3.3.8888; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Scholl FG, 1999, J CELL SCI, V112, P4601; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Suzuki H, 2008, FEBS LETT, V582, P341, DOI 10.1016/j.febslet.2007.12.028; Toll A, 2012, J AM ACAD DERMATOL, V67, P1310, DOI 10.1016/j.jaad.2012.03.007; Tsuneki M, 2013, LAB INVEST, V93, P921, DOI 10.1038/labinvest.2013.86; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamaguchi H, 2010, ONCOTARGET, V1, P320; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305; Yuan P, 2006, CANCER, V107, P563, DOI 10.1002/cncr.22061; Yurrita MM, 2014, INT J BIOCHEM CELL B, V46, P68, DOI 10.1016/j.biocel.2013.11.016; Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690	55	52	57	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4531	4544		10.1038/onc.2014.388	http://dx.doi.org/10.1038/onc.2014.388			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25486435	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000360189200012
J	Han, F; Liu, W; Jiang, X; Shi, X; Yin, L; Ao, L; Cui, Z; Li, Y; Huang, C; Cao, J; Liu, J				Han, F.; Liu, W.; Jiang, X.; Shi, X.; Yin, L.; Ao, L.; Cui, Z.; Li, Y.; Huang, C.; Cao, J.; Liu, J.			SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptional activating p53 in lung cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; DNA METHYLATION; BH3-ONLY MEMBER; GENE; EXPRESSION; DEATH; BCL-2; NOXA; INHIBITION; MEDIATOR	Although members of SOX family have been well documented for their essential roles in embryonic development, cell proliferation and disease, the functional role and molecular mechanism of SOX30 in cancer are largely unexplored. Here, we first identified SRY-box containing gene 30 (SOX30) as a novel preferentially methylated gene using genome-wide methylation screening. SOX30 hypermethylation was detected in 100% of lung cancer cell lines (9/9) and 70.83% (85/120) of primary lung tumor tissues compared with none (0/20) of normal and 8.0% (2/25) of peri-tumoral lung tissues (P<0.01). SOX30 was expressed in normal and peri-tumoral lung tissues in which SOX30 was unmethylated, but was silenced or downregulated in lung cancer cell lines and primary lung tumor tissues harboring a hypermethylated SOX30. De-methylation experiments further confirmed that silence of SOX30 was regulated by its hypermethylation. Ectopic expression of SOX30 induces cancer cell apoptosis with inhibiting proliferation in vitro and represses tumor formation in vivo, whereas knockdown of SOX30 demonstrates a reversed effect both in vitro and in vivo. At the molecular level, the antitumorigenic effect of SOX30 is mediated by directly binding to CACTTTG (+115 to +121) of p53 promoter region and activating p53 transcription, suggesting that SOX30 is a novel transcriptional activating factor of p53. Indeed, blockade of p53 attenuates the tumor inhibition of SOX30. Overall, these findings demonstrate that SOX30 is a novel epigenetic silenced tumor suppressor acting through direct regulation of p53 transcription and expression. This study provides novel insights on the mechanism of tumorigenesis in lung cancer.	[Han, F.; Liu, W.; Jiang, X.; Shi, X.; Yin, L.; Ao, L.; Cui, Z.; Li, Y.; Cao, J.; Liu, J.] Third Mil Med Univ, Coll Prevent Med, Inst Toxicol, Chongqing 400038, Peoples R China; [Han, F.; Liu, W.; Jiang, X.; Shi, X.; Yin, L.; Ao, L.; Cui, Z.; Li, Y.; Cao, J.; Liu, J.] Minist Educ China, Key Lab Med Protect Electromagnet Radiat, Chongqing, Peoples R China; [Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY USA	Army Medical University; Ministry of Education, China; New York University	Cao, J (corresponding author), Third Mil Med Univ, Coll Prevent Med, Inst Toxicol, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	caojia1962@126.com; jinyiliutmmu@163.com	Han, Fei/AAG-9260-2020; Han, Fei/AAH-2028-2020	Han, Fei/0000-0002-0265-5487; Huang, Chuanshu/0000-0003-4133-5096; Jiang, Xiao/0000-0001-8881-4890; Cui, Zhihong/0000-0001-9729-5375	National Natural Science Foundation of China [81172714, 81071695]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Natural Science Foundation of China (nos. 81172714 and 81071695).	Ballow D, 2006, DEV BIOL, V294, P161, DOI 10.1016/j.ydbio.2006.02.027; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chew LJ, 2009, J NEUROSCI RES, V87, P3277, DOI 10.1002/jnr.22128; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gorgoulis VG, 2003, EMBO J, V22, P1567, DOI 10.1093/emboj/cdg157; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; HALDAR S, 1994, CANCER RES, V54, P2095; Han F, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-98; HARPER JW, 1993, CELL, V75, P805; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Khare Sharad, 2012, Methods Mol Biol, V863, P177, DOI 10.1007/978-1-61779-612-8_10; Kim HR, 2013, J TOXICOL SCI, V38, P337, DOI 10.2131/jts.38.337; Liu WB, 2012, BIOCHEM BIOPH RES CO, V429, P180, DOI 10.1016/j.bbrc.2012.10.116; Liu WB, 2010, MOL CARCINOGEN, V49, P556, DOI 10.1002/mc.20621; Minguez B, 2011, DIS MARKERS, V31, P181, DOI [10.1155/2011/310675, 10.3233/DMA-2011-0841]; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Patai AV, 2012, DIGEST DIS, V30, P310, DOI 10.1159/000337004; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Suzuki S, 2009, CANCER SCI, V100, P759, DOI 10.1111/j.1349-7006.2009.01096.x; Tsao CM, 2012, HEPATOLOGY, V56, P2277, DOI 10.1002/hep.25933; Yang IV, 2011, AM J RESP CRIT CARE, V183, P1295, DOI 10.1164/rccm.201010-1579PP; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103; Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967	41	54	57	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4391	4402		10.1038/onc.2014.370	http://dx.doi.org/10.1038/onc.2014.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25435374	Green Published, hybrid			2022-12-28	WOS:000359494400010
J	Bai, XL; Zhang, Q; Ye, LY; Liang, F; Sun, X; Chen, Y; Hu, QD; Fu, QH; Su, W; Chen, Z; Zhuang, ZP; Liang, TB				Bai, X. L.; Zhang, Q.; Ye, L. Y.; Liang, F.; Sun, X.; Chen, Y.; Hu, Q. D.; Fu, Q. H.; Su, W.; Chen, Z.; Zhuang, Z. P.; Liang, T. B.			Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/beta-catenin signaling	ONCOGENE			English	Article							BREAST-CANCER CELLS; MESENCHYMAL TRANSITION; VASCULOGENIC MIMICRY; BETA-CATENIN; TUMOR-CELL; TRANSCRIPTION; MEF2C; EXPRESSION; PROGRESSION; MUTATIONS	Hepatocellular carcinoma (HCC) is one of the leading malignancies worldwide. Myocyte enhancer factor 2C (MEF2C) was traditionally regarded as a development-associated factor and was recently reported to be an oncogene candidate. We have previously reported overexpression of MEF2C in HCC; however, the roles of MEF2C in HCC remain to be clarified. In this study, HCC cell lines and a xenograft mouse model were used to determine the functions of MEF2C in vitro and in vivo, respectively. Specific plasmids and small interfering RNA were used to upregulate and downregulate MEF2C expression, respectively. Functional assays were performed to assess the influence of MEF2C on cell proliferation, and VEGF-induced vasculogenic mimicry, migration/invasion as well as angiogenesis. Co-immunoprecipitation was conducted to identify the interaction of MEF2C and beta-catenin. Human HCC tissue microarrays were used to investigate correlations among MEF2C, beta-catenin and involved biomarkers. MEF2C was found to mediate VEGF-induced vasculogenic mimicry, angiogenesis and migration/invasion, with involvement of the p38 MAPK and PKC signaling pathways. However, MEF2C itself inhibited tumor growth in vitro and in vivo. MEF2C was upregulated by and directly interacted with beta-catenin. The nuclear translocation of beta-catenin blocked by MEF2C was responsible for MEF2C-mediated growth inhibition. The nuclear translocation of MEF2C was associated with intracellular calcium signaling induced by beta-catenin. HCC microarrays showed correlations of nuclear MEF2C with the angiogenesis-associated biomarker, CD31, and cytosolic MEF2C with the proliferation-associated biomarker, Ki-67. MEF2C showed double-edged activities in HCC, namely mediating VEGF-induced malignancy enhancement while inhibiting cancer proliferation via blockade of Wnt/beta-catenin signaling. The overall effect of MEF2C in HCC progression regulation was dictated by its subcellular distribution. This should be determined prior to any MEF2C-associated intervention in HCC.	[Bai, X. L.; Zhang, Q.; Ye, L. Y.; Sun, X.; Hu, Q. D.; Fu, Q. H.; Su, W.; Liang, T. B.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310009, Zhejiang, Peoples R China; [Bai, X. L.; Zhang, Q.; Ye, L. Y.; Liang, T. B.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent, Hangzhou 310009, Zhejiang, Peoples R China; [Liang, F.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China; [Chen, Y.] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Gen Surg, Hangzhou 310009, Zhejiang, Peoples R China; [Chen, Z.] Zhejiang Chinese Med Univ, Zhejiang Hosp Tradit Chinese Med, Zhejiang Key Lab Gastrointestinal Pathophysiol, Hangzhou, Zhejiang, Peoples R China; [Zhuang, Z. P.] NINDS, NIH, Bethesda, MD 20892 USA	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang Chinese Medical University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Liang, TB (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	liangtingbo@zju.edu.cn	Hu, Qi-Da/B-4558-2009	Hu, Qi-Da/0000-0002-9092-7808	National Natural Science Foundation of China [81171884]; National Key Basic Research Program of China [2014CB542101]; Ministry-Province Co-supportive Project of China; Innovation and High-Level Talent Training Program of Department of Health of Zhejiang	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program of China(National Basic Research Program of China); Ministry-Province Co-supportive Project of China; Innovation and High-Level Talent Training Program of Department of Health of Zhejiang	We thank Professor Xu Qiang (State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, China) for the generous gift of MEF2C overexpression plasmid. We appreciate Mr Xie Shangzhi, Mr Hu Liqiang, and Miss Chen Conglin (The Second Affiliated Hospital, Zhejiang University School of Medicine, China) for their great help in certain experiments. This study was financially supported by the National Natural Science Foundation of China (No. 81171884), the National Key Basic Research Program of China (No. 2014CB542101), the Ministry-Province Co-supportive Project of China, and Innovation and High-Level Talent Training Program of Department of Health of Zhejiang.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bai X, 2008, J CANCER RES CLIN, V134, P83, DOI 10.1007/s00432-007-0252-7; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Bienvenu T, 2013, NEUROGENETICS, V14, P71, DOI 10.1007/s10048-012-0344-7; Borghi S, 2001, J CELL SCI, V114, P4477; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Jen KY, 2012, BLOOD, V119, P805, DOI 10.1182/blood-2011-01-327619; Kirschmann DA, 2012, CLIN CANCER RES, V18, P2726, DOI 10.1158/1078-0432.CCR-11-3237; Li BQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033393; Lin Q, 1998, DEVELOPMENT, V125, P4565; Liu YQ, 2013, J BIOL CHEM, V288, P11572, DOI 10.1074/jbc.M112.434951; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Maiti D, 2008, INVEST OPHTH VIS SCI, V49, P3640, DOI 10.1167/iovs.08-1760; Mcgee SL, 2008, DIABETES, V57, P860, DOI 10.2337/db07-0843; Novara F, 2013, EUR J MED GENET, V56, P260, DOI 10.1016/j.ejmg.2013.01.011; Oka M, 2008, Patent Number, Patent No. [CN100398663(C), 100398663]; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Riazi AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005698; Ribeiro MSJ, 2009, NUCLEIC ACIDS RES, V37, P6691, DOI 10.1093/nar/gkp724; Seftor REB, 2012, AM J PATHOL, V181, P1115, DOI 10.1016/j.ajpath.2012.07.013; Shang YL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001527; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Xu JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027165; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Zhang JJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-130; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhao JX, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199372; Zhou L, 2012, ONCOL REP, V28, P874, DOI 10.3892/or.2012.1880	38	58	60	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4089	4097		10.1038/onc.2014.337	http://dx.doi.org/10.1038/onc.2014.337			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25328135				2022-12-28	WOS:000358780500007
J	Song, JH; An, N; Chatterjee, S; Kistner-Griffin, E; Mahajan, S; Mehrotra, S; Kraft, AS				Song, J. H.; An, N.; Chatterjee, S.; Kistner-Griffin, E.; Mahajan, S.; Mehrotra, S.; Kraft, A. S.			Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing	ONCOGENE			English	Article							C-MYC; GLUTAMINE-METABOLISM; GENE-EXPRESSION; TRANSGENIC MICE; CANCER; KRAS; GROWTH; DETOXIFICATION; ONCOPROTEIN; COOPERATION	The Pim protein kinases contribute to transformation by enhancing the activity of oncogenic Myc and Ras, which drives significant metabolic changes during tumorigenesis. In this report, we demonstrate that mouse embryo fibroblasts (MEFs) lacking all three isoforms of Pim protein kinases, triple knockout (TKO), cannot tolerate the expression of activated K-Ras (K-Ras(G12V)) and undergo cell death. Transduction of K-Ras(G12V) into these cells markedly increased the level of cellular reactive oxygen species (ROS). The addition of N-acetyl cysteine attenuated ROS production and reversed the cytotoxic effects of K-Ras(G12V) in the TKO MEFs. The altered cellular redox state caused by the loss of Pim occurred as a result of lower levels of metabolic intermediates in the glycolytic and pentose phosphate pathways as well as abnormal mitochondrial oxidative phosphorylation. TKO MEFs exhibit reduced levels of superoxide dismutase (Sod), glutathione peroxidase 4 (Gpx4) and peroxiredoxin 3 (Prdx3) that render them susceptible to killing by K-Ras(G12V)-mediated ROS production. In contrast, the transduction of c-Myc into TKO cells can overcome the lack of Pim protein kinases by regulating cellular metabolism and Sod2. In the absence of the Pim kinases, c-Myc transduction permitted K-Ras(G12V)-induced cell growth by decreasing Ras-induced cellular ROS levels. These results demonstrate that the Pim protein kinases have an important role in regulating cellular redox, metabolism and K-Ras-stimulated cell growth.	[Song, J. H.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Song, J. H.; Chatterjee, S.; Kistner-Griffin, E.; Mahajan, S.; Mehrotra, S.; Kraft, A. S.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [An, N.; Kraft, A. S.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Chatterjee, S.; Mehrotra, S.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Kistner-Griffin, E.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Song, JH (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	songjin@musc.edu; kraft@musc.edu		SONG, JIN/0000-0002-0123-2909	Genomics Shared Resource at Hollings Cancer Center; Seahorse Biosciences Academic Core Facility, Medical University of South Carolina; NIH [P30-CA138313]; DOD [W81XWH-08-PCRP-IDA, R01 CA1732000]; American Cancer Society Institutional Research Grant; NATIONAL CANCER INSTITUTE [R01CA173200, P30CA138313] Funding Source: NIH RePORTER	Genomics Shared Resource at Hollings Cancer Center; Seahorse Biosciences Academic Core Facility, Medical University of South Carolina; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); American Cancer Society Institutional Research Grant(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the Genomics Shared Resource at Hollings Cancer Center and Seahorse Biosciences Academic Core Facility, Medical University of South Carolina. We thank Dr Allen J Ebens at Genentech Inc. and Novartis Oncology for providing the Pim kinase inhibitors used in this study. This work was supported by the NIH P30-CA138313, DOD W81XWH-08-PCRP-IDA, R01 CA1732000, and American Cancer Society Institutional Research Grant awarded to the Hollings Cancer Center, Medical University of South Carolina.	Adam M, 2006, CANCER RES, V66, P3828, DOI 10.1158/0008-5472.CAN-05-2309; Agrawal S, 2008, LEUKEMIA, V22, P78, DOI 10.1038/sj.leu.2404988; Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bhalla K, 2011, CANCER RES, V71, P6888, DOI 10.1158/0008-5472.CAN-11-1011; Cai HJ, 2012, CANCER RES, V72, P4672, DOI 10.1158/0008-5472.CAN-12-0228; COMPERE SJ, 1989, P NATL ACAD SCI USA, V86, P2224, DOI 10.1073/pnas.86.7.2224; de Groof AJC, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-54; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Diaz F, 2012, HUM MOL GENET, V21, P5066, DOI 10.1093/hmg/dds350; GAETANI GF, 1989, BLOOD, V73, P334; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Garcia PD, 2014, CLIN CANCER RES, V20, P1834, DOI 10.1158/1078-0432.CCR-13-2062; Gomez-Duran A, 2012, BBA-MOL BASIS DIS, V1822, P1216, DOI 10.1016/j.bbadis.2012.04.014; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Kim KT, 2005, BLOOD, V105, P1759, DOI 10.1182/blood-2004-05-2006; Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood-2013-01-481457; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Peek CB, 2013, SCIENCE, V342, P591, DOI 10.1126/science.1243417; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006; Song JH, 2012, CANCER RES, V72, P294, DOI 10.1158/0008-5472.CAN-11-3240; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Telang S, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-77; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang J, 2012, ONCOGENE, V31, P1794, DOI 10.1038/onc.2011.371; Wang JB, 2010, CANCER CELL, P18207; Wasik AM, 2013, SCI REP-UK, V3, DOI [10.1038/srep01400, 10.1038/srep02007]; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weiner J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040221; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	45	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3728	3736		10.1038/onc.2014.306	http://dx.doi.org/10.1038/onc.2014.306			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241892	Green Accepted			2022-12-28	WOS:000357679100010
J	Bessede, E; Dubus, P; Megraud, F; Varon, C				Bessede, E.; Dubus, P.; Megraud, F.; Varon, C.			Helicobacter pylori infection and stem cells at the origin of gastric cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; MARROW-DERIVED CELLS; MOUSE MODEL; INTESTINAL METAPLASIA; PROGENITOR-CELL; CHIEF CELLS; CAGA; PROGRESSION; ERADICATION; EXPRESSION	Helicobacter pylori infection is now recognized as the main and specific infectious cause of cancer in the world. It is responsible for gastric adenocarcinomas of both intestinal and diffuse types, which are the long-term consequences of the chronic infection of the gastric mucosa. Case-control studies have shown an association between the two, recognized as early as 1994 and further substantiated by interventional studies in which H. pylori eradication has led to the prevention of at least part of the gastric cancers. Experimental studies have highlighted the role of bone marrow-derived cells (BMDCs) and particularly mesenchymal stem cells, in the neoplastic process in about a quarter of the cases and possibly an epithelial-mesenchymal transition (EMT) in the other cases. Different studies have confirmed that chronic infection with H. pylori induces a chronic inflammation and subsequent damage of the gastric epithelial mucosa, leading to BMDC recruitment. Once recruited, these cells home and differentiate by cell-cell fusion with local gastric epithelial cells, bearing local stem cell failure and participating in tissue regeneration. The context of chronic infection and inflammation leads to an EMT and altered tissue regeneration and differentiation from both local epithelial stem cells and BMDC. EMT induces the emergence of CD44+ cells possessing mesenchymal and stem cell properties, resulting in metaplastic and dysplastic lesions to give rise, after additional epigenetic and mutational events, to the emergence of cancer stem cells (CSCs) and adenocarcinoma.	[Bessede, E.; Megraud, F.; Varon, C.] Univ Bordeaux, Lab Bacteriol, F-33076 Bordeaux, France; [Bessede, E.; Megraud, F.; Varon, C.] INSERM, U853, Bordeaux, France; [Dubus, P.] Univ Bordeaux, Lab Histol, F-33076 Bordeaux, France; [Dubus, P.] Univ Bordeaux, Histol & Pathol Mol Tumeurs, EA2406, F-33076 Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Megraud, F (corresponding author), Univ Bordeaux, INSERM, U853, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	francis.megraud@chu-bordeaux.fr		Dubus, Pierre/0000-0003-1803-4711; Varon, Christine/0000-0003-4026-2016	SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie) [INCa-DGOS-Inserm 6046]	SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie)	This project was supported by SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie) [Grant: INCa-DGOS-Inserm 6046]. We thank Genevieve Belleannee (Service Anatomopathologie, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux France) for her help in histopathological analysis of human gastric adenocarcinoma cases.	Almeida R, 2005, J PATHOL, V207, P396, DOI 10.1002/path.1861; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Backert S, 2008, CELL MICROBIOL, V10, P1573, DOI 10.1111/j.1462-5822.2008.01156.x; Backert S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-28; Backert S, 2010, HELICOBACTER, V15, P163, DOI 10.1111/j.1523-5378.2010.00759.x; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barros R, 2011, GUT, V60, P290, DOI 10.1136/gut.2010.222323; Baud J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060315; Bessede E, 2013, ONCOGENE; BLASER MJ, 1995, CANCER RES, V55, P2111; Cahill RJ, 1996, GUT, V38, P177, DOI 10.1136/gut.38.2.177; Cai X, 2005, GASTROENTEROLOGY, V128, P1937, DOI 10.1053/j.gastro.2005.02.066; CORREA P, 1992, CANCER RES, V52, P6735; Cover TL, 2003, CANCER RES, V63, P951; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029007; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019569; Ferreira RM, 2012, J CLIN MICROBIOL, V50, P3983, DOI 10.1128/JCM.02087-12; Fox JG, 2007, AM J PATHOL, V171, P1520, DOI 10.2353/ajpath.2007.070249; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; Gonzalez CA, 2012, ANN ONCOL, V23, P1320, DOI 10.1093/annonc/mdr384; Hahm KB, 2002, ALIMENT PHARM THERAP, V16, P115, DOI 10.1046/j.1365-2036.16.s2.3.x; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hutchinson L, 2011, STEM CELLS DEV, V20, P11, DOI 10.1089/scd.2010.0139; Janin A, 2009, BLOOD, V113, P1834, DOI 10.1182/blood-2008-07-171702; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Khurana SS, 2013, J BIOL CHEM, V288, P16085, DOI 10.1074/jbc.M112.445551; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Kuzushita N, 2005, GASTROENTEROLOGY, V129, P1544, DOI 10.1053/j.gastro.2005.07.056; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LEBLOND CP, 1948, SCIENCE, V108, P531, DOI 10.1126/science.108.2811.531; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; Lee YC, 2013, GUT, V62, P676, DOI 10.1136/gutjnl-2012-302240; Lu HS, 2009, J BIOL CHEM, V284, P23024, DOI 10.1074/jbc.M109.001008; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Nam KT, 2010, GASTROENTEROLOGY, V139, P2028, DOI 10.1053/j.gastro.2010.09.005; Nam KT, 2009, GASTROENTEROLOGY, V136, P1288, DOI 10.1053/j.gastro.2008.12.037; Occhialini A, 2001, INFECT IMMUN, V69, P1902, DOI 10.1128/IAI.69.3.1902-1908.2001; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Ohtani M, 2007, CARCINOGENESIS, V28, P2597, DOI 10.1093/carcin/bgm150; Okumura T, 2010, CANCER RES, V70, P8435, DOI 10.1158/0008-5472.CAN-10-1506; Palena C, 2012, FUTURE ONCOL, V8, P713, DOI [10.2217/FON.12.59, 10.2217/fon.12.59]; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peterson AJ, 2010, GASTROENTEROLOGY, V139, P2005, DOI 10.1053/j.gastro.2010.08.043; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Qiao XT, 2007, GASTROENTEROLOGY, V133, P1989, DOI 10.1053/j.gastro.2007.09.031; Quante M, 2010, GASTROENTEROLOGY, V139, P2018, DOI 10.1053/j.gastro.2010.08.003; Rogers AB, 2005, CANCER RES, V65, P10709, DOI 10.1158/0008-5472.CAN-05-1846; Sarosi G, 2008, DIS ESOPHAGUS, V21, P43, DOI 10.1111/j.1442-2050.2007.00744.x; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Solis MA, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/346972; Stange DE, 2013, CELL, V155, P357, DOI 10.1016/j.cell.2013.09.008; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Suzuki R, 2012, INFECT GENET EVOL, V12, P203, DOI 10.1016/j.meegid.2011.12.002; Takaishi S, 2005, GASTROENTEROLOGY, V128, P1965, DOI 10.1053/j.gastro.2005.03.027; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson LJ, 2004, INFECT IMMUN, V72, P4668, DOI 10.1128/IAI.72.8.4668-4679.2004; Touati E, 2003, GASTROENTEROLOGY, V124, P1408, DOI 10.1016/S0016-5085(03)00266-X; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Varon C, 2012, GASTROENTEROLOGY, V142, P281, DOI 10.1053/j.gastro.2011.10.036; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Watanabe T, 2014, INT J CANCER, V134, P2373, DOI 10.1002/ijc.28582; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Weis VG, 2009, GASTRIC CANCER, V12, P189, DOI 10.1007/s10120-009-0527-6; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Worthley DL, 2009, STEM CELLS, V27, P1463, DOI 10.1002/stem.63; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Wu C, 2013, GENE, V525, P18, DOI 10.1016/j.gene.2013.04.067; Wu CY, 2009, GASTROENTEROLOGY, V137, P1641, DOI 10.1053/j.gastro.2009.07.060; Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794; Zhu YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035147	85	62	65	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2547	2555		10.1038/onc.2014.187	http://dx.doi.org/10.1038/onc.2014.187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043305				2022-12-28	WOS:000354541300001
J	Patel, A; Burton, DGA; Halvorsen, K; Balkan, W; Reiner, T; Perez-Stable, C; Cohen, A; Munoz, A; Giribaldi, MG; Singh, S; Robbins, DJ; Nguyen, DM; Rai, P				Patel, A.; Burton, D. G. A.; Halvorsen, K.; Balkan, W.; Reiner, T.; Perez-Stable, C.; Cohen, A.; Munoz, A.; Giribaldi, M. G.; Singh, S.; Robbins, D. J.; Nguyen, D. M.; Rai, P.			MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways	ONCOGENE			English	Article							ONCOGENIC RAS; CANCER-CELLS; TUMOR-CELLS; DNA; SENESCENCE; P53; INHIBITION; APOPTOSIS; PROTEIN; GROWTH	Oncogenic RAS promotes production of reactive oxygen species (ROS), which mediate pro-malignant signaling but can also trigger DNA damage-induced tumor suppression. Thus RAS-driven tumor cells require redox-protective mechanisms to mitigate the damaging aspects of ROS. Here, we show that MutT Homolog 1 (MTH1), the mammalian 8-oxodGTPase that sanitizes oxidative damage in the nucleotide pool, is important for maintaining several KRAS-driven pro-malignant traits in a nonsmall cell lung carcinoma (NSCLC) model. MTH1 suppression in KRAS-mutant NSCLC cells impairs proliferation and xenograft tumor formation. Furthermore, MTH1 levels modulate KRAS-induced transformation of immortalized lung epithelial cells. MTH1 expression is upregulated by oncogenic KRAS and correlates positively with high KRAS levels in NSCLC human tumors. At a molecular level, in p53-competent KRAS-mutant cells, MTH1 loss provokes DNA damage and induction of oncogene-induced senescence. In p53-nonfunctional KRAS-mutant cells, MTH1 suppression does not produce DNA damage but reduces proliferation and leads to an adaptive decrease in KRAS expression levels. Thus, MTH1 not only enables evasion of oxidative DNA damage and its consequences, but can also function as a molecular rheostat for maintaining oncogene expression at optimal levels. Accordingly, our results indicate MTH1 is a novel and critical component of oncogenic KRAS-associated malignancy and its inhibition is likely to yield significant tumor-suppressive outcomes in KRAS-driven tumors.	[Patel, A.; Burton, D. G. A.; Halvorsen, K.; Perez-Stable, C.; Cohen, A.; Munoz, A.; Giribaldi, M. G.; Rai, P.] Univ Miami, Leonard M Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Reiner, T.; Perez-Stable, C.] Bruce W Carter Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Miami, FL USA; [Perez-Stable, C.; Robbins, D. J.; Nguyen, D. M.; Rai, P.] Univ Miami, Leonard M Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Cohen, A.] Univ Miami, Leonard M Miller Sch Med, David & Sheila Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Singh, S.; Robbins, D. J.; Nguyen, D. M.] Univ Miami, Leonard M Miller Sch Med, Dept Surg, Miami, FL 33136 USA	University of Miami; Geriatric Research Education & Clinical Center; University of Miami; University of Miami; University of Miami	Rai, P (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Med, RMSB 7094,D-503,1600 North West 10th Ave, Miami, FL 33136 USA.	prai@med.miami.edu	Singh, Samer/H-8468-2013	Singh, Samer/0000-0002-0921-1686; Rai, Priyamvada/0000-0001-7822-7553	James and Esther King Florida Biomedical New Investigator Research grant, a University of Miami Dean's Bridge Fund award; NIH/NCI grant [R01CA175086]; NATIONAL CANCER INSTITUTE [R01CA175086] Funding Source: NIH RePORTER	James and Esther King Florida Biomedical New Investigator Research grant, a University of Miami Dean's Bridge Fund award; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ramiro Verdun for helpful discussions, and Karen Alvarez Delfin for technical assistance. This work was supported by a James and Esther King Florida Biomedical New Investigator Research grant, a University of Miami Dean's Bridge Fund award and an NIH/NCI grant (R01CA175086) to PR.	Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Burton DGA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068003; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; Cho WCS, 2011, RNA BIOL, V8, P125, DOI 10.4161/rna.8.1.14259; Clark DW, 2012, FREE RADICAL BIO MED, V53, P51, DOI 10.1016/j.freeradbiomed.2012.04.024; Cogoi S, 2006, NUCLEIC ACIDS RES, V34, P2536, DOI 10.1093/nar/gkl286; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dobbs TA, 2008, DNA REPAIR, V7, P1372, DOI 10.1016/j.dnarep.2008.05.001; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FAN SJ, 1994, CANCER RES, V54, P5824; Fei DL, 2010, CANCER RES, V70, P1981, DOI 10.1158/0008-5472.CAN-09-2898; Finkel T, 2006, ANTIOXID REDOX SIGN, V8, P1857, DOI 10.1089/ars.2006.8.1857; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Ghosh A, 2009, J BIOL CHEM, V284, P31074, DOI 10.1074/jbc.M109.027532; Hommura F, 2000, CLIN CANCER RES, V6, P4073; Hu CM, 2012, CANCER CELL, V22, P36, DOI 10.1016/j.ccr.2012.04.038; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Janik J, 2011, MUTAT RES-FUND MOL M, V709-10, P21, DOI 10.1016/j.mrfmmm.2011.02.009; Kennedy CH, 2003, FREE RADICAL BIO MED, V34, P1447, DOI 10.1016/S0891-5849(03)00176-X; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Nakabeppu Y, 2001, MUTAT RES-FUND MOL M, V477, P59, DOI 10.1016/S0027-5107(01)00096-3; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Patel A, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-3; Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520; Rai P, 2009, P NATL ACAD SCI USA, V106, P169, DOI 10.1073/pnas.0809834106; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Reiner T, 2006, PROSTATE, V66, P1487, DOI 10.1002/pros.20478; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Speina E, 2005, JNCI-J NATL CANCER I, V97, P384, DOI 10.1093/jnci/dji058; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Szalai VA, 2002, J AM CHEM SOC, V124, P1625, DOI 10.1021/ja0119651; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	53	66	68	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2586	2596		10.1038/onc.2014.195	http://dx.doi.org/10.1038/onc.2014.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023700	Green Accepted			2022-12-28	WOS:000354541300005
J	Chen, X; Paranjape, T; Stahlhut, C; McVeigh, T; Keane, F; Nallur, S; Miller, N; Kerin, M; Deng, Y; Yao, X; Zhao, H; Weidhaas, JB; Slack, FJ				Chen, X.; Paranjape, T.; Stahlhut, C.; McVeigh, T.; Keane, F.; Nallur, S.; Miller, N.; Kerin, M.; Deng, Y.; Yao, X.; Zhao, H.; Weidhaas, J. B.; Slack, F. J.			Targeted resequencing of the microRNAome and 3 ' UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer	ONCOGENE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISMS; ACUTE MYELOID-LEUKEMIA; LARGE GENE LISTS; SOMATIC MUTATIONS; PCM1-JAK2 FUSION; BINDING-SITES; BREAST-CANCER; KRAS-VARIANT; RISK; GENOME	Ovarian cancer is a major cause of cancer deaths, yet there have been few known genetic risk factors identified, the best known of which are disruptions in protein coding sequences (BRCA1 and 2). Recent findings indicate that there are powerful genetic markers of cancer risk outside of these regions, in the noncoding mRNA control regions. To identify additional cancer-associated, functional non-protein-coding sequence germline variants associated with ovarian cancer risk, we captured DNA regions corresponding to all validated human microRNAs and the 3' untranslated regions (UTRs) of similar to 6000 cancer-associated genes from 31 ovarian cancer patients. Multiple single-nucleotide polymorphisms in the 3'UTR of the vascular endothelial growth factor receptor/FLT1, E2F2 and PCM1 oncogenes were highly enriched in ovarian cancer patients compared with the 1000 Genome Project. Sequenom validation in a case-control study (267 cases and 89 controls) confirmed a novel variant in the PCM1 3'UTR is significantly associated with ovarian cancer (P = 0.0086). This work identifies a potential new ovarian cancer locus and further confirms that cancer resequencing efforts should not ignore the study of noncoding regions of cancer patients.	[Chen, X.; Stahlhut, C.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Chen, X.; Zhao, H.] Yale Univ, Sch Med, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Paranjape, T.; Nallur, S.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; [McVeigh, T.; Miller, N.; Kerin, M.] Natl Univ Ireland Galway, Discipline Surg, Galway, Ireland; [McVeigh, T.; Miller, N.; Kerin, M.] Galway Univ, Hosp, Galway, Ireland; [Keane, F.] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Deng, Y.; Yao, X.] Yale Univ, Sch Med, Yale Ctr Analyt Sci, New Haven, CT 06520 USA; [Zhao, H.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; [Zhao, H.] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Yale University; Yale University; Yale University; Yale University	Slack, FJ (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, 266 Whitney Ave,POB 208103, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu; frank.slack@yale.edu	Miller, Nicola/F-4009-2018; McVeigh, Terri/AAX-8075-2021	Miller, Nicola/0000-0002-5416-7047; McVeigh, Terri/0000-0001-9201-9216; Stahlhut, Carlos/0000-0002-8472-7156; Slack, Frank/0000-0001-8263-0409; Weidhaas, Joanne/0000-0002-5096-3281; Kerin, Michael/0000-0003-4164-5561	Lo Graduate Fellowship for Excellence in Stem Cell Research; China Scholars Council; NATIONAL CANCER INSTITUTE [P30CA016359, R01CA157749] Funding Source: NIH RePORTER	Lo Graduate Fellowship for Excellence in Stem Cell Research; China Scholars Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	XC was supported by Lo Graduate Fellowship for Excellence in Stem Cell Research and a fellowship from the China Scholars Council. TP was supported by a donation from William Hyman, Yale College Class of 1980, in memory of Barbara Skydel. We thank I Tikhonova, M Mahajan and S Mane at the YCGA for performing the Nimblegen enrichment and Sequenom arrays. We thank M State for critical reading of this manuscript. This work was supported by a grant from an anonymous foundation.	Adelaide J, 2006, LEUKEMIA, V20, P536, DOI 10.1038/sj.leu.2404104; Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Albert TJ, 2007, NAT METHODS, V4, P903, DOI 10.1038/NMETH1111; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Batra J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-119; Blitzblau RC, 2010, MOL DIAGN THER, V14, P335, DOI 10.2165/11587600-000000000-00000; Bousquet M, 2005, ONCOGENE, V24, P7248, DOI 10.1038/sj.onc.1208850; Bowen NJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-71; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chien J, 2009, GYNECOL ONCOL, V114, P3, DOI 10.1016/j.ygyno.2009.04.002; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Collins FS, 2007, SCI AM, V296, P50, DOI 10.1038/scientificamerican0307-50; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; Cromer MK, 2012, J CLIN ENDOCR METAB, V97, pE1774, DOI 10.1210/jc.2012-1743; Despierre E, 2010, GYNECOL ONCOL, V117, P358, DOI 10.1016/j.ygyno.2010.02.012; Doherty JA, 2010, CANCER EPIDEM BIOMAR, V19, P245, DOI 10.1158/1055-9965.EPI-09-0729; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hodges E, 2007, NAT GENET, V39, P1522, DOI 10.1038/ng.2007.42; Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kato M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-5-r54; Kontorovich T, 2010, INT J CANCER, V127, P589, DOI 10.1002/ijc.25065; Kumaran GC, 2009, BRIT J CANCER, V100, P1, DOI 10.1038/sj.bjc.6604767; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li Y, 2008, GYNECOL ONCOL, V108, P409, DOI 10.1016/j.ygyno.2007.10.024; Liang D, 2010, CANCER RES, V70, P9765, DOI 10.1158/0008-5472.CAN-10-0130; Liu PY, 2012, CARCINOGENESIS, V33, P1270, DOI 10.1093/carcin/bgs148; Lurie G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020703; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Markman M, 2009, EXPERT OPIN PHARMACO, V10, P2269, DOI 10.1517/14656560903120907; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Okou DT, 2007, NAT METHODS, V4, P907, DOI 10.1038/NMETH1109; Paranjape T, 2011, LANCET ONCOL, V12, P377, DOI 10.1016/S1470-2045(11)70044-4; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pastrello C, 2010, CARCINOGENESIS, V31, P2124, DOI 10.1093/carcin/bgq184; Pearce CL, 2011, HUM MOL GENET, V20, P2263, DOI 10.1093/hmg/ddr087; Peethambaram P, 2011, INT J MOL EPIDEMIOL, V2, P185; Permuth-Wey J, 2011, CANCER RES, V71, P3896, DOI 10.1158/0008-5472.CAN-10-4167; Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538; Pongsavee M, 2009, GENET TEST MOL BIOMA, V13, P307, DOI 10.1089/gtmb.2008.0127; Ramakrishna M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009983; Ramsingh G, 2010, BLOOD, V116, P5316, DOI 10.1182/blood-2010-05-285395; Ratner ES, 2012, ONCOGENE, V31, P4559, DOI 10.1038/onc.2011.539; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Shen J, 2008, CARCINOGENESIS, V29, P1963, DOI 10.1093/carcin/bgn172; Shen J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-47; Smigielski EM, 2000, NUCLEIC ACIDS RES, V28, P352, DOI 10.1093/nar/28.1.352; Terry KL, 2010, INT J MOL EPIDEMIOL, V1, P272; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang LH, 2012, GENOME RES, V22, P208, DOI 10.1101/gr.123109.111; Wynendaele J, 2010, CANCER RES, V70, P9641, DOI 10.1158/0008-5472.CAN-10-0527; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	67	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2125	2137		10.1038/onc.2014.117	http://dx.doi.org/10.1038/onc.2014.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909162	Green Accepted, Green Published			2022-12-28	WOS:000353173400012
J	Alfano, L; Costa, C; Caporaso, A; Altieri, A; Indovina, P; Macaluso, M; Giordano, A; Pentimalli, F				Alfano, L.; Costa, C.; Caporaso, A.; Altieri, A.; Indovina, P.; Macaluso, M.; Giordano, A.; Pentimalli, F.			NONO regulates the intra-S-phase checkpoint in response to UV radiation	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; SPLICING-FACTOR; MESSENGER-RNA; CHK1 ACTIVATION; ATR ACTIVATION; RPA-SSDNA; PROTEIN; PHOSPHORYLATION; REPLICATION	The main risk factor for skin cancer is ultraviolet (UV) exposure, which causes DNA damage. Cells respond to UV-induced DNA damage by activating the intra-S-phase checkpoint, which prevents replication fork collapse, late origin firing and stabilizes fragile sites. Recently, the 54-kDa multifunctional protein NONO was found to be involved in the non-homologous end-joining DNA repair process and in poly ADP-ribose polymerase 1 activation. Interestingly, NONO is mutated in several tumour types and emerged as a crucial factor underlying both melanoma development and progression. Therefore, we set out to evaluate whether NONO could be involved in the DNA-damage response to UV radiations. We generated NONO-silenced HeLa cell clones and found that lack of NONO decreased cell growth rate. Then, we challenged NONO-silenced cells with exposure to UV radiations and found that NONO-silenced cells, compared with control cells, continued to synthesize DNA, failed to block new origin firing and impaired CHK1S345 phosphorylation showing a defective checkpoint activation. Consistently, NONO is present at the sites of UV-induced DNA damage where it localizes to RAD9 foci. To position NONO in the DNA-damage response cascade, we analysed the loading onto chromatin of various intra-S-phase checkpoint mediators and found that NONO favours the loading of topoisomerase II-binding protein 1 acting upstream of the ATM and Rad3-related kinase activity. Strikingly, re-expression of NONO, through an sh-resistant mRNA, rescued CHK1S345 phosphorylation in NONO-silenced cells. Interestingly, NONO silencing affected cell response to UV radiations also in a melanoma cell line. Overall, our data uncover a new role for NONO in mediating the cellular response to UV-induced DNA damage.	[Alfano, L.; Costa, C.; Altieri, A.; Pentimalli, F.] IRCCS, Ist Nazl Tumori Fdn G Pascale, CROM, Naples, Italy; [Caporaso, A.; Indovina, P.; Giordano, A.] Univ Siena, Dept Med Surg & Neurosci, Via Laterina 8, I-53100 Siena, Italy; [Caporaso, A.; Indovina, P.; Giordano, A.] ITT, Siena, Italy; [Indovina, P.; Macaluso, M.; Giordano, A.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA; [Indovina, P.; Macaluso, M.; Giordano, A.] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA	IRCCS Fondazione Pascale; University of Siena; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA.; Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA.; Pentimalli, F (corresponding author), IRCCS, Ist Nazl Per Lo Studio E La Cura Dei Tumori Fdn G, Oncol Res Ctr Mercogliano CROM, Via Ammiraglio Bianco, I-83013 Avellino, Italy.	giordano@temple.edu; f.pentimalli@istitutotumori.na.it	Giordano, Antonio/F-1927-2010; Giordano, Antonio/AAU-1201-2020; Alfano, Luigi/B-8330-2015; Costa, Caterina/N-1742-2019; Costa, Caterina/ABE-2452-2020; Pentimalli, Francesca/K-4936-2014	Giordano, Antonio/0000-0002-5959-016X; Giordano, Antonio/0000-0002-5959-016X; Alfano, Luigi/0000-0002-4516-9956; Costa, Caterina/0000-0003-0909-7366; Pentimalli, Francesca/0000-0003-4740-6801; Indovina, Paola/0000-0001-8416-435X	Sbarro Health Research Organization; Human Health Foundation; Commonwealth of Pennsylvania; Associazione Italiana per la Ricerca sul Cancro [AIRC IG 15690]	Sbarro Health Research Organization; Human Health Foundation; Commonwealth of Pennsylvania; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are thankful to the Sbarro Health Research Organization (http://www.shro.org), the Human Health Foundation (http://www.hhfonlus.org), the Commonwealth of Pennsylvania and the Associazione Italiana per la Ricerca sul Cancro (AIRC IG 15690) for their support. We are grateful to Pasquale Barba and Laura Pisapia (Consiglio Nazionale delle Ricerche-Institute of Genetics and Biophysics, Naples, Italy) for the FACS analyses. We also thank Larry M Karnitz, Division of Oncology Research, Mayo Clinic, Rochester, MN, USA for his help in sharing reagents and Marco G Paggi, Regina Elena National Cancer Institute, Rome, Italy for the M14 cell line. Prof Giordano is the director of research line 3 at CROM, Istituto Nazionale Tumori 'Fondazione G. Pascale'-IRCCS, Naples, Italy.	Adamson B, 2012, NAT CELL BIOL, V14, P318, DOI 10.1038/ncb2426; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bladen CL, 2005, J BIOL CHEM, V280, P5205, DOI 10.1074/jbc.M412758200; Branzei D, 2009, DNA REPAIR, V8, P1038, DOI 10.1016/j.dnarep.2009.04.014; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; Duursma AM, 2013, MOL CELL, V50, P116, DOI 10.1016/j.molcel.2013.03.006; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Ishiguro H, 2003, INT J CANCER, V105, P26, DOI 10.1002/ijc.11021; Ishii T, 2010, J BIOL CHEM, V285, P41993, DOI 10.1074/jbc.M110.161661; Kaufmann WK, 2010, CARCINOGENESIS, V31, P751, DOI 10.1093/carcin/bgp230; Kowalska E, 2013, P NATL ACAD SCI USA, V110, P1592, DOI 10.1073/pnas.1213317110; Krietsch J, 2012, NUCLEIC ACIDS RES, V40, P10287, DOI 10.1093/nar/gks798; Kuhnert A, 2012, J CELL BIOCHEM, V113, P1744, DOI 10.1002/jcb.24045; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lee J, 2010, MOL BIOL CELL, V21, P926, DOI 10.1091/mbc.E09-11-0958; Li SY, 2014, NUCLEIC ACIDS RES, V42, P9771, DOI 10.1093/nar/gku650; Li SY, 2009, NUCLEIC ACIDS RES, V37, P6746, DOI 10.1093/nar/gkp741; Liu QH, 2000, GENE DEV, V14, P1448; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Ma HT, 2011, METHODS MOL BIOL, V761, P151, DOI 10.1007/978-1-61779-182-6_10; Marechal A, 2014, MOL CELL, V53, P235, DOI 10.1016/j.molcel.2013.11.002; Martinez-Ramos I, 2005, J CELL BIOCHEM, V96, P79, DOI 10.1002/jcb.20428; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Medhurst AL, 2008, J CELL SCI, V121, P3933, DOI 10.1242/jcs.033688; Mordes DA, 2008, GENE DEV, V22, P1478, DOI 10.1101/gad.1666208; Nelson LD, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-38; Oakley GG, 2010, FRONT BIOSCI-LANDMRK, V15, P883, DOI 10.2741/3652; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Rappas M, 2011, NUCLEIC ACIDS RES, V39, P313, DOI 10.1093/nar/gkq743; Rosonina E, 2005, MOL CELL BIOL, V25, P6734, DOI 10.1128/MCB.25.15.6734-6746.2005; Salton M, 2010, CELL CYCLE, V9, P1568, DOI 10.4161/cc.9.8.11298; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Sievers C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012735; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Straub T, 2000, BIOCHEMISTRY-US, V39, P7552, DOI 10.1021/bi992898e; Swift LH, 2014, INT J MOL SCI, V15, P3403, DOI 10.3390/ijms15033403; Talman V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020053; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Willis N, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-13; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	59	21	21	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					567	576		10.1038/onc.2015.107	http://dx.doi.org/10.1038/onc.2015.107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893301				2022-12-28	WOS:000369548800004
J	Rebecca, VW; Amaravadi, RK				Rebecca, V. W.; Amaravadi, R. K.			Emerging strategies to effectively target autophagy in cancer	ONCOGENE			English	Review							STRESS-INDUCED AUTOPHAGY; ADVANCED SOLID TUMORS; PHASE-I TRIAL; CELL-SURVIVAL; REGULATE AUTOPHAGY; LINKS AUTOPHAGY; UP-REGULATION; INHIBITOR; HYDROXYCHLOROQUINE; P53	Autophagy serves a dichotomous role in cancer and recent advances have helped delineate the appropriate settings where inhibiting or promoting autophagy may confer therapeutic efficacy in patients. Our evolving understanding of the molecular machinery responsible for the tightly controlled regulation of this homeostatic mechanism has begun to bear fruit in the way of autophagy-oriented clinical trials and promising lead compounds to modulate autophagy for therapeutic benefit. In this manuscript we review the recent preclinical and clinical therapeutic strategies that involve autophagy modulation in cancer.	[Amaravadi, R. K.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19063 USA; [Amaravadi, R. K.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19063 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Amaravadi, RK (corresponding author), Univ Penn, Sch Med, Dept Med, 16 Penn Tower,3400 Spruce St, Philadelphia, PA 19063 USA.	ravi.amaravadi@uphs.upenn.edu			National Institutes of Health [R01 CA169134]; NATIONAL CANCER INSTITUTE [P01CA114046, R01CA169134] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by R01 CA169134 (RKA) from the National Institutes of Health.	Amaravadi R, 2014, CANCER DISCOV, V4, P873, DOI 10.1158/2159-8290.CD-14-0618; Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427; Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bowman CJ, 2014, NAT CELL BIOL, V16, P1202, DOI 10.1038/ncb3062; Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831; Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Cecconi F, 2007, AUTOPHAGY, V3, P506; Chang ZX, 2013, INT J MOL MED, V31, P1449, DOI 10.3892/ijmm.2013.1351; Chen M, 2014, NAT MED, V20, P507, DOI 10.1038/nm.3521; Cheng Y, 2012, MOL CANCER THER, V11, P154, DOI 10.1158/1535-7163.MCT-11-0606; Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108; Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072; Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Denton D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3916; Deretic V, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018481; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Eisenberg T, 2014, AUTOPHAGY, V10, P1143, DOI 10.4161/auto.28767; Eisenberg T, 2014, CELL METAB, V19, P431, DOI 10.1016/j.cmet.2014.02.010; Elgendy M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6637; Fujita KI, 2011, P NATL ACAD SCI USA, V108, P1427, DOI 10.1073/pnas.1014156108; Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458; Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716; Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006; Goodall ML, 2014, AUTOPHAGY, V10, P1120, DOI 10.4161/auto.28594; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harder LM, 2014, AUTOPHAGY, V10, P339, DOI 10.4161/auto.26863; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Horikawa I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5706; Iacobuzio-Donahue CA, 2014, NEW ENGL J MED, V370, P1352, DOI 10.1056/NEJMcibr1400189; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim S, 2014, CANCER IMMUNOL IMMUN, V63, P1009, DOI 10.1007/s00262-014-1573-4; Kishi-Itakura C, 2014, J CELL SCI, V127, P4089, DOI 10.1242/jcs.156034; Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244; Kraya AA, 2015, AUTOPHAGY, V11, P60, DOI 10.4161/15548627.2014.984273; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Kuang ES, 2013, TRENDS BIOCHEM SCI, V38, P453, DOI 10.1016/j.tibs.2013.06.008; Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614; Lan YY, 2014, CELL REP, V9, P180, DOI 10.1016/j.celrep.2014.08.074; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; Ma XH, 2011, CLIN CANCER RES, V17, P3478, DOI 10.1158/1078-0432.CCR-10-2372; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231; Mandell MA, 2014, DEV CELL, V30, P394, DOI 10.1016/j.devcel.2014.06.013; Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75; Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015; Mathew R, 2014, MOL CELL, V55, P916, DOI 10.1016/j.molcel.2014.07.019; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; McLendon PM, 2014, P NATL ACAD SCI USA, V111, pE5178, DOI 10.1073/pnas.1415589111; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mijaljica D, 2011, AUTOPHAGY, V7, P666, DOI 10.4161/auto.7.6.15812; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Pike LRG, 2013, BIOCHEM J, V449, P389, DOI 10.1042/BJ20120972; Platta HW, 2012, BIOCHEM J, V441, P399, DOI 10.1042/BJ20111424; Qiu LY, 2012, J LIPOSOME RES, V22, P245, DOI 10.3109/08982104.2012.684150; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ramakrishnan R, 2012, CANCER RES, V72, P5483, DOI 10.1158/0008-5472.CAN-12-2236; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118; Rao S, 2014, AUTOPHAGY, V10, P529, DOI 10.4161/auto.27643; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Ravikumar B, 2008, J CELL SCI, V121, P1649, DOI 10.1242/jcs.025726; Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078; Rebecca VW, 2014, PIGM CELL MELANOMA R, V27, P465, DOI 10.1111/pcmr.12227; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681; Rong YG, 2011, P NATL ACAD SCI USA, V108, P7826, DOI 10.1073/pnas.1013800108; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807; Sarraf SA, 2013, NATURE, V496, P372, DOI 10.1038/nature12043; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shukla S, 2014, J BIOL CHEM, V289, P22306, DOI 10.1074/jbc.M114.567032; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482; Thorburn J, 2014, CELL REP, V7, P45, DOI 10.1016/j.celrep.2014.02.036; Tomar D, 2012, BBA-MOL CELL RES, V1823, P316, DOI 10.1016/j.bbamcr.2011.11.015; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Wang K, 2011, AUTOPHAGY, V7, P297, DOI 10.4161/auto.7.3.14502; Wani WY, 2015, LAB INVEST, V95, P14, DOI 10.1038/labinvest.2014.131; Wei HJ, 2014, GENE DEV, V28, P1204, DOI 10.1101/gad.237354.113; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086; Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323; Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111; Wu H, 2014, AUTOPHAGY, V10, P1712, DOI 10.4161/auto.29568; Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096; Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056; Zou CG, 2014, P NATL ACAD SCI USA, V111, P12480, DOI 10.1073/pnas.1405032111	122	177	186	2	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					1	11		10.1038/onc.2015.99	http://dx.doi.org/10.1038/onc.2015.99			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25893285	Green Accepted			2022-12-28	WOS:000367812400001
J	Que, T; Song, Y; Liu, Z; Zheng, S; Long, H; Li, Z; Liu, Y; Wang, G; Liu, Y; Zhou, J; Zhang, X; Fang, W; Qi, S				Que, T.; Song, Y.; Liu, Z.; Zheng, S.; Long, H.; Li, Z.; Liu, Y.; Wang, G.; Liu, Y.; Zhou, J.; Zhang, X.; Fang, W.; Qi, S.			Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1	ONCOGENE			English	Article							HUMAN GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMA; NASOPHARYNGEAL CARCINOMA; TUMOR-SUPPRESSOR; EXPRESSION; MICRORNAS; PROLIFERATION; PAKT	Although increasing evidence indicated that the deregulation of microRNAs (miRNAs) contributes to tumorigenesis and invasion, little is known about the role of miR-637 in human gliomas. In the present study, we found that the expression level of miR-637 was significantly reduced in clinical glioma tissues compared with normal brain tissues. Moreover, we revealed that the introduction of miR-637 dramatically suppressed glioma cell growth, migration and invasion in vitro and in vivo. Further studies revealed that Akt1 is a direct target gene of miR-637. Silencing of Akt1 inhibited the growth and invasion of glioma cells by decreasing phosphorylated Akt, beta-catenin, phosphorylated Foxo1 and Cyclin D1 and inducing the expression of Foxo1, which was consistent with the effect of miR-637 overexpression. Suppressed expression of miR-637 and increased Akt1 protein levels were correlated with unfavorable progression and poor prognosis, respectively, and a negative relationship between the miR-637 expression and Akt1 protein levels was observed in gliomas. Our findings provide new insights into the role of miR-637 in the development of gliomas, and implicate the potential application of miR-637 in cancer therapy.	[Que, T.; Song, Y.; Zheng, S.; Long, H.; Li, Z.; Liu, Y.; Wang, G.; Liu, Y.; Zhang, X.; Qi, S.] Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Guangzhou 510515, Guangdong, Peoples R China; [Que, T.; Liu, Z.; Fang, W.] Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China; [Liu, Z.] Guangzhou Med Univ, Basic Sch, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Zhou, J.] Luzhou Med Coll, Affiliated Hosp, Dept Neurosurg, Luzhou, Sichuan, Peoples R China; [Fang, W.] Southern Med Univ, TCM Integrated Hosp, Canc Ctr, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Guangzhou Medical University; Southwest Medical University; Southern Medical University - China	Qi, S (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Neurosurg, 1838,North Guangzhou Ave, Guangzhou 510515, Guangdong, Peoples R China.	zhang-xi-an@hotmail.com; fangweiyi1975@163.com; qisongtaosjwk@163.com		Que, Tianshi/0000-0002-3838-8253; Wang, Gang/0000-0003-3827-2653	National Nature Science Fund of China [81372692]; Natural Science Fund of Guangdong Province [S2013010014886]; Medical Scientific Research Fund of Guangdong Province [B2013238]; Scientific Research Initiative Project Fund of Southern Medical University [B1012032]; President Fund of Nanfang Hospital [2011C007, 2012C011]; Science Fund of the Affiliated Hospital of Luzhou Medical College [2013-60]; Science and Technology Project of Luzhou [3-S-48]	National Nature Science Fund of China(National Natural Science Foundation of China (NSFC)); Natural Science Fund of Guangdong Province(National Natural Science Foundation of Guangdong Province); Medical Scientific Research Fund of Guangdong Province; Scientific Research Initiative Project Fund of Southern Medical University; President Fund of Nanfang Hospital; Science Fund of the Affiliated Hospital of Luzhou Medical College; Science and Technology Project of Luzhou	This study was supported by the National Nature Science Fund of China (NO. 81372692; http://www.nsfc.gov.cn), the Natural Science Fund of Guangdong Province (NO. S2013010014886; http://www.gdstc.gov.cn), the Medical Scientific Research Fund of Guangdong Province (NO. B2013238; http://www.medste.gd.cn), the Scientific Research Initiative Project Fund of Southern Medical University (NO. B1012032; http://www.fimmu.com), the President Fund of Nanfang Hospital (2011C007, 2012C011; http://www.nfyy.com), the Science Fund of the Affiliated Hospital of Luzhou Medical College (2013-60) and Science and Technology Project of Luzhou (3-S-48). The funders had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript.	Al-Harthi L, 2012, J NEUROIMMUNE PHARM, V7, P725, DOI 10.1007/s11481-012-9412-x; Antonelli M, 2012, NEUROPATHOLOGY, V32, P133, DOI 10.1111/j.1440-1789.2011.01252.x; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Besse A, 2013, TUMOR BIOL, V34, P1969, DOI 10.1007/s13277-013-0772-5; Cai N, 2013, RNA, V19, P85, DOI 10.1261/rna.035295.112; Dontula Ranadheer, 2013, Genes Cancer, V4, P285, DOI 10.1177/1947601913500141; Emdad L, 2012, FUTURE ONCOL, V8, P343, DOI [10.2217/FON.12.16, 10.2217/fon.12.16]; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Guo P, 2013, ONCOL REP, V30, P870, DOI 10.3892/or.2013.2526; Hobert O, 2007, CELL, V131, P22, DOI 10.1016/j.cell.2007.09.031; Jansen M, 2010, LANCET NEUROL, V9, P717, DOI 10.1016/S1474-4422(10)70105-8; Kim KH, 2013, NEURO-ONCOLOGY, V15, P161, DOI 10.1093/neuonc/nos299; Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089; Leivonen SK, 2014, MOL ONCOL, V8, P93, DOI 10.1016/j.molonc.2013.10.001; Li GQ, 2013, MOL CELL BIOCHEM, V372, P221, DOI 10.1007/s11010-012-1463-z; Li T, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-263; Liu Z, 2011, INT J CANCER, V128, P2562, DOI 10.1002/ijc.25595; Liu Z, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-270; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nan Y, 2010, BRAIN RES, V1359, P14, DOI 10.1016/j.brainres.2010.08.074; Pan SJ, 2012, INT J IMMUNOPATH PH, V25, P871, DOI 10.1177/039463201202500405; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Qi ST, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038842; Quintavalle C, 2012, ONCOGENE, V31, P858, DOI 10.1038/onc.2011.280; Rodriguez EF, 2011, ACTA NEUROPATHOL, V121, P407, DOI 10.1007/s00401-010-0784-9; Schlegel J, 2000, CANCER LETT, V158, P103, DOI 10.1016/S0304-3835(00)00515-2; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Stokowy T, 2014, HORM METAB RES, V46, P171, DOI 10.1055/s-0033-1363264; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suzuki Y, 2010, J RADIAT RES, V51, P343, DOI 10.1269/jrr.09109; Wang YY, 2012, J NEURO-ONCOL, V106, P217, DOI 10.1007/s11060-011-0679-1; Wlodarski P, 2006, FOLIA NEUROPATHOL, V44, P214; Wu S, 2012, ONCOGENE, V31, P3866, DOI 10.1038/onc.2011.551; Yin D, 2013, ONCOGENE, V32, P1155, DOI 10.1038/onc.2012.132; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang JF, 2011, HEPATOLOGY, V54, P2137, DOI 10.1002/hep.24595	36	96	100	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4952	4963		10.1038/onc.2014.419	http://dx.doi.org/10.1038/onc.2014.419			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25597410				2022-12-28	WOS:000361693000005
J	Golden, D; Cantley, LG				Golden, D.; Cantley, L. G.			Casein kinase 2 prevents mesenchymal transformation by maintaining Foxc2 in the cytoplasm	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; HEREDITARY LYMPHEDEMA; FORKHEAD BOX; CK2; TRANSITION; PHOSPHORYLATION; LOCALIZATION; CANCER; DOMAIN; CELLS	Nuclear Foxc2 is a transcriptional regulator of mesenchymal transformation during developmental epithelial-mesenchymal transition (EMT) and has been associated with EMT in malignant epithelia. Our laboratory has shown that in normal epithelial cells Foxc2 is maintained in the cytoplasm where it promotes an epithelial phenotype. The Foxc2 amino terminus has a consensus casein kinase 2 (CK2) phosphorylation site at serine 124, and we now show that CK2 associates with Foxc2 and phosphorylates this site in vitro. Knockdown or inhibition of the CK2 alpha/alpha a' kinase subunit in epithelial cells causes de novo accumulation of Foxc2 in the nucleus. Mutation of serine 124 to leucine promotes constitutive nuclear localization of Foxc2 and expression of mesenchymal genes, whereas an S124D phosphomimetic leads to constitutive cytoplasmic localization and epithelial maintenance. In malignant breast cancer cells, the CK2 beta regulatory subunit is downregulated and FOXC2 is found in the nucleus, correlating with an increase in a-smooth muscle actin (SMA) expression. Restoration of CK2 beta expression in these cells results in cytoplasmic localization of Foxc2, decreased alpha-SMA expression and reduced cell migration and invasion. In contrast, knockdown of CK2 beta in normal breast epithelial cells leads to FOXC2 nuclear localization, decreased E-cadherin expression, increased alpha-SMA and vimentin expression, and enhanced cell migration and invasion. Based on these findings, we propose that Foxc2 is functionally maintained in the cytoplasm of normal epithelial cells by CK2 alpha/alpha'-mediated phosphorylation at serine 124, which is dependent on proper targeting of the holoenzyme via the CK2 beta regulatory subunit.	[Golden, D.] Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; [Cantley, L. G.] Yale Univ, Sch Med, Dept Internal Med, Sect Nephrol, Haven, CT USA	University of Connecticut; Yale University	Golden, D (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, 263 Farmington Ave,MC 3501, Farmington, CT 06030 USA.	dgolden@uchc.edu		Golden, Diana/0000-0002-1080-9175	NIH [DK65109]; DG [DK094589]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007276, R01DK065109, F32DK094589] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DG; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH awards to LGC (DK65109) and DG (DK094589).	Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Bard JBL, 2008, DEV DYNAM, V237, P2748, DOI 10.1002/dvdy.21652; Barrett RMA, 2011, CELL CYCLE, V10, P538, DOI 10.4161/cc.10.3.14758; Berry FB, 2005, HUM MOL GENET, V14, P2619, DOI 10.1093/hmg/ddi295; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Deshiere A, 2013, ONCOGENE, V32, P1373, DOI 10.1038/onc.2012.165; Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Mueller T, 2009, HUM MOL GENET, V18, P3334, DOI 10.1093/hmg/ddp274; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Pagano MA, 2007, CHEMBIOCHEM, V8, P129, DOI 10.1002/cbic.200600293; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Schwindling SL, 2004, ONCOGENE, V23, P4155, DOI 10.1038/sj.onc.1207566; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Tu YF, 2011, BBA-BIOENERGETICS, V1807, P1125, DOI 10.1016/j.bbabio.2011.04.015; von Knethen A, 2010, J CELL SCI, V123, P192, DOI 10.1242/jcs.055475; WALLIN A, 1992, LAB INVEST, V66, P474; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331	28	22	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4702	4712		10.1038/onc.2014.395	http://dx.doi.org/10.1038/onc.2014.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25486430	Green Accepted			2022-12-28	WOS:000360931500004
J	Emelyanov, A; Bulavin, DV				Emelyanov, A.; Bulavin, D. V.			Wip1 phosphatase in breast cancer	ONCOGENE			English	Review							COMPARATIVE GENOMIC HYBRIDIZATION; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR ACTIVITY; GENE-EXPRESSION PATTERNS; IN-SITU HYBRIDIZATION; NF-KAPPA-B; PROGENITOR CELLS; COPY NUMBER; PROTEIN PHOSPHATASE	Understanding the factors contributing to tumor initiation, progression and evolution is of paramount significance. Among them, wild-type p53-induced phosphatase 1 (Wip1) is emerging as an important oncogene by virtue of its negative control on several key tumor suppressor pathways. Originally discovered as a p53-regulated gene, Wip1 has been subsequently found amplified and more recently mutated in a significant fraction of human cancers including breast tumors. Recent development in the field further uncovered the utility of anti-Wip1-directed therapies in delaying tumor onset or in reducing the tumor burden. Furthermore, Wip1 could be an important factor that contributes to tumor heterogeneity, suggesting that its inhibition may decrease the rate of cancer evolution. These effects depend on several signaling pathways modulated by Wip1 phosphatase in a spatial and temporal manner. In this review we discuss the recent development in understanding how Wip1 contributes to tumorigenesis with its relevance to breast cancer.	[Emelyanov, A.; Bulavin, D. V.] Univ Nice Sophia Antipolis, Ctr Antoine Lacassagne, CNRS, IRCAN,INSERM,U1081,UMR 7284, F-06189 Nice, France; [Bulavin, D. V.] Proteos, Inst Mol & Cell Biol, Singapore, Singapore	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Bulavin, DV (corresponding author), IRCAN, Nice, France.	Dmitry.Bulavin@unice.fr		Emelyanov, Alexander/0000-0002-8693-794X	Agency for Science, Technology and Research (Singapore); Foundation ARC (France)	Agency for Science, Technology and Research (Singapore)(Agency for Science Technology & Research (A*STAR)); Foundation ARC (France)	The research for DVB was supported by the Agency for Science, Technology and Research (Singapore) and for AE and DVB by the Foundation ARC (France).	Abraham SC, 2002, HUM PATHOL, V33, P39, DOI 10.1053/hupa.2002.30196; Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ali AY, 2012, ONCOGENE, V31, P2175, DOI 10.1038/onc.2011.399; Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Axlund SD, 2012, MOL CELL ENDOCRINOL, V357, P71, DOI 10.1016/j.mce.2011.09.021; Barlund M, 2000, CANCER RES, V60, P5340; Belgnaoui SM, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-13; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Bilal E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038575; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Bransteitter R, 2009, CELL MOL LIFE SCI, V66, P3137, DOI 10.1007/s00018-009-0070-y; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Buss MC, 2015, ONCOGENE, V34, P1126, DOI 10.1038/onc.2014.37; Carr JA, 2000, ARCH SURG-CHICAGO, V135, P1469, DOI 10.1001/archsurg.135.12.1469; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chen L, 2012, BREAST CANCER RES TR, V136, P129, DOI 10.1007/s10549-012-2246-7; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Clarke RB, 1997, CANCER RES, V57, P4987; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Cooke SL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4644; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Courjal F, 1997, CANCER RES, V57, P4368; Cruickshanks HA, 2009, GENOMICS, V94, P397, DOI 10.1016/j.ygeno.2009.08.013; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Dudgeon C, 2013, CELL CYCLE, V12, P2656, DOI 10.4161/cc.25694; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; Filipponi D, 2013, CANCER CELL, V24, P528, DOI 10.1016/j.ccr.2013.08.022; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Fuku T, 2007, PATHOL INT, V57, P566, DOI 10.1111/j.1440-1827.2007.02140.x; Gasior SL, 2006, J MOL BIOL, V357, P1383, DOI 10.1016/j.jmb.2006.01.089; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/nchembio.1427, 10.1038/NCHEMBIO.1427]; Goloudina AR, 2012, CELL CYCLE, V11, P1883, DOI 10.4161/cc.19901; Goloudina AR, 2012, P NATL ACAD SCI USA, V109, pE68, DOI 10.1073/pnas.1107017108; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Helman E, 2014, GENOME RES, V24, P1053, DOI 10.1101/gr.163659.113; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Horlings HM, 2010, CLIN CANCER RES, V16, P651, DOI 10.1158/1078-0432.CCR-09-0709; Horseman ND, 2014, J MOL ENDOCRINOL, V52, pR95, DOI 10.1530/JME-13-0220; Hu Wenwei, 2010, Genes Cancer, V1, P360; Hyman E, 2002, CANCER RES, V62, P6240; Jackson SP, 2013, MOL CELL, V49, P795, DOI 10.1016/j.molcel.2013.01.017; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Jiao L, 2014, ANTICANCER RES, V34, P2919; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kasahara K, 2002, CANCER GENET CYTOGEN, V137, P59, DOI 10.1016/S0165-4608(02)00552-6; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kelemen LE, 2009, CANCER EPIDEM BIOMAR, V18, P1864, DOI 10.1158/1055-9965.EPI-08-0486; Kleiblova P, 2013, J CELL BIOL, V201, P511, DOI 10.1083/jcb.201210031; Kong WH, 2009, CANCER BIOL THER, V8, P555, DOI 10.4161/cbt.8.6.7742; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lambros MB, 2010, MODERN PATHOL, V23, P1334, DOI 10.1038/modpathol.2010.121; Lamy PJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2824; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Li GB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060775; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lonning PE, 2013, ONCOGENE, V32, P5315, DOI 10.1038/onc.2013.48; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Lowe JM, 2010, J BIOL CHEM, V285, P5249, DOI 10.1074/jbc.M109.034579; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Ma D, 2014, MOL MED REP, V10, P191, DOI 10.3892/mmr.2014.2165; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Melchor L, 2005, CLIN CANCER RES, V11, P8577, DOI 10.1158/1078-0432.CCR-05-1278; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; MIKI Y, 1992, CANCER RES, V52, P643; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Moore E, 1999, J PATHOL, V187, P403, DOI 10.1002/(SICI)1096-9896(199903)187:4<403::AID-PATH284>3.0.CO;2-J; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; Nan FF, 2012, J CANCER RES CLIN, V138, P1937, DOI 10.1007/s00432-012-1272-5; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nguyen TA, 2010, DNA REPAIR, V9, P813, DOI 10.1016/j.dnarep.2010.04.005; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Parssinen J, 2007, BRIT J CANCER, V96, P1258, DOI 10.1038/sj.bjc.6603692; Parssinen J, 2008, CANCER GENET CYTOGEN, V182, P33, DOI 10.1016/j.cancergencyto.2007.12.013; Peng TS, 2014, EXP THER MED, V8, P430, DOI 10.3892/etm.2014.1762; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Raouf A, 2012, SEMIN CELL DEV BIOL, V23, P606, DOI 10.1016/j.semcdb.2012.04.009; Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7; Rennstam K, 2003, CANCER RES, V63, P8861; Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Rodic N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003402; Rosen Jeffrey M, 2003, Breast Dis, V18, P3; Roy S, 2013, P NATL ACAD SCI USA, V110, P4598, DOI 10.1073/pnas.1218682110; Roylance R, 1999, CANCER RES, V59, P1433; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sale S, 2013, NAT CELL BIOL, V15, P451, DOI 10.1038/ncb2725; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shaltiel IA, 2014, P NATL ACAD SCI USA, V111, P7313, DOI 10.1073/pnas.1322021111; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; Shimada M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00008; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Silwal-Pandit L, 2014, CLIN CANCER RES, V20, P3569, DOI 10.1158/1078-0432.CCR-13-2943; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Smith HC, 2012, SEMIN CELL DEV BIOL, V23, P258, DOI 10.1016/j.semcdb.2011.10.004; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spike Benjamin T, 2011, Genes Cancer, V2, P404, DOI 10.1177/1947601911410224; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Tao LW, 2014, STEM CELL REP, V2, P770, DOI 10.1016/j.stemcr.2014.04.004; Tarulli GA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3381; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Ulrich HD, 2012, J CELL SCI, V125, P249, DOI 10.1242/jcs.091801; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Vogel C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.59; Wagner KU, 2004, MOL CELL BIOL, V24, P5510, DOI 10.1128/MCB.24.12.5510-5520.2004; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Yagi H, 2012, BIOORG MED CHEM LETT, V22, P729, DOI 10.1016/j.bmcl.2011.10.084; Yang DH, 2012, GLAND SURG, V1, P33, DOI [10.3978/j.issn.2227-684X.2012.04.01, 10.3978/j.issn.2227-684X.2012.04.07]; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Yu E, 2007, BREAST CANCER RES TR, V101, P269, DOI 10.1007/s10549-006-9304-y; Yu Q, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-71; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang LW, 2014, NAT GENET, V46, P726, DOI 10.1038/ng.2995; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhang XN, 2009, CANCER RES, V69, P7960, DOI 10.1158/0008-5472.CAN-09-0634; Zhu YH, 2014, J CLIN INVEST, V124, P3263, DOI 10.1172/JCI73015	169	37	39	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4429	4438		10.1038/onc.2014.375	http://dx.doi.org/10.1038/onc.2014.375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25381821				2022-12-28	WOS:000360189200002
J	Kazami, T; Nie, H; Satoh, M; Kuga, T; Matsushita, K; Kawasaki, N; Tomonaga, T; Nomura, F				Kazami, T.; Nie, H.; Satoh, M.; Kuga, T.; Matsushita, K.; Kawasaki, N.; Tomonaga, T.; Nomura, F.			Nuclear accumulation of annexin A2 contributes to chromosomal instability by coilin-mediated centromere damage	ONCOGENE			English	Article							PRIMARY COLORECTAL-CANCER; EARLY PROTEIN VMW110; MITOTIC CHECKPOINT; DNA-REPLICATION; BREAST-CANCER; HUMAN-CELLS; ANEUPLOIDY; OVEREXPRESSION; EXPRESSION; SEGREGATION	Most human cancers show chromosomal instability (CIN), but the precise mechanisms remain uncertain. Annexin A2 is frequently overexpressed in human cancers, and its relationship to tumorigenesis is poorly understood. We found that annexin A2 is overexpressed in the nuclei of CIN cells compared with cells with microsatellite instability (MIN). Ectopic annexin A2 expression in MIN cells results in a high level of aneuploidy and induces lagging chromosomes; suppression of annexin A2 in CIN cells reduces such CIN signatures with apoptosis of highly aneuploid cells. Ectopic expression of annexin A2 in MIN cells reduces the expression of centromere proteins. Conversely, annexin A2-knockdown in CIN cells increases the expression of centromere proteins. Moreover, the endogenous expression levels of centromere proteins in CIN cells were greatly reduced compared with MIN cell lines. The reduced expression of centromere proteins likely occurred due to aberrant centromere localization of coilin, a major component of the Cajal bodies. These results suggest that nuclear accumulation of annexin A2 has a crucial role in CIN by disrupting centromere function.	[Kazami, T.; Nie, H.; Satoh, M.; Matsushita, K.; Kawasaki, N.; Tomonaga, T.; Nomura, F.] Chiba Univ, Dept Mol Diag F8, Grad Sch Med, Chuo Ku, Chiba, Japan; [Kuga, T.; Kawasaki, N.; Tomonaga, T.] Natl Inst Biomed Innovat, Lab Proteome Res, Ibaraki, Osaka 5670085, Japan	Chiba University; National Institute of Health Sciences - Japan	Tomonaga, T (corresponding author), Natl Inst Biomed Innovat, Lab Proteome Res, 7-6-8 Saito Asagi, Ibaraki, Osaka 5670085, Japan.	tomonaga@nibio.go.jp	Kuga, Takahisa/AAX-9334-2020; Matsushita, Kazuyuki/AAJ-5380-2020	Matsushita, Kazuyuki/0000-0001-6742-0761	Ministry of Education, Science, Sports and Culture of Japan; Grants-in-Aid for Scientific Research [26460081] Funding Source: KAKEN	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Masumi Ishibashi and Nobuko Tanaka for technical assistance. This work was supported by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan.	Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Bayani J, 2007, SEMIN CANCER BIOL, V17, P5, DOI 10.1016/j.semcancer.2006.10.006; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chuthapisith S, 2007, INT J ONCOL, V30, P1545; Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128; Eberhard DA, 2001, J CELL SCI, V114, P3155; Esposito I, 2006, J PATHOL, V208, P673, DOI 10.1002/path.1935; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kuga T, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.6; KUMBLE KD, 1992, J CELL SCI, V101, P35; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu Jie, 2003, BMC Biochem, V4, P10, DOI 10.1186/1471-2091-4-10; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Morency E, 2007, J CELL BIOL, V177, P757, DOI 10.1083/jcb.200612107; Nishimori T, 2006, PROTEOMICS, V6, P1011, DOI 10.1002/pmic.200500262; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; Sawyers CL, 2001, SCIENCE, V294, P1834; Seimiya M, 2008, HEPATOLOGY, V48, P519, DOI 10.1002/hep.22364; Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Takano S, 2008, ANN SURG ONCOL, V15, P3157, DOI 10.1245/s10434-008-0061-5; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Tomas A, 2004, J CELL BIOL, V165, P813, DOI 10.1083/jcb.200311054; Tomonaga T, 2007, HISTOL HISTOPATHOL, V22, P191, DOI 10.14670/HH-22.191; Tomonaga T, 2005, CANCER RES, V65, P4683, DOI 10.1158/0008-5472.CAN-04-3613; Tomonaga T, 2004, CLIN CANCER RES, V10, P2007, DOI 10.1158/1078-0432.CCR-03-0321; Tomonaga T, 2003, CANCER RES, V63, P3511; VISHWANATHA JK, 1993, J CELL SCI, V105, P533; Wang JL, 2004, BBA-GEN SUBJECTS, V1673, P75, DOI 10.1016/j.bbagen.2004.03.013; Wang TL, 2004, P NATL ACAD SCI USA, V101, P3089, DOI 10.1073/pnas.0308716101; Zhang NG, 2008, P NATL ACAD SCI USA, V105, P13033, DOI 10.1073/pnas.0801610105; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	48	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4177	4189		10.1038/onc.2014.345	http://dx.doi.org/10.1038/onc.2014.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347736				2022-12-28	WOS:000359199800004
J	Sherman, MY; Gabai, VL				Sherman, M. Y.; Gabai, V. L.			Hsp70 in cancer: back to the future	ONCOGENE			English	Review							HEAT-SHOCK-PROTEIN; ONCOGENE-INDUCED SENESCENCE; SMALL-MOLECULE INHIBITOR; HEAT-SHOCK-PROTEIN-70 HSP70; BAG3 PROTEIN; HEPATOCELLULAR-CARCINOMA; PROGNOSTIC-SIGNIFICANCE; EXPRESSION PATTERNS; SELECTIVE AUTOPHAGY; PANCREATIC-CANCER	Mechanistic studies from cell culture and animal models have revealed critical roles for the heat shock protein Hsp70 in cancer initiation and progression. Surprisingly, many effects of Hsp70 on cancer have not been related to its chaperone activity, but rather to its role(s) in regulating cell signaling. A major factor that directs Hsp70 signaling activity appears to be the co-chaperone Bag3. Here, we review these recent breakthroughs, and how these discoveries drive drug development efforts.	[Sherman, M. Y.; Gabai, V. L.] Boston Univ Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Sherman, MY (corresponding author), Boston Univ Sch Med, Dept Biochem, 715 Albany St,K323, Boston, MA 02118 USA.	sherma1@bu.edu; gabai@bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718	NCI NIH HHS [R01 CA081244, R01 CA176326] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA176326, R01CA081244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092041; Afanasyeva EA, 2007, INT J CANCER, V121, P2615, DOI 10.1002/ijc.22974; Alaiya AA, 2001, CELL MOL LIFE SCI, V58, P307, DOI 10.1007/PL00000858; Assimon VA, 2013, CURR PHARM DESIGN, V19, P404; Balaburski GM, 2013, MOL CANCER RES, V11, P219, DOI 10.1158/1541-7786.MCR-12-0547-T; Bauer K, 2012, CELL ONCOL, V35, P197, DOI 10.1007/s13402-012-0079-3; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bolhassani A, 2008, EXPERT REV VACCINES, V7, P1185, DOI 10.1586/14760584.7.8.1185; Boonjaraspinyo S, 2012, PATHOL ONCOL RES, V18, P227, DOI 10.1007/s12253-011-9432-5; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Braunstein MJ, 2011, J ONCOL, V2011, DOI 10.1155/2011/232037; Buchberger A, 2010, MOL CELL, V40, P238, DOI 10.1016/j.molcel.2010.10.001; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Cai MB, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-96; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Calderwood SK, 2005, EUR J IMMUNOL, V35, P2518, DOI 10.1002/eji.200535002; Calderwood SK, 2008, INT J HYPERTHER, V24, P31, DOI 10.1080/02656730701858305; Chang L, 2011, CHEM BIOL, V18, P210, DOI 10.1016/j.chembiol.2010.12.010; Chen D, 2005, BIOCHEM PHARMACOL, V69, P1421, DOI 10.1016/j.bcp.2005.02.022; Chen HQ, 2006, FEBS LETT, V580, P3145, DOI 10.1016/j.febslet.2006.04.066; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Chuma M, 2014, CARCINOGENESIS, V35, P272, DOI 10.1093/carcin/bgt343; Chung J, 2008, P NATL ACAD SCI USA, V105, P1739, DOI 10.1073/pnas.0705799105; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Colvin TA, 2014, CANCER RES, V74, P4731, DOI 10.1158/0008-5472.CAN-14-0747; Colvin TA, 2014, CELL CYCLE, V13, P2306, DOI 10.4161/cc.29296; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dodd K, 2015, ONCOGENE, V34, P1312, DOI 10.1038/onc.2014.63; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Falco A, 2013, AM J GASTROENTEROL, V108, P1178, DOI 10.1038/ajg.2013.128; Festa M, 2011, AM J PATHOL, V178, P2504, DOI 10.1016/j.ajpath.2011.02.002; Franceschelli S, 2008, J CELL PHYSIOL, V215, P575, DOI 10.1002/jcp.21397; Franco R, 2012, J INVEST DERMATOL, V132, P252, DOI 10.1038/jid.2011.257; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gabai VL, 2009, MOL CELL BIOL, V29, P559, DOI 10.1128/MCB.01041-08; Gamerdinger M, 2011, J MOL MED, V89, P1175, DOI 10.1007/s00109-011-0795-6; Gamerdinger M, 2011, EMBO REP, V12, P149, DOI 10.1038/embor.2010.203; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Guerriero L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.143; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hellman K, 2004, BRIT J CANCER, V91, P319, DOI 10.1038/sj.bjc.6601944; Huryn DM, 2011, P NATL ACAD SCI USA, V108, P6757, DOI 10.1073/pnas.1015251108; Hwang TS, 2003, J GASTROEN HEPATOL, V18, P690, DOI 10.1046/j.1440-1746.2003.03011.x; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Iwasaki M, 2007, CANCER RES, V67, P10252, DOI 10.1158/0008-5472.CAN-07-0618; Jinwal UK, 2013, FASEB J, V27, P1450, DOI 10.1096/fj.12-220889; Joo M, 2005, J KOREAN MED SCI, V20, P829, DOI 10.3346/jkms.2005.20.5.829; Kabakov A. E., 1997, HEAT SHOCK PROTEINS; KABAKOV AE, 1995, J CELL PHYSIOL, V165, P1, DOI 10.1002/jcp.1041650102; Kassis JN, 2006, EXP CELL RES, V312, P2962, DOI 10.1016/j.yexcr.2006.05.023; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Koren J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035566; Koren J, 2010, J BIOL CHEM, V285, P2498, DOI 10.1074/jbc.M109.057208; Lee HW, 2013, VIRCHOWS ARCH, V463, P489, DOI 10.1007/s00428-013-1461-x; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Leznicki P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059590; Li D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.158; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Lopez-Lazaro M, 2002, J ENZYM INHIB MED CH, V17, P25, DOI 10.1080/14756360290011744; Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310; Luk JM, 2006, PROTEOMICS, V6, P1049, DOI 10.1002/pmic.200500306; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Malusecka E, 2008, ANTICANCER RES, V28, P501; Massey AJ, 2010, CANCER CHEMOTH PHARM, V66, P535, DOI 10.1007/s00280-009-1194-3; McCubrey JA, 2012, ONCOTARGET, V3, P954, DOI 10.18632/oncotarget.652; Meng L, 2011, ONCOGENE, V30, P2836, DOI 10.1038/onc.2011.5; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Miyata Y, 2013, ACS CHEM NEUROSCI, V4, P930, DOI 10.1021/cn300210g; Miyata Y, 2012, CHEM BIOL, V19, P1391, DOI 10.1016/j.chembiol.2012.07.026; Mo JS, 2014, TRENDS CELL BIOL, V22, P339; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Nakajima M, 2002, CANCER LETT, V178, P99, DOI 10.1016/S0304-3835(01)00825-4; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; O'Callaghan-Sunol C, 2007, CANCER RES, V67, P11779, DOI 10.1158/0008-5472.CAN-07-2441; Park CS, 1999, GYNECOL ONCOL, V74, P53, DOI 10.1006/gyno.1999.5429; Partida-Rodriguez O, 2010, INT J CANCER, V126, P1861, DOI 10.1002/ijc.24773; Patury S, 2009, CURR TOP MED CHEM, V9, P1337, DOI 10.2174/156802609789895674; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Phillips PA, 2011, CANCER LETT, V308, P181, DOI 10.1016/j.canlet.2011.05.002; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Powers MV, 2010, CELL CYCLE, V9, P1542, DOI 10.4161/cc.9.8.11204; Ramp U, 2007, HISTOL HISTOPATHOL, V22, P1099, DOI 10.14670/HH-22.1099; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Ray S, 2004, J BIOL CHEM, V279, P35604, DOI 10.1074/jbc.M401851200; Rerole AL, 2011, CANCER RES, V71, P484, DOI 10.1158/0008-5472.CAN-10-1443; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; Rodina A, 2013, CHEM BIOL, V20, P1469, DOI 10.1016/j.chembiol.2013.10.008; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Rosati A, 2012, AM J PATHOL, V181, P1524, DOI 10.1016/j.ajpath.2012.07.016; Rousaki A, 2011, J MOL BIOL, V411, P614, DOI 10.1016/j.jmb.2011.06.003; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Shin E, 2011, J HEPATO-BIL-PAN SCI, V18, P544, DOI 10.1007/s00534-010-0367-0; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Syrigos KN, 2003, UROLOGY, V61, P677, DOI 10.1016/S0090-4295(02)02289-6; Szondy K, 2012, CANCER INVEST, V30, P317, DOI 10.3109/07357907.2012.657815; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tanaka KI, 2007, J BIOL CHEM, V282, P23240, DOI 10.1074/jbc.M704081200; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017; Tao Y, 2009, CARCINOGENESIS, V30, P175, DOI 10.1093/carcin/bgn256; Tavassol F, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-10; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Tsukahara F, 2010, BLOOD, V116, P3582, DOI 10.1182/blood-2009-10-249623; Ulbricht A, 2013, CURR BIOL, V23, P430, DOI 10.1016/j.cub.2013.01.064; Voellmy R, 1996, EXS, V77, P121; Vos MJ, 2008, BIOCHEMISTRY-US, V47, P7001, DOI 10.1021/bi800639z; Walerych D, 2009, ONCOGENE, V28, P4284, DOI 10.1038/onc.2009.281; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Wang AM, 2013, NAT CHEM BIOL, V9, P112, DOI [10.1038/NCHEMBIO.1140, 10.1038/nchembio.1140]; Wang XP, 2005, WORLD J GASTROENTERO, V11, P5561, DOI 10.3748/wjg.v11.i35.5561; Wang YZ, 2010, CLIN CHEM LAB MED, V48, P1657, DOI 10.1515/CCLM.2010.304; Weng DS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3102; Wiech M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051426; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796; Yu HJ, 2013, HISTOPATHOLOGY, V62, P788, DOI 10.1111/his.12087; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	138	143	145	2	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4153	4161		10.1038/onc.2014.349	http://dx.doi.org/10.1038/onc.2014.349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347739	Green Accepted			2022-12-28	WOS:000359199800001
J	Zhou, J; Qu, Z; Yan, S; Sun, F; Whitsett, JA; Shapiro, SD; Xiao, G				Zhou, J.; Qu, Z.; Yan, S.; Sun, F.; Whitsett, J. A.; Shapiro, S. D.; Xiao, G.			Differential roles of STAT3 in the initiation and growth of lung cancer	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-2; TAX-MEDIATED TUMORIGENESIS; SQUAMOUS-CELL CARCINOMA; EPITHELIAL-CELLS; K-RAS; NUCLEAR-LOCALIZATION; SIGNAL TRANSDUCER; DNA METHYLATION; TRANSCRIPTION 3; BREAST-CANCER	Signal transducer and activator of transcription 3 (STAT3) is linked to multiple cancers, including pulmonary adenocarcinoma. However, the role of STAT3 in lung cancer pathogenesis has not been determined. Using lung epithelial-specific inducible knockout strategies, we demonstrate that STAT3 has contrasting roles in the initiation and growth of both chemically and genetically induced lung cancers. Selective deletion of lung epithelial STAT3 in mice before cancer induction by the smoke carcinogen, urethane, resulted in increased lung tissue damage and inflammation, K-Ras oncogenic mutations and tumorigenesis. Deletion of lung epithelial STAT3 after establishment of lung cancer inhibited cancer cell proliferation. Simultaneous deletion of STAT3 and expression of oncogenic K-Ras in mouse lung elevated pulmonary injury, inflammation and tumorigenesis, but reduced tumor growth. These studies indicate that STAT3 prevents lung cancer initiation by maintaining pulmonary homeostasis under oncogenic stress, whereas it facilitates lung cancer progression by promoting cancer cell growth. These studies also provide a mechanistic basis for targeting STAT3 to lung cancer therapy.	[Zhou, J.; Qu, Z.; Yan, S.; Sun, F.; Shapiro, S. D.; Xiao, G.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Zhou, J.; Qu, Z.; Yan, S.; Sun, F.; Xiao, G.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15213 USA; [Whitsett, J. A.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Neonatol Perinatal & Pulm Biol,Coll Med, Cincinnati, OH USA; [Shapiro, S. D.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xiao, G (corresponding author), Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Inst Canc, Dept Microbiol & Mol Genet, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	xiaog2@upmc.edu	SUN, FAN/GWA-1524-2022; SUN, FAN/K-8683-2017; Yan, Shapei/AAB-1347-2021	SUN, FAN/0000-0002-3538-9701; 	National Institute of Health (NIH)/National Cancer Institute (NCI) [R01 CA172090, R21 CA175252, P30 CA047904]; American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship [RSG-06-066-01-MGO]; NATIONAL CANCER INSTITUTE [R21CA175252, R01CA172090, P30CA047904] Funding Source: NIH RePORTER	National Institute of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the National Institute of Health (NIH)/National Cancer Institute (NCI) grants R01 CA172090, R21 CA175252, P30 CA047904, as well as the American Lung Association (ALA) Lung Cancer Discovery Award and American Cancer Society (ACS) Fellowship RSG-06-066-01-MGO.	Ai T, 2012, INT J BIOL MARKER, V27, pE132, DOI 10.5301/JBM.2012.9146; Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06; Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Couto JP, 2012, P NATL ACAD SCI USA, V109, pE2361, DOI 10.1073/pnas.1201232109; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Dougan M, 2011, J CLIN INVEST, V121, P2436, DOI 10.1172/JCI44796; Fu J, 2010, ONCOGENE, V29, P6499, DOI 10.1038/onc.2010.374; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Ichikawa T, 1996, CANCER LETT, V107, P165, DOI 10.1016/0304-3835(96)04351-0; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; Matsuzaki Y, 2006, J IMMUNOL, V177, P527, DOI 10.4049/jimmunol.177.1.527; Mostertz W, 2010, JAMA-J AM MED ASSOC, V303, P535, DOI 10.1001/jama.2010.80; Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049; Pan YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054565; Pectasides E, 2010, CLIN CANCER RES, V16, P2427, DOI 10.1158/1078-0432.CCR-09-2658; Peyser ND, 2013, ONCOTARGETS THER, V6, P999, DOI 10.2147/OTT.S47903; Qing GL, 2005, J BIOL CHEM, V280, P40578, DOI 10.1074/jbc.M508776200; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Qu ZX, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-23; Qu ZX, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-18; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Smith CJ, 2006, INHAL TOXICOL, V18, P667, DOI 10.1080/08958370600742821; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; WANG XR, 1995, CANCER LETT, V91, P33, DOI 10.1016/0304-3835(94)03715-U; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yan PR, 2009, NEOPLASIA, V11, P1036, DOI 10.1593/neo.09752; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104	48	49	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3804	3814		10.1038/onc.2014.318	http://dx.doi.org/10.1038/onc.2014.318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25284582	Green Accepted			2022-12-28	WOS:000358001600006
J	Cai-McRae, X; Zhong, H; Karantza, V				Cai-McRae, X.; Zhong, H.; Karantza, V.			Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; BINDING PROTEIN P62; BREAST-CANCER; BETA-CATENIN; TRASTUZUMAB RESISTANCE; IN-SITU; AUTOPHAGY; PTEN; KINASE; P62/SQSTM1	Previous studies have shown that increased levels of the adaptor protein Sequestosome 1/p62 are observed in human breast cancers and significantly correlate with HER2 overexpression. However, the role of p62 in the pathophysiology of HER2-induced mammary tumorigenesis has not yet been investigated. In this study, we report that p62 facilitates HER2-mediated cell survival in both two-dimensional and three-dimensional cell culture and that HER2-induced cellular transformation requires p62, as well as NRF2, which is known to become stabilized by its release from Kelch-like ECH-associated protein 1 (KEAP1) via p62-KEAP1 interaction. In agreement with these results, genetic ablation of p62 delays HER2-induced mammary tumorigenesis in tumor cell allografts in nude mice, and in MMTV-Neu transgenic mice. We also report that ablation of p62 impairs AKT and beta-catenin activation in association with PTEN (phosphatase and tensin homolog deleted on chromosome ten) accumulation, both in vitro and in vivo. Further in vivo studies suggest that loss of p62 also impairs NF-kappa B and NRF2 activation. Collectively, our results provide compelling evidence that p62 contributes to HER2-induced mammary tumorigenesis through multiple signaling pathways, including the PTEN/phosphoinositide-3-kinase/AKT axis, WNT/beta-catenin signaling, the NF-kappa B pathway and the NRF2-KEAP1 axis, and offer novel insights into the potential role of p62 in the regulation of the tumor suppressor PTEN.	[Cai-McRae, X.; Karantza, V.] Rutgers State Univ, New Brunswick, NJ 08903 USA; [Cai-McRae, X.; Zhong, H.; Karantza, V.] Rutgers State Univ, Rutgers Canc Inst New Jersey, Dept Med Med Oncol, New Brunswick, NJ 08903 USA; [Zhong, H.] Rutgers Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ USA; [Karantza, V.] Rutgers Robert Wood Johnson Med Sch, Dept Internal Med, Div Med Oncol, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Karantza, V (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, Dept Med Med Oncol, 195 Little Albany St,Rm 3550, New Brunswick, NJ 08903 USA.	karantzav@gmail.com						Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Chang MA, 2014, PROSTATE, V74, P149, DOI 10.1002/pros.22737; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Geetha T, 2012, J BIOL CHEM, V287, P29672, DOI 10.1074/jbc.M111.322404; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Joung I, 2005, BIOCHEM BIOPH RES CO, V334, P654, DOI 10.1016/j.bbrc.2005.06.138; Karantza-Wadsworth V, 2008, METHOD ENZYMOL, V446, P61, DOI 10.1016/S0076-6879(08)01604-2; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIU E, 1992, ONCOGENE, V7, P1027; Lozy F, 2014, AUTOPHAGY, V10, P662, DOI 10.4161/auto.27867; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Ozes ON, 1999, NATURE, V401, P82; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Park K, 2006, HISTOPATHOLOGY, V48, P702, DOI 10.1111/j.1365-2559.2006.02403.x; Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123; Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Schade B, 2013, CANCER RES, V73, P4474, DOI 10.1158/0008-5472.CAN-12-3925; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	50	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2968	2977		10.1038/onc.2014.244	http://dx.doi.org/10.1038/onc.2014.244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088198	Bronze			2022-12-28	WOS:000356100500003
J	Santonico, E; Mattioni, A; Panni, S; Belleudi, F; Mattei, M; Torrisi, MR; Cesareni, G; Castagnoli, L				Santonico, E.; Mattioni, A.; Panni, S.; Belleudi, F.; Mattei, M.; Torrisi, M. R.; Cesareni, G.; Castagnoli, L.			RNF11 is a GGA protein cargo and acts as a molecular adaptor for GGA3 ubiquitination mediated by Itch	ONCOGENE			English	Article							TRANS-GOLGI NETWORK; EAR HOMOLOGY DOMAIN; VHS DOMAINS; PROXIMITY LIGATION; GAMMA-ADAPTIN; MEMBRANE-TRANSPORT; FINGER PROTEIN; BETA-SECRETASE; SORTING-SIGNAL; MET RECEPTOR	Ring finger protein 11 (RNF11) is a RING (really interesting new gene)-H2 E3 ligase that is overexpressed in several human tumor tissues. The mature protein, which is anchored to membranes via a double acylation, localizes to early endosome and recycling compartments. Apart from its subcellular localization, additional lines of evidence implicate RNF11 in the mechanisms underlying vesicle traffic. Here we identify two acidic-cluster dileucine (Ac-LL) motifs, which are recognized by the VHS domains of Golgi-localized, gamma adaptin era-containing, ADP-ribosylation factor-binding protein (GGA) adaptors, as the molecular determinants governing RNF11 sorting at the trans-Golgi network and its internalization from the plasma membrane. We also show that RNF11 recruits itch to drive the ubiquitination of GGA3. This function is experimentally detectable only in cells overexpressing an RNF11 variant that is inactivated in the RING domain, indicating that RNF11 recruits GGA3 and controls its ubiquitination by regulating itch activity. Accordingly, our data demonstrate the involvement of itch in regulating GGA3 stability. Indeed, we observe that the endogenous levels of GGA3 are increased in cells knocked down for itch and endogenous GGA3 is hyperubiquitinated in an itch-dependent manner in a cell line expressing catalytically inactive RNF11. Our data are consistent with a model whereby the RING E3 ligase RNF11 is a novel GGA cargo actively participating in regulating the ubiquitination of the GGA protein family. The results that we are presenting put RNF11 at the center of a finally regulated system where it acts both as an adaptor and a modulator of itch-mediated control of ubiquitination events underlying membrane traffic.	[Santonico, E.; Mattioni, A.; Mattei, M.; Cesareni, G.; Castagnoli, L.] Univ Roma Tor Vergata, Dept Mol Biol, I-00133 Rome, Italy; [Panni, S.] Univ Calabria, Dept Cell Biol, I-87036 Cosenza, Italy; [Belleudi, F.; Torrisi, M. R.] Univ Roma La Sapienza, Dept Clin & Mol Med, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; [Torrisi, M. R.] Azienda Osped S Andrea, Rome, Italy; [Cesareni, G.] IRCCS Fdn S Lucia, Rome, Italy	University of Rome Tor Vergata; University of Calabria; Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Santa Lucia	Santonico, E (corresponding author), Univ Roma Tor Vergata, Dept Mol Biol, Via Ric Sci, I-00133 Rome, Italy.	Elena.Santonico@uniroma2.it	Santonico, Elena/ABB-8919-2020; Mattei, Maurizio/AAC-1303-2019; Cesareni, Gianni/AAW-1382-2020	Santonico, Elena/0000-0002-3897-8990; Mattei, Maurizio/0000-0002-0814-8873; panni, simona/0000-0002-7500-4028; Castagnoli, Luisa/0000-0001-5283-8671	MIUR; AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy [IG 10272]	MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy(Fondazione AIRC per la ricerca sul cancro)	We would like to thank Dr Elena Romano and Dr Palma Mattioli of the Centre of Advanced Microscopy (CAM) of Tor Vergata University for their skillful assistance in the use of the facility. We thank Juan Bonifacino (National Institutes of Health, Bethesda, MD, USA) for the generous gifts of myc-GGA1, GGA2 and GGA3 expression vectors and Marino Zerial (Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany) for providing the GFP constructs for Rab4, Rab5, Rab7 and Rab11. A special thanks to Natalia Speranzini for generating stable cell lines and to Gemma Biondo, Anita Palma and Daniela Posca for technical support. This work was partially supported by grants from MIUR and from AIRC-Associazione Italiana per la Ricerca sul Cancro (IG 10272), Italy.	[Anonymous], 2003, BIOCH BIOPHYS ACTA, V1639, P104; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Boucher R, 2008, HISTOCHEM CELL BIOL, V130, P315, DOI 10.1007/s00418-008-0436-5; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Burger A, 2006, NEOPLASIA, V8, P689, DOI 10.1593/neo.06469; Chen C, 2008, OBES REV, V9, P1, DOI 10.1111/j.1467-789X.2007.00429.x; Clague MJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002422; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Doray B, 2012, TRAFFIC, V13, P1315, DOI 10.1111/j.1600-0854.2012.01396.x; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Ghosh P, 2004, EUR J CELL BIOL, V83, P257, DOI 10.1078/0171-9335-00374; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hoppe T, 2005, TRENDS BIOCHEM SCI, V30, P183, DOI 10.1016/j.tibs.2005.02.004; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Kostaras E, 2013, ONCOGENE, V32, P5220, DOI 10.1038/onc.2012.554; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Mattera R, 2011, J BIOL CHEM, V286, P2022, DOI 10.1074/jbc.M110.197178; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Oberst A, 2007, P NATL ACAD SCI USA, V104, P11280, DOI 10.1073/pnas.0701773104; Pak Y, 2006, J CELL BIOL, V175, P631, DOI 10.1083/jcb.200603001; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Santonico E, 2010, ONCOGENE, V29, P5604, DOI 10.1038/onc.2010.294; Santonico Elena, 2007, BMC Biochemistry, V8, P29, DOI 10.1186/1471-2091-8-29; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Seki N, 1999, BBA-GENE STRUCT EXPR, V1489, P421, DOI 10.1016/S0167-4781(99)00190-6; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Soderberg O, 2008, METHODS, V45, P227, DOI 10.1016/j.ymeth.2008.06.014; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; van Wijk SJL, 2010, FASEB J, V24, P981, DOI 10.1096/fj.09-136259; Weibrecht I, 2010, EXPERT REV PROTEOMIC, V7, P401, DOI 10.1586/EPR.10.10; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	50	13	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3377	3390		10.1038/onc.2014.256	http://dx.doi.org/10.1038/onc.2014.256			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25195858				2022-12-28	WOS:000356871700004
J	Jansson, MD; Damas, ND; Lees, M; Jacobsen, A; Lund, AH				Jansson, M. D.; Damas, N. D.; Lees, M.; Jacobsen, A.; Lund, A. H.			miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2	ONCOGENE			English	Article							NEGATIVE REGULATOR; CELL-PROLIFERATION; GROWTH ARREST; MICRORNA; CANCER; P21(WAF1/CIP1); MODULATION; ACTIVATION; LOOP	MicroRNAs (miRNAs) regulate many key cancer-relevant pathways and may themselves possess oncogenic or tumor-suppressor functions. Consequently, miRNA dysregulation has been shown to be a prominent feature in many human cancers. The p53 tumor suppressor acts as a negative regulator of cell proliferation in response to stress and represents the most commonly lost and mutated gene in human cancers. The function of p53 is inhibited by the MDM2 oncoprotein. Using a high-throughput screening approach, we identified miR-339-5p as a regulator of the p53 pathway. We demonstrate that this regulation occurs via the ability of miR-339-5p to target directly the 3'-untranslated region of MDM2 mRNA, reducing MDM2 expression and thus promoting p53 function. Consequently, overexpression of miR-339-5p positively impacts on p53-governed cellular responses such as proliferation arrest and senescence, whereas inhibition of miR-339-5p function perturbs the p53 response in cancer cells, allowing an increased proliferation rate. In addition, miR-339-5p expression is downregulated in tumors harboring wild-type TP53, suggesting that reduction of miR-339-5p level helps to suppress the p53 response in p53-competent tumor cells. Furthermore, we show that a negative correlation between miR-339-5p and MDM2 expression exists in human cancer, implying that the interaction is important for cancer development.	[Jansson, M. D.; Damas, N. D.; Lees, M.; Lund, A. H.] Univ Copenhagen, BRIC, DK-2200 Copenhagen, Denmark; [Jansson, M. D.; Damas, N. D.; Lees, M.; Lund, A. H.] Univ Copenhagen, Ctr Epigenet, DK-2200 Copenhagen, Denmark; [Jacobsen, A.] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA	University of Copenhagen; University of Copenhagen; Memorial Sloan Kettering Cancer Center	Lund, AH (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	anders.lund@bric.ku.dk	Lund, Anders H./F-4786-2014; Skanderup, Anders Jacobsen/K-1081-2013	Lund, Anders H./0000-0002-7407-3398; Skanderup, Anders Jacobsen/0000-0001-6847-4980; Djodij Damas, Nkerorema/0000-0002-1192-7704; Jansson, Martin/0000-0002-6946-145X	Danish National Advanced Technology Foundation; Danish National Research Foundation; Novo Nordisk Foundation; Lundbeck Foundation; Danish Cancer Society; Danish Medical Research Council; Lundbeck Foundation [R100-2011-8756, R108-2012-10312] Funding Source: researchfish	Danish National Advanced Technology Foundation; Danish National Research Foundation(Danmarks Grundforskningsfond); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden)	Work in the authors' laboratory was supported by the Danish National Advanced Technology Foundation, the Danish National Research Foundation, the Novo Nordisk Foundation, the Lundbeck Foundation and the Danish Cancer Society. Dr Jansson was supported by a grant from the Danish Medical Research Council. We acknowledge the The Cancer Genome Atlas Research Network for our use of their publically available tumor data sets. We thank Bert Vogelstein and Kristian Helin for cell lines.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burns DM, 2011, NATURE, V473, P105, DOI 10.1038/nature09908; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; FOX MH, 1980, CYTOMETRY, V1, P71, DOI 10.1002/cyto.990010114; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kheir TB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-29; Kumar M, 2011, ONCOGENE, V30, P843, DOI 10.1038/onc.2010.457; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li Jun-cai, 2010, Xibei Zhiwu Xuebao, V30, P30; Lize M, 2010, CELL DEATH DIFFER, V17, P452, DOI 10.1038/cdd.2009.188; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo Y, 2012, ONCOGENE, V31, P306, DOI 10.1038/onc.2011.244; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Vispe S, 2009, MOL CANCER THER, V8, P2780, DOI 10.1158/1535-7163.MCT-09-0549; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wu ZS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-542; Xiao JN, 2011, EMBO J, V30, P524, DOI 10.1038/emboj.2010.347; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063142	46	50	55	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1908	1918		10.1038/onc.2014.130	http://dx.doi.org/10.1038/onc.2014.130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882579				2022-12-28	WOS:000352725600005
J	Xiao, F; Qiu, H; Cui, H; Ni, X; Li, J; Liao, W; Lu, L; Ding, K				Xiao, F.; Qiu, H.; Cui, H.; Ni, X.; Li, J.; Liao, W.; Lu, L.; Ding, K.			MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN; TUMOR ANGIOGENESIS; JUVENILE POLYPOSIS; COLORECTAL-CANCER; EXPRESSION; ID1; GENES; DICER; MICE; RNAS	The previous studies in this lab discovered that microRNA-885-3p (miR-885-3p) was regulated by a sulfated polysaccharide that bound to bone morphogenetic protein receptor, type IA (BMPR1A) to inhibit angiogenesis. However, its specific role and its mechanism of action in tumor cells have not been elucidated. We show that miR-885-3p markedly suppresses angiogenesis in vitro and in vivo. MiR-885-3p inhibits Smad1/5/8 phosphorylation and downregulates DNA-binding protein inhibitor ID-1 (Id1), a proangiogenic factor, by targeting BMPR1A, leading to impaired angiogenesis. Overexpression or silencing of BMPR1A affects angiogenesis in a Smad/Id1-dependent manner. We further show that miR-885-3p impairs the growth of HT-29 colon cancer cell xenografts in nude mice by suppressing angiogenesis through disruption of BMPR1A and Smad/Id1 signaling. These results support a novel role for miR-885-3p in tumor angiogenesis by targeting BMPR1A, which regulates a proangiogenic factor, and provide new evidence that targeting miRNAs might be an effective therapeutic strategy for improving colon cancer treatment.	[Xiao, F.; Qiu, H.; Cui, H.; Ni, X.; Li, J.; Liao, W.; Lu, L.; Ding, K.] Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, Shanghai 201203, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Ding, K (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Chong Zhi Rd, Shanghai 201203, Peoples R China.	dingkan@simm.ac.cn	CUI, Hengxiang/AAO-1326-2021; Qiu, Hong/C-5888-2011; Liao, Wenfeng/GQP-7033-2022	Qiu, Hong/0000-0002-4088-7828; Ding, Kan/0000-0002-8140-9259	National Natural Science Foundation of China (NSFC) [81171914, 31230022]; New Drug Creation and Manufacturing Program [2012ZX09301001-003]; National Science Fund for Distinguished Young Scholars in China [81125025]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); New Drug Creation and Manufacturing Program; National Science Fund for Distinguished Young Scholars in China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars)	This work was supported by grants from the National Natural Science Foundation of China (NSFC) (81171914, 31230022), the New Drug Creation and Manufacturing Program (2012ZX09301001-003) and the National Science Fund for Distinguished Young Scholars in China (81125025).	Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Dong Y, 2011, BRIT J CANCER, V104, P893, DOI 10.1038/bjc.2011.57; El-Bizri N, 2008, CIRC RES, V102, P380, DOI 10.1161/CIRCRESAHA.107.161059; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Goulley J, 2007, CELL METAB, V5, P207, DOI 10.1016/j.cmet.2007.01.009; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Okamoto K, 2012, EMBO J, V31, P1752, DOI 10.1038/emboj.2012.25; Perk J, 2006, CANCER RES, V66, P10870, DOI 10.1158/0008-5472.CAN-06-2643; Qiu H, 2010, J BIOL CHEM, V285, P32638, DOI 10.1074/jbc.M110.105544; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Van Hattem WA, 2008, GUT, V57, P623, DOI 10.1136/gut.2007.142927; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	26	39	45	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1968	1978		10.1038/onc.2014.134	http://dx.doi.org/10.1038/onc.2014.134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882581				2022-12-28	WOS:000352725600011
J	Xue, J; Chi, Y; Chen, Y; Huang, S; Ye, X; Niu, J; Wang, W; Pfeffer, LM; Shao, ZM; Wu, ZH; Wu, J				Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Ye, X.; Niu, J.; Wang, W.; Pfeffer, L. M.; Shao, Z-m; Wu, Z-H; Wu, J.			MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; GENE-EXPRESSION; PACLITAXEL; MICRORNAS; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDICTOR; PROMOTES	MicroRNAs (miRNAs) have been demonstrated to have critical roles in regulating cancer cell proliferation, survival and sensitivity to chemotherapy. The potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms have not been completely understood. Here, we show a strong correlation between miR-621 expression and chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients. High level of miR-621 predicts better response to PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who also tend to achieve pathological complete response. Ectopic overexpression of miR-621 promoted apoptosis and increased chemosensitivity to PTX and CBP both in cultured breast cancer cells and in xenograft tumor model. We further show that FBXO11 is a direct functional target of miR-621 and miR-621 level is negatively correlated with FBXO11 expression in breast cancer patients. Ectopic expression of FBXO11 attenuated increased apoptosis in breast cancer cells overexpressing miR-621 upon PTX or CBP treatment. Consistently, high FBXO11 expression significantly correlated with poor survival in breast cancer patients. Mechanistically, we found in breast cancer cells FBXO11 interacts with p53 and promotes its neddylation, which suppressed the p53 transactivity. Accordingly, miR-621-dependent FBXO11 suppression enhanced p53 activity and increased apoptosis in breast cancer cells exposed to chemotherapeutics. Taken together, our data suggest that miR-621 enhances chemosensitivity of breast cancer cells to PTX/CBP chemotherapy by suppressing FBXO11depedent inhibition of p53. miR-621 may serve as a predictive biomarker and a potential therapeutic target in breast cancer treatment.	[Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Shao, Z-m; Wu, J.] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China; [Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Shao, Z-m; Wu, J.] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Xue, J.; Niu, J.; Wang, W.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, 19 S Manassas St, Memphis, TN 38163 USA; [Chen, Y.] Wenzhou Med Coll, Dept Surg Oncol, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Ye, X.] Fudan Univ, Inst Merieux Lab, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Niu, J.; Wang, W.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA	Fudan University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center; Wenzhou Medical University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center	Wu, J (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Wu, ZH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, 19 S Manassas St, Memphis, TN 38163 USA.	zwu6@uthsc.edu; wujiong1122@vip.sina.com		Pfeffer, Lawrence/0000-0003-2809-1234	National Natural Science Foundation of China (NSFC) [81272924]; National Cancer Institute [R01 CA149251]; American Cancer Society [RSG-13-186-01-CSM]; NATIONAL CANCER INSTITUTE [R01CA149251] Funding Source: NIH RePORTER	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Bert Vogelstein (Johns Hopkins University) for wild-type, DICER<SUP>-/-</SUP> and p53<SUP>-/-</SUP> HCT116 cells. This work was supported in part by the National Natural Science Foundation of China (NSFC) (81272924 to JW), National Cancer Institute (R01 CA149251 to ZW), and American Cancer Society (RSG-13-186-01-CSM to ZW).	Abbas T, 2013, MOL CELL, V49, P1147, DOI 10.1016/j.molcel.2013.02.003; Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573; Bonnefoi H, 2014, ANN ONCOL, V25, P1128, DOI 10.1093/annonc/mdu118; Borst P, 2010, CELL CYCLE, V9, P4836, DOI 10.4161/cc.9.24.14326; Chang XZ, 2008, BREAST CANCER RES TR, V111, P65, DOI 10.1007/s10549-007-9761-y; Chen XS, 2010, ANN ONCOL, V21, P961, DOI 10.1093/annonc/mdq041; Chen YZ, 2011, CANCER LETT, V302, P63, DOI 10.1016/j.canlet.2010.12.014; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dhami GK, 2013, MOL CELL, V50, P565, DOI 10.1016/j.molcel.2013.04.028; Dieras V, 2004, J CLIN ONCOL, V22, P4958, DOI 10.1200/JCO.2004.02.122; Duan S, 2012, NATURE, V481, P90, DOI 10.1038/nature10688; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Iwata H, 2011, JPN J CLIN ONCOL, V41, P867, DOI 10.1093/jjco/hyr081; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lawrence G, 2002, J CLIN ONCOL, V20, P2905, DOI 10.1200/JCO.2002.20.12.2905; Lee JK, 2010, CLIN CANCER RES, V16, P711, DOI 10.1158/1078-0432.CCR-09-2247; Li JY, 2012, BREAST CANCER RES TR, V131, P837, DOI 10.1007/s10549-011-1502-6; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Mamounas EP, 2012, J CLIN ONCOL, V30, P3960, DOI 10.1200/JCO.2011.40.8369; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Nowak AK, 2004, LANCET ONCOL, V5, P372, DOI 10.1016/S1470-2045(04)01494-9; Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Shivdasani RA, 2006, BLOOD, V108, P3646, DOI 10.1182/blood-2006-01-030015; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Skawran B, 2008, MODERN PATHOL, V21, P1479, DOI 10.1038/modpathol.2008.147; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Tabchy A, 2010, CLIN CANCER RES, V16, P5351, DOI 10.1158/1078-0432.CCR-10-1265; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Walerych D, 2012, CARCINOGENESIS, V33, P2007, DOI 10.1093/carcin/bgs232; Wang H, 2012, PLOS ONE, V7, P34210, DOI DOI 10.1371/J0URNAL.P0NE.0034210; Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125; Wu X, 2009, BIOINFORMATICS, V25, P832, DOI 10.1093/bioinformatics/btp059; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang CH, 2015, J BIOL CHEM, V290, P6037, DOI 10.1074/jbc.M114.632125; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337	50	84	86	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					448	458		10.1038/onc.2015.96	http://dx.doi.org/10.1038/onc.2015.96			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867061	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000369056700005
J	Lee, KM; Nam, K; Oh, S; Lim, J; Kim, RK; Shim, D; Choi, JH; Lee, SJ; Yu, JH; Lee, JW; Ahn, SH; Shin, I				Lee, K-m; Nam, K.; Oh, S.; Lim, J.; Kim, R. K.; Shim, D.; Choi, J-h; Lee, S-J; Yu, J-H; Lee, J. W.; Ahn, S. H.; Shin, I.			ECM1 regulates tumor metastasis and CSC-like property through stabilization of beta-catenin	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX PROTEIN-1; NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; LYMPHATIC METASTASIS; SELF-RENEWAL; CANCER; EXPRESSION; IDENTIFICATION; ACTIVATION	Extracellular Matrix Protein 1 (ECM1) is a marker for tumorigenesis and is correlated with invasiveness and poor prognosis in various types of cancer. However, the functional role of ECM1 in cancer metastasis is unclear. Here, we detected high ECM1 level in breast cancer patient sera that was associated with recurrence of tumor. The modulation of ECM1 expression affected not only cell migration and invasion, but also sphere-forming ability and drug resistance in breast cancer cell lines. In addition, ECM1 regulated the gene expression associated with the epithelial to mesenchymal transition (EMT) progression and cancer stem cell (CSC) maintenance. Interestingly, ECM1 increased beta-catenin expression at the post-translational level through induction of MUC1, which was physically associated with beta-catenin. Indeed, the association between beta-catenin and the MUC1 cytoplasmic tail was increased by ECM1. Furthermore, forced expression of beta-catenin altered the gene expression that potentiated EMT progression and CSC phenotype maintenance in the cells. These data provide evidence that ECM1 has an important role in cancer metastasis through beta-catenin stabilization.	[Lee, K-m; Nam, K.; Oh, S.; Lim, J.; Kim, R. K.; Shim, D.; Choi, J-h; Lee, S-J; Shin, I.] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea; [Yu, J-H; Lee, J. W.; Ahn, S. H.] Univ Ulsan, Coll Med, Dept Surg, Seoul, South Korea; [Yu, J-H; Lee, J. W.; Ahn, S. H.] Asan Med Ctr, Seoul, South Korea; [Shin, I.] Hanyang Univ, Nat Sci Inst, Seoul 133791, South Korea	Hanyang University; University of Ulsan; Hanyang University	Shin, I (corresponding author), Hanyang Univ, Dept Life Sci, Haengdang 1 Dong, Seoul 133791, South Korea.	incheol@hanyang.ac.kr	Lee, kyung-min/ABH-7692-2020; Choi, Jae-Hoon/R-6224-2016	Lee, kyung-min/0000-0001-8381-2423; Choi, Jae-Hoon/0000-0002-5265-3463	NRF grant from the Korea Research Foundation [2013-059143]; Converging Research Center Program [2014048814]	NRF grant from the Korea Research Foundation; Converging Research Center Program	This work was supported by an NRF grant (2013-059143) from the Korea Research Foundation and Converging Research Center Program (2014048814).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Gu MZ, 2013, INT J CLIN EXP PATHO, V6, P1132; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Horvay K, 2011, STEM CELLS DEV, V20, P737, DOI 10.1089/scd.2010.0188; Howe LR, 2003, CANCER RES, V63, P1906; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kebebew E, 2005, ANN SURG, V242, P353, DOI 10.1097/sla.0000179623.87329.6b; Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381; Lal G, 2009, ANN SURG ONCOL, V16, P2280, DOI 10.1245/s10434-009-0533-2; Lee KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0479-6; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Liu W, 2012, J INVEST DERMATOL, V132, P2828, DOI 10.1038/jid.2012.211; Maier HJ, 2010, CANCER LETT, V295, P214, DOI 10.1016/j.canlet.2010.03.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATHIEU E, 1994, J BONE MINER RES, V9, P903; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Neth P, 2007, STEM CELL REV, V3, P18, DOI 10.1007/s12015-007-0001-y; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sakai D, 2005, DEV GROWTH DIFFER, V47, P471, DOI 10.1111/j.1440-169X.2005.00821.x; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Takao Y, 2007, BIOCHEM BIOPH RES CO, V353, P699, DOI 10.1016/j.bbrc.2006.12.072; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tanida S, 2014, BBA-GEN SUBJECTS, V1840, P1790, DOI 10.1016/j.bbagen.2014.02.008; Wang LP, 2003, CANCER LETT, V200, P57, DOI 10.1016/S0304-3835(03)00350-1; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Wu QW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-47; Wu QW, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-132; Xiong GP, 2012, NEOPLASMA, V59, P409, DOI 10.4149/neo_2012_053; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhao QC, 2009, CANCER RES, V69, P6799, DOI 10.1158/0008-5472.CAN-09-1096	46	54	57	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6055	6065		10.1038/onc.2015.54	http://dx.doi.org/10.1038/onc.2015.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25746001				2022-12-28	WOS:000366113800003
J	Cao, K; Wang, G; Li, W; Zhang, L; Wang, R; Huang, Y; Du, L; Jiang, J; Wu, C; He, X; Roberts, AI; Li, F; Rabson, AB; Wang, Y; Shi, Y				Cao, K.; Wang, G.; Li, W.; Zhang, L.; Wang, R.; Huang, Y.; Du, L.; Jiang, J.; Wu, C.; He, X.; Roberts, A. I.; Li, F.; Rabson, A. B.; Wang, Y.; Shi, Y.			Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity	ONCOGENE			English	Article							T-CELLS; MEDIATED APOPTOSIS; TRANSCRIPTION FACTORS; MOLECULAR-MECHANISMS; CANCER PROGRESSION; CYCLOSPORINE-A; EXPRESSION; THERAPY; TUMORS; ANTIBODY	The poor efficacy of the in vivo anti-tumor immune response has been partially attributed to ineffective T-cell responses mounted against the tumor. Fas-FasL-dependent activation-induced cell death (AICD) of T cells is believed to be a major contributor to compromised anti-tumor immunity. The molecular mechanisms of AICD are well-investigated, yet the possibility of regulating AICD for cancer therapy remains to be explored. In this study, we show that histone deacetylase inhibitors (HDACIs) can inhibit apoptosis of CD4(+) T cells within the tumor, thereby enhancing anti-tumor immune responses and suppressing melanoma growth. This inhibitory effect is specific for AICD through suppressing NFAT1-regulated FasL expression on activated CD4(+) T cells. In gld/gld mice with mutation in FasL, the beneficial effect of HDACIs on AICD of infiltrating CD4(+) T cells is not seen, confirming the critical role of FasL regulation in the anti-tumor effect of HDACIs. Importantly, we found that the co-administration of HDACIs and anti-CTLA4 could further enhance the infiltration of CD4(+) T cells and achieve a synergistic therapeutic effect on tumor. Therefore, our study demonstrates that the modulation of AICD of tumor-infiltrating CD4(+) T cells using HDACIs can enhance anti-tumor immune responses, uncovering a novel mechanism underlying the anti-tumor effect of HDACIs.	[Cao, K.; Wang, G.; Li, W.; Huang, Y.; Du, L.; Li, F.; Wang, Y.; Shi, Y.] Shanghai Jiao Tong Univ Med, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, Shanghai, Peoples R China; [Zhang, L.; Roberts, A. I.; Rabson, A. B.; Shi, Y.] Rutgers Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Zhang, L.; Shi, Y.] Soochow Univ, Affiliated Hosp 1, Inst Translat Med, Suzhou 215123, Peoples R China; [Wang, R.] Cedars Sinai Med Ctr, Dept Med, Urooncol Res, Los Angeles, CA 90048 USA; [Jiang, J.; Wu, C.; He, X.] Soochow Univ, Affiliated Hosp 3, Changzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Soochow University - China; Cedars Sinai Medical Center; Soochow University - China	Shi, Y (corresponding author), Soochow Univ, Affiliated Hosp 1, Inst Translat Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	yingwang@sibs.ac.cn; yfshi@suda.edu.cn	cao, kai/AAG-6833-2021; Shi, Yufang/AAE-4431-2020; HUANG, YIN/AAH-6871-2020; Du, Liming/M-8227-2019	Shi, Yufang/0000-0001-8964-319X; HUANG, YIN/0000-0001-5602-9871; Du, Liming/0000-0002-0527-3556; cao, kai/0000-0002-7939-7279; wang, ying/0000-0002-2571-9367	Scientific Innovation Project of the Chinese Academy of Science [XDA 01040107, XDA 01040110]; Programs of National Natural Science of China [81330046]; Ministry of Science and Technology of China [2015CB964400]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Municipal Key Projects of Basic Research [12JC1409200]; Shanghai Rising-Star Program [14QA1404200]; Robert Wood Johnson Foundation [67038]	Scientific Innovation Project of the Chinese Academy of Science; Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Municipal Key Projects of Basic Research; Shanghai Rising-Star Program; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	This work was supported by grants from the Scientific Innovation Project of the Chinese Academy of Science (XDA 01040107 and XDA 01040110), the Programs of National Natural Science of China (81330046), the Ministry of Science and Technology of China (2015CB964400), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Municipal Key Projects of Basic Research (12JC1409200), Shanghai Rising-Star Program (14QA1404200). The Child Health Institute of New Jersey is supported by a grant from the Robert Wood Johnson Foundation (grant number 67038).	Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bolger TA, 2005, J NEUROSCI, V25, P9544, DOI 10.1523/JNEUROSCI.1826-05.2005; Boni A, 2008, BLOOD, V112, P4746, DOI 10.1182/blood-2008-07-169797; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Butler LM, 2000, CANCER RES, V60, P5165; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Devadas S, 2006, IMMUNITY, V25, P237, DOI 10.1016/j.immuni.2006.06.011; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jacobson M.D., 1996, BIOCH SCI, V21, P83, DOI DOI 10.1016/S0968-0004(96)20008-8; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Liu FY, 2012, J BIOL CHEM, V287, P25530, DOI 10.1074/jbc.M112.356279; Maecker HL, 2002, CANCER CELL, V2, P139, DOI 10.1016/S1535-6108(02)00095-8; Manicassainy S, 2007, J IMMUNOL, V178, P312, DOI 10.4049/jimmunol.178.1.312; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; MERION RM, 1984, NEW ENGL J MED, V310, P148, DOI 10.1056/NEJM198401193100303; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moreira JMA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-30; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Swann JB, 2007, J CLIN INVEST, V117, P1137, DOI 10.1172/JCI31405; Tanaka T, 2002, CANCER LETT, V181, P165, DOI 10.1016/S0304-3835(01)00799-6; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Wang RX, 1998, J IMMUNOL, V161, P2201; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Xu GW, 2007, CELL RES, V17, P759, DOI 10.1038/cr.2007.52; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yu P, 2006, LAB INVEST, V86, P231, DOI 10.1038/labinvest.3700389; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029	49	51	51	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5960	5970		10.1038/onc.2015.46	http://dx.doi.org/10.1038/onc.2015.46			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25745993	Green Published, hybrid			2022-12-28	WOS:000366113500003
J	Schenk, B; Fulda, S				Schenk, B.; Fulda, S.			Reactive oxygen species regulate Smac mimetic/TNF alpha-induced necroptotic signaling and cell death	ONCOGENE			English	Article							MIXED LINEAGE KINASE; DOMAIN-LIKE; PROGRAMMED NECROSIS; COMPLEX I; APOPTOSIS; DOWNSTREAM; ACTIVATION; RESISTANCE; RIP3; FADD	Necroptosis represents a key programmed cell death pathway involved in various physiological and pathophysiological conditions. However, the role of reactive oxygen species (ROS) in necroptotic signaling has remained unclear. In the present study, we identify ROS as critical regulators of BV6/tumor necrosis factor-alpha (TNF alpha)-induced necroptotic signaling and cell death. We show that BV6/TNF alpha-induced cell death depends on ROS production, as several ROS scavengers such as butylated hydroxyanisole, N-acetylcysteine, alpha-tocopherol and ethyl pyruvate significantly rescue cell death. Before cell death, BV6/TNF alpha-stimulated ROS generation promotes stabilization of the receptor-interacting protein kinase 1 (RIP1)/RIP3 necrosome complex via a potential positive feedback loop, as on the one hand radical scavengers attenuate RIP1/RIP3 necrosome assembly and phosphorylation of mixed lineage kinase domain like (MLKL), but on the other hand silencing of RIP1 or RIP3 reduces ROS production. Although MLKL knockdown effectively decreases BV6/TNF alpha-induced cell death, it does not affect RIP1/RIP3 interaction and only partly reduces ROS generation. Moreover, the deubiquitinase cylindromatosis (CYLD) promotes BV6/TNF alpha-induced ROS generation and necrosome assembly even in the presence of BV6, as CYLD silencing attenuates these events. Genetic silencing of phosphoglycerate mutase 5 or dynamin-related protein 1 (Drp1) fails to protect against BV6/TNF alpha-induced cell death. By demonstrating that ROS are involved in regulating BV6/TNF alpha-induced necroptotic signaling, our study provides new insights into redox regulation of necroptosis.	[Schenk, B.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60054 Frankfurt, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60054 Frankfurt, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft [SFB815]; BMBF	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF))	We thank D Vucic (Genentech Inc., South San Francisco, CA, USA) for providing Smac mimetic, X Wang (Beijing, China) for providing anti-RIP3 and anti-PGAM5 antibodies and C Hugenberg for expert secretarial assistance. This work has been partially supported by the Deutsche Forschungsgemeinschaft (SFB815) and the BMBF.	Arslan SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026069; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chen TY, 2009, FREE RADICAL BIO MED, V46, P643, DOI 10.1016/j.freeradbiomed.2008.11.022; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Coupienne I, 2011, PHOTOCH PHOTOBIO SCI, V10, P1868, DOI 10.1039/c1pp05213f; Davis CW, 2010, FREE RADICAL BIO MED, V48, P306, DOI 10.1016/j.freeradbiomed.2009.11.001; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Han D, 2009, ANTIOXID REDOX SIGN, V11, P2245, DOI [10.1089/ars.2009.2611, 10.1089/ARS.2009.2611]; He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Held JM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.R111.013037; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149; Irrinki KM, 2011, MOL CELL BIOL, V31, P3745, DOI 10.1128/MCB.05303-11; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kikuchi M, 2012, J BIOL CHEM, V287, P41165, DOI 10.1074/jbc.M112.419747; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kulathu Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2567; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Luedde M, 2014, CARDIOVASC RES, V103, P206, DOI 10.1093/cvr/cvu146; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; Morgan MJ, 2010, MOL CELLS, V30, P1, DOI 10.1007/s10059-010-0105-0; Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018; Remijsen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.531; Roca FJ, 2013, CELL, V153, P521, DOI 10.1016/j.cell.2013.03.022; Shindo R, 2015, BIOCHEM BIOPH RES CO, V436, P212; Shulga N, 2014, J CELL SCI, V127, P896, DOI 10.1242/jcs.140764; Shulga N, 2012, J CELL SCI, V125, P2995, DOI 10.1242/jcs.103093; Song KJ, 2011, PARASITE IMMUNOL, V33, P390, DOI 10.1111/j.1365-3024.2011.01297.x; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tait SWG, 2013, CELL REP, V5, P878, DOI 10.1016/j.celrep.2013.10.034; Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Vanlangenakker N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.111; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vernon PJ, 2013, ANTIOXID REDOX SIGN, V18, P677, DOI 10.1089/ars.2012.4810; Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Ye YC, 2012, INT IMMUNOPHARMACOL, V14, P674, DOI 10.1016/j.intimp.2012.08.003; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	53	152	160	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5796	5806		10.1038/onc.2015.35	http://dx.doi.org/10.1038/onc.2015.35			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25867066				2022-12-28	WOS:000365035200003
J	Barakat, DJ; Zhang, J; Barberi, T; Denmeade, SR; Friedman, AD; Paz-Priel, I				Barakat, D. J.; Zhang, J.; Barberi, T.; Denmeade, S. R.; Friedman, A. D.; Paz-Priel, I.			CCAAT/Enhancer binding protein beta controls androgen-deprivation-induced senescence in prostate cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SP1; C/EBP-BETA; GENE-EXPRESSION; SECRETORY PHENOTYPE; RECEPTOR; PROLIFERATION; DIFFERENTIATION; THERAPY; ALPHA; OVEREXPRESSION	The processes associated with transition to castration-resistant prostate cancer (PC) growth are not well understood. Cellular senescence is a stable cell cycle arrest that occurs in response to sublethal stress. It is often overcome in malignant transformation to confer a survival advantage. CCAAT/Enhancer Binding Protein (C/EBP) beta function is frequently deregulated in human malignancies and interestingly, androgen-sensitive PC cells express primarily the liver-enriched inhibitory protein isoform. We found that C/EBP beta expression is negatively regulated by androgen receptor (AR) activity and that treatment of androgen-sensitive cell lines with anti-androgens increases C/EBP beta mRNA and protein levels. Accordingly, we also find that C/EBP beta levels are significantly elevated in primary PC samples from castration-resistant compared with therapy-naive patients. Chromatin immunoprecipitation demonstrated enhanced binding of the AR to the proximal promoter of the CEBPB gene in the presence of dihydroxytestosterone. Upon androgen deprivation, induction of C/EBP beta is facilitated by active transcription as evident by increased histone 3 acetylation at the C/EBP beta promoter. Also, the androgen agonist R1881 suppresses the activity of a CEBPB promoter reporter. Loss of C/EBP beta expression prevents growth arrest following androgen deprivation or anti-androgen challenge. Accordingly, suppression of C/EBP beta under low androgen conditions results in reduced expression of senescence-associated secretory genes, significantly decreased number of cells displaying heterochromatin foci and increased numbers of Ki67-positive cells. Ectopic expression of C/EBP beta caused pronounced morphological changes, reduced PC cell growth and increased the number of senescent LNCaP cells. Lastly, we found that senescence contributes to PC cell survival under androgen deprivation, and C/EBP beta-deficient cells were significantly more susceptible to killing by cytotoxic chemotherapy following androgen deprivation. Our data demonstrate that upregulation of C/EBP beta is critical for complete maintenance of androgen deprivation-induced senescence and that targeting C/EBP beta expression may synergize with anti-androgen or chemotherapy in eradicating PC.	[Barakat, D. J.; Zhang, J.; Barberi, T.; Friedman, A. D.; Paz-Priel, I.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; [Denmeade, S. R.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Med Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Paz-Priel, I (corresponding author), Johns Hopkins Univ, Bunting Blaustein Canc Res Bldg 1,Room 208,1650 O, Baltimore, MD 21231 USA.	ipazpri1@jhmi.edu		Barakat, David/0000-0001-7057-178X	St Baldrick's Foundation; Mitchell Foundation; Walsh Prostate Cancer Research Fund; Samuel Waxman Cancer Research Foundation; Department of Defense [PC131609]; National Institutes of Health [T32 CA60441]; Giant Food Children's Cancer Research Fund;  [P30 CA006973]; NATIONAL CANCER INSTITUTE [P30CA006973, T32CA060441] Funding Source: NIH RePORTER	St Baldrick's Foundation; Mitchell Foundation; Walsh Prostate Cancer Research Fund; Samuel Waxman Cancer Research Foundation; Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Giant Food Children's Cancer Research Fund; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the St Baldrick's Foundation (to IP-P), the Mitchell Foundation (to IP-P), the Walsh Prostate Cancer Research Fund (to IP-P and ADF), the Samuel Waxman Cancer Research Foundation (to ADF), Department of Defense grant PC131609 (to DJB), National Institutes of Health T32 CA60441 (to TB), the Giant Food Children's Cancer Research Fund and P30 CA006973.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; American Cancer Society, 2013, CANC FACTS FIG 2013; Bagchi MK, 2006, CELL CYCLE, V5, P922, DOI 10.4161/cc.5.9.2712; Baretton GB, 1999, BRIT J CANCER, V80, P546, DOI 10.1038/sj.bjc.6690390; Bavik C, 2006, CANCER RES, V66, P794, DOI 10.1158/0008-5472.CAN-05-1716; Bedell VM, 2012, NATURE, V491, P114, DOI 10.1038/nature11537; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Burton DGA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068003; Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cermak T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr218; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Dean JP, 2008, BRIT J CANCER, V98, P245, DOI 10.1038/sj.bjc.6604087; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Denmeade S R, 1996, Adv Pharmacol, V35, P281, DOI 10.1016/S1054-3589(08)60278-1; Denmeade SR, 1996, PROSTATE, V28, P251; Ewald JA, 2013, PROSTATE, V73, P337, DOI 10.1002/pros.22571; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Henshall SM, 2001, CLIN CANCER RES, V7, P544; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Kawabata R, 2011, INT J ONCOL, V38, P1489, DOI 10.3892/ijo.2011.991; Kim MH, 2008, PROSTATE, V68, P1362, DOI 10.1002/pros.20801; Kim MH, 2009, PROSTATE, V69, P1435, DOI 10.1002/pros.20993; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kurz DJ, 2000, J CELL SCI, V113, P3613; Lee CT, 1999, CLIN CANCER RES, V5, P977; Lehmann BD, 2008, CANCER RES, V68, P7864, DOI 10.1158/0008-5472.CAN-07-6538; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; MacManus CF, 2007, MOL CANCER RES, V5, P737, DOI 10.1158/1541-7786.MCR-07-0032; Manna S, 2013, J IMMUNOL, V191, P2837, DOI 10.4049/jimmunol.1300895; Mantena SR, 2006, P NATL ACAD SCI USA, V103, P1870, DOI 10.1073/pnas.0507261103; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Mehta HH, 2011, CANCER RES, V71, P5154, DOI 10.1158/0008-5472.CAN-10-4513; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Paz-Priel I, 2011, BLOOD, V117, P4085, DOI 10.1182/blood-2010-07-294470; Pernicova Z, 2011, NEOPLASIA, V13, P526, DOI 10.1593/neo.11182; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Seaton A, 2008, CARCINOGENESIS, V29, P1148, DOI 10.1093/carcin/bgn109; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Steinman RA, 2000, MOL MED, V6, P736, DOI 10.1007/BF03402190; Svensson C, 2014, NUCLEIC ACIDS RES, V42, P999, DOI 10.1093/nar/gkt921; Tanabe A, 2000, BIOL PHARM BULL, V23, P1424, DOI 10.1248/bpb.23.1424; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Wang WZ, 2007, PROSTATE, V67, P1238, DOI 10.1002/pros.20595; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Yuan HQ, 2005, CARCINOGENESIS, V26, P793, DOI 10.1093/carcin/bgi021; Yusa K, 2011, P NATL ACAD SCI USA, V108, P1531, DOI 10.1073/pnas.1008322108; Zhang ZH, 2006, MODERN PATHOL, V19, P1339, DOI 10.1038/modpathol.3800655; Zhou JF, 2001, CANCER RES, V61, P2328	57	23	23	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5912	5922		10.1038/onc.2015.41	http://dx.doi.org/10.1038/onc.2015.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25772238	Green Accepted			2022-12-28	WOS:000365434000006
J	Kinugasa, H; Whelan, KA; Tanaka, K; Natsuizaka, M; Long, A; Guo, A; Chang, S; Kagawa, S; Srinivasan, S; Guha, M; Yamamoto, K; St Clair, DK; Avadhani, NG; Diehl, JA; Nakagawa, H				Kinugasa, H.; Whelan, K. A.; Tanaka, K.; Natsuizaka, M.; Long, A.; Guo, A.; Chang, S.; Kagawa, S.; Srinivasan, S.; Guha, M.; Yamamoto, K.; St Clair, D. K.; Avadhani, N. G.; Diehl, J. A.; Nakagawa, H.			Mitochondrial SOD2 regulates epithelial-mesenchymal transition and cell populations defined by differential CD44 expression	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; NF-KAPPA-B; OXIDATIVE STRESS; CANCER; EMT; PROMOTES; GROWTH; GENE; IDENTIFICATION; ACTIVATION	Epithelial-mesenchymal transition (EMT) promotes cancer cell invasion, metastasis and treatment failure. EMT may be activated in cancer cells by reactive oxygen species (ROS). EMT may promote conversion of a subset of cancer cells from a CD44(low)-CD24(high) (CD44L) epithelial phenotype to a CD44(high)-CD24(-/low) (CD44H) mesenchymal phenotype, the latter associated with increased malignant properties of cancer cells. ROS are required for cells undergoing EMT, although excessive ROS may induce cell death or senescence; however, little is known as to how cellular antioxidant capabilities may be regulated during EMT. Mitochondrial superoxide dismutase 2 (SOD2) is frequently overexpressed in oral and esophageal cancers. Here, we investigate mechanisms of SOD2 transcriptional regulation in EMT, as well as the functional role of this antioxidant in EMT. Using well-characterized genetically engineered oral and esophageal human epithelial cell lines coupled with RNA interference and flow cytometric approaches, we find that transforming growth factor (TGF)-beta stimulates EMT, resulting in conversion of CD44L to CD44H cells, the latter of which display SOD2 upregulation. SOD2 induction in transformed keratinocytes was concurrent with suppression of TGF-beta-mediated induction of both ROS and senescence. SOD2 gene expression appeared to be transcriptionally regulated by NF-kappa B and ZEB2, but not ZEB1. Moreover, SOD2-mediated antioxidant activity may restrict conversion of CD44L cells to CD44H cells at the early stages of EMT. These data provide novel mechanistic insights into the dynamic expression of SOD2 during EMT. In addition, we delineate a functional role for SOD2 in EMT via the influence of this antioxidant upon distinct CD44L and CD44H subsets of cancer cells that have been implicated in oral and esophageal tumor biology.	[Kinugasa, H.; Whelan, K. A.; Tanaka, K.; Natsuizaka, M.; Long, A.; Guo, A.; Chang, S.; Kagawa, S.; Diehl, J. A.; Nakagawa, H.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; [Kinugasa, H.; Whelan, K. A.; Tanaka, K.; Natsuizaka, M.; Long, A.; Guo, A.; Chang, S.; Kagawa, S.; Diehl, J. A.; Nakagawa, H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Kinugasa, H.; Yamamoto, K.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan; [Natsuizaka, M.] Hokkaido Univ, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan; [Srinivasan, S.; Guha, M.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Srinivasan, S.; Guha, M.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [St Clair, D. K.] Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, Lexington, KY USA; [Diehl, J. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Okayama University; Hokkaido University; University of Pennsylvania; University of Pennsylvania; University of Kentucky; Medical University of South Carolina	Nakagawa, H (corresponding author), Univ Penn, Dept Med, Div Gastroenterol, 421Curie Blvd,956 BRB, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu		Natsuizaka, Mitsuteru/0000-0002-1819-1955	NIH [P01CA098101, F32CA174176, F30CA175133, K26RR032714, R01CA073599]; Pennsylvania CURE Program Grant; Edward P. Evans Foundation; University of Pennsylvania University Research Foundation Award; University of Pennsylvania, Abramson Cancer Center Pilot Project Grant; NATIONAL CANCER INSTITUTE [F31CA174176, R01CA073599, P30CA177558, R01CA022762, P01CA098101, F32CA174146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR032714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K26OD011179] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania CURE Program Grant; Edward P. Evans Foundation; University of Pennsylvania University Research Foundation Award; University of Pennsylvania, Abramson Cancer Center Pilot Project Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to the Molecular Pathology & Imaging, Molecular Biology/Gene Expression and Cell Culture Core Facilities of the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306) and of the NIH P01CA098101. This study was supported in part by NIH Grants P01CA098101 (to HK, KAW, KT, MN, AL, AG, SC, SK, JAD and HN), F32CA174176 (KAW), F30CA175133 (AL), K26RR032714 (HN), R01CA073599 (DKS) as well as Pennsylvania CURE Program Grant (HN), the Edward P. Evans Foundation (DKS), University of Pennsylvania University Research Foundation Award (HN) and University of Pennsylvania, Abramson Cancer Center Pilot Project Grant (HN).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bai XY, 2011, J AM SOC NEPHROL, V22, P1252, DOI 10.1681/ASN.2010040367; Chaudhuri L, 2012, ONCOGENE, V31, P1207, DOI 10.1038/onc.2011.325; Chen PM, 2013, CARCINOGENESIS, V34, P2655, DOI 10.1093/carcin/bgt220; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Connor KM, 2007, CANCER RES, V67, P10260, DOI 10.1158/0008-5472.CAN-07-1204; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233; Dhar SK, 2012, FREE RADICAL BIO MED, V52, P2209, DOI 10.1016/j.freeradbiomed.2012.03.009; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Gammon L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062493; Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ji GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069351; Ju XM, 2014, CANCER RES, V74, P508, DOI 10.1158/0008-5472.CAN-13-1313; Kagawa S, 2015, ONCOGENE, V34, P2347, DOI 10.1038/onc.2014.169; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kriegel AJ, 2010, NUCLEIC ACIDS RES, V38, P8338, DOI 10.1093/nar/gkq718; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lin CH, 2013, INT J MOL SCI, V14, P13266, DOI 10.3390/ijms140713266; Liu Xiqiang, 2009, Cancer Genomics & Proteomics, V6, P131; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng XQ, 2013, GASTROENTEROLOGY, V145, P426, DOI 10.1053/j.gastro.2013.04.004; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nam EH, 2014, CARCINOGENESIS, V35, P302, DOI 10.1093/carcin/bgt340; Nam EH, 2012, CARCINOGENESIS, V33, P563, DOI 10.1093/carcin/bgs005; Natsuizaka M, 2014, AM J CANCER RES, V4, P29; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Wang Q, 2008, FASEB J, V22, P4126, DOI 10.1096/fj.08-112326; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Yeh CC, 1998, DNA CELL BIOL, V17, P921, DOI 10.1089/dna.1998.17.921; Yoon YS, 2005, ONCOGENE, V24, P1895, DOI 10.1038/sj.onc.1208262; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhou GF, 2009, AM J PHYSIOL-LUNG C, V297, pL1120, DOI 10.1152/ajplung.00007.2009; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	52	52	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5229	5239		10.1038/onc.2014.449	http://dx.doi.org/10.1038/onc.2014.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25659582	Green Accepted			2022-12-28	WOS:000362575400003
J	Chen, J; Lan, T; Zhang, W; Dong, L; Kang, N; Zhang, S; Fu, M; Liu, B; Liu, K; Zhang, C; Hou, J; Zhan, Q				Chen, J.; Lan, T.; Zhang, W.; Dong, L.; Kang, N.; Zhang, S.; Fu, M.; Liu, B.; Liu, K.; Zhang, C.; Hou, J.; Zhan, Q.			Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma	ONCOGENE			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR-RECEPTOR; PROTEIN-COUPLED RECEPTORS; BREAST-CANCER CELLS; VEIN ENDOTHELIAL-CELLS; FACTOR PAF; PHOSPHATIDYLINOSITOL 3-KINASE; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHATIDIC ACID; OPIOID RECEPTORS	Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide and occurs at a relatively high frequency in China, yet the mechanisms underlying its devastating outcome remain unclear. Here we report that platelet-activating factor receptor (PAFR), a type of G-protein-coupled receptor, was upregulated in ESCC tumors and cell lines, compared with controls; PAFR levels were positively correlated with ESCC clinical stages and survival time. Overexpression of PAFR promoted the malignant development of ESCC in vitro and in vivo, whereas depletion of PAFR suppressed these effects. Interestingly, PAFR was observed to activate PI3K/AKT (phosphatidylinositol 3-kinase/AKT) through the upregulation of FAK kinase activity. AKT-triggered nuclear factor-kappa B transcriptionally activated PAFR expression. This mutual positive regulation between PAFR and AKT was required for the aggressiveness of ESCC cells both in vitro and in vivo. Furthermore, treating mice bearing ESCC tumors with cholesterolconjugated PAFR small interfering RNA effectively inhibited tumor progression and the expression of AKT-mediated oncogenic proteins. Taken together, we made the first demonstration that dysregulation of PAFR and the positive regulatory loop between PAFR and pAKT contribute to malignant progression of ESCC.	[Chen, J.; Lan, T.; Zhang, W.; Dong, L.; Kang, N.; Zhang, S.; Fu, M.; Zhan, Q.] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100021, Peoples R China; [Chen, J.; Lan, T.; Zhang, W.; Dong, L.; Kang, N.; Zhang, S.; Fu, M.; Zhan, Q.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Lan, T.] Capital Med Univ, Dept Neurosurg, Beijing Sanbo Brain Hosp, Beijing, Peoples R China; [Liu, B.] Guangdong Pharmaceut Univ, Dept Pharmacol, Sch Pharm, Guangzhou, Guangdong, Peoples R China; [Liu, K.] Tsinghua Univ, Natl Key Lab Med Mol Biol, Inst Basic Med Sci, Peking Union Med Coll, Beijing 100084, Peoples R China; [Liu, K.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Zhang, C.; Hou, J.] China Acad Chinese Med Sci, Xiyuan Hosp, Inst Basic Med Sci, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Capital Medical University; Guangdong Pharmaceutical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS	Zhan, Q (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100021, Peoples R China.	zhanqimin@pumc.edu.cn	Lan, Ting/GWV-2392-2022		National 973 Program [2015CB553904]; National Natural Fund of China [81021061, 81230047]; China Postdoctoral Science Foundation [2013M530555]	National 973 Program(National Basic Research Program of China); National Natural Fund of China; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The ESCC cell lines (KYSE180, KYSE140, KYSE150, KYSE30, KYSE410, KYSE450 and KYSE510) were generously provided by Dr Shemada of Kyoto University. This work is supported by the National 973 Program (2015CB553904), National Natural Fund of China (81021061 and 81230047) and China Postdoctoral Science Foundation (2013M530555).	Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Cellai C, 2006, BRIT J CANCER, V94, P1637, DOI 10.1038/sj.bjc.6603156; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.312; Chen ML, 2012, CANCER EPIDEM BIOMAR, V21, P1126, DOI 10.1158/1055-9965.EPI-12-0020; Denizot Y, 2001, LUNG CANCER-J IASLC, V33, P195, DOI 10.1016/S0169-5002(01)00197-0; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; Ding YZ, 2003, CLIN CANCER RES, V9, P3406; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dulinska-Litewka J, 2013, CURR MED CHEM, V20, P144; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; Gibbs TC, 2009, PROSTATE, V69, P1493, DOI 10.1002/pros.20994; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; HEON SK, 2006, CANCER RES, V66, P4681; Hu H, 2013, CANCER CELL, V22, P781; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kato M, 2002, J IMMUNOL, V169, P5252, DOI 10.4049/jimmunol.169.9.5252; Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853; Kim Won Ho, 1993, Yonsei Medical Journal, V34, P45; Lango MN, 2002, J NATL CANCER I, V94, P375; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Li JX, 2004, CANCER RES, V64, P94, DOI 10.1158/0008-5472.CAN-03-0737; Li Y, 2009, DIS ESOPHAGUS, V22, P664, DOI 10.1111/j.1442-2050.2008.00928.x; Liu X, 2008, J PHARMACOL EXP THER, V326, P69, DOI 10.1124/jpet.107.134528; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583; Rosato A, 2006, INT J CANCER, V119, P1717, DOI 10.1002/ijc.21923; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Sahu RP, 2012, CARCINOGENESIS, V33, P694, DOI 10.1093/carcin/bgr322; Senga T, 2003, BLOOD, V101, P1185, DOI 10.1182/blood-2002-06-1881; SHINOZAKI K, 1994, LIFE SCI, V54, P429, DOI 10.1016/0024-3205(94)00701-2; Soldi R, 1996, ONCOGENE, V13, P515; Stokes JB, 2011, MOL CANCER THER, V10, P2135, DOI 10.1158/1535-7163.MCT-11-0261; Sud N, 2006, CANCER LETT, V233, P265, DOI 10.1016/j.canlet.2005.03.018; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Tanigawa N, 1997, CANCER, V79, P220; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VENABLE ME, 1993, J LIPID RES, V34, P691; Walsh CT, 2008, MOL INTERV, V8, P165, DOI 10.1124/mi.8.4.8; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Zhou WL, 2007, AM J PHYSIOL-HEART C, V292, pH2773, DOI 10.1152/ajpheart.01018.2006	48	31	35	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5114	5127		10.1038/onc.2014.434	http://dx.doi.org/10.1038/onc.2014.434			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25639872				2022-12-28	WOS:000362233400002
J	Kocab, AJ; Veloso, A; Paulsen, MT; Ljungman, M; Duckett, CS				Kocab, A. J.; Veloso, A.; Paulsen, M. T.; Ljungman, M.; Duckett, C. S.			Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling	ONCOGENE			English	Article							NF-KAPPA-B; LARGE-CELL LYMPHOMA; TRANSCRIPTION FACTORS; CD30; TNF; DEGRADATION; ACTIVATION; APOPTOSIS; PATHWAYS; COMPLEX	Cellular inhibitor of apoptosis proteins 1 and 2 (c-IAP1/2) have central roles in signal transduction mediated by numerous receptors that participate in inflammatory and immune responses. In certain pathways, such as activation of NF-kappa B, their degradation is a major regulatory event and is physiologically induced by activation of receptors. In addition, a number of synthetic compounds have been developed that also target the c-IAPs and induce their degradation. However, the extent of a synthetic IAP antagonist's ability to mirror the transcriptional program by a physiological signal remains unclear. Here we take a systems approach to compare the transcriptional programs triggered by activation of CD30, a well-characterized receptor previously shown to induce the degradation of the c-IAPs, to SM-164, a synthetic IAP antagonist that specifically triggers c-IAP degradation. Employing a technique that allows the specific analysis of newly transcribed RNA, we have generated comparative transcriptome profiles for CD30 activation and SM-164 treatment. Analysis of these profiles revealed that the genes regulated by each stimulus were not completely shared, indicating novel functions of IAP antagonists and consequences of c-IAP1/2 degradation. The data identified a role for c-IAP1/2 in the regulation of the ribosome and protein synthesis, which was subsequently confirmed by biological assays. These findings expand our knowledge of the roles of c-IAP1/2 in signaling and provide insight into the mechanism of synthetic IAP antagonists, furthering our understanding of their therapeutic potential.	[Kocab, A. J.] Univ Michigan, Grad Program Immunol, Ann Arbor, MI 48109 USA; [Kocab, A. J.; Duckett, C. S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Veloso, A.; Paulsen, M. T.; Ljungman, M.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Veloso, A.] Univ Michigan, Dept Computat Med & Bioinformat, Bioinformat Program, Ann Arbor, MI 48109 USA; [Ljungman, M.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Duckett, CS (corresponding author), Univ Michigan, Dept Pathol & Internal Med, NCRC Bldg 18,Rm 133,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	colind@med.umich.edu		Kocab, Andrew/0000-0001-6069-2166; Duckett, Colin/0000-0001-9413-2263	NIH [R01CA142809, 1R01HG006786, T32AI007413]; NATIONAL CANCER INSTITUTE [R01CA142809] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG006786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007413] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Drs Shaomeng Wang (University of Michigan, Ann Arbor, MI, USA) for the kind gift of SM-164, Judith Sebolt-Leopold (University of Michigan) for the gift of Trametinib, Niall Kenneth (Newcastle University, Newcastle upon Tyne, UK) for his insightful suggestions, Elizabeth Lawlor (University of Michigan, Ann Arbor, MI, USA) for her critical reading of the manuscript, Thomas Wilson (University of Michigan, Ann Arbor, MI, USA) for use of his data analysis software, the members of the Duckett laboratory for their helpful advice and the personnel at the University of Michigan Molecular and Behavioral Neuroscience Institute computing cluster and the University of Michigan Sequencing Core for their technical assistance. This work was supported in part by NIH R01CA142809 (to CSD), NIH 1R01HG006786 (to ML) and NIH T32AI007413 (to AJK).	Buchan SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045244; Chiarle R, 1999, CLIN IMMUNOL, V90, P157, DOI 10.1006/clim.1998.4636; Csomos RA, 2009, BIOCHEM J, V420, P83, DOI 10.1042/BJ20082140; Darding M, 2012, CELL DEATH DIFFER, V19, P58, DOI 10.1038/cdd.2011.163; Darding M, 2011, CELL DEATH DIFFER, V18, P1376, DOI 10.1038/cdd.2011.10; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Hacker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Kenneth NS, 2014, CELL CYCLE, V13, P1006, DOI 10.4161/cc.27922; Kenneth NS, 2012, CURR OPIN CELL BIOL, V24, P871, DOI 10.1016/j.ceb.2012.11.004; Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008-5472.CAN-08-2655; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Mir SS, 2000, BLOOD, V96, P4307; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Paulsen MT, 2014, METHODS, V67, P45, DOI 10.1016/j.ymeth.2013.08.015; Paulsen MT, 2013, P NATL ACAD SCI USA, V110, P2240, DOI 10.1073/pnas.1219192110; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Silke J, 2011, CURR OPIN IMMUNOL, V23, P620, DOI 10.1016/j.coi.2011.08.002; Smale ST, 2012, IMMUNOL REV, V246, P193, DOI 10.1111/j.1600-065X.2011.01091.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun HY, 2007, J AM CHEM SOC, V129, P15279, DOI 10.1021/ja074725f; TIAN ZG, 1995, CANCER RES, V55, P5335; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wright CW, 2007, J BIOL CHEM, V282, P10252, DOI 10.1074/jbc.M608817200; Wright CW, 2009, SCIENCE, V323, P251, DOI 10.1126/science.1162818; Zarnegar B, 2008, P NATL ACAD SCI USA, V105, P3503, DOI 10.1073/pnas.0707959105; Zhang JB, 2014, AUTOPHAGY, V10, P901, DOI 10.4161/auto.28267	38	7	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5472	5481		10.1038/onc.2015.3	http://dx.doi.org/10.1038/onc.2015.3			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659587	Green Accepted			2022-12-28	WOS:000363479700007
J	Zhao, D; Besser, AH; Wander, SA; Sun, J; Zhou, W; Wang, B; Ince, T; Durante, MA; Guo, W; Mills, G; Theodorescu, D; Slingerland, J				Zhao, D.; Besser, A. H.; Wander, S. A.; Sun, J.; Zhou, W.; Wang, B.; Ince, T.; Durante, M. A.; Guo, W.; Mills, G.; Theodorescu, D.; Slingerland, J.			Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation	ONCOGENE			English	Article							KINASE INHIBITOR P27(KIP1); GROWTH-FACTOR-BETA; CELL-CYCLE; DEPENDENT KINASE; BREAST-CANCER; CDK INHIBITOR; TARGETED THERAPIES; ONCOGENIC FUNCTION; MAMMALIAN-CELLS; MICE LACKING	p27 restrains normal cell growth, but PI3K-dependent C-terminal phosphorylation of p27 at threonine 157 (T157) and T198 promotes cancer cell invasion. Here, we describe an oncogenic feedforward loop in which p27pT157pT198 binds Janus kinase 2 (JAK2) promoting STAT3 (signal transducer and activator of transcription 3) recruitment and activation. STAT3 induces TWIST1 to drive a p27-dependent epithelial-mesenchymal transition (EMT) and further activates AKT contributing to acquisition and maintenance of metastatic potential. p27 knockdown in highly metastatic PI3K-activated cells reduces STAT3 binding to the TWIST1 promoter, TWIST1 promoter activity and TWIST1 expression, reverts EMT and impairs metastasis, whereas activated STAT3 rescues p27 knockdown. Cell cycle-defective phosphomimetic p27T157DT198D (p27CK-DD) activates STAT3 to induce a TWIST1-dependent EMT in human mammary epithelial cells and increases breast and bladder cancer invasion and metastasis. Data support a mechanism in which PI3K-deregulated p27 binds JAK2, to drive STAT3 activation and EMT through STAT3-mediated TWIST1 induction. Furthermore, STAT3, once activated, feeds forward to further activate AKT.	[Zhao, D.; Besser, A. H.; Wander, S. A.; Sun, J.; Zhou, W.; Wang, B.; Ince, T.; Durante, M. A.; Slingerland, J.] Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Zhao, D.; Besser, A. H.; Wander, S. A.; Durante, M. A.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Zhou, W.; Wang, B.; Slingerland, J.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Ince, T.] Univ Miami, Miller Sch Med, Stem Cell Res Inst, Dept Pathol, Miami, FL 33136 USA; [Guo, W.; Mills, G.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Guo, W.; Mills, G.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Theodorescu, D.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Slingerland, J.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Miami	Slingerland, J (corresponding author), Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Durante, Michael/ABH-8217-2020; Zhou, Wen/A-5763-2010; Zhao, Dekuang/H-5671-2015	Durante, Michael/0000-0003-3137-6847; Zhou, Wen/0000-0002-5496-5815; Ince, Tan/0000-0003-0315-6425; Zhao, Dekuang/0000-0002-7251-2481	UMSCCC Analytical Imaging Core Facility; Doris Duke Charitable Foundation;  [NCI-2R01CA105118-05A]; NATIONAL CANCER INSTITUTE [R01CA105118, R01CA075115, P50CA083639] Funding Source: NIH RePORTER	UMSCCC Analytical Imaging Core Facility; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the support of lab members, the UMSCCC Analytical Imaging Core Facility and Grant NCI-2R01CA105118-05A. A grant from the Doris Duke Charitable Foundation supported AB, SW and JMS.	Ansieau S, 2010, ONCOGENE, V29, P3173, DOI 10.1038/onc.2010.92; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Hidaka T, 2009, ANTICANCER RES, V29, P597; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jakel H, 2011, ONCOGENE, V30, P3502, DOI 10.1038/onc.2011.68; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kruck S, 2012, BJU INT, V109, P1565, DOI 10.1111/j.1464-410X.2011.10649.x; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Li H, 2012, CELL STEM CELL, V11, P845, DOI 10.1016/j.stem.2012.09.014; Li R, 2006, J UROLOGY, V175, P528, DOI 10.1016/S0022-5347(05)00151-5; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang J, 2002, COLD SPRING HARB CEL, V3; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lieblein JC, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-302; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Menchon C, 2011, CELL CYCLE, V10, P1435, DOI 10.4161/cc.10.9.15421; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Motti ML, 2004, CELL CYCLE, V3, P1074; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nitz MD, 2008, METHOD ENZYMOL, V439, P219, DOI 10.1016/S0076-6879(07)00417-X; Pippa R, 2012, ONCOGENE, V31, P4207, DOI 10.1038/onc.2011.582; Piva R, 1999, J NEUROPATH EXP NEUR, V58, P691, DOI 10.1097/00005072-199907000-00002; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Serres MP, 2011, ONCOGENE, V30, P2846, DOI 10.1038/onc.2011.9; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wander SA, 2013, BREAST CANCER RES TR, V138, P369, DOI 10.1007/s10549-012-2389-6; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	60	84	89	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5447	5459		10.1038/onc.2014.473	http://dx.doi.org/10.1038/onc.2014.473			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25684140	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000363479700005
J	Zhao, S; Kurenbekova, L; Gao, Y; Roos, A; Creighton, CJ; Rao, P; Hicks, J; Man, TK; Lau, C; Brown, AMC; Jones, SN; Lazar, AJ; Ingram, D; Lev, D; Donehower, LA; Yustein, JT				Zhao, S.; Kurenbekova, L.; Gao, Y.; Roos, A.; Creighton, C. J.; Rao, P.; Hicks, J.; Man, T-K; Lau, C.; Brown, A. M. C.; Jones, S. N.; Lazar, A. J.; Ingram, D.; Lev, D.; Donehower, L. A.; Yustein, J. T.			NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma	ONCOGENE			English	Article							PROMOTER HYPERMETHYLATION; P53; GENE; PROGRESSION; MEMBRANE; INVASION; PATHWAYS; MUTATION; BIOLOGY; ALPHA	Osteosarcoma (OS) is the most frequent pediatric malignant bone tumor that has a high propensity for metastases. Through osteoblast-specific alteration of p53 status, we developed a genetically engineered mouse model of localized and metastatic OS to gain an understanding into the molecular pathogenesis of OS. Microarray analysis of both localized tumors and metastatic tumors identified the downregulation of the naked cuticle homolog 2 (NKD2) gene, a negative regulator of Wnt signaling. Overexpression of NKD2 in metastatic human and mouse OS cells significantly decreases cell proliferation, migration and invasion ability in vitro and drastically diminishes OS tumor growth and metastasis in vivo, whereas downregulation enhances migratory and invasive potential. Evaluation of NKD2-overexpressing tumors revealed upregulation of tumor-suppressor genes and downregulation of molecules involved in blood vessel formation and cell migration. Furthermore, assessment of primary human OS revealed downregulation of NKD2 in metastatic and recurrent OS. Finally, we provide biological evidence that use of small-molecule inhibitors targeting the Wnt pathway can have therapeutic efficacy in decreasing metastatic properties in OS. Our studies provide compelling evidence that downregulation of NKD2 expression and alterations in associated regulated pathways have a significant role in driving OS tumor growth and metastasis.	[Zhao, S.; Kurenbekova, L.; Gao, Y.; Roos, A.; Rao, P.; Man, T-K; Lau, C.; Donehower, L. A.; Yustein, J. T.] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, Houston, TX 77030 USA; [Zhao, S.; Kurenbekova, L.; Gao, Y.; Roos, A.; Rao, P.; Man, T-K; Lau, C.; Donehower, L. A.; Yustein, J. T.] Baylor Coll Med, Texas Childrens Hematol Ctr, Dept Pediat, Houston, TX 77030 USA; [Roos, A.; Donehower, L. A.; Yustein, J. T.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Div Biostat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Hicks, J.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Brown, A. M. C.] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY USA; [Jones, S. N.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA; [Lazar, A. J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Lazar, A. J.; Ingram, D.] Univ Texas MD Anderson Canc Ctr, Sarcoma Res Ctr, Houston, TX 77030 USA; [Ingram, D.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Lev, D.] Ohio State Univ, Dept Canc Biol, Columbus, OH 43210 USA; [Donehower, L. A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Cornell University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; Ohio State University; Baylor College of Medicine	Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, One Baylor Plaza,Room 824D, Houston, TX 77030 USA.	yustein@bcm.edu	Lazar, Alexander J/A-3416-2008	Lazar, Alexander J/0000-0002-6395-4499; Man, Tsz-Kwong/0000-0001-5920-5746	Cancer Prevention and Research Institute of Texas; WWWW Foundation, Inc.; St Baldrick's Foundation; Sarcoma Foundation of America; NIH [R01 CA123238]; NCI/NIH [P30 CA125123]; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA123238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008539] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas; WWWW Foundation, Inc.; St Baldrick's Foundation; Sarcoma Foundation of America; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Yiqun Zhang for technical assistance and Dr Neha Parikh for her assistance with figure layout and design. This work was supported by The Cancer Prevention and Research Institute of Texas (to SZ, T-KM, CL, PR, JH, LK, CJC, LAD, JTY), WWWW Foundation, Inc. (QuadW) (to JTY), The St Baldrick's Foundation (to JTY), the Sarcoma Foundation of America (to LAD), NIH R01 CA123238 (to AMCB) and NCI/NIH grant P30 CA125123 (to CJC).	Bacci G, 2003, ANN ONCOL, V14, P1126, DOI 10.1093/annonc/mdg286; Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Baron Roland, 2007, Curr Osteoporos Rep, V5, P73; Brennecke P, 2014, CLIN EXP METASTAS, V31, P339, DOI 10.1007/s10585-013-9632-3; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Cheng JH, 2008, AM J PHYSIOL-GASTR L, V294, pG39, DOI 10.1152/ajpgi.00263.2007; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A, 2009, Nat Rev Cancer, V9, P831, DOI 10.1038/nrc2731; Dumble Melissa L, 2003, Methods Mol Biol, V234, P29; Edamura K, 2007, CANCER GENE THER, V14, P765, DOI 10.1038/sj.cgt.7701071; Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762; Flores RJ, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-50; Gotze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981; Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hong SH, 2009, INT J CANCER, V124, P2042, DOI 10.1002/ijc.24169; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Hu TH, 2010, J BIOL CHEM, V285, P13561, DOI 10.1074/jbc.M109.075945; Husmann K, 2013, BBA-MOL BASIS DIS, V1832, P347, DOI 10.1016/j.bbadis.2012.11.006; Johnson AS, 1998, CARCINOGENESIS, V19, P213, DOI 10.1093/carcin/19.1.213; Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132; Kanda M, 2011, MOL CARCINOGEN, V50, P571, DOI 10.1002/mc.20735; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549; Li CX, 2007, MOL BIOL CELL, V18, P3081, DOI 10.1091/mbc.E07-02-0172; Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585-005-0365-9; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Miretti S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001828; Mizobuchi Y, 2008, NEURO-ONCOLOGY, V10, P244, DOI 10.1215/15228517-2008-016; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Muff Roman, 2012, Sarcoma, V2012, P937506, DOI 10.1155/2012/937506; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005; Wlazlinski A, 2007, PROSTATE, V67, P1770, DOI 10.1002/pros.20667; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898	46	81	86	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5069	5079		10.1038/onc.2014.429	http://dx.doi.org/10.1038/onc.2014.429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25579177	Green Accepted			2022-12-28	WOS:000361693300007
J	Mapelli, P; Aboagye, EO; Stebbing, J; Sharma, R				Mapelli, P.; Aboagye, E. O.; Stebbing, J.; Sharma, R.			Epigenetic changes in gastroenteropancreatic neuroendocrine tumours	ONCOGENE			English	Review							HISTONE DEACETYLASE INHIBITORS; PANCREATIC ENDOCRINE; DNA METHYLTRANSFERASE; SOMATOSTATIN ANALOGS; METHYLATION PATTERN; MICRORNA EXPRESSION; SUPPRESSOR GENES; DOWN-REGULATION; VALPROIC ACID; BETA-CATENIN	An understanding of epigenetic drivers of tumorigenesis has developed rapidly during the last years. The identification of these changes including DNA methylation and histone modifications in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a step forward in trying to define underlying biologic processes in this heterogeneous disease. The reversible nature of these changes represents a potential therapeutic target. We present an overview of the current knowledge of epigenetic alterations related to GEP-NETs, focusing on the influence and impact these changes have on pathogenesis and prognosis. The potential role of demethylating agents in the management of this patient population is discussed.	[Mapelli, P.; Aboagye, E. O.; Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Surg & Canc, London, England; [Sharma, R.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Expt Med, London, England	Imperial College London; Imperial College London	Mapelli, P (corresponding author), Ist Sci San Raffaele, Dept Nucl Med, Via Olgettina 60, I-20132 Milan, Italy.	mapelli.paola@imperial.ac.uk	Mapelli, Paola/AAC-8990-2022	Mapelli, Paola/0000-0002-8780-5690; Stebbing, Justin/0000-0002-1117-6947; ABOAGYE, Eric/0000-0003-2276-6771	Cancer Research UK [16584] Funding Source: researchfish; National Institute for Health Research [NIHR/CS/009/009, NIHR-RP-011-053] Funding Source: researchfish; MRC [MR/J007986/1] Funding Source: UKRI; Cancer Research UK [10337, 12011, 14549] Funding Source: Medline; Medical Research Council [MR/J007986/1, G0700915] Funding Source: Medline; Department of Health [NIHR/CS/009/009, NIHR-RP-011-053, EME/13/122/01] Funding Source: Medline	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Adler JT, 2009, ANN SURG ONCOL, V16, P481, DOI 10.1245/s10434-008-0194-6; Alexander VM, 2010, INT J CLIN EXP MED, V3, P95; Arnold CN, 2008, INT J CANCER, V123, P1556, DOI 10.1002/ijc.23690; Arnold CN, 2007, INT J CANCER, V120, P2157, DOI 10.1002/ijc.22569; Baradari V, 2006, ENDOCR-RELAT CANCER, V13, P1237, DOI 10.1677/erc.1.01249; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen SF, 2013, HUM PATHOL, V44, P2199, DOI 10.1016/j.humpath.2013.04.025; Choi IS, 2007, MODERN PATHOL, V20, P802, DOI 10.1038/modpathol.3800825; Chu SH, 2012, MOL MED REP, V5, P138, DOI 10.3892/mmr.2011.620; de Wilde RF, 2012, MODERN PATHOL, V25, P1033, DOI 10.1038/modpathol.2012.53; Dejeux E, 2009, ENDOCR-RELAT CANCER, V16, P939, DOI 10.1677/ERC-08-0331; Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329; Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530; Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547; Fialova B, 2013, ONCOL REP, V29, P2039, DOI 10.3892/or.2013.2344; Fontaniere S, 2006, ENDOCR-RELAT CANCER, V13, P1223, DOI 10.1677/erc.1.01294; Fotouhi O, 2014, EPIGENETICS, V9, P7; Furlan D, 2013, VIRCHOWS ARCH, V462, P47, DOI 10.1007/s00428-012-1348-2; Geli J, 2008, CLIN CANCER RES, V14, P2551, DOI 10.1158/1078-0432.CCR-07-1867; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; Gordon Marilyn, 2012, Mol Biol Int, V2012, P365213, DOI 10.1155/2012/365213; Graham JS, 2009, EUR J CANCER, V45, P1129, DOI 10.1016/j.ejca.2009.01.003; Greenblatt DY, 2007, ONCOLOGIST, V12, P942, DOI 10.1634/theoncologist.12-8-942; Habbe N, 2007, PANCREATOLOGY, V7, P352, DOI 10.1159/000107270; Hagelgans A, 2013, EXP MOL PATHOL, V94, P458, DOI 10.1016/j.yexmp.2013.03.006; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; House MG, 2003, ANN SURG, V238, P423, DOI 10.1097/01.sla.0000086659.49569.9e; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Karahoca M, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-3; Kazazian HH, 2002, CELL, V110, P277, DOI 10.1016/S0092-8674(02)00868-1; Kim JT, 2013, CARCINOGENESIS, V34, P953, DOI 10.1093/carcin/bgt018; Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476; La Rosa S, 2012, AM J SURG PATHOL, V36, P601, DOI 10.1097/PAS.0b013e318242e21c; Larsson C, 2013, NEUROENDOCRINOLOGY, V97, P19, DOI 10.1159/000336087; Li SC, 2013, MODERN PATHOL, V26, P685, DOI 10.1038/modpathol.2012.216; Liu LL, 2006, CLIN CANCER RES, V12, P328, DOI 10.1158/1078-0432.CCR-05-2543; Lubomierski N, 2001, CANCER RES, V61, P5905; Magerl C, 2010, HUM PATHOL, V41, P181, DOI 10.1016/j.humpath.2009.08.007; Malpeli G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-351; Masramon L, 2006, J CELL SCI, V119, P1477, DOI 10.1242/jcs.02871; Meeker A, 2014, MOL CELL ENDOCRINOL, V386, P101, DOI 10.1016/j.mce.2013.07.015; Mei M, 2009, J CLIN ENDOCR METAB, V94, P3448, DOI 10.1210/jc.2009-0173; Modlin IM, 2010, ALIMENT PHARM THER, V31, P169, DOI 10.1111/j.1365-2036.2009.04174.x; Modlin IM, 2008, LANCET ONCOL, V9, P61, DOI 10.1016/S1470-2045(07)70410-2; Mohammed TA, 2011, ONCOLOGIST, V16, P835, DOI 10.1634/theoncologist.2011-0031; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366; Muscarella P, 1998, CANCER RES, V58, P237; Naldi I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098101; Oberg K, 2004, ANN ONCOL, V15, P966, DOI 10.1093/annonc/mdh216; Oberg K, 2012, ANN ONCOL, V23, P120, DOI 10.1093/annonc/mds267; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Pavlicek A, 2001, GENE, V276, P39, DOI 10.1016/S0378-1119(01)00645-X; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Pizzi S, 2005, J PATHOL, V206, P409, DOI 10.1002/path.1784; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rahman MM, 2010, HUM PATHOL, V41, P1069, DOI 10.1016/j.humpath.2010.01.011; Rius M, 2012, ONCOGENE, V31, P4257, DOI 10.1038/onc.2011.601; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Ruebel K, 2010, MODERN PATHOL, V23, P367, DOI 10.1038/modpathol.2009.161; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Serrano J, 2000, J CLIN ENDOCR METAB, V85, P4146, DOI 10.1210/jc.85.11.4146; Shah MH, 2006, CLIN CANCER RES, V12, P3997, DOI 10.1158/1078-0432.CCR-05-2689; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Stricker I, 2012, ANTICANCER RES, V32, P3699; Strosberg JR, 2011, CANCER-AM CANCER SOC, V117, P268, DOI 10.1002/cncr.25425; Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120; Tian J, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395574; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353; Verdugo AD, 2014, ENDOCR-RELAT CANCER, V21, pL5, DOI 10.1530/ERC-13-0481; Vijayaraghavalu S, 2013, CANCER LETT, V331, P122, DOI 10.1016/j.canlet.2012.12.009; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Warneboldt J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-388; Wild A, 2003, J CLIN ENDOCR METAB, V88, P1367, DOI 10.1210/jc.2002-021027; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Zhang HY, 2006, ENDOCRINE, V30, P299, DOI 10.1007/s12020-006-0008-1	83	8	8	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4439	4447		10.1038/onc.2014.379	http://dx.doi.org/10.1038/onc.2014.379			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25435371				2022-12-28	WOS:000360189200003
J	Licciardello, MP; Mullner, MK; Durnberger, G; Kerzendorfer, C; Boidol, B; Trefzer, C; Sdelci, S; Berg, T; Penz, T; Schuster, M; Bock, C; Kralovics, R; Superti-Furga, G; Colinge, J; Nijman, SM; Kubicek, S				Licciardello, M. P.; Muellner, M. K.; Duernberger, G.; Kerzendorfer, C.; Boidol, B.; Trefzer, C.; Sdelci, S.; Berg, T.; Penz, T.; Schuster, M.; Bock, C.; Kralovics, R.; Superti-Furga, G.; Colinge, J.; Nijman, S. M.; Kubicek, S.			NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation	ONCOGENE			English	Article							PATHWAY; TUMORS; SUMO; UBC9; IDENTIFICATION; GENERATION; LEUKEMIA; EFFICACY; REVEALS; PROTEIN	Breast cancer is genetically heterogeneous, and recent studies have underlined a prominent contribution of epigenetics to the development of this disease. To uncover new synthetic lethalities with known breast cancer oncogenes, we screened an epigenome-focused short hairpin RNA library on a panel of engineered breast epithelial cell lines. Here we report a selective interaction between the NOTCH1 signaling pathway and the SUMOylation cascade. Knockdown of the E2-conjugating enzyme UBC9 (UBE2I) as well as inhibition of the E1-activating complex SAE1/UBA2 using ginkgolic acid impairs the growth of NOTCH1-activated breast epithelial cells. We show that upon inhibition of SUMOylation NOTCH1-activated cells proceed slower through the cell cycle and ultimately enter apoptosis. Mechanistically, activation of NOTCH1 signaling depletes the pool of unconjugated small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 leading to increased sensitivity to perturbation of the SUMOylation cascade. Depletion of unconjugated SUMO correlates with sensitivity to inhibition of SUMOylation also in patient-derived breast cancer cell lines with constitutive NOTCH pathway activation. Our investigation suggests that SUMOylation cascade inhibitors should be further explored as targeted treatment for NOTCH-driven breast cancer.	[Licciardello, M. P.; Muellner, M. K.; Duernberger, G.; Kerzendorfer, C.; Boidol, B.; Trefzer, C.; Sdelci, S.; Berg, T.; Penz, T.; Schuster, M.; Bock, C.; Kralovics, R.; Superti-Furga, G.; Colinge, J.; Nijman, S. M.; Kubicek, S.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1090 Vienna, Austria; [Boidol, B.; Kubicek, S.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Christian Doppler Lab Chem Epigenet & Antiinfect, A-1090 Vienna, Austria	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences	Kubicek, S (corresponding author), Austrian Acad Sci, CeMM Res Ctr Mol Med, Lazarettgasse 14 AKH BT 25-3, A-1090 Vienna, Austria.	skubicek@cemm.oeaw.ac.at	Colinge, Jacques/Z-2613-2019; Superti-Furga, Giulio/AAE-5681-2019; Jessen-Trefzer, Claudia/E-3710-2019; sdelci, sara/S-2243-2018; Kubicek, Stefan/C-2089-2017; Colinge, Jacques/D-1578-2017; Bock, Christoph/AAE-7618-2019; Superti-Furga, Giulio/F-4755-2015	Colinge, Jacques/0000-0003-2466-4824; Jessen-Trefzer, Claudia/0000-0003-4216-8189; sdelci, sara/0000-0003-1330-4364; Kubicek, Stefan/0000-0003-0855-8343; Colinge, Jacques/0000-0003-2466-4824; Bock, Christoph/0000-0001-6091-3088; Schuster, Michael/0000-0003-2975-8969; Kralovics, Robert/0000-0002-6997-8539; Nijman, Sebastian/0000-0003-0464-6661; Superti-Furga, Giulio/0000-0002-0570-1768; Licciardello, Marco/0000-0003-3197-4855	Marie Curie Career Integration Grant; Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development	Marie Curie Career Integration Grant; Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development	We thank John Doench, Serena Silver and David E Root (Broad Institute of MIT and Harvard) for shRNA tools and screening protocols; Johannes Bigenzahn (CeMM) for providing the pMSCV-StrepHA-GW-hPGK-Bla vector; and Erika Schirghuber (CeMM) and Berend Snijder (CeMM) for critically reading the manuscript. SK acknowledges support by a Marie Curie Career Integration Grant, the Austrian Federal Ministry of Science, Research and Economy and the National Foundation for Research, Technology and Development.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Falk R, 2012, METHODS, V58, P69, DOI 10.1016/j.ymeth.2012.07.008; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fukuda I, 2009, CHEM BIOL, V16, P133, DOI 10.1016/j.chembiol.2009.01.009; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Johnson DG, 2013, CELL, V152, P685, DOI 10.1016/j.cell.2013.01.017; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kessler JD, 2011, SCIENCE, V335, P348; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mair B, 2014, TRENDS PHARMACOL SCI, V35, P136, DOI 10.1016/j.tips.2014.01.001; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; Maxmen A, 2012, NATURE, V485, pS50, DOI 10.1038/485S50a; Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moschos SJ, 2007, ONCOGENE, V26, P4216, DOI 10.1038/sj.onc.1210216; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Purow B, 2012, ADV EXP MED BIOL, V727, P305, DOI 10.1007/978-1-4614-0899-4_23; Radtke F, 2010, IMMUNITY, V32, P14, DOI 10.1016/j.immuni.2010.01.004; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rao SS, 2009, CANCER RES, V69, P3060, DOI 10.1158/0008-5472.CAN-08-4295; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Whitfield ML, 2000, MOL CELL BIOL, V20, P4188, DOI 10.1128/MCB.20.12.4188-4198.2000	49	35	36	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3780	3790		10.1038/onc.2014.319	http://dx.doi.org/10.1038/onc.2014.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263445				2022-12-28	WOS:000358001600004
J	Agarwal, A; MacKenzie, RJ; Eide, CA; Davare, MA; Watanabe-Smith, K; Tognon, CE; Mongoue-Tchokote, S; Park, B; Braziel, RM; Tyner, JW; Druker, BJ				Agarwal, A.; MacKenzie, R. J.; Eide, C. A.; Davare, M. A.; Watanabe-Smith, K.; Tognon, C. E.; Mongoue-Tchokote, S.; Park, B.; Braziel, R. M.; Tyner, J. W.; Druker, B. J.			Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; JAK3 MUTATIONS; DOWN-SYNDROME; SOMATIC MUTATIONS; JAK/STAT PATHWAY; FERM DOMAIN; STEM-CELLS; EXPRESSION	To understand the role of cytokine and growth factor receptor-mediated signaling in leukemia pathogenesis, we designed a functional RNA interference (RNAi) screen targeting 188 cytokine and growth factor receptors that we found highly expressed in primary leukemia specimens. Using this screen, we identified interleukin-2 gamma receptor (IL2R gamma) as a critical growth determinant for a JAK3A572V mutation-positive acute myeloid leukemia cell line. We observed that knockdown of IL2R. abrogates phosphorylation of JAK3 and downstream signaling molecules, JAK1, STAT5, MAPK and pS6 ribosomal protein. Overexpression of IL2R gamma in murine cells increased the transforming potential of activating JAK3 mutations, whereas absence of IL2R. completely abrogated the clonogenic potential of JAK3A572V, as well as the transforming potential of additional JAK3-activating mutations such as JAK3M511I. In addition, mutation at the IL2R gamma interaction site in the FERM domain of JAK3 (Y100C) completely abrogated JAK3mediated leukemic transformation. Mechanistically, we found IL2R gamma contributes to constitutive JAK3 mutant signaling by increasing JAK3 expression and phosphorylation. Conversely, we found that mutant, but not wild-type JAK3, increased the expression of IL2R gamma, indicating IL2R gamma and JAK3 contribute to constitutive JAK/STAT signaling through their reciprocal regulation. Overall, we demonstrate a novel role for IL2R gamma in potentiating oncogenesis in the setting of JAK3-mutation-positive leukemia. In addition, our study highlights an RNAi-based functional assay that can be used to facilitate the identification of non-kinase cytokine and growth factor receptor targets for inhibiting leukemic cell growth.	[Agarwal, A.; MacKenzie, R. J.; Eide, C. A.; Watanabe-Smith, K.; Druker, B. J.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA; [Agarwal, A.; MacKenzie, R. J.; Eide, C. A.; Watanabe-Smith, K.; Tognon, C. E.; Mongoue-Tchokote, S.; Park, B.; Tyner, J. W.; Druker, B. J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA; [Eide, C. A.; Tognon, C. E.; Druker, B. J.] Howard Hughes Med Inst, Portland, OR USA; [Davare, M. A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA; [Mongoue-Tchokote, S.; Park, B.] Oregon Hlth & Sci Univ, Biostat Shared Resource, Portland, OR 97239 USA; [Braziel, R. M.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA; [Tyner, J. W.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Agarwal, A (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd,Mailcode L592-BRB553, Portland, OR 97239 USA.	agarwala@ohsu.edu		Druker, Brian/0000-0001-8331-8206; Watanabe-Smith, Kevin/0000-0003-4231-8562; Davare, Monika/0000-0003-1802-7597; Eide, Christopher/0000-0001-8835-8928	National Cancer Institute [5 K99 CA151670-02, 5R00CA151457-04, 1R01CA183947-01]; Collins Foundation; Knight Pilot Project and Friends of Doernbecher grants; V-Foundation; Gabrielle's Angel Foundation; Leukemia & Lymphoma Society; NATIONAL CANCER INSTITUTE [P30CA069533, R00CA151457, K99CA151670, R00CA151670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM071338] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Collins Foundation; Knight Pilot Project and Friends of Doernbecher grants; V-Foundation; Gabrielle's Angel Foundation; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Sarah Bowden for administrative support. AA is supported by a National Cancer Institute Career Development Award (5 K99 CA151670-02), Collins Foundation, Knight Pilot Project and Friends of Doernbecher grants. JWT is supported by grants from the V-Foundation, Gabrielle's Angel Foundation and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01). BJD is a Howard Hughes Medical Institute investigator. This work is also supported by The Leukemia & Lymphoma Society. We thank Dr. Jamie Keck (Dr. Brian Druker's Laboratory, OHSU) for providing her technical assistance in creating Gateway compatible pMXs-IRES-Puromycin vector.	Bains T, 2012, LEUKEMIA, V26, P2144, DOI 10.1038/leu.2012.74; Baird AM, 1998, J LEUKOCYTE BIOL, V63, P669, DOI 10.1002/jlb.63.6.669; Bellanger D, 2014, LEUKEMIA, V28, P417, DOI 10.1038/leu.2013.271; Blink M, 2011, LEUKEMIA, V25, P1365, DOI 10.1038/leu.2011.86; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Candotti F, 1996, J EXP MED, V183, P2687, DOI 10.1084/jem.183.6.2687; Constantinescu SN, 2008, TRENDS BIOCHEM SCI, V33, P122, DOI 10.1016/j.tibs.2007.12.002; Cornejo MG, 2009, INT J BIOCHEM CELL B, V41, P2376, DOI 10.1016/j.biocel.2009.09.004; De Vita S, 2007, BRIT J HAEMATOL, V137, P337, DOI 10.1111/j.1365-2141.2007.06574.x; Ferretti E, 2012, J LEUKOCYTE BIOL, V92, P567, DOI 10.1189/jlb.0112036; Funakoshi-Tago M, 2008, MOL CELL BIOL, V28, P1792, DOI 10.1128/MCB.01447-07; Graf M, 2004, EUR J HAEMATOL, V72, P89, DOI 10.1046/j.0902-4441.2003.00184.x; Hercus TR, 2013, CYTOKINE GROWTH F R, V24, P189, DOI 10.1016/j.cytogfr.2013.03.002; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Ju W, 2011, BLOOD, V117, P1938, DOI 10.1182/blood-2010-09-305425; Kiss C, 2004, PEDIATR BLOOD CANCER, V42, P113, DOI 10.1002/pbc.10436; Kiyoi H, 2007, LEUKEMIA, V21, P574, DOI 10.1038/sj.leu.2404527; Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Murphy JM, 2006, VITAM HORM, V74, P1, DOI 10.1016/S0083-6729(06)74001-8; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; O'Shea JJ, 2005, CURR OPIN RHEUMATOL, V17, P305, DOI 10.1097/01.bor.0000160781.07174.db; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Rubin JB, 2009, SEMIN CANCER BIOL, V19, P116, DOI 10.1016/j.semcancer.2008.10.001; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Sakaguchi H, 2013, NAT GENET, V45, P937, DOI 10.1038/ng.2698; Sato T, 2008, BRIT J HAEMATOL, V141, P681, DOI 10.1111/j.1365-2141.2008.07081.x; Spivak JL, 2012, AM SOC HEMATOL BLOOD, V120, P427; Tang W, 2001, BIOCHEM BIOPH RES CO, V283, P598, DOI 10.1006/bbrc.2001.4824; Tefferi A, 2010, LEUKEMIA, V24, P1128, DOI 10.1038/leu.2010.69; Tefferi A, 2008, LEUKEMIA LYMPHOMA, V49, P388, DOI 10.1080/10428190801895360; Tyner JW, 2008, BLOOD, V111, P2238, DOI 10.1182/blood-2007-06-097253; Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347; Van Etten RA, 2007, ONCOGENE, V26, P6738, DOI 10.1038/sj.onc.1210758; Vijayakrishnan L, 2011, TRENDS PHARMACOL SCI, V32, P25, DOI 10.1016/j.tips.2010.10.004; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186	40	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2991	2999		10.1038/onc.2014.243	http://dx.doi.org/10.1038/onc.2014.243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25109334	Green Accepted			2022-12-28	WOS:000356100500005
J	Chaturvedi, R; de Sablet, T; Asim, M; Piazuelo, MB; Barry, DP; Verriere, TG; Sierra, JC; Hardbower, DM; Delgado, AG; Schneider, BG; Israel, DA; Romero-Gallo, J; Nagy, TA; Morgan, DR; Murray-Stewart, T; Bravo, LE; Peek, RM; Fox, JG; Woster, PM; Caser, RA; Correa, P; Wilson, KT				Chaturvedi, R.; de Sablet, T.; Asim, M.; Piazuelo, M. B.; Barry, D. P.; Verriere, T. G.; Sierra, J. C.; Hardbower, D. M.; Delgado, A. G.; Schneider, B. G.; Israel, D. A.; Romero-Gallo, J.; Nagy, T. A.; Morgan, D. R.; Murray-Stewart, T.; Bravo, L. E.; Peek, R. M., Jr.; Fox, J. G.; Woster, P. M.; Caser, R. A.; Correa, P., Jr.; Wilson, K. T.			Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; EPITHELIAL-CELLS; BIOLOGICAL-ACTIVITY; GENE POLYMORPHISMS; CAGA; INFECTION; CARCINOGENESIS; INDUCTION; APOPTOSIS; LESIONS	Helicobacter pylori infection causes gastric cancer, the third leading cause of cancer death worldwide. More than half of the world's population is infected, making universal eradication impractical. Clinical trials suggest that antibiotic treatment only reduces gastric cancer risk in patients with non-atrophic gastritis (NAG), and is ineffective once preneoplastic lesions of multifocal atrophic gastritis (MAG) and intestinal metaplasia (IM) have occurred. Therefore, additional strategies for risk stratification and chemoprevention of gastric cancer are needed. We have implicated polyamines, generated by the rate-limiting enzyme ornithine decarboxylase (ODC), in gastric carcinogenesis. During H. pylori infection, the enzyme spermine oxidase (SMOX) is induced, which generates hydrogen peroxide from the catabolism of the polyamine spermine. Herein, we assessed the role of SMOX in the increased gastric cancer risk in Colombia associated with the Andean mountain region when compared with the low-risk region on the Pacific coast. When cocultured with gastric epithelial cells, clinical strains of H. pylori from the high-risk region induced more SMOX expression and oxidative DNA damage, and less apoptosis than low-risk strains. These findings were not attributable to differences in the cytotoxin-associated gene A oncoprotein. Gastric tissues from subjects from the high-risk region exhibited greater levels of SMOX and oxidative DNA damage by immunohistochemistry and flow cytometry, and this occurred in NAG, MAG and IM. In Mongolian gerbils, a prototype colonizing strain from the high-risk region induced more SMOX, DNA damage, dysplasia and adenocarcinoma than a colonizing strain from the low-risk region. Treatment of gerbils with either alpha-difluoromethylornithine, an inhibitor of ODC, or MDL 72527 (N-1, N-4-Di(buta-2,3-dien-1-yl) butane-1,4-diamine dihydrochloride), an inhibitor of SMOX, reduced gastric dysplasia and carcinoma, as well as apoptosis-resistant cells with DNA damage. These data indicate that aberrant activation of polyamine-driven oxidative stress is a marker of gastric cancer risk and a target for chemoprevention.	[Chaturvedi, R.; de Sablet, T.; Asim, M.; Piazuelo, M. B.; Barry, D. P.; Verriere, T. G.; Sierra, J. C.; Hardbower, D. M.; Delgado, A. G.; Schneider, B. G.; Israel, D. A.; Romero-Gallo, J.; Nagy, T. A.; Morgan, D. R.; Peek, R. M., Jr.; Correa, P., Jr.; Wilson, K. T.] Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Med Ctr, Nashville, TN 37232 USA; [Hardbower, D. M.; Peek, R. M., Jr.; Wilson, K. T.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Murray-Stewart, T.; Correa, P., Jr.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Bravo, L. E.] Univ Valle, Sch Med, Dept Pathol, Cali, Colombia; [Fox, J. G.] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [Woster, P. M.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Johns Hopkins University; Johns Hopkins Medicine; Universidad del Valle; Massachusetts Institute of Technology (MIT); Medical University of South Carolina; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wilson, KT (corresponding author), Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Sch Med, 1030C MRB 4,2215B Garland Ave, Nashville, TN 37232 USA.	keith.wilson@vanderbilt.edu	Barry, Daniel P/B-5647-2008; Bravo, Luis Eduardo/G-9671-2013; Woster, Patrick M/A-5604-2010; Stewart, Tracy Murray/B-6137-2017; de Sablet, Thibaut/AAI-4513-2020; Bravo, Luis Eduardo/AAB-7209-2019; Bravo, Luis/K-9882-2014	Barry, Daniel P/0000-0002-3972-3914; Woster, Patrick M/0000-0002-9471-1916; Stewart, Tracy Murray/0000-0001-8679-6414; Bravo, Luis Eduardo/0000-0002-9708-0312; Bravo, Luis/0000-0002-9708-0312; Wilson, Keith/0000-0003-4421-1830; Casero, Robert/0000-0001-5653-3306; Schneider, Barbara/0000-0003-4421-1355	National Institutes of Health [R01DK053620, R01AT004821, P01CA028842, P01CA116087, R01CA077955, R01DK058587, R01CA051085, R01CA098454, K01AT007324]; Flow Cytometry Core of the Vanderbilt Digestive Disease Research Center [P30DK058404]; Flow Cytometry Core of the Vanderbilt Ingram Cancer Center [P30CA68485]; Office of Medical Research, Department of Veterans Affairs [1I01BX001453]; Philippe Foundation;  [UL1RR024975];  [T32GM008554]; NATIONAL CANCER INSTITUTE [R01CA077955, R01CA051085, P01CA116087, P01CA028842, R01CA190612, P30CA068485, R01CA098454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K01AT007324] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, R01DK053620, P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flow Cytometry Core of the Vanderbilt Digestive Disease Research Center; Flow Cytometry Core of the Vanderbilt Ingram Cancer Center; Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); Philippe Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by National Institutes of Health Grants R01DK053620 and R01AT004821 (to KTW), P01CA028842 (to KTW, JGF and PC), P01CA116087 (to RMP and KTW), R01CA077955 and R01DK058587 (to RMP), R01CA051085 and R01CA098454 (to RAC), K01AT007324 (to RC), the Flow Cytometry Core of the Vanderbilt Digestive Disease Research Center grant (P30DK058404), the Flow Cytometry Core of the Vanderbilt Ingram Cancer Center (P30CA68485), UL1RR024975 (Vanderbilt CTSA, Pilot Project to KTW) and Merit Review Grant 1I01BX001453 from the Office of Medical Research, Department of Veterans Affairs (to KTW). DMH was supported by T32GM008554. TDS was supported in part by the Philippe Foundation.	Babbar N, 2006, CANCER RES, V66, P11125, DOI 10.1158/0008-5472.CAN-06-3174; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Basso D, 2008, GASTROENTEROLOGY, V135, P91, DOI 10.1053/j.gastro.2008.03.041; Basu HS, 2009, CANCER RES, V69, P7689, DOI 10.1158/0008-5472.CAN-08-2472; BLASER MJ, 1995, CANCER RES, V55, P2111; Bravo LE, 2002, AM J GASTROENTEROL, V97, P2839, DOI 10.1111/j.1572-0241.2002.07031.x; CASERO RA, 1989, CANCER RES, V49, P3829; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; Chaturvedi R, 2011, GASTROENTEROLOGY, V141, P1696, DOI 10.1053/j.gastro.2011.07.045; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; CORREA P, 1988, CANCER RES, V48, P3554; CORREA P, 1990, CANCER RES, V50, P4731; Correa P, 2010, AM J GASTROENTEROL, V105, P493, DOI 10.1038/ajg.2009.728; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; CUELLO C, 1976, JNCI-J NATL CANCER I, V57, P1015, DOI 10.1093/jnci/57.5.1015; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Dominguez RL, 2013, CANCER CAUSE CONTROL, V24, P233, DOI 10.1007/s10552-012-0109-5; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Koike T, 1999, AM J GASTROENTEROL, V94, P3468, DOI 10.1111/j.1572-0241.1999.01593.x; Ma JL, 2012, J NATL CANCER I, V104, P488, DOI 10.1093/jnci/djs003; Mera R, 2005, GUT, V54, P1536, DOI 10.1136/gut.2005.072009; Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042; Morgan DR, 2013, JAMA-J AM MED ASSOC, V309, P578, DOI 10.1001/jama.2013.311; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660; Naito M, 2006, GASTROENTEROLOGY, V130, P1181, DOI 10.1053/j.gastro.2005.12.038; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 2010, PHYSIOL REV, V90, P831, DOI 10.1152/physrev.00039.2009; Sheh A, 2013, INFECT IMMUN, V81, P2468, DOI 10.1128/IAI.01182-12; Sicinschi LA, 2010, CLIN MICROBIOL INFEC, V16, P369, DOI 10.1111/j.1469-0691.2009.02811.x; Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050; Torres J, 2013, CANCER CAUSE CONTROL, V24, P249, DOI 10.1007/s10552-012-0114-8; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; TUMMURU MKR, 1994, INFECT IMMUN, V62, P2609, DOI 10.1128/IAI.62.6.2609-2613.1994; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Valentin-Vega YA, 2008, CELL DEATH DIFFER, V15, P1772, DOI 10.1038/cdd.2008.109; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; You WC, 2006, JNCI-J NATL CANCER I, V98, P974, DOI 10.1093/jnci/djj264; Zabaleta J, 2006, AM J GASTROENTEROL, V101, P163, DOI 10.1111/j.1572-0241.2006.00387.x; Zell JA, 2010, J NATL CANCER I, V102, P1513, DOI 10.1093/jnci/djq325	55	66	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3429	3440		10.1038/onc.2014.273	http://dx.doi.org/10.1038/onc.2014.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174398	Green Submitted, Green Accepted			2022-12-28	WOS:000356871700008
J	Oi, N; Yuan, J; Malakhova, M; Luo, K; Li, Y; Ryu, J; Zhang, L; Bode, AM; Xu, Z; Li, Y; Lou, Z; Dong, Z				Oi, N.; Yuan, J.; Malakhova, M.; Luo, K.; Li, Y.; Ryu, J.; Zhang, L.; Bode, A. M.; Xu, Z.; Li, Y.; Lou, Z.; Dong, Z.			Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; S-PHASE ARREST; RNASE ACTIVITY; CANCER CELLS; KAPPA-B; P53; G3BP; EXPRESSION; PHOSPHORYLATION; GROWTH	Resveratrol (trans-3,5,4'-truhydroxystilbene) possesses a strong anticancer activity exhibited as the induction of apoptosis through p53 activation. However, the molecular mechanism and direct target(s) of resveratrol-induced p53 activation remain elusive. Here, the Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) was identified as a potential target of resveratrol, and in vitro binding assay results using resveratrol-conjugated Sepharose 4B beads confirmed their direct binding. Depletion of G3BP1 significantly diminishes resveratrol-induced p53 expression and apoptosis. We also found that G3BP1 negatively regulates p53 expression by interacting with ubiquitin-specific protease 10 (USP10), a deubiquitinating enzyme of p53. Disruption of the interaction of p53 with USP10 by G3BP1 interference leads to the suppression of p53 deubiquitination. Resveratrol, on the other hand, directly binds to G3BP1 and prevents the G3BP1/USP10 interaction, resulting in enhanced USP10-mediated deubiquitination of p53, and consequently increased p53 expression. These findings disclose a novel mechanism of resveratrol-induced p53 activation and resveratrol-induced apoptosis by direct targeting of G3BP1.	[Oi, N.; Malakhova, M.; Ryu, J.; Bode, A. M.; Li, Y.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Yuan, J.; Luo, K.; Li, Y.; Xu, Z.] Tongji Univ, Res Ctr Translat Med, Sch Med, East Hosp, Shanghai 200092, Peoples R China; [Yuan, J.; Luo, K.; Li, Y.; Xu, Z.] Tongji Univ, Sch Med, East Hosp, Minist Educ China,Key Lab Arrhythmias, Shanghai 200092, Peoples R China; [Luo, K.; Li, Y.; Zhang, L.; Lou, Z.] Mayo Clin, Dept Oncol, Div Oncol Res, Rochester, MN 55902 USA	University of Minnesota System; Tongji University; Ministry of Education, China; Tongji University; Mayo Clinic	Lou, Z (corresponding author), Mayo Clin, Dept Oncol, Div Oncol Res, 200 1st St SW, Rochester, MN 55902 USA.	lou.zhenkun@mayo.edu; zgdong@hi.umn.edu			AgStar Minnesota; Hormel Foundation; National Institutes of Health Grants [CA111536, CA172457, CA166011, R37 CA081064, CA148940, CA108961]; National Basic Research Program of China (973 Program) [2013CB530700]; National Natural Science Foundation of China [81102011, 81222029, 31270806]; Kendall-Mayo Fellowship in Biochemistry, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81221001]; Shanghai Science and Technology Committee Modernization of Traditional Chinese Medicine special [11DZ1973801]; NATIONAL CANCER INSTITUTE [R01CA166011, R37CA081064, P50CA108961, R01CA187027, R01CA129344, R21CA172457, R01CA130996, R01CA148940, P30CA015083, R01CA111536] Funding Source: NIH RePORTER	AgStar Minnesota; Hormel Foundation; National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Kendall-Mayo Fellowship in Biochemistry, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee Modernization of Traditional Chinese Medicine special; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Yibin Deng (The Hormel Institute, University of Minnesota, Austin, MN, USA) for kindly providing the expression vectors of shRNA p53. This work was supported by AgStar Minnesota (to ZD), The Hormel Foundation (to ZD) and National Institutes of Health Grants CA111536 (to ZD), CA172457 (to ZD), CA166011 (to ZD), R37 CA081064 (to ZD), CA148940 (to ZL), CA108961 (to ZL), the National Basic Research Program of China (973 Program, Grant No. 2013CB530700), National Natural Science Foundation of China (81102011, 81222029 and 31270806) and Kendall-Mayo Fellowship in Biochemistry, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81221001) and Shanghai Science and Technology Committee Modernization of Traditional Chinese Medicine special (11DZ1973801).	ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Annibaldi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029024; Barnes CJ, 2002, CANCER RES, V62, P1251; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Celotti E, 1996, J CHROMATOGR A, V730, P47, DOI 10.1016/0021-9673(95)00962-0; Chen RS, 2002, J AGR FOOD CHEM, V50, P1665, DOI 10.1021/jf011134e; Chow SE, 2010, CANCER GENE THER, V17, P872, DOI 10.1038/cgt.2010.44; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Gautier-Bert K, 2003, MOL BIOL REP, V30, P1, DOI 10.1023/A:1022261925117; Gill C, 2007, PROSTATE, V67, P1641, DOI 10.1002/pros.20653; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; Hsieh TC, 1999, CANCER RES, V59, P2596; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Joe AK, 2002, CLIN CANCER RES, V8, P893; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Lev DC, 2003, MOL CANCER THER, V2, P753; Liu YX, 2001, CHINESE MED J-PEKING, V114, P35; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Niles RM, 2003, CANCER LETT, V190, P157, DOI 10.1016/S0304-3835(02)00676-6; Oi N, 2010, CANCER RES, V70, P9755, DOI 10.1158/0008-5472.CAN-10-2858; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pazman C, 2000, DEVELOPMENT, V127, P1715; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; She QB, 2001, CANCER RES, V61, P1604; Sobolev VS, 1999, J AGR FOOD CHEM, V47, P1435, DOI 10.1021/jf9809885; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Takahashi M, 2013, MOL CELL BIOL, V33, P815, DOI 10.1128/MCB.00763-12; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zannat MT, 2011, BIOCHEM BIOPH RES CO, V409, P171, DOI 10.1016/j.bbrc.2011.04.094; Zhang H, 2012, CANCER SCI, V103, P1848, DOI 10.1111/j.1349-7006.2012.02361.x; Zykova TA, 2008, MOL CARCINOGEN, V47, P797, DOI 10.1002/mc.20437	41	34	35	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2660	2671		10.1038/onc.2014.194	http://dx.doi.org/10.1038/onc.2014.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	24998844	Green Accepted			2022-12-28	WOS:000354541300012
J	Moody, SE; Schinzel, AC; Singh, S; Izzo, F; Strickland, MR; Luo, L; Thomas, SR; Boehm, JS; Kim, SY; Wang, ZC; Hahn, WC				Moody, S. E.; Schinzel, A. C.; Singh, S.; Izzo, F.; Strickland, M. R.; Luo, L.; Thomas, S. R.; Boehm, J. S.; Kim, S. Y.; Wang, Z. C.; Hahn, W. C.			PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; TRASTUZUMAB RESISTANCE; MONOCLONAL-ANTIBODY; SINGLE-AGENT; BETA-CATENIN; PHOSPHORYLATION; LAPATINIB; ACTIVATION; CHEMOTHERAPY; INHIBITION	Targeting HER2 with antibodies or small molecule inhibitors in HER2-positive breast cancer leads to improved survival, but resistance is a common clinical problem. To uncover novel mechanisms of resistance to anti-HER2 therapy in breast cancer, we performed a kinase open reading frame screen to identify genes that rescue HER2-amplified breast cancer cells from HER2 inhibition or suppression. In addition to multiple members of the MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase) signaling pathways, we discovered that expression of the survival kinases PRKACA and PIM1 rescued cells from anti-HER2 therapy. Furthermore, we observed elevated PRKACA expression in trastuzumab-resistant breast cancer samples, indicating that this pathway is activated in breast cancers that are clinically resistant to trastuzumab-containing therapy. We found that neither PRKACA nor PIM1 restored MAPK or PI3K activation after lapatinib or trastuzumab treatment, but rather inactivated the pro-apoptotic protein BAD, the BCl-2-associated death promoter, thereby permitting survival signaling through BCL-XL. Pharmacological blockade of BCL-XL/BCL-2 partially abrogated the rescue effects conferred by PRKACA and PIM1, and sensitized cells to lapatinib treatment. These observations suggest that combined targeting of HER2 and the BCL-XL/BCL-2 anti-apoptotic pathway may increase responses to anti-HER2 therapy in breast cancer and decrease the emergence of resistant disease.	[Moody, S. E.; Schinzel, A. C.; Singh, S.; Izzo, F.; Strickland, M. R.; Luo, L.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Moody, S. E.; Luo, L.; Hahn, W. C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Moody, S. E.; Luo, L.; Wang, Z. C.; Hahn, W. C.] Harvard Univ, Sch Med, Boston, MA USA; [Thomas, S. R.; Boehm, J. S.] Broad Inst MIT & Harvard, Cambridge, MA USA; [Kim, S. Y.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Wang, Z. C.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Wang, Z. C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Duke University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 1538, Boston, MA 02115 USA.	William_Hahn@dfci.harvard.edu		Luo, Leo/0000-0002-3061-4287; Boehm, Jesse/0000-0002-6795-6336	Department of Defense [W81XWH-10-1-0575]; Komen Grant [CCR13262292]; Breast Cancer Research Foundation; NIH [R01 CA130988, U01 CA176058, U54 CA112962]; NATIONAL CANCER INSTITUTE [U01CA176058, R01CA130988, U54CA112962] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); Komen Grant(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Drs Ines Luis, Nancy Lin and Eric Winer for assistance in obtaining patient tissue samples. This work was supported by the Department of Defense Grant W81XWH-10-1-0575 and the Komen Grant CCR13262292 (to SEM), by the Breast Cancer Research Foundation (to ZCW), and by the NIH grants R01 CA130988, U01 CA176058 and U54 CA112962 (to WCH).	Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Beristain AG, 2015, ONCOGENE, V34, P1160, DOI 10.1038/onc.2014.41; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Beuschlein F, 2014, NEW ENGL J MED, V370, P1019, DOI 10.1056/NEJMoa1310359; Blackwell KL, 2009, ANN ONCOL, V20, P1026, DOI 10.1093/annonc/mdn759; Cao YN, 2014, SCIENCE, V344, P913, DOI 10.1126/science.1249480; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fleming GF, 2012, BREAST CANCER RES TR, V136, P355, DOI 10.1007/s10549-011-1910-7; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gu L, 2009, CLIN CANCER RES, V15, P7196, DOI 10.1158/1078-0432.CCR-09-0585; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Honeyman JN, 2014, SCIENCE, V343, P1010, DOI 10.1126/science.1249484; Iyer GH, 2005, J BIOL CHEM, V280, P8800, DOI 10.1074/jbc.M407586200; Jegg AM, 2012, BREAST CANCER RES TR, V136, P683, DOI 10.1007/s10549-012-2252-9; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kataoka Y, 2010, ANN ONCOL, V21, P255, DOI 10.1093/annonc/mdp304; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2007, MOL CANCER THER, V6, P667, DOI 10.1158/1535-7163.MCT-06-0423; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; Vegran F, 2009, BRIT J CANCER, V101, P1357, DOI 10.1038/sj.bjc.6605310; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Vogel C, 2001, EUR J CANCER, V37, pS25, DOI 10.1016/S0959-8049(00)00405-6; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wehrman TS, 2006, P NATL ACAD SCI USA, V103, P19063, DOI 10.1073/pnas.0605218103; Wu CW, 2004, NATURE, V432, P640, DOI 10.1038/nature03173; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	42	56	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2061	2071		10.1038/onc.2014.153	http://dx.doi.org/10.1038/onc.2014.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909179	Green Accepted, Green Submitted			2022-12-28	WOS:000353173400006
J	Jiang, Y; Yan, B; Lai, W; Shi, Y; Xiao, D; Jia, J; Liu, S; Li, H; Lu, J; Li, Z; Chen, L; Chen, X; Sun, L; Muegge, K; Cao, Y; Tao, Y				Jiang, Y.; Yan, B.; Lai, W.; Shi, Y.; Xiao, D.; Jia, J.; Liu, S.; Li, H.; Lu, J.; Li, Z.; Chen, L.; Chen, X.; Sun, L.; Muegge, K.; Cao, Y.; Tao, Y.			Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8	ONCOGENE			English	Article							RNA-POLYMERASE-II; DNA METHYLATION; EXPRESSION; DEMETHYLATION; POLYCOMB; HISTONE; CELLS; 5-HYDROXYMETHYLCYTOSINE; TRANSCRIPTION; EPIGENETICS	Epstein-Barr virus (EBV) causes human lymphoid malignancies, and the EBV product latent membrane protein 1 (LMP1) has been identified as an oncogene in epithelial carcinomas such as nasopharyngeal carcinoma (NPC). EBV can epigenetically reprogram lymphocyte-specific processes and induce cell immortalization. However, the interplay between LMP1 and the NPC host cell remains largely unknown. Here, we report that LMP1 is important to establish the Hox gene expression signature in NPC cell lines and tumor biopsies. LMP1 induces repression of several Hox genes in part via stalling of RNA polymerase II (RNA Pol II). Pol II stalling can be overcome by irradiation involving the epigenetic regulator TET3. Furthermore, we report that HoxC8, one of the genes silenced by LMP1, has a role in tumor growth. Ectopic expression of HoxC8 inhibits NPC cell growth in vitro and in vivo, modulates glycolysis and regulates the expression of tricarboxylic acid (TCA) cycle-related genes. We propose that viral latency products may repress via stalling key mediators that in turn modulate glycolysis.	[Jiang, Y.; Yan, B.; Lai, W.; Shi, Y.; Jia, J.; Li, H.; Lu, J.; Chen, L.; Chen, X.; Cao, Y.; Tao, Y.] Cent S Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Jiang, Y.; Yan, B.; Lai, W.; Shi, Y.; Li, H.; Lu, J.; Chen, L.; Chen, X.; Cao, Y.; Tao, Y.] Cent S Univ, Ctr Mol Imaging, Changsha 410078, Hunan, Peoples R China; [Xiao, D.] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410078, Hunan, Peoples R China; [Jia, J.; Liu, S.] Cent S Univ, Xiangya Hosp, Ctr Med Res, Changsha 410078, Hunan, Peoples R China; [Sun, L.] Cent S Univ, Xiangya Hosp, Ctr Mol Med, Changsha 410078, Hunan, Peoples R China; [Muegge, K.] NCI, Mouse Canc Genet Program, Basic Sci Program, Leidos Biomed Res Inc,Frederick Natl Lab Canc Res, Frederick, MD 21701 USA	Central South University; Central South University; Central South University; Central South University; Central South University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cao, Y (corresponding author), Cent S Univ, Xiangya Sch Med, Xiangya Rd 110, Changsha 410078, Hunan, Peoples R China.	ycao98@vip.sina.com; taoyong@csu.edu.cn	Lu, Jianhong/AAM-8841-2020	Lu, Jianhong/0000-0002-4436-1217; Jiang, Yiqun/0000-0003-3262-9498	National Basic Research Program of China [2011CB504300, 2015CB553903]; Hunan Natural Science Foundation of China [12JJ1013]; Fundamental Research Funds for the Central Universities [2011JQ019, 2013ZZTS074, 2013ZZTS284]; National Natural Science Foundation of China [81171881, 81372427, 81271763, 81302354]; Hunan Provincial Innovation Foundation For Postgraduate [71380100002]; Frederick National Laboratory for Cancer Research, National Institutes of Health [HHSN261200800001E]; NATIONAL CANCER INSTITUTE [ZIABC010014] Funding Source: NIH RePORTER	National Basic Research Program of China(National Basic Research Program of China); Hunan Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Innovation Foundation For Postgraduate; Frederick National Laboratory for Cancer Research, National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Basic Research Program of China (2011CB504300 (YT); 2015CB553903 (YT)); the Hunan Natural Science Foundation of China (12JJ1013 (YT)); the Fundamental Research Funds for the Central Universities (2011JQ019 (YT), 2013ZZTS074 (BY), 2013ZZTS284 (WL)); and the National Natural Science Foundation of China (81171881 and 81372427 (YT), 81271763 (SL), 81302354 (YS)); and the Hunan Provincial Innovation Foundation For Postgraduate (71380100002 (YJ)). This project has been funded in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.	Adwan H, 2011, BRIT J CANCER, V105, P288, DOI 10.1038/bjc.2011.217; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bijl J, 2008, ONCOGENE, V27, P6356, DOI 10.1038/onc.2008.233; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen J, 2013, CANCER LETT, V330, P217, DOI 10.1016/j.canlet.2012.11.051; Chopra VS, 2009, GENE DEV, V23, P1505, DOI 10.1101/gad.1807309; Chopra VS, 2009, CURR BIOL, V19, P688, DOI 10.1016/j.cub.2009.02.055; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Cortazar D, 2011, NATURE, V470, P419, DOI 10.1038/nature09672; Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Du YB, 2014, J SURG RES, V188, P442, DOI 10.1016/j.jss.2014.01.017; Feng SH, 2010, P NATL ACAD SCI USA, V107, P8689, DOI 10.1073/pnas.1002720107; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; Hau PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021176; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Hyland PL, 2011, J VIROL, V85, P10999, DOI 10.1128/JVI.00160-11; Carmona FJ, 2012, J PATHOL, V228, P230, DOI 10.1002/path.4011; Jiang YQ, 2013, BBA-REV CANCER, V1835, P155, DOI 10.1016/j.bbcan.2012.12.003; Klein E, 2007, ONCOGENE, V26, P1297, DOI 10.1038/sj.onc.1210240; Lai WW, 2013, INT J MOL SCI, V14, P2355, DOI 10.3390/ijms14022355; Levine M, 2011, CELL, V145, P502, DOI 10.1016/j.cell.2011.04.021; Li L, 2012, ONCOGENE, V31, P3901, DOI 10.1038/onc.2011.541; Li Y, 2014, ONCOTARGET, V5, P2596, DOI 10.18632/oncotarget.1841; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lin XC, 2012, CANCER SCI, V103, P993, DOI 10.1111/j.1349-7006.2012.02271.x; Liu S, 2013, BIOL REV, V88, P40, DOI 10.1111/j.1469-185X.2012.00237.x; Liu S, 2012, MOL BIOL REP, V39, P6179, DOI 10.1007/s11033-011-1435-5; Ma XQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024647; Marra L, 2013, CURR MED CHEM, V20, P833; McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108; Merrifield Matt, 2013, Frontiers in Genetics, V4, P40, DOI 10.3389/fgene.2013.00040; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; Misteli T, 2009, NAT REV MOL CELL BIO, V10, P243, DOI 10.1038/nrm2651; Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; Niller HH, 2009, SEMIN CANCER BIOL, V19, P158, DOI 10.1016/j.semcancer.2009.02.012; Oermann EK, 2012, SEMIN CELL DEV BIOL, V23, P370, DOI 10.1016/j.semcdb.2012.01.013; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Palermo RD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002334; Pastor WA, 2013, NAT REV MOL CELL BIO, V14, P341, DOI 10.1038/nrm3589; Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003; Pogribny I, 2004, BIOCHEM BIOPH RES CO, V320, P1253, DOI 10.1016/j.bbrc.2004.06.081; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Poteet E, 2013, J BIOL CHEM, V288, P9153, DOI 10.1074/jbc.M112.440354; Raab-Traub Nancy, 2009, P259, DOI 10.1007/978-0-387-68945-6_12; Rodini CO, 2012, INT J ONCOL, V40, P1180, DOI 10.3892/ijo.2011.1321; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Skalska L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000951; Smits KM, 2014, RADIOTHER ONCOL, V111, P168, DOI 10.1016/j.radonc.2014.05.001; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611; Tao YG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009163; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Verweij FJ, 2011, EMBO J, V30, P2115, DOI 10.1038/emboj.2011.123; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu JW, 2002, J VIROL, V76, P4080, DOI 10.1128/JVI.76.8.4080-4086.2002; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366	70	41	45	4	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6079	6091		10.1038/onc.2015.53	http://dx.doi.org/10.1038/onc.2015.53			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25745994	Green Accepted			2022-12-28	WOS:000366113800005
J	Nakagawa, H; Wardell, CP; Furuta, M; Taniguchi, H; Fujimoto, A				Nakagawa, H.; Wardell, C. P.; Furuta, M.; Taniguchi, H.; Fujimoto, A.			Cancer whole-genome sequencing: present and future	ONCOGENE			English	Review							TERT PROMOTER MUTATIONS; SOMATIC MUTATIONS; GENE; IDENTIFICATION; LANDSCAPE; DNA; RETROTRANSPOSITION; REARRANGEMENTS; INTEGRATION; FREQUENCY	Recent explosive advances in next-generation sequencing technology and computational approaches to massive data enable us to analyze a number of cancer genome profiles by whole-genome sequencing (WGS). To explore cancer genomic alterations and their diversity comprehensively, global and local cancer genome-sequencing projects, including ICGC and TCGA, have been analyzing many types of cancer genomes mainly by exome sequencing. However, there is limited information on somatic mutations in non-coding regions including untranslated regions, introns, regulatory elements and non-coding RNAs, and rearrangements, sometimes producing fusion genes, and pathogen detection in cancer genomes remain widely unexplored. WGS approaches can detect these unexplored mutations, as well as coding mutations and somatic copy number alterations, and help us to better understand the whole landscape of cancer genomes and elucidate functions of these unexplored genomic regions. Analysis of cancer genomes using the present WGS platforms is still primitive and there are substantial improvements to be made in sequencing technologies, informatics and computer resources. Taking account of the extreme diversity of cancer genomes and phenotype, it is also required to analyze much more WGS data and integrate these with multi-omics data, functional data and clinical-pathological data in a large number of sample sets to interpret them more fully and efficiently.	[Nakagawa, H.; Wardell, C. P.; Furuta, M.; Taniguchi, H.; Fujimoto, A.] RIKEN Ctr Integrat Med Sci, Lab Genome Sequencing Anal, Tokyo, Japan	RIKEN	Nakagawa, H (corresponding author), RIKEN Ctr Integrat Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hidewaki@ims.u-tokyo.ac.jp	Taniguchi, Hiroaki/H-6329-2016; Wardell, Christopher/B-5053-2018	Wardell, Christopher/0000-0002-9416-7818; Taniguchi, Hiroaki/0000-0001-7270-390X	RIKEN President's Fund; Princess Takamatsu Cancer Research Fund; Takeda Science Foundation	RIKEN President's Fund; Princess Takamatsu Cancer Research Fund; Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank researchers and technical staffs in RIKEN-IMS and Professor Miyano and his fellows in Human Genome Center, Institute of Medical Science, The University of Tokyo for their great efforts to cancer genome sequencing in ICGC project. The supercomputing resource 'SHIROKANE' was provided by Human Genome Center, The University of Tokyo (http://sc.hgc.jp/shirokane.html). This work was supported partially by RIKEN President's Fund 2011, the Princess Takamatsu Cancer Research Fund, and Takeda Science Foundation.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Boutros PC, 2014, NAT GENET, V46, P318, DOI 10.1038/ng.2932; Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128; Cao SB, 2015, J VIROL, V89, P713, DOI 10.1128/JVI.02570-14; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Cook LB, 2014, BLOOD, V123, P3925, DOI 10.1182/blood-2014-02-553602; Dekker J, 2013, NAT REV GENET, V14, P390, DOI 10.1038/nrg3454; Dove ES, 2015, EUR J HUM GENET, V23, P1271, DOI 10.1038/ejhg.2014.196; DULBECCO R, 1986, SCIENCE, V231, P1055, DOI 10.1126/science.3945817; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fredriksson NJ, 2014, NAT GENET, V46, P1258, DOI 10.1038/ng.3141; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Kim TM, 2013, CELL, V155, P858, DOI 10.1016/j.cell.2013.10.015; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Korbel JO, 2013, CELL, V152, P1226, DOI 10.1016/j.cell.2013.02.023; Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Liang H, 2012, GENOME RES, V22, P2120, DOI 10.1101/gr.137596.112; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Mardis ER, 2009, HUM MOL GENET, V18, pR163, DOI 10.1093/hmg/ddp396; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Nagarajan N, 2013, NAT REV GENET, V14, P157, DOI 10.1038/nrg3367; Nakao M, 1996, LEUKEMIA, V10, P1911; Northcott PA, 2014, NATURE, V511, P428, DOI 10.1038/nature13379; Oda Y, 2009, CANCER SCI, V100, P200, DOI 10.1111/j.1349-7006.2008.01024.x; Oikonomou P, 2014, CELL REP, V7, P281, DOI 10.1016/j.celrep.2014.03.001; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shen R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035236; Shiraishi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114263; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Treangen TJ, 2012, NAT REV GENET, V13, P36, DOI 10.1038/nrg3117; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang QG, 2013, GENOME MED, V5, DOI 10.1186/gm495; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Yang LX, 2013, CELL, V153, P919, DOI 10.1016/j.cell.2013.04.010; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhao WX, 2014, NAT BIOTECHNOL, V32, P387, DOI 10.1038/nbt.2851	81	62	64	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5943	5950		10.1038/onc.2015.90	http://dx.doi.org/10.1038/onc.2015.90			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25823020				2022-12-28	WOS:000366113500001
J	Hernanda, PY; Chen, K; Das, AM; Sideras, K; Wang, W; Li, J; Cao, W; Bots, SJA; Kodach, LL; de Man, RA; Ijzermans, JNM; Janssen, HLA; Stubbs, AP; Sprengers, D; Bruno, MJ; Metselaar, HJ; Hagen, TLM; Kwekkeboom, J; Peppelenbosch, MP; Pan, Q				Hernanda, P. Y.; Chen, K.; Das, A. M.; Sideras, K.; Wang, W.; Li, J.; Cao, W.; Bots, S. J. A.; Kodach, L. L.; de Man, R. A.; Ijzermans, J. N. M.; Janssen, H. L. A.; Stubbs, A. P.; Sprengers, D.; Bruno, M. J.; Metselaar, H. J.; Ten Hagen, T. L. M.; Kwekkeboom, J.; Peppelenbosch, M. P.; Pan, Q.			SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEINS; GROWTH-FACTOR-BETA; TGF-BETA; COLORECTAL-CANCER; SIGNALING PATHWAYS; PANCREATIC-CANCER; SUPPRESSOR GENE; CELL-MIGRATION; EXPRESSION; LIVER	Further understanding of the molecular biology and pathogenesis of hepatocellular carcinoma (HCC) is crucial for future therapeutic development. SMAD4, recognized as an important tumor suppressor, is a central mediator of transforming growth factor beta (TGFB) and bone morphogenetic protein (BMP) signaling. This study investigated the role of SMAD4 in HCC. Nuclear localization of SMAD4 was observed in a cohort of 140 HCC patients using tissue microarray. HCC cell lines were used for functional assay in vitro and in immune-deficient mice. Nuclear SMAD4 levels were significantly increased in patient HCC tumors as compared with adjacent tissues. Knockdown of SMAD4 significantly reduced the efficiency of colony formation and migratory capacity of HCC cells in vitro and was incompatible with HCC tumor initiation and growth in mice. Knockdown of SMAD4 partially conferred resistance to the anti-growth effects of BMP ligand in HCC cells. Importantly, simultaneous elevation of SMAD4 and phosphorylated SMAD2/3 is significantly associated with poor patient outcome after surgery. Although high levels of SMAD4 can also mediate an antitumor function by coupling with phosphorylated SMAD1/5/8, this signaling, however, is absent in majority of our HCC patients. In conclusion, this study revealed a highly non-canonical tumor-promoting function of SMAD4 in HCC. The drastic elevation of nuclear SMAD4 in sub-population of HCC tumors highlights its potential as an outcome predictor for patient stratification and a target for personalized therapeutic development.	[Hernanda, P. Y.; Chen, K.; Sideras, K.; Wang, W.; Li, J.; Cao, W.; Bots, S. J. A.; Kodach, L. L.; de Man, R. A.; Janssen, H. L. A.; Sprengers, D.; Bruno, M. J.; Metselaar, H. J.; Kwekkeboom, J.; Peppelenbosch, M. P.; Pan, Q.] Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, Dept Gastroenterol & Hepatol, NL-3015 CE Rotterdam, Netherlands; [Hernanda, P. Y.; Chen, K.; Sideras, K.; Wang, W.; Li, J.; Cao, W.; Bots, S. J. A.; Kodach, L. L.; de Man, R. A.; Janssen, H. L. A.; Sprengers, D.; Bruno, M. J.; Metselaar, H. J.; Kwekkeboom, J.; Peppelenbosch, M. P.; Pan, Q.] Postgrad Sch Mol Med, NL-3015 CE Rotterdam, Netherlands; [Hernanda, P. Y.] Wijaya Kusuma Univ, Biomol Res Ctr, Lab Med Genet, Surabaya, Indonesia; [Chen, K.] Zhejiang Sci Tech Univ, Coll Life Sci, BioX Ctr, Hangzhou, Zhejiang, Peoples R China; [Das, A. M.; Ten Hagen, T. L. M.] Erasmus Univ, Med Ctr, Dept Surg, Lab Expt Surg Oncol Sect Surg Oncol, NL-3015 CE Rotterdam, Netherlands; [Ijzermans, J. N. M.] Erasmus Univ, Med Ctr, Dept Surg, NL-3015 CE Rotterdam, Netherlands; [Janssen, H. L. A.] Univ Hlth Network, Div Gastroenterol, Toronto, ON, Canada; [Stubbs, A. P.] Erasmus Univ, Med Ctr, Dept Bioinformat, NL-3015 CE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Zhejiang Sci-Tech University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Erasmus University Rotterdam; Erasmus MC	Pan, Q (corresponding author), Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, Dept Gastroenterol & Hepatol, Room Na 617,sGravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	q.pan@erasmusmc.nl	Peppelenbosch, Maikel P./U-5304-2019	Pan, Qiuwei/0000-0001-9982-6184; hernanda, pratika yuhyi/0000-0003-2025-2136; Peppelenbosch, Maikel/0000-0001-9112-6028; Kodach, Liudmila/0000-0003-2487-3204; Sideras, Kostandinos/0000-0002-4698-2105	Daniel den Hoed Foundation; Netherlands Organization for Scientific Research (NWO/ZonMw) [916-13-032]; Dutch Digestive Foundation (MLDS) [CDG 1304]; European Association for the Study of the Liver (EASL); Science and Technology Department Commonwealth Technology Applied Research Project of Zhejiang Province, China [2012F82G2060018]; National Nature Science Foundation of China [81272687]	Daniel den Hoed Foundation; Netherlands Organization for Scientific Research (NWO/ZonMw)(Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Health Research and Development); Dutch Digestive Foundation (MLDS); European Association for the Study of the Liver (EASL); Science and Technology Department Commonwealth Technology Applied Research Project of Zhejiang Province, China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank the support from the Daniel den Hoed Foundation for a Centennial Award fellowship (to Q Pan), the Netherlands Organization for Scientific Research (NWO/ZonMw) for a VENI grant (no. 916-13-032) (to Q Pan), the Dutch Digestive Foundation (MLDS) for a career development grant (no. CDG 1304) (to Q Pan) and the European Association for the Study of the Liver (EASL) for a Sheila Sherlock Fellowship (to Q Pan). Support from the Science and Technology Department Commonwealth Technology Applied Research Project (no. 2012F82G2060018) of Zhejiang Province, China and the National Nature Science Foundation of China (No. 81272687) (to K Chen) is gratefully acknowledged. We thank Dr Ron Smits from Erasmus Medical Center Rotterdam for critical reading of the manuscript and thank Dr Jie Xu from the Animal Care at Hangzhou Normal University, Hangzhou, China for helping with the animal experiments.	Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Argani P, 2001, CANCER, V91, P1332; Caputo V, 2012, AM J HUM GENET, V90, P161, DOI 10.1016/j.ajhg.2011.12.011; Carreira AC, 2014, J DENT RES, V93, P335, DOI 10.1177/0022034513518561; Chiu CY, 2012, MOL CANCER RES, V10, P415, DOI 10.1158/1541-7786.MCR-11-0293; Das AM, 2014, ANGIOGENESIS, V17, P163, DOI 10.1007/s10456-013-9385-2; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467; Hernanda PY, 2013, CARCINOGENESIS, V34, P2330, DOI 10.1093/carcin/bgt210; Hiwatashi K, 2009, ANN SURG ONCOL, V16, P3176, DOI 10.1245/s10434-009-0614-2; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Itatani Y, 2013, GASTROENTEROLOGY, V145, P1064, DOI 10.1053/j.gastro.2013.07.033; Kang YK, 2002, HUM PATHOL, V33, P877, DOI 10.1053/hupa.2002.127444; Kocabayoglu Peri, 2013, Front Biosci (Schol Ed), V5, P217; Kodach LL, 2008, CANCER, V112, P300, DOI 10.1002/cncr.23160; Kodach LL, 2007, GASTROENTEROLOGY, V133, P1272, DOI 10.1053/j.gastro.2007.08.021; Korsse SE, 2013, CARCINOGENESIS, V34, P1611, DOI 10.1093/carcin/bgt068; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li Q, 2013, CANCER SCI, V104, P398, DOI 10.1111/cas.12093; Maegdefrau U, 2012, EXP MOL PATHOL, V92, P74, DOI 10.1016/j.yexmp.2011.10.004; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Matsuzaki K, 2007, HEPATOLOGY, V46, P48, DOI 10.1002/hep.21672; Matsuzaki K, 2013, CYTOKINE GROWTH F R, V24, P385, DOI 10.1016/j.cytogfr.2013.06.002; Matsuzaki K, 2009, CANCER RES, V69, P5321, DOI 10.1158/0008-5472.CAN-08-4203; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Mullauer L, 1996, HEPATOLOGY, V23, P840, DOI 10.1002/hep.510230427; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Pan QW, 2008, ACTA ONCOL, V47, P135, DOI 10.1080/02841860701403053; Pan QW, 2011, FEBS LETT, V585, P1025, DOI 10.1016/j.febslet.2011.02.035; Pedroza-Gonzalez A, 2013, HEPATOLOGY, V57, P183, DOI 10.1002/hep.26013; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Sakai H, 2012, CLIN EXP METASTAS, V29, P327, DOI 10.1007/s10585-012-9453-9; Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Tangkijvanich P, 2000, J CLIN GASTROENTEROL, V31, P302, DOI 10.1097/00004836-200012000-00007; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; van Horssen R, 2006, J CELL BIOCHEM, V99, P1536, DOI 10.1002/jcb.20994; Virtanen S, 2011, EXP CELL RES, V317, P2136, DOI 10.1016/j.yexcr.2011.06.001; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wang L, 2012, INT J CANCER, V131, P1941, DOI 10.1002/ijc.27444; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yao L, 2012, ASIAN PAC J CANCER P, V13, P1297, DOI 10.7314/APJCP.2012.13.4.1297; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhang LX, 2012, CANCER RES, V72, P4276, DOI 10.1158/0008-5472.CAN-12-1013	52	51	53	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5055	5068		10.1038/onc.2014.425	http://dx.doi.org/10.1038/onc.2014.425			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531314				2022-12-28	WOS:000361693300006
J	Yoo, BH; Masson, O; Li, Y; Khan, IA; Gowda, PS; Rosen, KV				Yoo, B. H.; Masson, O.; Li, Y.; Khan, I. A.; Gowda, P. S.; Rosen, K. V.			Anoikis of colon carcinoma cells triggered by beta-catenin loss can be enhanced by tumor necrosis factor receptor 1 antagonists	ONCOGENE			English	Article							NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; DOWN-REGULATION; GROWTH-FACTOR; INDUCED RESISTANCE; APC MUTATIONS; UP-REGULATION; TNF RECEPTOR; IN-VIVO; APOPTOSIS	Detachment of non-malignant epithelial cells from the extracellular matrix causes their apoptosis, a phenomenon called anoikis. By contrast, carcinoma cells are anoikis-resistant, and this resistance is thought to be critical for tumor progression. Many oncogenes trigger not only anti-but also pr-apoptotic signals. The proapoptotic events represent an aspect of a phenomenon called oncogenic stress, which acts as a safeguard mechanism blocking tumor initiation. In cells that become malignant, oncogene-induced antiapoptotic signals outbalance the proapoptotic ones. It is now thought that treatments blocking the antiapoptotic events but preserving the proapoptotic signals can be particularly effective in killing tumor cells. Whether or not oncogenes induce any proanoikis signals that can be used for enhancing the efficiency of approaches aimed at triggering anoikis of cancer cells has never been explored. beta-Catenin is a major oncoprotein that is often activated in colorectal cancer and promotes tumor progression via mechanisms that are understood only in part. We found here that beta-catenin triggers both anti-and proanoikis signals in colon cancer cells. We observed that the antianoikis signals prevail and the cells become anoikis-resistant. We further established that one proanoikis signal in these cells is triggered by beta-catenin-induced downregulation of an apoptosis inhibitor tumor necrosis factor receptor 1 (TNFR1) and subsequent reduction of the activity of a transcription factor NF-kappa B (nuclear factor-kappa B), a mediator of TNFR1 signaling. We also found that the effect of beta-catenin on TNFR1 requires the presence of transcription factor TCF1, a beta-catenin effector. We demonstrated that ablation of beta-catenin in colon cancer cells triggers their anoikis and that this anoikis is enhanced even further if low TNFR1 or NF-kappa B activity is artificially preserved in the beta-catenin-deprived cells. Thus, inhibition of TNFR1 or NF-kappa B activity can be expected to enhance the efficiency of approaches aimed at blocking beta-catenin-driven anoikis resistance of colon carcinoma cells.	Dalhousie Univ, Dept Pediat, Halifax, NS B3H 3J5, Canada; Dalhousie Univ, Dept Biochem, Halifax, NS B3H 3J5, Canada; Dalhousie Univ, Dept Mol Biol, Halifax, NS B3H 3J5, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Rosen, KV (corresponding author), Atlantic Res Ctr, Room C-304,CRC,5849 Univ Ave,POB 15000, Halifax, NS B3H 4R2, Canada.	kirill.rosen@dal.ca		Rosen, Kirill/0000-0002-4317-9907	Canadian Institutes of Health Research/Nova Scotia Regional Partnership Program (CIHR/NS RPP) [125109]; IWK Health Centre	Canadian Institutes of Health Research/Nova Scotia Regional Partnership Program (CIHR/NS RPP)(Canadian Institutes of Health Research (CIHR)); IWK Health Centre	This study was supported by the Canadian Institutes of Health Research/Nova Scotia Regional Partnership Program (CIHR/NS RPP) Grant 125109 held by KR. KR was a recipient of the CIHR/NS RPP New Investigator Salary award. YL and PSG were recipients of the IWK Health Centre Post Doctoral Fellowship. BHY was a recipient of the IWK Health Centre Research Associateship.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; Au PYB, 2005, ONCOGENE, V24, P3196, DOI 10.1038/sj.onc.1208516; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Brasse-Lagnel C, 2007, FEBS J, V274, P5250, DOI 10.1111/j.1742-4658.2007.06047.x; Cohen-Lahav M, 2006, NEPHROL DIAL TRANSPL, V21, P889, DOI 10.1093/ndt/gfi254; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Delage B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.83; Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Frankel A, 2001, CANCER RES, V61, P4837; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Haigis KM, 2011, NAT GENET, V43, P177, DOI 10.1038/ng0311-177; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu DK, 1996, AM J PATHOL, V148, P1661; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jobin C, 1998, J IMMUNOL, V160, P410; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kaltschmidt B, 2006, MOL CELL BIOL, V26, P2936, DOI 10.1128/MCB.26.8.2936-2946.2006; KEMPER O, 1993, GENE, V134, P209, DOI 10.1016/0378-1119(93)90095-K; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim HRC, 1999, CANCER RES, V59, P4148; Kitamura T, 2005, AM J PHYSIOL-CELL PH, V289, pC82, DOI 10.1152/ajpcell.00486.2004; Kohler EM, 2009, HUM MOL GENET, V18, P213, DOI 10.1093/hmg/ddn338; Kontermann RE, 2008, J IMMUNOTHER, V31, P225, DOI 10.1097/CJI.0b013e31816a88f9; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Lei QB, 2006, DEV CELL, V11, P325, DOI 10.1016/j.devcel.2006.06.013; Li HB, 2009, J BIOL CHEM, V284, P2012, DOI 10.1074/jbc.M805612200; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Liu YC, 1996, EXP CELL RES, V228, P206, DOI 10.1006/excr.1996.0318; Liu Z, 2006, ONCOGENE, V25, P7680, DOI 10.1038/sj.onc.1209753; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; LJUBIMOV AV, 1992, INT J CANCER, V50, P562, DOI 10.1002/ijc.2910500412; Lobito AA, 2006, BLOOD, V108, P1320, DOI 10.1182/blood-2005-11-006783; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mahon PC, 2007, CANCER RES, V67, P6786, DOI 10.1158/0008-5472.CAN-07-0440; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Ratti M, 2014, ANTI-CANCER DRUG, V25, P127, DOI 10.1097/CAD.0000000000000035; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; Van Herreweghe F, 2010, CELL MOL LIFE SCI, V67, P1567, DOI 10.1007/s00018-010-0283-0; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810; Yoo BH, 2012, INT J CANCER, V131, P357, DOI 10.1002/ijc.26368; Yoshimura H, 2003, ANTICANCER RES, V23, P85; Yun K, 2009, J IMMUNOL, V183, P5129, DOI 10.4049/jimmunol.0802744	77	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4939	4951		10.1038/onc.2014.415	http://dx.doi.org/10.1038/onc.2014.415			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531320				2022-12-28	WOS:000361693000004
J	Dillon, LM; Bean, JR; Yang, W; Shee, K; Symonds, LK; Balko, JM; McDonald, WH; Liu, S; Gonzalez-Angulo, AM; Mills, GB; Arteaga, CL; Miller, TW				Dillon, L. M.; Bean, J. R.; Yang, W.; Shee, K.; Symonds, L. K.; Balko, J. M.; McDonald, W. H.; Liu, S.; Gonzalez-Angulo, A. M.; Mills, G. B.; Arteaga, C. L.; Miller, T. W.			P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer	ONCOGENE			English	Article							P21-ACTIVATED-KINASE-1 PAK1; TUMOR-SUPPRESSOR; EXCHANGE FACTOR; RAC-GEF; PATHWAY; KINASE; IDENTIFICATION; INHIBITOR; PHOSPHORYLATION; RESISTANCE	Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP3) in the inner leaflet of the plasma membrane. PIP3 recruits pleckstrin homology domain-containing proteins to the membrane to activate oncogenic signaling cascades. Anticancer therapeutics targeting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway are in clinical development. In a mass spectrometric screen to identify PIP3-regulated proteins in breast cancer cells, levels of the Rac activator PIP3-dependent Rac exchange factor-1 (P-REX1) increased in response to PI3K inhibition, and decreased upon loss of the PI3K antagonist phosphatase and tensin homolog (PTEN). P-REX1 mRNA and protein levels were positively correlated with ER expression, and inversely correlated with PI3K pathway activation in breast tumors as assessed by gene expression and phosphoproteomic analyses. P-REX1 increased activation of Rac1, PI3K/AKT and MEK/ERK signaling in a PTEN-independent manner, and promoted cell and tumor viability. Loss of P-REX1 or inhibition of Rac suppressed PI3K/AKT and MEK/ERK, and decreased viability. P-REX1 also promoted insulin-like growth factor-1 receptor activation, suggesting that P-REX1 provides positive feedback to activators upstream of PI3K. In support of a model where PIP3-driven P-REX1 promotes both PI3K/AKT and MEK/ERK signaling, high levels of P-REX1 mRNA (but not phospho-AKT or a transcriptomic signature of PI3K activation) were predictive of sensitivity to PI3K inhibitors among breast cancer cell lines. P-REX1 expression was highest in estrogen receptor-positive breast tumors compared with many other cancer subtypes, suggesting that neutralizing the P-REX1/Rac axis may provide a novel therapeutic approach to selectively abrogate oncogenic signaling in breast cancer cells.	[Dillon, L. M.; Bean, J. R.; Yang, W.; Shee, K.; Symonds, L. K.; Miller, T. W.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; [Balko, J. M.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37212 USA; [Balko, J. M.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program, Nashville, TN 37212 USA; [McDonald, W. H.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Prote Lab, Nashville, TN 37212 USA; [Liu, S.; Gonzalez-Angulo, A. M.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Liu, S.; Gonzalez-Angulo, A. M.; Mills, G. B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Arteaga, C. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37212 USA; [Miller, T. W.] Norris Cotton Canc Ctr, Geisel Sch Med Dartmouth, Comprehens Breast Canc Program, Lebanon, NH USA	Dartmouth College; Norris Cotton Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Vanderbilt University; Dartmouth College; Norris Cotton Cancer Center	Miller, TW (corresponding author), Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, One Med Ctr Dr HB-7936, Lebanon, NH 03756 USA.	Todd.W.Miller@Dartmouth.edu	Shee, Kevin/V-6803-2019; McDonald, W. Hayes/B-4109-2016	Shee, Kevin/0000-0001-5378-7650; McDonald, W. Hayes/0000-0002-3510-426X; Dillon, Lloye/0000-0002-5118-1126	NIH [K99/R00CA142899]; Dartmouth College Norris Cotton Cancer Center Support Grant [P30CA023108]; Vanderbilt-Ingram Cancer Center Breast Cancer Specialized Program of Research Excellence Grant [P50CA98131]; Vanderbilt-Ingram Cancer Center Support Grant [P30CA68485]; American Cancer Society [IRG-58-009-50, 121329-RSG-11-187-01-TBG]; Commonwealth Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R00CA142899, P50CA098131, P30CA023108, P30CA068485, K99CA142899] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dartmouth College Norris Cotton Cancer Center Support Grant; Vanderbilt-Ingram Cancer Center Breast Cancer Specialized Program of Research Excellence Grant; Vanderbilt-Ingram Cancer Center Support Grant; American Cancer Society(American Cancer Society); Commonwealth Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Chad Creighton for advice on gene expression analysis, and the Norris Cotton Cancer Center Transgenic and Genetic Construct Shared Resource and Genomics and Molecular Biology Shared Resource for assistance. This work was financially supported by NIH: K99/R00CA142899 (TWM), Dartmouth College Norris Cotton Cancer Center Support Grant P30CA023108, Vanderbilt-Ingram Cancer Center Breast Cancer Specialized Program of Research Excellence Grant P50CA98131 and Vanderbilt-Ingram Cancer Center Support Grant P30CA68485; the American Cancer Society IRG-58-009-50 (TWM) and 121329-RSG-11-187-01-TBG (to AMG); and The Commonwealth Foundation for Cancer Research (to AMG).	Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Guillermet-Guibert J, 2008, P NATL ACAD SCI USA, V105, P8292, DOI 10.1073/pnas.0707761105; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hernandez-Negrete I, 2007, J BIOL CHEM, V282, P23708, DOI 10.1074/jbc.M703771200; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Khatri S, 2010, J BIOL CHEM, V285, P15960, DOI 10.1074/jbc.M110.121871; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; Ma ZQ, 2009, J PROTEOME RES, V8, P3872, DOI 10.1021/pr900360j; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Martinez MN, 2012, J LIPID RES, V53, P379, DOI 10.1194/jlr.M019752; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Miller TW, 2009, CANCER RES, V69, P4192, DOI 10.1158/0008-5472.CAN-09-0042; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; O'Brien C, 2010, CLIN CANCER RES, V16, P3670, DOI 10.1158/1078-0432.CCR-09-2828; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Saini KS, 2013, CANCER TREAT REV, V39, P935, DOI 10.1016/j.ctrv.2013.03.009; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Yang HW, 2012, MOL CELL, V47, P281, DOI 10.1016/j.molcel.2012.05.007; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	46	67	76	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3968	3976		10.1038/onc.2014.328	http://dx.doi.org/10.1038/onc.2014.328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284585	Green Accepted			2022-12-28	WOS:000358544200009
J	Hsu, YL; Hung, JY; Chou, SH; Huang, MS; Tsai, MJ; Lin, YS; Chiang, SY; Ho, YW; Wu, CY; Kuo, PL				Hsu, Y-L; Hung, J-Y; Chou, S-H; Huang, M-S; Tsai, M-J; Lin, Y-S; Chiang, S-Y; Ho, Y-W; Wu, C-Y; Kuo, P-L			Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; CELL-MIGRATION; HIPPO PATHWAY; BREAST-CANCER; IN-VIVO; YAP; GROWTH; PROLIFERATION; OVEREXPRESSION; TRANSCRIPTION	Lung cancer is the leading cause of cancer death worldwide, with metastasis underlying majority of related deaths. Angiomotin (AMOT), a scaffold protein, has been shown to interact with oncogenic Yes-associated protein/transcriptional co-activator with a PDZ-binding motif (YAP/TAZ) proteins, suggesting a potential role in tumor progression. However, the functional role of AMOT in lung cancer remains unknown. This study aimed to identify the patho-physiological characteristics of AMOT in lung cancer progression. Results revealed that AMOT expression was significantly decreased in clinical lung cancer specimens. Knockdown of AMOT in a low metastatic CL1-0 lung cancer cell line initiated cancer proliferation, migration, invasion and epithelial-mesenchymal transition. The trigger of cancer progression caused by AMOT loss was transduced by decreased cytoplasmic sequestration and increased nuclear translocation of oncogenic co-activators YAP/TAZ, leading to increased expression of the growth factor, Cyr61. Tumor promotion by AMOT knockdown was reversed when YAP/TAZ or Cyr61 was absent. Further, AMOT knockdown increased the growth and spread of Lewis lung carcinoma in vivo. These findings suggest that AMOT is a crucial suppressor of lung cancer metastasis and highlight its critical role as a tumor suppressor and its potential as a prognostic biomarker and therapeutic target for lung cancer.	[Hsu, Y-L; Tsai, M-J] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan; [Hung, J-Y; Huang, M-S; Tsai, M-J; Lin, Y-S; Wu, C-Y] Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan; [Hung, J-Y; Huang, M-S] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung, Taiwan; [Chou, S-H] Kaohsiung Med Univ Hosp, Dept Surg, Div Chest Surg, Kaohsiung, Taiwan; [Chiang, S-Y; Ho, Y-W; Kuo, P-L] Kaohsiung Med Univ, Coll Med, Inst Clin Med, Kaohsiung, Taiwan; [Kuo, P-L] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung 807, Taiwan; [Kuo, P-L] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 80424, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; National Sun Yat Sen University	Kuo, PL (corresponding author), Kaohsiung Med Univ, Coll Med, Inst Clin Med, 100 Shih Chuan First Rd, Kaohsiung 807, Taiwan.	kuopolin@seed.net.tw	Tsai, Ming-Ju/D-5566-2011		National Science Council of Taiwan [NSC 101-2628-B-037-001-MY3, NSC 101-2320-B-037-043-MY3]; Ministry of Science and Technology [MOST 103-2320-B-037-006-MY3, MOST 103-2314-B-037-052]; Kaohsiung Medical University [KMU-DT103008]; Research Center for Environmental Medicine, Kaohsiung Medical University [KMU-TP103A19, KMU-TP103A20]; Kaohsiung Medical University Hospital Research Foundation [KMUH102-2T06]; Center for Resources, Research, and Development of Kaohsiung Medical University	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University; Research Center for Environmental Medicine, Kaohsiung Medical University; Kaohsiung Medical University Hospital Research Foundation; Center for Resources, Research, and Development of Kaohsiung Medical University	This study was supported by grants from the National Science Council of Taiwan (NSC 101-2628-B-037-001-MY3; NSC 101-2320-B-037-043-MY3), the Ministry of Science and Technology (MOST 103-2320-B-037-006-MY3; MOST 103-2314-B-037-052), the Kaohsiung Medical University "Aim for the top 500 universities grant, Grant No. KMU-DT103008", the Research Center for Environmental Medicine, Kaohsiung Medical University (KMU-TP103A19; KMU-TP103A20) and the Kaohsiung Medical University Hospital Research Foundation (KMUH102-2T06). We also thank the Center for Resources, Research, and Development of Kaohsiung Medical University for their support with the instrumentation.	Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Arigoni M, 2012, ANGIOGENESIS, V15, P305, DOI 10.1007/s10456-012-9263-3; Avruch J, 2012, CELL CYCLE, V11, P1090, DOI 10.4161/cc.11.6.19453; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Dai XM, 2013, J BIOL CHEM, V288, P34041, DOI 10.1074/jbc.M113.518019; Ernkvist M, 2008, BBA-MOL CELL RES, V1783, P429, DOI 10.1016/j.bbamcr.2007.11.018; Fanning AS, 2012, MOL BIOL CELL, V23, P577, DOI 10.1091/mbc.E11-09-0791; Harris LG, 2012, ONCOGENE, V31, P3370, DOI 10.1038/onc.2011.496; Holmgren L, 2006, P NATL ACAD SCI USA, V103, P9208, DOI 10.1073/pnas.0603110103; Hsu YL, 2013, CARCINOGENESIS, V34, P1370, DOI 10.1093/carcin/bgt040; Hung JJ, 2013, ANN SURG, V258, P1079, DOI 10.1097/SLA.0b013e31828920c0; Jandova J, 2012, CELL BIOCHEM FUNCT, V30, P687, DOI 10.1002/cbf.2853; Jones AC, 2012, PROSTATE, V72, P1159, DOI 10.1002/pros.22465; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kao YR, 2003, CLIN CANCER RES, V9, P2807; Kozu Y, 2013, EUR J CARDIO-THORAC, V44, pE53, DOI 10.1093/ejcts/ezt192; Lin JPA, 2012, CANCER IMMUNOL IMMUN, V61, P677, DOI 10.1007/s00262-011-1135-y; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Moleirinho S, 2014, FEBS LETT, V588, P2693, DOI 10.1016/j.febslet.2014.02.006; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Paramasivam M, 2011, MOL BIOL CELL, V22, P3725, DOI 10.1091/mbc.E11-04-0300; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Ranahan WP, 2011, CANCER RES, V71, P2203, DOI 10.1158/0008-5472.CAN-10-1995; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Schutte U, 2014, TRANSL ONCOL, V7, P309, DOI 10.1016/j.tranon.2014.02.005; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Su LL, 2012, CHINESE MED J-PEKING, V125, P4003, DOI 10.3760/cma.j.issn.0366-6999.2012.22.017; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sun XJ, 2014, CARCINOGENESIS, V35, P184, DOI 10.1093/carcin/bgt276; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wells CD, 2006, CELL, V125, P535, DOI 10.1016/j.cell.2006.02.045; Wu DD, 2014, J BIOL CHEM, V289, P5774, DOI 10.1074/jbc.M113.533042; Xu CM, 2013, CANCER GENE THER, V20, P453, DOI 10.1038/cgt.2013.40; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhi X, 2012, AM J PATHOL, V180, P2452, DOI 10.1016/j.ajpath.2012.02.025; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	52	62	69	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4056	4068		10.1038/onc.2014.333	http://dx.doi.org/10.1038/onc.2014.333			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25381822				2022-12-28	WOS:000358780500004
J	Jia, H; Cong, Q; Chua, JFL; Liu, H; Xia, X; Zhang, X; Lin, J; Habib, SL; Ao, J; Zuo, Q; Fu, C; Li, B				Jia, H.; Cong, Q.; Chua, J. F. L.; Liu, H.; Xia, X.; Zhang, X.; Lin, J.; Habib, S. L.; Ao, J.; Zuo, Q.; Fu, C.; Li, B.			p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance	ONCOGENE			English	Article							P57(KIP2) EXPRESSION; INHIBITOR P57(KIP2); CDK INHIBITORS; P38; P57; ATM; DIFFERENTIATION; CANCER; PROLIFERATION; PROTEIN	The DNA damage response (DDR) helps to maintain genome integrity, suppress tumorigenesis and mediate the radiotherapeutic and chemotherapeutic effects on cancer. Here we report that p57Kip2, a cyclin-dependent kinase (CDK) inhibitor implicated in the development of tumor-prone Beckwith-Wiedemann syndrome, is an effector molecule of the DNA-damage response. Genotoxic stress induces p57Kip2 expression via the bone morphogenetic protein-Smad1 and Atm-p38MAPK-Atf2 pathways in p53-proficient or -deficient cells and requires the Smad1-Atf2 complex that facilitates their recruitment to the p57Kip2 promoter. Elevated p57Kip2 induces G1/S phase cell cycle arrest but inhibits cell death in response to DNA damage and acts in parallel with p53 to suppress cell transformation and tumor formation. p57Kip2 is also upregulated in stage I and II clinical rectal tumor samples, likely due to genome instability of precancerous and/or early cancer cells. Targeting p57Kip2 in primary rectal cancer cells and tumor models resulted in increased sensitivity to doxorubicin, suggesting that p57Kip2 has a role in chemoresistance, which is consistent with its pro-survival function. These findings place p57Kip2 in DDR and uncover molecular mechanisms by which p57Kip2 suppresses tumorigenesis and causes chemoresistance.	[Jia, H.; Cong, Q.; Liu, H.; Xia, X.; Zhang, X.; Lin, J.; Li, B.] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200240, Peoples R China; [Chua, J. F. L.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Habib, S. L.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; [Habib, S. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Ao, J.] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200240, Peoples R China; [Zuo, Q.; Fu, C.] Second Mil Med Univ, Changhai Hosp, Dept Colorectal Surg, Shanghai, Peoples R China	Shanghai Jiao Tong University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; Shanghai Jiao Tong University; Naval Medical University	Li, B (corresponding author), Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Dongchuan Rd 800, Shanghai 200240, Peoples R China.	libj@sjtu.edu.cn	Cong, Qian/AAZ-4404-2021	Cong, Qian/0000-0002-9493-5784; Jia, Hao/0000-0003-1856-6013; Zuo, Qiao/0000-0003-4512-6363	Ministry of Science and Technology of China [2012CB966901]; National Natural Science Foundation of China [81130039, 31071229, 81121001]; Veterans Affairs [I01BX000924] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Veterans Affairs(US Department of Veterans Affairs)	We thank Lina Gao, IH In, C Deyu, GC Hong, L Soh, J Lin and T Cheng for technical assistance and Boehringer Ingelheim, Novartis, Dr Michael D. Schneider, Dr Ye-Guang Chen, Dr Yibin Wang, Dr Nelson J Dusetti, Dr Olivier Delattre, Dr Philipp Kaldis and Dr Michael Kastan for providing constructs, reagents and mice. The work was supported by grants from the Ministry of Science and Technology of China (The National Key Scientific Program (2012CB966901 to BL) and the National Natural Science Foundation of China (81130039, 31071229 and 81121001).	Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barascu A, 2012, EMBO J, V31, P1080, DOI 10.1038/emboj.2011.492; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Belyi VA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001198; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Bhoumik A, 2008, J BIOL CHEM, V283, P17605, DOI 10.1074/jbc.M802030200; Borriello A, 2007, CELL CYCLE, V6, P1053, DOI 10.4161/cc.6.9.4142; Borriello A, 2011, MOL CANCER RES, V9, P1269, DOI 10.1158/1541-7786.MCR-11-0220; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Caspary T, 1999, GENE DEV, V13, P3115, DOI 10.1101/gad.13.23.3115; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chau JFL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1832; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705; Furutachi S, 2013, EMBO J, V32, P970, DOI 10.1038/emboj.2013.50; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Giovannini C, 2012, AM J PATHOL, V181, P413, DOI 10.1016/j.ajpath.2012.04.019; Gosselet FP, 2007, CELL SIGNAL, V19, P731, DOI 10.1016/j.cellsig.2006.09.006; Gozdecka M, 2012, BIOCHEM SOC T, V40, P230, DOI 10.1042/BST20110630; Gu J, 2013, COLORECTAL DIS, V07, P677; Hopker K, 2012, EMBO J, V31, P3961, DOI 10.1038/emboj.2012.236; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Joaquin M, 2012, EMBO J, V31, P2952, DOI 10.1038/emboj.2012.122; Kavanagh E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.51; Kavanagh E, 2011, BBA-REV CANCER, V1816, P50, DOI 10.1016/j.bbcan.2011.03.002; Lai KP, 2010, EMBO J, V29, P2994, DOI 10.1038/emboj.2010.166; Li Shuangwei, 2010, Genes Cancer, V1, P316; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Mairet-Coello G, 2012, DEVELOPMENT, V139, P475, DOI 10.1242/dev.067314; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matsumoto A, 2011, CELL STEM CELL, V9, P262, DOI 10.1016/j.stem.2011.06.014; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Pateras IS, 2006, INT J CANCER, V119, P2546, DOI 10.1002/ijc.22214; Pateras IS, 2009, MOL CANCER RES, V7, P1902, DOI 10.1158/1541-7786.MCR-09-0317; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Sugihara E, 2006, CANCER RES, V66, P4020, DOI 10.1158/0008-5472.CAN-05-3250; Susaki E, 2009, CELL CYCLE, V8, P2497, DOI 10.4161/cc.8.16.9330; Susaki E, 2009, P NATL ACAD SCI USA, V106, P5192, DOI 10.1073/pnas.0811712106; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tremblay KD, 2001, DEVELOPMENT, V128, P3609; Ullah Z, 2008, GENE DEV, V22, P3024, DOI 10.1101/gad.1718108; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Vlachos P, 2007, CELL DEATH DIFFER, V14, P1497, DOI 10.1038/sj.cdd.4402158; Wang QE, 2013, NUCLEIC ACIDS RES, V41, P1722, DOI 10.1093/nar/gks1312; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062527; Zhao RY, 2013, CELL CYCLE, V12, P935, DOI 10.4161/cc.23883	62	18	18	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3568	3581		10.1038/onc.2014.287	http://dx.doi.org/10.1038/onc.2014.287			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195859				2022-12-28	WOS:000357434900009
J	Mo, P; Zhou, Q; Guan, L; Wang, Y; Wang, W; Miao, M; Tong, Z; Li, M; Majaz, S; Liu, Y; Su, G; Xu, J; Yu, C				Mo, P.; Zhou, Q.; Guan, L.; Wang, Y.; Wang, W.; Miao, M.; Tong, Z.; Li, M.; Majaz, S.; Liu, Y.; Su, G.; Xu, J.; Yu, C.			Amplified in breast cancer 1 promotes colorectal cancer progression through enhancing notch signaling	ONCOGENE			English	Article							STEROID-RECEPTOR COACTIVATOR-3; CELL-PROLIFERATION; TRANSCRIPTIONAL COACTIVATOR; COLON CARCINOGENESIS; SRC-3 COACTIVATOR; AIB1; ACTIVATION; GROWTH; OVEREXPRESSION; SUPPRESSION	Aberrant activation of Notch signaling has an essential role in colorectal cancer (CRC) progression. Amplified in breast cancer 1 (AIB1), also known as steroid receptor coactivator 3 or NCOA3, is a transcriptional coactivator that promotes cancer cell proliferation and invasiveness. However, AIB1 implication in CRC progression through enhancing Notch signaling is unknown. In this study, we found that several CRC cell lines expressed high levels of AIB1, and knockdown of AIB1 decreased cell proliferation, colony formation and tumorigenesis of these CRC cells. Specifically, knockdown of AIB1 inhibited cell cycle progression at G1 phase by decreasing the mRNA levels of cyclin A2, cyclin B1, cyclin E2 and hairy and enhancer of split (Hes) 1. Furthermore, AIB1 interacted with Notch intracellular domain and Mastermind-like 1 and was recruited to the Hes1 promoter to enhance Notch signaling. Downregulation of AIB1 also decreased CRC cell invasiveness in vitro and lung metastasis in vivo. Besides that, knockout of AIB1 in mice inhibited colon carcinogenesis induced by azoxymethane/dextran sodium sulfate treatment. The mRNA levels of cyclin B1 and Hes5 were downregulated, but p27, ATOH1 and MUC2 were upregulated in the colon tumors from AIB1-deficient mice compared with those from wild-type mice. Thus, our results signify the importance of AIB1 in CRC and demonstrate that AIB1 promotes CRC progression at least in part through enhancing Notch signaling, suggesting that AIB1 is a potential molecular target for CRC treatment.	[Mo, P.; Zhou, Q.; Guan, L.; Wang, Y.; Wang, W.; Miao, M.; Tong, Z.; Li, M.; Majaz, S.; Liu, Y.; Yu, C.] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China; [Su, G.] Xiamen Univ, Affiliated Hosp 1, Xiamen 361005, Fujian, Peoples R China; [Xu, J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Xiamen University; Xiamen University; Baylor College of Medicine	Yu, C (corresponding author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.	cdyu@xmu.edu.cn	Tong, Zhangwei/V-2475-2019; Zhou, Qiling/AAB-2493-2021		National Natural Science Foundation of China [81071671, 31170819]; Fundamental Research Funds for the Central Universities [2012121038]; New Teachers Award of the Ministry of Education [20110121120004]; 111 Project [B12001]; NIH [CA112403, DK058242]; NATIONAL CANCER INSTITUTE [R01CA112403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058242, P01DK059820] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); New Teachers Award of the Ministry of Education; 111 Project(Ministry of Education, China - 111 Project); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Dawang Zhou (Xiamen University) for providing HA-NICD, FLAG-NICD and Myc-NICD constructs, and Dr Lizhi Wu (University of Florida) for providing FLAG-MAML1 and pGL3-Hes1-promoter plasmids. This work was supported by grants from the National Natural Science Foundation of China (no. 81071671 and 31170819 to CY), the Fundamental Research Funds for the Central Universities (no. 2012121038 to CY), the New Teachers Award of the Ministry of Education (no. 20110121120004 to PM), and 111 Project B12001. JX is supported by the CA112403 and DK058242 NIH grants.	Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bar Y, 2008, DIABETES, V57, P2413, DOI 10.2337/db07-1323; Chen Q, 2012, HEPATOLOGY, V55, P1820, DOI 10.1002/hep.25549; Christofori G, 2011, CANCER CELL, V19, P6, DOI 10.1016/j.ccr.2011.01.003; Chung ACK, 2007, CANCER RES, V67, P5965, DOI 10.1158/0008-5472.CAN-06-3168; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Hansson ML, 2009, NUCLEIC ACIDS RES, V37, P2996, DOI 10.1093/nar/gkp163; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kishimoto H, 2005, CARCINOGENESIS, V26, P1706, DOI 10.1093/carcin/bgi137; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lin S, 2013, ONCOGENE, V32, P4845, DOI 10.1038/onc.2012.482; Liu YH, 2012, HEPATOLOGY, V56, P1015, DOI 10.1002/hep.25751; Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492; Long WW, 2010, MOL CELL, V37, P321, DOI 10.1016/j.molcel.2010.01.004; Louet JF, 2006, P NATL ACAD SCI USA, V103, P17868, DOI 10.1073/pnas.0608711103; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Miyamoto S, 2013, CARCINOGENESIS, V34, P2415, DOI 10.1093/carcin/bgt191; Monahan P, 2009, ENDOCRINOLOGY, V150, P4386, DOI 10.1210/en.2009-0206; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Qiao L, 2009, CARCINOGENESIS, V30, P1979, DOI 10.1093/carcin/bgp236; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Sikandar SS, 2010, CANCER RES, V70, P1469, DOI 10.1158/0008-5472.CAN-09-2557; Tien JCY, 2009, INT J BIOL SCI, V5, P256; Ueo T, 2012, DEVELOPMENT, V139, P1071, DOI 10.1242/dev.069070; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939; Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu Y, 2010, ONCOGENE, V29, P3386, DOI 10.1038/onc.2010.90; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yatim A, 2012, MOL CELL, V48, P445, DOI 10.1016/j.molcel.2012.08.022; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285-09; Zhang Y, 2010, CANCER-AM CANCER SOC, V116, P5207, DOI 10.1002/cncr.25449; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	46	24	25	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3935	3945		10.1038/onc.2014.324	http://dx.doi.org/10.1038/onc.2014.324			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263446	Green Accepted			2022-12-28	WOS:000358544200006
J	Prevete, N; Liotti, F; Visciano, C; Marone, G; Melillo, RM; de Paulis, A				Prevete, N.; Liotti, F.; Visciano, C.; Marone, G.; Melillo, R. M.; de Paulis, A.			The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FORMYLPEPTIDE RECEPTOR; ANNEXIN A1; PROTEIN; CELLS; ACTIVATION; EXPRESSION; GROWTH; FPR; CHEMOTAXIS	N-formyl peptide receptors (FPR1, FPR2 and FPR3) are involved in innate immunity, inflammation and cancer. FPR expression, initially described in immune cells, was later observed in non-hematopoietic cell populations and tissues. Several studies suggested a role for FPRs in the progression of various tumor histotypes, including gastric cancer (GC), for which a positive association with a specific FPR1 polymorphism has recently been described. We previously showed that FPRs are expressed on gastric epithelium and are required for wound repair and restitution of barrier integrity. Here we assess the role of FPRs in GC. We characterized the functions of FPRs in GC epithelial cells (MKN28, AGS and MKN45) cultured in vitro by assessing migration, proliferation, resistance to apoptosis and activation of the epithelial-to-mesenchymal transition. Activation of each FPR induced the epithelial-to-mesenchymal transition, proliferation, resistance to apoptosis and migration of GC cells in culture. Blocking compounds or RNA interference of each FPR reverted these effects. We also defined the in vivo tumorigenic potential of GC epithelial cells silenced for FPRs by xenograft experiments in immunocompromised mice. Interestingly, FPR1 silencing in GC cells (shFPR1) significantly enhanced xenograft growth with respect to shCTR, shFPR2 and shFPR3 xenografts, because of augmented vessel density and cell proliferation. Accordingly, HIF-1 alpha and VEGF mRNA levels were higher in shFPR1 xenografts than in controls. Moreover, the in vitro production of proangiogenic factors in response to FPR2/3 agonists (WKYMVm, LL-37, uPA, uPAR(84-95), AnxA1) or to other proinflammatory mediators (IL-1 alpha) was higher in shFPR1 GC cells than in shCTR, shFPR2 and shFPR3 cells, suggesting that FPR1 functions as an inhibitor of CG angiogenesis. Thus, we propose that FPR1 stimulation may represent a novel therapeutic approach to counteract tumor angiogenesis.	[Prevete, N.; Marone, G.; de Paulis, A.] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Prevete, N.; Marone, G.; de Paulis, A.] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, Naples, Italy; [Liotti, F.; Visciano, C.; Melillo, R. M.] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy; [Liotti, F.; Visciano, C.; Melillo, R. M.] CNR, Inst Expt Oncol & Endocrinol IEOS, I-80125 Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Melillo, RM (corresponding author), Dept Mol Med & Med Biotechnol, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it; depaulis@unina.it	melillo, rosa marina/O-5255-2015; Liotti, Federica/AAC-1614-2019	Liotti, Federica/0000-0002-0145-988X; MELILLO, Rosa Marina/0000-0002-9233-5275; de Paulis, Amato/0000-0003-0347-2540	Ministero della Salute (Ricerca Finalizzata - IZSM RF); Regione Campania CISI-Lab Project; CREME Project; TIMING Project	Ministero della Salute (Ricerca Finalizzata - IZSM RF); Regione Campania CISI-Lab Project; CREME Project; TIMING Project	We are grateful to Jean Ann Gilder (Scientific Communication srl., Naples, Italy) for editing the text. This work was supported by grants from Ministero della Salute (Ricerca Finalizzata 2009 - IZSM RF 2009), Regione Campania CISI-Lab Project, CREME Project and TIMING Project.	Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186; Babbin BA, 2007, J IMMUNOL, V179, P8112, DOI 10.4049/jimmunol.179.12.8112; Chen KD, 2013, J CLIN INVEST, V123, P1694, DOI 10.1172/JCI65569; Cheng TY, 2012, CANCER-AM CANCER SOC, V118, P5757, DOI 10.1002/cncr.27565; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110; D'Acquisto F, 2008, BRIT J PHARMACOL, V155, P152, DOI 10.1038/bjp.2008.252; de Paulis A, 2004, J IMMUNOL, V173, P5739, DOI 10.4049/jimmunol.173.9.5739; de Paulis A, 2004, J IMMUNOL, V172, P7734, DOI 10.4049/jimmunol.172.12.7734; de Paulis A, 2009, J IMMUNOL, V183, P3761, DOI 10.4049/jimmunol.0900863; dePaulis A, 1996, J ALLERGY CLIN IMMUN, V98, P152, DOI 10.1016/S0091-6749(96)70237-3; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Devosse T, 2011, J IMMUNOL, V187, P1475, DOI 10.4049/jimmunol.1003545; Gao JL, 2007, J IMMUNOL, V178, P1450, DOI 10.4049/jimmunol.178.3.1450; Huang J, 2010, BRIT J CANCER, V102, P1052, DOI 10.1038/sj.bjc.6605591; Jing YY, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-98; Kalia S, 2008, J BIOCHEM MOL TOXIC, V22, P371, DOI 10.1002/jbt.20252; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Leoni G, 2013, J CLIN INVEST, V123, P443, DOI 10.1172/JCI65831; Liu L, 2012, ASIAN PAC J CANCER P, V13, P3089, DOI 10.7314/APJCP.2012.13.7.3089; Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009; Otani T, 2011, BIOCHEM BIOPH RES CO, V405, P356, DOI 10.1016/j.bbrc.2010.12.136; Pang MY, 2010, KIDNEY INT, V78, P257, DOI 10.1038/ki.2010.154; Paul SAM, 2004, J CELL PHYSIOL, V200, P20, DOI 10.1002/jcp.10479; Pott J, 2012, EMBO REP, V13, P684, DOI 10.1038/embor.2012.96; Prevete N, 2013, J BIOL REG HOMEOS AG, V27, P827; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Seifert R, 2001, J BIOL CHEM, V276, P42043, DOI 10.1074/jbc.M106621200; Shao GH, 2011, AM J RESP CELL MOL, V44, P264, DOI 10.1165/rcmb.2010-0246RC; Takahashi A, 2002, ONCOLOGY-BASEL, V62, P121, DOI 10.1159/000048257; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Zhang XG, 2011, INVEST OPHTH VIS SCI, V52, P3160, DOI 10.1167/iovs.10-5156; Zhou Y, 2005, JNCI-J NATL CANCER I, V97, P823, DOI 10.1093/jnci/dji142	35	60	63	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3826	3838		10.1038/onc.2014.309	http://dx.doi.org/10.1038/onc.2014.309			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263443				2022-12-28	WOS:000358001600008
J	Paul, BT; Blanchard, Z; Ridgway, M; ElShamy, WM				Paul, B. T.; Blanchard, Z.; Ridgway, M.; ElShamy, W. M.			BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CYCLIN D1 EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; ANOIKIS RESISTANCE; CLINICAL ACTIVITY; GROWTH-FACTORS; CANCER; TRKB; OVEREXPRESSION; PROMOTES	Ovarian cancer is the first in mortalities among gynecologic cancers in the United States, often due to late diagnosis and/or acquired platinum-resistant recurrences. This study investigates whether BRCA1-IRIS is a novel treatment target for ovarian cancers and in platinum-resistant recurrences. Here we show that more than half of the ovarian cancer samples analyzed showed BRCA1-IRIS and survivin overexpression and lacked nuclear FOXO3a expression. Normal ovarian epithelial cells overexpressing BRCA1-IRIS formed metastasis in mice when injected in the peritoneal cavity, whereas aggressive ovarian cancer cell lines failed to form tumors or metastases in mice when BRCA1-IRIS was silenced in them. We show that BRCA1-IRIS activates two autocrine signaling loops, brain-derived neurotrophic factor/tyrosine kinase B receptor (BDNF/TrkB) and neuregulin 1 (NRG1)/ErbB2. These loops are involved in anoikis resistance and metastasis promotion. These loops operate in several ovarian cancer cell lines, and BRCA1-IRIS silencing or inactivation using a novel inhibitory peptide renders both non-functional and promoted cell death. In a mouse xenograft model, BRCA1-IRIS inactivation using this novel inhibitory peptide resulted in significant reduction in ovarian tumor growth. More importantly, this treatment sensitized ovarian tumors to low cisplatin concentrations. Taken together, these data strongly suggest that BRCA1-IRIS and/or BDNF/TrkB and NRG1/ErbB2 could serve as rational therapeutic targets for advanced ovarian cancers.	[Paul, B. T.; Blanchard, Z.; ElShamy, W. M.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA; [Paul, B. T.; Blanchard, Z.; ElShamy, W. M.] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; [Ridgway, M.] Univ Mississippi, Med Ctr, Dept Obstet & Gynecol, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	ElShamy, WM (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 North State St,G651,G362, Jackson, MS 39216 USA.	welshamy@umc.edu	ElShamy, Wael M./L-1090-2018; ElShamy, Wael/AAF-2867-2019					Alcantara S, 1997, J NEUROSCI, V17, P3623; Auersperg N, 2013, GYNECOL ONCOL, V130, P246, DOI 10.1016/j.ygyno.2013.03.021; Banerjee S, 2009, ONCOLOGIST, V14, P706, DOI 10.1634/theoncologist.2009-0013; BIRLING MC, 1995, CURR OPIN CELL BIOL, V7, P878, DOI 10.1016/0955-0674(95)80073-5; Blank SV, 2010, GYNECOL ONCOL, V119, P451, DOI 10.1016/j.ygyno.2010.08.008; Brader S, 2004, TUMORI J, V90, P2, DOI 10.1177/030089160409000102; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chen LF, 2013, INT J GYNECOL CANCER, V23, P256, DOI 10.1097/IGC.0b013e31827ad2b8; Chock K, 2010, ONCOGENE, V29, P5274, DOI 10.1038/onc.2010.262; Chock KL, 2010, CANCER RES, V70, P8782, DOI 10.1158/0008-5472.CAN-10-1352; Choudhury KR, 2010, J HISTOCHEM CYTOCHEM, V58, P95, DOI 10.1369/jhc.2009.953554; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Felsher DW, 2008, APMIS, V116, P629, DOI 10.1111/j.1600-0463.2008.01037.x; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Gordon MS, 2006, J CLIN ONCOL, V24, P4324, DOI 10.1200/JCO.2005.05.4221; Hao L, 2007, INT J CANCER, V121, P39, DOI 10.1002/ijc.22597; Hondermarck H, 2012, CYTOKINE GROWTH F R, V23, P357, DOI 10.1016/j.cytogfr.2012.06.004; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Jiang L, 2013, ONCOL LETT, P51605; Jungbluth S, 1997, DEVELOPMENT, V124, P1877; Kim H, 2004, J BIOL CHEM, V279, P33538, DOI 10.1074/jbc.M404115200; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Lafky JM, 2008, BBA-REV CANCER, V1785, P232, DOI 10.1016/j.bbcan.2008.01.001; Liguang Z., 2007, Experimental Oncology, V29, P121; Liu AX, 1998, CANCER RES, V58, P2973; Makhija S, 2010, J CLIN ONCOL, V28, P1215, DOI 10.1200/JCO.2009.22.3354; MASANA Y, 1993, J NEUROSCI RES, V35, P468, DOI 10.1002/jnr.490350503; Matheny RW, 2009, BIOCHEM BIOPH RES CO, V389, P117, DOI 10.1016/j.bbrc.2009.08.101; Matsuo K, 2010, EXPERT OPIN INV DRUG, V19, P1339, DOI 10.1517/13543784.2010.515585; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; Monsalve M, 2011, CURR DRUG TARGETS, V12, P1322, DOI 10.2174/138945011796150307; Nakuci E, 2006, EXP CELL RES, V312, P3120, DOI 10.1016/j.yexcr.2006.06.021; OHANLAN KA, 1995, GYNECOL ONCOL, V59, P200; Okamura K, 2012, LUNG CANCER, V78, P100, DOI 10.1016/j.lungcan.2012.07.011; Page C, 2000, ANTICANCER RES, V20, P407; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Puehringer D, 2013, NAT NEUROSCI, V16, P407, DOI 10.1038/nn.3333; Ricci A, 2010, GROWTH FACTORS, V28, P221, DOI 10.3109/08977191003677402; Santo EE, 2013, CANCER RES, V73, P2189, DOI 10.1158/0008-5472.CAN-12-3767; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shimizu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034102; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; Smit MA, 2011, ONCOGENE, V30, P3735, DOI 10.1038/onc.2011.96; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Tanner B, 2006, J CLIN ONCOL, V24, P4317, DOI 10.1200/JCO.2005.04.8397; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Ween MP, 2011, INT J MOL SCI, V12, P1009, DOI 10.3390/ijms12021009; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Weng DH, 2009, CANCER LETT, V273, P257, DOI 10.1016/j.canlet.2008.08.027; Yang J, 2004, CELL; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yu XH, 2008, CANCER SCI, V99, P543, DOI 10.1111/j.1349-7006.2007.00722.x; Yu YJ, 2010, APMIS, V118, P188, DOI 10.1111/j.1600-0463.2009.02577.x; Yue W, 2010, REGUL PEPTIDES, V180, P33; Zhang HY, 2009, EUR J OBSTET GYN R B, V146, P81, DOI 10.1016/j.ejogrb.2009.04.035; Zheng WP, 2011, TUMORI, V97, P756, DOI 10.1700/1018.11093	62	26	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3036	3052		10.1038/onc.2014.237	http://dx.doi.org/10.1038/onc.2014.237			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25132263				2022-12-28	WOS:000356100500009
J	Kroiss, A; Vincent, S; Decaussin-Petrucci, M; Meugnier, E; Viallet, J; Ruffion, A; Chalmel, F; Samarut, J; Allioli, N				Kroiss, A.; Vincent, S.; Decaussin-Petrucci, M.; Meugnier, E.; Viallet, J.; Ruffion, A.; Chalmel, F.; Samarut, J.; Allioli, N.			Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2	ONCOGENE			English	Article							RECEPTOR; EXPRESSION; GROWTH; RECOGNITION; PATHWAY; KINASE	Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer (PCa) initiation and progression. Identifying new downstream effectors of the androgens/AR pathway will allow a better understanding of these mechanisms and could reveal novel biomarkers and/or therapeutic agents to improve the rate of patient survival. We compared the microRNA expression profiles in androgen-sensitive LNCaP cells stimulated or not with 1 nM R1881 by performing a high-throughput reverse transcriptase-quantitative PCR and found that miR-135a was upregulated. After androgen stimulation, we showed that AR directly activates the transcription of miR-135a2 gene by binding to an androgen response element in the promoter region. Our findings identify miR-135a as a novel effector in androgens/AR signaling. Using xenograft experiments in chick embryos and adult male mice, we showed that miR-135a overexpression decreases in vivo invasion abilities of prostate PC-3 cells. Through in vitro wound-healing migration and invasion assays, we demonstrated that this effect is mediated through downregulating ROCK1 and ROCK2 expression, two genes that we characterized as miR-135a direct target genes. In human surgical samples from prostatectomy, we observed that miR-135a expression was lower in tumoral compared with paired adjacent normal tissues, mainly in tumors classified with a high Gleason score (>= 8). Moreover, miR-135a expression is lower in invasive tumors, showing extraprostatic extension, as compared with intraprostatic localized tumors. In tumor relative to normal glands, we also showed a more frequently higher ROCK1 protein expression determined using a semi-quantitative immunohistochemistry analysis. Therefore, in tumor cells, the lower miR-135a expression could lead to a higher ROCK1 protein expression, which could explain their invasion abilities. The highlighted relationship between miR-135a expression level and the degree of disease aggressiveness suggests that miR-135a may be considered as a prognostic marker in human PCa.	[Kroiss, A.; Vincent, S.; Decaussin-Petrucci, M.; Ruffion, A.; Samarut, J.; Allioli, N.] Univ Lyon 1, Ecole Normale Super Lyon, Inst Genom Fonct Lyon, F-69365 Lyon, France; [Decaussin-Petrucci, M.; Ruffion, A.; Samarut, J.] Univ Lyon 1, Fac Med & Maieut Lyon Sud Charles Merieux, F-69365 Lyon, France; [Decaussin-Petrucci, M.] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Serv Anat & Cytol Pathol, F-69310 Pierre Benite, France; [Meugnier, E.] Univ Lyon 1, Fac Med & Maieut Lyon Sud Charles Merieux, Lab CarMen, INRA1362,INSERM U1060, Oullins, France; [Viallet, J.] Univ Grenoble, CRI INSERM UJF U823, Inst Albert Bonniot, In Ovo, La Tronche, France; [Ruffion, A.] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Serv Urol, F-69310 Pierre Benite, France; [Chalmel, F.] Univ Rennes 1, GERHM, INSERM Irset U1085, Rennes, France; [Samarut, J.] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Serv Bioch Biol Mol Sud, F-69310 Pierre Benite, France; [Allioli, N.] Univ Lyon 1, Fac Pharm Lyon, Inst Sci Pharmaceut & Biol, F-69365 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Allioli, N (corresponding author), Inst Genom Fonct Lyon, 32-34 Ave Tony Garnier, F-69007 Lyon, France.	jacques.samarut@ens-lyon.fr; nathalie.allioli@univ-lyon1.fr	Chalmel, Frédéric/AAM-1079-2021; Samarut, Jacques/AAD-2587-2019; DECAUSSIN PETRUCCI, MYRIAM/GWZ-7373-2022; Chalmel, Frederic/M-1297-2016; Chalmel, Frédéric/L-5360-2018	Chalmel, Frédéric/0000-0002-0535-3628; Chalmel, Frédéric/0000-0002-0535-3628; meugnier, emmanuelle/0000-0002-2291-7691	Institut Merieux; Ligue Contre le Cancer	Institut Merieux; Ligue Contre le Cancer(Ligue nationale contre le cancer)	This work was supported by grants from the Institut Merieux and the Ligue Contre le Cancer. We thank Julien Dugas (CarMen Lab) for his contribution in statistical analyses, Celine Michaux, Karine Castellano and Beatrice Bancel (Service d'Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon) for providing patient samples and performing IHC staining, Jean Viallet for performing in ovo assay, Christophe Chamot and Claire Lionnet (Microscopy core facility) and Patrick Manas (AniRA-PBES platform) of UMS3444/US8 SFR Biosciences Gerland-Lyon Sud, for assistance in wound-healing assay and performing xenograft assay in mice, respectively.	Allioli N, 2011, PROSTATE, V71, P1239, DOI 10.1002/pros.21340; Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bouyssou JMC, 2014, BBA-REV CANCER, V1845, P255, DOI 10.1016/j.bbcan.2014.02.002; Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108; Chen YT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-111; Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cunha GR, 2004, J STEROID BIOCHEM, V92, P221, DOI 10.1016/j.jsbmb.2004.10.017; Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009-0310; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fendler A, 2011, CLIN CHEM, V57, P954, DOI 10.1373/clinchem.2010.157727; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Golubovskaya VM, 2014, ANTI-CANCER AGENT ME, V14, P18, DOI 10.2174/187152061401140108113435; Gonzalez-Montelongo MC, 2010, MOL ENDOCRINOL, V24, P1007, DOI 10.1210/me.2009-0472; Green SM, 2012, MOL CELL ENDOCRINOL, V360, P3, DOI 10.1016/j.mce.2011.09.046; Hassan O, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-9; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Leung CON, 2014, CARCINOGENESIS; Li YW, 2012, EPIGENETICS-US, V7, P940, DOI 10.4161/epi.21236; Ma S, 2011, CANCER RES, V71, P583, DOI 10.1158/0008-5472.CAN-10-2587; Matsumoto T, 2013, ANNU REV PHYSIOL, V75, P201, DOI 10.1146/annurev-physiol-030212-183656; Murata T, 2010, PROSTATE CANCER P D, V13, P356, DOI 10.1038/pcan.2010.32; Nadiminty N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032832; Rao S, 2012, ONCOGENE, V31, P716, DOI 10.1038/onc.2011.273; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Shin JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085205; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Sun D, 2014, ONCOGENE, V33, P1448, DOI 10.1038/onc.2013.77; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang BD, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/763569; Wang GH, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-S2-S22; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; Wen SM, 2013, PROSTATE, V73, P1306, DOI 10.1002/pros.22676; White RWD, 2009, UROL ONCOL-SEMIN ORI, V27, P307, DOI 10.1016/j.urolonc.2009.01.004; Xi Jianzhong Jeff, 2013, Cancer Treat Res, V158, P119, DOI 10.1007/978-3-642-31659-3_5; Zheng C, 2012, MED ONCOL, V29, P815, DOI 10.1007/s12032-011-9934-8; Zhou WW, 2012, ACTA BIOCH BIOPH SIN, V44, P838, DOI 10.1093/abbs/gms071	47	86	90	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2846	2855		10.1038/onc.2014.222	http://dx.doi.org/10.1038/onc.2014.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25065599	Green Submitted			2022-12-28	WOS:000355324300004
J	Jiang, N; Hjorth-Jensen, K; Hekmat, O; Iglesias-Gato, D; Kruse, T; Wang, C; Wei, W; Ke, B; Yan, B; Niu, Y; Olsen, JV; Flores-Morales, A				Jiang, N.; Hjorth-Jensen, K.; Hekmat, O.; Iglesias-Gato, D.; Kruse, T.; Wang, C.; Wei, W.; Ke, B.; Yan, B.; Niu, Y.; Olsen, J. V.; Flores-Morales, A.			In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth	ONCOGENE			English	Article							ANDROGEN RECEPTOR; HIPPO PATHWAY; LNCAP MODEL; PHOSPHORYLATION; PTEN; MTOR; INHIBITOR; PROGRESSION; ACTIVATION; EXPRESSION	Prostate cancer remains a leading cause of cancer-related mortality worldwide owing to our inability to treat effectively castration-resistant tumors. To understand the signaling mechanisms sustaining castration-resistant growth, we implemented a mass spectrometry-based quantitative proteomic approach and use it to compare protein phosphorylation in orthotopic xenograft tumors grown in either intact or castrated mice. This investigation identified changes in phosphorylation of signaling proteins such as MEK, LYN, PRAS40, YAP1 and PAK2, indicating the concomitant activation of several oncogenic pathways in castration-resistant tumors, a notion that was confirmed by tumor transcriptome analysis. Further analysis demonstrated that the activation of mTORC1, PAK2 and the increased levels of YAP1 in castration-resistant tumors can be explained by the loss of androgen inhibitory actions. The analysis of clinical samples demonstrated elevated levels of PAK2 and YAP1 in castration-resistant tumors, whereas knockdown experiments in androgen-independent cells demonstrated that both YAP1 and PAK2 regulate cell colony formation and cell invasion activity. PAK2 also influenced cell proliferation and mitotic timing. Interestingly, these phenotypic changes occur in the absence of obvious alterations in the activity of AKT, MAPK or mTORC1 pathways, suggesting that PAK2 and YAP1 may represent novel targets for the treatment of castration-resistant prostate cancer. Pharmacologic inhibitors of PAK2 (PF-3758309) and YAP1 (Verteporfin) were able to inhibit the growth of androgen-independent PC3 xenografts. This work demonstrates the power of applying high-resolution mass spectrometry in the proteomic profiling of tumors grown in vivo for the identification of novel and clinically relevant regulatory proteins.	[Jiang, N.; Hjorth-Jensen, K.; Hekmat, O.; Iglesias-Gato, D.; Kruse, T.; Olsen, J. V.; Flores-Morales, A.] Univ Copenhagen, Dept Hlth Sci, Novo Nordisk Fdn Ctr Prot Res, Fac Hlth & Med Sci, Copenhagen, Denmark; [Jiang, N.; Wang, C.; Wei, W.; Ke, B.; Yan, B.; Niu, Y.] Tianjin Med Univ, Tianjin Inst Urol, Tianjin, Peoples R China	University of Copenhagen; Tianjin Medical University	Niu, Y (corresponding author), Tianjin Inst Urol, 23 Pingjiang Rd, Tianjin 300211, Peoples R China.	Amilcar.Flores@cpr.ku.dk; niuyuanjie9317@163.com; Amilcar.Flores@cpr.ku.dk	Olsen, Jesper/ABH-4638-2020; Hekmat, Omid/AAU-4182-2021; Iglesias-Gato, Diego/R-1794-2016	Olsen, Jesper/0000-0002-4747-4938; Iglesias-Gato, Diego/0000-0002-8982-9936	Novo Nordisk Foundation, Movember; Danish Council for Independent Research; Science Foundation of Tianjin [11JCZDJC19700, 09ZCZDSF04300]; National Natural Science Foundation of China [2012CB518304, 2012DFG32220]; Novo Nordisk Fonden [NNF12OC0002286] Funding Source: researchfish	Novo Nordisk Foundation, Movember; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Science Foundation of Tianjin(Natural Science Foundation of Tianjin); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Novo Nordisk Fonden(Novo Nordisk Foundation)	This work was supported by grants to AF-M from the Novo Nordisk Foundation, Movember and the Danish Council for Independent Research. JN and NY are supported by the Science Foundation of Tianjin (No.: 11JCZDJC19700) and 09ZCZDSF04300 and the National Natural Science Foundation of China Grant numbers: 2012CB518304 and 2012DFG32220.	Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Blando J, 2009, AM J PATHOL, V174, P1869, DOI 10.2353/ajpath.2009.080055; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chuan YC, 2010, ONCOGENE, V29, P1531, DOI 10.1038/onc.2009.442; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Crawford ED, 2009, UROLOGY, V73, P4, DOI 10.1016/j.urology.2009.03.001; D'Antonio JM, 2008, PROSTATE, V68, P698, DOI 10.1002/pros.20677; Das Thakur M, 2010, CURR BIOL, V20, P657, DOI 10.1016/j.cub.2010.02.035; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Drake JM, 2013, P NATL ACAD SCI USA, V110, pE4762, DOI 10.1073/pnas.1319948110; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hekmat O, 2013, J PROTEOME RES, V12, P4136, DOI 10.1021/pr400457u; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; Lundby A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1871; Ma L, 2007, CANCER RES, V67, P7106, DOI 10.1158/0008-5472.CAN-06-4798; Mann M, 2013, MOL CELL, V49, P583, DOI 10.1016/j.molcel.2013.01.029; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mukherjee R, 2011, BRIT J CANCER, V104, P1920, DOI 10.1038/bjc.2011.163; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Nakabayashi M, 2012, BJU INT, V110, P1729, DOI 10.1111/j.1464-410X.2012.11456.x; Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Olsen JV, 2013, MOL CELL PROTEOMICS, V12, P3444, DOI 10.1074/mcp.O113.034181; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Olsen JV, 2009, MOL CELL PROTEOMICS, V8, P2759, DOI 10.1074/mcp.M900375-MCP200; Pan CP, 2009, MOL CELL PROTEOMICS, V8, P2796, DOI 10.1074/mcp.M900285-MCP200; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Saramaki O, 2007, FRONT BIOSCI-LANDMRK, V12, P3287, DOI 10.2741/2312; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Schaeffer EM, 2008, ONCOGENE, V27, P7180, DOI 10.1038/onc.2008.327; Schayowitz A, 2010, BRIT J CANCER, V103, P1001, DOI 10.1038/sj.bjc.6605882; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; THALMANN GN, 1994, CANCER RES, V54, P2577; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VISAKORPI T, 1994, EUR J CANCER, V30A, P129, DOI 10.1016/S0959-8049(05)80037-1; Ye Diana Zi, 2012, Cell Logist, V2, P105; Zhang G, 2012, J CELL SCI, V125, P3243, DOI 10.1242/jcs.104208; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	55	50	52	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2764	2776		10.1038/onc.2014.206	http://dx.doi.org/10.1038/onc.2014.206			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065596				2022-12-28	WOS:000354979500009
J	De Mei, C; Ercolani, L; Parodi, C; Veronesi, M; Lo Vecchio, C; Bottegoni, G; Torrente, E; Scarpelli, R; Marotta, R; Ruffili, R; Mattioli, M; Reggiani, A; Wade, M; Grimaldi, B				De Mei, C.; Ercolani, L.; Parodi, C.; Veronesi, M.; Lo Vecchio, C.; Bottegoni, G.; Torrente, E.; Scarpelli, R.; Marotta, R.; Ruffili, R.; Mattioli, M.; Reggiani, A.; Wade, M.; Grimaldi, B.			Dual inhibition of REV-ERB beta and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells	ONCOGENE			English	Article							CIRCADIAN CLOCK; ALPHA; METABOLISM; TIME; IDENTIFICATION; SIGNATURE; BEHAVIOR; DESIGN; LIGAND	REV-ERB alpha and REV-ERB beta nuclear receptors regulate several physiological processes, including circadian rhythm and metabolism. A previous study reported the REV-ERB alpha gene to be co-overexpressed with ERBB2 in breast cancer cell lines. Surprisingly, we found that several tumor types, including a number of breast cancer cell lines, predominantly express the REV-ERB beta variant. This pattern was independent of ERBB2 and ER status, and opposite to that of non-cancer mammary epithelial HMEC cells, in which REV-ERB alpha was the major variant. Consistent with this molecular profile, REV-ERB target genes in both circadian and metabolic pathways were derepressed upon silencing of REV-ERB beta, but not REV-ERB alpha. Strikingly, we found that REV-ERB beta is a determinant of sensitivity to chloroquine, a clinically relevant lysosomotropic agent that suppresses autophagy. The cytoprotective function of REV-ERB beta appears to operate downstream of autophagy blockade. Through compound screening, we identified ARN5187, a novel lysosomotropic REV-ERB beta ligand with a dual inhibitory activity toward REV-ERB-mediated transcriptional regulation and autophagy. Remarkably, although ARN5187 and chloroquine share similar lysosomotropic potency and have a similar effect on autophagy inhibition, ARN5187 is significantly more cytotoxic. Collectively, our results reveal that dual inhibition of REV-ERB beta and autophagy is an effective strategy for eliciting cytotoxicity in cancer cells. Furthermore, our discovery of a novel inhibitor compound of both REV-ERB and autophagy may provide a scaffold for the discovery of new multifunctional anticancer agents.	[De Mei, C.; Ercolani, L.; Parodi, C.; Veronesi, M.; Lo Vecchio, C.; Bottegoni, G.; Torrente, E.; Scarpelli, R.; Reggiani, A.; Grimaldi, B.] Ist Italiano Tecnol, Dept Drug Discovery & Dev, I-16136 Genoa, Italy; [Marotta, R.; Ruffili, R.] Ist Italiano Tecnol, EM Lab, Dept Nanochem, I-16136 Genoa, Italy; [Mattioli, M.; Wade, M.] Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, Milan, Italy	Istituto Italiano di Tecnologia - IIT; Istituto Italiano di Tecnologia - IIT; Istituto Italiano di Tecnologia - IIT	Grimaldi, B (corresponding author), Ist Italiano Tecnol, Dept Drug Discovery & Dev, Via Morego 30, I-16136 Genoa, Italy.	benedetto.grimaldi@iit.it	Mattioli, Michela/K-3951-2013; Marotta, Roberto/B-5382-2014; Marotta, Roberto/HGV-1599-2022; Scarpelli, Rita/O-9422-2015; Wade, Mark/B-6719-2009; VERONESI, MARINA/A-2749-2012	Mattioli, Michela/0000-0002-1692-9178; Wade, Mark/0000-0002-2688-5965; Ercolani, Luisa/0000-0002-0418-3460; VERONESI, MARINA/0000-0001-8491-8844; Bottegoni, Giovanni/0000-0003-1251-583X; Grimaldi, Benedetto/0000-0002-2589-9302	Istituto Italiano di Tecnologia (IIT)	Istituto Italiano di Tecnologia (IIT)	We thank Professor Daniele Piomelli for helpful discussions and for revising the manuscript. We thank Dr Gennaro Colella for MCF-7, HEP-G2 and HCT-116 cell lines, and Dr Natalia Realini for providing cDNA from H-1299, HEP-G2, A-375, A-431 and HCT-116 cells. We also thank Professor Mariapia Abbracchio, Dr Ana Guijarro, Dr Andrea Contestabile and Dr Francesco Niola for discussions. Dr L Ercolani is supported by an interdepartmental post-doctoral fellowship from the Istituto Italiano di Tecnologia (IIT).	Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bugge A, 2012, GENE DEV, V26, P657, DOI 10.1101/gad.186858.112; Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133; Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324; Checinska A, 2011, PIGM CELL MELANOMA R, V24, P1116, DOI 10.1111/j.1755-148X.2011.00927.x; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; Dalvit C, 2002, COMB CHEM HIGH T SCR, V5, P605, DOI 10.2174/1386207023329923; Duez H, 2009, J APPL PHYSIOL, V107, P1972, DOI 10.1152/japplphysiol.00570.2009; Engelen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056623; Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072; Grimaldi B, 2010, CELL METAB, V12, P509, DOI 10.1016/j.cmet.2010.10.005; Grimaldi B, 2009, INT J BIOCHEM CELL B, V41, P81, DOI 10.1016/j.biocel.2008.08.035; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; Hastak K, 2010, CANCER RES, V70, P7970, DOI 10.1158/0008-5472.CAN-09-4521; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hu C, 2008, BIOORGAN MED CHEM, V16, P7888, DOI 10.1016/j.bmc.2008.07.076; Kelleher FC, 2014, CANCER LETT, V342, P9, DOI 10.1016/j.canlet.2013.09.040; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kojetin D, 2011, ACS CHEM BIOL, V6, P131, DOI 10.1021/cb1002575; Konigshoff M, 2003, CLIN CHEM, V49, P219, DOI 10.1373/49.2.219; Kourtidis A, 2010, CANCER RES, V70, P1783, DOI 10.1158/0008-5472.CAN-09-1550; Kumar N, 2010, ENDOCRINOLOGY, V151, P3015, DOI 10.1210/en.2009-0800; Marotta R, 2013, METHODS MOL BIOL, V1025, P179, DOI 10.1007/978-1-62703-462-3_14; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010; Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708; Nishimura Masuhiro, 2004, Drug Metab Pharmacokinet, V19, P135, DOI 10.2133/dmpk.19.135; Ozturk N, 2009, P NATL ACAD SCI USA, V106, P2841, DOI 10.1073/pnas.0813028106; Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344; Rossetti S, 2012, CELL CYCLE, V11, P350, DOI 10.4161/cc.11.2.18792; Sahar S, 2009, NAT REV CANCER, V9, P886, DOI 10.1038/nrc2747; Savvidis C, 2012, MOL MED, V18, P1249, DOI 10.2119/molmed.2012.00077; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Tagad HD, 2011, BIOORGAN MED CHEM, V19, P5238, DOI 10.1016/j.bmc.2011.07.002; Teboul M, 2009, J APPL PHYSIOL, V107, P1965, DOI 10.1152/japplphysiol.00515.2009; Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004; Totrov M, 2008, CHEM BIOL DRUG DES, V71, P15, DOI 10.1111/j.1747-0285.2007.00605.x; Trump RP, 2013, J MED CHEM, V56, P4729, DOI 10.1021/jm400458q; Vulpetti A, 2012, DRUG DISCOV TODAY, V17, P890, DOI 10.1016/j.drudis.2012.03.014; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Woldt E, 2013, NAT MED, V19, P1039, DOI 10.1038/nm.3213; Zhou CH, 2012, AUTOPHAGY, V8, P1215, DOI 10.4161/auto.20284	44	74	79	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2597	2608		10.1038/onc.2014.203	http://dx.doi.org/10.1038/onc.2014.203			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023698	Green Published, hybrid			2022-12-28	WOS:000354541300006
J	Kohlmaier, A; Fassnacht, C; Jin, Y; Reuter, H; Begum, J; Dutta, D; Edgar, BA				Kohlmaier, A.; Fassnacht, C.; Jin, Y.; Reuter, H.; Begum, J.; Dutta, D.; Edgar, B. A.			Src kinase function controls progenitor cell pools during regeneration and tumor onset in the Drosophila intestine	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; STEM-CELL; C-SRC; TERMINAL DIFFERENTIATION; DEPENDENT REGULATION; BACTERIAL-INFECTION; TYROSINE KINASES; STAT3 ACTIVATION; CYCLE REGULATION; FACTOR RECEPTOR	Src non-receptor kinases have been implicated in events late in tumor progression. Here, we study the role of Src kinases in the Drosophila intestinal stem cell (ISC) lineage, during tissue homeostasis and tumor onset. The adult Drosophila intestine contains only two progenitor cell types, division-capable ISCs and their daughters, postmitotic enteroblasts (EBs). We found that Drosophila Src42a and Src64b were required for optimal regenerative ISC division. Conversely, activation of Src42a, Src64b or another nonreceptor kinase, Ack, promoted division of quiescent ISCs by coordinately stimulating G1/S and G2/M cell cycle phase progression. Prolonged Src kinase activation caused tissue overgrowth owing to cytokine receptor-independent Stat92E activation. This was not due to increased symmetric division of ISCs, but involved accumulation of weakly specified Notch(+) but division-capable EB-like cells. Src activation triggered expression of a mitogenic module consisting of String/Cdc25 and Cyclin E that was sufficient to elicit division not only of ISCs but also of EBs. A small pool of similarly division-capable transit-amplifying Notch(+) EBs was also identified in the wild type. Expansion of intermediate cell types that do not robustly manifest their transit-amplifying potential in the wild type may also contribute to regenerative growth and tumor development in other tissues in other organisms.	[Kohlmaier, A.; Fassnacht, C.; Jin, Y.; Reuter, H.; Begum, J.; Dutta, D.; Edgar, B. A.] Univ Heidelberg ZMBH Allianz, Deutsch Krebsforschungszentrum DKFZ, Zentrum Mol Biol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Edgar, BA (corresponding author), DKFZ ZMBH Alliance, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	b.edgar@zmbh.uni-heidelberg.de	Jin, Yinhua/AAU-5460-2021	Jin, Yinhua/0000-0003-4698-8555; Dutta, Devanjali/0000-0002-4993-9639; von Gugelberg (born Fassnacht), Christina/0000-0001-5379-2687	ERC [268515]; NIH [R01 GM51186]; DFG [SFB873]; Human Frontiers in Science Program Long-Term postdoctoral fellowship [LT00316/2008-L]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051186] Funding Source: NIH RePORTER	ERC(European Research Council (ERC)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DFG(German Research Foundation (DFG)); Human Frontiers in Science Program Long-Term postdoctoral fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank David Ibbserson and the Deep Sequencing Core Facility of CellNetworks University of Heidelberg and the Fred Hutchinson Cancer Research Center Seattle for RNA and library preparations and sequencing. We thank Nicholas Harden, Yuh Nung Jan, Marco Milan, Steven Hou, Sarah Bray, Sol Sotillos and the Yale FlyTrap consortium (USA) for gifts of fly stocks. We are grateful to Sylvia Kreger for experimental support and Monika Langlotz (ZMBH) for help with FACS. We thank Juanita Reetz for critically reading of the manuscript. Work in BAE's laboratory was funded by ERC Grant 268515, NIH Grant R01 GM51186 and DFG Grant SFB873. AK was supported by a Human Frontiers in Science Program Long-Term postdoctoral fellowship (LT00316/2008-L).	Abdallah AM, 2013, DEV BIOL, V378, P141, DOI 10.1016/j.ydbio.2013.02.025; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Amcheslavsky A, 2009, CELL STEM CELL, V4, P49, DOI 10.1016/j.stem.2008.10.016; Apidianakis Y, 2009, P NATL ACAD SCI USA, V106, P20883, DOI 10.1073/pnas.0911797106; Baonza A, 2002, NAT CELL BIOL, V4, P976, DOI 10.1038/ncb887; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Beebe K, 2010, DEV BIOL, V338, P28, DOI 10.1016/j.ydbio.2009.10.045; Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Buchon N, 2013, CELL REP, V3, P1725, DOI 10.1016/j.celrep.2013.04.001; Buchon N, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-152; Buchon N, 2009, GENE DEV, V23, P2333, DOI 10.1101/gad.1827009; Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003; Buttitta LA, 2007, CURR OPIN CELL BIOL, V19, P697, DOI 10.1016/j.ceb.2007.10.004; Buttitta LA, 2007, DEV CELL, V12, P631, DOI 10.1016/j.devcel.2007.02.020; Buttitta LA, 2010, J CELL BIOL, V189, P981, DOI 10.1083/jcb.200910006; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chau J, 2009, GENETICS, V182, P121, DOI 10.1534/genetics.109.100693; Choi NH, 2008, AGING CELL, V7, P318, DOI 10.1111/j.1474-9726.2008.00380.x; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Cordero JB, 2012, DEVELOPMENT, V139, P4524, DOI 10.1242/dev.078261; Cronin SJF, 2009, SCIENCE, V325, P340, DOI 10.1126/science.1173164; de Navascues J, 2012, EMBO J, V31, P2473, DOI 10.1038/emboj.2012.106; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; Enomoto M, 2013, EMBO REP, V14, P65, DOI 10.1038/embor.2012.185; Fernandez BG, 2014, ONCOGENE, V33, P2027, DOI 10.1038/onc.2013.155; Goulas S, 2012, CELL STEM CELL, V11, P529, DOI 10.1016/j.stem.2012.06.017; Guest ST, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-65; Herranz H, 2008, EMBO J, V27, P1633, DOI 10.1038/emboj.2008.84; Herranz H, 2012, GENE DEV, V26, P1602, DOI 10.1101/gad.192021.112; Herranz H, 2012, CURR BIOL, V22, P651, DOI 10.1016/j.cub.2012.02.050; Huang HL, 2014, DEV BIOL, V385, P211, DOI 10.1016/j.ydbio.2013.11.008; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Jiang HQ, 2011, CELL STEM CELL, V8, P84, DOI 10.1016/j.stem.2010.11.026; Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014; Jiang HQ, 2009, DEVELOPMENT, V136, P483, DOI 10.1242/dev.026955; Kapuria S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003045; Kim M, 2004, MOL CELL BIOL, V24, P573, DOI 10.1128/MCB.24.2.573-583.2004; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; Kohlmaier A, 2008, CURR OPIN CELL BIOL, V20, P699, DOI 10.1016/j.ceb.2008.10.002; Lee WC, 2009, DEVELOPMENT, V136, P2255, DOI 10.1242/dev.035196; Liu W, 2010, J CELL BIOCHEM, V109, P992, DOI 10.1002/jcb.22482; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Micchelli CA, 2006, NATURE, V439, P475, DOI 10.1038/nature04371; Nasmyth K, 2001, CELL, V107, P689, DOI 10.1016/S0092-8674(01)00604-3; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; O'Brien LE, 2011, CELL, V147, P603, DOI 10.1016/j.cell.2011.08.048; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Ohlstein B, 2007, SCIENCE, V315, P988, DOI 10.1126/science.1136606; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Perdigoto CN, 2011, DEVELOPMENT, V138, P4585, DOI 10.1242/dev.065292; Pesin JA, 2008, ANNU REV CELL DEV BI, V24, P475, DOI 10.1146/annurev.cellbio.041408.115949; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Prieto-Echagile V., 2011, J SIGNAL TRANSDUCT, V2011; Prokopenko SN, 2005, SEMIN CELL DEV BIOL, V16, P423, DOI 10.1016/j.semcdb.2005.02.005; Quesnelle KM, 2007, J CELL BIOCHEM, V102, P311, DOI 10.1002/jcb.21475; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Reis T, 2004, CELL, V117, P253, DOI 10.1016/S0092-8674(04)00247-8; Ren FF, 2013, CELL RES, V23, P1133, DOI 10.1038/cr.2013.101; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Schaeffer V, 2004, CURR BIOL, V14, P630, DOI 10.1016/j.cub.2004.03.040; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schoenherr JA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002725; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sem KP, 2002, MOL CELL BIOL, V22, P3685, DOI 10.1128/MCB.22.11.3685-3697.2002; Shaw RL, 2010, DEVELOPMENT, V137, P4147, DOI 10.1242/dev.052506; Shcherbata HR, 2004, DEVELOPMENT, V131, P3169, DOI 10.1242/dev.01172; Shibutani ST, 2008, DEV CELL, V15, P890, DOI 10.1016/j.devcel.2008.10.003; Shindo M, 2008, DEVELOPMENT, V135, P1355, DOI 10.1242/dev.015982; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Sotillos S, 2013, DEVELOPMENT, V140, P1507, DOI 10.1242/dev.092320; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vidal M, 2007, CANCER RES, V67, P10278, DOI 10.1158/0008-5472.CAN-07-1376; Wang HY, 2007, NATURE, V449, P96, DOI 10.1038/nature06056; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zeng XK, 2010, GENESIS, V48, P607, DOI 10.1002/dvg.20661; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zielke N, 2008, GENE DEV, V22, P1690, DOI 10.1101/gad.469108; Zielke N, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012948; Zielke N, 2011, NATURE, V480, P123, DOI 10.1038/nature10579	98	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2371	2384		10.1038/onc.2014.163	http://dx.doi.org/10.1038/onc.2014.163			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24975577				2022-12-28	WOS:000353824800010
J	Cai, LM; Lyu, XM; Luo, WR; Cui, XF; Ye, YF; Yuan, CC; Peng, QX; Wu, DH; Liu, TF; Wang, E; Marincola, FM; Yao, KT; Fang, WY; Cai, HB; Li, X				Cai, L-M; Lyu, X-M; Luo, W-R; Cui, X-F; Ye, Y-F; Yuan, C-C; Peng, Q-X; Wu, D-H; Liu, T-F; Wang, E.; Marincola, F-M; Yao, K-T; Fang, W-Y; Cai, H-B; Li, X.			EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; ENCODED MICRORNAS; TARGETING PTEN; LUNG-CANCER; E-CADHERIN; EXPRESSION; PROTEIN; INVASION	The epithelial-mesenchymal transition (EMT) is crucial to cancer progression and metastasis. Although multiple cellular miRNAs have been identified to regulate the EMT and metastasis in cancers, the role of viral miRNAs in cancer progression remains largely unknown. Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy typically characterized by its early metastasis. In the present study, we have discovered the involvement of a viral miRNA, EBV-miR-BART7-3p, in the EMT and metastasis of NPC cells. Initially, we observed that EBV-miR-BART7-3p was highly expressed in NPC and positively correlated with lymph node metastasis and clinical stage of NPC. Subsequently, we demonstrated that EBV-miR-BART7-3p enhanced cell migration/invasion in vitro, cancer metastasis in vivo, and particularly the EMT characterized by loss of epithelial markers and gain of mesenchymal features in NPC cells. Furthermore, mechanistic studies disclosed that EBV-miR-BART7-3p targeted a major human tumor suppressor PTEN, modulating PI3K/Akt/GSK-3 beta signaling and eventually leading to the high expression and nuclear accumulation of Snail and beta-catenin, which favor EMT. Knockdown of PTEN could phenocopy the effect of EBV-miR-BART7-3p, whereas re-expression of PTEN resulted in a phenotypic reversion. Moreover, these findings were supported by an observation of an EBV-positive cell model in which silencing of endogenous EBV-miR-BART7-3p partially attenuated cell migration/invasion and altered EMT protein expression pattern via reverting PI3K/Akt, Snail and beta-catenin expression. Thus, this study suggests a novel mechanism by which EBV-miR-BART7-3p modulates the EMT and metastasis of NPC cells, and a clinical implication of EBV-miR-BART7-3p as a potential biomarker or therapeutic target.	[Cai, L-M; Lyu, X-M; Luo, W-R; Ye, Y-F; Yuan, C-C; Yao, K-T; Fang, W-Y; Li, X.] Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China; [Lyu, X-M] Southern Med Univ, Dept Lab Med, Affiliated Hosp 3, Guangzhou 510515, Guangdong, Peoples R China; [Cui, X-F] 463 Hosp Chinese PLA, Dept ENT, Shenyang, Peoples R China; [Peng, Q-X; Cai, H-B] Southern Med Univ, Sch Chinese Tradit Med, Guangzhou 510515, Guangdong, Peoples R China; [Wu, D-H] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Liu, T-F] Southern Med Univ, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Wang, E.; Marincola, F-M] NIH, Infect Dis & Immunogenet Sect, DTM, Ctr Clin, Bethesda, MD 20892 USA	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Li, X (corresponding author), Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China.	fangweiyi1975@yahoo.com.cn; chbing2008@126.com; xinli268@gmail.com	Lyu, Xiaoming/AAC-8564-2020; Luo, Weiren/AAI-8364-2020	Lyu, Xiaoming/0000-0002-6243-3536; Luo, Weiren/0000-0002-2762-6332; Li, Xin/0000-0003-0958-1078	National Natural Science Foundation of China [81372895, 81172586]; Research Fund for the Doctoral Program of Higher Education of China [20134433110013]; Natural Science Foundation of Guangdong Province [S2011010004157]; Guangzhou Science and Technology research project [2014J4100149]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology research project	This study was financially supported by grants from National Natural Science Foundation of China (No. 81372895, 81172586), Research Fund for the Doctoral Program of Higher Education of China (No. 20134433110013), Natural Science Foundation of Guangdong Province (No. S2011010004157) and Guangzhou Science and Technology research project (No. 2014J4100149).	Barth S, 2008, NUCLEIC ACIDS RES, V36, P666, DOI 10.1093/nar/gkm1080; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Cai Xuezhong, 2006, PLoS Pathogens, V2, P236, DOI 10.1371/journal.ppat.0020023; Cao MR, 2012, INT J ONCOL, V41, P869, DOI 10.3892/ijo.2012.1535; Chan JYW, 2012, ANTICANCER RES, V32, P3201; Chen DY, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-50; Chen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056929; Chen SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012745; Choi H, 2013, J VIROL, V87, P8135, DOI 10.1128/JVI.03159-12; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998; Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Ho FCH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-98; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Hsu CY, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003974; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Iwakiri D, 2005, ONCOGENE, V24, P1767, DOI 10.1038/sj.onc.1208357; Johansson J, 2013, ONCOGENE, V32, P5614, DOI 10.1038/onc.2013.322; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Ke Y, 2013, BIOCHEM RES INT, V2013, DOI 10.1155/2013/506731; Kim DN, 2007, J VIROL, V81, P1033, DOI 10.1128/JVI.02271-06; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lei T, 2013, INT J CANCER, V133, P79, DOI 10.1002/ijc.28007; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu HO, 2012, CANCER SCI, V103, P2072, DOI 10.1111/cas.12017; Lo AKF, 2012, J PATHOL, V227, P392, DOI 10.1002/path.4025; Lo AKF, 2007, P NATL ACAD SCI USA, V104, P16164, DOI 10.1073/pnas.0702896104; Lung RWM, 2009, NEOPLASIA, V11, P1174, DOI 10.1593/neo.09888; Luo ZH, 2013, CARCINOGENESIS, V34, P415, DOI 10.1093/carcin/bgs329; Luo Zhaohui, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P604, DOI 10.3969/j.issn.1672-7347.2011.07.004; Lyu XM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-51; McLaughlin-Drubin ME, 2008, BBA-MOL BASIS DIS, V1782, P127, DOI 10.1016/j.bbadis.2007.12.005; MIN HQ, 1994, INT J RADIAT ONCOL, V30, P1037; Mishra Prajna, 2010, J Mol Signal, V5, P9, DOI 10.1186/1750-2187-5-9; Nachmani D, 2009, CELL HOST MICROBE, V5, P376, DOI 10.1016/j.chom.2009.03.003; Pagano JS, 1999, P ASSOC AM PHYSICIAN, V111, P573, DOI 10.1046/j.1525-1381.1999.t01-1-99220.x; Pan YR, 2008, CELL MICROBIOL, V10, P2447, DOI 10.1111/j.1462-5822.2008.01221.x; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Qiu J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002193; Qu CJ, 2012, CELL CYCLE, V11, P785, DOI 10.4161/cc.11.4.19228; Ramakrishnan R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027271; Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Talbot Lindsay J, 2012, Int J Biochem Mol Biol, V3, P117; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Villarejo A, 2014, J BIOL CHEM, V289, P930, DOI 10.1074/jbc.M113.528026; Wang X, 2008, ONCOGENE, V27, P5454, DOI 10.1038/onc.2008.242; Wong AMG, 2012, CANCER-AM CANCER SOC, V118, P698, DOI 10.1002/cncr.26309; Yang HJ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-314; Ye YF, 2013, BIOCHEM BIOPH RES CO, V436, P19, DOI 10.1016/j.bbrc.2013.05.008; Zhang GJ, 2014, DIGEST DIS SCI, V59, P98, DOI 10.1007/s10620-013-2858-8; Zhang J. P., 2013, ONCOGENE, V33, P4069; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6; Zhang LY, 2013, CARCINOGENESIS, V34, P454, DOI 10.1093/carcin/bgs346; Zheng HX, 2013, EUR J CANCER, V49, P2734, DOI 10.1016/j.ejca.2013.03.014	63	141	150	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2156	2166		10.1038/onc.2014.341	http://dx.doi.org/10.1038/onc.2014.341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	25347742				2022-12-28	WOS:000353473000002
J	Marcel, V; Catez, F; Diaz, JJ				Marcel, V.; Catez, F.; Diaz, J-J			p53, a translational regulator: contribution to its tumour-suppressor activity	ONCOGENE			English	Review							RNA-BINDING PROTEINS; EXTENDS LIFE-SPAN; GENE-EXPRESSION; NONCODING RNA; POLYMERASE I; P53-RNA INTERACTIONS; TERMINAL DOMAIN; MICE DEFICIENT; TARGET; CANCER	A growing body of evidences indicate that deregulation of translation contributes to tumourigenesis. In tumours, alterations of translational control of specific mRNAs encoding oncogenes or tumour suppressors have been extensively reported. Moreover, restricting the rate of protein synthesis has been shown to delays tumourigenesis in C-Myc overexpressing or PTEN deleted mice models. Finally, the specific inhibition of RNA polymerase I (RNA pol I) has been shown to kill cancer cells without affecting normal cells. It thus emerges that a tight coordination between the rate of global protein synthesis and a defined translational program is required to prevent tumour development. In this review, we expose the evidences supporting that p53 acts as a translational regulator. In addition, this review discusses the notion that the ability to maintain both a selective translational program and a low level of protein synthesis could directly contribute to the p53 tumour-suppressor activity.	[Marcel, V.; Catez, F.; Diaz, J-J] Ctr Leon Berard, UMR INSERM CNRS 5286 1052, Canc Cell Plast Dept, Ctr Rech Cancerol Lyon, F-69373 Lyon, France; [Marcel, V.; Catez, F.; Diaz, J-J] Univ Lyon 1, ISPB, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Marcel, V (corresponding author), Canc Res Ctr Lyon, Canc Cell Plast, 28 Rue Laennec, F-69622 Rhone, France.	virginie.marcel@lyon.unicancer.fr	Marcel, Virginie/H-3037-2011; MARCEL, Virginie/ABF-1904-2020; CATEZ, Frédéric/GQP-7328-2022; DIAZ, Jean-Jacques/H-3018-2014; DIAZ, Jean-Jacques/AAT-3846-2021; CATEZ, Frédéric/AAM-4854-2020	Marcel, Virginie/0000-0002-9557-8221; MARCEL, Virginie/0000-0002-9557-8221; DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319; CATEZ, Frédéric/0000-0001-8255-9091	CNRS; INSERM; Universite Claude Bernard Lyon 1; Centre Leon Berard; Fondation ARC pour la Recherche sur le Cancer [SFI20121205802]; Ligue Nationale Contre le Cancer Comite Rhone-Alpes-Auvergne et Saone et Loire [13-763C]; ANR [13-BSV8-0012-01 Ribometh]; PAIR Sein [ARC_INCa_LNCC_7625]	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Claude Bernard Lyon 1; Centre Leon Berard; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale Contre le Cancer Comite Rhone-Alpes-Auvergne et Saone et Loire; ANR(French National Research Agency (ANR)); PAIR Sein	We apologize to those works that have not been cited in this article because of lack of space. This article was supported by CNRS, INSERM, Universite Claude Bernard Lyon 1, Centre Leon Berard, Fondation ARC pour la Recherche sur le Cancer (no SFI20121205802), Ligue Nationale Contre le Cancer Comite Rhone-Alpes-Auvergne et Saone et Loire (no13-763C), ANR (13-BSV8-0012-01 Ribometh) and PAIR Sein (noARC_INCa_LNCC_7625). VM was a recipient of a postdoctoral fellowship from Centre Leon Berard. VM and J-JD are members of INSERM. FC is member of CNRS.	Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200; Anger AM, 2013, NATURE, V497, P80, DOI 10.1038/nature12104; Barkic M, 2009, MOL CELL BIOL, V29, P2489, DOI 10.1128/MCB.01588-08; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Bellodi C, 2013, CELL REP, V3, P1493, DOI 10.1016/j.celrep.2013.04.030; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bisio A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-552; Boldrup L, 2012, EUR J CANCER, V48, P1401, DOI 10.1016/j.ejca.2011.06.032; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Boominathan L, 2010, CANCER METAST REV, V29, P613, DOI 10.1007/s10555-010-9257-9; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Cam M, 2014, J BIOL CHEM, V289, P4083, DOI 10.1074/jbc.M113.530303; Candi E, 2015, CELL DEATH DIFFER, V22, P12, DOI 10.1038/cdd.2014.113; Castello A, 2013, TRENDS GENET, V29, P318, DOI 10.1016/j.tig.2013.01.004; Chakraborty A, 2011, WIRES RNA, V2, P507, DOI 10.1002/wrna.73; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Comas M, 2012, AGING-US, V4, P715, DOI 10.18632/aging.100496; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Constantinou C, 2003, EUR J BIOCHEM, V270, P3122, DOI 10.1046/j.1432-1033.2003.03687.x; Crawford L V, 1984, Mol Biol Med, V2, P261; Delloye-Bourgeois C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002456; Deng GR, 2013, INT J MOL SCI, V14, P18319, DOI 10.3390/ijms140918319; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 2012, AGING-US, V4, P660, DOI 10.18632/aging.100494; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Freeman JA, 2013, BRIEF FUNCT GENOMICS, V12, P46, DOI 10.1093/bfgp/els058; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Griseri P, 2014, WORLD J CLIN ONCOL, V5, P323, DOI 10.5306/wjco.v5.i3.323; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Henras AK, 2008, CELL MOL LIFE SCI, V65, P2334, DOI 10.1007/s00018-008-8027-0; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jenner L, 2012, CURR OPIN STRUC BIOL, V22, P759, DOI 10.1016/j.sbi.2012.07.013; Komarova EA, 2012, AGING-US, V4, P709, DOI 10.18632/aging.100498; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Krastev DB, 2011, NAT CELL BIOL, V13, P809, DOI 10.1038/ncb2264; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin SC, 2013, AGING CELL, V12, P863, DOI 10.1111/acel.12108; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Loayza-Puch F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r32; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Marcel V, 2013, ONCOTARGET, V4, P1554, DOI 10.18632/oncotarget.1511; Marcel V, 2013, CANCER CELL, V24, P318, DOI 10.1016/j.ccr.2013.08.013; Martinez-Salas E, 2013, INT J MOL SCI, V14, P21705, DOI 10.3390/ijms141121705; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Meijer HA, 2013, SCIENCE, V340, P82, DOI 10.1126/science.1231197; Melnikov S, 2012, NAT STRUCT MOL BIOL, V19, P560, DOI 10.1038/nsmb.2313; Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Muller-McNicoll M, 2013, NAT REV GENET, V14, P275, DOI 10.1038/nrg3434; Nathan CAO, 2000, CANCER RES, V60, P3599; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Pederson T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a000521; Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009; Petersson J, 2012, BIOL CELL, V104, P462, DOI 10.1111/boc.201100099; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Riley KJL, 2007, RNA, V13, P1825, DOI 10.1261/rna.673407; Riley KJL, 2007, BIOCHEM BIOPH RES CO, V363, P381, DOI 10.1016/j.bbrc.2007.08.181; Riley KJL, 2006, RNA, V12, P620, DOI 10.1261/rna.2286706; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2013, COLD SPRING HARB PER, V5; Sharathchandra A, 2014, WIRES RNA, V5, P131, DOI 10.1002/wrna.1202; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Simeonova I, 2013, CELL REP, V3, P2046, DOI 10.1016/j.celrep.2013.05.028; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Teng T, 2013, CURR OPIN GENET DEV, V23, P63, DOI 10.1016/j.gde.2013.02.001; Tessarz P, 2014, NATURE, V505, P564, DOI 10.1038/nature12819; Tilleray V, 2006, FEBS LETT, V580, P1766, DOI 10.1016/j.febslet.2006.02.030; Timofeev O, 2013, CELL REP, V3, P1512, DOI 10.1016/j.celrep.2013.04.008; Trere D, 2004, J HISTOCHEM CYTOCHEM, V52, P1601, DOI 10.1369/jhc.4A6454.2004; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vilborg A, 2010, J MOL MED, V88, P645, DOI 10.1007/s00109-010-0609-2; White RJ, 2008, TRENDS GENET, V24, P622, DOI 10.1016/j.tig.2008.10.003; Williams GT, 2012, NAT REV CANCER, V12, P84, DOI 10.1038/nrc3195; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Wurth L, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/178525; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Xue SF, 2012, NAT REV MOL CELL BIO, V13, P355, DOI 10.1038/nrm3359; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Zaccara S, 2014, CELL DEATH DIFFER, V21, P1522, DOI 10.1038/cdd.2014.79; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang Q, 2014, SCIENCE, V343, P298, DOI 10.1126/science.1246384; Zhu NX, 2005, BIOCHEM BIOPH RES CO, V335, P1272, DOI 10.1016/j.bbrc.2005.08.026	118	58	61	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5513	5523		10.1038/onc.2015.25	http://dx.doi.org/10.1038/onc.2015.25			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25728674				2022-12-28	WOS:000364594000001
J	Xing, F; Sharma, S; Liu, Y; Mo, YY; Wu, K; Zhang, YY; Pochampally, R; Martinez, LA; Lo, HW; Watabe, K				Xing, F.; Sharma, S.; Liu, Y.; Mo, Y-Y; Wu, K.; Zhang, Y-Y; Pochampally, R.; Martinez, L. A.; Lo, H-W; Watabe, K.			nmiR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-alpha	ONCOGENE			English	Article							BARRIER PERMEABILITY; PROSTATE-CANCER; MICRORNAS; EXPRESSION; LET-7; MICE	The median survival time of breast cancer patients with brain metastasis is less than 6 months, and even a small metastatic lesion often causes severe neurological disabilities. Because of the location of metastatic lesions, a surgical approach is limited and most chemotherapeutic drugs are ineffective owing to the blood brain barrier (BBB). Despite this clinical importance, the molecular basis of the brain metastasis is poorly understood. In this study, we have isolated RNA from samples obtained from primary breast tumors and also from brain metastatic lesions followed by microRNA profiling analysis. Our results revealed that the miR-509 is highly expressed in the primary tumors, whereas the expression of this microRNA is significantly decreased in the brain metastatic lesions. MicroRNA target prediction and the analysis of cytokine array for the cells ectopically expressed with miR-509 demonstrated that this microRNA was capable of modulating the two genes essential for brain invasion, RhoC and TNF-alpha that affect the invasion of cancer cells and permeability of BBB, respectively. Importantly, high levels of TNF-alpha and RhoC-induced MMP9 were significantly correlated with brain metastasis-free survival of breast cancer patients. Furthermore, the results of our in vivo experiments indicate that miR-509 significantly suppressed the ability of cancer cells to metastasize to the brain. These findings suggest that miR-509 has a critical role in brain metastasis of breast cancer by modulating the RhoC-TNF-alpha network and that this miR-509 axis may represent a potential therapeutic target or serve as a prognostic tool for brain metastasis.	[Xing, F.; Sharma, S.; Liu, Y.; Wu, K.; Lo, H-W; Watabe, K.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; [Xing, F.; Sharma, S.; Liu, Y.; Wu, K.; Lo, H-W; Watabe, K.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; [Mo, Y-Y; Zhang, Y-Y; Pochampally, R.; Martinez, L. A.] Univ Mississippi, Med Ctr, Canc Inst, Jackson, MS 39216 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Mississippi; University of Mississippi Medical Center	Watabe, K (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	kwatabe@wakehealth.edu	Mo, Yin-Yuan/R-8255-2019	Pochampally, Radhika/0000-0002-4263-0364	National Institutes of Health [R01CA124650, R01CA129000, R01CA173499]; US Department of Defense [BC096982]; NATIONAL CANCER INSTITUTE [R01CA173499, R01CA129000, R01CA151851, R01CA124650, R01CA154989, P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087169] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the National Institutes of Health (grants R01CA124650, R01CA129000 and R01CA173499 to K Watabe) and the US Department of Defense (BC096982 to K Watabe).	Arora S, 2011, INT J CANCER, V129, P2621, DOI 10.1002/ijc.25939; Arslan C, 2010, EXPERT OPIN PHARMACO, V11, P1089, DOI 10.1517/14656561003702412; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bindal AK, 1996, J NEUROSURG, V84, P748, DOI 10.3171/jns.1996.84.5.0748; BINDAL RK, 1993, J NEUROSURG, V79, P210, DOI 10.3171/jns.1993.79.2.0210; Bockhorn J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2393; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Eichler AF, 2008, CANCER, V112, P2359, DOI 10.1002/cncr.23468; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iiizumi M, 2008, CANCER RES, V68, P7613, DOI 10.1158/0008-5472.CAN-07-6700; Izraely S, 2012, INT J CANCER, V131, P1071, DOI 10.1002/ijc.27324; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Langley RR, 2003, CANCER RES, V63, P2971; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Nagpal N, 2013, CARCINOGENESIS, V34, P1889, DOI 10.1093/carcin/bgt107; Nie WW, 2013, CANCER BIOTHER RADIO, V28, P71, DOI 10.1089/cbr.2012.1311; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Ramakrishna Rohan, 2013, Surg Neurol Int, V4, pS256, DOI 10.4103/2152-7806.111303; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Rosenthal DT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040979; SAIJA A, 1995, LIFE SCI, V56, P775, DOI 10.1016/0024-3205(95)00008-T; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; Tie J, 2011, HISTOL HISTOPATHOL, V26, P1353, DOI 10.14670/HH-26.1353; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; van Golen KL, 2000, CANCER RES, V60, P5832; Volinia S, 2013, P NATL ACAD SCI USA, V110, P7413, DOI 10.1073/pnas.1304977110; Wang W, 2011, EUR J GASTROEN HEPAT, V23, P552, DOI 10.1097/MEG.0b013e3283470212; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wilhelm I, 2013, INT J MOL SCI, V14, P1383, DOI 10.3390/ijms14011383; Yang GY, 1999, MOL BRAIN RES, V69, P135, DOI 10.1016/S0169-328X(99)00007-8; Yang YL, 2004, WORLD J GASTROENTERO, V10, P3161; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	40	60	64	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4890	4900		10.1038/onc.2014.412	http://dx.doi.org/10.1038/onc.2014.412			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25659578	Green Accepted			2022-12-28	WOS:000361050000009
J	Chen, C; Wang, X; Xiong, X; Liu, Q; Huang, Y; Xu, Q; Hu, J; Ge, G; Ling, K				Chen, C.; Wang, X.; Xiong, X.; Liu, Q.; Huang, Y.; Xu, Q.; Hu, J.; Ge, G.; Ling, K.			Targeting type I. phosphatidylinositol phosphate kinase inhibits breast cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LEPTIN RECEPTOR; TYROSINE KINASE; SPLICE VARIANTS; CELL-MIGRATION; C-MET; GAMMA; EXPRESSION; 5-KINASE; ANGIOGENESIS	Most deaths from breast cancer are caused by metastasis, a complex behavior of cancer cells involving migration, invasion, survival and microenvironment manipulation. Type I. phosphatidylinositol phosphate kinase ( PIPKI gamma) regulates focal adhesion assembly and its phosphorylation at Y639 is critical for cell migration induced by EGF. However, the role of this lipid kinase in tumor metastasis remains unclear. Here we report that PIPKI. is vital for breast cancer metastasis. Y639 of PIPKI gamma can be phosphorylated by stimulation of EGF and hepatocyte growth factor ( HGF), two promoting factors for breast cancer progression. Histological analysis revealed elevated Y639 phosphorylation of PIPKI gamma in invasive ductal carcinoma lesions and suggested a positive correlation with tumor grade. Orthotopically transplanted PIPKI.-depleted breast cancer cells showed substantially reduced growth and metastasis, as well as suppressed expression of multiple genes related to cell migration and microenvironment manipulation. Re-expression of wild-type PIPKI. in PIPKI.-depleted cells restored tumor growth and metastasis, reinforcing the importance of PIPKI gamma in breast cancer progression. Y639-to-F or a kinase-dead mutant of PIPKI gamma could not recover the diminished metastasis in PIPKI gamma-depleted cancer cells, suggesting that Y639 phosphorylation and lipid kinase activity are both required for development of metastasis. Further analysis with in vitro assays indicated that depleting PIPKI gamma inhibited cell proliferation, MMP9 secretion and cell migration and invasion, lending molecular mechanisms for the eliminated cancer progression. These results suggest that PIPKI gamma, downstream of EGF and/or HGF receptor, participates in breast cancer progression from multiple aspects and deserves further studies to explore its potential as a therapeutic target.	[Chen, C.; Huang, Y.; Xu, Q.; Hu, J.; Ling, K.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Wang, X.] Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; [Xiong, X.] Oklahoma Univ Med, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA; [Liu, Q.; Ge, G.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Hu, J.] Mayo Clin, Dept Hypertens & Nephrol, Rochester, MN 55905 USA; [Ling, K.] Mayo Clin, Canc Ctr, Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; University of Oklahoma System; University of Oklahoma Health Sciences Center; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Mayo Clinic; Mayo Clinic	Ling, K (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Ctr Canc, Guggenheim 16-04,200 First St SW, Rochester, MN 55905 USA.	ling.kun@mayo.edu			National Cancer Institute [1R01CA149039-01A1]; Susan G Komen for the Cure [KG100902]; NATIONAL CANCER INSTITUTE [R01CA149039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK099160, R01DK090038] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Daniel Visscher (Mayo Clinic) for scoring the breast cancer tissue microarrays, Dr Wilma Lingle (Mayo Clinic) for providing human breast cancer tissue samples and tissue microarrays, Dr Vijayalakshmi Shridhar (Mayo Clinic) for sharing the 4T1 cells and Dr Kah Whye Peng (Mayo Clinic) for providing the luciferase system. This work was supported by research grants from the National Cancer Institute (1R01CA149039-01A1) and Susan G Komen for the Cure (KG100902).	Ali S, 2007, CANCER METAST REV, V26, P401, DOI 10.1007/s10555-007-9073-z; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Bhati R, 2008, AM J PATHOL, V172, P1381, DOI 10.2353/ajpath.2008.070988; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Courtwright A, 2009, CANCER RES, V69, P4621, DOI 10.1158/0008-5472.CAN-08-3402; Datta D, 2006, CANCER RES, V66, P9509, DOI 10.1158/0008-5472.CAN-05-4345; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; El Sayegh TY, 2007, MOL BIOL CELL, V18, P3026, DOI 10.1091/mbc.E06-12-1159; Garofalo C, 2006, CLIN CANCER RES, V12, P1447, DOI 10.1158/1078-0432.CCR-05-1913; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giudici ML, 2006, FEBS LETT, V580, P6933, DOI 10.1016/j.febslet.2006.11.052; Giudici ML, 2004, BIOCHEM J, V379, P489, DOI 10.1042/BJ20031394; Gonzalez RR, 2006, J BIOL CHEM, V281, P26320, DOI 10.1074/jbc.M601991200; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Keshtgar MRS, 1999, EUR J NUCL MED, V26, P57, DOI 10.1007/s002590050360; Landi L, 2013, CURR OPIN ONCOL, V25, P130, DOI 10.1097/CCO.0b013e32835daf37; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Ling K, 2006, TRENDS CELL BIOL, V16, P276, DOI 10.1016/j.tcb.2006.03.007; Lippitz BE, 2013, LANCET ONCOL, V14, pE218, DOI 10.1016/S1470-2045(12)70582-X; Liu JL, 2007, MOL BIOL CELL, V18, P4483, DOI 10.1091/mbc.E07-05-0461; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; McMurtry V, 2009, CLIN EXP METASTAS, V26, P197, DOI 10.1007/s10585-008-9231-x; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mulligan AM, 2013, CLIN CANCER RES, V19, P336, DOI 10.1158/1078-0432.CCR-11-3314; Perera CN, 2008, J ENDOCRINOL, V199, P221, DOI 10.1677/JOE-08-0215; Ponzo MG, 2010, CELL CYCLE, V9, P1043, DOI 10.4161/cc.9.6.11033; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Schill NJ, 2009, BIOCHEM J, V422, P473, DOI 10.1042/BJ20090638; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sun Y, 2007, J CELL BIOL, V178, P297, DOI 10.1083/jcb.200701078; Sun Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2471; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wang YJ, 2004, J CELL BIOL, V167, P1005, DOI 10.1083/jcb.200408008; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xiong XH, 2012, MOL BIOL CELL, V23, P87, DOI 10.1091/mbc.E11-05-0449; Yan D, 2012, J BIOL CHEM, V287, P8598, DOI 10.1074/jbc.M111.322800	50	22	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4635	4646		10.1038/onc.2014.393	http://dx.doi.org/10.1038/onc.2014.393			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486426	Green Accepted			2022-12-28	WOS:000360189300009
J	Bianco, S; Jangal, M; Garneau, D; Gevry, N				Bianco, S.; Jangal, M.; Garneau, D.; Gevry, N.			LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression	ONCOGENE			English	Article							LIVER RECEPTOR HOMOLOG-1; KINASE INHIBITOR P21; CANCER CELLS; GENOMICS DATA; ALPHA; TRANSCRIPTION; ENHANCERS; CHROMATIN; TARGET; PROGRESSION	Liver receptor homolog-1 (LRH-1, NR5A2) is an orphan nuclear receptor that has an essential role in cancer progression, notably in breast cancer. Although its role in promoting cancer cell proliferation and migration is well documented, the molecular basis is not completely established. Here, we report that LRH-1 inhibition affects two-and three-dimensional cell proliferation of different types of breast cancer cells, including estrogen receptor alpha (ER alpha)-positive and triple-negative cells. This phenotype is accompanied by the upregulation of the cyclin-dependent kinase inhibitor CDKN1A (aka p21(CIP1/WAF1)) in a p53-independent manner. Chromatin immunoprecipitation analysis shows that LRH-1 cooperates with FOXA1 and binds directly to CDKN1A promoter and a distal regulatory region found at - 62 kb from its transcriptional start sites, allowing repression of CDKN1A transcription. LRH-1 or FOXA1 depletion induces CDKN1A upregulation by removing histone deacetylase 2 from the promoter and distal regulatory elements and permitting histone acetylation in these regions. Analysis of breast cancer samples reveals that a high LRH-1 level is inversely correlated with CDKN1A expression in breast cancer patients and is associated with poor prognosis. This study reveals a novel mechanism of control of cell proliferation by LRH-1 regulating CDKN1A transcription in breast cancer cells, independent of ERa and p53 status. Targeting LRH-1 may provide an attractive prospect for treatment of tumors that are resistant to hormonal and targeted therapy.	[Bianco, S.; Jangal, M.; Garneau, D.; Gevry, N.] Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke	Gevry, N (corresponding author), Univ Sherbrooke, Fac Sci, Dept Biol, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.	nicolas.gevry@usherbrooke.ca			Canadian Institute of Health Research (CIHR); Reseau Quebecois en Reproduction (RQR)	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Reseau Quebecois en Reproduction (RQR)	We thank Alain Lavigueur and Bruce Murphy for critical comments on the manuscript. We are also grateful to Robert Clark for providing the MCF7/LCC2 and MCF7/LCC9 cell lines and Mien-Chie Hung for the MCF7/HER2-18 cell line. This work was supported with fund from the Canadian Institute of Health Research (CIHR) to NG. SB was the recipient of a postdoctoral fellowship from the Reseau Quebecois en Reproduction (RQR).	Ai NP, 2011, NUCLEIC ACIDS RES, V39, P9592, DOI 10.1093/nar/gkr698; Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950; Atkin SD, 2013, MOL ENDOCRINOL, V27, P598, DOI 10.1210/me.2012-1371; Benod C, 2011, P NATL ACAD SCI USA, V108, P16927, DOI 10.1073/pnas.1112047108; Bianco S, 2012, TRANSCRIPTION, V3, P4165; Bianco S, 2014, CANCER RES, V74, P2015, DOI 10.1158/0008-5472.CAN-13-2351; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Boyle AP, 2008, BIOINFORMATICS, V24, P2537, DOI 10.1093/bioinformatics/btn480; Brunner N, 1997, CANCER RES, V57, P3486; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chand AL, 2010, ENDOCR-RELAT CANCER, V17, P965, DOI 10.1677/ERC-10-0179; Chand AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031593; Chand AL, 2011, STEROIDS, V76, P741, DOI 10.1016/j.steroids.2011.02.024; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384; Duggavathi R, 2008, GENE DEV, V22, P1871, DOI 10.1101/gad.472008; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Han SW, 2004, CLIN CANCER RES, V10, P1911, DOI 10.1158/1078-0432.CCR-03-0985; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hlobilkova A, 2006, ANTICANCER RES, V26, P1015; Holmstrom SR, 2011, GENE DEV, V25, P1674, DOI 10.1101/gad.16860911; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Jangal M, 2014, NUCLEIC ACIDS RES, V42, P11339, DOI 10.1093/nar/gku791; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403; Knower KC, 2013, BREAST CANCER RES TR, V142, P211, DOI 10.1007/s10549-013-2716-6; Lai CF, 2013, NUCLEIC ACIDS RES, V41, P10228, DOI 10.1093/nar/gkt827; Lam SW, 2014, CANCER TREAT REV, V40, P129, DOI 10.1016/j.ctrv.2013.06.006; Lazarus KA, 2013, BIOCHEM BIOPH RES CO, V438, P533, DOI 10.1016/j.bbrc.2013.07.101; Lazarus KA, 2012, J STEROID BIOCHEM, V130, P138, DOI 10.1016/j.jsbmb.2011.12.017; Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Mandal S, 2010, J CELL PHYSIOL, V224, P28, DOI 10.1002/jcp.22078; Miki Y, 2006, CANCER LETT, V244, P24, DOI 10.1016/j.canlet.2005.11.038; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Oosterveer MH, 2012, J CLIN INVEST, V122, P2817, DOI 10.1172/JCI62368; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Robinson Jessica L L, 2012, Front Endocrinol (Lausanne), V3, P68, DOI 10.3389/fendo.2012.00068; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Sidler D, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19459; Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284; Thiruchelvam PTR, 2011, BREAST CANCER RES TR, V127, P385, DOI 10.1007/s10549-010-0994-9; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang SL, 2008, MOL CELL BIOCHEM, V308, P93, DOI 10.1007/s11010-007-9616-1; Yamaguchi T, 2010, GENE DEV, V24, P455, DOI 10.1101/gad.552310; Zhang C, 2013, NAT MED, V19, P1061, DOI 10.1038/nm.3192; Zupkovitz G, 2010, MOL CELL BIOL, V30, P1171, DOI 10.1128/MCB.01500-09	54	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4509	4518		10.1038/onc.2014.382	http://dx.doi.org/10.1038/onc.2014.382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25435372				2022-12-28	WOS:000360189200010
J	Roy, BC; Subramaniam, D; Ahmed, I; Jala, VR; Hester, CM; Greiner, KA; Haribabu, B; Anant, S; Umar, S				Roy, B. C.; Subramaniam, D.; Ahmed, I.; Jala, V. R.; Hester, C. M.; Greiner, K. A.; Haribabu, B.; Anant, S.; Umar, S.			Role of bacterial infection in the epigenetic regulation of Wnt antagonist WIF1 by PRC2 protein EZH2	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; BREAST-CANCER; E-CADHERIN; IN-VIVO; CATENIN; PROLIFERATION; REPRESSION; PATHWAY; OVEREXPRESSION; TUMORIGENESIS	The enhancer of zeste homolog-2 (EZH2) represses gene transcription through histone H3 lysine-27-trimethylation (H3K27me3). Citrobacter rodentium (CR) promotes crypt hyperplasia and tumorigenesis by aberrantly regulating Wnt/beta-catenin signaling. We aimed at investigating EZH2's role in epigenetically regulating Wnt/beta-catenin signaling following bacterial infection. NIH: Swiss outbred and Apc(Min/+) mice were infected with CR (10(8) CFU); BLT1(-/)-Apc(Min/+) mice, azoxymethane (AOM)/dextran sodium sulfate (DSS)-treated mice and de-identified human adenocarcinoma samples were the models of colon cancer. Following infection with wild-type but not mutant CR, elevated EZH2 levels in the crypt at days 6 and 12 (peak hyperplasia) coincided with increases in H3K27me3 and beta-catenin levels, respectively. Chromatin immunoprecipitation revealed EZH2 and H3K27me3's occupancy on WIF1 (Wnt inhibitory factor 1) promoter resulting in reduced WIF1 mRNA and protein expression. Following EZH2 knockdown via small interfering RNA or EZH2-inhibitor deazaneplanocin A (Dznep) either alone or in combination with histone deacetylase inhibitor suberoylanilide hydroxamic acid, WIF1 promoter activity increased significantly while the overexpression of EZH2 attenuated WIF1 reporter activity. Ectopic overexpression of SET domain mutant (F681Y) almost completely rescued WIF1 reporter activity and partially rescued WIF1 protein levels, whereas H3K27me3 levels were significantly attenuated suggesting that an intact methyltransferases activity is required for EZH2-dependent effects. Interestingly, although beta-catenin levels were lower in EZH2-knocked down cells, F681Y mutants exhibited only partial reduction in beta-catenin levels. Besides EZH2, increases in miR-203 expression in the crypts at days 6 and 12 post infection correlated with reduced levels of its target WIF1; overexpression of miR-203 in primary colonocytes decreased WIF1 mRNA and protein levels. Elevated levels of EZH2 and beta-catenin with concomitant decrease in WIF1 expression in the polyps of CR-infected Apc(Min/+) mice paralleled changes recorded in BLT1(-/-) Apc(Min/+), AOM/DSS and human adenocarcinomas. Thus, EZH2-induced downregulation of WIF1 expression may partially regulate Wnt/beta-catenin-dependent crypt hyperplasia in response to CR infection.	[Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Mol Physiol, Kansas City, KS 66160 USA; [Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Integrat Physiol, Kansas City, KS 66160 USA; [Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Family Med Res Div, Kansas City, KS 66160 USA; [Jala, V. R.; Haribabu, B.] Univ Kansas, James Graham Brown Canc Ctr, Kansas City, KS 66160 USA; [Jala, V. R.; Haribabu, B.] Univ Kansas, Dept Microbiol & Immunol, Kansas City, KS 66160 USA; [Anant, S.; Umar, S.] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas; University of Kansas	Umar, S (corresponding author), Univ Kansas, Med Ctr, Ctr Canc, 3901 Rainbow Blvd,4028 Wahl Hall East, Kansas City, KS 66160 USA.	sumar@kumc.edu	Bodduluri, Haribabu/A-2584-2010; Anant, Shrikant/AAF-8020-2020; Jala, Venkatakrishna R/K-7255-2018	Bodduluri, Haribabu/0000-0002-8261-3294; Jala, Venkatakrishna R/0000-0002-4206-7305	National Institutes of Health [R01 CA131413]; University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE [R01CA131413] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Philip R Hardwidge (Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA) for Citrobacter rodentium mutants. This work was partially supported by the National Institutes of Health Grant R01 CA131413 and start-up funds from the University of Kansas Medical Center, Kansas City, KS, USA.	Ahmed I, 2013, AM J PHYSIOL-GASTR L, V304, pG356, DOI 10.1152/ajpgi.00372.2012; Ahmed I, 2012, INFECT IMMUN, V80, P3107, DOI 10.1128/IAI.00236-12; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Chan DW, 2006, GASTROENTEROLOGY, V131, P1218, DOI 10.1053/j.gastro.2006.07.020; Chandrakesan P, 2014, ONCOGENE, V33, P2639, DOI 10.1038/onc.2013.210; Chandrakesan P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079432; Chandrakesan P, 2010, J BIOL CHEM, V285, P33485, DOI 10.1074/jbc.M110.129353; Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009; Hayashi Y, 2013, GUT, V62, P1536, DOI 10.1136/gutjnl-2011-301625; Ihara A, 2007, J PHARMACOL SCI, V103, P24, DOI 10.1254/jphs.FP0060651; Joshi P, 2008, J BIOL CHEM, V283, P27757, DOI 10.1074/jbc.M804442200; Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Sellin JH, 2001, CANCER RES, V61, P2899; Sellin JH, 2009, EXP CELL RES, V315, P97, DOI 10.1016/j.yexcr.2008.10.019; Shen L, 2013, ONCOTARGETS THER, V6, P321, DOI 10.2147/OTT.S42453; Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387; Umar S, 2005, ONCOGENE, V24, P6709, DOI 10.1038/sj.onc.1208820; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006; Umar S, 2012, CURR COLORECT CANC R, V8, P298, DOI 10.1007/s11888-012-0143-4; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	38	21	22	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4519	4530		10.1038/onc.2014.386	http://dx.doi.org/10.1038/onc.2014.386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25486432	Green Accepted			2022-12-28	WOS:000360189200011
J	Shanzer, M; Ricardo-Lax, I; Keshet, R; Reuven, N; Shaul, Y				Shanzer, M.; Ricardo-Lax, I.; Keshet, R.; Reuven, N.; Shaul, Y.			The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner	ONCOGENE			English	Article							CELL CONTACT INHIBITION; MAMMARY-TUMORS; SIZE-CONTROL; TAZ; YAP; PHOSPHORYLATION; INDUCTION; IDENTIFICATION; TRANSFORMATION; PROLIFERATION	The polyomavirus middle T antigen (PyMT) is an oncogene that activates the non-receptor tyrosine kinase, c-Src, and physically interacts with Taz (WWTR1). Taz is a pro-oncogenic transcription coactivator of the Tead transcription factors. The Hippo tumor suppressor pathway activates the kinase Lats, which phosphorylates Taz, leading to its nuclear exclusion and blunting Tead coactivation. We found that Taz was required for transformation by PyMT, but counter-intuitively, Taz was exclusively cytoplasmic in the presence of PyMT. We demonstrate that in the presence of PyMT, wild-type Taz was phosphorylated by Lats, in a Src-dependent manner. Consistently, a Lats refractory Taz mutant did not undergo cytoplasmic retention by PyMT. We show that Yap, the Taz paralog, and Shp2 phosphatase were nuclear excluded as well. Our findings describe a noncanonical activation of Lats, and an unprecedented Tead-independent role for Taz and Yap in viral-mediated oncogenesis.	[Shanzer, M.; Ricardo-Lax, I.; Keshet, R.; Reuven, N.; Shaul, Y.] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Herzel 1, IL-76100 Rehovot, Israel.	yosef.shaul@weizmann.ac.il	Reuven, Nina/AAM-8711-2020; Ricardo-Lax, Inna/ABE-7179-2020	Reuven, Nina/0000-0003-1569-3818; Ricardo-Lax, Inna/0000-0002-9590-9692	Israel Science Foundation [551/11]; Minerva Foundation; Federal German Ministry for Education and Research	Israel Science Foundation(Israel Science Foundation); Minerva Foundation; Federal German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF))	We thank Drs R Bassel-Duby for pCDNA3-Flag-mTaz, pCDNA-myc-mTaz and pCDNA-myc-mTazWA plasmids; M Sudol for pCMV-Yap1 plasmid; J Zhang for pBP-GFP-hTaz-4SA plasmid; H Sasaki for pBS-8xGTIIC-Luc (8xGTIIC) Tead reporter plasmid; A Elson for mSrc sequence; M Oren for Myc-tagged human Lats2 constructs; and XJ Yang for HA-tagged Lats2, Lats-KM, Mst1 and WW45 constructs; B Neel for Shp2 C459S and E76K constructs. We thank Dr Z Porat for his help with ImageStream technology. This work was supported by grants from the Israel Science Foundation (grant No. 551/11), Israel Cancer Research Fund and from the Minerva Foundation with funding from the Federal German Ministry for Education and Research.	CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Carey MF, 2009, COLD SPRING HARB PRO, V2009; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Primo L, 2000, ONCOGENE, V19, P3632, DOI 10.1038/sj.onc.1203708; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; Schaffhausen BS, 2009, VIROLOGY, V384, P304, DOI 10.1016/j.virol.2008.09.042; Tian Y, 2004, J VIROL, V78, P12657, DOI 10.1128/JVI.78.22.12657-12664.2004; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Tsutsumi R, 2013, DEV CELL, V26, P658, DOI 10.1016/j.devcel.2013.08.013; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; Yang Y, 2011, VIROLOGY, V409, P204, DOI 10.1016/j.virol.2010.09.032; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997	39	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4190	4198		10.1038/onc.2014.347	http://dx.doi.org/10.1038/onc.2014.347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362852				2022-12-28	WOS:000359199800005
J	Sriram, G; Jankowski, W; Kasikara, C; Reichman, C; Saleh, T; Nguyen, KQ; Li, J; Hornbeck, P; Machida, K; Liu, T; Li, H; Kalodimos, CG; Birge, RB				Sriram, G.; Jankowski, W.; Kasikara, C.; Reichman, C.; Saleh, T.; Nguyen, K-Q; Li, J.; Hornbeck, P.; Machida, K.; Liu, T.; Li, H.; Kalodimos, C. G.; Birge, R. B.			Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; MEDIATED CELL-ADHESION; SH3 DOMAIN; APOPTOTIC CELLS; ADAPTER PROTEIN; C-ABL; SIGNALING PROTEIN; STRUCTURAL BASIS; FACTOR RECEPTOR; FACTOR C3G	Crk, the prototypical member of a class of Src homology-2 (SH2) and Src homology-3 (SH3) domain containing proteins that controls the coordinated assembly of signaling complexes, is regulated by phosphorylation of Y221 in the linker region, which forms an intramolecular SH2-pY221 auto-clamp to interrupt SH2-N-terminal SH3 domain (SH3N) signaling. Here, we show using LC-MS/MS and by generating phospho-specific antibodies that, iteratively with Y221, the Crk C-terminal SH3 domain (SH3C) is routinely phosphorylated on Y239 and/or Y251 by several extracellular stimuli known to engage Crk. Although phosphorylation at Y221 auto-inhibits the Crk SH2, phosphorylation of the SH3C generates an unconventional phosphoSH3C-SH3N unit in which the SH3N is fully functional to bind polyproline type II ligands and the phosphoSH3C binds de novo to other SH2 domains. Using high-throughput SH2 domain profiling, artificial neural network and position-specific scoring matrix-based bioinformatics approaches, and unbiased mass spectometry, we found that the phosphoSH3C binds several SH2 domain containing proteins, including specific non-receptor tyrosine kinases-Abl via pY251 and C-terminal Src kinase via pY239. Functionally, we show that the phosphoSH3C modulates the Abl-mediated phenotypes of cell spreading and motility. Together, these studies describe a versatile mechanism wherein phosphorylation of Crk at Y221 is not an off switch but redirects signaling from the SH2-SH3N axis to a phosphoSH3C-SH3N axis, with the SH3N as a common denominator.	[Sriram, G.; Kasikara, C.; Reichman, C.; Nguyen, K-Q; Birge, R. B.] Rutgers Biomed & Hlth Sci, Dept Biochem & Mol Biol, Newark, NJ USA; [Jankowski, W.; Saleh, T.; Kalodimos, C. G.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ USA; [Li, J.; Hornbeck, P.] Cell Signaling Technol, Danvers, MA USA; [Machida, K.] Univ Connecticut Hlth Ctr, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet & Mol Med, Farmington, CT USA; [Liu, T.; Li, H.] Rutgers Biomed & Hlth Sci, Ctr Adv Prote Res, Newark, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Connecticut; Rutgers State University New Brunswick; Rutgers State University Medical Center	Birge, RB (corresponding author), Rutgers Biomed & Hlth Sci Canc Ctr H121, Dept Biochem & Mol Biol, 205 South Orange Ave, Newark, NJ 07103 USA.	birgera@njms.rutgers.edu	Kalodimos, Charalampos/Q-9846-2018; Hornbeck, Peter V/K-2226-2017; Saleh, Tamjeed/M-8698-2016	Kalodimos, Charalampos/0000-0001-6354-2796; Hornbeck, Peter V/0000-0002-1126-5149; Li, Hong/0000-0001-5731-5335; Saleh, Tamjeed/0000-0002-7539-7300	NIH [CA165077, GM080308, NS046593]; Rutgers Foundation; NATIONAL CANCER INSTITUTE [R01CA165077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS046593] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rutgers Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the NIH grant CA165077 to RBB and Rutgers Foundation grant to RBB and in part by NIH grant to CGK and RBB GM080308. The LC-MS/MS work was funded in part by an NIH grant NS046593, for the support of the Rutgers Neuroproteomics Core Facility. We thank Chingiz Underbayev, WenI Tsou and Anita Antes for technical support; Sushil Kumar and Stanley Kimani for discussion.	Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Antoku S, 2008, J CELL SCI, V121, P3071, DOI 10.1242/jcs.031575; Antoku S, 2009, J CELL SCI, V122, P4228, DOI 10.1242/jcs.054627; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Chen S, 2008, J MOL BIOL, V383, P414, DOI 10.1016/j.jmb.2008.08.040; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Huang HM, 2008, MOL CELL PROTEOMICS, V7, P768, DOI 10.1074/mcp.M700312-MCP200; Jankowski W, 2012, NAT CHEM BIOL, V8, P590, DOI [10.1038/NCHEMBIO.954, 10.1038/nchembio.954]; Janostiak R, 2011, MOL BIOL CELL, V22, P4256, DOI 10.1091/mbc.E11-03-0207; Jin H, 2007, MOL BIOL CELL, V18, P4143, DOI 10.1091/mbc.E07-01-0085; Kardinal C, 1999, ANN NY ACAD SCI, V886, P289, DOI 10.1111/j.1749-6632.1999.tb09439.x; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kobashigawa Y, 2007, J BIOTECHNOL, V131, P458, DOI 10.1016/j.jbiotec.2007.07.956; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lamorte L, 2002, J BIOL CHEM, V277, P37904, DOI 10.1074/jbc.M201743200; Li L, 2008, NUCLEIC ACIDS RES, V36, P3263, DOI 10.1093/nar/gkn161; Machida K, 2007, MOL CELL, V26, P899, DOI 10.1016/j.molcel.2007.05.031; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Muralidharan V, 2006, BIOCHEMISTRY-US, V45, P8874, DOI 10.1021/bi060590z; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Reichman C, 2005, ONCOGENE, V24, P8187, DOI 10.1038/sj.onc.1208988; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004; Sarkar P, 2011, NAT CHEM BIOL, V7, P51, DOI 10.1038/NCHEMBIO.494; Seeliger MA, 2005, PROTEIN SCI, V14, P3135, DOI 10.1110/ps.051750905; Tinti M, 2013, CELL REP, V3, P1293, DOI 10.1016/j.celrep.2013.03.001; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632	42	8	8	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4260	4269		10.1038/onc.2014.361	http://dx.doi.org/10.1038/onc.2014.361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25381819	Green Accepted			2022-12-28	WOS:000359199800012
J	De Simone, V; Franze, E; Ronchetti, G; Colantoni, A; Fantini, MC; Di Fusco, D; Sica, GS; Sileri, P; MacDonald, TT; Pallone, F; Monteleone, G; Stolfi, C				De Simone, V.; Franze, E.; Ronchetti, G.; Colantoni, A.; Fantini, M. C.; Di Fusco, D.; Sica, G. S.; Sileri, P.; MacDonald, T. T.; Pallone, F.; Monteleone, G.; Stolfi, C.			Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth	ONCOGENE			English	Article							COLITIS-ASSOCIATED CANCER; INTESTINAL EPITHELIAL-CELLS; COLON-CANCER; TRANSCRIPTION FACTOR; MOUSE MODEL; T-CELLS; IMMUNE CELLS; HELPER-CELLS; TUMOR-GROWTH; KAPPA-B	Colorectal cancers (CRCs) often show a dense infiltrate of cytokine-producing immune/inflammatory cells. The exact contribution of each immune cell subset and cytokine in the activation of the intracellular pathways sustaining CRC cell growth is not understood. Herein, we isolate tumor-infiltrating leukocytes (TILs) and lamina propria mononuclear cells (LPMCs) from the tumor area and the macroscopically unaffected, adjacent, colonic mucosa of patients who underwent resection for sporadic CRC and show that the culture supernatants of TILs, but not of LPMCs, potently enhance the growth of human CRC cell lines through the activation of the oncogenic transcription factors signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kappa B (NF-kB). Characterization of immune cell complexity of TILs and LPMCs reveals no differences in the percentages of T cells, natural killer T cells, natural killer (NK) cells, macrophages and B cells. However, T cells from TILs show a functional switch compared with those from LPMCs to produce large amounts of T helper type 17 (Th17)-related cytokines (that is, interleukin-17A (IL-17A), IL-17F, IL-21 and IL-22), tumor necrosis factor-alpha (TNF-alpha) and IL-6. Individual neutralization of IL-17A, IL-17F, IL-21, IL-22, TNF-alpha or IL-6 does not change TIL-derived supernatant-driven STAT3 and NF-kB activation, as well as their proproliferative effect in CRC cells. In contrast, simultaneous neutralization of both IL-17A and TNF-alpha, which abrogates NF-kB signaling, and IL-22 and IL-6, which abrogates STAT3 signaling, reduces the mitogenic effect of supernatants in CRC cells. IL-17A, IL-21, IL-22, TNF-alpha and IL-6 are also produced in excess in the early colonic lesions in a mouse model of sporadic CRC, associated with enhanced STAT3/NF-kB activation. Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas. These data suggest that strategies aimed at the cotargeting of STAT3/NF-kB activation and interaction between them might represent an attractive and novel approach to combat CRC.	[De Simone, V.; Franze, E.; Ronchetti, G.; Colantoni, A.; Fantini, M. C.; Di Fusco, D.; Pallone, F.; Monteleone, G.; Stolfi, C.] Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy; [Sica, G. S.; Sileri, P.] Univ Roma Tor Vergata, Dept Surg, I-00133 Rome, Italy; [MacDonald, T. T.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Immunol & Infect Dis, London, England	University of Rome Tor Vergata; University of Rome Tor Vergata; University of London; Queen Mary University London	Stolfi, C (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, Via Montpellier 1, I-00133 Rome, Italy.	carmine.stolfi@uniroma2.it	Stolfi, Carmine/J-4524-2019; Monteleone, Giovanni/AAE-1418-2021; Sileri, Pierpaolo/W-9593-2019	Sileri, Pierpaolo/0000-0002-1104-6237; Di Fusco, Davide/0000-0002-8908-9237; Stolfi, Carmine/0000-0002-6354-2443; Franze, Eleonora/0000-0003-4343-221X	'Fondazione Umberto di Mario ONLUS', Rome; AIRC [MFAG-12108, IG-13049]	'Fondazione Umberto di Mario ONLUS', Rome; AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the 'Fondazione Umberto di Mario ONLUS', Rome, and AIRC (MFAG-12108 to CS and IG-13049 to GM).	Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Caprioli F, 2008, J IMMUNOL, V180, P1800, DOI 10.4049/jimmunol.180.3.1800; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Chae WJ, 2010, P NATL ACAD SCI USA, V107, P5540, DOI 10.1073/pnas.0912675107; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Hyun YS, 2012, CARCINOGENESIS, V33, P931, DOI 10.1093/carcin/bgs106; Issa AY, 2007, CARCINOGENESIS, V28, P1978, DOI 10.1093/carcin/bgm161; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jauch D, 2011, GUT, V60, P1678, DOI 10.1136/gutjnl-2011-300612; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Lanca T, 2012, ONCOIMMUNOLOGY, V1, P717, DOI 10.4161/onci.20068; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Monteleone G, 2012, INT J MOL SCI, V13, P11071, DOI 10.3390/ijms130911071; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; SENIK A, 1980, ANN INST PASTEUR IMM, VC131, P349; Song XY, 2014, IMMUNITY, V40, P140, DOI 10.1016/j.immuni.2013.11.018; Stolfi C, 2008, BIOCHEM PHARMACOL, V75, P668, DOI 10.1016/j.bcp.2007.09.020; Stolfi C, 2011, J EXP MED, V208, P2279, DOI 10.1084/jem.20111106; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tannenbaum CS, 2000, SEMIN CANCER BIOL, V10, P113, DOI 10.1006/scbi.2000.0314; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Wang KP, 2013, ANN RHEUM DIS, V72, P100, DOI 10.1136/annrheumdis-2012-202201; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Xu XL, 1998, CANCER RES, V58, P2832; Yamane H, 2013, IMMUNOL REV, V252, P12, DOI 10.1111/imr.12032; Yen HR, 2009, J IMMUNOL, V183, P7161, DOI 10.4049/jimmunol.0900368; Yeste A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4753; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109	46	331	335	4	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3493	3503		10.1038/onc.2014.286	http://dx.doi.org/10.1038/onc.2014.286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25174402	Green Published, hybrid			2022-12-28	WOS:000357434900002
J	Liu, XD; Yao, J; Tripathi, DN; Ding, Z; Xu, Y; Sun, M; Zhang, J; Bai, S; German, P; Hoang, A; Zhou, L; Jonasch, D; Zhang, X; Conti, CJ; Efstathiou, E; Tannir, NM; Eissa, NT; Mills, GB; Walker, CL; Jonasch, E				Liu, X-D; Yao, J.; Tripathi, D. N.; Ding, Z.; Xu, Y.; Sun, M.; Zhang, J.; Bai, S.; German, P.; Hoang, A.; Zhou, L.; Jonasch, D.; Zhang, X.; Conti, C. J.; Efstathiou, E.; Tannir, N. M.; Eissa, N. T.; Mills, G. B.; Walker, C. L.; Jonasch, E.			Autophagy mediates HIF2 alpha degradation and suppresses renal tumorigenesis	ONCOGENE			English	Article							REGULATE AUTOPHAGY; CELL CARCINOMA; DIRECT BINDING; INHIBITION; UBIQUITIN; PROTEIN; P62; PHOSPHORYLATION; MECHANISMS; BECLIN-1	Autophagy is a conserved process involved in lysosomal degradation of protein aggregates and damaged organelles. The role of autophagy in cancer is a topic of intense debate, and the underlying mechanism is still not clear. The hypoxia-inducible factor 2 alpha (HIF2 alpha), an oncogenic transcription factor implicated in renal tumorigenesis, is known to be degraded by the ubiquitin-proteasome system (UPS). Here, we report that HIF2 alpha is in part constitutively degraded by autophagy. HIF2 alpha interacts with autophagy-lysosome system components. Inhibition of autophagy increases HIF2 alpha, whereas induction of autophagy decreases HIF2 alpha. The E3 ligase von Hippel-Lindau and autophagy receptor protein p62 are required for autophagic degradation of HIF2 alpha. There is a compensatory interaction between the UPS and autophagy in HIF2 alpha degradation. Autophagy inactivation redirects HIF2 alpha to proteasomal degradation, whereas proteasome inhibition induces autophagy and increases the HIF2 alpha-p62 interaction. Importantly, clear-cell renal cell carcinoma (ccRCC) is frequently associated with monoallelic loss and/or mutation of autophagy-related gene ATG7, and the low expression level of autophagy genes correlates with ccRCC progression. The protein levels of ATG7 and beclin 1 are also reduced in ccRCC tumors. This study indicates that autophagy has an anticancer role in ccRCC tumorigenesis, and suggests that constitutive autophagic degradation of HIF2 alpha is a novel tumor suppression mechanism.	[Liu, X-D; Sun, M.; Bai, S.; German, P.; Hoang, A.; Zhou, L.; Zhang, X.; Efstathiou, E.; Tannir, N. M.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77030 USA; [Yao, J.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Tripathi, D. N.; Zhang, J.; Jonasch, D.; Walker, C. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Ding, Z.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Xu, Y.; Eissa, N. T.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Conti, C. J.] Texas A&M Hlth Sci Ctr, Dept Mol & Cellular Med, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xliu10@mdanderson.org; ejonasch@mdanderson.org	Tripathi, Durga Nand/H-3247-2019	Tripathi, Durga Nand/0000-0001-8736-4808; Liu, xiande/0000-0002-9639-0458	Nanomedicine Roadmap Initiative Grant; Renee Kaye Cure Fur Cancer Grant; MD Anderson Cancer Center Kidney Cancer Research Program; NATIONAL CANCER INSTITUTE [R01CA143811, P30CA016672] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY016525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES023512] Funding Source: NIH RePORTER	Nanomedicine Roadmap Initiative Grant; Renee Kaye Cure Fur Cancer Grant; MD Anderson Cancer Center Kidney Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the TCGA Research network. This work was supported by the Nanomedicine Roadmap Initiative Grant, the Renee Kaye Cure Fur Cancer Grant and the MD Anderson Cancer Center Kidney Cancer Research Program.	Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188; Ding ZY, 2012, J BIOMOL SCREEN, V17, P572, DOI 10.1177/1087057112436557; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014; Hacker KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003801; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hubbi ME, 2013, J BIOL CHEM, V288, P10703, DOI 10.1074/jbc.M112.414771; Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu XD, 2012, J BIOL CHEM, V287, P19687, DOI 10.1074/jbc.M112.350934; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853; Prasad SR, 2006, RADIOGRAPHICS, V26, P1795, DOI 10.1148/rg.266065010; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143; Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	45	54	57	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2450	2460		10.1038/onc.2014.199	http://dx.doi.org/10.1038/onc.2014.199			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998849	Green Accepted			2022-12-28	WOS:000354190400004
